PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Olson, EE; Lyuboslavsky, T; Traynelis, SF; McKeon, RJ				Olson, EE; Lyuboslavsky, T; Traynelis, SF; McKeon, RJ			PAR-1 deficiency protects against neuronal damage and neurologic deficits after unilateral cerebral hypoxia/ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						protease activated receptors; serine protease; cerebral ischemia; neuronal death	PROTHROMBIN-MESSENGER-RNA; THROMBIN-RECEPTOR ACTIVATION; TISSUE-PLASMINOGEN ACTIVATOR; NIGRAL DOPAMINERGIC-NEURONS; SIGNALING PATHWAYS; PROTEASE THROMBIN; NERVOUS-SYSTEM; BRAIN-DAMAGE; CELL-DEATH; RAT-BRAIN	Cardiovascular and neurologic surgeries often involve a temporary reduction in cerebral blood flow. In these conditions, as well as during cerebral ischemia and traumatic brain injury, the temporary loss of oxygen and glucose initiates a cascade of cellular events that culminate in neuronal death and damage. Understanding the mechanisms that contribute to neuronal death after hypoxia/ischemia is critically important for treatment of such brain injury. Here, we use a model of combined cerebral hypoxia/ischemia (H/I) to examine the role of protease-activated receptor-1 (PAR-1) in hypoxic/ischemic neuronal damage. Our data show that PAR-1-deficient mice have smaller lesion volumes than wild-type controls after 45 minutes of H/I. The results of the genetic block of PAR-I were corroborated using a PAR-1 antagonist, which decreased infarct volume in wild-type C57B16 mice. Examination of cellular responses to H/I reveals that PAR-1 -/- animals have less cellular death and diminished glial fibrillary acidic protein expression. Additionally, PAR-1 -/- mice exhibit less motor behavior impairment in rotorod and inverted wire-hang tests. These data suggest that PAR-1 contributes to hypoxic/ischemic brain injury and are consistent with other studies that implicate serine proteases and their receptors in neuropathology after cerebral insults.	Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA	McKeon, RJ (corresponding author), Emory Univ, Dept Cell Biol, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	mckeon@cellbio.emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042717, R29NS035986, R01NS039419] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42717, NS 35986, NS 39419] Funding Source: Medline		Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Busch E, 1997, ACT NEUR S, V70, P206; Carreno-Muller E, 2003, J NEUROCHEM, V84, P1201, DOI 10.1046/j.1471-4159.2003.01634.x; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Choi SH, 2003, J NEUROSCI, V23, P5877; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Debeir T, 1996, BRAIN RES, V708, P159, DOI 10.1016/0006-8993(95)01237-0; Derian CK, 2003, J PHARMACOL EXP THER, V304, P855, DOI 10.1124/jpet.102.042663; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1997, J NEUROSCI, V17, P5316; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P404, DOI 10.1097/00004647-200204000-00004; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kessler C, 1997, ANAESTHESIA, V52, P433, DOI 10.1111/j.1365-2044.1997.113-az0107.x; Khanna G, 2000, NEW J PHYS, V2, P31, DOI 10.1088/1367-2630/2/1/303; Kim YD, 2002, BRAIN RES BULL, V58, P491, DOI 10.1016/S0361-9230(02)00823-7; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Masada T, 2000, BRAIN RES, V867, P173, DOI 10.1016/S0006-8993(00)02302-7; Motohashi O, 1997, J NEUROTRAUM, V14, P747, DOI 10.1089/neu.1997.14.747; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; O'Donnell SL, 2002, GLIA, V39, P85, DOI 10.1002/glia.10081; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; SAMSON D, 1994, NEUROSURGERY, V34, P22; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Turgeon VL, 1999, J NEUROPATH EXP NEUR, V58, P499, DOI 10.1097/00005072-199905000-00009; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Vannucci SJ, 1996, J CEREBR BLOOD F MET, V16, P77, DOI 10.1097/00004647-199601000-00009; Vannucci SJ, 2001, J CEREBR BLOOD F MET, V21, P52, DOI 10.1097/00004647-200101000-00007; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x	41	39	40	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2004	24	9					964	971		10.1097/01.WCB.0000128266.87474.BF			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	853CO	WOS:000223804100002	15356417	Bronze			2021-06-18	
J	Bardach, NS; Olson, SJ; Elkins, JS; Smith, WS; Lawton, MT; Johnston, SC				Bardach, NS; Olson, SJ; Elkins, JS; Smith, WS; Lawton, MT; Johnston, SC			Regionalization of treatment for subarachnoid hemorrhage - A cost-utility analysis	CIRCULATION			English	Article						cost-benefit analysis; quality of health care; hemorrhage, subarachnoid	UNRUPTURED CEREBRAL ANEURYSMS; TRAUMATIC BRAIN-INJURY; INTERHOSPITAL TRANSPORT; HOSPITALS; VOLUME; STROKE; CARE; HELICOPTER; MORTALITY; PROPHYLAXIS	Background-Previous studies have shown that for the treatment of subarachnoid hemorrhage (SAH), outcomes are improved but costs are higher at hospitals with a high volume of admissions for SAH. Whether regionalization of care for SAH is cost-effective is unknown. Methods and Results-In a cost-utility analysis, health outcomes for patients with SAH were modeled for 2 scenarios: 1 representing the current practice in California in which most patients with SAH are treated at the closest hospital and 1 representing the regionalization of care in which patients at hospitals with <20 SAH admissions annually ( low volume) would be transferred to hospitals with >= 20 SAH admissions annually ( high volume). Using a Markov model, we compared net quality-adjusted life-years (QALYs) and cost per QALY. Inputs were chosen from the literature and derived from a cohort study in California. Transferring a patient with SAH from a low- to a high-volume hospital would result in a gain of 1.60 QALYs at a cost of $10 548/QALY. For transfer to result in only borderline cost-effectiveness ($50 000/QALY), differences in case fatality rates between low- and high-volume hospitals would have to be one fifth as large (2.2%) or risk of death during transfer would have to be 5 times greater (9.8%) than estimated in the base case. Conclusions-Transfer of patients with SAH from low- to high-volume hospitals appears to be cost-effective, and regionalization of care may be justified. However, current estimates of the impact of hospital volume on outcome require confirmation in more detailed cohort studies.	Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Neurol Surg, San Francisco, CA 94143 USA; Univ Calif Berkeley, Richard & Rhoda Goldman Sch Publ Policy, Berkeley, CA 94720 USA	Johnston, SC (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, Box 0114,505 Parnassus Ave, San Francisco, CA 94143 USA.	clay.johnston@ucsfmedctr.org		Bardach, Naomi/0000-0002-5178-0719	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS002254] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02 NS 02254] Funding Source: Medline		Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Arfken CL, 1998, J TRAUMA, V45, P785, DOI 10.1097/00005373-199810000-00031; Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B; Berman MF, 2003, STROKE, V34, P2200, DOI 10.1161/01.STR.0000086528.32334.06; *CDC, MORT DAT; Dewhurst AT, 2001, ANAESTHESIA, V56, P882, DOI 10.1046/j.1365-2044.2001.02059-2.x; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; EHRENWERTH J, 1986, CRIT CARE MED, V14, P543, DOI 10.1097/00003246-198606000-00005; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gearhart PA, 1997, ANN EMERG MED, V30, P500, DOI 10.1016/S0196-0644(97)70010-6; Gebremichael M, 2000, CRIT CARE MED, V28, P79, DOI 10.1097/00003246-200001000-00013; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; Johansson M, 2001, STROKE, V32, P2845, DOI 10.1161/hs1201.099416; Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799; Johnston SC, 1999, NEUROLOGY, V52, P1806, DOI 10.1212/WNL.52.9.1806; KANTER RK, 1989, PEDIATRICS, V84, P43; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Matz PG, 2003, STROKE, V34, P2206, DOI 10.1161/01.STR.0000089683.66849.5E; Naimark D, 1997, MED DECIS MAKING, V17, P152, DOI 10.1177/0272989X9701700205; *OFF STAT PLANN DE, 1999, CAL HOSP DISCH DAT R; Prencipe M, 1998, STROKE, V29, P126, DOI 10.1161/01.STR.29.1.126; RIDLEY S, 1989, ANAESTHESIA, V44, P822, DOI 10.1111/j.1365-2044.1989.tb09099.x; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; Selevan JS, 1999, ANN EMERG MED, V33, P33, DOI 10.1016/S0196-0644(99)70414-2; Solomon RA, 1996, STROKE, V27, P13, DOI 10.1161/01.STR.27.1.13; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Taylor CL, 1997, J NEUROSURG, V86, P583, DOI 10.3171/jns.1997.86.4.0583; Werman HA, 1999, AM J EMERG MED, V17, P130, DOI 10.1016/S0735-6757(99)90043-8; Wuerz R, 1994, Prehosp Disaster Med, V9, P50	34	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-7322	1524-4539		CIRCULATION	Circulation	MAY 11	2004	109	18					2207	2212		10.1161/01.CIR.0000126433.12527.E6			6	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	819NU	WOS:000221322600011	15117848	Bronze			2021-06-18	
J	Martelli, MF; Zasler, ND; Bender, MC; Nicholson, K				Martelli, MF; Zasler, ND; Bender, MC; Nicholson, K			Psychological, neuropsychological, and medical considerations in assessment and management of pain	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; biopsychosocial; brain injury; pain; treatment	COPING STRATEGIES; ILLNESS BEHAVIOR; DISABILITY; DEPRESSION; INJURY; PERFORMANCE; IMPAIRMENT; VALIDATION; INVENTORY; DISORDER	Pain is a common yet challenging problem, particularly following traumatic injuries to the head or neck. It is a complex, multidimensional subjective experience with no clear or objective measures; yet it can have a significantly disabling effect across a wide range of functions. Persisting misconceptions owing to mind-body dualism have hampered advances in its understanding and treatment. In this article, a conceptualization of pain informed by recent research and derived from a more useful biopsychosocial model guides discussion of relevant medical, psychological, and neuropsychological considerations. This pain process model explains chronicity in terms of hyperresponsiveness and dysregulation of inhibitory or excitatory pain modulation mechanisms. Related neurocognitive effects of chronic pain are examined and recommendations for minimizing its confounding effects in neuropsychological evaluations are offered. A biopsychosocial assessment model is presented to guide understanding of the myriad of factors that contribute to chronicity. A brief survey of general classes and samples of the more useful pain assessment instruments is included. Finally, this model offers a rational means of organizing and planning individually tailored pain interventions, and some of the most useful pharmacologic, physical, and behavioral strategies are reviewed.	Concuss Care Ctr Virginia & Tree Life, Glen Allen, VA 23060 USA; Pinnacle Rehabil Inc, Richmond, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA USA; Univ Virginia, Charlottesville, VA USA; Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada	Martelli, MF (corresponding author), Concuss Care Ctr Virginia & Tree Life, 10120 W Broad St,Suites G-H, Glen Allen, VA 23060 USA.	mfmartelli@cccv-ltd.com					ANDRASIK F, 1990, NEUROL CLIN, V8, P961, DOI 10.1016/S0733-8619(18)30329-3; Auerbach S. M., 1998, STRESS MANAGEMENT PS; BABITSKY S, 2000, SYMTOM MAGNIFICATION; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLANCHARD EB, 1994, HDB PSYCHOTHERAPY BE; BROWN GK, 1987, PAIN, V31, P53, DOI 10.1016/0304-3959(87)90006-6; BRUNS D, 2003, HLTH PSYCHOL REHABIL; Butcher, 1989, MINNESOTA MULTIPHASI; Butler R. W., 1989, PSYCHOL ASSESSMENT J, V1, P41; CHAPMAN CR, 1995, ADV PAIN RES THER, V22, P283; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; *COLL PHYS SURG ON, 2000, EV REC MED MAN CHRON; DAHLSTROM WG, 1975, MMPI HDB RES APPL, V2; DeVore JR, 2002, FUNCTIONAL MED DISOR, P21; Dimeo F, 2001, BRIT J SPORT MED, V35, P114, DOI 10.1136/bjsm.35.2.114; EIMER BN, 1995, USERS GUIDE PAIN ASS; Fishbain DA, 1999, CLIN J PAIN, V15, P244, DOI 10.1097/00002508-199912000-00002; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; FLOR H, 1985, J CONSULT CLIN PSYCH, V53, P354, DOI 10.1037/0022-006X.53.3.354; FORDYCE WE, 1988, AM PSYCHOL, V43, P276, DOI 10.1037/0003-066X.43.4.276; Fors EA, 2002, J PSYCHIATR RES, V36, P179, DOI 10.1016/S0022-3956(02)00003-1; Gabriel M, 1995, FRONTIER PAIN RES, P197; Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332; Gatchel RJ, 1999, PSYCHOSOCIAL FACTORS; Gonzales VA, 2000, NEUROREHABILITATION, V14, P69; Gramling SE, 1996, J BEHAV THER EXP PSY, V27, P245, DOI 10.1016/S0005-7916(96)00027-4; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; HENDLER N, 1979, PSYCHOSOMATICS, V20, P801; HINNANT DW, 1994, HDB CHRONIC PAIN MAN, P18; HOLROYD KA, 1978, J CONSULT CLIN PSYCH, V46, P1036; HOLROYD KA, 1999, PSYCHOSOCIAL FACTORS, P193; JAY GW, 2001, CURRENT TREND DIAGNO; JENSEN MP, 1991, PAIN, V44, P263, DOI 10.1016/0304-3959(91)90095-F; Kirsch D. L., 1999, SCI CRANIAL ELECTROT; Kirsch DL, 2000, NEUROREHABILITATION, V14, P85; KIRSCH DL, 2002, PAIN MANAGEMENT PRAC, P759; Kulich RJ, 1999, EVALUATION TREATMENT, P301; Lorenz J, 1997, PAIN, V73, P369, DOI 10.1016/S0304-3959(97)00123-1; MAILIS A, 2002, FUNCTIONAL MED DISOR, P131; Main CJ, 2000, PAIN MANAGEMENT INTE; Martelli M. F., 2002, PAIN MANAGEMENT PRAC, P125; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Martelli MF, 2002, PAIN MANAGEMENT PRAC, P465; Martelli MF, 2002, FUNCTIONAL MED DISOR, P147; MARTELLI MF, 2001, J CONTROVERSIAL MED, V8, P1; Martelli MF, 2002, PAIN MANAGEMENT PRAC, P895; MARTELLI MF, 2003, VILLAMARTELLI DISABI; MARTELLI MF, 2002, FUNCTIONAL MED DISOR, P167; MARTELLI MF, 2003, INT J FORENSIC PSYCH, V1, P26; MARTELLI MF, IN PRESS CASEBOOK ET; MARTELLI MF, 1999, GUIDE FUNCTIONAL CAP, V3, P1; MARTIN PR, 1993, PSYCHOSOCIAL MANAGME; McQuay H., 1998, EVIDENCE BASED RESOU; Merskey H, 1994, CLASSIFICATION CHRON; Miller L, 2000, NEUROREHABILITATION, V14, P25; Miller L., 1993, PSYCHOTHERAPY BRAIN; MILLER L, 1990, COGNITIVE REHABILITA, V8, P12; MILLON T, 1977, MCMI II MANUAL; MILLON T, 1999, INTERPRETIVE STRATEG; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Morey L. C., 1991, PERSONALITY ASSESSME; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Nicholson K, 2000, NEUROREHABILITATION, V14, P57; Nicholson K, 2000, NEUROREHABILITATION, V14, P3; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; NICHOLSON K, IN PRESS CASEBOOK ET; Olness K, 1999, HEADACHE, V39, P101, DOI 10.1046/j.1526-4610.1999.3902101.x; PACKARD RC, 1993, HEADACHE, V33, P359, DOI 10.1111/j.1526-4610.1993.hed3307359.x; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; PILOWSKY I, 1975, J PSYCHOSOM RES, V19, P279, DOI 10.1016/0022-3999(75)90026-4; PILOWSKY I, 1976, PAIN, V2, P61, DOI 10.1016/0304-3959(76)90047-6; Porro CA, 2002, J NEUROSCI, V22, P3206, DOI 10.1523/JNEUROSCI.22-08-03206.2002; Price DD, 1988, PSYCHOL NEURAL MECH, Vx; RICE DD, 2001, HDB PAIN ASSESSMENT, P53; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; Rudy TE, 1989, MULTIAXIAL ASSESSMEN; Senior G, 2001, NEUROREHABILITATION, V16, P203; Spielberger C.D., 1999, STATE TRAIT ANGER EX; Todd D., 1998, COGNIPHOBIA SCALE C, pdomain; Todd D, 1998, FORENSIC EXAMINER, V7, P14; Turk D, 1992, HDB PAIN ASSESSMENT, V2nd; TURK DC, 1990, PAIN, V43, P27, DOI 10.1016/0304-3959(90)90047-H; Turk DC, 1986, PAIN MANAGEMENT HDB, P1; Tyrer S, 2003, NEUROPSYCHOL REHABIL, V13, P189, DOI 10.1080/09602010244000381; Vogt BA, 1993, NEUROBIOLOGY CINGULA, P313; WADE JB, 1992, PAIN, V51, P67, DOI 10.1016/0304-3959(92)90010-9; WILLIMS A, 2000, PAIN EUROPE, V3, P162; ZASLER ND, IN PRESS NEUROPSYCHI; ZASLER ND, 2002, PAIN MANAGEMENT PRAC, P789; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V13, P508, DOI 10.1001/archpsyc.1965.01730060026004	95	39	39	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					10	28		10.1097/00001199-200401000-00003			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000003	14732828				2021-06-18	
J	Bain, AC; Shreiber, DI; Meaney, DF				Bain, AC; Shreiber, DI; Meaney, DF			Modeling of microstructural kinematics during simple elongation of central nervous system tissue	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							AXONAL INJURY; STRETCH; HEAD	Damage to axons and glial cells in the central nervous system (CNS) white matter is a nearly universal feature of traumatic brain injury, yet it is not clear how the tissue mechanical deformations are transferred to the cellular components of the CNS. Defining how cellular deformations relate to the applied tissue deformation field can both highlight cellular populations at risk for mechanical injury, and define the fraction of cells in a specific population that will exhibit damage. In this investigation, microstructurally based models of CNS white matter were developed and tested against measured transformations of the CNS tissue microstructure under simple elongation. Results show that axons in the unstretched optic nerves were significantly wavy or undulated, where the measured axonal path length was greater than the end-to-end distance of the axon. The average undulation parameter-defined as the true axonal length divided by the end-to-end length-was 1.13. In stretched nerves, mean axonal undulations decreased with increasing applied stretch ratio (lambda)-the mean undulation values decreased to 1.06 at lambda = 1.06, 1.04 at lambda =1.12, and 1.02 at lambda =1.25. A model describing the gradual coupling, or tethering, of the axons to the surrounding glial cells best fit the experimental data. These modeling efforts indicate the fraction of the axonal and glial populations experiencing deformation increases with applied elongation, consistent with the observation that both axonal and glial cell injury increases at higher levels of white matter injury. Ultimately, these results can be used in conjunction with computational simulations of traumatic brain injury to aid in establishing the relative risk of cellular structures in the CNS white matter to mechanical injury.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 120 Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Shreiber, David/0000-0001-8248-419X; Meaney, David/0000-0002-0954-4122	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD41699] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 N535712] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER		Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BANDAK FA, 1996, AGARD HEAD INJ SPEC; Billiar KL, 1997, J BIOMECH, V30, P753, DOI 10.1016/S0021-9290(97)00019-5; BREIG A, 1960, BIOMECHANICS CENTRAL, P183; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; LANIR Y, 1979, J BIOMECH, V12, P423, DOI 10.1016/0021-9290(79)90027-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RIGBY BJ, 1959, J GEN PHYSIOL, V43, P265, DOI 10.1085/jgp.43.2.265; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Smith DH, 1999, J NEUROSCI, V19, P4263; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; VIIDIK A, 1968, Journal of Biomechanics, V1, P3, DOI 10.1016/0021-9290(68)90032-8; WAXMAN SG, 1995, AXON STRUCTURE FUNCT, P682; ZAR J.H., 1999, BIOSTATISTICAL ANAL; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	19	39	39	0	3	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	DEC	2003	125	6					798	804		10.1115/1.1632627			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	767XR	WOS:000188499600006	14986404				2021-06-18	
J	Suzuki, T; Bramlett, HM; Dietrich, WD				Suzuki, T; Bramlett, HM; Dietrich, WD			The importance of gender on the beneficial effects of posttraumatic hypothermia	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; gender; hormones; histopathology; hypothermia	TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; ESTROGEN-RECEPTOR; CORTICAL IMPACT; FOCAL ISCHEMIA; DAMAGE	The authors studied the importance of gender on the consequences of mild posttraumatic hypothermia following parasagittal fluid-percussion (F-P) brain injury in rats. After traumatic brain injury (TBI), brain temperature was maintained at nonnothermia (37degreesC) or reduced to 33degreesC for 4 h starting 30 min after the insult followed by a 1.5-h slow rewarming period. Animals (n = 48) were allowed to survive for 3 days before quantitative histopathological and immunocytochemical examination. As previously reported, contusion volume in nonnothermic animals (37degreesC) was smaller (P < 0.05) in intact females compared to males. In addition, numbers of NeuN-positive cortical neurons were greater in females versus males after TBI. Posttraumatic hypothermia significantly reduced overall contusion volume in males (P < 0.05), while not significantly reducing contusion volume in females. Likewise, hypothermia protected against the loss of cortical neurons in males but had no effect in females. Ovariectomized females showed contusion volumes and neuronal cell counts comparable to those seen in males as well as a significant reduction in contusion volumes and greater neuronal counts following posttraumatic hypothermia. These data are the first to demonstrate that posttraumatic hypothermia (4 h) does not affect short-term histopathological outcomes in female rats. Potential mechanisms underlying this gender difference are discussed. Finally, these experimental findings may have important implications in terms of clinical trials using therapeutic hypothermia targeting patients with central nervous system (CNS) injury. (C) 2003 Elsevier Inc. All rights reserved.	Univ Miami, Sch Med, Neurotrauma Res Ctr, Dept Neurol Surg,Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133, NS43233, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043233, P50NS030291, R01NS042133] Funding Source: NIH RePORTER		Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dubal DB, 1999, J NEUROSCI, V19, P6385; Farace E, 2001, J NEUROSURG, V94, P863; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HAYASHI N, 1996, J CRIT MED, V8, P295; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Paxinos G., 1982, RAT BRAIN STEREOTAXI; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; WAGNER AK, 2002, J NEUROTRAUM, V19, P1367; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; ZILLES L, 1985, CORTEX RAT STEREOTAX	60	39	41	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2003	184	2					1017	1026		10.1016/S0014-4886(03)00389-3			10	Neurosciences	Neurosciences & Neurology	758KW	WOS:000187634400050	14769396				2021-06-18	
J	Kang, SK; Jun, ES; Bae, YC; Jung, JS				Kang, SK; Jun, ES; Bae, YC; Jung, JS			Interactions between human adipose stromal cells and mouse neural stem cells in vitro	DEVELOPMENTAL BRAIN RESEARCH			English	Article						neural stem cell; adipose stromal cell; neuron; differentiation; proliferation	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR PRODUCTION; ADULT MAMMALIAN BRAIN; BONE-MARROW; NEURONAL DIFFERENTIATION; DOPAMINERGIC-NEURONS; FUNCTIONAL RECOVERY; RAT; TRANSPLANTATION; MICE	Transplantation of adult mesenchymal stem cells (MSCs) into adult rat brain has been known to reduce functional deficits associated with stroke and traumatic brain injury. However, in injured brains, there is no evidence that transplanted MSCs replace lost host brain tissue. In this study, we determined in vitro interaction between human adipose tissue stromal cells (hATSCs), a kind of MSC, and neural stem cells (NSCs). hATSCs were isolated and proliferated from human adipose tissues, and NSCs from the subventricular zone of postnatal mice. When NSCs were cultured on mitomycin-treated hATSC monolayers, their proliferation was decreased, but neuronal differentiation was significantly induced. The percentage of neurons significantly increased in 7 days in cultures of NSCs on hATSCs feeder as compared to NSCs cultured on laminin-coated dishes. When the duration of the cultures was extended to 14 days, hATSCs supported the survival of neurons derived from NSCs. To determine the role of soluble factors from hATSCs, NSCs were cultured with hATSCs conditioned medium or co-cultured with permeable filter on which hATSCs were grown. Although proliferation of NSCs significantly decreased and glial differentiation increased under these experimental conditions, their neuronal differentiation was not affected, indicating that direct physical contact between hATSCs and NSCs is required for induction of neuronal differentiation. These data indicate that hATSCs may provide supportive roles on endogenous neural stem cells, when they are transplanted into damaged brain. (C) 2003 Elsevier B.V. All rights reserved.	Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Dept Plast Surg, Pusan 602739, South Korea	Jung, JS (corresponding author), Pusan Natl Univ, Coll Med, Dept Physiol, 1 Ga Ami Dong, Pusan 602739, South Korea.	jsjung@pusan.ac.kr					Blondel O, 2000, J NEUROSCI, V20, P8012; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681; Imura T, 2003, J NEUROSCI, V23, P2824; Kang SK, 2001, NEUROSCI RES COMMUN, V29, P183, DOI 10.1002/nrc.10011; KANG SK, IN PRESS EXP NEUROL; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lou SJ, 2003, BRAIN RES, V968, P114, DOI 10.1016/S0006-8993(03)02224-8; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MICHAEL AS, 2002, DEV BRAIN RES, V137, P115; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; PARK LW, 2000, NEUROSCI RES, V40, P615; PETTERSSON P, 1984, ACTA MED SCAND, V215, P447; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; TOMQVIST N, 2000, EXP NEUROL, V164, P130; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	44	39	41	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	OCT 10	2003	145	1					141	149		10.1016/S0165-3806(03)00224-4			9	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	733RG	WOS:000186014000013	14519500				2021-06-18	
J	Goldstein, LB				Goldstein, LB			Neuropharmacology of TBI-induced plasticity	BRAIN INJURY			English	Article							LONG-TERM POTENTIATION; SENSORIMOTOR CORTEX INJURY; HIPPOCAMPAL DENTATE GYRUS; TRAUMATIC BRAIN INJURY; CLOSED HEAD-INJURY; MOTOR RECOVERY; DOUBLE-BLIND; LASTING POTENTIATION; VISUAL-CORTEX; BEAM-WALKING	Primary objective: The purpose of this report is to review both fundamental studies in laboratory animals and preliminary clinical data suggesting that certain drugs may affect behavioural recovery after brain injury. Main outcomes and results: Laboratory studies show that systemically-administered drugs that affect specific central neurotransmitters including norepinephrine and GABA influence recovery in a predictable manner. Although some drugs such as d-amphetamine have the potential to enhance recovery, others such as neuroleptics and other central dopamine receptor antagonists, benzodiazepines and the anti-convulsants phenytoin and phenobarbital may be detrimental. In one study, 72% of patients with traumatic brain injury received one or a combination of the drugs that may impair recovery based on both animal experiments and studies in recovering stroke patients. Conclusions: Until the true impact of these classes of drugs are better understood, care should be exercised in the use of medications that may interfere with the recovery process in patients with traumatic brain injury. Additional research needs to be completed before the clinical efficacy of drugs that may enhance recovery can be established.	Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis,Dept Med Neurol, Head Stroke Policy Program,Ctr Clin Hlth Policy R, Durham, NC 27710 USA; Durham Dept Vet Affairs Med Ctr, Durham, NC USA	Goldstein, LB (corresponding author), Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis,Dept Med Neurol, Head Stroke Policy Program,Ctr Clin Hlth Policy R, Box 3651, Durham, NC 27710 USA.						ALTMAN HJ, 1983, BEHAV BRAIN RES, V7, P51, DOI 10.1016/0166-4328(83)90004-9; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; ARTOLA A, 1989, NMDA RECEPTOR, P153; BENVENGA MJ, 1988, PHARMACOL BIOCHEM BE, V30, P205, DOI 10.1016/0091-3057(88)90445-5; BLISS TVP, 1982, TRENDS NEUROSCI, V5, P289, DOI 10.1016/0166-2236(82)90181-3; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; CORBETT D, 1980, BRAIN RES BULL, V5, P637, DOI 10.1016/0361-9230(80)90198-7; CORWIN JV, 1986, EXP NEUROL, V94, P683, DOI 10.1016/0014-4886(86)90247-5; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; CROW TJ, 1968, NATURE, V219, P736, DOI 10.1038/219736a0; DAHL D, 1990, BRAIN RES, V526, P347, DOI 10.1016/0006-8993(90)91245-C; DAHL D, 1989, P NATL ACAD SCI USA, V86, P4776, DOI 10.1073/pnas.86.12.4776; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; DIETRICH WD, 1990, STROKE, V21, P147; DOUGLAS RM, 1983, J COMP NEUROL, V219, P285, DOI 10.1002/cne.902190304; DOUGLAS RM, 1982, BRAIN RES, V240, P259, DOI 10.1016/0006-8993(82)90221-9; DUNBAR G L, 1989, Society for Neuroscience Abstracts, V15, P132; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVERITT BJ, 1983, NEUROSCIENCE, V10, P397, DOI 10.1016/0306-4522(83)90142-2; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; Goldstein LB, 2000, NEUROPHARMACOLOGY, V39, P852, DOI 10.1016/S0028-3908(99)00249-X; GOLDSTEIN LB, 1992, BRAIN RES, V580, P129, DOI 10.1016/0006-8993(92)90936-4; Goldstein LB, 1999, REV NEUROL-FRANCE, V155, P731; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; GOLDSTEIN LB, 1990, STROKE, V21, P139; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; GOLDSTEIN LB, 1990, J NEURO REHAB, V4, P137; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HERNANDEZ TD, 1994, BRAIN RES, V635, P300, DOI 10.1016/0006-8993(94)91451-6; HOPKINS WF, 1984, SCIENCE, V226, P350, DOI 10.1126/science.6091272; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HOVDA DA, 1983, FED PROC, V42, P1157; INNES IR, 1985, PHARMACOL BASIS THER, P477; ITO T, 1988, CAN J PHYSIOL PHARM, V66, P1010, DOI 10.1139/y88-165; KASAMATSU T, 1979, J COMP NEUROL, V185, P163, DOI 10.1002/cne.901850110; KELLER A, 1990, J COMP NEUROL, V300, P47, DOI 10.1002/cne.903000105; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Larsson M, 1988, Compr Gerontol A, V2, P53; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIPSEY JR, 1984, LANCET, V1, P297; Marshall L. F., 1985, CENTRAL NERVOUS SYST, P45; MATHEW RJ, 1985, PSYCHOPHARMACOLOGY, V87, P298, DOI 10.1007/BF00432711; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; MOSKOWITZ MA, 1975, P NATL ACAD SCI USA, V72, P834, DOI 10.1073/pnas.72.3.834; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; PEROUTKA SJ, 1977, NEUROPHARMACOLOGY, V16, P549, DOI 10.1016/0028-3908(77)90023-5; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; REDING MJ, 1995, NEUROLOGY, V45, pA222; REDING MJ, NEUROLOGY S4, V45, P95; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHALLERT T, 1992, PHYS MED REHABIL, V6, P375; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; STANTON PK, 1985, BRAIN RES, V361, P276, DOI 10.1016/0006-8993(85)91299-5; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; SWANSON LW, 1982, NEUROSCI RES PROG B, V20, P612; VANHASSELT P, 1973, NEUROPHARMACOLOGY, V12, P245, DOI 10.1016/0028-3908(73)90109-3; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; VARGO JM, 1989, BEHAV NEUROSCI, V103, P1017, DOI 10.1037/0735-7044.103.5.1017; Walker-Batson D, 2001, STROKE, V32, P2093, DOI 10.1161/hs0901.095720; WALKERBATSON D, 1992, RESTOR NEUROL NEUROS, V4, P47, DOI 10.3233/RNN-1992-4106; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WILLIAMS S, 1988, SCIENCE, V242, P84, DOI 10.1126/science.2845578	86	39	43	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					685	694		10.1080/0269905031000107179			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500006	12850953				2021-06-18	
J	Schoenberg, MR; Duff, K; Scott, JG; Adams, RL				Schoenberg, MR; Duff, K; Scott, JG; Adams, RL			An evaluation of the clinical utility of the OPIE-3 as an estimate of premorbid WAIS-III FSIQ	CLINICAL NEUROPSYCHOLOGIST			English	Article							DEMOGRAPHIC-VARIABLES; COMBINED PERFORMANCE; INTELLIGENCE; SCORES; DEPRESSION; SEVERITY; DECLINE; AGE	The clinical utility of the Oklahoma Premorbid Intelligence Estimate-3 (OPIE-3; Schoenberg, Scott, Duff, & Adams, 2002) in estimating premorbid FSIQ was investigated with the WAIS-III standardization sample. The OPIE-3 algorithms combine Vocabulary, Information, Matrix Reasoning, and Picture Completion subtest raw scores with demographic variables to predict FSIQ. Estimated WAIS-III FSIQ scores are presented for patients' diagnosed with dementia, traumatic brain injury, Huntington's disease, Korsakoff's disease, chronic alcohol use, temporal lobectomy, and schizophrenia. A group of patients with depression was employed as a clinical control group. The OPIE-3V and OPIE-3MR algorithms performed well, with the average predicted FSIQ of the combined clinical sample approximating the mean FSIQ of healthy adults. The OPIE-3(Best), which is a procedure that employs either the OPIE-3V, OPIE-3MR, or OPIE-3(2ST) algorithms in a best performance method, is presented. Recommendations in the application of the OPIE-3 are made and future research is proposed.	Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland, Dept Neurol, Cleveland, OH 44106 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; INTEGRIS Jim Thorpe Rehabil Ctr, Oklahoma City, OK USA; Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA	Schoenberg, MR (corresponding author), Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland, Dept Neurol, 11100 E Euclid Ave, Cleveland, OH 44106 USA.		Schultz, Susan K./M-3516-2019; Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			ALEKOUMBIDES A, 1987, INT J CLIN NEUROPSYC, V9, P11; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 1999, ARCH CLIN NEUROPSYCH, V14, P341, DOI 10.1016/S0887-6177(98)00028-6; BAADE LE, IN PRESS ARCH CLIN N; BOONE KB, 1995, NEUROPSYCHOLOGY, V9, P390, DOI 10.1037/0894-4105.9.3.390; Cockburn J, 2000, J CLIN EXP NEUROPSYC, V22, P508, DOI 10.1076/1380-3395(200008)22:4;1-0;FT508; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLLINS LF, 2000, THESIS U MEMPHIS, V60, P4210; CORRELL RE, 1985, PSYCHOL REP, V57, P295, DOI 10.2466/pr0.1985.57.1.295; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Franzen MD, 1997, ARCH CLIN NEUROPSYCH, V12, P711, DOI 10.1016/S0887-6177(97)00046-2; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LYNCH JK, 1997, PRACTICE NEUROPSYCHO, P91; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; MURREY GJ, 2000, FORENSIC EVALUATION; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Psychological Corporation, 2001, MAN WECHSL TEST AD R; RUSSELL EW, 1972, J CONSULT CLIN PSYCH, V39, P133, DOI 10.1037/h0033212; SCHINKA JA, 2000, CLIN GUIDE NEUROPSYC; Schoenberg MR, 2002, CLIN NEUROPSYCHOL, V16, P426, DOI 10.1076/clin.16.4.426.13913; Schopp LH, 2001, REHABIL PSYCHOL, V46, P279, DOI 10.1037/0090-5550.46.3.279; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; Silverstein M L, 1990, Arch Clin Neuropsychol, V5, P317, DOI 10.1016/0887-6177(90)90030-S; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M	33	39	39	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2003	17	3					308	321		10.1076/clin.17.3.308.18088			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	748DP	WOS:000186847100003	14704882				2021-06-18	
J	Blaha, M; Lazar, D; Winn, RH; Ghatan, S				Blaha, M; Lazar, D; Winn, RH; Ghatan, S			Hemorrhagic complications of intracranial pressure monitors in children	PEDIATRIC NEUROSURGERY			English	Article						intracranial pressure monitoring; complications; children; head injury	TRAUMATIC BRAIN INJURY; CLINICAL-PRACTICE; HEAD TRAUMA; EXPERIENCE; DEVICE; TRIAL; RISK	Intracranial pressure (ICP) monitoring plays a valuable role in the management of head injuries and other causes of raised ICP in the pediatric population. The purpose of this study was to investigate the incidence of hemorrhage after ICP monitor insertion, and to classify these complications in a clinically relevant manner. Hospital charts of 431 children (ages 0-16 years) admitted to a level 1 trauma center over a 2-year period were reviewed and 112 patients (134 insertions) who underwent intraparenchymal ICP monitoring were identified. The authors reviewed postoperative neuroradiological studies. One hundred and nineteen procedures were carried out without any hemorrhage (grade 0). After 10 insertions, a small punctate hemorrhage or localized subarachnoid hemorrhage occurred (grade 1). Three patients sustained an intracerebral hemorrhage that did not require evacuation or manifest as a new neurological deficit (grade 2). There were no hemorrhagic complications that necessitated evacuation or resulted in a noticeable change in the patient's clinical condition (grade 3). We propose a new grading system for hemorrhage after ICP monitor insertion. We found a complication rate close to 10% in our pediatric patients. Fortunately, these hemorrhages were clinically silent and no neurosurgical intervention was necessary. However, grade 1 and grade 2 hemorrhages may manifest with a false reading of high ICP, and the long-term consequences of these complications are not known. Of note, only 23% of these complications were reflected in the patients charts, which may explain the low complication rates reported in other studies that did not analyze postoperative neuroradiological studies.	Childrens Hosp & Med Ctr, Dept Neurol Surg, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA	Ghatan, S (corresponding author), Childrens Hosp & Med Ctr, Dept Neurol Surg, Seattle, WA 98105 USA.	ghatan@u.washington.edu		Blaha, Martin/0000-0002-9611-498X			Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; BLAHA M, 2000, ANEST NEODKL PECE, V2, P54; Bochicchio M, 1996, INTENS CARE MED, V22, P1070, DOI 10.1007/BF01699230; BULLCOK R, 2001, NEUROTRAUMA CRIT FAL; Campisi M, 1989, Minerva Anestesiol, V55, P205; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DEAN JM, 1981, NEUROSURGERY, V9, P627; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Filippi R, 2000, NEUROSURG REV, V23, P94; Guyot LL, 1998, ACT NEUR S, V71, P47; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Lane PL, 2000, CAN J SURG, V43, P442; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Schurer L, 1997, ACT NEUR S, V70, P296; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Spitzfaden AC, 1999, PEDIATR NEUROSURG, V31, P194, DOI 10.1159/000028861; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Winkelman C, 2000, Am J Crit Care, V9, P373; WINN HR, 1977, SURG NEUROL, V8, P41; WOSTER PS, 1990, CLIN PHARMACY, V9, P762; YABLON JS, 1993, J CLIN MONITOR, V9, P171, DOI 10.1007/BF01617024	27	39	40	1	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	JUL	2003	39	1					27	31		10.1159/000070877			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	690CH	WOS:000183529400008	12784075				2021-06-18	
J	Schuhmann, MU; Mokhtarzadeh, M; Stichtenoth, DO; Skardelly, M; Klinge, PA; Gutzki, FM; Samii, M; Brinker, T				Schuhmann, MU; Mokhtarzadeh, M; Stichtenoth, DO; Skardelly, M; Klinge, PA; Gutzki, FM; Samii, M; Brinker, T			Temporal profiles of cerebrospinal fluid leukotrienes, brain edema and inflammatory response following experimental brain injury	NEUROLOGICAL RESEARCH			English	Article; Proceedings Paper	52nd Annual Meeting of the German-Neurosurgical-Society	2001	BIELEFELD, GERMANY	German Neurosurg Soc		brain edema; cerebral contusion; leukotrienes; inflammation; LTB4; LTC4; traumatic brain injury	CONTROLLED CORTICAL IMPACT; MAGNETIC-RESONANCE-SPECTROSCOPY; SUBARACHNOID HEMORRHAGE; BARRIER PERMEABILITY; FOCAL ISCHEMIA; RAT-BRAIN; POLYMORPHONUCLEAR LEUKOCYTES; NEUTROPHIL ACCUMULATION; CYSTEINYL-LEUKOTRIENES; PERITONEAL-MACROPHAGES	The post-traumatic changes of leukotrienes LTC4, LTD4, LTE4, and LTB4 in cerebrospinal fluid of rats from 10 min to 7 days were investigated after controlled cortical impact in relation to brain edema and cellular inflammatory response. LTC4 increased five-fold at 4 h, normalized at 24 h, and showed another tour-told increase at 7 days. The same pattern was observed for LTD4 and LTE4. LTB4 however, behaved differently: concentrations were lower and levels peaked two-fold at 24 h. Edema in the injured hemisphere increased continuously up to 24 h without change contralaterally. Leukocyte infiltration, macrophage presence and microglia activation were most prominent at 24 h, 7 days and 24 h respectively. Leukotriene changes in CSF seem to reflect those in the affected tissue, with a time delay and in lower concentrations, and were not linearly correlated to brain edema. The initially high leukotriene levels are rather likely to contribute to the cytotoxic edema than to enhance a vasogenic edema component. The profile of LTB4 was parallel to the time course of leukocyte infiltration, indicating initiation of infiltration as well as prolonged production by leukocytes themselves. The second leukotriene peak at 7 days is likely to follow a different pathway and might be related to a production in macrophages or activated glia.	Hannover Med Sch, Dept Neurosurg, D-3000 Hannover, Germany; Hannover Med Sch, Dept Clin Pharmacol, D-3000 Hannover, Germany; Nordstadt Hosp, Dept Neurosurg, Hannover, Germany	Schuhmann, MU (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Neurochirurg, Johannisallee 34, D-04103 Leipzig, Germany.	mschuh@gmx.de	Skardelly, Marco/AAF-8680-2021				ABE M, 1992, PROSTAG LEUKOTR ESS, V45, P59, DOI 10.1016/0952-3278(92)90103-P; ABE M, 1990, BIOCHEM BIOPH RES CO, V171, P1344, DOI 10.1016/0006-291X(90)90834-A; AKTAN S, 1991, PROSTAG LEUKOTR ESS, V43, P247, DOI 10.1016/0952-3278(91)90037-6; BABA T, 1992, J NEUROSURG, V77, P403, DOI 10.3171/jns.1992.77.3.0403; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BLACK KL, 1994, J NEUROSURG, V81, P745, DOI 10.3171/jns.1994.81.5.0745; BLACK KL, 1986, ANN NEUROL, V19, P592, DOI 10.1002/ana.410190613; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; Brock TG, 1998, BIOCHEM J, V329, P519; CENEDELLA RJ, 1975, LIPIDS, V10, P290, DOI 10.1007/BF02532702; CHEN S, 2003, IN PRESS EXP NEUROL; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DEMPSEY R J, 1986, Neurological Research, V8, P53; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DOROVINIZIS K, 1992, J NEUROPATH EXP NEUR, V51, P194, DOI 10.1097/00005072-199203000-00009; Dreher W, 1998, MAGNET RESON MED, V39, P878, DOI 10.1002/mrm.1910390605; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; FAULER J, 1991, CLIN SCI, V80, P497, DOI 10.1042/cs0800497; GAETANI P, 1992, ACTA NEUROL SCAND, V86, P184, DOI 10.1111/j.1600-0404.1992.tb05063.x; GAETANI P, 1991, NEUROSURGERY, V28, P853, DOI 10.1227/00006123-199106000-00011; Girard J, 1996, EUR J PHARMACOL, V300, P43, DOI 10.1016/0014-2999(95)00804-7; HARIRI RJ, 1989, J TRAUMA, V29, P1203, DOI 10.1097/00005373-198909000-00003; HAUPTS M, 1992, ACTA NEUROL SCAND, V85, P365; HOEHNBERLAGE M, 1995, MAGN RESON MED, V34, P824, DOI 10.1002/mrm.1910340607; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; HYNES N, 1991, BRAIN RES, V553, P4, DOI 10.1016/0006-8993(91)90222-H; Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007; KAEVER V, 1990, BIOCHEM PHARMACOL, V39, P1313, DOI 10.1016/0006-2952(90)90007-8; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MABE H, 1990, Neurological Research, V12, P165; MAMOT C, 1995, MOL BRAIN RES, V33, P79, DOI 10.1016/0169-328X(95)00108-5; Marmarou A, 2000, ACT NEUR S, V76, P349; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MINAMI N, 1991, ACTA NEUROPATHOL, V81, P401, DOI 10.1007/BF00293461; MINAMISAWA H, 1988, STROKE, V19, P372, DOI 10.1161/01.STR.19.3.372; NAMURA Y, 1994, ACTA NEUROCHIR, P296; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; PALMBLAD J, 1981, BLOOD, V58, P658; PAOLETTI P, 1988, J NEUROSURG, V69, P488, DOI 10.3171/jns.1988.69.4.0488; Portella G, 2000, ACT NEUR S, V76, P273; REID GK, 1990, J BIOL CHEM, V265, P19818; Rosnowska M, 1997, Pol Merkur Lekarski, V2, P254; SAFAYHI H, 1992, J PHARMACOL EXP THER, V261, P1143; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; SCHUHMANN MU, 2002, THESIS MED HOCHSCHUL; SEREGI A, 1990, J PHARM PHARMACOL, V42, P191, DOI 10.1111/j.2042-7158.1990.tb05383.x; SERHAN CN, 1984, PROSTAG OTH LIPID M, V27, P563, DOI 10.1016/0090-6980(84)90092-3; SHEPARD SR, 1990, ACT NEUR S, V51, P58; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIMMET T, 1990, J NEUROCHEM, V54, P2091, DOI 10.1111/j.1471-4159.1990.tb04915.x; Stroop R, 1998, ACT NEUR S, V71, P303; Tsikas D, 1996, ANAL BIOCHEM, V236, P175, DOI 10.1006/abio.1996.0149; TSIKAS D, 1993, J CHROMATOGR-BIOMED, V622, P1, DOI 10.1016/0378-4347(93)80242-V; vanderToorn A, 1996, MAGN RESON MED, V36, P52, DOI 10.1002/mrm.1910360110; Whalen MJ, 1998, ACT NEUR S, V71, P212; Winking M, 1998, CEREBROVASC DIS, V8, P318, DOI 10.1159/000015874; Winking M, 1996, J CEREBR BLOOD F MET, V16, P737, DOI 10.1097/00004647-199607000-00026; Winking M, 1997, ACTA NEUROCHIR, V139, P764, DOI 10.1007/BF01420051; WINKING M, 1992, EICOSANOIDS OTHER BI	75	39	42	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	2003	25	5					481	491		10.1179/016164103101201896			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	704PP	WOS:000184348900008	12866196				2021-06-18	
J	Ernest, D; French, C				Ernest, D; French, C			Propofol infusion syndrome - Report of an adult fatality	ANAESTHESIA AND INTENSIVE CARE			English	Article						propofol : cardiac failure; metabolic acidosis; rhabdomyolysis		This report describes a fatal case of the propofol infusion syndrome in an adult patient being sedated for a closed head injury using high doses' of propofol. The features of circulatory collapse, metabolic acidosis, mild rhabdomyolysis and renal impairment are consistent with the syndrome and not readily attributable to alternative aetiologies. Potential mechanisms for the syndrome may relate to antagonism of beta-receptors, impaired myocardial oxygen utilization and a specific disruption to fatty-acid oxidation. This is the first published Australian case of the propofol infusion syndrome in an adult and should serve as an additional case report to the existing literature highlighting this potentially fatal syndrome in adults.	Box Hill Hosp, Intens Care Unit, Box Hill, Vic 3128, Australia; Western Hosp, Melbourne, Vic, Australia	Ernest, D (corresponding author), Box Hill Hosp, Intens Care Unit, Nelson Rd, Box Hill, Vic 3128, Australia.		French, Craig/ABF-5087-2020; Ernest, David/I-1699-2013	French, Craig/0000-0003-1363-9711; /0000-0002-4157-5148			Badr AE, 2001, ANESTHESIOLOGY, V94, P536, DOI 10.1097/00000542-200103000-00030; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; BRUSSEL T, 1989, ANESTH ANALG, V69, P35; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; DIPRIVAN, 2002, 2002 MIMS ANN, P16; Kelly DF, 2001, J NEUROSURG, V95, P925, DOI 10.3171/jns.2001.95.6.0925; Murray M., 2001, ANESTHESIOLOGY, V95, pA378; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	13	39	39	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	2003	31	3					316	319					4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	696EQ	WOS:000183873900014	12879680				2021-06-18	
J	Carbonell, WS; Mandell, JW				Carbonell, WS; Mandell, JW			Transient neuronal but persistent astroglial activation of ERK/MAP kinase after focal brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; C57bl/6 mice; extracellular signal-regulated kinase; forebrain stab lesion; gliosis; MAP kinase; traumatic brain injury	PROTEIN-KINASE; MAP KINASE; IN-VIVO; RAT; TRAUMA; ASTROCYTES; ISCHEMIA; CELL; TRANSCRIPTION; FOREBRAIN	Astrogliosis is a nearly ubiquitous response to a variety of insults to the central nervous system (CNS). This reaction is triggered rapidly, but can persist for years after the initial trauma. Little is known about the signaling mechanisms responsible for this activation and its chronic maintenance. Extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) activation is implicated in several functions important to the reactive glial phenotype such as cellular proliferation and motility. Here we utilize immunohistochemistry with a phosphorylation state-specific antibody (pERK) to characterize the temporal and spatial pattern of ERK/MAPK activation in neurons and glia following a forebrain stab lesion (FSL) in mice. Early activation (1 h) was primarily in perilesional neuronal elements, particularly of the hippocampus. Occasional perilesional glia were also positive for pERK. Additionally, ependymal cells bilaterally stained prominently for pERK. These patterns of pERK immunoreactivity at 1 h were abolished by pretreatment with the selective MEK inhibitor, SL327. ERK/MAPK activation at later time points between 1 day (d) and 30d was primarily restricted to perilesional astrocytes with maximum labeling at 3d. However, pERK-positive astrocytes represented only a subset of total GFAP-positive cells and were found more proximal to the lesion suggesting specific functional activation of these cells. Finally, immunostaining for the phosphorylated form of cAMP response element-binding (CREB) protein, a downstream target of the ERK/MAPK cascade, was increased in perilesional glia 7d after FSL. Sustained activation of the ERK/MAPK signaling pathway in perilesional reactive glia suggests a critical role for this cascade in astrogliosis.	Univ Virginia, Sch Med, Dept Pathol Neuropathol, HSC, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Grad Program Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Med Scientist Training Program, Charlottesville, VA 22908 USA	Mandell, JW (corresponding author), Univ Virginia, Sch Med, Dept Pathol Neuropathol, HSC, POB 800904, Charlottesville, VA 22908 USA.	jwm2m@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS002065] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5 T32 GM07267-23] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02 NS02065] Funding Source: Medline		ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Crepel V, 1998, J NEUROSCI, V18, P1196; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; Davies SJA, 1997, NATURE, V390, P680; Derkinderen P, 1999, NEUROREPORT, V10, pR24; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; FITCH MT, 1999, CNS REGENERATION BAS, P55; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Garrido YCS, 1998, BRAIN RES BULL, V47, P223, DOI 10.1016/S0361-9230(98)00075-6; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LAPING NJ, 1994, BRAIN PATHOL, V4, P259, DOI 10.1111/j.1750-3639.1994.tb00841.x; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Lee WJ, 2003, GLIA, V41, P15, DOI 10.1002/glia.10131; Lin BW, 1998, ACTA NEUROPATHOL, V95, P511, DOI 10.1007/s004010050832; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Miura T, 2000, EXP NEUROL, V166, P115, DOI 10.1006/exnr.2000.7493; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Rajan P, 1998, J NEUROSCI, V18, P3620; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUZUKI T, 1995, NEUROSCI RES, V22, P277, DOI 10.1016/0168-0102(95)00902-6; Varga AW, 2000, LEARN MEMORY, V7, P321, DOI 10.1101/lm.35300; Wang H, 2001, BIOCHEM BIOPH RES CO, V286, P869, DOI 10.1006/bbrc.2001.5482; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	43	39	41	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					327	336		10.1089/089771503765172282			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900002	12866812				2021-06-18	
J	Dempsey, RJ; Rao, VLR				Dempsey, RJ; Rao, VLR			Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats	JOURNAL OF NEUROSURGERY			English	Article						cytidinediphosphocholine; controlled cortical impact; hippocampus; neuroprotection; phospholipase; secondary neuronal death; rat	GLUTAMATE TRANSPORTER GLT-1; NITRIC-OXIDE SYNTHASE; BARRIER BREAKDOWN; CDP-CHOLINE; CITICOLINE; COMBINATION; ACTIVATION; DEFICITS; IMPACT; EDEMA	Object. In previous studies at their laboratory the authors showed that cytidinediphosphocholine (CDP-choline), an intermediate of phosphatidylcholine synthesis, decreases edema formation and blood-brain barrier disruption following traumatic brain injury (TBI). In the present study the authors investigate whether CDP-choline protects hippocampal neurons after controlled cortical impact (CCI)-induced TBI in adult rats. Methods. After adult male Sprague-Dawley rats had been anesthetized with halothane, a moderate-grade TBI was induced with the aid of a CCI device set at a velocity of 3 m/second, creating a 2-mm deformation. Sham-operated rats, which underwent craniectomy without impact served as controls. The CDP-choline (100, 200, and 400 mg/kg body weight) or saline was injected into the animals twice (once immediately postinjury and once 6 hours postinjury). Seven days after the injury, the rats were neurologically evaluated and killed, and the number of hippocampal neurons was estimated by examining thionine-stained brain sections. By 7 days postinjury, there was a significant amount of neuronal death in the ipsilateral hippocampus in the CA2 (by 53 +/- 7%, p < 0.05) and CA3 (by 59 +/- 9%, p < 0.05) regions and a contusion (volume 34 +/- 8 mm(3)) in the ipsilateral cortex compared with sham-operated control animals. Rats subjected to TBI also displayed severe neurological deficit at 7 days postinjury. Treating rats with CDP-choline (200 and 400 mg/kg, intraperitoneally) significantly prevented TBI-induced neuronal loss in the hippocampus, decreased cortical contusion volume, and improved neurological recovery. Conclusions. Treatment with CDP-choline decreased brain damage following TBI.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, K4-818 CSC,600 Highland Ave, Madison, WI 53792 USA.	Dempsey@neurosurg.wisc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28000, NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER		Adibhatla RM, 2002, J NEUROCHEM, V80, P12; Alkan T., 2001, Archives of Physiology and Biochemistry, V109, P161, DOI 10.1076/apab.109.2.161.4273; Andersen M, 1999, STROKE, V30, P1464, DOI 10.1161/01.STR.30.7.1464; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Bonventre JV, 1997, J LIPID MEDIAT CELL, V16, P199; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mukhin A, 1996, J NEUROSCI, V16, P6012; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.3.CO;2-2; RAO AM, 2001, STROKE, V32, P2376; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2001, BRAIN RES, V911, P96; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shuaib A, 2000, EXP NEUROL, V161, P733, DOI 10.1006/exnr.1999.7314; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	45	39	44	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2003	98	4					867	873		10.3171/jns.2003.98.4.0867			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	662AD	WOS:000181922400021	12691414				2021-06-18	
J	Regard, M; Knoch, D; Gutling, E; Landis, T				Regard, Marianne; Knoch, Daria; Guetling, Eva; Landis, Theodor			Brain Damage and Addictive Behavior: A Neuropsychological and Electroencephalogram Investigation With Pathologic Gamblers	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						Cerebral dysfunction; Impulse control disorder; Pathologic gambling		Background: Gambling is a form of nonsubstance addiction classified as an impulse control disorder. Pathologic gamblers are considered healthy with respect to their cognitive status. Lesions of the frontolimbic systems, mostly of the right hemisphere, are associated with addictive behavior. Because gamblers are not regarded as "brain-lesioned" and gambling is nontoxic, gambling is a model to test whether addicted "healthy" people are relatively impaired in frontolimbic neuropsychological functions. Methods: Twenty-one nonsubstance dependent gamblers and nineteen healthy subjects underwent a behavioral neurologic interview centered on incidence, origin, and symptoms of possible brain damage, a neuropsychological examination, and an electroencephalogram. Results: Seventeen gamblers (81%) had a positive medical history for brain damage (mainly traumatic head injury, pre- or perinatal complications). The gamblers, compared with the controls, were significantly more impaired in concentration, memory, and executive functions, and evidenced a higher prevalence of non-right-handedness (43%) and, non-left-hemisphere language dominance (52%). Electroencephalogram (EEG) revealed dysfunctional activity in 65% of the gamblers, compared with 26% of controls. Conclusions: This study shows that the "healthy" gamblers are indeed brain-damaged. Compared with a matched control population, pathologic gamblers evidenced more brain injuries, more fronto-temporo-limbic neuropsychological dysfunctions and more EEG abnormalities. The authors thus conjecture that addictive gambling may be a consequence of brain damage, especially of the frontolimbic systems, a finding that may well have medicolegal consequences.	[Regard, Marianne] Univ Zurich Hosp, Dept Neurol, Neuropsychol Unit, CH-8091 Zurich, Switzerland; Univ Hosp, Dept Neurol, Geneva, Switzerland	Regard, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Neuropsychol Unit, CH-8091 Zurich, Switzerland.	mregard@npsy.unizh.ch	Knoch, Daria/H-7324-2012		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32.40682.94]	The authors thank Drs. Maria Stegmann and Mario Gmur and Gambler's Anonymous, Zurich, Switzerland, for their help in assessing and recruiting subjects. This study was supported in part by the Swiss National Science Foundation grant No. 32.40682.94.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1690, DOI 10.1016/S0028-3932(02)00016-7; Brickenkamp R., 1981, TEST D2 AUFMERKSAMKE, V7th; CARLTON PL, 1992, NEUROPSYCHOBIOLOGY, V25, P44, DOI 10.1159/000118808; CARLTON PL, 1987, J CLIN PSYCHIAT, V48, P487; Cavedini P, 2002, BIOL PSYCHIAT, V51, P334, DOI 10.1016/S0006-3223(01)01227-6; CHAPMAN LJ, 1987, BRAIN COGNITION, V6, P175, DOI 10.1016/0278-2626(87)90118-7; Crockford DN, 1998, CAN J PSYCHIAT, V43, P43, DOI 10.1177/070674379804300104; Cummings JL, 1997, BRAIN LANG, V57, P22, DOI 10.1006/brln.1997.1832; De Marchi N, 1998, ACTA PSYCHIAT SCAND, V97, P62; GESCHWIND N, 1982, P NATL ACAD SCI-BIOL, V79, P5097, DOI 10.1073/pnas.79.16.5097; Glosser G, 2000, J NEUROL NEUROSUR PS, V68, P53, DOI 10.1136/jnnp.68.1.53; GOLDENBERG G, 1989, BEHAV NEUROL, V2, P79; GOLDSTEIN L, 1985, BIOL PSYCHIAT, V20, P1232, DOI 10.1016/0006-3223(85)90180-5; Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980; Knecht T, 1993, Arch Kriminol, V191, P65; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; Nyffeler T, 2001, NEUROPSY NEUROPSY BE, V14, P73; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Potenza M N, 2001, Semin Clin Neuropsychiatry, V6, P217, DOI 10.1053/scnp.2001.22929; Potenza MN, 2001, JAMA-J AM MED ASSOC, V286, P141, DOI 10.1001/jama.286.2.141; Rahman S, 1999, BRAIN, V122, P1469, DOI 10.1093/brain/122.8.1469; Regard M, 1997, NEUROLOGY, V48, P1185, DOI 10.1212/WNL.48.5.1185; REGARD M, 1994, NEUROPSY NEUROPSY BE, V7, P303; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; REGARD M, 1985, NEUROPSYCHOLOGIA, V23, P431, DOI 10.1016/0028-3932(85)90031-4; Regard M, 1983, THESIS, V43, P2714; Rosenberg DR, 1997, J PSYCHIATR NEUROSCI, V22, P29; Rosenthal R J, 1997, Psychoanal Rev, V84, P593; RUGLE L, 1993, J NERV MENT DIS, V181, P107, DOI 10.1097/00005053-199302000-00006; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Soutullo CA, 1998, PSYCHIAT ANN, V28, P592, DOI 10.3928/0048-5713-19981001-10; Specker S M, 1995, Ann Clin Psychiatry, V7, P175, DOI 10.3109/10401239509149623; Spreen O., 1998, COMPENDIUM NEUROPSYC; Trimble MR, 1997, J NEUROPSYCH CLIN N, V9, P429	40	39	42	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1543-3633			COGN BEHAV NEUROL	Cogn. Behav. Neurol.	MAR	2003	16	1					47	53		10.1097/00146965-200303000-00006			7	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	V21VM	WOS:000208235100006	14765001				2021-06-18	
J	Strauss, DJ; Day, SM; Shavelle, RM; Wu, YW				Strauss, DJ; Day, SM; Shavelle, RM; Wu, YW			Remote symptomatic epilepsy - Does seizure severity increase mortality?	NEUROLOGY			English	Article							LIFE EXPECTANCY; LONG-TERM; COHORT; CHILDREN; DEATH	Objective: To investigate the excess mortality due to remote symptomatic epilepsy, taking account of frequency and type of seizures. Methods: The authors compared mortality in persons with (n = 8,156) and without (n = 72,526) history of epilepsy in a 1988 to 1999 California population of persons with mild developmental disabilities. Subjects had traumatic brain injury, cerebral palsy, Down syndrome, autism, or no identifiable condition. There were 506,204 person-years of data, with 1,523 deaths. Excess death rates and standardized mortality ratios were computed for the persons in the study with epilepsy, relative to those in the study without epilepsy. Controlled comparisons were made using logistic regression on person-years. Results: Compared to subjects with no epilepsy, the excess mortality was six (deaths per 1,000 persons per year) for persons with a recent (<12 months) history of status epilepticus, five for a recent history of generalized tonic-clonic seizure, three for a recent history of nonconvulsive seizures, and less than one for a history of epilepsy but no recent events. Proportion in remission and excess mortality showed no change over the 12-year study period. Conclusions: Persistent seizures are associated with increased mortality in remote symptomatic epilepsy. Mortality is highest among individuals with status epilepticus or generalized convulsions.	Univ Calif San Francisco, Life Expectancy Project, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Day, SM (corresponding author), 1439 17th Ave, San Francisco, CA 94122 USA.		Day, Steven/P-1002-2019	Day, Steven/0000-0001-8305-5813; Day, Marc/0000-0002-1711-3963			AGRESTI A, 1990, CATEGORICAL DATA ANA, P366; ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; Bak S, 2000, Ugeskr Laeger, V162, P3578; Bell GS, 2001, SEIZURE-EUR J EPILEP, V10, P306, DOI 10.1053/seiz.2001.0584; BRACKENRIDGE RDC, 1998, MED SELECTION LIFE R; *CAL DEP DEV SERV, 1986, CLIENT DEV EV REP; *CIT ASS, 1998, IND EV DEP DEV SERV; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; *DEP HLTH SERV CTR, 1983, STAT CAL 1983 1997 A; HARRIS CW, 1982, INTERRATER RELIABILI; HARVEY AS, 1993, EPILEPSIA, V34, P597, DOI 10.1111/j.1528-1157.1993.tb00434.x; Kahn HA, 1989, STAT METHODS EPIDEMI, P97; Lew EA, 1990, MED RISKS TRENDS MOR; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lindsten H, 2000, EPILEPSIA, V41, P1469, DOI 10.1111/j.1528-1157.2000.tb00124.x; Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Olafsson E, 1998, EPILEPSIA, V39, P89, DOI 10.1111/j.1528-1157.1998.tb01279.x; PRESTON TW, 1965, J I ACTUARIES, V92, P27; Shackleton DP, 1999, J NEUROL NEUROSUR PS, V66, P636, DOI 10.1136/jnnp.66.5.636; Shackleton DP, 2002, EPILEPSIA, V43, P445, DOI 10.1046/j.1528-1157.2002.10301.x; Shinnar S, 2002, J CHILD NEUROL, V17, pS4, DOI 10.1177/08830738020170010201; *SOC ACT ASS LIF I, 1986, MED IMP STUD 1983, V1; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; *STAT CAL DEP FIN, 1988, STAT CAL DEP FIN RAC; Strauss D, 2000, J Insur Med, V32, P217; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; WIDAMANT KF, 1984, 92 ANN M AM PSYCH AS	33	39	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 11	2003	60	3					395	399		10.1212/WNL.60.3.395			5	Clinical Neurology	Neurosciences & Neurology	646BG	WOS:000181014500007	12578917				2021-06-18	
J	Cherian, L; Robertson, CS				Cherian, L; Robertson, CS			L-arginine and free radical scavengers increase cerebral blood flow and brain tissue nitric oxide concentrations after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						D-arginine; L-arginine; cortical impact injury; hypotension; intracranial hypertension; nitric oxide; superoxide dismutase; traumatic brain injury	SUPEROXIDE GENERATION; SYNTHASE; INHIBITION	To examine the mechanism of the increase in cerebral blood flow induced by L-arginine administration after traumatic brain injury, the cerebral hemodynamic effects Of L-arginine, D-arginine, and the free radical scavengers superoxide dismutase (SOD) and catalase were compared in the controlled cortical impact injury model in rats. Animals were anesthetized with isoflurane. Measured parameters included mean blood pressure, intracranial pressure, cerebral blood flow using laser Doppler flowmetry (LDF) and brain tissue nitric oxide (NO) concentrations using an NO electrode. L-arginine, but not D-arginine, administration resulted in a significant increase in tissue NO concentrations and an improvement in LDF at the impact site, compared to control animals given saline. Administration of SOD alone and in combination with catalase resulted in a significant increase in brain tissue NO concentrations. However, LDF was consistently improved only when both SOD and catalase were given. These studies support the theory that L-arginine administration improves post-traumatic cerebral blood flow by increasing NO production. Free radical production after trauma may also contribute to the reduction in CBF by inactivating NO.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	lcherian@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; KIMURA M, 1994, STROKE, V25, P2227, DOI 10.1161/01.STR.25.11.2227; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kontos HA, 1998, AM J PHYSIOL-HEART C, V274, pH974; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Rehman A, 1997, BRIT J PHARMACOL, V122, P1702, DOI 10.1038/sj.bjp.0701556; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	25	39	41	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2003	20	1					77	85		10.1089/08977150360517209			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	641BB	WOS:000180723200007	12614590				2021-06-18	
J	Pong, K; Zaleska, MM				Pong, Kevin; Zaleska, Margaret M.			Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; cerebral ischemia; immunophilin ligands; Parkinson's disease; neurodegeneration; spinal cord injury; traumatic brain injury		There is a significant unmet need for therapeutic agents in the treatment of neurodegenerative diseases. Given their clinical importance, prototypical molecules that clearly exhibit both neuroprotective and neuroregenerative activities have been highly sought after. The journey led to the exploitation of neurotrophins, a family of proteins that had extraordinary therapeutic properties in pre-clinical models of neurodegeneration. Although experimentally promising, clinical development of neurotrophins for various neurological indications, such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Parkinson's Disease was met with severe obstacles and setbacks, such as the inability to deliver these large proteins to target population of neurons, instability of the proteins, and non-specific activity. Immunophilins are proteins that act as receptors for immunosuppresant drugs, i.e. FK506 (tacrolimus), cyclosporin A, and rapamycin (sirolimus, Rapamune). Studies indicate immunophilins are expressed 10-100 fold higher in CNS and PNS tissue than in immune tissue. Subsequent studies revealed potent neuroprotective and neuroregenerative properties of immunophilin ligands in both culture and animal models. In contrast to neurotrophins, most immunophilin ligands are highly stable, small molecules that can readily cross the blood-brain barrier and are orally bioavailable. Taken together, these data prompted the development of nonimmunosuppressive immunophilin ligands with potent therapeutic activities, although the potency of select compounds has come into question in more recent studies. This review will examine the experimental evidence supporting the use of immunophilin ligands for the treatment of neurodegenerative diseases and the current progression of these molecules in clinical trials.	[Pong, Kevin; Zaleska, Margaret M.] Wyeth Res, Dept Neurosci, CN 8000, Princeton, NJ 84543 USA	Pong, K (corresponding author), Wyeth Res, Dept Neurosci, CN 8000, Princeton, NJ 84543 USA.	pongk@wyeth.com					Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Anneser JMH, 2001, NEUROREPORT, V12, P2663, DOI 10.1097/00001756-200108280-00015; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Becker DB, 2000, J RECONSTR MICROSURG, V16, P613, DOI 10.1055/s-2000-9379; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; Bocquet A, 2001, EUR J PHARMACOL, V415, P173, DOI 10.1016/S0014-2999(01)00850-0; Butcher SP, 1997, J NEUROSCI, V17, P6939; Carreau A, 1997, NEUROPHARMACOLOGY, V36, P1755, DOI 10.1016/S0028-3908(97)00160-3; Castilho RF, 2000, EXP NEUROL, V164, P94, DOI 10.1006/exnr.2000.7405; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 2000, NEUROSCIENCE, V100, P515, DOI 10.1016/S0306-4522(00)00312-2; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; Costantini LC, 2001, EUR J NEUROSCI, V13, P1085, DOI 10.1046/j.0953-816x.2001.01473.x; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Eberling JL, 2002, EXP NEUROL, V178, P236, DOI 10.1006/exnr.2002.8023; Emborg ME, 2001, EXP NEUROL, V168, P171, DOI 10.1006/exnr.2000.7592; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo X, 2001, ANN NEUROL, V50, P6, DOI 10.1002/ana.1030; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; Hamilton GS, 2002, J MED CHEM, V45, P3549, DOI 10.1021/jm010556c; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Harper S, 1999, NEUROSCIENCE, V88, P257, DOI 10.1016/S0306-4522(98)00221-8; Herr I, 1999, BRAIN RES, V826, P210, DOI 10.1016/S0006-8993(99)01288-3; Iwasaki Y, 2002, NEUROL RES, V24, P573, DOI 10.1179/016164102101200555; Kealey J.T, 2003, FRONT BIOSCI C, V8, P1; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Keswani SC, 2003, ANN NEUROL, V53, P57, DOI 10.1002/ana.10401; Khan Z, 2002, NEUROSCIENCE, V114, P601, DOI 10.1016/S0306-4522(02)00314-7; KITAMURA Y, 1994, J NEUROIMMUNOL, V50, P221; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Lench NJ, 1997, HUM GENET, V99, P547, DOI 10.1007/s004390050404; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Li PA, 2001, BRAIN RES, V890, P306, DOI 10.1016/S0006-8993(00)03179-6; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; LYONS WE, 1995, J NEUROSCI, V15, P2985; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Nakai A, 1997, NEUROBIOL DIS, V4, P288, DOI 10.1006/nbdi.1997.0146; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Parker EM, 2000, NEUROPHARMACOLOGY, V39, P1913, DOI 10.1016/S0028-3908(00)00028-9; Pong K, 2003, EXPERT OPIN BIOL TH, V3, P127; Revill WP, 2002, J PHARMACOL EXP THER, V302, P1278, DOI 10.1124/jpet.102.034264; Ross DT, 2001, NEUROSCI LETT, V297, P113, DOI 10.1016/S0304-3940(00)01683-9; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sauer H, 1999, BRAIN RES, V842, P109, DOI 10.1016/S0006-8993(99)01851-X; Sezen SF, 2001, NAT MED, V7, P1073, DOI 10.1038/nm1001-1073; Sharkey J, 1996, STROKE, V27, P2282, DOI 10.1161/01.STR.27.12.2282; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Shefner JM, 2001, NEUROLOGY, V57, P1857, DOI 10.1212/WNL.57.10.1857; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Shiraishi S, 2001, J PHARMACOL EXP THER, V297, P657; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Small SL, 1996, ANN NEUROL, V40, P575, DOI 10.1002/ana.410400406; Springer JE, 2000, J NEUROSCI, V20, P7246; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Sugawara T, 1999, NEUROREPORT, V10, P3949, DOI 10.1097/00001756-199912160-00041; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TALUKDER G, 1995, J NEUROPHYSIOL, V73, P73; Tanaka K, 2002, NEUROSCI LETT, V321, P45, DOI 10.1016/S0304-3940(01)02547-2; Tanaka K, 2002, NEUROSCI LETT, V330, P147, DOI 10.1016/S0304-3940(02)00755-3; Tanaka K, 2001, BRAIN RES, V889, P225, DOI 10.1016/S0006-8993(00)02851-1; Tanaka K, 2000, ACTA MED OKAYAMA, V54, P275; Tanaka KI, 2002, SYNAPSE, V43, P219, DOI 10.1002/syn.10031; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Terashima A, 1998, BRAIN RES, V786, P255, DOI 10.1016/S0006-8993(97)01435-2; Terashima A, 2000, NEUROPHARMACOLOGY, V39, P1920, DOI 10.1016/S0028-3908(00)00015-0; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang M S, 1999, J Spinal Cord Med, V22, P287; Wu YQ, 2002, J MED CHEM, V45, P3558, DOI 10.1021/jm0200456; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Zhang CY, 2001, J NEUROSCI, V21; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998	91	39	41	0	0	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2003	2	6					349	356		10.2174/1568007033482652			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5WX	WOS:000497811900001	14683462				2021-06-18	
J	Beukelman, DR; Fager, S; Ullman, C; Hanson, E; Logemann, J				Beukelman, DR; Fager, S; Ullman, C; Hanson, E; Logemann, J			The impact of speech supplementation and clear speech on the intelligibility and speaking rate of people with traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article; Proceedings Paper	Conference on Motor Speech	MAR 14-17, 2002	WILLIAMSBURG, VA				LINGUISTIC CUES	The purpose of this study was to investigate the differences in speech intelligibility and speaking rate for (a) habitual speech, (b) clear speech, (c) alphabet-supplemented speech, and (d) topic-supplemented speech. Eight people with severe dysarthria following traumatic brain injury participated in this project. Speakers were video recorded as they produced ten sentences under each of the four conditions. Five listeners transcribed each of the speech samples. The alphabet-supplemented speech intervention yielded significantly larger higher observed intelligibility scores than habitual speech, clear speech, topic-supplemented speech, or alphabet-supplemented habitual speech.	Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, Lincoln, NE USA; Amer Speech Language Hearing Assoc, Commun Sci & Disorders Clin Trials Res Grp, Rockville, MD USA	Beukelman, DR (corresponding author), Univ Nebraska, Barkley Mem Ctr 202, Lincoln, NE 68583 USA.	dbeukelman1@unl.edu					Ball LJ, 2001, J NEUROL SCI, V191, P43, DOI 10.1016/S0022-510X(01)00623-2; BEUKELMAN DR, 1977, J SPEECH HEAR DISORD, V42, P265, DOI 10.1044/jshd.4202.265; BEUKELMAN DR, 1979, J COMMUN DISORD, V12, P189, DOI 10.1016/0021-9924(79)90040-6; CROW E, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P99; DONGILLI P, 1994, MOTOR SPEECH DISORDE, P175; DOWDEN P, 1997, AUGMENTATIVE ALTERNA, V13; GIOLAS TG, 1963, J SPEECH HEAR RES, V6, P349, DOI 10.1044/jshr.0604.349; HAMMEN VL, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P43; Hustad KC, 2002, J SPEECH LANG HEAR R, V45, P545, DOI 10.1044/1092-4388(2002/043); Hustad KC, 2001, J SPEECH LANG HEAR R, V44, P497, DOI 10.1044/1092-4388(2001/039); LINDBLOM B, 1990, AAC (Augmentative and Alternative Communication), V6, P220, DOI 10.1080/07434619012331275504; MCHENRY MA, 1994, J MED SPEECH-LANG PA, V2, P59; MURDOCH BE, 1999, BRAIN DAM B, P211; NETSELL R, 1979, ARCH PHYS MED REHAB, V60, P502; NETSELL R, 1992, SPECIAL INTEREST DIV, V2, P1; NILSSON M, 1994, J ACOUST SOC AM, V95, P1085, DOI 10.1121/1.408469; PINCHEY M, 1989, J SPEECH HEAR RES, V32, P600; PINCHEY M, 1986, J SPEECH HEAR RES, V29, P434; Robin D., 1996, DISORDERS MOTOR SPEE, P67; YORKSTON K, 2000, AUGMENTATIVE ALTERNA; YORKSTON KM, 1991, COMMUNICATION DISORD, P251	21	39	39	0	11	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	DEC	2002	10	4					237	242					6	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	659LW	WOS:000181779000005					2021-06-18	
J	Irazuzta, JE; Pretzlaff, RK; Zingarelli, B; Xue, V; Zemlan, F				Irazuzta, JE; Pretzlaff, RK; Zingarelli, B; Xue, V; Zemlan, F			Modulation of nuclear factor-kappa B activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis	CRITICAL CARE MEDICINE			English	Article						hypothermia; meningitis; brain injury; nuclear factor-kappa B; critical care; cleaved tau protein; neurobehavioral performance; long-term outcome	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; CLEAVED TAU-PROTEIN; MONOCLONAL-ANTIBODIES; WATER-CONTENT; CELL-DEATH; RAT; DAMAGE; INDUCTION; TISSUE	Objective: This study was designed to evaluate the use of moderate hypothermia in a model of meningitis-induced brain injury and its effect on the activation of nuclear factor-kappaB, biological markers of neuronal injury, and neurobehavioral performance. Design: Randomized, prospective animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: Animals underwent a basilar cistern tap receiving either sterile saline as a placebo or an equivalent volume of a group B streptococcal suspension. Sixteen hours after inoculation, animals were stratified by their clinical severity score, were randomized to either hypothermic (32-34degreesC) or normothermic (37-39degreesC) conditions, and received antibiotics. Hypothermic animals were kept under these temperature conditions for 6 hrs before rewarming. Two protocols were used. For the first protocol, changes in nuclear factor-kappaB activation and heat shock protein induction at 24 firs and 48 hrs after inoculation were evaluated. In the second protocol, serum C-tau concentrations at 5 days and neurobehavioral performances at 3 wks were assessed. Measurements and Main Results. Meningitis triggered a > 50% increase in cerebral nuclear factor-kappaB activation. The addition of a 6-hr period of hypothermia reduced nuclear factor-kappaB activation by 32% when measured at the end of the hypothermic period. At 48 hrs, this decrease in nuclear factor-kappaB activation was no longer apparent, but there was a significant decrease in the heat shock response. Serum C-tau concentrations at 5 days postinjury, a biomarker of brain injury, were reduced by 69% in hypothermic treated animals. Furthermore, hypothermia reduced the brain water content of infected animals. However, hypothermia did not improve the animals' neurobehavioral performance. Conclusion: The findings from this study suggest that hypothermia produces a transitory attenuation of nuclear factor-kappaB activation in meningitic brain injury and improvement in some biomarkers, of neuronal injury. The consequence of intermittent suppression of nuclear factor-kappaB activation by inducing specific periods of hypothermia requires further study.	Tufts Univ, New England Med Ctr, Floating Hosp Children, Div Crit Care Med, Boston, MA 02111 USA; Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA	Irazuzta, JE (corresponding author), Tufts Univ, New England Med Ctr, Floating Hosp Children, Div Crit Care Med, Boston, MA 02111 USA.						Abraham E, 2000, CRIT CARE MED, V28, pN100, DOI 10.1097/00003246-200004001-00012; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Bethea JR, 1998, J NEUROSCI, V18, P3251; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Canevari L, 1999, BRAIN RES, V817, P241, DOI 10.1016/S0006-8993(98)01278-5; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DODGE PR, 1984, NEW ENGL J MED, V311, P869, DOI 10.1056/NEJM198410043111401; Engel JA, 2000, BRAIN RES, V863, P233, DOI 10.1016/S0006-8993(00)02149-1; Gideon P, 1999, MAGN RESON IMAGING, V17, P301, DOI 10.1016/S0730-725X(98)00161-1; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hu WX, 2000, BRAIN RES, V868, P370, DOI 10.1016/S0006-8993(00)02360-X; Irazuzta JE, 2000, LIFE SCI, V67, P365, DOI 10.1016/S0024-3205(00)00637-8; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; Irazuzta JE, 2001, BRAIN RES, V913, P95, DOI 10.1016/S0006-8993(01)02764-0; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Koedel U, 2000, J INFECT DIS, V182, P1437, DOI 10.1086/315877; KONKOL RJ, 1987, ANN NEUROL, V21, P353, DOI 10.1002/ana.410210407; KOSIK KS, 1987, J NEUROSCI, V7, P3142; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCALLISTER CK, 1975, J INFECT DIS, V132, P355, DOI 10.1093/infdis/132.4.355; Meager A, 1999, CYTOKINE GROWTH F R, V10, P27, DOI 10.1016/S1359-6101(98)00024-0; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; *NIH, 1996, GUID CAR US LAB AN; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; Rossi J, 2000, DRUG CHEM TOXICOL, V23, P113, DOI 10.1081/DCT-100100106; Rowin ME, 2001, INFLAMMATION, V25, P137, DOI 10.1023/A:1011044312536; SAEZLLORENS X, 1991, J CLIN INVEST, V88, P2003, DOI 10.1172/JCI115527; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; Schneider A, 1999, NAT MED, V5, P554; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; SLOVITER RS, 1992, J NEUROSCI, V12, P3004; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TAUBER MG, 1987, J INFECT DIS, V156, P456, DOI 10.1093/infdis/156.3.456; TAUBER MG, 1992, AM J PATHOL, V141, P53; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 1999, J NEUROCHEM, V73, P437; Zingarelli B, 2001, GUT, V48, P610, DOI 10.1136/gut.48.5.610; Zysk G, 1996, J NEUROPATH EXP NEUR, V55, P722, DOI 10.1097/00005072-199606000-00006	54	39	42	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2002	30	11					2553	2559		10.1097/00003246-200211000-00025			7	Critical Care Medicine	General & Internal Medicine	616UZ	WOS:000179322900024	12441769				2021-06-18	
J	Servadei, F; Verlicchi, A; Soldano, F; Zanotti, B; Piffer, S				Servadei, F; Verlicchi, A; Soldano, F; Zanotti, B; Piffer, S			Descriptive epidemiology of head injury in Romagna and Trentino	NEUROEPIDEMIOLOGY			English	Article						head injury; epidemiology; hospital registry; prevention; bicycles; road accidents; Italy	TRAUMATIC BRAIN INJURY; UNITED-STATES; POPULATION; TRENDS; FEATURES; COUNTY	We studied the occurrence of head injury in two different Italian regions: Romagna and Trentino. Both geographical areas attract large numbers of seasonal tourists. The study was carried out over 1 year (January 1, 1998 to December 31, 1998), prospectively in Romagna and retrospectively in Trentino because of their different head injury management protocols. The study was based on all admissions to hospital extracted by medical staff from the case records, and all cases were identified by the ICD-9 codes (ranges: 800.0-800.3, 801.0-801.3, 803.0-803.3, 850, 851.0-851.1, 852.0-852.1, 853.0-853.1, 854.0-854.1). The annual incidence of hospitalization for head injury was 314/100,000, 297 for Romagna and 332 for Trentino. The causes of head trauma and the type of injuries were similar to those reported in the international literature, and so were the characteristics of the population at risk. Romagna recorded a higher incidence of head injury among the elderly, probably due to the widespread use of bicycles without safety helmets. In Romagna, where neurosurgery departments exist, hospital mortality was low (8/100,000/year). Based on similar international literature findings, different prevention measures are suggested to reduce the occurrence and severity of head injury. Copyright (C) 2002 S. Karger AG, Basel.	Maurizio Bufalini Hosp, Div Neurotraumatol, I-47023 Cesena, Italy; Santa Chiara Hosp, Div Neurol, Trento, Italy; Azienda Provinciale Serv Sanitari, Observ Epidemiol, Trent, Italy; Univ Udine, Fac Med, Dept Med Stat, I-33100 Udine, Italy; Santa Maria Misericordia Hosp, Div Neurosurg, Udine, Italy; Borgo Trento City Hosp, Dept Neurosurg, Verona, Italy	Servadei, F (corresponding author), Maurizio Bufalini Hosp, Div Neurotraumatol, I-47023 Cesena, Italy.			Servadei, Franco/0000-0002-3595-3464			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; BAKER SP, 1984, INJURY FACT BOOK, P27; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GRAHAM D, 1986, SERIES, V13; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hillier SL, 1997, BRAIN INJURY, V11, P649; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; MacKenzie E J, 1989, Md Med J, V38, P725; MCSWAIN NE, 1984, J TRAUMA, V24, P233, DOI 10.1097/00005373-198403000-00009; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; Servadei F, 1985, J Neurosurg Sci, V29, P297; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; SERVADEI F, 1993, PROF SANIT PUBBLICA, V2, P50; SERVADEI F, 1993, TRAUMI RICERCA PREVE, P39; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1997, INCIDENTALITA STRADA; 1990, CONSUMER REP, V55, P348	35	39	40	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350			NEUROEPIDEMIOLOGY	Neuroepidemiology	NOV-DEC	2002	21	6					297	304		10.1159/000065523			8	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	616DX	WOS:000179287400006	12411733				2021-06-18	
J	Hinton-Bayre, AD; Geffen, G				Hinton-Bayre, AD; Geffen, G			Severity of sports-related concussion and neuropsychological test performance	NEUROLOGY			English	Article								Concussion severity grades according to the Cantu, Colorado Medical Society, and American Academy of Neurology systems were not clearly related to the presence or duration of impaired neuropsychological test performance in 21 professional rugby league athletes. The use of concussion severity guidelines and neuropsychological testing to assist return to play decisions requires further investigation.	Griffith Univ, Sch Appl Psychol, Nathan, Qld, Australia; Univ Queensland, Cognit Psychophysiol Lab, Brisbane, Qld, Australia	Hinton-Bayre, AD (corresponding author), Univ Queensland, Sch Med, CPL Edith Cavell Bldg, Herston, Qld 4006, Australia.						CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colorado Medical Society, 1990, REP SPORTS MED COMM; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Kelly JP, 1997, NEUROLOGY, V48, P581; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068	8	39	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	OCT 8	2002	59	7					1068	1070		10.1212/WNL.59.7.1068			3	Clinical Neurology	Neurosciences & Neurology	601HP	WOS:000178440600019	12370464				2021-06-18	
J	Kinoshita, K; Chatzipanteli, K; Alonso, OF; Howard, M; Dietrich, WD				Kinoshita, K; Chatzipanteli, K; Alonso, OF; Howard, M; Dietrich, WD			The effect of brain temperature on hemoglobin extravasation after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						hemoglobin; traumatic brain injury; hypothermia; hyperthermia; secondary injury; rat	CORTICAL IMPACT INJURY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; PERMEABILITY CHANGES; BARRIER DISRUPTION	Object. Although the benefits of posttraumatic hypothermia have been reported in experimental studies, the potential for therapeutic hypothermia to increase intracerebral hemorrhage remains a clinical concern. The purpose of this study was to quantify the amount of extravasated hemoglobin after traumatic brain injury (TBI) and to assess the charges in intracerebral hemoglobin concentrations under posttraumatic hypothermic and hyperthermic conditions. Methods. Intubated and anesthetized rats were subjected to fluid-percussion injury (FPI). In the first experiment, rats were divided into moderate (1.8-2.2 atm) and severe (2.4-2.7 arm) TBI groups. In the second experiment, the effects of 3 hours of posttraumatic hypothermia (33 or 30degreesC), hyperthermia (39degreesC), or normothermia (37degreesC) on hemoglobin levels following moderate trauma were assessed. The rats were pet-fused with saline at 24 hours postinjury, and then the traumatized and contralateral hemispheres, including the cerebellum, were dissected from whole brain. The hemoglobin level in each brain was quantified using a spectrophotometric hemoglobin assay. The results of these assays indicate that moderate and severe FPI induce increased levels of hemoglobin in the ipsilateral hemisphere (p < 0.0001). After severe TBI, the hemoglobin concentration was also significantly increased in the contralateral hemisphere (p < 0.05) and cerebellum (p < 0.005). Posttraumatic hypothermia (30degreesC) attenuated hemoglobin levels (p < 0.005) in the ipsilateral hemisphere, %vhcreas hyperthermia had a marked adverse effect on the hemoglobin concentration in the contralateral hemisphere (p < 0.05) and cerebellum (p < 0.005). Conclusions. Injury severity is an important determinant of the degree of hemoglobin extravasation after TBI. Posttraumatic hypothermia reduced hemoglobin extravasation, whereas hyperthermia increased hemoglobin levels compared with normothermia. These findings are consistent with previous data reporting that posttraumatic temperature manipulations alter the cerebrovascular and inflammatory consequences of TBI.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, POB 016960, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; ELSABBAN F, 1995, INT J BIOMETEOROL, V38, P92, DOI 10.1007/BF01270666; FAHIM MA, 1995, ANAT REC, V242, P77, DOI 10.1002/ar.1092420110; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; JENKINS A, 1989, NEUROPATH APPL NEURO, V15, P477, DOI 10.1111/j.1365-2990.1989.tb01247.x; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kazui S, 1997, STROKE, V28, P2370, DOI 10.1161/01.STR.28.12.2370; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Klatzo I, 1969, Clin Neurosurg, V16, P472; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Krause KR, 2000, AM SURGEON, V66, P348; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MURRAY J, 1999, TRAUMA SCI BASIC CAR, P122; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PATT A, 1988, SURG CLIN N AM, V68, P775; Peng ZC, 1997, BRAIN RES BULL, V42, P119, DOI 10.1016/S0361-9230(96)00206-7; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; REED RL, 1990, CIRC SHOCK, V32, P141; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sagher O, 1997, J NEUROSURG, V87, P431, DOI 10.3171/jns.1997.87.3.0431; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SOKRAB TEO, 1988, ACTA NEUROPATHOL, V75, P557, DOI 10.1007/BF00686200; SPEZIALI G, 1994, J SURG RES, V57, P80, DOI 10.1006/jsre.1994.1114; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zilles K., 1985, CORTEX RAT STEREOTAX	77	39	40	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2002	97	4					945	953		10.3171/jns.2002.97.4.0945			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	604MY	WOS:000178626400035	12405386				2021-06-18	
J	McCarthy, ML; Serpi, T; Kufera, JA; Demeter, LA; Paidas, C				McCarthy, ML; Serpi, T; Kufera, JA; Demeter, LA; Paidas, C			Factors influencing admission among children with a traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article						admission; emergency department; pediatric; traumatic brain injury; children	CLOSED HEAD-INJURY; UNITED-STATES; HOSPITAL ADMISSION; INSURANCE STATUS; MYOCARDIAL-INFARCTION; INTELLECTUAL ABILITY; HEALTH-INSURANCE; SEVERITY SCORE; CARE; EMERGENCY	Objectives: To describe the epidemiology of traumatic brain injury (TBI) among children in Maryland and to examine factors that influence hospital admission. Methods: Statewide mortality, hospital discharge, and ambulatory care data were used to identify all TBI-related emergency department (ED) visits, hospitalizations, and deaths that occurred in 1998 to children aged 0-19 years according to the Centers for Disease Control and Prevention's standard case definition and protocol. Inpatient admission was modeled as a function of patient, injury, and hospital characteristics. Results: The overall incidence of pediatric TBI (i.e., ED visits, hospitalizations, and deaths) in 1998 was 670/100,000. After controlling for injury severity and other factors, uninsured children were 40% less likely to be hospitalized (95% CI = 0.43 to 0.82) and children with Medicaid were 90% more likely to be hospitalized (95% CI = 1.42 to 2.54) than were those with private insurance. The presence of a major associated injury significantly influenced the likelihood of hospitalization, especially among children with a minor (OR = 8.8) to moderate (OR = 11.6) TBI. Children who presented to a trauma center hospital were significantly more likely to be hospitalized than children treated at a non-trauma center hospital, although this varied depending on income (OR = 1.8 for high versus low) and hospital volume (OR = 2.6 for a small hospital and OR = 29.0 for a large hospital). Conclusions: After adjusting for TBI severity and the presence of associated injuries, significant differences in hospitalization rates may exist among different patient subgroups and hospitals for children who sustain TBIs. Key words: admission; emergency department pediatric; traumatic brain injury; children.	Johns Hopkins Univ, Dept Emergency Med, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Surg, Sch Med, Baltimore, MD 21205 USA; Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA; Natl Study Ctr Trauma & Emergency Med Syst, Baltimore, MD USA	McCarthy, ML (corresponding author), Johns Hopkins Univ, Dept Emergency Med, Sch Med, Suite 6-102,1830 E Monument St, Baltimore, MD 21205 USA.				ODCDC CDC HHS [U17/CCU314059-03] Funding Source: Medline		*ASS ADV AUT MED, 1974, INJ SEV SCOR DEV POT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Best A E, 1999, J Med Syst, V23, P175, DOI 10.1023/A:1020515419714; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BULL JP, 1975, ACCIDENT ANAL PREV, V7, P249, DOI 10.1016/0001-4575(75)90026-3; Byck GR, 2000, PEDIATRICS, V106, P14, DOI 10.1542/peds.106.1.14; CASEY R, 1986, PEDIATRICS, V78, P497; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; COOPER A, 1992, J PEDIATR SURG, V27, P149, DOI 10.1016/0022-3468(92)90303-O; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; DUNN KA, 1999, REPORT CONSENSUS DEV, P1; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; GREEN LA, 1994, MED CARE, V32, P1086, DOI 10.1097/00005650-199411000-00002; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Halm EA, 2000, ARCH INTERN MED, V160, P98, DOI 10.1001/archinte.160.1.98; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kerr E A, 1993, J Health Care Poor Underserved, V4, P133; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Krug SE, 1997, PEDIATR EMERG CARE, V13, P87, DOI 10.1097/00006565-199704000-00001; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MacKenzie E J, 1989, Md Med J, V38, P725; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mayberry RM, 2000, MED CARE RES REV, V57, P108, DOI 10.1177/107755800773743628; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; McBean A M, 1994, Health Care Financ Rev, V15, P77; McCarthy ML, 2001, ACCIDENT ANAL PREV, V33, P821, DOI 10.1016/S0001-4575(00)00096-8; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; PEARSON SD, 1994, HEALTH SERV RES, V29, P59; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P25; Poole GV, 1996, J TRAUMA, V40, P951, DOI 10.1097/00005373-199606000-00014; RUNYAN CW, 1985, AM J PUBLIC HEALTH, V75, P1429, DOI 10.2105/AJPH.75.12.1429; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sox CM, 1998, AM J MED, V105, P506, DOI 10.1016/S0002-9343(98)00324-6; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; Thomas SHL, 1996, HUM EXP TOXICOL, V15, P915, DOI 10.1177/096032719601501109; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Weinick RM, 1998, HEALTH AFFAIR, V17, P127, DOI 10.1377/hlthaff.17.2.127; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1995, TRAUMATIC HEAD INJUR	56	39	39	0	7	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUL	2002	9	7					684	693					10	Emergency Medicine	Emergency Medicine	569VN	WOS:000176623200004	12093708				2021-06-18	
J	Ciccone, AM; Stewart, KC; Meyers, BF; Guthrie, TJ; Battafarano, RJ; Trulock, EP; Cooper, JD; Patterson, GA				Ciccone, AM; Stewart, KC; Meyers, BF; Guthrie, TJ; Battafarano, RJ; Trulock, EP; Cooper, JD; Patterson, GA			Does donor cause of death affect the outcome of lung transplantation?	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Article; Proceedings Paper	81st Annual Meeting of the American-Association-for-Thoracic-Surgery	MAY 06-09, 2001	SAN DIEGO, CALIFORNIA	Amer Assoc Thorac Surg			BRAIN-DEATH; SURVIVAL; BRONCHIOLITIS; DYSFUNCTION; ALLOGRAFTS; REJECTION; EMBOLI; RAT	Background: Accumulating evidence suggests that the donor's cause of death may influence posttransplantation allograft function. We conducted a retrospective analysis of our adult lung transplant experience to investigate the influence of donor traumatic brain injury versus nontraumatic brain injury on posttransplantation outcome. Methods: We retrospectively reviewed donor records and recipient medical charts for 500 consecutive lung transplants performed between July 1988 and December 1999. Recipient follow-up was complete, with a minimum follow-up of 1 year of survival. Results: There were 295 and 205 donors in the traumatic and nontraumatic brain injury groups, respectively. Young male donors predominated in the traumatic brain injury group. Recipients receiving donor lungs from the traumatic and nontraumatic brain injury groups did not differ by age, sex, diagnosis, type of transplant (single-lung versus double-lung) or requirement for pretransplantation mechanical ventilatory assistance. Recipients did not differ in immediate or 24-hour PaO2/inspired oxygen ratio, ventilation time, hospital stay, hospital mortality, or overall survival. Recipients of organs from donors who died of traumatic brain injury showed a higher severity and frequency of rejection episodes during the first year after transplantation. Freedoms from bronchiolitis obliterans syndrome at 5 years were 34.5% and 50.8% for recipients of organs from donors who died of traumatic and nontraumatic brain injury, respectively (P =.002). Conclusions: The cause of donor brain death does not appear to influence early results of lung transplantation. Traumatic brain injury, or some phenomenon associated with it, may predispose a transplanted lung and its recipient toward more severe early rejection episodes and subsequent development of bronchiolitis obliterans syndrome.	Washington Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Pulm Med, St Louis, MO 63110 USA	Patterson, GA (corresponding author), 1 Barnes Jewish Plaza,3108 Queeny Tower, St Louis, MO 63110 USA.						BANDO K, 1995, J THORAC CARDIOV SUR, V110, P4, DOI 10.1016/S0022-5223(05)80003-0; BUSSON M, 1995, TRANSPLANT P, V27, P1662; COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P713; Meyers B F, 1998, Semin Thorac Cardiovasc Surg, V10, P213; Meyers BF, 1999, ANN SURG, V230, P362, DOI 10.1097/00000658-199909000-00009; Meyers BF, 1999, J THORAC CARDIOV SUR, V117, P358, DOI 10.1016/S0022-5223(99)70434-4; Novick RJ, 1999, J HEART LUNG TRANSPL, V18, P425, DOI 10.1016/S1053-2498(98)00057-6; NOVITSKY D, 1984, HEART TRANSPLANT, V4, P63; Novitzky D, 1997, TRANSPLANT P, V29, P3770, DOI 10.1016/S0041-1345(97)01149-4; Pratschke J, 1999, TRANSPLANT P, V31, P874, DOI 10.1016/S0041-1345(98)01813-2; ROSENDALE BE, 1992, J HEART LUNG TRANSPL, V11, P72; SHANLIN RJ, 1988, J AM COLL CARDIOL, V12, P727, DOI 10.1016/S0735-1097(88)80065-2; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Simonetti VA, 1998, CLIN TRANSPLANT, V12, P504; Smith MA, 1998, J THORAC CARDIOV SUR, V116, P812, DOI 10.1016/S0022-5223(98)00444-9; SUNDARESAN S, 1995, J THORAC CARDIOV SUR, V109, P1075, DOI 10.1016/S0022-5223(95)70190-7; SUNDARESAN S, 1993, ANN THORAC SURG, V56, P1409, DOI 10.1016/0003-4975(93)90699-I; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001; Varela A, 1997, J THORAC CARDIOV SUR, V114, P1119, DOI 10.1016/S0022-5223(97)70029-1; WALLER DA, 1995, J HEART LUNG TRANSPL, V14, P318; Yousem SA, 1996, J HEART LUNG TRANSPL, V15, P1	24	39	39	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0022-5223			J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	MAR	2002	123	3					429	436		10.1067/mtc.2002.120732			8	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	531TV	WOS:000174434100007	11882812				2021-06-18	
J	Worrall, L; McCooey, R; Davidson, B; Larkins, B; Hickson, L				Worrall, L; McCooey, R; Davidson, B; Larkins, B; Hickson, L			The validity of functional assessments of communication and the Activity/Participation components of the ICIDH-2: do they reflect what really happens in real-life?	JOURNAL OF COMMUNICATION DISORDERS			English	Article						functional communication; ICIDH-2; functional assessment; functional treatment of aphasia	APHASIA; PERSPECTIVE	This paper aims to provide a better understanding of the nature of functional communication activities so that assessment and treatment efforts are based on a theoretical framework and empirical data, Three sources of information are discussed. The first is the Activity/Participation dimensions of the World Health Organization's International Classification of Functioning, Disability, and Health. The second source is existing assessments of functional communication. The final source is data obtained from observational studies conducted in our research unit. The studies have observed the everyday communication of people with aphasia, people with Traumatic Brain Injury (TBI), and patients in hospital. The simplification of real-life communication in the WHO classification scheme, the variability of item sampling in existing assessments, and the complexity of communication observed in real-life settings has led to the conclusion that there are three levels of functional communication assessment: generic, population-specific, and individualized. Clinicians may choose which level suits their purpose. When clinicians routinely choose from a range of sophisticated functional assessments to inform their therapy, the seed that Martha Taylor Sarno planted and nourished for the past 30 years or more will truly flourish throughout the world of speech-language pathology. Learning outcomes: As a result of this activity, participants will (1) understand the theoretical framework and data base that motivates assessment and treatment of functional communication activities, (2) be able to discuss the World Health Organization's Classification of Functioning, Disability and Health and (3) gain information about functional assessment and observational sampling of real world communication activities across three levels. (C) 2002 Elsevier Science Inc. All rights reserved.	Univ Queensland, Dept Speech Pathol & Audiol, Commun Disabil Ageing Res Unit, Brisbane, Qld 4072, Australia	Worrall, L (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Commun Disabil Ageing Res Unit, Brisbane, Qld 4072, Australia.		Davidson, Bronwyn/F-8741-2010; Worrall, Linda/D-2579-2010; Hickson, Louise MH/F-8748-2010	Worrall, Linda/0000-0002-3283-7038; Hickson, Louise MH/0000-0001-6832-4173; O'Halloran, Robyn/0000-0002-2772-2164			*AM SPEECH LANG HE, 2001, SCOP PRACT SPEECH LA; BAKERR, 2000, NEUROGENIC COMMUNICA, P81; CAREY R, 1990, ADV CLIN REHABILITAT, V3, P217; DAVIDSON B, 1998, 8 INT APH REH C KWA; Davidson B, 2000, NEUROGENIC COMMUNICA, P19; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; Enderby P. M., 2000, NEUROGENIC COMMUNICA, P247; Fratalli C., 2000, NEUROGENIC COMMUNICA; Frattali C M, 1993, Disabil Rehabil, V15, P1; FRATTALI CM, 1992, APHASIOLOGY, V6, P63, DOI 10.1080/02687039208248577; Frattali CM., 1998, MEASURING OUTCOMES S; Frattali CM, 1995, AM SPEECH LANGUAGE H; FRATTALI CM, 2000, NEUROGENIC COMMUNICA, P67; Holland A., 1998, COMMUNICATION ACTIVI; Holland A, 1980, COMMUNICATIVE ABILIT; Holmes J., 1992, INTRO SOCIOLINGUISTI; Hustad Katherine C., 1998, Seminars in Speech and Language, V19, P291, DOI 10.1055/s-2008-1064051; JORDAN L, 1996, ASPHASIA SOCIAL APPR; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Larkins B., 2000, NEUROGENIC COMMUNICA, P206; LEDORZE G, 1995, APHASIOLOGY, V9, P239; LOMAS J, 1989, J SPEECH HEAR DISORD, V54, P113, DOI 10.1044/jshd.5401.113; McDowell I, 1996, MEASURING HLTH GUIDE; PARR S, 2000, NEUROGENIC COMMUNICA, P55; Pye D. J., 2000, NEUROGENIC COMMUNICA, P312; Rogers M A, 1999, Phys Med Rehabil Clin N Am, V10, P907; Sarno M, 1969, FUNCTIONAL COMMUNICA; SimmonsMackie NN, 1996, DISABIL REHABIL, V18, P540, DOI 10.3109/09638289609166315; Spradley J.P., 1980, PARTICIPANT OBSERVAT; TOFFOLO D, 1995, AUSTR ASS SPEECH HEA; *WHO, 1997, ICIDH 2 INT CLASS IM; World Health Organization, 2000, INT CLASS FUNCT DIS; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS; WORRALL L, 1992, APHASIOLOGY, V6, P105, DOI 10.1080/02687039208248581; WORRALL L, 1995, TREATMENT APHASIA TH, P47; WORRALL L, 1999, 2000 EMBRACING CHANG, P5; WORRALL L, 1999, FUNCTIONAL COMMUNICA	38	39	43	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	MAR-APR	2002	35	2					107	137	PII S0021-9924(02)00060-6	10.1016/S0021-9924(02)00060-6			31	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	553BE	WOS:000175655000003	12036147				2021-06-18	
J	Deutsch, A; Fiedler, RC; Granger, CV; Russell, CF				Deutsch, A; Fiedler, RC; Granger, CV; Russell, CF			The Uniform Data System for Medical Rehabilitation report of patients discharged from comprehensive medical rehabilitation programs in 1999	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						activities of daily living; functional assessment; disability evaluation; rehabilitation	FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN INJURY; FIRST ADMISSIONS; ASSESSMENT SCALES; 1ST ADMISSIONS; RELIABILITY; STROKE; VALIDITY; FIM	This is the 10th annual report describing patients discharged from comprehensive medical rehabilitation programs in the United States that subscribe to the Uniform Data System for Medical Rehabilitation. The analysis included 298,973 complete records of first admission cases discharged alive from 676 facilities in 1999. The data show that patients receiving care in comprehensive rehabilitation programs show measurable functional improvement and that a high percentage of patients are discharged to community-based settings.	SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, Buffalo, NY 14214 USA	Deutsch, A (corresponding author), SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, 232 Parker Hall,3435 Main St, Buffalo, NY 14214 USA.			Deutsch, Anne/0000-0003-2290-7757			*CARF REH ACCR COM, 1999, 1999 MED REH STAND M; CARTER GM, 2000, WORK PLAN INPATIENT; CARTER GM, 1997, PATIENT CLASSIFICATI; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Deutsch A, 1996, CRIT REV PHYS REHABI, V8, P267; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fiedler RC, 1997, AM J PHYS MED REHAB, V76, P76, DOI 10.1097/00002060-199701000-00017; Fiedler RC, 1996, AM J PHYS MED REHAB, V75, P125, DOI 10.1097/00002060-199603000-00010; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P69, DOI 10.1097/00002060-199801000-00013; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1992, STROKE, V23, P978, DOI 10.1161/01.STR.23.7.978; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P62, DOI 10.1097/00002060-199501000-00011; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P52, DOI 10.1016/S0003-9993(98)90208-8; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; Hamilton BB, 1999, ARCH PHYS MED REHAB, V80, P385, DOI 10.1016/S0003-9993(99)90274-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; *HLTH CARE FIN ADM, 2000, 1999 HCFA STAT; Iwanenko W, 2001, AM J PHYS MED REHAB, V80, P56, DOI 10.1097/00002060-200101000-00014; Iwanenko W, 1999, AM J PHYS MED REHAB, V78, P384, DOI 10.1097/00002060-199907000-00020; *JOINT COMM ACCR H, 2001, LIST PERF MEAS SYST; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; ROTH E, 1990, CLIN REHABIL, V4, P277, DOI DOI 10.1177/026921559000400405; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; Stineman MG, 1997, ARCH PHYS MED REHAB, V78, P980, DOI 10.1016/S0003-9993(97)90061-7; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; *SUNY BUFF, 1996, GUID UN DAT SET MED; *SUNY BUFF, 1996, GETT START UN DAT SY; Turpin RS, 1997, AM J PHYS MED REHAB, V76, P138, DOI 10.1097/00002060-199703000-00010	37	39	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2002	81	2					133	142		10.1097/00002060-200202000-00010			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	515GJ	WOS:000173486800009	11807350				2021-06-18	
J	Vasa, RA; Gerring, JP; Grados, M; Slomine, B; Christensen, JR; Rising, W; Denckla, MB; Riddle, MA				Vasa, RA; Gerring, JP; Grados, M; Slomine, B; Christensen, JR; Rising, W; Denckla, MB; Riddle, MA			Anxiety after severe pediatric closed head injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						closed head injury; anxiety	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ATTENTION-DEFICIT; CHILDREN; ADOLESCENTS; COMA	Objective: To assess the frequency of anxiety symptoms and disorders 1 year after severe pediatric closed head injury (CHI) and to determine the risk factors associated with these postinjury outcomes. Method: Ninety-seven subjects were prospectively followed for 1 year after severe CHI (Glasgow Coma Scale Score = 3-8). Assessments of preinjury and 1 year postinjury psychiatric status and psychosocial adversity were conducted. Frequency of anxiety symptoms and disorders 1 year after injury were the outcome measures. Data collection occurred between 1992 and 1996. Results: There was a significant increase in the total number of anxiety symptoms after injury compared with before injury. The most frequent symptoms were overanxious symptoms, followed by obsessive-compulsive symptoms, separation anxiety symptoms, and simple phobia symptoms. There was a trend toward an increase in the frequency of overanxious disorder after injury. Preinjury anxiety symptoms correlated positively with postinjury anxiety symptoms and disorders, Younger age at injury correlated positively with postinjury anxiety symptoms. Conclusions: One year after severe CHI, children are at risk for a variety of anxiety symptoms and, possibly, overanxious disorder. Preinjury anxiety and younger age at injury are risk factors for these disturbances.	Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA	Vasa, RA (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	vasa@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO-RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		Blacker D., 2000, HDB PSYCHIAT MEASURE, P7; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Costello E. Jane, 1995, P109; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P1569, DOI 10.1097/00004583-199912000-00019; Last CG, 1996, J AM ACAD CHILD PSY, V35, P1502, DOI 10.1097/00004583-199611000-00019; LAST CG, 1987, AM J PSYCHIAT, V144, P1580; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; REEVES JC, 1987, J AM ACAD CHILD PSY, V26, P144, DOI 10.1097/00004583-198703000-00004; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Sattler J. M., 1992, ASSESSMENT CHILDREN; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; TEASDALE G, 1974, LANCET, V2, P81; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	24	39	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	FEB	2002	41	2					148	156		10.1097/00004583-200202000-00008			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	514PZ	WOS:000173451400008	11837404				2021-06-18	
J	Thomas, SH; Orf, J; Wedel, SK; Conn, AK				Thomas, SH; Orf, J; Wedel, SK; Conn, AK			Hyperventilation in traumatic brain injury patients: Inconsistency between consensus guidelines and clinical practice	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	30th International Educational and Scientific Symposium of the Society-for-Critical-Care-Medicine	FEB 11-14, 2001	SAN FRANCISCO, CA	Soc Crit Care Med		traumatic brain injury; hyperventilation; hypocarbia	CEREBRAL-BLOOD-FLOW; TIDAL CARBON-DIOXIDE; SEVERE HEAD-INJURY; INTRAHOSPITAL TRANSPORT; HEMORRHAGIC-SHOCK; CAPNOGRAPHY; OXYGENATION; DIFFERENCE; METABOLISM; COMATOSE	Background: This study assessed patients with traumatic brain injury (TBI) to determine whether prehospital and community hospital providers employed hyperventilation therapy inconsistent with consensus recommendation against its routine use. Methods: This prospective analysis of 37 intubated TBI patients without herniation, undergoing helicopter transport to an urban Level I center, entailed flight crews' noting of assisted ventilation rate (AVR) and end-tidal carbon dioxide (ETco(2)) upon their arrival at trauma scenes or community hospitals. A priori-set levels of AVR and ETco(2) were used to assess frequency of guideline-inconsistent hyperventilation, and Fisher's exact and Kruskal-Wallis tests assessed association between guideline-inconsistent hyperventilation and manual vs. mechanical ventilation mode. Results: Inappropriately high AVR and low ETco(2) were seen in 60% and 70% of patients, respectively. Manual ventilation was associated with guideline-inconsistent hyperventilation assessed by AVR (p = 0.038) and ETco(2) (p = 0.022). Conclusion: Prehospital and community hospital hyperventilation practices are not consistent with consensus recommendations for limitation of hyperventilation therapy.	Massachusetts Gen Hosp, Dept Emergency Serv, Boston MedFlight Crit Care Transport Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA; Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA; Boston Med Ctr, Boston, MA 02118 USA	Thomas, SH (corresponding author), Massachusetts Gen Hosp, Dept Emergency Serv, Boston MedFlight Crit Care Transport Serv, MGH Clin Bldg,Room 115,55 Fruit St, Boston, MA 02114 USA.	thomas.stephen@mgh.harvard.edu		Thomas, Stephen/0000-0003-4153-3965			BHAVANISHANKAR K, 1992, CAN J ANAESTH, V8, P139; Bhende M, 1999, PEDIATR EMERG CARE, V15, P64, DOI 10.1097/00006565-199902000-00019; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BURROWS FA, 1989, ANESTHESIOLOGY, V70, P219, DOI 10.1097/00000542-198902000-00007; FORTUNE JB, 1995, J TRAUMA, V39, P463; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SANTHI PB, 1994, SOLVENT EXTR ION EXC, V12, P633, DOI 10.1080/07366299408918229; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Tobias JD, 1999, PEDIATR EMERG CARE, V15, P173, DOI 10.1097/00006565-199906000-00002; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; WEINER DL, 2000, TXB PEDIAT EMERGENCY, P553; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	29	39	39	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2002	52	1					47	52		10.1097/00005373-200201000-00010			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	514PF	WOS:000173449700010	11791051				2021-06-18	
J	Mori, T; Wang, XY; Kline, AE; Siao, CJ; Dixon, CE; Tsirka, SE; Lo, EH				Mori, T; Wang, XY; Kline, AE; Siao, CJ; Dixon, CE; Tsirka, SE; Lo, EH			Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma	NEUROREPORT			English	Article						blood-brain barrier; brain edema; extracellular matrix; neuroprotection; proteolysis	FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; NEURONAL DEATH; GENE; MATRIX-METALLOPROTEINASE-9; HIPPOCAMPUS; APOPTOSIS; SEIZURE; DAMAGE; STROKE	Tissue plasminogen activator (tPA) may play a deleterious role after brain injury. Here, we compared the response to traumatic brain injury in tPA knockout (KO) and wildtype (WT) mice after controlled cortical impact. At 6 h after trauma, blood-brain barrier permeability was equally increased in all mice. However, by 24 h specific gravity measurements of brain edema were significantly worse in WT mice than in KO mice. At 1 and 2 days post-trauma, mice showed deficits in rotarod performance, but by day 7 all mice recovered motor function and there were no differences between WT and KO mice. At 7 days, cortical lesion volumes were significantly reduced in KO mice compared with WT mice. However, there were no significant differences: in CA3 hippocampal neuron survival. These data suggest that tPA amplifies cortical brain damage and edema in this mouse model of traumatic brain injury. NeuroReport 12:4117-4120 (C) 2001 Lippincott Williams & Wilkins.	Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Neurosci, Charlestown, MA 02129 USA; Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, MGH E 149-2322, Charlestown, MA 02129 USA.		Tsirka, Stella/AAD-4018-2019				Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CUZNER ML, 2001, NEUROPROTECTION; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.0.CO;2-8; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; Gary DS, 2001, J NEUROCHEM, V76, P1485, DOI 10.1046/j.1471-4159.2001.00173.x; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hacke W, 1999, NEUROLOGY, V53, pS3; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; Nicole O, 2001, NAT MED, V7, P59; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rogove AD, 1999, J CELL SCI, V112, P4007; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang XY, 1999, NEUROSCI LETT, V274, P79, DOI 10.1016/S0304-3940(99)00682-5; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228	28	39	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	DEC 21	2001	12	18					4117	4120		10.1097/00001756-200112210-00051			4	Neurosciences	Neurosciences & Neurology	502LT	WOS:000172745600062	11742249				2021-06-18	
J	Dennis, M; Barnes, MA				Dennis, M; Barnes, MA			Comparison of literal, inferential, and intentional text comprehension in children with mild or severe closed head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed-head injury; inferential language; language of mental states and intentions; literal language; text comprehension deficit	ELABORATIVE INFERENCES; PRETENSE THEORY; DISCOURSE; ADOLESCENTS; MEMORY; CONSTRAINTS; NARRATIVES; CHILDHOOD; DECEPTION; DEFICITS	Background: Children with head injury have impairments in pragmatic language at the level of both single words and texts. Text comprehension deficits are likely to be the more consequential for everyday and academic function, yet the relative magnitudes of literal and nonliteral text comprehension deficits have not been measured. Design: We compared the magnitude of the impairment in three forms of text comprehension for children with mild or severe head injury relative with controls: literal language (understanding literal text information), inferential language (making pragmatic inferences, textual coherence inferences, or enriching inferences), and the language of mental states and intentions (eg, producing speech acts, appreciating irony, and understanding deception). Measures: Effect sizes were used to measure the magnitude of the difference between children with head injury and age-matched controls, Results: Children with severe closed-head injury were significantly impaired on tasks of literal text understanding, inferencing, and intentionality. Children with mild head injury were impaired on some inferencing and all intentionality tasks, although they had no literal text comprehension deficits. Conclusions: For both groups, the greatest deficits (ie, the largest effect sizes) were on tasks requiring understanding of the language of mental states and intentions. The data bear on the long-term effects of childhood closed-head injury on text- and discourse-level language and also on the nature and timing of language rehabilitation in children with head injury.	Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Hosp Sick Children, Dept Psychol, Brain & Behav Program, Toronto, ON M5G 1X8, Canada	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mdennis@sickkids.on.ca			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2RO1NS 21889-16] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARA BG, 1998, COGNITION CONTEXT; Bara Bruno G., 1995, COGNITIVE SCI DEV AP; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BARNES MA, 2001, BRAIN LANG, P76; BJORKLUND DF, 1986, J EXP CHILD PSYCHOL, V41, P367, DOI 10.1016/0022-0965(86)90045-7; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Carlson SM, 1998, CHILD DEV, V69, P672, DOI 10.2307/1132197; CASTEEL MA, 1993, DEV PSYCHOL, V29, P346, DOI 10.1037/0012-1649.29.2.346; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1999, BRAIN DAM B, P235; CLARK HH, 1984, J EXP PSYCHOL GEN, V113, P121, DOI 10.1037/0096-3445.113.1.121; Cohen J., 1977, STAT POWER ANAL BEHA, P1; DEMOREST A, 1984, CHILD DEV, V55, P1527, DOI 10.2307/1130022; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dews S, 1999, J PRAGMATICS, V31, P1579, DOI 10.1016/S0378-2166(99)00005-3; DEWS S, 1995, AM PSYCHOL ASS NEW Y; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL; Fillmore Ch. J, 1968, UNIVERSALS LINGUISTI, P1; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Giora R, 1997, COGN LINGUIST, V8, P183, DOI 10.1515/cogl.1997.8.3.183; HALL WS, 1987, J PSYCHOLINGUIST RES, V16, P289, DOI 10.1007/BF01069284; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; Johnson-Laird P. N., 1983, MENTAL MODELS COGNIT; JORDAN F M, 1990, Brain Injury, V4, P27; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORGENSEN J, 1984, J EXP PSYCHOL GEN, V113, P112, DOI 10.1037/0096-3445.113.1.112; KAUFER DS, 1981, J PRAGMATICS, V5, P495, DOI 10.1016/0378-2166(81)90015-1; KINTSCH W, 1994, AM PSYCHOL, V49, P294, DOI 10.1037/0003-066X.49.4.294; KREUZ RJ, 1989, J EXP PSYCHOL GEN, V118, P374, DOI 10.1037/0096-3445.118.4.374; KREUZ RJ, 1993, METAPHOR SYMB ACT, V8, P97, DOI 10.1207/s15327868ms0802_2; KUMONNAKAMURA S, 1995, J EXP PSYCHOL GEN, V124, P3, DOI 10.1037/0096-3445.124.1.3; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LONG DL, 1988, DISCOURSE PROCESS, V11, P35, DOI 10.1080/01638538809544690; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S., 2000, ADV UNDERSTANDING CO; MCKOON G, 1992, PSYCHOL REV, V99, P440, DOI 10.1037/0033-295X.99.3.440; MORROW DG, 1990, INFERENCES TEXT COMP; Muecke, 1969, COMPASS IRONY; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.1111/j.1467-8624.1996.tb01824.x; PESKIN J, 1989, UNPUB CONCEALING 1 I; Pexman PM, 2000, DISCOURSE PROCESS, V29, P201, DOI 10.1207/S15326950dp2903_2; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCHOLNICK EK, 1991, PERSPECTIVES LANGUAG; SODIAN B, 1994, CHILDRENS EARLY UNDE; Sperber D., 1986, RELEVANCE COMMUNICAT; Sperber Dan, 1981, RADICAL PRAGMATICS; Srinivas, 2000, METAPHOR SYMBOL, V15, P47, DOI [10.1080/10926488.2000.9678864, DOI 10.1080/10926488.2000.9678864]; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WHITNEY P, 1991, DISCOURSE PROCESS, V14, P133, DOI 10.1080/01638539109544779; WHITNEY P, 1987, READ RES QUART, V22, P299, DOI 10.2307/747970; Wiig E.H., 1985, TEST LANGUAGE COMPET; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Winner E., 1997, PROBLEM MEANING BEHA; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	69	39	39	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2001	16	5					456	468		10.1097/00001199-200110000-00005			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483JF	WOS:000171631700005	11574041				2021-06-18	
J	Whyte, J; Cifu, D; Dikmen, S; Temkin, N				Whyte, J; Cifu, D; Dikmen, S; Temkin, N			Prediction of functional outcomes after traumatic brain injury: A comparison of 2 measures of duration of unconsciousness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; Glasgow Coma Scale; neuropsychological tests; rehabilitation	HEAD-INJURY; RECOVERY; SCALE	Objective: To compare the usefulness of time until motor localization occurs versus time until commands are followed in predicting outcome after traumatic brain injury (TBI). Design: A retrospective analysis of data from a prospective cohort study of subjects with severe TBI. Setting: Seventeen Traumatic Brain Injury Model System programs. Participants: A total of 496 subjects, recruited through the TBI Model System programs, with loss of consciousness greater than 1 day, with no late neurosurgical complications, and complete data for all measures. Interventions: Not applicable. Main Outcome Measures: Time until Glasgow Coma Scale (GCS) motor score of 5 (time to motor localization) and time until GCS motor score of 6 (time until commands were followed) were abstracted from medical records. Functional outcomes were assessed at inpatient rehabilitation admission and discharge, along with acute and rehabilitation lengths of stay and charges. Results: Time until commands were followed was a better predictor of all of the outcomes assessed than time until motor localization occurred. In multiple regression models, time until motor localization did not add significantly to the prediction provided by time until commands were followed. The predictive power of time to command following was superior even in the subgroup with poor language comprehension as measured by the Token Test. Conclusion: Despite the theoretical appeal of time to motor localization (eg, in persons with language comprehension problems), time to command following appears to be a more powerful predictor of outcome after severe brain injury.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg & Biostat, Seattle, WA 98195 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd,Korman Bldg,Ste 211, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474; Cifu, David/0000-0003-1600-9387			Benton A, 1989, MULTILINGUAL APHASIA; CHOI SC, 1977, BIOMETRIKA, V64, P645, DOI 10.2307/2345351; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Hagen C., 1972, LEVELS COGNITIVE FUN; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764	18	39	39	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2001	82	10					1355	1359		10.1053/apmr.2001.26091			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	479NQ	WOS:000171410800002	11588737				2021-06-18	
J	Firsching, R; Woischneck, D				Firsching, R; Woischneck, D			Present status of neurosurgical trauma in Germany	WORLD JOURNAL OF SURGERY			English	Article								Exact epidemiological data on head injury in Germany are limited and based on data from death certificates, the Federal Board of Statistics (Bundesamt fur Statistik), small regional cohort studies, and health insurance. With a population of 82 million people there had been 279,029 head injuries admitted to hospital in Germany in 1996. The majority had the diagnosis. "concussion," which refers to completely reversible lesions. Head injury caused the deaths of 9415 patients in 1996, which amounts to a mortality of 11.5 per 100,000 inhabitants. At the same time there were 135 independent neurosurgical units, all of which had a computerized tomography scanner available. Of all fatal cases, however, 68.4% died before they reached a hospital. The exact cost is difficult to assess, because head injury causes more costs than only the hospital stay and rehabilitation.	Otto Von Guericke Univ Magdeburg, Fak Med, Neurochirurg Klin, D-39120 Magdeburg, Germany	Firsching, R (corresponding author), Otto Von Guericke Univ Magdeburg, Fak Med, Neurochirurg Klin, Leipziger Str 44, D-39120 Magdeburg, Germany.						BOUILLION B, 1998, ZENTRALBL NEUROCHIR, V59, P4; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; *EUR STUD GROUP NI, 1994, J NEUROSURG, V80, P804; FIRSCHING R, 1998, ZENTRALBL NEUROCHIRU, V3, P195; Gesundheitsberichterstattung des Bundes, 1998, GESUNDHEITSBERICHT D; KARIMI R, 1999, ZENTRALBL NEUROCHIR, P93; Kosubek C, 1996, Rehabilitation (Stuttg), V35, P29; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; TORNER JC, 1999, TRAUMATIC BRAIN INJU, P9; INFOSYTEM VERKEHR GE; 1997, NOTFALLMEDIZIN, V10, P466; 1998, STATISCHES BUNDESAMT	12	39	42	0	4	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1221	1223					3	Surgery	Surgery	471NB	WOS:000170934500021	11571961				2021-06-18	
J	Kelly, DF; Becker, DP				Kelly, DF; Becker, DP			Advances in management of neurosurgical trauma: USA and Canada	WORLD JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; SPINAL-CORD INJURY; CEREBRAL PERFUSION-PRESSURE; SAN-DIEGO-COUNTY; COMA DATA-BANK; BRAIN INJURY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; TIRILAZAD MESYLATE; GUNSHOT WOUNDS	Traumatic brain and spinal cord injuries continue to pose serious challenges for physicians around the world. In North America, the annual number of serious head and spinal injuries has decreased over the last two decades, and of those patients who reach a hospital, the mortality and long-term morbidity have also declined. The two major reasons for this reduction in death and disability after craniospinal trauma in the United States and Canada appear to be (1) widespread implementation of prevention measures, safety legislation, and public education initiatives; and (2) further improvements in and wider availability of emergency medical systems and regional trauma centers. Improvements in neurocritical care and the implementation of evidence-based treatment guidelines for severe head injury victims may also, in part, be responsible for improved survival rates and reduced disability rates. Unfortunately, numerous clinical trials of putative neuroprotective agents conducted in North America and elsewhere during the 1990s have failed to demonstrate efficacy in head-injured patients. However, methylprednisolone does appear to confer some benefit to a select population of spinal cord injury patients. These advances in the areas of prevention, regional trauma systems, treatment guidelines, and neurocritical care that have influenced survival rates and recovery of function are discussed.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA	Kelly, DF (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Box 957039,Room 18-218 NPI, Los Angeles, CA 90095 USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AVOLIO AEC, 1992, NEUROSURGERY, V31, P557, DOI 10.1227/00006123-199209000-00019; BAKER SP, 1992, INJURY FACT BOOK, P8; BAKER SP, 1992, INJURY FACT BOOK, P149; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; *COMM TRAUM NAT RE, 1966, ACC DEATH DIS NEGL D; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Frank RG, 1992, PSYCHOL HEALTH, V6, P129; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JAGGER J, 1992, J NEUROTRAUM, V9, pS313; JENNETT B, 1978, INJURY, V10, P31; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Kraus JF, 1993, HEAD INJURY, P1; KRAUS JF, 1996, NEUROTRAUMA, P13; LEVY ML, 1993, NEUROSURGERY, V33, P1018; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOBOSKY JM, 1996, NEUROTRAUMA, P1049; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MacKenzie E J, 1989, Md Med J, V38, P725; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARMAROU A, 1991, J NEUROSURG, V75, P559; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall SB, 1991, J NEUROSURG S, V75, P14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; O'Keefe GE, 1999, ANN SURG, V229, P409, DOI 10.1097/00000658-199903000-00015; Peitzman AB, 1999, ANN SURG, V230, P87, DOI 10.1097/00000658-199907000-00013; Pitts L H, 1995, New Horiz, V3, P546; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rivara FP, 1999, PEDIATRICS, V103, P883; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Seguin J, 1999, J TRAUMA, V47, pS99; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; *US DEP TRANSP, 1994, NAT HIGHW TRAFF SURG; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Wright M, 1995, Inj Prev, V1, P81, DOI 10.1136/ip.1.2.81; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	70	39	41	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1179	1185					7	Surgery	Surgery	471NB	WOS:000170934500016	11571956				2021-06-18	
J	Zhao, YD; Wang, WH				Zhao, YD; Wang, WH			Neurosurgical trauma in People's Republic of China	WORLD JOURNAL OF SURGERY			English	Article								An epidemiological investigation for neurological disorders was conducted in the People's Republic of China in 1983 and 1985. The incidence of traumatic neurological injury was 55.4 patients per 100,000 population in the six big cities and 64.1 patients in the 21 rural areas. The mortality rates were 6.3 per 100,000 population (male:female = 1.7:1.0) in the six cities and 9.7 (m:f = 2.5:1) in the rural areas. In the cities, the causes of brain injury were vehicle accidents (31.7%), followed by assaults (23.8%), falls (21.8%), stumbles (15.4%), and others. Brain concussion was 68.4%, contusion was 26.0%, and intracranial hematoma was 5.6%. The incidence of spinal cord injury was 0.67 per 100,000 population in Beijing and 1.37 in Shanghai. Male versus female ratio was 7 to 1 and the peak incidence was found in ages from 20 to 30 years old. In the past decade, vehicle accidents increased along with the increasing, number of cars and motor bicycles. As a result of a series of administrative measures, such as improvement of traffic control and safe-driving education, mean mortality decreased from 33.4 per 10,000 motor vehicles in 1990 to 22.0 in 1995. It has been estimated that approximately 50,000 to 60,000 people die from vehicle accidents per year. Among these cases, brain injury accounts for 39% to 57% and spinal cord injury about 10%. Since vehicle accidents are the most common cause for neurotraumatic death, an effort is needed to prevent and to decrease the incidence of these accidental traumatic injuries.	Beijing Neurosurg Inst, Dept Neurosurg, Beijing 100050, Peoples R China; Beijing Neurosurg Inst, Dept Neuroepidemiol, Beijing 100050, Peoples R China	Zhao, YD (corresponding author), Beijing Neurosurg Inst, Dept Neurosurg, 6 Tiantan Xili, Beijing 100050, Peoples R China.						FENG QN, 1993, CHIN J SPINE SPINAL, V6, P266; SHI YQ, 1994, PRACTICAL NEUROLOGY, P319; WANG ZG, 1995, J TRAFFIC MED, V23, P71; WANG ZG, 1996, CHIN J TRAUMATOL, V12, P141; YANG JH, 1996, CHINESE BIOCH J, V12, P143; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23; Zhu GL, 1989, CHIN J NEUROSURG S, V5, P44	7	39	45	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1202	1204					3	Surgery	Surgery	471NB	WOS:000170934500018	11571958				2021-06-18	
J	Sihver, S; Marklund, N; Hillered, L; Langstrom, B; Watanabe, Y; Bergstrom, M				Sihver, S; Marklund, N; Hillered, L; Langstrom, B; Watanabe, Y; Bergstrom, M			Changes in mACh, NMDA and GABA(A) receptor binding after lateral fluid-percussion injury: in vitro autoradiography of rat brain frozen sections	JOURNAL OF NEUROCHEMISTRY			English	Article						binding potential; [C-11]cyano-dizocilpine; [C-11]flumazenil; lateral fluid percussion injury; 4-N-[C-11]methylpiperidylbenzilate; positron emission tomography	POSITRON-EMISSION-TOMOGRAPHY; D-ASPARTATE RECEPTOR; CORTICAL DAMAGE; AMINO-ACIDS; RELEASE; MK-801; INVIVO; SCOPOLAMINE; ANTAGONIST; TRAUMA	Adult rats were subjected to a moderate lateral fluid percussion injury (FPI), followed by survival periods of 2 and 12 h. Regional NMDA subtype glutamate, muscarinic acetylcholine and GABAA receptor binding in various brain regions was analysed by quantitative in vitro autoradiography and short-lived positron emission tomography tracers [C-11]cyanodizocilpine, 4-N-[C-11]methylpiperidylbenzilate (4-N-[C-11]MPB), and [C-11]flumazenil, respectively. The binding potential (BP, B-max/K-D) was calculated. The data with [C-11]cyano-dizocilpine showed a significant decrease in BP bilaterally for the frontoparietal cortex and hippocampus at both time points, in comparison with that of the sham-operated controls. At 12 h the decrease was significantly more prominent for the ipsilateral cortex and hippocampus than for the contralateral side. The BP of 4-N-[C-11]MPB was significantly decreased after 2 h for the trauma-side hippocampus, and after 12 h it had decreased for the trauma-site cortex and the bilateral hippocampus. The [C-11]flumazenil exhibited a significant decrease in BP for the trauma-site cortex and the underlying hippocampus by 2 h after the traumatic brain injury. After 12 h a significantly decreased BP was observed only for the trauma-site cortex. The finding of a decreased BP demonstrates the involvement of these receptor systems in the development of cellular dysfunction, which is widespread and not limited to the site of lateral FPI.	Uppsala Univ, Univ Hosp, PET Ctr, S-75185 Uppsala, Sweden; Uppsala Univ, Fac Med, Dept Neurosci, Pharmacol Unit, Uppsala, Sweden; Uppsala Univ, Fac Med, Neurosurg Unit, Uppsala, Sweden; Uppsala Univ, Fac Med, Dept Neurosci, Unit Clin Chem, Uppsala, Sweden; Osaka Biosci Inst, Dept Neurosci, Osaka, Japan; Osaka City Univ, Grad Sch Med, Dept Physiol, Osaka 558, Japan	Bergstrom, M (corresponding author), Uppsala Univ, Univ Hosp, PET Ctr, S-75185 Uppsala, Sweden.	mats.bergstrom@pet.uu.se		Marklund, Niklas/0000-0002-9797-5626			Andersson Y, 1998, J LABELLED COMPD RAD, V41, P567, DOI 10.1002/(SICI)1099-1344(199806)41:6<567::AID-JLCR96>3.0.CO;2-8; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Heiss WD, 1997, STROKE, V28, P2045, DOI 10.1161/01.STR.28.10.2045; Heiss WD, 1998, STROKE, V29, P454, DOI 10.1161/01.STR.29.2.454; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANGSTROM B, 1987, J NUCL MED, V28, P1037; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; MAZIERE M, 1984, INT J APPL RADIAT IS, V35, P973, DOI 10.1016/0020-708X(84)90215-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LG, 1988, PSYCHOPHARMACOLOGY, V96, P385, DOI 10.1007/BF00216067; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; MULHOLLAND G K, 1988, Journal of Nuclear Medicine, V29, P768; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Rudolf J, 2000, LANCET, V355, P115, DOI 10.1016/S0140-6736(99)04280-4; Sihver S, 1999, J PHARMACOL EXP THER, V290, P917; Sihver S, 1998, J NEURAL TRANSM, V105, P117; TANAKA H, 1994, ACTA NEUROCHIR, P524; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yamaki T, 1996, J NUCL MED, V37, P1166	37	39	41	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2001	78	3					417	423		10.1046/j.1471-4159.2001.00428.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	460TZ	WOS:000170325800001	11483644				2021-06-18	
J	Shepard, MF; Markolf, KL; Dunbar, AM				Shepard, MF; Markolf, KL; Dunbar, AM			The effects of partial and total interosseous membrane transection on load-sharing in the cadaver forearm	JOURNAL OF ORTHOPAEDIC RESEARCH			English	Article								This study was performed to examine the effects of partial and total transection of the interosseous membrane (TOM) on load transfer in the forearm. Twenty fresh frozen forearms were instrumented with custom designed load cells placed in the proximal radius and distal ulna. Simultaneous measurements of load cell forces, radial head displacement relative to the capitellum, and local tension within the central band of the IOM were made as the wrist was loaded to 134 N with the forearm at 90 degrees of elbow flexion and in neutral pronation supination. For valgus elbow alignment (radial head contacting the capitellum), mean force carried by the distal ulna was 7.1 % of the applied wrist force and mean force transferred from radius to ulna through the IOM was 4.4%. For varus elbow alignment (mean 2.0 mm gap between the radial head and capitellum), mean distal ulna force was 28% and mean TOM force was 51%. Section of the proximal and distal one-thirds of the IOM had no significant effect upon mean distal ulnar force or mean IOM force. Total IOM section significantly increased mean distal ulnar force for varus elbow alignment in all wrist positions tested. The mean level of applied wrist force necessary to close the varus gap (89 N) decreased significantly after both partial TOM section (71 N) and total IOM section (25 N). The IOM became loaded only when the radius displaced proximally relative to the ulna, closing the gap between the radius and capitellum. As the radius displaced proximally, the wrist becomes increasingly ulnar positive, which in turn leads to direct loading of the distal ulna. This shift of force to the distal ulna could present clinically as ulnar sided wrist pain or as ulnar impaction after IOM injury. (C) 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.	Univ Calif Los Angeles, Dept Orthopaed Surg, Div Biomech, Los Angeles, CA 90095 USA	Markolf, KL (corresponding author), Univ Calif Los Angeles, Dept Orthopaed Surg, Div Biomech, Rehabil Bldg,Room 21-67,100 Vet Ave, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR043735] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR43735] Funding Source: Medline		BIRBECK DP, 1997, J HAND SURG A, V22, P975; EDWARDS GS, 1988, CLIN ORTHOP RELAT R, P61; FRIEDMAN SL, 1993, J HAND SURG-AM, V18A, P713, DOI 10.1016/0363-5023(93)90325-W; Furry KL, 1998, CLIN ORTHOP RELAT R, P40; HOPPENFELD S, 1984, SURGICAL EXPOSURES O, P109; HOTCHKISS RN, 1989, J HAND SURG-AM, V14, P256, DOI 10.1016/0363-5023(89)90017-8; HOTCHKISS RN, 1994, HAND CLIN, V10, P391; Markolf KL, 1998, J BONE JOINT SURG AM, V80A, P879, DOI 10.2106/00004623-199806000-00012; MIKIC ZD, 1983, CLIN ORTHOP RELAT R, P220; MORREY BF, 1988, J BONE JOINT SURG AM, V70A, P250, DOI 10.2106/00004623-198870020-00014; Pfaeffle HJ, 1996, J ORTHOP RES, V14, P842, DOI 10.1002/jor.1100140525; RABINOWITZ RS, 1994, J HAND SURG-AM, V19A, P385, DOI 10.1016/0363-5023(94)90050-7; SCHNEIDERMAN G, 1993, J TRAUMA, V35, P879, DOI 10.1097/00005373-199312000-00014; SELLMAN DC, 1995, J ORTHOP TRAUMA, V9, P516, DOI 10.1097/00005131-199509060-00010; Skahen JR, 1997, J HAND SURG-AM, V22A, P986, DOI 10.1016/S0363-5023(97)80037-8; Skahen JR, 1997, J HAND SURG-AM, V22A, P981, DOI 10.1016/S0363-5023(97)80036-6; SOWA DT, 1995, CLIN ORTHOP RELAT R, P106; Wallace AL, 1997, J BONE JOINT SURG BR, V79B, P422, DOI 10.1302/0301-620X.79B3.7142	18	39	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0736-0266			J ORTHOPAED RES	J. Orthop. Res.	JUL	2001	19	4					587	592		10.1016/S0736-0266(00)00059-0			6	Orthopedics	Orthopedics	461LQ	WOS:000170366100014	11518266				2021-06-18	
J	Henshall, DC; Skradski, SL; Bonislawski, DP; Lan, JQ; Simon, RP				Henshall, DC; Skradski, SL; Bonislawski, DP; Lan, JQ; Simon, RP			Caspase-2 activation is redundant during seizure-induced neuronal death	JOURNAL OF NEUROCHEMISTRY			English	Article						brain; epilepsy; kainic acid; programmed cell death; rat; TNF	TRAUMATIC BRAIN INJURY; EVOKED LIMBIC SEIZURES; CELL-DEATH; DNA FRAGMENTATION; KAINIC ACID; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; SIGNALING COMPLEX; ADAPTER MOLECULE; RAT-BRAIN	Seizure-induced neuronal death may be under the control of the caspase family of cell death proteases. We examined the role of caspase-2 in a model of focally evoked limbic seizures with continuous EEG recording. Seizures were elicited by microinjection of kainic acid into the amygdala of the rat and terminated after 40 min by diazepam. Caspase-2 was constitutively present in brain, mostly within neurons, and was detected in both cytoplasm and nucleus. Cleaved caspase-2 (12 kDa) was detected immediately following seizure termination within injured ipsilateral hippocampus, contiguous with increased Val-Asp-Val-Ala-Asp (VDVADase) activity, a putative measure of activated caspase-2. Expression of receptor interacting protein (RIP)-associated Ich-l-homologous protein with death domain (RAIDD) was increased following seizures, whereas expression of RIP and tumor necrosis factor receptor associated protein with death domain (TRADD), other components thought to be linked to the caspase-2 activation and signaling mechanism, were unchanged. Intracerebroventricular administration of z-VDVAD-fluoromethyl ketone blocked seizure-induced caspase-2 activity but did not alter caspase-8 activity and failed to affect DNA fragmentation or neuronal death. These data support activation of caspase-2 following seizures but suggest that parallel caspase pathways may circumvent deficits in caspase-2 function to complete the cell death process.	Legacy Clin Res & Technol Ltd, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA	Henshall, DC (corresponding author), Legacy Clin Res & Technol Ltd, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	dhenshall@DowNeurobiology.org	Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039016] Funding Source: NIH RePORTER		Ahmad M, 1997, CANCER RES, V57, P615; Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen J, 1998, J NEUROSCI, V18, P4914; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 2000, ACTA NEUROPATHOL, V99, P245, DOI 10.1007/PL00007434; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2000, BRAIN RES, V858, P290, DOI 10.1016/S0006-8993(99)02452-X; Henshall DC, 1999, J NEUROCHEM, V73, P1573, DOI 10.1046/j.1471-4159.1999.0731573.x; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kinoshita M, 1997, J CEREBR BLOOD F MET, V17, P507, DOI 10.1097/00004647-199705000-00004; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Paxinos P., 1997, RAT BRAIN STEREOTAXI; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; POLLARD H, 1994, NEUROREPORT, V5, P1053, DOI 10.1097/00001756-199405000-00009; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TANAKA S, 1988, BRAIN RES, V463, P163, DOI 10.1016/0006-8993(88)90541-0; Troy CM, 2000, J NEUROSCI, V20, P1386; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WASTERLAIN CG, 1994, BRAIN DEV-JPN, V16, P279, DOI 10.1016/0387-7604(94)90025-6; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x; Zheng TS, 2000, NAT MED, V6, P1241	45	39	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2001	77	3					886	895		10.1046/j.1471-4159.2001.00291.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	429WX	WOS:000168541900018	11331417	Bronze			2021-06-18	
J	Yan, HQ; Yu, JY; Kline, AE; Letart, P; Jenkins, LW; Marion, DW; Dixon, CE				Yan, HQ; Yu, JY; Kline, AE; Letart, P; Jenkins, LW; Marion, DW; Dixon, CE			Evaluation of combined fibroblast growth factor-2 and moderate hypothermia therapy in traumatically brain injured rats	BRAIN RESEARCH			English	Article						controlled cortical impact; neurotrophin; MWM	SPINAL-CORD INJURY; CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC HYPOTHERMIA; CDP-CHOLINE; BEHAVIORAL DEFICITS; HIPPOCAMPAL-NEURONS; FUNCTIONAL RECOVERY; UP-REGULATION; LONG-TERM; CELL LOSS	Both the exogenous administration of fibroblast growth factor-2 (FGF-2) or the induction of moderate hypothermia have been shown to attenuate histopathology and improve functional outcome after traumatic brain injury (TBI). Since combined therapeutic strategies may be more beneficial than single therapies, we examined the potential synergistic effect of FGF-2 combined with moderate hypothermia treatment induced 10 min after TBI on functional and histological outcome following controlled cortical impact (CCI) injury. Fifty male Sprague-Dawley rats were randomized to one sham and four CCI treatment groups: Sham+vehicle (VEH); FGF-2 (45 mug/kg/h for 3 h i.v.)+Normothermia (37 +/- 0.5 degreesC); FGF-2+Hypothermia (32 +/- 0.5 degreesC for 3 h); VEH+Norm; VEH+Hypo. Vestibulomotor performance on the beam balance and beam-walk (BW) tasks on post-operative days 1-5 and spatial memory acquisition in the Morris water maze (MWM) on days 14-18 were assessed. After 4 weeks survival, histological evaluations (CA(1) and CA(3) cell counts and lesion volume) were performed. MWM performance improved in all treatment groups, but combined treatment was not more efficacious than either alone. The FGF-2+Hypo group performed significantly better than the other injured treatment groups in the BW task. Lastly, no significant group differences in beam balance or histological outcome were observed. These data suggest a suboptimal and incomplete synergy of combined FGF-2 and hypothermia treatment. These data may indicate that either our dose of FGF-2 or combination therapy was not optimized in our model. (C) 2000 Elsevier Science BN. All rights reserved.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Loyola Univ Chicago, Dept Neurosurg, Maywood, IL 60153 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R01NS033150, P01NS030318, R01NS040125, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS40125, NS30318] Funding Source: Medline		BAFFOUR R, 1995, J NEUROSURG, V83, P105, DOI 10.3171/jns.1995.83.1.0105; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Bethel A, 1997, STROKE, V28, P609, DOI 10.1161/01.STR.28.3.609; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUKI A, 1999, NEUROL RES, V21, P585; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cuevas P, 1998, SURG NEUROL, V49, P77, DOI 10.1016/S0090-3019(97)00193-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DORMAN RV, 1983, J NEUROCHEM, V40, P276, DOI 10.1111/j.1471-4159.1983.tb12682.x; Fitzsimonds RM, 1998, PHYSIOL REV, V78, P143; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; JONES SB, 1984, J APPL PHYSIOL, V57, P808; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kusumoto M, 1997, METAB BRAIN DIS, V12, P113, DOI 10.1007/BF02674733; Lee TT, 1999, J NEUROTRAUM, V16, P347, DOI 10.1089/neu.1999.16.347; LIU Z, 1993, BRAIN RES, V626, P335, DOI 10.1016/0006-8993(93)90598-H; LOUIS JC, 1993, EUR J NEUROSCI, V5, P1610, DOI 10.1111/j.1460-9568.1993.tb00230.x; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1996, CRIT CARE MED, V24, pS81; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Ramirez JJ, 1999, NEUROREPORT, V10, P1201, DOI 10.1097/00001756-199904260-00008; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; Valouskova V, 1999, NEUROBIOL LEARN MEM, V71, P132, DOI 10.1006/nlme.1998.3877; YING Z, 1993, J CEREBR BLOOD F MET, V13, P378, DOI 10.1038/jcbfm.1993.51	52	39	39	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 22	2000	887	1					134	143		10.1016/S0006-8993(00)03002-X			10	Neurosciences	Neurosciences & Neurology	387HH	WOS:000166116800016	11134598				2021-06-18	
J	Ginis, I; Hallenbeck, JM; Liu, J; Spatz, M; Jaiswal, R; Shohami, E				Ginis, I; Hallenbeck, JM; Liu, J; Spatz, M; Jaiswal, R; Shohami, E			Tumor necrosis factor and reactive oxygen species cooperative cytotoxicity is mediated via inhibition of NF-kappa B	MOLECULAR MEDICINE			English	Article							CLOSED-HEAD INJURY; DNA-BINDING ACTIVITY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; BETA-PEPTIDE TOXICITY; FACTOR-ALPHA; TNF-ALPHA; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS	Background: Tumor necrosis factor alpha (TNF alpha) plays a key role in pathogenesis of brain injury. However, TNF alpha exhibits no cytotoxicity in primary cultures of brain cells. This discrepancy suggests that other pathogenic stimuli that exist in the setting of brain injury precipitate TNF alpha cytotoxicity. The hypothesis was tested that reactive oxygen species (ROS), that are released early after brain injury, act synergistically with TNF alpha in causing cell death. Materials and Methods: Cultured human and rat brain capillary endothelial cells (RBEC), and cortical astrocytes were treated with TNF alpha alone or together with different doses of H2O2, and apoptotic cell death and DNA fragmentation were measured by means of 3'-OH-terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and Hoechst fluorescence assay, respectively. The effect of H2O2 on TNF alpha -induced activation of nuclear factor kappa B (NF-kappaB) was measured by Western blots of cytoplasmic and nuclear extracts of RBEC using anti-inhibitor of NF-kappaB (I kappaB) and anti-p65 subunit of NF-kappaB antibodies. Nuclear translocation of NF-kappaB was investigated by immunofluorescent staining of RBEC with anti-p65 antibodies. Results: TNF alpha alone had no cytotoxic effect in brain endothelial cells and astrocytes at concentrations up to 100 ng/ml. Go-treatment with 5-10 muM of H2O2 caused a two-fold increase in the number of apoptotic cells 24 hr later. Similar doses (1-3 muM) of H2O2 initiated early DNA fragmentation. H2O2 inhibited TNF alpha -induced accumulation of p69 in the nucleus, although it had no effect on degradation of the I kappaB in cytoplasm. Immunostaining confirmed that H2O2 inhibited p65 transport to the nucleus. Conclusions: Reactive oxygen species could act synergistically with TNF alpha in causing cytotoxicity via inhibition of a cytoprotective branch of TNF alpha signaling pathways, which starts with NF-kappaB activation.	NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		ginisi@ninds.nih.gov					Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BARGER SW, 1998, NEUROPROTECTIVE SIGN, P163; Baronet AM, 1999, CLIN PSYCHOL REV, V19, P819, DOI 10.1016/S0272-7358(98)00076-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; Carroll JE, 1998, MOL BRAIN RES, V56, P186, DOI 10.1016/S0169-328X(98)00045-X; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Furukawa K, 1998, J NEUROCHEM, V70, P1876; Ginis I, 1997, AM J PHYSIOL-CELL PH, V272, pC295; GINIS I, 1995, J IMMUNOL, V155, P802; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Hallenbeck JM, 1997, NEUROLOGY, V49, pS5, DOI 10.1212/WNL.49.5_Suppl_4.S5; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; ISRAEL N, 1992, J IMMUNOL, V149, P3386; ITO A, 1995, J NEUROCHEM, V65, P463; Jornot L, 1997, FEBS LETT, V416, P381, DOI 10.1016/S0014-5793(97)01244-1; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Love S, 1999, BRAIN PATHOL, V9, P119; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MEIRSTRELL ME, 1997, SHOCK, V8, P341; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; OHARA Y, IN PRESS ACTA NEUROC; Piette J, 1997, BIOL CHEM, V378, P1237; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; Rahman A, 1998, AM J PHYSIOL-LUNG C, V275, pL533; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Schneider A, 1999, NAT MED, V5, P554; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 1996, FASEB J, V10, P709; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Spatz M, 1997, AM J PHYSIOL-CELL PH, V272, pC231; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tenneti L, 1998, J NEUROCHEM, V71, P946; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YAMASAKI T, 1992, J NEUROSURG, V77, P279, DOI 10.3171/jns.1992.77.2.0279; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	83	39	39	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	DEC	2000	6	12					1028	1041		10.1007/BF03402054			14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	392MT	WOS:000166415800004	11474119	DOAJ Gold, Green Published			2021-06-18	
J	Sallis, RE; Jones, K				Sallis, RE; Jones, K			Prevalence of headaches in football players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						athletic injuries; brain concussion; football; head injuries	CEREBRAL CONCUSSION; HEAD-INJURIES; 2ND IMPACT; SPORTS; MANAGEMENT; PREVENTION; TRAUMA; SCHOOL	Background: Football coaches and team physicians rely heavily on players' reports of symptoms in deciding whether a player may return to the game after sustaining head trauma. The decision is made difficult by the wide variety of associated symptoms, some of which (e.g., headache is among the most common) may or may not be associated with serious head injury. More information is needed about the clinical significance of football-related headache. Methods: To assess the frequency of headache associated with playing football, we analyzed responses to our questionnaire asking about incidence, frequency, and outcome of football-related headache from 443 football players (320 from college, 123 from high school). Results: Eighty-five percent of respondents reported previous headache related to hitting in football. Asked specifically about their most recent game, 21% of respondents reported having had headache during that game. Of players who had headache, only 19% informed the team physician, trainer, or coach, and only 6% were removed from the game. Twenty-seven percent of respondents reported previous diagnosis of cerebral concussion by medical personnel. Defensive backs (25%), defensive linemen (19%), and offensive linemen (18%) were most likely to have headache, related to hitting. Conclusions: Our data confirm that posttraumatic headache is commonly associated with football participation and often goes unreported. Given that the most serious complications of head injuries (e.g., second-impact syndrome) occur infrequently, headache aa an isolated symptom lacks specificity in predicting such complications in football players. Therefore, unless it persists or is accompanied by additional symptoms, headache alone may not reliably suggest the need to remove players from the game.	Kaiser Permanente Med Ctr, Dept Family Med, Fontana, CA USA; Pomona Coll, Dept Phys Educ, Claremont, CA 91711 USA	Sallis, RE (corresponding author), Kaiser Permanente Med Off, Dept Family Med Sports Med, 10850 Arrow Rt, Rancho Cucamonga, CA 91730 USA.	robert.e.sallis@kp.org					CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P31; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Sallis R. E., 1998, Medicine and Science in Sports and Exercise, V30, pS157; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F; SCHNEIDER RC, 1985, SPORTS INJURIES MECH, P877; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; *SPORTS MED COMM C, 1991, GUID MAN CONC SPORTS, P4; *UCLA SCH MED, 1995, SPORTS MED, V17, P1; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	24	39	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	NOV	2000	32	11					1820	1824		10.1097/00005768-200011000-00002			5	Sport Sciences	Sport Sciences	372ED	WOS:000165220600002	11079509				2021-06-18	
J	Whalen, MJ; Carlos, TM; Wisniewski, SR; Clark, RSB; Melick, JA; Marion, DW; Kochanek, PM				Whalen, MJ; Carlos, TM; Wisniewski, SR; Clark, RSB; Melick, JA; Marion, DW; Kochanek, PM			Effect of neutropenia and granulocyte colony stimulating factor-induced neutrophilia on blood-brain barrier permeability and brain edema after traumatic brain injury in rats	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; rats; granulocyte colony stimulating factor; blood-brain barrier; edema; controlled cortical impact; neutrophils	NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; ADHESION MOLECULES; CEREBROSPINAL-FLUID; REPERFUSION INJURY; ACUTE-INFLAMMATION; SMOOTH-MUSCLE; IN-VIVO	Objective: Granulocyte colony stimulating factor (GCSF) has been used to increase systemic absolute neutrophil count (ANC) in patients with severe traumatic brain injury to reduce nosocomial infection risk. However, the effect of increasing systemic ANC on the pathogenesis of experimental traumatic brain injury has not been studied. Thus, we evaluated the effect of systemic ANC on blood-brain barrier (BBB) damage and brain edema after traumatic brain injury in rats. Design: Experimental study. Setting: Research laboratory at the University of Pittsburgh, PA. Subjects: Forty-three adult male Sprague-Dawley rats. Interventions: Protocol I: rats were randomized to receive either vinblastine sulfate to reduce ANC, GCSF to increase ANC, or saline before controlled cortical impact (CCI) of moderate overall severity. Evans blue was used to assess BBB damage at 4-24 hrs after CGI. Protocol II: rats received GCSF or saline before CCI. Brain edema was estimated at 24 hrs using (wet - dry) / wet weight method. Protocol III: rats received GCSF or saline before CCI. Brain neutrophil accumulation was estimated at 24 hrs using a myeloperoxidase assay. Measurements and Main Results: Physiologic variables were controlled before CCI was maintained at normal in all animals before traumatic brain injury. No rats were anemic, hypoglycemic, or hypotensive before CCI. Protocol I: compared with control, systemic ANC decreased in vinblastine-treated rats and increased in GCSF-treated rats. BBB damage correlated with systemic ANC. Protocol II: mean systemic ANC before traumatic brain injury Increased 15-fold in rats given GCSF vs. control; however no difference in brain edema was observed at 24 hrs after injury between groups. Protocol III: median systemic ANC at the time of CCI was increased ten-fold in rats given GCSF vs. control. No difference in brain myeloperoxidase activity 24 hrs after CCI was observed in rats treated with GCSF vs. control. Conclusions: Systemic ANC influences BBB damage after traumatic brain injury produced by CGI. Because BBB damage and brain edema are discordant, mechanisms other than BBB damage likely predominate in the pathogenesis of brain edema after contusion. The implications of increased BBB permeability with the administration of GCSF in our model remains to be determined. Increasing systemic ANG before CCI with GCSF administration does not increase posttraumatic brain neutrophil accumulation or brain edema after CCI in rats. The finding that neutrophil infiltration is not enhanced by systemic neutrophilia suggests that the ability of GCSF-stimulated neutrophils to migrate into injured tissue may be impaired, Further studies are needed to evaluate the effects of GCSF administration on secondary injury and functional outcome in experimental models of traumatic brain injury.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Brain Trauma Res Ctr, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 4th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		Adamson P, 1999, J IMMUNOL, V162, P2964; Adelson PD, 1998, ACT NEUR S, V71, P104; Azzara A, 1996, BRIT J HAEMATOL, V92, P161, DOI 10.1046/j.1365-2141.1996.00295.x; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Deetjen C, 1999, IMMUNOPHARMACOLOGY, V43, P23, DOI 10.1016/S0162-3109(99)00036-3; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Goldman S, 1998, CLIN PERINATOL, V25, P699; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.2307/2333011; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Katayama Y, 1998, ACT NEUR S, V71, P289; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDSBERG PJ, 1995, J NEUROSURG, V82, P269, DOI 10.3171/jns.1995.82.2.0269; Matsumoto T, 1997, LAB INVEST, V77, P119; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; Pajkrt D, 1997, BLOOD, V90, P1415, DOI 10.1182/blood.V90.4.1415.1415_1415_1424; Peter FW, 1998, MICROSURG, V18, P290, DOI 10.1002/(SICI)1098-2752(1998)18:4<290::AID-MICR15>3.3.CO;2-U; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Rosenbloom AJ, 1999, J LEUKOCYTE BIOL, V66, P83; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Soares HD, 1995, J NEUROSCI, V15, P8223; Squadrito F, 1997, BRIT J PHARMACOL, V120, P333, DOI 10.1038/sj.bjp.0700904; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; TERASHIMA T, 1995, AM J RESP CELL MOL, V13, P69, DOI 10.1165/ajrcmb.13.1.7541223; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yakovlev A., 1994, Society for Neuroscience Abstracts, V20, P423; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; YOUNG AB, 1985, NEUROSURGERY, V16, P725	67	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2000	28	11					3710	3717		10.1097/00003246-200011000-00029			8	Critical Care Medicine	General & Internal Medicine	376AQ	WOS:000165436000022	11098978				2021-06-18	
J	van der Naalt, J; Van Zomeren, AH; Sluiter, WJ; Minderhoud, JM				van der Naalt, J; Van Zomeren, AH; Sluiter, WJ; Minderhoud, JM			Acute behavioural disturbances related to imaging studies and outcome in mild-to-moderate head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; AGITATION; REHABILITATION; SEQUELAE; PATIENT	The frequency of behavioural disturbances early after injury in relation to outcome was prospectively investigated in a series of 67 patients with mild-to-moderate head injury (as defined by GCS on admission). In more than half of the patients, behavioural disturbances were observed. Restlessness occured in 40% of patients, whereas agitation was seen in 19% of patients. In all patients, restlessness and agitation disappeared before resolution of PTA. In multiple regression analysis, restlessness and PTA were found to be separate factors in predicting outcome. On imaging studies, twice as many lesions were seen in patients with restlessness and agitation (81% compared to 39%), mainly localized in the frontotemporal region. In two thirds of patients with early behavioural disturbances, residual emotional and cognitive impairments were seen 1 year after injury. This study suggests that behavioural disturbances in the early phase after injury are related to frontotemporal lesions and lends support for the view of the existence of a separate profile of patient behaviour in mild-to-moderate head injury.	Univ Groningen Hosp, Dept Neurol, NL-9700 RB Groningen, Netherlands	van der Naalt, J (corresponding author), Univ Groningen Hosp, Dept Neurol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@neuro.azg.nl					BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MCLAURIN RL, 1965, J NEUROSURG, V23, P296, DOI 10.3171/jns.1965.23.3.0296; Minderhoud J M, 1979, Acta Neurochir Suppl (Wien), V28, P63; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Silver BV, 1996, BRAIN INJURY, V10, P609; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207	19	39	39	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2000	14	9					781	788					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357YT	WOS:000089530300002	11030452				2021-06-18	
J	Stablum, F; Umilta, C; Mogentale, C; Carlan, M; Guerrini, C				Stablum, F; Umilta, C; Mogentale, C; Carlan, M; Guerrini, C			Rehabilitation of executive deficits in closed head injury and anterior communicating artery aneurysm patients	PSYCHOLOGICAL RESEARCH-PSYCHOLOGISCHE FORSCHUNG			English	Article							RECOVERY; CONCUSSION; IMPAIRMENT; ADJUSTMENT; COGNITION; ATTENTION	This paper reports a study that was aimed to rehabilitate executive functions in closed head injury (CHI) and anterior communicating artery (ACoA) aneurysm patients. The groups tested comprised 10 CHI patients, 9 ACoA aneurysm patients and 19 controls. We employed a dual-task paradigm that is known to tap the ability to co-ordinate two actions. The treatment consisted of five experimental sessions, in which the dual-task paradigm was used. In the CHI study, the dual-task cost was measured before the treatment (assessment), immediately after the treatment (retest), and 3 months after the treatment (follow-up). In the ACoA aneurysm study, the dual-task cost was also assessed 12 months after the treatment. A significant reduction of the dual-task cost from assessment to retest was found. This reduction remained stable in the follow-up sessions. The results are discussed with reference to the absence of spontaneous recovery of this specific executive function and to the possibility that the beneficial effect of the treatment generalises to other executive functions and/or daily living activities.	Univ Padua, Dipartimento Psicol Gen, I-35131 Padua, Italy	Stablum, F (corresponding author), Univ Padua, Dipartimento Psicol Gen, Via Venezia 8, I-35131 Padua, Italy.			Stablum, Franca/0000-0003-0123-5090			Allport D. A, 1993, ATTENTION PERFORM, P183; BENYISHAY Y, 1979, REHABILITATION MONOG, V61; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; DELUCA J, 1995, J CLIN EXP NEUROPSYC, V17, P100, DOI 10.1080/13803399508406586; Fuster JM., 1980, PREFRONTAL CORTEX; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LAWSON MJ, 1989, J EXPT CLIN NEUROPSY, V11, P824; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; PASHLER H, 1989, Q J EXP PSYCHOL-A, V41, P19, DOI 10.1080/14640748908402351; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prigatano G., 1985, NEUROPSYCHOLOGICAL R; SHALLICE T, 1994, ATTENTION PERFORM, V15, P395; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; TEASDALE G, 1974, LANCET, V2, P81; TEXLER LE, 1982, COGNITIVE REHABILITA; Umilta C, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P37; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wood R L, 1987, Int Disabil Stud, V9, P149	43	39	39	0	9	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0340-0727			PSYCHOL RES-PSYCH FO	Psychol. Res.-Psychol. Forsch.	AUG	2000	63	3-4					265	278		10.1007/s004269900002			14	Psychology, Experimental	Psychology	350DJ	WOS:000089085200005	11004880				2021-06-18	
J	Hrbac, J; Kohen, R				Hrbac, J; Kohen, R			Biological redox activity: Its importance, methods for its quantification and implication for health and disease	DRUG DEVELOPMENT RESEARCH			English	Article						redox potential; biological redox state; cyclic voltammetry; antioxidants; reactive oxygen species	CLOSED-HEAD INJURY; OXIDATIVE STRESS; ANTIOXIDANT CAPACITY; CYCLIC VOLTAMMETRY; IN-VIVO; REDUCTION; TISSUES	Cellular redox phenomena are involved in numerous biochemical pathways and play a key role in many pathological events and clinical situations. The overall oxidation/reduction (redox) state present in biological compartments is a major target for possible pharmaceutical intervention and, consequently, the processes associated with its change have attracted increased attention in recent years. This overview describes the methods for evaluating the concentrations of redox active compounds and their redox activity and the methods for evaluating the overall biological fluids and tissues redox capacity, with a focus on the redox potential parameter, its modulation, its measurement, and its importance for diagnosis and treatment. Examples of voltammetric measurement of reducing power profiles of biological tissues and fluids in healthy and disease states are discussed. (C) 2000 Wiley-Liss, Inc.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel	Kohen, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, POB 12065, IL-91120 Jerusalem, Israel.	ronko@cc.huji.ac.il	Hrbac, Jan/A-1007-2009				Alexander R W, 1998, Trans Am Clin Climatol Assoc, V109, P129; Berry EM, 1999, MED HYPOTHESES, V53, P397, DOI 10.1054/mehy.1998.0786; Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272; BLAU S, 2000, IN PRESS DIGEST DIS; Cao GH, 1999, METHOD ENZYMOL, V299, P50; CLARK WM, 1965, OXIDATION REDUCTION; Dolan ME, 1998, ANTI-CANCER DRUG, V9, P437, DOI 10.1097/00001813-199806000-00011; Elangovan V, 2000, FREE RADICAL RES, V32, P125, DOI 10.1080/10715760000300131; Engelhardt JF, 1999, ANTIOXID REDOX SIGN, V1, P5, DOI 10.1089/ars.1999.1.1-5; Halliwell B., 1989, FREE RADICAL BIO MED, P160; HAWKRIDGE FM, 1973, ANAL CHEM, V45, P1021, DOI 10.1021/ac60329a038; Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kohen R, 1999, BIOMED PHARMACOTHER, V53, P181, DOI 10.1016/S0753-3322(99)80087-0; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kohen R, 2000, FREE RADICAL BIO MED, V28, P871, DOI 10.1016/S0891-5849(00)00191-X; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KOHEN R, 2000, IN PRESS TOXICOLOGY; KOHEN R, 1993, 100 ILSI; Kuhn DM, 1998, J NEUROSCI, V18, P7111; LOXTON GE, 1953, NATURE, V171, P524, DOI 10.1038/171524a0; NOEL M, 1990, CYCLIC VOLTAMMETRY F, P62; O'Neill RD, 1998, CRIT REV NEUROBIOL, V12, P69, DOI 10.1615/CritRevNeurobiol.v12.i1-2.40; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.0.CO;2-Q; Prieto-Alamo MJ, 1999, CARCINOGENESIS, V20, P415, DOI 10.1093/carcin/20.3.415; RIGO A, 1977, FEBS LETT, V80, P130, DOI 10.1016/0014-5793(77)80422-5; ROSSITER BW, 1986, PHYSICAL METHODS CHE, V2; ROUILLON JD, 1987, J PHARMACOL METHOD, V17, P179, DOI 10.1016/0160-5402(87)90029-5; Sen CK, 1996, FASEB J, V10, P709; SHAPIRO HM, 1972, J SURG RES, V13, P138, DOI 10.1016/0022-4804(72)90057-1; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Torimura M, 1998, ANAL CHEM, V70, P4690, DOI 10.1021/ac980621z; Wang S, 1998, P SOC EXP BIOL MED, V217, P197, DOI 10.3181/00379727-217-44223; WEISSENBERGER A, 1971, PHYSICAL METHODS CHE, V1; YANNAI EB, 1997, J CEREB BLOOD FLOW M, V17, P273; ZHANG C, 1998, INT SER ON ADVANC FR, V2, P1	41	39	39	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0272-4391	1098-2299		DRUG DEVELOP RES	Drug Dev. Res.	JUL-AUG	2000	50	3-4					516	527		10.1002/1098-2299(200007/08)50:3/4<516::AID-DDR35>3.0.CO;2-B			12	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	359TK	WOS:000089628000035					2021-06-18	
J	Meeuwisse, WH; Hagel, BE; Mohtadi, NGH; Butterwick, DJ; Fick, GH				Meeuwisse, WH; Hagel, BE; Mohtadi, NGH; Butterwick, DJ; Fick, GH			The distribution of injuries in men's Canada west university football - A 5-year analysis	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							HIGH-SCHOOL FOOTBALL; HEAD; CONCUSSION; SPORTS; FATALITIES; REGISTRY	We conducted a prospective cohort study from 1993 to 1997 to determine the frequency and severity of injury in men's Canada West university football. The Canadian Intercollegiate Sport Injury Registry was used to document baseline preseason data, daily athlete participation, and subsequent injury from five varsity football teams. An injury was defined as "any injury resulting in one or more complete or partial sessions of time loss" or "any concussion or transient neck neurologic injury." The annual proportion of injured athletes ranged from 53.5% to 60.4%, with a 5-year total of 1811 injuries. Regression analysis indicated that the rate of nonconcussion, nonneck neurologic injuries increased. Concussion (N = 110), hamstring strain (N = 88), and brachial plexus (N = 84) injuries were the most common, specific injury diagnoses. Knee injuries resulted in the highest rate of severe (greater than or equal to 7 sessions of time loss) injury and resulted in the most time loss (3350.5 sessions). Ligament sprains and muscle strains and spasms accounted for approximately half of all injury diagnoses. A total of 1173 injuries (65%) were related to contact between players or between players and other obstacles. Future studies should be conducted to identify risk factors for the ultimate purpose of implementing injury prevention strategies.	Univ Calgary, Ctr Sports Med, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada	Meeuwisse, WH (corresponding author), Univ Calgary, Ctr Sports Med, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.		Hagel, Brent/AAK-3319-2020				ADKISON JW, 1974, CLIN ORTHOP RELAT R, P131; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ALLEY RH, 1964, JAMA-J AM MED ASSOC, V188, P418; BLYTH CS, 1974, PHYSICIAN SPORTSMED, V2, P45; BLYTH CS, 1974, PHYSICIAN SPORTSMED, V2, P49; BLYTH CS, 1974, PHYSICIAN SPORTSMED, V2, P71; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cahill B R, 1979, Am J Sports Med, V7, P183, DOI 10.1177/036354657900700309; CANALE ST, 1981, AM J SPORT MED, V9, P384, DOI 10.1177/036354658100900608; CANTU RC, 1992, CLIN J SPORT MED, V2, P180; DAGLAU RF, 1980, AM J SPORTS MED, V8, P257; DEHAVEN KE, 1986, AM J SPORT MED, V14, P218, DOI 10.1177/036354658601400307; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V12, P122; GRONWALL D, 1975, LANCET, V2, P995; KARPAKKA J, 1993, BRIT J SPORT MED, V27, P135, DOI 10.1136/bjsm.27.2.135; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, AM SOC TEST MATER, V1305, P35, DOI 10.1520/STP11770S; LINDER MM, 1995, CLIN J SPORT MED, V5, P167, DOI 10.1097/00042752-199507000-00006; MEEUWISSE WH, 1988, CAN J SPORT SCI, V13, P35; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Meeuwisse WH, 1999, J INFORMATICS PRIM C, P2; MEEUWISSE WH, 1994, THESIS U CALGARY CAL; Mueller F O, 1974, J Sports Med, V2, P1; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; MUELLER FO, 1984, ATHLETIC TRAINING, V19, P189; Murphy R J, 1978, Phys Sportsmed, V6, P94, DOI 10.1080/00913847.1978.11710760; *NAT COLL ATHL ASS, 1998, INJ SURV SYST; *NAT COLL ATHL ASS, 1996, INJ SURV SYST; Olson O C, 1979, Phys Sportsmed, V7, P75, DOI 10.1080/00913847.1979.11710899; POWELL J, 1987, Athletic Training, V22, P19; Powell J W, 1988, Am J Sports Med, V16 Suppl 1, pS134; POWELL JW, 1992, AM J SPORT MED, V20, P686, DOI 10.1177/036354659202000609; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; PRITCHETT JW, 1980, AM J SPORT MED, V8, P197, DOI 10.1177/036354658000800310; PRITCHETT JW, 1982, J BONE JOINT SURG AM, V64, P240, DOI 10.2106/00004623-198264020-00015; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; VERESCHAGIN KS, 1991, PHYSICIAN SPORTSMED, V19, P96; Whitley RI, 1985, HERPESVIRUSES, V3, P1; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	44	39	40	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JUL-AUG	2000	28	4					516	523		10.1177/03635465000280041201			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	337PK	WOS:000088370700012	10921643				2021-06-18	
J	Russo, RN; O'Flaherty, S				Russo, RN; O'Flaherty, S			Bromocriptine for the management of autonomic dysfunction after severe traumatic brain injury	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						autonomic dysfunction; bromocriptine; traumatic brain injury	SEVERE HEAD-INJURY; HYPERTENSION	This case report describes a child with severe traumatic brain injury with clinical features of autonomic dysfunction in the immediate post-traumatic period. A history of severe asthma in this child contraindicated the use of beta-blockers, the first line approach, and she was managed with bromocriptine (0.05 mg/kg t.d.s) with good effect.	Royal Alexandra Hosp Children, Dept Rehabil Med, Parramatta, NSW, Australia	Russo, RN (corresponding author), Womens & Childrens Hosp, Child Dev & Rehab Dept, 72 King William Rd, N Adelaide, SA 5006, Australia.						BRINK J, 1980, J PEDIATR, V5, P721; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; HEIMER L, 1983, HUMAN BRAIN SPINAL C, P303; HORN LJ, 1996, MED REHABILITATION T, P540; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KANTER RK, 1985, CLIN PEDIATR, V24, P320, DOI 10.1177/000992288502400603; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; LABI M L C, 1990, Brain Injury, V4, P365, DOI 10.3109/02699059009026189; MCLEAN DE, 1995, J HEAD TRAUMA REHAB, V5, P1; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; OVERGAARD J, 1973, LANCET, V2, P631; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROSNER B, 1993, J PEDIATR-US, V123, P871, DOI 10.1016/S0022-3476(05)80382-8; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SHIOZAKI T, 1993, J NEUROSURG, V78, P501, DOI 10.3171/jns.1993.78.3.0501; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022	24	39	43	0	0	BLACKWELL SCIENCE ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	1034-4810			J PAEDIATR CHILD H	J. Paediatr. Child Health	JUN	2000	36	3					283	285		10.1046/j.1440-1754.2000.00485.x			3	Pediatrics	Pediatrics	317LQ	WOS:000087227200020	10849235				2021-06-18	
J	Greenspan, AI; Mackenzie, EJ				Greenspan, AI; Mackenzie, EJ			Use and need for post-acute services following paediatric head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CHILDREN; REHABILITATION	This paper aims to document the types of inpatient and outpatient post-acute services children receive after discharge from an acute care hospital for head injury and to better understand the extent to which children fail to receive services and the reasons for not receiving needed services. A follow-up was conducted on 95 children (aged 5-15) 1 year after they were hospitalized for head injury. Parents were interviewed by phone concerning their child's use of and need for medical, rehabilitation, and social services since the injury. Questions were also asked regarding the child's current health status and behaviour. Inpatient records were reviewed to obtain information on the characteristics of the injury. Overall use of outpatient rehabilitation and social services was low during the year following injury, ranging from 0-18%, of the study sample. Although need for and use of services was positively correlated with head injury severity, it appears that unmet need was highest for children with the least severe head injuries. Finally, need for physical or occupational therapy and mental health services was unrecognized for one third of children with physical limitations and 40% of children with at least 14 identified behaviour problems. These findings underscore the need for physicians and other health care professionals to thoroughly evaluate children during follow-up visits as well as during the initial hospitalization for head injury-related deficits. Identification of functional deficits or behavioural problems should be followed-up by evaluation and treatment by qualified rehabilitation professionals.	Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21218 USA	Greenspan, AI (corresponding author), Emory Univ, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.						Aday L.A., 1980, HLTH CARE US EQUITAB; ADAY LA, 1984, ACCESS MED CARE US H; ANDERSEN R, 1978, MED CARE, V16, P533, DOI 10.1097/00005650-197807000-00001; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; *COMM TRAUM RES CO, 1985, INJ AM CONT HLTH PRO; EISEN M, 1980, R2313HEW; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; GREENSPAN AI, 1989, MARYLAND MED J, V28, P239; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hulka B S, 1978, J Community Health, V4, P140, DOI 10.1007/BF01318950; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; JAFFE KM, 1992, PEDIATR ANN, V21, P443; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; SOLOMON E, 1988, THESIS J HOPKINS U B; STONNINGTON HH, 1991, VIRGINIA MED Q, V18, P159; TEASDALE G, 1974, LANCET, V2, P81; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Zill N, 1985, BEHAV PROBLEM SCALES; ZILL N, 1985, BEHAV PROBLEMS INDEX	24	39	39	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2000	14	5					417	429					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	316MQ	WOS:000087171500003	10834337				2021-06-18	
J	Jones, SJ; Pato, MV; Sprague, L; Stokes, M; Munday, R; Haque, N				Jones, SJ; Pato, MV; Sprague, L; Stokes, M; Munday, R; Haque, N			Auditory evoked potentials to spectro-temporal modulation of complex tones in normal subjects and patients with severe brain injury	BRAIN			English	Article						auditory evoked potentials; auditory cortex; brain injury; coma; mismatch negativity	EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY; TRAUMATIC COMA; HEAD-INJURY; CORTEX; TOOL; REPRESENTATION; NEUROSCIENCE; RESPONSES; PARADIGM	In order to assess higher auditory processing capabilities, long-latency auditory evoked potentials (AEPs) were recorded to synthesized musical instrument tones in 22 post-comatose patients with severe brain injury causing variably attenuated behavioural responsiveness. On the basis of normative studies, three different types of spectre-temporal modulation were employed. When a continuous 'clarinet) tone changes pitch once every few seconds, N1/P2 potentials are evoked at latencies of similar to 90 and 180 ms, respectively. Their distribution in the fronto-central region is consistent with generators in the supratemporal cortex of both hemispheres. When the pitch is modulated at a much faster rate (similar to 16 changes/s), responses to each change are virtually abolished but potentials with similar distribution are still elicited by changing the timbre (e.g. 'clarinet' to 'oboe') every few seconds. These responses appear to represent the cortical processes concerned with spectral pattern analysis and the grouping of frequency components to form sound 'objects'. Following a period of 16/s oscillation between two pitches, a more anteriorly distributed negativity is evoked on resumption of a steady pitch. Various lines of evidence suggest that this is probably equivalent to the 'mismatch negativity' (MMN), reflecting a pre-perceptual, memory-based process for detection of change in spectrotemporal sound patterns. This method requires no offline subtraction of AEPs evoked by the onset of a tone, and the MMN is produced rapidly and robustly with considerably larger amplitude (usually >5 mu V) than that to discontinuous pure tones. In the brain-injured patients, the presence of AEPs to two or more complex tone stimuli (in the combined assessment of two authors who mere 'blind! to the clinical and behavioural data) was significantly associated with the demonstrable possession of discriminative hearing (the ability to respond differentially to verbal commands, in the assessment of a further author who was blind to the AEP findings). Behavioural and electrophysiological findings were in accordance in 18/22 patients, but no AEPs could be recorded in two patients who had clear behavioural evidence of discriminative hearing. The absence of long-latency AEPs should not, therefore, be considered indicative of complete functional deafness. Conversely, AEPs mere substantially preserved in two patients without behavioural evidence of discriminative hearing. Although not necessarily indicative of conscious 'awareness', such AEP preservation might help to identify sentient patients who are prevented by severe motor disability from communicating their perception.	UCL Natl Hosp Neurol & Neurosurg, Dept Clin Neurophysiol, London WC1N 3BG, England; Royal Hosp Neurodisabil, Res Dept, London, England; Royal Hosp Neurodisabil, Occupat Therapy Dept, London, England	Jones, SJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Clin Neurophysiol, Queen Sq, London WC1N 3BG, England.	sjjones@ion.ucl.ac.uk	da Assuncao AMC Vaz Patto, Maria/A-1091-2017; Stokes, Maria/G-2288-2011	da Assuncao AMC Vaz Patto, Maria/0000-0002-0653-3428; Stokes, Maria/0000-0002-4204-0890			ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; Bregman A.S., 1990, AUDITORY SCENE ANAL; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; COWAN N, 1984, PSYCHOL BULL, V96, P341, DOI 10.1037/0033-2909.96.2.341; EGGERMONT JJ, 1995, NEUROREPORT, V6, P1645, DOI 10.1097/00001756-199508000-00014; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GUERIT JM, 1999, ELECTROEN CLIN NEURO, V110, P1260; Halliday A., 1993, EVOKED POTENTIALS CL; Jones SJ, 1998, EVOKED POTENTIAL, V108, P355, DOI 10.1016/S0168-5597(98)00009-4; Jones SJ, 1998, EVOKED POTENTIAL, V108, P131, DOI 10.1016/S0168-5597(97)00077-4; Jones SJ, 1999, EEG CL N SU, P41; JONES SJ, 2000, P 4 INT S MEM AW AN, V4, P269; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; NAATANEN R, 1995, EAR HEARING, V16, P6; Pato MV, 1999, COGNITIVE BRAIN RES, V7, P295; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Rappaport M, 1990, J Neuropsychiatry Clin Neurosci, V2, P399; RITTER W, 1995, EAR HEARING, V16, P52, DOI 10.1097/00003446-199502000-00005; RUIJS MBM, 1993, NEUROPEDIATRICS, V24, P307, DOI 10.1055/s-2008-1071562; SAMSON S, 1994, NEUROPSYCHOLOGIA, V32, P231, DOI 10.1016/0028-3932(94)90008-6; Schreiner CE, 1998, AUDIOL NEURO-OTOL, V3, P104, DOI 10.1159/000013785; SHIN DY, 1989, ARCH PHYS MED REHAB, V70, P189; Signorino M, 1997, J PSYCHOPHYSIOL, V11, P59; STEINSCHNEIDER M, 1995, BRAIN RES, V674, P147, DOI 10.1016/0006-8993(95)00008-E; Versnel H, 1998, J ACOUST SOC AM, V103, P2502, DOI 10.1121/1.422771; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685; Yabe H, 1998, PSYCHOPHYSIOLOGY, V35, P615, DOI 10.1017/S0048577298000183	33	39	42	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2000	123		5				1007	1016		10.1093/brain/123.5.1007			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	323TK	WOS:000087580900014	10775545	Bronze			2021-06-18	
J	Nell, V; Yates, DW; Kruger, J				Nell, V; Yates, DW; Kruger, J			An extended Glasgow Coma Scale (GCS-E) with enhanced sensitivity to mild brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Aspen Neurobehavioral Conference	APR, 1998	ASPEN, COLORADO			Glasgow Coma Scale; mild traumatic brain injury; posttraumatic amnesia; developing countries; rehabilitation	HEAD-INJURY	Objective: The Glasgow Coma Scale-Extended (GCS-E) was developed to flag mild cases of concussion (corresponding to Grades I and II concussion as defined by the American Academy of Neurology) at the time of first contact with the health care system. Subjects and Setting: The GCS-E was applied to 561 consecutive admissions with GCS scores of 13 to 15 at two hospitals in South Africa and two in the United Kingdom (UK). Results: The amnesia scale was readily learned and reliably applied by emergency department staff without affecting the standard scoring of the GCS itself. Among patients with an admitting GCS of 15, 27% in the UK and 31% in South Africa reported amnesia of some duration. Conclusions: Wide use of the GCS-E would hold mild traumatic brain injury cases in the treatment loop, improve access to counselling, rehabilitation services, and personal injury compensation, and reduce the "cognitive dissonance" between victims of mild traumatic brain injury and treating professionals.	Univ S Africa, Inst Social & Hlth Sci, ZA-0001 Pretoria, South Africa; Univ S Africa, Dept Psychol, ZA-0001 Pretoria, South Africa; Univ Manchester, Dept Surg, Manchester, Lancs, England	Nell, V (corresponding author), Univ S Africa, Inst Social & Hlth Sci, POB 392, ZA-0001 Pretoria, South Africa.						Benton A. L, 1989, MILD HEAD INJURY, P3; BLAKELY TA, 1993, MED SCI LAW, V33, P231, DOI 10.1177/002580249303300309; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Jennett B, 1989, MILD HEAD INJURY, P23; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marshall LF, 1989, MILD HEAD INJURY, P276; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; NELL V, 1997, 972 U S AFR HLTH PSY; Norusis M.J., 1993, SPSS WINDOWS BASE SY; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Romer CJ, 1995, PREVENTION CRITICAL; TEASDALE G, 1974, LANCET, V2, P81; THURMAN DJ, 1995, WHO STANDARDS SURVEI; Wilson B.A., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [10.1080/09602019208401410, DOI 10.1080/09602019208401410]	16	39	42	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2000	81	5					614	617		10.1053/mr.2000.3877			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	311CT	WOS:000086867800013	10807101				2021-06-18	
J	Sahjpaul, R; Girotti, M				Sahjpaul, R; Girotti, M			Intracranial pressure monitoring in severe traumatic brain injury - Results of a Canadian survey	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTENSIVE-CARE; UNITED-KINGDOM; MANAGEMENT; METABOLISM; HYPOTHERMIA; MORTALITY	Objective: The purpose of this study was to obtain information from Canadian neurosurgeons regarding their opinions on, and utilization of, intracranial pressure (ICP) monitoring for severe traumatic brain injury (TBT). Methods: A brief survey was sent to practicing Canadian neurosurgeons questioning them about their utilization of, and confidence in, intracranial pressure monitoring in the management of patients with severe TBI. Results: One hundred and ninety-six surveys were mailed. There were 103 responses for a response rate of 52.6%. The vast majority of responding neurosurgeons (98.1%) utilized ICP monitoring in the management of patients with severe TB I, with most (63.4%) using it in more than 75% of their patients, 14.9% using it in 50-75% of patients, 14.9% in 25-50% of patients, and 6.9% using it in less than 25% of patients. The level of confidence that routine monitoring improves outcome from severe TBI ranged from 23.3% having a low level of confidence, 56,3% having an intermediate level of confidence, to 20.4% having a high level of confidence. Most respondents (78.6%) felt that some form of prospective trial evaluating the role of ICP monitoring in improving outcome from severe TBI was warranted; 17.4% felt such a trial was not warranted and 3.9% were uncertain. Conclusions: While ICP monitoring has gained almost universal acceptance among responding Canadian neurosurgeons, their level of confidence that routine monitoring improves outcome from severe TBI was quite variable, with only 20.4% of respondents having a high level of confidence. Over 75% of respondents felt that some form of prospective trial evaluating the utility of ICP monitoring is warranted. This information is being used in consideration of a prospective trial addressing this issue.	London Hlth Sci Ctr, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada	Sahjpaul, R (corresponding author), London Hlth Sci Ctr, Dept Clin Neurol Sci, Univ Campus,339 Windermere Rd, London, ON N6A 5A5, Canada.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Chesnut RM, 1998, SURG NEUROL, V50, P187, DOI 10.1016/S0090-3019(98)00075-5; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1997, AM ASS NEUROLOGI SUM, P2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schneck MJ, 1998, CRIT CARE MED, V26, P1787, DOI 10.1097/00003246-199811000-00012; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601	33	39	46	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2000	27	2					143	147					5	Clinical Neurology	Neurosciences & Neurology	313DY	WOS:000086986100010	10830348				2021-06-18	
J	Crevits, L; Hanse, MC; Tummers, P; Van Maele, G				Crevits, L; Hanse, MC; Tummers, P; Van Maele, G			Antisaccades and remembered saccades in mild traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						antisaccades; remembered saccades; mild traumatic brain injury; frontal lobe	POSITRON EMISSION TOMOGRAPHY; HEAD-INJURY; CORTICAL CONTROL	The most common site of focal lesions after mild traumatic brain injury (MTBI) is the frontal lobe. This lobe, however, is difficult to examine clinically. Neuroimaging is not performed routinely and usually shows normal results in uncomplicated trauma. Antisaccades (AS) and remembered saccades (RS) are neuro-ophthalmological tests of frontal function. This study examined whether there are disturbances of latency time or error rate of; AS and RS in patients within 24 h after MTBI. Eye movements were studied with infrared-oculography. Data were obtained prospectively from 25 patients. An additional group of 6 patients with MTBI and alcohol intoxication were also examined. No statistical differences in AS or RS, either for errors or for latency time, were found between a group of age-matched controls and the patients, except in the group of alcohol-intoxicated MTBI patients. Our findings indicate that visual reflex inhibition and initiation of voluntary saccades were not disturbed in the nonintoxicated patients. It is hypothesized that the responsible frontal area was not affected. It is concluded that error rate and latency time of AS and RS are inappropriate measures for evaluating acute MTBI.	Univ Hosp Ghent, Dept Neurol, Neuroophthalmol Unit, B-9000 Ghent, Belgium; Univ Hosp Ghent, Dept Med Informat & Stat, B-9000 Ghent, Belgium	Crevits, L (corresponding author), Univ Hosp Ghent, Dept Neurol, Neuroophthalmol Unit, De Pintelaan 185, B-9000 Ghent, Belgium.						BOHNEN N, 1992, NEUROSURGERY, V30, P692; Gale BW, 1996, INVEST OPHTH VIS SCI, V37, P339; HADLEY DM, 1988, CLIN RADIOL, V39, P131; JANNTI V, 1983, PSYCHOPHARMACOLOGY B, V79, P251; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kronsbein H., 1994, Blutalkohol, V31, P57; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; PIERROTDESEILLIGNY C, 1995, ANN NEUROL, V37, P557, DOI 10.1002/ana.410370504; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203	12	39	39	0	12	DR DIETRICH STEINKOPFF VERLAG	DARMSTADT	PLATZ DER DEUTSCHEN EINHEIT 25, D-64293 DARMSTADT, GERMANY	0340-5354			J NEUROL	J. Neurol.	MAR	2000	247	3					179	182		10.1007/s004150050559			4	Clinical Neurology	Neurosciences & Neurology	303ZC	WOS:000086457200004	10787111				2021-06-18	
J	Legros, B; Fournier, P; Chiaroni, P; Ritz, O; Fusciardi, J				Legros, B; Fournier, P; Chiaroni, P; Ritz, O; Fusciardi, J			Basal fracture of the skull and lower (IX, X, XI, XII) cranial nerves palsy: Four case reports including two fractures of the occipital condyle - A literature review	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							FATAL TRAFFIC ACCIDENTS; COLLET-SICARD SYNDROME; CLOSED-HEAD-INJURY		CHU Tours, Dept Anesthesiol & Intens Care 2, F-37044 Tours, France	Legros, B (corresponding author), CHU Tours, Dept Anesthesiol & Intens Care 2, F-37044 Tours, France.						AHLGREN P, 1962, ROFO-FORTSCHR RONTG, V97, P388; ALKER GJ, 1975, RADIOLOGY, V114, P611; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; Aubry M, 1968, Ann Otolaryngol Chir Cervicofac, V85, P338; BELL C, 1817, MIDDLESEX HOSP J, V4, P469; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; Brennan Richard J., 1993, Journal of Emergency Medicine, V11, P167, DOI 10.1016/0736-4679(93)90514-8; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; BUCHOLZ RW, 1979, J TRAUMA, V19, P768, DOI 10.1097/00005373-197910000-00009; CASTLING B, 1995, BRIT J ORAL MAX SURG, V33, P171, DOI 10.1016/0266-4356(95)90292-9; Clavier E, 1986, J Radiol, V67, P323; CLAYMAN DA, 1994, AM J NEURORADIOL, V15, P1309; Collet FJ, 1915, LYON MED, V124, P121; Cottalorda J, 1996, J PEDIATR ORTHOP B, V5, P61, DOI 10.1097/01202412-199605010-00013; Curri D, 1988, J Neurosurg Sci, V32, P157; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; GRUNDY DJ, 1984, SPINE, V9, P339, DOI 10.1097/00007632-198405000-00002; HARDINGSMITH J, 1981, J BONE JOINT SURG AM, V63, P1170, DOI 10.2106/00004623-198163070-00016; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; HEINZE J, 1969, MED J AUSTRALIA, V2, P1246, DOI 10.5694/j.1326-5377.1969.tb103371.x; Hollerhage H G, 1986, Zentralbl Neurochir, V47, P250; Jubier P, 1970, Rev Otoneuroophtalmol, V42, P189; LACOMBE H, 1989, ENCY MED CHIR PARIS, P20; Laine FJ, 1998, NEUROIMAG CLIN N AM, V8, P69; Lam CH, 1996, CAN J NEUROL SCI, V23, P145, DOI 10.1017/S0317167100038890; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; PALEY MD, 1995, BRIT J ORAL MAX SURG, V33, P239, DOI 10.1016/0266-4356(95)90008-X; Peeters F, 1983, Rofo, V138, P631, DOI 10.1055/s-2008-1055803; RAILA FA, 1993, SKELETAL RADIOL, V22, P269; Rebattu J, 1925, ANN MALADIES OREILE, V44, P1013; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SHLIACK H, 1965, NERVENARZT, V36, P362; Sicard J.A., 1917, MARSEILLE MED, V53, P385; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; STROOBANTS J, 1994, J NEUROSURG, V81, P137, DOI 10.3171/jns.1994.81.1.0137; Urculo E, 1996, J NEUROSURG, V84, P522, DOI 10.3171/jns.1996.84.3.0522; VIADAR F, 1995, ENCYCL MED CHIR, P9; WANI MA, 1991, J TRAUMA, V31, P1437, DOI 10.1097/00005373-199110000-00025; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008	41	39	41	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2000	48	2					342	348		10.1097/00005373-200002000-00031			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	284MH	WOS:000085335800036	10697104				2021-06-18	
J	Stiefel, D; Eich, G; Sacher, P				Stiefel, D; Eich, G; Sacher, P			Posttraumatic dural sinus thrombosis in children	EUROPEAN JOURNAL OF PEDIATRIC SURGERY			English	Article						dural sinus thrombosis; head injury; children	CLOSED HEAD-INJURY; SUPERIOR	Posttraumatic dural sinus thrombosis (DST) in children has rarely been described in the literature. Over a period of two years (1994-1996) we treated 131 children (n = 131) with minor or severe head-injury requiring a cranial computed tomography (CT) scan. DST was found in eight patients (6.1%), five with mild and three with severe cranial trauma. Diagnosis was suspected either because of a skull fracture crossing over a dural sinus or because of a hyperdensity at a dural sinus in the noncontrast CT scan. Enhanced CT scan was used to confirm DST. No specific symptoms related to DST were observed. DST was managed conservatively in all patients and recovery was uneventful. Recanalization of the sinus was documented to occur within three weeks to six months in six children. One patient showed a residual clot after five months and another did not have a follow-up CT scan. Based on our data we conclude that neither surgical nor medical intervention is indicated in traumatic DST in children.	Univ Zurich, Childrens Hosp, Dept Pediat Surg, Zurich, Switzerland; Univ Zurich, Childrens Hosp, Dept Radiol, Zurich, Switzerland	Stiefel, D (corresponding author), UCL, Inst Child Hlth, Neurol Dev Unit, 30 Guilford St, London WC1N 1EH, England.						CURE JK, 1995, AM J NEURORADIOL, V16, P1539; GARCIA RDJ, 1995, PEDIATR INFECT DIS J, V14, P617; HESSELBROCK R, 1985, NEUROSURGERY, V16, P825, DOI 10.1227/00006123-198506000-00017; KINAL ME, 1967, J NEUROSURG, V27, P142, DOI 10.3171/jns.1967.27.2.0142; Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7; RICH C, 1993, STROKE, V24, P603, DOI 10.1161/01.STR.24.4.603; SCHULZ U, 1994, KLIN PADIATR, V206, P342, DOI 10.1055/s-2008-1046627; STRINGER WL, 1983, NEUROSURGERY, V12, P95; Sugiura Y, 1996, NEUROL SURG TOKYO, V24, P379; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; TARRAS S, 1988, ARCH NEUROL-CHICAGO, V45, P214, DOI 10.1001/archneur.1988.00520260102029; TODOROW S, 1972, ROFO FORTSCHR RONTG, V117, P544	12	39	40	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-7248			EUR J PEDIATR SURG	Eur. J. Pediatr. Surg.	FEB	2000	10	1					41	44		10.1055/s-2008-1072321			4	Pediatrics; Surgery	Pediatrics; Surgery	301QL	WOS:000086321000008	10770246				2021-06-18	
J	Elangovan, V; Shohami, E; Gati, I; Kohen, R				Elangovan, V; Shohami, E; Gati, I; Kohen, R			Increased hepatic lipid soluble antioxidant capacity as compared to other organs of streptozotocin-induced diabetic rats: A cyclic voltammetry study	FREE RADICAL RESEARCH			English	Article						low molecular weight antioxidant capacity; cyclic voltammetry; oxidative stress; reducing equivalents; vitamin C; alpha-tocopherol; liver	CLOSED-HEAD INJURY; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; MELLITUS; DAMAGE; LIVER	It has been suggested that oxidative stress plays an important role in the chronic complications of diabetes. The experimental findings regarding the changes in tissue antioxidant enzymes and lipid peroxidation of diabetic tissues have been inconsistent. Previous studies in our laboratory demonstrated that the reducing power of a specific tissue correlates with its low molecular weight antioxidant (LMWA) capacity. In the present study, the overall LMWA capacity (reducing equivalents) of plasma and tissues of streptozotocin (STZ)-induced diabetic rats (1-4 weeks) and insulin treated diabetic rats were measured by cyclic voltammetry. Levels of water and lipid soluble LMWA capacity progressively decreased in the diabetic plasma, kidney, heart and brain, while the diabetic liver, at 2, 3 and 4 weeks after STZ injection, showed a significant increase in the overall lipid soluble LMWA capacity (p < 0.001). Subsequently, analysis of specific components by high pressure liquid chromatography (electrochemical detection) showed decreased levels of ascorbic acid in plasma, kidney, heart and brain of diabetic animals. The alpha-tocopherol level dropped in all tissues, except for the liver in which there was a significant increase (p < 0.01 and p < 0.001 at 2-4 weeks). Lipid peroxidation was assessed by conjugated diene levels, which increased significantly in all diabetic tissues except the liver. Insulin treatment that was started after 3 weeks of diabetes and continued for 3 weeks showed no change in the conjugated dienes and in the overall LMWA capacity in all organs. Our results suggest a unique behavior of the liver in the STZ-induced diabetic rats to the stress and indicate its higher capacity to cope with oxidative stress as compared to other organs.	Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel	Kohen, R (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	ronko@cc.huji.ac.il					Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Buege J A, 1978, Methods Enzymol, V52, P302; Ceriello A, 1997, DIABETES CARE, V20, P194, DOI 10.2337/diacare.20.2.194; GODIN DV, 1988, MOL CELL BIOCHEM, V84, P223, DOI 10.1007/BF00421057; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; LOW PA, 1991, DIABETES, V40, P873, DOI 10.2337/diabetes.40.7.873; Mak DHF, 1996, MOL CELL BIOCHEM, V162, P153; Maxwell SRJ, 1997, EUR J CLIN INVEST, V27, P484, DOI 10.1046/j.1365-2362.1997.1390687.x; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; PARINANDI NL, 1990, BIOCHIM BIOPHYS ACTA, V1047, P63, DOI 10.1016/0005-2760(90)90261-U; Sano T, 1998, DIABETOLOGIA, V41, P1355, DOI 10.1007/s001250051076; SAXENA AK, 1993, BIOCHEM PHARMACOL, V45, P539, DOI 10.1016/0006-2952(93)90124-F; Sechi LA, 1997, DIABETOLOGIA, V40, P23, DOI 10.1007/s001250050638; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; SUKALSKI KA, 1993, FREE RADICAL BIO MED, V14, P57, DOI 10.1016/0891-5849(93)90509-S; Sundaram RK, 1996, CLIN SCI, V90, P255, DOI 10.1042/cs0900255; WOHAIEB SA, 1987, DIABETES, V36, P1014, DOI 10.2337/diabetes.36.9.1014; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YOUNG IS, 1992, FREE RADICAL BIO MED, V13, P41, DOI 10.1016/0891-5849(92)90164-C	29	39	40	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.		2000	32	2					125	134		10.1080/10715760000300131			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	276HG	WOS:000084871500003	10653483				2021-06-18	
J	Thatcher, RW				Thatcher, RW			EEG operant conditioning (biofeedback) and traumatic brain injury	CLINICAL ELECTROENCEPHALOGRAPHY			English	Article						discriminant functions; EEG biofeedback; normative databases; quantitative EEG; traumatic brain injury	CLOSED-HEAD INJURY; QUANTITATIVE EEG; FOLLOW-UP; REHABILITATION; NEUROFEEDBACK; ATTENTION		Univ S Florida, Vet Adm Med Ctr, Coll Med, Tampa, FL 33620 USA; Def & Vet Head Injury Program, Washington, DC USA	Thatcher, RW (corresponding author), Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33504 USA.						ALLEN JB, 1996, PSYCHOLPHYSIOLOGY S, V33, pSU7; AYERS ME, 1987, NATL HEAD INJURY SYL, P380; Baehr E, 1998, INT J PSYCHOPHYSIOL, V31, P89, DOI 10.1016/S0167-8760(98)00041-5; Baehr E, 1998, J NEUROTHER, V2, P12; BARTH J, 1983, NEUROSURGERY, V13, P520; BERNAD PG, 1988, CLIN ELECTROENCEPHAL, V19, P174; BYERS AP, 1995, J NEUROTHERAPY, V1, P22, DOI DOI 10.1300/J184V01N01_; CAVENESS W, 1977, TRAUMA, V18, P61; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen M. J., 1975, 8 ANN WINT C BRAIN R, P1; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FOX SS, 1968, SCIENCE, V162, P1299, DOI 10.1126/science.162.3859.1299; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Ham LP, 1996, BIOFEEDBACK SELF-REG, V21, P93, DOI 10.1007/BF02284689; HETZLER BE, 1977, PHYSIOL BEHAV, V19, P527, DOI 10.1016/0031-9384(77)90229-3; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOFFMAN DA, 1996, CLIN ELECTROENCEPHAL, V27, P6; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JOHN ER, 1977, SCIENCE, V196, P1393, DOI 10.1126/science.867036; JONES CL, 1992, HDB HEAD TRAUMA; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; Lubar JF, 1997, APPL PSYCHOPHYS BIOF, V22, P111, DOI 10.1023/A:1026276228832; LUBAR JF, 1981, ARCH NEUROL-CHICAGO, V38, P700, DOI 10.1001/archneur.1981.00510110060009; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; LUBAR JF, 1991, BIOFEEDBACK SELF-REG, V16, P210; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; NEHAM A, 1998, QUANTITATIVE MULTIVA; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 1996, BRAIN TOPOGR, V8, P201, DOI 10.1007/BF01184770; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; Peniston E, 1993, ADV MED PSYCHOTHER, V6, P37; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Rattok Jack, 1994, P703; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENFELD JP, 1971, PHYSIOL BEHAV, V7, P489, DOI 10.1016/0031-9384(71)90099-0; ROSENFELD JP, 1969, SCIENCE, V165, P821, DOI 10.1126/science.165.3895.821; ROSENFELD JP, 1990, BIOFEEDBACK SELF-REG, V15, P99, DOI 10.1007/BF00999142; ROSENFELD JP, 1995, BIOFEEDBACK SELF-REG, V20, P241, DOI 10.1007/BF01474516; SALAZAR AM, 1998, EFFICACY TRAUMATIC B; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; STERMAN MB, 1974, EPILEPSIA, V15, P395, DOI 10.1111/j.1528-1157.1974.tb04016.x; Sterman MB, 1996, BIOFEEDBACK SELF-REG, V21, P3, DOI 10.1007/BF02214147; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher R.W, 1998, J NEUROTHERAPY, V24, P8; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; THATCHER RW, 1999, INTRO QUANTITATIVE E; TINIUS T, 1996, 4 ANN SSNR C MARC IS; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; WILDER CS, 1976, HLTH INTERVIEW SURVE	64	39	43	0	16	CLINICAL EEG	PEWAUKEEE	N27 W23957 PAUL RD, STE 202, PEWAUKEEE, WI 53072 USA	0009-9155			CLIN ELECTROENCEPHAL	Clin. Electroencephalogr.	JAN	2000	31	1					38	44		10.1177/155005940003100110			7	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	269NY	WOS:000084485500008	10638351				2021-06-18	
J	Hannay, HJ; Feldman, Z; Phan, P; Keyani, A; Panwar, N; Goodman, JC; Robertson, CS				Hannay, HJ; Feldman, Z; Phan, P; Keyani, A; Panwar, N; Goodman, JC; Robertson, CS			Validation of a controlled cortical impact model of head injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						beam balancing; behavioral outcome; controlled cortical impact; contusion; grasp strength; head injury; hippocampus; Morris water maze; motor coordination; mouse; slant board	TRAUMATIC BRAIN INJURY; COGNITIVE DEFICITS; MEMORY DEFICITS; RATS; VELOCITY; VA-045; MOTOR; MOUSE	A controlled cortical impact model of head injury was validated with mice, Mice were randomly assigned to moderate head injury, mild head injury, and sham injury groups, Beam balancing, open field activity, slant board inclination, grasp strength, and motor coordination were assessed prior to the injury and on days 1-5 postinjury, Morris water maze performance was evaluated on days 11-15 postinjury, Moderately head-injured mice took a significantly longer time to complete the motor coordination task and to find the hidden platform on the Morris water maze and had significantly fewer successful trials on bath tasks than the mildly head-injured and sham-injured mice, Mildly head-injured and sham-injured mice performed similarly on both tasks, Contusion volume at the site of impact varied with severity of injury, Moderately head-injured mice had significantly larger contusions than mice with a mild head injury, and these mice in turn had significantly larger contusions than the sham-injured mice, Both moderately and mildly head injured mice had significantly fewer surviving cells in CA1 than the sham-injured mice but did not differ from each other in this regard, Although there was a group effect, only the mildly head-injured mice had significantly fewer surviving cells in CA3.	Univ Houston, Dept Psychol, Houston, TX 77204 USA; Tel Aviv Univ, Dept Neurosurg, IL-69978 Tel Aviv, Israel; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Hannay, HJ (corresponding author), Univ Houston, Dept Psychol, 4800 Calhoun, Houston, TX 77204 USA.			Hannay, H. Julia/0000-0001-7023-912X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHUNG SY, 1995, J NUTR, V125, P1484; DELATORRE JC, 1995, NEUROSURGERY, V37, P273, DOI 10.1227/00006123-199508000-00012; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANNAY HJ, 1993, 11 ANN NEUR S WASH D; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; Tang YP, 1997, BEHAV BRAIN RES, V83, P195, DOI 10.1016/S0166-4328(97)86068-8; Tang YP, 1997, BRIT J PHARMACOL, V122, P257, DOI 10.1038/sj.bjp.0701385	21	39	40	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1103	1114		10.1089/neu.1999.16.1103			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500008	10595826				2021-06-18	
J	Karlovits, T; McColl, MA				Karlovits, T; McColl, MA			Coping with community reintegration after severe brain injury: a description of stresses and coping strategies	BRAIN INJURY			English	Article							DISEASE-RELATED STRESSORS; CLOSED HEAD-INJURY; MENTAL-ILLNESS; INTEGRATION; INDIVIDUALS; ADJUSTMENT; ADULTS	A basic qualitative approach was used to describe the stresses and coping strategies of 11 adults with severe brain injury during a critical period of reintegrating into a new community. Subjects identified nine problems as stressful. The: stresses conform to a theoretical model of community integration, consisting of four factors. social support, independent living, occupation, and a general integration faster. These stresses identified by subjects may be used in the development of a new measure of stress for persons with brain injury. Subjects used eight coping strategies to deal with these stresses. The coping strategies represent a sampling of three major types of coping: problem-focused, perception-focused, and emotion-focused. The findings show that subjects made more use of problem-focused coping strategies than any other type of coping, suggesting that persons with brain injury have awareness of the problems they face and the ability to assert some control over eliminating or managing these problems. The stresses and coping strategies are consistent with existing studies involving persons with brain injury. However, significant differences in some coping strategies reported in this study change how some forms of coping are thought about. The findings delineate the need for professionals to assist persons with brain injury develop more positive, adaptive coping strategies.	N Bay Psychiat Hosp, Minist Hlth, N Bay, ON P1B 8L1, Canada; Queens Univ, Kingston, ON K7L 3N6, Canada	Karlovits, T (corresponding author), N Bay Psychiat Hosp, Minist Hlth, Box 3010,HWY 11N, N Bay, ON P1B 8L1, Canada.						ALBRECHT TL, 1982, SOC WORK, V6, P201; BOWLBY J, 1960, ATTACHMENT LOSS ATTA, V1; CARLING PJ, 1990, AM PSYCHOL, V45, P969, DOI 10.1037/0003-066X.45.8.969; CARLSON P, 1991, ONTARIO PSYCHOL, V23, P12; CERVELLI L, 1990, REHABILITATION ADULT; COGSWELL B, 1977, SOCIAL PSYCHOL ASPEC, P123; CUTLER DL, 1983, EFFECTIVE AFTERCARE; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Field P., 1985, NURSING RES APPL QUA; FOLDMAN S, 1986, J PERS SOC PSYCHOL, V50, P571; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; GOVE WR, 1973, AM J SOCIOL, V78, P812, DOI 10.1086/225404; HOLAHAN CJ, 1986, J PERS SOC PSYCHOL, V51, P389, DOI 10.1037/0022-3514.51.2.389; HOLMES T, 1989, LIFE CHANGING LIFE E; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOLOHAN CJ, 1985, J PERS SOC PSYCHOL, V49, P739; ITTENBACH RF, 1993, RES DEV DISABIL, V14, P275, DOI 10.1016/0891-4222(93)90022-C; Jean VM, 1997, MULT SCLER J, V3, P191, DOI 10.1177/135245859700300304; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; KASL SV, 1970, PSYCHOSOM MED, V32, P19, DOI 10.1097/00006842-197001000-00002; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lazarus R. S., 1977, HUMAN BEHAV ENV CURR; LAZARUS RS, 1974, COPING ADAPTATION, P207; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCHAFFIE HE, 1992, J ADV NURS, V17, P933, DOI 10.1111/j.1365-2648.1992.tb02021.x; MCNETT S, 1997, NURS RES, V36, P98; MECHANIC D, 1962, STUDENTS STRESS; Merriam S. B., 1998, QUALITATIVE RES CASE; MILLER SM, 1988, J PERS SOC PSYCHOL, V54, P142, DOI 10.1037/0022-3514.54.1.142; Monat A., 1985, STRESS COPING ANTHOL, V2nd ed.; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Moos R.H., 1982, HDB STRESS THEORETIC, P212; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nieves C C, 1991, Rehabil Nurs, V16, P129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; *ONT BRAIN INJ ASS, 1996, STAT CANADA; Parkes CM, 1972, BEREAVEMENT STUDIES; PEARLIN LI, 1978, J HLTH SOCIAL BEHAV, V19, P1; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; RAHE RH, 1964, J PSYCHOSOM RES, V8, P35, DOI 10.1016/0022-3999(64)90020-0; SPIRITO A, 1995, J AM ACAD CHILD PSY, V34, P283, DOI 10.1097/00004583-199503000-00011; Strauss A, 1990, BASIS QUALITATIVE RE; THOITS PA, 1986, J CONSULT CLIN PSYCH, V54, P416, DOI 10.1037/0022-006X.54.4.416; THOMPSON BE, 1984, EXP FLUIDS, V2, P47; WEISS JP, 1976, J APPL PHOTOGR ENG, V2, P7; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	58	39	39	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1999	13	11					845	861					17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253FZ	WOS:000083547000002	10579657				2021-06-18	
J	Nakamura, M; Saatman, KE; Galvin, JE; Scherbel, U; Raghupathi, R; Trojanowski, JQ; McIntosh, TK				Nakamura, M; Saatman, KE; Galvin, JE; Scherbel, U; Raghupathi, R; Trojanowski, JQ; McIntosh, TK			Increased vulnerability of NFH-LacZ transgenic mouse to traumatic brain injury-induced behavioral deficits and cortical damage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						neurofilament; inclusion body; Lewy body; neuromotor function; neurodegeneration	FIBROBLAST GROWTH-FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; FOCAL CEREBRAL-ISCHEMIA; LEWY BODY DEMENTIAS; NEUROFILAMENT SUBUNIT; ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; HEAT-SHOCK; MESSENGER-RNA	The authors evaluated the neurobehavioral and neuropathologic sequelae after traumatic brain injury (TBI) in transgenic (TG) mice expressing truncated high molecular weight neurofilament (NF) protein fused to beta-galactosidase (NFH-LacZ), which develop Lewy body-like NF-rich inclusions throughout the CNS. TG mice and their wild-type (WT) littermates were subjected to controlled cortical impact brain injury (TG, n = 19; WT, n = 17) or served as uninjured controls (TG, n = 11; WT, n = 11). During a 3-week period, mice were evaluated with an array of neuromotor function tests including neuroscore, beam balance, and both fast and slow acceleration rotarod. Brain-injured WT and TG mice showed significant motor dysfunction until 15 days and 21 days postinjury, respectively (P < .025). Compared with brain-injured WT mice, brain-injured TG mice had significantly greater motor dysfunction as assessed by neuroscore (P < .01) up to and including 15 days post-injury. Similarly, brain-injured TG mice performed significantly worse than brain-injured WT mice on slow acceleration rotarod at 2, 8, and 15 days post-injury (P < .05), and beam balance over 2 weeks post-injury (P < .01). Histopathologic analysis showed significantly greater tissue loss in the injured hemisphere in TG mice at 4 weeks postinjury (P < .01). Together these data show that NFH-LacZ TG mice are more behaviorally and histologically vulnerable to TBI than WT mice, suggesting that the presence of NF-rich inclusions may exacerbate neuromotor dysfunction and cell death after TBI.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Dept Neurol, Philadelphia, PA 19102 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		Galvin, James/AAM-7492-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline		Clark RSB, 1997, J NEUROSCI, V17, P9172; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; Conner JM, 1997, J NEUROSCI, V17, P2295; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIXON CE, 1991, J NEUROSCI METH, V39, P353; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GALVIN JE, IN PRESS ADV NEUROL; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GONZALEZ AM, 1994, BRAIN RES, V665, P285, DOI 10.1016/0006-8993(94)91349-8; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; ITOH T, 1992, ACTA NEUROPATHOL, V83, P240, DOI 10.1007/BF00296785; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LANDMESSER L, 1992, NEURON, V8, P291, DOI 10.1016/0896-6273(92)90296-P; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Liberini P, 1996, TRENDS PHARMACOL SCI, V17, P155, DOI 10.1016/0165-6147(96)81592-6; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock John T., 1993, P185; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; SINSON G, 1995, J NEUROCHEM, V65, P2209; TOKUTAKE S, 1990, INT J BIOCHEM, V22, P1; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; TROJANOWSKI JQ, 1994, ANN NY ACAD SCI, V747, P92; TU PH, 1995, J CELL BIOL, V129, P1629, DOI 10.1083/jcb.129.6.1629; Tu PH, 1997, LAB INVEST, V76, P441; Tu PH, 1997, J NEUROSCI, V17, P1064; VICKERS JC, 1994, J NEUROSCI, V14, P5603; WILLARD M, 1981, J CELL BIOL, V89, P198, DOI 10.1083/jcb.89.2.198; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMASAKI H, 1992, LAB INVEST, V66, P734	55	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	1999	19	7					762	770		10.1097/00004647-199907000-00006			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	277TC	WOS:000084948800006	10413031	Bronze			2021-06-18	
J	Whyte, J; DiPasquale, MC; Vaccaro, M				Whyte, J; DiPasquale, MC; Vaccaro, M			Assessment of command-following in minimally conscious brain injured patients	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							VEGETATIVE STATE; COMA; SCALE	Objective: To develop a method for establishing the presence of command-following in individuals with traumatic brain injury, based on the principles of single-subject experimental design. Design: A series of single-subject experiments, individualized to the particular command-following question about a particular patient. Setting: An inpatient rehabilitation hospital with a specialized program for vegetative and minimally conscious brain injured patients. Patients: Eight individuals with serious brain injury of traumatic or nontraumatic origin, presenting in vegetative or minimally conscious states. Interventions: The frequency of performance of the behavior in question was assessed in response to commands and in relation to appropriate control conditions. Data were analyzed with chi(2) Or Fisher's exact test, as well as measures derived from signal detection theory. Main Outcome Measures: The frequency of performance of a specific behavior in the presence of a command and in relevant contrasting conditions. Results: This method identified whether a specific behavior was being performed in response to command and whether the reliability of this behavior was changing over time either spontaneously or in response to treatment. Conclusions: Quantitative assessment of command-following based on principles of single-subject experimental design can determine whether patients are capable of following commands and whether this ability changes over time or in response to treatment. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Edgington E.S., 1987, RANDOMIZATION TESTS; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; *GIV BIOM I, 1996, ASP CONS C WORKGR VE; HAGAN C, 1979, REHABILIATATION HEAD; Macmillan NA, 1991, DETECTION THEORY USE; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WHYTE J, IN PRESS REHABILITAT	15	39	39	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1999	80	6					653	660		10.1016/S0003-9993(99)90168-5			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	204LG	WOS:000080765300008	10378491				2021-06-18	
J	Makatura, TJ; Lam, CS; Leahy, BJ; Castillo, MT; Kalpakjian, CZ				Makatura, TJ; Lam, CS; Leahy, BJ; Castillo, MT; Kalpakjian, CZ			Standardized memory tests and the appraisal of everyday memory	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PERFORMANCE	Although ecological validity of traditional tests of memory has been questioned, use of these tests remains the standard in clinical practice. More recently, however, standardized measures with more emphasis on ecological relevance have been developed. One hundred and nineteen adults with diagnosed brain injuries completed traditional instruments of memory assessment, the Luria Nebraska Neuropsychological Battery Memory Scale (LNNB-M) and the Wechsler Memory Scale-Revised (WMS-R). Subjects also completed the Rivermead Behavioural Memory Test (RBMT), an instrument designed to measure everyday memory. Additionally, clinicians rated subjects' day-to-day memory functioning at the rehabilitation facility. Results suggest that RBMT is most accurate in classifying severity of memory impairment as rated by clinicians. The LNNB-M and WMS-R were relatively accurate at classifying severely impaired and unimpaired subjects, but were much less accurate at classifying subjects in the mild and moderate impairment ranges. Implications for interpretation and use of these instruments in rehabilitation settings are discussed.	IIT, Inst Psychol, Chicago, IL 60616 USA	Lam, CS (corresponding author), IIT, Inst Psychol, 3101 S Dearborn, Chicago, IL 60616 USA.			Kalpakjian, Claire/0000-0001-6652-1245			BACH P J, 1981, Clinical Neuropsychology, V3, P19; BEHRICK HP, 1984, EVERYDAY MEMORY ACTI, P19; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bornstein R A, 1989, Arch Clin Neuropsychol, V4, P15, DOI 10.1016/0887-6177(89)90003-6; Brooks D N, 1979, Int Rehabil Med, V1, P166; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; BUTTERS N, 1975, HIPPOCAMPUS, V2, P377; CERMAK LS, 1982, HUMAN MEMORY AMNESIA; CONKEY RC, 1938, ARCH PSYCHOL, V232, P1; CRONHOLM B, 1957, Acta Chir Scand, V113, P263; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; ELWOOD RW, 1991, CLIN NEUROPSYCHOL, V5, P329; ERICKSON RC, 1977, PSYCHOL BULL, V84, P1130, DOI 10.1037/0033-2909.84.6.1130; Faust D, 1988, Arch Clin Neuropsychol, V3, P145, DOI 10.1016/0887-6177(88)90060-1; FILSKOV S, 1981, HDB CLIN NEUROPSYCHO; GOLDEN CJ, 1978, J CONSULT CLIN PSYCH, V46, P1258, DOI 10.1037/0022-006X.46.6.1258; GOLDEN CJ, 1981, J CONSULT CLIN PSYCH, V49, P304, DOI 10.1037/0022-006X.49.2.304; GOLDEN CJ, 1982, J CONSULT CLIN PSYCH, V50, P452, DOI 10.1037/0022-006X.50.3.452; GOLDEN CJ, 1985, LURIA NEBRASKA NEURO; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; HERMANN D, 1978, PRACTICAL ASPECTS ME, P35; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P239, DOI 10.1080/01688638508401257; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lishman W. A., 1987, ORGANIC PSYCHIAT; MAKATURA TJ, 1993, DISS ABSTR INT, V54, P1078; Mayes A., 1992, HDB NEUROPSYCHOLOGIC, P73; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; STRUBB RL, 1977, MENTAL STATUS EXAMIN; SUNDERLAND A, 1986, J GERONTOL, V41, P376, DOI 10.1093/geronj/41.3.376; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wedding D, 1989, Arch Clin Neuropsychol, V4, P233, DOI 10.1016/0887-6177(89)90016-4; WILKINS AJ, 1978, PRACTICAL ASPECTS ME, P27; Wilson B.A, 1987, REHABILITATION MEMOR; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; WILSON BA, 1985, REVERMEAD BEHAV MEMO	45	39	41	0	25	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1999	13	5					355	367					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	200LE	WOS:000080541100004	10367146				2021-06-18	
J	Park, NW; Proulx, GB; Towers, WM				Park, NW; Proulx, GB; Towers, WM			Evaluation of the attention process training programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED HEAD-INJURY; RECOVERY; MEMORY	This study evaluated the effectiveness of attention process training (APT), a training programme that provides practice in a variety of tasks requiring several different types of attention. The APT programme was administered to 23 traumatically brain-injured (TBI) participants. Training lasted about 40 hours, and typically consisted of 2-hour sessions spread out over 7 months. Results show that performance of the TBI participants improved after training on the primary outcome measures, but did not improve significantly more than the performance of a control group, given the outcome measures twice, but no training. We conclude that direct training does not improve the integrity of damaged attention functions, but does result in learning of specific skills.	Baycrest Ctr Geriatr Care, Kunin Lunenfeld Clin Res Unit, N York, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Dept Psychol, N York, ON M6A 2E1, Canada							Barlow D.H., 1984, SINGLE CASE EXPT DES; Beck A.T., 1987, BECK DEPRESSION INVE; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DOBBS AR, 1989, PSYCHOL AGING, V4, P500, DOI 10.1037/0882-7974.4.4.500; GORDON WA, 1991, COGNITIVE REHABILITA, P13; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heaton R., 1993, WISCONSIN CARD SORTI; KAZNIAK AW, 1985, DEPRESSION ELDERLY I; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; KOLERS PA, 1984, J VERB LEARN VERB BE, V23, P425, DOI 10.1016/S0022-5371(84)90282-2; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LURIA AR, 1996, HUMAN BRAIN PSYCHOL; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; MATEER CA, 1990, DEV CLIN NEUROPSYCHO, P68; MORRIS CD, 1977, J VERB LEARN VERB BE, V16, P519, DOI 10.1016/S0022-5371(77)80016-9; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; PONSFORD J, 1990, COGNITIVE REHABILITA, P48; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; Roediger HL., 1989, VARIETIES MEMORY CON, P3; ROTHI LJ, 1983, J CLIN NEUROPSYCHOL, V5, P73, DOI 10.1080/01688638308401152; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spreen O., 1991, COMPENDIUM NEUROPSYC; STURM W, 1977, NEUROPSYCHOLOGICAL R, V7, P81; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VONZOMEREN AH, 1981, REACTION TIME ATTENT; Wood R L, 1987, Int Disabil Stud, V9, P149; Zangwill OL, 1947, B J PSYCHOL-GEN SECT, V37, P60, DOI 10.1111/j.2044-8295.1947.tb01121.x	40	39	40	0	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR	1999	9	2					135	154		10.1080/713755595			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	185ZJ	WOS:000079701300002					2021-06-18	
J	Farooque, M; Isaksson, J; Olsson, Y				Farooque, M; Isaksson, J; Olsson, Y			Improved recovery after spinal cord trauma in ICAM-1 and P-selectin knockout mice	NEUROREPORT			English	Article						ICAM-1; knockout mice; mice; P-selectin; spinal cord injury	CEREBRAL-ARTERY OCCLUSION; INTERCELLULAR-ADHESION MOLECULE-1; SYSTEM ISCHEMIC-INJURY; BRAIN INJURY; NEUTROPHILS; RAT; PATHOGENESIS; ANTIBODY; STROKE; REDUCTION	TRAUMATIC spinal cord injury is followed by infiltration of leukocytes, influenced by endothelial adhesion molecules such as ICAM-1 and P-selectin. In order to evaluate the pathogenetical role of these molecules, wild-type mice and mice lacking ICAM-1 and P-selectin were subjected to an experimental spinal cord compression of two degrees of severity. Hind limb motor function decreased after injury in all animals but the groups of injured ICAM-1/P-selectin knockout animals had a better functional outcome during the entire observation period of 14 days. This difference was statistically significant on day 1. Our results indicate that adhesion molecules influence the functional outcome after spinal cord injury in a negative way and may be a target for future therapy of neurotrauma. (C) 1999 Lippincott Williams & Wilkins.	Univ Uppsala Hosp, Dept Genet & Pathol, Res Grp Neuropathol, S-75185 Uppsala, Sweden	Farooque, M (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Res Grp Neuropathol, S-75185 Uppsala, Sweden.						BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; FAROOQUE M, UNPUB; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; ISAKSSON J, IN PRESS J NEUROTRAU; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, BRAIN RES, V799, P264, DOI 10.1016/S0006-8993(98)00459-4; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	21	39	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JAN 18	1999	10	1					131	134		10.1097/00001756-199901180-00024			4	Neurosciences	Neurosciences & Neurology	179TW	WOS:000079346100027	10094148				2021-06-18	
J	Gordon, WR; Brown, M; Sliwinski, M; Hibbard, MR; Patti, N; Weiss, MJ; Kalinsky, R; Sheerer, M				Gordon, WR; Brown, M; Sliwinski, M; Hibbard, MR; Patti, N; Weiss, MJ; Kalinsky, R; Sheerer, M			The enigma of "hidden" traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MILD HEAD-INJURY; SEQUELAE	Objective: To examine individuals with "hidden" traumatic brain injury (TBI), defined in this study as those who sustained a blow to the head, with altered mental status, and experienced a substantial number of the cognitive, behavioral, and emotional sequelae typically associated with brain injury but did not make the causal connection between the injury and its consequences. Design: Comparison of four groups of individuals matched for age, gender, years of education, and duration of loss of consciousness. Setting: This study of hidden TBI followed the identification of 143 individuals who, within a larger study of people with TBI who live in the community, identified themselves as "nondisabled" (they were to be part of the comparison sample) but who had experienced a blow to the head that left them at minimum dazed and confused. Participants: 21 of these 143 individuals also reported large numbers of Symptoms (eg, headaches, memory problems) associated with TBI. This group (Hidden TBI-High Symptoms group) was compared to three other matched samples: one with known TBI (Known Mild TBI group) and one with no disability (No Disability group) (both of which were drawn from the larger study), and one group of individuals who identified themselves as having no disability but who had experienced a blow to the head that resulted in a few symptoms (Head Trauma-Low Symptoms group). Main Outcome Measures: All study participants were administered an interview that incorporated several existing instruments documenting levels of reported symptoms, emotional well-being/distress, and vocational/social handicaps. Results: The Hidden TBI-High Symptoms group was found to be similar to the Known Mild TBI group in terms of the number and types of symptoms experienced, whereas the Head Trauma-Low Symptoms group was similar in this respect to the No Disability group. The two former groups also evidenced high levels of emotional distress, whereas the two latter groups did not. However, on measures of handicap, the Hidden TBI-High Symptoms and Head Trauma-Low Symptoms groups were similar to the No Disability group and dissimilar from the Known Mild TBI group in that the last group experienced vocational handicap, in particular, whereas the other groups did not. Conclusions: We conclude that hidden TBI occurs at a nontrivial level (7% of our nondisabled sample). Also, individuals with hidden TBI (with persistent symptoms), unlike those with known mild TBI, are likely to experience emotional distress but not vocational handicap following injury.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA	Gordon, WR (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.						Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Beck A.T., 1987, BECK DEPRESSION INVE; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; EVANS RW, 1992, NEUROL CLIN, V10, P815; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; OMMAYA AK, 1997, SEMINARS CLIN NEUROP, V2, P163; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; *SAS I INC, 1992, SAS STAT SOFTW REL 6; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SYMONDS C, 1962, LANCET, V1, P1; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA	31	39	39	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					39	56		10.1097/00001199-199812000-00006			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300006	9885317				2021-06-18	
J	Fox, GB; Faden, AI				Fox, GB; Faden, AI			Traumatic brain injury causes delayed motor and cognitive impairment in a mutant mouse strain known to exhibit delayed Wallerian degeneration	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain trauma; motor and cognitive tests; Wld(s) (Ola) mutant mouse	ADULT-RAT HIPPOCAMPUS; MEDIAL TEMPORAL-LOBE; GENETIC INFLUENCES; CELLULAR REACTIONS; PERIPHERAL-NERVE; MUTATION WLD(S); MODEL; MICE; REGENERATION; EXPRESSION	Delayed Wallerian degeneration after neuronal injury is a feature of the C57BL/Wld(S) mouse mutant. In the present study, we examined the effect of unilateral controlled cortical impact (CCI) on motor and cognitive performance in C57BL/6 and C57BL/Wld(S) mice. Performance on a beam-walking task was impaired in both injured groups over the first 3 weeks; however, between 28 and 35 days post injury, C57BL/6 mice continued to improve whereas C57BL/Wld(S) mice showed increased footfaults, In a spatial learning task, C57BL/WldS animals performed consistently better than C57BL/6 mice when tested 7-10 days and 14-17 days following CCI, C57BL/WldS mice also demonstrated improved working memory performance as compared with C57BL/6 mice when trained on days 21-22 after injury; this effect was lost on days 23 and 24, and was not evident in other animals tested in the same task at 28-31 days following injury, These results indicate a marked delay in motor and cognitive impairment following CCI in C57BL/Wld(S) mice compared with injured C57BL/6 controls. This is consistent with previous work showing delayed temporal evolution of neuronal degeneration in C57BL/Wld(S) mice and suggests CCI may be a suitable model for examining the functional consequences of traumatic brain injury (TBI) in genetically altered mice, (C) 1998 Wiley-Liss, Inc.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Room EP-04, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; FOX GB, 1995, J NEUROCHEM, V65, P2796; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujiki M, 1996, J COMP NEUROL, V371, P469; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; HOFF SF, 1981, BRAIN RES, V222, P1, DOI 10.1016/0006-8993(81)90936-7; LEONARD BW, 1995, J NEUROSCI, V15, P5637; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; LYON MF, 1993, P NATL ACAD SCI USA, V90, P9717, DOI 10.1073/pnas.90.20.9717; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OConnell AW, 1997, J NEUROCHEM, V68, P2538; PERRY VH, 1990, EUR J NEUROSCI, V2, P408, DOI 10.1111/j.1460-9568.1990.tb00433.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; Povlishock JT., 1996, NEUROTRAUMA, P1325; Schauwecker PE, 1997, J COMP NEUROL, V380, P82, DOI 10.1002/(SICI)1096-9861(19970331)380:1<82::AID-CNE6>3.0.CO;2-P; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEWARD O, 1992, EXP NEUROL, V118, P340, DOI 10.1016/0014-4886(92)90192-S; Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484; Zhang ZY, 1996, J COMP NEUROL, V371, P485; Zhang ZY, 1998, EXP NEUROL, V149, P221, DOI 10.1006/exnr.1997.6717	28	39	39	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 15	1998	53	6					718	727		10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8			10	Neurosciences	Neurosciences & Neurology	117AF	WOS:000075757000009	9753199				2021-06-18	
J	Bombardier, CH; Thurber, CA				Bombardier, CH; Thurber, CA			Blood alcohol level and early cognitive status after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; STROKE PATIENTS; ABUSE; REHABILITATION; INTOXICATION; POPULATION	Statement of Purpose: This archival study sought to clarify the relationship between admission blood alcohol level (BAL) after traumatic brain injury (TBI) and subsequent neuropsychological functioning. It was hypothesized that BAL would be positively correlated with impairment on basic neuropsychological tests and that this relation would weaken as time since TBI increased. Methods: Fifty-eight patients were tested within 60 days of their TBI. Correlational analyses were used to test the relation between neuropsychological performance and admission BAL. Results: As expected, BAL was unrelated to demographic variables or lag time bt tween TBI and time of testing. Bivariate correlations showed that higher BAL predicted poorer performance on a broad range of neuropsychological tests. Patients tested less than 30 days after their TBI showed the strongest effects. Conclusions: Neuropsychological impairments detected 1-2 months after TBI may be affected by BAL at the time of hospital admission. The influence of BAL seems greatest during the first month postinjury, but may persist beyond 30 days in some areas of cognitive function. Blood alcohol at the time of injury may have a direct effect on cognitive functioning or may be a proxy for the effects of chronic alcohol use or abuse. Clinical implications are discussed.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359740, Seattle, WA 98104 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002570, U48/CCU009654, R49/CCR011714-01] Funding Source: Medline		ABRAHAM E, 1995, AM PSYCH ASS CONV TO; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; FEIN G, 1990, WESTERN J MED, V152, P531; FREEDLAND E, 1993, EMERGENCY MED CLIN N, V11, P255; GALSKI T, 1993, STROKE, V24, P1794, DOI 10.1161/01.STR.24.12.1794; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; LAMARRE CJ, 1994, J PSYCHIATR NEUROSCI, V19, P103; MITRUSHINA M, 1994, J PSYCHIATR RES, V28, P85, DOI 10.1016/0022-3956(94)90037-X; OSMON DC, 1992, ARCH PHYS MED REHAB, V73, P414; Rey A, 1964, EXAMEN CLIN PSYCHOL; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; ROURKE SB, 1996, NEUROPSYCHOLOGICAL A, P423; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Spreen O., 1991, COMPENDIUM NEUROPSYC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	31	39	40	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					725	734		10.1080/026990598122124			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500001	9755364				2021-06-18	
J	Kroppenstedt, SN; Schneider, GH; Thomale, UW; Unterberg, AW				Kroppenstedt, SN; Schneider, GH; Thomale, UW; Unterberg, AW			Protective effects of aptiganel HCl (Cerestat (R)) following controlled cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						aptiganel HCl; brain edema; contusion volume; excitatory amino acids; intracranial pressure; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL STROKE; GLUTAMATE; MODEL; ISCHEMIA; CALCIUM; EDEMA; ANTAGONIST; MECHANISMS	Recent studies have demonstrated a neuroprotective effect of the noncompetitive N-methyl-D-aspartate receptor antagonist aptiganel HCl (Cerestat (R)) in focal cerebral ischemia. In the present study, we investigated the protective ability of aptiganel HCl after controlled cortical impact injury (impact depth = 2 mm; impactor velocity = 7 mm/sec) of the left temporoparietal cortex in rats. Intravenous aptiganel HCl (2 mg/kg) or a respective volume of vehicle was injected 15 min after trauma. Animals were sacrificed 24 h after trauma. Contusion volume was measured planimetrically from hematoxylin-eosin-stained coronal slices. Hemispheric swelling and water content were determined gravimetrically. Thirty minutes before sacrifice, a Codman intracranial pressure (ICP) probe was placed in the right hemisphere, and ICP as well as mean arterial blood pressure (MABP) and cerebral perfusion pressure (CPP) were monitored. Aptiganel HCl reduced contusion volume by 13.6% in treated rats (p < 0.05). Hemispheric swelling was also significantly diminished by 31.5% in accordance to a decrease in hemispheric water content (controls, 82.78 +/- 0.12%, vs. aptiganel HCl, 82.30 +/- 0.18%, p < 0.05). Posttraumatic ICP was not significantly lower in the aptiganel HCl treated animals (25.5 +/- 2.4 mm Hg vs. 32.0 +/- 2.7 mm Hg, p = 0.096). MABP was found to be higher in the treatment group 24 h after injury (107.8 +/- 3.6 mm Hg vs. 89.9 +/- 2.4 mm Hg, p < 0.001), resulting in a higher CPP (82.6 +/- 4.2 mm Hg vs. 57.2 +/- 4.6 mm Hg, p < 0.05). Taken together, aptiganel HCl exerts various beneficial effects following experimental traumatic brain injury. It decreases contusion volume and hemispheric swelling as well as water content. Thus, this drug appears promising for further clinical trials in brain trauma.	Humboldt Univ, Rudolf Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany	Kroppenstedt, SN (corresponding author), Humboldt Univ, Rudolf Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.						ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ARONOWSKI J, 1994, STROKE, V25, P2235, DOI 10.1161/01.STR.25.11.2235; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1996, NEUROTRAUMA, P375; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FIELDS RD, 1991, J NEUROSCI, V11, P134; KATAYAMA Y, 1990, ACT NEUR S, V51, P183; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1994, INTRACRANAL PRESSURE, V11, P331; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1993, STROKE, V24, P2074, DOI 10.1161/01.STR.24.12.2074; Muir KW, 1995, ANN NY ACAD SCI, V765, P279, DOI 10.1111/j.1749-6632.1995.tb16585.x; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PARK CK, 1994, ACTA NEUROCHIR, P279; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; TORREGROSA G, 1994, J VASC RES, V31, P221, DOI 10.1159/000159047; UNTERBERG AW, 1996, ACTA NEUROCHIR WIE S, V70, P106; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	41	39	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					191	197		10.1089/neu.1998.15.191			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500004	9528919				2021-06-18	
J	Max, JE; Castillo, CS; Lindgren, SD; Arndt, S				Max, JE; Castillo, CS; Lindgren, SD; Arndt, S			The neuropsychiatric rating schedule: Reliability and validity	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						assessment; children; Neuropsychiatric Rating Schedule		Objective: To evaluate reliability and validity for the Neuropsychiatric Rating Schedule (NPRS) interview designed to permit diagnosis of organic personality syndrome (OPS) or personality change due to a general medical condition (PC). Method: Subjects from prospective (n = 50) and retrospective (n = 72) studies of traumatic brain injury were aged 6 through 18 years. Parents and children were informants for the NPRS. Convergent and discriminant validity of subtypes of OPS/PC were assessed against standard scales completed by parents and teachers. Interrater reliability data (n = 20), test-retest reliability data (n = 42), as well as sensitivity-to-change data (n = 37) were collected. Results: All subtypes of OPS/PC were diagnosed, but apathy and paranoia subtypes were rare. Rating scale data supported convergent validity of OPS/PC subtypes generated With the NPRS. Affective instability, rage/aggression, and inappropriate social judgment were moderately to highly correlated, but apathy and paranoia could be discriminated from each of these subtypes. Interrater agreement for NPRS items was fair to excellent for all but one item (paranoia). Test-retest reliability was fair to good, and sensitivity to change was demonstrated. Conclusion: The NPRS generated reliable and valid diagnoses of the common subtypes of OPS/PC.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Cedar Ctr Psychiat Grp, Cedar Rapids, IA USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH043271, R01MH031593, P50MH043271, R01MH040856, R37MH031593] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MHCRC43271, MH40856, MH31593] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Gerson AC, 1996, PSYCHIAT RES, V65, P189, DOI 10.1016/S0165-1781(96)02851-X; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LISHMAN WA, 1987, ORGANIC PSYCHIATRY, P137; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MESULAM MM, 1985, PRINCIPLES BEHAVIORA, P1; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Silver Jonathan M., 1994, P313; TEASDALE G, 1974, LANCET, V2, P81	14	39	39	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAR	1998	37	3					297	304		10.1097/00004583-199803000-00015			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	YY719	WOS:000072177000015	9519635				2021-06-18	
J	Gilkey, SJ; Ramadan, NM; Aurora, TK; Welch, KMA				Gilkey, SJ; Ramadan, NM; Aurora, TK; Welch, KMA			Cerebral blood flow in chronic posttraumatic headache	HEADACHE			English	Article						headache; closed head injury; cerebral blood flow	TRAUMATIC BRAIN INJURY; MANAGEMENT	Background and Purpose.-Headache is the most common neurologic symptom following minor closed head injury. There is often a lack of objective evidence supporting an organic basis of cerebral pathology in these cases. This pilot study considers the possibility of alterations in cerebral blood flow, indicating evidence of an organic disorder in posttraumatic headache. Methods.-Regional cerebral blood flow studies of 35 patients with chronic posttraumatic headache (PTH) (International Headache Society criteria), identified retrospectively from our cerebral blood flow data base, were compared with those of 49 nonheadache controls and 92 migraineurs (Ad Hoc Committee criteria). Regional cerebral blood flow (initial slope index method) was measured using the xenon Xe 133 inhalation technique. Results.-Compared to migraineurs and controls, and after adjusting for differences (analysis of covariance) in baseline variables such as blood pressure, hematocrit and Pco(2),, patients with PTH had: (1)significantly lower mean initial slope indices (P<0.001, P=0.002, respectively); (2) regional interhemispheric flow differences (rIFD), with higher distribution of regional asymmetrical probe pairs (rIFD greater than or equal to 7%: P[PTH versus control]=0.006, P[PTH versus migraine]=0.016; rIFD greater than or equal to 10%: P[PTH versus control]=0.011, P[PTH versus migraine]=0.003); and (3) more hemispheric asymmetries (P[PTH versus control]=0.023. P[PTH versus migraine]=0.57). Lower mean initial slope indices and hemispheric asymmetry (mean interhemispheric flow difference greater than or equal to 3.2%) predicted PTH over control (P=0.023 and 0.002, respectively). Lower mean initial slope indices predicted PTH over migraine (P=0.002). Conclusions.-Patients with PTH have reduced regional cerebral blood flow, and regional and hemispheric asymmetries. These cerebral hemodynamic alterations support an organic basis to chronic posttraumatic headache.	HENRY FORD HOSP & HLTH SCI CTR, DEPT NEUROL, HEADACHE CTR, DETROIT, MI USA							Ad Hoc Committee on the Classification of Headache, 1962, ARCH NEUROL-CHICAGO, V6, P173, DOI [10. 1001/archneur. 1962. 00450210001001, DOI 10.1001/ARCHNEUR.1962.00450210001001]; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; APPENZELLER O, 1987, WOLFFS HEADACHE OTHE, P289; Bailey B. N., 1989, TXB HEAD INJURY, P308; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; CARTLIDGE NEF, 1981, INJURY, P95; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Haas David C., 1993, P629; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; LANGFITT TW, 1982, CLIN NEUR, V29, P353; MELAMED E, 1980, STROKE, V11, P31, DOI 10.1161/01.STR.11.1.31; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Northfield DWC, 1938, BRAIN, V61, P133, DOI 10.1093/brain/61.2.133; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1975, HEAD INJURIES, P11; Pickering GW, 1933, CLIN SCI, V1, P77; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAMADAN NM, 1994, STROKE, V25, P1219, DOI 10.1161/01.STR.25.6.1219; RISBERG J, 1975, STROKE, V6, P142, DOI 10.1161/01.STR.6.2.142; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SPEED WG, 1989, HEADACHE, V29, P643, DOI 10.1111/j.1526-4610.1989.hed2910643.x; TAYLOR AR, 1966, LANCET, V2, P178; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67	27	39	41	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	OCT	1997	37	9					583	587		10.1046/j.1526-4610.1997.3709583.x			5	Clinical Neurology	Neurosciences & Neurology	YF401	WOS:A1997YF40100009	9385758				2021-06-18	
J	Rodriguez, DJ; Benzel, EC; Clevenger, FW				Rodriguez, DJ; Benzel, EC; Clevenger, FW			The metabolic response to spinal cord injury	SPINAL CORD			English	Article						spinal cord injury; nitrogen balance; nutrition; metabolism; indirect calorimetry	ENERGY-EXPENDITURE; FUNCTIONAL RECOVERY; NITROGEN-BALANCE; OPERATION; FRACTURES	The metabolic response to trauma, including neurotrauma in general, has been studied extensively, but the acute metabolic response to spinal cord injury (SCI) has not. Therefore, 12 patients with SCI are presented in whom intensive nutrition assessment and management were instituted immediately after injury. Nitrogen balance (NB), predicted energy expenditure (PEE), and actual energy expenditure (MEE) were calculated or measured in each patient. A persistent negative NE was observed in all but one of the 12 patients. The single patient who did not exhibit persistent negative NE (no positive NE from week 2 to week 4 in the face of appropriate feeding) had an incomplete myelopathy, thus implying that the degree of motor dysfunction correlates with the obligatory nature of the negative NE. The negative NE observed in several of the patients did not occur until the second or third post-injury week. In addition, calculations of PEE by successively multiplying the Harris-Benedict equation by an activity factor of 1.2 and then by a stress factor of 1.6, resulted in excessive feeding (as assessed by metabolic cart measurements; ie indirect calorimetry) in the majority of the patients. In all of the 11 patients with persistent negative NBs, protein administration in the amount of 2 g/k of ideal body weight and aggressive caloric delivery did not alter the negative pattern of the NBs. Therefore, it is concluded that the negative NE following SCI is obligatory. Furthermore, the extent of SCI (extent of myelopathy or of neurological injury) correlates with the obligatory nature of the negative NE. In addition, the results from using the above method for estimating caloric requirements and the delayed manifestation of the negative NE may cause an additional tendency to acutely overfeed SCI patients. Therefore, eliminating the activity factor of 1.2 (due to the diminished activity arising from paralysis) and a diminution of the stress factor is recommended for initial PEE calculations. Serial metabolic cart (indirect calorimetry) measurements are recommended to accurately assess the patient's subsequent metabolic requirements.	UNIV NEW MEXICO, SCH MED, DEPT SURG, DIV NEUROSURG, ALBUQUERQUE, NM 87131 USA							AGARWAL N, 1984, JPEN-PARENTER ENTER, V8, P98; *AM DIAB ASS AM DI, 1977, GUID PROF EFF APPL E, P17; BENZEL EC, 1987, NEUROSURGERY, V20, P742, DOI 10.1227/00006123-198705000-00012; BENZEL EC, 1986, NEUROSURGERY, V19, P772, DOI 10.1227/00006123-198611000-00009; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BUNKER VW, 1987, BRIT J NUTR, V57, P211, DOI 10.1079/BJN19870027; CLEVENGER FW, 1992, J SURG RES, V52, P135, DOI 10.1016/0022-4804(92)90294-A; COX SAR, 1985, J TRAUMA, V25, P419, DOI 10.1097/00005373-198505000-00008; Daley BJ, 1994, NUTR CRITICAL CARE, P9; DEITRICK JE, 1948, AM J MED, V4, P3, DOI 10.1016/0002-9343(48)90370-2; FRY DE, 1987, PROB GEN SURG, V4, P427; Greenway R M, 1970, Paraplegia, V7, P301; KAUFMAN HH, 1985, NEUROSURGERY, V16, P309, DOI 10.1227/00006123-198503000-00005; KEARNS PJ, 1982, JPEN, V6, P577; KINNEY JM, 1970, J CLIN PATHO, V14, P65; KOLPEK JH, 1989, JPEN-PARENTER ENTER, V13, P277, DOI 10.1177/0148607189013003277; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; MCKENZIE TA, 1985, AM C NUTR, V4, P575; RODRIGUEZ D J, 1990, Journal of Parenteral and Enteral Nutrition, V14, p15S; RODRIGUEZ DJ, 1991, JPEN-PARENTER ENTER, V15, P319, DOI 10.1177/0148607191015003319; Shronts E, 1989, NUTR SUPPORT CORE CU, P199; Young B, 1991, Neurosurg Clin N Am, V2, P301	22	39	42	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	SEP	1997	35	9					599	604		10.1038/sj.sc.3100439			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XV931	WOS:A1997XV93100008	9300966	Bronze			2021-06-18	
J	Mukhin, AG; Ivanova, SA; Faden, AI				Mukhin, AG; Ivanova, SA; Faden, AI			mGluR modulation of post-traumatic neuronal death: role of NMDA receptors	NEUROREPORT			English	Article						in vitro model; metabotropic glutamate receptor; neuronal death; neuroprotection; NMDA receptor	METABOTROPIC GLUTAMATE RECEPTORS; SPINAL-CORD INJURY; SIGNAL TRANSDUCTION; BRAIN INJURY; AMINO-ACIDS; ANTAGONIST; CELLS; NEUROTOXICITY; AGONIST; CALCIUM	THE potential interaction between group I metabotropic glutamate receptors (mGluR) and NMDA receptors in mediating of post-traumatic neuronal death was studied using an in vitro trauma model. Treatment with group I mGluR antagonists provided significant neuroprotection either in the presence or absence of an NMDA receptor antagonist. In contrast, treatment with a group I mGluR agonist alone significantly exacerbated injury; this exacerbation was significantly, but incompletely, reduced in the presence of an NMDA receptor antagonist. These findings are consistent with the conclusion that the effects of group I mGluR activation on posttraumatic cell death are mediated only in part through NMDA receptor modulation and suggest that group I mGluR antagonists may have important therapeutic potential.	GEORGETOWN UNIV, MED CTR, INST COGNIT & COMPUTAT SCI, WASHINGTON, DC 20007 USA					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		ABE T, 1992, J BIOL CHEM, V267, P13361; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1987, J NEUROSCI, V7, P369; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Mukhin A, 1996, J NEUROSCI, V16, P6012; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; WONG EHF, 1988, J NEUROCHEM, V50, P274, DOI 10.1111/j.1471-4159.1988.tb13260.x; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WONG EHF, 1986, BRIT J PHARMACOL, V89, P536; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	25	39	39	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JUL 28	1997	8	11					2561	2566		10.1097/00001756-199707280-00028			6	Neurosciences	Neurosciences & Neurology	XP313	WOS:A1997XP31300031	9261827				2021-06-18	
J	Onifer, SM; Cannon, AB; Whittemore, SR				Onifer, SM; Cannon, AB; Whittemore, SR			Altered differentiation of CNS neural progenitor cells after transplantation into the injured adult rat spinal cord	CELL TRANSPLANTATION			English	Article; Proceedings Paper	3rd Annual Conference of the American-Society-for-Neural-Transplantation	APR 25-27, 1996	CLEARWATER BEACH, FL	Amer Soc Neural Transplantat		neural progenitor cells; neuronal differentiation; CNS transplantation; spinal cord injury	RECEPTOR MESSENGER-RNA; EMBRYONIC BRAIN-STEM; LOCUS COERULEUS; RAPHE NEURONS; GROWTH; GRAFTS; LINE; IMMUNOREACTIVITY; TISSUE; REINNERVATION	Denervation of CNS neurons and peripheral organs is a consequence of traumatic SCI, Intraspinal transplantation of embryonic CNS neurons is a potential strategy for reinnervating these targets, Neural progenitor cell lines are being investigated as alternates to embryonic CNS neurons, RN33B is an immortalized neural progenitor cell line derived from embryonic rat raphe nuclei following infection with a retrovirus encoding the temperature-sensitive mutant of SV40 large T-antigen, Transplantation studies have shown that local epigenetic signals in intact or partially neuron-depleted adult rat hippocampal formation or striatum direct RN33B cell differentiation to complex multipolar morphologies resembling endogenous neurons, After transplantation into neuron-depleted regions of the hippocampal formation or striatum, RN33B cells were relatively undifferentiated or differentiated with bipolar morphologies, The present study examines RN33B cell differentiation after transplantation into normal spinal cord and under different lesion conditions, Adult rats underwent either unilateral lesion of lumbar spinal neurons by intraspinal injection of kainic acid or complete transection at the T10 spinal segment, Neonatal rats underwent either unilateral lesion of lumbar motoneurons by sciatic nerve crush or complete transection at the T10 segment, At 2 or 6-7 wk postinjury, lacZ-labeled RN33B cells were transplanted into the lumbar enlargement of injured and age-matched normal rats, At 2 wk posttransplantation, bipolar and some multipolar RN33B cells were found throughout normal rat gray matter, In contrast, only bipolar RN33B cells were seen in gray matter of kainic acid lesioned, sciatic nerve crush, or transection rats, These observations suggest that RN33B cell multipolar morphological differentiation in normal adult spinal cord is mediated by direct cell-cell interaction through surface molecules on endogenous neurons and may be suppressed by molecules released after SCI, They also indicate that the fate of immortalized neural progenitor cell lines in injured CNS must be stringently characterized. (C) 1997 Elsevier Science Inc.	MIAMI PROJECT CURE PARALYSIS, DEPT NEUROL SURG, MIAMI, FL 33136 USA; MIAMI PROJECT CURE PARALYSIS, DEPT PHYSIOL & BIOPHYS, MIAMI, FL 33136 USA	Onifer, SM (corresponding author), UNIV MIAMI, SCH MED, MIAMI PROJECT CURE PARALYSIS, 1600 NW 10TH AVE R-48, MIAMI, FL 33136 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26887] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026887, R55NS026887] Funding Source: NIH RePORTER		Adams FS, 1996, NEUROCHEM RES, V21, P619, DOI 10.1007/BF02527762; BAKHIT C, 1991, BRAIN RES, V554, P264, DOI 10.1016/0006-8993(91)90199-6; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BENVENISTE EN, 1997, IMMUNOLOGY NERVOUS S, P419; BJORKLUND A, 1986, NEUROSCIENCE, V18, P685, DOI 10.1016/0306-4522(86)90063-1; Bregman B. S., 1994, FUNCTIONAL NEURAL TR, P489; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; Brundin P, 1987, PROG BRAIN RES <D>, V71, P293; BRUNELLO N, 1990, NEUROSCI LETT, V118, P238, DOI 10.1016/0304-3940(90)90636-N; BUCHANAN JT, 1986, BRAIN RES, V381, P225, DOI 10.1016/0006-8993(86)90071-5; BUNGE R, 1983, SPINAL CORD RECONSTR, P341; BUNGE RP, 1993, ADV NEUROL, V59, P75; CATTANEO E, 1994, DEV BRAIN RES, V83, P197, DOI 10.1016/0165-3806(94)00137-5; DAS GD, 1983, J NEUROL SCI, V62, P191, DOI 10.1016/0022-510X(83)90199-5; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; FAROOQUE M, 1995, J NEUROTRAUM, V12, P41, DOI 10.1089/neu.1995.12.41; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; FOSTER GA, 1990, PROG BRAIN RES, V82, P247; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FRISEN J, 1994, EXP NEUROL, V129, P183, DOI 10.1006/exnr.1994.1160; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Giordano M, 1996, CELL TRANSPLANT, V5, P563, DOI 10.1016/0963-6897(96)00027-9; HOFFER BJ, 1991, TRENDS NEUROSCI, V14, P384, DOI 10.1016/0166-2236(91)90168-T; HORVAT JC, 1991, RESTOR NEUROL NEUROS, V2, P289, DOI 10.3233/RNN-1991-245618; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; MOORMAN SJ, 1990, BRAIN RES, V508, P194, DOI 10.1016/0006-8993(90)90396-S; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; NOTHIAS F, 1990, J COMP NEUROL, V301, P520, DOI 10.1002/cne.903010404; NYGREN LG, 1977, BRAIN RES, V129, P227, DOI 10.1016/0006-8993(77)90003-8; ONIFER SM, 1993, CELL TRANSPLANT, V2, P131, DOI 10.1177/096368979300200207; ONIFER SM, 1993, EXP NEUROL, V122, P130, DOI 10.1006/exnr.1993.1114; PRIVAT A, 1990, PROGR BRAIN RES, V78, P155; RAJAOFETRA N, 1992, BRAIN RES, V572, P329, DOI 10.1016/0006-8993(92)90495-U; REIER PJ, 1992, EXP NEUROL, V115, P177, DOI 10.1016/0014-4886(92)90245-L; REYNOLDS ME, 1991, BRAIN RES, V559, P149, DOI 10.1016/0006-8993(91)90298-A; RISLING M, 1992, J NEUROCYTOL, V21, P79, DOI 10.1007/BF01189007; ROMANES GJ, 1946, J ANAT, V80, P117; ROUDET C, 1995, BRAIN RES, V677, P1, DOI 10.1016/0006-8993(95)00068-2; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SEIGER A, 1985, NEURAL GRAFTING MAMM, P71; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Shihabuddin LS, 1996, J NEUROCYTOL, V25, P101, DOI 10.1007/BF02284789; SHIMOHAMA S, 1989, MOL BRAIN RES, V5, P271, DOI 10.1016/0169-328X(89)90061-2; SIERADZAN K, 1989, NEUROSCIENCE, V31, P115, DOI 10.1016/0306-4522(89)90034-1; STEINBUSCH HWM, 1983, CHEM NEUROANATOMY, P131; Sugar O, 1940, J NEUROPHYSIOL, V3, P1; TAGO H, 1989, BRAIN RES, V495, P271, DOI 10.1016/0006-8993(89)90221-7; TESSLER A, 1988, J COMP NEUROL, V270, P537, DOI 10.1002/cne.902700407; White LA, 1997, J NEUROSCI RES, V47, P242, DOI 10.1002/(SICI)1097-4547(19970201)47:3<242::AID-JNR2>3.0.CO;2-I; WHITE LA, 1992, J CHEM NEUROANAT, V5, P327, DOI 10.1016/0891-0618(92)90020-Q; WHITE LA, 1994, J NEUROIMMUNOL, V49, P135, DOI 10.1016/0165-5728(94)90189-9; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; WICTORIN K, 1992, NEUROREPORT, V3, P1045, DOI 10.1097/00001756-199212000-00003; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0; YAKOVLEFF A, 1995, EXP BRAIN RES, V106, P69	62	39	47	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.	MAY-JUN	1997	6	3					327	338		10.1016/S0963-6897(97)00037-7			12	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	XA193	WOS:A1997XA19300014	9171165				2021-06-18	
J	PohlmannEden, B; Bruckmeir, J				PohlmannEden, B; Bruckmeir, J			Predictors and dynamics of posttraumatic epilepsy	ACTA NEUROLOGICA SCANDINAVICA			English	Article						severe head trauma; posttraumatic epilepsy; predictors	POST-TRAUMATIC EPILEPSY; SEIZURES	Objectives - The goal of our study was to identify clinical, neurophysiological and neuroradiological variables in severe head trauma (SHT) with predictive value for posttraumatic epilepsy (PTE) and to evaluate the influence of each risk factor for the dynamics of epilepsy. Material and methods - We systematically compared 57 PTE patients with 50 age and sex-matched control patients with SHT and no PTE. Mean follow-up was a years. Results - Of all PTE-patients 68.5% had their first seizure within 2 years after the trauma. Significant risk factors for PTE were focal signs in the first examination (P<0.01), missile injuries (P<0.01), frontal lesions (P<0.01), intracerebral hemorrhage (P<0.01), diffuse contusion (P<0.01), prolonged posttraumatic amnesia (P<0.001), depression fracture (P<0.01) and cortical-subcortical lesions (P<0.001). The combination of the last 3 variables conferred a particularly high risk for PTE (logistic regression analysis). Combined seizure pattern, high seizure frequency, AED-noncompliance and alcohol abuse predicted poor seizure control. Conclusion The risk for PTE is clearly determined by those variables which correlate with the severity, the extent of tissue loss and the penetrating nature of the brain trauma.		PohlmannEden, B (corresponding author), UNIV HEIDELBERG,DEPT NEUROL,MANNHEIM HOSP,D-68135 MANNHEIM,GERMANY.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; DASILVA AM, 1990, ACT NEUR S, V50, P48; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HAUSER WA, 1990, NEW ENGL J MED, V325, P540; JANZ D, 1982, NERVENARZT, V53, P238; JENNETT WB, 1975, EPILEPSY NONMISSILE; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MIZUKAWA K, 1991, JPN J PSYCHIAT NEUR, V45, P285; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WILMORE LJ, 1992, NEUROL CLIN, V4, P869	15	39	41	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	MAY	1997	95	5					257	262		10.1111/j.1600-0404.1997.tb00206.x			6	Clinical Neurology	Neurosciences & Neurology	WZ792	WOS:A1997WZ79200001	9188898				2021-06-18	
J	Glang, A; Todis, B; Cooley, E; Wells, J; Voss, J				Glang, A; Todis, B; Cooley, E; Wells, J; Voss, J			Building social networks for children and adolescents with traumatic brain injury: A school-based intervention	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						education; pediatrics; social support; traumatic brain injury	SEVERE DISABILITIES; GENERAL-EDUCATION; HEAD-INJURY; FOLLOW-UP; STUDENTS; PEERS; SUPPORT; REHABILITATION; CLASSROOM; MODERATE	Objective: Three boys, ages 8, 11, and 13, who experienced social isolation as a result of traumatic brain injury, were studied to investigate the effectiveness of a school-based, educator-mediated intervention aimed at increasing the social networks of students with traumatic brain injury. ii four-phase problem-solving process was instituted in which a student-centered school team identified goals and strategies for increasing the student's social opportunities and then met frequently to review progress toward the goals. Main Outcome Measures: Frequency of students' social contacts with nondisabled peers, parent and educator social validation ratings, and participant observations, Results: The number of social contacts for each strident increased over baseline levels and was maintained over the course of the study. Parents, teachers, and students were generally satisfied with the process and with the concomitant increases in students' degree of social integration. Anecdotal follow-up reports indicated that these results were not maintained over time. Conclusions: The study's findings raise important questions about the varying perspectives on the importance of social integration, the degree to which educators can serve as change agents in students' social experiences, and the type of follow-up support required to maintain increases in students' social interactions.	W ED FAR W LAB,SPECIAL EDUC PROJECTS,SAN FRANCISCO,CA; OREGON CTR APPL SCI,EUGENE,OR	Glang, A (corresponding author), WESTERN OREGON STATE COLL,99 W 10TH,SUITE 370,EUGENE,OR 97401, USA.						BADMAN LJ, 1992, HLTH ED Q, V19, P9; Begali V., 1987, HEAD INJURY CHILDREN; BELLE D, 1984, M AM PSYCHOL ASS TOR; BLOSSER J, 1995, J HEAD TRAUMA REHAB, V10, P46, DOI 10.1097/00001199-199504000-00006; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; COOLEY E, STUDENTS ACQUIRED BR; COWEN EL, 1988, AM J COMMUN PSYCHOL, V16, P591, DOI 10.1007/BF00922773; DEATON AV, 1994, ED DIMENSIONS ACQUIR; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; EVANS IM, 1994, J ASSOC PERS SEVERE, V19, P326, DOI 10.1177/154079699401900408; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GERSTEN R, 1995, EXCEPT CHILDREN, V62, P52; GOETHE KE, 1984, PSYCHIAT ANN, V14, P540, DOI 10.3928/0048-5713-19840701-11; GRENOTSCHEYER M, 1994, J ASSOC PERS SEVERE, V19, P253, DOI 10.1177/154079699401900402; HALL LJ, 1994, J ASSOC PERS SEVERE, V19, P302, DOI 10.1177/154079699401900406; HELMSTETTER E, 1994, J ASSOC PERS SEVERE, V19, P263, DOI 10.1177/154079699401900403; Hux K, 1996, INTERV SCH CLIN, V31, P158, DOI 10.1177/105345129603100305; JENKINS JR, 1992, EXCEPT CHILDREN, V58, P555, DOI 10.1177/001440299205800610; KAMPS DM, 1994, J APPL BEHAV ANAL, V27, P49, DOI 10.1901/jaba.1994.27-49; KENNEDY CH, 1994, J ASSOC PERS SEVERE, V19, P1; KEPLER KL, 1996, CHILDREN ACQUIRED BR; KISHI GS, 1994, J ASSOC PERS SEVERE, V19, P277, DOI 10.1177/154079699401900404; KLONOFF H, 1974, CLIN NEUROPSYCHOLOGY; LEAHEM J, 1996, BRAIN INJURY, V10, P27; LEHR E, 1990, PSYCHOL MANAGEMENT T, P155; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LUCYSHYN JM, 1996, CHILDREN ACQUIRED BR; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; OSWALD H, 1994, SOCIAL NETWORKS SOCI; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RUTTER M, 1983, DEV NEUROPSYCHIATRY; SALISBURY CL, 1995, EXCEPT CHILDREN, V62, P125, DOI 10.1177/001440299506200203; SANDLER IN, 1989, MARSHALING SOCIAL SU; SAVAGE RC, 1996, CHILDREN ACQUIRED BR; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; SINGER GHS, 1996, CHILDREN ACQUIRED BR; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; SOWERS JA, 1996, ROAD AUTONOMY PROMOT; STAINBACK S, 1984, EXCEPT CHILDREN, V50, P400; STAUB D, 1994, J ASSOC PERS SEVERE, V19, P314, DOI 10.1177/154079699401900407; TODIS B, 1993, FAMILIES DISABILITY; Vieth AZ, 1996, BRAIN INJURY, V10, P465, DOI 10.1080/026990596124322; Wechsler D., 1974, WECHSLER ADULT INTEL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLER B, 1990, CAN J REHABIL, V2, P167; WILLIAMS J, 1991, HEAD INJURY FAMILY M; WOLCHIK S, 1989, CHILDRENS SOCIAL NET; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	54	39	39	0	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1997	12	2					32	47		10.1097/00001199-199704000-00005			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WT782	WOS:A1997WT78200006					2021-06-18	
J	Bohnert, AM; Parker, JG; Warschausky, SA				Bohnert, AM; Parker, JG; Warschausky, SA			Friendship and social adjustment of children following a traumatic brain injury: An exploratory investigation	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; BEHAVIOR	Despite evidence that suggests that children who survive traumatic brain injuries (TBIs) experience disruptions in their peer relationships, the peer experiences of children with TBIs have rarely been studied empirically to date. Data were gathered on measures of peer adjustment for a sample of 22 children with TBIs and were compared with children from a matched control group. Children with TBIs were found to be less socially and athletically competent than children who had not experienced a TBI. Among boys, TBI was also related to lower academic competence. Children with more severe injuries had greater difficulty managing conflict, coordinating play, and developing intimacy in their closest friendships. Girls were more likely than boys to have friendships that predated the injury. Results are discussed in terms of the significance of the social disruption that apparently occurs surrounding injury.	UNIV MICHIGAN,ANN ARBOR,MI 48109	Bohnert, AM (corresponding author), PENN STATE UNIV,DEPT PSYCHOL,314 MOORE BLDG,UNIVERSITY PK,PA 16802, USA.			Bohnert, Amy/0000-0002-0864-2900			ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARTER S, 1986, MANUAL SELFPERCEPTIO; Lehr E, 1990, PSYCHOL MANAGEMENT T; OKUN A, 1994, DEV PSYCHOPATHOL, V6, P77, DOI 10.1017/S0954579400005897; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Parker JG, 1996, DEV PSYCHOL, V32, P1025, DOI 10.1037/0012-1649.32.6.1025; PARKER JG, 1993, DEV PSYCHOL, V29, P611, DOI 10.1037/0012-1649.29.4.611; Parker JG, 1995, DEV PSYCHOPATHOL, V2, P96; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Thurstone LL, 1927, AM J PSYCHOL, V38, P368, DOI 10.2307/1415006; WARSCHAUSKY S, 1995, M SOC RES CHILD DEV	15	39	39	0	5	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		1997	13	4					477	486		10.1080/87565649709540688			10	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	YH782	WOS:A1997YH78200001					2021-06-18	
J	Sangal, RB; Sangal, JAM				Sangal, RB; Sangal, JAM			Closed head injury patients with mild cognitive complaints without neurological or psychiatric findings have abnormal visual P300 latencies	BIOLOGICAL PSYCHIATRY			English	Article						P300; closed head injury; cognitive deficits; evoked potentials; event-related potentials; brain topography			WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202	Sangal, RB (corresponding author), SLEEP DISORDERS UNIT,44199 DEQUINDRE,STE 311,TROY,MI 48098, USA.			Sangal, R/0000-0003-4031-7814			HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; SANGAL RB, 1995, CLIN ELECTROENCEPHAL, V26, P146, DOI 10.1177/155005949502600305; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	5	39	39	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	FEB 15	1996	39	4					305	307		10.1016/0006-3223(95)00447-5			3	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	TW730	WOS:A1996TW73000013	8645780				2021-06-18	
J	Reinhard, DL; Whyte, J; Sandel, ME				Reinhard, DL; Whyte, J; Sandel, ME			Improved arousal and initiation following tricyclic antidepressant use in severe brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SENSORIMOTOR CORTEX INJURY; VISUAL CORTICAL PLASTICITY; NOREPINEPHRINE DEPLETION; LOCOMOTOR FUNCTION; DEPTH-PERCEPTION; VEGETATIVE STATE; HEAD-INJURY; RECOVERY; AMPHETAMINE; ABLATION	Three patients with severe traumatic brain injury demonstrated significant improvement in arousal and initiation after administration of tricyclic antidepressants. The first patient showed improved motor and speech initiation in response to amitriptyline following several months of functional plateau. The second patient was minimally responsive 2 months after injury and demonstrated improved arousal following the use of desipramine. Both patients deteriorated when the medications were discontinued and improved again when they were restarted. These two cases provide strong evidence for a medication effect, The third patient began to verbalize following desipramine administration, despite being mute for more than a year after injury. Previous case reports describe cognitive-enhancing effects, such as improved arousal, attention, memory, and initiation, of dopaminergic agents, and in the case of tricyclic antidepressants, effects on agitation. The role of norepinephrine in promoting neurological recovery after brain lesions has been demonstrated in animals. The cases presented here provide some of the first data to show similar efficacy in humans and underscore the need for contolled trials to better determine which patients will benefit. (C) 1996 by The American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV PENN,MED CTR,DEPT REHABIL MED,PHILADELPHIA,PA 19104; DRUCKER BRAIN INJURY CTR,MOSS REHABIL RES INST,PHILADELPHIA,PA; TEMPLE UNIV,PHILADELPHIA,PA 19122				Whyte, John/0000-0002-4381-1474			ASTONJONES G, 1981, J NEUROSCI, V1, P887; ASTONJONES G, 1985, PHYSIOL PSYCHOL, V13, P118; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BOYESON MG, 1994, ARCH NEUROL-CHICAGO, V51, P405, DOI 10.1001/archneur.1994.00540160107014; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, AM J PHYS MED REHABI, V72, P268; Campagnolo Denis I., 1992, Archives of Physical Medicine and Rehabilitation, V73, P975; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Dombovy Mary L., 1992, Archives of Physical Medicine and Rehabilitation, V73, P975; ECHIVERRI HC, 1988, PEDIATR NEUROL, V4, P228, DOI 10.1016/0887-8994(88)90036-7; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FOOTE SL, 1983, PHYSIOL REV, V63, P844; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; GOLDSTEIN LB, 1990, STROKE, V21, P179; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GUPTA SR, 1992, ARCH PHYS MED REHAB, V73, P373, DOI 10.1016/0003-9993(92)90012-L; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HOMAN R, 1990, Society for Neuroscience Abstracts, V16, P439; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; KASAMATSU T, 1981, J NEUROPHYSIOL, V45, P254; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; KASAMATSU T, 1982, EXP BRAIN RES, V45, P317, DOI 10.1007/BF01208591; KASAMATSU T, 1979, J COMP NEUROL, V185, P163, DOI 10.1002/cne.901850110; KATZ RT, 1995, ARCH PHYS MED REHAB, V76, P82, DOI 10.1016/S0003-9993(95)80048-4; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; MORRISON JH, 1979, SCIENCE, V205, P313, DOI 10.1126/science.451605; PETTIGREW JD, 1978, NATURE, V271, P761, DOI 10.1038/271761a0; PORCH B, 1985, Society for Neuroscience Abstracts, V11, P52; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; WALKERBATSON D, 1993, RESTOR NEUROL NEUROS, V4, P47; WATSON M, 1984, BRAIN RES, V296, P129, DOI 10.1016/0006-8993(84)90518-3; WROBLEWSKI B, 1992, J HEAD TRAUMA REHAB, V7, P109; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009	46	39	40	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1996	77	1					80	83		10.1016/S0003-9993(96)90225-7			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TN532	WOS:A1996TN53200016	8554480				2021-06-18	
J	Berry, DTR; Wetter, MW; Baer, RA; Youngjohn, JR; Gass, CS; Lamb, DG; Franzen, MD; MacInnes, WD; Buchholz, D				Berry, DTR; Wetter, MW; Baer, RA; Youngjohn, JR; Gass, CS; Lamb, DG; Franzen, MD; MacInnes, WD; Buchholz, D			Overreporting of closed-head injury symptoms on the MMPI-2	PSYCHOLOGICAL ASSESSMENT			English	Article							TRAUMATIC BRAIN INJURY; DEFICITS	Minnesota Multiphasic Personality Inventory( MMPI-2) validity scales were compared in 4 groups: nonclinical participants answering under standard instructions (n = 20), nonclinical participants instructed to fake closed-head injury (CHI) symptoms (n = 18), non-compensation-seeking CHI patients (n = 31), and compensation-seeking CHI patients (n = 30). The highest scores on MMPI-2 overreporting scales were obtained by nonclinical participants faking CHI, and significantly higher scores on these scales were obtained by compensation-seeking relative to non-compensation-seeking CHI patients. These results suggest that MMPI-2 overreporting scales are sensitive to fabrication of CHI complaints, and possibly to exaggeration of CHI complaints, although further research is necessary to evaluate the latter hypothesis fully.	VET AFFAIRS MED CTR, PSYCHOL SERV, MIAMI, FL 33125 USA; BARROW NEUROL INST, DEPT NEUROPSYCHOL, PHOENIX, AZ 85013 USA; ALLEGHENY NEUROPSYCHIAT INST, DEPT NEUROPSYCHOL, PITTSBURGH, PA USA; MIDMICHIGAN NEUROPSYCHOL ASSOCIATES PLC, MIDLAND, MI USA; VET AFFAIRS MED CTR, PSYCHOL SERV, LOUISVILLE, KY USA	Berry, DTR (corresponding author), UNIV KENTUCKY, DEPT PSYCHOL, KASTLE HALL, LEXINGTON, KY 40506 USA.		Gass, Carlton/AAO-5906-2020				Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ARBISI P, 1993, 28TH ANN S REC DEV M; Berry D. T. R., 1992, PSYCHOL ASSESSMENT, V4, P340, DOI [10.1037/1040-3590.4.3.340, DOI 10.1037/1040-3590.4.3.340, 10.1037/1040-3590.4.3.340.]; BERRY DTR, 1991, CLIN PSYCHOL REV, V11, P585, DOI 10.1016/0272-7358(91)90005-F; BERRY DTR, 1991, PSYCHOL ASSESSMENT J, V3, P418, DOI DOI 10.1037/1040-3590.3.3.418; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BUCHHOLZ D, 1984, CLIN PSYCHOL REV, V4, P693, DOI 10.1016/0272-7358(84)90012-6; Butcher JN, 1989, MANUAL ADM SCORING M; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; FAUST D, 1991, BRAIN DAMAGE CLAIMS; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; GOUGH HG, 1950, J CONSULT PSYCHOL, V14, P408; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Hathaway SR, 1951, MINNESOTA MULTIPHASI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; KRAUS J, 1994, NEUROPSYCHAITRY TRAU; Lamb DG, 1994, PSYCHOL ASSESSMENT, V6, P8; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Lees-Haley P. R., 1992, AM J FORENSIC PSYCH, V10, P25; LEESHALEY P, IN PRESS ARCH CLIN N; LOVELL M, 1994, NEUROPSYCHIATRY TRAU; MILLIS S, 1995, 30TH ANN S REC DEV U; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; POPE KS, 1993, MMPI MMPI 2 MMPI A C; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; ROGERS R, 1988, CLIN ASSESSMENT MALI; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; TAYLOR C, 1994, NEUROPSYCHIATRY TRAU; Wetter M. W., 1992, PSYCHOL ASSESSMENT, V4, P369, DOI 10.1037/1040-3590.4.3.369; Wetter M. W., 1993, PSYCHOL ASSESSMENT, V5, P317; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	45	39	39	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	DEC	1995	7	4					517	523					7	Psychology, Clinical	Psychology	TL180	WOS:A1995TL18000013					2021-06-18	
J	KAITARO, T; KOSKINEN, S; KAIPIO, ML				KAITARO, T; KOSKINEN, S; KAIPIO, ML			NEUROPSYCHOLOGICAL PROBLEMS IN EVERYDAY LIFE - A 5-YEAR FOLLOW-UP-STUDY OF YOUNG SEVERELY CLOSED-HEAD-INJURED PATIENTS	BRAIN INJURY			English	Article								The aim of this follow-up study was to examine the long-term disabilities and handicaps caused by severe head injuries and their effects on the everyday life of patients and their relatives. The group studied consisted of 19 subjects who had suffered a severe closed-head injury during 1984 and had been rehabilitated in the Kapyla Rehabilitation Center. In 1989 a thorough functional assessment of these patients was carried out. In addition, information concerning the quality of life, activities of daily living (ADL) and social situation was gathered by means of questionnaires filled in by the patient and, if possible, by a close relative. The results indicated the importance of changes in cognitive functions, personality and emotional reactions. Changes in personality and emotional reactions were especially emphasized by the relatives. We also correlated the patients' and their relatives' estimates of the occurrence of memory problems in everyday life with the results of objective memory tests. We found that verbal memory tests reached significant correlations with the estimates of everyday memory problem, whereas tests of visual memory, though able to discriminate the brain-injured from normal subjects, did not correlate on a statistically significant level with the estimates of patients and relatives. The implications of the results for methods of assessment and the planning of rehabilitation programmes are discussed.	KAPYLA REHABIL CTR, SF-00160 HELSINKI, FINLAND							BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1988, SCAND J REHABIL MED, P41; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GOODGOLD J, 1988, REHABILITATION MED; KAITARO T, 1992, ML114 SOC INS I PUBL; MAHONEY F I, 1965, Md State Med J, V14, P61; MOSKOWITZ E, 1957, J Chronic Dis, V5, P342, DOI 10.1016/0021-9681(57)90092-9; NIEMI ML, 1988, STROKE, V19, P1101, DOI 10.1161/01.STR.19.9.1101; NOTT PN, 1975, BRIT J SOC CLIN PSYC, V14, P199, DOI 10.1111/j.2044-8260.1975.tb00170.x; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PIETILA ML, 1992, ML114 SOC INS I PUBL, P35; RANKIN J, 1957, Scott Med J, V2, P200; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; VIITANEN M, 1987, UMEA U MED DISSERTAT, V201; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; 1986, HDB FINNISH VERSION	19	39	39	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	1995	9	7					713	727		10.3109/02699059509008227			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RZ814	WOS:A1995RZ81400004	8680398				2021-06-18	
J	SACKS, GS; BROWN, RO; TEAGUE, D; DICKERSON, RN; TOLLEY, EA; KUDSK, KA				SACKS, GS; BROWN, RO; TEAGUE, D; DICKERSON, RN; TOLLEY, EA; KUDSK, KA			EARLY NUTRITION SUPPORT MODIFIES IMMUNE FUNCTION IN PATIENTS SUSTAINING SEVERE HEAD-INJURY	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article							PARENTERAL-NUTRITION; SEPTIC SHOCK; SEPSIS; HYPERALIMENTATION; SURVIVAL; CYTOKINE; TRAUMA; ORGAN; GUT	Background: Immunosuppression after severe head injury has been characterized by a depressed CD4 (T-helper/inducer)-CD8 (T-suppressor/cytotoxic) ratio and decreased T-lymphocyte responsiveness. Some investigators propose that this immunocompromized state is the result of an injury-associated hypermetabolic response and inadequate nutrient delivery during the immediate postinjury recovery phase. Previous observations from our institution demonstrated a preserved CD4-CD8 ratio in severe closed-head injury (CHI) patients receiving early parenteral nutrition (PN). It was unclear whether early PN or other aspects of patient care eliminated the characteristic depression in cellular immunity. The purpose of this study was to further investigate the effect of early PN on the immune function of CHI patients. Methods: Nine patients sustaining severe CHI were prospectively randomized to either early PN (n = 4) at day 1 or delayed PN (n = 5) at day 5. Total nutrient administration was delivered at 2 g of protein/kg per day and 40 nonprotein kcal/kg per day for at least the first 14 days of hospitalization. Analysis for T-lymphocyte expression of CD4 and CD8 cell surface antigens and interleukin-6 was performed on days 1, 3, 7, and 14 of hospitalization. T-lymphocyte activation in response to stimulation by concanavalin A (Con A), phytohemagglutinin (PHA), and pokeweed mitogens (PWM) was also assessed on these days. Results: Significant increases in total CD4 cell counts (2048 +/- 194 to 2809 +/- 129 vs 1728 +/- 347 to 1825 +/- 563, p < .05) and CD4% (42.6 +/- 4.4% to 56.2 +/- 2.6% vs 36.6 +/- 6.6% to 36.6 +/- 11.3%, p < .05) were observed at day 14 in patients receiving early vs delayed PN. An improved lymphocyte response from baseline to day 14 after Con A stimulation was demonstrated in the early PN group (3850 +/- 1596 to 16144 +/- 5024 cpm, p < .05). A significant rise in the CD4-CD8 ratio over baseline to day 14 was also noted in the early PN group (1.43 +/- 0.17 to 2.38 +/- 0.54, p < .05). Conclusions: The early aggressive nutrition support of CHI patients appears to modify immunologic function by increasing CD4 cells, CD4-CD8 ratios, and T-lymphocyte responsiveness to Con A.	UNIV TENNESSEE,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT CLIN PHARM,MEMPHIS,TN 38163; UNIV TENNESSEE,DEPT BIOSTAT,MEMPHIS,TN 38163			Dickerson, Roland N/C-5185-2008	Dickerson, Roland/0000-0002-2086-6317			ALVERDY J, 1985, ANN SURG, V202, P681, DOI 10.1097/00000658-198512000-00003; ALVERDY JC, 1988, SURGERY, V104, P185; BOOP FA, 1985, NEUROSURGERY, V16, P725; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; FORD TC, 1993, FOCUS, V15, P2; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HELLING TS, 1988, J TRAUMA, V11, P1575; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; HOYT DB, 1990, J TRAUMA, V7, P759; HUNT D, 1985, JPEN-PARENTER ENTER, V9, P121; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; KUDSK KA, 1994, ARCH SURG-CHICAGO, V129, P66; LIN C-N, 1992, Kaohsiung Journal of Medical Sciences, V8, P202; LUTZ H, 1976, TOTAL PARENTERAL ALI, P214; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; OTT L, 1991, NUTRITION CLIN PRACT, V6, P223; PAGE C, 1987, CONTEMP SURG, V32, P14; PAULSON G, 1971, CLIN CHEM, V17, P644; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; Rapp R. P., 1993, Clinical Nutrition, V12, pS70, DOI 10.1016/S0261-5614(09)90012-7; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P505; SCHLUTER B, 1991, J TRAUMA, V31, P1663, DOI 10.1097/00005373-199112000-00017; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; WILMORE DW, 1988, SURGERY, V104, P917	29	39	42	0	0	AMER SOC PARENTERAL & ENTERAL NUTRITION	SILVER SPRING	8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910	0148-6071			JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	SEP-OCT	1995	19	5					387	392		10.1177/0148607195019005387			6	Nutrition & Dietetics	Nutrition & Dietetics	RW055	WOS:A1995RW05500010	8577017				2021-06-18	
J	TENNANT, A; MACDERMOTT, N; NEARY, D				TENNANT, A; MACDERMOTT, N; NEARY, D			THE LONG-TERM OUTCOME OF HEAD-INJURY - IMPLICATIONS FOR SERVICE PLANNING	BRAIN INJURY			English	Article								As most of those experiencing traumatic brain injury tend to be young, disabled survivors will be gradually accruing in each locality as each year passes. How many need continuing care a decade after injury? How many need day care, or need help with finding work, or continuing support for carers? 190 patients who had been admitted to two UK regional neurosurgical units on average some 7 years earlier were followed up. With an average age of 29 years these patients stayed in hospital for an average 33 days. At follow-up 23% were classified as having moderate disability or worse on the Glasgow Outcome Scale, including 7.4% who had died subsequent to discharge. Survivors were given a neuropsychological assessment and a socioeconomic interview. Of the survivors, 17% had failed to make a good recovery, but 36% were failing to occupy their time in a meaningful way. Age over 30 at time of injury, not occupied before injury, and above-average length of stay were some of the predictors for failing to occupy time. Quality of life was severely curtailed for those who could not occupy their time, as was the case for their carers. Appropriate counselling, Vocational evaluation and family support in the early years following injury may help to improve quality of life for both the head-injured person and their carers.	MANCHESTER ROYAL INFIRM,DEPT NEUROL,MANCHESTER M13 9WL,LANCS,ENGLAND	TENNANT, A (corresponding author), UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND.						[Anonymous], 1980, INT CLASSIFICATION I; COADY MSE, 1991, RESOURCE IMPLICATION; COCKBURN JM, 1988, CLIN REHABIL, V2, P315; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; EDWARDS FC, 1990, HLTH SERVICES ADULTS; FAHY TJ, 1967, LANCET, V2, P475; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; HUNT SM, 1986, MEASURING HLTH STATU; JENNETT B, 1975, LANCET, V1, P480; JOHNSON R, 1987, INJURY, V18, P7, DOI 10.1016/0020-1383(87)90374-3; Kinsella G, 1989, Int Disabil Stud, V11, P9; KREUTZER JS, 1988, INT DISABILITY STUDI, V13, P162; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LONDON PS, 1989, BRIT J OCCUPATIONAL, V52, P101; MURPHY L D, 1990, Brain Injury, V4, P95, DOI 10.3109/02699059009026153; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; WILKINSON SM, 1989, CLIN REHABIL, V3, P317; 1990, LANCET, V335, P886; 1989, CARING PEOPLE; 1988, MANAGEMENT TRAUMATIC	21	39	40	0	1	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1995	9	6					595	605		10.3109/02699059509008218			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RU016	WOS:A1995RU01600006	7581355				2021-06-18	
J	WILDBURGER, R; ZARKOVIC, N; EGGER, G; PETEK, W; ZARKOVIC, K; HOFER, HP				WILDBURGER, R; ZARKOVIC, N; EGGER, G; PETEK, W; ZARKOVIC, K; HOFER, HP			BASIC FIBROBLAST GROWTH-FACTOR (BFGF) IMMUNOREACTIVITY AS A POSSIBLE LINK BETWEEN HEAD-INJURY AND IMPAIRED BONE-FRACTURE HEALING	BONE AND MINERAL			English	Article						BASIC FIBROBLAST GROWTH FACTOR; ENHANCED OSTEOGENESIS; HETEROTOPIC OSSIFICATION; BONE FRACTURE HEALING; HEAD INJURY	AFFINITY-CHROMATOGRAPHY; HEPARIN-SEPHAROSE; FACTOR FGF; PITUITARY; TISSUES; INVITRO; CALLUS; MATRIX	Healing of fractures of long bones or large joints is often accelerated in patients with severe traumatic brain injury (TBI). However, in these patients an early fracture healing is accompanied by hypertrophic callus formation or heterotopic ossifications which might even result in an ankylosis of the affected joints. It seems that enhanced osteogenesis in patients suffering from TBI could be caused by some humoral factors, since the sera of these patients strongly promote the growth of osteoblast cells in vitro. However, humoral growth promoting factors which could perhaps induce enhanced osteogenesis are not yet identified. Hence, the aim of this study was to analyse if basic fibroblast growth factor (bFGF) could be related to the phenomenon of enhanced osteogenesis, since bFGF stimulates the growth of osteoblasts in vitro and could be found both in the brain and the bone tissue. For that purpose the values of bFGF immunoreactivity were determined in the sera of patients with TBI and bone fractures (n = 8) as well as in the sera of patients with either TBI alone (n = 10) or bone fractures alone (n = 7), during a period of three months after injury. Quantification of the bFGF immunoreactivity was done using the ELISA based on monoclonal antibodies raised against the recombinant human bFGF. The bFGF immunoreactivity values obtained were also compared with the values determined in the sera of normal, healthy persons (n = 9). In the group of patients with bone fractures alone only a transient increase of bFGF immunoreactivity (threefold above the normal values) was observed in the second week after injury. A similar increase of the values of bFGF immunoreactivity was also determined in the sera of patients with TBI only, but it lasted longer (from the Ist until the 7th to 8th week after injury). In the case of patients with TBI and bone fractures a specific pattern of post-traumatic dynamic change of the values of serum bFGF immunoreactivity was observed. Namely, the increase of bFGF immunoreactivity (up to seven-fold above the normal values) was determined even during the first week after injury. Afterwards, periods of high values of bFGF immunoreactivity observed during the 2nd, 4th and the 7-10th weeks after injury were interrupted by sudden decreases even to the normal values (during the 3rd and the 5-6th week after injury). Thus, post-traumatic increase of the serum bFGF immunoreactivity was induced both by bone fractures and TBI, while the unusual pattern of its changes could be related to the phenomenon of enhanced osteogenesis in the patients with brain injury.	RUDJER BOSKOVIC INST,ZAGREB,CROATIA; GRAZ UNIV,INST GEN & EXPTL PATHOL,GRAZ,AUSTRIA; GRAZ UNIV,SCH MED,CLIN CHEM LAB,GRAZ,AUSTRIA; UNIV ZAGREB,SCH MED,INST NEUROPATHOL,ZAGREB 41001,CROATIA	WILDBURGER, R (corresponding author), GRAZ UNIV,SCH MED,DEPT TRAUMATOL,AUENBRUGGERPLATZ 15,A-8036 GRAZ,AUSTRIA.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CANALIS E, 1988, TRIANGLE, V27, P11; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; FINKLESTEIN SP, 1990, STROKE, V21, P122; FRAUTSCHY SA, 1991, BRAIN RES, V12, P291; GAUTHIER T, 1987, BIOCHEM BIOPH RES CO, V145, P775, DOI 10.1016/0006-291X(87)91032-1; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477; LOGAN A, 1992, J NEUROSCI, V12, P3828; MAZUE G, 1992, TOXICOL LETT, V329, P64; MORMEDE P, 1985, BIOCHEM BIOPH RES CO, V128, P1108, DOI 10.1016/0006-291X(85)91054-X; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RIVA MA, 1992, MOL BRAIN RES, V15, P311, DOI 10.1016/0169-328X(92)90123-S; RODAN SB, 1992, CYTOKINES BONE METAB, P115; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; WILDBURGER R, 1992, ZBL CHIR, V117, P515	25	39	45	0	4	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0169-6009			BONE MINER	Bone Miner.	DEC	1994	27	3					183	192		10.1016/S0169-6009(08)80192-4			10	Endocrinology & Metabolism	Endocrinology & Metabolism	QF121	WOS:A1994QF12100002	7696886				2021-06-18	
J	YONEDA, Y; OGITA, K				YONEDA, Y; OGITA, K			RAPID AND SELECTIVE ENHANCEMENT OF DNA-BINDING ACTIVITY OF THE TRANSCRIPTION FACTOR AP1 BY SYSTEMIC ADMINISTRATION OF N-METHYL-D-ASPARTATE IN MURINE HIPPOCAMPUS	NEUROCHEMISTRY INTERNATIONAL			English	Article							CEREBELLAR GRANULE CELLS; MESSENGER-RNA EXPRESSION; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; C-FOS PROTEIN(S); PRIMARY CULTURES; JUN; STIMULATION; ACTIVATION; RECEPTORS	Brain nuclear extracts of ddY mice contained 3 different transcription factors with leucine-zipper domains, including activator protein-1 (AP1), cyclic AMP responsive element binding protein (CREB) and Myc. An intraperitoneal injection of N-methyl-D-aspartate (NMDA) was effective in selectively inducing 6-fold enhancement of DNA binding activity of AP1 in the hippocampus 2 h after the administration. Furthermore, NMDA induced less than 2-fold potentiation of the AP1 binding in the striatum, hypothalamus, medulla-pons and cerebral cortex in a rank order of decreasing magnitude. However, the AP1 binding was not significantly affected by the systemic injection of NMDA in the midbrain and cerebellum In contrast, NMDA virtually did not alter DNA binding activities of both CREB and Myc in discrete structures of murine brain under similar experimental conditions. These results suggest that the systemic administration of NMDA may induce rapid and selective enhancement of DNA binding activity of AP1 in murine hippocampus.		YONEDA, Y (corresponding author), SETSUNAN UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL,45-1 NAGAOTOGE CHO,HIRAKATA,OSAKA 57301,JAPAN.		Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X			BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVAL JL, 1989, J NEUROCHEM, V52, P1954, DOI 10.1111/j.1471-4159.1989.tb07285.x; DESSI F, 1993, J NEUROCHEM, V60, P1953, DOI 10.1111/j.1471-4159.1993.tb13427.x; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; KARIN M, 1992, FASEB J, V6, P2581; KATO GJ, 1992, FASEB J, V6, P3065; LIU F, 1993, J BIOL CHEM, V268, P6714; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OGITA K, 1994, IN PRESS J NEUROCHEM; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; SHIN C, 1990, J NEUROCHEM, V55, P1050, DOI 10.1111/j.1471-4159.1990.tb04595.x; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; YONEDA Y, 1989, ANAL BIOCHEM, V177, P250, DOI 10.1016/0003-2697(89)90047-X; YONEDA Y, 1993, NEUROSCI LETT, V161, P161, DOI 10.1016/0304-3940(93)90284-R; YONEDA Y, 1993, J NEUROCHEM, V61, pS256	30	39	39	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0197-0186			NEUROCHEM INT	Neurochem. Int.	SEP	1994	25	3					263	271		10.1016/0197-0186(94)90070-1			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH035	WOS:A1994PH03500007	7833794				2021-06-18	
J	OMMAYA, AK; THIBAULT, L; BANDAK, FA				OMMAYA, AK; THIBAULT, L; BANDAK, FA			MECHANISMS OF IMPACT HEAD-INJURY	INTERNATIONAL JOURNAL OF IMPACT ENGINEERING			English	Article							DIFFUSE AXONAL INJURY; CEREBRAL CONCUSSION; NERVE; MEMBRANE; BRAIN; CA-2+	A review of research on brain trauma mechanisms operative during head impact is presented from a clinically relevant biomechanical perspective. Emphasis is placed on microscopic mechanisms, gleaned from isolated neural tissue and cellular biomechanics research, and their relation to macro sale mechanisms observed in head injury victims and in experimental physical model experiments. Experimental and clinico-pathologic research, past and ongoing, substantiating the centripetal theory for concussive brain injury is also reviewed in the context of recent advancements in computations biomechanics of head injury brought about by the expanding availability of high speed super computers and brain imaging. A synopsis of our current computational research activities in head impact simulation is presented and some preliminary results are cited.	CTR INTERDISCIPLINARY BRAIN RES, BETHESDA, MD USA; NATL HIGHWAY TRAFF SAFETY ADM, DIV BIOMECH RES, WASHINGTON, DC USA; UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA	OMMAYA, AK (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20037 USA.						ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; AKKAS N, 1980, J BIOMECH, V13, P737; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BANDAK FA, UNPUB EXPT COMPUTATI; BANDAK FA, UNPUB CUMULATIVE DAM; BANDAK FA, UNPUB 3 DIMENSIONAL; BANDAK FA, UNPUB ANATOMICAL FIN; BARBEE KA, 1991, THESIS U PENNSYLVANI; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; CHAN PC, UNPUB INFLUENCE SUBA; CHAN RKC, 1986, WIN ASME 86 WA NE 3; CRONWELL D, 1979, LANCET, V2, P605; DENNYBROWN D, 1941, BRAIN, P64; DIMASI F, 1991, NATIONAL HIGHWAY TRA, V1; EVANS EA, 1976, BIOPHYS J, V16, P585, DOI 10.1016/S0006-3495(76)85713-X; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; GADD CW, 1966, 10TH P STAPP CAR CRA; GALBRAITH JA, 1988, THESIS U PENNSYLVANI; GANOT G, 1981, BIOCHIM BIOPHYS ACTA, V649, P487, DOI 10.1016/0005-2736(81)90440-5; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1971, 15TH P STAPP CAR CRA; GHIBAULT IE, 1974, ACEMB, V16, P176; GOLDBERG A, 1983, INFORM PROCESS LETT, V16, P213, DOI 10.1016/0020-0190(83)90127-8; GOLDBERG RN, 1973, THERMOCHIM ACTA, V6, P1; GOLDSMITH W, 1978, J BIOMECH ENG-T ASME, V100, P25, DOI 10.1115/1.3426186; GOLDSMITH W, 1983, J BIOMECH ENG, V105, P196; GOLDSMITH W, 1984, BIOMECHANICS IMPACT; GOLDSMITH W, 1974, INT J MECH SCI, V16, P609; GOLDSMITH W, 1974, 7TH P US NAT C APPL, P160; GOLDSMITH W, 1987, J BIOMECH, V20, P487; GOLDSMITH W, 1989, OCT AAAM M NEED ANG; GOLDSMITH W, 1987, J BIOMECH, V20, P471; GOLDSMITH W, 1979, J BIOMECH, V12, P211; GOLDSMITH W, 1906, HEAD INJURY; GRAHAM DI, 1993, HEAD INJURY; GRAY JAB, 1954, J PHYSIOL-LONDON, V124, P84, DOI 10.1113/jphysiol.1954.sp005087; Gurdjian ES, 1975, IMPACT HEAD INJURY; Holbourn AHS, 1943, LANCET, V2, P438; HUMAYUN MS, 1987, P SOC NEUROSCI; HUNTER CM, 1988, EFFECTS MECHANICAL L; JANE J, 1982, SEMINARS NEUROLOGIC; JENKINS A, 1986, LANCET, V2, P445; JONES HB, 1983, J NEUROCYTOL, V12, P439, DOI 10.1007/BF01159384; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LILES DR, 1978, J COMPUT PHYS, V26, P390, DOI 10.1016/0021-9991(78)90077-3; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MERRILL T, 1984, J BIOMECH, V17, P81, DOI 10.1016/0021-9290(84)90126-X; MORGAN BP, 1986, CELL CALCIUM, V7, P399, DOI 10.1016/0143-4160(86)90042-4; Newman J. A, 1986, P IRCOBI C, P121; OCHS S, 1977, NATURE, V270, P748, DOI 10.1038/270748a0; OMMAYA A, 1984, BIOMECHANICS TRAUMA; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1987, PUBLIC HEALTH REP, V102, P587; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1968, J BIOMECH; OMMAYA AK, 1966, 10TH P STAPP CAR CRA; OMMAYA AK, UNPUB TRAUMATIC UNCO; OMMAYA AK, 1973, NHTSA DOTHS0811106 C; OMMAYA AK, 1994, ASTM STP, P1229; OMMAYA AK, 1969, ACCIDENT PATHOLOGY; OMMAYA AK, 1983, DOT HS806434; OMMAYA AK, 1982, NEUROLOGICAL SURGERY, V4, P1877; ONO K, 1981, 24TH P STAPP CAR CRA; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PINCEMAILLE Y, 1989, 892439 STAPP CAR CRA; REILLY PL, 1975, LANCET, V2, P375; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1969, HDB CLIN NEUROLOGY, V3, P293; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHLIWA M, 1981, CELL BIOL, V78, P1037; SHATSKY S, 1974, 18TH P STAPP CAR CRA, P351; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; TERAKAWA S, 1982, PFLUG ARCH EUR J PHY, V395, P59, DOI 10.1007/BF00584969; THIBAULT L, 1990, 34TH P AAAM; THIBAULT LE, 1990, P INT IRCOBI C LYON; VARSACE J, 1971, 15TH P STAPP CAR CRA; VIANO D, 1989, 811708 STAPP CAR CRA; WINSTON FK, 1989, THESIS U PENNSYLVANI; WINTERS JM, 1983, J BIOMECH ENG-T ASME, V105, P63, DOI 10.1115/1.3138386; 1989, SENSORS, V6, P32; 1988, COMMITTEE REV INJURY; 1985, COMMITTEE TRAUMA RES	92	39	41	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0734-743X	1879-3509		INT J IMPACT ENG	Int. J. Impact Eng.	AUG	1994	15	4					535	560		10.1016/0734-743X(94)80033-6			26	Engineering, Mechanical; Mechanics	Engineering; Mechanics	NX410	WOS:A1994NX41000015					2021-06-18	
J	CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR				CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR			INFANT WALKER-RELATED INJURIES - A PROSPECTIVE-STUDY OF SEVERITY AND INCIDENCE	PEDIATRICS			English	Article						INFANT WALKERS; INJURY CONTROL; HEAD INJURIES	CONTINUING PROBLEM; BABY WALKERS	Objective. To determine the incidence and significance of walker-related injuries in infants. Methods. During a 3-year, 8-month period, all infants who were brought to the University of Virginia Pediatric Emergency Department with a walker-related injury were prospectively studied. During the emergency department visit, demographic and epidemiologic information were recorded. The annual incidence of walker-related injuries occurring in infants <1 year of age that resulted in a hospital emergency department visit was calculated from the home zip codes of the injured patients and from the population of infants <1 year of age living in Charlottesville and in Albemarle County. Results. Sixty-five patients were enrolled in the study. The age distribution ranged from 3 months to 17 months, with 95% younger <1 year old. Mechanisms associated with walker-related injuries included stairway falls in 46 infants (71%), tip-overs in 14 infants (21%), falls from a porch in 2 infants (3%), and burns in 3 infants (5%). These injuries predominantly involved the head and neck region (97%), with few injuries to the extremities (6%) and trunk (3%). Although the majority of injuries were minor, significant injuries occurred in 19 infants (29%). These injuries included skull fracture, concussion, intracranial hemorrhage, full-thickness burns, c-spine fracture, and death. After excluding the burned patients, all the serious injuries resulted from falls down stairs. The annual incidence of injuries occurring in infants <1 year of age, related to the use of walkers, and resulting in an emergency department visit was 8.9/1000, and for serious injuries was 1.7/1000. Conclusions. The incidence and significance of infant walker-related injuries in infants are unacceptably high.		CHIAVIELLO, CT (corresponding author), UNIV VIRGINIA,DEPT PEDIAT,DIV EMERGENCY MED,BOX 523-21,CHARLOTTESVILLE,VA 22908, USA.						BIRCHALL MA, 1988, BURNS, V14, P244, DOI 10.1016/0305-4179(88)90049-6; COATS TJ, 1991, ARCH EMERG MED, V8, P52; COURY DL, 1992, AJDC, V146, pA507; CROUCHMAN M, 1986, DEV MED CHILD NEUROL, V28, P757; DIMARIO FJ, 1990, CLIN PEDIATR, V29, P405, DOI 10.1177/000992289002900709; FAZEN LE, 1982, PEDIATRICS, V70, P106; GAUDREAULT P, 1986, ANN EMERG MED, V15, P808, DOI 10.1016/S0196-0644(86)80378-X; GLEADHILL DNS, 1987, ARCH DIS CHILD, V62, P491, DOI 10.1136/adc.62.5.491; HOLM VA, 1983, AM J DIS CHILD, V137, P1189, DOI 10.1001/archpedi.1983.02140380049016; JOHNSON C F, 1990, Pediatric Emergency Care, V6, P58, DOI 10.1097/00006565-199003000-00017; KAUFFMAN IB, 1977, PERCEPT MOTOR SKILL, V45, P1323, DOI 10.2466/pms.1977.45.3f.1323; KAVANAGH CA, 1982, AM J DIS CHILD, V136, P205, DOI 10.1001/archpedi.1982.03970390019005; MEYER M, 1988, BURNS, V14, P145, DOI 10.1016/0305-4179(88)90222-7; MILLAR R, 1975, INJURY, V7, P8, DOI 10.1016/0020-1383(75)90051-0; PARTINGTON MD, 1991, ANN EMERG MED, V20, P652, DOI 10.1016/S0196-0644(05)82386-8; RIDENOUR MV, 1982, PERCEPT MOTOR SKILL, V55, P1201, DOI 10.2466/pms.1982.55.3f.1201; RIEDER MJ, 1986, PEDIATRICS, V78, P488; SILVERSTEIN MK, 1984, CLIN PEDIATR, V23, P330; STOFFMAN JM, 1984, CAN MED ASSOC J, V131, P573; 1980, INT CLASSIFICATION D, V1	20	39	42	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	JUN	1994	93	6					974	976					3	Pediatrics	Pediatrics	NP678	WOS:A1994NP67800018	8190586				2021-06-18	
J	AISEN, ML; ARNOLD, A; BAIGES, I; MAXWELL, S; ROSEN, M				AISEN, ML; ARNOLD, A; BAIGES, I; MAXWELL, S; ROSEN, M			THE EFFECT OF MECHANICAL DAMPING LOADS ON DISABLING ACTION TREMOR	NEUROLOGY			English	Article								Patients with severe action tremor have uncontrollable, relatively rapid oscillatory motion superimposed on otherwise useable slower voluntary motor activity. Because a mechanical damper produces an opposing force proportional to velocity, applying damping loads to tremorous limbs should attenuate the (high-velocity) tremor component of movement while permitting the slower purposeful portion to proceed relatively unopposed. In this study, the effect of upper extremity damping in three degrees of freedom was examined in 10 patients with cerebellar action tremor due to multiple sclerosis or traumatic brain injury. Variable amounts of damping were applied by prototype energy-dissipating orthoses which generated resistive viscous loads by means of computer-controlled magnetic particle brakes. All patients experienced statistically and functionally significant tremor reduction with the application of damping.	MIT,CAMBRIDGE,MA 02139; UNIV PUERTO RICO,RIO PIEDRAS,PR 00931; UNIV PUERTO RICO,PUERTO,NY	AISEN, ML (corresponding author), CORNELL UNIV,BURKE REHAB HOSP,COLL MED,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.						AISEN M, 1991, ARCH NEUROL-CHICAGO, V49, P513; ARNOLD A, 1992, THESIS MIT; HEWER LR, 1972, BRAIN, V95, P579; HOMBERG V, 1987, J NEUROL NEUROSUR PS, V50, P568, DOI 10.1136/jnnp.50.5.568; MAXWELL S, THESIS MIT; MORRICE B L, 1987, Society for Neuroscience Abstracts, V13, P1700; ROSEN M, IN PRESS J REHABIL R; SANES JN, 1988, J NEUROL NEUROSUR PS, V51, P934, DOI 10.1136/jnnp.51.7.934	8	39	39	0	6	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology	JUL	1993	43	7					1346	1350		10.1212/WNL.43.7.1346			5	Clinical Neurology	Neurosciences & Neurology	LM104	WOS:A1993LM10400015	8327136				2021-06-18	
J	LAZARUS, JAC				LAZARUS, JAC			ASSOCIATED MOVEMENT IN HEMIPLEGIA - THE EFFECTS OF FORCE EXERTED, LIMB USAGE AND INHIBITORY TRAINING	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						HEMIPLEGIA; INHIBITION; TRAUMATIC BRAIN INJURY	COORDINATION	The intensity of associated movement or motor overflow in the contralateral limb during a unimanual task was evaluated in postacute traumatic brain injured (TBI) young adults with left side hemiplegia and age-matched controls. Both groups demonstrated increased overflow with increasing active limb force, although the trend was for greater overflow to occur in the TBI group, particularly when the spastic limb was active. Following three successive days of inhibitory training with electromyographic feedback, TBI subjects were able to significantly reduce the amount of overflow in the contralateral limb, greater inhibition occurring in the noninvolved limb during spastic limb movement. The results are discussed in terms of a dual model of inhibitory control and the role of such processes in uncoupling the limbs for independent limb usage.		LAZARUS, JAC (corresponding author), UNIV WISCONSIN,DEPT PHYS EDUC & DANCE,2000 OBSERV DR,MADISON,WI 53706, USA.						BRODAL A, 1973, BRAIN, V96, P675, DOI 10.1093/brain/96.4.675; Burke D, 1988, Adv Neurol, V47, P401; BURKE D, 1970, J NEUROL NEUROSUR PS, V33, P216, DOI 10.1136/jnnp.33.2.216; CAMBIER J, 1977, NEUROLOGY, V27, P646, DOI 10.1212/WNL.27.7.646; CERNACEK J, 1961, ARCH NEUROL-CHICAGO, V4, P165, DOI 10.1001/archneur.1961.00450080047005; COHEN HJ, 1967, J PEDIATR-US, V71, P39, DOI 10.1016/S0022-3476(67)80228-2; DENNIS M, 1976, NEUROPSYCHOLOGIA, V14, P455, DOI 10.1016/0028-3932(76)90074-9; FOG E, 1963, CLIN DEV MED, V10, P52; JEBSON RH, 1971, ARCH PHYS MED REHAB, V51, P170; KELSO JAS, 1979, J EXP PSYCHOL HUMAN, V5, P229, DOI 10.1037/0096-1523.5.2.229; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; LANCE JW, 1974, ARCH PHYS MED REHAB, V55, P332; LAZARUS JAC, 1991, DEV MED CHILD NEUROL, V33, P32; LAZARUS JAC, 1987, DEV MED CHILD NEUROL, V29, P726; MARTENIUK RG, 1980, TUTORIALS MOTOR BEHA; MOORE J, 1980, RECOVERY FUNCTION TH, P9; MORASSO P, 1983, HUM MOVEMENT SCI, V2, P197, DOI 10.1016/0167-9457(83)90017-9; MULLEY G, 1982, SCAND J REHABIL MED, V14, P117; SEMMES J, 1968, NEUROPSYCHOLOGIA, V6, P11, DOI 10.1016/0028-3932(68)90035-3; STERN JA, 1976, MENTAL HLTH CHILDREN, V2, P113; TODOR JI, 1986, DEV MED CHILD NEUROL, V28, P205; TODOR JI, 1986, PSYCHOL MOTOR BEHAV, P239; WALTER CB, 1990, J MOTOR BEHAV, V22, P451; Winer BJ., 1971, STAT PRINCIPLES EXPT; YENSEN R, 1965, PERCEPT MOTOR SKILL, V20, P967, DOI 10.2466/pms.1965.20.3.967; Zulch K. J., 1969, HDB CLIN NEUROLOGY, P404; Zulch KJ, 1975, CEREBRAL LOCALIZATIO, P32	27	39	44	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1992	73	11					1044	1049					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	JX141	WOS:A1992JX14100004	1444770				2021-06-18	
J	DURE, LS; YOUNG, AB; PENNEY, JB				DURE, LS; YOUNG, AB; PENNEY, JB			COMPARTMENTALIZATION OF EXCITATORY AMINO-ACID RECEPTORS IN HUMAN STRIATUM	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							GLUTAMATE-BINDING-SITES; TRAUMATIC BRAIN INJURY; CENTRAL NERVOUS-SYSTEM; DOPAMINE UPTAKE SITES; BASAL GANGLIA; HUNTINGTONS-DISEASE; SUBSTANCE-P; CAUDATE-NUCLEUS; PROJECTION NEURONS; NMDA RECEPTOR	Division of the mammalian neostriatum into two intermingled compartments called striosomes and matrix has been established by analysis of enzyme activity, neuropeptide distribution, nucleic acid hybridization, and neurotransmitter receptor binding. Striosomes and matrix are distinct with respect to afferent and efferent connections, and these regions provide the potential for modulation and integration of information flow within basal ganglia circuitry. The primary neurotransmitters of corticostriatal afferents are excitatory amino acids, but to date no correlation of excitatory amino acid receptors and striatal compartments has been described. We examined binding to the three pharmacologically distinct ion-otropic excitatory amino acid receptors, N-methyl-D-aspartate, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, and kainate, in human striatum using in vitro receptor autoradiography and compared the binding to striosomes and matrix histochemically defined by acetylcholinesterase activity. Our findings reveal increased binding to N-methyl-D-aspartate receptors and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in matrix relative to striosomes and increased kainate receptor binding in striosomes relative to matrix. These results suggest that afferent input to the two striatal compartments may be mediated by pharmacologically distinct excitatory amino acid receptor subtypes.		DURE, LS (corresponding author), UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109, USA.		Young, Anne/AAF-4283-2020; Dure, Leon/B-3243-2008		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 08671] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19613, NS 15655] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS019613, P50NS015655, P01NS015655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG008671] Funding Source: NIH RePORTER		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; AUER R, 1985, ACTA NEUROPATHOL, V67, P279, DOI 10.1007/BF00687813; BESSON MJ, 1988, NEUROSCIENCE, V26, P101, DOI 10.1016/0306-4522(88)90130-3; BESSON MJ, 1990, NEUROSCIENCE, V39, P33, DOI 10.1016/0306-4522(90)90220-X; BOLAM JP, 1990, BRAIN RES, V529, P57, DOI 10.1016/0006-8993(90)90811-O; BOLAM JP, 1988, NEUROSCIENCE, V24, P853, DOI 10.1016/0306-4522(88)90073-5; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; CHAPMAN AG, 1989, NEUROSCI LETT, V107, P256, DOI 10.1016/0304-3940(89)90827-6; CHESSELET MF, 1986, NEUROSCIENCE, V17, P547, DOI 10.1016/0306-4522(86)90030-8; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; DONNAN GA, 1991, J COMP NEUROL, V304, P419, DOI 10.1002/cne.903040307; DURE LS, 1991, ANN NEUROL, V30, P785, DOI 10.1002/ana.410300607; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAULL RLM, 1986, BRAIN RES, V381, P153, DOI 10.1016/0006-8993(86)90704-3; FAULL RLM, 1989, BRAIN RES, V488, P381, DOI 10.1016/0006-8993(89)90735-X; FERRANTE RJ, 1987, BRAIN RES, V416, P141, DOI 10.1016/0006-8993(87)91506-X; GENESERJENSEN FA, 1971, Z ZELLFORSCH MIK ANA, V114, P460, DOI 10.1007/BF00325634; GERFEN CR, 1985, J COMP NEUROL, V236, P454, DOI 10.1002/cne.902360404; GERFEN CR, 1987, J NEUROSCI, V7, P3935; GERFEN CR, 1985, P NATL ACAD SCI USA, V82, P8780, DOI 10.1073/pnas.82.24.8780; GERFEN CR, 1984, NATURE, V311, P461, DOI 10.1038/311461a0; GERFEN CR, 1989, SCIENCE, V246, P385, DOI 10.1126/science.2799392; GERFEN CR, 1988, BRAIN RES, V460, P161, DOI 10.1016/0006-8993(88)91217-6; GIMENEZAMAYA JM, 1991, J NEUROSCI, V11, P779; GIMENEZAMAYA JM, 1990, NEUROSCIENCE, V34, P111, DOI 10.1016/0306-4522(90)90306-O; GOTO S, 1989, ANN NEUROL, V25, P298, DOI 10.1002/ana.410250315; GOTO S, 1990, ACTA NEUROPATHOL, V80, P88, DOI 10.1007/BF00294227; GRAYBIEL AM, 1978, P NATL ACAD SCI USA, V75, P5723, DOI 10.1073/pnas.75.11.5723; GRAYBIEL AM, 1984, NEUROSCIENCE, V13, P1157, DOI 10.1016/0306-4522(84)90293-8; GRAYBIEL AM, 1980, P NATL ACAD SCI-BIOL, V77, P1214, DOI 10.1073/pnas.77.2.1214; GRAYBIEL AM, 1981, NEUROSCIENCE, V6, P377, DOI 10.1016/0306-4522(81)90131-7; GRAYBIEL AM, 1981, P NATL ACAD SCI-BIOL, V78, P5871, DOI 10.1073/pnas.78.9.5871; GRAYBIEL AM, 1989, P NATL ACAD SCI USA, V86, P9020, DOI 10.1073/pnas.86.22.9020; GRAYBIEL AM, 1983, CHEM NEUROANATOMY, P427; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; GREENAMYRE JT, 1985, J PHARMACOL EXP THER, V233, P254; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GREENAMYRE JT, 1984, J NEUROSCI, V4, P2133; GROVES PM, 1988, J NEUROSCI, V8, P892; HABER SN, 1986, HUM NEUROBIOL, V5, P159; HEDREEN J C, 1990, Society for Neuroscience Abstracts, V16, P1119; HERKENHAM M, 1981, NATURE, V291, P415, DOI 10.1038/291415a0; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; JANSEN KLR, 1990, BRAIN RES, V532, P351, DOI 10.1016/0006-8993(90)91783-D; JIMENEZCASTELLANOS J, 1989, NEUROSCIENCE, V32, P297, DOI 10.1016/0306-4522(89)90080-8; JOHNSTON JG, 1990, DEV BRAIN RES, V57, P93, DOI 10.1016/0165-3806(90)90189-6; KAWAGUCHI Y, 1990, J NEUROSCI, V10, P3421; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; LANGER LF, 1989, BRAIN RES, V498, P344, DOI 10.1016/0006-8993(89)91114-1; LONDON ED, 1979, MOL PHARMACOL, V15, P492; LOOPUIJT LD, 1989, BRAIN RES BULL, V22, P805, DOI 10.1016/0361-9230(89)90023-3; LOWENSTEIN PR, 1989, J COMP NEUROL, V288, P428, DOI 10.1002/cne.902880306; LOWENSTEIN PR, 1990, BRAIN RES, V510, P122, DOI 10.1016/0006-8993(90)90736-U; MALACH R, 1986, J NEUROSCI, V6, P3436; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURRIN LC, 1989, BRAIN RES, V480, P170; NIELSEN EO, 1990, J NEUROCHEM, V54, P686, DOI 10.1111/j.1471-4159.1990.tb01925.x; PALACIOS JM, 1981, NEUROSCI LETT, V25, P101, DOI 10.1016/0304-3940(81)90315-3; PENNY GR, 1988, J COMP NEUROL, V269, P275, DOI 10.1002/cne.902690211; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PETIT F, 1986, NEUROPHARMACOLOGY, V25, P1015, DOI 10.1016/0028-3908(86)90196-6; PLAITAKIS A, 1990, ANN NEUROL, V28, P3, DOI 10.1002/ana.410280103; QUIRION R, 1985, BRAIN RES, V331, P358, DOI 10.1016/0006-8993(85)91563-X; RAGSDALE CW, 1990, P NATL ACAD SCI USA, V87, P6196, DOI 10.1073/pnas.87.16.6196; RAGSDALE CW, 1981, BRAIN RES, V208, P259, DOI 10.1016/0006-8993(81)90556-4; RAINBOW TC, 1984, BRAIN RES, V309, P173, DOI 10.1016/0006-8993(84)91025-4; REID M, 1988, EUR J PHARMACOL, V147, P411, DOI 10.1016/0014-2999(88)90176-8; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; REINER A, 1990, BRAIN RES REV, V15, P251, DOI 10.1016/0165-0173(90)90003-7; RICHFIELD EK, 1987, J COMP NEUROL, V262, P446, DOI 10.1002/cne.902620308; SAKURAI SY, 1991, NEUROSCIENCE, V40, P533, DOI 10.1016/0306-4522(91)90139-F; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIMASKO SM, 1984, EUR J PHARMACOL, V106, P653, DOI 10.1016/0014-2999(84)90074-8; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SUGIMOTO T, 1987, J COMP NEUROL, V263, P607, DOI 10.1002/cne.902630411; TURNER BH, 1988, BRAIN RES, V473, P60, DOI 10.1016/0006-8993(88)90315-0; TURSKI L, 1990, BRAIN RES, V512, P125, DOI 10.1016/0006-8993(90)91180-O; VANDERKOOY D, 1984, DEV BRAIN RES, V14, P300, DOI 10.1016/0165-3806(84)90318-3; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WIELOCH T, 1985, NEUROSCI LETT, V58, P25, DOI 10.1016/0304-3940(85)90323-4; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; Young AB, 1986, QUANTITATIVE RECEPTO, P79; ZAHM DS, 1990, J COMP NEUROL, V296, P403, DOI 10.1002/cne.902960306	91	39	39	0	0	NATL ACAD PRESS	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 15	1992	89	16					7688	7692		10.1073/pnas.89.16.7688			5	Multidisciplinary Sciences	Science & Technology - Other Topics	JJ321	WOS:A1992JJ32100083	1380163	Bronze, Green Published			2021-06-18	
J	MARMAROU, A				MARMAROU, A			INTRACELLULAR ACIDOSIS IN HUMAN AND EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			EXPERIMENTAL HEAD-INJURY; CEREBRAL BLOOD-FLOW; CEREBROSPINAL-FLUID; IMPACT-ACCELERATION; OXYGEN-CONSUMPTION; LACTIC-ACIDOSIS; METABOLISM; RAT; TRAUMA; CAT	Brain tissue acidosis is considered to play a role in the complex sequence of events following traumatic brain injury. This report reviews the experimental and clinical research conducted at the Medical College of Virginia to help clarify the extent of metabolic derangement that occurs and to evaluate the effect of treatment. Experimental injury models in ventilated animals showed that trauma produces a mild brain tissue acidosis that recovers within hours of injury. Hypoxia combined with trauma produces a relative ischemia and exacerbates the acidosis, which eventually resolves with resuscitation. Other studies revealed that CSF lactate measurements should be interpreted with caution, particularly in patients with subarachnoid hemorrhage. The results of two randomized clinical trials testing therapeutic effects of sustained hyperventilation and treatment with tromethamine (THAM) are discussed.		MARMAROU, A (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,NEUROSURG RES LABS,BOX 508,MCV STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587, NS-19235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS019235, P01NS012587, R01NS019235, P50NS012587] Funding Source: NIH RePORTER		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; ANDERSEN BJ, 1989, J CEREB BLOOD FLOW M, V9, pS386; BERNTMAN L, 1978, ACTA PHYSIOL SCAND, V104, P101, DOI 10.1111/j.1748-1716.1978.tb06255.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARLSSON C, 1975, ACTA PHYSL SCAND, V95, P202; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FOLBERGROVA J, 1972, J NEUROCHEM, V19, P2507, DOI 10.1111/j.1471-4159.1972.tb01310.x; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAKANSON E, 1984, CLIN PHYSIOL, V4, P461, DOI 10.1111/j.1475-097X.1984.tb00132.x; HOVDA DA, 1990, ACT NEUR S, V51, P331; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; LEVI L, 1991, P AM ASS NEUROLOGICA, P288; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LIDDELL MJ, 1979, SURG GYNECOL OBSTET, V149, P822; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MILLEN JE, 1980, J APPL PHYSIOL, V49, P856; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; PETROFF OAC, 1986, ANN NEUROL, V20, P185, DOI 10.1002/ana.410200203; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSEN MJ, 1984, J NEUROSURG, V61, P76; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; ROVETTO MJ, 1975, CIRC RES, V37, P742, DOI 10.1161/01.RES.37.6.742; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SOOD SC, 1980, ACTA NEUROCHIR, V53, P47, DOI 10.1007/BF02074520; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	39	39	39	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S551	S562					12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900012	1613813				2021-06-18	
J	GOLDSTEIN, LH; POLKEY, CE				GOLDSTEIN, LH; POLKEY, CE			BEHAVIORAL MEMORY AFTER TEMPORAL LOBECTOMY OR AMYGDALO-HIPPOCAMPECTOMY	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							SEVERE HEAD-INJURY; EVERYDAY MEMORY; FAILURES; EPILEPSY	A total of 46 patients who had undergone surgery for the relief of temporal lobe epilepsy were tested on the Rivermead Behavioural Memory Test (RBMT) and two traditional tests of memory. The patient and a relative or close friend were also asked to complete a questionnaire about the everyday memory problems experienced by the patients. Scores on the RBMT failed to distinguish between patients who had undergone either a traditional en bloc temporal lobectomy or a more restricted resection, the amygdalo-hippocampectomy, although scores on one of the traditional memory tests did. Epilepsy-related variables did not alter the outcome of data analyses. Only relatives' questionnaire ratings of patients' memory correlated with patients' scores on the RBMT.	MAUDSLEY HOSP & INST PSYCHIAT,NEUROSURG UNIT,LONDON SE5 8AZ,ENGLAND	GOLDSTEIN, LH (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Goldstein, Laura/E-7817-2010	Goldstein, Laura/0000-0001-9387-3035			BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENNETTLEVY J, 1980, CORTEX, V18, P513; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; GOLDSTEIN LH, 1991, J ROY SOC MED, V84, P460; JONESGOTMAN M, 1987, SURGICAL TREATMENT E; LINCOLN NB, 1989, BRIT J CLIN PSYCHOL, V28, P61, DOI 10.1111/j.2044-8260.1989.tb00812.x; POLKEY CE, 1989, J NEUROL NEUROSUR PS, V52, P1050, DOI 10.1136/jnnp.52.9.1050; POLKEY CE, 1987, SURGICAL TREATMENT E; POWELL GE, 1985, BRIT J CLIN PSYCHOL, V24, P109, DOI 10.1111/j.2044-8260.1985.tb01321.x; POWELL GE, 1987, J NEUROL NEUROSUR PS, V50, P665, DOI 10.1136/jnnp.50.6.665; POWELL GE, 1979, J CLIN PSYCHOL, V35, P335, DOI 10.1002/1097-4679(197904)35:2<335::AID-JCLP2270350223>3.0.CO;2-4; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; WIESER HG, 1982, SURG NEUROL, V17, P445, DOI 10.1016/S0090-3019(82)80016-5; WILSON B, 1985, RIVERMEAD BEHAVIOURA; Wilson B.A, 1987, REHABILITATION MEMOR	17	39	40	0	1	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER, LEICS, ENGLAND LE1 7DR	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	FEB	1992	31		1				75	81		10.1111/j.2044-8260.1992.tb00969.x			7	Psychology, Clinical	Psychology	HE518	WOS:A1992HE51800006	1559119				2021-06-18	
J	GEFFEN, GM; ENCEL, JS; FORRESTER, GM				GEFFEN, GM; ENCEL, JS; FORRESTER, GM			STAGES OF RECOVERY DURING POSTTRAUMATIC AMNESIA AND SUBSEQUENT EVERYDAY MEMORY DEFICITS	NEUROREPORT			English	Article						PTA SCALE; BRAIN INJURY; EVERYDAY MEMORY; INDEX OF SEVERITY	HEAD-INJURY; SCALE; VALIDATION; COMA	POST-TRAUMATIC amnesia (PTA) is the period following brain trauma when patients are unable to acquire and retain information. Nineteen patients with brain injury were assessed for PTA, with a new scale, after they regained consciousness, every 24 h. Patients recovered orientation and their capacity to recognise new information, and finally their ability to recall this information. The longer the duration of PTA, the poorer was performance on an everyday memory test given one month after recovery from PTA. Patients with orthopaedic injuries and without brain injury showed minimal impairment on the PTA scale. The predictive value of the scale (multiple R = 0.88) with respect to subsequent everyday memory performance indicates its usefulness as an index of severity of brain injury.	FLINDERS UNIV,ADELAIDE,AUSTRALIA	GEFFEN, GM (corresponding author), JULIA FARR CTR,NEUROPSYCHOL RES UNIT,103 FISHER ST,ADELAIDE,SA 5063,AUSTRALIA.						ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BROOKS DN, 1983, REHABILITATION HEAD, P185; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Nelson H., 1982, NATIONAL ADULT READI; RICHARDSON JTE, 1984, COGN NEUROPSYCHOL, V1, P217, DOI 10.1080/02643298408252023; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; WILSON B, 1985, RIVERMEAD BEHAVIOURA	18	39	40	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	FEB	1991	2	2					105	108		10.1097/00001756-199102000-00010			4	Neurosciences	Neurosciences & Neurology	FA926	WOS:A1991FA92600010	1883986				2021-06-18	
J	BUCKLEY, WE				BUCKLEY, WE			CONCUSSIONS IN COLLEGE FOOTBALL - A MULTIVARIATE-ANALYSIS	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article										BUCKLEY, WE (corresponding author), PENN STATE UNIV,HLTH ASPECTS SPORTS,DEPT HLTH EDUC,19D WHITE BLDG,UNIVERSITY PK,PA 16802, USA.							0	39	40	1	9	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1988	16	1					51	56		10.1177/036354658801600109			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	P9831	WOS:A1988P983100009	3344880				2021-06-18	
J	GOLDSTEIN, FC; LEVIN, HS				GOLDSTEIN, FC; LEVIN, HS			EPIDEMIOLOGY OF PEDIATRIC CLOSED HEAD-INJURY - INCIDENCE, CLINICAL CHARACTERISTICS, AND RISK-FACTORS	JOURNAL OF LEARNING DISABILITIES			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Choux M., 1986, HEAD INJURIES NEWBOR, P163; COOPER PR, 1982, HEAD INJURY, P1; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; CRAFT AW, 1972, HDB CLIN NEUROLOGY, V23, P445; DECKER MD, 1984, JAMA-J AM MED ASSOC, V252, P2571, DOI 10.1001/jama.252.18.2571; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FLETCHER JM, 1985, INJURED CHILD, P30; FRANKOWSKI RF, 1985, INJURED CHILD, P20; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOETHE KE, 1986, ADV CLIN NEUROPSYCHO, V3, P213; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GURDJIAN ES, 1958, HEAD INJURIES MECHAN; JAMISON DL, 1974, ARCH DIS CHILD, V49, P376, DOI 10.1136/adc.49.5.376; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1981, MANAGEMENT HEAD INJU; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KLAUBER MR, 1986, PREV MED, V15, P139, DOI 10.1016/0091-7435(86)90084-8; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1980, J NEUROSURG S, V53, P35; KRAUS JF, 1987, HEAD INJURY, P1; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H. S., 1984, AGING RECOVERY FUNCT, P169; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MOYES CD, 1980, CHILD CARE HLTH DEV, V6, P1, DOI 10.1111/j.1365-2214.1980.tb00791.x; OKA H, 1977, BRAIN, V100, P287, DOI 10.1093/brain/100.2.287; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1981, AM J PSYCHIAT, V138, P1535; SCHERZ RG, 1981, PEDIATRICS, V68, P572; SMITH MD, 1975, J TRAUMA, V15, P987, DOI 10.1097/00005373-197511000-00008; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TAKAHASHI H, 1980, CHILD BRAIN, V7, P124; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Velardi F., 1986, HEAD INJURIES NEWBOR, P125; WILLIAMS AF, 1981, PEDIATRICS, V68, P576	49	39	41	0	0	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1987	20	9					518	525		10.1177/002221948702000903			8	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	K8155	WOS:A1987K815500006	3320241				2021-06-18	
J	KOBRINE, AI; TIMMINS, E; RAJJOUB, RK; RIZZOLI, HV; DAVIS, DO				KOBRINE, AI; TIMMINS, E; RAJJOUB, RK; RIZZOLI, HV; DAVIS, DO			DEMONSTRATION OF MASSIVE TRAUMATIC BRAIN-SWELLING WITHIN 20 MINUTES AFTER INJURY - CASE-REPORT	JOURNAL OF NEUROSURGERY			English	Article									GEORGE WASHINGTON UNIV,MED CTR,DEPT NEUROL SURG,WASHINGTON,DC 20006; GEORGE WASHINGTON UNIV,MED CTR,DEPT RADIOL,WASHINGTON,DC 20006							Kobrine A I, 1973, Surg Neurol, V1, P34	1	39	40	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1977	46	2					256	258		10.3171/jns.1977.46.2.0256			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CT438	WOS:A1977CT43800017	833645				2021-06-18	
J	MARTIN, JP				MARTIN, JP			SIGNS OF OBSTRUCTION OF THE SUPERIOR LONGITUDINAL SINUS FOLLOWING CLOSED HEAD INJURIES (TRAUMATIC HYDROCEPHALUS)	BRITISH MEDICAL JOURNAL			English	Article																COLLIER W, 1891, BRIT MED J, V1, P521; GARCIN R, 1949, THROMBO PHLEBITES CE; Holmes G, 1915, Br Med J, V2, P493; MARTIN IP, 1941, BRIT MEDICAL J, V2, P537; MARTIN IP, 1941, BRIT MEDICAL J, V1, P349; McAlpine D, 1937, BRAIN, V60, P180, DOI 10.1093/brain/60.2.180; Symonds C P, 1940, Br Med J, V2, P348; SYMONDS CP, 1944, P ROY SOC MED, V37, P386; TURNER A, 1931, INTRACRANIAL PYOGENI	9	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.		1955	2	AUG20					467	470		10.1136/bmj.2.4937.467			4	Medicine, General & Internal	General & Internal Medicine	WB459	WOS:A1955WB45900007	13240151	Green Published			2021-06-18	
J	Turner, JWA				Turner, JWA			Facial palsy in closed head injuries - The prognosis	LANCET			English	Article																Davies DO, 1943, BRIT J SURG, V30, P237, DOI 10.1002/bjs.18003011909; Howe HA, 1937, ARCH NEURO PSYCHIATR, V38, P1190, DOI 10.1001/archneurpsyc.1937.02260240070005; KEIPER GF, 1923, ANN OTOL ST LOUIS, V32, P236; Leigh AD, 1943, LANCET, V1, P38; Symonds CP, 1943, LANCET, V1, P7; Turner JWA, 1943, BRAIN, V66, P140; Weddell G, 1943, LANCET, V1, P236	7	39	39	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1944	1						756	757					2	Medicine, General & Internal	General & Internal Medicine	V9626	WOS:000188752300495					2021-06-18	
J	Thelin, E; Al Nimer, F; Frostell, A; Zetterberg, H; Blennow, K; Nystrom, H; Svensson, M; Bellander, BM; Piehl, F; Nelson, DW				Thelin, Eric; Al Nimer, Faiez; Frostell, Arvid; Zetterberg, Henrik; Blennow, Kaj; Nystrom, Harriet; Svensson, Mikael; Bellander, Bo-Michael; Piehl, Fredrik; Nelson, David W.			A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional outcome; injury severity assessment; neuroradiology; protein biomarkers; serum analysis; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; NEURON-SPECIFIC ENOLASE; NEUROFILAMENT LIGHT PROTEIN; S-100B PROTEIN; PROGNOSTIC ANALYSIS; PLASMA-LEVELS; TAU PROTEINS; S100B; BLOOD	Brain-enriched protein biomarkers of tissue fate are being introduced clinically to aid in traumatic brain injury (TBI) management. The aim of this study was to determine how concentrations of six different protein biomarkers, measured in samples collected during the first weeks after TBI, relate to injury severity and outcome. We included neurocritical care TBI patients that were prospectively enrolled from 2007 to 2013, all having one to three blood samples drawn during the first 2 weeks. The biomarkers analyzed were S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), tau, and neurofilament-light (NF-L). Glasgow Outcome Score (GOS) was assessed at 12 months. In total, 172 patients were included. All serum markers were associated with injury severity as classified on computed tomography scans at admission. Almost all biomarkers outperformed other known outcome predictors with higher levels the first 5 days, correlating with unfavorable outcomes, and UCH-L1 (0.260, pseduo-R-2) displaying the best discrimination in univariate analyses. After adjusting for acknowledged TBI outcome predictors, GFAP and NF-L added most independent information to predict favorable/unfavorable GOS, improving the model from 0.38 to 0.51 pseudo-R-2. A correlation matrix indicated substantial covariance, with the strongest correlation between UCH-L1, GFAP, and tau (r = 0.827-0.880). Additionally, the principal component analysis exhibited clustering of UCH-L1 and tau, as well as GFAP, S100B, and NSE, which was separate from NF-L. In summary, a panel of several different protein biomarkers, all associated with injury severity, with different cellular origin and temporal trajectories, improve outcome prediction models.	[Thelin, Eric; Al Nimer, Faiez; Frostell, Arvid; Nystrom, Harriet; Svensson, Mikael; Bellander, Bo-Michael; Piehl, Fredrik] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Thelin, Eric; Al Nimer, Faiez; Piehl, Fredrik] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden; [Thelin, Eric] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Nystrom, Harriet] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden; [Svensson, Mikael; Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Nelson, David W.] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden	Thelin, E (corresponding author), Karolinska Univ Sjukhuset Solna, BioClin J5 20, Tema Neuro, Forskargrp Svensson, S-17176 Stockholm, Sweden.	eric.thelin@ki.se	Thelin, Eric Peter/K-2144-2012; Svensson, Mikael/F-8662-2012; Nimer, Faiez Al/ABB-9465-2020	Thelin, Eric Peter/0000-0002-2338-4364; Svensson, Mikael/0000-0003-1179-7003; Al Nimer, Faiez/0000-0003-0937-5995			Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Blennow K, 2018, J INTERN MED, V284, P643, DOI 10.1111/joim.12816; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Dadas A, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0045-y; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Korfias S, 2006, BRAIN INJURY, V20, P867, DOI 10.1080/02699050600832395; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Lee JY, 2015, J KOREAN NEUROSURG S, V58, P93, DOI 10.3340/jkns.2015.58.2.93; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Lumpkins KM, 2008, J TRAUMA, V65, P782; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pandey S, 2017, BRIT J NEUROSURG, V31, P356, DOI 10.1080/02688697.2017.1297378; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Posti JP, 2017, J NEUROTRAUM, V34, P1427, DOI 10.1089/neu.2016.4442; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; R Core Team, 2008, R LANG ENV STAT COMP; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rodriguez-Rodriguez A, 2016, NEUROL RES, V38, P130, DOI 10.1080/01616412.2016.1144410; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sjostedt E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130028; Soderstrom CA, 1997, J TRAUMA, V43, P925; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002368; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00300; Thelin EP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1450-y; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	85	38	39	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2019	36	20					2850	2862		10.1089/neu.2019.6375		JUN 2019	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JC0JD	WOS:000472064000001	31072225	Green Published, Other Gold			2021-06-18	
J	Kochanek, PM; Tasker, RC; Bell, MJ; Adelson, PD; Carney, N; Vavilala, MS; Selden, NR; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Bell, Michael J.; Adelson, P. David; Carney, Nancy; Vavilala, Monica S.; Selden, Nathan R.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Wainwright, Mark S.			Management of Pediatric Severe Traumatic Brain Injury: 2019 Consensus and Guidelines-Based Algorithm for First and Second Tier Therapies	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						barbiturate; decompressive craniectomy; head injury; herniation; hyperosmolar; intracranial pressure	EARLY DECOMPRESSIVE CRANIECTOMY; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; SINGLE-CENTER EXPERIENCE; TISSUE OXYGEN-TENSION; HYPERTONIC SALINE; DEXAMETHASONE THERAPY; HYPOTHERMIA THERAPY; LUMBAR DRAINAGE	Objectives: To produce a treatment algorithm for the ICU management of infants, children, and adolescents with severe traumatic brain injury. Data Sources: Studies included in the 2019 Guidelines for the Management of Pediatric Severe Traumatic Brain Injury (Glasgow Coma Scale score <= 8), consensus when evidence was insufficient to formulate a fully evidence-based approach, and selected protocols from included studies. Data Synthesis: Baseline care germane to all pediatric patients with severe traumatic brain injury along with two tiers of therapy were formulated. An approach to emergent management of the crisis scenario of cerebral herniation was also included. The first tier of therapy focuses on three therapeutic targets, namely preventing and/or treating intracranial hypertension, optimizing cerebral perfusion pressure, and optimizing partial pressure of brain tissue oxygen (when monitored). The second tier of therapy focuses on decompressive craniectomy surgery, barbiturate infusion, late application of hypothermia, induced hyperventilation, and hyperosmolar therapies. Conclusions: This article provides an algorithm of clinical practice for the bedside practitioner based on the available evidence, treatment protocols described in the articles included in the 2019 guidelines, and consensus that reflects a logical approach to mitigate intracranial hypertension, optimize cerebral perfusion, and improve outcomes in the setting of pediatric severe traumatic brain injury.	[Kochanek, Patrick M.] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med,Sch Med, Pittsburgh, PA 15260 USA; [Tasker, Robert C.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Tasker, Robert C.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA; [Tasker, Robert C.] Harvard Med Sch, Boston, MA 02115 USA; [Bell, Michael J.] Childrens Natl Med Ctr, Crit Care Med, Washington, DC 20010 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Pediat Neurosurg, Phoenix, AZ USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA; [Vavilala, Monica S.] Univ Washington, HIPRC, Seattle, WA 98195 USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Bratton, Susan L.] Univ Utah, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, Child & Family Res Inst, British Columbias Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Dept Pediat, Div Pediat Crit Care Med, Sch Nursing,Sch Med, Durham, NC 27706 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med,Sch Med, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Adelson, David/W-2083-2019; Tasker, Robert C/R-5837-2019; Kissoon, Niranjan/AAC-6140-2021	Reuter-Rice, Karin/0000-0003-1501-8994; Kissoon, Niranjan/0000-0001-8847-9973	U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911 QY-14-C-0086]; Brain Trauma Foundation	Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to Stanford University (W911 QY-14-C-0086), a subcontract awarded to Oregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Bramwell KJ, 2006, PEDIATR EMERG CARE, V22, P90, DOI 10.1097/01.pec.0000199563.64264.3a; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; FANCONI S, 1988, INTENS CARE MED, V14, P163; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Horvat CM, 2017, JAMA PEDIATR, V171, P942, DOI 10.1001/jamapediatrics.2017.2390; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kapapa T, 2010, J CHILD NEUROL, V25, P274, DOI 10.1177/0883073809332699; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Leeper CM, 2018, J TRAUMA ACUTE CARE, V85, P12, DOI 10.1097/TA.0000000000001836; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG-PEDIATR, V16, P508, DOI 10.3171/2014.10.PEDS14117; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Perez SE, 2011, J TRAUMA, V71, P133; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; PITTMAN T, 1989, PEDIATR NEUROSCI, V15, P13, DOI 10.1159/000120433; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Schibler A, 2012, CRIT CARE RESUSC, V14, P20; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Sigurta A, 2013, INTENS CARE MED, V39, P129, DOI 10.1007/s00134-012-2748-0; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011	78	38	38	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2019	20	3					269	279		10.1097/PCC.0000000000001737			11	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	HN4QS	WOS:000460169200016	30830015				2021-06-18	
J	Ge, XT; Li, WZ; Huang, S; Yin, ZY; Xu, X; Chen, FL; Kong, XD; Wang, HC; Zhang, JN; Lei, P				Ge, Xintong; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Xu, Xin; Chen, Fanglian; Kong, Xiaodong; Wang, Haichen; Zhang, Jianning; Lei, Ping			The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Blood-brain barrier; Pyroptosis; Inflammasome; NOD-like receptors; AIM2	THERAPEUTIC HYPOTHERMIA; CEREBROSPINAL-FLUID; CELL-DEATH; IN-VITRO; ACTIVATION; ASC; MICE; EXPRESSION; CHALLENGES; IMPROVES	Pyroptosis is a highly specific type of inflammatory programmed cell death that different from necrosis or apoptosis. It is initiated by cellular detection of acute damage via recognizing pathogen-associated molecular patterns (PAMPs) by NOD-like receptors (NLRs) or AIM2-like receptor (AIM2). NLRs and AIM2 could trigger the formation of a multi-protein complex, known as inflammasome. It also contains apoptotic speck-containing protein (ASC) and pro-Caspase-1, and could process the signals to induce a cascade of inflammatory response. Recently, growing evidence showed that inflammasome-mediated pyroptosis is involved in the pathogenesis of traumatic brain injury (TBI). However, less attention has been paid to their particular roles in regulating blood-brain barrier (BBB) damage, the central pathological change in secondary brain damage of TBI. Thus, we designed this research to explore the impact and mechanism of NLRs and AIM2 inflammasome-mediated pyroptosis in BBB after TBI. We employed the controlled cortical impact (CCI) mice model and manipulated the severity of pyroptosis in BBB using Caspase-1 inhibitor, Ac-YVAD-cmk. We found that TBI led to NLRs and AIM2 inflammasome-mediated pyroptosis in brain microvascular endothelial cells (BMVECs) from injured cerebral cortex. Ac-YVAD-cmk treatment inhibited pyroptosis in injured BMVECs by suppressing the expression of essential inflammasome subunit - Caspase-1 and pivotal downstream pro-inflammatory cytokines (IL-1 beta and IL-18), as well as hindering GSDMD cleavage and ASC oligomerization. In addition, inhibiting pyroptosis could alleviate TBI-induced BBB leakage, brain edema, loss of tight junction proteins, and the inflammatory response in injured BMVECs. These effects contributed to improving the neurological outcome of CCI mice. In conclusion, NLRs and AIM2 inflammasome-mediated pyroptosis could aggravate BBB damage after TBI. Targeting and controlling pyroptosis in injured BBB would be a promising therapeutic strategy for TBI in the future. (C) 2018 Elsevier B.V. All rights reserved.	[Ge, Xintong; Xu, Xin; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Ge, Xintong; Xu, Xin; Chen, Fanglian; Zhang, Jianning] Tianjin Med Univ, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin Neurol Inst, Gen Hosp, Tianjin 300052, Peoples R China; [Ge, Xintong; Xu, Xin; Chen, Fanglian; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Ge, Xintong; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Kong, Xiaodong; Lei, Ping] Tianjin Med Univ, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin Geriatr Inst, Gen Hosp, Tianjin 300052, Peoples R China; [Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Kong, Xiaodong; Lei, Ping] Tianjin Med Univ, Dept Geriatr, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Wang, Haichen] Duke Univ, Dept Neurol, Med Ctr, Durham, NC 27710 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ, Dept Geriatr, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com; leiping1974@163.com	Ge, Xintong/X-4889-2019	Xu, Xin/0000-0003-3395-9923; Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81772060, 81720108015, 81471252]; Tianjin Municipal Science and Technology Commission [16PTSYJC00180, 15JCYBJC50500]	This work was supported by the National Natural Science Foundation of China (grant numbers 81501055, 81772060, 81720108015 and 81471252); and the Tianjin Municipal Science and Technology Commission natural fund project (grant numbers 16PTSYJC00180, 15JCYBJC50500). The authors appreciate Chunsheng Kang, Shu Zhang, Li Liu, Weiyun Cui and Lei Zhou from Tianjin Neurological Institute for their technical support.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Antonopoulos C, 2013, J IMMUNOL, V191, P4789, DOI 10.4049/jimmunol.1300645; Awad F, 2018, PHARM THER; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2014, J NEUROL SCI, V342, P93, DOI 10.1016/j.jns.2014.04.032; Chen X, 2013, CRIT CARE, V17, DOI 10.1186/cc13067; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Dick MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11929; Dietrich WD, 2016, BRAIN RES, V1640, P94, DOI 10.1016/j.brainres.2015.12.034; Edwards P, 2005, LANCET, V365, P1957; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Ge X, 2018, J NEUROTRAUMA; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Geng FY, 2016, NEUROIMMUNOMODULAT, V23, P122, DOI 10.1159/000445689; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S., 2018, J NEUROTRAUMA; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Lugrin J, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2292; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Nagyoszi P, 2015, J NEUROCHEM, V135, P551, DOI 10.1111/jnc.13197; Nasser M, 2016, CNS NEUROL DISORD-DR, V15, P1030, DOI 10.2174/1871527315666160815093525; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Ruck T, 2014, JOVE-J VIS EXP, DOI 10.3791/52204; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wang XL, 2015, TOXICOLOGY, V334, P104, DOI 10.1016/j.tox.2015.06.006; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Zacharek A, 2006, NEUROSCI LETT, V404, P28, DOI 10.1016/j.neulet.2006.05.027; Zhang Y, 2014, CNS NEUROSCI THER, V20, P119, DOI 10.1111/cns.12170; Zhang YY, 2018, CELL RES, V28, P9, DOI 10.1038/cr.2017.133; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	68	38	41	1	40	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 15	2018	1697						10	20		10.1016/j.brainres.2018.06.008			11	Neurosciences	Neurosciences & Neurology	GR8LK	WOS:000442975200002	29886252				2021-06-18	
J	Hoye, A				Hoye, Alena			Bicycle helmets - To wear or not to wear? A meta-analyses of the effects of bicycle helmets on injuries	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Bicycle helmet; Meta-analysis; Head injury	HEAD-INJURIES; SAFETY HELMETS; MOTOR-VEHICLES; TRAUMA CENTER; BRAIN-INJURY; ROAD TRAUMA; RISK; CYCLISTS; CRASHES; ACCIDENTS	A meta-analysis has been conducted of the effects of bicycle helmets on serious head injury and other injuries among crash involved cyclists. 179 effect estimates from 55 studies from 1989-2017 are included in the metaanalysis. The use of bicycle helmets was found to reduce head injury by 48%, serious head injury by 60%, traumatic brain injury by 53%, face injury by 23%, and the total number of killed or seriously injured cyclists by 34%. Bicycle helmets were not found to have any statistically significant effect on cervical spine injury. There is no indication that the results from bicycle helmet studies are affected by a lack of control for confounding variables, time trend bias or publication bias. The results do not indicate that bicycle helmet effects are different between adult cyclists and children. Bicycle helmet effects may be somewhat larger when bicycle helmet wearing is mandatory than otherwise; however, helmet wearing rates were not found to be related to bicycle helmet effectiveness. It is also likely that bicycle helmets have larger effects among drunk cyclists than among sober cyclists, and larger effects in single bicycle crashes than in collisions with motor vehicles. In summary, the results suggest that wearing a helmet while cycling is highly recommendable, especially in situations with an increased risk of single bicycle crashes, such as on slippery or icy roads.	[Hoye, Alena] Inst Transport Econ, Gaustadalleen 21, N-0349 Oslo, Norway	Hoye, A (corresponding author), Inst Transport Econ, Gaustadalleen 21, N-0349 Oslo, Norway.	Alena.Hoye@toi.no			Norwegian Public Roads Administration; Department of Transport and Communications	The study has partly been financed by the Norwegian Public Roads Administration and the Department of Transport and Communications. It is a part of the regular updating of the Handbook of Road Safety Measures (Elvik et al., 2009).	Airaksinen Noora, 2010, Ann Adv Automot Med, V54, P267; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bahrololoom S., 2016, 38 AUSTR TRANSP RES; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Bergenstal John, 2012, W V Med J, V108, P78; Borglund S T, 1999, J Emerg Nurs, V25, P496, DOI 10.1016/S0099-1767(99)70013-9; Boufous S, 2012, ACCIDENT ANAL PREV, V49, P404, DOI 10.1016/j.aap.2012.03.011; Christensen P, 2003, 6922003 TOI I TRANSP; COOKE CT, 1993, MED J AUSTRALIA, V159, P783, DOI 10.5694/j.1326-5377.1993.tb141349.x; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Crocker P, 2012, J EMERG MED, V43, P244, DOI 10.1016/j.jemermed.2011.05.029; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; Dinh MM, 2015, EMERG MED AUSTRALAS, V27, P323, DOI 10.1111/1742-6723.12407; Dinh MM, 2013, MED J AUSTRALIA, V198, P415, DOI 10.5694/mja12.11580; Dinh MM, 2010, MED J AUSTRALIA, V193, P619, DOI 10.5694/j.1326-5377.2010.tb04078.x; Doom R, 2005, CP02392 BRSI CDO; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Ekstrom C, 2017, FATALLY INJURED CYCL; Elvik R, 2005, TRANSPORT RES REC, P230; Elvik R, 2009, HANDBOOK OF ROAD SAFETY MEASURES, 2ND EDITION, P1; Elvik R., 2013, ACCIDENT ANAL PREV, V43, P1245; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Erke A, 2008, ACCIDENT ANAL PREV, V40, P167, DOI 10.1016/j.aap.2007.05.002; Erke A, 2009, ACCIDENT ANAL PREV, V41, P914, DOI 10.1016/j.aap.2009.05.005; Finvers KA, 1996, CLIN J SPORT MED, V6, P102, DOI 10.1097/00042752-199604000-00007; Forbes AE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185367; Fyhri A, 2012, TRANSPORT RES F-TRAF, V15, P612, DOI 10.1016/j.trf.2012.06.003; Gulack BC, 2015, SURGERY, V158, P556, DOI 10.1016/j.surg.2015.02.025; Hagel BE, 2006, ACCIDENT ANAL PREV, V38, P277, DOI 10.1016/j.aap.2005.09.004; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Harada MY, 2015, INT J SURG, V24, P14, DOI 10.1016/j.ijsu.2015.10.013; Hausotter W, 2000, Versicherungsmedizin, V52, P28; Helak K, 2017, SOUTH MED J, V110, P441, DOI 10.14423/SMJ.0000000000000665; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hooten KG, 2014, J NEUROTRAUM, V31, P1329, DOI 10.1089/neu.2013.3253; Hoye A, 2017, 15972017 TOI I TRANS; HOye A, 2016, 14782016 TOI I TRANS; Hoye A, 2016, 15172016 TOI I TRANS; Hoye A, 2014, ACCIDENT ANAL PREV, V73, P200, DOI 10.1016/j.aap.2014.09.001; Hynd D, 2011, PPR446 TRL, P1; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Ji M, 2006, ACCIDENT ANAL PREV, V38, P128, DOI 10.1016/j.aap.2005.08.002; Joseph B, 2017, AM J SURG, V213, P413, DOI 10.1016/j.amjsurg.2016.05.021; Juhra C, 2012, INJURY, V43, P2026, DOI 10.1016/j.injury.2011.10.016; Kaushik R, 2015, INJURY EPIDEMIOL, V2, P1; Kuo CY, 2017, TRAFFIC INJ PREV, V18, P193, DOI 10.1080/15389588.2016.1235270; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; Lindsay H, 2014, CHRONIC DIS INJURIES, V34; Linn S, 1998, Inj Prev, V4, P122; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Malczyk A, 2014, IRCOBI C P; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2013, J AUSTRALAS COLL ROA, V24, P11; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; McNally DS, 2013, ACCIDENT ANAL PREV, V59, P469, DOI 10.1016/j.aap.2013.07.022; Moore DN, 2011, ACCIDENT ANAL PREV, V43, P621, DOI 10.1016/j.aap.2010.09.015; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.3.CO;2-G; Olivier J, 2016, 2016 IRCOBI C P INT; Olivier J, 2017, INT J EPIDEMIOL, V46, P278, DOI 10.1093/ije/dyw153; Olivier JG, 2017, TRAFFIC INJ PREV, V5; Olofsson E, 2017, SAFETY SCI, V92, P311, DOI 10.1016/j.ssci.2015.11.024; Orsi C, 2014, ACCIDENT ANAL PREV, V65, P97, DOI 10.1016/j.aap.2013.12.019; Otte D, 2014, SAE INT J TRANSP SAF, V2, P257, DOI 10.4271/2014-01-0517; Park Jun Chul, 2017, Korean J Neurotrauma, V13, P90, DOI 10.13004/kjnt.2017.13.2.90; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Phillips J. L, 2016, J EPIDEMIOL PUBLIC H, V1; Povey L. J, 2003, INVESTIGATION RELATI; Rivara F P, 1997, Inj Prev, V3, P110, DOI 10.1136/ip.3.2.110; Rizzi M, 2013, INT RES COUNC BIOM I; Robinson DL, 2007, ACCIDENT ANAL PREV, V39, P86, DOI 10.1016/j.aap.2006.06.007; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Schepers P, 2014, INJURY PREV, V21, P138; Sethi M, 2015, INJURY, V46, P2483, DOI 10.1016/j.injury.2015.07.030; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; Statens vegvesen, 2014, 294 STAT VEGV; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stier R, 2016, ARCH TRAUMA RES, V5, DOI 10.5812/atr.30011; Sze NN, 2011, HONG KONG J EMERG ME, V18, P136; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson D. C, 1999, COCHRANE DB SYST REV, V4; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Thornley SJ, 2008, INJURY PREV, V14, P11, DOI 10.1136/ip.2007.016675; Vavatsoulas K, 2013, 13 WCTR; Wagner J, 2012, AM SURGEON, V78, P1066; Wall SP, 2016, SAFETY, V2, DOI 10.3390/safety2040026; Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108; Webman R, 2013, J TRAUMA ACUTE CARE, V75, P877, DOI 10.1097/TA.0b013e3182a85f97; Whyte T, 2015, 24 INT TECHN C ENH S; Zibung E, 2015, EUR J TRAUMA EMERG S, V41, P517, DOI 10.1007/s00068-014-0471-y	96	38	38	2	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	AUG	2018	117						85	97		10.1016/j.aap.2018.03.026			13	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	GL1SI	WOS:000436888400009	29677686				2021-06-18	
J	Gabler, LF; Crandall, JR; Panzer, MB				Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.			Development of a Metric for Predicting Brain Strain Responses Using Head Kinematics	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Brain deformation; Finite element modeling; Rotational; Second-order system	INJURY; CONCUSSION; DIRECTION	Diffuse brain injuries are caused by excessive brain deformation generated primarily by rapid rotational head motion. Metrics that describe the severity of brain injury based on head motion often do not represent the governing physics of brain deformation, rendering them ineffective over a broad range of head impact conditions. This study develops a brain injury metric based on the response of a second-order mechanical system, and relates rotational head kinematics to strain-based brain injury metrics: maximum principal strain (MPS) and cumulative strain damage measure (CSDM). This new metric, universal brain injury criterion (UBrIC), is applicable over a broad range of kinematics encountered in automotive crash and sports. Efficacy of UBrIC was demonstrated by comparing it to MPS and CSDM predicted in 1600 head impacts using two different finite element (FE) brain models. Relative to existing metrics, UBrIC had the highest correlation with the FE models, and performed better in most impact conditions. While UBrIC provides a reliable measurement for brain injury assessment in a broad range of head impact conditions, and can inform helmet and countermeasure design, an injury risk function was not incorporated into its current formulation until validated strain-based risk functions can be developed and verified against human injury data.	[Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, Dept Mech & Aerosp Engn, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA	Panzer, MB (corresponding author), Univ Virginia, Ctr Appl Biomech, Dept Mech & Aerosp Engn, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	mbp2q@virginia.edu			Partnership for Dummy Technology and Biomechanics (PDB)	The authors thank the Partnership for Dummy Technology and Biomechanics (PDB) for support and funding for this research.	Alshareef A, 2018, J NEUROTRAUM, V35, P780, DOI 10.1089/neu.2017.5362; [Anonymous], J2111 SAE INT; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Forman Jason, 2008, Ann Adv Automot Med, V52, P141; Frieden T. R., 2015, C TRAUM BRAIN INJ US; Gabler LF, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4038357; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Gadd C.W., 1966, SAE TECHNICAL PAPER; Gennarelli T, 1971, P 15 STAPP CAR CRASH; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, ANN BIOMED ENG, V43, P1877, DOI 10.1007/s10439-014-1193-3; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King AI, 2003, IRCOBI C LISB PORT S; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laituri T. R., 2015, SAE TECHNICAL PAPER; Lobo B, 2015, LECT NOTES COMPUT SC, V9502, P114, DOI 10.1007/978-3-319-27293-1_11; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Milton S. J., 2002, INTRO PROBABILITY ST; Mueller B., 2015, P 24 INT TECHN C ENH; National Operating Committee on the Standards for Athletic Equipment (NOCSAE), 2012, STAND TEST METH EQ U; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman J.A, 1986, P 1986 INT IRCOBI C; NHTSA NVS | Vehicle Crash Test Database, VEH CRASH TEST DAT; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Panzer MB, 2016, INT J AUTOMOT ENG, V7, P37, DOI 10.20485/jsaeijae.7.1_37; Patrick L. M, 1963, P 7 STAPP CAR CRASH; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Sanchez EJ, 2017, J NEUROTRAUM, V34, P2410, DOI 10.1089/neu.2016.4681; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Saunders J, 2015, 24 INT TECHN C ENH S; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts E. G, 2011, 11026 BRIC; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thibault L. E, 1985, SAE TECHNICAL PAPER; Versace J, 1971, REV SEVERITY INDEX; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; von Gierke H. E, 1964, BIOASTRONAUTICS, P61; Yanaoka T., 2015, SAE TECHNICAL PAPER	46	38	38	1	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JUL	2018	46	7					972	985		10.1007/s10439-018-2015-9			14	Engineering, Biomedical	Engineering	GH8GR	WOS:000433906500005	29594689				2021-06-18	
J	Ziogas, NK; Koliatsos, VE				Ziogas, Nikolaos K.; Koliatsos, Vassilis E.			Primary Traumatic Axonopathy in Mice Subjected to Impact Acceleration: A Reappraisal of Pathology and Mechanisms with High-Resolution Anatomical Methods	JOURNAL OF NEUROSCIENCE			English	Article						axonopathy; NMNAT2-SARM1; CLARITY; corticospinal tract; traumatic brain injury; 2-photon microscopy	AMYLOID PRECURSOR PROTEIN; BRAIN-INJURY; AXONAL INJURY; WALLERIAN DEGENERATION; ACTIVATION; SARM1; HEAD; MICROGLIA; CLEAVAGE; DAMAGE	Traumatic axonal injury (TAI) is a common neuropathology in traumatic brain injury and is featured by primary injury to axons. Here, wegenerated TAI with impact acceleration of the head in male Thy1-eYFP-H transgenic mice in which specific populations of neurons and their axons are labeled with yellow fluorescent protein. This model results in axonal lesions in multiple axonal tracts along with bloodbrain barrier disruption and neuroinflammation. The corticospinal tract, a prototypical long tract, is severely affected and is the focus of this study. Using optimized CLARITY at single-axon resolution, we visualized the entire corticospinal tract volume from the pons to the cervical spinal cord in 3D and counted the total number of axonal lesions and their progression over time. Our results divulged the presence of progressive traumatic axonopathy that was maximal at the pyramidal decussation. The perikarya of injured corticospinal neurons atrophied, but there was no evidence of neuronal cell death. We also used CLARITY at single-axon resolution to explore the role of the NMNAT2-SARM1 axonal self-destruction pathway in traumatic axonopathy. When we interfered with this pathway by genetically ablating SARM1 or by pharmacological strategies designed to increase levels of Nicotinamide (Nam), a feedback inhibitor of SARM1, we found a significant reduction in the number of axonal lesions early after injury. Our findings show that high-resolution neuroanatomical strategies reveal important features of TAI with biological implications, especially the progressive axonopathic nature of TAI and the role of the NMNAT2-SARM1 pathway in the early stages of axonopathy.	[Ziogas, Nikolaos K.; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Ziogas, NK; Koliatsos, VE (corresponding author), Johns Hopkins Univ, Sch Med, 720 Rutland Ave,Ross Res Bldg,Room 558, Baltimore, MD 21205 USA.	nziogas1@jhmi.edu; koliat@jhmi.edu			Department of DefenseUnited States Department of Defense [W81XWH-14-0396]; State of Maryland TEDCO [2015-MSCRFI-1718]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1EY028039]; Sidran Family Foundation; Spyros N. Lemos Memorial Fund; Johns Hopkins-LIBRA fellowship program; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY028039] Funding Source: NIH RePORTER	This work was supported by Department of Defense W81XWH-14-0396, State of Maryland TEDCO 2015-MSCRFI-1718, National Institutes of Health RO1EY028039, the Sidran Family Foundation, and the Spyros N. Lemos Memorial Fund. N.K.Z. was supported by the Johns Hopkins-LIBRA fellowship program. We thank J. Boyd for advice and invaluable assistance with 2-photon microscopy; J. Ryu and W. Gilliam for breeding of Thy1-eYFP-H/SARM1<SUP>-/-</SUP> mice; T. Omer for assistance with axon counts; K.T. Ramesh and F. Madouh for technical assistance with the impact acceleration device; A. Hoke for supplying SARM1<SUP>-/-</SUP> founders; A. Popratiloff and C. Brantner of the Nanofabrication and Imaging Center of George Washington University for help with 2-photon imaging resources; and all members of the V.E.K. laboratory for feedback and support.	Blackstad TW, 1981, NEUROANATOMICAL TRAC, P1; Bruzzone S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007897; Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267; Capurso SA, 1997, J NEUROSCI, V17, P7372; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Clatterbuck RE, 1998, NEUROBIOL DIS, V5, P17, DOI 10.1006/nbdi.1998.0181; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Finn JT, 2000, J NEUROSCI, V20, P1333; Gerdts J, 2016, NEURON, V89, P449, DOI 10.1016/j.neuron.2015.12.023; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gu YZ, 2017, J CELL BIOL, V216, P2179, DOI 10.1083/jcb.201606065; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kobeissy F.H., 2015, BRAIN NEUROTRAUMA MO; Li JR, 2007, BIOMED SCI INSTRUM, V43, P24; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Nahimana A, 2009, BLOOD, V113, P3276, DOI 10.1182/blood-2008-08-173369; National Academy Press, 2011, GUID CAR US LAB AN; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Paxinos G, 2012, PAXINOS FRANKLINS MO; Porrero C, 2010, BRAIN RES, V1345, P59, DOI 10.1016/j.brainres.2010.05.061; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Sasaki Y, 2016, ELIFE, V5, DOI 10.7554/eLife.19749; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Summers DW, 2016, P NATL ACAD SCI USA, V113, pE6271, DOI 10.1073/pnas.1601506113; Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Van Gool F, 2009, NAT MED, V15, P206, DOI 10.1038/nm.1906; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]; Wang JT, 2015, P NATL ACAD SCI USA, V112, P10093, DOI 10.1073/pnas.1508337112; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Weil A, 2013, TXB NEUROPATHOLOGY, P45; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yamada J, 2013, J COMP NEUROL, V521, P1184, DOI 10.1002/cne.23228; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501	56	38	38	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 18	2018	38	16					4031	4047		10.1523/JNEUROSCI.2343-17.2018			17	Neurosciences	Neurosciences & Neurology	GD5NU	WOS:000430554500014	29567804	Green Published, Bronze			2021-06-18	
J	Oddo, M; Poole, D; Helbok, R; Meyfroidt, G; Stocchetti, N; Bouzat, P; Cecconi, M; Geeraerts, T; Martin-Loeches, I; Quintard, H; Taccone, FS; Geocadin, RG; Hemphill, C; Ichai, C; Menon, D; Payen, JF; Perner, A; Smith, M; Suarez, J; Videtta, W; Zanier, ER; Citerio, G				Oddo, Mauro; Poole, Daniele; Helbok, Raimund; Meyfroidt, Geert; Stocchetti, Nino; Bouzat, Pierre; Cecconi, Maurizio; Geeraerts, Thomas; Martin-Loeches, Ignacio; Quintard, Herve; Taccone, Fabio Silvio; Geocadin, Romergryko G.; Hemphill, Claude; Ichai, Carole; Menon, David; Payen, Jean-Francois; Perner, Anders; Smith, Martin; Suarez, Jose; Videtta, Walter; Zanier, Elisa R.; Citerio, Giuseppe			Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations	INTENSIVE CARE MEDICINE			English	Article						Evidence-based medicine; Guidelines; Fluid therapy; Traumatic brain injury; Subarachnoid haemorrhage; Intracerebral haemorrhage; Stroke; Mannitol; Hypertonic; Neurointensive care	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; ANEURYSMAL SUBARACHNOID HEMORRHAGE; INCREASED INTRACRANIAL-PRESSURE; RANDOMIZED CONTROLLED-TRIAL; HYPERTONIC SALINE RESUSCITATION; MULTICENTER PROSPECTIVE COHORT; END-DIASTOLIC VOLUME; ISCHEMIC-STROKE; HEAD-INJURY	Objective: To report the ESICM consensus and clinical practice recommendations on fluid therapy in neurointensive care patients. Design: A consensus committee comprising 22 international experts met in October 2016 during ESICM LIVES2016. Teleconferences and electronic-based discussions between the members of the committee subsequently served to discuss and develop the consensus process. Methods: Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles generated. The consensus focused on three main topics: (1) general fluid resuscitation and maintenance in neurointensive care patients, (2) hyperosmolar fluids for intracranial pressure control, (3) fluid management in delayed cerebral ischemia after subarachnoid haemorrhage. After an extensive literature search, the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system were applied to assess the quality of evidence (from high to very low), to formulate treatment recommendations as strong or weak, and to issue best practice statements when applicable. A modified Delphi process based on the integration of evidence provided by the literature and expert opinions-using a sequential approach to avoid biases and misinterpretations-was used to generate the final consensus statement. Results: The final consensus comprises a total of 32 statements, including 13 strong recommendations and 17 weak recommendations. No recommendations were provided for two statements. Conclusions: We present a consensus statement and clinical practice recommendations on fluid therapy for neurointensive care patients.	[Oddo, Mauro] Univ Lausanne, Fac Biol & Med, Dept Med Surg Intens Care Med, CHUV, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland; [Poole, Daniele] San Martino Hosp, Anesthesia & Intens Care Operat Unit, Belluno, Italy; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurol Intens Care Unit, Innsbruck, Austria; [Meyfroidt, Geert] Univ Hosp Leuven, Dept Intens Care Med, Louvain, Belgium; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci Intens Care Unit, Dept Anesthesia & Crit Care, Milan, Italy; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Bouzat, Pierre; Payen, Jean-Francois] CHU Grenoble Alpes, Dept Anesthesia & Crit Care, F-38000 Grenoble, France; [Cecconi, Maurizio] St Georges Univ Hosp, Dept Anaesthesia & Intens Care, London, England; [Geeraerts, Thomas] Univ Toulouse 3 Paul Sabatier, Toulouse Univ Hosp, Dept Anaesthesia & Intens Care, F-31059 Toulouse, France; [Martin-Loeches, Ignacio] St James Univ Hosp, Dept Intens Care Med, Jamess St,POB 580, Dublin 8, Ireland; [Quintard, Herve] CHU Nice, Univ Cote Azur, Serv Reanimat Med Chirurg, Hop Pasteur 2, F-06000 Nice, France; [Quintard, Herve] CNRS, Unite 7275, Sophia Antipolis, France; [Taccone, Fabio Silvio] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Geocadin, Romergryko G.; Suarez, Jose] Johns Hopkins Univ, Neurosci Crit Care, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Geocadin, Romergryko G.; Suarez, Jose] Johns Hopkins Univ, Neurosci Crit Care, Dept Neurol, Baltimore, MD 21205 USA; [Geocadin, Romergryko G.; Suarez, Jose] Johns Hopkins Univ, Neurosci Crit Care, Dept Neurosurg, Baltimore, MD 21205 USA; [Hemphill, Claude] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Ichai, Carole] CHU Nice, Serv Reanimat Polyvalente, Hop Pasteur 2, 30 Voie Romaine,CS 51069, F-06001 Nice 1, France; [Menon, David] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England; [Perner, Anders] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care 4131, Copenhagen, Denmark; [Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurosurg & Neurol, Dept Neuroanesthesia & Neurocrit Care, London, England; [Videtta, Walter] Hosp Nacl Prof Alejandro Posadas, Buenos Aires, DF, Argentina; [Zanier, Elisa R.] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] ASST Monza, San Gerardo Hosp, Neurointens Care, I-20900 Monza, Italy	Oddo, M (corresponding author), Univ Lausanne, Fac Biol & Med, Dept Med Surg Intens Care Med, CHUV, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Zanier, Elisa/AAA-8095-2020; Payen, Jean-Francois/L-6667-2014; Citerio, Giuseppe/B-1839-2015; Helbok, Raimund/AAA-8361-2021; Bouzat, Pierre/AAC-4105-2019; Poole, Daniele/X-7210-2019; Bouzat, Pierre/L-6881-2014; martin-loeches, Prof. Ignacio/Q-6645-2018; Cecconi, Maurizio/A-6241-2012	Citerio, Giuseppe/0000-0002-5374-3161; Bouzat, Pierre/0000-0003-4667-6738; Poole, Daniele/0000-0001-5279-9844; Perner, Anders/0000-0002-4668-0123; Zanier, Elisa/0000-0002-3011-8718; martin-loeches, Prof. Ignacio/0000-0002-5834-4063; Cecconi, Maurizio/0000-0002-4376-6538			Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Al-Rawi PG, 2010, STROKE, V41, P122, DOI 10.1161/STROKEAHA.109.560698; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bereczki D, 2003, STROKE, V34, P1730, DOI 10.1161/01.STR.0000078658.52316.E8; CANDELISE L, 1988, LANCET, V1, P318; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Dhar R, 2012, J NEUROSURG, V116, P648, DOI 10.3171/2011.9.JNS11691; Dharmasaroja PA, 2016, TRANSL STROKE RES, V7, P49, DOI 10.1007/s12975-015-0439-1; Diringer MN, 2012, NEUROSURGERY, V70, P1215, DOI 10.1227/NEU.0b013e3182417bc2; Diringer MN, 2011, NEUROCRIT CARE, V14, P11, DOI 10.1007/s12028-010-9465-8; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; Ekelund A, 2002, ACTA NEUROCHIR, V144, P703, DOI 10.1007/s00701-002-0959-9; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Ginsberg MD, 2013, LANCET NEUROL, V12, P1049, DOI 10.1016/S1474-4422(13)70223-0; Hartl R, 1997, ACT NEUR S, V70, P126; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Helbok R, 2011, J NEUROL NEUROSUR PS, V82, P378, DOI 10.1136/jnnp.2009.198754; Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Huang ZC, 2002, CLIN NEUROPHYSIOL, V113, P446, DOI 10.1016/S1388-2457(02)00012-3; Ibrahim GM, 2013, NEUROCRIT CARE, V19, P140, DOI 10.1007/s12028-013-9860-z; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7; JAFAR JJ, 1986, J NEUROSURG, V64, P754, DOI 10.3171/jns.1986.64.5.0754; Jagannatha AT, 2016, J CLIN NEUROSCI, V27, P68, DOI 10.1016/j.jocn.2015.08.035; Jost SC, 2005, J NEUROSURG, V103, P25, DOI 10.3171/jns.2005.103.1.0025; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Kim CY, 2003, ACTA NEUROCHIR, V145, P571, DOI 10.1007/s00701-003-0024-3; Kissoon NR, 2015, J STROKE CEREBROVASC, V24, P2245, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.027; Kurtz P, 2014, NEUROCRIT CARE, V20, P247, DOI 10.1007/s12028-013-9910-6; Kuwabara K, 2013, J NEUROL, V260, P820, DOI 10.1007/s00415-012-6710-4; Launey Y, 2014, J NEUROTRAUM, V31, P984, DOI 10.1089/neu.2012.2829; Lehmann L, 2013, NEUROCRIT CARE, V18, P5, DOI 10.1007/s12028-012-9764-3; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Major EH, 2015, IRISH J MED SCI, V184, P159, DOI 10.1007/s11845-014-1080-9; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Manno EM, 1999, NEUROLOGY, V52, P583, DOI 10.1212/WNL.52.3.583; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; Martini RP, 2012, NEUROCRIT CARE, V17, P191, DOI 10.1007/s12028-011-9573-0; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Misra UK, 2007, EUR J NEUROL, V14, P1118, DOI 10.1111/j.1468-1331.2007.01918.x; MORI K, 1995, STROKE, V26, P1620, DOI 10.1161/01.STR.26.9.1620; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; Mutoh T, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0482-4; Mutoh T, 2014, STROKE, V45, P1280, DOI 10.1161/STROKEAHA.114.004739; Myburgh J, 2007, NEW ENGL J MED, V357, P874; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Palesch YY, 2006, STROKE, V37, P2107, DOI 10.1161/01.STR.0000231389.34701.b5; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rabinstein AA, 2011, NEUROCRIT CARE, V15, P354, DOI 10.1007/s12028-011-9585-9; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2013, CRIT CARE, V17, DOI 10.1186/cc12686; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Scalfani M. T., 2012, J CRIT CARE, V27, pe527; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; Sekhon MS, 2011, J CRIT CARE, V26, P357, DOI 10.1016/j.jcrc.2010.12.001; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHIMODA M, 1993, J NEUROSURG, V78, P423, DOI 10.3171/jns.1993.78.3.0423; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Suarez JI, 2004, J NEUROSURG, V100, P585, DOI 10.3171/jns.2004.100.4.0585; Tagami T, 2014, NEUROCRIT CARE, V21, P462, DOI 10.1007/s12028-014-9973-z; Tagami T, 2014, CRIT CARE MED, V42, P1348, DOI 10.1097/CCM.0000000000000163; TANABE T, 1982, ACTA NEUROCHIR, V63, P291, DOI 10.1007/BF01728884; Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f; Tseng MY, 2008, BRIT J NEUROSURG, V22, P257, DOI 10.1080/02688690701832100; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wang X, 2015, STROKE, V46, P2762, DOI 10.1161/STROKEAHA.115.009357; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; YAMAKAMI I, 1987, NEUROSURGERY, V21, P303, DOI 10.1227/00006123-198709000-00004; Ye H, 2013, ACTA CIR BRAS, V28, P106, DOI 10.1590/S0102-86502013000200004; Yoneda H, 2013, STROKE, V44, P2155, DOI 10.1161/STROKEAHA.113.001015	90	38	41	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2018	44	4					449	463		10.1007/s00134-018-5086-z			15	Critical Care Medicine	General & Internal Medicine	GE4FR	WOS:000431171300005	29500701				2021-06-18	
J	Makinde, HM; Cuda, CM; Just, TB; Perlman, HR; Schwulst, SJ				Makinde, Hadijat M.; Cuda, Carla M.; Just, Talia B.; Perlman, Harris R.; Schwulst, Steven J.			Nonclassical Monocytes Mediate Secondary Injury, Neurocognitive Outcome, and Neutrophil Infiltration after Traumatic Brain Injury	JOURNAL OF IMMUNOLOGY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MACROPHAGE INFILTRATION; ISCHEMIC-STROKE; BLOOD; MICROGLIA; RECRUITMENT; MOUSE; CELLS; CCR2; NEUROTOXICITY	Traumatic brain injury (TBI) results in rapid recruitment of leukocytes into the injured brain. Monocytes constitute a significant proportion of the initial infiltrate and have the potential to propagate secondary brain injury or generate an environment of repair and regeneration. Monocytes are a diverse population of cells (classical, intermediate, and nonclassical) with distinct functions, however, the recruitment order of these subpopulations to the injured brain largely remains unknown. Thus, we examined which monocyte subpopulations are required for the generation of early inflammatory infiltrate within the injured brain, and whether their depletion attenuates secondary injury or neurocognitive outcome. Global monocyte depletion correlated with significant improvements in brain edema, motor coordination, and working memory, and abrogated neutrophil infiltration into the injured brain. However, targeted depletion of classical monocytes alone had no effect on neutrophil recruitment to the site of injury, implicating the nonclassical monocyte in this process. In contrast, mice that have markedly reduced numbers of nonclassical monocytes (CX3CR1(-/-)) exhibited a significant reduction in neutrophil infiltration into the brain after TBI as compared with control mice. Our data suggest a critical role for nonclassical monocytes in the pathology of TBI in mice, including important clinical outcomes associated with mortality in this injury process.	[Makinde, Hadijat M.; Just, Talia B.; Schwulst, Steven J.] Northwestern Univ, Div Trauma & Crit Care, Dept Surg, 676 N St Clair St,Suite 650, Chicago, IL 60611 USA; [Cuda, Carla M.; Perlman, Harris R.] Northwestern Univ, Div Rheumatol, Dept Med, Chicago, IL 60611 USA	Schwulst, SJ (corresponding author), Northwestern Univ, Div Trauma & Crit Care, Dept Surg, 676 N St Clair St,Suite 650, Chicago, IL 60611 USA.	s-schwulst@northwestem.edu		Cuda, Carla/0000-0002-2022-8171; Just, Talia/0000-0002-6372-7974; Schwulst, Steven/0000-0003-4248-8545; Makinde, Hadijat-Kubura/0000-0001-8492-4187	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM117341, AR064313, AR064546, HL134375, AG049665, UH2AR067687]; American College of Surgeons C. James Carrico Research Fellowship; United States-Israel Binational Science FoundationUS-Israel Binational Science Foundation [2013247]; Rheumatology Research Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001422] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL134375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [UH2AR067687, T32AR007611, R01AR064546, K01AR064313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM117341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG049665] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant GM117341 and The American College of Surgeons C. James Carrico Research Fellowship to S.J.S.; National Institutes of Health Grant AR064313 to C.M.C.; National Institutes of Health Grants AR064546, HL134375, AG049665, and UH2AR067687, the United States-Israel Binational Science Foundation (Award 2013247), and the Rheumatology Research Foundation (Agreement 05/06/14) to H.R.P. H.R.P. is also the Mabel Greene Myers Professor of Medicine.	Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buck BH, 2008, STROKE, V39, P355, DOI 10.1161/STROKEAHA.107.490128; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Christophi GP, 2009, J VIROL, V83, P522, DOI 10.1128/JVI.01210-08; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Collins CE, 2010, FRONT NEUROANAT, V4, DOI 10.3389/neuro.05.005.2010; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Diserbo M, 2002, CAN J PHYSIOL PHARM, V80, P670, DOI 10.1139/Y02-070; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FORD AL, 1995, J IMMUNOL, V154, P4309; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Getts DR, 2008, J EXP MED, V205, P2319, DOI 10.1084/jem.20080421; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; Lucin KM, 2009, J NEUROCHEM, V110, P1409, DOI 10.1111/j.1471-4159.2009.06232.x; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; Misharin AV, 2014, CELL REP, V9, P591, DOI 10.1016/j.celrep.2014.09.032; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Nikodemova M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-147; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Polfliet MMJ, 2001, J NEUROIMMUNOL, V116, P188, DOI 10.1016/S0165-5728(01)00282-X; Price CJS, 2004, STROKE, V35, P1659, DOI 10.1161/01.STR.0000130592.71028.92; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Soares HD, 1995, J NEUROSCI, V15, P8223; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Trahanas DM, 2015, SHOCK, V43, P255, DOI 10.1097/SHK.0000000000000291; Tran EH, 1998, J IMMUNOL, V161, P3767; Weiss C, 1998, NEUROSCI RES COMMUN, V23, P77, DOI 10.1002/(SICI)1520-6769(199809/10)23:2<77::AID-NRC2>3.0.CO;2-Y; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	51	38	38	0	10	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 15	2017	199	10					3583	3591		10.4049/jimmunol.1700896			9	Immunology	Immunology	FM0MK	WOS:000414660600018	28993515	Green Accepted, Bronze			2021-06-18	
J	Jin, N; Zhu, HZ; Liang, X; Huang, W; Xie, QG; Xiao, P; Ni, JZ; Liu, Q				Jin, Na; Zhu, Huazhang; Liang, Xiao; Huang, Wei; Xie, Qingguo; Xiao, Peng; Ni, Jiazuan; Liu, Qiong			Sodium selenate activated Wnt/beta-catenin signaling and repressed amyloid-beta formation in a triple transgenic mouse model of Alzheimer's disease	EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer's disease (AD); Sodium selenate; Wnt/beta-catenin signaling; Protein phosphatases of type 2A (PP2A); beta-Amyloid (A beta); Neuronal apoptosis	PROTEIN PHOSPHATASE 2A; TRAUMATIC BRAIN-INJURY; PRECURSOR PROTEIN; HYPERPHOSPHORYLATED TAU; COGNITIVE DECLINE; A-BETA; THIOREDOXIN REDUCTASE; SURVIVIN EXPRESSION; CYTOPLASMIC DOMAIN; ACQUIRED EPILEPSY	Accumulating evidences show that selenium dietary intake is inversely associated with the mortality of Alzheimer's disease (AD). Sodium selenate has been reported to reduce neurofibrillary tangles (NFT) in the tauopathic mouse models, but its effects on the Wnt/beta-catenin signaling pathway and APP processing remain unknown during AD formation. In this paper, triple transgenic AD mice (3 x Tg-AD) had been treated with sodium selenate in drinking water for 10 month before the detection of hippocampal pathology. Increased A beta generation, tau hyperphosphorylation and neuronal apoptosis were found in the hippocampus of AD model mouse. Down-regulation of Wnt/beta-catenin signaling is closely associated with the alteration of AD pathology. Treatment with sodium selenate significantly promoted the activity of protein phosphatases of type 2A (PP2A) and repressed the hallmarks of AD. Activation of PP2A by sodium selenate could increase active beta-catenin level and inhibit GSK3 beta activity in the hippocampal tissue and primarily cultured neurons of AD model mouse, leading to activation of Wnt/beta-catenin signaling and transactivation of target genes, including positively-regulated genes c-myc, survivin, TXNRD2 and negatively-regulated gene BACE1. Meanwhile, APP phosphorylation was also reduced on the Thr668 residue after selenate treatment, causing the decreases of APP cleavage and A beta generation. These findings reveal that the Wnt/beta-catenin signaling is a potential target for prevention of AD and sodium selenate may be developed as a new drug for AD treatment. (C) 2017 Published by Elsevier Inc.	[Jin, Na; Zhu, Huazhang; Ni, Jiazuan; Liu, Qiong] Shenzhen Univ, Coll Life Sci & Oceanog, Shenzhen Key Lab Marine Biotechnol & Ecol, Shenzhen 518060, Peoples R China; [Liang, Xiao; Xie, Qingguo; Xiao, Peng] Huazhong Univ Sci & Technol, Coll Life Sci, Wuhan 430073, Hubei, Peoples R China; [Huang, Wei] Natl Qual Supervis & Inspect Ctr Selenium Enriche, Enshi 445000, Peoples R China	Liu, Q (corresponding author), Shenzhen Univ, Coll Life Sci & Oceanog, Shenzhen 518060, Guangdong, Peoples R China.	liuqiong@szu.edu.cn	Liu, Qiong/AAK-1556-2021		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31470804]; Shenzhen Bureau of Science, Technology and Information [JCYJ20150529164656093, JSGG20140703163838793]	This work was supported by the National Natural Science Foundation of China (No. 31470804), the Shenzhen Bureau of Science, Technology and Information (Nos. JCYJ20150529164656093, JSGG20140703163838793).	Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Alzheimers Assoc, 2011, ALZHEIMERS DEMENT, V7, P208, DOI 10.1016/j.jalz.2011.02.004; Beaudoin GMJ, 2012, NAT PROTOC, V7, P1741, DOI 10.1038/nprot.2012.099; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brady RD, 2016, J MUSCULOSKEL NEURON, V16, P369; Buee L, 2010, BIOCHEM SOC T, V38, P967, DOI 10.1042/BST0380967; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Caraci F, 2008, NEUROCHEM RES, V33, P2401, DOI 10.1007/s11064-008-9710-0; Cardoso BR, 2014, J TRACE ELEM MED BIO, V28, P422, DOI 10.1016/j.jtemb.2014.08.009; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Chang KA, 2006, MOL CELL BIOL, V26, P4327, DOI 10.1128/MCB.02393-05; Chu XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep32935; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Feng HY, 2016, EUR J NUCL MED MOL I, V43, P113, DOI 10.1007/s00259-015-3134-2; Fortress AM, 2016, NEUROSCIENTIST, V22, P278, DOI 10.1177/1073858415574728; Grimm MOW, 2014, CELL PHYSIOL BIOCHEM, V34, P92, DOI 10.1159/000362987; Gwon AR, 2010, NEUROSCI LETT, V469, P391, DOI 10.1016/j.neulet.2009.12.035; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoffmann PR, 2007, NUCLEIC ACIDS RES, V35, P3963, DOI 10.1093/nar/gkm355; Inestrosa NC, 2014, J MOL CELL BIOL, V6, P64, DOI 10.1093/jmcb/mjt051; Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481-012-9417-5; Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755; Ishrat T, 2009, BRAIN RES, V1281, P117, DOI 10.1016/j.brainres.2009.04.010; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Kania KD, 2011, BRAIN RES, V1418, P1, DOI 10.1016/j.brainres.2011.08.044; Kipp AP, 2012, BBA-GEN SUBJECTS, V1820, P1588, DOI 10.1016/j.bbagen.2012.05.016; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Lin H, 2014, AM J RESP CRIT CARE, V189, P697, DOI 10.1164/rccm.201310-1776OC; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu Rong, 2009, Pathophysiology, V16, P273, DOI 10.1016/j.pathophys.2009.02.008; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Lovell MA, 2000, FREE RADICAL BIO MED, V28, P418, DOI 10.1016/S0891-5849(99)00258-0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Oliveira JM, 2015, J ALZHEIMERS DIS, V45, P495, DOI 10.3233/JAD-142664; Parr C, 2015, FASEB J, V29, P623, DOI 10.1096/fj.14-253211; Pillai R, 2014, IUBMB LIFE, V66, P229, DOI 10.1002/iub.1262; Purro SA, 2014, J MOL CELL BIOL, V6, P75, DOI 10.1093/jmcb/mjt049; Rosi MC, 2010, J NEUROCHEM, V112, P1539, DOI 10.1111/j.1471-4159.2009.06566.x; Sanchez-Elexpuru G, 2017, EPILEPSIA, V58, P467, DOI 10.1111/epi.13656; Schmitt U, 2009, NEUROSCIENCE, V162, P234, DOI 10.1016/j.neuroscience.2009.04.046; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Selenius M, 2010, ANTIOXID REDOX SIGN, V12, P867, DOI 10.1089/ars.2009.2884; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Shin RW, 2007, ACTA NEUROPATHOL, V113, P627, DOI 10.1007/s00401-007-0211-z; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Silva-Alvarez C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00097; Solovyev ND, 2015, J INORG BIOCHEM, V153, P1, DOI 10.1016/j.jinorgbio.2015.09.003; Song GL, 2014, J ALZHEIMERS DIS, V41, P85, DOI 10.3233/JAD-131805; Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007; Triaca V, 2016, AGING CELL, V15, P661, DOI 10.1111/acel.12473; Tung YT, 2008, NEUROSCI LETT, V440, P38, DOI 10.1016/j.neulet.2008.05.048; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vargas JY, 2014, J NEUROSCI, V34, P2191, DOI 10.1523/JNEUROSCI.0862-13.2014; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Voronkov M, 2011, FUTURE MED CHEM, V3, P821, DOI [10.4155/FMC.11.47, 10.4155/fmc.11.47]; Wan WB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/301575; Wang LY, 2015, PHYS MED BIOL, V60, P137, DOI 10.1088/0031-9155/60/1/137; Weekley CM, 2013, CHEM SOC REV, V42, P8870, DOI 10.1039/c3cs60272a; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Xiong SL, 2007, ANTIOXID REDOX SIGN, V9, P457, DOI 10.1089/ars.2006.1363; Yin HW, 2011, DIFFERENTIATION, V81, P49, DOI 10.1016/j.diff.2010.09.180; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540; Zenzmaier C, 2009, J NEUROCHEM, V110, P653, DOI 10.1111/j.1471-4159.2009.06158.x; Zhang JW, 2015, BRATISL MED J, V116, P184, DOI 10.4149/BLL_2015_037; Zhang S, 2010, MECH AGEING DEV, V131, P253, DOI 10.1016/j.mad.2010.02.006; Zhang T, 2001, CANCER RES, V61, P8664; Zhang Y, 2008, J BIOL CHEM, V283, P2427, DOI 10.1074/jbc.M707951200; Zhang ZH, 2017, J NEUROSCI, V37, P2449, DOI 10.1523/JNEUROSCI.3229-16.2017; Zhang ZH, 2016, METALLOMICS, V8, P782, DOI [10.1039/C6MT00117C, 10.1039/c6mt00117c]; Zheng L, 2016, SCI REP-UK, V6, DOI 10.1038/srep39290; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9; Zhu HX, 2010, CANCER SCI, V101, P1156, DOI 10.1111/j.1349-7006.2010.01528.x	79	38	44	1	46	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2017	297						36	49		10.1016/j.expneurol.2017.07.006			14	Neurosciences	Neurosciences & Neurology	FJ3GA	WOS:000412617300004	28711506				2021-06-18	
J	Taib, T; Leconte, C; Van Steenwinckel, J; Cho, AH; Palmier, B; Torsello, E; Kuen, RL; Onyeomah, S; Ecomard, K; Benedetto, C; Coqueran, B; Novak, AC; Deou, E; Plotkine, M; Gressens, P; Marchand-Leroux, C; Besson, VC				Taib, Toufik; Leconte, Claire; Van Steenwinckel, Juliette; Cho, Angelo H.; Palmier, Bruno; Torsello, Egle; Kuen, Rene Lai; Onyeomah, Somfieme; Ecomard, Karine; Benedetto, Chiara; Coqueran, Berard; Novak, Anne-Catherine; Deou, Edwige; Plotkine, Michel; Gressens, Pierre; Marchand-Leroux, Catherine; Besson, Valerie C.			Neuroinflammation, myelin and behavior: Temporal patterns following mild traumatic brain injury in mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; WHITE-MATTER; AXONAL INJURY; IMPAIRMENT; DEFICITS; NEURODEGENERATION; INCREASES; PATHOLOGY; DAMAGE	Traumatic brain injury (TBI) results in white matter injury (WMI) that is associated with neurological deficits. Neuroinflammation originating from microglial activation may participate in WMI and associated disorders. To date, there is little information on the time courses of these events after mild TBI. Therefore we investigated (i) neuroinflammation, (ii) WMI and (iii) behavioral disorders between 6 hours and 3 months after mild TBI. For that purpose, we used experimental mild TBI in mice induced by a controlled cortical impact. (i) For neuroinflammation, IL-1b protein as well as microglial phenotypes, by gene expression for 12 microglial activation markers on isolated CD11b(+) cells from brains, were studied after TBI. IL-1b protein was increased at 6 hours and 1 day. TBI induced a mixed population of microglial phenotypes with both pro-inflammatory, anti-inflammatory and immunomodulatory markers from 6 hours to 3 days post-injury. At 7 days, microglial activation was completely resolved. (ii) Three myelin proteins were assessed after TBI on ipsi-and contralateral corpus callosum, as this structure is enriched in white matter. TBI led to an increase in 2', 3'-cyclic-nucleotide 3'-phosphodiesterase, a marker of immature and mature oligodendrocyte, at 2 days post-injury; a bilateral demyelination, evaluated by myelin basic protein, from 7 days to 3 months post-injury; and an increase in myelin oligodendrocyte glycoprotein at 6 hours and 3 days post-injury. Transmission electron microscopy study revealed various myelin sheath abnormalities within the corpus callosum at 3 months post-TBI. (iii) TBI led to sensorimotor deficits at 3 days post-TBI, and late cognitive flexibility disorder evidenced by the reversal learning task of the Barnes maze 3 months after injury. These data give an overall invaluable overview of time course of neuroinflammation that could be involved in demyelination and late cognitive disorder over a time-scale of 3 months in a model of mild TBI. This model could help to validate a pharmacological strategy to prevent post-traumatic WMI and behavioral disorders following mild TBI.	[Taib, Toufik; Leconte, Claire; Cho, Angelo H.; Palmier, Bruno; Torsello, Egle; Onyeomah, Somfieme; Ecomard, Karine; Benedetto, Chiara; Coqueran, Berard; Novak, Anne-Catherine; Deou, Edwige; Plotkine, Michel; Marchand-Leroux, Catherine; Besson, Valerie C.] Univ Paris 05, Fac Pharm Paris, Pharmacol Circulat Cerebrale EA4475, Sorbonne Paris Cite, Paris, France; [Van Steenwinckel, Juliette; Gressens, Pierre] Univ Paris Diderot, PROTECT U1141, INSERM, Sorbonne Paris Cite, Paris, France; [Kuen, Rene Lai] Univ Paris 05, Sorbonne Paris Cite, Cellular & Mol Imaging Platform, Fac Pharm Paris,INSERM US25,UMS CNRS 3612,CRP2, F-CRP2 Paris, France	Besson, VC (corresponding author), Univ Paris 05, Fac Pharm Paris, Pharmacol Circulat Cerebrale EA4475, Sorbonne Paris Cite, Paris, France.	valerie.besson@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020; gressens, pierre/M-7557-2017; besson, valerie C/L-7388-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380; gressens, pierre/0000-0002-0909-4221; besson, valerie C/0000-0002-1491-2380; Van Steenwinckel, Juliette/0000-0003-3463-4856	Fondation des Gueules Cassees	This work was supported by Fondation des Gueules Cassees (VCB; CML); 2013; 2014; 40-2015 (www.gueules-cassees.asso.fr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Asahi M, 2001, J NEUROSCI, V21, P7724; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; BOISSIER JR, 1967, ARCH INT PHARMACOD T, V169, P312; Bondi CO, 2014, J NEUROTRAUM, V31, P926, DOI 10.1089/neu.2013.3295; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chou A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151418; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; File SE, 2001, BEHAV BRAIN RES, V125, P151, DOI 10.1016/S0166-4328(01)00292-3; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Flygt J, 2016, J NEUROPATH EXP NEUR, V75, P503, DOI 10.1093/jnen/nlw025; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Ihara M, 2010, ACTA NEUROPATHOL, V119, P579, DOI 10.1007/s00401-009-0635-8; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jin X, 2012, PLOS ONE, V7; Johns TG, 1999, J NEUROCHEM, V72, P1, DOI 10.1046/j.1471-4159.1999.0720001.x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Leconte C, 2009, STROKE, V40, P3349, DOI 10.1161/STROKEAHA.109.557314; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Liu NK, 2014, BRAIN RES, V1576, P18, DOI 10.1016/j.brainres.2014.05.042; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1016/j.ctim.2007.01.003, 10.1002/0471142735.im1501s77]; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Radtke C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/608496; Robinson AP, 2014, HAND CLINIC, V122, P173, DOI 10.1016/B978-0-444-52001-2.00008-X; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SCOLDING NJ, 1989, IMMUNOLOGY, V67, P441; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Szczygielski J, 2016, J NEUROTRAUM, V33, P122, DOI 10.1089/neu.2014.3835; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	76	38	38	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184811	10.1371/journal.pone.0184811			25	Multidisciplinary Sciences	Science & Technology - Other Topics	FH0VR	WOS:000410859200098	28910378	DOAJ Gold, Green Published			2021-06-18	
J	Koerte, IK; Nichols, E; Tripodis, Y; Schultz, V; Lehner, S; Igbinoba, R; Chuang, AZ; Mayinger, M; Klier, EM; Muehlmann, M; Kaufmann, D; Lepage, C; Heinen, F; Schulte-Koerne, G; Zafonte, R; Shenton, ME; Sereno, AB				Koerte, Inga K.; Nichols, Elizabeth; Tripodis, Yorghos; Schultz, Vivian; Lehner, Stefan; Igbinoba, Randy; Chuang, Alice Z.; Mayinger, Michael; Klier, Eliana M.; Muehlmann, Marc; Kaufmann, David; Lepage, Christian; Heinen, Florian; Schulte-Koerne, Gerd; Zafonte, Ross; Shenton, Martha E.; Sereno, Anne B.			Impaired Cognitive Performance in Youth Athletes Exposed to Repetitive Head Impacts	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; cognitive improvement; heading; repetitive head impact; soccer; sports-related brain trauma	PROFESSIONAL SOCCER PLAYERS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; EXERCISE; CONCUSSION; SWIMMERS; SPORTS; HUMANS; TIME	Worldwide, more than 22 million children and adolescents are exposed to repetitive head impacts (RHI) in soccer. Evidence indicates cumulative effects on brain structure, but it is not known whether exposure to RHI affects cognitive improvement in adolescents. The aim of the study was to determine whether exposure to RHI while heading the ball in soccer affects improvement in cognitive performance in adolescents over time. The study group consisted of a convenience sample of 16 male soccer players (mean age 15.7 - 0.7 years). A comparison cohort of 14 male non-contact sports athletes (mean age 14.9 - 1.1 years) was recruited from competitive athletic clubs and group-matched in age. Using the ProPoint and AntiPoint tasks, sensorimotor and cognitive functions were measured over both immediate (pre- vs. post-training) as well as across multiple time points within a play season. The number and type of head impacts that occurred during the training were counted. The main outcome measure was the change in response time (RT) in the ProPoint and AntiPoint tasks. The immediate (pre-vs. post-training) and longer-term (across a play season) change in RT was analyzed, and the effect of the number and type of head impacts was tested. Thirty athletes with and without exposure to RHI demonstrated a decrease in RT in both tasks immediately after training. Over the play season, both groups showed improvement in sensorimotor function. While the control group also improved in cognitive performance, the soccer players did not, however. Further, the more long headers performed, the slower the improvement in RT over the season. Youth athletes experience an immediate cognitive improvement after training most likely because of physical exercise. Results of this study also suggest an association between exposure to specific RHI (long headers) and lack of improvement in cognitive performance in youth athletes over time.	[Koerte, Inga K.; Nichols, Elizabeth; Schultz, Vivian; Mayinger, Michael; Schulte-Koerne, Gerd] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Koerte, Inga K.; Schultz, Vivian; Mayinger, Michael; Lepage, Christian; Shenton, Martha E.] Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 75 Francis St, Boston, MA 02115 USA; [Koerte, Inga K.; Schultz, Vivian; Mayinger, Michael; Lepage, Christian; Shenton, Martha E.] Harvard Med Sch, Boston, MA USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Lehner, Stefan] Univ Appl Sci, Dept Appl Sci & Mechatron, Munich, Germany; [Igbinoba, Randy; Klier, Eliana M.; Sereno, Anne B.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Chuang, Alice Z.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA; [Muehlmann, Marc] Ludwig Maximilians Univ Munchen, Inst Clin Radiol, Munich, Germany; [Kaufmann, David] Charite, Dept Radiol, Berlin, Germany; [Heinen, Florian] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat Neurol, Munich, Germany; [Zafonte, Ross] Harvard Med Sch, Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp,Dept Phys Med & Rehabil, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA	Koerte, IK (corresponding author), Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Schulte-Korne, Gerd/AAI-4828-2021; Shenton, Martha/V-8780-2019; Heinen, Florian/B-6594-2015	Schulte-Korne, Gerd/0000-0002-9960-1572; Heinen, Florian/0000-0002-3872-6136; Lepage, Chris/0000-0001-5719-0982; Tripodis, Yorghos/0000-0003-2190-7608	Else Kroner-Fresenius-Stiftung, Germany; U.S. Department of State Fulbright Scholarship; Mission Connect, a program of TIRR Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30-EY010608]; VA Merit AwardUS Department of Veterans Affairs; German Academic Exchange ServiceDeutscher Akademischer Austausch Dienst (DAAD); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	We thank all study participants. This study was in part supported by the Else Kroner-Fresenius-Stiftung, Germany (IK), the U.S. Department of State Fulbright Scholarship, 2014-2015 (EN), Mission Connect, a program of TIRR Foundation (AS), NIH P30-EY010608 (AC), a VA Merit Award (MES), and the German Academic Exchange Service PROMOS Award (VS).	Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Billat V, 1996, ERGONOMICS, V39, P267, DOI 10.1080/00140139608964457; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Budde H, 2008, NEUROSCI LETT, V441, P219, DOI 10.1016/j.neulet.2008.06.024; Byun KH, 2014, NEUROIMAGE, V98, P336, DOI 10.1016/j.neuroimage.2014.04.067; Clery J, 2015, J NEUROSCI, V35, P4179, DOI 10.1523/JNEUROSCI.3031-14.2015; DeSouza JFX, 2003, J NEUROPHYSIOL, V89, P1016, DOI 10.1152/jn.00562.2002; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Field DT, 2005, CURR BIOL, V15, P453, DOI 10.1016/j.cub.2004.12.081; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; Hogervorst E, 1996, PERCEPT MOTOR SKILL, V83, P479, DOI 10.2466/pms.1996.83.2.479; HOLMER I, 1974, J APPL PHYSIOL, V36, P711; Kemppainen J, 2005, J PHYSIOL-LONDON, V568, P323, DOI 10.1113/jphysiol.2005.091355; Kirchgessner MA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00453; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maier JX, 2008, CURR BIOL, V18, P963, DOI 10.1016/j.cub.2008.05.043; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Pang EW, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00170; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Sereno A. B., United States patent application, Patent No. [US 2014/ 0249447 A1, 20140249447]; Suchomel A., 2010, INT J TABLE TENNIS S, V6; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tonnessen E, 2013, INT J SPORT PHYSIOL, V8, P323, DOI 10.1123/ijspp.8.3.323; Tsushima WT, 2016, APPL NEUROPSYCH-CHIL, V5, P149, DOI 10.1080/21622965.2015.1052813; WARREN JB, 1984, CLIN SCI, V66, P87, DOI 10.1042/cs0660087; Winter B, 2007, NEUROBIOL LEARN MEM, V87, P597, DOI 10.1016/j.nlm.2006.11.003; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364; Zouhal H, 2008, SPORTS MED, V38, P401, DOI 10.2165/00007256-200838050-00004	35	38	38	6	37	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2017	34	16					2389	2395		10.1089/neu.2016.4960			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FC6RI	WOS:000406968400002	28381107	Green Published			2021-06-18	
J	Rangaprakash, D; Deshpande, G; Daniel, TA; Goodman, AM; Robinson, JL; Salibi, N; Katz, JS; Denney, TS; Dretsch, MN				Rangaprakash, D.; Deshpande, Gopikrishna; Daniel, Thomas A.; Goodman, Adam M.; Robinson, Jennifer L.; Salibi, Nouha; Katz, Jeffrey S.; Denney, Thomas S., Jr.; Dretsch, Michael N.			Compromised Hippocampus-Striatum Pathway as a Potential Imaging Biomarker of Mild-Traumatic Brain Injury and Posttraumatic Stress Disorder	HUMAN BRAIN MAPPING			English	Article						functional magnetic resonance imaging; functional connectivity; dynamic connectivity; posttraumatic stress disorder; mild traumatic brain injury; network dynamics; hippocampus	MULTIPLE MEMORY-SYSTEMS; RESTING-STATE FMRI; FUNCTIONAL CONNECTIVITY; HUMAN THALAMUS; WAR VETERANS; DIFFUSION; NETWORKS; CLASSIFICATION; MODULATION; METAANALYSIS	Objectives: Military service members risk acquiring posttraumatic stress disorder (PTSD) and mild-traumatic brain injury (mTBI), with high comorbidity. Owing to overlapping symptomatology in chronic mTBI or postconcussion syndrome (PCS) and PTSD, it is difficult to assess the etiology of a patient's condition without objective measures. Using resting-state functional MRI in a novel framework, we tested the hypothesis that their neural signatures are characterized by functionally hyperconnected brain regions which are less variable over time. Additionally, we predicted that such connectivities possessed the highest ability in predicting the diagnostic membership of a novel subject (top-predictors) in addition to being statistically significant. Methods: U.S. Army Soldiers (N=87) with PTSD and comorbid PCS1PTSD were recruited along with combat controls. Static and dynamic functional connectivities were evaluated. Group differences were obtained in accordance with our hypothesis. Machine learning classification (MLC) was employed to determine top predictors. Results: From whole-brain connectivity, we identified the hippocampus-striatum connectivity to be significantly altered in accordance with our hypothesis. Diffusion tractography revealed compromised white-matter integrity between aforementioned regions only in the PCS1PTSD group, suggesting a structural etiology for the PCS1PTSD group rather than being an extreme subset of PTSD. Employing MLC, connectivities provided worst-case accuracy of 84% (9% more than psychological measures). Additionally, the hippocampus-striatum connectivities were found to be top predictors and thus a potential biomarker of PTSD/mTBI. Conclusions: PTSD/mTBI are associated with hippocampal-striatal hyperconnectivity from which it is difficult to disengage, leading to a habit-like response toward episodic traumatic memories, which fits well with behavioral manifestations of combat-related PTSD/mTBI. (C) 2017 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.	[Rangaprakash, D.; Deshpande, Gopikrishna; Robinson, Jennifer L.; Salibi, Nouha; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, AU MRI Res Ctr, Auburn, AL 36849 USA; [Rangaprakash, D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Deshpande, Gopikrishna; Daniel, Thomas A.; Goodman, Adam M.; Robinson, Jennifer L.; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA; [Deshpande, Gopikrishna; Robinson, Jennifer L.; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Auburn Univ, Alabama Adv Imaging Consortium, Birmingham, AL 35203 USA; [Deshpande, Gopikrishna; Robinson, Jennifer L.; Katz, Jeffrey S.; Denney, Thomas S., Jr.] Univ Alabama Birmingham, Birmingham, AL 35294 USA; [Daniel, Thomas A.] Westfield State Univ, Dept Psychol, Westfield, MA USA; [Goodman, Adam M.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Salibi, Nouha] Siemens Healthcare, MR R&D, Malvern, PA USA; [Dretsch, Michael N.] US Army Aeromed Res Lab, Ft Rucker, AL 36362 USA; [Dretsch, Michael N.] HQ TRADOC, Human Dimens Div, Ft Eustis, VI 23604 USA	Deshpande, G (corresponding author), Auburn Univ, Dept Elect & Comp Engn, AU MRI Res Ctr, Auburn, AL 36849 USA.; Deshpande, G (corresponding author), Auburn Univ, Dept Psychol, Auburn, AL 36849 USA.; Deshpande, G (corresponding author), Auburn Univ, Alabama Adv Imaging Consortium, Birmingham, AL 35203 USA.; Deshpande, G (corresponding author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.; Dretsch, MN (corresponding author), US Army Aeromed Res Lab, Ft Rucker, AL 36362 USA.; Dretsch, MN (corresponding author), HQ TRADOC, Human Dimens Div, Ft Eustis, VI 23604 USA.	gopi@auburn.edu; michael.n.dretsch.mil@mail.mil	Goodman, Adam/AAI-3643-2021	Goodman, Adam/0000-0002-7550-679X; Rangaprakash, D/0000-0001-9553-1354; Denney, Thomas/0000-0002-6695-4777	U.S. Army Medical Research and Materiel Command (MRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [00007218]	Contract grant sponsor: U.S. Army Medical Research and Materiel Command (MRMC); Contract grant number: 00007218	Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Boccia M, 2016, BRAIN IMAGING BEHAV, V10, P226, DOI 10.1007/s11682-015-9387-3; Brodersen KH, 2014, NEUROIMAGE-CLIN, V4, P98, DOI 10.1016/j.nicl.2013.11.002; Chen G, 2011, RADIOLOGY, V259, P213, DOI 10.1148/radiol.10100734; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cisler JM, 2014, J PSYCHIATR RES, V48, P47, DOI 10.1016/j.jpsychires.2013.09.013; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Craddock RC, 2012, HUM BRAIN MAPP, V33, P1914, DOI 10.1002/hbm.21333; Craddock RC, 2009, MAGN RESON MED, V62, P1619, DOI 10.1002/mrm.22159; Deshpande G, 2009, P ISMRM 17 SCI M HON; Deshpande G, 2006, LECT NOTES COMPUT SC, V4091, P17; Deshpande G, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00670; Deshpande G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014277; Dickstein BD, 2015, ASSESSMENT, V22, P289, DOI 10.1177/1073191114548683; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Favaro A, 2014, PSYCHIAT RES-NEUROIM, V223, P157, DOI 10.1016/j.pscychresns.2014.05.006; Foerde K, 2006, P NATL ACAD SCI USA, V103, P11778, DOI 10.1073/pnas.0602659103; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Ghiglieri V, 2011, PROG NEUROBIOL, V94, P102, DOI 10.1016/j.pneurobio.2011.04.005; Goodman J, 2012, REV NEUROSCIENCE, V23, P627, DOI 10.1515/revneuro-2012-0049; Greiser KH, 2009, EUR J EPIDEMIOL, V24, P123, DOI 10.1007/s10654-009-9317-z; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Handwerker DA, 2004, NEUROIMAGE, V21, P1639, DOI 10.1016/j.neuroimage.2003.11.029; Hansen ECA, 2015, NEUROIMAGE, V105, P525, DOI 10.1016/j.neuroimage.2014.11.001; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Hayes JP, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00089; Henry RG, 2003, J MAGN RESON IMAGING, V18, P420, DOI 10.1002/jmri.10379; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Jia H, 2014, BRAIN CONNECT, V4, P741, DOI 10.1089/brain.2014.0300; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Keilholz SD, 2013, BRAIN CONNECT, V3, P31, DOI 10.1089/brain.2012.0115; Kennis M, 2015, HUM BRAIN MAPP, V36, P99, DOI 10.1002/hbm.22615; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Li X, 2014, HUM BRAIN MAPP, V35, P1761, DOI 10.1002/hbm.22290; Liu F, 2015, BRAIN TOPOGR, V28, P221, DOI 10.1007/s10548-014-0386-2; Majeed W, 2011, NEUROIMAGE, V54, P1140, DOI 10.1016/j.neuroimage.2010.08.030; Marquand AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069237; Mattfeld AT, 2015, HIPPOCAMPUS, V25, P900, DOI 10.1002/hipo.22411; Mattfeld AT, 2011, CEREB CORTEX, V21, P647, DOI 10.1093/cercor/bhq144; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Packard MG, 2009, BRAIN RES, V1293, P121, DOI 10.1016/j.brainres.2009.03.029; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Sakoglu U, 2010, MAGN RESON MATER PHY, V23, P351, DOI 10.1007/s10334-010-0197-8; Schwabe L, 2013, BIOL PSYCHIAT, V74, P801, DOI 10.1016/j.biopsych.2013.06.001; Schwabe L, 2012, J NEUROSCI, V32, P11042, DOI 10.1523/JNEUROSCI.1484-12.2012; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Thompson GJ, 2013, HUM BRAIN MAPP, V34, P3280, DOI 10.1002/hbm.22140; Vapnik V., 1995, NATURE STAT LEARNING; Wang L., 2005, SUPPORT VECTOR MACHI; Weathers F.W, 2015, PTSD CHECKLIST DSM 5; Woo CW, 2015, PAIN, V156, P1379, DOI 10.1097/j.pain.0000000000000223; Wu GR, 2013, MED IMAGE ANAL, V17, P365, DOI 10.1016/j.media.2013.01.003; Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013; Yeh P, 2015, P ANN M ORG HUM BRAI; Yousef M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-144	63	38	39	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2017	38	6					2843	2864		10.1002/hbm.23551			22	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EZ7XV	WOS:000404939900005	28295837	Green Published, Other Gold			2021-06-18	
J	Palleria, C; Leo, A; Andreozzi, F; Citraro, R; Iannone, M; Spiga, R; Sesti, G; Constanti, A; De Sarro, G; Arturi, F; Russo, E				Palleria, Caterina; Leo, Antonio; Andreozzi, Francesco; Citraro, Rita; Iannone, Michelangelo; Spiga, Rosangela; Sesti, Giorgio; Constanti, Andrew; De Sarro, Giovambattista; Arturi, Franco; Russo, Emilio			Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects	BEHAVIOURAL BRAIN RESEARCH			English	Article						Streptozotocin; Diabetes mellitus; Rats; Cognitive functions; Neurodegeneration; GLP-1 receptors; Liraglutide; mTOR signaling	GLUCAGON-LIKE PEPTIDE-1; DEPRESSIVE-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT; ABSENCE EPILEPSY; SPATIAL MEMORY; MOUSE MODEL; NEUROPROTECTIVE ACTIONS; RECEPTOR ACTIVATION	Diabetes has been identified as a risk factor for cognitive dysfunctions. Glucagone like peptide 1 (GLP-1) receptor agonists have neuroprotective effects in preclinical animal models. We evaluated the effects of GLP-1 receptor agonist, liraglutide (LIR), on cognitive decline associated with diabetes. Furthermore, we studied LIR effects against hippocampal neurodegeneration induced by streptozotocin (STZ), a well-validated animal model of diabetes and neurode-generation associated with cognitive decline. Diabetes and/or cognitive decline were induced in Wistar rats by intraperitoneal or intracerebroventricular injection of STZ and then rats were treated with LIR (300 mu g/kg daily subcutaneously) for 6 weeks. Rats underwent behavioral tests: Morris water maze, passive avoidance, forced swimming (FST), open field, elevated plus maze, rotarod tests. Furthermore, LIR effects on hippocampal neurode-generation and mTOR pathway (AKT, AMPK, ERK and p70S6K) were assessed. LIR improved learning and memory only in STZ-treated animals. Anxiolytic effects were observed in all LIR-treated groups but pro-depressant effects in CTRL rats were observed. At a cellular/molecular level, intracerebroventricular STZ induced hippocampal neurodegeneration accompanied by decreased phosphorylation of AMPK, AKT, ERK and p70S6K. LIR reduced hippocampal neuronal death and prevented the decreased phosphorylation of AKT and p70S6K; AMPK was hyper-phosphorylated in comparison to CTRL group, while LIR had no effects on ERK. LIR reduced animal endurance in the rotarod test and this effect might be also linked to a reduction in locomotor activity during only the last two minutes of the FST. LIR had protective effects on cognitive functions in addition to its effects on blood glucose levels. LIR effects in the brain also comprised anxiolytic and pro-depressant actions (although influenced by reduced endurance). Finally, LIR protected from diabetes-dependent hippocampal neurodegeneration likely through an effect on mTOR pathway. (C) 2017 Elsevier B.V. All rights reserved.	[Palleria, Caterina; Leo, Antonio; Citraro, Rita; De Sarro, Giovambattista; Russo, Emilio] Magna Graecia Univ Catanzaro, Sch Med, Dept Hlth Sci, Catanzaro, Italy; [Andreozzi, Francesco; Spiga, Rosangela; Sesti, Giorgio; Arturi, Franco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Viale Europa, I-88100 Catanzaro, Italy; [Iannone, Michelangelo] CNR, Inst Neurol Sci, Pharmacol Sect, Catanzaro, Italy; [Constanti, Andrew] UCL Sch Pharm, Dept Pharmacol, 29-39 Brunswick Sq, London, England	Russo, E (corresponding author), Univ Catanzaro, Sch Med, Dept Hlth Sci, Chair Pharmacol, Via T Campanella 115, I-88100 Catanzaro, Italy.	erusso@unicz.it	Spiga, Rosangela/AAB-4421-2020; Leo, Antonio/AAC-4052-2020; Russo, Emilio/G-5241-2010; Iannone, Michelangelo/L-4675-2013; Andreozzi, Francesco/J-4073-2018	Spiga, Rosangela/0000-0002-3331-6568; Leo, Antonio/0000-0002-0061-1608; Russo, Emilio/0000-0002-1279-8123; Iannone, Michelangelo/0000-0002-0426-5191; Andreozzi, Francesco/0000-0001-9375-1513			Abbas T, 2009, BEHAV BRAIN RES, V205, P265, DOI 10.1016/j.bbr.2009.06.035; Ahmad W., 2016, MOL NEUROBIOL; Antion MD, 2008, MOL CELL BIOL, V28, P2996, DOI 10.1128/MCB.00201-08; Bagetta G, 2004, NEUROSCI LETT, V368, P87, DOI 10.1016/j.neulet.2004.06.062; Bekinschtein P, 2007, NEUROBIOL LEARN MEM, V87, P303, DOI 10.1016/j.nlm.2006.08.007; Briyal S, 2014, NEUROSCIENCE, V281, P269, DOI 10.1016/j.neuroscience.2014.09.064; Brunetti L, 2008, PEPTIDES, V29, P1377, DOI 10.1016/j.peptides.2008.04.007; Cai HY, 2014, NEUROSCIENCE, V277, P6, DOI 10.1016/j.neuroscience.2014.02.022; Cheng G, 2012, INTERN MED J, V42, P484, DOI 10.1111/j.1445-5994.2012.02758.x; Citraro R., 2016, EPILEPSIA; Citraro R, 2014, EPILEPSIA, V55, P1284, DOI 10.1111/epi.12686; Citraro R, 2013, NEUROPHARMACOLOGY, V69, P115, DOI 10.1016/j.neuropharm.2012.11.017; Dash SK, 2013, RECENT PATENTS ENDOC, V7, P155, DOI 10.2174/1872214811307020009; Du LL, 2015, J ALZHEIMERS DIS, V43, P775, DOI 10.3233/JAD-140564; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Egefjord L, 2012, DAN MED J, V59; Elcioglu HK, 2015, ACTA HISTOCHEM, V117, P176, DOI 10.1016/j.acthis.2014.12.002; Gilman CP, 2003, J NEUROCHEM, V87, P1137, DOI 10.1046/j.1471-4159.2003.02073.x; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Grieb P, 2016, MOL NEUROBIOL, V53, P1741, DOI 10.1007/s12035-015-9132-3; Gupta D, 2014, METAB BRAIN DIS, V29, P737, DOI 10.1007/s11011-014-9540-5; Gupta D, 2014, PHYSIOL BEHAV, V129, P73, DOI 10.1016/j.physbeh.2014.02.036; Halloran J, 2012, NEUROSCIENCE, V223, P102, DOI 10.1016/j.neuroscience.2012.06.054; Hamilton A, 2011, J NEUROSCI RES, V89, P481, DOI 10.1002/jnr.22565; Hendarto H, 2012, METABOLISM, V61, P1422, DOI 10.1016/j.metabol.2012.03.002; Holscher C, 2014, J ENDOCRINOL, V221, pT31, DOI 10.1530/JOE-13-0221; Inoue T, 2015, ATHEROSCLEROSIS, V240, P250, DOI 10.1016/j.atherosclerosis.2015.03.026; Isacson R, 2011, EUR J PHARMACOL, V650, P249, DOI 10.1016/j.ejphar.2010.10.008; Javed H, 2011, BRAIN RES, V1389, P133, DOI 10.1016/j.brainres.2011.02.072; Jernigan CS, 2011, PROG NEURO-PSYCHOPH, V35, P1774, DOI 10.1016/j.pnpbp.2011.05.010; Kamble M, 2016, EUR J PHARMACOL, V774, P64, DOI 10.1016/j.ejphar.2016.02.003; Kim W, 2008, PHARMACOL REV, V60, P470, DOI 10.1124/pr.108.000604; Kimura R, 2009, NEUROSCIENCE, V162, P1212, DOI 10.1016/j.neuroscience.2009.05.025; Kodl CT, 2008, ENDOCR REV, V29, P494, DOI 10.1210/er.2007-0034; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; Lee CH, 2011, J NEUROSCI RES, V89, P1103, DOI 10.1002/jnr.22596; Lennox R, 2014, PEPTIDES, V61, P38, DOI 10.1016/j.peptides.2014.08.014; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Liu W, 2015, NEUROSCIENCE, V303, P42, DOI 10.1016/j.neuroscience.2015.06.054; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lund A, 2014, EUR J INTERN MED, V25, P407, DOI 10.1016/j.ejim.2014.03.005; Luque MA, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730465; McClean PL, 2014, NEUROPHARMACOLOGY, V86, P241, DOI 10.1016/j.neuropharm.2014.07.015; McClean PL, 2014, NEUROPHARMACOLOGY, V76, P57, DOI 10.1016/j.neuropharm.2013.08.005; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; McIntyre RS, 2013, BEHAV BRAIN RES, V237, P164, DOI 10.1016/j.bbr.2012.09.021; Oliveira WH, 2016, BRAIN RES, V1644, P149, DOI 10.1016/j.brainres.2016.05.013; Palleria C, 2016, FRONT NEUROENDOCRIN, V42, P76, DOI 10.1016/j.yfrne.2016.07.002; Parthsarathy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058784; Prickaerts J, 2000, J NEURAL TRANSM, V107, P745, DOI 10.1007/s007020070056; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Rai S, 2014, PHARMACOL BIOCHEM BE, V117, P104, DOI 10.1016/j.pbb.2013.11.035; Redondo A, 2003, MOL CELL ENDOCRINOL, V204, P43, DOI 10.1016/S0303-7207(03)00146-1; Russo E, 2013, EPILEPSY BEHAV, V28, P232, DOI 10.1016/j.yebeh.2013.05.002; Russo E, 2013, NEUROPHARMACOLOGY, V69, P25, DOI 10.1016/j.neuropharm.2012.09.019; Russo E, 2013, NEUROPHARMACOLOGY, V64, P371, DOI 10.1016/j.neuropharm.2012.06.039; Russo E, 2011, BEHAV BRAIN RES, V225, P373, DOI 10.1016/j.bbr.2011.07.030; Sheikh BA, 2015, BIOCHIMIE, V112, P57, DOI 10.1016/j.biochi.2015.02.008; Shiga T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146136; Shoham S, 2003, EXP NEUROL, V184, P1043, DOI 10.1016/j.expneurol.2003.08.015; Velmurugan K, 2012, J NEUROCHEM, V123, P919, DOI 10.1111/jnc.12036; Wang KX, 2015, BIOL PHARM BULL, V38, P1142, DOI 10.1248/bpb.b15-00024; Wang S, 2014, METAB BRAIN DIS, V29, P729, DOI 10.1007/s11011-014-9528-1; Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029; Wong Michael, 2013, Biomed J, V36, P40, DOI 10.4103/2319-4170.110365; Xiong H, 2013, J ALZHEIMERS DIS, V37, P623, DOI 10.3233/JAD-130584; Yamazaki S, 2014, ENDOCRINOLOGY, V155, P3288, DOI 10.1210/en.2013-2157	68	38	40	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2017	321						157	169		10.1016/j.bbr.2017.01.004			13	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EL1TJ	WOS:000394403600018	28062257				2021-06-18	
J	Nielson, JL; Cooper, SR; Yue, JK; Sorani, MD; Inoue, T; Yuh, EL; Mukherjee, P; Petrossian, TC; Paquette, J; Lum, PY; Carlsson, GE; Vassar, MJ; Lingsma, HF; Gordon, WA; Valadka, AB; Okonkwo, DO; Manley, GT; Ferguson, AR				Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Sorani, Marco D.; Inoue, Tomoo; Yuh, Esther L.; Mukherjee, Pratik; Petrossian, Tanya C.; Paquette, Jesse; Lum, Pek Y.; Carlsson, Gunnar E.; Vassar, Mary J.; Lingsma, Hester F.; Gordon, Wayne A.; Valadka, Alex B.; Okonkwo, David O.; Manley, Geoffrey T.; Ferguson, Adam R.		TRACK-TBI Investigators	Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis	PLOS ONE			English	Article							COMMON DATA ELEMENTS; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; POLYMORPHISM; COMT; CLASSIFICATION; PREDICTION; PROTEIN	Background Traumatic brain injury (TBI) is a complex disorder that is traditionally stratified based on clinical signs and symptoms. Recent imaging and molecular biomarker innovations provide unprecedented opportunities for improved TBI precision medicine, incorporating patho-ana-tomical and molecular mechanisms. Complete integration of these diverse data for TBI diag-nosis and patient stratification remains an unmet challenge. Methods and findings The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot multicenter study enrolled 586 acute TBI patients and collected diverse common data elements (TBI-CDEs) across the study population, including imaging, genetics, and clinical outcomes. We then applied topology-based data-driven discovery to identify natural sub-groups of patients, based on the TBI-CDEs collected. Our hypothesis was two-fold: 1) A machine learning tool known as topological data analysis (TDA) would reveal data-driven patterns in patient outcomes to identify candidate biomarkers of recovery, and 2) TDA-iden-tified biomarkers would significantly predict patient outcome recovery after TBI using more traditional methods of univariate statistical tests. TDA algorithms organized and mapped the data of TBI patients in multidimensional space, identifying a subset of mild TBI patients with a specific multivariate phenotype associated with unfavorable outcome at 3 and 6 months after injury. Further analyses revealed that this patient subset had high rates of post-trau-matic stress disorder (PTSD), and enrichment in several distinct genetic polymorphisms associated with cellular responses to stress and DNA damage (PARP1), and in striatal dopamine processing (ANKK1, COMT, DRD2). Conclusions TDA identified a unique diagnostic subgroup of patients with unfavorable outcome after mild TBI that were significantly predicted by the presence of specific genetic polymorphisms. Machine learning methods such as TDA may provide a robust method for patient stratifica-tion and treatment planning targeting identified biomarkers in future clinical trials in TBI patients.	[Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Inoue, Tomoo; Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam R.] Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94110 USA; [Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Sorani, Marco D.; Inoue, Tomoo; Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Cooper, Shelly R.; Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Petrossian, Tanya C.; Paquette, Jesse; Lum, Pek Y.; Carlsson, Gunnar E.] Ayasdi Inc, Palo Alto, CA USA; [Lingsma, Hester F.] Erasmus MC, Publ Hlth, Rotterdam, Netherlands; [Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; [Ferguson, Adam R.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA	Manley, GT; Ferguson, AR (corresponding author), Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94110 USA.; Manley, GT; Ferguson, AR (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Ferguson, AR (corresponding author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA.	manleyg@neurosurg.ucsf.edu; adam.ferguson@ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Markowitz, Amy/0000-0001-9314-2814; Martin, Alastair/0000-0002-7963-4000; Cooper, Shelly/0000-0003-0026-6688; Hemphill, Claude/0000-0003-4019-7525; Wang, Kevin/0000-0002-9343-6473; Petrossian, Tanya/0000-0002-1205-9144; Nielson, Jessica/0000-0002-3677-3959; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Ferguson, Adam/0000-0001-7102-1608; Bodien, Yelena/0000-0003-4858-2903	Department of Defense (DoD)United States Department of Defense [W81XWH-131-0441]; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS067092, NS069409, NS069409-0251]; Craig H. Neilsen Foundation (ARF); Wings for Life Foundation (ARF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067092, U01NS086090] Funding Source: NIH RePORTER	This work was funded by the following: Department of Defense (DoD) grant W81XWH-131-0441 (GTM): http://cdmrp.army.mil/funding/phtbi.shtml; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) grants NS067092 (ARF), NS069409 (GTM) and NS069409-0251 (GTM): http://www.runds.nih.govt/; Craig H. Neilsen Foundation (ARF): http://chnfoundation.org/; and Wings for Life Foundation (ARF): http://www.wingsforlrie.com/en/.	Benedetti F, 2009, PSYCHOPHARMACOLOGY, V203, P155, DOI 10.1007/s00213-008-1381-7; Bodenmann S, 2009, CLIN PHARMACOL THER, V85, P296, DOI 10.1038/clpt.2008.222; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; CDC, GET FACTS CONC TRAUM; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chan JM, 2013, P NATL ACAD SCI USA, V110, P18566, DOI 10.1073/pnas.1313480110; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kyeong S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137296; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lum PY, 2013, SCI REP, V3, P1518; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marshall Lawrence F., 2009, J NEUROSURGERY PUBLI; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Nielson JL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9581; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Romano D, 2014, HUM BRAIN MAPP, V35, P4904, DOI 10.1002/hbm.22521; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sarikonda G, 2014, J AUTOIMMUNITY; Sarnaik AA, 2010, J NEUROTRAUM, V27, P465, DOI 10.1089/neu.2009.1171; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; The National Institute of Neurlogical Disorders and Stroke, 2015, NINDS COMM DAT EL TR; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Yue JK, 2016, NEUROGENETICS; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	41	38	38	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2017	12	3							e0169490	10.1371/journal.pone.0169490			19	Multidisciplinary Sciences	Science & Technology - Other Topics	EN5BR	WOS:000396021100002	28257413	DOAJ Gold, Green Published			2021-06-18	
J	Tucker, LB; Burke, JF; Fu, AH; McCabe, JT				Tucker, Laura B.; Burke, John F.; Fu, Amanda H.; McCabe, Joseph T.			Neuropsychiatric Symptom Modeling in Male and Female C57BL/6J Mice after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; depression; mouse; sex differences; TBI	CONTROLLED CORTICAL IMPACT; STRESS-INDUCED HYPERTHERMIA; ANXIETY-LIKE BEHAVIOR; ELEVATED PLUS-MAZE; SEX-DIFFERENCES; OPEN-FIELD; PSYCHIATRIC-DISORDERS; ANIMAL-MODELS; ESTROUS-CYCLE; MOUSE MODEL	Psychiatric symptoms such as anxiety and depression are frequent and persistent complaints following traumatic brain injury (TBI). Modeling these symptoms in animal models of TBI affords the opportunity to determine mechanisms underlying behavioral pathologies and to test potential therapeutic agents. However, testing these symptoms in animal models of TBI has yielded inconsistent results. The goal of the current study was to employ a battery of tests to measure multiple anxiety-and depressive-like symptoms following TBI in C57BL/6J mice, and to determine if male and female mice are differentially affected by the injury. Following controlled cortical impact (CCI) at a parietal location, neither male nor female mice showed depressive-like symptoms as measured by the Porsolt forced-swim test and sucrose preference test. Conclusions regarding anxiety-like behaviors were dependent upon the assay employed; CCI-induced thigmotaxis in the open field suggested an anxiogenic effect of the injury; however, results from the elevated zero maze, light-dark box, and marble-burying tests indicated that CCI reduced anxiety-like behaviors. Fewer anxiety-like behaviors were also associated with the female sex. Increased levels of activity were also measured in female mice and injured mice in these tests, and conclusions regarding anxiety should be taken with caution when experimental manipulations induce changes in baseline activity. These results underscore the irreconcilability of results from studies attempting to model TBI-induced neuropsychiatric symptoms. Changes in injury models or better attempts to replicate the clinical syndrome may improve the translational applicability of rodent models of TBI-induced anxiety and depression.	[Tucker, Laura B.; Burke, John F.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD 20814 USA; [Tucker, Laura B.; Burke, John F.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, FE Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA	McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Preclin Studies Core, Bethesda, MD 20814 USA.; McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, FE Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Joseph.McCabe@usuhs.edu		Burke, John/0000-0003-1519-9078; Tucker, Laura/0000-0002-5984-6399	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855-300600-7.01]	This work was supported by The Center for Neuroscience and Regenerative Medicine, 60855-300600-7.01. The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the United States Army, Department of Defense, the United States government, or the Uniformed Services University of the Health Sciences. The use of trade names does not constitute an official endorsement or approval of the use of such reagents or commercial hardware or software. This document may not be cited for purposes of advertisement. The authors express appreciation for being able to use the laboratory of Dr. Yumin Zhang for tissue sectioning.	ACKERLY DD, 1990, OECOLOGIA, V82, P474, DOI 10.1007/BF00319788; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; Angoa-Perez M, 2013, JOVE-J VIS EXP, DOI 10.3791/50978; ARCHER J, 1975, BEHAV BIOL, V14, P451, DOI 10.1016/S0091-6773(75)90636-7; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bouwknecht JA, 2007, NEUROSCI BIOBEHAV R, V31, P41, DOI 10.1016/j.neubiorev.2006.02.002; Bouwknecht JA, 2008, BEHAV PHARMACOL, V19, P385, DOI 10.1097/FBP.0b013e32830c3658; Braun AA, 2011, PHARMACOL BIOCHEM BE, V97, P406, DOI 10.1016/j.pbb.2010.09.013; BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Collins TJ, 2007, BIOTECHNIQUES, V43, P25; Cook MN, 2002, BEHAV GENET, V32, P113, DOI 10.1023/A:1015249706579; Cope EC, 2012, NEUROREHAB NEURAL RE, V26, P907, DOI 10.1177/1545968311435337; Crawley J.N., 2007, WHATS WRONG MY MOUSE; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Cryan JF, 2004, MOL PSYCHIATR, V9, P326, DOI 10.1038/sj.mp.4001457; CUNHA JM, 1978, PHARMACOLOGY, V16, P259, DOI 10.1159/000136777; DAWSON GR, 1995, PSYCHOPHARMACOLOGY, V118, P316, DOI 10.1007/BF02245961; Deacon RMJ, 2005, BEHAV BRAIN RES, V156, P241, DOI 10.1016/j.bbr.2004.05.027; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; Donner NC, 2013, PFLUG ARCH EUR J PHY, V465, P601, DOI 10.1007/s00424-013-1271-7; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fernandes C, 1999, PHARMACOL BIOCHEM BE, V64, P731, DOI 10.1016/S0091-3057(99)00139-2; File SE, 2001, BEHAV BRAIN RES, V125, P151, DOI 10.1016/S0166-4328(01)00292-3; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GYERTYAN I, 1995, BEHAV PHARMACOL, V6, P24; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Heredia L, 2014, J PHARMACOL TOX MET, V69, P108, DOI 10.1016/j.vascn.2013.12.005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hubscher CH, 2006, BRAIN RES, V1100, P118, DOI 10.1016/j.brainres.2006.05.003; Jirkof P, 2014, J NEUROSCI METH, V234, P139, DOI 10.1016/j.jneumeth.2014.02.001; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P273, DOI 10.1016/0149-7634(81)90009-9; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kokras N, 2014, BRIT J PHARMACOL, V171, P4595, DOI 10.1111/bph.12710; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; McAllister BB, 2015, BEHAV BRAIN RES, V290, P102, DOI 10.1016/j.bbr.2015.04.049; Millan MJ, 2003, EUR J PHARMACOL, V463, P67, DOI 10.1016/S0014-2999(03)01275-5; Milner LC, 2008, GENES BRAIN BEHAV, V7, P496, DOI 10.1111/j.1601-183X.2007.00385.x; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Morgan MA, 2002, BEHAV BRAIN RES, V132, P85, DOI 10.1016/S0166-4328(01)00398-9; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nichols JN, 2016, BEHAV BRAIN RES, V298, P111, DOI 10.1016/j.bbr.2015.10.052; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; O'Leary OF, 2013, CELL TISSUE RES, V354, P141, DOI 10.1007/s00441-013-1587-9; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Ferreira APO, 2014, PSYCHOPHARMACOLOGY, V231, P1935, DOI 10.1007/s00213-013-3336-x; Olivier B, 2003, EUR J PHARMACOL, V463, P117, DOI 10.1016/S0014-2999(03)01326-8; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Palanza P, 2001, NEUROSCI BIOBEHAV R, V25, P219, DOI 10.1016/S0149-7634(01)00010-0; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pires GN, 2015, BEHAV NEUROSCI, V129, P621, DOI 10.1037/bne0000076; POLING A, 1981, J EXP ANAL BEHAV, V35, P31, DOI 10.1901/jeab.1981.35-31; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sajja VSSS, 2015, SHOCK, V44, P71, DOI 10.1097/SHK.0000000000000311; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Scholten A.C., 2016, J NEUROTRAUMA; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Sierra-Mercado D, 2015, BRAIN RES, V1606, P133, DOI 10.1016/j.brainres.2015.02.031; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Slattery DA, 2014, ILAR J, V55, P297, DOI 10.1093/ilar/ilu026; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y; Thompson T, 2015, PHARMACOL BIOCHEM BE, V133, P7, DOI 10.1016/j.pbb.2015.03.011; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Voikar V, 2005, GENES BRAIN BEHAV, V4, P240, DOI 10.1111/j.1601-183X.2004.00103.x; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Weiss SM, 1998, NEUROSCI BIOBEHAV R, V23, P265, DOI 10.1016/S0149-7634(98)00027-X; Wheaton P, 2011, J PSYCHOPHARMACOL, V25, P1581, DOI 10.1177/0269881110388331; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	109	38	38	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					890	905		10.1089/neu.2016.4508			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200017	27149139	Other Gold, Green Published			2021-06-18	
J	Baker, A; Barker, S; Sampson, A; Martin, C				Baker, Anne; Barker, Samantha; Sampson, Amanda; Martin, Clarissa			Caregiver outcomes and interventions: a systematic scoping review of the traumatic brain injury and spinal cord injury literature	CLINICAL REHABILITATION			English	Article						Burden of care; carers; caregiver; spinal cord injury; systematic review; traumatic brain injury	FAMILY CAREGIVERS; SUPPORT GROUPS; BURDEN; PROGRAM; IMPACT; QUALITY; REHABILITATION; EFFICACY; BEHAVIOR; PEOPLE	Aim: To identify factors reported with negative and positive outcomes for caregivers of the traumatic brain injury and spinal cord injury cohorts, to investigate what interventions have been studied to support carers and to report what effectiveness has been found. Methods: Scoping systematic review. Electronic databases and websites were searched from 1990 to December 2015. Studies were agreed for inclusion using pre-defined criteria. Relevant information from included studies was extracted and quality assessment was completed. Data were synthesised using qualitative methods. Results: A total of 62 studies reported caregiver outcomes for the traumatic brain injury cohort; 51 reported negative outcomes and 11 reported positive outcomes. For the spinal cord injury cohort, 18 studies reported caregiver outcomes; 15 reported negative outcomes and three reported positive outcomes. Burden of care was over-represented in the literature for both cohorts, with few studies looking at factors associated with positive outcomes. Good family functioning, coping skills and social support were reported to mediate caregiver burden and promote positive outcomes. A total of 21 studies further described interventions to support traumatic brain injury caregivers and four described interventions to support spinal cord injury caregivers, with emerging evidence for the effectiveness of problem-solving training. Further research is required to explore the effects of injury severity of the care recipient, as well as caregiver age, on the outcome of the interventions. Conclusion: Most studies reported negative outcomes, suggesting that barriers to caregiving have been established, but not facilitators. The interventions described to support carers are limited and require further testing to confirm their effectiveness.	[Baker, Anne] Australian Catholic Univ, Sch Allied Hlth, Melbourne, Vic, Australia; [Barker, Samantha; Sampson, Amanda] Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic, Australia; [Martin, Clarissa] Monash Univ, Dept Physiotherapy, Melbourne, Vic, Australia	Baker, A (corresponding author), Australian Catholic Univ, Occupat Therapy, Locked Bag 4115, Fitzroy, Vic 3065, Australia.	Anne.Baker@acu.edu.au		Baker, Anne/0000-0002-3779-5463			Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Australian Bureau of Statistics, 2012, 4430 0 DIS AG CAR; Australian Institute of Health and Welfare, 2004, CAR AUSTR ASS FRAIL; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Bunn F, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001331; Butera-Prinzi F, 2010, NEUROREHABILITATION, V27, P31, DOI 10.3233/NRE-2010-0579; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Couchman G, 2014, NEUROPSYCHOL REHABIL, V24, P809, DOI 10.1080/09602011.2014.912957; Damianakis T, 2016, J HEAD TRAUMA REHAB, V31, pE12, DOI 10.1097/HTR.0000000000000178; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Gerber GJ, 2015, BRAIN INJURY, V29, P722, DOI 10.3109/02699052.2015.1004745; Geurtsen GJ, 2011, BRAIN INJURY, V25, P691, DOI 10.3109/02699052.2011.574675; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Kreutzer JS, 2015, J HEAD TRAUMA REHAB, V30, P249, DOI 10.1097/HTR.0000000000000144; Kreutzer JS, 2010, NEUROREHABILITATION, V27, P19, DOI 10.3233/NRE-2010-0578; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Man D, 1999, BRAIN INJURY, V13, P433, DOI 10.1080/026990599121485; Moriarty H, 2016, PM&R, V8, P495, DOI 10.1016/j.pmrj.2015.10.008; National Health and Medical Research Council (NHMRC), 2009, NHMRC ADD LEV EV GRA; Palmisano B, 2007, BEHAV CHANGE, V24, P36, DOI 10.1375/bech.24.1.36; Powell JM, 2016, J HEAD TRAUMA REHAB, V31, P180, DOI 10.1097/HTR.0000000000000167; Reddy NK, 2012, DISABIL CBR INCLUSIV, V23, P137; Rigby H, 2009, INT J STROKE, V4, P285, DOI 10.1111/j.1747-4949.2009.00289.x; Rivera P, 2003, TOP SPINAL CORD INJ, V9, P53, DOI [DOI 10.1310/G82F-BR2R-T69L-3QX8, 10.1310/G82F-BR2R-T69L-3QX8]; Schulz R, 2009, REHABIL PSYCHOL, V54, P1, DOI 10.1037/a0014932; Sheija A, 2005, INT J REHABIL RES, V28, P379, DOI 10.1097/00004356-200512000-00015; Smith MJ, 2006, J HEAD TRAUMA REHAB, V21, P76, DOI 10.1097/00001199-200601000-00008; Teasdale TW, 2009, J NEUROL NEUROSUR PS, V80, P781, DOI 10.1136/jnnp.2008.162966	31	38	38	0	24	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2017	31	1					45	60		10.1177/0269215516639357			16	Rehabilitation	Rehabilitation	EF5XJ	WOS:000390402800006	27009058				2021-06-18	
J	Shahim, P; Linemann, T; Inekci, D; Karsdal, MA; Blennow, K; Tegner, Y; Zetterberg, H; Henriksen, K				Shahim, Pashtun; Linemann, Thomas; Inekci, Dilek; Karsdal, Morten Asser; Blennow, Kaj; Tegner, Yelverton; Zetterberg, Henrik; Henriksen, Kim			Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players	JOURNAL OF NEUROTRAUMA			English	Article						ice hockey; serum biomarkers; sports-related concussion; tau fragments	TRAUMATIC BRAIN-INJURY; BIOMARKERS	The diagnosis of sports-related concussion is mainly based on subjective clinical symptoms and neuropsychological tests. Therefore, reliable brain injury biomarkers to assess when it is safe to return to play are highly desirable. The overall objective of this study was to evaluate the utility of two newly described tau fragments for diagnosis and prognosis of sports-related concussions. This multi-center prospective cohort study involved all 12 teams of the top professional ice hockey league in Sweden. A total of 288 players consented to participate in the study. Thirty-five players sustained concussions, of whom 28 underwent repeated blood samplings at 1, 12, 36, and 144 h after the trauma, or when the player returned to play (7 to > 90 days). There was no significant increase in the levels of Tau-A in post-concussion samples compared with preseason values. However, serum levels of Tau-C were significantly higher in post-concussion samples compared with preseason. Further, levels of Tau-A correlated with the duration of post-concussive symptoms. Tau-A in serum, which is newly discovered biomarker, could be used to predict when it is safe to return to play after a sports-related concussion.	[Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden; [Linemann, Thomas; Inekci, Dilek; Karsdal, Morten Asser; Henriksen, Kim] Nord Biosci, Biomarkers & Res, Herlev, Denmark; [Tegner, Yelverton] Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, Lulea, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Queen Sq, London, England	Henriksen, K (corresponding author), Nord Biosci AS, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.	kh@nordicbioscience.com		Karsdal, Morten/0000-0001-5026-8740; Tegner, Yelverton/0000-0003-3628-0705	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Centrum for Idrottsforskning; Emil and Maria Palm Foundation; Danish Research Foundation (Den Danske Forskningsfond); Danish Ministry for Science, Technology, and Education	We thank all study participants and the teams for contributing to this research. The study was supported by grants from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Centrum for Idrottsforskning, and the Emil and Maria Palm Foundation. Kim Henriksen and Thomas Linemann have received funding from the Danish Research Foundation (Den Danske Forskningsfond). Dilek Inekci is funded by the Danish Ministry for Science, Technology, and Education.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Henriksen K, 2015, J ALZHEIMERS DIS, V43, P1331, DOI 10.3233/JAD-140984; Henriksen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064990; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Wang Y, 2012, Int J Alzheimers Dis, V2012, P209409, DOI 10.1155/2012/209409; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399	17	38	39	1	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2016	33	22					1995	1999		10.1089/neu.2014.3741			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EC4OL	WOS:000388112300002	25621407				2021-06-18	
J	Myer, GD; Yuan, WH; Foss, KDB; Thomas, S; Smith, D; Leach, J; Kiefer, AW; Dicesare, C; Adams, J; Gubanich, PJ; Kitchen, K; Schneider, DK; Braswell, D; Krueger, D; Altaye, M				Myer, Gregory D.; Yuan, Weihong; Foss, Kim D. Barber; Thomas, Staci; Smith, David; Leach, James; Kiefer, Adam W.; Dicesare, Chris; Adams, Janet; Gubanich, Paul J.; Kitchen, Katie; Schneider, Daniel K.; Braswell, Daniel; Krueger, Darcy; Altaye, Mekibib			Analysis of head impact exposure and brain microstructure response in a season-long application of a jugular vein compression collar: a prospective, neuroimaging investigation in American football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; DIFFUSION TENSOR; WHITE-MATTER; PROTECTIVE EQUIPMENT; RUGBY UNION; INJURY; EPIDEMIOLOGY; LOCALIZATION; ADOLESCENTS	Background Historical approaches to protect the brain from outside the skull (eg, helmets and mouthpieces) have been ineffective in reducing internal injury to the brain that arises from energy absorption during sports-related collisions. We aimed to evaluate the effects of a neck collar, which applies gentle bilateral jugular vein compression, resulting in cerebral venous engorgement to reduce head impact energy absorption during collision. Specifically, we investigated the effect of collar wearing during head impact exposure on brain microstructure integrity following a competitive high school American football season. Methods A prospective longitudinal controlled trial was employed to evaluate the effects of collar wearing (n=32) relative to controls (CTRL; n=30) during one competitive football season (age: 17.04 +/- 0.67 years). Impact exposure was collected using helmet sensors and white matter (WM) integrity was quantified based on diffusion tensor imaging (DTI) serving as the primary outcome. Results With similar overall g-forces and total head impact exposure experienced in the two study groups during the season (p>0.05), significant preseason to postseason changes in mean diffusivity, axial diffusivity and radial diffusivity in the WM integrity were noted in the CTRL group (corrected p<0.05) but not in the collar group (p>0.05). The CTRL group demonstrated significantly larger preseason to postseason DTI change in multiple WM regions compared with the collar group (corrected p<0.05). Discussion Reduced WM diffusivity alteration was noted in participants wearing a neck collar after a season of competitive football. Collar wearing may have provided a protective effect against brain microstructural changes after repetitive head impacts.	[Myer, Gregory D.; Foss, Kim D. Barber; Thomas, Staci; Smith, David; Kiefer, Adam W.; Dicesare, Chris; Gubanich, Paul J.; Kitchen, Katie; Schneider, Daniel K.; Braswell, Daniel] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Foss, Kim D. Barber; Thomas, Staci; Kiefer, Adam W.; Dicesare, Chris; Kitchen, Katie; Schneider, Daniel K.; Braswell, Daniel] Cincinnati Childrens Hosp Med Ctr, SPORT Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Kiefer, Adam W.; Gubanich, Paul J.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Penn, Dept Orthopaed, Philadelphia, PA 19104 USA; [Myer, Gregory D.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Myer, Gregory D.] Univ Cincinnati, Dept Orthopaed Surg, Cincinnati, OH USA; [Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Yuan, Weihong] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Foss, Kim D. Barber] Mt St Joseph Univ, Dept Athlet Training, Div Hlth Sci, Cincinnati, OH USA; [Foss, Kim D. Barber] Rocky Mt Univ Hlth Profess, Provo, UT USA; [Leach, James; Adams, Janet] Cincinnati Childrens Hosp Med Ctr, Div Radiol, Cincinnati, OH 45229 USA; [Kiefer, Adam W.] Univ Cincinnati, Dept Psychol, Ctr Cognit Act & Percept, Cincinnati, OH 45221 USA; [Schneider, Daniel K.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Krueger, Darcy] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA	Myer, GD (corresponding author), Cincinnati Childrens Hosp, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	Greg.Myer@cchmc.org	DiCesare, Christopher/AAA-3327-2021; Kiefer, Adam/F-1756-2018; DiCesare, Christopher/ABH-9573-2020; Myer, Gregory/H-6572-2016	DiCesare, Christopher/0000-0002-6576-4904; Myer, Gregory/0000-0002-9983-8422	Q30 Innovations [FP00009108]	Q30 Innovations (Funding Proposal: FP00009108).	Babcock L, 2015, J PEDIATR REHAB MED, V8, P285, DOI 10.3233/PRM-150347; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Fridman L, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-30; GILLAND O, 1969, AMER J ROENTGENOL RA, V106, P369, DOI 10.2214/ajr.106.2.369; Hatt A, 2015, AM J NEURORADIOL, V36, P1971, DOI 10.3174/ajnr.A4361; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Leach JL, 2013, AM SOC NEUR ANN M; Lloyd J, 2016, J NEUROSURG, V124, P667, DOI 10.3171/2014.11.JNS141742; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P575; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McGuine T, 2013, ORTHOP J SPORTS MED, P1; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mongan P, 2013, PRACTICAL APPROACH N; Mori S., 2005, AM SOC NEURORADIOLOG; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Myer GD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00074; Myer GD, 2014, J ORTHOP SPORT PHYS, V44, P164, DOI 10.2519/jospt.2014.5298; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schneider DK, 2017, BRIT J SPORT MED, V51, P1473, DOI 10.1136/bjsports-2015-095645; Smith DW, 2013, ORTHOP J SPORTS MED, V1, DOI 10.1177/2325967113511588; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Winters Jackson, 2014, General Dentistry, V62, P34; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	57	38	39	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2016	50	20					1276	+		10.1136/bjsports-2016-096134			11	Sport Sciences	Sport Sciences	DY7AZ	WOS:000385282900015	27307271	Green Published, Other Gold			2021-06-18	
J	Bisogno, T; Oddi, S; Piccoli, A; Fazio, D; Maccarrone, M				Bisogno, Tiziana; Oddi, Sergio; Piccoli, Alessandra; Fazio, Domenico; Maccarrone, Mauro			Type-2 cannabinoid receptors in neurodegeneration	PHARMACOLOGICAL RESEARCH			English	Article						Type-2 cannabinoid receptors; Neurodegeneration; Endocannabinoid system	IMPROVES FUNCTIONAL RECOVERY; ACID AMIDE HYDROLASE; CB2 RECEPTOR; ALZHEIMERS-DISEASE; ENDOCANNABINOID SYSTEM; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; BASAL GANGLIA; IN-VIVO; INFLAMMATORY RESPONSES	Based on its wide expression in immune cells, type-2 cannabinoid (CB2) receptors were traditionally thought to act as "peripheral receptors" with an almost exclusively immunomodulatory function. However, their recent identification in mammalian brain areas, as well as in distinct neuronal cells, has opened the way to a re-consideration of CB2 signaling in the context of brain pathophysiology, synaptic plasticity and neuroprotection. To date, accumulated evidence from several independent preclinical studies has offered new perspectives on the possible involvement of CB2 signaling in brain and spinal cord traumatic injury, as well as in the most relevant neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and Huntington's chorea. Here, we will review available information on CB2 in these disease conditions, along with data that support also its therapeutic potential to treat them. (C) 2016 Elsevier Ltd. All rights reserved.	[Bisogno, Tiziana] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Pozzuoli, Italy; [Bisogno, Tiziana; Piccoli, Alessandra; Fazio, Domenico; Maccarrone, Mauro] Campus Biomed Univ Rome, Dept Med, Via Alvaro del Portillo 21, I-00128 Rome, Italy; [Oddi, Sergio] Univ Teramo, Fac Vet Med, Via Balzarini 1, I-64100 Teramo, Italy; [Oddi, Sergio; Maccarrone, Mauro] IRCCS Santa Lucia Fdn, European Ctr Brain Res, Via Fosso di Fiorano 64, I-00143 Rome, Italy	Maccarrone, M (corresponding author), Campus Biomed Univ Rome, Dept Med, Via Alvaro del Portillo 21, I-00128 Rome, Italy.	m.maccarrone@unicampus.it	Oddi, Sergio/B-6668-2009; Maccarrone, Mauro/K-5398-2012	Oddi, Sergio/0000-0002-6217-698X; Maccarrone, Mauro/0000-0002-3990-2963; Fazio, Domenico/0000-0002-1235-9999	italian Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN)Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN) [2010BN3MXM_004]	This investigation was partly supported by the italian Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN 2010-2011 2010BN3MXM_004 project to TB and MM).	Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arevalo-Martin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049057; Arevalo-Martin A, 2010, NEUROBIOL DIS, V38, P304, DOI 10.1016/j.nbd.2010.02.002; Aso E, 2013, J ALZHEIMERS DIS, V35, P847, DOI 10.3233/JAD-130137; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Baty Darric E, 2008, Clin Neurosurg, V55, P172; Bedse G, 2015, J ALZHEIMERS DIS, V43, P1115, DOI 10.3233/JAD-141635; Benito C, 2003, J NEUROSCI, V23, P11136; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Bisogno T, 2010, CNS NEUROL DISORD-DR, V9, P564, DOI 10.2174/187152710793361568; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Bonnet AE, 2015, AGING DIS, V6, P400, DOI 10.14336/AD.2015.0617; Bouchard J, 2012, J NEUROSCI, V32, P18259, DOI 10.1523/JNEUROSCI.4008-12.2012; Brusco A, 2008, ANN NY ACAD SCI, V1139, P450, DOI 10.1196/annals.1432.037; Carrier EJ, 2004, MOL PHARMACOL, V65, P999, DOI 10.1124/mol.65.4.999; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; Chiarlone A, 2014, P NATL ACAD SCI USA, V111, P8257, DOI 10.1073/pnas.1400988111; Chiurchiu V, 2015, IMMUNOLOGY, V144, P352, DOI 10.1111/imm.12441; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; Concannon RM, 2015, EXP NEUROL, V269, P133, DOI 10.1016/j.expneurol.2015.04.007; Garcia MC, 2015, NEUROSCI LETT, V587, P1, DOI 10.1016/j.neulet.2014.12.003; den Boon FS, 2014, PFLUG ARCH EUR J PHY, V466, P2257, DOI 10.1007/s00424-014-1502-6; den Boon FS, 2012, P NATL ACAD SCI USA, V109, P3534, DOI 10.1073/pnas.1118167109; Depino AM, 2003, EUR J NEUROSCI, V18, P2731, DOI 10.1111/j.1460-9568.2003.03014.x; Di Marzo V, 2000, FASEB J, V14, P1432, DOI 10.1096/fj.14.10.1432; Dowie MJ, 2014, J CHEM NEUROANAT, V59-60, P62, DOI 10.1016/j.jchemneu.2014.06.004; Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Esposito G, 2007, J PHARMACOL EXP THER, V322, P1144, DOI 10.1124/jpet.107.121566; Fernandez-Espejo E, 2005, NEUROBIOL DIS, V18, P591, DOI 10.1016/j.nbd.2004.10.015; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Fernandez-Ruiz J, 2015, NEUROTHERAPEUTICS, V12, P793, DOI 10.1007/s13311-015-0381-7; Fernandez-Ruiz J, 2015, HANDB EXP PHARMACOL, V231, P233, DOI 10.1007/978-3-319-20825-1_8; Fernandez-Ruiz J, 2010, CNS NEUROSCI THER, V16, pe72, DOI 10.1111/j.1755-5949.2010.00144.x; Fernandez-Ruiz J, 2009, BRIT J PHARMACOL, V156, P1029, DOI 10.1111/j.1476-5381.2008.00088.x; Fezza F, 2014, MOLECULES, V19, P17078, DOI 10.3390/molecules191117078; Franklin A, 2003, J NEUROSCI, V23, P7767; Garcia C, 2011, BRIT J PHARMACOL, V163, P1495, DOI 10.1111/j.1476-5381.2011.01278.x; Garcia-Ovejero D, 2009, NEUROBIOL DIS, V33, P57, DOI 10.1016/j.nbd.2008.09.015; Giacobini E, 2013, NAT REV NEUROL, V9, P677, DOI 10.1038/nrneurol.2013.223; GLASS M, 1993, NEUROSCIENCE, V56, P523, DOI 10.1016/0306-4522(93)90352-G; Glass M, 2000, NEUROSCIENCE, V97, P505, DOI 10.1016/S0306-4522(00)00008-7; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Gomez-Galvez Y, 2016, PROG NEURO-PSYCHOPH, V64, P200, DOI 10.1016/j.pnpbp.2015.03.017; Gonzalez S, 2006, BRAIN RES, V1073, P209, DOI 10.1016/j.brainres.2005.12.014; Graham DI, 1996, ACT NEUR S, V66, P96; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Gruenblatt E, 2007, J ALZHEIMERS DIS, V12, P291; Gubellini P, 2002, J NEUROSCI, V22, P6900; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Heller Joshua E, 2009, Clin Neurosurg, V56, P84; Hoang T, 2009, FREE RADICAL BIO MED, V47, P1049, DOI 10.1016/j.freeradbiomed.2009.07.013; Hoban DB, 2013, BRAIN BEHAV IMMUN, V27, P91, DOI 10.1016/j.bbi.2012.10.001; Horti AG, 2010, BIOORGAN MED CHEM, V18, P5202, DOI 10.1016/j.bmc.2010.05.058; Howlett AC, 2005, HANDB EXP PHARMACOL, V168, P53; Iannotti FA, 2016, PROG LIPID RES, V62, P107, DOI 10.1016/j.plipres.2016.02.002; Janefjord E, 2014, CELL MOL NEUROBIOL, V34, P31, DOI 10.1007/s10571-013-9984-x; Kelsey JE, 2009, BEHAV BRAIN RES, V203, P304, DOI 10.1016/j.bbr.2009.04.035; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Koppel J, 2013, MOL MED, V19, P357, DOI 10.2119/molmed.2013.00140; Lastres-Becker I, 2001, EUR J NEUROSCI, V14, P1827, DOI 10.1046/j.0953-816x.2001.01812.x; Lastres-Becker I, 2002, NEUROTOX RES, V4, P601, DOI 10.1080/10298420290030514; Latini L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.364; Li Y, 2015, NEUROSCIENCE, V311, P253, DOI 10.1016/j.neuroscience.2015.10.041; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Moreno JLLS, 2016, J NEUROL, V263, P1390, DOI 10.1007/s00415-016-8145-9; Lu HC, 2016, BIOL PSYCHIAT, V79, P516, DOI 10.1016/j.biopsych.2015.07.028; Maccarrone M., 2015, TRENDS PHARMACOL SCI, V36; Maccarrone M, 2007, PROG NEUROBIOL, V81, P349, DOI 10.1016/j.pneurobio.2006.11.006; Maccarrone M, 2010, TRENDS BIOCHEM SCI, V35, P601, DOI 10.1016/j.tibs.2010.05.008; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Malfitano AM, 2014, SEMIN IMMUNOL, V26, P369, DOI 10.1016/j.smim.2014.04.002; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin-Moreno AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-8; Martin-Moreno AM, 2011, MOL PHARMACOL, V79, P964, DOI 10.1124/mol.111.071290; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; McIntosh TK, 1996, LAB INVEST, V74, P315; Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; Molina-Holgado F, 2002, J NEUROSCI RES, V67, P829, DOI 10.1002/jnr.10165; More SV, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0012-0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paradisi A, 2006, CURR DRUG TARGETS, V7, P1539, DOI 10.2174/1389450110607011539; Pisani A, 2005, ANN NEUROL, V57, P777, DOI 10.1002/ana.20462; Price DA, 2009, EUR J NEUROSCI, V29, P2177, DOI 10.1111/j.1460-9568.2009.06764.x; Pryce G, 2015, J NEUROIMMUNE PHARM, V10, P281, DOI 10.1007/s11481-014-9575-8; Rafii MS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0297-4; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Romero J, 2000, LIFE SCI, V66, P485, DOI 10.1016/S0024-3205(99)00618-9; Sagredo O., 2012, CNS DRUG DISCOV, V7, P41, DOI DOI 10.2174/157488912798842278; Sagredo O, 2007, MOL NEUROBIOL, V36, P82, DOI 10.1007/s12035-007-0004-3; Sagredo O, 2009, GLIA, V57, P1154, DOI 10.1002/glia.20838; Savonenko AV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129618; Schmole AC, 2015, NEUROBIOL AGING, V36, P710, DOI 10.1016/j.neurobiolaging.2014.09.019; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Sheng WS, 2005, GLIA, V49, P211, DOI 10.1002/glia.20108; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Solas M, 2013, NEUROBIOL AGING, V34, P805, DOI 10.1016/j.neurobiolaging.2012.06.005; Tabrizi MA, 2016, CHEM REV, V116, P519, DOI 10.1021/acs.chemrev.5b00411; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Valdeolivas S, 2015, NEUROTHERAPEUTICS, V12, P185, DOI 10.1007/s13311-014-0304-z; Van der Stelt M, 2006, CELL MOL LIFE SCI, V63, P1410, DOI 10.1007/s00018-006-6037-3; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Walsh S, 2011, NEUROSCIENCE, V175, P251, DOI 10.1016/j.neuroscience.2010.12.005; Walter L, 2003, J NEUROSCI, V23, P1398; Wotherspoon G, 2005, NEUROSCIENCE, V135, P235, DOI 10.1016/j.neuroscience.2005.06.009; Wu J, 2013, NEUROBIOL AGING, V34, P791, DOI 10.1016/j.neurobiolaging.2012.06.011	117	38	40	0	16	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	SEP	2016	111						721	730		10.1016/j.phrs.2016.07.021			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DY0JV	WOS:000384784000069	27450295				2021-06-18	
J	Raheja, A; Sinha, S; Samson, N; Bhoi, S; Subramanian, A; Sharma, P; Sharma, BS				Raheja, Amol; Sinha, Sumit; Samson, Neha; Bhoi, Sanjeev; Subramanian, Arulselvi; Sharma, Pushpa; Sharma, Bhawani Shankar			Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled Phase II clinical trial	JOURNAL OF NEUROSURGERY			English	Article						glial fibrillary acidic protein; interleukin-6; progesterone; predictors of outcome; serum biomarkers; severe traumatic brain injury; trauma	NEURON-SPECIFIC ENOLASE; CRITICALLY-ILL; PROGESTERONE; INTERLEUKIN-6; PROTEIN; S100B; NEUROINFLAMMATION; MARKERS; IL-6	OBJECTIVE There has been increased interest in the potential importance of biochemical parameters as predictors of outcome in severe traumatic brain injury (sTBI). METHODS Of 107 patients with sTBI (age 18-65 years with a Glasgow Coma Scale score of 4-8 presenting within 8 hours after injury) who were randomized for a placebo-controlled Phase II trial of progesterone with or without hypothermia, the authors serially analyzed serum biomarkers (S100-B, glial fibrillary acidic protein [GFAP], neuron-specific enolase [NSE], tumor necrosis factor-alpha, interleukin-6 [IL-6], estrogen [Eg], and progesterone [Pg]). This analysis was performed using the sandwich enzyme-linked immunosorbent assay technique at admission and 7 days later for 86 patients, irrespective of assigned group. The long-term predictive values of serum biomarkers for dichotomized Glasgow Outcome Scale (GOS) score, functional independence measure, and survival status at 6 and 12 months were analyzed using an adjusted binary logistic regression model and receiver operating characteristic curve. RESULTS A favorable GOS score (4-5) at 1 year was predicted by higher admission IL-6 (above 108.36 pg/ml; area under the curve [AUC] 0.69, sensitivity 52%, and specificity 78.6%) and Day 7 Pg levels (above 3.15 ng/ml; AUC 0.79, sensitivity 70%, and specificity 92.9%). An unfavorable GOS score (1-3) at 1 year was predicted by higher Day 7 GFAP levels (above 9.50 ng/ml; AUC 0.82, sensitivity 78.6%, and specificity 82.4%). Survivors at 1 year had significantly higher Day 7 Pg levels (above 3.15 ng/ml; AUC 0.78, sensitivity 66.7%, and specificity 90.9%). Nonsurvivors at 1 year had significantly higher Day 7 GFAP serum levels (above 11.14 ng/ml; AUC 0.81, sensitivity 81.8%, and specificity 88.9%) and Day 7 IL-6 serum levels (above 71.26 pg/ml; AUC 0.87, sensitivity 81.8%, and specificity 87%). In multivariate logistic regression analysis, independent predictors of outcome at 1 year were serum levels of Day 7 Pg (favorable GOS OR 3.24, CI 1.5-7, p = 0.003; and favorable survival OR 2, CI 1.2-3.5, p = 0.01); admission IL-6 (favorable GOS OR 1.04, CI 1.00-1.08, p = 0.04); and Day 7 GFAP (unfavorable GOS OR 0.79, CI 0.65-0.95, p = 0.01; and unfavorable survival-OR 0.80, CI 0.66-0.96, p = 0.01). CONCLUSIONS Serial Pg, GFAP, and IL-6 monitoring could aid in prognosticating outcomes in patients with acute sTBI. A cause and effect relationship or a mere association of these biomarkers to outcome needs to be further studied for better understanding of the pathophysiology of sTBI and for choosing potential therapeutic targets.	[Raheja, Amol; Sinha, Sumit; Samson, Neha; Sharma, Bhawani Shankar] All India Inst Med Sci, Dept Neurosurg, New Delhi, India; [Bhoi, Sanjeev] All India Inst Med Sci, Dept Emergency Med, New Delhi, India; [Subramanian, Arulselvi] All India Inst Med Sci, Dept Lab Med, New Delhi, India; [Sharma, Pushpa] Uniformed Serv Univ Hlth Sci, Dept Anaesthesiol, Bethesda, MD 20814 USA	Sinha, S (corresponding author), All India Inst Med Sci, Dept Neurosurg & Gamma Knife, Neurosci Ctr, F25,Aiims Campus, New Delhi 110029, India.	sumitneuro@gmail.com	Subramanian, arulselvi/AAG-1670-2020; Sharma, Pushpa/AAY-8756-2020	Subramanian, arulselvi/0000-0001-7797-6683; 	Department of Biotechnology, Ministry of Science and Technology, India	This study was funded by the Department of Biotechnology, Ministry of Science and Technology, India.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; SCHAARSCHMIDT H, 1994, STROKE, V25, P558, DOI 10.1161/01.STR.25.3.558; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698	37	38	39	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2016	125	3					631	641		10.3171/2015.6.JNS15674			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DT8YS	WOS:000381782300014	26722854	Bronze			2021-06-18	
J	Wang, WZ; Li, HG; Yu, JT; Hong, M; Zhou, J; Zhu, L; Wang, Y; Luo, M; Xia, Z; Yang, ZJ; Tang, T; Ren, P; Huang, X; Wang, J				Wang, Wenzhu; Li, Haigang; Yu, Jintao; Hong, Michael; Zhou, Jing; Zhu, Lin; Wang, Yang; Luo, Min; Xia, Zian; Yang, Zeng-Jin; Tang, Tao; Ren, Ping; Huang, Xi; Wang, Jian			Protective Effects of Chinese Herbal Medicine Rhizoma drynariae in Rats After Traumatic Brain Injury and Identification of Active Compound	MOLECULAR NEUROBIOLOGY			English	Article						Microglia; Rhizoma drynariae; Traumatic brain injury; UPLC	CHAIHU-SHUGAN-SAN; INTRACEREBRAL HEMORRHAGE; SIGNALING PATHWAY; MERANZIN HYDRATE; HEAD-INJURY; MICE; CELL; TRANSPLANTATION; PROGESTERONE; NRF2	Traumatic brain injury (TBI) is a leading cause of death and disability in the USA. Effective therapeutic strategies for TBI are needed, and increasing attention is turning toward traditional herbal medicine. Rhizoma drynariae is a traditional Chinese medicine that has immunomodulatory and anti-inflammatory effects. Here, using the controlled cortical impact model of TBI in rats, we examined whether oral administration of R. drynariae can reduce TBI-induced brain injury in rats. We also identified the likely active compound among its four major phytochemicals in decoction. We found that post-treatment with R. drynariae decreased brain lesion volume, improved neurologic and cognitive function, and reduced anxiety- and depression-like behaviors. These changes were accompanied by reduced blood levels of IL-6 and increased IL-10. R. drynariae treatment also reversed the TBI-induced decrease in blood monocyte numbers and percentage of blood CD3 and CD4 T lymphocytes while inhibiting microglial/macrophage activation. Furthermore, by using ultra performance liquid chromatography and comparing retention times with authentic standards, we identified eriodictyol as the putative active compound of R. drynariae extract in the blood of rats with TBI. These novel findings indicate that the traditional Chinese herbal medicine R. drynariae protects brain against TBI-induced brain injury, possibly via immune-promoting, anti-inflammatory, and neuroprotective effects. Eriodictyol could be its active compound.	[Wang, Wenzhu; Li, Haigang; Zhou, Jing; Zhu, Lin; Wang, Yang; Luo, Min; Xia, Zian; Tang, Tao; Huang, Xi] Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Wang, Wenzhu; Hong, Michael; Yang, Zeng-Jin; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA; [Yu, Jintao] Cent S Univ, Xiangya Hosp, Dept Otolaryngol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Ren, Ping] Cent S Univ, Xiangya Hosp, Off Good Clin Practice, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Huang, Xi] Nanjing Univ Tradit Chinese Med, Inst TCM Related Depress Comorbid, 138 Xianling Rd, Nanjing 210064, Jiangsu, Peoples R China	Huang, X (corresponding author), Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.; Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA.; Huang, X (corresponding author), Nanjing Univ Tradit Chinese Med, Inst TCM Related Depress Comorbid, 138 Xianling Rd, Nanjing 210064, Jiangsu, Peoples R China.	huangx59@163.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Li, Hai-Gang/0000-0003-2346-6527	NSFCNational Natural Science Foundation of China (NSFC) [81072967]; National Key Clinical Specialist Vocational School of TCM encephalopathy; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]; China Scholarship Council Joint PhD Training award (CSC)China Scholarship Council [201406370078]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER	This work was supported by grants from NSFC (No. 81072967), the fund from National Key Clinical Specialist Vocational School of TCM encephalopathy, and NIH (R01NS078026, R01AT007317). Wenzhu Wang is the recipient of the China Scholarship Council Joint PhD Training award (CSC NO. 201406370078). We thank Jiarui Wang and Claire Levine for assistance with this manuscript.	An HJ, 2012, NAT PROD COMMUN, V7, P905; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Anuja GI, 2010, J ETHNOPHARMACOL, V132, P456, DOI 10.1016/j.jep.2010.08.038; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Fogaca MV, 2015, PHARMACOL BIOCHEM BE, V129, P7, DOI 10.1016/j.pbb.2014.11.013; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Gao Y, 2008, CHIN J MED CHEM, V8, P284; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Huang W, 2012, PHARMAZIE, V67, P586, DOI 10.1691/ph.2012.1142; Jing X, 2013, TOXICOL APPL PHARM, V273, P672, DOI 10.1016/j.taap.2013.10.018; Li M, 2015, CHINESE MED J-PEKING, V128, P1072, DOI 10.4103/0366-6999.155094; Lou HY, 2012, NEUROCHEM INT, V61, P251, DOI 10.1016/j.neuint.2012.05.013; Ma HD, 2013, CLIN REV ALLERG IMMU, V44, P229, DOI 10.1007/s12016-012-8332-0; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Qiu XJ, 2011, J ETHNOPHARMACOL, V137, P205, DOI 10.1016/j.jep.2011.05.009; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Shang ZhenPing, 2010, Practical Pharmacy and Clinical Remedies, V13, P262; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Taylor AE, 2011, BRIT J SPORT MED, V45, P1243, DOI 10.1136/bjsports-2011-090024; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Vermeij JD, 2013, J NEUROTRAUM, V30, P2073, DOI 10.1089/neu.2013.3060; Wang HC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/720870; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang JP, 2015, BRAIN BEHAV IMMUN, V45, P98, DOI 10.1016/j.bbi.2014.12.015; Wang JP, 2015, BRAIN BEHAV IMMUN, V43, P172, DOI 10.1016/j.bbi.2014.07.022; Wang JP, 2014, BEHAV BRAIN RES, V265, P171, DOI 10.1016/j.bbr.2014.02.033; Wang WZ, 2012, J ETHNOPHARMACOL, V142, P300, DOI 10.1016/j.jep.2012.04.031; Wang Y, 2012, CHIN J INTEGR MED, V18, P690, DOI 10.1007/s11655-012-1053-7; Wang Y, 2012, CURR TOP MED CHEM, V12, P1356, DOI 10.2174/156802612801319034; Warner N, 2010, CURR OPIN OPHTHALMOL, V21, P459, DOI 10.1097/ICU.0b013e32833f00c9; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Xie Y, 2013, NEUROPHARMACOLOGY, V67, P318, DOI 10.1016/j.neuropharm.2012.10.003; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang YJ, 2011, BRAIN RES BULL, V86, P222, DOI 10.1016/j.brainresbull.2011.07.002; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	48	38	38	0	34	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	SEP	2016	53	7					4809	4820		10.1007/s12035-015-9385-x			12	Neurosciences	Neurosciences & Neurology	DS3JI	WOS:000380678600043	26334614	Green Accepted			2021-06-18	
J	Hwang, J; Castelli, DM; Gonzalez-Lima, F				Hwang, Jungyun; Castelli, Darla M.; Gonzalez-Lima, F.			Cognitive enhancement by transcranial laser stimulation and acute aerobic exercise	LASERS IN MEDICAL SCIENCE			English	Article						Low-level laser therapy; Photobiomodulation; Cognitive enhancement; Transcranial laser stimulation; Acute aerobic exercise	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; WORKING-MEMORY; SLEEP-DEPRIVATION; INFRARED LIGHT; PERFORMANCE; LEVEL; THERAPY; TASK; MECHANISMS	This is the first randomized, controlled study comparing the cognitive effects of transcranial laser stimulation and acute aerobic exercise on the same cognitive tasks. We examined whether transcranial infrared laser stimulation of the prefrontal cortex, acute high-intensity aerobic exercise, or the combination may enhance performance in sustained attention and working memory tasks. Sixty healthy young adults were randomly assigned to one of the following four treatments: (1) low-level laser therapy (LLLT) with infrared laser to two forehead sites while seated (total 8 min, 1064 nm continuous wave, 250 mW/cm(2), 60 J/cm(2) per site of 13.6 cm(2)); (2) acute exercise (EX) of high-intensity (total 20 min, with 10-min treadmill running at 85-90 % VO(2)max); (3) combined treatment (LLLT + EX); or (4) sham control (CON). Participants were tested for prefrontal measures of sustained attention with the psychomotor vigilance task (PVT) and working memory with the delayed match-to-sample task (DMS) before and after the treatments. As compared to CON, both LLLT and EX reduced reaction time in the PVT [F(1.56) = 4.134, p = 0.01, eta (2) = 0.181] and increased the number of correct responses in the DMS [F(1.56) = 4.690, p = 0.005, eta (2) = 0.201], demonstrating a significant enhancing effect of LLLT and EX on cognitive performance. LLLT + EX effects were similar but showed no significantly greater improvement on PVT and DMS than LLLT or EX alone. The transcranial infrared laser stimulation and acute aerobic exercise treatments were similarly effective for cognitive enhancement, suggesting that they augment prefrontal cognitive functions similarly.	[Hwang, Jungyun; Castelli, Darla M.] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA; [Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA; [Gonzalez-Lima, F.] Univ Texas Austin, Inst Neurosci, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA	Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Dept Psychol, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA.; Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Inst Neurosci, 108 E Dean Keeton Stop A8000, Austin, TX 78712 USA.	gonzalezlima@utexas.edu	Castelli, Darla/G-1307-2015	Castelli, Darla/0000-0002-8862-578X; Hwang, Jungyun/0000-0001-7538-4414; Gonzalez-Lima, Francisco/0000-0001-9856-0775	FGL from an institutional research fellowship from the College of Liberals Arts of the University of Texas at Austin	The authors thank the Kinetic kidz laboratory members including Yen T. Chen, Jihoon Kim, Yeonhak Jung, Jeremy Setty, Hannah G. Calvert, and Elizabeth M. Glowacki for their help with data collection. The authors would also like to thank Dr. Douglas Barrett for their support with the cognitive tasks and Dr. R. Matthew Brothers and Dr. John L. Ivy for their support of our research. JH did this study in partial fulfillment of the requirements for a Ph.D. degree at The University of Texas at Austin. Research reported in this publication was supported by FGL from an institutional research fellowship from the College of Liberals Arts of the University of Texas at Austin. FGL holds the endowed George I. Sanchez Centennial Professorship in Liberal Arts and Sciences.	Ando S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063630; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Basner M, 2011, ACTA ASTRONAUT, V69, P949, DOI 10.1016/j.actaastro.2011.07.015; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Castaneda AE, 2008, J AFFECT DISORDERS, V106, P1, DOI 10.1016/j.jad.2007.06.006; Chang YK, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00156; Chudasama Y, 2010, ENCY PSYCHOPHARMACOL, VI, P372; Coles K, 2008, J SPORT SCI, V26, P333, DOI 10.1080/02640410701591417; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Drummond SPA, 2005, SLEEP, V28, P1059; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gligoroska Jasmina Pluncevic, 2012, Mater Sociomed, V24, P198, DOI 10.5455/msm.2012.24.198-202; Gonzalez-Lima F, 2014, BIOCHEM PHARMACOL, V88, P584, DOI 10.1016/j.bcp.2013.11.010; Gonzalez-Lima F, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00036; Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; Ide K, 2000, PROG NEUROBIOL, V61, P397, DOI 10.1016/S0301-0082(99)00057-X; Kamijo K, 2004, CLIN NEUROPHYSIOL, V115, P2693, DOI 10.1016/j.clinph.2004.06.016; Kaufman N. L., 1990, KAUFMAN BRIEF INTELL, P1; Lara T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088820; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099222; Maguire EA, 1999, BRAIN, V122, P1839, DOI 10.1093/brain/122.10.1839; Martins AQ, 2013, PSYCHOL SPORT EXERC, V14, P323, DOI 10.1016/j.psychsport.2012.11.010; MILLER LS, 1992, PHYSIOL BEHAV, V52, P839, DOI 10.1016/0031-9384(92)90359-A; Mueller ST, 2014, J NEUROSCI METH, V222, P250, DOI 10.1016/j.jneumeth.2013.10.024; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; Ogoh S, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12163; Ogoh S, 2009, J APPL PHYSIOL, V107, P1370, DOI 10.1152/japplphysiol.00573.2009; Picard M, 2014, P NATL ACAD SCI USA, V111, P7, DOI 10.1073/pnas.1321881111; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Scott JPR, 2006, PHYSIOL BEHAV, V87, P396, DOI 10.1016/j.physbeh.2005.11.009; Shansky RM, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00123; Sibley BA, 2007, J SPORT EXERCISE PSY, V29, P783, DOI 10.1123/jsep.29.6.783; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Yanagisawa H, 2010, NEUROIMAGE, V50, P1702, DOI 10.1016/j.neuroimage.2009.12.023; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	46	38	38	1	27	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-8921	1435-604X		LASER MED SCI	Lasers Med. Sci.	AUG	2016	31	6					1151	1160		10.1007/s10103-016-1962-3			10	Engineering, Biomedical; Surgery	Engineering; Surgery	DR4CQ	WOS:000379849500014	27220529				2021-06-18	
J	Loring, DW; Goldstein, FC; Chen, CQ; Drane, DL; Lah, JJ; Zhao, LP; Larrabee, GJ				Loring, David W.; Goldstein, Felicia C.; Chen, Chuqing; Drane, Daniel L.; Lah, James J.; Zhao, Liping; Larrabee, Glenn J.		Alzheimer's Dis Neuroimaging	False-Positive Error Rates for Reliable Digit Span and Auditory Verbal Learning Test Performance Validity Measures in Amnestic Mild Cognitive Impairment and Early Alzheimer Disease	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Performance validity test; False-positive rate; Test specificity; Reliable Digit Span; AVLT	MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; DETECTING POOR EFFORT; IQ-ADJUSTED NORMS; SYMPTOM VALIDITY; CLASSIFICATION ACCURACY; EFFORT INDICATORS; AGES 56; DEMENTIA; VALIDATION	Objective: The objective is to examine failure on three embedded performance validity tests [Reliable Digit Span (RDS), Auditory Verbal Learning Test (AVLT) logistic regression, and AVLT recognition memory] in early Alzheimer disease (AD; n = 178), amnestic mild cognitive impairment (MCI; n = 365), and cognitively intact age-matched controls (n = 206). Method: Neuropsychological tests scores were obtained from subjects participating in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Results: RDS failure using a a parts per thousand currency sign7 RDS threshold was 60/178 (34%) for early AD, 52/365 (14%) for MCI, and 17/206 (8%) for controls. A a parts per thousand currency sign6 RDS criterion reduced this rate to 24/178 (13%) for early AD, 15/365 (4%) for MCI, and 7/206 (3%) for controls. AVLT logistic regression probability of a parts per thousand yen.76 yielded unacceptably high false-positive rates in both clinical groups [early AD = 149/178 (79%); MCI = 159/365 (44%)] but not cognitively intact controls (13/206, 6%). AVLT recognition criterion of a parts per thousand currency sign9/15 classified 125/178 (70%) of early AD, 155/365 (42%) of MCI, and 18/206 (9%) of control scores as invalid, which decreased to 66/178 (37%) for early AD, 46/365 (13%) for MCI, and 10/206 (5%) for controls when applying a a parts per thousand currency sign5/15 criterion. Despite high false-positive rates across individual measures and thresholds, combining RDS a parts per thousand currency sign 6 and AVLT recognition a parts per thousand currency sign9/15 classified only 9/178 (5%) of early AD and 4/365 (1%) of MCI patients as invalid performers. Conclusions: Embedded validity cutoffs derived from mixed clinical groups produce unacceptably high false-positive rates in MCI and early AD. Combining embedded PVT indicators lowers the false-positive rate.	[Loring, David W.; Goldstein, Felicia C.; Drane, Daniel L.; Lah, James J.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Loring, David W.; Drane, Daniel L.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Chen, Chuqing] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Zhao, Liping] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA	Loring, DW (corresponding author), Emory Univ, Brain Hlth Ctr, 12 Execut Pk, Atlanta, GA 30329 USA.	dloring@emory.edu		Loring, David/0000-0003-2497-1074	Emory Alzheimer's Disease Research Center [NIH-NIA 5 P50 AG025688]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904, P50AG025688] Funding Source: NIH RePORTER	This work was also supported by the Emory Alzheimer's Disease Research Center (NIH-NIA 5 P50 AG025688).	Aisen PS, 2010, ALZHEIMERS DEMENT, V6, P239, DOI 10.1016/j.jalz.2010.03.006; Army Individual Test Battery, 1944, MAN DIR SCOR; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Bashem JR, 2014, CLIN NEUROPSYCHOL, V28, P851, DOI 10.1080/13854046.2014.927927; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Bondi MW, 2014, J INT NEUROPSYCH SOC, V20, P129, DOI 10.1017/S1355617714000010; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P1397, DOI 10.1080/13854046.2012.728627; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P83; Kaplan E., 1983, BOSTON NAMING TEST; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Kurland, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Loring DW, 2014, CLIN NEUROPSYCHOL, V28, P556, DOI 10.1080/13854046.2012.762552; Martinson BC, 2010, J PHYS ACT HEALTH, V7, P127, DOI 10.1123/jpah.7.1.127; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Mitrushina M., 2005, HDB NORMATIVE DATA N; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Schmidt M., 1996, REY AUDITORY VERBAL; Silverberg N, 2005, J CLIN EXP NEUROPSYC, V27, P907, DOI 10.1080/13803390490919326; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P280, DOI 10.1080/13854040590945229; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Straus S.E., 2010, EVIDENCE BASED MED P; Tierney M. C., 1994, PSYCHOL ASSESSMENT, V6, P129, DOI DOI 10.1037/1040-3590.6.2.129; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Whitney KA, 2015, ARCH CLIN NEUROPSYCH, V30, P130, DOI 10.1093/arclin/acu094; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	45	38	38	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2016	31	4					313	331		10.1093/arclin/acw014			19	Psychology, Clinical; Psychology	Psychology	DN9RG	WOS:000377417200004	27084732	Bronze, Green Published			2021-06-18	
J	Sykora, M; Czosnyka, M; Liu, XY; Donnelly, J; Nasr, N; Diedler, J; Okoroafor, F; Hutchinson, P; Menon, D; Smielewski, P				Sykora, Marek; Czosnyka, Marek; Liu, Xiuyun; Donnelly, Joseph; Nasr, Nathalie; Diedler, Jennifer; Okoroafor, Francois; Hutchinson, Peter; Menon, David; Smielewski, Peter			Autonomic Impairment in Severe Traumatic Brain Injury: A Multimodal Neuromonitoring Study	CRITICAL CARE MEDICINE			English	Article						autonomic; baroreflex; heart rate variability; intracranial pressure; outcome; traumatic brain injury	HEART-RATE-VARIABILITY; CEREBROVASCULAR PRESSURE REACTIVITY; CARDIOVASCULAR VARIABILITY; INTRACRANIAL HYPERTENSION; BAROREFLEX SENSITIVITY; POWER; FREQUENCY; CARE; TONE	Objectives: Autonomic impairment after acute traumatic brain injury has been associated independently with both increased morbidity and mortality. Links between autonomic impairment and increased intracranial pressure or impaired cerebral autoregulation have been described as well. However, relationships between autonomic impairment, intracranial pressure, impaired cerebral autoregulation, and outcome remain poorly explored. Using continuous measurements of heart rate variability and baroreflex sensitivity we aimed to test whether autonomic markers are associated with functional outcome and mortality independently of intracranial variables. Further, we aimed to evaluate the relationships between autonomic functions, intracranial pressure, and cerebral autoregulation. Design: Retrospective analysis of a prospective database. Setting: Neurocritical care unit in a university hospital. Subjects: Sedated patients with severe traumatic brain injury. Measurements and Main Results: Waveforms of intracranial pressure and arterial blood pressure, baseline Glasgow Coma Scale and 6 months Glasgow Outcome Scale were recorded. Baroreflex sensitivity was assessed every 10 seconds using a modified cross-correlational method. Frequency domain analyses of heart rate variability were performed automatically every 10 seconds from a moving 300 seconds of the monitoring time window. Mean values of baroreflex sensitivity, heart rate variability, intracranial pressure, arterial blood pressure, cerebral perfusion pressure, and impaired cerebral autoregulation over the entire monitoring period were calculated for each patient. Two hundred and sixty-two patients with a median age of 36 years entered the analysis. The median admission Glasgow Coma Scale was 6, the median Glasgow Outcome Scale was 3, and the mortality at 6 months was 23%. Baroreflex sensitivity (adjusted odds ratio, 0.9; p = 0.02) and relative power of a high frequency band of heart rate variability (adjusted odds ratio, 1.05; p < 0.001) were individually associated with mortality, independently of age, admission Glasgow Coma Scale, intracranial pressure, pressure reactivity index, or cerebral perfusion pressure. Baroreflex sensitivity showed no correlation with intracranial pressure or cerebral perfusion pressure; the correlation with pressure reactivity index was strong in older patients (age, > 60 yr). The relative power of high frequency correlated significantly with intracranial pressure and cerebral perfusion pressure, but not with pressure reactivity index. The relative power of low frequency correlated significantly with pressure reactivity index. Conclusions: Autonomic impairment, as measured by heart rate variability and baroreflex sensitivity, is significantly associated with increased mortality after traumatic brain injury. These effects, though partially interlinked, seem to be independent of age, trauma severity, intracranial pressure, or autoregulatory status, and thus represent a discrete phenomenon in the pathophysiology of traumatic brain injury. Continuous measurements of heart rate variability and baroreflex sensitivity in the neuromonitoring setting of severe traumatic brain injury may carry novel pathophysiological and predictive information.	[Sykora, Marek; Czosnyka, Marek; Liu, Xiuyun; Donnelly, Joseph; Nasr, Nathalie; Okoroafor, Francois; Hutchinson, Peter; Smielewski, Peter] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Sykora, Marek] Heidelberg Univ, Dept Neurol, Heidelberg, Germany; [Nasr, Nathalie] CHU Toulouse, Dept Neurol, Unite Neurol Vasc, Toulouse, France; [Nasr, Nathalie] Univ Toulouse 3, INSERM U1048, I2MC Toulouse, Team 11, F-31062 Toulouse, France; [Diedler, Jennifer] Univ Tubingen, Dept Neurol & Neurosurg, Tubingen, Germany; [Menon, David] Univ Cambridge, Dept Anaesthesiol, Cambridge, England	Sykora, M (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge, England.; Sykora, M (corresponding author), Heidelberg Univ, Dept Neurol, Heidelberg, Germany.	marek.sykora@med.uni-heidelberg.de	Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/N-6803-2019; NASR, NATHALIE/K-3521-2019; Donnelly, Joseph/E-9235-2018	Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Nasr, Nathalie/0000-0003-1660-8718; Smielewski, Peter/0000-0001-5096-3938	National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish; Department of HealthEuropean Commission [NIHR-RP-R3-12-013, 12/35/57] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: Medline		ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Billman GE, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00026; Billman GE, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00086; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; De Raedt S, 2015, J NEUROL SCI, V348, P24, DOI 10.1016/j.jns.2014.12.007; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; GOLDSTEIN B, 1994, PEDIATR RES, V36, P358, DOI 10.1203/00006450-199409000-00016; Goldstein DS, 2011, EXP PHYSIOL, V96, P1255, DOI 10.1113/expphysiol.2010.056259; Gunther A, 2012, ACTA NEUROL SCAND, V126, P189, DOI 10.1111/j.1600-0404.2011.01626.x; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; Hall S, 2014, BRIT J NEUROSURG, V28, P181, DOI 10.3109/02688697.2013.835373; JENNETT B, 1975, LANCET, V1, P480; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Kox M, 2012, J NEUROTRAUM, V29, P747, DOI 10.1089/neu.2011.2035; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; Mazzeo AT, 2011, ACTA ANAESTH SCAND, V55, P797, DOI 10.1111/j.1399-6576.2011.02466.x; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Parati G, 2006, J APPL PHYSIOL, V101, P676, DOI 10.1152/japplphysiol.00446.2006; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Sykora M, 2009, STROKE, V40, pE678, DOI 10.1161/STROKEAHA.109.565838; Team RDC, 2010, R LANG ENV STAT COMP; Westerhof BE, 2004, J HYPERTENS, V22, P1371, DOI 10.1097/01.hjh.0000125439.28861.ed; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	31	38	38	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2016	44	6					1173	1181		10.1097/CCM.0000000000001624			9	Critical Care Medicine	General & Internal Medicine	DL9EK	WOS:000375944200046	26968025				2021-06-18	
J	Furman, JL; Sompol, P; Kraner, SD; Pleiss, MM; Putman, EJ; Dunkerson, J; Abdul, HM; Roberts, KN; Scheff, SW; Norris, CM				Furman, Jennifer L.; Sompol, Pradoldej; Kraner, Susan D.; Pleiss, Melanie M.; Putman, Esther J.; Dunkerson, Jacob; Abdul, Hafiz Mohmmad; Roberts, Kelly N.; Scheff, Stephen W.; Norris, Christopher M.			Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						astrocytes; brain injury; calcineurin; calcium; glia; synapse	LONG-TERM DEPRESSION; FIBRILLARY ACIDIC PROTEIN; ACTIVATED T-CELLS; TRANSCRIPTION FACTOR; REACTIVE ASTROCYTES; ALZHEIMERS-DISEASE; NUCLEAR FACTOR; DUAL ROLE; NFAT; BETA	Increasing evidence suggests that the calcineurin (CN)-dependent transcription factor NFAT (Nuclear Factor of Activated T cells) mediates deleterious effects of astrocytes in progressive neurodegenerative conditions. However, the impact of astrocytic CN/NFAT signaling on neural function/recovery after acute injury has not been investigated extensively. Using a controlled cortical impact (CCI) procedure in rats, we show that traumatic brain injury is associated with an increase in the activities of NFATs 1 and 4 in the hippocampus at 7 d after injury. NFAT4, but not NFAT1, exhibited extensive labeling in astrocytes and was found throughout the axon/dendrite layers of CA1 and the dentate gyrus. Blockade of the astrocytic CN/NFAT pathway in rats using adeno-associated virus (AAV) vectors expressing the astrocyte-specific promoter Gfa2 and the NFAT-inhibitory peptide VIVIT prevented the injury-related loss of basal CA1 synaptic strength and key synaptic proteins and reduced the susceptibility to induction of long-term depression. In conjunction with these seemingly beneficial effects, VIVIT treatment elicited a marked increase in the expression of the prosynaptogenic factor SPARCL1 (hevin), especially in hippocampal tissue ipsilateral to the CCI injury. However, in contrast to previous work on Alzheimer's mouse models, AAV-Gfa2-VIVIT had no effects on the levels of GFAP and Iba1, suggesting that synaptic benefits of VIVIT were not attributable to a reduction in glial activation per se. Together, the results implicate the astrocytic CN/NFAT4 pathway as a key mechanism for disrupting synaptic remodeling and homeostasis in the hippocampus after acute injury.	[Furman, Jennifer L.; Pleiss, Melanie M.; Norris, Christopher M.] Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA; [Sompol, Pradoldej; Kraner, Susan D.; Pleiss, Melanie M.; Putman, Esther J.; Dunkerson, Jacob; Abdul, Hafiz Mohmmad; Roberts, Kelly N.; Scheff, Stephen W.; Norris, Christopher M.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Norris, CM (corresponding author), Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA.	cnorr2@uky.edu		Kraner, Susan/0000-0002-1062-4007	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG027297, AG000242, AG047762]; Kentucky Spinal Cord and Head Injury Research trust [12-10A, 12-16A]; PhRMA Foundation; Irene and Eric Simon Brain Research Foundation; Hazel Embry Research Trust; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027297, T32AG000242, RF1AG027297, F31AG047762] Funding Source: NIH RePORTER	This work was supported by grants the National Institutes of Health (Grant AG027297 to C.M.N., Grant AG000242 to P.S., and Grant AG047762 to M.M.P.); the Kentucky Spinal Cord and Head Injury Research trust (Grant 12-10A to C.M.N. and Grant 12-16A to S.W.S.); the PhRMA Foundation (graduate fellowships to J.L.F. and M.M.P.); the Irene and Eric Simon Brain Research Foundation (undergraduate fellowship to E.J.P.); and the Hazel Embry Research Trust. We thank Linda Simmerman and Adam Bachstetter for technical assistance.	Abdul HM, 2011, AGING CELL, V10, P103, DOI 10.1111/j.1474-9726.2010.00645.x; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Albrecht D, 2012, MOL CELL NEUROSCI, V49, P364, DOI 10.1016/j.mcn.2012.01.005; Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; Ansari MA, 2013, J NEUROTRAUM, V30, P1542, DOI 10.1089/neu.2013.2910; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bales JW, 2010, J NEUROTRAUM, V27, P109, DOI 10.1089/neu.2009.1072; Blakely PK, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00344; Burda JE, 2015, EXP NEUROL; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Canellada A, 2008, GLIA, V56, P709, DOI 10.1002/glia.20647; Caraveo G, 2014, P NATL ACAD SCI USA, V111, pE3544, DOI 10.1073/pnas.1413201111; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.3.CO;2-9; Celsi F, 2007, NEUROBIOL DIS, V26, P342, DOI 10.1016/j.nbd.2006.12.022; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de Leeuw B, 2006, J NEUROSCI RES, V83, P744, DOI 10.1002/jnr.20776; Dumas TC, 2012, HIPPOCAMPUS, V22, P188, DOI 10.1002/hipo.20881; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Foster TC, 2007, NEUROBIOL LEARN MEM, V87, P522, DOI 10.1016/j.nlm.2006.12.009; Furman JL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0158-7; Furman JL, 2012, J NEUROSCI, V32, P16129, DOI 10.1523/JNEUROSCI.2323-12.2012; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hashimoto T, 1998, J NEUROCHEM, V70, P1289; Hassoun PM, 2009, J AM COLL CARDIOL, V54, pS10, DOI 10.1016/j.jacc.2009.04.006; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199-6203.2001; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Huang W, 2005, P NATL ACAD SCI USA, V102, P12242, DOI 10.1073/pnas.0505138102; Jones EV, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/321209; Jones EV, 2011, J NEUROSCI, V31, P4154, DOI 10.1523/JNEUROSCI.4757-10.2011; Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x; Kucukdereli H, 2011, P NATL ACAD SCI USA, V108, pE440, DOI 10.1073/pnas.1104977108; Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622; Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012; Liu F, 2005, J BIOL CHEM, V280, P1790, DOI 10.1074/jbc.M410775200; Lively S, 2008, NEUROCHEM RES, V33, P1692, DOI 10.1007/s11064-008-9606-z; Lively S, 2011, J NEUROPATH EXP NEUR, V70, P913, DOI 10.1097/NEN.0b013e318231151e; Lundkvist A, 2004, J CELL SCI, V117, P3481, DOI 10.1242/jcs.01221; Ma T, 2012, J NEUROSCI, V32, P13701, DOI 10.1523/JNEUROSCI.2107-12.2012; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; Mathis DM, 2011, JOVE-J VIS EXP, DOI 10.3791/2330; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; Nagamoto-Combs K, 2010, J NEUROSCI, V30, P9641, DOI 10.1523/JNEUROSCI.0828-10.2010; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Neria F, 2013, GLIA, V61, P1052, DOI 10.1002/glia.22494; Nguyen T, 2008, INT J DEV NEUROSCI, V26, P141, DOI 10.1016/j.ijdevneu.2007.10.004; Norris C.M., 2014, ADV BIOCH HLTH DIS, P17, DOI DOI 10.1007/978-1-4614-9099-9_2; Norris CM, 2016, EXP NEUROL, V276, P5, DOI 10.1016/j.expneurol.2015.11.006; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Norris CM, 1996, J NEUROSCI, V16, P5382; O'Dell T J, 1994, Learn Mem, V1, P129; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Parpura V, 2012, J NEUROCHEM, V121, P4, DOI 10.1111/j.1471-4159.2012.07664.x; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perez-Ortiz JM, 2008, EUR J NEUROSCI, V27, P2453, DOI 10.1111/j.1460-9568.2008.06197.x; Rosenkranz K, 2012, J PROTEOME RES, V11, P5794, DOI 10.1021/pr3005869; Sama DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038170; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shioda N, 2006, J NEUROCHEM, V98, P310, DOI 10.1111/j.1471-4159.2006.03874.x; Shiratori M, 2010, J NEUROCHEM, V114, P810, DOI 10.1111/j.1471-4159.2010.06809.x; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Sullivan MM, 2004, INT J BIOCHEM CELL B, V36, P991, DOI 10.1016/j.biocel.2004.01.017; Tomimoto H, 1997, ACTA NEUROPATHOL, V94, P146, DOI 10.1007/s004010050686; Vihma H, 2008, GENOMICS, V92, P279, DOI 10.1016/j.ygeno.2008.06.011; Vouimba RM, 2000, BRAIN RES BULL, V53, P783, DOI 10.1016/S0361-9230(00)00377-4; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; WIGSTROM H, 1986, J PHYSIOL-PARIS, V81, P228; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010; Yan HQ, 2014, BRAIN RES, V1548, P63, DOI 10.1016/j.brainres.2013.12.028; Yu HX, 2007, CARDIOVASC DRUG REV, V25, P175, DOI 10.1111/j.1527-3466.2007.00011.x; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	87	38	44	1	20	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	FEB 3	2016	36	5					1502	1515		10.1523/JNEUROSCI.1930-15.2016			14	Neurosciences	Neurosciences & Neurology	DC4HR	WOS:000369182200008	26843634	Bronze, Green Published			2021-06-18	
J	Nelson, LD; Guskiewicz, KM; Barr, WB; Hammeke, TA; Randolph, C; Ahn, KW; Wang, YZ; McCrea, MA				Nelson, Lindsay D.; Guskiewicz, Kevin M.; Barr, William B.; Hammeke, Thomas A.; Randolph, Christopher; Ahn, Kwang Woo; Wang, Yanzhi; McCrea, Michael A.			Age Differences in Recovery After Sport-Related Concussion: A Comparison of High School and Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; adolescents; adults	MILD HEAD-INJURY; POSTURAL STABILITY; FOOTBALL PLAYERS; PROLONGED RECOVERY; MANAGEMENT; BRAIN; PERFORMANCE; SEVERITY; SYMPTOMS; IMPACT	Context: Younger age has been hypothesized to be a risk factor for prolonged recovery after sport-related concussion, yet few studies have directly evaluated age differences in acute recovery. Objective: To compare clinical recovery patterns for high school and collegiate athletes. Design: Prospective cohort study. Setting: Large, multicenter prospective sample collected from 1999-2003 in a sports medicine setting. Subjects: Concussed athletes (n = 621; 545 males and 76 females) and uninjured controls (n = 150) participating in high school and collegiate contact and collision sports (79% in football, 15.7% in soccer, and the remainder in lacrosse or ice hockey). Main Outcome Measure(s): Participants underwent evaluation of symptoms (Graded Symptom Checklist), cognition (Standardized Assessment of Concussion, paper-and-pencil neuropsychological tests), and postural stability (Balance Error Scoring System). Athletes were evaluated preinjury and followed serially at several time points after concussive injury: immediately, 3 hours postinjury, and at days 1, 2, 3, 5, 7, and 45 or 90 (with neuropsychological measures administered at baseline and 3 postinjury time points). Results: Comparisons of concussed high school and collegiate athletes with uninjured controls suggested that high school athletes took 1 to 2 days longer to recover on a cognitive (Standardized Assessment of Concussion) measure. Comparisons with the control group on other measures (symptoms, balance) as well as direct comparisons between concussed high school and collegiate samples revealed no differences in the recovery courses between the high school and collegiate groups on any measure. Group-level recovery occurred at or before 7 days postinjury on all assessment metrics. Conclusions: The findings suggest no clinically significant age differences exist in recovery after sport-related concussion, and therefore, separate injury-management protocols are not needed for high school and collegiate athletes.	[Nelson, Lindsay D.; Hammeke, Thomas A.; Ahn, Kwang Woo; McCrea, Michael A.] Med Coll Wisconsin, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC USA; [Barr, William B.] NYU, Sch Med, New York, NY 10003 USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Chicago, IL 60611 USA; [Wang, Yanzhi] Univ Illinois, Coll Med, Peoria, IL 61656 USA	Nelson, LD (corresponding author), Med Coll Wisconsin, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	Meijer, Anna/K-5118-2016	Barr, William/0000-0001-7711-7758	NCAA and the National Operating Committee on Standards for Athletic Equipment; Centers for Disease Control and Prevention's National Center for Injury Prevention and Control, University of North Carolina Injury Prevention Research Center; Waukesha Memorial Hospital Foundation; National Academy of Neuropsychology; National Federation of State High School Associations; NFL Charities; Green Bay Packer Foundation; Milwaukee Bucks; Herbert H. Kohl Charities; Waukesha Service Club; Medical College of Wisconsin General Clinical Research Center (National Institutes of Health) [M01 RR00058]; Michael Emme; Centers for Disease Control and Prevention's National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000058] Funding Source: NIH RePORTER	This research was supported by the NCAA and the National Operating Committee on Standards for Athletic Equipment, Centers for Disease Control and Prevention's National Center for Injury Prevention and Control, University of North Carolina Injury Prevention Research Center, Waukesha Memorial Hospital Foundation, National Academy of Neuropsychology, National Federation of State High School Associations, NFL Charities, Green Bay Packer Foundation, Milwaukee Bucks, Herbert H. Kohl Charities, Waukesha Service Club, Michael Emme, and the Medical College of Wisconsin General Clinical Research Center (M01 RR00058 from the National Institutes of Health).	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Golden CJ, 2002, STROOP COLOR WORD TE; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2014, J INT NEUROPSYCH SOC, V20, P324, DOI 10.1017/S1355617713001471; Landis Matthew J, 2007, WMJ, V106, P312; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Reitan RM., 1985, HALSTEAD REITAN NEUR; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rubin DB., 1987, MULTIPLE IMPUTATION; Smith A., 1982, SYMBOL DIGIT MODALIT; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor AM, 2012, CURR OPIN PEDIATR, V24, P717, DOI 10.1097/MOP.0b013e32835a279b; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	56	38	38	0	25	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2016	51	2					142	152		10.4085/1062-6050-51.4.04			11	Sport Sciences	Sport Sciences	DK2OW	WOS:000374755300006	26974186	Bronze, Green Published			2021-06-18	
J	Gioia, GA				Gioia, Gerard A.			Medical-School Partnership in Guiding Return to School Following Mild Traumatic Brain Injury in Youth	JOURNAL OF CHILD NEUROLOGY			English	Article						mild traumatic brain injury; TBI; youth; pediatric; concussion	CONCUSSION; EXERCISE; SPORT; RECOMMENDATIONS; REST	Mild traumatic brain injury is recognized as a prevalent and significant risk concern for youth. Appropriate school return is particularly challenging. The medical and school systems must be prepared partners to support the school return of the student with mild traumatic brain injury. Medical providers must be trained in assessment and management skills with a focused understanding of school demands. Schools must develop policies and procedures to prepare staff to support a gradual return process with the necessary academic accommodations. Ongoing communication between the family, student, school, and medical provider is essential to supporting recovery. A systematic gradual return to school process is proposed including levels of recommended activity and criteria for advancement. Targets for intervention are described with associated strategies for supporting recovery. A 10-element Progressive Activities of Controlled Exertion (PACE) model for activity-exertion management is introduced to manage symptom exacerbation. A strong medical-school partnership will maximize outcomes for students with mild traumatic brain injury.	[Gioia, Gerard A.] George Washington Univ, Sch Med, Childrens Natl Hlth Syst, Div Pediat Neuropsychol, Rockville, MD USA	Gioia, GA (corresponding author), Childrens Natl Hlth Syst, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	ggioia@childrensnational.org			CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/ CCU323352, U49CE001385]; NIH from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01RR020359]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HDO40677-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001385] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This paper was supported in part by CDC Awards U17/ CCU323352 and U49CE001385, and NIH Grants M01RR020359 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH P30/HDO40677-07.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Awlward B, 2009, HDB PEDIAT PSYCHOL, P3; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, HELP STUD REC CONC C; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Centers for Disease Control and Prevention US Department of Health and Human Services, RET SCH CONC FACT SH; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2012, PEDIATR ANN, V41, P198, DOI 10.3928/00904481-20120426-10; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Institute of Medicine's Committee on Sports-Related Concussions in Youth, 2013, SPORTS REL CONC YOUT; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McAvoy K., 2011, REAP BENEFITS GOOD C; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V37, P141; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Oregon Center for Applied Science, 2007, BRAIN 101 CONC PLAYB; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	28	38	38	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JAN	2016	31	1			SI		93	108		10.1177/0883073814555604			16	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CY8HW	WOS:000366650400010	25535055	Green Accepted			2021-06-18	
J	Butler, CR; Boychuk, JA; Smith, BN				Butler, Corwin R.; Boychuk, Jeffery A.; Smith, Bret N.			Effects of Rapamycin Treatment on Neurogenesis and Synaptic Reorganization in the Dentate Gyrus after Controlled Cortical Impact Injury in Mice	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						epilepsy; trauma; hippocampus; mTOR; dentate granule cell; mossy fiber sprouting; adult neurogenesis; doublecortin	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; GRANULE CELL NEUROGENESIS; ACID-TREATED RATS; MOUSE MODEL; MAMMALIAN TARGET; HIPPOCAMPAL NEUROGENESIS; POSTTRAUMATIC EPILEPSY; ENHANCED NEUROGENESIS; RECURRENT EXCITATION	Post-traumatic epilepsy (PTE) is one consequence of traumatic brain injury (TBI). A prominent cell signaling pathway activated in animal models of both TBI and epilepsy is the mammalian target of rapamycin (mTOR). Inhibition of rnTOR with rapamycin has shown promise as a potential modulator of epileptogenesis in several animal models of epilepsy, but cellular mechanisms linking mTOR expression and epileptogenesis are unclear. In this study, the role of mTOR in modifying functional hippocampal circuit reorganization after focal TBI induced by controlled cortical impact (CCI) was investigated. Rapamycin (3 or 10 mg/kg), an inhibitor of rnTOR signaling, was administered by intraperitoneal injection beginning on the day of injury and continued daily until tissue collection. Relative to controls, rapamycin treatment reduced dentate granule cell area in the hemisphere ipsilateral to the injury two weeks post-injury. Brain injury resulted in a significant increase in doublecortin immunolabeling in the dentate gyrus ipsilateral to the injury, indicating increased neurogenesis shortly after TBI. Rapamycin treatment prevented the increase in doublecortin labeling, with no overall effect on Fluoro-Jade B staining in the ipsilateral hemisphere, suggesting that rapamycin treatment reduced posttraumatic neurogenesis but did not prevent cell loss after injury. At later times post-injury (8-13 weeks), evidence of mossy fiber sprouting and increased recurrent excitation of dentate granule cells was detected, which were attenuated by rapamycin treatment. Rapamycin treatment also diminished seizure prevalence relative to vehicle-treated controls after TBI. Collectively, these results support a role for adult neurogenesis in PTE development and suggest that suppression of epileptogenesis by mTOR inhibition includes effects on post-injury neurogenesis.	[Butler, Corwin R.; Boychuk, Jeffery A.; Smith, Bret N.] Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40506 USA; [Boychuk, Jeffery A.; Smith, Bret N.] Univ Kentucky, Epilepsy Ctr, Lexington, KY USA; [Boychuk, Jeffery A.] Univ Kentucky, Ctr Adv Translat Stroke Sci, Lexington, KY USA; [Smith, Bret N.] Univ Kentucky, Spiul Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA	Smith, BN (corresponding author), Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40506 USA.	bret.smith@uky.edu		Butler, Corwin/0000-0001-5134-4151; Boychuk, Jeffery A/0000-0002-7003-1553	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088608] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS088608] Funding Source: Medline		ALTMAN J, 1965, NATURE, V207, P953, DOI 10.1038/207953a0; Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Bhaskaran MD, 2010, EXP NEUROL, V223, P529, DOI 10.1016/j.expneurol.2010.01.021; Buckmaster PS, 2011, EPILEPSIA, V52, P2057, DOI 10.1111/j.1528-1167.2011.03253.x; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Heng K, 2013, EPILEPSIA, V54, P1535, DOI 10.1111/epi.12246; Hester MS, 2013, J NEUROSCI, V33, P8926, DOI 10.1523/JNEUROSCI.5161-12.2013; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kron MM, 2010, J NEUROSCI, V30, P2051, DOI 10.1523/JNEUROSCI.5655-09.2010; LaSarge CL, 2015, NEUROBIOL DIS, V75, P142, DOI 10.1016/j.nbd.2014.12.029; Liu JL, 1998, J NEUROSCI, V18, P7768; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lynch M, 2000, J NEUROPHYSIOL, V83, P693; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 1997, CURR OPIN NEUROL, V10, P103, DOI 10.1097/00019052-199704000-00006; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Pun RYK, 2012, NEURON, V75, P1022, DOI 10.1016/j.neuron.2012.08.002; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sunnen CN, 2011, EPILEPSIA, V52, P2065, DOI 10.1111/j.1528-1167.2011.03280.x; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin N R, 1998, Adv Neurol, V76, P179; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Wiltgen BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.037.2009; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009	64	38	38	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5137			FRONT SYST NEUROSCI	Front. Syst. Neurosci.	NOV 27	2015	9									10.3389/fnsys.2015.00163			14	Neurosciences	Neurosciences & Neurology	CZ0TK	WOS:000366818700001	26640431	DOAJ Gold, Green Published			2021-06-18	
J	Almeida-Suhett, CP; Prager, EM; Pidoplichko, V; Figueiredo, TH; Marini, AM; Li, Z; Eiden, LE; Braga, MFM				Almeida-Suhett, Camila P.; Prager, Eric M.; Pidoplichko, Volodymyr; Figueiredo, Taiza H.; Marini, Ann M.; Li, Zheng; Eiden, Lee E.; Braga, Maria F. M.			GABAergic interneuronal loss and reduced inhibitory synaptic transmission in the hippocampal CM region after mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury; CA1; Synaptic transmission; Controlled cortical impact; Cognitive impairment	LONG-TERM POTENTIATION; CLOSED-HEAD-INJURY; PROFESSIONAL FOOTBALL PLAYERS; CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; GABA(A) RECEPTOR; COGNITIVE DEFICITS; RETROGRADE-AMNESIA; MEMORY IMPAIRMENT; NMDA RECEPTOR	Patients that suffer mild traumatic brain injuries (mTBI) often develop cognitive impairments, including memory and learning deficits. The hippocampus shows a high susceptibility to mTBI-induced damage due to its anatomical localization and has been implicated in cognitive and neurological impairments after mTBI. However, it remains unknown whether mTBI cognitive impairments are a result of morphological and pathophysiological alterations occurring in the CA1 hippocampal region. We investigated whether mTBI induces morphological and pathophysiological alterations in the CA1 using the controlled cortical impact (CCI) model. Seven days after CCI, animals subjected to mTBI showed cognitive impairment in the passive avoidance test and deficits to long-term potentiation (LTP) of synaptic transmission. Deficiencies in inducing or maintaining LTP were likely due to an observed reduction in the activation of NMDA but not AMPA receptors. Significant reductions in the frequency and amplitude of spontaneous and miniature GABA(A)-receptor mediated inhibitory postsynaptic currents (IPSCs) were also observed 7 days after CCI. Design-based stereology revealed that although the total number of neurons was unaltered, the number of GABAergic interneurons is significantly reduced in the CA1 region 7 days after CCI. Additionally, the surface expression of alpha 1, beta 2/3, and gamma 2 subunits of the GABA(A) receptor were reduced, contributing to a reduced mIPSC frequency and amplitude, respectively. Together, these results suggest that mTBI causes a significant reduction in GABAergic inhibitory transmission and deficits to NMDA receptor mediated currents in the CA1, which may contribute to changes in hippocampal excitability and subsequent cognitive impairments after mTBI. Published by Elsevier Inc.	[Almeida-Suhett, Camila P.; Prager, Eric M.; Marini, Ann M.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA; [Pidoplichko, Volodymyr; Figueiredo, Taiza H.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA; [Almeida-Suhett, Camila P.; Marini, Ann M.; Li, Zheng; Eiden, Lee E.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Li, Zheng] NIMH, Sect Clin Studies, Intramural Res Program, Bethesda, MD 20892 USA; [Eiden, Lee E.] NIMH, Sect Mol Neurosci, Intramural Res Program, Bethesda, MD 20892 USA	Braga, MFM (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	camila.almeida.ctr@usuhs.edu; eprager@wiley.com; volodymyr.pidoplichko.ctr@usuhs.edu; taiza.figueiredo.ctr@usuhs.edu; ann.marini@usuhs.edu; Lizheng2@mail.nih.gov; eidenl@mail.nih.gov; maria.braga@usuhs.edu	Li, Zheng/I-8016-2014; Prager, Eric/O-1567-2015; Almeida-Suhett, Camila/I-8045-2016	Li, Zheng/0000-0002-2978-2531; Prager, Eric/0000-0002-3810-0985; Almeida-Suhett, Camila/0000-0002-7588-9487	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1702Z]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002386, ZIAMH002881] Funding Source: NIH RePORTER	The authors acknowledge the Department of Defense in the Center for Neuroscience and Regenerative Medicine for financially supporting the present work. Grant# G1702Z. URL of funder's website: http://www.usuhs.mil/cnrm/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Almeida-Suhett CP, 2014, J NEUROTRAUM, V31, P683, DOI 10.1089/neu.2013.3029; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Antonucci F, 2012, J NEUROSCI, V32, P1989, DOI 10.1523/JNEUROSCI.2720-11.2012; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bassani S, 2013, CELL MOL LIFE SCI, V70, P4411, DOI 10.1007/s00018-013-1309-1; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bliss TVP, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-5; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brun VH, 2001, J NEUROSCI, V21, P356, DOI 10.1523/JNEUROSCI.21-01-00356.2001; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; COLLINGRIDGE G, 1987, NATURE, V330, P604, DOI 10.1038/330604a0; Collingridge GL, 2013, NEUROPHARMACOLOGY, V64, P13, DOI 10.1016/j.neuropharm.2012.06.051; Collinson N, 2002, J NEUROSCI, V22, P5572; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Daumas S, 2005, LEARN MEMORY, V12, P375, DOI 10.1101/lm.81905; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Drexel M, 2015, NEUROPHARMACOLOGY, V88, P122, DOI 10.1016/j.neuropharm.2014.08.023; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gonzalez MI, 2013, EPILEPSIA, V54, P616, DOI 10.1111/epi.12063; Goodkin HP, 2008, J NEUROSCI, V28, P2527, DOI 10.1523/JNEUROSCI.3426-07.2008; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Grosshans D., 2002, SCI STKE, V2002, P18; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall J, 2001, J NEUROSCI, V21, P2186, DOI 10.1523/JNEUROSCI.21-06-02186.2001; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Harvey CD, 2007, NATURE, V450, P1195, DOI 10.1038/nature06416; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Henley Jeremy M, 2013, Dialogues Clin Neurosci, V15, P11; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill LE, 2010, J PSYCHOPHARMACOL, V24, P745, DOI 10.1177/0269881108096983; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Holman D, 2007, J NEUROSCI METH, V160, P302, DOI 10.1016/j.jneumeth.2006.09.018; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P260, DOI 10.1016/0165-6147(91)90567-C; Ji JZ, 2008, LEARN MEMORY, V15, P244, DOI 10.1101/lm.794808; KARASAWA Y, 1994, STROKE, V25, P645, DOI 10.1161/01.STR.25.3.645; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Leung L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053569; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu YH, 2009, NEUROCHEM RES, V34, P1209, DOI 10.1007/s11064-008-9897-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Murray AJ, 2011, NAT NEUROSCI, V14, P297, DOI 10.1038/nn.2751; Myhrer T, 2003, BRAIN RES REV, V41, P268, DOI 10.1016/S0165-0173(02)00268-0; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Paxinos G., 2005, RAT BRAIN STEROTAXIC, Vfifth; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Perreault ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033348; Pidoplichko VI, 2005, J NEUROSCI METH, V142, P55, DOI 10.1016/j.jneumeth.2004.07.012; Prager EM, 2014, NEUROTOXICOLOGY, V44, P335, DOI 10.1016/j.neuro.2014.08.007; Prager EM, 2014, NEUROPHARMACOLOGY, V81, P64, DOI 10.1016/j.neuropharm.2014.01.035; Prager EM, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00038; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Riedel G, 2003, BEHAV BRAIN RES, V140, P1, DOI 10.1016/S0166-4328(02)00272-3; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sangha S, 2012, LEARN MEMORY, V19, P194, DOI 10.1101/lm.025874.112; Schmitz C, 2000, J CHEM NEUROANAT, V20, P93, DOI 10.1016/S0891-0618(00)00066-1; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; SHARMA AC, 1990, METHOD FIND EXP CLIN, V12, P175; Shetty AK, 2009, J CELL MOL MED, V13, P2408, DOI 10.1111/j.1582-4934.2009.00675.x; Shors TJ, 1997, BEHAV BRAIN SCI, V20, P634, DOI 10.1017/S0140525X97461599; Shors TJ, 1997, BEHAV BRAIN SCI, V20, P597, DOI 10.1017/S0140525X97001593; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Stanley DP, 2004, J NEUROCHEM, V89, P204, DOI 10.1111/j.1471-4159.2004.02318.x; STAUBLI U, 1994, P NATL ACAD SCI USA, V91, P777, DOI 10.1073/pnas.91.2.777; Stern SA, 2013, WIRES SYST BIOL MED, V5, P37, DOI 10.1002/wsbm.1196; Stief F, 2007, EUR J NEUROSCI, V25, P519, DOI 10.1111/j.1460-9568.2006.05296.x; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Sutherland RJ, 2001, HIPPOCAMPUS, V11, P27, DOI 10.1002/1098-1063(2001)11:1<27::AID-HIPO1017>3.0.CO;2-4; Sutherland RJ, 2010, NEUROPSYCHOLOGIA, V48, P2357, DOI 10.1016/j.neuropsychologia.2010.04.015; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vago DR, 2007, HIPPOCAMPUS, V17, P977, DOI 10.1002/hipo.20329; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Wang D, 2005, J BIOL CHEM, V280, P18703, DOI 10.1074/jbc.M500381200; Whiting MD, 2008, BRAIN RES, V1213, P69, DOI 10.1016/j.brainres.2008.01.107; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wolosker H, 2007, MOL NEUROBIOL, V36, P152, DOI 10.1007/s12035-007-0038-6; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; YONKOV D I, 1985, Acta Physiologica et Pharmacologica Bulgarica, V11, P44; Zarrindast MR, 2002, J PSYCHOPHARMACOL, V16, P313, DOI 10.1177/026988110201600405; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020; Zhao Bo, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P236; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	135	38	41	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2015	273						11	23		10.1016/j.expneurol.2015.07.028			13	Neurosciences	Neurosciences & Neurology	CW7BB	WOS:000365151800002	26238734				2021-06-18	
J	Chandler, JA				Chandler, Jennifer A.			The use of neuroscientific evidence in Canadian criminal proceedings	JOURNAL OF LAW AND THE BIOSCIENCES			English	Article						Canadian criminal justice system; criminal law; law and neuroscience; brain damage; fetal alcohol spectrum disorder; FASD; traumatic brain injury		This article addresses the question of how neuroscientific evidence is currently used in the Canadian criminal justice system, with a view to identifying the main contexts in which this evidence is raised, as well as to discern the impact of this evidence on judgements of responsibility, dangerousness, and treatability. The most general Canadian legal database was searched for cases in the five-year period between 2008 and 2012 in which neuroscientific evidence related to the responsibility and recidivism risk of criminal offenders was considered. Canadian courts consider neuroscientific evidence of many types, particularly evidence of prenatal alcohol exposure, traumatic brain injury, and neuropsychological testing. The majority of the cases are sentencing decisions, which is useful given that it offers an opportunity to observe how judges wrestle with the tension that evidence of diminished capacity due to brain damage tends to reduce moral blameworthiness, while it also tends to increase perceptions of risk and dangerousness. This so-called double-edged sword of the biological explanation of criminal behavior was reflected in this study, and raises questions about whether and when the pursuit of such evidence is advisable from the defense perspective.	[Chandler, Jennifer A.] Univ Ottawa, Common Law, 57 Louis Pasteur St, Ottawa, ON K1N 6N5, Canada	Chandler, JA (corresponding author), Univ Ottawa, Common Law, 57 Louis Pasteur St, Ottawa, ON K1N 6N5, Canada.	chandler@uottawa.ca					Aspinwall LG, 2012, SCIENCE, V337, P846, DOI 10.1126/science.1219569; Boyce J., 2013, ADULT CRIMINAL COURT; Cashmore AR, 2010, P NATL ACAD SCI USA, V107, pE150, DOI 10.1073/pnas.1011107107; Cashmore AR, 2010, P NATL ACAD SCI USA, V107, P4499, DOI 10.1073/pnas.0915161107; Colantonio A, 2014, J CORRECT HEALTH CAR, V20, P271, DOI 10.1177/1078345814541529; Dauvergne Mia, 1992, YOUTH COURT STAT CAN; Denno D.W, 2015, BOSTON COLL LAW REV, V56, P493; Dolphin Myles, 2014, YUKON NEWS      1126; Goodenough OR, 2010, ANNU REV LAW SOC SCI, V6, P61, DOI 10.1146/annurev.lawsocsci.093008.131523; Greene Joshua, PHIL T ROYAL SOC B, V359, P1785; Greene Joshua, PHIL T ROYAL SOC B, V359, P1775; Health Canada, 2006, FETAL ALCOHOL SPECTR; Institute of Health Economics, 2013, CONS STAT LEG ISS FE, P22; Jones Owen D., 2012, INT NEUROLAW A COMP, P351; Jones Simon Verdun, 2012, CRIMINAL JUSTICE INC, V163, P177; Katz-Schiavone S.M., 2008, J CRIMINAL JUSTICE P, V15, P291; Katz-Schiavone Stacey, 2008, J CRIM JUST POP CULT, V15, P311; Morse S. J., 2010, LAW NEUROSCIENCE CUR, V13, P529; PENNEY STEVEN, 2011, CRIMINAL PROCEDURE C, P689; Public Safety Canada, 2012, 2012 CORR COND REL S; Puranik D.A., 2009, P 20 ALL IND FOR SCI, P815; Rigoni D, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00160; Roach K., 2009, U B C L REV, V42, P1, DOI [10.3366/ajicl.2011.0005, DOI 10.3366/AJICL.2011.0005]; Roach K., 2009, UBC LAW REV, V41, P68; SCHNEIDER RICHARD D., 2013, MENTAL DISORDER LAW, P132; Statistics Canada, 2013, AD CRIM COURT STAT C; Williams Huw, 2012, REPORT COMMISSIONED	27	38	38	1	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	2053-9711			J LAW BIOSCI	J. Law Biosci.	NOV	2015	2	3					550	579		10.1093/jlb/lsv026			30	Ethics; Law; Medical Ethics; Medicine, Legal	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	DJ8XO	WOS:000374497800004	27774212	DOAJ Gold, Green Published			2021-06-18	
J	Taka, E; Mazzio, EA; Goodman, CB; Redmon, N; Flores-Rozas, H; Reams, R; Darling-Reed, S; Soliman, KFA				Taka, Equar; Mazzio, Elizabeth A.; Goodman, Carl B.; Redmon, Natalie; Flores-Rozas, Hernan; Reams, Renee; Darling-Reed, Selina; Soliman, Karam F. A.			Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Cytokines; Nitric oxide; Microglial cells, Parkinson's, neurodegeneration; Thymoquinone; Black cumin seed	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; MOUSE DENDRITIC CELLS; NIGELLA-SATIVA; PARKINSONS-DISEASE; OXIDATIVE STRESS; IN-VITRO; INFLAMMATORY RESPONSES; OSTEOPONTIN EXPRESSION; LIPID-PEROXIDATION	Thymoquinone (TQ), the main pharmacological active ingredient within the black cumin seed (Nigella sativa) is believed to be responsible for the therapeutic effects on chronic inflammatory conditions such as arthritis, asthma and neurodegeneration. In this study, we evaluated the potential anti-inflammatory role of TQ in lipopolysaccharide (LPS)-stimulated BV-2 murine microglia cells. The results obtained indicate that TQ was effective in reducing NO2- with an IC50 of 5.04 mu M, relative to selective iNOS inhibitor LNIL-L-N6-(1-iminoethyl)lysine (IC50 4.09 mu M). TQ mediated reduction in NO2- was found to parallel the decline of iNOS protein expression as confirmed by immunocytochemistry. In addition, we evaluated the anti-inflammatory effects of TQ on ninety-six (96) cytokines using a RayBio AAM-CYT-3 and 4 cytokine antibody protein array. Data obtained establish a baseline protein expression profile characteristic of resting BV-2 cells in the order of osteopontin > MIP-1alpha > MIP-1 g> IGF-1 and MCP-I. In the presence of LPS [1 ug/ml], activated BV-2 cells produced a sharp rise in specific pro-inflammatory cytokines/chemokine's IL-6, IL-12p40/70, CCL12 /MCP-5, CCL2/MCP-1, and G-CSF which were attenuated by the addition of TQ (10 mu M). The TQ mediated attenuation of MCP-5, MCP-1 and IL-6 protein in supernatants from activated BV-2 cells were corroborated by independent ELISA. Moreover, the data obtained from the (RTPCR)-P-2 demonstrated a similar pattern where the LPS mediated elevation of mRNA for IL-6, CCL12/MCP-5, CCL2/MCP-1 were significantly attenuated by TQ (10 mu M). Also, in this study, consistent data were obtained for both protein antibody array densitometry and ELISA assays. In addition, TQ was found to reduce LPS mediated elevation in gene expression of Cxcl10 and a number of other cytokines in the panel. These findings demonstrate the significant anti-inflammatory properties of TQ in LPS activated microglial cells. Therefore, the obtained results might indicate the usefulness of TQ in delaying the onset of inflammation-mediated neurodegenerative disorders involving activated microglia cells. 2015 Elsevier B.V. All rights reserved.	[Taka, Equar; Mazzio, Elizabeth A.; Goodman, Carl B.; Redmon, Natalie; Flores-Rozas, Hernan; Reams, Renee; Darling-Reed, Selina; Soliman, Karam F. A.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA	Soliman, KFA (corresponding author), Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Room 104 Dyson Pharm Bldg,1520 ML King Blvd, Tallahassee, FL 32307 USA.	karam.soliman@famu.edu			National Institute of Minority Health and Health Disparities of the National Institutes of Health [8 G12MD007582-28, 1P20 MD006738-01]; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD006738, G12MD007582] Funding Source: NIH RePORTER	This research was supported by the National Institute of Minority Health and Health Disparities of the National Institutes of Health through Grant Number 8 G12MD007582-28 and Grant Number 1P20 MD006738-01. We would like to also thank Elisabetta Blasi (Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy) for providing the BV-2 microglial cell line.	Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1; Al-Majed AA, 2006, EUR J PHARMACOL, V543, P40, DOI 10.1016/j.ejphar.2006.05.046; Ali BH, 2003, PHYTOTHER RES, V17, P299, DOI 10.1002/ptr.1309; Alkharfy KM, 2011, INT IMMUNOPHARMACOL, V11, P250, DOI 10.1016/j.intimp.2010.11.032; Ammar ESM, 2011, INT IMMUNOPHARMACOL, V11, P2232, DOI 10.1016/j.intimp.2011.10.013; Basarslan F, 2012, HUM EXP TOXICOL, V31, P726, DOI 10.1177/0960327111433185; Batool Sidra, 2013, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V12, P129; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Brown A, 2012, TRANSL NEUROSCI, V3, P288, DOI 10.2478/s13380-012-0028-7; Butt MS, 2010, CRIT REV FOOD SCI, V50, P654, DOI 10.1080/10408390902768797; Dariani S, 2013, J MOL NEUROSCI, V51, P679, DOI 10.1007/s12031-013-0043-3; Del Rio P, 2011, GLIA, V59, P821, DOI 10.1002/glia.21155; Evans SM, 2001, TOXICOL IN VITRO, V15, P579, DOI 10.1016/S0887-2333(01)00064-9; Furusawa JI, 2009, INT IMMUNOPHARMACOL, V9, P499, DOI 10.1016/j.intimp.2009.01.031; Gilhotra N, 2011, PHARMACOL REP, V63, P660, DOI 10.1016/S1734-1140(11)70577-1; Gyoneva S, 2014, NEUROBIOL DIS, V67, P191, DOI 10.1016/j.nbd.2014.03.004; Hasegawa-Ishii S, 2011, BRAIN BEHAV IMMUN, V25, P83, DOI 10.1016/j.bbi.2010.08.006; Hirai S, 2007, LIFE SCI, V81, P1272, DOI 10.1016/j.lfs.2007.09.001; Hosseinzadeh H, 2007, PHYTOMEDICINE, V14, P621, DOI 10.1016/j.phymed.2006.12.005; Idris-Khodja N, 2012, N-S ARCH PHARMACOL, V385, P749, DOI 10.1007/s00210-012-0749-8; Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013; Jang TC, 2006, AM J PATHOL, V168, P1676, DOI 10.2353/ajpath.2006.050400; Jung HW, 2013, AM J CHINESE MED, V41, P99, DOI 10.1142/S0192415X13500080; Kalkonde YV, 2007, BRAIN RES, V1128, P1, DOI 10.1016/j.brainres.2006.08.041; Kim M, 2013, BMB REP, V46, P398, DOI 10.5483/BMBRep.2013.46.8.237; Kim S, 2013, J PHARM PHARMACOL, V65, P895, DOI 10.1111/jphp.12049; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kundu JK, 2013, BIOCHEM BIOPH RES CO, V438, P721, DOI 10.1016/j.bbrc.2013.07.110; Landa P, 2013, NAT PROD COMMUN, V8, P105; Liao Yuan, 2011, Zhonghua Bing Li Xue Za Zhi, V40, P585; Lu Y, 2013, NEUROSCIENCE, V241, P22, DOI 10.1016/j.neuroscience.2013.03.003; Manivannan J, 2013, NEUROSCIENCE, V253, P40, DOI 10.1016/j.neuroscience.2013.08.023; Mansour MA, 2002, CELL BIOCHEM FUNCT, V20, P143, DOI 10.1002/cbf.968; Matusan-Ilijas K, 2008, PATHOL ONCOL RES, V14, P293, DOI 10.1007/s12253-008-9058-4; Mayer AMS, 2011, TOXICOL SCI, V121, P63, DOI 10.1093/toxsci/kfr045; Mohamed A., 2005, V41, P388; Mohamed A, 2003, BIOMED SCI INSTRUM, V39, P440; More SV, 2013, J PHARMACOL SCI, V121, P119, DOI 10.1254/jphs.12170FP; Nili-Ahmadabadi A, 2011, DARU, V19, P282; Okamura T, 2012, J NEUROSCI RES, V90, P2127, DOI 10.1002/jnr.23105; Padhye Subhash, 2008, Cancer Ther, V6, P495; Park SY, 2012, NEUROCHEM INT, V61, P767, DOI 10.1016/j.neuint.2012.06.020; Passos GF, 2009, AM J PATHOL, V175, P1586, DOI 10.2353/ajpath.2009.081113; Radad K, 2014, EXP TOXICOL PATHOL, V66, P13, DOI 10.1016/j.etp.2013.07.002; Ramsey CP, 2014, EXP NEUROL, V256, P126, DOI 10.1016/j.expneurol.2013.05.014; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Rizzo F, 2014, CELL MOL LIFE SCI, V71, P999, DOI 10.1007/s00018-013-1480-4; Russo I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-52; Sacino AN, 2014, J NEUROSCI, V34, P12368, DOI 10.1523/JNEUROSCI.2102-14.2014; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016/j.intimp.2005.06.008; Sankaranarayanan C, 2011, CHEM-BIOL INTERACT, V190, P148, DOI 10.1016/j.cbi.2011.02.029; Shabana A, 2013, CARDIOVASC TOXICOL, V13, P9, DOI 10.1007/s12012-012-9181-z; Shivers KY, 2014, BBA-MOL BASIS DIS, V1842, P1707, DOI 10.1016/j.bbadis.2014.06.020; Soliman ML, 2013, LIPIDS, V48, P651, DOI 10.1007/s11745-013-3799-x; Tambuyzer BR, 2012, CELL BIOL INT, V36, P1233, DOI 10.1042/CBI20120172; Tekeoglu I, 2007, PHYTOTHER RES, V21, P895, DOI 10.1002/ptr.2143; Tesarova H, 2011, NAT PROD COMMUN, V6, P213; Ullah I, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-11; Umar S, 2012, CHEM-BIOL INTERACT, V197, P40, DOI 10.1016/j.cbi.2012.03.003; Uzawa A, 2010, MULT SCLER J, V16, P1443, DOI 10.1177/1352458510379247; Wilkins Renee, 2011, Biomed Sci Instrum, V47, P222; Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016/j.bcp.2011.09.029; Xuan NT, 2010, CELL PHYSIOL BIOCHEM, V25, P307, DOI 10.1159/000276563; Yamaguchi Y, 2013, J BIOL CHEM, V288, P3097, DOI 10.1074/jbc.M112.362954; Yang WT, 2012, CELL PHYSIOL BIOCHEM, V29, P21, DOI 10.1159/000337583; Ye JM, 2013, NEUROSCI LETT, V553, P72, DOI 10.1016/j.neulet.2013.08.020; Yeh CH, 2014, ENVIRON TOXICOL, V29, P1162, DOI 10.1002/tox.21847	68	38	39	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	SEP 15	2015	286						5	12		10.1016/j.jneuroim.2015.06.011			8	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CQ9RG	WOS:000360952100002	26298318	Green Accepted			2021-06-18	
J	Ilie, G; Mann, RE; Hamilton, H; Adlaf, EM; Boak, A; Asbridge, M; Rehm, J; Cusimano, MD				Ilie, Gabriela; Mann, Robert E.; Hamilton, Hayley; Adlaf, Edward M.; Boak, Angela; Asbridge, Mark; Rehm, Juergen; Cusimano, Michael D.			Substance Use and Related Harms Among Adolescents With and Without Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescents; alcohol use; concussion; drugs; smoking; substance use; traumatic brain injury	DRUG-USE; MENTAL-HEALTH; UNITED-STATES; ALCOHOL; CANNABIS; ABUSE; CLASSIFICATION; ASSOCIATION; POPULATION; PREVALENCE	Objective: The relationship between self-reported lifetime traumatic brain injury (TBI) and drug and alcohol use and associated harms was examined using an epidemiological sample of Canadian adolescents. Settings and Design: Data were derived from a 2011 population-based cross-sectional school survey, which included 6383 Ontario 9th-12th graders who self-completed anonymous self-administered questionnaires in classrooms. Traumatic brain injury was defined as loss of consciousness for at least 5 minutes or a minimum 1-night hospital stay due to symptoms. Results: Relative to high schoolers without a history of TBI, those who acknowledged having a TBI in their lifetime had odds 2 times greater for binge drinking (5+ drinks per occasion in the past 4 weeks), 2.5 times greater for daily cigarette smoking, 2.9 times greater for nonmedical use of prescription drugs, and 2.7 times greater for consuming illegal drug in the past 12 months. Adolescents with a history of TBI had greater odds for experiencing hazardous/harmful drinking (adjusted odds ratio [aOR] = 2.3), cannabis problems (aOR = 2.4), and drug problems (aOR = 2.1), compared with adolescents who were never injured. Conclusion: There are strong and demographically stable associations between TBI and substance use. These associations may not only increase the odds of injury but impair the quality of postinjury recovery.	[Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Mann, Robert E.; Hamilton, Hayley; Adlaf, Edward M.; Boak, Angela; Rehm, Juergen] St Michaels Hosp, Ctr Addict & Mental Hlth, Social & Epidemiol Res, Toronto, ON M5B 1W8, Canada; [Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada	Ilie, G (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	ilieg@smh.ca	Ilie, Gabriela/AAM-9122-2021; Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation; AUTO21; Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada (NSERC); Social Sciences and Humanities Research CouncilSocial Sciences and Humanities Research Council of Canada (SSHRC); Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	This work was financially supported by a STAIR Team Grant from the Canadian Institutes of Health Research (TIR-103946) and by the Ontario Neurotrauma Foundation. Additional funding was obtained from a grant from AUTO21, a member of the Networks of Centres of Excellence program that is administered and funded by the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, in partnership with Industry Canada, and ongoing funding support from the Ontario Ministry of Health and Long-Term Care.	ADLAF EM, 2005, EPIDEMIOLOGY DRUG AB, P99; [Anonymous], 2012, INJ PREV CONTR TRAUM; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Becker B, 2001, DISABIL STUD Q, V21; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Cherpitel CJ, 2007, DRUG ALCOHOL REV, V26, P201, DOI 10.1080/09595230601146686; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Courser MW, 2009, EVALUATION REV, V33, P370, DOI 10.1177/0193841X09337228; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Dicker BG, 1989, HEAD TRAUMA REHABIL, V4, P73; Dikmen S, 2003, NEUROPSYCHOLOGY, V7, P296; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Frances A, DSM 4 CLASSIFICATION; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Groves R.M., 2009, SURVEY METHODOLOGY, VVol. 561; Groves RM, 2008, PUBLIC OPIN QUART, V72, P167, DOI 10.1093/poq/nfn011; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heeringa SG, 2010, APPL SURVEY DATA; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Knight JR, 2002, ARCH PEDIAT ADOL MED, V156, P607, DOI 10.1001/archpedi.156.6.607; Korn EL, 1999, ANAL HLTH SURVEYS, V1st; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; Laird RD, 2005, DEV PSYCHOPATHOL, V17, P127, DOI 10.1017/S0954579405050078; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martin G, 2006, DRUG ALCOHOL DEPEN, V83, P90, DOI 10.1016/j.drugalcdep.2005.10.014; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mohler-Kuo M, 2003, J AM COLL HEALTH, V52, P17, DOI 10.1080/07448480309595719; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Institute on Drug Abuse, 2012, DRUG FACTS HIGH SCH; OuCH, 2012, OUTC FOLL CONC HOCK; Paglia-Boak A., 2011, CAMH RES DOCUMENT SE, V32; Paglia-Boak A, 2013, CAMH RES DOCUMENT SE, V36; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Patton GC, 2002, BMJ-BRIT MED J, V325, P1195, DOI 10.1136/bmj.325.7374.1195; Perle JG, 2013, J CHILD ADOLES SUBST, V22, P1, DOI 10.1080/1067828X.2012.724289; Rey JM, 2002, BRIT J PSYCHIAT, V180, P216, DOI 10.1192/bjp.180.3.216; Ryan L M, 1996, Appl Neuropsychol, V3, P49, DOI 10.1207/s15324826an0302_1; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Turner A., 2009, HDB REHABILITATION P, P241; West BT, 2008, STATA J, V8, P520, DOI 10.1177/1536867X0800800404; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Winqvist S, 2006, J ADOLESCENT HEALTH, V39; Winqvist S, 2007, NEUROEPIDEMIOLOGY, V29, P136, DOI 10.1159/000110741; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264; Zernicke R. F., 2009, Journal of Intercollegiate Sport, V2, P42	69	38	38	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					293	301		10.1097/HTR.0000000000000101			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400007	25427256	Green Accepted			2021-06-18	
J	Yang, ZH; Wang, P; Morgan, D; Lin, D; Pan, JC; Lin, F; Strang, KH; Selig, TM; Perez, PD; Febo, M; Chang, BG; Rubenstein, R; Wang, KKW				Yang, Zhihui; Wang, Ping; Morgan, Drake; Lin, Dan; Pan, Jianchun; Lin, Fan; Strang, Kevin H.; Selig, Tyler M.; Perez, Pablo D.; Febo, Marcelo; Chang, Binggong; Rubenstein, Richard; Wang, Kevin K. W.			Temporal MRI characterization, neurobiochemical and neurobehavioral changes in a mouse repetitive concussive head injury model	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; ANXIETY; HIPPOCAMPUS; DYSFUNCTION; MECHANISMS; PLAYERS; MILD	Single and repeated sports-related mild traumatic brain injury (mTBI), also referred to as concussion, can result in chronic post-concussive syndrome (PCS), neuropsychological and cognitive deficits, or chronic traumatic encephalopathy (CTE). However PCS is often difficult to diagnose using routine clinical, neuroimaging or laboratory evaluations, while CTE currently only can be definitively diagnosed postmortem. We sought to develop an animal model to simulate human repetitive concussive head injury for systematic study. In this study, mice received single or multiple head impacts by a stereotaxic impact device with a custom-made rubber tip-fitted impactor. Dynamic changes in MRI, neurobiochemical markers (Tau hyperphosphorylation and glia activation in brain tissues) and neurobehavioral functions such as anxiety, depression, motor function and cognitive function at various acute/subacute (1-7 day post-injury) and chronic (14-60 days post-injury) time points were examined. To explore the potential biomarkers of rCHI, serum levels of total Tau (T-Tau) and phosphorylated Tau (P-Tau) were also monitored at various time points. Our results show temporal dynamics of MRI consistent with structural perturbation in the acute phase and neurobiochemical changes (P-Tau and GFAP induction) in the subacute and chronic phase as well as development of chronic neurobehavioral changes, which resemble those observed in mTBI patients.	[Yang, Zhihui; Wang, Ping; Lin, Dan; Lin, Fan; Strang, Kevin H.; Selig, Tyler M.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Yang, Zhihui; Wang, Ping; Lin, Dan; Lin, Fan; Strang, Kevin H.; Selig, Tyler M.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Wang, Ping; Lin, Dan] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Morgan, Drake; Perez, Pablo D.; Febo, Marcelo] Univ Florida, McKnight Brain Inst, Dept Psychiat, Gainesville, FL 32611 USA; [Chang, Binggong; Rubenstein, Richard] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA	Yang, ZH (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA.	zhihuiyang@ufl.edu; drakem@ufl.edu; Richard.Rubenstein@downstate.edu; kwang@ufl.edu	Febo, Marcelo/G-5718-2011; Morgan, Drake/F-6664-2012; Febo, Marcelo/X-6769-2019	Febo, Marcelo/0000-0001-8981-4163; Wang, Kevin/0000-0002-9343-6473; Bruijnzeel, Adriaan/0000-0001-8466-1970	Florida state BSCIRTF; McKnight Brain Institute; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA019946]; National Science Foundation CooperativeNational Science Foundation (NSF) [DMR-1157490]; State of Florida; SUNY Downstate Medical Center; Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DoD) Broad Agency Announcement [W81XWH-14-2-0166, W81XWH-11-2-0069]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA019946] Funding Source: NIH RePORTER	Funding support was provided in part by Florida state BSCIRTF (K.K. Wang). M. Febo and P. D. Perez were supported by the McKnight Brain Institute and NIH grant DA019946. The imaging studies of this work were conducted in the UF McKnight Brain Institute at the National High Magnetic Field Laboratory's AMRIS Facility, which is supported by National Science Foundation Cooperative Agreement No. DMR-1157490 and the State of Florida. A portion of this work was supported by both the SUNY Downstate Medical Center (RR) and the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DoD) Broad Agency Announcement under Award #'s W81XWH-14-2-0166 and W81XWH-11-2-0069 (BC, RR). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the DoD. For the DoD, the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.	Beauquis J, 2014, HIPPOCAMPUS, V24, P257, DOI 10.1002/hipo.22219; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; Can A, 2012, JOVE-J VIS EXP, DOI 10.3791/3638; Etkin A, 2012, DEPRESS ANXIETY, V29, P355, DOI 10.1002/da.21957; Etkin A, 2010, CURR TOP BEHAV NEURO, V2, P251, DOI 10.1007/7854_2009_5; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kalisch R, 2006, NEUROPSYCHOPHARMACOL, V31, P925, DOI 10.1038/sj.npp.1300910; Kepe V, 2013, J ALZHEIMERS DIS, V36, P145, DOI 10.3233/JAD-130032; Li CY, 2011, CURR ALZHEIMER RES, V8, P67; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka L. E., 2004, J NEUROTRAUM, V11, P1; Pineda JA, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-47; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rubenstein R., 2014, J NEUROTRAU IN PRESS; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang K., 2013, P SPIE, V8723; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105	29	38	38	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 10	2015	5								11178	10.1038/srep11178			14	Multidisciplinary Sciences	Science & Technology - Other Topics	CK3AO	WOS:000356087600001	26058556	DOAJ Gold, Green Published			2021-06-18	
J	Jalloh, I; Carpenter, KLH; Helmy, A; Carpenter, TA; Menon, DK; Hutchinson, PJ				Jalloh, Ibrahim; Carpenter, Keri L. H.; Helmy, Adel; Carpenter, T. Adrian; Menon, David K.; Hutchinson, Peter J.			Glucose metabolism following human traumatic brain injury: methods of assessment and pathophysiological findings	METABOLIC BRAIN DISEASE			English	Article						C-13 labelling; Glucose; Magnetic resonance spectroscopy; Microdialysis; Positron emission tomography; Traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; TRICARBOXYLIC-ACID CYCLE; PENTOSE-PHOSPHATE PATHWAY; FLUID PERCUSSION INJURY; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; COMBINED MICRODIALYSIS; C-13-LABELED MICRODIALYSIS; SUBSTRATE DELIVERY; LACTATE UPTAKE	The pathophysiology of traumatic brain (TBI) injury involves changes to glucose uptake into the brain and its subsequent metabolism. We review the methods used to study cerebral glucose metabolism with a focus on those used in clinical TBI studies. Arterio-venous measurements provide a global measure of glucose uptake into the brain. Microdialysis allows the in vivo sampling of brain extracellular fluid and is well suited to the longitudinal assessment of metabolism after TBI in the clinical setting. A recent novel development is the use of microdialysis to deliver glucose and other energy substrates labelled with carbon-13, which allows the metabolism of glucose and other substrates to be tracked. Positron emission tomography and magnetic resonance spectroscopy allow regional differences in metabolism to be assessed. We summarise the data published from these techniques and review their potential uses in the clinical setting.	[Jalloh, Ibrahim; Carpenter, Keri L. H.; Helmy, Adel; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Carpenter, T. Adrian; Menon, David K.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge CB2 0QQ, England	Jalloh, I (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167 Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	ij232@cam.ac.uk	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Hutchinson, Peter/0000-0002-2796-1835; Carpenter, Keri/0000-0001-8236-7727	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277 ID 98489]; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowship; National Institute for Health Research Senior Investigator Awards; National Institute for Health Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B, G0001354, G0802251, G1002277, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	We gratefully acknowledge financial support as follows. Authors' support: I.J. - Medical Research Council (Grant no. G1002277 ID 98489) and National Institute for Health Research Biomedical Research Centre, Cambridge; K.L.H.C. - National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); A.H. - Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (Grant no. G0802251) and Raymond and Beverly Sackler Fellowship; D.K.M. - National Institute for Health Research Senior Investigator Awards; P.J.H. - National Institute for Health Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship.	Aaen GS, 2010, PEDIATRICS, V125, P295, DOI 10.1542/peds.2008-3312; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen T, 2000, ACT NEUR S, V76, P359; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529; FERRIS EB, 1946, AM J PHYSIOL, V147, P517; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRUETTER R, 1994, J NEUROCHEM, V63, P1377; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hamilton G, 2006, J MAGN RESON IMAGING, V23, P459, DOI 10.1002/jmri.20524; Hattori N, 2003, J NUCL MED, V44, P1709; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Hetherington HP, 2001, MAGNET RESON MED, V45, P46, DOI 10.1002/1522-2594(200101)45:1<46::AID-MRM1008>3.0.CO;2-N; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P161, DOI 10.1038/jcbfm.1987.39; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Leegsma-Vogt G, 2001, J NEUROSCI RES, V66, P795, DOI 10.1002/jnr.10046; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2009, J NEUROTRAUM, V26, P1281, DOI [10.1089/neu.2008.0827, 10.1089/neu.2008-0827]; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Moreno A, 2001, MAGNET RESON MED, V46, P39, DOI 10.1002/mrm.1158; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Osteen CL, 2004, AGE DEPENDENCY 45CAL; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Paraforou Theoniki, 2011, BMC Res Notes, V4, P540, DOI 10.1186/1756-0500-4-540; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; Pattinson K, 2005, BJA EDUC, V5, P130, DOI 10.1093/bjaceaccp/mki035; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PHELPS ME, 1991, NEUROCHEM RES, V16, P929, DOI 10.1007/BF00965836; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rostami Elham, 2011, J Diabetes Sci Technol, V5, P596; Rothman DL, 2011, NMR BIOMED, V24, P943, DOI 10.1002/nbm.1772; Sampol Denys, 2013, Front Neuroenergetics, V5, P5, DOI 10.3389/fnene.2013.00005; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schonfeld P, 2013, J CEREBR BLOOD F MET, V33, P1493, DOI 10.1038/jcbfm.2013.128; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	96	38	38	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	JUN	2015	30	3					615	632		10.1007/s11011-014-9628-y			18	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CH1YZ	WOS:000353821000002	25413449	Green Published, Other Gold			2021-06-18	
J	Zhou, GW; Brodsky, JR				Zhou, Guangwei; Brodsky, Jacob R.			Objective Vestibular Testing of Children with Dizziness and Balance Complaints Following Sports-Related Concussions	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article						sports-related concussions; dizziness; vertigo; imbalance; vestibular function	TRAUMATIC BRAIN-INJURY; DYNAMIC VISUAL-ACUITY; HEAD-INJURY; POSTURAL STABILITY; CEREBRAL CONCUSSION; HEARING-LOSS; HIGH-SCHOOL; DEFICITS; REHABILITATION; INDIVIDUALS	Objective To conduct objective assessment of children with balance and vestibular complaints following sports-related concussions and identify the underlying deficits by analyzing laboratory test outcomes. Study Designs Case series with chart review. Setting Pediatric tertiary care facility. Subjects and Methods Medical records were reviewed of 42 pediatric patients with balance and/or vestibular complaints following sports-related concussions who underwent comprehensive laboratory testing on their balance and vestibular function. Patients' characteristics were summarized and results analyzed. Results More than 90% of the children with protracted dizziness or imbalance following sports-related concussion had at least 1 abnormal finding from the comprehensive balance and vestibular evaluation. The most frequent deficit was found in dynamic visual acuity test, followed by Sensory Organization Test and rotational test. Patient's balance problem associated with concussion seemed to be primarily instigated by vestibular dysfunction. Furthermore, semicircular canal dysfunction was involved more often than dysfunction of otolith organs. Yet, <10% of the children experienced a hearing loss following sports-related concussion. Conclusions Vestibular impairment is common among children with protracted dizziness or imbalance following sports-related concussion. Our study demonstrated that proper and thorough evaluation is imperative to identify these underlying deficits and laboratory tests were helpful in the diagnosis and recommendation of following rehabilitations.	[Zhou, Guangwei; Brodsky, Jacob R.] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Waltham, MA 02453 USA; [Zhou, Guangwei; Brodsky, Jacob R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA	Zhou, GW (corresponding author), Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Balance & Vestibular Program, 9 Hope Ave, Waltham, MA 02453 USA.	guangwei.zhou@childrens.harvard.edu		Brodsky, Jacob/0000-0001-9656-5855			Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bland DC, 2011, BRAIN INJURY, V25, P664, DOI 10.3109/02699052.2011.576306; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dannenbaum E, 2005, J OTOLARYNGOL, V34, P13, DOI 10.2310/7070.2005.03105; Dannenbaum E, 2009, OTOL NEUROTOL, V30, P368, DOI 10.1097/MAO.0b013e31819bda35; Dault MC, 2002, BRAIN INJURY, V16, P231, DOI 10.1080/02699050110103300; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Herdman SJ, 1998, AM J OTOL, V19, P790; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; MAKISHIMA K, 1976, LARYNGOSCOPE, V86, P1303, DOI 10.1288/00005537-197609000-00002; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peters BT, 2012, J VESTIBUL RES-EQUIL, V22, P145, DOI 10.3233/VES-2012-0440; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Tian JR, 2001, ANN NY ACAD SCI, V942, P501; YLIKOSKI J, 1982, AM J OTOL, V3, P343; Zhou GW, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000037	45	38	38	0	23	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	JUN	2015	152	6					1133	1139		10.1177/0194599815576720			7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	CJ7QJ	WOS:000355692300028	25820582				2021-06-18	
J	Haring, RS; Narang, K; Canner, JK; Asemota, AO; George, BP; Selvarajah, S; Haider, AH; Schneider, EB				Haring, R. Sterling; Narang, Kunal; Canner, Joseph K.; Asemota, Anthony O.; George, Benjamin P.; Selvarajah, Shalini; Haider, Adil H.; Schneider, Eric B.			Traumatic brain injury in the elderly: morbidity and mortality trends and risk factors	JOURNAL OF SURGICAL RESEARCH			English	Article						Older adult; TBI; Mortality; Morbidity; Risk factors	UNITED-STATES; SEVERITY SCORE; OLDER; DISABILITY; OUTCOMES; CARE; TBI; AGE	An estimated 1.7 million people sustain a traumatic brain injury (TBI) annually in the United States. We sought to examine factors contributing to mortality among TBI patients aged >= 65 y in the United States. TBI data from the Nationwide Inpatient Sample were combined from 2000-2010. Patients were stratified by age, sex, mechanism of injury, payer status, comorbidity, injury severity, and other factors. Odds of death were explored using an adjusted multivariable logistic regression. A total of 950,132 TBI-related hospitalizations and 107,666 TBI-related deaths occurred among adults aged >= 65 y from 2000-2010. The most common mechanism of injury was falling, and falls were more common among the oldest age groups. Logistic regression analysis showed highest odds of death among male patients, those whose mechanism of injury was motor vehicle related, patients with three or more comorbidities, and patients who were designated as self-paying. (C) 2015 Elsevier Inc. All rights reserved.	[Haring, R. Sterling; Haider, Adil H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Haring, R. Sterling] Lake Erie Coll Osteopath Med, Dept Osteopath Med, Bradenton, FL USA; [Haring, R. Sterling; Narang, Kunal; Canner, Joseph K.; Asemota, Anthony O.; George, Benjamin P.; Selvarajah, Shalini; Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Univ, CSTOR, Dept Surg, Baltimore, MD USA; [Asemota, Anthony O.] Johns Hopkins Univ, Dept Neurol & Neurosurg, Baltimore, MD USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	Schneider, EB (corresponding author), Johns Hopkins Univ Hosp, Dept Surg, CSTOR, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	eschnei1@jhmi.edu		Narang, Kunal/0000-0001-5980-4845; Haring, R. Sterling/0000-0002-5417-3914	Patient-Centered Outcomes Research InstitutePatient-Centered Outcomes Research Institute - PCORI [AD-1306-03980]; American College of Surgeons; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112-01]; World Health Organization, Geneva, SwitzerlandWorld Health Organization; Karolinska Institutet, Stockholm, Sweden; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	R.S.H., K.N., J.K.C., A.O.A., B.P.G., and S.S. had no competing interests. A.H.H. receives funding from the Patient-Centered Outcomes Research Institute, (AD-1306-03980) the American College of Surgeons, (C. James Carrico Fellowship) and the National Institute of General Medical Sciences (K23GM093112-01). E.B.S. has pending patents regarding central nervous system trauma, is amember of Bergeim, LLC, and receives support for consulting from the World Health Organization, Geneva, Switzerland and Karolinska Institutet, Stockholm, Sweden.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P33; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clark DE., 2010, ICDPIC STATA MODULE; Committee on Injury Scaling, 1980, AM ASS AUTOMOT MED; Coronado V, 2012, EPIDEMIOLOG IN PRESS; Coronado V, 2006, JAMA-J AM MED ASSOC, V295, P201; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cuthbert J, 2011, ARCH PHYS MED REHABI, V92; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Day J., 1996, POPULATION PROJECTIO; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Haider A, 2007, ARCH SURG-CHICAGO, V143, P945; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; HCUP National Inpatient Sample (NIS), 2000, HEALTHC COST UT PROJ; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI 10.1097/00005650-198506000-00008; Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003-4819-153-12-201012210-00008; O'Keefe G, 2001, INJ CONTROL; Ortman Jennifer M., 2009, US POPULATION PROJEC; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Quigley P, 2007, ONLINE J ISSUES NURS, V12, P1; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneider EB, 2012, J SURG RES, V177, P295, DOI 10.1016/j.jss.2012.06.022; Sears JM, 2013, J OCCUP REHABIL, V23, P19, DOI 10.1007/s10926-012-9377-x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; StataCorp, 2011, STAT STAT SOFTW; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; U.S. Census Bureau DID, POP EST; Xian Y, 2011, ANN INTERN MED, V154, P152, DOI 10.7326/0003-4819-154-3-201102010-00004	36	38	39	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY 1	2015	195	1					1	9		10.1016/j.jss.2015.01.017			9	Surgery	Surgery	CE9CA	WOS:000352139900001	25724764				2021-06-18	
J	Mac Donald, CL; Adam, OR; Johnson, AM; Nelson, EC; Werner, NJ; Rivet, DJ; Brody, DL				Mac Donald, Christine L.; Adam, Octavian R.; Johnson, Ann M.; Nelson, Elliot C.; Werner, Nicole J.; Rivet, Dennis J.; Brody, David L.			Acute post-traumatic stress symptoms and age predict outcome in military blast concussion	BRAIN			English	Article						traumatic brian injury; post-traumatic stress; clinical outcome; concussion	TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL RATING-SCALE; OPERATION IRAQI FREEDOM; HEAD-INJURY; NOS-TBI; STRUCTURED INTERVIEWS; PSYCHIATRIC-DISORDERS; OEF/OIF VETERANS; NATIONAL-GUARD; MENTAL-HEALTH	High rates of adverse outcomes have been reported following blast-related concussive traumatic brain injury in US military personnel, but the extent to which such adverse outcomes can be predicted acutely after injury is unknown. We performed a prospective, observational study of US military personnel with blast-related concussive traumatic brain injury (n = 38) and controls (n = 34) enrolled between March and September 2012. Importantly all subjects returned to duty and did not require evacuation. Subjects were evaluated acutely 0-7 days after injury at two sites in Afghanistan and again 6-12 months later in the United States. Acute assessments revealed heightened post-concussive, post-traumatic stress, and depressive symptoms along with worse cognitive performance in subjects with traumatic brain injury. At 6-12 months follow-up, 63% of subjects with traumatic brain injury and 20% of controls had moderate overall disability. Subjects with traumatic brain injury showed more severe neurobehavioural, post-traumatic stress and depression symptoms along with more frequent cognitive performance deficits and more substantial headache impairment than control subjects. Logistic regression modelling using only acute measures identified that a diagnosis of traumatic brain injury, older age, and more severe post-traumatic stress symptoms provided a good prediction of later adverse global outcomes (area under the receiver-operating characteristic curve = 0.84). Thus, US military personnel with concussive blast-related traumatic brain injury in Afghanistan who returned to duty still fared quite poorly on many clinical outcome measures 6-12 months after injury. Poor global outcome seems to be largely driven by psychological health measures, age, and traumatic brain injury status. The effects of early interventions and longer term implications of these findings are unknown.	[Mac Donald, Christine L.; Johnson, Ann M.; Nelson, Elliot C.; Werner, Nicole J.; Brody, David L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Adam, Octavian R.; Rivet, Dennis J.] Naval Med Ctr Portsmouth, Portsmouth, VA 23708 USA	Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA.	cmacd@uw.edu			Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT090444]	The study was funded by the Congressionally Directed Medical Research Program (PT090444 Supplement, PI: D. Brody). The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Navy, Department of Defense, or U.S. Government. The principal investigators O. Adam, D. Brody and study director C. Mac Donald had full access to all of the data and take full responsibility for the integrity of the data and the accuracy of the analysis. The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Benton AL, 1983, MULTILINGUAL APHASIA; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Conaton E, 2012, DOD POLICY GUIDANCE; Conners C., 2000, CONNERS CONTINUOUS P; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Dempsey KE, 2009, J TRAUMA NURS, V16, P10; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Maguen S, 2012, J TRAUMA STRESS, V25, P3, DOI 10.1002/jts.21669; Matthews C, 1964, INSTRUCTION MANUAL A; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Norris JN, 2013, MIL MED, V178, P767, DOI 10.7205/MILMED-D-12-00493; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reitan R. M., 1992, TRAIL MAKING TEST MA; Ruff R, 1996, ARCH CLIN NEUROPSYCH, V11, P313, DOI 10.1016/0887-6177(95)00031-3; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; SNAITH RP, 1986, BRIT J PSYCHIAT, V148, P599, DOI 10.1192/bjp.148.5.599; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Taniellian T, 2008, INVISIBLE WOUNDS WAR; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tombough T., 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 2001, WECHSLER TEST ADULT; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Wilde EA, 2010, J NEUROTRAUM, V27, P983, DOI 10.1089/neu.2009.1194; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	71	38	38	1	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY 1	2015	138		5				1314	1326		10.1093/brain/awv038			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CH2DB	WOS:000353834100019	25740219	Bronze, Green Published			2021-06-18	
J	Ryan, NP; Catroppa, C; Cooper, JM; Beare, R; Ditchfield, M; Coleman, L; Silk, T; Crossley, L; Beauchamp, MH; Anderson, VA				Ryan, Nicholas P.; Catroppa, Cathy; Cooper, Janine M.; Beare, Richard; Ditchfield, Michael; Coleman, Lee; Silk, Timothy; Crossley, Louise; Beauchamp, Miriam H.; Anderson, Vicki A.			The Emergence of Age-Dependent Social Cognitive Deficits After Generalized Insult to the Developing Brain: A Longitudinal Prospective Analysis Using Susceptibility-Weighted Imaging	HUMAN BRAIN MAPPING			English	Article						child; brain injuries; magnetic resonance imaging; Theory of Mind; neurobiology	DIFFUSE AXONAL INJURY; WHITE-MATTER DAMAGE; CLINICAL-APPLICATIONS; EMOTION RECOGNITION; HEAD-INJURY; CHILDREN; MIND; CHILDHOOD; PLASTICITY; OUTCOMES	Childhood and adolescence are critical periods for maturation of neurobiological processes that underlie complex social and emotional behavior including Theory of Mind (ToM). While structural correlates of ToM are well described in adults, less is known about the anatomical regions subsuming these skills in the developing brain or the impact of cerebral insult on the acquisition and establishment of high-level social cognitive skills. This study aimed to examine the differential influence of age-at-insult and brain pathology on ToM in a sample of children and adolescents with traumatic brain injury (TBI). Children and adolescents with TBI (n=112) were categorized according to timing of brain insult: (i) middle childhood (5-9 years; n=41); (ii) late childhood (10-11 years; n=39); and (iii) adolescence (12-15 years; n=32) and group-matched for age, gender, and socioeconomic status to a typically developing (TD) control group (n=43). Participants underwent magnetic resonance imaging including a susceptibility-weighted imaging (SWI) sequence 2-8 weeks postinjury and were assessed on a battery of ToM tasks at 6- and 24-months after injury. Results showed that for adolescents with TBI, social cognitive dysfunction at 6- and 24-months postinjury was associated with diffuse neuropathology and a greater number of lesions detected using SWI. In the late childhood TBI group, we found a time-dependent emergence of social cognitive impairment, linked to diffuse neuropathology. The middle childhood TBI group demonstrated performance unrelated to SWI pathology and comparable to TD controls. Findings indicate that the full extent of social cognitive deficits may not be realized until the associated skills reach maturity. Evidence for brain structure-function relationships suggests that the integrity of an anatomically distributed network of brain regions and their connections is necessary for the acquisition and establishment of high-level social cognitive skills. Hum Brain Mapp 36:1677-1691, 2015. (c) 2014 Wiley Periodicals, Inc.	[Ryan, Nicholas P.; Catroppa, Cathy; Cooper, Janine M.; Crossley, Louise; Anderson, Vicki A.] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Beare, Richard; Silk, Timothy] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia; [Ditchfield, Michael] Monash Hlth, Dept Paediat Imaging, Melbourne, Vic, Australia; [Ditchfield, Michael] Monash Univ, Dept Paediat, Meloburne, Australia; [Coleman, Lee] Royal Childrens Hosp, Dept Radiol, Melbourne, Vic, Australia; [Silk, Timothy] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada	Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Ryan, Nicholas/K-5445-2019; Silk, Tim/K-4295-2019	Ryan, Nicholas/0000-0002-0878-8889; Beare, Richard/0000-0002-7530-5664; Silk, Tim/0000-0002-7290-512X	Victoria Neurotrauma Initiative, Australia; Victorian Government	This work was supported by a grant from the Victoria Neurotrauma Initiative, Australia and the Victorian Government Operational Infrastructure Support Program. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2010, BRAIN, V133, P45; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Blakemore SJ, 2011, CHILD PSYCHOLOGY AND PSYCHIATRY: FRAMEWORKS FOR PRACTICE, 2ND EDITION, P62; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Coffey C., 1991, Psychopathology and the Brain, V3, P243; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2000, AUTISM, V4, P370, DOI DOI 10.1177/1362361300004004003; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M, 2014, NEUROPSYCHOL REV, V24, P389, DOI 10.1007/s11065-014-9261-x; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Follett PL, 2009, J CHILD NEUROL, V24, P1205, DOI 10.1177/0883073809338627; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Herbet G, 2014, BRAIN, V137, P944, DOI 10.1093/brain/awt370; Herbet G, 2013, CORTEX, V49, P2711, DOI 10.1016/j.cortex.2013.08.003; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Johnson MH, 2001, NAT REV NEUROSCI, V2, P475, DOI 10.1038/35081509; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Mosch SC, 2005, COGN BEHAV NEUROL, V18, P5, DOI 10.1097/01.wnn.0000152207.80819.3c; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Nelson EE, 2005, PSYCHOL MED, V35, P163, DOI 10.1017/S0033291704003915; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Scherf KS, 2013, HORM BEHAV, V64, P298, DOI 10.1016/j.yhbeh.2013.05.011; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sengpiel F, 2007, CURR BIOL, V17, pR742, DOI 10.1016/j.cub.2007.06.017; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Sodian B, 2007, DEVELOPMENTAL SCI, V10, P199, DOI 10.1111/j.1467-7687.2007.00580.x; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; Tabachnick B., 2001, USING MULTIVARIATE S; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yurgelun-Todd D, 2007, CURR OPIN NEUROBIOL, V17, P251, DOI 10.1016/j.conb.2007.03.009; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	85	38	38	1	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2015	36	5					1677	1691		10.1002/hbm.22729			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CG1XH	WOS:000353068300004	25537228	Green Published			2021-06-18	
J	Laccheo, I; Sonmezturk, H; Bhatt, AB; Tomycz, L; Shi, YP; Ringel, M; DiCarlo, G; Harris, D; Barwise, J; Abou-Khalil, B; Haas, KF				Laccheo, Ikuko; Sonmezturk, Hasan; Bhatt, Amar B.; Tomycz, Luke; Shi, Yaping; Ringel, Marianna; DiCarlo, Gina; Harris, DeAngelo; Barwise, John; Abou-Khalil, Bassel; Haas, Kevin F.			Non-convulsive Status Epilepticus and Non-convulsive Seizures in Neurological ICU Patients	NEUROCRITICAL CARE			English	Article						Neurological ICU; Critical care; Altered mental status; Non-convulsive seizures; Non-convulsive status epilepticus; EEG	INTENSIVE-CARE-UNIT; REFRACTORY STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; NEUROCRITICAL CARE; CLINICAL-FEATURES; MANAGEMENT; PREVALENCE; MORTALITY	Non-convulsive seizures (NCS) or non-convulsive status epilepticus (NCSE) has been reported in 8-20 % of critically ill patient populations, and delayed diagnosis and treatment of NCSE may lead to increased mortality. This study seeks to better understand the risk factors, characteristics, and outcome of NCS/NCSE in the neurological ICU. This is a prospective observational study, recruiting consecutive patients admitted to the adult neurological ICU with altered mental status. Patients with anoxic brain injury were excluded from the study. Data were collected and analyzed for prevalence of NCSE/NCS, EEG patterns, associated risk factors, treatment response, and final outcome. NCSE/NCS was detected in 21 % of 170 subjects. Clinical seizures preceded EEG diagnosis of NCSE/NCS in 25 % of cases. Significant risk factors for NCSE/NCS were a past medical history of intracranial tumor, epilepsy, or meningitis/encephalitis, or MRI evidence of encephalomalacia. Subtle clinical findings such as twitching of oral or ocular muscles and eye deviations were found on exam in 50 % of the NCSE/NCS group. Mortality was increased in NCSE cases as 31 % of NCSE/NCS patients died compared to 14 % in non-NCSE/NCS group. Specific clinical features along with history and imaging findings may be used to identify patients at high risk of NCSE/NCS in the neurological ICU.	[Laccheo, Ikuko] Vet Affairs Med Ctr, Epilepsy Ctr Excellence, Richmond, VA 23224 USA; [Laccheo, Ikuko] Virginia Commonwealth Univ, Richmond, VA USA; [Sonmezturk, Hasan; Bhatt, Amar B.; Shi, Yaping; Ringel, Marianna; DiCarlo, Gina; Harris, DeAngelo; Barwise, John; Abou-Khalil, Bassel; Haas, Kevin F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Tomycz, Luke] Seattle Childrens Hosp, Seattle, WA USA	Laccheo, I (corresponding author), Vet Affairs Med Ctr, Epilepsy Ctr Excellence, Richmond, VA 23224 USA.	ikuko.laccheo@gmail.com					Benbadis SR, 2000, NEUROLOGY, V55, P1421, DOI 10.1212/WNL.55.9.1421-a; Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Cocito L, 2001, ARCH NEUROL-CHICAGO, V58, P1310, DOI 10.1001/archneur.58.8.1310; Cooper AD, 2009, ARCH NEUROL-CHICAGO, V66, P1505, DOI 10.1001/archneurol.2009.273; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; Drislane FW, 2008, J CLIN NEUROPHYSIOL, V25, P181, DOI 10.1097/WNP.0b013e31817be70e; Flores-Cordero JM, 2003, INTENS CARE MED, V29, P1967, DOI 10.1007/s00134-003-1935-4; Holtkamp M, 2005, J NEUROL NEUROSUR PS, V76, P534, DOI 10.1136/jnnp.2004.041947; Husain AM, 2003, J NEUROL NEUROSUR PS, V74, P189, DOI 10.1136/jnnp.74.2.189; Jordan Kenneth G, 2009, Am J Electroneurodiagnostic Technol, V49, P94; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; Khan SF, 2005, CLIN NEUROPHYSIOL, V116, P2454, DOI 10.1016/j.clinph.2005.06.024; Kramer AH, 2012, CAN J NEUROL SCI, V39, P328, DOI 10.1017/S0317167100013469; Little AS, 2007, J NEUROSURG, V106, P805, DOI 10.3171/jns.2007.106.5.805; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Maschio M, 2012, J NEURO-ONCOL, V109, P1, DOI 10.1007/s11060-012-0867-7; Mecarelli O, 2011, CEREBROVASC DIS, V31, P191, DOI 10.1159/000321872; Meierkord H, 2010, EUR J NEUROL, V17, P348, DOI 10.1111/j.1468-1331.2009.02917.x; Mirski MA, 2008, CRIT CARE CLIN, V24, P115, DOI 10.1016/j.ccc.2007.11.005; Narayanan JT, 2007, EPILEPSIA, V48, P900, DOI 10.1111/j.1528-1167.2007.01099.x; Ney JP, 2013, NEUROLOGY, V81, P2002, DOI 10.1212/01.wnl.0000436948.93399.2a; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Spindler M, 2013, J CLIN NEUROPHYSIOL, V30, P339, DOI 10.1097/WNP.0b013e31829ddcdb; Sutter R, 2014, NEUROLOGY, V82, P656, DOI 10.1212/WNL.0000000000000009; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 2006, EPILEPSY RES, V68, pS77, DOI 10.1016/j.eplepsyres.2005.07.020; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2005, CURR OPIN CRIT CARE, V11, P133, DOI 10.1097/01.ccx.0000155353.01489.58; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Walker MC, 2003, J NEUROL, V250, P401, DOI 10.1007/s00415-003-1042-z; Waterhouse EJ, 1999, EPILEPSIA, V40, P752, DOI 10.1111/j.1528-1157.1999.tb00774.x; Young GB, 1999, J CLIN NEUROPHYSIOL, V16, P354, DOI 10.1097/00004691-199907000-00008; Young GB, 1996, NEUROLOGY, V47, P83; Zoons E, 2008, NEUROLOGY, V70, P2109, DOI 10.1212/01.wnl.0000288178.91614.5d	49	38	41	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2015	22	2					202	211		10.1007/s12028-014-0070-0			10	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CD9VK	WOS:000351447100005	25246236				2021-06-18	
J	Peltz, ED; D'Alessandro, A; Moore, EE; Chin, T; Silliman, CC; Sauaia, A; Hansen, KC; Banerjee, A				Peltz, Erik D.; D'Alessandro, Angelo; Moore, Ernest E.; Chin, Theresa; Silliman, Christopher C.; Sauaia, Angela; Hansen, Kirk C.; Banerjee, Anirban			Pathologic metabolism: An exploratory study of the plasma metabolome of critical injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Metabolomics; trauma; energy metabolism; proteolysis; lipolysis; ketoacidosis	TRAUMATIC BRAIN-INJURY; MULTIPLE ORGAN FAILURE; LUNG INJURY; HEMORRHAGIC-SHOCK; ROUTINE STORAGE; BASE DEFICIT; IN-VITRO; ACID; LACTATE; CARE	BACKGROUND: Severe trauma is associated with massive alterations in metabolism. Thus far, investigations have relied on traditional bioanalytic approaches including calorimetry or nuclear magnetic resonance. However, recent strides in mass spectrometry (MS)-based metabolomics present enhanced analytic opportunities to characterize a wide range of metabolites in the critical care setting. METHODS: MS-based metabolomics analyses were performed on plasma samples from severely injured patients' trauma activation field blood and plasma samples obtained during emergency department thoracotomy. These were compared against the metabolic profiles of healthy controls. RESULTS: Few significant alterations were observed between trauma activation field blood and emergency department thoracotomy patients. In contrast, we identified trauma-dependent metabolic signatures, which support a state of hypercatabolism, driven by sugar consumption, lipolysis and fatty acid use, accumulation of ketone bodies, proteolysis and nucleoside breakdown, which provides carbon and nitrogen sources to compensate for trauma-induced energy consumption and negative nitrogen balance. Unexpectedly, metabolites of bacterial origin (including tricarballylate and citramalate) were detected in plasma from trauma patients. CONCLUSION: In the future, the correlation between metabolomics adaptation and recovery outcomes could be studied by MS-based approaches, and this work can provide a method for assessing the efficacy of alternative resuscitation strategies. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Peltz, Erik D.; Moore, Ernest E.; Chin, Theresa; Silliman, Christopher C.; Sauaia, Angela] Univ Colorado Denver, Sch Med, Dept Surg, Trauma Res Ctr, Aurora, CO USA; [D'Alessandro, Angelo; Hansen, Kirk C.] Univ Colorado Denver, Sch Med, Dept Biochem & Mol Genet, Aurora, CO USA; [Sauaia, Angela] Univ Colorado Denver, Sch Med, Dept Hlth Care Policy & Res, Aurora, CO USA; [Silliman, Christopher C.] Univ Colorado Denver, Sch Med, Dept Pediat Haematol Oncol, Anschutz Med Campus Childrens Hosp Colorado, Aurora, CO USA; [Moore, Ernest E.] Denver Hlth Med Ctr, Dept Surg, Aurora, CO USA; [Silliman, Christopher C.] Belle Bonfils Blood Ctr, Denver, CO USA	Peltz, ED (corresponding author), Univ Colorado Anschutz Med Campus, Dept Surg, 12631 E 17th Ave,Room 6001, Aurora, CO 80045 USA.	Erik.Peltz@ucdenver.edu	D'Alessandro, Angelo/AAA-4695-2019	D'Alessandro, Angelo/0000-0002-2258-6490	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32-GM008315, P50-GM049222]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008315, P50GM049222] Funding Source: NIH RePORTER	This study was supported in part by National Institute of General Medical Sciences grants T32-GM008315 and P50-GM049222. E.D.P., A.D., E.E.M., T.C., C.C.S., A.S., K.C.H., and A.B. have no reported biomedical financial interests or potential conflicts of interest.	Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Beloborodova N, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-89; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Bruegger D, 2007, CRIT CARE, V11, DOI 10.1186/cc6200; Chaleckis R, 2014, MOL BIOSYST, V10, P2538, DOI 10.1039/c4mb00346b; CLOWES GHA, 1985, ANN SURG, V202, P446, DOI 10.1097/00000658-198510000-00006; Cohen MJ, 2010, J TRAUMA, V69, P31, DOI 10.1097/TA.0b013e3181e043fe; Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2; D'Alessandro A, 2015, VOX SANG, V108, P131, DOI 10.1111/vox.12193; D'Alessandro A, 2015, TRANSFUSION, V55, P205, DOI 10.1111/trf.12804; D'Alessandro A, 2012, HAEMATOL-HEMATOL J, V97, P107, DOI 10.3324/haematol.2011.051789; Dettmer K, 2007, MASS SPECTROM REV, V26, P51, DOI 10.1002/mas.20108; Dieterle F, 2011, METHODS MOL BIOL, V691, P385, DOI 10.1007/978-1-60761-849-2_24; Forni LG, 2005, CRIT CARE, V9, pR591, DOI 10.1186/cc3806; FORSE RA, 1987, ANN SURG, V206, P744, DOI 10.1097/00000658-198712000-00010; Franconi F, 2001, THROMB RES, V102, P255, DOI 10.1016/S0049-3848(01)00249-3; FRANKENFIELD DC, 1994, CRIT CARE MED, V22, P1796; Hasenboehler Erik, 2006, World J Emerg Surg, V1, P29, DOI 10.1186/1749-7922-1-29; Heron Melonie, 2013, Natl Vital Stat Rep, V62, P1; Kaplan LJ, 2004, CRIT CARE MED, V32, P1120, DOI 10.1097/01.CCM.0000125517.28517.74; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kinross JM, 2011, J PROTEOME RES, V10, P277, DOI 10.1021/pr1003278; Koek MM, 2011, METABOLOMICS, V7, P307, DOI 10.1007/s11306-010-0254-3; KOIKE K, 1994, CRIT CARE MED, V22, P1438, DOI 10.1097/00003246-199409000-00014; Lee SJ, 2006, NEPHROL DIAL TRANSPL, V21, P3; Lexcen DR, 2012, J TRAUMA ACUTE CARE, V73, pS147, DOI 10.1097/TA.0b013e3182609821; Lusardi TA, 2009, CURR NEUROPHARMACOL, V7, P228, DOI 10.2174/157015909789152137; Mackay GM, 2006, EUR J NEUROL, V13, P30, DOI 10.1111/j.1468-1331.2006.01220.x; Mao HL, 2009, J PROTEOME RES, V8, P5423, DOI 10.1021/pr900576y; Martin M, 2005, J TRAUMA, V58, P238, DOI 10.1097/01.TA.0000152535.97968.4E; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; MOORE FA, 1992, J TRAUMA, V33, P58, DOI 10.1097/00005373-199207000-00012; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Moviat M, 2008, CRIT CARE MED, V36, P752, DOI 10.1097/CCM.0B013E31816443CB; Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314; Peltz ED, 2009, SURGERY, V146, P347, DOI 10.1016/j.surg.2009.02.022; PIEK J, 1985, INTENS CARE MED, V11, P192, DOI 10.1007/BF00272402; Pitt J, 2002, J INHERIT METAB DIS, V25, P83, DOI 10.1023/A:1015654608166; Scalbert A, 2009, METABOLOMICS, V5, P435, DOI 10.1007/s11306-009-0168-0; SCHUMER W, 1986, J TRAUMA, V26, P1009, DOI 10.1097/00005373-198611000-00009; Serkova NJ, 2011, AM J RESP CRIT CARE, V184, P647, DOI 10.1164/rccm.201103-0474CI; SEYDEWITZ HH, 1984, THROMB RES, V33, P487, DOI 10.1016/0049-3848(84)90014-8; Silliman CC, 2011, TRANSFUSION, V51, P2549, DOI 10.1111/j.1537-2995.2011.03186.x; Spath B, 2012, PLATELETS, V23, P60, DOI 10.3109/09537104.2011.590255; VANDERMEER C, 1981, CIRC SHOCK, V8, P375; WEISSMAN C, 1990, ANESTHESIOLOGY, V73, P308, DOI 10.1097/00000542-199008000-00020; Wischmeyer PE, 2014, CRIT CARE, V18, DOI 10.1186/cc13836; Zallen G, 1999, J SURG RES, V83, P83, DOI 10.1006/jsre.1999.5569	50	38	39	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2015	78	4					742	751		10.1097/TA.0000000000000589			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CE8EJ	WOS:000352074000013	25807403	Green Accepted			2021-06-18	
J	Perez-Polo, JR; Rea, HC; Johnson, KM; Parsley, MA; Unabia, GC; Xu, GY; Prough, D; DeWitt, DS; Spratt, H; Hulsebosch, CE				Perez-Polo, J. R.; Rea, H. C.; Johnson, K. M.; Parsley, M. A.; Unabia, G. C.; Xu, G. -Y.; Prough, D.; DeWitt, D. S.; Spratt, H.; Hulsebosch, C. E.			A Rodent Model of Mild Traumatic Brain Blast Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						mild traumatic blast brain injury; inflammation; cytokines; phosphorylated Tau protein; memory; righting reflex response	CHEMOKINE EXPRESSION; RIGHTING REFLEX; RAT MODEL; ENCEPHALOPATHY; DEFICITS; TAU; MICROINJECTION; CONSEQUENCES; ORGANIZATION; INFLAMMATION	One of the criteria defining mild traumatic brain injury (mTBI) in humans is a loss of consciousness lasting for less than 30 min. mTBI can result in long-term impairment of cognition and behavior. In rats, the length of time it takes a rat to right itself after injury is considered to be an analog for human return to consciousness. This study characterized a rat mild brain blast injury (mBBI) model defined by a righting response reflex time (RRRT) of more than 4 min but less than 10 min. Assessments of motor coordination relying on beam-balance and foot-fault assays and reference memory showed significant impairment in animals exposed to mBBI. This study's hypothesis is that there are inflammatory outcomes to mTBI over time that cause its deleterious effects. For example, mBBI significantly increased brain levels of interleukin (IL)-1 and tumor necrosis factor- (TNF) protein. There were significant inflammatory responses in the cortex, hippocampus, thalamus, and amygdala 6 hr after mBBI, as evidenced by increased levels of the inflammatory markers associated with activation of microglia and macrophages, ionized calcium binding adaptor 1 (IBA1), impairment of the blood-brain barrier, and significant neuronal losses. There were significant increases in phosphorylated Tau (p-Tau) levels, a putative precursor to the development of neuroencephalopathy, as early as 6 hr after mBBI in the cortex and the hippocampus but not in the thalamus or the amygdala. There was an apparent correlation between RRRTs and p-Tau protein levels but not IBA1. These results suggest potential therapies for mild blast injuries via blockade of the IL-1 and TNF receptors. (c) 2014 Wiley Periodicals, Inc.	[Perez-Polo, J. R.; Rea, H. C.; Johnson, K. M.; Parsley, M. A.; Unabia, G. C.; Xu, G. -Y.; Prough, D.; DeWitt, D. S.; Spratt, H.; Hulsebosch, C. E.] Univ Texas Med Branch, Galveston, TX 77555 USA	Perez-Polo, JR (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	regino.perez-polo@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; BIGNALL KE, 1974, EXP NEUROL, V42, P566, DOI 10.1016/0014-4886(74)90079-X; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CDC, 2003, REP C MILD TRAUM BRA; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs, 2009, CLIN PRACT GUID MAN; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Masel BE, 2012, J NEUROTRAUM, V29, P2143, DOI 10.1089/neu.2011.2258; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mediavilla Varas Jesus, 2011, Front Neurol, V2, P58, DOI 10.3389/fneur.2011.00058; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sukhotinsky I, 2007, EUR J NEUROSCI, V25, P1417, DOI 10.1111/j.1460-9568.2007.05399.x; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	54	38	38	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2015	93	4					549	561		10.1002/jnr.23513			13	Neurosciences	Neurosciences & Neurology	CB4LZ	WOS:000349600500002	25410497				2021-06-18	
J	Stergiopoulos, V; Cusi, A; Bekele, T; Skosireva, A; Latimer, E; Schutz, C; Fernando, I; Rourke, SB				Stergiopoulos, V.; Cusi, A.; Bekele, T.; Skosireva, A.; Latimer, E.; Schuetz, C.; Fernando, I.; Rourke, S. B.			Neurocognitive impairment in a large sample of homeless adults with mental illness	ACTA PSYCHIATRICA SCANDINAVICA			English	Article						cognition; homeless persons; mental disorders; neuropsychology	TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSIVE DISORDER; NEUROPSYCHIATRIC INTERVIEW MINI; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL IMPAIRMENT; EXECUTIVE FUNCTION; TEST BATTERY; RISK-FACTORS; ILL PERSONS; SCHIZOPHRENIA	ObjectiveThis study examines neurocognitive functioning in a large, well-characterized sample of homeless adults with mental illness and assesses demographic and clinical factors associated with neurocognitive performance. MethodA total of 1500 homeless adults with mental illness enrolled in the At Home Chez Soi study completed neuropsychological measures assessing speed of information processing, memory, and executive functioning. Sociodemographic and clinical data were also collected. Linear regression analyses were conducted to examine factors associated with neurocognitive performance. ResultsApproximately half of our sample met criteria for psychosis, major depressive disorder, and alcohol or substance use disorder, and nearly half had experienced severe traumatic brain injury. Overall, 72% of participants demonstrated cognitive impairment, including deficits in processing speed (48%), verbal learning (71%) and recall (67%), and executive functioning (38%). The overall statistical model explained 19.8% of the variance in the neurocognitive summary score, with reduced neurocognitive performance associated with older age, lower education, first language other than English or French, Black or Other ethnicity, and the presence of psychosis. ConclusionHomeless adults with mental illness experience impairment in multiple neuropsychological domains. Much of the variance in our sample's cognitive performance remains unexplained, highlighting the need for further research in the mechanisms underlying cognitive impairment in this population.	[Stergiopoulos, V.; Cusi, A.; Skosireva, A.; Fernando, I.; Rourke, S. B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City, Toronto, ON M5B 1W8, Canada; [Stergiopoulos, V.; Rourke, S. B.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Bekele, T.; Rourke, S. B.] Ontario HIV Treatment Network, Toronto, ON, Canada; [Latimer, E.] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada; [Latimer, E.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Schuetz, C.] Univ British Columbia, Dept Psychiat, Inst Mental Hlth, Vancouver, BC, Canada	Stergiopoulos, V (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	stergiopoulosv@smh.ca		Bekele, Tsegaye/0000-0002-8735-5941; Latimer, Eric/0000-0002-4485-1056	Health Canada	The authors would like to thank Jayne Barker (2008-11), Ph.D., Cameron Keller (2011-12), and Catharine Hume (2012-present) Mental Health Commission of Canada At Home/Chez Soi National Project Leads, Paula Goering, Ph.D., the National Research Lead, the National Research Team, the five site research teams, the Site Coordinators, and the numerous service and housing providers, as well as persons with lived experience, who have contributed to this project and the research. This research has been made possible through a financial contribution from Health Canada. The views expressed herein solely represent the authors.	*AM PSYCH ASS, 1994, DIGAN STAT MAN MENT; Amorim P, 1998, EUR PSYCHIAT, V13, P26, DOI 10.1016/S0924-9338(97)86748-X; Andersen J, 2014, DISABIL REHABIL, V36, P2210, DOI 10.3109/09638288.2014.895870; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Backer Thomas Earl, 2007, J Prim Prev, V28, P375, DOI 10.1007/s10935-007-0100-1; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Boothroyd RA, 2008, ADM POLICY MENT HLTH, V35, P370, DOI 10.1007/s10488-008-0179-6; Bousman CA, 2010, J NERV MENT DIS, V198, P790, DOI 10.1097/NMD.0b013e3181f97dff; Brandt J., 2001, HOPKINS VERBAL LEARN; Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; Burra TA, 2009, CAN J PSYCHIAT, V54, P123, DOI 10.1177/070674370905400210; Caplan B, 2006, SCHIZOPHR RES, V83, P77, DOI 10.1016/j.schres.2005.11.013; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Caton CLM, 2005, AM J PUBLIC HEALTH, V95, P1753, DOI 10.2105/AJPH.2005.063321; City of Toronto, 2013, STREET NEEDS ASS; Conrad K J, 2001, Ment Health Serv Res, V3, P141, DOI 10.1023/A:1011571531303; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cotman A, 1997, J COGN REHABIL, V15, P16; Culhane DP, 2001, J EPIDEMIOL COMMUN H, V55, P515, DOI 10.1136/jech.55.7.515; Dickinson D, 2007, ARCH GEN PSYCHIAT, V64, P532, DOI 10.1001/archpsyc.64.5.532; Diez-Roux AV, 1999, AM J PUBLIC HEALTH, V89, P302, DOI 10.2105/AJPH.89.3.302; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Eberle Planning and Research, 2013, VANC HOM COUNT 2013; Fazel S, 2008, PLOS MED, V5, P1670, DOI 10.1371/journal.pmed.0050225; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; Folsom D, 2002, ACTA PSYCHIAT SCAND, V105, P404, DOI 10.1034/j.1600-0447.2002.02209.x; Geddes J R, 1996, Health Bull (Edinb), V54, P276; Gilchrist G, 2005, EUR J PUBLIC HEALTH, V15, P587, DOI 10.1093/eurpub/cki036; GOLDBERG TE, 1993, AM J PSYCHIAT, V150, P1355; Gonzalez EA, 2001, J NERV MENT DIS, V189, P176, DOI 10.1097/00005053-200103000-00006; Green MF, 2006, J CLIN PSYCHIAT, V67, P3; Greenwood RM, 2005, AM J COMMUN PSYCHOL, V36, P223, DOI 10.1007/s10464-005-8617-z; Harvey PD, 2009, J CLIN EXP NEUROPSYC, V31, P462, DOI 10.1080/13803390802251386; Heaton R.K., 1986, NEUROPSYCHOLOGICAL A, P100; Heaton RK, 2004, REVISED COMPREHENSIV; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Highley JL, 2008, TRAUMATIC BRAIN INJU; Hwang SW, 2000, JAMA-J AM MED ASSOC, V283, P2152, DOI 10.1001/jama.283.16.2152; Hwang SW, 2001, CAN MED ASSOC J, V164, P229; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; Kurtz MM, 2009, NEUROPSYCHOLOGY, V23, P551, DOI 10.1037/a0016277; Lee RSC, 2012, J AFFECT DISORDERS, V140, P113, DOI 10.1016/j.jad.2011.10.023; Leung WW, 2008, J INT NEUROPSYCH SOC, V14, P479, DOI 10.1017/S1355617708080600; Newbold K.B., 2010, CAN ISSUES, P28; Norman MA, 2011, J CLIN EXP NEUROPSYC, V33, P793, DOI 10.1080/13803395.2011.559157; Pluck G, 2012, CAN J BEHAV SCI, V44, P9, DOI 10.1037/a0025382; Pluck G, 2011, BRIT J CLIN PSYCHOL, V50, P33, DOI 10.1348/014466510X490253; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Raphael-Greenfield E, 2012, OCCUP THER INT, V19, P135, DOI 10.1002/oti.1328; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riley ED, 2007, J URBAN HEALTH, V84, P415, DOI 10.1007/s11524-006-9153-3; Robertson MJ, 1996, ANNU REV PUBL HEALTH, V17, P311; Schaefer J, 2013, SCHIZOPHR RES, V150, P42, DOI 10.1016/j.schres.2013.07.009; Schuitevoerder S, 2013, J ANXIETY DISORD, V27, P550, DOI 10.1016/j.janxdis.2013.01.001; Schutt RK, 2007, SCHIZOPHRENIA BULL, V33, P1388, DOI 10.1093/schbul/sbm037; Seidman LJ, 2003, PSYCHIAT SERV, V54, P905, DOI 10.1176/appi.ps.54.6.905; Seidman LJ, 1997, J NERV MENT DIS, V185, P3, DOI 10.1097/00005053-199701000-00002; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; Statistics Canada, 2006, 2006 CENS CAN VIS MI; Statistics Canada, 2006, 2006 CENS CAN POP AB; Stergiopoulos V, 2011, J NERV MENT DIS, V199, P854, DOI 10.1097/NMD.0b013e3182349cfc; TEESSON M, 1993, HOSP COMMUNITY PSYCH, V44, P1187; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; van Holst Ruth Janke, 2011, Curr Drug Abuse Rev, V4, P42; Wagner S, 2012, ACTA PSYCHIAT SCAND, V125, P281, DOI 10.1111/j.1600-0447.2011.01762.x; Waldmann CA, 2004, HLTH HOMELESS PERSON, P237; Wechsler D., 1981, WAIS R MANUAL WECHSL; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	72	38	38	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-690X	1600-0447		ACTA PSYCHIAT SCAND	Acta Psychiatr. Scand.	APR	2015	131	4					256	268		10.1111/acps.12391			13	Psychiatry	Psychiatry	CD5SC	WOS:000351147200007	25604122				2021-06-18	
J	Cui, HJ; Yang, AL; Zhou, HJ; Wang, C; Luo, JK; Lin, Y; Zong, YX; Tang, T				Cui, Han-Jin; Yang, A-Li; Zhou, Hua-Jun; Wang, Cong; Luo, Jie-Kun; Lin, Yuan; Zong, Yan-Xia; Tang, Tao			Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage	BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE			English	Article						Intracerebral hemorrhage; Angiogenesis; Vascular endothelial growth factor receptor-2; Phosphorylation; PI3K/Akt; Buyang huanwu decoction	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-PROLIFERATION; SHEAR-STRESS; EXPRESSION; STROKE; VEGF; RECOVERY; RATS; INHIBITOR	Background: Intracerebral hemorrhage (ICH) is a fatal subtype of stroke that lacks effective treatments. Angiogenesis following ICH is an important response mediating brain recovery and repair. Phosphorylation of vascular endothelial growth factor receptor 2 (pVEGFR2) via PI3K/Akt signaling plays a key role in mediating cellular processes involved in repair, such as mitogenesis, angiogenesis, and vascular permeability. This study aimed to investigate the potential effects of Buyang Huanwu Decoction (BYHWD), a traditional Chinese medicine formula, on angiogenesis by VEGFR2 activation through the phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathway in a mouse model of ICH. Methods: Adult male Kunming mice (n = 50) were randomly assigned into sham and ICH-operated groups and treated with one of the followings SU5416 (VEGFR2 inhibitor), BYHWT and BYHWT + SU5416. ICH was induced in mice by injecting collagenase (type VII) into the right globus pallidus of the mouse brain. BYHWD (4.36 g/kg) was administrated in mice by intragastric infusion. Neurological function was evaluated in mice by a modified Neurological Severity Scores (mNSS) as well as corner turn and foot-fault tests. Angiogenesis was examined by intraperitoneal injection of 5-bromodeoxyuridine (BrdU) in mice to quantify new brain vessel growth. SU5416 treatment and assessment of VEGFR2 phosphorylation as well as alterations in PI3K/Akt signaling were performed to determine whether the effect of BYHWD on angiogenesis was partly mediated by phosphorylation of VEGFR2 via the PI3K/Akt signaling pathway. Results: We show that BYHWD treated mice exhibited (i) significantly better recovery from neurological dysfunction, (ii) increased BrdU(+) nuclei in vWF(+) dilated brain vessels and (iii) higher VEGFR2 phosphorylation immunoreactivity in brain microvessels (P<0.05), (iv) higher expression of PI3K and pAkt at the protein level (P<0.05) when compared to untreated ICH mice. These beneficial effects were reversed by SU5416 (P<0.05). Conclusions: BYHWD promoted neurological recovery and angiogenesis after ICH in mice by enhancing VEGFR2 phosphorylation through the PI3K/Akt signaling pathway.	[Cui, Han-Jin; Wang, Cong; Luo, Jie-Kun; Zong, Yan-Xia; Tang, Tao] Cent S Univ, Inst Integrat Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Yang, A-Li] Cent S Univ, Inst Neurol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Cui, Han-Jin; Yang, A-Li; Zhou, Hua-Jun; Wang, Cong; Luo, Jie-Kun; Lin, Yuan; Zong, Yan-Xia; Tang, Tao] Key Lab Chinese Gan SATCM, Changsha 410008, Hunan, Peoples R China; [Zhou, Hua-Jun] China Three Gorges Univ, Inst Neurol, Coll Clin Med Sci 1, Yichang 443003, Hubei, Peoples R China	Tang, T (corresponding author), Cent S Univ, Inst Integrat Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.	falcontang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81473573, 81173175, 81202625]; Project for New Century Excellent Talent [NCET-11-0522]; Hunan Provincial Natural Science FoundationNatural Science Foundation of Hunan Province [14JJ2024]; Hunan TCM Project [201424]	This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81473573, 81173175, 81202625), the Project for New Century Excellent Talent (NCET-11-0522), the Hunan Provincial Natural Science Foundation (Grant Nos. 14JJ2024), and Hunan TCM Project (Grant Nos. 201424)	Adeoye O, 2010, NAT REV NEUROL, V6, P593, DOI 10.1038/nrneurol.2010.146; Adjei AA, 2007, CLIN LUNG CANCER, V8, pS74, DOI 10.3816/CLC.2007.s.005; Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Cai GX, 2007, J ETHNOPHARMACOL, V113, P292, DOI 10.1016/j.jep.2007.06.007; Cecatto RB, 2014, AM J PHYS MED REHAB, V93, P791, DOI 10.1097/PHM.0000000000000104; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Del Bigio MR, 1999, NEUROL RES, V21, P415, DOI 10.1080/01616412.1999.11740953; Dellinger MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028947; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fournier NM, 2012, NEUROPHARMACOLOGY, V63, P642, DOI 10.1016/j.neuropharm.2012.04.033; Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489; Hao CZ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/630124; Imbe H, 2010, BRAIN RES, V1329, P103, DOI 10.1016/j.brainres.2010.03.006; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444; Kieran MW, 2009, PEDIATR BLOOD CANCER, V52, P169, DOI 10.1002/pbc.21873; Kleim JA, 2007, ILAR J, V48, P374, DOI 10.1093/ilar.48.4.374; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Krafft PR, 2014, BEHAV BRAIN RES, V264, P151, DOI 10.1016/j.bbr.2014.01.052; Lakshmikanthan S, 2011, BLOOD, V118, P2015, DOI 10.1182/blood-2011-04-349282; Lee Hyoshin, 2007, Plant Biology (Rockville), V2007, P156; Li WL, 2011, EXP BRAIN RES, V214, P503, DOI 10.1007/s00221-011-2849-y; Liu Hua, 2005, Chin J Integr Med, V11, P167; Narantuya D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011746; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Shimotake J, 2010, STROKE, V41, P343, DOI 10.1161/STROKEAHA.109.564229; Sho E, 2003, EXP MOL PATHOL, V75, P1, DOI 10.1016/S0014-4800(03)00032-7; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Smith JK, 2004, ONCOL RES, V14, P175; Tang T, 2007, BRAIN RES, V1175, P134, DOI 10.1016/j.brainres.2007.08.028; Tiwari A, 2012, HEMATOLOGY SCI PRACT, P253; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Urbich C, 2003, FEBS LETT, V535, P87, DOI 10.1016/S0014-5793(02)03879-6; Urschel K, 2011, ATHEROSCLEROSIS, V219, P499, DOI 10.1016/j.atherosclerosis.2011.09.045; van der Meer AD, 2010, BIORHEOLOGY, V47, P179, DOI 10.3233/BIR-2010-0569; Wang DZ, 2009, CURR NEUROL NEUROSCI, V9, P13, DOI 10.1007/s11910-009-0003-z; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wei RL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/138484; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu XG, 2011, NEURAL REGEN RES, V6, P656, DOI 10.3969/j.issn.1673-5374.2011.09.003; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang L, 2011, J PHARMACOL EXP THER, V338, P485, DOI 10.1124/jpet.111.180992; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhang ZQ, 2007, CHIN J INTEGR MED, V13, P285, DOI 10.1007/s11655-007-0285-4; Zhao LD, 2012, J ETHNOPHARMACOL, V140, P339, DOI 10.1016/j.jep.2012.01.026; Zhong XS, 2004, BIOCHEM BIOPH RES CO, V324, P471, DOI 10.1016/j.bbrc.2004.09.082	52	38	41	0	28	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1472-6882			BMC COMPLEM ALTERN M	BMC Complement. Altern. Med.	MAR 28	2015	15								91	10.1186/s12906-015-0605-8			10	Integrative & Complementary Medicine	Integrative & Complementary Medicine	CE5TT	WOS:000351899300001	25886469	DOAJ Gold, Green Published			2021-06-18	
J	Dawes, AJ; Sacks, GD; Cryer, HG; Gruen, JP; Preston, C; Gorospe, D; Cohen, M; McArthur, DL; Russell, MM; Maggard-Gibbons, M; Ko, CY				Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Gruen, J. Peter; Preston, Christy; Gorospe, Deidre; Cohen, Marilyn; McArthur, David L.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.		Los Angeles Cty Trauma Consortium	Intracranial pressure monitoring and inpatient mortality in severe traumatic brain injury: A propensity score-matched analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 09-13, 2014	Philadelphia, PA	Amer Assoc Surg Trauma		Traumatic brain injury; intracranial pressure monitoring; mortality; propensity score	EVIDENCE-BASED GUIDELINES; UNITED-STATES; CARE; HOSPITALIZATION; IMPROVEMENT; MANAGEMENT; OUTCOMES	BACKGROUND: Although intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI) is recommended by the Brain Trauma Foundation, the benefits remain controversial. We sought to determine the impact of ICP monitor placement on inpatient mortality within a regional trauma system after correcting for selection bias through propensity score matching. METHODS: Data were collected on all severe TBI cases presenting to 14 trauma centers during the 2-year study period (2009-2010). Inclusion criteria were as follows: blunt injury, Glasgow Coma Scale (GCS) score of 8 or lower in the emergency department, and abnormal intracranial findings on head computed tomography (CT). Two separate multivariate logistic regression models were used to predict ICP monitor placement and inpatient mortality after controlling for demographics, severity of injury, comorbidities, and TBI-specific variables (GCS score, pupil reactivity, international normalized ratio, and nine specific head CT findings). To account for selection bias, we developed a propensity score-matched model to estimate the "true'' effect of ICP monitoring on in-hospital mortality. RESULT: A total of 844 patients met inclusion criteria; 22 died on arrival to the emergency department. Inpatient mortality was 38.8%; 46.0% of the patients underwent ICP monitor placement. Unadjusted mortality rates were significantly lower in the ICP monitoring group (30.7% vs. 45.7%, p < 0.001). ICP monitor placement was positively associated with CT findings of subdural hematoma, intraparenchymal contusion, and mass effect and negatively associated with age, alcoholism, and elevated international normalized ratio. After adjusting for selection bias via propensity score matching, ICP monitor placement was associated with an 8.3 percentage point reduction in the risk-adjusted mortality rate. CONCLUSION: ICP monitor placement occurred in only 46% of eligible patients but was associated with significantly decreased mortality after adjusting for baseline risk profile and the propensity to undergo monitoring. As the individual impact of ICP monitoring may vary, future efforts must determine who stands to benefit from invasive monitoring techniques. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)	[Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Cohen, Marilyn; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; [McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Dawes, Aaron J.; Sacks, Greg D.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA; [Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Gruen, J. Peter] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA; [Preston, Christy; Gorospe, Deidre] Cty Los Angeles, Dept Hlth Serv, Emergency Med Serv Agcy, Los Angeles, CA USA	Dawes, AJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ronald Reagan UCLA Med Ctr, 757 Westwood Plaza B7-11, Los Angeles, CA 90095 USA.	adawes@mednet.ucla.edu	Dawes, Aaron/I-1680-2019	Dawes, Aaron/0000-0003-4574-6765	VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program	A.J.D. was supported by the VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program.	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; DRAKE C, 1993, BIOMETRICS, V49, P1231, DOI 10.2307/2532266; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Fraser, 2010, PROPENSITY SCORE ANA; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shafi S, 2014, J NEUROSURG, V120, P773, DOI 10.3171/2013.12.JNS132151; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Veterans Health Initiative, 2010, TRAUMATIC BRAIN INJU, P1	24	38	42	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2015	78	3					492	501		10.1097/TA.0000000000000559			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CE8DQ	WOS:000352072000011	25710418				2021-06-18	
J	Ding, K; Wang, HD; Wu, Y; Zhang, L; Xu, JG; Li, T; Ding, Y; Zhu, L; He, J				Ding, Ke; Wang, Handong; Wu, Yong; Zhang, Li; Xu, Jianguo; Li, Tao; Ding, Yu; Zhu, Lin; He, Jin			Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis	JOURNAL OF SURGICAL RESEARCH			English	Article						Rapamycin; Traumatic brain injury; Apoptosis; Mammalian target of rapamycin; p53; Bax	CLOSED-HEAD INJURY; CELL-DEATH; KETOGENIC DIET; JUVENILE RATS; MODEL; P53; BCL-2; INHIBITION; DISRUPTION; AUTOPHAGY	Background: Rapamycin has proven to be a neuroprotective agent in traumatic brain injury (TBI). However, there is a lack of data regarding the effect of rapamycin on apoptotic neuronal death after TBI. Thus, the present study was designed to detect the modulatory role of rapamycin on apoptosis and explore the potential involvement of the mammalian target of rapamycin (mTOR)-p53-Bax axis after TBI. Material and methods: Neurologic severity score tests were performed to measure behavioral outcomes. The effect of rapamycin treatment on neuronal death was analyzed using immunofluorescence analysis of NeuN. Terminal deoxynucleotidyl transferase-mediated dUTP nick 3'-end labeling was performed to detect apoptotic cells. The expression of Bax and phosphorylated protein of p53 was detected using Western blotting analyses and immunofluorescence staining. Phosphorylated protein of the mTOR in the ipsilateral cortex was detected using Western blotting analyses. Results: Rapamycin administration after TBI was associated with an increased number of neurons, decreased apoptosis index, and improved neurobehavioral function, which was potentially mediated by inactivation of the mTOR-p53-Bax axis. Conclusions: Rapamycin can protect neurons from apoptotic neuronal death after TBI. This study presents a new insight into the antiapoptosis mechanisms, which are responsible for the neuroprotection of rapamycin, with the potential involvement of the mTOR-p53-Bax axis. (C) 2015 Elsevier Inc. All rights reserved.	[Ding, Ke; Wang, Handong; Wu, Yong; Zhang, Li; Xu, Jianguo; Li, Tao; Ding, Yu; Zhu, Lin; He, Jin] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81271377, 81371357]; Research Project of Jinling Hospital [2014040]	This work was supported by grants obtained from the Natural Science Fund of China (Nos. 81271377 and 81371357) and the Research Project of Jinling Hospital (No. 2014040).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P374, DOI 10.4161/oxim.3.6.14787; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Concha NO, 2002, CURR MED CHEM, V9, P713, DOI 10.2174/0929867023370761; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Hong LZ, 2010, NEUROSCI BULL, V26, P232, DOI 10.1007/s12264-010-1111-0; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Koehl GE, 2004, TRANSPLANTATION, V77, P1319, DOI 10.1097/00007890-200405150-00002; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lopez NE, 2012, BRAIN RES, V1489, P140, DOI 10.1016/j.brainres.2012.10.031; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wan CH, 2014, J NEUROSCI RES, V92, P1, DOI 10.1002/jnr.23305; Xia DY, 2013, BRAZ J MED BIOL RES, V46, P580, DOI 10.1590/1414-431X20133161; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yin LL, 2012, INT J NEUROSCI, V122, P748, DOI 10.3109/00207454.2012.721827; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	38	38	41	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAR	2015	194	1					239	247		10.1016/j.jss.2014.09.026			9	Surgery	Surgery	CC5FH	WOS:000350384000031	25438952				2021-06-18	
J	Zhang, J; Teng, ZQ; Song, YP; Hu, M; Chen, C				Zhang, Jian; Teng, Zhaoqian; Song, Yunping; Hu, Mei; Chen, Chu			Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Alzheimer's disease; 2-arachidonoylglycerol; chronic traumatic encephalopathy; monoacylglycerol lipase; neurodegeneration; trauma brain injury	BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; SPECTRUM; 2-AG; MICE; NEURODEGENERATION; PATHOGENESIS; IMPAIRMENTS; METABOLISM	Emerging evidence suggests that the risk of developing chronic traumatic encephalopathy (CTE), a progressive neurodegenerative disease, is significantly increased in military personnel and contact sports players who have been exposed to repetitive trauma brain injury (TBI). Unfortunately there are no effective medications currently available for prevention and treatment of CTE. Here we demonstrate that inhibition of monoacylglycerol lipase (MAGL), the key enzyme that metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain, significantly reduced CTE-like neuropathologic changes in a mouse model of repetitive mild closed head injury (rmCHI). Inhibition of 2-AG metabolism promoted neurologic recovery following rmCHI and reduced proinflammatory cytokines, astroglial reactivity, expression of amyloid precursor protein and the enzymes that make A beta, as well as formation of A beta. Importantly, neurodegeneration, TDP-43 protein aggregation, and tau phosphorylation, which are the neuropathologic hallmarks of CTE, were significantly suppressed by MAGL inactivation. Furthermore, alterations in expression of glutamate receptor subunits and impairments in basal synaptic transmission, long-term synaptic plasticity, and spatial learning and memory were recovered by inhibition of 2-AG metabolism in animals exposed to rmCHI. Our results suggest that MAGL inhibition, which boosts 2-AG and reduces 2-AG metabolites prostaglandins in the brain, may lead to a new therapy for CTE.	[Zhang, Jian; Teng, Zhaoqian; Song, Yunping; Hu, Mei; Chen, Chu] Louisiana State Univ, Neurosci Ctr Excellence, Sch Med, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Chen, Chu] Louisiana State Univ, Dept Otorhinolaryngol, Sch Med, Hlth Sci Ctr, New Orleans, LA 70112 USA	Chen, C (corresponding author), Louisiana State Univ, Neurosci Ctr Excellence, Sch Med, Hlth Sci Ctr, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	cchen@lsuhsc.edu	Teng, Zhao-Qian/AAD-1033-2021; Teng, Zhao-Qian/J-6260-2015	Teng, Zhao-Qian/0000-0002-7232-3381; Teng, Zhao-Qian/0000-0002-7232-3381	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS076815]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076815] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grant NS076815.	Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen RQ, 2013, CELL, V155, P1154, DOI 10.1016/j.cell.2013.10.042; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Lakis N, 2013, NEUROL RES, V35, P290, DOI 10.1179/1743132813Y.0000000177; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Long JZ, 2009, CHEM BIOL, V16, P744, DOI 10.1016/j.chembiol.2009.05.009; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Piro JR, 2012, CELL REP, V1, P617, DOI 10.1016/j.celrep.2012.05.001; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu JY, 2015, NEUROSCIENTIST, V21, P152, DOI 10.1177/1073858414524632; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200; Zhang J, 2014, J NEUROSCI, V34, P14919, DOI 10.1523/JNEUROSCI.1165-14.2014	40	38	38	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2015	35	3					443	453		10.1038/jcbfm.2014.216			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CC5IZ	WOS:000350393600013	25492114	Green Published, Bronze			2021-06-18	
J	Chun, IY; Mao, X; Breedlove, EL; Leverenz, LJ; Nauman, EA; Talavage, TM				Chun, I. Y.; Mao, X.; Breedlove, E. L.; Leverenz, L. J.; Nauman, E. A.; Talavage, T. M.			DTI Detection of Longitudinal WM Abnormalities Due to Accumulated Head Impacts	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				TRAUMATIC BRAIN-INJURY; WHITE-MATTER	Longitudinal evaluation using diffusion-weighted imaging and collision event monitoring was performed on high school athletes who participate in American football. Observed changes in white matter health were suggestive of injury and found to be correlated with accumulation of head collision events during practices and games.	[Chun, I. Y.; Mao, X.; Talavage, T. M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Breedlove, E. L.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, L. J.] Purdue Univ, Dept Hlth Kinesiol, W Lafayette, IN 47907 USA; [Nauman, E. A.] Purdue Univ, Sch Mech Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Nauman, E. A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Talavage, T. M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Chun, IY (corresponding author), Purdue Univ, Sch Elect & Comp Engn, 465 Northwestern Ave, W Lafayette, IN 47907 USA.	chuni@purdue.edu	Chun, Il Yong/AAL-2113-2021	Chun, Il Yong/0000-0002-4226-3760	Indiana State Department of Health Spinal Cord and Brain Injury Research Fund	This work was supported by the Indiana State Department of Health Spinal Cord and Brain Injury Research Fund.	Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024	12	38	38	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		92	97		10.1080/87565641.2015.1020945			6	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CH6UW	WOS:000354172800008	25961592				2021-06-18	
J	Semple, BD; Trivedi, A; Gimlin, K; Noble-Haeusslein, LJ				Semple, Bridgette D.; Trivedi, Alpa; Gimlin, Kayleen; Noble-Haeusslein, Linda J.			Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; neutrophil elastase; cell death; behavior; pathology; pediatric	SPINAL-CORD-INJURY; PERIOPERATIVE INFLAMMATORY RESPONSE; GLUTATHIONE-PEROXIDASE ACTIVITY; PEDIATRIC HEART-SURGERY; HEME OXYGENASE-1 HO-1; SERINE PROTEASES; MATRIX METALLOPROTEINASES; CARDIOPULMONARY BYPASS; INHIBITOR SIVELESTAT; OXIDATIVE STRESS	While neutrophil elastase (NE), released by activated neutrophils, is a key mediator of secondary pathogenesis in adult models of brain ischemia and spinal cord injury, no studies to date have examined this protease in the context of the injured immature brain, where there is notable vulnerability resulting from inadequate antioxidant reserves and prolonged exposure to infiltrating neutrophils. We thus reasoned that NE may be a key determinant of secondary pathogenesis, and as such, adversely influence long-term neurological recovery. To address this hypothesis, wild-type (WT) and NE knockout (KO) mice were subjected to a controlled cortical impact at postnatal day 21, approximating a toddler-aged child. To determine if NE is required for neutrophil infiltration into the injured brain, and whether this protease contributes to vasogenic edema, we quantified neutrophil numbers and measured water content in the brains of each of these genotypes. While leukocyte trafficking was indistinguishable between genotypes, vasogenic edema was markedly attenuated in the NE KO. To determine if early pathogenesis is dependent on NE, indices of cell death (TUNEL and activated caspase-3) were quantified across genotypes. NE KO mice showed a reduction in these markers of cell death in the injured hippocampus, which corresponded to greater preservation of neuronal integrity as well as reduced expression of heme oxygenase-1, a marker of oxidative stress. WT mice, treated with a competitive inhibitor of NE at 2, 6 and 12 h post-injury, likewise showed a reduction in cell death and oxidative stress compared to vehicle-treated controls. We next examined the long-term behavioral and structural consequences of NE deficiency. NE KO mice showed an improvement in long-term spatial memory retention and amelioration of injury-induced hyperactivity. However, volumetric and stereological analyses found comparable tissue loss in the injured cortex and hippocampus independent of genotype. Further, WT mice treated acutely with the NE inhibitor showed no long-term behavioral or structural improvements. Together, these findings validate the central role of NE in both acute pathogenesis and chronic functional recovery, and support future exploration of the therapeutic window, taking into account the prolonged period of neutrophil trafficking into the injured immature brain. (C) 2014 Elsevier Inc. All rights reserved.	[Semple, Bridgette D.; Trivedi, Alpa; Gimlin, Kayleen; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Semple, Bridgette D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3000, Australia; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA	Semple, BD (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 513 Parnassus Ave,Room HSE-860, San Francisco, CA 94143 USA.	Bridgette.Semple@ucsf.edu; Alpa.Mahuvakar@ucsf.edu; Kayleen.Gimlin@ucsf.edu; Linda.Noble@ucsf.edu	Tercovich, Kayleen/I-8941-2018	Tercovich, Kayleen/0000-0003-0450-8912	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050159, NS077767]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC); American Australian Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767, R01NS050159] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS R01 NS050159 and NS077767 (LJ. Noble- Haeusslein), a CJ Martin Biomedical Postdoctoral Fellowship from the National Health and Medical Research Council of Australia (B.D. Semple), and a Sir Keith Murdoch Postdoctoral Fellowship from the American Australian Association (B.D. Semple).	Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Allen C, 2012, J IMMUNOL, V189, P381, DOI 10.4049/jimmunol.1200409; Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Becker Kyra J, 2002, Curr Med Res Opin, V18 Suppl 2, ps18, DOI 10.1185/030079902125000688; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Cojocaru Inimioara Mihaela, 2006, Rom J Intern Med, V44, P317; Cousar JL, 2006, DEV NEUROSCI-BASEL, V28, P342, DOI 10.1159/000094160; Davis MJ, 2012, BEHAV BRAIN RES, V229, P21, DOI 10.1016/j.bbr.2011.12.037; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dredge BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021585; Easton AS, 2013, INT IMMUNOPHARMACOL, V17, P1218, DOI 10.1016/j.intimp.2013.06.015; Eisener-Dorman AF, 2009, BRAIN BEHAV IMMUN, V23, P318, DOI 10.1016/j.bbi.2008.09.001; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Fitrolaki DM, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-31; Frankowski H, 2012, METHODS MOL BIOL, V814, P221, DOI 10.1007/978-1-61779-452-0_15; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Gould TD, 2009, NEUROMETHODS, V42, P1, DOI 10.1007/978-1-60761-303-9_1; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Grenda DS, 2002, BLOOD, V100, P3221, DOI 10.1182/blood-2002-05-1372; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ikegame Y, 2010, HYPERTENS RES, V33, P703, DOI 10.1038/hr.2010.58; Inoue N, 2013, INT HEART J, V54, P149, DOI 10.1536/ihj.54.149; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Iwamoto Satoshi, 2009, Interact Cardiovasc Thorac Surg, V8, P606, DOI 10.1510/icvts.2008.197244; Iwatsuki K, 1998, NEUROL RES, V20, P397; Jackson PL, 2010, MOL MED, V16, P159, DOI 10.2119/molmed.2009.00109; Junger WG, 2013, SHOCK, V40, P366, DOI 10.1097/SHK.0000000000000038; Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kikuchi T., 2006, J ANESTH, V20; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kohira S, 2013, ARTIF ORGANS, V37, P1027, DOI 10.1111/aor.12103; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Krams M, 2003, STROKE, V34, P2543, DOI 10.1161/01.STR.0000092527.33910.89; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Lee TW, 2008, NEURON GLIA BIOL, V4, P223, DOI 10.1017/S1740925X09990172; Liu Shimin, 2010, J Exp Stroke Transl Med, V3, P47; Matayoshi H, 2009, BRAIN RES, V1259, P98, DOI 10.1016/j.brainres.2008.12.070; Matsumoto S, 2009, J ANESTH, V23, P288, DOI 10.1007/s00540-008-0735-y; MEHTA JL, 1994, CARDIOVASC RES, V28, P947, DOI 10.1093/cvr/28.7.947; Meyer-Hoffert U, 2011, CURR OPIN HEMATOL, V18, P19, DOI 10.1097/MOH.0b013e32834115d1; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Nagy Z, 1998, BLOOD COAGUL FIBRIN, V9, P471, DOI 10.1097/00001721-199809000-00003; Natale JE, 2006, DEV NEUROSCI-BASEL, V28, P276, DOI 10.1159/000094154; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Noble LJ, 2002, J NEUROSCI, V22, P7526; PHAN SH, 1992, AM J RESP CELL MOL, V6, P270, DOI 10.1165/ajrcmb/6.3.270; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Pinheiro J, 2012, NLME LINEAR NONLINEA; Potts Mathew B, 2006, NeuroRx, V3, P143; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shapiro SD, 2002, AM J RESP CELL MOL, V26, P266, DOI 10.1165/ajrcmb.26.3.f233; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; SOMMERHOFF CP, 1991, EUR J PHARMACOL, V193, P153, DOI 10.1016/0014-2999(91)90030-T; Starcher B, 1996, J INVEST DERMATOL, V107, P159, DOI 10.1111/1523-1747.ep12329559; Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009; Stowe AM, 2009, NEUROBIOL DIS, V35, P82, DOI 10.1016/j.nbd.2009.04.006; Team R.C, 2012, R LANG ENV STAT COMP; Tiefenbacher CP, 1997, PFLUG ARCH EUR J PHY, V433, P563, DOI 10.1007/s004240050315; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Weinzierl M, 2004, BRAIN RES, V1030, P125, DOI 10.1016/j.brainres.2004.09.060; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; WILLIAMS JC, 1991, AM REV RESPIR DIS, V144, P875, DOI 10.1164/ajrccm/144.4.875; WOODMAN RC, 1993, BLOOD, V82, P2188; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Young ME, 2009, LEARN MOTIV, V40, P160, DOI 10.1016/j.lmot.2008.10.004; Young RE, 2007, BRIT J PHARMACOL, V151, P628, DOI 10.1038/sj.bjp.0707267; Young RE, 2004, J IMMUNOL, V172, P4493, DOI 10.4049/jimmunol.172.7.4493; Zeiher BG, 2002, CRIT CARE MED, V30, pS281, DOI 10.1097/00003246-200205001-00018; Zhou XH, 2012, FRONT BIOSCI-LANDMRK, V17, P2278, DOI 10.2741/4051	109	38	39	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2015	74						263	280		10.1016/j.nbd.2014.12.003			18	Neurosciences	Neurosciences & Neurology	CB5GQ	WOS:000349655900025	25497734	Green Accepted			2021-06-18	
J	Chio, CC; Lin, MT; Chang, CP				Chio, Chung-Ching; Lin, Mao-Tsun; Chang, Ching-Ping			Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury	CURRENT MEDICINAL CHEMISTRY			English	Article						Brain; cytokines; free radicals; microglia; traumatic injury	NECROSIS-FACTOR-ALPHA; HYPERBARIC-OXYGEN THERAPY; IMPROVES FUNCTIONAL RECOVERY; GLYCINE-PROLINE-GLUTAMATE; MESENCHYMAL STEM-CELLS; TNF-ALPHA; PROINFLAMMATORY CYTOKINE; DOUBLECORTIN EXPRESSION; MITOCHONDRIAL-FUNCTION; CEREBRAL-ISCHEMIA	Microglia and several inflammatory cytokines and neurotrophic growth factors are involved in traumatic brain injury (TBI). Tumor necrosis factor-alpha (TNF-alpha) can be released by microglia, astrocytes, and neurons. TNF-alpha has been reported to be both proneurogenic and antineurogenic, depending upon the model, method, and cell-derived region. There are two subtypes of microglia: M1 and M2. The former (or M1 subtype of non-phagocytic microglia) is able to secrete higher levels of TNF-alpha but lower levels of interleukin (IL)-10 (IL-10), an anti-inflammatory cytokine. Both the proinflammatory and the pro-apoptotic function can also be promoted by activation of tumor necrosis factor-receptor 1 (TNF-R1). In contrast, M2 activation produces lower levels of TNF-alpha but higher levels of IL-10. Pro-growth and survival pathways can be promoted by the activation of TNF-R2. During the acute stage of TBI, both M1 subtype of microglia and TNF-R1 are activated to cause higher levels of TNF-alpha but lower levels of IL-10, which lead to suppressed neurogenesis, neuronal loss and organ dysfunction (so-called microglial activation I). In contrast, activation of both M2 subtype of microglia and TNF-R2 is able to promote neurogenesis and tissue recovery (so-called microglial activation II). The severity of TBI depends upon the net effects between microglial activation I and microglial activation II. Indeed, by using rodent models of TBI, therapeutic evaluation studies reveal that several agents or strategies attenuate contused brain volume and neurological deficits by inhibiting microglial activation I but inducing microglial activation II. For example, etanercept therapy might attenuate contused brain volume and neurological deficits by inactivating the M1 subtype and TNF-R1 to reduce the microglial activation I response, but it might promote neurogenesis and functional recovery by activating the M2 subtype and TNF-R2. Therefore, based on microglial responses I and II, we conclude that future studies should focus on multiple therapeutic agents and strategies for optimal TBI therapy.	Southern Taiwan Univ Sci & Technol, Dept Surg, Tainan, Taiwan; Southern Taiwan Univ Sci & Technol, Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Chang, Ching-Ping] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan	Chang, CP (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.	jessica@mail.stust.edu.tw		Chang, Ching-Ping/0000-0003-0890-9414	Ministry of Science and Technology, Taiwan, R.O.CMinistry of Science and Technology, Taiwan [NSC 102-2628-B-384001-MY3, NSC 102-2314-B-384-003-MY2]; Mr. Wen-Lung Hsu Foundation of Chi Mei Medical Center (Tainan, Taiwan)	This work was supported by the Ministry of Science and Technology, Taiwan, R.O.C (NSC 102-2628-B-384001-MY3 and NSC 102-2314-B-384-003-MY2) and the Mr. Wen-Lung Hsu Foundation of Chi Mei Medical Center (Tainan, Taiwan).	Alexi T, 1999, EXP NEUROL, V159, P84, DOI 10.1006/exnr.1999.7168; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Batchelor DC, 2003, ANAL BIOCHEM, V323, P156, DOI 10.1016/j.ab.2003.08.032; Bell S, 2000, LANCET, V355, P858, DOI 10.1016/S0140-6736(99)00442-0; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Caso JR, 2006, NEUROSCIENCE, V142, P59, DOI 10.1016/j.neuroscience.2006.06.009; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SH, 2005, CRIT CARE MED, V33, P1377, DOI 10.1097/01.CCM.0000165966.28936.89; Chen SH, 2014, CELL TRANSPLANT, V23, P959, DOI 10.3727/096368913X667006; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chio C. C., 2012, SCIENCE S, V338, P59; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Forrest EH, 2002, LIVER, V22, P317, DOI 10.1034/j.1600-0676.2002.01649.x; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; GILAD GM, 1995, LIFE SCI, V58, pPL41, DOI 10.1016/0024-3205(95)02274-0; Guan Jian, 2008, Recent Pat CNS Drug Discov, V3, P112, DOI 10.2174/157488908784534630; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Iosif RE, 2008, J CEREBR BLOOD F MET, V28, P1574, DOI 10.1038/jcbfm.2008.47; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Kuo JR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/145214; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Long JM, 1998, NEUROBIOL AGING, V19, P497, DOI 10.1016/S0197-4580(98)00088-8; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Perry SW, 2002, J NEUROVIROL, V8, P611, DOI 10.1080/13550280290101021; Ren H, 2001, Chin J Traumatol, V4, P239; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287; Tsuji M, 2000, PEDIATR RES, V47, P79, DOI 10.1203/00006450-200001000-00015; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Welser JV, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-89; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; Zou JX, 2002, CLIN EXP RHEUMATOL, V20, pS34	124	38	42	0	18	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.		2015	22	6					759	770		10.2174/0929867321666141106124657			12	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	CB1LI	WOS:000349388600008	25386818				2021-06-18	
J	Dunkley, BT; Da Costa, L; Bethune, A; Jetly, R; Pang, EW; Taylor, MJ; Doesburg, SM				Dunkley, B. T.; Da Costa, L.; Bethune, A.; Jetly, R.; Pang, E. W.; Taylor, M. J.; Doesburg, S. M.			Low-frequency connectivity is associated with mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury (mTBI); Magnetoencephalography (MEG); Resting-state; Attention; Depression; Anxiety; Functional connectivity; Neural oscillations	RESTING-STATE NETWORKS; FUNCTIONAL CONNECTIVITY; ATTENTIONAL NETWORKS; HEAD TRAUMA; IMAGING APPROACH; PHASE SYNCHRONY; WORKING-MEMORY; DELTA WAVES; EEG-ALPHA; DEPRESSION	Mild traumatic brain injury (mTBI) occurs from a closed-head impact. Often referred to as concussion, about 20% of cases complain of secondary psychological sequelae, such as disorders of attention and memory. Known as post-concussive symptoms (PCS), these problems can severely disrupt the patient's quality of life. Changes in local spectral power, particularly low-frequency amplitude increases and/or peak alpha slowing have been reported in mTBI, but large-scale connectivity metrics based on inter-regional amplitude correlations relevant for integration and segregation in functional brain networks, and their association with disorders in cognition and behaviour, remain relatively unexplored. Here, we used non-invasive neuroimaging with magnetoencephalography to examine functional connectivity in a resting-state protocol in a group with mTBI (n = 20), and a control group (n=21). We observed a trend for atypical slow-wave power changes in subcortical, temporal and parietal regions in mTBI, as well as significant long-range increases in amplitude envelope correlations among deep-source, temporal, and frontal regions in the delta, theta, and alpha bands. Subsequently, we conducted an exploratory analysis of patterns of connectivity most associated with variability in secondary symptoms of mTBI, including inattention, anxiety, and depression. Differential patterns of altered resting state neurophysiological network connectivity were found across frequency bands. This indicated that multiple network and frequency specific alterations in large scale brain connectivity may contribute to overlapping cognitive sequelae in mTBI. In conclusion, we show that local spectral power content can be supplemented with measures of correlations in amplitude to define general networks that are atypical in mTBI, and suggest that certain cognitive difficulties are mediated by disturbances in a variety of alterations in network interactions which are differentially expressed across canonical neurophysiological frequency ranges. Crown Copyright (C) 2015 Published by Elsevier Inc.	[Dunkley, B. T.; Taylor, M. J.; Doesburg, S. M.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Dunkley, B. T.; Pang, E. W.; Taylor, M. J.; Doesburg, S. M.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Da Costa, L.; Bethune, A.] Sunnybrook Med Ctr, Div Neurosurg, Toronto, ON, Canada; [Jetly, R.] Canadian Forces Hlth Serv, Directorate Mental Hlth, Ottawa, ON, Canada; [Pang, E. W.; Taylor, M. J.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [Doesburg, S. M.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Taylor, M. J.; Doesburg, S. M.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada	Dunkley, BT (corresponding author), Dept Diagnost Imaging, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ben.dunkley@sickkids.ca	da Costa, Leodante/F-7474-2010	da Costa, Leodante/0000-0002-3222-4944; Dunkley, Ben/0000-0001-6173-1171	Defence Research and Development Canada (DRDC); Canadian Forces Health Services [W7719-135182/001/TOR]	Thanks are given to Amanda Robertson and Marc Lalancette for their help in the data collection, and Daniel Cassel for his help with the data analysis pipeline. This work was supported by funding from Defence Research and Development Canada (DRDC) and the Canadian Forces Health Services to MJT and EWP (contract # W7719-135182/001/TOR).	Ball G.J., 1977, ELECTROENCEPHALOGR C, V43, P346; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BRADY EU, 1992, PSYCHOL BULL, V111, P244, DOI 10.1037/0033-2909.111.2.244; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; CLARKE DM, 1991, AUST NZ J PSYCHIAT, V25, P322, DOI 10.3109/00048679109062632; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Dunkley BT, 2014, NEUROIMAGE-CLIN, V5, P377, DOI 10.1016/j.nicl.2014.07.017; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Fan J, 2007, J NEUROSCI, V27, P6197, DOI 10.1523/JNEUROSCI.1833-07.2007; Fan J, 2009, BRAIN COGNITION, V70, P209, DOI 10.1016/j.bandc.2009.02.002; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hari R, 2012, NEUROIMAGE, V61, P386, DOI 10.1016/j.neuroimage.2011.11.074; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KLIMESCH W, 1994, ELECTROEN CLIN NEURO, V91, P428, DOI 10.1016/0013-4694(94)90164-3; Klimesch W., 1993, Brain Topography, V5, P241, DOI 10.1007/BF01128991; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Palva JM, 2005, J NEUROSCI, V25, P3962, DOI 10.1523/JNEUROSCI.4250-04.2005; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Raz A, 2006, NAT REV NEUROSCI, V7, P367, DOI 10.1038/nrn1903; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sadaghiani S, 2012, J NEUROSCI, V32, P14305, DOI 10.1523/JNEUROSCI.1358-12.2012; Schaul N, 1998, ELECTROEN CLIN NEURO, V106, P101, DOI 10.1016/S0013-4694(97)00111-9; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tewarie P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069318; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758; Wang XJ, 2010, PHYSIOL REV, V90, P1195, DOI 10.1152/physrev.00035.2008; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; Wittchen HU, 2002, J CLIN PSYCHIAT, V63, P24; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zalesky A, 2012, NEUROIMAGE, V60, P1055, DOI 10.1016/j.neuroimage.2012.01.068; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	65	38	38	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	7						611	621		10.1016/j.nicl.2015.02.020			11	Neuroimaging	Neurosciences & Neurology	DI0GE	WOS:000373172600066	25844315	DOAJ Gold, Green Published			2021-06-18	
J	Kostyun, RO; Hafeez, I				Kostyun, Regina O.; Hafeez, Imran			Protracted Recovery From a Concussion: A Focus on Gender and Treatment Interventions in an Adolescent Population	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; sex; adolescent; treatment intervention	SPORT-RELATED CONCUSSION; STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; VESTIBULAR REHABILITATION; SEX-DIFFERENCES; SYMPTOMS; DISORDERS; ANXIETY; DEPRESSION; MANAGEMENT	Background: Several studies have demonstrated that age and sex may influence concussion recovery time frames, with female athletes and adolescents being potentially more susceptible to a protracted recovery course. Currently, limited work has examined the influence sex may have on concussion management strategies and treatment interventions, especially for younger individuals suffering persistent concussion symptoms and cognitive dysfunctions. Hypothesis: Female athletes are prescribed more treatment interventions than male athletes during a protracted recovery from a concussion. Study Design: Descriptive epidemiology study. Methods: Data were retrospectively collected for adolescent athletes presenting to a sports medicine concussion clinic between September 2010 and September 2011. Results: A total of 266 adolescent athletes were evaluated and treated for concussion. Female athletes had a longer recovery course (P = 0.002) and required more treatment interventions (P < 0.001) for their symptoms and dysfunction. Female athletes were more likely to require academic accommodations (P < 0.001), vestibular therapy (P < 0.001), or medication (P < 0.001). Conclusion: Medical providers should be aware that during the recovery course, adolescent female athletes may require a management plan that will most likely include additional treatment interventions beyond the standard cognitive and physical rest.	[Kostyun, Regina O.; Hafeez, Imran] Connecticut Childrens Med Ctr, Elite Sports Med, 399 Farmington Ave, Farmington, CT 06032 USA	Kostyun, RO (corresponding author), Connecticut Childrens Med Ctr, Elite Sports Med, 399 Farmington Ave, Farmington, CT 06032 USA.	rkostyun@connecticutchildrens.org					Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barth JT, 2001, J ATHL TRAINING, V36, P253; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Broshek DK, 2014, J CHILD NEUROL, V29, P17, DOI 10.1177/0883073812464525; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dumont IP, 2012, J AM BOARD FAM MED, V25, P291, DOI 10.3122/jabfm.2012.03.110056; Fernandez-de-Las-Penas Cesar, 2007, Curr Pain Headache Rep, V11, P365, DOI 10.1007/s11916-007-0219-z; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grills AE, 2002, J CLIN CHILD ADOLESC, V31, P59, DOI 10.1207/153744202753441675; Grills-Taquechel AE, 2010, ANXIETY STRESS COPIN, V23, P493, DOI 10.1080/10615800903494127; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kinnaman KA, 2013, ACTA PAEDIATR, V102, pE424, DOI 10.1111/apa.12315; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; MCGEE R, 1992, J AM ACAD CHILD PSY, V31, P50, DOI 10.1097/00004583-199201000-00009; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Missaghi Babak, 2004, J Can Chiropr Assoc, V48, P201; Morin AK, 2007, PHARMACOTHERAPY, V27, P89, DOI 10.1592/phco.27.1.89; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	42	38	38	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	JAN-FEB	2015	7	1					52	57		10.1177/1941738114555075			6	Sport Sciences	Sport Sciences	V20GY	WOS:000214876300006	25553213	Green Published			2021-06-18	
J	Marshall, CM; Vernon, H; Leddy, JJ; Baldwin, BA				Marshall, Cameron M.; Vernon, Howard; Leddy, John J.; Baldwin, Bradley A.			The role of the cervical spine in post-concussion syndrome	PHYSICIAN AND SPORTSMEDICINE			English	Article						Brain concussion; post-concussion syndrome; whiplash injuries; pathophysiology; musculoskeletal manipulations	TRAUMATIC BRAIN-INJURY; CERVICOCEPHALIC KINESTHETIC SENSIBILITY; MYOFASCIAL TRIGGER POINTS; GROWTH-FACTOR INJECTION; TENSOR IMAGING FINDINGS; CEREBRAL-BLOOD-FLOW; NECK PAIN; MILD HEAD; TECHNETIUM-99M-HMPAO SPECT; MITOCHONDRIAL DYSFUNCTION	While much is known regarding the pathophysiology surrounding concussion injuries in the acute phase, there is little evidence to support many of the theorized etiologies to post-concussion syndrome (PCS); the chronic phase of concussion occurring in similar to 10-15% of concussed patients. This paper reviews the existing literature surrounding the numerous proposed theories of PCS and introduces another potential, and very treatable, cause of this chronic condition; cervical spine dysfunction due to concomitant whiplash-type injury. We also discuss a short case-series of five patients with diagnosed PCS having very favorable outcomes following various treatment and rehabilitative techniques aimed at restoring cervical spine function.	[Marshall, Cameron M.; Vernon, Howard] Canadian Mem Chiropract Coll, Dept Grad Studies, Toronto, ON, Canada; [Leddy, John J.] SUNY Buffalo, Univ Sports Med, Dept Physiol & Family Med, Buffalo, NY 14260 USA; [Baldwin, Bradley A.] Private Practice Sports Med & Rehab Ctr, Angus, ON, Canada	Marshall, CM (corresponding author), Canadian Mem Chiropract Coll, Dept Grad Studies, 6100 Leslie St, Toronto, ON, Canada.	dr.cmarshall@outlook.com					Alptekin K, 2001, PSYCHIAT RES-NEUROIM, V107, P51, DOI 10.1016/S0925-4927(01)00086-5; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; APRILL C, 1990, SPINE, V15, P458, DOI 10.1097/00007632-199006000-00005; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bakhtadze MA, 2012, J MANIP PHYSIOL THER, V35, P76, DOI 10.1016/j.jmpt.2011.12.006; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bogduk N, 2001, CRANIO-CERVICAL SYNDROME, P110; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BOUNDS JR, 1995, NEUROLOGY, V45, P2117; Bracher ESB, 2000, J MANIP PHYSIOL THER, V23, P96, DOI 10.1016/S0161-4754(00)90074-5; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; CHAN KH, 1992, NEUROSURGERY, V30, P697; Chen J, 2012, ASIAN PAC J TROP MED, V5, P67, DOI 10.1016/S1995-7645(11)60248-4; Cooper G, 2007, PAIN MED, V8, P344, DOI 10.1111/j.1526-4637.2006.00201.x; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; de Jong P T, 1977, Ann Neurol, V1, P240, DOI 10.1002/ana.410010307; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Farhadi HF, 2013, WORLD NEUROSURG, V80, P794, DOI 10.1016/j.wneu.2013.10.023; Fernandez-De-Las-Penas C, 2007, CEPHALALGIA, V27, P383, DOI 10.1111/j.1468-2982.2007.01295.x; Findling O, 2011, GAIT POSTURE, V34, P473, DOI 10.1016/j.gaitpost.2011.06.021; Freitag P, 2001, NEUROREHAB NEURAL RE, V15, P31, DOI 10.1177/154596830101500105; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Gimse R, 1996, J CLIN EXP NEUROPSYC, V18, P178, DOI 10.1080/01688639608408273; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOBEL S, 1981, ORAL FACIAL SENSORY, P211; GRAY BG, 1992, J NUCL MED, V33, P52; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Heikkila HV, 1998, ARCH PHYS MED REHAB, V79, P1089, DOI 10.1016/S0003-9993(98)90176-9; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Holmberg J, 2003, NEUROREPORT, V14, P1007, DOI 10.1097/01.wnr.0000070191.28954.a5; HU JW, 1993, PAIN, V55, P243, DOI 10.1016/0304-3959(93)90153-G; Hu JW, 2005, BRAIN RES, V1044, P93, DOI 10.1016/j.brainres.2005.03.004; Hu JW, 1997, PROG PAIN RES MANAG, V8, P497; Hutchinson M., 2014, BRIT J SPORT MED, V48, P610; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; ICHISE M, 1994, J NUCL MED, V35, P217; Ito H, 1996, J NUCL MED, V37, P410; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Jull G, 2004, MANUAL THER, V9, P89, DOI 10.1016/S1356-689X(03)00086-9; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lord SM, 1996, NEW ENGL J MED, V335, P1721, DOI 10.1056/NEJM199612053352302; Lord SM., 1996, J MUSCULOSKELET PAIN, V4, P81; MAHLSTEDT K, 1992, LARYNGO RHINO OTOL, V71, P246, DOI 10.1055/s-2007-997289; Makowska A, 2005, EXP NEUROL, V191, P301, DOI 10.1016/j.expneurol.2004.10.001; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; Marshall Cameron M, 2012, J Can Chiropr Assoc, V56, P299; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Morch CD, 2007, EUR J NEUROSCI, V26, P142, DOI 10.1111/j.1460-9568.2007.05608.x; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Nakamura Y, 2014, J ORTHOP SCI, V19, P384, DOI 10.1007/s00776-014-0534-2; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Palmgren PJ, 2006, J MANIP PHYSIOL THER, V29, P100, DOI 10.1016/j.jmpt.2005.12.002; Panfil C, 2006, CEPHALALGIA, V26, P128, DOI 10.1111/j.1468-2982.2005.01005.x; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Richmond FJR, 2001, CRANIO-CERVICAL SYNDROME, P14; Roth JK, 2007, CEPHALALGIA, V27, P375, DOI 10.1111/j.1468-2982.2007.01296.x; RUBIN AM, 1995, AM J OTOL, V16, P216; Ruhe A, 2011, CHIROPR MAN THER, V19, DOI 10.1186/2045-709X-19-13; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; SCHWARTZ RB, 1994, AM J ROENTGENOL, V162, P943, DOI 10.2214/ajr.162.4.8141022; Sessle Barry J, 2002, J Dent Educ, V66, P108; Shin P, 2005, EXP BRAIN RES, V163, P314, DOI 10.1007/s00221-004-2172-y; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Silva AG, 2013, PHYSIOTHER THEOR PR, V29, P1, DOI 10.3109/09593985.2012.677111; Sizer J, 2002, J MANUAL MANIPULATIV, V10, P136; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Treleaven J, 2006, MANUAL THER, V11, P99, DOI 10.1016/j.math.2005.04.003; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2012, BRAIN INJURY PATHOGE, P501; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vernon H, 2009, J MANIP PHYSIOL THER, V32, P506, DOI 10.1016/j.jmpt.2009.08.012; Vincent MB, 2011, CURR PAIN HEADACHE R, V15, P324, DOI 10.1007/s11916-011-0195-1; Vuillerme N, 2009, EXP BRAIN RES, V192, P723, DOI 10.1007/s00221-008-1639-7; Williams M, 2007, SPINE, V32, pE764, DOI 10.1097/BRS.0b013e31815b6565; Yacovino D, 2004, REV NEUROLOGIA, V38, P1061, DOI 10.33588/rn.3811.2003642; Yadla S, 2008, CURR REV MUSCULOSKE, V1, P65, DOI 10.1007/s12178-007-9008-x; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	114	38	38	0	35	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.		2015	43	3					274	284		10.1080/00913847.2015.1064301			11	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	CR4TF	WOS:000361331100011	26138797				2021-06-18	
J	Saunders, GH; Frederick, MT; Arnold, M; Silverman, S; Chisolm, TH; Myers, P				Saunders, Gabrielle H.; Frederick, Melissa T.; Arnold, Michelle; Silverman, ShienPei; Chisolm, Theresa H.; Myers, Paula			Auditory difficulties in blast-exposed Veterans with clinically normal hearing	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory processing disorder; blast injuries; central auditory dysfunction; combat disorders; hearing; hearing loss; mild traumatic brain injury; rehabilitation; traumatic brain injury; Veterans; Veterans health	TRAUMATIC BRAIN-INJURY; IN-NOISE TEST; TEST-PERFORMANCE; GAP DETECTION; MEMORY SPAN; SPEECH; DYSFUNCTION; AGE; FREQUENCY; CHANNEL	Vast numbers of blast-injured Operation Iraqi Freedom/Operation Enduring Freedom/Operation New Dawn personnel report postconcussive symptoms that include headache, dizziness, poor memory, and difficulty concentrating. In addition, many report hearing problems, such as difficulty understanding speech in noise, yet have no measureable peripheral auditory deficits. In this article, self-report and performance-based measures were used to assess 99 blast-exposed Veterans. All participants reported auditory problems in difficult listening situations but had clinically normal hearing. Participants' scores on self-report questionnaires of auditory difficulties were more similar to scores of older individuals with hearing impairment than to those of younger individuals with normal hearing. Participants showed deficits relative to published normative data on a number of performance-based tests that have demonstrated sensitivity to auditory processing deficits. There were several measures on which more than the expected number of participants (15.9%) performed one or more standard deviations below the mean. These were assessments of speech understanding in noise, binaural processing, temporal resolution, and speech segregation. Performance was not universally poor, with approximately 53% of participants performing abnormally on between 3 and 6 of the 10 measures. We concluded that participants exhibited task-specific deficits that add to the evidence suggesting that blast injury results in damage to the central auditory system.	[Saunders, Gabrielle H.; Frederick, Melissa T.; Silverman, ShienPei] Dept Vet Affairs Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA; [Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA; [Arnold, Michelle; Chisolm, Theresa H.] Univ S Florida, Dept Commun Sci & Disorders, Tampa, FL 33620 USA; [Arnold, Michelle; Myers, Paula] James A Haley Vet Hosp, Tampa, FL USA	Saunders, GH (corresponding author), VA Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	gabrielle.saunders@va.gov	Saunders, Gabrielle/V-2288-2019	Saunders, Gabrielle/0000-0002-9997-0845	Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development [C7054R]; Veterans AffairsUS Department of Veterans Affairs [I01RX000209] Funding Source: NIH RePORTER	This material was based on work supported by the Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development (grant C7054R).	American Speech-Language-Hearing Association, 2005, GUID MAN PUR TON THR; [Anonymous], 1969, IEEE T ACOUST SPEECH, VAU17, P225; [Anonymous], 2014, POSTD HEALTHC CHALL; Banh J, 2012, J AM ACAD AUDIOL, V23, P81, DOI 10.3766/jaaa.23.2.2; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Brown DK, 2010, J AM ACAD AUDIOL, V21, P629, DOI 10.3766/jaaa.21.10.3; Cameron S, 2006, J AM ACAD AUDIOL, V17, P306, DOI 10.3766/jaaa.17.5.2; Cameron S, 2009, J AM ACAD AUDIOL, V20, P128, DOI 10.3766/jaaa.20.2.6; Chan RK, 2012, J TRAUMA ACUTE CARE, V73, pS453, DOI 10.1097/TA.0b013e3182754868; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fischer H., 2014, GUIDE US MILITARY CA; Formby C, 1998, J ACOUST SOC AM, V103, P3554, DOI 10.1121/1.423084; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Gatehouse S, 2004, INT J AUDIOL, V43, P85, DOI 10.1080/14992020400050014; Golden CJ, 2002, STROOP COLOR WORD TE; Grose JH, 2001, J ACOUST SOC AM, V109, P1587, DOI 10.1121/1.1354983; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; House Ear Institute, 2001, HINT WIND 6 1 US GUI; JERGER J, 1984, ARCH OTOLARYNGOL, V110, P290; Katz J., 1998, SSW TEST MANUAL; Killion MC, 2004, J ACOUST SOC AM, V116, P2395, DOI 10.1121/1.1784440; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lister JJ, 2011, INT J AUDIOL, V50, P211, DOI 10.3109/14992027.2010.526967; Lister Jennifer J, 2006, Am J Audiol, V15, P133, DOI 10.1044/1059-0889(2006/017); Lister JJ, 2005, J SPEECH LANG HEAR R, V48, P482, DOI 10.1044/1092-4388(2005/033); Lister JJ, 2000, EAR HEARING, V21, P141, DOI 10.1097/00003446-200004000-00008; Macera CA, 2012, J REHABIL RES DEV, V49, P1197, DOI 10.1682/JRRD.2011.07.0131; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; MATHER M, 2001, EXAMINERS MANUAL WOO; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; NILSSON M, 1994, J ACOUST SOC AM, V95, P1085, DOI 10.1121/1.408469; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Psychological Corporation, 1997, WAIS 3 WESCHL AD INT; Reynolds CR, 1997, ARCH CLIN NEUROPSYCH, V12, P29, DOI 10.1016/S0887-6177(96)00015-7; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Saunders GH, 2012, J REHABIL RES DEV, V49, P1043, DOI 10.1682/JRRD.2010.08.0157; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; U.S. Institute of Medicine, 2014, GULF WAR HLTH LONG T; Vander Werff KR, 2012, PERSPECTIVES HEARING, V16, P3, DOI DOI 10.1044/HHD16.13; Vaughan N, 2006, J AM ACAD AUDIOL, V17, P506, DOI 10.3766/jaaa.17.7.6; Wilde NJ, 2004, J CLIN EXP NEUROPSYC, V26, P539, DOI 10.1080/13803390490496605; Wilson Richard H, 2003, J Am Acad Audiol, V14, P1, DOI 10.3766/jaaa.14.1.2; Zendel BR, 2012, PSYCHOL AGING, V27, P410, DOI 10.1037/a0024816	56	38	39	0	9	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2015	52	3					343	359		10.1682/JRRD.2014.11.0275			17	Rehabilitation	Rehabilitation	CN0NR	WOS:000358111100009	26237266	Bronze			2021-06-18	
J	Amenta, PS; Jallo, JI; Tuma, RF; Hooper, DC; Elliott, MB				Amenta, Peter S.; Jallo, Jack I.; Tuma, Ronald F.; Hooper, D. Craig; Elliott, Melanie B.			Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Controlled cortical impact; Traumatic brain injury; Cannabinoid; Inflammation; Intracellular adhesion molecule	BARRIER PERMEABILITY CHANGES; CENTRAL-NERVOUS-SYSTEM; CB2 RECEPTOR; MOUSE-BRAIN; RAT MODEL; ACTIVATION; AGONIST; MICROGLIA; CLEARANCE; MIGRATION	Background: Immunomodulatory therapies have been identified as interventions for secondary injury after traumatic brain injury (TBI). The cannabinoid receptor type-2 (CB2R) is proposed to play an important, endogenous role in regulating inflammation. The effects of CB2R stimulation, blockade, and deletion on the neurovascular inflammatory responses to TBI were assessed. Methods: Wild-type C57BL/6 or CB2R knockout mice were randomly assigned to controlled cortical impact (CCI) injury or to craniotomy control groups. The effects of treatment with synthetic, selective CB2R agonists (0-1966 and JWH-133), a selective CB2R antagonist, or vehicle solution administered to CCI groups were assessed at 1-day after injury. Changes in TNF-alpha, intracellular adhesion molecule (ICAM-1), inducible nitric oxide synthase (iNOS), macrophage/microglial ionized calcium-binding adaptor molecule, and blood-brain-barrier (BBB) permeability were assessed using ELISA, quantitative RT-PCR, immunohistochemistry, and fluorometric analysis of sodium fluorescein uptake. CB2R knockouts and wild-type mice with CCI injury were treated with a CB2R agonist or vehicle treatment. Results: TNF-alpha mRNA increased at 6 hours and 1 to 3 days after CCI; a CB2R antagonist and genetic knockout of the CB2R exacerbated TNF-alpha mRNA expression. Treatment with a CB2R agonist attenuated TNF-alpha protein levels indicating post-transcriptional mechanisms. Intracellular adhesion molecule (ICAM-1) mRNA was increased at 6 hours, and at 1 to 2 days after CCI, reduced in mice treated with a CB2R agonist, and increased in CB2R knockout mice with CCI. Sodium fluorescein uptake was increased in CB2R knockouts after CCI, with and without a CB2R agonist. iNOS mRNA expression peaked early (6 hours) and remained increased from 1 to 3 days after injury. Treatment with a CB2R agonist attenuated increases in iNOS mRNA expression, while genetic deletion of the CB2R resulted in substantial increases in iNOS expression. Double label immunohistochemistry confirmed that iNOS was expressed by macrophage/microglia in the injured cortex. Conclusion: Findings demonstrate that the endogenous cannabinoid system and CB2R play an important role in regulating inflammation and neurovascular responses in the traumatically injured brain. CB2R stimulation with two agonists (0-1966 and JWH-133) dampened post-traumatic inflammation, while blockade or deletion of the CB2R worsened inflammation. Findings support previous evidence that modulating the CB2R alters infiltrating macrophages and activated resident microglia. Further investigation into the role of the CB2R on specific immune cell populations in the injured brain is warranted.	[Amenta, Peter S.; Jallo, Jack I.; Elliott, Melanie B.] Thomas Jefferson Univ, Dept Neurol Surg, Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; [Hooper, D. Craig] Thomas Jefferson Univ, Dept Canc Biol, Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; [Tuma, Ronald F.] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA	Elliott, MB (corresponding author), Thomas Jefferson Univ, Dept Neurol Surg, Thomas Jefferson Univ Hosp, 1020 Locust St, Philadelphia, PA 19107 USA.	Melanie.elliott@jefferson.edu		Jallo, Jack/0000-0002-5512-1729	DODUnited States Department of Defense [W81XWH-12-1-0326]	Research support by DOD Award W81XWH-12-1-0326 to Dr. Elliott. We would also like to thank Rhonda Kean (Dr. Hooper's laboratory) for help with RT-PCR and members from Dr. Elliott's laboratory including Brittany Diautolo, Ashley Tyburski, and Christine Macolino for making RT-PCR, immunohisto-chemistry, and surgical contributions.	Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Ashton JC, 2012, HIPPOCAMPUS, V22, P643, DOI 10.1002/hipo.20946; Ashton JC, 2011, BRIT J PHARMACOL, V163, P1113, DOI 10.1111/j.1476-5381.2010.01139.x; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Cabral GA, 2005, J LEUKOCYTE BIOL, V78, P1192, DOI 10.1189/jlb.0405216; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215; Dietrich JB, 2002, J NEUROIMMUNOL, V128, P58, DOI 10.1016/S0165-5728(02)00114-5; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Erickson MA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-150; Fabis MJ, 2008, P NATL ACAD SCI USA, V105, P15511, DOI 10.1073/pnas.0807656105; Fishbein-Kaminietsky M, 2014, J NEUROSCI RES, V92, P1669, DOI 10.1002/jnr.23452; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; Fraga D, 2011, J NEUROIMMUNE PHARM, V6, P566, DOI 10.1007/s11481-011-9291-6; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giambelluca M, 2013, OA INFLAMMATION, V1, P3; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Landry RP, 2012, J PAIN, V13, P836, DOI 10.1016/j.jpain.2012.05.013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lombard C, 2007, CLIN IMMUNOL, V122, P259, DOI 10.1016/j.clim.2006.11.002; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Montecucco F, 2008, AM J PHYSIOL-HEART C, V294, pH1145, DOI 10.1152/ajpheart.01328.2007; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nag Sukriti, 2003, Methods Mol Med, V89, P97; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Pertwee RG, 2010, CURR MED CHEM, V17, P1360, DOI 10.2174/092986710790980050; Phares TW, 2007, J IMMUNOL, V178, P7334, DOI 10.4049/jimmunol.178.11.7334; Phares TW, 2006, J IMMUNOL, V176, P7666, DOI 10.4049/jimmunol.176.12.7666; Price DA, 2009, EUR J NEUROSCI, V29, P2177, DOI 10.1111/j.1460-9568.2009.06764.x; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Reglero-Real N, 2012, CELL MOL LIFE SCI, V69, P3079, DOI 10.1007/s00018-012-0987-4; Romero-Sandoval EA, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-25; Sacerdote P, 2000, J NEUROIMMUNOL, V109, P155, DOI 10.1016/S0165-5728(00)00307-6; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Tomkins Oren, 2011, Cardiovasc Psychiatry Neurol, V2011, P765923, DOI 10.1155/2011/765923; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wiley JL, 2002, J PHARMACOL EXP THER, V301, P679, DOI 10.1124/jpet.301.2.679; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	63	38	39	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	NOV 22	2014	11								191	10.1186/s12974-014-0191-6			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AW6KW	WOS:000346379400001	25416141	DOAJ Gold, Green Published			2021-06-18	
J	Marini, A; Zettin, M; Galetto, V				Marini, Andrea; Zettin, Marina; Galetto, Valentina			Cognitive correlates of narrative impairment in moderate traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						Moderate traumatic brain injury; Narrative analysis; Neurolinguistics; Neuropsychology; Language	CLOSED-HEAD-INJURY; DISCOURSE PRODUCTION; WORD RETRIEVAL; FOLLOW-UP; COMMUNICATION PARTNERS; EXECUTIVE FUNCTIONS; STORY NARRATIVES; MILD; ADULTS; LANGUAGE	Traumatic brain injuries (TBIs) are often associated with communicative deficits. The incoherent and impoverished language observed in non-aphasic individuals with severe TBI has been linked to a problem in the global organization of information at the text level. The present study aimed to analyze the features of narrative discourse impairment in a group of adults with moderate TBI (modTBI). 10 non-aphasic speakers with modTBI and 20 neurologically intact participants were recruited for the experiment. Their cognitive, linguistic and narrative skills were thoroughly assessed. The persons with modTBI exhibited normal phonological, lexical and grammatical skills. However, their narratives were characterized by lower levels of Lexical Informativeness and more errors of both Local and Global Coherence that, at times, made their narratives vague and ambiguous. Significant correlations were found between these narrative difficulties and the production of both perseverative and non-perseverative errors on the WCST. These disturbances confirm previous findings which suggest a deficit at the interface between cognitive and linguistic processing rather than a specific linguistic disturbance in these patients. (C) 2014 Elsevier Ltd. All rights reserved.	[Marini, Andrea] Univ Udine, Dipartimento Sci Umane, I-33100 Udine, Italy; [Marini, Andrea] IRCCS E Medea La Nostra Famiglia, San Vito Al Tagliamento, Pn, Italy; [Zettin, Marina; Galetto, Valentina] Ctr Puzzle, Turin, Italy; [Zettin, Marina; Galetto, Valentina] Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy	Marini, A (corresponding author), Univ Udine, Dipartimento Sci Umane, Via Margreth 3, I-33100 Udine, Italy.	andrea.marini@uniud.it	Marini, Andrea/A-1206-2012	Marini, Andrea/0000-0002-6058-3864	IRCCS "E. Medea"	Funding for this study was provided by IRCCS "E. Medea". The IRCCS "E. Medea" had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Adamovich B.L.B., 2005, APHASIA RELATED NEUR; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Ash S, 2006, NEUROLOGY, V66, P1405, DOI 10.1212/01.wnl.0000210435.72614.38; Barrow IM, 2003, J TRAUMA, V54, P888, DOI 10.1097/01.TA.0000057150.60668.7C; Barrow IM, 2006, BRAIN INJURY, V20, P845, DOI 10.1080/02699050600832445; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Body R., 1999, COMMUNICAITON DISORE; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Carlomagno S, 2011, BRAIN INJURY, V25, P1010, DOI 10.3109/02699052.2011.605097; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Coelho C, 2012, NEUROPSYCHOLOGIA, V50, P3564, DOI 10.1016/j.neuropsychologia.2012.09.005; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Douglas J., 2004, EVIDENCE BASED PRACT, P59; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Galetto V, 2013, J NEUROLINGUIST, V26, P649, DOI 10.1016/j.jneuroling.2013.05.004; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GILLIS R, 1996, TRAUMATIC BRAIN INJU; Goozee J V, 2001, Logoped Phoniatr Vocol, V26, P51; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton R., 1993, WISCONSIN CARD SORTI; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Hough MS, 2008, APHASIOLOGY, V22, P644, DOI 10.1080/02687030701541024; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Jorgensen M, 2009, BRAIN INJURY, V23, P727, DOI 10.1080/02699050903133954; Kertesz A., 1982, W APHASIA BATTERY; King KA, 2006, APHASIOLOGY, V20, P233, DOI 10.1080/02687030500473155; King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; Linebarger MC, 2004, COGN NEUROPSYCHOL, V21, P267, DOI 10.1080/02643290342000537; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2011, APHASIOLOGY, V25, P1372, DOI 10.1080/02687038.2011.584690; Marini A, 2012, J COGNITIVE NEUROSCI, V24, P2211, DOI 10.1162/jocn_a_00283; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Raven J. C., 1938, PROGR MATRICES PERCE; Reitan R. M, 1992, TRAIL MAKING TEST; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sherratt S, 2007, APHASIOLOGY, V21, P375, DOI 10.1080/02687030600911435; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sim P, 2013, BRAIN INJURY, V27, P717, DOI 10.3109/02699052.2013.775485; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 2000, BRAIN INJURY, V14, P397; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Tu LV, 2011, BRAIN INJURY, V25, P560, DOI 10.3109/02699052.2011.571655; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Ylvisaker M., 2001, LANGUAGE INTERVENTIO; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	61	38	39	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	NOV	2014	64						282	288		10.1016/j.neuropsychologia.2014.09.042			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	AU6TL	WOS:000345734500028	25281884				2021-06-18	
J	Staib-Lasarzik, I; Kriege, O; Timaru-Kast, R; Pieter, D; Werner, C; Engelhard, K; Thal, SC				Staib-Lasarzik, Irina; Kriege, Oliver; Timaru-Kast, Ralph; Pieter, Dana; Werner, Christian; Engelhard, Kristin; Thal, Serge C.			Anesthesia for Euthanasia Influences mRNA Expression in Healthy Mice and after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						anesthesia; gene expression; early regulated genes; organ sampling; real-time PCR; traumatic brain injury	GENE-EXPRESSION; NEURONAL INJURY; HEAT-SHOCK; C-FOS; ISCHEMIA; STRESS; RAT; NEUROPROTECTION; ISOFLURANE; INDUCTION	Tissue sampling for gene expression analysis is usually performed under general anesthesia. Anesthetics are known to modulate hemodynamics, receptor-mediated signaling cascades, and outcome parameters. The present study determined the influence of anesthetic paradigms typically used for euthanization and tissue sampling on cerebral mRNA expression in mice. Naive mice and animals with acute traumatic brain injury induced by controlled cortical impact (CCI) were randomized to the following euthanasia protocols (n = 10-11/group): no anesthesia (NA), 1 min of 4 vol% isoflurane in room air (ISO), 3 min of a combination of 5 mg/kg midazolam, 0.05 mg/kg fentanyl, and 0.5 mg/kg medetomidine intra-peritoneally (COMB), or 3 min of 360 mg/kg chloral hydrate intraperitoneally (CH). mRNA expression of actin-1-related gene (Act1), FBJ murine osteosarcoma viral oncogene homolog B (FosB), tumor necrosis factor alpha (TNF alpha), heat shock protein beta-1 (HspB1), interleukin (IL)-6, tight junction protein 1 (ZO-1), IL-1 beta, cyclophilin A, micro RNA 497 (miR497), and small cajal body-specific RNA 17 were determined by real-time polymerase chain reaction (PCR) in hippocampus samples. In naive animals, Act1 expression was downregulated in the CH group compared with NA. FosB expression was downregulated in COMB and CH groups compared with NA. CCI reduced Act1 and FosB expression, whereas HspB1 and TNF alpha expression increased. After CCI, HspB1 expression was significantly higher in ISO, COMB, and CH groups, and TNF alpha expression was elevated in ISO and COMB groups. MiR497, IL-6, and IL-1 beta were upregulated after CCI but not affected by anesthetics. Effects were independent of absolute mRNA copy numbers. The data demonstrate that a few minutes of anesthesia before tissue sampling are sufficient to induce immediate mRNA changes, which seem to predominate in the early-regulated gene cluster. Anesthesia-related effects on gene expression might explain limited reproduciblity of real-time PCR data between studies or research groups and should therefore be considered for quantitative PCR data.	[Staib-Lasarzik, Irina; Kriege, Oliver; Timaru-Kast, Ralph; Pieter, Dana; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, D-55131 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729	German Research Foundation (DFG)German Research Foundation (DFG) [TH1430/3-1]; Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF 01EO1003]	This work was supported by the German Research Foundation (DFG grant TH1430/3-1 to Dr. Thal) and by the Federal Ministry of Education and Research (BMBF 01EO1003). The data presented in this manuscript are part of the doctoral theses presented by Oliver Kriege to the Medical Faculty of the Johannes Gutenberg-University, Mainz, Germany.	Briet F, 2009, CAN J ANAESTH, V56, P921, DOI 10.1007/s12630-009-9201-z; Cao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051431; Ebihara K, 2011, NEUROSCI LETT, V496, P90, DOI 10.1016/j.neulet.2011.03.087; Falvo JV, 2010, CURR DIR AUTOIMMUN, V11, P27, DOI 10.1159/000289196; Franklin TB, 2005, INT J HYPERTHER, V21, P379, DOI 10.1080/02656730500069955; Hamaya Y, 2000, ANESTH ANALG, V90, P1177, DOI 10.1097/00000539-200005000-00034; Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003; Johnson PL, 2011, J PSYCHOPHARMACOL, V25, P26, DOI 10.1177/0269881109353464; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Kim GS, 2012, NEUROBIOL DIS, V46, P440, DOI 10.1016/j.nbd.2012.02.008; Kulisch C, 2011, J NEUROSCI METH, V201, P340, DOI 10.1016/j.jneumeth.2011.08.022; Lasarzik I, 2011, J NEUROSURG ANESTH, V23, P215, DOI 10.1097/ANA.0b013e31821a1150; Li H, 2013, NEUROBIOL DIS, V54, P216, DOI 10.1016/j.nbd.2012.12.014; Liu CY, 2012, J NEUROCHEM, V120, P830, DOI 10.1111/j.1471-4159.2011.07624.x; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Nellgard B, 2000, ANESTH ANALG, V91, P145, DOI 10.1097/00000539-200007000-00027; Olsvik PA, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-48; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; SHARP FR, 1994, NEUROTOXICOLOGY, V15, P51; Stetler RA, 2012, J NEUROSCI, V32, P2667, DOI 10.1523/JNEUROSCI.5169-11.2012; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Trosse C, 2010, FISH PHYSIOL BIOCHEM, V36, P1217, DOI 10.1007/s10695-010-9401-z; Valentine H, 2012, J AM ASSOC LAB ANIM, V51, P50; Wu X, 2012, NEUROBIOL AGING, V33, P1364, DOI 10.1016/j.neurobiolaging.2010.11.002; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	29	38	38	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1664	1671		10.1089/neu.2013.3243			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400008	24945082	Green Published			2021-06-18	
J	Lee, LK; Monroe, D; Bachman, MC; Glass, TF; Mahajan, PV; Cooper, A; Stanley, RM; Miskin, M; Dayan, PS; Holmes, JF; Kuppermann, N				Lee, Lois K.; Monroe, David; Bachman, Michael C.; Glass, Todd F.; Mahajan, Prashant V.; Cooper, Arthur; Stanley, Rachel M.; Miskin, Michelle; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		TBI Working Grp PECARN	Isolated Loss of Consciousness in Children With Minor Blunt Head Trauma	JAMA PEDIATRICS			English	Article							CRANIAL COMPUTED-TOMOGRAPHY; SIGNIFICANT INTRACRANIAL INJURY; DECISION RULE; RADIATION-EXPOSURE; NEUROLOGIC EXAMINATION; BRAIN-INJURIES; RISK; PREDICT; SCANS; METAANALYSIS	IMPORTANCE A history of loss of consciousness (LOC) is frequently a driving factor for computed tomography use in the emergency department evaluation of children with blunt head trauma. Computed tomography carries a nonnegligible risk for lethal radiation-induced malignancy. The Pediatric Emergency Care Applied Research Network (PECARN) derived 2 age-specific prediction rules with 6 variables for clinically important traumatic brain injury (ciTBI), which included LOC as one of the risk factors. OBJECTIVE To determine the risk for ciTBIs in children with isolated LOC. DESIGN, SETTING, AND PARTICIPANTS This was a planned secondary analysis of a large prospective multicenter cohort study. The study included 42 412 children aged 0 to 18 years with blunt head trauma and Glasgow Coma Scale scores of 14 and 15 evaluated in 25 emergency departments from 2004-2006. EXPOSURE A history of LOC after minor blunt head trauma. MAIN OUTCOMES AND MEASURES The main outcome measures were ciTBIs (resulting in death, neurosurgery, intubation for >24 hours, or hospitalization for >= 2 nights) and a comparison of the rates of ciTBIs in children with no LOC, any LOC, and isolated LOC (ie, with no other PECARN ciTBI predictors). RESULTS A total of 42 412 children were enrolled in the parent study, with 40 693 remaining in the current analysis after exclusions. Of these, LOC occurred in 15.4%(6286 children). The prevalence of ciTBI with any history of LOC was 2.5% and for no history of LOC was 0.5% (difference, 2.0%; 95% CI, 1.7-2.5). The ciTBI rate in children with isolated LOC, with no other PECARN predictors, was 0.5%(95% CI, 0.2-0.8; 13 of 2780). When comparing children who have isolated LOC with those who have LOC and other PECARN predictors, the risk ratio for ciTBI in children younger than 2 years was 0.13 (95% CI, 0.005-0.72) and for children 2 years or older was 0.10 (95% CI, 0.06-0.19). CONCLUSIONS AND RELEVANCE Children with minor blunt head trauma presenting to the emergency department with isolated LOC are at very low risk for ciTBI and do not routinely require computed tomographic evaluation.	[Lee, Lois K.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Monroe, David] Howard Cty Gen Hosp, Dept Emergency Med, Columbia, MD USA; [Bachman, Michael C.] Newark Beth Israel Med Ctr, Dept Emergency Med, Newark, NJ USA; [Bachman, Michael C.] Newark Beth Israel Med Ctr, Dept Pediat, Newark, NJ USA; [Glass, Todd F.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Mahajan, Prashant V.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; [Cooper, Arthur] Columbia Univ, Harlem Hosp, Med Ctr, Dept Surg, New York, NY USA; [Stanley, Rachel M.] Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI USA; [Miskin, Michelle] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Dayan, Peter S.] Columbia Univ, Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Emergency Med, New York, NY USA; [Kuppermann, Nathan] Univ Calif, Davis Sch Med, Dept Emergency Med, Sacramento, CA USA; [Kuppermann, Nathan] Univ Calif, Davis Sch Med, Dept Pediat, Sacramento, CA USA	Lee, LK (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	lois.lee@childrens.harvard.edu		Tsung, James/0000-0002-4718-8325; Holubkov, Richard/0000-0003-0431-3381	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB) Division of Research, Education and Training (DRTE) [R40MC02461]; Emergency Medical Services for Children (EMSC) Program; HRSA/MCHB/EMSC Program [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]; EMSC program of the MCHB/HRSA [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	This study was supported by grant R40MC02461 from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB) Division of Research, Education and Training (DRTE) and the Emergency Medical Services for Children (EMSC) Program. The PECARN is supported by the HRSA/MCHB/EMSC Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. The PECARN is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685 from the EMSC program of the MCHB/HRSA.	ABIM Foundation American Academy of Pediatrics, 2013, CHOOS WIS 5 THINGS P; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larson DB, 2011, RADIOLOGY, V258, P164, DOI 10.1148/radiol.10100640; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Munafo S, 2013, ACAD EMERG MED, V20, ps235; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shah P, 2012, ACAD EMERG MED, V19, ps156; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Smith-Bindman R, 2012, JAMA-J AM MED ASSOC, V307, P2400, DOI 10.1001/jama.2012.5960; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Walker G, PECARN PEDIAT HEAD I	44	38	39	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	SEP	2014	168	9					837	843		10.1001/jamapediatrics.2014.361			7	Pediatrics	Pediatrics	AO8AS	WOS:000341575200012	25003654	Bronze			2021-06-18	
J	Deer, TR; Mekhail, N; Petersen, E; Krames, E; Staats, P; Pope, J; Saweris, Y; Lad, SP; Diwan, S; Falowski, S; Feler, C; Slavin, K; Narouze, S; Merabet, L; Buvanendran, A; Fregni, F; Wellington, J; Levy, RM				Deer, Timothy R.; Mekhail, Nagy; Petersen, Erika; Krames, Elliot; Staats, Peter; Pope, Jason; Saweris, Youssef; Lad, Shivanand P.; Diwan, Sudhir; Falowski, Steven; Feler, Claudio; Slavin, Konstantin; Narouze, Samer; Merabet, Lotfi; Buvanendran, Asokumar; Fregni, Felipe; Wellington, Joshua; Levy, Robert M.			The Appropriate Use of Neurostimulation: Stimulation of the Intracranial and Extracranial Space and Head for Chronic Pain	NEUROMODULATION			English	Article						Cranial nerve stimulation; deep brain stimulation; migraine; motor cortex stimulation; neurostimulation; occipital nerve stimulation; peripheral nerve stimulation; trigeminal nerve stimulation; vagal nerve stimulation	OCCIPITAL NERVE-STIMULATION; MOTOR-CORTEX-STIMULATION; DEEP BRAIN-STIMULATION; SPINAL-CORD STIMULATION; CHRONIC CLUSTER HEADACHE; TERM-FOLLOW-UP; DORSAL-ROOT GANGLION; LOW-BACK-PAIN; SUBCUTANEOUS FIELD STIMULATION; CHRONIC NEUROPATHIC PAIN	Introduction: The International Neuromodulation Society (INS) has identified a need for evaluation and analysis of the practice of neurostimulation of the brain and extracranial nerves of the head to treat chronic pain. Methods: The INS board of directors chose an expert panel, the Neuromodulation Appropriateness Consensus Committee (NACC), to evaluate the peer-reviewed literature, current research, and clinical experience and to give guidance for the appropriate use of these methods. The literature searches involved key word searches in PubMed, EMBASE, and Google Scholar dated 1970-2013, which were graded and evaluated by the authors. Results: The NACC found that evidence supports extracranial stimulation for facial pain, migraine, and scalp pain but is limited for intracranial neuromodulation. High cervical spinal cord stimulation is an evolving option for facial pain. Intracranial neurostimulation may be an excellent option to treat diseases of the nervous system, such as tremor and Parkinson's disease, and in the future, potentially Alzheimer's disease and traumatic brain injury, but current use of intracranial stimulation for pain should be seen as investigational. Conclusions: The NACC concludes that extracranial nerve stimulation should be considered in the algorithmic treatment of migraine and other disorders of the head. We should strive to perfect targets outside the cranium when treating pain, if at all possible.	[Deer, Timothy R.; Pope, Jason] Ctr Pain Relief, Charleston, WV 25301 USA; [Mekhail, Nagy; Saweris, Youssef] Cleveland Clin, Evidence Based Pain Management Res & Educ, Cleveland, OH 44106 USA; [Petersen, Erika] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Krames, Elliot] Pacific Pain Treatment Ctr, San Francisco, CA USA; [Staats, Peter] Premier Pain Management Ctr, Shrewsbury, NJ USA; [Staats, Peter] Johns Hopkins Univ, Baltimore, MD USA; [Lad, Shivanand P.] Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA; [Diwan, Sudhir] Lenox Hill Hosp, Manhattan Spine & Pain Med, New York, NY 10021 USA; [Falowski, Steven] St Lukes Neurosurg Associates, Bethlehem, PA USA; [Feler, Claudio] Univ Tennessee, Memphis, TN USA; [Feler, Claudio] Valley View Hosp, Glenwood Springs, CO USA; [Slavin, Konstantin] Univ Illinois, Chicago, IL USA; [Narouze, Samer] Summa Western Reserve Hosp, Cuyahoga Falls, OH USA; [Merabet, Lotfi] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA; [Merabet, Lotfi] Harvard Univ, Schepens Eye Res Inst, Sch Med, Boston, MA USA; [Buvanendran, Asokumar] Rush Univ, Dept Anesthesia, Med Ctr, Chicago, IL 60612 USA; [Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA; [Wellington, Joshua] Indiana Univ, Pain Med Ctr, Indianapolis, IN 46204 USA; [Levy, Robert M.] Univ Florida, Coll Med, Jacksonville, FL USA	Deer, TR (corresponding author), Ctr Pain Relief, 400 Court St,Ste 100, Charleston, WV 25301 USA.	doctdeer@aol.com	Slavin, Konstantin/H-3269-2019; Merabet, Lotfi B./V-2735-2017; merabet, lotfi/AAU-8259-2020	Slavin, Konstantin/0000-0002-7946-8639; Merabet, Lotfi B./0000-0002-8094-9536; merabet, lotfi/0000-0002-8094-9536; Petersen, Erika/0000-0002-8548-1450; Fregni, Felipe/0000-0001-9359-8643	International Neuromodulation Society; Medtronic Inc.Medtronic; St. Jude Medical Inc.St. Jude Medical; Boston Scientific Corp.Boston Scientific; Nevro Corp.; Spinal Modulation Inc.	This project was supported by the International Neuromodulation Society and was partially funded by a series of unrestricted educational grants from Medtronic Inc., St. Jude Medical Inc., Boston Scientific Corp., Nevro Corp., and Spinal Modulation Inc. No corporate entities had any direct input into the contents of this manuscript, or the conclusions of the collaborators.	Abejon D, 2009, NEUROMODULATION, V12, P1, DOI 10.1111/j.1525-1403.2009.00192.x; Acar F, 2008, STEREOT FUNCT NEUROS, V86, P106, DOI 10.1159/000113872; Aderjan D, 2010, PAIN, V151, P97, DOI 10.1016/j.pain.2010.06.024; Amin S, 2008, CEPHALALGIA, V28, P355, DOI 10.1111/j.1468-2982.2008.01535.x; Ansarinia M, 2010, HEADACHE, V50, P1164, DOI 10.1111/j.1526-4610.2010.01661.x; Antal A, 2004, INVEST OPHTH VIS SCI, V45, P702, DOI 10.1167/iovs.03-0688; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; ANTHONY M, 1992, CLIN NEUROL NEUROSUR, V94, P297, DOI 10.1016/0303-8467(92)90177-5; Asensio-Samper Juan M, 2008, Pain Pract, V8, P120, DOI 10.1111/j.1533-2500.2007.00165.x; Bajbouj M, 2010, J CLIN PSYCHOPHARM, V30, P273, DOI 10.1097/JCP.0b013e3181db8831; BAROLAT G, 1993, J NEUROSURG, V78, P233, DOI 10.3171/jns.1993.78.2.0233; Barolat Giancarlo, 1993, Stereotactic and Functional Neurosurgery, V61, P60, DOI 10.1159/000100624; Bartsch T, 2009, CURR OPIN NEUROL, V22, P262, DOI 10.1097/WCO.0b013e32832ae61e; Beltrutti Diego, 2004, Pain Pract, V4, P204, DOI 10.1111/j.1533-2500.2004.04305.x; Bernard E J Jr, 1987, Br J Neurosurg, V1, P81, DOI 10.3109/02688698709034343; Beving H, 1996, BLOOD COAGUL FIBRIN, V7, P80, DOI 10.1097/00001721-199601000-00010; Bittar RG, 2005, J CLIN NEUROSCI, V12, P12, DOI 10.1016/j.jocn.2004.03.025; Boccard SGJ, 2013, NEUROSURGERY, V72, P221, DOI 10.1227/NEU.0b013e31827b97d6; Broggi G, 2009, NEUROL SCI, V30, pS75, DOI 10.1007/s10072-009-0082-2; Broggi G, 2010, NEUROL SCI, V31, P87, DOI 10.1007/s10072-010-0293-6; Brown JA, 2005, NEUROSURGERY, V56, P290, DOI 10.1227/01.neu.0000148905.75845.98; Bullard DE, 1997, STEREOT FUNCT NEUROS, V68, P168, DOI 10.1159/000099918; Burgher AH, 2012, NEUROMODULATION, V15, P100, DOI 10.1111/j.1525-1403.2011.00388.x; Burkey AR, 2010, PAIN MED, V11, P127, DOI 10.1111/j.1526-4637.2009.00764.x; Burns B, 2008, LANCET NEUROL, V7, P1001, DOI 10.1016/S1474-4422(08)70217-5; Burns B, 2007, LANCET, V369, P1099, DOI 10.1016/S0140-6736(07)60328-6; Burns B, 2009, NEUROLOGY, V72, P341, DOI 10.1212/01.wnl.0000341279.17344.c9; Campbell CM, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-012-0307-6; Carroll D, 2000, PAIN, V84, P431, DOI 10.1016/S0304-3959(99)00245-6; Cecchini AP, 2009, NEUROL SCI, V30, pS101, DOI 10.1007/s10072-009-0073-3; Chiou RJ, 2013, BRAIN RES, V18, P756; Cianchetti C, 2012, CEPHALALGIA, V32, P778, DOI 10.1177/0333102412449930; Coffey RJ, 2001, PAIN MED, V2, P183, DOI 10.1046/j.1526-4637.2001.01029.x; CRUE BL, 1956, NEUROLOGY, V6, P196, DOI 10.1212/WNL.6.3.196; de Louw AJA, 2001, EUR J PAIN-LONDON, V5, P169; Deer T, 2011, ATLAS IMPLANTABLE TH; Deer T, 2008, PAIN MED, V9, pS82, DOI 10.1111/j.1526-4637.2008.00443.x; Deer TR, 2014, NEUROMODULA IN PRESS; Deshpande KK, 2011, PAIN PHYSICIAN, V14, P37; Dieckhofer A, 2006, CLIN NEUROPHYSIOL, V117, P2221, DOI 10.1016/j.clinph.2006.07.136; DIECKMANN G, 1982, APPL NEUROPHYSIOL, V45, P167; Doleys Daniel M, 2006, Neurosurg Focus, V21, pE1; Drummond PD, 2008, CEPHALALGIA, V28, P782, DOI 10.1111/j.1468-2982.2008.01575.x; Dunteman E, 2002, NEUROMODULATION, V5, P32, DOI 10.1046/j.1525-1403.2002._2006.x; Ebel H, 1996, ACTA NEUROCHIR, V138, P1300, DOI 10.1007/BF01411059; Eglen RM, 1999, TRENDS PHARMACOL SCI, V20, P337, DOI 10.1016/S0165-6147(99)01372-3; Erdine S., 2007, TECH REG ANEST PAIN, V11, P63; Fahy BG, 2010, J CLIN ANESTH, V22, P213, DOI 10.1016/j.jclinane.2009.10.002; Falco FJE, 2009, PAIN PHYSICIAN, V12, P965; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Ghaemi K, 2008, STEREOT FUNCT NEUROS, V86, P391, DOI 10.1159/000175802; Gharabaghi A, 2005, NEUROSURGERY, V57, P114, DOI 10.1227/01.NEU.0000164385.42652.9E; Goadsby P, 2013, AM AC NEUR 65 ANN M; Goadsby PJ, 2006, CEPHALALGIA, V26, P1168, DOI 10.1111/j.1468-2982.2006.01173.x; Goadsby PJ, 2008, HEADACHE, V48, P313, DOI 10.1111/j.1526-4610.2007.01022.x; Goadsby PJ, 2013, CEPHALALGIA, V33, P214, DOI 10.1177/0333102412468680; Goadsby PJ, 1997, J ANAT, V190, P367, DOI 10.1046/j.1469-7580.1997.19030367.x; Green AL, 2003, J CLIN NEUROSCI, V10, P512, DOI 10.1016/S0967-5868(03)00088-2; Green MW, 2003, HEADACHE, V43, P479, DOI 10.1046/j.1526-4610.2003.03093.x; Hamani C, 2006, PAIN, V125, P188, DOI 10.1016/j.pain.2006.05.019; Hammer M, 2001, NEUROMODULATION, V4, P47, DOI 10.1046/j.1525-1403.2001.00047.x; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hasegawa T, 1996, SPINE, V21, P1005, DOI 10.1097/00007632-199605010-00001; HASEGAWA T, 1993, SEMIN ULTRASOUND CT, V14, P404, DOI 10.1016/S0887-2171(05)80034-4; Hayek SM, 2009, PAIN PHYSICIAN, V12, P867; Holsheimer J, 1998, NEUROMODULATION, V1, P129, DOI 10.1111/j.1525-1403.1998.tb00006.x; Hord ED, 2003, J PAIN, V4, P530, DOI 10.1016/j.jpain.2003.08.001; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; HOSOBUCHI Y, 1973, ARCH NEUROL-CHICAGO, V29, P158, DOI 10.1001/archneur.1973.00490270040005; HOSOBUCHI Y, 1986, J NEUROSURG, V64, P543, DOI 10.3171/jns.1986.64.4.0543; Hosobuchi Y, 1993, Adv Neurol, V63, P215; HOSOBUCHI Y, 1987, PACE, V10, P213, DOI 10.1111/j.1540-8159.1987.tb05951.x; Hosobuchi Y, 1974, J NEUROSURG, V41, P740, DOI [10.3171/jns.1974.41.6.0740, DOI 10.3171/JNS.1974.41.6.0740]; Jasper JF, 2008, PAIN PHYSICIAN, V11, P187; Nguyen JP, 2011, NAT REV NEUROL, V7, P699, DOI 10.1038/nrneurol.2011.138; Jenkins B, 2011, HEADACHE, V51, P1254, DOI 10.1111/j.1526-4610.2011.01966.x; Johnson MD, 2004, NEUROSURGERY, V55, P135, DOI 10.1227/01.NEU.0000126874.08468.89; Johnstone CSH, 2006, NEUROMODULATION, V9, P41, DOI 10.1111/j.1525-1403.2006.00041.x; Kapural L, 2005, ANESTH ANALG, V101, P171, DOI 10.1213/01.ANE.0000156207.73396.8E; Katayama Y, 1998, J NEUROSURG, V89, P585, DOI 10.3171/jns.1998.89.4.0585; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Kotsis SV, 2013, PLAST RECONSTR SURG, V131, P1194, DOI 10.1097/PRS.0b013e318287a0b3; Krames E, 2009, NEUROMODULATION, V12, P104, DOI 10.1111/j.1525-1403.2009.00197.x; Krames ES, 2011, NEUROMODULATION, V14, P299, DOI 10.1111/j.1525-1403.2011.00373.x; Kumar K, 2006, NEUROSURGERY, V58, P481, DOI 10.1227/01.NEU.0000192162.99567.96; Kumar K, 1998, SURG NEUROL, V50, P110, DOI 10.1016/S0090-3019(98)00012-3; KUMAR K, 1990, NEUROSURGERY, V26, P774, DOI 10.1227/00006123-199005000-00007; Leone M, 2004, CEPHALALGIA, V24, P934, DOI 10.1111/j.1468-2982.2004.00742.x; Leone M, 2003, NEUROL SCI, V24, pS143; LEVY RM, 1987, NEUROSURGERY, V21, P885, DOI 10.1227/00006123-198712000-00017; Levy R, 2010, PAIN PHYSICIAN, V13, P157; Liem L, 2013, NEUROMODULATION, V16, P471, DOI 10.1111/ner.12072; Lord SM, 1996, NEW ENGL J MED, V335, P1721, DOI 10.1056/NEJM199612053352302; Luedtke K, 2012, CLIN J PAIN, V28, P452, DOI 10.1097/AJP.0b013e31823853e3; Magis D, 2007, LANCET NEUROL, V6, P314, DOI 10.1016/S1474-4422(07)70058-3; Manchikanti L, 2000, Pain Physician, V3, P374; Manola L, 2005, MED BIOL ENG COMPUT, V43, P335, DOI 10.1007/BF02345810; Matharu MS, 2004, BRAIN, V127, P220, DOI 10.1093/brain/awh022; Matsunaga K, 2004, CLIN NEUROPHYSIOL, V115, P456, DOI 10.1016/S1388-2457(03)00362-6; Mauskop A, 2005, CEPHALALGIA, V25, P82, DOI 10.1111/j.1468-2982.2005.00611.x; McAuley J, 2013, NEUROMODULATION, V16, P530, DOI 10.1111/j.1525-1403.2012.00513.x; Medtronic Neurologic, MRI GUID; Melvin Eugene A Jr, 2007, Pain Physician, V10, P453; MEYERSON BA, 1993, ACTA NEUROCHIR, P150; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Mironer YE, 2011, NEUROMODULATION, V14, P151, DOI 10.1111/j.1525-1403.2010.00316.x; Monn MF, 2013, J SURG EDUC, V70, P180, DOI 10.1016/j.jsurg.2012.11.006; Muller PA, 2012, BRAIN STIMUL, V5, P320, DOI 10.1016/j.brs.2011.05.003; Narouze S, 2009, PAIN MED, V10, P221; Narouze S., 2009, TECH REG ANESTH PAIN, V13, P198; NASH TP, 1986, PAIN, V24, P67, DOI 10.1016/0304-3959(86)90027-8; Navarro RM, 2012, NEUROMODULATION, V15, P124, DOI 10.1111/j.1525-1403.2011.00422.x; Nesbitt A, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-S1-P230; Nesbitt AD, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-S1-P231; Neuman SA, 2011, CLIN J PAIN, V27, P556, DOI 10.1097/AJP.0b013e31820d276d; Nguyen JP, 2003, PAIN RES CL, V15, P197; Nguyen JP, 1997, ADV STER F, V12, P54; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; North RB, 2006, NEUROMODULATION, V9, P56, DOI 10.1111/j.1525-1403.2006.00043.x; Nuti C, 2005, PAIN, V118, P43, DOI 10.1016/j.pain.2005.07.020; Oh MY, 2004, NEUROMODULATION, V7, P103, DOI 10.1111/j.1094-7159.2004.04014.x; Oluigbo CO, 2011, PROG NEUROL SURG, V24, P171, DOI 10.1159/000323049; Oshinsky ML, 2007, HEADACHE, V47, P1026, DOI 10.1111/j.1526-4610.2007.00871.x; Oshinsky ML, 2012, HEADACHE, V52, P1336, DOI 10.1111/j.1526-4610.2012.02247.x; Owen SLF, 2007, ACTA NEUROCHIR SUPPL, V97, P111; Paulus W, 2004, CLIN NEUROPHYSIOL, V57, P708, DOI DOI 10.1016/S1567-424X(09)70411-8; Pereira Erlick A C, 2013, Handb Clin Neurol, V116, P277, DOI 10.1016/B978-0-444-53497-2.00023-1; Perryman L, 2013, 11 WORLD C INT NEUR; Pirotte B, 2008, NEUROSURGERY, V62, P941, DOI [10.1227/01.neu.0000333762.38500.ac, 10.1227/01.NEU.0000144837.31665.29]; PLOTKIN R, 1982, APPL NEUROPHYSIOL, V45, P173; Plow EB, 2012, J PAIN, V13, P411, DOI 10.1016/j.jpain.2012.02.001; Popeney CA, 2003, HEADACHE, V43, P369, DOI 10.1046/j.1526-4610.2003.03072.x; Rainov NG, 1997, CLIN NEUROL NEUROSUR, V99, P205, DOI 10.1016/S0303-8467(97)00017-6; Rapoport AM, 2013, 11 WORLD C INT NEUR; Rasche Dirk, 2006, Neurosurg Focus, V21, pE8; Ray C D, 1980, Acta Neurochir Suppl (Wien), V30, P289; Reed KL, 2010, CEPHALALGIA, V30, P260, DOI 10.1111/j.1468-2982.2009.01996.x; Rodrigo-Royo MD, 2005, NEUROMODULATION, V8, P241, DOI 10.1111/j.1525-1403.2005.00032.x; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Sadler RM, 2002, CEPHALALGIA, V22, P482, DOI 10.1046/j.1468-2982.2002.00387.x; Saitoh Y, 2001, Neurosurg Focus, V11, pE1; Saitoh Y, 2003, ACTA NEUROCHIR SUPPL, V87, P149; Saitoh Y, 2000, J NEUROSURG, V92, P150, DOI 10.3171/jns.2000.92.1.0150; Sandwell Stephen E, 2011, Surg Neurol Int, V2, P128, DOI 10.4103/2152-7806.85467; Saper JR, 2011, CEPHALALGIA, V31, P271, DOI 10.1177/0333102410381142; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Schwedt TJ, 2007, CEPHALALGIA, V27, P153, DOI 10.1111/j.1468-2982.2007.01272.x; Schwedt TJ, 2006, CEPHALALGIA, V26, P1025, DOI 10.1111/j.1468-2982.2006.01142.x; Serra G, 2012, PAIN PHYSICIAN, V15, P245; Sharan AD, 2003, NEUROSURG CLIN N AM, V14, P437, DOI 10.1016/S1042-3680(03)00014-7; Sheng SR, 2010, EUR SPINE J, V19, P46, DOI 10.1007/s00586-009-1192-5; Silberstein S, 2008, CEPHALALGIA, V28, P484, DOI 10.1111/j.1468-2982.2008.01555.x; Silberstein SD, 2012, CEPHALALGIA, V32, P1165, DOI 10.1177/0333102412462642; Simopoulos T, 2010, HEADACHE, V50, P1064, DOI 10.1111/j.1526-4610.2010.01694.x; Sjoqvist O, 1939, Yale J Biol Med, V11, P593; Slavin KV, 2006, NEUROSURGERY, V58, P112, DOI 10.1227/01.NEU.0000192163.55428.62; Slavin KV, 2005, NEUROMODULATION, V8, P7, DOI 10.1111/j.1094-7159.2005.05215.x; Smith H, 2001, Neurosurg Focus, V11, pE2; Sol JC, 2001, STEREOT FUNCT NEUROS, V77, P172, DOI 10.1159/000064616; Son BC, 2003, J NEUROSURG, V98, P175, DOI 10.3171/jns.2003.98.1.0175; Sparkes E, 2012, CHRONIC ILLN, V8, P239, DOI 10.1177/1742395311433132; Sparkes E, 2010, PAIN, V150, P284, DOI 10.1016/j.pain.2010.05.001; Taha JM, 1996, NEUROSURGERY, V38, P865, DOI 10.1097/00006123-199605000-00001; Tani N, 2004, J NEUROSURG, V101, P687, DOI 10.3171/jns.2004.101.4.0687; Taub E, 1997, J NEUROSURG, V86, P197, DOI 10.3171/jns.1997.86.2.0197; Tomycz ND, 2011, HEADACHE, V51, P418, DOI 10.1111/j.1526-4610.2010.01829.x; Trentman TL, 2008, HEADACHE, V48, P319, DOI 10.1111/j.1526-4610.2007.01023.x; Trentman TL, 2008, PAIN PHYSICIAN, V11, P253; Trescher WH, 2008, NEUROLOGY CLIN PRACT; Tsubokawa T, 1991, Acta Neurochir Suppl (Wien), V52, P137; TSUBOKAWA T, 1991, PACE, V14, P131, DOI 10.1111/j.1540-8159.1991.tb04058.x; Vad VB, 2002, SPINE, V27, P11, DOI 10.1097/00007632-200201010-00005; Vaisman J, 2012, NEUROMODULATION, V15, P374, DOI 10.1111/j.1525-1403.2012.00455.x; Van Zundert J, 2007, PAIN, V127, P173, DOI 10.1016/j.pain.2006.09.002; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Weiner RL, 1999, NEUROMODULATION, V2, P217, DOI 10.1046/j.1525-1403.1999.00217.x; Yakovlev AE, 2010, NEUROMODULATION, V13, P137, DOI 10.1111/j.1525-1403.2009.00249.x; Young RF, 1996, NEUROSURGERY CHRONIC	185	38	39	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	AUG	2014	17	6					551	570		10.1111/ner.12215			20	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	AN3PK	WOS:000340500200004	25112890				2021-06-18	
J	Hoffman, K; Cole, E; Playford, ED; Grill, E; Soberg, HL; Brohi, K				Hoffman, Karen; Cole, Elaine; Playford, E. Diane; Grill, Eva; Soberg, Helene L.; Brohi, Karim			Health Outcome after Major Trauma: What Are We Measuring?	PLOS ONE			English	Article							QUALITY-OF-LIFE; SEVERE MULTIPLE INJURIES; INTERNATIONAL CLASSIFICATION; REHABILITATION OUTCOMES; FUNCTIONAL OUTCOMES; BRAIN-INJURY; MULTIDISCIPLINARY REHABILITATION; PHYSICAL RECOVERY; GENERAL HEALTH; GLOBAL BURDEN	Importance: Trauma is a global disease and is among the leading causes of disability in the world. The importance of outcome beyond trauma survival has been recognised over the last decade. Despite this there is no internationally agreed approach for assessment of health outcome and rehabilitation of trauma patients. Objective: To systematically examine to what extent outcomes measures evaluate health outcomes in patients with major trauma. Data Sources: MEDLINE, EMBASE, and CINAHL (from 2006-2012) were searched for studies evaluating health outcome after traumatic injuries. Study selection and data extraction: Studies of adult patients with injuries involving at least two body areas or organ systems were included. Information on study design, outcome measures used, sample size and outcomes were extracted. The World Health Organisation International Classification of Function, Disability and Health (ICF) were used to evaluate to what extent outcome measures captured health impacts. Results: 34 studies from 755 studies were included in the review. 38 outcome measures were identified. 21 outcome measures were used only once and only five were used in three or more studies. Only 6% of all possible health impacts were captured. Concepts related to activity and participation were the most represented but still only captured 12% of all possible concepts in this domain. Measures performed very poorly in capturing concepts related to body function (5%), functional activities (11%) and environmental factors (2%). Conclusion: Outcome measures used in major trauma capture only a small proportion of health impacts. There is no inclusive classification for measuring disability or health outcome following trauma. The ICF may provide a useful framework for the development of a comprehensive health outcome measure for trauma care.	[Hoffman, Karen; Cole, Elaine; Brohi, Karim] Queen Mary Univ London, Ctr Trauma Sci, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, London, England; [Playford, E. Diane] UCL, Inst Neurol, Natl Hosp Neurol & Neurosurg, London, England; [Grill, Eva] Univ Munich, Inst Med Informat Biometry & Epidemiol IBE, Munich, Germany; [Soberg, Helene L.] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway	Hoffman, K (corresponding author), Queen Mary Univ London, Ctr Trauma Sci, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, London, England.	K.hoffman@qmul.ac.uk; karim@trauma.org	Grill, Eva/D-1875-2010; Grill, Eva/AAF-8104-2020	Grill, Eva/0000-0002-0273-7984; Grill, Eva/0000-0002-0273-7984; Cole, Elaine/0000-0002-3642-3537; Playford, E Diane/0000-0001-7314-787X	National Institute for Health Research University College London Hospitals Biomedical Research Centre	We would like to thank Melissa Selb, MSc, Coordinator, ICF Research Branch, a cooperation partner of the WHO Family of International Classifications in Germany who assisted in coordinating authors for the review. Diane Playford was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.	Ashley J, 1990, Health Trends, V22, P135; Attenberger C, 2012, INJURY, V43, P1566, DOI 10.1016/j.injury.2011.01.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ballabeni P, 2011, J OCCUP REHABIL, V21, P43, DOI 10.1007/s10926-010-9255-3; Baranyi A, 2010, PSYCHOSOMATICS, V51, P237, DOI 10.1176/appi.psy.51.3.237; Black JA, 2011, J TRAUMA, V71, P1003, DOI 10.1097/TA.0b013e3182238833; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Bowling A, 2005, J EPIDEMIOL COMMUN H, V59, P342, DOI 10.1136/jech.2004.021204; Cameron PA, 2006, INJURY, V37, P1178, DOI 10.1016/j.injury.2006.07.015; Christensen MC, 2011, J TRAUMA, V70, P1524, DOI 10.1097/TA.0b013e3181f053c2; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; Cieza A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-218; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Derrett S, 2010, NEW ZEAL MED J, V123, P66; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Franzen C, 2009, J CLIN NURS, V18, P108, DOI 10.1111/j.1365-2702.2008.02436.x; Gabbe BJ, 2006, J TRAUMA, V61, P1393, DOI 10.1097/01.ta.0000225926.34180.47; Gabbe BJ, 2013, SURG-J R COLL SURG E, V11, P114, DOI 10.1016/j.surge.2012.11.002; Gabbe BJ, 2012, ANN SURG, V255, P1009, DOI 10.1097/SLA.0b013e31824c4b91; Geyh S, 2007, QUAL LIFE RES, V16, P833, DOI 10.1007/s11136-007-9174-8; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Gore FM, 2011, LANCET, V377, P2093, DOI 10.1016/S0140-6736(11)60512-6; Gradinger F, 2011, SLEEP MED REV, V15, P33, DOI 10.1016/j.smrv.2010.07.001; Harris IA, 2008, J TRAUMA, V64, P969, DOI 10.1097/01.ta.0000245972.83948.1a; Hobart JC, 2007, LANCET NEUROL, V6, P1094, DOI 10.1016/S1474-4422(07)70290-9; Holtslag H, 2006, EUR J TRAUMA, V32, P365, DOI [DOI 10.1007/S00068-006-5112-7, 10.1007/s00068-006-5112-7]; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Horwitz DA, 2008, CURR OPIN CRIT CARE, V14, P445, DOI 10.1097/MCC.0b013e328307f25f; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; JENKINSON C, 1993, BRIT MED J, V307, P449, DOI 10.1136/bmj.307.6901.449; Khan F, 2012, BRIT J SURG, V99, P88, DOI 10.1002/bjs.7776; Khan F, 2007, DISABIL REHABIL, V29, P205, DOI 10.1080/09638280600756141; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Langley J, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-68; Laxe S, 2012, CLIN NEUROL NEUROSUR, V114, P645, DOI 10.1016/j.clineuro.2011.12.038; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; Lyons RA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001140; MacKenzie EJ, 2008, J BONE JOINT SURG AM, V90A, P101, DOI 10.2106/JBJS.F.01225; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Neugebauer E, 2006, EUROPEAN J TRAUMA, V32, P44, DOI [10.1007/s00068-006-0150-8, DOI 10.1007/S00068-006-0150-8]; Orwelius L, 2012, J TRAUMA ACUTE CARE, V72, P504, DOI 10.1097/TA.0b013e31821a416a; Pape HC, 2010, J TRAUMA, V69, P1243, DOI 10.1097/TA.0b013e3181ce1fa1; Pirente N, 2007, LANGENBECK ARCH SURG, V392, P739, DOI 10.1007/s00423-007-0171-8; Posl M, 2007, QUAL LIFE RES, V16, P1521, DOI 10.1007/s11136-007-9259-4; Polinder S, 2008, ACCIDENT ANAL PREV, V40, P182, DOI 10.1016/j.aap.2007.05.001; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-783; Probst C, 2010, J TRAUMA, V68, P706, DOI 10.1097/TA.0b013e3181a8b21c; Resnik LJ, 2007, J REHABIL RES DEV, V44, P991, DOI 10.1682/JRRD.2007.05.0071; Ringburg AN, 2011, J TRAUMA, V70, P916, DOI 10.1097/TA.0b013e3181f6bce8; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Siddharthan K, 2008, REHABIL NURS, V33, P221, DOI 10.1002/j.2048-7940.2008.tb00231.x; Sleat GKJ, 2011, EMERG MED J, V28, P1008, DOI 10.1136/emermed-2011-200326; Soberg HL, 2012, ARCH PHYS MED REHAB, V93, P765, DOI 10.1016/j.apmr.2011.08.050; Soberg HL, 2010, ARCH PHYS MED REHAB, V91, P481, DOI 10.1016/j.apmr.2009.11.007; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Stelfox HT, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-31; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; Sutherland AG, 2006, J TRAUMA, V61, P1408, DOI 10.1097/01.ta.0000197562.34651.df; Sutherland AG, 2011, J ORTHOP TRAUMA, V25, P228, DOI 10.1097/BOT.0b013e3181ee40a9; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; Valent F, 2004, LANCET, V363, P2032, DOI 10.1016/S0140-6736(04)16452-0; van Aswegen H, 2011, EUR J TRAUMA EMERG S, V37, P419, DOI 10.1007/s00068-010-0071-4; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Velstra IM, 2011, PM&R, V3, P846, DOI 10.1016/j.pmrj.2011.03.014; Weninger P, 2008, J TRAUMA, V65, P799, DOI 10.1097/TA.0b013e3181820dae; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organisation, 2001, WHO INT CLASS FUNCT; Zeckey C, 2011, BRAIN INJURY, V25, P551, DOI 10.3109/02699052.2011.568036; Zelle B, 2003, CHIRURG, V74, P361, DOI 10.1007/s00104-003-0621-y	76	38	39	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2014	9	7							e103082	10.1371/journal.pone.0103082			11	Multidisciplinary Sciences	Science & Technology - Other Topics	AM0QO	WOS:000339551100085	25051353	DOAJ Gold, Green Published			2021-06-18	
J	Bompadre, V; Jinguji, TM; Yanez, ND; Satchell, EK; Gilbert, K; Burton, M; Conrad, EU; Herring, SA				Bompadre, Viviana; Jinguji, Thomas M.; Yanez, N. David; Satchell, Emma K.; Gilbert, Kaiulani; Burton, Monique; Conrad, Ernest U., III; Herring, Stanley A.			Washington State's Lystedt Law in Concussion Documentation in Seattle Public High Schools	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion incidence; sports injuries; adolescents	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; UNITED-STATES; EPIDEMIOLOGY; LEGISLATION; PREVENTION; COACHES; IMPACT; YOUTH	Context: The Lystedt law requires high school athletes who have sustained a concussion to be removed from practice and play and not to be allowed to return until cleared by a medical professional. Objective: To determine the effect of the Lystedt law on injury and concussion documentation in the Seattle public high schools. Design: Cross-sectional study. Setting: Seattle public high schools. Patients or Other Participants: The numbers of students, aged 13 to 19 years in the 2008-2009, 2009-2010, and 2010-2011 school years, were 4348, 4925, and 4806, respectively. Main Outcome Measure(s): All injuries documented in SportsWare by athletic trainers in Seattle public high schools. We evaluated all injuries, including concussions recorded during the 2008-2009 school year, before the Lystedt law, and during the 2 school years after the law took effect (2009-2010 and 2010-2011). Incidence rates before and after the law were estimated and compared. Results: The concussion rate was -1.09% in 2008-2009, 2.26% in 2009-2010, and 2.26% in 2010-2011. A comparison of relative risks showed that the incidence rates of concussions were different before and 1 year after the Lystedt law (relative risk = 2.10; 95% confidence interval [CI] = 1.50, 2.93) and 2 years after the law (relative risk = 2.10; 95% CI = 1.49, 2.93). Overall, the mean number of days out of play after 2008-2009 was almost 7 days greater after the law took effect (difference = 6.9 days; 95% CI = 0.70, 13.1). For females, the mean number of days out of play after 2008-2009 was more than 17 days in 2009-2010 (difference = 17.2 days; 95% CI = 4.81, 29.5) and was more than 6 days in 2010-2011 (difference = 6.3 days; 95% CI = 1.62, 11.0). Conclusions: The number of documented concussions more than doubled after the institution of the Lystedt law, which may be attributed to heightened awareness and closer monitoring.	[Bompadre, Viviana; Jinguji, Thomas M.; Yanez, N. David; Satchell, Emma K.; Gilbert, Kaiulani; Burton, Monique; Conrad, Ernest U., III; Herring, Stanley A.] Seattle Childrens Hosp, Seattle, WA 98105 USA; [Yanez, N. David; Burton, Monique; Conrad, Ernest U., III; Herring, Stanley A.] Univ Washington, Seattle, WA 98195 USA	Bompadre, V (corresponding author), Seattle Childrens Hosp, 4800 Sand Point Way NE,M-S W-7706, Seattle, WA 98105 USA.	viviana.bompadre@seattlechildrens.org			Center for Clinical and Translational Research at Seattle Children's Research Institute; National Institutes of Health's National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000423] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014] Funding Source: NIH RePORTER	We acknowledge all ATs working in the Seattle Public Schools system for their commitment in keeping the students safe. The Seattle, Washington, Children's Core for Biomedical Statistics is supported by the Center for Clinical and Translational Research at Seattle Children's Research Institute and by grant UL1RR025014 from the National Institutes of Health's National Center for Research Resources.	Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; Almquist J, 2008, J ATHL TRAINING, V43, P416, DOI 10.4085/1062-6050-43.4.416; [Anonymous], ZACK LYST LAW SPORTS; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Murphy A, 2012, PM&R, V4, P419, DOI 10.1016/j.pmrj.2012.03.013; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	28	38	38	0	6	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2014	49	4					486	492		10.4085/1062-6050-49.3.30			7	Sport Sciences	Sport Sciences	AQ4LO	WOS:000342768700008	24870293	Green Published, Bronze			2021-06-18	
J	Schaible, EV; Windschugl, J; Bobkiewicz, W; Kaburov, Y; Dangel, L; Kramer, T; Huang, CS; Sebastiani, A; Luh, C; Werner, C; Engelhard, K; Thal, SC; Schafer, MKE				Schaible, Eva-Verena; Windschuegl, Julia; Bobkiewicz, Wiesia; Kaburov, Yordan; Dangel, Larissa; Kraemer, Tobias; Huang, Changsheng; Sebastiani, Anne; Luh, Clara; Werner, Christian; Engelhard, Kristin; Thal, Serge C.; Schaefer, Michael K. E.			2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1 response after traumatic brain injury in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						2-methoxyestradiol; alternative splicing; cerebral ischemia; HIF-1; neuroprotection; traumatic brain injury	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; PROLYL HYDROXYLASE INHIBITION; TUMOR-NECROSIS-FACTOR; FACTOR-I; HIF-1-ALPHA PROTEIN; GENE-EXPRESSION; FACTOR 1-ALPHA; UP-REGULATION	HIF-1 is pivotal for cellular homeostasis in response to cerebral ischemia. Pharmacological inhibition of HIF-1 may reduce secondary brain damage by targeting post-translational mechanisms associated with its proteasomal degradation and nuclear translocation. This study examined the neuroprotective effects of 2-methoxyestradiol (2ME2), the involved HIF-1-dependent response, and alternative splicing in exon 14 of HIF-1 (HIF-1Ex14) after traumatic brain injury (TBI) in mice. Intraperitoneal 2ME2 administration 30min after TBI caused a dose-dependent reduction in secondary brain damage after 24h. 2ME2 was physiologically tolerated, showed no effects on immune cell brain migration, and mitigated trauma-induced brain expression of neuropathologically relevant HIF-1 target genes encoding for Plasminogen activator inhibitor 1 and tumor necrosis factor alpha. Moreover, TBI-induced expression of pro-apoptotic BNIP3 was attenuated by 2ME2 treatment. Alternatively, spliced HIF-1Ex14 was substantially up-regulated from 6 to 48h after TBI. In vitro, nuclear location and gene transcription activity of HIF-1Ex14 were impaired compared to full-length HIF-1, but no effects on nuclear translocation of the transcriptional complex partner HIF-1 were observed. This study demonstrates that 2ME2 confers neuroprotection after TBI. While the role of alternatively spliced HIF-1Ex14 remains elusive, the in vivo data provide evidence that inhibition of a maladaptive HIF-1-dependent response contributes to the neuroprotective effects of 2ME2. We examined neuroprotective effects of 2-methoxyestradiol (2ME2) and the hypoxia-inducible factor 1- (HIF-1) response following traumatic brain injury in mice. Early 2ME2 administration reduced the secondary brain damage and neuronal HIF-1 probably involving ubiquitin proteasome system-mediated degradation. The up-regulation of neuropathological HIF-1 target genes and pro-apoptotic BNIP3 protein was attenuated. We propose that the inhibition of a maladaptive HIF-1 response may contribute to 2ME2-mediated neuroprotection.	[Schaible, Eva-Verena; Windschuegl, Julia; Bobkiewicz, Wiesia; Kaburov, Yordan; Dangel, Larissa; Kraemer, Tobias; Huang, Changsheng; Sebastiani, Anne; Luh, Clara; Werner, Christian; Engelhard, Kristin; Thal, Serge C.; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, D-55131 Mainz, Germany; [Dangel, Larissa; Werner, Christian; Engelhard, Kristin; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci FTN, D-55131 Mainz, Germany	Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	michael.schaefer@unimedizin-mainz.de; michael.schaefer@unimedizin-mainz.de	Thal, Serge/D-6593-2011; Changsheng, Huang/M-6033-2018	Thal, Serge/0000-0002-1222-8729; Huang, Changsheng/0000-0003-0535-1865; Kramer, Tobias/0000-0001-6900-3486; Schafer, Michael K.E./0000-0001-6055-6244	Focus program Translational Neuroscience, Johannes Gutenberg-University Mainz, Germany	We thank Dr. Jacques Pouyssegur (Nice, France) for providing HA-tagged HIF-1 alpha pcDNA3 expression constructs and M. C. Simon (Philadelphia, United States) for HRE luciferase reporter construct. We are grateful to Dana Pieter and Frieda Kornes for excellent technical assistance. L. D. was supported by a PhD fellowship of the Focus program Translational Neuroscience, Johannes Gutenberg-University Mainz, Germany. Data presented in this manuscript are parts of the doctor theses of J.W. and Y.K. and of the professorial dissertation (Habilitation) of E. V. S. presented to the Medical Faculty of the Johannes Gutenberg-University Mainz, Germany.	Ahn YT, 2010, INT J ONCOL, V37, P1627, DOI 10.3892/ijo_00000817; Althaus J, 2006, NEUROCHEM INT, V48, P687, DOI 10.1016/j.neuint.2005.12.008; Aminova LR, 2008, ANTIOXID REDOX SIGN, V10, P1989, DOI 10.1089/ars.2008.2039; Aminova LR, 2005, J BIOL CHEM, V280, P3996, DOI 10.1074/jbc.M409223200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Banerjee S, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-4; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Carbonaro M, 2012, J BIOL CHEM, V287, P11859, DOI 10.1074/jbc.M112.345587; Carbonaro M, 2011, J CELL BIOL, V192, P83, DOI 10.1083/jcb.201004145; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chauhan D, 2003, ONCOGENE, V22, P6296, DOI 10.1038/sj.onc.1206734; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Chen CH, 2010, J NEUROSCI RES, V88, P2046, DOI 10.1002/jnr.22361; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chen W, 2009, EXP NEUROL, V216, P7, DOI 10.1016/j.expneurol.2008.10.016; Chun YS, 2002, BIOCHEM J, V362, P71, DOI 10.1042/0264-6021:3620071; Chun YS, 2001, J CELL SCI, V114, P4051; Conde E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033258; Duncan GS, 2012, P NATL ACAD SCI USA, V109, P21034, DOI 10.1073/pnas.1215558110; Elks PM, 2011, BLOOD, V118, P712, DOI 10.1182/blood-2010-12-324186; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fan X, 2009, BRAIN RES REV, V62, P99, DOI 10.1016/j.brainresrev.2009.09.006; Funakoshi T, 2006, EXP EYE RES, V83, P1102, DOI 10.1016/j.exer.2006.05.016; Gao LG, 2012, J CLIN PATHOL, V65, P872, DOI 10.1136/jclinpath-2012-200828; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johansson L, 2000, STROKE, V31, P26, DOI 10.1161/01.STR.31.1.26; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Karuppagounder SS, 2012, J CEREBR BLOOD F MET, V32, P1347, DOI 10.1038/jcbfm.2012.28; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kupershmidt L, 2010, J NEUROCHEM, V113, P363, DOI 10.1111/j.1471-4159.2010.06619.x; LaVallee TM, 2002, CANCER RES, V62, P3691; Lee HT, 2010, J NEUROCHEM, V113, P79, DOI 10.1111/j.1471-4159.2010.06584.x; Li AH, 2013, J MOL NEUROSCI, V51, P1052, DOI 10.1007/s12031-013-0084-7; Liao H, 2007, FASEB J, V21, P935, DOI 10.1096/fj.06-6285com; Lip GYH, 2002, BLOOD COAGUL FIBRIN, V13, P339, DOI 10.1097/00001721-200206000-00010; Lisy K, 2008, CELL DEATH DIFFER, V15, P642, DOI 10.1038/sj.cdd.4402315; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Marx M, 2012, NEUROGENETICS, V13, P49, DOI 10.1007/s10048-011-0307-4; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Mueck AO, 2010, STEROIDS, V75, P625, DOI 10.1016/j.steroids.2010.02.016; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ricker JL, 2004, CLIN CANCER RES, V10, P8665, DOI 10.1158/1078-0432.CCR-04-1393; Ross S. A., 1998, BRIT J NEUROSURG, V12, P475; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Schaible EV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071056; Sears JE, 2008, P NATL ACAD SCI USA, V105, P19898, DOI 10.1073/pnas.0805817105; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shay JES, 2012, SEMIN CELL DEV BIOL, V23, P389, DOI 10.1016/j.semcdb.2012.04.004; Sibonga JD, 2003, ENDOCRINOLOGY, V144, P785, DOI 10.1210/en.2002-220632; Singh N, 2012, CELL MOL NEUROBIOL, V32, P491, DOI 10.1007/s10571-012-9803-9; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sumbayev VV, 2003, FEBS LETT, V535, P106, DOI 10.1016/S0014-5793(02)03887-5; Sutherland TE, 2007, DRUG DISCOV TODAY, V12, P577, DOI 10.1016/j.drudis.2007.05.005; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Tofovic SP, 2005, J CARDIOVASC PHARM, V46, P430, DOI 10.1097/01.fjc.0000175878.32920.17; Tuttolomondo A, 2009, ATHEROSCLEROSIS, V203, P503, DOI 10.1016/j.atherosclerosis.2008.06.030; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu C, 2013, BIOCHEM BIOPH RES CO, V437, P469, DOI 10.1016/j.bbrc.2013.06.107; Yan JH, 2006, EXP NEUROL, V202, P348, DOI 10.1016/j.expneurol.2006.06.009; Yeh SH, 2011, BRAIN PATHOL, V21, P249, DOI 10.1111/j.1750-3639.2010.00443.x; Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664; Yuan WS, 2013, CARDIOVASC DRUG THER, V27, P17, DOI 10.1007/s10557-012-6428-7; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhang WD, 2006, J NEUROIMMUNOL, V174, P63, DOI 10.1016/j.jneuroim.2006.01.014	88	38	49	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2014	129	6					940	954		10.1111/jnc.12708			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AJ5WI	WOS:000337760500005	24606183	Bronze			2021-06-18	
J	Powers, KC; Cinelli, ME; Kalmar, JM				Powers, Kaley C.; Cinelli, Michael E.; Kalmar, Jayne M.			Cortical hypoexcitability persists beyond the symptomatic phase of a concussion	BRAIN INJURY			English	Article						Concussion; evoked potentials; sport	TRANSCRANIAL MAGNETIC STIMULATION; SPORTS CONCUSSION; FORCE; ABNORMALITIES; INHIBITION; GLUTAMATE; RECOVERY; GABA; TMS	Primary objective: The purpose of this research was to assess cortical excitability, voluntary activation of muscle and force sensation beyond the initial highly symptomatic period post-concussion (1-4 weeks post-injury). It was hypothesized that reduced excitability of the motor cortex may impair muscle activation and alter perceptions of force and effort. Research design: Eight concussed varsity football players were age-and position-matched with eight healthy teammates to control for training and body size. Healthy controls had not suffered a concussion in the previous 12 months. Methods and procedures: Paired-pulse transcranial magnetic stimulation was used to assess cortical excitability, voluntary activation was calculated using cortical twitch interpolation technique and sense of force was determined using constant-force sensation contractions. Main outcomes and results: The concussed group had lower intra-cortical facilitation (p = 0.036), lower maximal voluntary muscle activation (p = 0.038) and greater perceptions of force (p<0.05), likely due to compensatory increases in upstream drive, than their healthy matched teammates. Conclusions: Taken together, these findings suggest a state of hypoexcitability that persists beyond the immediate acute phase of a concussion and may result in neuromuscular impairments that would call to question the athlete's readiness to return to sport.	[Powers, Kaley C.; Cinelli, Michael E.; Kalmar, Jayne M.] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON N2L 3C5, Canada	Kalmar, JM (corresponding author), Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, 75 Univ Ave W,Rm 501, Waterloo, ON N2L 3C5, Canada.	jkalmar@wlu.ca	Cinelli, Michael/ABE-7625-2020	Cinelli, Michael/0000-0002-5802-2590	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [386601]	This research was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC Discovery Grant 386601 to J. Kalmar).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Daskalakis ZJ, 2003, CLIN NEUROPHYSIOL, V114, P938, DOI 10.1016/S1388-2457(03)00038-5; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Jones LA, 1995, ADV EXP MED BIOL, V384, P305; JONES LA, 1983, EXP NEUROL, V81, P640, DOI 10.1016/0014-4886(83)90332-1; Kennedy DM, 2011, EXP BRAIN RES, V213, P351, DOI 10.1007/s00221-011-2777-x; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Plaskett CJ, 2001, J APPL PHYSIOL, V91, P1535; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Stagg CJ, 2011, J PHYSIOL-LONDON, V589, P5845, DOI 10.1113/jphysiol.2011.216978; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Todd G, 2004, J APPL PHYSIOL, V97, P236, DOI 10.1152/japplphysiol.01336.2003; Tracy BL, 2007, HUM MOVEMENT SCI, V26, P796, DOI 10.1016/j.humov.2007.07.001; Tremblay S, 2013, J NEUROPHYSIOL, V109, P1343, DOI 10.1152/jn.00704.2012; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Vaillancourt DE, 2001, NEUROPSYCHOLOGIA, V39, P1410, DOI 10.1016/S0028-3932(01)00061-6; Welsh SJ, 2007, EXP BRAIN RES, V179, P219, DOI 10.1007/s00221-006-0785-z; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; Ziemann U, 2003, SUPPL CLIN NEUROPHYS, V56, P226	30	38	38	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2014	28	4					465	471		10.3109/02699052.2014.888759			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AF5GL	WOS:000334741900010	24702432				2021-06-18	
J	Hook, GR; Yu, J; Sipes, N; Pierschbacher, MD; Hook, V; Kindy, MS				Hook, Gregory R.; Yu, Jin; Sipes, Nancy; Pierschbacher, Michael D.; Hook, Vivian; Kindy, Mark S.			The Cysteine Protease Cathepsin B Is a Key Drug Target and Cysteine Protease Inhibitors Are Potential Therapeutics for Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cathepsin B; cysteine protease inhibitor; motor function; traumatic brain injury	CELL-FREE DNA; MITOCHONDRIAL-DNA; PREDICTIVE MARKER; RAT-BRAIN; DAMAGE; REPAIR; NUCLEAR; DEATH	There are currently no effective therapeutic agents for traumatic brain injury (TBI), but drug treatments for TBI can be developed by validation of new drug targets and demonstration that compounds directed to such targets are efficacious in TBI animal models using a clinically relevant route of drug administration. The cysteine protease, cathepsin B, has been implicated in mediating TBI, but it has not been validated by gene knockout (KO) studies. Therefore, this investigation evaluated mice with deletion of the cathepsin B gene receiving controlled cortical impact TBI trauma. Results indicated that KO of the cathepsin B gene resulted in amelioration of TBI, shown by significant improvement in motor dysfunction, reduced brain lesion volume, greater neuronal density in brain, and lack of increased proapoptotic Bax levels. Notably, oral administration of the small-molecule cysteine protease inhibitor, E64d, immediately after TBI resulted in recovery of TBI-mediated motor dysfunction and reduced the increase in cathepsin B activity induced by TBI. E64d outcomes were as effective as cathepsin B gene deletion for improving TBI. E64d treatment was effective even when administered 8h after injury, indicating a clinically plausible time period for acute therapeutic intervention. These data demonstrate that a cysteine protease inhibitor can be orally efficacious in a TBI animal model when administered at a clinically relevant time point post-trauma, and that E64d-mediated improvement of TBI is primarily the result of inhibition of cathepsin B activity. These results validate cathepsin B as a new TBI therapeutic target.	[Hook, Gregory R.; Sipes, Nancy; Pierschbacher, Michael D.] Amer Life Sci Pharmaceut, San Diego, CA USA; [Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Yu, Jin; Kindy, Mark S.] Appl Neurotechnol Inc, Charleston, SC USA; [Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Kindy, MS (corresponding author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA.	kindyms@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44AG032784, 5R01ES016774-02]; VA Merit ReviewUS Department of Veterans Affairs [1I01RX000331-01]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES016774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG032784] Funding Source: NIH RePORTER	The authors thank Christoph Peters, MD, of Albert Ludwig University (Freiburg, Germany) for providing the cathepsin B-deficient mice and Lawrence Marshall, MD, for reviewing the manuscript. This work was supported, in part, by NIH grants R44AG032784 (to American Life Science Pharmaceuticals; ALSP) and 5R01ES016774-02 (to M. S. K.) and VA Merit Review 1I01RX000331-01 (to M.S.K.).	Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Coppede F, 2009, CURR ALZHEIMER RES, V6, P36, DOI 10.2174/156720509787313970; Goldshtein H, 2009, ANN CLIN BIOCHEM, V46, P488, DOI 10.1258/acb.2009.009002; Jiang YL, 2008, CANCER RES, V68, P6425, DOI 10.1158/0008-5472.CAN-08-1173; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lan J, 2003, J CEREBR BLOOD F MET, V23, P1324, DOI 10.1097/01.WCB.0000091540.60196.F2; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li WJ, 2006, J CEREBR BLOOD F MET, V26, P181, DOI 10.1038/sj.jcbfm.9600180; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Martin LJ, 2010, PHARMACEUTICALS, V3, P839, DOI 10.3390/ph3040839; Ohayon S, 2012, J NEUROTRAUM, V29, P261, DOI 10.1089/neu.2011.1938; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Santos RX, 2012, FREE RADICAL RES, V46, P565, DOI 10.3109/10715762.2011.648188; Swarup V, 2011, DNA CELL BIOL, V30, P389, DOI 10.1089/dna.2010.1165; Valiyaveettil M, 2013, NEUROSCI LETT, V539, P1, DOI 10.1016/j.neulet.2013.01.028; Vasko MR, 2011, DNA REPAIR, V10, P942, DOI 10.1016/j.dnarep.2011.06.004; Wang J, 2005, J NEUROCHEM, V93, P953, DOI 10.1111/j.1471-4159.2005.03053.x; Wang JYJ, 2001, CELL DEATH DIFFER, V8, P1047, DOI 10.1038/sj.cdd.4400938; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Widyarini S, 2006, J VET SCI, V7, P217, DOI 10.4142/jvs.2006.7.3.217; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zhou BR, 2008, PHOTODERMATOL PHOTO, V24, P175, DOI 10.1111/j.1600-0781.2008.00356.x	31	38	38	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					515	529		10.1089/NEU.2013.2944			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600250	24083575	Green Published			2021-06-18	
J	Stewart, TC; Gilliland, J; Fraser, DD				Stewart, Tanya Charyk; Gilliland, Jason; Fraser, Douglas D.			An epidemiologic profile of pediatric concussions: Identifying urban and rural differences	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Epidemiology-injury; concussion; mild traumatic brain injury; urban; rural	SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; HEAD-INJURIES; UNITED-STATES; BRAIN; ADOLESCENTS; EMERGENCY; FOOTBALL; CHILDREN	BACKGROUND The objective of this study was to describe the epidemiology of concussions presenting to the emergency department (ED). METHODS A retrospective cohort of concussions for pediatric (age < 18 years) patients treated in the ED of a regional pediatric Level 1 trauma center from 2006 to 2011 was examined. Descriptive and geographic analyses were completed, with comparisons by age groups and residence (urban/rural). RESULTS There were a total of 2,112 treated pediatric concussions. Two thirds of the concussions occurred in males (67%), with a median age of 13 years (interquartile range [IQR], 6). Nearly half of the pediatric concussions were sports related (48%); 36% of these concussions were from hockey. Significant differences were found in the distribution of the mechanism of injury across age groups (p < 0.001). Falls were most prevalent among young children, and sports concussions, for children 10 years and older. Two fifths of concussions occurred during winter months. Discharge disposition significantly differed by age (p < 0.001), with home discharge increasing with age up to 14 years. There were a total of 387 rural (19%) and 1,687 urban (81%) concussed patients, for a mean ED concussion visit rate of 2.2 per 1,000 and 3.5 per 1,000, respectively. Rural patients were older (14 [IQR, 6] vs. 13 [IQR, 6], p = 0.019] and sustained 2.5 times more concussions from a motor vehicle crash compared with urban youth patients (p < 0.001). CONCLUSION Males in early adolescence are at highest risk for concussion, particularly from sport-related activities. Urban and rural children have differences in their etiology and severity of concussions. Concussions are predictable, and their prevention should be targeted based on epidemiologic and environmental data. LEVEL OF EVIDENCE Epidemiologic, study, level III.	[Stewart, Tanya Charyk] London Hlth Sci Ctr, Trauma Program, London, ON N6A 5W9, Canada; [Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada; [Gilliland, Jason] Univ Western Ontario, Dept Geog, London, ON N6A 5C2, Canada; [Gilliland, Jason; Fraser, Douglas D.] Univ Western Ontario, Dept Pediat, London, ON N6A 3K7, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Gilliland, Jason] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada; [Gilliland, Jason; Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada	Stewart, TC (corresponding author), London Hlth Sci Ctr, Trauma Program, 800 Commissioners Rd East, London, ON N6A 5W9, Canada.	tanya.charyk@lhsc.on.ca	Gilliland, Jason A/E-3393-2019; El-Bagdady, Moe/S-8621-2019; University, HEAL Western/T-1323-2019	Gilliland, Jason A/0000-0002-2909-2178; 	Children's Health Foundation, London, Ontario, Canada	Financial support was provided by The Children's Health Foundation (www.childhealth.ca), London, Ontario, Canada.	[Anonymous], 2012, INJ PREV CONTR TRAUM; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barzarian JJ, 2005, EMERG MED J, V22, P473; Brain Injury Association of Canada, 2012, CONC HITT YOUTH EV; Canadian Institute for Health Information, 2012, INT STAT CLASS DIS R; Canadian Institute for Health Information, 2008, NAT TRAUM REG 2007 I; Centers for Disease Control and Prevention, 2012, PROT ON YOU LOV CHIL; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Forward K, 2010, J TRAUMA, V69, P1294, DOI 10.1097/TA.0b013e3181fa7e25; Franklin CC, 2012, CURR OPIN PEDIATR, V24, P64, DOI 10.1097/MOP.0b013e32834ec618; Fung M, 2006, PEDIATRICS, V126, P597; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Joffe Ari R, 2006, J Intensive Care Med, V21, P227, DOI 10.1177/0885066606288944; JOLY MF, 1991, REV EPIDEMIOL SANTE, V39, P345; Jones CS, 2005, J RURAL HEALTH, V21, P70, DOI 10.1111/j.1748-0361.2005.tb00064.x; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Katcher MJ, 1996, PEDIATRICS, V97, P765; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Laflamme L, 2000, Inj Prev, V6, P293, DOI 10.1136/ip.6.4.293; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Morrison Gavin, 2013, Pathophysiology, V20, P49, DOI 10.1016/j.pathophys.2012.02.006; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Patel DR, 2010, PEDIATR CLIN N AM, V57, P649, DOI 10.1016/j.pcl.2010.03.006; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Puderer HA, 2009, URBAN PERSPECTIVES M; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674; Vogt KN, 2009, BOYS THEIR TOYS REGI	37	38	38	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					736	742		10.1097/TA.0b013e3182aafdf5			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100038	24553542				2021-06-18	
J	Brezova, V; Moen, KG; Skandsen, T; Vik, A; Brewer, JB; Salvesen, O; Haberg, AK				Brezova, Veronika; Moen, Kent Goran; Skandsen, Toril; Vik, Anne; Brewer, James B.; Salvesen, Oyvind; Haberg, Asta K.			Prospective longitudinal MRI study of brain volumes and diffusion changes during the first year after moderate to severe traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Post-traumatic amnesia; Diffuse axonal injury; Glasgow Coma Scale; ADC; Outcome	HEAD-INJURY; AXONAL INJURY; WHITE-MATTER; WALLERIAN DEGENERATION; PROGRESSIVE ATROPHY; ALZHEIMERS-DISEASE; NEURONAL INJURY; TIME-COURSE; HIPPOCAMPUS; TENSOR	The objectives of this prospective study in 62 moderate-severe TBI patients were to investigate volume change in cortical gray matter (GM), hippocampus, lenticular nucleus, lobar white matter (WM), brainstem and ventricles using a within subject design and repeated MRI in the early phase (1-26 days) and 3 and 12 months postinjury and to assess changes in GM apparent diffusion coefficient (ADC) in normal appearing tissue in the cortex, hippocampus and brainstem. The impact of Glasgow Coma Scale (GCS) score at admission, duration of post-traumatic amnesia (PTA), and diffusion axonal injury (DAI) grade on brain volumes and ADC values over time was assessed. Lastly, we determined ifMRI-derived brain volumes from the 3-month scans provided additional, significant predictive value to 12-month outcome classified with the Glasgow Outcome Scale-Extended after adjusting for GCS, PTA and age. Cortical GM loss was rapid, largely finished by 3 months, but the volume reduction was unrelated to GCS score, PTA, or presence of DAI. However, cortical GM volume at 3 months was a significant independent predictor of 12-month outcome. Volume loss in the hippocampus and lenticular nucleus was protracted and statistically significant first at 12 months. Slopes of volume reduction over time for the cortical and subcortical GGM were significantly different. Hippocampal volume loss was most pronounced and rapid in individuals with PTA > 2 weeks. The 3-month volumes of the hippocampus and lentiform nucleus were the best independent predictors of 12-month outcome after adjusting for GCS, PTA and age. In the brainstem, volume loss was significant at both 3 and 12 months. Brainstem volume reduction was associated with lower GCS score and the presence of DAI. Lobar WM volume was significantly decreased first after 12 months. Surprisingly DAI grade had no impact on lobar WM volume. Ventricular dilation developed predominantly during the first 3 months, and was strongly associated with volume changes in the brainstem and cortical GM, but not lobar WM volume. Higher ADC values were detected in the cortex in individuals with severe TBI, DAI and PTA > 2 weeks, from 3 months. There were no associations between ADC values and brain volumes, and ADC values did not predict outcome. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license	[Brezova, Veronika] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Brezova, Veronika; Haberg, Asta K.] Univ Trondheim Hosp, St Olavs Hosp, Dept Med Imaging, Trondheim, Norway; [Moen, Kent Goran; Skandsen, Toril; Vik, Anne; Haberg, Asta K.] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, N-7491 Trondheim, Norway; [Moen, Kent Goran; Vik, Anne] St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Brewer, James B.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Salvesen, Oyvind] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, N-7491 Trondheim, Norway; [Brewer, James B.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA	Haberg, AK (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, N-7491 Trondheim, Norway.	asta.haberg@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Brandstack N, 2011, CLIN NEURORADIOL, V21, P75, DOI 10.1007/s00062-011-0058-5; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Cipolotti L, 2006, CURR OPIN NEUROL, V19, P593, DOI 10.1097/01.wco.0000247608.42320.f9; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Conti AC, 1998, J NEUROSCI, V18, P5663; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox NC, 2001, LANCET, V358, P201, DOI 10.1016/S0140-6736(01)05408-3; Gao X., 2011, PLOS ONE, V6; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; GENTRY LR, 1994, RADIOLOGY, V191, P1; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gwet K. L., 2008, WILEY ENCY; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holland D, 2012, HUM BRAIN MAPP, V33, P2586, DOI 10.1002/hbm.21386; Holland D, 2009, P NATL ACAD SCI USA, V106, P20954, DOI 10.1073/pnas.0906053106; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jenkins A., 1986, LANCET, V445- 4462874424; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Klimas A, 2013, CLIN IMAG, V37, P637, DOI 10.1016/j.clinimag.2013.01.013; LeGrand SA, 2007, J NEUROTRAUM, V24, P1437, DOI 10.1089/neu.2007.0293; Lin Y, 2013, INT J MED SCI, V10, P515, DOI 10.7150/ijms.5423; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Ng H., 1994, CLIN NEUROL NEUROSUR, V34; Ng K., 2008, ARCH PHYS MED REHAB; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Ozturk A, 2008, AM J NEURORADIOL, V29, P1124, DOI 10.3174/ajnr.A0998; Primus EA, 1997, BRAIN INJURY, V11, P577; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Thompson PM, 2004, NEUROIMAGE, V22, P1754, DOI 10.1016/j.neuroimage.2004.03.040; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Watanabe M, 2013, RADIOLOGY, V266, P575, DOI 10.1148/radiol.12112420; White NS, 2013, HUM BRAIN MAPP, V34, P327, DOI 10.1002/hbm.21454; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008	74	38	38	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						128	140		10.1016/j.nicl.2014.03.012			13	Neuroimaging	Neurosciences & Neurology	CB5LF	WOS:000349667800016	25068105	DOAJ Gold, Green Published			2021-06-18	
J	Hanak, BW; Walcott, BP; Nahed, BV; Muzikansky, A; Mian, MK; Kimberly, WT; Curry, WT				Hanak, Brian W.; Walcott, Brian P.; Nahed, Brian V.; Muzikansky, Alona; Mian, Matthew K.; Kimberly, William T.; Curry, William T.			Postoperative Intensive Care Unit Requirements After Elective Craniotomy	WORLD NEUROSURGERY			English	Article						Craniotomy; Elective; ICU; Postoperative care	TRAUMATIC BRAIN-INJURY; RESOURCE USE; TUMOR SURGERY; ICU CARE; COST; EXPERIENCE	OBJECTIVE: Commonly, patients undergoing craniotomy are admitted to an intensive care setting postoperatively to allow for close monitoring. We aim to determine the frequency with which patients who have undergone elective craniotomies require intensive care unit (ICU) elevel interventions or experience significant complications during the postoperative period to identify a subset of patients for whom an alternative to ICU-level care may be appropriate. METHODS: Following Institutional Review Board approval, a prospective, consecutive cohort of adult patients undergoing elective craniotomy was established at the Massachusetts General Hospital between the dates of April 2010 and March 2011. Inclusion criteria were intradural operations requiring craniotomy performed on adults (18 years of age or older). Exclusion criteria were cases of an urgent or emergent nature, patients who remained intubated postoperatively, and patients who had a ventriculostomy drain in place at the conclusion of the case. RESULTS: Four hundred patients were analyzed. Univariate analysis revealed that patients with diabetes (P = 0.00047), those who required intraoperative blood product administration (P = 0.032), older patients (P < 0.0001), those with higher intraoperative blood losses (P = 0.041), and those who underwent longer surgical procedures (P = 0.021) were more likely to require ICU-level interventions or experience significant postoperative complications. Multivariate analysis only found diabetes (P = 0.0005) and age (P = 0.0091) to be predictive of a patient's need for postoperative ICU admission. CONCLUSIONS: Diabetes and older age predict the need for ICU-level intervention after elective craniotomy. Properly selected patients may not require postcraniotomy ICU monitoring. Further study of resource utilization is necessary to validate these preliminary findings, particularly in different hospital types.	[Hanak, Brian W.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurosurg, Seattle, WA 98104 USA; [Walcott, Brian P.; Nahed, Brian V.; Mian, Matthew K.; Curry, William T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA; [Muzikansky, Alona] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Biostat Unit, Boston, MA USA; [Kimberly, William T.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA	Walcott, BP (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	; Nahed, Brian/E-4239-2014	Hanak, Brian/0000-0002-3155-7413; Nahed, Brian/0000-0001-8537-106X	Harvard Catalyst; Harvard Clinical and Translational Science Center (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 RR 025758]; Harvard University; Council of State Neurosurgical Societiese-Congress of Neurological Surgeons (Medical Student Summer Fellowship in Socioeconomic Research); Council of State Neurological Societies Socioeconomic fellowship; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS076597] Funding Source: NIH RePORTER	This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH Award UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Center for Research Resources, or the National Institutes of Health. Funding was also provided by the Council of State Neurosurgical Societiese-Congress of Neurological Surgeons (Medical Student Summer Fellowship in Socioeconomic Research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Walcott is supported by the Council of State Neurological Societies Socioeconomic fellowship (2012-2013).	Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Beauregard CL, 2003, SURG NEUROL, V60, P483, DOI 10.1016/S0090-3019(03)00517-2; Bernstein M, 2001, CAN J NEUROL SCI, V28, P120, DOI 10.1017/S0317167100052781; Boulton M, 2008, J NEUROSURG, V108, P649, DOI 10.3171/JNS/2008/108/4/0649; Bui JQH, 2011, J NEUROSURG, V115, P1236, DOI 10.3171/2011.8.JNS11105; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Grundy PL, 2008, BRIT J NEUROSURG, V22, P360, DOI 10.1080/02688690801961858; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; Hartman M, 2010, HLTH CARE EXPENDITUR; Iapichino G, 2005, HEALTH POLICY, V73, P228, DOI 10.1016/j.healthpol.2004.11.015; Iwashyna TJ, 2009, CRIT CARE MED, V37, P1545, DOI 10.1097/CCM.0b013e31819fe8f8; Khaldi A, 2010, J NEUROSURG, V113, P1021, DOI 10.3171/2009.11.JNS081048; Lattimore SU, 2003, STROKE, V34, pE55, DOI 10.1161/01.STR.0000073789.12120.F3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Moerer O, 2007, CRIT CARE, V11, DOI 10.1186/cc5952; Morasch MD, 1996, J AM COLL SURGEONS, V183, P387; Nitahara J A, 1998, Neurosurg Focus, V5, pe4; Rhondali O, 2011, J NEUROSURG ANESTH, V23, P118, DOI 10.1097/ANA.0b013e318206d5f8; Shorr Andrew F, 2002, Curr Opin Crit Care, V8, P337, DOI 10.1097/00075198-200208000-00011; TAYLOR WAS, 1995, J NEUROSURG, V82, P48, DOI 10.3171/jns.1995.82.1.0048; Varelas PN, 2008, NEUROCRIT CARE, V9, P293, DOI 10.1007/s12028-008-9050-6; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Ward NS, 2008, CRIT CARE MED, V36, P471, DOI 10.1097/CCM.0B013E3181629511; Ziai WC, 2003, CRIT CARE MED, V31, P2782, DOI 10.1097/01.CCM.0000098860.52812.24	26	38	39	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2014	81	1					165	172		10.1016/j.wneu.2012.11.068			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AC2DV	WOS:000332309200048	23182731	Green Accepted, Green Published			2021-06-18	
J	Ling, JM; Klimaj, S; Toulouse, T; Mayer, AR				Ling, Josef M.; Klimaj, Stefan; Toulouse, Trent; Mayer, Andrew R.			A prospective study of gray matter abnormalities in mild traumatic brain injury	NEUROLOGY			English	Article							CORTICAL IMPACT INJURY; AXONAL INJURY; TIME-COURSE; ENCEPHALOPATHY; NEUROPATHOLOGY; PERFORMANCE; ANISOTROPY; INTEGRITY; RECOVERY; ATROPHY	Objective: To examine the underlying pathophysiology of mild traumatic brain injury through changes in gray matter diffusion and atrophy during the semiacute stage. Methods: Fifty patients and 50 sex-, age-, and education-matched controls were evaluated with a clinical and neuroimaging battery approximately 14 days postinjury, with 26 patients returning for follow-up 4 months postinjury. Clinical measures included tests of attention, processing speed, executive function, working memory, memory, and self-reported postconcussive symptoms. Measures of diffusion (fractional anisotropy [FA], mean diffusivity) and atrophy were obtained for cortical and subcortical structures to characterize effects of injury as a function of time. Results: Patients reported more cognitive, somatic, and emotional complaints during the semiacute injury phase, which were significantly reduced 4 months postinjury. Patients showed evidence of increased FA in the bilateral superior frontal cortex during the semiacute phase, with the left superior frontal cortex remaining elevated 4 months postinjury. There were no significant differences between patients and matched controls on neuropsychological testing or measures of gray matter atrophy/mean diffusivity at either time point. Conclusions: Increased cortical FA is largely consistent with an emerging animal literature of gray matter abnormalities after neuronal injury. Potential mechanistic explanations for increased FA include cytotoxic edema or reactive gliosis. In contrast, there was no evidence of cortical or subcortical atrophy in the current study, suggesting that frank neuronal or neuropil loss does not occur early in the chronic disease course for patients with typical mild traumatic brain injury.	[Ling, Josef M.; Klimaj, Stefan; Toulouse, Trent; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87108 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87108 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	Supported by the NIH (R24-HD050836, R21-NS064464-01A1, and 3 R21 NS064464-01S1 to A.R.M.).	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Conti AC, 1998, J NEUROSCI, V18, P5663; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Halassa MM, 2007, J NEUROSCI, V27, P6473, DOI 10.1523/JNEUROSCI.1419-07.2007; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wright MJ, 2013, BRAIN IMAGING B 0501; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	37	38	39	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	DEC 10	2013	81	24					2121	2127		10.1212/01.wnl.0000437302.36064.b1			7	Clinical Neurology	Neurosciences & Neurology	AA0FZ	WOS:000330772300015	24259552	Green Published			2021-06-18	
J	Ryan, NP; Anderson, V; Godfrey, C; Eren, S; Rosema, S; Taylor, K; Catroppa, C				Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy			Social communication mediates the relationship between emotion perception and externalizing behaviors in young adult survivors of pediatric traumatic brain injury (TBI)	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Emotion perception; Social communication; Externalizing behaviors; Childhood; Traumatic brain injury	CLOSED-HEAD-INJURY; FACIAL EXPRESSION; CHILDREN; ADOLESCENTS; RECOGNITION; CHILDHOOD; ABILITY; COMPETENCE; ADJUSTMENT; AGGRESSION	Traumatic brain injury (TBI) is a common cause of childhood disability, and is associated with elevated risk for long-term social impairment. Though social (pragmatic) communication deficits may be among the most debilitating consequences of childhood TBI, few studies have examined very long-term communication outcomes as children with TBI make the transition to young adulthood. In addition, the extent to which reduced social function contributes to externalizing behaviors in survivors of childhood TBI remains poorly understood. The present study aimed to evaluate the extent of social communication difficulty among young adult survivors of childhood TB! (n=34, injury age: 1.0-7.0 years; M time since injury: 16.55 years) and examine relations among aspects of social function including emotion perception, social communication and externalizing behaviors rated by close-other proxies. Compared to controls the TBI group had significantly greater social communication difficulty, which was associated with more frequent externalizing behaviors and poorer emotion perception. Analyses demonstrated that reduced social communication mediated the association between poorer emotion perception and more frequent externalizing behaviors. Our findings indicate that socio-cognitive impairments may indirectly increase the risk for externalizing behaviors among young adult survivors of childhood TBI, and underscore the need for targeted social skills interventions delivered soon after injury, and into the very long-term. (C) 2013 ISDN. Published by Elsevier Ltd. All rights reserved.	[Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Anderson, Vicki; Taylor, Kaitlyn; Catroppa, Cathy] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Godfrey, Celia; Rosema, Stefanie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au; vicki.anderson@rch.org.au; celia.godfrey@mcri.edu.au; senem.eren@mcri.edu.au; stefanie.rosema@mcri.edu.au; kaitlyn.taylor@mcri.edu.au; cathy.catroppa@mcri.edu.au	Ryan, Nicholas/K-5445-2019	Ryan, Nicholas/0000-0002-0878-8889	Victorian Neurotrauma Initiative, National Health and Medical Research Council (NHMRC) Fellowship (VA)National Health and Medical Research Council of Australia; NHMRCNational Health and Medical Research Council of Australia; Victorian Government Operational Infrastructure Scheme	Victorian Neurotrauma Initiative, National Health and Medical Research Council (NHMRC) Fellowship (VA), NHMRC Career Development Award (CC), Victorian Government Operational Infrastructure Scheme.	Achenbach T. M., 2003, MANUAL ASEBA ADULT F; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Anderson V., 2012, DEV SOCIAL NEUROSCIE, P231; Anderson VA, 2003, STUD NEUROPSYCHOL DE, P217; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Denham SA, 2003, CHILD DEV, V74, P238, DOI 10.1111/1467-8624.00533; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2010, BRAIN IMPAIR, V11, P171, DOI 10.1375/brim.11.2.171; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Guercio John M, 2002, Case Manager, V13, P55, DOI 10.1067/tcmg.2002.122043; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hanten G., 2012, DEV SOCIAL NEUROSCIE, P254; Hawkins JD, 2005, ARCH PEDIAT ADOL MED, V159, P25, DOI 10.1001/archpedi.159.1.25; Holdnack J, 2011, ASSESSMENT, V18, P192, DOI 10.1177/1073191110394771; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Karow Colleen M., 2003, Seminars in Speech and Language, V24, P69, DOI 10.1055/s-2003-38900; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KUPERSMIDT JB, 1990, CHILD DEV, V61, P1350, DOI 10.1111/j.1467-8624.1990.tb02866.x; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S., 2000, ADV UNDERSTANDING CO; McDonald S., 2012, DEV SOCIAL NEUROSCIE, P325; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; MORRISON RL, 1981, BEHAV THER, V12, P69, DOI 10.1016/S0005-7894(81)80107-4; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Parker J. G., 2006, DEV PSYCHOPATHOLOGY, P419, DOI DOI 10.1002/9780470939383.CH12; Pearson, 2009, ADV CLIN SOLUTIONS W; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Poggi G, 2005, BRAIN INJURY, V19, P777, DOI 10.1080/0269905500110132; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Ryan N.P., 2013, J NEUROTRAU IN PRESS; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Sengpiel F, 2007, CURR BIOL, V17, pR742, DOI 10.1016/j.cub.2007.06.017; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Sobel M.E., 1982, SOCIOLOGICAL METHODO, V13, P290, DOI [10.2307/270723., DOI 10.2307/270723, 10.2307/270723]; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tenneij NH, 2007, J APPL RES INTELLECT, V20, P391, DOI 10.1111/j.1468-3148.2007.00383.x; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J., 2007, BRAIN IMPAIR, V18, P458; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	76	38	38	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	DEC	2013	31	8					811	819		10.1016/j.ijdevneu.2013.10.002			9	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	283TP	WOS:000329270200013	24140241				2021-06-18	
J	Scholl, EA; Dudek, FE; Ekstrand, JJ				Scholl, E. A.; Dudek, F. E.; Ekstrand, J. J.			NEURONAL DEGENERATION IS OBSERVED IN MULTIPLE REGIONS OUTSIDE THE HIPPOCAMPUS AFTER LITHIUM PILOCARPINE-INDUCED STATUS EPILEPTICUS IN THE IMMATURE RAT	NEUROSCIENCE			English	Article						Fluoro-jade B; lithium pilocarpine; status epilepticus; immature brain	TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; TRAUMATIC BRAIN-INJURY; FLUORO-JADE-B; LIMBIC EPILEPSY; ACQUIRED EPILEPTOGENESIS; MEDIODORSAL NUCLEUS; FUNCTIONAL-ANATOMY; AMYGDALOID COMPLEX; ENTORHINAL CORTEX	Although hippocampal sclerosis is frequently identified as a possible epileptic focus in patients with temporal lobe epilepsy, neuronal loss has also been observed in additional structures, including areas outside the temporal lobe. The claim from several researchers using animal models of acquired epilepsy that the immature brain can develop epilepsy without evidence of hippocampal neuronal death raises the possibility that neuronal death in some of these other regions may also be important for epileptogenesis. The present study used the lithium pilocarpine model of acquired epilepsy in immature animals to assess which structures outside the hippocampus are injured acutely after status epilepticus. Sprague Dawley rat pups were implanted with surface EEG electrodes, and status epilepticus was induced at 20 days of age with lithium pilocarpine. After 72 h, brain tissue from 12 animals was examined with Fluoro-Jade B, a histochemical marker for degenerating neurons. All animals that had confirmed status epilepticus demonstrated Fluoro-Jade B staining in areas outside the hippocampus. The most prominent staining was seen in the thalamus (mediodorsal, paratenial, reuniens, and ventral lateral geniculate nuclei), amygdala (ventral lateral, posteromedial, and basomedial nuclei), ventral premammillary nuclei of hypothalamus, and paralimbic cortices (perirhinal, entorhinal, and piriform) as well as parasubiculum and dorsal endopiriform nuclei. These results demonstrate that lithium pilocarpine-induced status epilepticus in the immature rat brain consistently results in neuronal injury in several distinct areas outside of the hippocampus. Many of these regions are similar to areas damaged in patients with temporal lobe epilepsy, thus suggesting a possible role in epileptogenesis. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Scholl, E. A.; Ekstrand, J. J.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84108 USA; [Dudek, F. E.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84108 USA	Ekstrand, JJ (corresponding author), Univ Utah, Sch Med, Dept Pediat, 420 Chipeta Way,Suite 1700, Salt Lake City, UT 84108 USA.	jeffrey.ekstrand@hsc.utah.edu			National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS-070957]; CounterACT Program, National Institutes of Health Office of the Director (NIH OD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [HHS N271201100029C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS070957, R01NS045144] Funding Source: NIH RePORTER	The project was supported directly by the National Institute of Neurological Disorders and Stroke (NINDS) Grant K08-NS-070957 with additional support from the CounterACT Program, National Institutes of Health Office of the Director (NIH OD), and NINDS, Grant HHS N271201100029C which was subcontracted to the University of Utah (W81XWH-12-2-0122).	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060.abs; Andre V, 2003, EPILEPSIA, V44, P893, DOI 10.1046/j.1528-1157.2003.61802.x; Baram TZ, 2011, EPILEPSY CURR, V11, P21, DOI 10.5698/1535-7511-11.1.21; Bertram EH, 2009, EPILEPSY BEHAV, V14, P32, DOI 10.1016/j.yebeh.2008.09.017; Bertram EH, 2001, EPILEPSIA, V42, P967, DOI 10.1046/j.1528-1157.2001.042008967.x; Bertram EH, 1998, EPILEPSY RES, V32, P194, DOI 10.1016/S0920-1211(98)00051-5; Bertram EH, 2000, EPILEPSIA, V41, pS3, DOI 10.1111/j.1528-1157.2000.tb01548.x; BOAST CA, 1976, BRAIN RES, V103, P527, DOI 10.1016/0006-8993(76)90450-9; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO, V31; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; CAVALHEIRO EA, 1987, DEV BRAIN RES, V37, P43, DOI 10.1016/0165-3806(87)90227-6; CAVANAGH JB, 1956, BRIT MED J, V2, P1403, DOI 10.1136/bmj.2.5006.1403; CLIFFORD DB, 1987, NEUROSCIENCE, V23, P953, DOI 10.1016/0306-4522(87)90171-0; Cossart R, 2001, NAT NEUROSCI, V4, P52; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Drexel M, 2011, NEUROSCIENCE, V189, P316, DOI 10.1016/j.neuroscience.2011.05.021; Druga R, 2005, EPILEPSY RES, V63, P43, DOI 10.1016/j.eplepsyres.2004.11.001; DU F, 1993, EPILEPSY RES, V16, P223, DOI 10.1016/0920-1211(93)90083-J; Dube C, 2001, EXP NEUROL, V167, P227, DOI 10.1006/exnr.2000.7561; Dudek FE, 2006, MODELS OF SEIZURES AND EPILEPSY, P415, DOI 10.1016/B978-012088554-1/50036-0; Dudek FE, 2010, EPILEPSY CURR, V10, P95, DOI 10.1111/j.1535-7511.2010.01369.x; Ekstrand JJ, 2011, NEUROSCIENCE, V192, P699, DOI 10.1016/j.neuroscience.2011.05.022; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FEINDEL W, 1991, CAN J NEUROL SCI, V18, P603; Fernandes MJD, 1999, J CEREBR BLOOD F MET, V19, P195; Francois J, 2011, NEUROPHARMACOLOGY, V61, P313, DOI 10.1016/j.neuropharm.2011.04.018; Frank TC, 2003, NEUROSCIENCE, V118, P667, DOI 10.1016/S0306-4522(03)00019-8; Fritsch B, 2009, NEUROSCIENCE, V163, P415, DOI 10.1016/j.neuroscience.2009.06.034; Fujikawa DG, 1996, BRAIN RES, V725, P11, DOI 10.1016/S0006-8993(96)00203-X; GLOOR P, 1992, P505; GOLDRING S, 1992, J NEUROSURG, V77, P185, DOI 10.3171/jns.1992.77.2.0185; Hasson H, 2008, EPILEPSY BEHAV, V13, P62, DOI 10.1016/j.yebeh.2008.02.008; HIRSCH E, 1992, BRAIN RES, V583, P120, DOI 10.1016/S0006-8993(10)80015-0; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; HUDSON LP, 1993, ANN NEUROL, V33, P622, DOI 10.1002/ana.410330611; Knopp A, 2005, J COMP NEUROL, V483, P476, DOI 10.1002/cne.20460; Kobayashi M, 2003, J NEUROSCI, V23, P8471; Kubova H, 2005, EPILEPSIA, V46, P38, DOI 10.1111/j.1528-1167.2005.01005.x; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Kubova H, 2004, EUR J NEUROSCI, V19, P3255, DOI 10.1111/j.0953-816X.2004.03410.x; Kubova H, 2002, EPILEPSIA, V43, P54, DOI 10.1046/j.1528-1157.43.s.5.36.x; Kullmann DM, 2011, BRAIN, V134, P2800, DOI 10.1093/brain/awr246; Lado FA, 2002, EPILEPTIC DISORD, V4, P83; Larsson E, 2001, BRAIN RES, V913, P117, DOI 10.1016/S0006-8993(01)02762-7; Laufs H, 2012, CURR OPIN NEUROL, V25, P194, DOI 10.1097/WCO.0b013e3283515db9; LOSCHER W, 1995, BRAIN RES, V697, P197, DOI 10.1016/0006-8993(95)00843-F; Mares P, 2005, EPILEPSIA, V46, P31, DOI 10.1111/j.1528-1167.2005.01004.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; MILLER LA, 1994, J NEUROL NEUROSUR PS, V57, P1099, DOI 10.1136/jnnp.57.9.1099; Morin F, 1998, J NEUROPHYSIOL, V80, P2836; Nairismagi J, 2006, EPILEPSIA, V47, P479, DOI 10.1111/j.1528-1167.2006.00455.x; Noebels JL, JASPERS BASIC MECH E; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Pitkanen A, 1998, EPILEPSY RES, V32, P233, DOI 10.1016/S0920-1211(98)00055-2; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Priel MR, 1996, EPILEPSY RES, V26, P115, DOI 10.1016/S0920-1211(96)00047-2; QUESNEY LF, 1988, ACTA NEUROL SCAND, V78, P52, DOI 10.1111/j.1600-0404.1988.tb08004.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raol YSH, 2003, ANN NEUROL, V53, P503, DOI 10.1002/ana.10490; Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x; Sankar R, 1998, J NEUROSCI, V18, P8382; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scallet AC, 2004, TOXICOL SCI, V81, P364, DOI 10.1093/toxsci/kfh224; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Simerly R., 1994, RAT NERVOUS SYSTEM; SO N, 1989, ANN NEUROL, V25, P423, DOI 10.1002/ana.410250502; SPENCER DD, 1984, NEUROSURGERY, V15, P667, DOI 10.1227/00006123-198411000-00005; SPENCER SS, 1994, EPILEPSIA, V35, P721, DOI 10.1111/j.1528-1157.1994.tb02502.x; Spencer SS, 2002, EPILEPSIA, V43, P219, DOI 10.1046/j.1528-1157.2002.26901.x; SPERBER EF, 1991, DEV BRAIN RES, V60, P88, DOI 10.1016/0165-3806(91)90158-F; Stafstrom CE, 2005, EPILEPSY BEHAV, V7, pS18, DOI 10.1016/j.yebeh.2005.08.005; STAFSTROM CE, 1992, DEV BRAIN RES, V65, P227, DOI 10.1016/0165-3806(92)90184-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Tuunanen J, 1999, NEUROSCIENCE, V94, P473, DOI 10.1016/S0306-4522(99)00251-1; Tuunanen J, 1996, EUR J NEUROSCI, V8, P2711, DOI 10.1111/j.1460-9568.1996.tb01566.x; van Vliet EA, 2004, EXP NEUROL, V187, P367, DOI 10.1016/j.expneurol.2004.01.016; Wieser HG, 2004, EPILEPSIA, V45, P32; WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019; Xu B, 2004, EUR J NEUROSCI, V20, P403, DOI 10.1111/j.1460-9568.2004.03489.x	88	38	40	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 12	2013	252						45	59		10.1016/j.neuroscience.2013.07.045			15	Neurosciences	Neurosciences & Neurology	236YS	WOS:000325836000005	23896573	Green Accepted			2021-06-18	
J	Fakhran, S; Yaeger, K; Alhilali, L				Fakhran, Saeed; Yaeger, Karl; Alhilali, Lea			Symptomatic White Matter Changes in Mild Traumatic Brain Injury Resemble Pathologic Features of Early Alzheimer Dementia	RADIOLOGY			English	Article							SLEEP-WAKE DISTURBANCES; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; TENSOR IMAGING FINDINGS; COGNITIVE IMPAIRMENT; SPATIAL STATISTICS; AXONAL INJURY; DISEASE; IMPACT; SPECIFICITY	Purpose: To evaluate white matter integrity in patients with mild traumatic brain injury (TBI) who did not have morphologic abnormalities at conventional magnetic resonance (MR) imaging with diffusion-tensor imaging to determine any relationship between patterns of white matter injury and severity of postconcussion symptoms. Materials and Methods: The institutional review board approved this study, with waiver of informed consent. Diffusion-tensor images from 64 consecutive patients with mild TBI obtained with conventional MR imaging were evaluated retrospectively. Fractional anisotropy (FA) maps were generated as a measure of white matter integrity. All patients underwent a neurocognitive evaluation. Correlations between skeletonized FA values in white matter, total concussion symptom score, and findings of sleep and wake disturbances were analyzed with regression analysis that used tract-based spatial statistics. Results: Total concussion symptom scores varied from 2 to 97 (mean 6 standard deviation, 32.7 +/- 24.4), with 34 patients demonstrating sleep and wake disturbances. Tract-based spatial statistics showed a significant correlation between high total concussion symptom score and reduced FA at the gray matter-white matter junction (P < .05), most prominently in the auditory cortex (P < .05). FA in the parahippocampal gyri was significantly decreased in patients with sleep and wake disturbances relative to patients without such disturbances (0.26 and 0.37, respectively; P < .05). Conclusion: The distribution of white matter abnormalities in patients with symptomatic mild TBI is strikingly similar to the distribution of pathologic abnormalities in patients with early Alzheimer dementia, a finding that may help direct research strategies. (C) RSNA, 2013	[Fakhran, Saeed; Yaeger, Karl; Alhilali, Lea] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA	Fakhran, S (corresponding author), Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Presby South Tower,8th Floor,8 Nor, Pittsburgh, PA 15213 USA.	fakhrans@upmc.edu					Baloyannis SJ, 2011, ACTA OTO-LARYNGOL, V131, P610, DOI 10.3109/00016489.2010.539626; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Ginestroni A, 2009, J NEUROL, V256, P925, DOI 10.1007/s00415-009-5044-3; Golob EJ, 2007, BRAIN, V130, P740, DOI 10.1093/brain/awl375; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; Huang YF, 2012, ARCH NEUROL-CHICAGO, V69, P51, DOI 10.1001/archneurol.2011.235; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Romito-DiGiacomo RR, 2007, J NEUROSCI, V27, P8496, DOI 10.1523/JNEUROSCI.1008-07.2007; Salimi-Khorshidi G, 2011, NEUROIMAGE, V54, P2006, DOI 10.1016/j.neuroimage.2010.09.088; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Van Hoesen GW, 2000, ANN NY ACAD SCI, V911, P254; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Viswanathan A, 2006, STROKE, V37, P2690, DOI 10.1161/01.STR.0000245091.28429.6a; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Yallampalli R, 2010, J NEUROIMAGING; Yoshiura T, 2006, ACAD RADIOL, V13, P1460, DOI 10.1016/j.acra.2006.09.042	42	38	38	0	27	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2013	269	1					249	257		10.1148/radiol.13122343			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	225YH	WOS:000325000700028	23781117	Bronze			2021-06-18	
J	Kim, JY; Kim, N; Zheng, Z; Lee, JE; Yenari, MA				Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Lee, Jong Eun; Yenari, Midori A.			The 70 kDa heat shock protein protects against experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Brain injury; Heat shock protein; Cerebral hemorrhage	OXYGEN-GLUCOSE DEPRIVATION; MATRIX METALLOPROTEINASES; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; INFLAMMATORY RESPONSE; BARRIER DISRUPTION; STRESS-RESPONSE; OVEREXPRESSION; BLOOD; MATRIX-METALLOPROTEINASE-9	Traumatic brain injury (TBI) causes disruption of the blood brain barrier (BBB) leading to hemorrhage which can complicate an already catastrophic illness. Matrix metalloproteinases (MMPs) involved in the breakdown of the extracellular matrix may lead to brain hemorrhage. We explore the contribution of the 70 kDa heat shock protein (Hsp70) to outcome and brain hemorrhage in a model of TBI. Male, wildtype (Wt), Hsp70 knockout (Ko) and transgenic (Tg) mice were subjected to TBI using controlled cortical impact (CCI). Motor function, brain hemorrhage and lesion size were assessed at 3, 7 and 14 days. Brains were evaluated for the effects of Hsp70 on MMPs. In Hsp70 Tg mice, CCI led to smaller brain lesions, decreased hemorrhage and reduced expression and activation of MMPs compared to Wt. CCI also significantly decreased right-biased swings and corner turns in the Hsp70 Tg mice. Conversely, Hsp70 Ko mice had significantly increased lesion size, worsened brain hemorrhage and increased expression and activation of MMPs with worsened behavioral outcomes compared to Wt. Hsp70 is protective in experimental TBI. To our knowledge, this is the direct demonstration of brain protection by Hsp70 in a TBI model. Our data demonstrate a new mechanism linking TBI-induced hemorrhage and neuronal injury to the suppression of MMPs by Hsp70, and support the development of Hsp70 enhancing strategies for the treatment of TBI. Published by Elsevier Inc.	[Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; [Kim, Jong Youl; Kim, Nuri; Zheng, Zhen; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Lee, Jong Eun] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea; [Lee, Jong Eun] Yonsei Univ, Coll Med, BK Project Med Sci 21, Seoul, South Korea	Yenari, MA (corresponding author), VAMC 4150 Clement St, San Francisco, CA 94121 USA.	yenari@alum.mit.edu		Lee, Jong Eun/0000-0001-6203-7413	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS40516]; Veteran's Merit Award; American Heart Association Western States Affiliate Postdoctoral FellowshipAmerican Heart Association [13POST14810019]; NRF of KOREA; Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012-0005827]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040516] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (NS40516) and the Veteran's Merit Award to MY, an American Heart Association Western States Affiliate Postdoctoral Fellowship (13POST14810019) to JYK and Basic Science Research Program through the NRF of KOREA funded by the Ministry of Education, Science and Technology (2012-0005827) to JEL. Grants to MY and JYK were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. The authors wish to thank Dr. Linda Noble-Haeusslein for helpful discussion and advice.	Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Chang EF, 2003, J NEUROSCI, V23, P3689; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; DeGracia DJ, 2007, NEUROL RES, V29, P356, DOI 10.1179/016164107X204666; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Grossetete M, 2008, J CEREBR BLOOD F MET, V28, P752, DOI 10.1038/sj.jcbfm.9600572; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Kelly S, 2002, ANN NEUROL, V52, P160, DOI 10.1002/ana.10264; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim JY, 2011, TRANSL STROKE RES, V2, P195, DOI 10.1007/s12975-011-0082-4; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kwon HM, 2008, NEUROL RES, V30, P740, DOI 10.1179/174313208X289615; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lee JE, 2004, NEUROREPORT, V15, P499, DOI 10.1097/00001756-200403010-00023; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Manaenko A, 2011, ACTA NEUROCHIR SUPPL, V111, P161, DOI 10.1007/978-3-7091-0693-8_27; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Noble LJ, 2002, J NEUROSCI, V22, P7526; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Ouyang YB, 2005, NEUROSCI LETT, V380, P229, DOI 10.1016/j.neulet.2005.01.055; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vilalta A, 2008, ACTA NEUROCHIR SUPPL, V102, P415, DOI 10.1007/978-3-211-85578-2_81; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang Q, 2009, NEUROBIOL DIS, V36, P223, DOI 10.1016/j.nbd.2009.07.018; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Xu LJ, 2003, NEUROL RES, V25, P697, DOI 10.1179/016164103101202183; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	56	38	41	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	OCT	2013	58						289	295		10.1016/j.nbd.2013.06.012			7	Neurosciences	Neurosciences & Neurology	207GC	WOS:000323585900033	23816752	Green Accepted, Green Published			2021-06-18	
J	De Bonis, P; Sturiale, CL; Anile, C; Gaudino, S; Mangiola, A; Martucci, M; Colosimo, C; Rigante, L; Pompucci, A				De Bonis, Pasquale; Sturiale, Carmelo Lucio; Anile, Carmelo; Gaudino, Simona; Mangiola, Annunziato; Martucci, Matia; Colosimo, Cesare; Rigante, Luigi; Pompucci, Angelo			Decompressive craniectomy, interhemispheric hygroma and hydrocephalus: A timeline of events?	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Decompressive craniectomy; Hydrocephalus; Interhemispheric hygroma; Subdural hygroma; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HYDROCEPHALUS; INTRACRANIAL HYPERTENSION; RISK-FACTORS; HEAD-INJURY; HEMICRANIECTOMY; EVACUATION; SECONDARY; DYNAMICS	Background: Decompressive craniectomy (DC) is a known risk factor for the development of post-traumatic hydrocephalus. The occurrence of subdural hygroma (SH) was also reported in 23-56% of patients after DC and it seemed to precede hydrocephalus in more than 80% of cases. We analyzed the relationship among DC, SH and hydrocephalus. Methods: From 2007 to 2011, 64 patients underwent DC after head trauma. Variables we analyzed were: intaventricular hemorrhage, age, GCS, distance of craniectomy from-the midline, evacuation of a hemorrhagic contusion (HC) and infection. Logistic regression was used to assess the independent contribution of the predictive factors to the development of hydrocephalus. Results: Nineteen patients (29.7%) developed hydrocephalus. Interhemispheric SH was present in 8/19 patients with hydrocephalus and temporally preceded the occurrence of ventricular enlargement. Moreover, most patients who developed a interhemispheric SH had been undergone DC whose superior margin was close to the midline. Logistic regression analysis showed that craniectomy closer than 25 mm to the midline was the only factor independently associated with the development of hydrocephalus. Conclusion: Craniectomy close to the midline can predispose patients to the development of hydrocephalus. SH could be generated with the same mechanism, and these three events could be correlated on a timeline. (C) 2012 Elsevier B.V. All rights reserved.	[De Bonis, Pasquale; Sturiale, Carmelo Lucio; Anile, Carmelo; Mangiola, Annunziato; Rigante, Luigi; Pompucci, Angelo] Catholic Univ, Sch Med, Inst Neurosurg, I-00168 Rome, Italy; [Gaudino, Simona; Martucci, Matia; Colosimo, Cesare] Catholic Univ, Sch Med, Dept Bio Imaging, I-00168 Rome, Italy	Sturiale, CL (corresponding author), Catholic Univ, Sch Med, Inst Neurosurg, Lgo A Gemelli 8, I-00168 Rome, Italy.	cropcircle.2000@virgilio.it	de bonis, pasquale/K-8200-2016; Sturiale, Carmelo Lucio/K-6412-2016	de bonis, pasquale/0000-0002-9879-8940; Sturiale, Carmelo Lucio/0000-0002-4080-2492; Gaudino, Simona/0000-0003-1681-4343; Rigante, Luigi/0000-0003-0539-526X; Colosimo, Cesare/0000-0003-3800-3648			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Anile C, 2009, CHILD NERV SYST, V25, P325, DOI 10.1007/s00381-008-0749-7; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Dandy WE, 1932, PRACTICE SURG, P306; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P49, DOI 10.1016/j.clineuro.2012.04.012; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Ishikawa M, 2008, NEUROL MED-CHIR, V48, pS1, DOI 10.2176/nmc.48.S1; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Licata C, 2001, J Neurosurg Sci, V45, P141; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; NAKAGAWA Y, 1974, J NEUROSURG, V41, P427, DOI 10.3171/jns.1974.41.4.0427; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Relkin Norman, 2005, Neurosurgery, V57, pS4; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; Takeuchi S, 2012, CLIN NEUROLOGY NEURO; Takeuchi S, 2011, J NEUROSURG, V115, P194, DOI 10.3171/2011.2.JNS11122; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2009, MED PRIN PRACT, V18, P16, DOI 10.1159/000163040; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	31	38	39	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	AUG	2013	115	8					1308	1312		10.1016/j.clineuro.2012.12.011			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	198NJ	WOS:000322929300020	23290122				2021-06-18	
J	Wolf, H; Frantal, S; Pajenda, GS; Salameh, O; Widhalm, H; Hajdu, S; Sarahrudi, K				Wolf, Harald; Frantal, Sophie; Pajenda, Gholam S.; Salameh, Olivia; Widhalm, Harald; Hajdu, Stefan; Sarahrudi, Kambiz			Predictive value of neuromarkers supported by a set of clinical criteria in patients with mild traumatic brain injury: S100B protein and neuron-specific enolase on trial	JOURNAL OF NEUROSURGERY			English	Article						computed tomography scanning; adult brain injury; assessment tool; guideline; neuromarker; traumatic brain injury	MINOR HEAD-INJURY; FIBRILLARY ACIDIC PROTEIN; COMPUTED-TOMOGRAPHY; INTRACRANIAL LESIONS; SCREENING TOOL; SERUM-LEVELS; S-100B; MARKERS; DAMAGE; ANTICOAGULATION	Object. The role of the neuromarkers S100B protein and neuron-specific enolase (NSE) in minor head injury is well established. Moreover, there are sensitive decision rules available in the literature to identify clinically important brain lesions. However, it is not clear if using the biomarkers has an influence on the predictability of the decision rule. The purpose of this study was to determine if a set of preclinical and clinical parameters combined with 2 neuromarker levels could serve as reliable guidance for accurate diagnosis. Methods. Prospective evaluation of a cohort of head trauma patients with Glasgow Coma Scale scores of 13-15 was performed at an academic, Level I trauma center. Blood samples and cranial CT studies were obtained for all patients within 3 hours after injury. The hypothesis of the study was whether the combination of an increase of S100B and NSE levels in serum and other defined risk factors are associated with a pathological finding on CT. A forward stepwise logistic regression model was used. Results. The study included 107 head trauma patients with a mean age of 59 +/- 23 years. Twenty-five patients (23.4%) had traumatic lesions on CT. Eight patients underwent craniotomy. The analysis provided a model with good overall accuracy for discriminating cases with clinically important brain injury, including the 6 variables of S100B, NSE, nausea, amnesia, vomiting, and loss of consciousness. The area under the curve (AUC) was 0.88 (0.83-0.93). The receiver operating characteristic curve plots detecting clinically important brain injury for the single variables of S100B and NSE showed an AUC of 0.63 and 0.64, respectively. Conclusions. The integration of the neuromarker panel as part of a diagnostic rule including the high-risk factors of nausea, vomiting, amnesia, and loss of consciousness is safe and reliable in determining a diagnosis, pending the availability of more brain-specific neuromarkers.	[Wolf, Harald; Pajenda, Gholam S.; Salameh, Olivia; Widhalm, Harald; Hajdu, Stefan; Sarahrudi, Kambiz] Med Univ Vienna, Dept Trauma Surg, AKH Wien, A-1090 Vienna, Austria; [Frantal, Sophie] Med Univ Vienna, Dept Med Stat, A-1090 Vienna, Austria	Wolf, H (corresponding author), Med Univ Vienna, Dept Trauma Surg, AKH Wien, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Harald.Wolf@meduniwien.ac.at	Widhalm, Harald/ABE-8863-2020	Widhalm, Harald/0000-0001-9739-6176; Aschacher, Olivia/0000-0002-2321-156X			Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Karni A, 2001, AM SURGEON, V67, P1098; Lange RT, 2010, J TRAUMA, V68, P1065, DOI 10.1097/TA.0b013e3181bb9890; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Munoz-Sanchez MA, 2009, BRAIN INJURY, V23, P39, DOI 10.1080/02699050802590346; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Nessen SC, 2008, WAR SURG AFGHANISTAN, P431; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Straume-Naesheim TM, 2008, NEUROSURGERY, V62, P1297, DOI 10.1227/01.neu.0000333301.34189.3d; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vogel T, 2008, UNFALLCHIRURG, V111, P898, DOI 10.1007/s00113-008-1502-0; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	33	38	42	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1298	1303		10.3171/2013.1.JNS121181			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400028	23451906				2021-06-18	
J	Mondello, S; Buki, A; Italiano, D; Jeromin, A				Mondello, Stefania; Buki, Andras; Italiano, Domenico; Jeromin, Andreas			alpha-Synuclein in CSF of patients with severe traumatic brain injury	NEUROLOGY			English	Article							LEWY BODIES; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HEAD-INJURY; DEMENTIA; TRAJECTORIES; BIOMARKERS; DIAGNOSIS; MECHANISMS; EXOCYTOSIS	Objective: The study aims to examine alpha-synuclein in the CSF of patients with severe traumatic brain injury (TBI) and its relationship with clinical characteristics and long-term outcomes. Methods: This prospective case-control study enrolled patients with severe TBI (Glasgow Coma Score <= 8) who underwent ventriculostomy. CSF samples were taken from each TBI patient at admission and daily for up to 8 days after injury and successively assessed by ELISA. Control CSF was collected for analysis from subjects receiving lumbar puncture for other medical reasons. We used trajectory analysis to identify distinct temporal profiles of CSF alpha-synuclein that were compared with clinical outcomes. Results: CSF alpha-synuclein was elevated in TBI patients after injury as compared to controls (p = 0.0008). Overall, patients who died had higher concentrations (area under the curve) over 8 days of observation compared to those who survived at 6 months postinjury (p = 0.002). Two distinct temporal alpha-synuclein profiles were recognized over time. Subjects who died had consistently elevated alpha-synuclein levels compared to those who survived with alpha-synuclein levels near controls. High-risk trajectory was a strong and accurate predictor of death with 100% specificity and a very high sensitivity (83%). Conclusions: Taken together, these data support the hypothesis that in severe TBI patients, substantial increase of CSF alpha-synuclein may indicate widespread neurodegeneration and reflect secondary neuropathologic events occurring after injury. The determination of CSF alpha-synuclein may be a valuable prognostic marker, adding to the clinical assessment and creating opportunities for medical intervention.	[Mondello, Stefania; Jeromin, Andreas] Banyan Biomarkers Inc, Clin Dept, Alachua, FL USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; Hungarian Acad Sci, Clin Neurosci Image Ctr, Pecs, Hungary; [Italiano, Domenico] Univ Messina, Dept Clin & Expt Med & Pharmacol, Messina, Italy	Mondello, S (corresponding author), Banyan Biomarkers Inc, Clin Dept, Alachua, FL USA.	stm_mondello@hotmail.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03- 1-0066]; Banyan Biomarkers, Inc.	Supported by the Department of Defense (DAMD17-03-1-0772 and DAMD17-03- 1-0066).; S. Mondello is an employee and receives salaries from Banyan Biomarkers, Inc. A. Buki is a consultant for Banyan Biomarkers, Inc. D. Italiano reports no disclosures. A. Jeromin was an employee and received salaries from Banyan Biomarkers, Inc. Go to Neurology.org for full disclosures.	Adou K, 2009, ANAL CHEM, V81, P10186, DOI 10.1021/ac902275h; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Clough RL, 2011, J NEUROCHEM, V117, P275, DOI 10.1111/j.1471-4159.2011.07199.x; Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Foulds PG, 2012, NEUROBIOL DIS, V45, P188, DOI 10.1016/j.nbd.2011.08.003; Gure TR, 2010, J GERONTOL A-BIOL, V65, P434, DOI 10.1093/gerona/glp197; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jones DJ, 2010, J CLIN CHILD ADOLESC, V39, P667, DOI 10.1080/15374416.2010.501286; Kasuga K, 2010, J NEUROL NEUROSUR PS, V81, P608, DOI 10.1136/jnnp.2009.197483; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kramer ML, 2007, J NEUROSCI, V27, P1405, DOI 10.1523/JNEUROSCI.4564-06.2007; Larsen KE, 2006, J NEUROSCI, V26, P11915, DOI 10.1523/JNEUROSCI.3821-06.2006; Lee EJ, 2010, J IMMUNOL, V185, P615, DOI 10.4049/jimmunol.0903480; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Lovell MA, 2008, NEUROLOGY, V70, P2212, DOI 10.1212/01.wnl.0000312383.39973.88; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mollenhauer B, 2011, LANCET NEUROL, V10, P230, DOI 10.1016/S1474-4422(11)70014-X; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nagin D, 1999, CHILD DEV, V70, P1181, DOI 10.1111/1467-8624.00086; Reesink FE, 2010, J ALZHEIMERS DIS, V22, P87, DOI 10.3233/JAD-2010-100186; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Tokuda T, 2010, NEUROLOGY, V75, P1766, DOI 10.1212/WNL.0b013e3181fd613b; Vekrellis K, 2012, EXPERT OPIN THER TAR, V16, P421, DOI 10.1517/14728222.2012.674111; Vekrellis K, 2011, LANCET NEUROL, V10, P1015, DOI 10.1016/S1474-4422(11)70213-7; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	37	38	38	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	APR	2013	80	18					1662	1668		10.1212/WNL.0b013e3182904d43			7	Clinical Neurology	Neurosciences & Neurology	141AC	WOS:000318696600014	23553480				2021-06-18	
J	Hines, DJ; Haydon, PG				Hines, Dustin J.; Haydon, Philip G.			Inhibition of a SNARE-Sensitive Pathway in Astrocytes Attenuates Damage following Stroke	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; SYNAPTIC-TRANSMISSION; MOLECULAR-MECHANISMS; IN-VIVO; DEPENDENT NEURODEGENERATION; GLUTAMATE RELEASE; NEURONAL-ACTIVITY; NMDA ANTAGONISTS; CLINICAL-TRIALS; MOTOR CORTEX	A strong body of research has defined the role of excitotoxic glutamate in animal models of brain ischemia and stroke; however, clinical trials of glutamate receptor antagonists have demonstrated their limited capacity to prevent brain damage following ischemia. We propose that astrocyte-neuron signaling represents an important modulatory target that may be useful in mediating damage following stroke. To assess the impact of astrocyte signaling on damage following stroke, we have used the astrocyte-specific dominant-negative SNARE mouse model (dnSNARE). Recent findings have shown that the astrocytic SNARE signaling pathway can affect neuronal excitability by regulating the surface expression of NMDA receptors. Using focal photothrombosis via the Rose Bengal method, as well as excitotoxic NMDA lesions, we show that dnSNARE animals exhibited a sparing of damaged tissue quantified using Nissl and NeuN staining. At the same time point, animals were also tested in behavioral tasks that probe the functional integrity of stroke- or lesion-damaged motor and somatosensory areas. We found that dnSNARE mice performed significantly better than littermate controls on rung walk and adhesive dot removal tasks following lesion. Together, our results demonstrate the important role of astrocytic signaling under ischemic conditions. Drugs targeting astrocyte signaling have a potential benefit for the outcome of stroke in human patients by limiting the spread of damage.	[Hines, Dustin J.; Haydon, Philip G.] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	Haydon, PG (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.	philip.haydon@tufts.edu	Hines, Dustin/AAC-6394-2021	Hines, Dustin/0000-0003-2952-9824	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS037585, R01 MH095385]; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH095385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037585, R01NS054770] Funding Source: NIH RePORTER	This work was supported by NIH Grants R01 NS037585, R01 MH095385 to P. G. H., and by grants from The Heart and Stroke Foundation of Canada to D.J.H..	Aarts Michelle M, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403007087; Aguado F, 2002, J NEUROSCI, V22, P9430; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 1998, J NEUROSCI, V18, P6822; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Barber Philip A, 2003, Adv Neurol, V92, P151; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Brown CE, 2010, J CEREBR BLOOD F MET, V30, P783, DOI 10.1038/jcbfm.2009.241; Deng QD, 2011, GLIA, V59, P1084, DOI 10.1002/glia.21181; Ding SH, 2009, GLIA, V57, P767, DOI 10.1002/glia.20804; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Farr TD, 2006, J NEUROSCI METH, V153, P104, DOI 10.1016/j.jneumeth.2005.10.011; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fellin T, 2009, P NATL ACAD SCI USA, V106, P15037, DOI 10.1073/pnas.0906419106; GINSBERG MD, 1994, ANN NEUROL, V36, P553, DOI 10.1002/ana.410360402; Halassa MM, 2009, NEURON, V61, P213, DOI 10.1016/j.neuron.2008.11.024; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kim SH, 2006, MOL PHARMACOL, V69, P691, DOI 10.1124/mol.105.016428; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1007/BF03206570; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Oliet SHR, 2004, GLIA, V47, P258, DOI 10.1002/glia.20032; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Tennant KA, 2011, CEREB CORTEX, V21, P865, DOI 10.1093/cercor/bhq159; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Zorec R, 2012, ASN NEURO, V4, P103, DOI 10.1042/AN20110061	40	38	40	0	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 6	2013	33	10					4234	4240		10.1523/JNEUROSCI.5495-12.2013			7	Neurosciences	Neurosciences & Neurology	103OB	WOS:000315926300003	23467341	Green Accepted, Green Published, Bronze			2021-06-18	
J	Sanchez-Aguilar, M; Tapia-Perez, JH; Sanchez-Rodriguez, JJ; Vinas-Rios, JM; Martinez-Perez, P; de la Cruz-Mendoza, E; Sanchez-Reyna, M; Torres-Corzo, JG; Gordillo-Moscoso, A				Sanchez-Aguilar, Martin; Tapia-Perez, J. Humberto; Juan Sanchez-Rodriguez, Jose; Manuel Vinas-Rios, Juan; Martinez-Perez, Patricia; de la Cruz-Mendoza, Esperanza; Sanchez-Reyna, Martin; Gerardo Torres-Corzo, Jaime; Gordillo-Moscoso, Antonio			Effect of rosuvastatin on cytokines after traumatic head injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; rosuvastatin; cytokine; disability	BRAIN-INJURY; STATINS; SIMVASTATIN; RATS; AMNESIA; DISEASE; SCALE	Object. The favorable effect of statin treatment after traumatic brain injury (TBI) has been shown in animal studies and is probably true in humans as well. The objective of this study was to determine whether acute statin treatment following TBI could reduce inflammatory cytokines and improve functional outcomes in humans. Methods. The authors performed a double-blind randomized clinical trial in patients with moderate to severe TBI. Exclusion criteria were as follows: prior severe disability; use of modifiers of statin metabolism; multisystem trauma; prior use of mannitol, barbiturates, corticosteroids, or calcium channel blockers; isolated brainstem lesions; allergy to statins; previous hepatopathy or myopathy; previous treatment at another clinic; and pregnancy. Patients were randomly selected to receive 20 mg of rosuvastatin or placebo for 10 days. The main goal was to determine the effect of rosuvastatin on plasma levels of tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-6, and IL-10 after 72 hours of TBI. Amnesia, disorientation, and disability were assessed 3 and 6 months after TBI. Results. Thirty-six patients were analyzed according to intention-to-treat analysis; 19 patients received rosuvastatin and 17 received placebo. The best-fit mixed model showed a significant effect of rosuvastatin on the reduction of tumor necrosis factor-alpha levels (p = 0.004). Rosuvastatin treatment did not appear to affect the levels of IL-1 beta, IL-6, and IL-10. The treatment was associated with a reduction in disability scores (p = 0.03), indicating a favorable functional outcome. Life-threatening adverse effects were not observed. Conclusions. The authors' data suggest that statins may induce an antiinflammatory effect and may promote recovery after TBI. The role of statins in TBI therapy should be confirmed in larger clinical trials. Clinical trial registration no.: NCT00990028. (http://thejns.org/doi/abs/10.3171/2012.12.JNS121084)	[Sanchez-Aguilar, Martin; Juan Sanchez-Rodriguez, Jose; Manuel Vinas-Rios, Juan; Sanchez-Reyna, Martin; Gordillo-Moscoso, Antonio] Univ Autonoma San Luis Potosi, Dept Clin Epidemiol, San Luis Potosi 78210, Mexico; [de la Cruz-Mendoza, Esperanza] Univ Autonoma San Luis Potosi, Dept Nucl Med Lab, San Luis Potosi 78210, Mexico; [Juan Sanchez-Rodriguez, Jose; Manuel Vinas-Rios, Juan; Gerardo Torres-Corzo, Jaime] Hosp Cent Dr Ignacio Morones Prieto, Dept Neurosurg, San Luis Potosi, Mexico; [Martinez-Perez, Patricia] Hosp Cent Dr Ignacio Morones Prieto, Dept Neuropsychol & Rehabil, San Luis Potosi, Mexico; [Tapia-Perez, J. Humberto] Otto Von Guericke Univ, Neurochirurg Klin, Magdeburg, Germany	Sanchez-Aguilar, M (corresponding author), Univ Autonoma San Luis Potosi, Dept Clin Epidemiol, Av Venustiano Carranza 2405, San Luis Potosi 78210, Mexico.	jemarsan7@hotmail.com		TORRES-CORZO, JAIME G./0000-0002-3981-0831	Programa Integral de Fortalecimiento Institucional de la Universidad Autonoma de San Luis Potosi [C1O-PIFI-09-12.41, C1O-PIFI-03-06.06]	This study was supported by the "Programa Integral de Fortalecimiento Institucional de la Universidad Autonoma de San Luis Potosi" (C1O-PIFI-09-12.41 and C1O-PIFI-03-06.06). The medication was provided by AstraZeneca.	Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Floyd JS, 2012, JAMA-J AM MED ASSOC, V307, P1580, DOI 10.1001/jama.2012.489; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2010, ACTA NEUROCHIR, V152, P953, DOI 10.1007/s00701-009-0584-y; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt OI, 2007, ORTHOPADE, V36, P248, DOI 10.1007/s00132-007-1061-z; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Tapia-Perez JH, 2010, NEUROSURG REV, V33, P259, DOI 10.1007/s10143-010-0259-4; Turkoglu OF, 2009, SURG NEUROL, V72, P146, DOI 10.1016/j.surneu.2008.07.004; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Wood WG, 2010, ANN NY ACAD SCI, V1199, P69, DOI 10.1111/j.1749-6632.2009.05359.x	25	38	40	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2013	118	3					669	675		10.3171/2012.12.JNS121084			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	094DW	WOS:000315244200031	23289819				2021-06-18	
J	Hendricks, AM; Amara, J; Baker, E; Charns, MP; Gardner, JA; Iverson, KM; Kimerling, R; Krengel, M; Meterko, M; Pogoda, TK; Stolzmann, KL; Lew, HL				Hendricks, Ann M.; Amara, Jomana; Baker, Errol; Charns, Martin P.; Gardner, John A.; Iverson, Katherine M.; Kimerling, Rachel; Krengel, Maxine; Meterko, Mark; Pogoda, Terri K.; Stolzmann, Kelly L.; Lew, Henry L.			Screening for mild traumatic brain injury in OEF-OIF deployed US military: An empirical assessment of VHA's experience	BRAIN INJURY			English	Article						Afghanistan; blast injuries; brain injuries; depression; Iraq; non-blast injuries; post-traumatic stress disorder; screening; Veterans	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MENTAL-HEALTH PROBLEMS; VETERANS; IRAQ; AFGHANISTAN; TBI; CHALLENGES; DIAGNOSES; OUTCOMES	Background: VHA screens for traumatic brain injury (TBI) among patients formerly deployed to Afghanistan or Iraq, referring those who screen positive for a Comprehensive TBI Evaluation (CTBIE). Methods: To assess the programme, rates were calculated of positive screens for potential TBI in the population of patients screened in VHA between October 2007 through March 2009. Rates were derived of TBI confirmed by comprehensive evaluations from October 2008 through July 2009. Patient characteristics were obtained from Department of Defense and VHA administrative data. Results: In the study population, 21.6% screened positive for potential TBI and 54.6% of these had electronic records of a CTBIE. Of those with CTBIE records, evaluators confirmed TBI in 57.7%, yielding a best estimate that 6.8% of all those screened were confirmed to have TBI. Three quarters of all screened patients and virtually all those evaluated (whether TBI was confirmed or not) had VHA care the following year. Conclusions: VHA's TBI screening process is inclusive and has utility in referring patients with current symptoms to appropriate care. More than 90% of those evaluated received further VHA care and confirmatory evaluations were associated with significantly higher average utilization. Generalizability is limited to those who seek VHA healthcare.	[Hendricks, Ann M.; Baker, Errol; Charns, Martin P.; Gardner, John A.; Iverson, Katherine M.; Krengel, Maxine; Meterko, Mark; Pogoda, Terri K.; Stolzmann, Kelly L.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Hendricks, Ann M.; Charns, Martin P.; Meterko, Mark; Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Amara, Jomana] USN, Postgrad Sch, DRMI, Monterey, CA USA; [Iverson, Katherine M.; Krengel, Maxine] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA; [Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Lew, Henry L.] Univ Hawaii Manoa, Honolulu, HI 96822 USA	Hendricks, AM (corresponding author), VA Boston Healthcare Syst, 150 S Huntington Ave,152 H, Boston, MA 02130 USA.	ahendricksphd@gmail.com	; Pogoda, Terri/F-6243-2012	Krengel, Maxine/0000-0001-7632-590X; Charns, Martin/0000-0002-7102-5331; Kimerling, Rachel/0000-0003-0996-4212; Pogoda, Terri/0000-0003-1397-8780	Office of Research and Development, Health Services R&D Service, Department of Veterans AffairsUS Department of Veterans Affairs [SDR 08-405]	This paper is based on work supported by the Office of Research and Development, Health Services R&D Service, Department of Veterans Affairs, through SDR 08-405. The opinions expressed in this article are the authors' and do not reflect those of the Department of Veterans Affairs, the Veterans Health Administration, Health Services Research and Development, the Defense and Veterans Brain Injury Center or the Department of Defense. We thank Douglas Bidelspach, David Cifu, Carlos Tun and three anonymous reviewers for comments on prior versions of this paper.	Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Committee on Gulf War and Health, 2008, BRAIN INJ VET LONG T, V7; Department of Defense, NUMBERS TRAUMATIC BR; Department of Veterans Affairs, 2011, VA ANN BUDG REQ FY 2; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU, P32; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Golding H, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0081; Hendricks A, 2012, PTSD MILD TRAUMATIC, P260; Hendricks A, 2011, HSR D 2011 NAT M WAS; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kupersmith J, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0079; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2007, AM J PHYS MED REHAB, V86, P1035, DOI 10.1097/01.phm.0000297446.70510.d4; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lew HL, 2007, J REHABILITATION RES, V44, P179; Lew HL, 2006, ARCH PHYS MED REHAB, V87, pe6; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Office of Rehabilitation Services Veterans Health Administration, 2010, STAT COMPR TBI EV; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pogoda TK, 2009, AM J PHYS MED REHAB, V88, P1043, DOI 10.1097/PHM.0b013e3181c1eef5; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; U.S. Government Accountability Office, 2008, 08276 GAO; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	41	38	38	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2013	27	2					125	134		10.3109/02699052.2012.729284			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	083PX	WOS:000314478500001	23384211				2021-06-18	
J	Namjoshi, DR; Martin, G; Donkin, J; Wilkinson, A; Stukas, S; Fan, JJ; Carr, M; Tabarestani, S; Wuerth, K; Hancock, REW; Wellington, CL				Namjoshi, Dhananjay R.; Martin, Georgina; Donkin, James; Wilkinson, Anna; Stukas, Sophie; Fan, Jianjia; Carr, Michael; Tabarestani, Sepideh; Wuerth, Kelli; Hancock, Robert E. W.; Wellington, Cheryl L.			The Liver X Receptor Agonist GW3965 Improves Recovery from Mild Repetitive Traumatic Brain Injury in Mice Partly through Apolipoprotein E	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; AXONAL INJURY; HEAD-INJURY; AMYLOID DEPOSITION; E POLYMORPHISM; MOUSE MODEL; LIPOPROTEIN PARTICLES; APP23 MICE	Traumatic brain injury (TBI) increases Alzheimer's disease (AD) risk and leads to the deposition of neurofibrillary tangles and amyloid deposits similar to those found in AD. Agonists of Liver X receptors (LXRs), which regulate the expression of many genes involved in lipid homeostasis and inflammation, improve cognition and reduce neuropathology in AD mice. One pathway by which LXR agonists exert their beneficial effects is through ATP-binding cassette transporter A1 (ABCA1)-mediated lipid transport onto apolipoprotein E (apoE). To test the therapeutic utility of this pathway for TBI, we subjected male wild-type (WT) and apoE(-/-) mice to mild repetitive traumatic brain injury (mrTBI) followed by treatment with vehicle or the LXR agonist GW3965 at 15 mg/kg/day. GW3965 treatment restored impaired novel object recognition memory in WT but not apoE(-/-) mice. GW3965 did not significantly enhance the spontaneous recovery of motor deficits observed in all groups. Total soluble A beta(40) and A beta(42) levels were significantly elevated in WT and apoE(-/-) mice after injury, a response that was suppressed by GW3965 in both genotypes. WT mice showed mild but significant axonal damage at 2 d post-mrTBI, which was suppressed by GW3965. In contrast, apoE(-/-) mice showed severe axonal damage from 2 to 14 d after mrTBI that was unresponsive to GW3965. Because our mrTBI model does not produce significant inflammation, the beneficial effects of GW3965 we observed are unlikely to be related to reduced inflammation. Rather, our results suggest that both apoE-dependent and apoE-independent pathways contribute to the ability of GW3965 to promote recovery from mrTBI.	[Namjoshi, Dhananjay R.; Martin, Georgina; Donkin, James; Wilkinson, Anna; Stukas, Sophie; Fan, Jianjia; Carr, Michael; Tabarestani, Sepideh; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Wuerth, Kelli; Hancock, Robert E. W.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada	Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.	cheryl@cmmt.ubc.ca	Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Stukas, Sophie/0000-0001-8819-8821; Wuerth, Kelli/0000-0001-5260-9166; Namjoshi, Dhananjay/0000-0003-1753-5581	operating grant from the Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP 67088]; Alzheimer Society Research Program (ASRP, Alzheimer Society of Canada) doctoral award; ASRP post-doctoral award; CIHR Vanier studentshipCanadian Institutes of Health Research (CIHR); Child & Family Research Institute studentship	This work was supported by an operating grant (MOP 67088) to C.L.W. from the Canadian Institutes of Health Research (CIHR). D.R.N. was supported by Alzheimer Society Research Program (ASRP, Alzheimer Society of Canada) doctoral award. J.D. was supported by an ASRP post-doctoral award. S.S. was supported by a CIHR Vanier studentship. J.F. was supported by a Child & Family Research Institute studentship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeCuypere M, 2012, SURG CLIN N AM, V92, P939, DOI 10.1016/j.suc.2012.04.005; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Donkin JJ, 2010, J BIOL CHEM, V285, P34144, DOI 10.1074/jbc.M110.108100; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fitz NF, 2010, J NEUROSCI, V30, P6862, DOI 10.1523/JNEUROSCI.1051-10.2010; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Groot PHE, 2005, J LIPID RES, V46, P2182, DOI 10.1194/jlr.M500116-JLR200; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iwata A, 2005, J NEUROSCI RES, V82, P103, DOI 10.1002/jnr.20607; Jamroz-Wisniewska Anna, 2007, Postepy Hig Med Dosw (Online), V61, P760; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; May S, 2011, J NEUROLOGY NEUROSCI, V2, P1; Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450-JLR200; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Petit-Turcotte C, 2007, NEUROSCIENCE, V150, P58, DOI 10.1016/j.neuroscience.2007.05.021; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Riddell DR, 2007, MOL CELL NEUROSCI, V34, P621, DOI 10.1016/j.mcn.2007.01.011; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wahrle SE, 2008, J CLIN INVEST, V118, P671, DOI 10.1172/JCI33622; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wojcicka Grazyna, 2007, Postepy Hig Med Dosw (Online), V61, P736; Zelcer N, 2007, P NATL ACAD SCI USA, V104, P10601, DOI 10.1073/pnas.0701096104; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	68	38	39	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2013	8	1							e53529	10.1371/journal.pone.0053529			14	Multidisciplinary Sciences	Science & Technology - Other Topics	073JI	WOS:000313738900009	23349715	DOAJ Gold, Green Published			2021-06-18	
J	Brenner, LA; Homaifar, BY; Olson-Madden, JH; Nagamoto, HT; Huggins, J; Schneider, AL; Forster, JE; Matarazzo, B; Corrigan, JD				Brenner, Lisa A.; Homaifar, Beeta Y.; Olson-Madden, Jennifer H.; Nagamoto, Herbert T.; Huggins, Joe; Schneider, Alexandra L.; Forster, Jeri E.; Matarazzo, Bridget; Corrigan, John D.			Prevalence and Screening of Traumatic Brain Injury Among Veterans Seeking Mental Health Services	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mental health; screening; sensitivity; specificity; traumatic brain injury; Veterans	IDENTIFICATION; RELIABILITY; VALIDITY; TBI; INDIVIDUALS	Objectives: To assess the prevalence of traumatic brain injury (TBI) among Veterans seeking mental health services using a 4-item tool, the Traumatic Brain Injury-4 (TBI-4), and to establish the classification accuracy of the TBI-4 using the Ohio State University TBI-Identification Method as the criterion standard. Study Design: Archival and observational data collected from individuals seeking care at a Mountain State VA Medical Center. Participants: The sample for the archival study was 1810. Three hundred sixteen Veterans completed observational study measures. Main Measures: For the archival study, TBI-4 and demographic data extracted from electronic medical records. For the observational study, the Ohio State University TBI-Identification Method and a demographic questionnaire were used. TBI-4 data were also obtained from electronic medical records. Results: The prevalence of probable TBI among those seeking VA MH treatment was 45%. Sensitivity and specificity of the TBI-4 were 0.74 and 0.56, respectively. Veterans with all levels of TBI severity sought care within this VA mental health setting. Conclusions: The prevalence of TBI in this VA mental health treatment population was higher than expected. Additional research is required to assess the clinical utility of screening for TBI among this population of Veterans.	[Brenner, Lisa A.; Homaifar, Beeta Y.; Olson-Madden, Jennifer H.; Nagamoto, Herbert T.; Huggins, Joe; Schneider, Alexandra L.; Forster, Jeri E.; Matarazzo, Bridget] VA VISN 19 Mental Illness Res Educ & Clin Ctr MIR, Denver, CO USA; [Brenner, Lisa A.; Olson-Madden, Jennifer H.; Nagamoto, Herbert T.; Matarazzo, Bridget] Univ Colorado Denver, Sch Med, Dept Psychiat, Aurora, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Neurol, Aurora, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Forster, Jeri E.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA; [Homaifar, Beeta Y.] VA Boston Healthcare Syst, Boston, MA USA; [Homaifar, Beeta Y.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA; [Nagamoto, Herbert T.] Eastern Colorado Hlth Care Syst, Vet Affairs Med Ctr, Denver, CO USA; [Forster, Jeri E.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Brenner, LA (corresponding author), VISN 19 Mental Illness Res Educ & Clin Ctr MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019	Huggins, Joe/0000-0001-8151-5062	Colorado Traumatic Brain Injury Trust Fund Program	Support for this project was provided by the Colorado Traumatic Brain Injury Trust Fund Program.	Ahmed II, 1998, SEMIN CLIN NEUROPSYC, V3, P23; [Anonymous], 2008, SAS COMP PROGR VERS, V9, P2; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Arciniegas DB, 2010, PSYCHIAT ANN, V40, P540, DOI 10.3928/00485713-20101022-05; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Brenner LA, 2011, 2011 DOD VA ANN SUIC; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Coetzer R, 2009, CNS SPECTRUMS, V14, P632, DOI 10.1017/S1092852900023877; Corrigan JD, 2007, OHIO STATE U TBI IDE; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Department of Veterans Affairs Department of Defense, VA DOD CLIN PRACT GU; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; GIZLICE Z, 2002, HLTH CONDITIONS BEHA; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; McFall RM, 1999, ANNU REV PSYCHOL, V50, P215, DOI 10.1146/annurev.psych.50.1.215; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Office of Applied Studies, 2005, ALC US ALC REL RISK; Olson-Madden JH, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/174579; Olson-Madden JH, 2010, J HEAD TRAUMA REHAB, V25, P470, DOI 10.1097/HTR.0b013e3181d717a7; Pepe MS, 2003, STAT EVALUATION MED; Streiner DL, 2003, J PERS ASSESS, V81, P209, DOI 10.1207/S15327752JPA8103_03; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *US DEP HHS, HEADS FACTS PHYS MIL; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P82; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50	31	38	38	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					21	30		10.1097/HTR.0b013e31827df0b5			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400003	23288308				2021-06-18	
J	Grujicic, M; Yavari, R; Snipes, JS; Ramaswami, S; Runt, J; Tarter, J; Dillon, G				Grujicic, M.; Yavari, R.; Snipes, J. S.; Ramaswami, S.; Runt, J.; Tarter, J.; Dillon, G.			Molecular-level computational investigation of shock-wave mitigation capability of polyurea	JOURNAL OF MATERIALS SCIENCE			English	Article							MATERIAL MODEL; DEFORMATION; TRANSITION; DYNAMICS; GLASS	Various static and (equilibrium and non-equilibrium) dynamic molecular-level computational methods and tools are utilized in order to investigate the basic shock-wave physics and shock-wave material interactions in polyurea (a nano-phase segregated elastomeric co-polymer). The main goal of this investigation was to establish relationships between the nano-segregated polyurea microstructure (consisting of rod-shaped, discrete, so-called "hard domains" embedded into a highly compliant, so-called soft matrix) and the experimentally established superior capability of this material to disperse and attenuate resident shock waves (e.g., those generated as a result of blast-wave impact). By analyzing molecular-level interactions of the shock waves with polyurea, an attempt was made to identify and quantify main phenomena and viscous/inelastic deformation and microstructure-altering processes taking place at the shock front, which are most likely responsible for the superior shock-mitigation behavior of polyurea. Direct molecular-level simulations of shock-wave generation and propagation in the "strong-shock" regime are utilized in order to construct the appropriate shock-Hugoniot relations (relations which are used in the construction of the associated continuum-level material models). Extension of these relations into the "weak-shock" regime of interest from the traumatic brain injury prevention point of view is also discussed.	[Grujicic, M.; Yavari, R.; Snipes, J. S.; Ramaswami, S.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA; [Runt, J.] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16082 USA; [Tarter, J.; Dillon, G.] Penn State Univ, Appl Res Labs, University Pk, PA 16082 USA	Grujicic, M (corresponding author), Clemson Univ, Dept Mech Engn, 241 Engn Innovat Bldg, Clemson, SC 29634 USA.	gmica@clemson.edu			Office of Naval Research (ONR) through the Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]; Office of Naval Research (ONR) through Army Research Office (ARO) [W911NF-09-1-0513]; Office of Naval Research (ONR) through Army Research Laboratory (ARL) [W911NF-06-2-0042]	The material presented in this paper is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head", Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University, the Army Research Office (ARO) research contract entitled "Multilength Scale Material Model Development for Armor-grade Composites", Contract Number W911NF-09-1-0513, and the Army Research Laboratory (ARL) research contract entitled "Computational Analysis and Modeling of Various Phenomena Accompanying Detonation Explosives Shallow-Buried in Soil" Contract Number W911NF-06-2-0042. The authors are indebted to Drs. Roshdy Barsoum of ONR and Larry C. Russell, Jr. of ARO for their continuing support and interest in this study.	Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; Arman B, 2012, MACROMOLECULES, V45, P3247, DOI 10.1021/ma3001934; Bogoslovov RB, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2745212; Castagna AM, 2012, MACROMOLECULES UNPUB; Choi T, 2012, MACROMOLECULES, V45, P3581, DOI 10.1021/ma300128d; Davison L, 2008, SHOCK WAVE HIGH PRES, P1; Grujicic A, 2012, J MATER ENG PERFORM, V21, P1562, DOI 10.1007/s11665-011-0065-3; Grujicic M, 2008, SOIL DYN EARTHQ ENG, V28, P20, DOI 10.1016/j.soildyn.2007.05.001; Grujicic M, 2004, MAT SCI ENG B-SOLID, V107, P204, DOI 10.1016/j.mseb.2003.11.012; Grujicic M, 2011, MULTIDISCIP MODEL MA, V7, P96, DOI 10.1108/15736101111157064; Grujicic M, 2012, MATER DESIGN, V35, P144, DOI 10.1016/j.matdes.2011.08.031; Grujicic M, 2011, J MATER SCI, V46, P7298, DOI 10.1007/s10853-011-5691-5; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Grujicic M, 2012, J MATER ENG PERFORM, V21, P2, DOI 10.1007/s11665-011-9875-6; Grujicic M, 2011, MAT SCI ENG A-STRUCT, V528, P3799, DOI 10.1016/j.msea.2011.01.081; Grujicic M, 2010, MAT SCI ENG A-STRUCT, V527, P7741, DOI 10.1016/j.msea.2010.08.042; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2007, MULTIDISCIP MODEL MA, V3, P287, DOI 10.1163/157361107781389562; Grujicic M, 2009, APPL SURF SCI, V253; Grujicic M, 2012, MULTIDISCIP MODEL MA, V8; Grujicic M, 2011, J MATER SCI, V46, P1767, DOI 10.1007/s10853-010-4998-y; HOLIAN BL, 1979, PHYS REV LETT, V43, P1598, DOI 10.1103/PhysRevLett.43.1598; HOLIAN BL, 1980, PHYS REV A, V22, P2798, DOI 10.1103/PhysRevA.22.2798; Mock W, 2009, AIP CONF PROC, V1195, P1241; Qiao J, 2011, MECH MATER, V43, P598, DOI 10.1016/j.mechmat.2011.06.012; Runt J, 2012, IN PRESS; Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v; THEODOROU DN, 1986, MACROMOLECULES, V19, P139, DOI 10.1021/ma00155a022	28	38	38	0	62	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-2461	1573-4803		J MATER SCI	J. Mater. Sci.	DEC	2012	47	23					8197	8215		10.1007/s10853-012-6716-4			19	Materials Science, Multidisciplinary	Materials Science	005BX	WOS:000308726500027					2021-06-18	
J	Li, HF; Graber, KD; Jin, S; McDonald, W; Barres, BA; Prince, DA				Li, Huifang; Graber, Kevin D.; Jin, Sha; McDonald, Whitney; Barres, Ben A.; Prince, David A.			Gabapentin decreases epileptiform discharges in a chronic model of neocortical trauma	NEUROBIOLOGY OF DISEASE			English	Article						Gabapentin; Posttraumatic epileptiform activity; Synapse formation; EPSCs; GFAP; Gliosis; Neocortex; TSPs; Alpha2delta1 subunit; Fluoro-Jade C	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CALCIUM-CHANNEL SUBUNIT; V PYRAMIDAL NEURONS; FLUORO-JADE; SYNAPTIC REORGANIZATION; POSTTRAUMATIC SEIZURES; NEUROPATHIC PAIN; UP-REGULATION; BRAIN-INJURY; CA2+ INFLUX	Gabapentin (GBP) is an anticonvulsant that acts at the alpha 2 delta-1 submit of the L-type calcium channel. It is recently reported that GBP is a potent inhibitor of thrombospondin (TSP)-induced excitatory synapse formation in vitro and in vivo. Here we studied effects of chronic GBP administration on epileptogenesis in the partial cortical isolation ("undercut") model of posttraumatic epilepsy, in which abnormal axonal sprouting and aberrant synaptogenesis contribute to occurrence of epileptiform discharges. Results showed that 1) the incidence of evoked epileptiform discharges in undercut cortical slices studied 1 day or similar to 2 weeks after the last GBP dose, was significantly reduced by GBP treatments, beginning on the day of injury; 2) the expression of GFAP and TSP1 protein, as well as the number of FJC stained cells was decreased in GBP treated undercut animals; 3) in vivo GBP treatment of rats with undercuts for 3 or 7 days decreased the density of vGlut1-PSD95 close appositions (presumed synapses) in comparison to saline treated controls with similar lesions;4) the electrophysiological data are compatible with the above anatomical changes, showing decreases in mEPSC and sEPSC frequency in the GBP treated animals. These results indicate that chronic administration of GBP after cortical injury is antiepileptogenic in the undercut model of post-traumatic epilepsy, perhaps by both neuroprotective actions and decreases in excitatory synapse formation. The findings may suggest the potential use of GBP as an antiepileptogenic agent following traumatic brain injury. (c) 2012 Elsevier Inc. All rights reserved.	[Li, Huifang; Graber, Kevin D.; Jin, Sha; McDonald, Whitney; Prince, David A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Barres, Ben A.] Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Prince, DA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	daprince@stanford.edu	Ritter, Stefanie L/D-9312-2012		Citizens United for Research in Epilepsy (CURE); NIH from the NINDS [NS12151]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012151, P01NS012151, R01NS006477] Funding Source: NIH RePORTER	The work was supported by a grant from the Citizens United for Research in Epilepsy (CURE) and NIH grant NS12151 from the NINDS. We thank Dr. Richard Reimer for providing vGluR1 antibody, and Isabel Parada for providing images of Fig. 4C, D, E and F. Cagla Eroglu provided valuable advice during the course of these experiments.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BABB TL, 1992, DENDRON, V1, P7; Bauer CS, 2009, J NEUROSCI, V29, P4076, DOI 10.1523/JNEUROSCI.0356-09.2009; Baydas G, 2005, ACTA PHARMACOL SIN, V26, P417, DOI 10.1111/j.1745-7254.2005.00072.x; Bayer K, 2004, NEUROPHARMACOLOGY, V46, P743, DOI 10.1016/j.neuropharm.2003.11.010; Bertrand S, 2003, SYNAPSE, V50, P95, DOI 10.1002/syn.10247; Calabresi P, 2000, STROKE, V31, P766, DOI 10.1161/01.STR.31.3.766; Carmichael ST, 2002, J NEUROSCI, V22, P6062; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Comi A.M., 2008, PEDIATR RES, V64, P81; Cunningham MO, 2004, EUR J NEUROSCI, V20, P1566, DOI 10.1111/j.1460-9568.2004.03625.x; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005; ECHLIN FA, 1959, ELECTROEN CLIN NEURO, V11, P697, DOI 10.1016/0013-4694(59)90110-5; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.3.CO;2-H; Emmez H, 2010, WORLD NEUROSURG, V73, P729, DOI 10.1016/j.wneu.2010.04.008; Eroglu C, 2009, J CELL COMMUN SIGNAL, V3, P167, DOI 10.1007/s12079-009-0078-y; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Faria LC, 2010, J NEUROPHYSIOL, V104, P280, DOI 10.1152/jn.00351.2010; Field MJ, 2006, P NATL ACAD SCI USA, V103, P17537, DOI 10.1073/pnas.0409066103; Fink K, 2000, BRIT J PHARMACOL, V130, P900, DOI 10.1038/sj.bjp.0703380; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Hendrich J, 2008, P NATL ACAD SCI USA, V105, P3628, DOI 10.1073/pnas.0708930105; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Ide CF, 1996, PROG BRAIN RES, V108, P365, DOI 10.1016/S0079-6123(08)62552-2; ISOKAWA M, 1993, J NEUROSCI, V13, P1511, DOI 10.1523/jneurosci.13-04-01511.1993; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kale A, 2011, J NEUROSURG-SPINE, V15, P228, DOI 10.3171/2011.4.SPINE10583; Kato AS, 2007, CURR OPIN DRUG DISC, V10, P565; Kim YS, 2009, J PHARMACOL SCI, V109, P144, DOI 10.1254/jphs.08067SC; KORN H, 1987, P NATL ACAD SCI USA, V84, P5981, DOI 10.1073/pnas.84.16.5981; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lagreze WA, 2001, GRAEF ARCH CLIN EXP, V239, P845, DOI 10.1007/s00417-001-0383-5; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li CY, 2006, PAIN, V125, P20, DOI 10.1016/j.pain.2006.04.022; Li H., 2009, ANN EP SOC ABSTR; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Liu Y, 2006, EPILEPSY RES, V70, P263, DOI 10.1016/j.eplepsyres.2006.03.007; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Maneuf YP, 2006, SEMIN CELL DEV BIOL, V17, P565, DOI 10.1016/j.semcdb.2006.09.003; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; MASUKAWA LM, 1992, BRAIN RES, V579, P119, DOI 10.1016/0006-8993(92)90750-4; Matoth I, 2000, NEUROSCI RES, V38, P209, DOI 10.1016/S0168-0102(00)00127-9; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Ng GYK, 2001, MOL PHARMACOL, V59, P144; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Prince D.A., 2012, JASPERS BASIC MECH E, P315; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RADULOVIC LL, 1995, DRUG METAB DISPOS, V23, P441; ROTHSTEIN JD, 1995, J NEUROCHEM, V65, P643; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Staley Kevin J, 2006, Epilepsy Curr, V6, P199, DOI 10.1111/j.1535-7511.2006.00145.x; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Stewart TH, 2010, J NEUROPHYSIOL, V104, P3345, DOI 10.1152/jn.00398.2010; Striano P, 2008, DRUG TODAY, V44, P353, DOI 10.1358/dot.2008.44.5.1186403; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; SUTOR B, 1995, PERSPECT DEV NEUROBI, V2, P409; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Traa BS, 2008, PEDIATR RES, V64, P81, DOI 10.1203/PDR.0b013e318174e70e; TSENG GF, 1993, J COMP NEUROL, V335, P92, DOI 10.1002/cne.903350107; van Hooft JA, 2002, EUR J PHARMACOL, V449, P221, DOI 10.1016/S0014-2999(02)02044-7; Vega-Hernandez A, 2002, CELL MOL NEUROBIOL, V22, P185, DOI 10.1023/A:1019865822069; VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830; Wang L, 2008, BRAIN RES, V1241, P157, DOI 10.1016/j.brainres.2008.07.097; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, CHILD BRAIN, V10, P185	94	38	40	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2012	48	3					429	438		10.1016/j.nbd.2012.06.019			10	Neurosciences	Neurosciences & Neurology	018VG	WOS:000309694000017	22766033	Green Accepted			2021-06-18	
J	Schoknecht, K; Shalev, H				Schoknecht, Karl; Shalev, Hadar			Blood-brain barrier dysfunction in brain diseases: Clinical experience	EPILEPSIA			English	Article						Blood-brain barrier; Epilepsy; Stroke; Traumatic brain injury; Schizophrenia	ACUTE ISCHEMIC-STROKE; TEMPORAL-LOBE EPILEPSY; SERUM S100B LEVELS; THROMBOLYTIC THERAPY; MAJOR DEPRESSION; HEMORRHAGIC TRANSFORMATION; SCHIZOPHRENIC-PATIENTS; S100-BETA PROTEIN; RISK-FACTORS; INJURY	The bloodbrain barrier, a unique feature of the cerebral vasculature, is gaining attention as a feature in common neurologic disorders including stroke, traumatic brain injury, epilepsy, and schizophrenia. Although acute bloodbrain barrier dysfunction can induce cerebral edema, seizures, or neuropsychiatric symptoms, epileptogenesis and cognitive decline are among the chronic effects. The mechanisms underlying bloodbrain barrier dysfunction are diverse and may range from physical endothelial damage in traumatic brain injury to degradation of extracellular matrix proteins via matrix metalloproteinases as part of an inflammatory response. Clinically, bloodbrain barrier dysfunction is often detected using contrast-enhanced imaging. However, these techniques do not give any insights into the underlying mechanism. Elucidating the specific pathways of bloodbrain barrier dysfunction at different time points and in different brain diseases using novel imaging techniques promises a more accurate bloodbrain barrier terminology as well as new treatment options and personalized treatment.	[Schoknecht, Karl] Charite, Inst Neurophysiol, D-13347 Berlin, Germany; [Shalev, Hadar] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Psychiat, IL-84105 Beer Sheva, Israel; [Shalev, Hadar] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Schoknecht, K (corresponding author), Charite, Inst Neurophysiol, Oudenarder St 16, D-13347 Berlin, Germany.	karl.schoknecht@charite.de					Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Arolt V, 2003, EUR NEUROPSYCHOPHARM, V13, P235, DOI 10.1016/S0924-977X(03)00016-6; Austinat M, 2009, STROKE, V28, P5; Balami JS, 2011, LANCET NEUROL, V10, P357, DOI 10.1016/S1474-4422(10)70313-6; Beer C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-71; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Castellanos M, 2007, STROKE, V38, P1855, DOI 10.1161/STROKEAHA.106.481556; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dassan P, 2009, CEREBROVASC DIS, V27, P295, DOI 10.1159/000199468; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; de Klerk OL, 2010, PSYCHIAT RES-NEUROIM, V183, P151, DOI 10.1016/j.pscychresns.2010.05.002; Esposito G, 2006, LIFE SCI, V78, P2707, DOI 10.1016/j.lfs.2005.10.023; Gama CS, 2006, PROG NEURO-PSYCHOPH, V30, P512, DOI 10.1016/j.pnpbp.2005.11.009; Gattaz WF, 2000, SCHIZOPHR RES, V43, P91, DOI 10.1016/S0920-9964(99)00146-2; Gorelick PB, 2004, STROKE, V35, P2620, DOI 10.1161/01.STR.0000143318.70292.47; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Hanson DR, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-7; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Herman ST, 2011, NEUROLOGY, V77, P1776, DOI 10.1212/WNL.0b013e31823b4e73; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Ivens S, 2010, J NEUROL, V257, P615, DOI 10.1007/s00415-009-5384-z; Jang BS, 2008, PSYCHIAT INVEST, V5, P193, DOI 10.4306/pi.2008.5.3.193; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kim SY, 2012, EPILEPSIA, V53, P37, DOI 10.1111/j.1528-1167.2012.03701.x; Kumar S, 2010, LANCET NEUROL, V9, P105, DOI 10.1016/S1474-4422(09)70266-2; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Levi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039636; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018200; Marchi N, 2010, BRAIN RES, V1353, P176, DOI 10.1016/j.brainres.2010.06.051; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; MULLER N, 1995, SCHIZOPHR RES, V14, P223, DOI 10.1016/0920-9964(94)00045-A; Neumann-Haefelin C, 2002, STROKE, V33, P1392, DOI 10.1161/01.STR.0000014619.59851.65; Pascoe MC, 2011, INT J STROKE, V6, P128, DOI 10.1111/j.1747-4949.2010.00565.x; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rothermundt M, 2004, NEUROPSYCHOPHARMACOL, V29, P1004, DOI 10.1038/sj.npp.1300403; Rothermundt M, 2009, GEN PHYSIOL BIOPHYS, V28, pF76; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052-200304000-00008; Sarandol A, 2007, PROG NEURO-PSYCHOPH, V31, P1164, DOI 10.1016/j.pnpbp.2007.03.008; Schroeter ML, 2008, J AFFECT DISORDERS, V111, P271, DOI 10.1016/j.jad.2008.03.005; Schroeter ML, 2002, NEUROREPORT, V13, P1675, DOI 10.1097/00001756-200209160-00021; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shalev H., 2009, CARDIOVASC PSYCHIAT, V2009, P27853, DOI [10.1155/2009/278531, DOI 10.1155/2009/278531]; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Slot KB, 2009, STROKE, V40, P1585, DOI 10.1161/STROKEAHA.108.531533; Sotgiu S, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-84; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Sutcigil L, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/76396; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vezzani A, 2008, EPILEPSIA, V49, P24, DOI 10.1111/j.1528-1167.2008.01490.x; Warach S, 2004, STROKE, V35, P2659, DOI 10.1161/01.STR.0000144051.32131.09; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; Wunder A, 2012, EPILEPSIA, V53, P14, DOI 10.1111/j.1528-1167.2012.03698.x; Yang Y, 2011, STROKE, V332, P3; Zhang XY, 2010, J PSYCHIATR RES, V44, P1236, DOI 10.1016/j.jpsychires.2010.04.023	72	38	39	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2012	53			6	SI		7	13		10.1111/j.1528-1167.2012.03697.x			7	Clinical Neurology	Neurosciences & Neurology	033LI	WOS:000310797400002	23134490	Bronze			2021-06-18	
J	Gallaway, MS; Fink, DS; Millikan, AM; Bell, MR				Gallaway, Michael Shayne; Fink, David S.; Millikan, Amy M.; Bell, Michael R.			Factors Associated With Physical Aggression Among US Army Soldiers	AGGRESSIVE BEHAVIOR			English	Article						aggression; military; deployment; combat	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; INTIMATE PARTNER VIOLENCE; AFGHANISTAN WAR VETERANS; COMBAT VETERANS; ALCOHOL-PROBLEMS; SPOUSE ABUSE; IRAQ WAR; DEPLOYMENT; MILITARY	There are a growing number of studies that have approximated levels of aggression and associated outcomes among combat veterans returning from Iraq and Afghanistan using brief screening assessments. However, further research to evaluate the relative role of combat exposures and overt physical behaviors is required to further elucidate potential associations between military service, combat deployment, and overt physical aggression. The purpose of the current study was to assess the prevalence of self-reported physical aggression in a sample of US Army soldiers using an adaptation of the Revised Conflict Tactics Scale (CTS2), and examine factors associated with higher levels of aggression. A population-based cross-sectional study was conducted at a single US Army Installation within a sample of active duty US Army soldiers (n = 6,128) from two large units. Anonymous surveys were collected 6 months following deployment to measure overt aggressive behaviors, posttraumatic stress disorder, anxiety, depression, traumatic brain injury, and misuse of alcohol. There were a relatively higher number of minor and severe physical overt aggressive actions reported among soldiers who previously deployed, notably highest among deployed soldiers reporting the highest levels of combat intensity. Soldiers screening positive for the misuse of alcohol were also significantly more likely to report relatively higher levels of physical aggression. This study quantified overt aggressive behaviors and associated factors, showing increasing combat exposures may result in increased physical aggression. Clinicians treating service members returning from combat may consider assessing relative levels of combat. Aggr. Behav. 38:357-367, 2012. Published 2012 Wiley Periodicals, Inc.	[Gallaway, Michael Shayne; Fink, David S.; Millikan, Amy M.] USA, BSHOP, Inst Publ Hlth, Publ Hlth Command, Aberdeen Proving Ground, MD 21010 USA; [Bell, Michael R.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Gallaway, MS (corresponding author), USA, BSHOP, Inst Publ Hlth, Publ Hlth Command, Aberdeen Proving Ground, MD 21010 USA.	shayne.gallaway@us.army.mil	Fink, David S./F-1634-2014	Fink, David S./0000-0003-1531-1525			Acierno R., 2000, SCREENING MEASURES D; Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Bell NS, 2006, ALCOHOL CLIN EXP RES, V30, P1721, DOI 10.1111/j.1530-0277.2006.00214.x; Bell NS, 2004, ALCOHOL CLIN EXP RES, V28, P1890, DOI 10.1097/01.ALC.0000148102.89841.9B; Bohannon J R, 1995, Violence Vict, V10, P133; Booth-Kewley S, 2010, AGGRESSIVE BEHAV, V36, P330, DOI 10.1002/ab.20355; Bulmer M. G., 1979, PRINCIPLES STAT; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Cherpitel CJ, 2002, ALCOHOL CLIN EXP RES, V26, P1686, DOI 10.1097/01.ALC.0000036300.26619.78; Elbogen EB, 2010, AM J PSYCHIAT, V167, P1051, DOI 10.1176/appi.ajp.2010.09050739; Foran HM, 2011, J CONSULT CLIN PSYCH, V79, P391, DOI 10.1037/a0022962; Forgey MA, 2006, J FAM VIOLENCE, V21, P369, DOI 10.1007/s10896-006-9033-3; Freeman TW, 2001, J NERV MENT DIS, V189, P317, DOI 10.1097/00005053-200105000-00008; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Heyman RE, 1999, J CONSULT CLIN PSYCH, V67, P239, DOI 10.1037/0022-006X.67.2.239; Hodge J.G., 2004, PUBLIC HLTH PRACTICE; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hufmann A.H, 2000, INT REV ARMED FORCES, V73, P191; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Martin C. B., 2007, MSMR MED SURVEILLANC, V14, P2; Millikan AM, 2008, 14HKOB1U09 EP CONS; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Newby JH, 2005, MIL MED, V170, P643, DOI 10.7205/MILMED.170.8.643; Office of the Surgeon General United States Army Medical Command & Office of the Command Surgeon HQ US-CENTCOM & Office of the Command Surgeon US Forces Afghanistan (USFOR-A), 2011, JOINT MENT HLTH ADV; Richardson, 1994, HUMAN AGGRESSION; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Slep AMS, 2010, J COMMUN HEALTH, V35, P375, DOI 10.1007/s10900-010-9264-3; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sontag D., 2008, WAR TORN 1; Straus M.A., 2003, CONFLICT TACTICS SCA; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1999, AM SOC CRIM TOR ONT; Taft CT, 2007, J FAM PSYCHOL, V21, P270, DOI 10.1037/0893-3200.21.2.270; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; US Department of Health and Human Services National Institute of Health (NIH), 2003, NAT I HLTH NIH PUBL; Zoricic Z, 2003, EUR J PSYCHIAT, V17, P243	40	38	40	0	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0096-140X			AGGRESSIVE BEHAV	Aggressive Behav.	SEP-OCT	2012	38	5					357	367		10.1002/ab.21436			11	Behavioral Sciences; Psychology, Multidisciplinary	Behavioral Sciences; Psychology	989MP	WOS:000307564500003	22898873				2021-06-18	
J	Smith, BA; Xie, BW; van Beek, ER; Que, I; Blankevoort, V; Xiao, SZ; Cole, EL; Hoehn, M; Kaijzel, EL; Lowik, CWGM; Smith, BD				Smith, Bryan A.; Xie, Bang-Wen; van Beek, Ermond R.; Que, Ivo; Blankevoort, Vicky; Xiao, Shuzhang; Cole, Erin L.; Hoehn, Mathias; Kaijzel, Eric L.; Lowik, Clemens W. G. M.; Smith, Bradley D.			Multicolor Fluorescence Imaging of Traumatic Brain Injury in a Cryolesion Mouse Model	ACS CHEMICAL NEUROSCIENCE			English	Article						Traumatic brain injury; multicolor fluorescence imaging; cell death imaging; blood-brain-barrier; annexin V; zinc(II)-dipicolylamine	IN-VIVO; BARRIER PERMEABILITY; MOLECULAR PROBE; REAL-TIME; APOPTOSIS; MICE; PHOSPHATIDYLSERINE; RECOGNITION; DISRUPTION; INFECTION	Traumatic brain injury is characterized by initial tissue damage, which then can lead to secondary processes such as cell death and blood-brain-barrier disruption. Clinical and preclinical studies of traumatic brain injury typically employ anatomical imaging techniques and there is a need for new molecular imaging methods that provide complementary biochemical information. Here, we assess the ability of a targeted, near-infrared fluorescent probe, named PSS-794, to detect cell death in a brain cryolesion mouse model that replicates certain features of traumatic brain injury. In short, the model involves brief contact of a cold rod to the head of a living, anesthetized mouse. Using noninvasive whole-body fluorescence imaging, PSS-794 permitted visualization of the cryolesion in the living animal. Ex vivo imaging and histological analysis confirmed PSS-794 localization to site of brain cell death. The nontargeted, deep-red Tracer-653 was validated as a tracer dye for monitoring blood-brain-barrier disruption, and a binary mixture of PSS-794 and Tracer-653 was employed for multicolor imaging of cell death and blood-brain-barrier permeability in a single animal. The imaging data indicates that at 3 days after brain cryoinjury the amount of cell death had decreased significantly, but the integrity of the blood-brain-barrier was still impaired; at 7 days, the blood-brain-barrier was still three times more permeable than before cryoinjury.	[Xie, Bang-Wen; van Beek, Ermond R.; Que, Ivo; Blankevoort, Vicky; Kaijzel, Eric L.; Lowik, Clemens W. G. M.] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Netherlands; [Smith, Bryan A.; Xiao, Shuzhang; Cole, Erin L.; Smith, Bradley D.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Hoehn, Mathias] Max Planck Inst Neurol Res, D-50931 Cologne, Germany	Lowik, CWGM (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	c.w.g.m.lowik@lumc.nl; smith.115@nd.edu		Kaijzel, Eric/0000-0003-3118-9910	Center for Translational Molecular Medicine, project MUSIS [03O-202]; NIH GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01GM059078, T32GM075762]; Volkswagen Grant [183443]; ENCITE project [201842]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM059078, T32GM075762] Funding Source: NIH RePORTER	This study was supported by the Center for Translational Molecular Medicine, project MUSIS (Grant 03O-202); NIH Grants R01GM059078 (B.D.S.) and T32GM075762 (B.A.S.), Volkswagen Grant 183443, and the ENCITE project 201842.	Abulrob A, 2008, MOL IMAGING, V7, P248, DOI 10.2310/7290.2008.00025; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Bahamni P., 2011, J CEREB BLOOD FLOW M, V31, P1311; Beekman CAC, 2011, APPL RADIAT ISOTOPES, V69, P656, DOI 10.1016/j.apradiso.2010.12.012; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Blankenberg FG, 2008, J NUCL MED, V49, p81S, DOI 10.2967/jnumed.107.045898; Burtea C, 2009, MOL PHARMACEUT, V6, P1903, DOI 10.1021/mp900106m; Chapon C, 2009, MAGN RESON MATER PHY, V22, P167, DOI 10.1007/s10334-008-0161-z; Cole E. L., 2011, ORG BIOMOL CHEM, DOI 10/1039/c20606783h; del Valle J, 2008, J NEUROSCI METH, V174, P42, DOI 10.1016/j.jneumeth.2008.06.025; Eriskat J, 2003, ACTA NEUROCHIR SUPPL, V86, P265; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hanshaw RG, 2005, BIOORGAN MED CHEM, V13, P5035, DOI 10.1016/j.bmc.2005.04.071; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kobayashi H, 2007, NANO LETT, V7, P1711, DOI 10.1021/nl0707003; Kosaka N, 2009, J INVEST DERMATOL, V129, P2818, DOI 10.1038/jid.2009.161; Leblond F, 2010, J PHOTOCH PHOTOBIO B, V98, P77, DOI 10.1016/j.jphotobiol.2009.11.007; Lederle W, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-26; Leevy WM, 2006, J AM CHEM SOC, V128, P16476, DOI 10.1021/ja0665592; Lin KJ, 2012, ANN NUCL MED, V26, P272, DOI 10.1007/s12149-012-0571-x; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Mitsunaga M, 2011, CANCER PREV RES, V4, P767, DOI 10.1158/1940-6207.CAPR-10-0334; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Netherlands Inspectorate for Health Protection Commodities and Veterinary Public Health, 1999, COD PRACT AN EXP CAN, P1; Niu G, 2010, J NUCL MED, V51, P1659, DOI 10.2967/jnumed.110.078584; Ntziachristos V, 2004, P NATL ACAD SCI USA, V101, P12294, DOI 10.1073/pnas.0401137101; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; O'Neil EJ, 2006, COORDIN CHEM REV, V250, P3068, DOI 10.1016/j.ccr.2006.04.006; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith BA, 2011, APOPTOSIS, V16, P722, DOI 10.1007/s10495-011-0601-5; Smith BA, 2011, MOL PHARMACEUT, V8, P583, DOI 10.1021/mp100395u; Smith BA, 2010, J AM CHEM SOC, V132, P67, DOI 10.1021/ja908467y; Spaeth N, 2004, J NUCL MED, V45, P1931; Stoffel M, 2004, J NEUROTRAUM, V21, P733, DOI 10.1089/0897715041269678; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderheyden JL, 2006, NUCL MED BIOL, V33, P135, DOI 10.1016/j.nucmedbio.2005.09.002; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson JRF, 2009, EUR J TRAUMA EMERG S, V35, P176, DOI 10.1007/s00068-008-8095-8; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Xiong CY, 2011, J MED CHEM, V54, P1825, DOI 10.1021/jm101477d; Yamamoto N, 2011, INT J CLIN ONCOL, V16, P84, DOI 10.1007/s10147-011-0201-y; Yang M, 2007, CANCER RES, V67, P5195, DOI 10.1158/0008-5472.CAN-06-4590; Zhao M, 2009, ANTI-CANCER AGENT ME, V9, P1018, DOI 10.2174/187152009789377691; Zheng H, 2011, J AM CHEM SOC, V133, P15280, DOI 10.1021/ja205911n	51	38	38	0	30	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	JUL	2012	3	7					530	537		10.1021/cn3000197			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	975VO	WOS:000306539800006	22860222	Green Published			2021-06-18	
J	Yuan, F; Ding, J; Chen, H; Guo, Y; Wang, G; Gao, WW; Chen, SW; Tian, HL				Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li			Predicting outcomes after traumatic brain injury: The development and validation of prognostic models based on admission characteristics	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Prognostic models; prediction; traumatic brain injury; validation; outcome	ISCHEMIC-STROKE; HEAD-INJURY; D-DIMER; CALCIUM; IMPACT; HEMORRHAGE	BACKGROUND: Early estimation of prognosis for the patient with traumatic brain injury is an important factor in making treatment decisions, resource allocation, classify patients, or communicating with family. We aimed to develop and validate practical prognostic models for mortality at 30 days and for 6 months unfavorable outcome after moderate and severe traumatic brain injury. METHODS: Retrospectively collected data from our department were used to develop prognostic models for outcome. We developed four prognostic models based on admission predictors with logistic regression analysis. The performance of models was assessed with respect to discrimination and calibration. Discriminative ability was evaluated with C statistic, equal to the area under the receiver operating characteristic curve. Calibrative ability was assessed with the Hosmer-Lemeshow test (H-L test). The internal validity of models was evaluated with the bootstrap re-sampling technique. We validated three of the models in an external series of 203 patients that collected from another research center. Discrimination and calibration were further assessed to indicate the performance of the models in external patients. RESULTS: Logistic regression showed that age, pupillary reactivity, motor Glasgow Coma Score, computed tomography characters, glucose, hemoglobin, D-dimer, serum calcium, and intracranial pressure were independent prognostic factors of outcome. The models discriminated well in the development patients (C statistic 0.709-0.939). We extensively validate three of the models. Internal validation showed no overoptimism in any of the models' predictive C statistics. External validity was much better (C statistic 0.844-0.902). Calibration was also good (H-L tests, p > 0.05). Computer-based calculator that based on prognostic models was developed for clinical use. CONCLUSION: Our validated prognostic models have good performance and are generalizable to be used to predict outcome of new patients. We recommend the use of prognostic models to complement clinical decision making. (J Trauma Acute Care Surg. 2012; 73: 137-145. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Yuan, Fang; Ding, Jun; Chen, Hao; Guo, Yan; Wang, Gan; Gao, Wen-Wei; Chen, Shi-Wen; Tian, Heng-Li] Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, Shanghai, Peoples R China	Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, Shanghai, Peoples R China.	tianhengli1964@yahoo.com.cn			Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1412500]	Supported in part by a grant from the Shanghai Science and Technology Committee (Grant 10JC1412500).	Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Brain Trauma Foundation. American Association of Neurological Surgeons & Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pi, DOI DOI 10.1089/NEU.2007.9999; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Ovbiagele B, 2006, NEUROLOGY, V67, P170, DOI 10.1212/01.wnl.0000223629.07811.ae; Ovbiagele B, 2008, STROKE, V39, P2231, DOI 10.1161/STROKEAHA.107.513499; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Servadei F, 2000, NEUROSURGERY, V46, P70; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Tymianski Michael, 1996, Neurosurgery (Baltimore), V38, P1176, DOI 10.1097/00006123-199606000-00028; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803	25	38	45	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					137	145		10.1097/TA.0b013e31824b00ac			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	979JU	WOS:000306814100020	22743383				2021-06-18	
J	Cannon, RL; Baldwin, DR; Shaw, TL; Diloreto, DJ; Phillips, SM; Scruggs, AM; Riehl, TC				Cannon, Rex L.; Baldwin, Debora R.; Shaw, Tiffany L.; Diloreto, Dominic J.; Phillips, Sherman M.; Scruggs, Annie M.; Riehl, Timothy C.			Reliability of quantitative EEG (qEEG) measures and LORETA current source density at 30 days	NEUROSCIENCE LETTERS			English	Article						EEG reliability; LORETA; Current source density; Neuroimaging reliability	RESOLUTION ELECTROMAGNETIC TOMOGRAPHY; TRAUMATIC BRAIN INJURY; ANTERIOR CINGULATE; PSYCHIATRY; ELECTROENCEPHALOGRAPHY; NEUROFEEDBACK; SYMPTOMS; SPIKES; INDEX; POWER	There is a growing interest for using quantitative EEG and LORETA current source density in clinical and research settings. Importantly, if these indices are to be employed in clinical settings then the reliability of these measures is of great concern. Neuroguide (Applied Neurosciences) is sophisticated software developed for the analyses of power, and connectivity measures of the EEG as well as LORETA current source density. To date there are relatively few data evaluating topographical EEG reliability contrasts for all 19 channels and no studies have evaluated reliability for LORETA calculations. We obtained 4 min eyes-closed and eyes-opened EEG recordings at 30-day intervals. The EEG was analyzed in Neuroguide and FFT power, coherence and phase was computed for traditional frequency bands (delta, theta, alpha and beta) and LORETA current source density was calculated in 1 Hz increments and summed for total power in eight regions of interest (ROI). In order to obtain a robust measure of reliability we utilized a random effects model with an absolute agreement definition. The results show very good reproducibility for total absolute power and coherence. Phase shows lower reliability coefficients. LORETA current source density shows very good reliability with an average 0.81 for ECB and 0.82 for EOB. Similarly, the eight regions of interest show good to very good agreement across time. Implications for future directions and use of gEEG and LORETA in clinical populations are discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Cannon, Rex L.; Baldwin, Debora R.; Shaw, Tiffany L.; Diloreto, Dominic J.; Phillips, Sherman M.; Scruggs, Annie M.; Riehl, Timothy C.] Univ Tennessee, Dept Psychol, Clin Neurosci Self Regulat & Biol Psychol Lab, Knoxville, TN 37996 USA; [Cannon, Rex L.; Shaw, Tiffany L.] Univ Tennessee, Cole Neurosci Ctr, Med Ctr, Knoxville, TN 37920 USA	Cannon, RL (corresponding author), Univ Tennessee, Dept Psychol, Clin Neurosci Self Regulat & Biol Psychol Lab, Knoxville, TN 37996 USA.	rcannon2@utk.edu					Benbadis SR, 2009, NEUROLOGY, V73, P843, DOI 10.1212/WNL.0b013e3181b78425; Bjork MH, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-89; Brown GG, 2011, NEUROIMAGE, V54, P2163, DOI 10.1016/j.neuroimage.2010.09.076; Cannon R., 2011, J NEUROTHERAPY INVES, V15, P358, DOI [10.1080/10874208.2011.623093, DOI 10.1080/10874208.2011.623093]; Cannon R. L., 2011, J NEUROTHERAPY, V15, P3; Cannon R, 2008, APPL PSYCHOPHYS BIOF, V33, P223, DOI 10.1007/s10484-008-9067-9; Cannon R, 2007, INT J NEUROSCI, V117, P337, DOI 10.1080/00207450500514003; Cannon R, 2009, INT J NEUROSCI, V119, P404, DOI 10.1080/00207450802480325; Coburn KL, 2006, J NEUROPSYCH CLIN N, V18, P460, DOI 10.1176/appi.neuropsych.18.4.460; Corsi-Cabrera M, 2007, CLIN NEUROPHYSIOL, V118, P9, DOI 10.1016/j.clinph.2006.08.013; Coutin-Churchman P, 2003, CLIN NEUROPHYSIOL, V114, P2294, DOI 10.1016/S1388-2457(03)00228-1; Grossberg S, 2008, BRAIN RES, V1218, P278, DOI 10.1016/j.brainres.2008.04.024; Hu SQ, 2010, IEEE T SYST MAN CY B, V40, P1294, DOI 10.1109/TSMCB.2009.2037237; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Oakes TR, 2004, HUM BRAIN MAPP, V21, P257, DOI 10.1002/hbm.20004; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Pizzagalli DA, 2003, PSYCHOPHYSIOLOGY, V40, P939, DOI 10.1111/1469-8986.00112; Prichep LS, 2002, CLIN ELECTROENCEPHAL, V33, P8, DOI 10.1177/155005940203300104; Saletu B, 1997, NEUROPSYCHOBIOLOGY, V36, P130, DOI 10.1159/000119374; Sanei S., 2007, EEG SIGNAL PROCESSIN; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher RW, 2003, CLIN ELECTROENCEPHAL, V34, P39, DOI 10.1177/155005940303400203; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; Zuidema SU, 2011, INT J GERIATR PSYCH, V26, P127, DOI 10.1002/gps.2499; Zumsteg D, 2006, CLIN NEUROPHYSIOL, V117, P1380, DOI 10.1016/j.clinph.2006.02.019	28	38	38	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 14	2012	518	1					27	31		10.1016/j.neulet.2012.04.035			5	Neurosciences	Neurosciences & Neurology	964RR	WOS:000305714900007	22575610				2021-06-18	
J	Shenouda, C; Hendrickson, P; Davenport, K; Barber, J; Bell, KR				Shenouda, Christian; Hendrickson, Peter; Davenport, Kathleen; Barber, Jason; Bell, Kathleen R.			The Effects of Concussion Legislation One Year Later-What Have We Learned: A Descriptive Pilot Survey of Youth Soccer Player Associates	PM&R			English	Article							HIGH-SCHOOL; FOOTBALL SOCCER; HEAD-INJURIES; SPORTS	Objective: To assess the knowledge of youth soccer athletes parents, coaches, and soccer officials regarding concussion and return-to-play guidelines contained in the Lystedt Law in Washington State. Design: Survey study. Setting: Surveys were distributed via the youth soccer association monthly electronic newsletter in September and October 2010. Links to the survey also were provided via the Washington Youth Soccer Facebook page and Twitter feed. Participants: Respondents were 18 years or older and were associated with Washington Youth Soccer. Main Outcome Measures: The percentage of correct responses to questions regarding the identification and management of concussion symptoms and return to play guidelines as outlined in the Lystedt Law. Results: A total of 391 adults responded; 63% were exclusively parents, 20% were coaches, and 17% were noncoaches (eg, club officers, referees, or volunteers). A total of 96% knew that concussions were a type of traumatic brain injury, 93% identified concussions as serious, and 93% knew that loss of consciousness is not universal. From the responses, 98% identified neurological manifestations of concussions, 90% chose to delay return to play in the presence of neurological symptoms, 85% were aware of the Lystedt Law, and only 73% knew that players must receive written clearance to return to play. A total of 88% were aware that a parent or legal guardian was not allowed to clear an athlete to return to play if a trained professional was not available. Survey respondents were less sure of soccer association guidelines for reporting medical clearance to club officials. Conclusions: These data suggest that, although general knowledge of parents, coaches, and referees in youth soccer in Washington State is high, gaps in knowledge and practice regarding the prevention of concussion in youth soccer athletes still exist. PM R 2012;4:427-435	[Shenouda, Christian; Hendrickson, Peter; Davenport, Kathleen; Barber, Jason; Bell, Kathleen R.] Univ Washington, Seattle, WA 98195 USA	Shenouda, C (corresponding author), NIH, Dept Rehabil Med, 10 Ctr Dr,Room 1-1469,MSC 1604, Bethesda, MD 20892 USA.	christianshenouda@hotmail.com		Bell, Kathleen/0000-0002-0928-2046	TBI Model Systems, NIDRR, Department of Education [H133A070032]	Funded in part by grant #H133A070032, TBI Model Systems, NIDRR, Department of Education.	Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Niedfeldt MW, 2011, CURR SPORT MED REP, V10, P324, DOI 10.1249/JSR.0b013e318237be53; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; WITHNALL C, 2005, BR J SPORTS MED S1, V39, P48	15	38	38	1	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2012	4	6					427	435		10.1016/j.pmrj.2012.02.016			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	969EO	WOS:000306038700006	22543038				2021-06-18	
J	Caswell, SV; Lincoln, AE; Almquist, JL; Dunn, RE; Hinton, RY				Caswell, Shane V.; Lincoln, Andrew E.; Almquist, Jon L.; Dunn, Reginald E.; Hinton, Richard Y.			Video Incident Analysis of Head Injuries in High School Girls' Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; head injury; concussion; sports; girls' lacrosse	TRAUMATIC BRAIN-INJURY; SURVEILLANCE SYSTEM; WOMENS LACROSSE; UNITED-STATES; FOOTBALL; EPIDEMIOLOGY; MECHANISMS; SPORTS	Background: Knowledge of injury mechanisms and game situations associated with head injuries in girls' high school lacrosse is necessary to target prevention efforts. Purpose: To use video analysis and injury data to provide an objective and comprehensive visual record to identify mechanisms of injury, game characteristics, and penalties associated with head injury in girls' high school lacrosse. Study Design: Descriptive epidemiology study. Methods: In the 25 public high schools of 1 school system, 529 varsity and junior varsity girls' lacrosse games were videotaped by trained videographers during the 2008 and 2009 seasons. Video of head injury incidents was examined to identify associated mechanisms and game characteristics using a lacrosse-specific coding instrument. Results: Of the 25 head injuries (21 concussions and 4 contusions) recorded as game-related incidents by athletic trainers during the 2 seasons, 20 head injuries were captured on video, and 14 incidents had sufficient image quality for analysis. All 14 incidents of head injury (11 concussions, 3 contusions) involved varsity-level athletes. Most head injuries resulted from stick-to-head contact (n = 8), followed by body-to-head contact (n = 4). The most frequent player activities were defending a shot (n = 4) and competing for a loose ball (n = 4). Ten of the 14 head injuries occurred inside the 12-m arc and in front of the goal, and no penalty was called in 12 injury incidents. All injuries involved 2 players, and most resulted from unintentional actions. Turf versus grass did not appear to influence number of head injuries. Conclusion: Comprehensive video analysis suggests that play near the goal at the varsity high school level is associated with head injuries. Absence of penalty calls on most of these plays suggests an area for exploration, such as the extent to which current rules are enforced and the effectiveness of existing rules for the prevention of head injury.	[Caswell, Shane V.] George Mason Univ, Sports Med Assessment Res & Testing Lab, Sch Recreat Hlth & Tourism, Manassas, VA 20110 USA	Caswell, SV (corresponding author), George Mason Univ, Sports Med Assessment Res & Testing Lab, Sch Recreat Hlth & Tourism, 10900 Univ Blvd,MS 4E5, Manassas, VA 20110 USA.	scaswell@gmu.edu			National Operating Committee on Standards for Athletic Equipment; US Lacrosse Sports Science & Safety Committee	One or more of the authors has declared the following potential conflict of interest or source of funding: Funded in part by a grant from the National Operating Committee on Standards for Athletic Equipment and from the US Lacrosse Sports Science & Safety Committee. The funding organizations had no other role in the study.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Appleby B, 2002, J SCI MED SPORT, V5, P129, DOI 10.1016/S1440-2440(02)80034-2; Carter EA, 2010, INT J INJ CONTROL SA, V17, P111, DOI 10.1080/17457300903524888; DaSilva M, LACROSSE MAGAZINE; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P173; Drew K, CNYCENTRAL; Feil J, POINTS TAKEN COACHES; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; Olsen E, 1997, Science and football III, V3rd, P209; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schwarz A, 2011, NY TIMES, pB13; US Lacrosse, PART SURV US LACR; US Lacrosse, 2010, OFF RUL GIRLS WOM LA	21	38	38	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	APR	2012	40	4					756	762		10.1177/0363546512436647			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	918XO	WOS:000302285100003	22328707				2021-06-18	
J	Micklewright, JL; King, TZ; O'Toole, K; Henrich, C; Floyd, FJ				Micklewright, Jackie L.; King, Tricia Z.; O'Toole, Kathleen; Henrich, Chris; Floyd, Frank J.			Parental Distress, Parenting Practices, and Child Adaptive Outcomes Following Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Head injury; Family; Adolescence; Recovery; Adaptive outcomes; Indirect effects	SHORT-TERM; FAMILY BURDEN; ADAPTATION; BEHAVIOR; MODERATOR	Moderate and severe pediatric traumatic brain injuries (TBI) are associated with significant familial distress and child adaptive sequelae. Our aim was to examine the relationship between parental psychological distress, parenting practices (authoritarian, permissive, authoritative), and child adaptive functioning 12-36 months following TBI or orthopedic injury (OI). Injury type was hypothesized to moderate the relationship between parental distress and child adaptive functioning, demonstrating a significantly stronger relationship in the TBI relative to OI group. Authoritarian parenting practices were hypothesized to mediate relationship between parental distress and child adaptive functioning across groups. Groups (TBI n=21, OI n=23) did not differ significantly on age at injury, time since injury, sex, race, or SES. Parents completed the Brief Symptom Inventory, Parenting Practices Questionnaire, and Vineland-II. Moderation and mediation hypotheses were tested using hierarchical multiple regression and a bootstrapping approach, respectively. Results supported moderation and revealed that higher parental psychological distress was associated with lower child adaptive functioning in the TBI group only. Mediation results indicated that higher parental distress was associated with authoritarian parenting practices and lower adaptive functioning across groups. Results suggest that parenting practices are an important area of focus for studies attempting to elucidate the relationship between parent and child functioning following TBI. (JINS, 2012, 18, 343-350)	[Micklewright, Jackie L.] Hennepin Cty Med Ctr, Dept Neuropsychol, Minneapolis, MN 55415 USA; [Micklewright, Jackie L.; King, Tricia Z.; Henrich, Chris] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA; [O'Toole, Kathleen] Childrens Healthcare Atlanta Scottish Rite, Dept Neuropsychol, Atlanta, GA USA; [Floyd, Frank J.] Univ Hawaii, Dept Psychol, Honolulu, HI 96822 USA	Micklewright, JL (corresponding author), Hennepin Cty Med Ctr, Dept Neuropsychol, 701 Pk Ave S, Minneapolis, MN 55415 USA.	jmicklewright1@gmail.com			American Psychological Association; Georgia State University Research Foundation; Georgia State University; North American Brain Injury Society	We are greateful to our participants and their families who gave their time to make this research possible. The research described in this study was supported by dissertation grants to Jackie Micklewright from the American Psychological Association and Georgia State University Research Foundation. Funding for Jackie Micklewright was also provided by the Georgia State University Brains & Behavior Research Fellowship. This research was also recognized by Division 22 of the American Psychological Association, the Department of Veterans Affairs Rehabilitation Research and Development Service, and the North American Brain Injury Society's Charles W. Haynes Fellowship Award. There are no conflicts of interest associated with the current study.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BAUMRIND D, 1966, CHILD DEV, V37, P887, DOI 10.1111/j.1467-8624.1966.tb05416.x; Bornstein MH, 2003, MON PARENT, P29; Centers for Disease Control and Prevention Division of Injury and Disability Outcomes and Progress, 2004, TRAUM BRAIN INJ US E; Chapieski L, 2005, EPILEPSY BEHAV, V7, P246, DOI 10.1016/j.yebeh.2005.05.002; de Bildt A, 2005, J AUTISM DEV DISORD, V35, P53, DOI 10.1007/s10803-004-1033-7; Derogatis L. R., 1993, BSI BRIEF SYMPTOM IN; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fletcher J., 1998, HDB PEDIAT PSYCHOL, P258; Gamble WC, 2007, EARLY CHILD RES Q, V22, P72, DOI 10.1016/j.ecresq.2006.11.004; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Locke LM, 2002, CLIN PSYCHOL REV, V22, P895, DOI 10.1016/S0272-7358(02)00133-2; Lucas JA, 2006, CLIN NEUROPSYCHOLOGY, P351; McNett Molly, 2007, J Neurosci Nurs, V39, P68; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Patterson G.R., 1982, SOCIAL LEARNING APPR, V3; Patterson G. R., 1983, STRESS COPING DEV CH; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Sattler JM, 2006, ASSESSMENT CHILDREN; Sparrow S, 2005, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Whaley SE, 1999, J CONSULT CLIN PSYCH, V67, P826, DOI 10.1037/0022-006X.67.6.826; Winsler A, 2005, EARLY CHILD RES Q, V20, P1, DOI 10.1016/j.ecresq.2005.01.007; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	38	38	39	2	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2012	18	2					343	350		10.1017/S1355617711001792			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	899DI	WOS:000300794600018	22314012				2021-06-18	
J	Singh, P; Doshi, S; Spaethling, JM; Hockenberry, AJ; Patel, TP; Geddes-Klein, DM; Lynch, DR; Meaney, DF				Singh, Pallab; Doshi, Shachee; Spaethling, Jennifer M.; Hockenberry, Adam J.; Patel, Tapan P.; Geddes-Klein, Donna M.; Lynch, David R.; Meaney, David F.			N-Methyl-D-aspartate Receptor Mechanosensitivity Is Governed by C Terminus of NR2B Subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; NR2B-CONTAINING NMDA RECEPTORS; EXCITATORY AMINO-ACIDS; IN-VITRO; DIFFERENTIAL ROLES; SIGNALING PATHWAYS; DISTINCT ROLES; NEURONAL DEATH; NR1 SUBUNIT; CELL-DEATH	N-Methyl-D-aspartate receptors (NMDARs), critical mediators of both physiologic and pathologic neurological signaling, have previously been shown to be sensitive to mechanical stretch through the loss of its native Mg2+ block. However, the regulation of this mechanosensitivity has yet to be further explored. Furthermore, as it has become apparent that NMDAR-mediated signaling is dependent on specific NMDAR subtypes, as governed by the identity of the NR2 subunit, a crucial unanswered question is the role of subunit composition in observed NMDAR mechanosensitivity. Here, we used a recombinant system to assess the mechanosensitivity of specific subtypes and demonstrate that the mechanosensitive property is uniquely governed by the NR2B subunit. NR1/NR2B NMDARs displayed significant stretch sensitivity, whereas NR1/NR2A NMDARs did not respond to stretch. Furthermore, NR2B mechanosensitivity was regulated by PKC activity, because PKC inhibition reduced stretch responses in transfected HEK 293 cells and primary cortical neurons. Finally, using NR2B point mutations, we identified a PKC phosphorylation site, Ser-1323 on NR2B, as a unique critical regulator of stretch sensitivity. These data suggest that the selective mechanosensitivity of NR2B can significantly impact neuronal response to traumatic brain injury and illustrate that the mechanical tone of the neuron can be dynamically regulated by PKC activity.	[Doshi, Shachee; Lynch, David R.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19194 USA; [Lynch, David R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Singh, Pallab; Spaethling, Jennifer M.; Hockenberry, Adam J.; Patel, Tapan P.; Geddes-Klein, Donna M.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122; Patel, Tapan/0000-0001-8959-6645; Hockenberry, Adam/0000-0001-9476-0104	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD41699, NS35712, NS015212]; U.S. Department of DefenseUnited States Department of Defense [W911NF-10-1-0526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS015212, R01NS035712] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants HD41699, NS35712, and NS015212. This work was also supported by a U.S. Department of Defense Grant W911NF-10-1-0526.	Al-Hallaq RA, 2007, J NEUROSCI, V27, P8334, DOI 10.1523/JNEUROSCI.2155-07.2007; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BOECKMAN FA, 1994, NEUROSCI LETT, V173, P189, DOI 10.1016/0304-3940(94)90180-5; Boeckman FA, 1996, J PHARMACOL EXP THER, V279, P515; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Casado M, 1998, J PHYSIOL-LONDON, V513, P317, DOI 10.1111/j.1469-7793.1998.317bb.x; Chen BS, 2007, NEUROPHARMACOLOGY, V53, P362, DOI 10.1016/j.neuropharm.2007.05.018; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Chen M, 2008, STROKE, V39, P3042, DOI 10.1161/STROKEAHA.108.521898; Cull-Candy Stuart G, 2004, Sci STKE, V2004, pre16, DOI 10.1126/stke.2552004re16; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ehlers MD, 1998, J NEUROSCI, V18, P720; Erreger K, 2005, J PHYSIOL-LONDON, V563, P345, DOI 10.1113/jphysiol.2004.080028; Ewald RC, 2008, J NEUROSCI, V28, P850, DOI 10.1523/JNEUROSCI.5078-07.2008; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Foster KA, 2010, J NEUROSCI, V30, P2676, DOI 10.1523/JNEUROSCI.4022-09.2010; Gallagher MJ, 1996, J BIOL CHEM, V271, P9603, DOI 10.1074/jbc.271.16.9603; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Gogas KR, 2006, CURR OPIN PHARMACOL, V6, P68, DOI 10.1016/j.coph.2005.11.001; Grant ER, 1998, J NEUROCHEM, V71, P1471; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Hatton CJ, 2005, NEURON, V46, P261, DOI 10.1016/j.neuron.2005.03.005; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jin SX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011732; Jones ML, 2005, J NEUROCHEM, V92, P1431, DOI 10.1111/j.1471-4159.2004.02985.x; Kashiwagi K, 2002, MOL PHARMACOL, V61, P533, DOI 10.1124/mol.61.3.533; Kendrick SJ, 1996, J NEUROCHEM, V67, P608; Kim MJ, 2005, NEURON, V46, P745, DOI 10.1016/j.neuron.2005.04.031; Kinney JW, 2006, J NEUROSCI, V26, P1604, DOI 10.1523/JNEUROSCI.4722-05.2006; Kohr G, 2003, J NEUROSCI, V23, P10791; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; Li SM, 2006, J NEUROSCI, V26, P1721, DOI 10.1523/JNEUROSCI.3990-05.2006; Liao GY, 2001, MOL PHARMACOL, V59, P960; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu XB, 2004, J NEUROSCI, V24, P8885, DOI 10.1523/JNEUROSCI.2476-04.2004; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; Lynch DR, 2002, J PHARMACOL EXP THER, V300, P717, DOI 10.1124/jpet.300.3.717; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Matsuda S, 1999, NEUROSCI RES, V34, P157, DOI 10.1016/S0168-0102(99)00046-2; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nelson TJ, 2008, EUR J PHARMACOL, V585, P76, DOI 10.1016/j.ejphar.2008.01.051; Neyton J, 2006, J NEUROSCI, V26, P1331, DOI 10.1523/JNEUROSCI.5242-05.2006; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Rao VLR, 2001, BRAIN RES, V911, P96; Rauner C, 2011, J BIOL CHEM, V286, P7558, DOI 10.1074/jbc.M110.182600; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Santucci DM, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000208; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Singh P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002106; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Tovar KR, 1999, J NEUROSCI, V19, P4180; von Engelhardt J, 2007, NEUROPHARMACOLOGY, V53, P10, DOI 10.1016/j.neuropharm.2007.04.015; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; Wu HY, 2007, J BIOL CHEM, V282, P20075, DOI 10.1074/jbc.M700624200; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhou M, 2006, J NEUROSCI, V26, P2956, DOI 10.1523/JNEUROSCI.4299-05.2006; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	75	38	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2012	287	6					4348	4359		10.1074/jbc.M111.253740			12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	894EX	WOS:000300410900065	22179603	Green Published, Other Gold			2021-06-18	
J	Coldren, RL; Russell, ML; Parish, RV; Dretsch, M; Kelly, MP				Coldren, Rodney L.; Russell, Michael L.; Parish, Robert V.; Dretsch, Michael; Kelly, Mark P.			The ANAM Lacks Utility as a Diagnostic or Screening Tool for Concussion More Than 10 Days Following Injury	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; RECOVERY; IRAQ; DEPLOYMENT; PERSONNEL; FOOTBALL; OUTCOMES; TIME	Congress has mandated that the Department of Defense perform screening for concussion. or mild traumatic brain injury, on all service members redeploying from Iraq and Afghanistan. However, the retrospective diagnosis of concussion is complicated by the subjective nature of the complaints, overlap of symptoms with other conditions, and the normally rapid recovery of neurocognitive function following a concussive event. One diagnostic and screening test in current use by the Department of Defense is the Automated Neuropsychological Assessment Metrics (ANAM). A team of researchers deployed to Iraq between January and April 2009 to test the validity of the ANA M for the diagnosis of concussion in the combat environment. Performance by concussed participants on all six ANAM subtests was compared with that of controls. The ANAM appears to have no utility as an individual diagnostic or population screening tool for the detection of neurocognitive dysfunction from a single. uncomplicated concussion when administered 10 or more days following injury. Further studies are required to determine the modalities providing optimal sensitivity and specificity for use as diagnostic or screening tests beyond the first 72-hour acute postinjury period.	[Coldren, Rodney L.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Russell, Michael L.] Lincoln Ctr, Off Surgeon Gen, R2D, San Antonio, TX 78230 USA; [Parish, Robert V.] CMR, Landstuhl Reg Med Ctr, APO, AE 09180 USA; [Dretsch, Michael] USA, Aeromed Res Lab, Ft Rucker, AL 36362 USA; [Kelly, Mark P.] Walter Reed Army Med Ctr, Dept Psychol, Washington, DC USA	Coldren, RL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland;  [W81XWH-09-2-0057]	Sponsor of this award is provided by The U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland and is the awarding and administering acquisition office. Material provided in this presentation under award W81XWH-09-2-0057 does not necessarily reflect the position or the policy of the Government, and no of endorsement should be interred. The views expressed in this letter are those of the authors and do not reflect the official policy of the Department of Army. Department of Defense. or U.S. Government.	Barr W., 2008, TXB CLIN NEUROPSYCHO, P660; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	19	38	38	0	8	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	FEB	2012	177	2					179	183		10.7205/MILMED-D-11-00278			5	Medicine, General & Internal	General & Internal Medicine	886KC	WOS:000299852300012	22360064	Bronze			2021-06-18	
J	Egea, J; Martin-de-Saavedra, MD; Parada, E; Romero, A; del Barrio, L; Rosa, AO; Garcia, AG; Lopez, MG				Egea, J.; Martin-de-Saavedra, M. D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A. O.; Garcia, A. G.; Lopez, M. G.			Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation	NEUROPHARMACOLOGY			English	Article						Galantamine; Ischemia; Neuroprotection; ROS	ALPHA-7 NICOTINIC RECEPTORS; NITRIC-OXIDE; ACETYLCHOLINESTERASE INHIBITORS; MEDIATED NEUROPROTECTION; GLUCOSE DEPRIVATION; ALZHEIMERS-DISEASE; CORTICAL CULTURES; INDUCED APOPTOSIS; OXIDATIVE STRESS; HEME OXYGENASE-1	Galantamine is a drug currently used to treat Alzheimer's disease (AD); in this group of patients it has been observed that concomitant ischemic brain injury can accelerate their cognitive deficit. We have previously shown that galantamine can afford neuroprotection on in vitro and in vivo models related to brain ischemia. In this context, this study was planned to investigate the intracellular signaling pathways implicated in the protective effect of galantamine on an in vitro brain ischemia-reperfusion model, namely rat hippocampal slices subjected to oxygen and glucose deprivation (OGD) followed by reoxygenation. Galantamine protected hippocampal slices subjected to OGD in a concentration-dependent manner; at 15 mu M, cell death was reduced to almost control levels. The neuroprotective effects of galantamine were reverted by mecamylamine and AG490, but not by atropine, indicating that nicotinic receptors and Jak2 participated in this action. Galantamine also prevented p65 translocation into the nucleus induced by OGD; this effect was also linked to nicotinic receptors and Jak2. Furthermore, galantamine reduced iNOS induction and production of NO caused by OGD via Jak2. ROS production by NADPH oxidase (NOX) activation was also inhibited by galantamine. In conclusion, galantamine afforded neuroprotection under OGD-reoxygenation conditions by activating a signaling pathway that involves nicotinic receptors, Jak2 and the consequent inhibition of NOX and NF kappa B/iNOS. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'. (C) 2011 Elsevier Ltd. All rights reserved.	[Egea, J.; Martin-de-Saavedra, M. D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A. O.; Garcia, A. G.; Lopez, M. G.] Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, E-28029 Madrid, Spain; [Egea, J.; Martin-de-Saavedra, M. D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A. O.; Garcia, A. G.; Lopez, M. G.] Univ Autonoma Madrid, Inst Teofilo Hernando, Madrid 28029, Spain; [Garcia, A. G.] Hosp Univ de la Princesa, Inst Invest Sanitaria, Serv Farmacol Clin, Madrid, Spain; [Egea, J.; Romero, A.; Lopez, M. G.] Univ Autonoma Madrid, Inst Univ la Paz IdiPaz, Madrid 28029, Spain	Egea, J (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Calle Arzobispo Morcillo 4, E-28029 Madrid, Spain.	javier.egea@uam.es	Egea, Javier/X-7281-2019; Lopez, Manuela G/D-2164-2015; Romero, Alejandro/A-8282-2018; Martin-de-Saavedra, M. Dolores/AAA-3119-2019; Barrio, Laura/B-3767-2017; Romero, Alejandro/N-9686-2019; GARCIA, ANTONIO G/E-9961-2018	Egea, Javier/0000-0003-4704-3019; Lopez, Manuela G/0000-0003-4461-8788; Romero, Alejandro/0000-0001-5483-4973; Barrio, Laura/0000-0001-9203-3296; Romero, Alejandro/0000-0001-5483-4973; GARCIA, ANTONIO G/0000-0002-6517-3565; da Rosa, Angelo/0000-0003-3715-4751; Martin-de-Saavedra, Maria Dolores/0000-0001-8527-493X	Spanish Ministry of Science and InnovationSpanish Government [SAF2009-12150]; Spanish Ministry of Health (Instituto de Salud Carlos III)Instituto de Salud Carlos IIISpanish Government [RETICS-RD06/0026]; Comunidad Autonoma de MadridComunidad de Madrid [SAL2006/0275]; Agencia Lain Entralgo [NDG07/9]; Fundacion C.I.E.N.; Instituto Carlos IIIInstituto de Salud Carlos III [85016/09]; Spanish Ministry of Science and InnovationSpanish Government; Fundacion Teofilo Hernando	This work was supported in part by grants from Spanish Ministry of Science and Innovation Ref. SAF2009-12150 to MGL, the Spanish Ministry of Health (Instituto de Salud Carlos III) RETICS-RD06/0026 and Comunidad Autonoma de Madrid Ref. SAL2006/0275 to AGG and MGL, Agencia Lain Entralgo Ref. NDG07/9 and Fundacion C.I.E.N., Instituto Carlos III Ref. 85016/09. MDMS has a pre-doctoral fellowship from the Spanish Ministry of Science and Innovation. We would also like to thank "Fundacion Teofilo Hernando" for its continued support.	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Arias E, 2004, NEUROPHARMACOLOGY, V46, P103, DOI 10.1016/S0028-3908(03)00317-4; Arias E, 2005, J PHARMACOL EXP THER, V315, P1346, DOI 10.1124/jpet.105.090365; Belluardo N, 2000, ADV RES NEURODEGENER, V8, P227; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Borovikova LV, 2000, NATURE, V405, P458; Cardenas A, 1998, EUR J PHARMACOL, V354, P161, DOI 10.1016/S0014-2999(98)00458-0; Cardenas A, 2000, J NEUROCHEM, V74, P2041, DOI 10.1046/j.1471-4159.2000.0742041.x; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Du J., 2009, AM J PHYSL CELL PHYS; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Egea J, 2007, J NEUROCHEM, V102, P1842, DOI 10.1111/j.1471-4159.2007.04665.x; Erkinjuntti T, 2003, CLIN THER, V25, P1765, DOI 10.1016/S0149-2918(03)80168-6; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Gahring LC, 2003, J NEUROCHEM, V87, P1125, DOI 10.1046/j.1471-4159.2003.02074.x; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Gilby KL, 2005, BRAIN RES, V1035, P196, DOI 10.1016/j.brainres.2004.12.015; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Hejmadi MV, 2003, MOL CELL NEUROSCI, V24, P779, DOI 10.1016/S1044-7431(03)00244-6; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Ji XH, 2007, NEUROSCI LETT, V416, P92, DOI 10.1016/j.neulet.2007.01.053; Kihara T, 2004, BIOCHEM BIOPH RES CO, V325, P976, DOI 10.1016/j.bbrc.2004.10.132; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kox M, 2009, BIOCHEM PHARMACOL, V78, P863, DOI 10.1016/j.bcp.2009.06.096; Lorrio S, 2007, J PHARMACOL EXP THER, V322, P591, DOI 10.1124/jpet.107.122747; Madrigal Jose L. M., 2006, CNS & Neurological Disorders-Drug Targets, V5, P561; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; Moriguchi S, 2004, J PHARMACOL EXP THER, V310, P933, DOI 10.1124/jpet.104.067603; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Parada E, 2010, FREE RADICAL BIO MED, V49, P1815, DOI 10.1016/j.freeradbiomed.2010.09.017; Pereira EFR, 2002, J NEUROBIOL, V53, P479, DOI 10.1002/neu.10146; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rojo AI, 2006, FREE RADICAL BIO MED, V41, P247, DOI 10.1016/j.freeradbiomed.2006.04.002; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Santos MD, 2002, MOL PHARMACOL, V61, P1222, DOI 10.1124/mol.61.5.1222; Schrattenholz A, 1996, MOL PHARMACOL, V49, P1; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Shaw S, 2002, J BIOL CHEM, V277, P44920, DOI 10.1074/jbc.M204610200; Shen H, 2010, BRIT J PHARMACOL, V161, P127, DOI 10.1111/j.1476-5381.2010.00894.x; Sobrado M, 2004, NEUROSCI LETT, V365, P132, DOI 10.1016/j.neulet.2004.04.067; Stevens TR, 2003, J NEUROSCI, V23, P10093; Sugano N, 1998, BIOCHEM BIOPH RES CO, V252, P25, DOI 10.1006/bbrc.1998.9599; Tabet N, 2006, AGE AGEING, V35, P336, DOI 10.1093/ageing/afl027; Takada-Takatori Y, 2006, EUR J PHARMACOL, V549, P19, DOI 10.1016/j.ejphar.2006.08.017; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; THOMSEN T, 1990, LIFE SCI, V46, P1553, DOI 10.1016/0024-3205(90)90429-U; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445; Xu J, 2008, NEUROPHARMACOLOGY, V54, P1029, DOI 10.1016/j.neuropharm.2008.01.014; Zhou W, 2008, CELL MOL NEUROBIOL, V28, P263, DOI 10.1007/s10571-007-9251-0	56	38	38	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2012	62	2					1082	1090		10.1016/j.neuropharm.2011.10.022			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	909FZ	WOS:000301549300059	22085833				2021-06-18	
J	Lopez, NE; Krzyzaniak, MJ; Blow, C; Putnam, J; Ortiz-Pomales, Y; Hageny, AM; Eliceiri, B; Coimbra, R; Bansal, V				Lopez, Nicole E.; Krzyzaniak, Michael J.; Blow, Chelsea; Putnam, James; Ortiz-Pomales, Yan; Hageny, Ann-Marie; Eliceiri, Brian; Coimbra, Raul; Bansal, Vishal			Ghrelin Prevents Disruption of the Blood-Brain Barrier after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; blood-brain barrier; ghrelin; traumatic brain injury	PRO-INFLAMMATORY CYTOKINES; PHORBOL-MYRISTATE ACETATE; V1A RECEPTOR ANTAGONIST; HEAD-INJURY; CELL-DEATH; NEUTROPHIL INFILTRATION; HIPPOCAMPAL-NEURONS; EDEMA; RATS; AQUAPORIN-4	Significant effort has been focused on reducing neuronal damage from post-traumatic brain injury (TBI) inflammation and blood-brain barrier (BBB)-mediated edema. The orexigenic hormone ghrelin decreases inflammation in sepsis models, and has recently been shown to be neuroprotective following subarachnoid hemorrhage. We hypothesized that ghrelin modulates cerebral vascular permeability and mediates BBB breakdown following TBI. Using a weight-drop model, TBI was created in three groups of mice: sham, TBI, and TBI/ghrelin. The BBB was investigated by examining its permeability to FITC-dextran and through quantification of perivascualar aquaporin-4 (AQP-4). Finally, we immunoblotted for serum S100B as a marker of brain injury. Compared to sham, TBI caused significant histologic neuronal degeneration, increases in vascular permeability, perivascular expression of AQP-4, and serum levels of S100B. Treatment with ghrelin mitigated these effects; after TBI, ghrelin-treated mice had vascular permeability and perivascular AQP-4 and S100B levels that were similar to sham. Our data suggest that ghrelin prevents BBB disruption after TBI. This is evident by a decrease in vascular permeability that is linked to a decrease in AQP-4. This decrease in vascular permeability may diminish post-TBI brain tissue damage was evident by decreased S100B.	[Bansal, Vishal] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA	Bansal, V (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	v3bansal@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916; Lopez, Nicole/0000-0002-4807-7360	American Surgical Association Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER	Funding for this work was supported partly by American Surgical Association Foundation.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Bansal V., 2010, J NEUROTRAUMA; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hinson SR, 2010, NEUROSCIENCE, V168, P1009, DOI 10.1016/j.neuroscience.2009.08.032; Huber JD, 2006, AM J PHYSIOL-HEART C, V290, pH732, DOI 10.1152/ajpheart.00747.2005; Iseri SO, 2008, REGUL PEPTIDES, V146, P73, DOI 10.1016/j.regpep.2007.08.014; Jacob A, 2010, FASEB J, V24, P1682, DOI 10.1096/fj.09-138834; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kwan RO, 2010, J TRAUMA, V68, P1186, DOI [10.1097/TA.0b013e3181bb9878, 10.1155/2010/273486]; Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416; Lee J, 2010, CANCER RES, V70, P10131, DOI 10.1158/0008-5472.CAN-10-2740; Liu YJ, 2006, CHINESE J PHYSIOL, V49, P244; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marmarou A, 2003, ACT NEUR S, V86, P7; Miao YY, 2007, BIOCHEM BIOPH RES CO, V359, P795, DOI 10.1016/j.bbrc.2007.05.192; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Patel TH, 2008, NEUROSCI LETT, V444, P222, DOI 10.1016/j.neulet.2008.08.020; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Qi X, 2008, J CLIN INVEST, V118, P173, DOI 10.1172/JCI32636; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Sehirli O, 2008, PEPTIDES, V29, P1231, DOI 10.1016/j.peptides.2008.02.012; Simard M, 2003, J NEUROSCI, V23, P9254; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Xu JJ, 2009, NEUROSCI LETT, V453, P58, DOI 10.1016/j.neulet.2009.01.067; Zelenina M, 2010, NEUROCHEM INT, V57, P468, DOI 10.1016/j.neuint.2010.03.022	49	38	43	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					385	393		10.1089/neu.2011.2053			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300017	21939391	Green Published			2021-06-18	
J	Anderson, V; Catroppa, C; Godfrey, C; Rosenfeld, JV				Anderson, Vicki; Catroppa, Cathy; Godfrey, Celia; Rosenfeld, Jeffrey V.			Intellectual Ability 10 Years after Traumatic Brain Injury in Infancy and Childhood: What Predicts Outcome?	JOURNAL OF NEUROTRAUMA			English	Article						children; intelligence; recovery of function; traumatic brain injury	CLOSED HEAD-INJURY; NEUROBEHAVIORAL RECOVERY; ACADEMIC-ACHIEVEMENT; SOCIAL OUTCOMES; SHORT-TERM; CHILDREN; TBI; ADOLESCENTS; AGE; PLASTICITY	The long-term consequences of child traumatic brain injury (TBI) are poorly understood, but there are indications of ongoing deterioration in skills with time since injury. This study investigated outcomes up to 10 years post-injury, to determine the influences of injury severity, injury age, and environment. The study design was prospective and longitudinal. Participants included consecutive admissions to the Royal Children's Hospital, Melbourne, Australia. Children sustaining TBI between 2 and 12 years of age (n = 76) were recruited on admission and divided according to injury severity (mild, moderate, and severe) and injury age (2-7 years and 8-12 years). Cognitive abilities were evaluated using standard measures of intellectual function (IQ) acutely and at 12 months, 30 months, and 10 years post-injury. At 10 years, mean IQs for survivors fell within the low average to average range. There were no significant effects of injury severity, injury age, or time since injury. In contrast, elevated rates of impairment were identified in association with severe TBI (global deficits), and early injury (non-verbal deficits). Impairments in processing speed were related to injury severity and age at injury. Predictors of 10-year outcome included pre-injury and social factors, injury age, and family function. Child survivors of serious TBI are at elevated risk of cognitive impairment, with recovery continuing into the third year post-injury. However, between 30 months and 10 years post-insult, children appear to make appropriate developmental gains, contrary to the speculation that these children "grow into their deficits.''	[Anderson, Vicki; Catroppa, Cathy; Godfrey, Celia] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Rosenfeld, Jeffrey V/B-7249-2011		Australian National Heath and Medical Research Council; Victorian Government	This research was supported by grants from the Australian National Heath and Medical Research Council and the Victorian Government Operational Infrastructure Support Program.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 2011, BRAIN, DOI [10.1093/brain//awr103, DOI 10.1093/BRAIN//AWR103]; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bayley N., 1969, BAYLEY SCALES INFANT; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M., 2007, COGNITIVE RESERVE TH, P53; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Noller P, 1988, ICPS FAMILY FU UNPUB; Nybo T, 1999, BRAIN INJURY, V13, P759; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Romema S., SOCIAL OUTC IN PRESS; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Walsh K., 1985, NEUROPSYCHOLOGY CLIN; Wechsler D, 1991, MANUAL WECHSLER SCAL; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D, 1989, MANUAL PRESCHOOL PRI; Yeates K. O., 2006, BEHAVIOUR, V14, P141; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	62	38	38	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					143	153		10.1089/neu.2011.2012			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300017	22022835				2021-06-18	
J	Sakakima, H; Khan, M; Dhammu, TS; Shunmugavel, A; Yoshida, Y; Singh, I; Singh, AK				Sakakima, Harutoshi; Khan, Mushfiquddin; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Yoshida, Yoshihiro; Singh, Inderjit; Singh, Avtar K.			Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						GSNO; IR; motor exercise; neurorepair; neurobehavior; rehabilitation; S-nitrosylation; stroke	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NF-KAPPA-B; NITRIC-OXIDE; EXPERIMENTAL STROKE; NEUROVASCULAR UNIT; GLUTATHIONE; ACTIVATION; PATHWAY; NITROSYLATION	Purpose: Stroke disability stems from insufficient neurorepair mechanisms. Improvement of functions has been achieved through rehabilitation or therapeutic agents. Therefore, we combined exercise with a neurovascular protective agent, S-nitrosoglutathione (GSNO), to accelerate functional recovery. Methods: Stroke was induced by middle cerebral artery occlusion for 60 min followed by reperfusion in adult male rats. Animals were treated with vehicle (IR group), GSNO (0.25 mg/kg, GSNO group), rotarod exercise (EX group) and GSNO plus exercise (GSNO+EX group). The groups were studied for 14 days to determine neurorepair mechanisms and functional recovery. Results: Treated groups showed reduced infarction, decreased neuronal cell death, enhanced neurotrophic factors, and improved neurobehavioral functions. However, the GSNO+EX showed greater functional recovery (p < 0.05) than the GSNO or the EX group. A GSNO sub group, treated 24 hours after IR, still showed motor function recovery (p < 0.001). The protective effect of GSNO or exercise was blocked by the inhibition of Akt activity. Conclusions: GSNO and exercise aid functional recovery by stimulating neurorepair mechanisms. The improvements by GSNO and exercise depend mechanistically on the Akt pathway. A combination of exercise and GSNO shows greater functional recovery. Improved recovery with GSNO, even administered 24 hours post-IR, demonstrates its clinical relevance.	[Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Sakakima, Harutoshi; Khan, Mushfiquddin; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Sakakima, Harutoshi; Yoshida, Yoshihiro] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Singh, AK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 508 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu			Veteran Administration; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511, NS-22576, NS-37766]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS022576, R01NS072511, R01NS022576, R01NS037766] Funding Source: NIH RePORTER	This work was supported by grants from Veteran Administration merit awards and NIH (NS-72511, NS-22576 and NS-37766). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan for her technical help, and Ms. Chara Williams for her secretarial assistance. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript.	Aledia AS, 2002, ASAIO J, V48, P526, DOI 10.1097/00002480-200209000-00015; Chen MJ, 2005, MOL BRAIN RES, V135, P181, DOI 10.1016/j.molbrainres.2004.12.001; Cheng XW, 2010, CIRCULATION, V122, P707, DOI 10.1161/CIRCULATIONAHA.109.909218; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; CHOLLET F, 2011, OPTN SRTR ANN REP, V10, P123, DOI DOI 10.1016/S1474-4422(10)70314-8; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Clarkson AN, 2011, J NEUROSCI, V31, P3766, DOI 10.1523/JNEUROSCI.5780-10.2011; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Colagiovanni DB, 2011, INT J TOXICOL, V30, P466, DOI 10.1177/1091581811412084; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; Ding Y, 2004, NEUROSCIENCE, V123, P667, DOI 10.1016/j.neuroscience.2003.08.031; Fortenberry JD, 2001, INFLAMM RES, V50, P89; Foster MW, 2009, TRENDS MOL MED, V15, P391, DOI 10.1016/j.molmed.2009.06.007; Gladstone DJ, 2006, STROKE, V37, P179, DOI 10.1161/01.STR.0000195169.42447.78; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kaposzta Z, 2002, CIRCULATION, V106, P3057, DOI 10.1161/01.CIR.0000041251.07332.28; Ke Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016643; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim MW, 2005, BRAIN RES, V1052, P16, DOI 10.1016/j.brainres.2005.05.070; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kluge I, 1997, J NEUROCHEM, V69, P2599; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Lima B, 2009, P NATL ACAD SCI USA, V106, P6297, DOI 10.1073/pnas.0901043106; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Lo EH, 2008, BRIT J PHARMACOL, V153, pS396, DOI 10.1038/sj.bjp.0707626; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matsuda F, 2011, ACTA PHYSIOL, V201, P275, DOI [10.1111/j.1748-1716.2010.02174.x, 10.1111/j.1748-1708.2010.02174.x]; Molloy J, 1998, CIRCULATION, V98, P1372, DOI 10.1161/01.CIR.98.14.1372; Monville C, 2006, J NEUROSCI METH, V158, P219, DOI 10.1016/j.jneumeth.2006.06.001; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/ajrccm.165.7.2105032; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Wellman TL, 2003, FASEB J, V17, P379, DOI 10.1096/fj.03-0143fje; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369	46	38	39	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2012	30	5					383	396		10.3233/RNN-2012-110209			14	Neurosciences	Neurosciences & Neurology	004UO	WOS:000308706800003	22717646	Green Accepted, Bronze			2021-06-18	
J	Shahrokhi, N; Haddad, MK; Joukar, S; Shabani, M; Keshavarzi, Z; Shahozehi, B				Shahrokhi, Nader; Haddad, Mohammad Khaksari; Joukar, Siavash; Shabani, Mohammad; Keshavarzi, Zekie; Shahozehi, Bidoallah			Neuroprotective antioxidant effect of sex steroid hormones in traumatic brain injury	PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						TBI; sex steroids; estrogen; progesterone; GPx; SOD; MDA; neuroprotection	OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; EDEMA FORMATION; FREE-RADICALS; IN-VITRO; RATS; PROGESTERONE; ESTROGEN; PROTECTS; DAMAGE	The aim of the present study was to evaluate the effect of different doses of sex steroid hormones on brain edema, BBB permeability, brain antioxidant enzyme activity, and MDA level after traumatic brain injury (TBI) in ovarectomized (OVX) rats. Female rats were divided into six (One sham and 5 TBI) groups including: vehicle, estrogen in physiologic (33.3 mu g/kg) and pharmacologic (1 mg/kg) doses, progesterone in physiologic (1.7 mg/kg) and pharmacological doses (8 mg/kg). The results showed that compared to vehicle group, estrogen and progesterone groups showed significantly lower brain water content (P<0.001). Evans blue content was significantly lower in both estrogen doses and in progesterone physiologic dose (P<0.001). Evans blue content was significantly higher in progesterone pharmacologic dose (P<0.001). Superoxide dismutase (SOD) activity was significantly higher in estrogen and progesterone pharmacologic doses (P<0.001). Glutathione peroxidase (GPx) activity was significantly lower in estrogen physiologic dose (P<0.001). It was concluded that the neuroprotective effect of different doses of sex steroid hormones after TBI, may be mediated by changes in oxidant agent activity.	[Haddad, Mohammad Khaksari; Joukar, Siavash; Shahozehi, Bidoallah] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Shahrokhi, Nader; Shabani, Mohammad] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Bam Int Unit, Kerman, Iran; [Keshavarzi, Zekie] Kerman Univ Med Sci, Dept Physiol, Kerman, Iran	Haddad, MK (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran.	nshahrokhisa@yahoo.com	Haddad, Mohammad Khaksari/AAB-9025-2019; Shahrokhi, Nader/AAV-3747-2020	Haddad, Mohammad Khaksari/0000-0003-0770-4281; Shahrokhi, Nader/0000-0002-0149-7819; Shabani, Mohammad/0000-0002-2082-5849; Joukar, Siyavash/0000-0002-9937-6985			Calegare BFA, 2010, PSYCHONEUROENDOCRINO, V35, P775, DOI 10.1016/j.psyneuen.2009.11.004; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; Behl C, 2002, J STEROID BIOCHEM, V83, P195, DOI 10.1016/S0960-0760(02)00271-6; Behl C, 1997, MOL PHARMACOL, V51, P535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Dhote VV, 2007, LIFE SCI, V81, P188, DOI 10.1016/j.lfs.2007.05.010; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Huang CY, 2010, J SURG RES, V164, pE1, DOI 10.1016/j.jss.2010.07.041; Kasimay O, 2009, RENAL FAILURE, V31, P711, DOI 10.3109/08860220903134563; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kerksick C, 2008, MED SCI SPORT EXER, V40, P1772, DOI 10.1249/MSS.0b013e31817d1cce; Kuebler JF, 2003, CRIT CARE MED, V31, P1786, DOI 10.1097/01.CCM.0000063441.41446.23; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Pajovic SB, 2003, PHYSIOL RES, V52, P189; Palomar-Morales M, 2010, PANCREAS, V39, P193, DOI 10.1097/MPA.0b013e3181c156d9; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Soylemez S, 2008, VASC PHARMACOL, V49, P97, DOI 10.1016/j.vph.2008.06.006; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; SUN Y, 1988, CLIN CHEM, V34, P497; Traupe T, 2007, HYPERTENSION, V49, P1364, DOI 10.1161/HYPERTENSIONAHA.106.081554; Unfer TC, 2006, CLIN CHIM ACTA, V369, P73, DOI 10.1016/j.cca.2006.01.006; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Verma Y, 2008, ARH HIG RADA TOKSIKO, V59, P1, DOI 10.2478/10004-1254-59-2008-1835; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Zandi PP, 2004, ARCH NEUROL-CHICAGO, V61, P82, DOI 10.1001/archneur.61.1.82	39	38	43	1	4	UNIV KARACHI	KARACHI	UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN	1011-601X			PAK J PHARM SCI	Pak. J. Pharm. Sci.	JAN	2012	25	1					219	225					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	889JV	WOS:000300070900033	22186333				2021-06-18	
J	Sheth, KN; Nutter, T; Stein, DM; Scalea, TM; Bernat, JL				Sheth, Kevin N.; Nutter, Tyree; Stein, Deborah M.; Scalea, Thomas M.; Bernat, James L.			Autoresuscitation after asystole in patients being considered for organ donation	CRITICAL CARE MEDICINE			English	Article						donation after circulatory death; organ donation; traumatic brain injury	LIVER-TRANSPLANTATION; CARDIAC DEATH; DONORS; SURVIVAL	Objectives: A fundamental issue in organ donation after circulatory death is the determination of death. There are limited data regarding the incidence and timing of autoresuscitation after asystole. Prevailing guidelines suggest a 2- to 5-min observation after mechanical asystole before the declaration of death. This study tested the hypothesis that a 2-min observation period after asystole is sufficient for the declaration of death in patients being considered for organ donation after circulatory death. Design: Single-center observational study using prospectively collected data. Setting: University hospital, Level I trauma center. Patients: Those patients identified by the organ donation registry that underwent organ donation after circulatory death from 2000 to 2008, during which time the institutional protocol required a 5-min observation period. Interventions: None. Measurements and Main Results: Documentation of medical history, serial Glasgow Coma Scale scores, time of extubation, and time to asystole, hypotension, pulseless electrical activity, and declaration of death were ascertained. Seventy-three patients were identified. The most common mechanism of injury was traumatic brain injury, and eight patients were aged <18 yrs. Patients had a mean Glasgow Coma Scale score of 5 on admission and were taken to organ donation after circulatory death an average of 6.6 days after admission. The average time from extubation to death was 22 mins. No patients exhibited autoresuscitation during the 5-min waiting observation period, including the first 2 mins after asystole. Conclusions: The absence of autoresuscitation in our series suggests that a 2-min observation period is sufficient for the determination of death after cardiac arrest, including patients younger than 18 yrs. These data may inform practice guidelines. (Crit Care Med 2012; 40:158-161)	[Sheth, Kevin N.] Univ Maryland, Med Ctr, Dept Neurol Neurosurg & Emergency Med, Baltimore, MD 21201 USA; [Stein, Deborah M.; Scalea, Thomas M.] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Scalea, Thomas M.] Shock Trauma & Anesthesiol Res Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; [Bernat, James L.] Dartmouth Hitchcock Med Ctr, Dept Neurol, Lebanon, NH 03766 USA	Sheth, KN (corresponding author), Univ Maryland, Med Ctr, Dept Neurol Neurosurg & Emergency Med, Baltimore, MD 21201 USA.	ksheth@som.umaryland.edu		Stein, Deborah/0000-0003-3683-3963	American Academy of Neurology	Dr. Sheth received grant support from the American Academy of Neurology. The remaining authors have not disclosed any potential conflicts of interest.	Abt PL, 2004, ANN SURG, V239, P87, DOI 10.1097/01.sla.0000103063.82181.2c; Antommaria AHM, 2009, JAMA-J AM MED ASSOC, V301, P1902, DOI 10.1001/jama.2009.637; Bernat JL, 2008, NEW ENGL J MED, V359, P669, DOI 10.1056/NEJMp0804161; Bernat JL, 2010, CRIT CARE MED, V38, P963, DOI 10.1097/CCM.0b013e3181c58916; Boucek MM, 2008, NEW ENGL J MED, V359, P709, DOI 10.1056/NEJMoa0800660; Caplan Arthur L., 1993, Kennedy Institute of Ethics Journal, V3, P251; Curfman GD, 2008, NEW ENGL J MED, V359, P749, DOI 10.1056/NEJMe0805480; DeVita M A, 2001, Prog Transplant, V11, P58; DeVita MA, 2000, CRIT CARE MED, V28, P1709, DOI 10.1097/00003246-200006000-00002; DeVita MA, 2001, CRIT CARE MED, V29, P1826; Herdman R, 1998, KENNEDY INST ETHIC J, V8, P83; Hornby K, 2010, CRIT CARE MED, V38, P1246, DOI 10.1097/CCM.0b013e3181d8caaa; *I MED, 2000, 0309066417 I MED; Jackson A, 2008, J HEART LUNG TRANSPL, V27, P348, DOI 10.1016/j.healun.2007.12.006; Kootstra G, 2002, WORLD J SURG, V26, P181; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2965; Lee KW, 2006, TRANSPLANTATION, V82, P1683, DOI 10.1097/01.tp.0000250936.73034.98; President's Council on Bioethics, 2008, CONTR DET DEATH; Wijdicks EFM, 2004, NEUROLOGY, V62, P673, DOI 10.1212/WNL.62.4.673; XIAO F, 1995, CRIT CARE MED S, V23, pA17; YOUNGNER SJ, 1993, JAMA-J AM MED ASSOC, V269, P2769, DOI 10.1001/jama.269.21.2769	21	38	39	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2012	40	1					158	161		10.1097/CCM.0b013e31822f0b2a			4	Critical Care Medicine	General & Internal Medicine	866KO	WOS:000298379800023	21926577				2021-06-18	
S	Uteshev, VV		Islam, MS		Uteshev, Victor V.			alpha 7 Nicotinic ACh Receptors as a Ligand-Gated Source of Ca2+ Ions: The Search for a Ca2+ Optimum	CALCIUM SIGNALING	Advances in Experimental Medicine and Biology		English	Article; Book Chapter						alpha 7 nAChR; NMDA; Ca2+; Permeability; Ion channel; Receptor; ACh; Choline; Nicotinic; Positive allosteric modulator; PNU-120596; Neuroprotection; Cognitive; Cognition; Dementia; Neurotoxicity; Synaptic; Extrasynaptic; Alzheimer; Schizophrenia; Trauma; Auditory; Gating	METHYL-D-ASPARTATE; BETA-AMYLOID PEPTIDE; ALPHA-7-NICOTINIC ACETYLCHOLINE-RECEPTOR; POSITIVE ALLOSTERIC MODULATION; CULTURED CORTICAL-NEURONS; SEVERE ALZHEIMERS-DISEASE; RAT HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; SINGLE-CHANNEL PROPERTIES; TRAUMATIC BRAIN-INJURY	The spatiotemporal distribution of cytosolic Ca2+ ions is a key determinant of neuronal behavior and survival. Distinct sources of Ca2+ ions including ligand-and voltage-gated Ca2+ channels contribute to intracellular Ca2+ homeostasis. Many normal physiological and therapeutic neuronal functions are Ca2+-dependent, however an excess of cytosolic Ca2+ or a lack of the appropriate balance between Ca2+ entry and clearance may destroy cellular integrity and cause cellular death. Therefore, the existence of optimal spatiotemporal patterns of cytosolic Ca2+ elevations and thus, optimal activation of ligand-and voltage-gated Ca2+ ion channels are postulated to benefit neuronal function and survival. Alpha7 nicotinic acetylcholine receptors (nAChRs) are highly permeable to Ca2+ ions and play an important role in modulation of neurotransmitter release, gene expression and neuroprotection in a variety of neuronal and non-neuronal cells. In this review, the focus is placed on a 7 nAChR-mediated currents and Ca2+ influx and how this source of Ca2+ entry compares to NMDA receptors in supporting cytosolic Ca2+ homeostasis, neuronal function and survival.	Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	Uteshev, VV (corresponding author), Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	Victor.Uteshev@unthsc.edu			NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK082625] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK082625] Funding Source: NIH RePORTER		Aarsland D, 2009, LANCET NEUROL, V8, P613, DOI 10.1016/S1474-4422(09)70146-2; Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Albuquerque EX, 2000, BEHAV BRAIN RES, V113, P131, DOI 10.1016/S0166-4328(00)00208-4; ALKONDON M, 1994, J PHARMACOL EXP THER, V271, P494; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Alva Gustavo, 2008, Psychiatry (Edgmont), V5, P27; ARENDASH GW, 1995, BRAIN RES, V674, P252, DOI 10.1016/0006-8993(94)01449-R; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; Asomugha CO, 2010, J NEUROCHEM, V112, P214, DOI 10.1111/j.1471-4159.2009.06447.x; Asztely F, 1997, NEURON, V18, P281, DOI 10.1016/S0896-6273(00)80268-8; Atri A, 2008, ALZ DIS ASSOC DIS, V22, P209, DOI 10.1097/WAD.0b013e31816653bc; Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Barron SC, 2009, MOL PHARMACOL, V76, P253, DOI 10.1124/mol.109.056226; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; Bertrand D, 2008, MOL PHARMACOL, V74, P1407, DOI 10.1124/mol.107.042820; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005; Bitner RS, 2010, J PHARMACOL EXP THER, V334, P875, DOI 10.1124/jpet.110.167213; Bitner RS, 2007, J NEUROSCI, V27, P10578, DOI 10.1523/JNEUROSCI.2444-07.2007; Blair LAC, 1999, J NEUROSCI, V19, P1940; Boess FG, 2007, J PHARMACOL EXP THER, V321, P716, DOI 10.1124/jpet.106.118976; Bok J, 2007, MOL CELL NEUROSCI, V36, P13, DOI 10.1016/j.mcn.2007.05.008; Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Brandt SK, 2011, NEUROSCIENCE, V172, P387, DOI 10.1016/j.neuroscience.2010.10.071; Briggs CA, 1997, PHARMACOL BIOCHEM BE, V57, P231, DOI 10.1016/S0091-3057(96)00354-1; Briggs CA, 2009, BRIT J PHARMACOL, V158, P1486, DOI 10.1111/j.1476-5381.2009.00426.x; Brown KL, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00166; Buccafusco JJ, 2007, BIOCHEM PHARMACOL, V74, P1202, DOI 10.1016/j.bcp.2007.07.010; Buccafusco JJ, 2005, TRENDS PHARMACOL SCI, V26, P352, DOI 10.1016/j.tips.2005.05.007; Buccafusco JJ, 2004, J ALZHEIMERS DIS, V6, pS85; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Catassi A, 2008, MUTAT RES-REV MUTAT, V659, P221, DOI 10.1016/j.mrrev.2008.04.002; Catassi A, 2008, EUR J CANCER, V44, P2296, DOI 10.1016/j.ejca.2008.06.045; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Clifford PM, 2008, BRAIN RES, V1234, P158, DOI 10.1016/j.brainres.2008.07.092; COLLINS F, 1991, J NEUROSCI, V11, P2582; Conroy WG, 2003, NEURON, V38, P759, DOI 10.1016/S0896-6273(03)00324-6; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Creeley CE, 2008, NEUROBIOL AGING, V29, P153, DOI 10.1016/j.neurobiolaging.2006.10.020; D'Andrea MR, 2006, CURR PHARM DESIGN, V12, P677, DOI 10.2174/138161206775474224; Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006; Davare MA, 2003, P NATL ACAD SCI USA, V100, P16018, DOI 10.1073/pnas.2236970100; Davis R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007524; Dineley KT, 2007, FRONT BIOSCI-LANDMRK, V12, P5030, DOI 10.2741/2445; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P25056, DOI 10.1074/jbc.M200066200; Dinklo T, 2011, J PHARMACOL EXP THER, V336, P560, DOI 10.1124/jpet.110.173245; Disterhoft JF, 2007, AGING CELL, V6, P327, DOI 10.1111/j.1474-9726.2007.00297.x; Dunbar GC, 2011, J PSYCHOPHARMACOL, V25, P1020, DOI 10.1177/0269881110367727; Dziewczapolski G, 2009, J NEUROSCI, V29, P8805, DOI 10.1523/JNEUROSCI.6159-08.2009; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Ehlers MD, 2007, NEURON, V54, P447, DOI 10.1016/j.neuron.2007.04.010; El-Hajj RA, 2007, LIFE SCI, V81, P1317, DOI 10.1016/j.lfs.2007.08.039; Ellis JR, 2006, INT J NEUROPSYCHOPH, V9, P175, DOI 10.1017/S1461145705005407; Faghih Ramin, 2007, Recent Pat CNS Drug Discov, V2, P99; Farlow MR, 2010, CLIN THER, V32, P1234, DOI 10.1016/j.clinthera.2010.06.019; Felix R, 1997, NEUROSCIENCE, V81, P1009, DOI 10.1016/S0306-4522(97)00224-8; Ferchmin PA, 2003, J PHARMACOL EXP THER, V305, P1071, DOI 10.1124/jpet.102.048173; Fernandes CC, 2010, J NEUROSCI, V30, P8841, DOI 10.1523/JNEUROSCI.6236-09.2010; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Frazier CJ, 1998, J NEUROSCI, V18, P8228; FREEDMAN R, 1995, BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; Freedman R, 2000, J CHEM NEUROANAT, V20, P299, DOI 10.1016/S0891-0618(00)00109-5; Freir DB, 2003, BRAIN RES, V967, P27, DOI 10.1016/S0006-8993(02)04190-2; Fu HJ, 2006, J NEUROCHEM, V98, P1400, DOI 10.1111/j.1471-4159.2006.03960.x; Fucile S, 2004, NEUROSCIENCE, V127, P53, DOI 10.1016/j.neuroscience.2004.04.017; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Fucile S, 2003, CELL CALCIUM, V34, P205, DOI 10.1016/S0143-4160(03)00071-X; Fucile S, 2002, P NATL ACAD SCI USA, V99, P3956, DOI 10.1073/pnas.052699599; Fujii S, 2000, NEUROSCI LETT, V286, P134, DOI 10.1016/S0304-3940(00)01076-4; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Gilbert D, 2009, CELL CALCIUM, V45, P198, DOI 10.1016/j.ceca.2008.10.003; Green A, 2005, PHARMACOL BIOCHEM BE, V81, P575, DOI 10.1016/j.pbb.2005.04.010; Groc L, 2009, NEUROSCIENCE, V158, P4, DOI 10.1016/j.neuroscience.2008.05.029; Groc L, 2006, P NATL ACAD SCI USA, V103, P18769, DOI 10.1073/pnas.0605238103; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Gusev AG, 2010, J PHARMACOL EXP THER, V332, P588, DOI 10.1124/jpet.109.162099; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Hao JW, 2011, EXP NEUROL, V227, P110, DOI 10.1016/j.expneurol.2010.09.020; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Hatton GI, 2002, J NEUROSCI, V22, P29, DOI 10.1523/JNEUROSCI.22-01-00029.2002; Hefft S, 1999, J PHYSIOL-LONDON, V515, P769, DOI 10.1111/j.1469-7793.1999.769ab.x; Herman MA, 2007, J NEUROSCI, V27, P9736, DOI 10.1523/JNEUROSCI.3009-07.2007; Hernandez CM, 2010, J NEUROSCI, V30, P2442, DOI 10.1523/JNEUROSCI.5038-09.2010; Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1; Hu M, 2007, BRAIN RES, V1151, P227, DOI 10.1016/j.brainres.2007.03.051; Hu M, 2009, BRIT J PHARMACOL, V158, P1857, DOI 10.1111/j.1476-5381.2009.00474.x; Hurst RS, 2005, J NEUROSCI, V25, P4396, DOI 10.1523/JNEUROSCI.5269-04.2005; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; JAHR CE, 1993, P NATL ACAD SCI USA, V90, P11573, DOI 10.1073/pnas.90.24.11573; Jenden DJ, 1996, LIFE SCI, V58, P2003, DOI 10.1016/0024-3205(96)00191-9; Jonnala RR, 2001, J NEUROSCI RES, V66, P565, DOI 10.1002/jnr.10022; De Rosa MJ, 2009, LIFE SCI, V85, P444, DOI 10.1016/j.lfs.2009.07.010; Kaczorowski CC, 2009, LEARN MEMORY, V16, P362, DOI 10.1101/lm.1365609; Kalappa BI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013964; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kawashima K, 2003, LIFE SCI, V74, P675, DOI 10.1016/j.lfs.2003.09.037; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Khiroug SS, 2002, J PHYSIOL-LONDON, V540, P425, DOI 10.1113/jphysiol.2001.013847; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kirrane RM, 2001, SCHIZOPHR RES, V48, P1, DOI 10.1016/S0920-9964(00)00059-1; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Klein J, 1998, NEUROCHEM INT, V32, P479, DOI 10.1016/S0197-0186(97)00127-7; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Koller G, 2003, NEUROPSYCHOBIOLOGY, V48, P87, DOI 10.1159/000072883; Kotermanski SE, 2009, J NEUROSCI, V29, P2774, DOI 10.1523/JNEUROSCI.3703-08.2009; Koval L, 2011, INT J BIOCHEM CELL B, V43, P516, DOI 10.1016/j.biocel.2010.12.003; Kullmann DM, 2000, PROG BRAIN RES, V125, P339; Leiser SC, 2009, PHARMACOL THERAPEUT, V122, P302, DOI 10.1016/j.pharmthera.2009.03.009; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-2999(00)00035-2; LeonS FE, 1997, J CLIN NEUROPHYSIOL, V14, P144, DOI 10.1097/00004691-199703000-00007; Leroi I, 2009, MOVEMENT DISORD, V24, P1217, DOI 10.1002/mds.22495; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; LESTER RAJ, 1992, J NEUROSCI, V12, P635; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; Levin O S, 2009, Neurosci Behav Physiol, V39, P597, DOI 10.1007/s11055-009-9167-x; Li YX, 2002, J NEUROCHEM, V81, P853, DOI 10.1046/j.1471-4159.2002.00891.x; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; Lipton SA, 2007, NAT REV NEUROSCI, V8, P803, DOI 10.1038/nrn2229; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; LONDON ED, 1989, NEUROCHEM RES, V14, P745, DOI 10.1007/BF00964952; Lopez JR, 2008, J NEUROCHEM, V105, P262, DOI 10.1111/j.1471-4159.2007.05135.x; Lopez-Hernandez GY, 2009, NEUROPHARMACOLOGY, V56, P821, DOI 10.1016/j.neuropharm.2009.01.011; Loughead J, 2010, BIOL PSYCHIAT, V67, P715, DOI 10.1016/j.biopsych.2010.01.016; Lyford LK, 2002, BBA-BIOMEMBRANES, V1559, P69, DOI 10.1016/S0005-2736(01)00437-0; Lynch G, 2011, PHARMACOL BIOCHEM BE, V99, P116, DOI 10.1016/j.pbb.2010.12.024; Malysz J, 2009, J PHARMACOL EXP THER, V330, P257, DOI 10.1124/jpet.109.151886; Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394; MARTIN EJ, 1994, DRUG DEVELOP RES, V31, P135, DOI 10.1002/ddr.430310208; Martin LF, 2007, INT REV NEUROBIOL, V78, P225, DOI 10.1016/S0074-7742(06)78008-4; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; Mashkina AP, 2007, NEUROCHEM INT, V51, P356, DOI 10.1016/j.neuint.2007.04.009; Mashkina AP, 2010, CELL MOL NEUROBIOL, V30, P901, DOI 10.1007/s10571-010-9519-7; Maskell PD, 2003, BRIT J PHARMACOL, V140, P1313, DOI 10.1038/sj.bjp.0705559; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; Mennerick S, 2000, MOL NEUROBIOL, V22, P41; Meyer EM, 1997, BRAIN RES, V768, P49, DOI 10.1016/S0006-8993(97)00536-2; Meyer EM, 1998, J PHARMACOL EXP THER, V284, P1026; Meyer EM, 1998, BRAIN RES, V786, P252, DOI 10.1016/S0006-8993(97)00300-4; Mielke JG, 2009, NEUROSCI RES, V65, P296, DOI 10.1016/j.neures.2009.08.003; Mike A, 2000, BRAIN RES, V882, P155, DOI 10.1016/S0006-8993(00)02863-8; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; Nakazawa H, 1999, J NEUROCHEM, V73, P1075, DOI 10.1046/j.1471-4159.1999.0731075.x; Nimmrich V, 2008, J NEUROSCI, V28, P788, DOI 10.1523/JNEUROSCI.4771-07.2008; Nizri E, 2006, NEUROPHARMACOLOGY, V50, P540, DOI 10.1016/j.neuropharm.2005.10.013; Nizri E, 2009, J IMMUNOL, V183, P6681, DOI 10.4049/jimmunol.0902212; Nordberg A, 2001, BIOL PSYCHIAT, V49, P200, DOI 10.1016/S0006-3223(00)01125-2; NORDBERG A, 1986, NEUROSCI LETT, V72, P115, DOI 10.1016/0304-3940(86)90629-4; North WG, 2010, BREAST CANCER RES TR, V122, P307, DOI 10.1007/s10549-009-0556-1; NUTTER TJ, 1995, J GEN PHYSIOL, V105, P701, DOI 10.1085/jgp.105.6.701; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Oh MM, 2006, NEUROSCIENCE, V137, P113, DOI 10.1016/j.neuroscience.2005.08.063; Okubo Y, 2010, P NATL ACAD SCI USA, V107, P6526, DOI 10.1073/pnas.0913154107; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI 10.1001/archpsyc.63.6.630; Paleari L, 2008, CELL PROLIFERAT, V41, P936, DOI 10.1111/j.1365-2184.2008.00566.x; Palma E, 1999, J BIOL CHEM, V274, P18335, DOI 10.1074/jbc.274.26.18335; Papadia S, 2007, NEUROSCIENTIST, V13, P572, DOI 10.1177/1073858407305833; Papke RL, 1996, NEUROSCI LETT, V213, P201; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Parikh V, 2006, J NEUROCHEM, V97, P488, DOI 10.1111/j.1471-4159.2006.03766.x; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Pichat P, 2007, NEUROPSYCHOPHARMACOL, V32, P17, DOI 10.1038/sj.npp.1301188; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Plosker GL, 2005, PHARMACOECONOMICS, V23, P193, DOI 10.2165/00019053-200523020-00010; Pokorska A, 2003, J NEUROCHEM, V84, P447, DOI 10.1046/j.1471-4159.2003.01504.x; Qi XL, 2007, NEUROCHEM INT, V51, P377, DOI 10.1016/j.neuint.2007.04.002; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Ren K, 2007, NEUROSCIENCE, V148, P230, DOI 10.1016/j.neuroscience.2007.05.013; Ren K, 2007, NEUROSCIENCE, V145, P314, DOI 10.1016/j.neuroscience.2006.11.023; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Roncarati R, 2008, ASSAY DRUG DEV TECHN, V6, P181, DOI 10.1089/adt.2007.120; Rosa AO, 2006, J MOL NEUROSCI, V30, P61, DOI 10.1385/JMN:30:1:61; Ross RG, 2010, J CHILD PSYCHOL PSYC, V51, P535, DOI 10.1111/j.1469-7610.2009.02187.x; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rusakov DA, 2004, CEREB CORTEX, V14, P748, DOI 10.1093/cercor/bhh035; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; Sarkar SN, 2008, P NATL ACAD SCI USA, V105, P15148, DOI 10.1073/pnas.0802379105; Sarter M, 2005, NAT REV NEUROSCI, V6, P48, DOI 10.1038/nrn1588; Schneider LS, 2011, ARCH NEUROL-CHICAGO, V68, P58, DOI 10.1001/archneurol.2010.343; Schugens MM, 1997, NEUROSCI LETT, V224, P57, DOI 10.1016/S0304-3940(97)13452-8; Scragg JL, 2004, FASEB J, V18, P150, DOI 10.1096/fj.04-2659fje; SCREMIN OU, 1991, STROKE, V22, P643, DOI 10.1161/01.STR.22.5.643; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shao ZY, 2000, J PHYSIOL-LONDON, V527, P507, DOI 10.1111/j.1469-7793.2000.00507.x; Sharma G, 2002, J NEUROBIOL, V53, P524, DOI 10.1002/neu.10114; Shimohama S, 1998, BRAIN RES, V779, P359, DOI 10.1016/S0006-8993(97)00194-7; SHIMOHAMA S, 1986, J NEUROCHEM, V46, P288, DOI 10.1111/j.1471-4159.1986.tb12960.x; Shimohama S, 2001, BIOL PSYCHIAT, V49, P233, DOI 10.1016/S0006-3223(00)01100-8; Skok MV, 2007, LIFE SCI, V80, P2334, DOI 10.1016/j.lfs.2007.02.005; Smith CC, 2006, J NEUROSCI, V26, P8517, DOI 10.1523/JNEUROSCI.5279-05.2006; Soderman A, 2008, BRAIN RES, V1227, P240, DOI 10.1016/j.brainres.2008.06.062; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stevens KE, 1996, NEUROPSYCHOPHARMACOL, V15, P152, DOI 10.1016/0893-133X(95)00178-G; Sudweeks SN, 2000, J PHYSIOL-LONDON, V527, P515, DOI 10.1111/j.1469-7793.2000.00515.x; Swerdlow NR, 2009, NEUROPSYCHOPHARMACOL, V34, P1854, DOI 10.1038/npp.2009.7; Tachibana N, 2010, INTERNAL MED, V49, P2167, DOI 10.2169/internalmedicine.49.4069; Takeuchi H, 2009, J NEUROSCI RES, V87, P576, DOI 10.1002/jnr.21869; Tatsumi R, 2006, J MED CHEM, V49, P4374, DOI 10.1021/jm060249c; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Thibault O, 2001, J NEUROSCI, V21, P9744, DOI 10.1523/JNEUROSCI.21-24-09744.2001; Thomsen MS, 2010, CURR PHARM DESIGN, V16, P323, DOI 10.2174/138161210790170094; Timmermann DB, 2007, J PHARMACOL EXP THER, V323, P294, DOI 10.1124/jpet.107.120436; Tovar KR, 2002, NEURON, V34, P253; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Ueda K, 1997, J NEUROCHEM, V68, P265; Uteshev VV, 2010, ACTA BIOCH BIOPH SIN, V42, P8, DOI 10.1093/abbs/gmp101; Uteshev VV, 1997, BIOPHYS J, V72, P1127, DOI 10.1016/S0006-3495(97)78761-7; Uteshev VV, 1996, PFLUG ARCH EUR J PHY, V432, P607, DOI 10.1007/s004240050176; Uteshev VV, 2005, NEUROSCIENCE, V134, P133, DOI 10.1016/j.neuroscience.2005.03.013; Uteshev VV, 1996, BIOPHYS J, V71, P1256, DOI 10.1016/S0006-3495(96)79325-6; Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002; Uteshev VV, 2002, BRAIN RES, V948, P33, DOI 10.1016/S0006-8993(02)02946-3; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Valera E, 2008, NEUROCHEM INT, V53, P148, DOI 10.1016/j.neuint.2008.07.007; van Kampen M, 2004, PSYCHOPHARMACOLOGY, V172, P375, DOI 10.1007/s00213-003-1668-7; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Vercelletto M, 2011, J ALZHEIMERS DIS, V23, P749, DOI 10.3233/JAD-2010-101632; Virginio C, 2002, EUR J PHARMACOL, V445, P153, DOI 10.1016/S0014-2999(02)01750-8; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HY, 2009, J NEUROSCI, V29, P10961, DOI 10.1523/JNEUROSCI.6088-08.2009; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2003, J BIOL CHEM, V278, P31547, DOI 10.1074/jbc.M212532200; WEISS JH, 1994, J NEUROCHEM, V62, P372; Wishka DG, 2006, J MED CHEM, V49, P4425, DOI 10.1021/jm0602413; Woodruff-Pak DS, 2000, EXP AGING RES, V26, P323, DOI 10.1080/036107300750015723; Woodruff-Pak DS, 2003, BEHAV BRAIN RES, V143, P159, DOI 10.1016/S0166-4328(03)00039-1; WOODRUFFPAK DS, 1994, BRAIN RES, V645, P309, DOI 10.1016/0006-8993(94)91665-9; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Young GT, 2008, P NATL ACAD SCI USA, V105, P14686, DOI 10.1073/pnas.0804372105; Yu CR, 1998, J PHYSIOL-LONDON, V509, P651, DOI 10.1111/j.1469-7793.1998.651bm.x; Yu CR, 1998, J PHYSIOL-LONDON, V509, P667, DOI 10.1111/j.1469-7793.1998.667bm.x; Zhang ZW, 1996, NEURON, V17, P1231, DOI 10.1016/S0896-6273(00)80253-6; Zheng KY, 2008, BIOPHYS J, V95, P4584, DOI 10.1529/biophysj.108.129874	251	38	38	0	5	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	978-94-007-2887-5; 978-94-007-2888-2	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2012	740						603	638		10.1007/978-94-007-2888-2_27	10.1007/978-94-007-2888-2		36	Medicine, Research & Experimental; Neurosciences	Research & Experimental Medicine; Neurosciences & Neurology	BA3EQ	WOS:000334165700028	22453962	Green Accepted			2021-06-18	
J	Zhang, ZR; Zhang, ZY; Wu, YZ; Schluesener, HJ				Zhang, Zhiren; Zhang, Zhi-Yuan; Wu, Yuzhang; Schluesener, Hermann J.			Immunolocalization of Toll-Like Receptors 2 and 4 as well as Their Endogenous Ligand, Heat Shock Protein 70, in Rat Traumatic Brain Injury	NEUROIMMUNOMODULATION			English	Article						Traumatic brain injury; Toll-like receptor 2; Toll-like receptor 4; Myeloid differentiation factor 88; Heat shock protein 70; Innate immunity	CENTRAL-NERVOUS-SYSTEM; HEAT-SHOCK PROTEINS; INNATE IMMUNE-SYSTEM; CEREBRAL ISCHEMIA/REPERFUSION; EXPERIMENTAL STROKE; HEME OXYGENASE-1; HSP70; INFLAMMATION; EXPRESSION; ISCHEMIA	Objective: Toll-like receptors (TLRs) are essential to the innate immune system for recognizing not only microbial pathogens but also endogenous ligands from injured cells, suggesting that TLRs are a sensitive detection system to tissue injury and play roles in initiating tissue degeneration/regeneration. In this study, the effects of traumatic brain injury (TBI) on lesional expression of TLR2, TLR4, their most common adaptor molecule myeloid differentiation factor 88 (MyD88) and their endogenous ligand, heat shock protein 70 (HSP70), were investigated. Methods: Rat TBI was induced using an open-skull weight-drop model. TLR2, TLR4, MyD88 and HSP70 expression was studied by immunohistochemistry. Results: TLR2, TLR4, HSP70 and MyD88 were mainly found in lesioned regions and subcortical white matter. While infiltration of TLR2+ cells became significant on day 2, significant accumulation of TLR4+, MyD88+ and HSP70+ cells was already seen on day 1, and the numbers of immunopositive cells increased continuously until day 4. Furthermore, double staining together with morphological classification showed that major cellular sources for TLR2, TLR4 and MyD88 were macrophages/microglia in lesioned areas and astrocytes in subcortical white matter. But for HSP70, the major cellular sources were neurons in perilesion and macrophages/microglia in lesion areas and astrocytes in subcortical white matter. Discussion: In summary, our data reveal distinct patterns of localization of TLR+ resident and infiltrating cells in TBI rat brain. Infiltrating activated monocytic cells are the major source of TLR+ cells. These findings warrant further investigation of the roles of TLRs in controlling immune and degenerative/regenerative processes after TBI. Copyright (C) 2011 S. Karger AG, Basel	[Zhang, Zhiren; Wu, Yuzhang] Third Mil Univ PLA, Inst Immunol, Chongqing, Peoples R China; [Zhang, Zhiren; Zhang, Zhi-Yuan; Schluesener, Hermann J.] Univ Tubingen, Inst Brain Res, Tubingen, Germany	Zhang, ZR (corresponding author), Third Mil Med Univ PLA, Inst Immunol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835; Zhang, Zhi-Yuan/0000-0001-9067-0670; Wu, Yuzhang/0000-0002-4049-0214	Natural Science Foundation of CQ CSTCNatural Science Foundation Project of CQ CSTC [2010BB5025]	This research was partly supported by the Natural Science Foundation Project of CQ CSTC (contract No. 2010BB5025).	Ahn TB, 2006, BRAIN RES, V1087, P159, DOI 10.1016/j.brainres.2006.02.097; Aravalli RN, 2007, J NEUROIMMUNE PHARM, V2, P297, DOI 10.1007/s11481-007-9071-5; Arumugam TV, 2009, SHOCK, V32, P4, DOI 10.1097/SHK.0b013e318193e333; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bhat R, 2009, NEURON, V64, P123, DOI 10.1016/j.neuron.2009.09.015; Bian QM, 2007, BRAIN RES, V1184, P270, DOI 10.1016/j.brainres.2007.09.054; Brown MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1201, DOI 10.2741/1304; Carpentier PA, 2008, BRAIN BEHAV IMMUN, V22, P140, DOI 10.1016/j.bbi.2007.08.011; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Crack PJ, 2007, IMMUNOL CELL BIOL, V85, P476, DOI 10.1038/sj.icb.7100103; DeGracia DJ, 2007, NEUROL RES, V29, P356, DOI 10.1179/016164107X204666; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; Kinoshita Y, 2001, J NEUROTRAUM, V18, P435, DOI 10.1089/089771501750171038; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Kumar H, 2009, BIOCHEM BIOPH RES CO, V388, P621, DOI 10.1016/j.bbrc.2009.08.062; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Marsh BJ, 2009, NEUROSCIENCE, V158, P1007, DOI 10.1016/j.neuroscience.2008.07.067; Mautes AEM, 2000, BRAIN RES, V883, P233, DOI 10.1016/S0006-8993(00)02846-8; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Papadimitraki ED, 2007, J AUTOIMMUN, V29, P310, DOI 10.1016/j.jaut.2007.09.001; Park C, 2008, NEUROSCI LETT, V431, P123, DOI 10.1016/j.neulet.2007.11.057; Pavlik A, 2007, PROG BRAIN RES, V162, P417, DOI 10.1016/S0079-6123(06)62020-7; Pineau I, 2009, GLIA, V57, P351, DOI 10.1002/glia.20763; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Reddy SJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E4; Reynolds LPR, 2003, CEREBELLUM, V2, P171, DOI 10.1080/14734220310016114; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Shirali AC, 2008, CURR OPIN ORGAN TRAN, V13, P20, DOI 10.1097/MOT.0b013e3282f3df04; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tanaka S, 2002, J NEUROSCI RES, V67, P37, DOI 10.1002/jnr.10078.abs; Tsan MF, 2009, J LEUKOCYTE BIOL, V85, P905, DOI 10.1189/jlb.0109005; Tytell M, 2005, INT J HYPERTHER, V21, P445, DOI 10.1080/02656730500041921; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; van Noort JM, 2009, PROG BRAIN RES, V175, P139, DOI 10.1016/S0079-6123(09)17509-X; Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299; Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zhang ZY, 2009, NEUROSCIENCE, V159, P136, DOI 10.1016/j.neuroscience.2008.12.034; Zhang ZR, 2006, EXP NEUROL, V197, P252, DOI 10.1016/j.expneurol.2005.09.015; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	49	38	42	0	17	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2012	19	1					10	19		10.1159/000326771			10	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	844MH	WOS:000296750800002	22067617				2021-06-18	
J	Lepore, AC; O'Donnell, J; Kim, AS; Yang, EJ; Tuteja, A; Haidet-Phillips, A; O'Banion, CP; Maragakis, NJ				Lepore, Angelo C.; O'Donnell, John; Kim, Andrew S.; Yang, Eun Ju; Tuteja, Alisha; Haidet-Phillips, Amanda; O'Banion, Colin P.; Maragakis, Nicholas J.			Reduction in Expression of the Astrocyte Glutamate Transporter, GLT1, Worsens Functional and Histological Outcomes Following Traumatic Spinal Cord Injury	GLIA			English	Article						secondary injury; GLT1+/- mice; crush injury; glutamate uptake; excitotoxicity	MICE LACKING; BRAIN-INJURY; AMINO-ACIDS; MECHANISMS; DISEASE; NMDA; TRANSPLANTATION; CONTRIBUTES; ANTAGONIST; PATHOLOGY	The astrocyte glutamate transporter, GLT1, is responsible for the vast majority of glutamate uptake in the adult central nervous system (CNS), thereby regulating extracellular glutamate homeostasis and preventing excitotoxicity. Glutamate dysregulation plays a central role in outcome following traumatic spinal cord injury (SCI). To determine the role of GLT1 in secondary cell loss following SCI, mice heterozygous for the GLT1 astrocyte glutamate transporter (GLT1(+/-)) and wild-type mice received thoracic crush SCI. Compared with wild-type controls, GLT1(+/-) mice had an attenuated recovery in hindlimb motor function, increased lesion size, and decreased tissue sparing. GLT1(+/-) mice showed a decrease in intraspinal GLT1 protein and functional glutamate uptake compared with wild-type mice, accompanied by increased apoptosis and neuronal loss following crush injury. These results suggest that astrocyte GLT1 plays a role in limiting secondary cell death following SCI, and also show that compromise of key astrocyte functions has significant effects on outcome following traumatic CNS injury. These findings also suggest that increasing intraspinal GLT1 expression may represent a therapeutically relevant target for SCI treatment. (C) 2011 Wiley-Liss, Inc.	[O'Donnell, John; Kim, Andrew S.; Yang, Eun Ju; Tuteja, Alisha; Haidet-Phillips, Amanda; O'Banion, Colin P.; Maragakis, Nicholas J.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Lepore, Angelo C.] Thomas Jefferson Univ, Coll Med, Dept Neurosci, Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA	Maragakis, NJ (corresponding author), Johns Hopkins Sch Med, Dept Neurol, 855 N Wolfe St,Rangos 250, Baltimore, MD 21205 USA.	nmaragak@jhmi.edu		O'Donnell, John/0000-0002-0774-9028	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32-NS059155]; Paralyzed Veterans of America [160837]; Craig H. Neilsen Foundation [190140]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS059155] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant number: F32-NS059155; Grant sponsor: Paralyzed Veterans of America; Grant number: 160837; Grant sponsor: Craig H. Neilsen Foundation; Grant number: 190140;	Agrawal SK, 1997, J NEUROSCI, V17, P1055; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Cao H, 2008, NEUROSCI BIOBEHAV R, V32, P972, DOI 10.1016/j.neubiorev.2008.03.009; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; HOLTZ A, 1991, ACTA NEUROL SCAND, V84, P334, DOI 10.1111/j.1600-0404.1991.tb04964.x; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Lepore AC, 2008, NAT NEUROSCI, V11, P1294, DOI 10.1038/nn.2210; Lepore AC, 2011, J NEUROSCI RES, V89, P1001, DOI 10.1002/jnr.22624; Li S, 1999, J Neurosci, V19, pRC16; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; McDonald JW, 2003, AM J PHYS MED REHAB, V82, pS38, DOI 10.1097/01.PHM.0000086994.53716.17; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Mu XJ, 2002, J NEUROTRAUM, V19, P917, DOI 10.1089/089771502320317078; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Olsen ML, 2010, BRAIN, V133, P1013, DOI 10.1093/brain/awq049; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Pardo AC, 2006, EXP NEUROL, V201, P120, DOI 10.1016/j.expneurol.2006.03.028; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Paul C, 2009, SPINE, V34, P328, DOI 10.1097/BRS.0b013e31819403ce; Plemel JR, 2008, J NEUROTRAUM, V25, P350, DOI 10.1089/neu.2007.0426; Rosenberg LJ, 1999, J NEUROSCI, V19, P464; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Vera-Portocarrero LP, 2002, BRAIN RES, V927, P104, DOI 10.1016/S0006-8993(01)03329-7; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu GY, 2005, NEUROSCI LETT, V384, P271, DOI 10.1016/j.neulet.2005.04.100; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	36	38	39	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0894-1491			GLIA	Glia	DEC	2011	59	12					1996	2005		10.1002/glia.21241			10	Neurosciences	Neurosciences & Neurology	833KY	WOS:000295885500017	21882244	Green Accepted			2021-06-18	
J	Rabago, CA; Wilken, JM				Rabago, Christopher A.; Wilken, Jason M.			Application of a Mild Traumatic Brain Injury Rehabilitation Program in a Virtual Realty Environment: A Case Study	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						mild traumatic brain injury; postconcussive syndrome military; rehabilitation; virtual reality; visual vertigo	STABILITY FOLLOWING CONCUSSION; SPATIAL ORIENTATION; POSTURAL STABILITY; VISUAL VERTIGO; HEAD-INJURY; BALANCE; REALITY; RELIABILITY; VALIDITY	Background and Purpose: Mild traumatic brain injury (mTBI) can compromise reaction time, visual perception, memory, attention, balance, and gait. These deficits, especially if persistent, can restrict participation in daily activities and the resumption of personal and profession roles. The purpose of this case study is to describe an mTBI-specific clinical assessment and rehabilitation intervention administered in a virtual reality environment. Case Description: The case involved a 31-year-old male service member who had sustained an mTBI (concussion) during a recreational softball game 36 days prior to physical therapist evaluation. He had complaints of severe visual and physical motion intolerance. He demonstrated impaired static balance and was restricted from full military duty. Interventions: The assessment included measurements of postural and gait balance during cognitive, visual, and vestibular challenges within a Computer-Assisted Rehabilitation Environment. Phase 1 of the intervention consisted of clinical techniques (ie, optokinetic stimulation/habituation, visual/physical perturbations, and postural stability exercises) targeting specific impairments. Phase 2 training consisted of weapon handling and target recognition tasks to simulate the requirements of his military occupation. Outcomes: At the conclusion of 6 treatments, the patient demonstrated significant increases in postural and gait balance with a near complete resolution of all postconcussion symptoms. He successfully returned to full duty and training for combat deployment. Discussion: Service members and civilians exhibit similar impairments, limitations, and restrictions following mTBI. A rehabilitation program delivered in a virtual-reality environment can be structured to manage complex mTBI symptoms through the integration of multiple treatment modalities specific to a patient's personal and professional roles.	[Rabago, Christopher A.; Wilken, Jason M.] Brooke Army Med Ctr, Dept Orthoped & Rehabil, Ctr Intrepid, Ft Sam Houston, TX 78234 USA	Rabago, CA (corresponding author), Brooke Army Med Ctr, Dept Orthoped & Rehabil, Ctr Intrepid, 3851 Roger Brooke Drv, Ft Sam Houston, TX 78234 USA.	Christopher.Rabago@amedd.army.mil		Wilken, Jason/0000-0002-5556-7667; Rabago, Christopher/0000-0002-4484-0613	Medical Research and Material Command's Military Operational Medicine Research Program; Brooke Army Medical Center's traumatic brain injury service	Support provided by Medical Research and Material Command's Military Operational Medicine Research Program (to J.M.W.).; We thank our CAREN application designer, Michael Vernon, for his technical expertise in the development of treatment applications; Mustafa Shinta for data collection assistance; Dr Tedesco-Evans and Mrs Marina LeBlanc for the patient referral; and all the providers at Brooke Army Medical Center's traumatic brain injury service for their support.	Akin FW, 2003, J REHABIL RES DEV, V40, P415, DOI 10.1682/JRRD.2003.09.0415; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bisson E, 2007, CYBERPSYCHOL BEHAV, V10, P16, DOI 10.1089/cpb.2006.9997; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Chang CP, 2008, CYBERPSYCHOL BEHAV, V11, P495, DOI 10.1089/cpb.2007.0075; Clendaniel RA, 2010, J NEUROL PHYS THER, V34, P111, DOI 10.1097/NPT.0b013e3181deca01; Cox DJ, 2010, MIL MED, V175, P411, DOI 10.7205/MILMED-D-09-00081; Flynn Sheryl, 2007, J Neurol Phys Ther, V31, P180, DOI 10.1097/NPT.0b013e31815d00d5; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Guerraz M, 2001, BRAIN, V124, P1646, DOI 10.1093/brain/124.8.1646; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keshner EA, 2009, STUD HEALTH TECHNOL, V145, P209, DOI 10.3233/978-1-60750-018-6-209; Lovell M, 2009, PHYS MED REH CLIN N, V20, P39, DOI 10.1016/j.pmr.2008.10.003; McAndrew PM, 2010, J BIOMECH, V43, P1470, DOI 10.1016/j.jbiomech.2010.02.003; McComas J, 2002, J NEUROL PHYS THER, V26, P55, DOI DOI 10.1097/01253086-200226020-00002; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Plisky PJ, 2006, J ORTHOP SPORT PHYS, V36, P911, DOI 10.2519/jospt.2006.2244; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; van der Eerden WJ, 1999, ST HEAL T, V62, P373; Whitney SL, 2007, ARCH PHYS MED REHAB, V88, P99, DOI 10.1016/j.apmr.2006.10.027; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D	30	38	42	0	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	DEC	2011	35	4					185	193		10.1097/NPT.0b013e318235d7e6			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	890YU	WOS:000300183800006	22027473				2021-06-18	
J	Higgins, GC; Devenish, RJ; Beart, PM; Nagley, P				Higgins, Gavin C.; Devenish, Rodney J.; Beart, Philip M.; Nagley, Phillip			Autophagic activity in cortical neurons under acute oxidative stress directly contributes to cell death	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						Neurons; Oxidative stress; Programmed cell death; Autophagy; Caspases; LC3; Atg7; Beclin 1	CASPASE-MEDIATED CLEAVAGE; TRAUMATIC BRAIN-INJURY; HYPOXIA-ISCHEMIA; CROSS-TALK; IN-VITRO; BECLIN 1; APOPTOSIS; MITOCHONDRIAL; MECHANISMS; NEURODEGENERATION	Primary neurons undergo insult-dependent programmed cell death. We examined autophagy as a process contributing to cell death in cortical neurons after treatment with either hydrogen peroxide (H(2)O(2)) or staurosporine. Although caspase-9 activation and cleavage of procaspase-3 were significant following staurosporine treatment, neither was observed following H(2)O(2) treatment, indicating a non-apoptotic death. Autophagic activity increased rapidly with H(2)O(2), but slowly with staurosporine, as quantified by processing of endogenous LC3. Autophagic induction by both stressors increased the abundance of fluorescent puncta formed by GFP-LC3, which could be blocked by 3-methyladenine. Significantly, such inhibition of autophagy blocked cell death induced by H(2)O(2) but not staurosporine. Suppression of Atg7 inhibited cell death by H(2)O(2), but not staurosporine, whereas suppression of Beclin 1 prevented cell death by both treatments, suggesting it has a complex role regulating both apoptosis and autophagy. We conclude that autophagic mechanisms are activated in an insult-dependent manner and that H(2)O(2) induces autophagic cell death.	[Higgins, Gavin C.; Devenish, Rodney J.; Nagley, Phillip] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [Devenish, Rodney J.; Nagley, Phillip] Monash Univ, Ctr Excellence Struct & Funct Microbial Genom, Australian Res Council, Clayton, Vic 3800, Australia; [Beart, Philip M.] Univ Melbourne, Florey Neurosci Inst, Parkville, Vic 3010, Australia; [Beart, Philip M.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia	Nagley, P (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Bldg 13D,Clayton Campus, Clayton, Vic 3800, Australia.	phillip.nagley@monash.edu	Higgins, Gavin/I-3731-2019	Higgins, Gavin/0000-0003-4045-9687	National Health and Medical Research Council (Australia)National Health and Medical Research Council of Australia; Australian Research CouncilAustralian Research Council	We thank Ms. Sue Ekkel for technical assistance with Western immunoblotting and Dr. Danielle Smith for technical advice. This work was supported by the National Health and Medical Research Council (Australia), of which Philip M. Beart is a Research Fellow. Phillip Nagley and Rodney J. Devenish are also supported by the Australian Research Council.	Baba H, 2009, J VASC SURG, V50, P381, DOI 10.1016/j.jvs.2009.03.042; Barbouti A, 2007, FREE RADICAL BIO MED, V43, P1377, DOI 10.1016/j.freeradbiomed.2007.06.020; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Beart PM, 2007, J NEUROCHEM, V103, P2408, DOI 10.1111/j.1471-4159.2007.04937.x; Blomgren K, 2007, APOPTOSIS, V12, P993, DOI 10.1007/s10495-007-0754-4; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; Chakrabarti L, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-24; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163; Cheung NS, 2000, J NEUROCHEM, V74, P1613, DOI 10.1046/j.1471-4159.2000.0741613.x; Chu CT, 2009, METHOD ENZYMOL, V453, P217, DOI 10.1016/S0076-6879(08)04011-1; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Diwakarla S, 2009, CELL MOL LIFE SCI, V66, P156, DOI 10.1007/s00018-008-8490-7; Diwakarla S, 2009, J NEUROCHEM, V109, P198, DOI 10.1111/j.1471-4159.2009.05937.x; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004; Garcia-Arencibia M, 2010, SEMIN CELL DEV BIOL, V21, P691, DOI 10.1016/j.semcdb.2010.02.008; Gill MB, 2008, NEUROCHEM RES, V33, P2379, DOI 10.1007/s11064-008-9649-1; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Higgins GC, 2010, J ALZHEIMERS DIS, V20, pS453, DOI 10.3233/JAD-2010-100321; Higgins GC, 2009, CELL MOL LIFE SCI, V66, P2773, DOI 10.1007/s00018-009-0079-2; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16; Jenner Peter, 2007, Handb Clin Neurol, V83, P507, DOI 10.1016/S0072-9752(07)83024-7; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lang-Rollin ICJ, 2003, J NEUROSCI, V23, P11015; Lee YJ, 2000, FREE RADICAL BIO MED, V29, P684, DOI 10.1016/S0891-5849(00)00366-X; Lim MLR, 2006, EXP CELL RES, V312, P1174, DOI 10.1016/j.yexcr.2006.01.026; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377; Maycotte P, 2010, J NEUROSCI RES, V88, P73, DOI 10.1002/jnr.22168; Mehrpour M, 2010, AM J PHYSIOL-CELL PH, V298, pC776, DOI 10.1152/ajpcell.00507.2009; Nagley P, 2010, BBA-MOL BASIS DIS, V1802, P167, DOI 10.1016/j.bbadis.2009.09.004; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yamashima T, 2009, PROG NEUROBIOL, V89, P343, DOI 10.1016/j.pneurobio.2009.09.003; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	60	38	40	0	11	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	NOV	2011	68	22					3725	3740		10.1007/s00018-011-0667-9			16	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	849LB	WOS:000297125900011	21437645				2021-06-18	
J	Talving, P; Lustenberger, T; Lam, L; Inaba, K; Mohseni, S; Plurad, D; Green, DJ; Demetriades, D				Talving, Peep; Lustenberger, Thomas; Lam, Lydia; Inaba, Kenji; Mohseni, Shahin; Plurad, David; Green, Donald J.; Demetriades, Demetrios			Coagulopathy After Isolated Severe Traumatic Brain Injury in Children	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Traumatic brain injury; Children; Pediatric; Coagulopathy; Outcome; Risk factor; Mortality	SEVERE HEAD-INJURY; COAGULATION; ADOLESCENTS; DISORDERS	Introduction: Few previous studies have been conducted on the severe traumatic brain injury (sTBI)-associated coagulopathy in children. The purpose of this study was to evaluate the incidence and risk factors of sTBI coagulopathy in a pediatric cohort and to evaluate its impact on outcomes. Methods: Retrospective analysis of pediatric patients (younger than 18 years) sustaining isolated sTBI [head Abbreviated Injury Scale (AIS) score >= 3 and extracranial injuries AIS score <3]. Criteria for sTBI-associated coagulopathy included thrombocytopenia (platelet count <100,000 per mm(3)) and/or elevated international normalized ratio >1.2 and/or prolonged activated partial thromboplastin time >36 seconds. Incidence and risk factors of sTBI coagulopathy and its impact on in-hospital outcomes were analyzed. Results: Overall, 42.8% (n = 137) of the 320 patients studied developed coagulopathy, with increasing incidence in a stepwise fashion with escalating head AIS score (31.1, 46.2, and 88.6% for head AIS score 3, 4, and 5, respectively; p < 0.001). Depressed GCS, increasing age, an ISS >= 16, and brain contusions/lacerations were independently associated with the presence of coagulopathy. The case fatality rate was 7.8% (n = 25); 17.5% versus 0.5% in coagulopathic versus noncoagulopathic patients, respectively. After logistic regression to adjust for confounders, no statistical significant mortality difference in patients with and without coagulopathy was noted (adjusted p = 0.912). Conclusions: Incidence of coagulopathy in children suffering isolated sTBI is exceedingly high at 40% and reflect the head injury severity. A low GCS, increasing age, ISS >= 16 and intraparenchymal lesions proved to be independently associated with TBI coagulopathy.	[Talving, Peep; Lustenberger, Thomas; Lam, Lydia; Inaba, Kenji; Mohseni, Shahin; Plurad, David; Green, Donald J.; Demetriades, Demetrios] Univ So Calif, Div Acute Care Surg Trauma Emergency Surg & Surg, Dept Surg, Keck Sch Med,Med Ctr, Los Angeles, CA 90033 USA	Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles Cty Gen Hosp LAC USC, 1200 N State St,C5L100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	INABA, KENJI/AAC-8532-2020; Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jakob H, 2010, EUR J TRAUMA EMERG S, V36, P325, DOI 10.1007/s00068-010-1125-3; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Melo JRT, 2009, CHILD NERV SYST, V25, P1077, DOI 10.1007/s00381-009-0924-5; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	21	38	38	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1205	1210		10.1097/TA.0b013e31820d151d			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600026	21427617				2021-06-18	
J	Beziaud, T; Chen, XR; El Shafey, N; Frechou, M; Teng, F; Palmier, B; Beray-Berthat, V; Soustrat, M; Margaill, I; Plotkine, M; Marchand-Leroux, C; Besson, VC				Beziaud, Tiphaine; Chen, Xiao Ru; El Shafey, Nelly; Frechou, Magalie; Teng, Fei; Palmier, Bruno; Beray-Berthat, Virginie; Soustrat, Mathieu; Margaill, Isabelle; Plotkine, Michel; Marchand-Leroux, Catherine; Besson, Valerie C.			Simvastatin in traumatic brain injury: Effect on brain edema mechanisms	CRITICAL CARE MEDICINE			English	Article						blood-brain barrier; brain edema; claudin; polymorphonuclear neutrophil; simvastatin; traumatic brain injury	CADHERIN TYROSINE PHOSPHORYLATION; REDUCES NEUROLOGICAL DEFICIT; MEDIATED UP-REGULATION; VE-CADHERIN; ENDOTHELIAL-CELLS; BARRIER BREAKDOWN; TIGHT JUNCTIONS; ALPHA AGONIST; NITRIC-OXIDE; RATS	Objectives: Traumatic brain injury causes deleterious brain edema, leading to high mortality and morbidity. Brain edema exacerbates neurologic deficits and may be attributable to the breakdown of endothelial cell junction protein, leukocyte infiltration, and matrix metalloproteinase activation. These all contribute to loss of blood-brain barrier integrity. The pleiotropic effects of statins, hydroxymethylglutaryl-coenzyme A reductase inhibitors, may inhibit posttraumatic brain edema. We therefore investigated the effect of acute simvastatin on neurologic deficits, cerebral edema, and its origins. Design: Randomized laboratory animal study. Settings: University-affiliated research laboratory. Subjects: Male Sprague-Dawley rats. Interventions: Rats were subjected to lateral fluid percussion traumatic brain injury. Our preliminary dose-effect study indicated that 37.5 mg/kg simvastatin, administered orally 1 hr and 6 hrs after traumatic brain injury, has the greatest anti-edematous effect. This dose was used to study its effects on brain edema and on its mechanisms. Measurements and Main Results: We first assessed the effects of simvastatin 24 hrs after traumatic brain injury on brain edema, brain claudin-5 expression, and the vascular endothelial-cadherin pTyr731)/total vascular endothelial-cadherin ratio, matrix metalloproteinase-9 activity, intercellular adhesion molecule-1 expression, and polymorphonuclear neutrophil infiltration. We also evaluated blood-brain barrier permeability by measuring Evans blue and fluorescein sodium salt extravasation into the cerebral parenchyma. We then investigated whether simvastatin reduces neurologic deficits, edema, and blood-brain barrier permeability earlier than 24 hrs; these effects were evaluated 6 hrs after traumatic brain injury. The anti-edematous effect of simvastatin 24 hrs after traumatic brain injury was associated with increased claudin-5 and decreased intercellular adhesion molecule-1, polymorphonuclear neutrophil infiltration, and blood-brain barrier permeability, with no effect on matrix metalloproteinase-9 activity or vascular endothelial-cadherin phosphorylation. Earlier, 6-hrs after traumatic brain injury, simvastatin reduced neurologic deficits, cerebral edema, and blood-brain barrier permeability. Conclusions: Simvastatin could be a new therapy for reducing posttraumatic edema by preventing damage to tight junctions and neutrophil infiltration into the parenchyma, thus preserving blood-brain barrier integrity. (Crit Care Med 2011; 39:2300-2307)	[Beziaud, Tiphaine; Chen, Xiao Ru; El Shafey, Nelly; Frechou, Magalie; Teng, Fei; Palmier, Bruno; Beray-Berthat, Virginie; Soustrat, Mathieu; Margaill, Isabelle; Plotkine, Michel; Marchand-Leroux, Catherine; Besson, Valerie C.] Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA4475, Paris, France	Besson, VC (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA4475, Paris, France.	valerie.besson@parisdescartes.fr	BESSON, VALERIE/AAZ-9989-2020; MARCHAND-LEROUX, Catherine/L-7453-2017; besson, valerie C/L-7388-2017; Margaill, Isabelle/ABA-4362-2020; Frechou, Magalie/I-6598-2015	BESSON, VALERIE/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; besson, valerie C/0000-0002-1491-2380; Margaill, Isabelle/0000-0002-7941-6644; Frechou, Magalie/0000-0001-8676-1000	Fondation Des Gueules Cassees	Supported, in part, by the Fondation Des Gueules Cassees.	Allingham MJ, 2007, J IMMUNOL, V179, P4053, DOI 10.4049/jimmunol.179.6.4053; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Batteur-Parmentier S, 2000, J CEREBR BLOOD F MET, V20, P812, DOI 10.1097/00004647-200005000-00007; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Blecharz KG, 2010, MULT SCLER J, V16, P293, DOI 10.1177/1352458509358189; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; Gavard J, 2008, NAT CELL BIOL, V10, P883, DOI 10.1038/ncb0808-883; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hu JL, 2007, NAT REV DRUG DISCOV, V6, P480, DOI 10.1038/nrd2308; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Kamio K, 2010, EUR RESPIR J, V35, P637, DOI 10.1183/09031936.00134707; Kanoski SE, 2010, J ALZHEIMERS DIS, V21, P207, DOI 10.3233/JAD-2010-091414; Kim SE, 2009, EXP MOL MED, V41, P277, DOI 10.3858/emm.2009.41.4.031; Kurzepa J, 2006, FOLIA BIOL-PRAGUE, V52, P181; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Massaro M, 2010, CARDIOVASC RES, V86, P311, DOI 10.1093/cvr/cvp375; Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/S0008-6363(96)00146-0; Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894; Morofuji Y, 2010, CELL MOL NEUROBIOL, V30, P727, DOI 10.1007/s10571-010-9497-9; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nagyoszi P, 2010, NEUROCHEM INT, V57, P556, DOI 10.1016/j.neuint.2010.07.002; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Soares HD, 1995, J NEUROSCI, V15, P8223; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Turkoglu OF, 2009, SURG NEUROL, V72, P146, DOI 10.1016/j.surneu.2008.07.004; Turowski P, 2005, CELL MOL NEUROBIOL, V25, P153, DOI 10.1007/s10571-004-1380-0; Turowski P, 2008, J CELL SCI, V121, P29, DOI 10.1242/jcs.022681; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360	49	38	42	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2011	39	10					2300	2307		10.1097/CCM.0b013e3182227e4a			8	Critical Care Medicine	General & Internal Medicine	821EU	WOS:000294958500014	21666443				2021-06-18	
J	Gandhi, S; Ranganathan, LK; Solanki, M; Mathew, GC; Singh, I; Bither, S				Gandhi, Sumir; Ranganathan, Laxman Kumar; Solanki, Manisha; Mathew, George C.; Singh, Inderjot; Bither, Saurab			Pattern of maxillofacial fractures at a tertiary hospital in northern India: a 4-year retrospective study of 718 patients	DENTAL TRAUMATOLOGY			English	Article							FACIAL FRACTURES; INJURIES; NIGERIA	Purpose: Pattern and aetiology of maxillofacial injuries varies from one country to another and even within the same country depending on prevailing socio-economic, cultural and environmental factors. Various studies have been carried out in various countries to study the epidemiology and demographics of the maxillofacial injuries but the studies from India are few. Material and methods: Retrospective study was undertaken at Christian Medical College Ludhiana (India) from January 2006 to December 2009. Treatment records of the patients was checked and age, gender, aetiology of injury, associated injuries, maxillofacial fractures and treatment offered were recorded. Results: A total of 1075 fractures were recorded in 718 patients, ranging from 11 months to 85 years of age. Male: female ratio was 6.6:1. Maxillofacial injuries were most common in third decade of life. A total of 517 patients suffered injuries because of road traffic accident, 115 because of accidental fall and 67 because of interpersonal violence. A total of 184 patients had 221 associated injuries of which 56.1% head injuries, 29.0% orthopaedic injuries and 14.9% other injuries were present. Of 596 middle third fractures, 29.8% were managed conservatively; for 21.7% and 48.7% of fractures, closed reduction and open reduction were performed respectively. Of 479 mandibular fractures, 1.8% was managed conservatively; for 16.7% and 81.5% fractures, closed reduction and open reduction were performed respectively. Conclusion: Better socio-economic status of people, increased vehicular movements and non-implementation of road safety norms have increased road traffic accidents. Proper education of the people who are most commonly involved in the RTA can be one of the possible ways to reduce the maxillofacial injuries.	[Gandhi, Sumir; Ranganathan, Laxman Kumar; Solanki, Manisha; Mathew, George C.; Singh, Inderjot; Bither, Saurab] Christian Med Coll & Hosp, Christian Dent Coll, Dept Oral & Maxillofacial Surg, Ludhiana, Punjab, India	Gandhi, S (corresponding author), Christian Med Coll & Hosp, Christian Dent Coll, Dept Oral & Maxillofacial Surg, Ludhiana, Punjab, India.	sumirgandhi@gmail.com	Singh, Inderjot/ABB-6281-2020; Gandhi, Sumir/AAU-9555-2020; Solanki, Manisha/ABB-8078-2020	Singh, Inderjot/0000-0003-1863-3546; Solanki, Manisha/0000-0003-4766-574X; Gandhi, Sumir/0000-0002-3956-5768			Al-Khateeb T, 2007, J ORAL MAXIL SURG, V65, P1094, DOI 10.1016/j.joms.2006.09.013; Arosarena OA, 2009, ARCH FACIAL PLAST S, V11, P48, DOI 10.1001/archfacial.2008.507; Bakardjiev A, 2007, J CRANIO MAXILL SURG, V35, P147, DOI 10.1016/j.jcms.2007.01.005; Bither S, 2008, DENT TRAUMATOL, V24, P468, DOI 10.1111/j.1600-9657.2008.00606.x; Cheema SA, 2006, BRIT J ORAL MAX SURG, V44, P232, DOI 10.1016/j.bjoms.2005.05.017; Eggensperger NM, 2006, J ORAL MAXIL SURG, V64, P270, DOI 10.1016/j.joms.2005.10.016; Kieser J, 2002, INT J ORAL MAX SURG, V31, P206, DOI 10.1054/ijom.2002.0208; Klenk G, 2003, J CRANIOFAC SURG, V14, P78, DOI 10.1097/00001665-200301000-00014; Lee JH, 2010, J CRANIO MAXILL SURG, V38, P192, DOI 10.1016/j.jcms.2009.06.002; Oji C, 1999, BRIT J ORAL MAX SURG, V37, P106, DOI 10.1054/bjom.1997.0083; SAWHNEY CP, 1988, BRIT J ORAL MAX SURG, V26, P430, DOI 10.1016/0266-4356(88)90097-6; SHEKAR BRC, 2008, INDIAN J DENT RES, V19, P304; Subhashraj K, 2007, BRIT J ORAL MAX SURG, V45, P637, DOI 10.1016/j.bjoms.2007.03.012; Ugboko VI, 2002, BRIT J ORAL MAX SURG, V40, P433, DOI 10.1016/S0266-4356(02)00181-X; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1	15	38	41	1	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	AUG	2011	27	4					257	262		10.1111/j.1600-9657.2011.00996.x			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	790RS	WOS:000292607500003	21635691				2021-06-18	
J	Clarner, T; Parabucki, A; Beyer, C; Kipp, M				Clarner, T.; Parabucki, A.; Beyer, C.; Kipp, M.			Corticosteroids Impair Remyelination in the Corpus Callosum of Cuprizone-Treated Mice	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						glucocorticoid; dexamethasone; oligodendrocyte; corpus callosum; myelin	CENTRAL-NERVOUS-SYSTEM; LYSOLECITHIN-INDUCED DEMYELINATION; BRAIN-BARRIER PERMEABILITY; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; THYROID-HORMONE; GROWTH-FACTORS; MATTER PATHOLOGY; MYELIN REPAIR; RAT	Corticosteroids (CS) are effective in the treatment of many brain disorders, such as multiple sclerosis (MS) or traumatic brain injury. This has been scrutinised in different experimental animal models. However, neither the mechanisms, nor the site of CS action are fully understood. Short-term high-dose CS treatment improves MS symptoms and severity of clinical disability during an acute inflammatory exacerbation of disease. In the present study, we analysed the influence of CS on the expression of cellular and molecular markers of spontaneous endogenous remyelination in the toxic non-immune cuprizone animal model at early (9 days) and intermediate (21 days) remyelination, as well as steroidal effects in primary astrocytes and oligodendrocyte progenitor cultures. Dexamethasone (Dex) and methylprednisolone (MP) induced a higher expression of the differentiation markers myelin basic protein and proteolipid protein (PLP) in cultured oligodendrocyte progenitor cells (OPC). CS exposure of primary cultured astrocytes resulted in a greater expression of those genes involved in OPC proliferation [fibroblast growth factor 2 (FGF2) and platelet-derived growth factor (PDGF)-alpha alpha] and a reduced expression of the pro-maturation factor insulin-like growth factor 1. Pro-maturating effects of CS were completely blocked by FGF2 and PDGF-alpha alpha co-application in OPC cultures. MP treatment in vivo resulted in a reduced recovery of PLP-staining intensity, whereas the re-population of the demyelinated corpus callosum with adenomatous polyposis coli-expressing oligodendrocytes was not affected. The numbers of brain intrinsic inflammatory cells, microglia and astrocytes during remyelination were similar in placebo and MP-treated animals. Our findings suggest that treatment with CS might have, in addition to the well-known benefical effects on inflammatory processes, a negative influence on remyelination.	[Clarner, T.; Beyer, C.; Kipp, M.] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany; [Parabucki, A.] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Neurobiol, Belgrade, Serbia	Kipp, M (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Wendlingweg 2, D-52074 Aachen, Germany.	mkipp@ukaachen.de	MatJafri, Mohd Zubir/F-6340-2010; Kipp, Markus/K-2694-2015	MatJafri, Mohd Zubir/0000-0001-9313-7548; 	Faculty of Medicine, RWTH Aachen University; Hertie-Foundation	This project was supported by the START Program (M. K.) of the Faculty of Medicine, RWTH Aachen University and by the Hertie-Foundation (M. K.). The excellent technical support by H. Helten and U. Zahn is honored.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; ALMAZAN G, 1986, DEV NEUROSCI-BASEL, V8, P14, DOI 10.1159/000112237; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arnett HA, 2003, J NEUROSCI, V23, P9824; BAKKER DA, 1987, J NEUROL SCI, V78, P125, DOI 10.1016/0022-510X(87)90055-4; Baracskay KL, 2002, J NEUROSCI RES, V70, P645, DOI 10.1002/jnr.10418; BARRES BA, 1994, DEVELOPMENT, V120, P1097; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; Biancotti JC, 2008, NEUROCHEM RES, V33, P2615, DOI 10.1007/s11064-008-9792-8; BLAKEMORE WF, 1973, J NEUROL SCI, V20, P73, DOI 10.1016/0022-510X(73)90119-6; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOHN MC, 1991, J STEROID BIOCHEM, V40, P105, DOI 10.1016/0960-0760(91)90173-3; Braun A, 2009, NEUROCHEM INT, V55, P610, DOI 10.1016/j.neuint.2009.06.004; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chari DM, 2006, J NEUROSCI RES, V83, P594, DOI 10.1002/jnr.20763; Chesik D, 2010, NEUROSCI LETT, V468, P178, DOI 10.1016/j.neulet.2009.10.051; Ciccone A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006264.pub2; Clarner T, 2011, J MOL NEUROSCI, V43, P268, DOI 10.1007/s12031-010-9419-9; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; de Seze J, 2004, MULT SCLER J, V10, P596, DOI 10.1191/1352458504ms1079sr; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dunlop S A, 1997, J Matern Fetal Med, V6, P309; Fernandez M, 2004, P NATL ACAD SCI USA, V101, P16363, DOI 10.1073/pnas.0407262101; Franco PG, 2008, EXP NEUROL, V212, P458, DOI 10.1016/j.expneurol.2008.04.039; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Geurts JJG, 2008, LANCET NEUROL, V7, P841, DOI 10.1016/S1474-4422(08)70191-1; Geurts JJG, 2009, J NEUROL SCI, V282, P12, DOI 10.1016/j.jns.2009.01.018; Groebe A, 2009, CEREBELLUM, V8, P163, DOI 10.1007/s12311-009-0099-3; GUMBINAS M, 1973, BIOL NEONATE, V22, P355; Halliday A M, 1981, Adv Neurol, V31, P201; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Hinkerohe D, 2010, BRAIN RES, V1329, P45, DOI 10.1016/j.brainres.2010.03.012; Holzknecht C, 2010, NEUROIMMUNOMODULAT, V17, P23, DOI 10.1159/000243082; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Joubert L, 2010, J NEUROSCI RES, V88, P2546, DOI 10.1002/jnr.22434; Keegan BM, 2002, ANNU REV MED, V53, P285, DOI 10.1146/annurev.med.53.082901.103909; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; KOMOLY S, 1992, P NATL ACAD SCI USA, V89, P1894, DOI 10.1073/pnas.89.5.1894; KONDO A, 1987, BRAIN RES, V425, P186, DOI 10.1016/0006-8993(87)90499-9; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Krukowski K, 2011, BRAIN BEHAV IMMUN, V25, P239, DOI 10.1016/j.bbi.2010.07.244; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; Liu LP, 2010, NAT NEUROSCI, V13, P319, DOI 10.1038/nn.2491; Llanos SL, 1999, BIOCELL, V23, P29; Mason JL, 2000, J NEUROSCI, V20, P5703; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MCKINNON RD, 1991, ANN NY ACAD SCI, V638, P378, DOI 10.1111/j.1749-6632.1991.tb49048.x; MILLER H, 1961, LANCET, V1, P127; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; NICOLOFF JT, 1970, J CLIN INVEST, V49, P1922, DOI 10.1172/JCI106411; Njenga MK, 1999, J NEUROPATH EXP NEUR, V58, P78, DOI 10.1097/00005072-199901000-00009; Norkute A, 2010, CELLS TISSUES ORGANS, V191, P57, DOI 10.1159/000223232; Patani R, 2007, NEUROPATH APPL NEURO, V33, P277, DOI 10.1111/j.1365-2990.2007.00805.x; Patrikios P, 2006, BRAIN, V129, P3165, DOI 10.1093/brain/awl217; Pavelko KD, 1998, J NEUROSCI, V18, P2498; Pott F, 2009, BRAIN RES, V1305, P137, DOI 10.1016/j.brainres.2009.09.084; PRESTON SL, 1984, J NEUROCHEM, V42, P262, DOI 10.1111/j.1471-4159.1984.tb09727.x; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Raschke C, 2008, ANAT HISTOL EMBRYOL, V37, P95, DOI 10.1111/j.1439-0264.2007.00807.x; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; Shen SM, 2008, NAT NEUROSCI, V11, P1024, DOI 10.1038/nn.2172; Sloka JS, 2005, MULT SCLER J, V11, P425, DOI 10.1191/1352458505ms1190oa; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Sun YY, 2010, J NEUROSCI, V30, P9621, DOI 10.1523/JNEUROSCI.2295-10.2010; TRIARHOU LC, 1986, ARCH NEUROL-CHICAGO, V43, P121, DOI 10.1001/archneur.1986.00520020015008; Wei ZS, 2011, NEUROIMMUNOMODULAT, V18, P28, DOI 10.1159/000314736; WILBER JF, 1969, J CLIN INVEST, V48, P2096, DOI 10.1172/JCI106176; Xu J, 2009, J NEUROSCI, V29, P2022, DOI 10.1523/JNEUROSCI.2621-08.2009; Zhou Y, 2007, J NEUROCHEM, V102, P667, DOI 10.1111/j.1471-4159.2007.04535.x; Zivadinov R, 2001, NEUROLOGY, V57, P1239, DOI 10.1212/WNL.57.7.1239	71	38	38	3	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	JUL	2011	23	7					601	611		10.1111/j.1365-2826.2011.02140.x			11	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	788SU	WOS:000292465500007	21507085				2021-06-18	
J	Marfia, G; Madaschi, L; Marra, F; Menarini, M; Bottai, D; Formenti, A; Bellardita, C; Di Giulio, AM; Carelli, S; Gorio, A				Marfia, Giovanni; Madaschi, Laura; Marra, Francesca; Menarini, Mauro; Bottai, Daniele; Formenti, Alessandro; Bellardita, Carmelo; Di Giulio, Anna Maria; Carelli, Stephana; Gorio, Alfredo			Adult neural precursors isolated from post mortem brain yield mostly neurons: An erythropoietin-dependent process	NEUROBIOLOGY OF DISEASE			English	Article						Adult neural progenitors; Erythropoietin; Gene regulation; Hypoxia- inducible factor-1 (HIF-1); mTOR; Neural plasticity	HYPOXIA-INDUCIBLE FACTOR; SPINAL-CORD-INJURY; GATED CALCIUM-CHANNELS; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC STEM-CELLS; SUBVENTRICULAR ZONE; NEUROLOGICAL FUNCTION; ISCHEMIC TOLERANCE; PROGENITOR CELLS; GROWTH-FACTOR	This study was aimed at the isolation of neural precursor cells (NPCs) capable of resisting to a prolonged ischemic insult as this may occur at the site of traumatic and ischemic CNS injuries. Adult mice were anesthetized and then killed by cervical dislocation. The cadavers were maintained at room temperature or at 4 degrees C for different time periods. Post mortem neural precursors (PM-NPCs) were isolated, grown in vitro and their differentiation capability was investigated by evaluating the expression of different neuronal markers. PM-NPCs differentiate mostly in neurons, show activation of hypoxia-inducible factor-1 and MAPK, and express both erythropoietin (EPO) and its receptor ( EPO-R). The exposure of PM-NPCs to neutralizing antibodies to EPO or EPO-R dramatically reduced the extent of neuronal differentiation to about 11% of total PM-NPCs. The functionality of mTOR and MAPK is also required for the expression of the neuronal phenotype by PM-NPCs. These results suggest that PM-NPCs can be isolated from animal cadaver even several hours after death and their self-renewable capability is comparable to normal neural precursors. Differently, their ability to achieve a neural phenotype is superior to that of NPCs, and this is mediated by the activation of hypoxia-induced factor 1 and EPO signaling. PM-NPCs may represent good candidates for transplantation studies in animal models of neurodegenerative diseases. (C) 2011 Elsevier Inc. All rights reserved.	[Marfia, Giovanni; Madaschi, Laura; Marra, Francesca; Bottai, Daniele; Di Giulio, Anna Maria; Carelli, Stephana; Gorio, Alfredo] Univ Milan, Dept Med Surg & Dent, Pharmacol Lab, Milan, Italy; [Menarini, Mauro] Osped Montecatone, Bologna, Italy; [Formenti, Alessandro; Bellardita, Carmelo] Univ Milan, Sch Med, Dept Human Physiol, I-20122 Milan, Italy; [Carelli, Stephana; Gorio, Alfredo] IRCCS Humanitas, Clin Pharmacol, Milan, Italy	Gorio, A (corresponding author), Univ Milan, Dept Med Surg & Dent, Pharmacol Lab, Via A di Rudini 8, Milan, Italy.	alfredo.gorio@unimi.it	Marfia, Giovanni/AAB-8702-2020; Bellardita, Carmelo/N-5467-2019; Bottai, Daniele/O-2586-2017; Formenti, Alessandro/F-7013-2011; Carelli, Stephana/AAB-2365-2021; Marfia, Giovanni/N-4650-2014	Marfia, Giovanni/0000-0002-5849-7000; Bellardita, Carmelo/0000-0001-6198-243X; Bottai, Daniele/0000-0002-7951-9512; Carelli, Stephana/0000-0003-4603-396X; Marfia, Giovanni/0000-0002-5849-7000; Di Giulio, Anna Maria/0000-0002-5702-4623	Fondazione Montecatone; PRINMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)	This work was supported in part by a grant from Fondazione Montecatone and PRIN 2005 to Alfredo Gorio.	Adelman D M, 2002, Methods Mol Biol, V185, P55; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Arnhold S, 2000, INT J DEV NEUROSCI, V18, P201, DOI 10.1016/S0736-5748(99)00089-1; Baer K, 2007, EXP NEUROL, V204, P828, DOI 10.1016/j.expneurol.2006.12.008; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; Bottai D, 2008, MOL MED, V14, P634, DOI 10.2119/2008-00077.Bottai; Bottai D, 2010, EXP NEUROL, V223, P452, DOI 10.1016/j.expneurol.2010.01.010; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Carelli S, 2007, MOL MED, V13, P166, DOI 10.2119/2006-00091.Carelli; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Chen HL, 2007, STEM CELLS, V25, P2291, DOI 10.1634/stemcells.2006-0609; Cino I, 2008, BBA-BIOMEMBRANES, V1778, P2437, DOI 10.1016/j.bbamem.2008.07.006; Corbin JG, 2008, J NEUROCHEM, V106, P2272, DOI 10.1111/j.1471-4159.2008.05522.x; D'Ascenzo M, 2006, EUR J NEUROSCI, V23, P935, DOI 10.1111/j.1460-9568.2006.04628.x; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Francis KR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.22; Fricker-Gates RA, 2006, NEUROREPORT, V17, P1081, DOI 10.1097/01.wnr.0000230505.32726.65; Goetz M, 1998, TRENDS NEUROSCI, V21, P135, DOI 10.1016/S0166-2236(98)01228-4; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hoge RD, 2001, J CHEM NEUROANAT, V22, P43, DOI 10.1016/S0891-0618(01)00114-4; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; Lesma E, 2005, AM J PATHOL, V167, P1093, DOI 10.1016/S0002-9440(10)61198-4; Lesma E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003558; Lipscombe D, 2004, J NEUROPHYSIOL, V92, P2633, DOI 10.1152/jn.00486.2004; Marti-Fabregas J, 2010, NEUROLOGY, V74, P357, DOI 10.1212/WNL.0b013e3181cbccec; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Moreno-Manzano V, 2010, J BIOL CHEM, V285, P1333, DOI 10.1074/jbc.M109.008326; Moreno-Manzano V, 2009, STEM CELLS, V27, P733, DOI 10.1002/stem.24; Mottet D, 2002, ANN NY ACAD SCI, V973, P448, DOI 10.1111/j.1749-6632.2002.tb04681.x; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Park MH, 2006, BIOCHEM BIOPH RES CO, V339, P1021, DOI 10.1016/j.bbrc.2005.10.218; Parnavelas JG, 2001, NEURON, V31, P881, DOI 10.1016/S0896-6273(01)00437-8; Pong K, 2004, EXPERT OPIN THER TAR, V8, P125, DOI 10.1517/eott.8.2.125.30244; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Prado-Lopez S, 2010, STEM CELLS, V28, P407, DOI 10.1002/stem.295; Ramirez-Bergeron DL, 2001, STEM CELLS, V19, P279, DOI 10.1634/stemcells.19-4-279; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Santilli G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008575; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; Studer L, 2000, J NEUROSCI, V20, P7377; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; Tuoc TC, 2009, J NEUROSCI, V29, P8335, DOI 10.1523/JNEUROSCI.5669-08.2009; Tyler WA, 2009, J NEUROSCI, V29, P6367, DOI 10.1523/JNEUROSCI.0234-09.2009; Verdier F, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wu LY, 2008, NEUROCHEM RES, V33, P2118, DOI 10.1007/s11064-008-9728-3; Zhu LL, 2005, BRAIN RES, V1055, P1, DOI 10.1016/j.brainres.2005.04.075	60	38	40	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUL	2011	43	1			SI		86	98		10.1016/j.nbd.2011.02.004			13	Neurosciences	Neurosciences & Neurology	771RZ	WOS:000291179700012	21324364				2021-06-18	
J	Raso, GM; Esposito, E; Vitiello, S; Iacono, A; Santoro, A; D'Agostino, G; Sasso, O; Russo, R; Piazza, PV; Calignano, A; Meli, R				Raso, G. Mattace; Esposito, E.; Vitiello, S.; Iacono, A.; Santoro, A.; D'Agostino, G.; Sasso, O.; Russo, R.; Piazza, P. V.; Calignano, A.; Meli, R.			Palmitoylethanolamide Stimulation Induces Allopregnanolone Synthesis in C6 Cells and Primary Astrocytes: Involvement of Peroxisome-Proliferator Activated Receptor-alpha	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						palmitoylethanolamide; allopregnanolone; peroxisome-proliferator activated receptor-alpha; astrocyte	ACUTE REGULATORY PROTEIN; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; 5-ALPHA-REDUCED NEUROSTEROIDS; N-PALMITOYLETHANOLAMIDE; COGNITIVE DEFICITS; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS	Palmitoylethanolamide (PEA) regulates many pathophysiological processes in the central nervous system, including pain perception, convulsions and neurotoxicity, and increasing evidence points to its neuroprotective action. In the present study, we report that PEA, acting as a ligand of peroxisome-proliferator activated receptor (PPAR)-alpha, might regulate neurosteroidogenesis in astrocytes, which, similar to other glial cells and neurones, have the enzymatic machinery for neurosteroid de novo synthesis. Accordingly, we used the C6 glioma cell line and primary murine astrocytes. In the mitochondrial fraction from cells stimulated with PEA, we demonstrated an increase in steroidogenic acute regulatory protein (StAR) and cytochrome P450 enzyme (P450scc) expression, both comprising proteins considered to be involved in crucial steps of neurosteroid formation. The effects of PEA were completely blunted by GW6471, a selective PPAR-alpha antagonist, or by PPAR-alpha silencing by RNA interference. Accordingly, allopregnanolone (ALLO) levels were increased in supernatant of PEA-treated astrocytes, as revealed by gas chromatography-mass spectrometry, and this effect was inhibited by GW6471. Moreover, PEA showed a protective effect, reducing malondialdehyde formation in cells treated with L-buthionine-(S, R)sulfoximine, a glutathione depletor and, interestingly, the effect of PEA was partially inhibited by finasteride, a 5 alpha-reductase inhibitor. A similar profile of activity was demonstrated by ALLO and the lack of an additive effect with PEA suggests that the reduction of oxidative stress by PEA is mediated through ALLO synthesis. The present study provides evidence indicating the involvement of the saturated acylethanolamide PEA in ALLO synthesis through PPAR-a in astrocytes and explores the antioxidative activity of this molecule, confirming its homeostatic and protective role both under physiological and pathological conditions.	[Raso, G. Mattace; Iacono, A.; Santoro, A.; D'Agostino, G.; Sasso, O.; Russo, R.; Calignano, A.; Meli, R.] Univ Naples Federico 2, Dept Expt Pharmacol, I-80131 Naples, Italy; [Vitiello, S.; Piazza, P. V.] Univ Bordeaux, Inst F Magendie, INSERM, U862, Bordeaux, France; [Esposito, E.] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy	Meli, R (corresponding author), Univ Naples Federico 2, Dept Expt Pharmacol, Via D Montesano 49, I-80131 Naples, Italy.	meli@unina.it	D'Agostino, Giuseppe/F-3399-2012; Calignano, Antonio/K-2542-2018; russo, roberto/A-3193-2012	D'Agostino, Giuseppe/0000-0002-3502-4251; russo, roberto/0000-0001-5950-1617; Mattace Raso, Giuseppina/0000-0002-5254-139X; Santoro, Anna/0000-0002-2276-5659	Ministero dell'Universita e della Ricerca Scientifica e Tecnologica PRIN, ItalyMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)	This study was supported by a grant from the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica PRIN, Italy. The authors greatly acknowledge the excellent technical assistance of Dr. Guido Mele.	Agis-Balboa RC, 2006, P NATL ACAD SCI USA, V103, P14602, DOI 10.1073/pnas.0606544103; Akk G, 2007, PHARMACOL THERAPEUT, V116, P35, DOI 10.1016/j.pharmthera.2007.03.004; Azzolina B, 1997, J STEROID BIOCHEM, V61, P55, DOI 10.1016/S0960-0760(97)00002-2; BACHUR NR, 1965, J BIOL CHEM, V240, P1019; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; Bose HS, 2002, ENDOCR RES, V28, P295, DOI 10.1081/ERC-120016800; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Burudi EME, 1999, GLIA, V25, P44, DOI 10.1002/(SICI)1098-1136(19990101)25:1<44::AID-GLIA5>3.0.CO;2-C; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Agostino G, 2007, J PHARMACOL EXP THER, V322, P1137, DOI 10.1124/jpet.107.123265; D'Agostino G, 2009, EUR J PHARMACOL, V613, P54, DOI 10.1016/j.ejphar.2009.04.022; Darmani NA, 2005, NEUROPHARMACOLOGY, V48, P1154, DOI 10.1016/j.neuropharm.2005.01.001; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50; Duval C, 2007, BBA-MOL CELL BIOL L, V1771, P961, DOI 10.1016/j.bbalip.2007.05.003; Finn DA, 2006, CNS DRUG REV, V12, P53, DOI 10.1111/j.1527-3458.2006.00053.x; Franklin A, 2003, J NEUROSCI, V23, P7767; Furukawa A, 1998, J NEUROCHEM, V71, P2231; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Higuchi Y, 1999, ARCH BIOCHEM BIOPHYS, V363, P33, DOI 10.1006/abbi.1998.1067; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; KAINU T, 1994, NEUROREPORT, V5, P2481, DOI 10.1097/00001756-199412000-00019; Karri S, 2007, J NEUROENDOCRINOL, V19, P860, DOI 10.1111/j.1365-2826.2007.01600.x; Keller AF, 2004, J NEUROSCI, V24, P907, DOI 10.1523/JNEUROSCI.4642-03.2004; Lambert DM, 2001, EPILEPSIA, V42, P321, DOI 10.1046/j.1528-1157.2001.41499.x; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; LoVerme J, 2006, J PHARMACOL EXP THER, V319, P1051, DOI 10.1124/jpet.106.111385; MARRIOT DR, 1995, NEURAL CELL CULTURE, P83; Melcangi RC, 1998, J STEROID BIOCHEM, V65, P295, DOI 10.1016/S0960-0760(98)00030-2; Mellon SH, 2002, TRENDS ENDOCRIN MET, V13, P35, DOI 10.1016/S1043-2760(01)00503-3; Mellon SH, 2007, PHARMACOL THERAPEUT, V116, P107, DOI 10.1016/j.pharmthera.2007.04.011; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Morita K, 2008, J MOL NEUROSCI, V34, P193, DOI 10.1007/s12031-007-9034-6; Ocvirk R, 2008, PAIN, V138, P402, DOI 10.1016/j.pain.2008.01.019; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; Sasso O, 2010, EUR NEUROPSYCHOPHARM, V20, P195, DOI 10.1016/j.euroneuro.2009.09.003; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Tokuda K, 2010, J NEUROSCI, V30, P16788, DOI 10.1523/JNEUROSCI.4101-10.2010; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Waters SL, 1997, AM J PHYSIOL-RENAL, V273, pF869; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x	59	38	38	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0953-8194			J NEUROENDOCRINOL	J. Neuroendocrinol.	JUL	2011	23	7					591	600		10.1111/j.1365-2826.2011.02152.x			10	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	788SU	WOS:000292465500006	21554431				2021-06-18	
J	Windelov, NA; Welling, KL; Ostrowski, SR; Johansson, PI				Windelov, Nis A.; Welling, Karen-Lise; Ostrowski, Sisse R.; Johansson, Par I.			The prognostic value of thrombelastography in identifying neurosurgical patients with worse prognosis	BLOOD COAGULATION & FIBRINOLYSIS			English	Article							TRAUMATIC INTRACRANIAL HEMORRHAGE; COAGULOPATHY; PROGRESSION	Coagulopathy in patients with intracranial haemorrhage or traumatic brain injury (TBI) is associated with clinical deterioration and worse outcome. Whole blood viscoelastic haemostatic assays, like thrombelastography (TEG), might aid conventional coagulation assays in identification of patients with worse prognosis. We performed a review of patients (totalling 78 patients) with primary acute intracranial haemorrhage or isolated TBI admitted to a neurointensive care unit (NICU) for more than 24 h during a period of 9 months, who had TEG analysis performed at admission. Primary outcome was all-cause 30-day mortality, whereas decline in Glasgow Coma Scale (GCS) score at 24 h after admission or death due to cerebral incarceration were secondary outcomes. Patients were defined as hypocoaguable if TEG reaction time was more than 8 min, angle less than 55 degrees and/or maximal amplitude less than 51 mm. Patients were defined hypocoaguable according to conventional coagulation assays if international normalized ratio was more than 1.3, platelet counts less than 100 X 10(9)/l and/or activated partial thromboplastine time more than 35s. Eight patients were hypocoaguable by TEG on admission to NICU and had higher 30-day mortality (63% vs. 16%, P=0.008), more often declined in GCS (57% vs. 16%, P=0.02) and expired due to cerebral incarceration (50% vs. 6%, P=0.02). Hypocoagulability by TEG, lower admission GCS and subarachnoid haemorrhage were independently associated with higher 30-day mortality [TEG: odds ratio (OR) 14.8 (2.2-100.1), P=0.006; GCS: OR 1.3 (1.1-1.5), P=0.006; subarachnoid haemorrhage: OR: 5.3 (1.3-22.3), P=0.02]. Only two patients were hypocoaguable by both conventional coagulation assays and TEG. The current data indicate that hypocoagulability by TEG at admission to NICU predicts worse prognosis. Low concordance with conventional coagulation assays indicates that TEG might be valuable in identifying patients with clinically relevant coagulopathy. Blood Coagul Fibrinolysis 22:416-419 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Windelov, Nis A.; Ostrowski, Sisse R.; Johansson, Par I.] Copenhagen Univ Hosp, Rigshosp, Capital Reg Blood Bank, Transfus Med Sect, DK-2100 Copenhagen, Denmark; [Windelov, Nis A.] Copenhagen Univ Hosp, Rigshosp, Dept Anaesthesia, Ctr Head & Orthoped, DK-2100 Copenhagen, Denmark; [Welling, Karen-Lise] Copenhagen Univ Hosp, Rigshosp, Dept Neurointens Care, DK-2100 Copenhagen, Denmark	Windelov, NA (corresponding author), Copenhagen Univ Hosp, Rigshosp, Capital Reg Blood Bank, Transfus Med Sect, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	nis.windelov@gmail.com	Ostrowski, Sisse R/E-7423-2011; Johansson, Par I/P-9283-2015	Ostrowski, Sisse R/0000-0001-5288-3851; Johansson, Par I/0000-0001-9778-5964			Aguilar MI, 2010, CURR TREAT OPTION NE, V12, P113, DOI 10.1007/s11940-010-0061-1; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Gerlach R, 2009, ACTA NEUROCHIR, V151, P873, DOI 10.1007/s00701-009-0409-z; Kung WM, 2010, INJURY; Larsen CC, 2010, ACTA NEUROCHIR, V152, P1577, DOI 10.1007/s00701-010-0699-1; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1	9	38	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0957-5235			BLOOD COAGUL FIBRIN	Blood Coagul. Fibrinolysis	JUL	2011	22	5					416	419		10.1097/MBC.0b013e3283464f53			4	Hematology	Hematology	789HP	WOS:000292506600010	21467918				2021-06-18	
J	Skandsen, T; Kvistad, KA; Solheim, O; Lydersen, S; Strand, IH; Vik, A				Skandsen, Toril; Kvistad, Kjell Arne; Solheim, Ole; Lydersen, Stian; Strand, Ingrid Haavde; Vik, Anne			Prognostic Value of Magnetic Resonance Imaging in Moderate and Severe Head Injury: A Prospective Study of Early MRI Findings and One-Year Outcome	JOURNAL OF NEUROTRAUMA			English	Article						cohort study; craniocerebral trauma; Glasgow Outcome Scale; magnetic resonance imaging; treatment outcome	TRAUMATIC BRAIN-INJURY; PRACTICAL SCALE; STEM; CLASSIFICATION; DAMAGE; CONSCIOUSNESS; PREDICTION; MECHANISM; RECOVERY; LESIONS	The clinical benefit of early magnetic resonance imaging (MRI) in severe and moderate head injury is unclear. We sought to explore the prognostic value of the depth of lesions depicted with early MRI, and also to describe the prevalence and impact of traumatic brainstem lesions. In a cohort of 159 consecutive patients with moderate to severe head injury (age 5-65 years and surviving the acute phase) admitted to a regional level 1 trauma center, 106 (67%) were examined with MRI within 4 weeks post-injury. Depth of lesions in MRI was categorized as: hemisphere level, central level, and brainstem injury (BSI). The outcome measure was Glasgow Outcome Scale Extended (GOSE) 12 months post-injury. Forty-six percent of patients with severe injuries and 14% of patients with moderate injuries had BSI. In severe head injury, central or brainstem lesions in MRI, together with higher Rotterdam CT score, pupillary dilation, and secondary adverse events were significantly associated with a worse outcome in age-adjusted analyses. Bilateral BSI was strongly associated with a poor outcome in severe injury, with positive and negative predictive values of 0.86 and 0.88, respectively. In moderate injury, only age was significantly associated with outcome in multivariable analyses. Limitations of the current study include lack of blinded outcome evaluations and insufficient statistical power to assess the added prognostic value of MRI when combined with clinical information. We conclude that in patients with severe head injury surviving the acute phase, depth of lesion on the MRI was associated with outcome, and in particular, bilateral brainstem injury was strongly associated with poor outcomes. In moderate head injury, surprisingly, there was no association between MRI findings and outcome when using the GOSE score as outcome measure.	[Skandsen, Toril] Univ Trondheim Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, N-7006 Trondheim, Norway; [Skandsen, Toril; Solheim, Ole; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Trondheim, Norway; [Kvistad, Kjell Arne] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Imaging, Fac Med, Trondheim, Norway; [Lydersen, Stian] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Unit Appl Clin Res, Trondheim, Norway; [Kvistad, Kjell Arne; Strand, Ingrid Haavde] Univ Trondheim Hosp, Dept Diagnost Imaging, St Olavs Hosp, N-7006 Trondheim, Norway; [Solheim, Ole; Vik, Anne] Univ Trondheim Hosp, Dept Neurosurg, St Olavs Hosp, N-7006 Trondheim, Norway	Skandsen, T (corresponding author), Univ Trondheim Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, N-7006 Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Solheim, Ole/0000-0002-5954-4817	Liaison Committee	We wish to thank neuroradiologist Mari Folvik (M. F.) for evaluation of MRI scans, and neuroradiologist Jana Rydland (J.R.) for her contribution to the reliability evaluation; Beate Holmqvist Karlsen, Otto Aarhaug, and Brit Sorum for participating in management of the database and the GOSE interviews; Kent Goran Moen for his work with the data files; the residents at the neurosurgical department for collection of the injury-related variables; the staff at the MRI unit for their cooperation with the MRI examinations; Toril Skandsen (T. S.) and Ole Solheim (O.S.) have received research grants from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), T. S. during the whole study period, and O.S. during the period of manuscript preparation.	Altman D. G., 1999, PRACTICAL STAT MED R; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENTRY LR, 2002, HEAD TRAUMA; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MITCHELL DE, 1973, LANCET, V2, P215; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	32	38	38	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					691	699		10.1089/neu.2010.1590			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100270	21401308				2021-06-18	
J	Paterniti, I; Melani, A; Cipriani, S; Corti, F; Mello, T; Mazzon, E; Esposito, E; Bramanti, P; Cuzzocrea, S; Pedata, F				Paterniti, Irene; Melani, Alessia; Cipriani, Sara; Corti, Francesca; Mello, Tommaso; Mazzon, Emanuela; Esposito, Emanuela; Bramanti, Placido; Cuzzocrea, Salvatore; Pedata, Felicita			Selective adenosine A(2A) receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects	JOURNAL OF NEUROINFLAMMATION			English	Article							EVOKED GLUTAMATE RELEASE; TRAUMATIC BRAIN-INJURY; AMINO-ACIDS; IN-VIVO; INDEPENDENT MECHANISMS; INDUCED EXCITOTOXICITY; COMPRESSION INJURY; CEREBRAL-ISCHEMIA; CELL-ACTIVATION; FOCAL ISCHEMIA	Background: Permanent functional deficits following spinal cord injury (SCI) arise both from mechanical injury and from secondary tissue reactions involving inflammation. Enhanced release of adenosine and glutamate soon after SCI represents a component in the sequelae that may be responsible for resulting functional deficits. The role of adenosine A(2A) receptor in central ischemia/trauma is still to be elucidated. In our previous studies we have demonstrated that the adenosine A(2A) receptor-selective agonist CGS21680, systemically administered after SCI, protects from tissue damage, locomotor dysfunction and different inflammatory readouts. In this work we studied the effect of the adenosine A(2A) receptor antagonist SCH58261, systemically administered after SCI, on the same parameters. We investigated the hypothesis that the main action mechanism of agonists and antagonists is at peripheral or central sites. Methods: Spinal trauma was induced by extradural compression of SC exposed via a four-level T5-T8 laminectomy in mouse. Three drug-dosing protocols were utilized: a short-term systemic administration by intraperitoneal injection, a chronic administration via osmotic minipump, and direct injection into the spinal cord. Results: SCH58261, systemically administered (0.01 mg/kg intraperitoneal. 1, 6 and 10 hours after SCI), reduced demyelination and levels of TNF-alpha, Fas-L, PAR, Bax expression and activation of JNK mitogen-activated protein kinase (MAPK) 24 hours after SCI. Chronic SCH58261 administration, by mini-osmotic pump delivery for 10 days, improved the neurological deficit up to 10 days after SCI. Adenosine A(2A) receptors are physiologically expressed in the spinal cord by astrocytes, microglia and oligodendrocytes. Soon after SCI (24 hours), these receptors showed enhanced expression in neurons. Both the A(2A) agonist and antagonist, administered intraperitoneally, reduced expression of the A(2A) receptor, ruling out the possibility that the neuroprotective effects of the A(2A) agonist are due to A(2A) receptor desensitization. When the A(2A) antagonist and agonist were centrally injected into injured SC, only SCH58261 appeared neuroprotective, while CGS21680 was ineffective. Conclusions: Our results indicate that the A(2A) antagonist protects against SCI by acting on centrally located A(2A) receptors. It is likely that blockade of A(2A) receptors reduces excitotoxicity. In contrast, neuroprotection afforded by the A(2A) agonist may be primarily due to peripheral effects.	[Melani, Alessia; Cipriani, Sara; Corti, Francesca; Pedata, Felicita] Univ Florence, Dept Pharmacol, I-50121 Florence, Italy; [Paterniti, Irene; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; [Mazzon, Emanuela; Esposito, Emanuela; Bramanti, Placido; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Mello, Tommaso] Univ Florence, Gastroenterol Unit, Dept Clin Pathophysiol, I-50121 Florence, Italy	Pedata, F (corresponding author), Univ Florence, Dept Pharmacol, I-50121 Florence, Italy.	felicita.pedata@unifi.it	Mello, Tommaso/AAO-7831-2021; Mazzon, Emanuela/AAL-4334-2020; Mello, Tommaso/I-4715-2012; Bramanti, Placido/K-5117-2016	Mello, Tommaso/0000-0002-6192-6902; Mello, Tommaso/0000-0002-6192-6902; Pedata, Felicita/0000-0002-6841-3712; mazzon, emanuela/0000-0002-5073-717X	IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy; Italian Ministry of HealthMinistry of Health, Italy	This investigation was supported by grants from IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy and Italian Ministry of Health.	ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Back SA, 2006, MENT RETARD DEV D R, V12, P129, DOI 10.1002/mrdd.20107; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Bronstein JM, 2000, J NEUROSCI RES, V60, P284, DOI 10.1002/(SICI)1097-4547(20000501)60:3<284::AID-JNR2>3.0.CO;2-T; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2008, CURR PHARM DESIGN, V14, P1490, DOI 10.2174/138161208784480126; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; CHOUKE RA, 2008, MOL MED, V14, P116; Corsi C, 1999, NEUROREPORT, V10, P687, DOI 10.1097/00001756-199903170-00005; Corsi C, 2000, NEUROREPORT, V11, P2591, DOI 10.1097/00001756-200008030-00048; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2010, J BIOL REG HOMEOS AG, V24, P73; Genovese T, 2009, SHOCK, V32, P578, DOI 10.1097/SHK.0b013e3181a20792; Gessi S, 2000, BRIT J PHARMACOL, V129, P2, DOI 10.1038/sj.bjp.0703045; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Howe CL, 2004, NEUROBIOL DIS, V15, P120, DOI 10.1016/j.nbd.2003.09.002; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Jurewicz A, 2006, GLIA, V53, P158, DOI 10.1002/glia.20249; Lappas CM, 2006, J EXP MED, V203, P2639, DOI 10.1084/jem.20061097; Li Y, 2006, NEUROSCIENCE, V141, P2029, DOI 10.1016/j.neuroscience.2006.05.014; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Matute C, 2002, EUR J PHARMACOL, V447, P239, DOI 10.1016/S0014-2999(02)01847-2; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McAdoo DJ, 2000, BRAIN RES, V854, P152, DOI 10.1016/S0006-8993(99)02333-1; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Melani A, 2006, BRAIN RES, V1073, P470, DOI 10.1016/j.brainres.2005.12.010; Melani A, 2003, BRAIN RES, V959, P243, DOI 10.1016/S0006-8993(02)03753-8; Melani A, 2009, BRAIN, V132, P1480, DOI 10.1093/brain/awp076; Minei JP, 2002, J TRAUMA, V53, P229; Mirabet M, 1999, J CELL SCI, V112, P491; Miyazaki N, 2008, PFLUG ARCH EUR J PHY, V457, P441, DOI 10.1007/s00424-008-0542-1; Monopoli A, 1998, J PHARMACOL EXP THER, V285, P9; Moreno-Flores Maria Teresa, 2006, Recent Pat CNS Drug Discov, V1, P55, DOI 10.2174/157488906775245264; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Pintor A, 2001, EUR J PHARMACOL, V421, P177, DOI 10.1016/S0014-2999(01)01058-5; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Reece TB, 2004, J SURG RES, V121, P130, DOI 10.1016/j.jss.2004.04.006; Rivlin A S, 1978, Surg Neurol, V10, P38; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROKKAS CK, 1994, ANN THORAC SURG, V58, P312, DOI 10.1016/0003-4975(94)92200-4; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Sebastiao AM, 2009, BRIT J PHARMACOL, V158, P15, DOI 10.1111/j.1476-5381.2009.00157.x; Sitkovsky MV, 2003, BIOCHEM PHARMACOL, V65, P493, DOI 10.1016/S0006-2952(02)01548-4; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; Wirkner K, 2004, NEUROPHARMACOLOGY, V46, P994, DOI 10.1016/j.neuropharm.2004.01.008; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yin KJ, 2005, NEUROBIOL DIS, V20, P881, DOI 10.1016/j.nbd.2005.05.026; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; Zocchi C, 1996, BRIT J PHARMACOL, V117, P1381, DOI 10.1111/j.1476-5381.1996.tb15296.x	68	38	40	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 12	2011	8								31	10.1186/1742-2094-8-31			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	765EY	WOS:000290687400001	21486435	DOAJ Gold, Green Published			2021-06-18	
J	Hindman, BJ; Palecek, JP; Posner, KL; Traynelis, VC; Lee, LA; Sawin, PD; Tredway, TL; Todd, MM; Domino, KB				Hindman, Bradley J.; Palecek, John P.; Posner, Karen L.; Traynelis, Vincent C.; Lee, Lorri A.; Sawin, Paul D.; Tredway, Trent L.; Todd, Michael M.; Domino, Karen B.			Cervical Spinal Cord, Root, and Bony Spine Injuries A Closed Claims Analysis	ANESTHESIOLOGY			English	Article							POSTERIOR-FOSSA SURGERY; SITTING POSITION; NEUROLOGIC DETERIORATION; ATLANTOAXIAL INSTABILITY; ENDOTRACHEAL INTUBATION; SIPHON CONTROVERSY; AIRWAY MANAGEMENT; MYELOPATHY; ANTERIOR; TETRAPLEGIA	Background: The aim of this study was to characterize cervical cord, root, and bony spine claims in the American Society of Anesthesiologists Closed Claims database to formulate hypotheses regarding mechanisms of injury. Methods: All general anesthesia claims (1970-2007) in the Closed Claims database were searched to identify cervical injuries. Three independent teams, each consisting of an anesthesiologist and neurosurgeon, used a standardized review form to extract data from claim summaries and judge probable contributors to injury. Results: Cervical injury claims (n = 48; mean +/- SD age 47 +/- 15 yr; 73% male) comprised less than 1% of all general anesthesia claims. When compared with other general anesthesia claims (19%), cervical injury claims were more often permanent and disabling (69%; P < 0.001). In addition, cord injuries (n = 37) were more severe than root and/or bony spine injuries (n = 10; P < 0.001), typically resulting in quadriplegia. Although anatomic abnormalities (e.g., cervical stenosis) were often present, cord injuries usually occurred in the absence of traumatic injury (81%) or cervical spine instability (76%). Cord injury occurred with cervical spine (65%) and noncervical spine (35%) procedures. Twenty-four percent of cord injuries were associated with the sitting position. Probable contributors to cord injury included anatomic abnormalities (81%), direct surgical complications (24% [38%, cervical spine procedures]), preprocedural symptomatic cord injury (19%), intraoperative head/neck position (19%), and airway management (11%). Conclusion: Most cervical cord injuries occurred in the absence of traumatic injury, instability, and airway difficulties. Cervical spine procedures and/or sitting procedures appear to predominate. In the absence of instability, cervical spondylosis was the most common factor associated with cord injury.	[Hindman, Bradley J.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Fac Dev, Iowa City, IA USA; [Todd, Michael M.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, Iowa City, IA USA; [Palecek, John P.] Iowa Methodist Med Ctr, Des Moines, IA USA; [Posner, Karen L.; Lee, Lorri A.; Domino, Karen B.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Tredway, Trent L.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA USA; [Traynelis, Vincent C.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; [Sawin, Paul D.] Orlando Neurosurg PA, Winter Pk, FL USA	Hindman, BJ (corresponding author), Univ Iowa Hosp & Clin, Dept Anesthesia, Iowa City, IA 52242 USA.	brad-hindman@uiowa.edu		Hindman, Bradley/0000-0003-2242-7980	American Society of Anesthesiologists (Park Ridge, Illinois); Department of Anesthesia, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City; Medtronic, Inc. (Minneapolis, Minnesota)Medtronic; Globus Medical, Inc. (Audubon, Pennsylvania); Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons (Rolling Meadows, Illinois)	Received from the Department of Anesthesia, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, and the Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington. Submitted for publication August 30, 2010. Accepted for publication December 28, 2010. Supported in part by the American Society of Anesthesiologists (Park Ridge, Illinois) and the Department of Anesthesia, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City. Dr. Traynelis has received research and educational grants from Medtronic, Inc. (Minneapolis, Minnesota), Globus Medical, Inc. (Audubon, Pennsylvania), and the Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons (Rolling Meadows, Illinois) for management of cervical spine disease. He is also a paid consultant for United HealthCare Services, Inc. (Minneapolis, Minnesota) and Medtronic, Inc. In addition, Dr. Traynelis holds the following patents from which he has received patent and/or licensing royalties: U. S. patent 7 727 266, Method and apparatus for retaining screws in a plate; U. S. patent 7 276 082, Artificial spinal discs and associated implantation and revision methods; U. S. patent 7 300 441, Technique and instrumentation for preparation of vertebral members. Dr. Sawin is a paid consultant for NuVasive, Inc. (San Diego, California). Dr. Tredway has received honoraria from Synthes, Inc. (West Chester, Pennsylvania) and Medtronic, Inc., for lecturing on related topics. The remaining authors are not supported by, nor maintain any financial interest in, any commercial activity that may be associated with the topic of this article. Presented in part at the annual Midwest Anesthesia Residents Conference, Saint Louis, Missouri, April 14, 2007, and at the annual meeting of the American Society of Anesthesiologists, San Diego, California, October 18, 2010.	American College of Surgeons Committee on Trauma, 2008, ADV TRAUM LIF SUPP S, V8; Baron EM, 2007, NEUROSURGERY, V60, P35, DOI 10.1227/01.NEU.0000215383.64386.82; BLACK S, 1988, ANESTHESIOLOGY, V69, P49, DOI 10.1097/00000542-198807000-00008; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; Bose Bikash, 2004, Spine J, V4, P202, DOI 10.1016/j.spinee.2003.06.001; Buchowski JM, 2005, SPINE, V30, pE103, DOI 10.1097/01.brs.0000153704.92369.f7; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; Cheney FW, 1999, ANESTHESIOLOGY, V91, P552, DOI 10.1097/00000542-199908000-00030; Crosby ET, 2006, ANESTHESIOLOGY, V104, P1293, DOI 10.1097/00000542-200606000-00026; Drummond JC, 2009, APSF NEWSLETTER, V24, P6; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Emery SE, 1998, J BONE JOINT SURG AM, V80A, P941, DOI 10.2106/00004623-199807000-00002; Farmer J, 1998, J SPINAL DISORD, V11, P192; FIROOZNIA H, 1985, SURG NEUROL, V23, P165, DOI 10.1016/0090-3019(85)90337-4; Fujioka S, 2003, ANESTH ANALG, V97, P979, DOI 10.1213/01.ANE.0000078585.67412.FE; Gisolf J, 2005, AM J PHYSIOL-REG I, V289, pR627, DOI 10.1152/ajpregu.00709.2004; Haisa T, 1996, NEUROSURGERY, V38, P819, DOI 10.1227/00006123-199604000-00037; HARLEY EH, 1994, ARCH OTOLARYNGOL, V120, P159; HARROP JS, 2007, NEUROSURGERY S, V60, pS1, DOI DOI 10.1227/01.NEU.0000215380.71097.EC; Hashimoto M, 2010, EUR SPINE J, V19, P1702, DOI 10.1007/s00586-010-1427-5; HASTINGS RH, 1993, ANESTHESIOLOGY, V78, P580, DOI 10.1097/00000542-199303000-00022; Hata T, 2005, ANESTHESIOLOGY, V102, P680, DOI 10.1097/00000542-200503000-00030; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Hicks JW, 2005, AM J PHYSIOL-REG I, V289, pR629, DOI 10.1152/ajpregu.00810.2004; Hilibrand AS, 2004, J BONE JOINT SURG AM, V86A, P1248, DOI 10.2106/00004623-200406000-00018; Hirose Hitoshi, 2005, Ann Thorac Cardiovasc Surg, V11, P270; HITSELBERGER WE, 1980, ARCH OTOLARYNGOL, V106, P69; Houten JK, 2008, J NEUROSURG-SPINE, V9, P237, DOI 10.3171/SPI/2008/9/9/237; HUKUDA S, 1972, J NEUROSURG, V37, P631, DOI 10.3171/jns.1972.37.6.0631; Jones SJ, 2003, J NEUROL NEUROSUR PS, V74, P273, DOI 10.1136/jnnp.74.2.273; Kelleher MO, 2008, J NEUROSURG-SPINE, V8, P215, DOI 10.3171/SPI/2008/8/3/215; Khan MH, 2006, SPINE, V31, pE105, DOI 10.1097/01.brs.0000200163.71909.1f; Koyanagi I, 2000, J NEUROSURG, V93, P15, DOI 10.3171/spi.2000.93.1.0015; KRIPPENDORFF K, 2004, CONTENT ANAL INTRO I, P238; LAROCHE M, 1992, CLIN RHEUMATOL, V11, P533, DOI 10.1007/BF02283114; Lee JY, 2006, SPINE, V31, P1916, DOI 10.1097/01.brs.0000228724.01795.a2; Lee L, 2010, APSF NEWSLETTER, V24, P45; Lee Lorri A, 2002, Anesthesiol Clin North Am, V20, P485; Lee MJ, 2007, J BONE JOINT SURG AM, V89A, P376, DOI 10.2106/JBJS.F.00437; Lewandrowski KU, 2006, SPINE, V31, P1056, DOI 10.1097/01.brs.0000214968.58581.44; Liang BA, 1999, J CLIN ANESTH, V11, P349, DOI 10.1016/S0952-8180(99)00050-1; MATJASKO J, 1985, NEUROSURGERY, V17, P695, DOI 10.1227/00006123-198511000-00001; Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929; McLeod ADM, 2000, BRIT J ANAESTH, V84, P705, DOI 10.1093/bja/84.6.705; MENEZES AH, 1992, PEDIATR NEUROSURG, V18, P24, DOI 10.1159/000120638; Mercieri M, 2009, ANAESTHESIA, V64, P1010, DOI 10.1111/j.1365-2044.2009.05944.x; Morandi X, 2004, NEUROSURGERY, V54, P1512, DOI 10.1227/01.NEU.0000125008.93625.5E; Muckart DJJ, 1997, ANESTHESIOLOGY, V87, P418, DOI 10.1097/00000542-199708000-00029; Muhle C, 1998, INVEST RADIOL, V33, P444, DOI 10.1097/00004424-199808000-00004; Muhle C, 1998, AM J NEURORADIOL, V19, P1763; MUNIS J, 2008, APSF NEWSL, V22, P82; Naja Z, 2005, ANESTH ANALG, V101, P1883; Nitta H, 1997, NEUROSURGERY, V40, P1082, DOI 10.1097/00006123-199705000-00039; Nowak DD, 2009, J AM ACAD ORTHOP SUR, V17, P756, DOI 10.5435/00124635-200912000-00004; Okada E, 2009, SPINE, V34, P706, DOI 10.1097/BRS.0b013e31819c2003; PATEL A, 1993, AM HEART J, V126, P184, DOI 10.1016/S0002-8703(07)80027-5; Patil PG, 2005, NEUROSURGERY, V57, P753, DOI 10.1227/01.NEU.0000175729.79119.1d; Pohl A, 2005, J CLIN ANESTH, V17, P463, DOI 10.1016/j.jclinane.2004.09.012; POSNER KL, 1990, STAT MED, V9, P1103, DOI 10.1002/sim.4780090917; Posner KL, 1996, ANESTHESIOLOGY, V85, P1049, DOI 10.1097/00000542-199611000-00013; POWELL JF, 1990, ANAESTHESIA, V45, P1049, DOI 10.1111/j.1365-2044.1990.tb14886.x; Powell R M, 1996, J R Army Med Corps, V142, P79; Rao R, 2002, J BONE JOINT SURG AM, V84A, P1872, DOI 10.2106/00004623-200210000-00021; Redl G, 1998, ANESTHESIOLOGY, V89, P1262, DOI 10.1097/00000542-199811000-00031; Resnick DK, 2009, J NEUROSURG-SPINE, V11, P245, DOI 10.3171/2009.2.SPINE08730; SALATHE M, 1989, ANESTHESIOLOGY, V70, P869, DOI 10.1097/00000542-198905000-00027; Sebastian C, 1997, Eur Spine J, V6, P316, DOI 10.1007/BF01142677; Shamji MF, 2008, J NEUROSURG-SPINE, V9, P10, DOI 10.3171/SPI/2008/9/7/010; Shedid D, 2007, NEUROSURGERY, V60, P7, DOI 10.1227/01.NEU.0000215430.86569.C4; Smith PN, 2007, SPINE J, V7, P83, DOI 10.1016/j.spinee.2006.04.008; Sung RD, 2001, SPINE, V26, P67, DOI 10.1097/00007632-200101010-00013; Taunt CJ, 2005, SPINE, V30, P1970, DOI 10.1097/01.brs.0000176321.02963.72; TERESI LM, 1987, RADIOLOGY, V164, P83, DOI 10.1148/radiology.164.1.3588931; Tsirikos AI, 2004, J SPINAL DISORD TECH, V17, P385, DOI 10.1097/01.bsd.0000095825.98982.1a; Wang MC, 2007, SPINE, V32, P342, DOI 10.1097/01.brs.0000254120.25411.ae; Westerveld LA, 2009, EUR SPINE J, V18, P145, DOI 10.1007/s00586-008-0764-0; WILDER BL, 1982, NEUROSURGERY, V11, P530; Woodward LJ, 2009, ANAESTHESIA, V64, P540, DOI 10.1111/j.1365-2044.2008.05794.x; YASZEMSKI MJ, 1990, SPINE, V15, P338, DOI 10.1097/00007632-199004000-00017; YOUNG ML, 1986, NEUROSURGERY, V18, P157, DOI 10.1227/00006123-198602000-00007; Zeidman SM, 1997, J SPINAL DISORD, V10, P523	81	38	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2011	114	4					782	795		10.1097/ALN.0b013e3182104859			14	Anesthesiology	Anesthesiology	739DT	WOS:000288694400009	21326090	Bronze			2021-06-18	
J	Ben-David, BM; Nguyen, LLT; van Lieshout, PHHM				Ben-David, Boaz M.; Nguyen, Linh L. T.; van Lieshout, Pascal H. H. M.			Stroop Effects in Persons with Traumatic Brain Injury: Selective Attention, Speed of Processing, or Color-Naming? A Meta-analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Stroop; Head injury; Selective attention; Information processing; Color perception; Executive function	CLOSED-HEAD-INJURY; ANTERIOR CINGULATE CORTEX; COGNITIVE CONTROL; WORD TEST; DIVIDED ATTENTION; SENSORY ORIGIN; FOLLOW-UP; INFORMATION; TASK; DEFICITS	The color word Stroop test is the most common tool used to assess selective attention in persons with traumatic brain injury (TBI). A larger Stroop effect for TBI patients, as compared to controls, is generally interpreted as reflecting a decrease in selective attention. Alternatively, it has been suggested that this increase in Stroop effects is influenced by group differences in generalized speed of processing (SOP). The current study describes an overview and meta-analysis of 10 studies, where persons with TBI (N = 324) were compared to matched controls (N = 501) on the Stroop task. The findings confirmed that Stroop interference was significantly larger for TBI groups (p = .008). However, these differences may be strongly biased by TBI-related slowdown in generalized SOP (r(2) = .81 in a Brinley analysis). We also found that TBI-related changes in sensory processing may affect group differences. Mainly, a TBI-related increase in the latency difference between reading and naming the font color of a color-neutral word (r(2) = .96) was linked to Stroop effects. Our results suggest that, in using Stroop, it seems prudent to control for both sensory factors and SOP to differentiate potential changes in selective attention from other changes following TBI. (JINS, 2011, 17,354-363)	[Ben-David, Boaz M.; Nguyen, Linh L. T.; van Lieshout, Pascal H. H. M.] Univ Toronto, Dept Speech Language Pathol, Oral Dynam Lab, Toronto, ON M5G 1V7, Canada; [Ben-David, Boaz M.; van Lieshout, Pascal H. H. M.] Toronto Rehabil Inst, Toronto, ON, Canada; [Ben-David, Boaz M.; Nguyen, Linh L. T.; van Lieshout, Pascal H. H. M.] Univ Toronto Mississauga, Dept Psychol, Toronto, ON, Canada; [van Lieshout, Pascal H. H. M.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada	Ben-David, BM (corresponding author), Univ Toronto, Dept Speech Language Pathol, Oral Dynam Lab, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	boaz.ben.david@utoronto.ca	van Lieshout, Pascal HHM/A-1371-2008	van Lieshout, Pascal HHM/0000-0001-8139-8900; Ben-David, Boaz/0000-0002-0392-962X	Ontario Neurotrauma Foundation [2008-ABI-PDF-659]; Canada Research Chairs programCanada Research Chairs [303712CRC]	B.M. Ben-David was partially supported by a grant from the Ontario Neurotrauma Foundation (2008-ABI-PDF-659). This research was undertaken, in part, thanks to funding from the Canada Research Chairs program (303712CRC) awarded to P.H.H.M. van Lieshout.	Alferes V, 2003, METAANALYSIS FIXED R; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Balota DA, 2010, PSYCHOL AGING, V25, P208, DOI 10.1037/a0017474; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Ben-David BM, 2011, BRAIN INJURY, V25, P206, DOI 10.3109/02699052.2010.536197; Ben-David BM, 2010, AGING NEUROPSYCHOL C, V17, P730, DOI 10.1080/13825585.2010.510553; Ben-David BM, 2009, AGING NEUROPSYCHOL C, V16, P505, DOI 10.1080/13825580902855862; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; Brinley J. F., 1965, BEHAV AGING NERVOUS, P114; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; CERELLA J, 1994, ACTA PSYCHOL, V86, P109, DOI 10.1016/0001-6918(94)90002-7; CERELLA J, 1990, HDB PSYCHOL AGING, P201, DOI DOI 10.1016/B978-0-12-101280-9.50018-8; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eidels A, 2010, COGNITION, V114, P129, DOI 10.1016/j.cognition.2009.08.008; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; FERRARO RF, 1996, BRAIN COGNITION, V32, P429; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goethals I, 2004, J NEUROTRAUM, V21, P1059, DOI 10.1089/0897715041651051; Golden C., 1978, STROOP COLOR WORD TE; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hedges L.V., 1985, STAT METHODS META AN; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Koh SB, 2008, EUR NEUROL, V60, P174, DOI 10.1159/000148244; Lannoo E, 1997, PSYCHOL BELG, V37, P141; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MACLEOD CM, 1992, J EXP PSYCHOL GEN, V121, P12, DOI 10.1037/0096-3445.121.1.12; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mani TM, 2007, NEUROCASE, V13, P229, DOI 10.1080/13554790701594862; McDowd J. M., 2000, HDB AGING COGNITION, P221; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Melara RD, 2003, PSYCHOL REV, V110, P422, DOI 10.1037/0033-295X.110.3.422; MILLER EM, 1994, PERS INDIV DIFFER, V17, P803, DOI 10.1016/0191-8869(94)90049-3; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 1998, NEUROPSYCHOLOGY, V12, P414, DOI 10.1037/0894-4105.12.3.414; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1975, LOYOLA S, P55; RANDOLPH A, 1988, ARCH BIOCHEM BIOPHYS, V267, P46, DOI 10.1016/0003-9861(88)90006-9; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Sabri M, 2001, J EXP PSYCHOL HUMAN, V27, P515, DOI 10.1037/0096-1523.27.3.515; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schmitter-Edgecombe M, 1996, J Int Neuropsychol Soc, V2, P111; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Verhaeghen P, 2002, NEUROSCI BIOBEHAV R, V26, P849, DOI 10.1016/S0149-7634(02)00071-4; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	72	38	38	3	47	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					354	363		10.1017/S135561771000175X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900016	21320377				2021-06-18	
J	Inness, EL; Howe, JA; Niechwiej-Szwedo, E; Jaglal, SB; McIlroy, WE; Verrier, MC				Inness, Elizabeth L.; Howe, Jo-Anne; Niechwiej-Szwedo, Ewa; Jaglal, Susan B.; McIlroy, William E.; Verrier, Molly C.			Measuring Balance and Mobility after Traumatic Brain Injury: Validation of the Community Balance and Mobility Scale (CB&M)	PHYSIOTHERAPY CANADA			English	Article						balance; brain injuries; posture; mobility limitations; outcome assessment	ASSESSMENT-TOOL HIMAT; GAIT VARIABILITY; OLDER ADULTS; PARAMETERS; AMBULATION; RECOVERY; VALIDITY; STROKE	Purpose: To further investigate the construct validity of the Community Balance and Mobility Scale (CB&M), developed for ambulatory individuals with traumatic brain injury (TBI). Methods: A convenience sample of 35 patients with TBI (13 in-patients, 22 outpatients) was recruited. Analyses included a comparison of CB&M and Berg Balance Scale (BBS) admission and change scores and associations between the CB&M and measures of postural sway, gait, and dynamic stability; the Community Integration Questionnaire (CIQ); and the Activities-specific Balance Confidence (ABC) Scale. Results: Mean admission scores on the BBS and the CB&M were 53.6/56 (SD = 4.3) and 57.8/96 (SD = 23.3) respectively. Significant correlations were demonstrated between the CB&M and spatiotemporal measures of gait, including walking velocity, step length, step width, and step time; measures of dynamic stability, including variability in step length and step time; and the ABC (p < 0.05). Significant correlations between the CB&M and CIQ were revealed with a larger data set (n = 47 outpatients) combined from previous phases of research. Conclusions: In patients with TBI, the CB&M is less susceptible to a ceiling effect than the BBS. The construct validity of the CB&M was supported, demonstrating associations with laboratory measures of dynamic stability, measures of community integration, and balance confidence.	[Inness, Elizabeth L.] Toronto Rehabil Inst, Mobil & Falls Clin, Toronto, ON M5G 2A2, Canada; [Inness, Elizabeth L.; Howe, Jo-Anne; Jaglal, Susan B.; Verrier, Molly C.] Univ Toronto, Fac Med, Dept Phys Therapy, Toronto, ON, Canada; [Niechwiej-Szwedo, Ewa] Hosp Sick Children, Dept Ophthalmol, Toronto, ON M5G 1X8, Canada; [Jaglal, Susan B.; McIlroy, William E.; Verrier, Molly C.] Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON, Canada; [McIlroy, William E.] Univ Waterloo, Dept Kinesiol, Fac Sci Appl, Waterloo, ON N2L 3G1, Canada	Inness, EL (corresponding author), Toronto Rehabil Inst, Mobil & Falls Clin, 550 Univ Ave 11015, Toronto, ON M5G 2A2, Canada.	inness.liz@torontorehab.on.ca		Jaglal, Susan/0000-0002-2930-1443; Inness, Elizabeth L./0000-0002-9217-4619	Ontario Neurotrauma Foundation [ONBO-00020]; Toronto Rehabilitation Institute under Ontario Ministry of Health and Long-Term Care; Toronto Rehabilitation Institute Chair at the University of Toronto	This research was funded by the Ontario Neurotrauma Foundation (grant #ONBO-00020). We also acknowledge the support of the Toronto Rehabilitation Institute, which receives funding under the Provincial Rehabilitation Research Program from the Ontario Ministry of Health and Long-Term Care. Dr. Jaglal is supported by the Toronto Rehabilitation Institute Chair at the University of Toronto.	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Colton T., 1974, STAT MED; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; *HAM BRAIN INJ ASS, BRAIN INJ FACTS; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hillier SL, 1997, BRAIN INJURY, V11, P661; Howe JA, 2006, CLIN REHABIL, V20, P885, DOI 10.1177/0269215506072183; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Lerner-Frankiel MB, 1986, CLIN MANAG PHYS THER, V6, P12; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; OBERG T, 1993, J REHABIL RES DEV, V30, P210; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; ROBINETT CS, 1988, PHYS THER, V68, P1371, DOI 10.1093/ptj/68.9.1371; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WEINSTEIN C, 1989, ARCH PHYS MED REHAB, V70, P755; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Williams G, 2005, BRAIN INJURY, V19, P925, DOI 10.1080/02699050500058687; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Wright JG, 1997, J CLIN EPIDEMIOL, V50, P239, DOI 10.1016/S0895-4356(96)00373-3; Zar J. H., 1984, BIOSTATISTICAL ANAL, V3	29	38	38	0	12	UNIV TORONTO PRESS INC	TORONTO	JOURNALS DIVISION, 5201 DUFFERIN ST, DOWNSVIEW, TORONTO, ON M3H 5T8, CANADA	0300-0508			PHYSIOTHER CAN	Physiother. Can.	SPR	2011	63	2					199	208		10.3138/ptc.2009-45			10	Rehabilitation	Rehabilitation	843MZ	WOS:000296677300011	22379260	Green Published			2021-06-18	
J	Kaya, T; Karatepe, AG; Gunaydin, R; Koc, A; Ercan, UA				Kaya, Taciser; Karatepe, Altinay Goksel; Gunaydin, Rezzan; Koc, Aysegul; Ercan, Ulku Altundal			Inter-rater reliability of the Modified Ashworth Scale and modified Modified Ashworth Scale in assessing poststroke elbow flexor spasticity	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						hemiplegia; muscle spasticity; inter-rater variation	TRAUMATIC BRAIN-INJURY; MUSCLE SPASTICITY	The Modified Ashworth Scale (MAS) is commonly used in clinical practice for grading spasticity. However, it was modified recently by omitting grade '1 +' of the MAS and redefining grade '2'. The aim of this study was to investigate the inter-rater reliability of MAS and modified MAS (MMAS) for the assessment of poststroke elbow flexor spasticity. Sixty-four patients with poststroke hemiplegia were enrolled. The mean age and time since the stroke were 60.5 +/- 11.9 years and 15.7 +/- 10.2 weeks, respectively. The patients were tested by two raters having equal experience in applying MAS. They were not subjected to any training for administering MMAS. After performing no more than two test movements, the raters graded the resistance felt, according to the MAS and MMAS, respectively based on same stretch. The degree of agreement was analyzed using the weighted kappa (kw) statistic. Inter-rater agreements were very good for both MAS and MMAS, with weighted kappa values of 0.868 and 0.892, respectively. The highest agreements were observed for grade '0' in applying MAS and for grade '2' in applying MMAS; on the other hand, the lowest agreements were observed for grade '2' in applying MAS and for grade '3' in applying MMAS. According to our results, MAS and MMAS have very good inter-rater reliability for assessment of poststroke elbow flexor spasticity. Neither of the scales is superior to each other when using them to grade spasticity in patients with hemiplegia for this muscle group.	[Kaya, Taciser; Karatepe, Altinay Goksel; Gunaydin, Rezzan; Koc, Aysegul; Ercan, Ulku Altundal] Izmir Bozyaka Training & Res Hosp, Dept Phys Therapy & Rehabil, Izmir, Turkey	Kaya, T (corresponding author), Ilica Mah Bodur Sk 1-1, TR-35320 Narlidere Izmir, Turkey.	taciserkaya@gmail.com	Kaya, Taciser/ABH-5966-2020	Kaya, Taciser/0000-0002-8848-8420; Goksel Karatepe, Altinay/0000-0001-8086-9942			Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; Annaswamy T, 2007, AM J PHYS MED REHAB, V86, P404, DOI 10.1097/PHM.0b013e31804a7d85; Ansari Noureddin Nakhostin, 2006, Physiotherapy Theory and Practice, V22, P119, DOI 10.1080/09593980600724188; Ansari NN, 2009, NEUROREHABILITATION, V25, P235, DOI 10.3233/NRE-2009-0520; Ansari NN, 2009, NEUROREHABILITATION, V24, P225, DOI 10.3233/NRE-2009-0472; Ansari Noureddin Nakhostin, 2008, Physiotherapy Theory and Practice, V24, P205, DOI 10.1080/09593980701523802; Biering-Sorensen F, 2006, SPINAL CORD, V44, P708, DOI 10.1038/sj.sc.3101928; Blackburn M, 2002, PHYS THER, V82, P25, DOI 10.1093/ptj/82.1.25; Bohannon RW, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-30; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; Clopton Nancy, 2005, Pediatr Phys Ther, V17, P268, DOI 10.1097/01.pep.0000186509.41238.1a; Craven BC, 2010, SPINAL CORD, V48, P207, DOI 10.1038/sc.2009.107; Fleuren JFM, 2010, J NEUROL NEUROSUR PS, V81, P46, DOI 10.1136/jnnp.2009.177071; Ghotbi N, 2009, BRAIN INJURY, V23, P815, DOI 10.1080/02699050903200548; Gregson JM, 1999, ARCH PHYS MED REHAB, V80, P1013, DOI 10.1016/S0003-9993(99)90053-9; Levin MF, 2005, CLIN NEUROPHYSIOL, V116, P1754, DOI 10.1016/j.clinph.2005.03.004; Mutlu A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-44; Naghdi Soofia, 2008, Physiotherapy Theory and Practice, V24, P372, DOI 10.1080/09593980802278959; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Pierce SR, 2006, ARCH PHYS MED REHAB, V87, P697, DOI 10.1016/j.apmr.2006.01.020; Platz T, 2005, DISABIL REHABIL, V27, P7, DOI 10.1080/09638280400014634; Smith AW, 2002, AM J PHYS MED REHAB, V81, P202, DOI 10.1097/00002060-200203000-00008	23	38	42	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	2011	34	1					59	64		10.1097/MRR.0b013e32833d6cdf			6	Rehabilitation	Rehabilitation	733UR	WOS:000288289400008	20671560				2021-06-18	
J	Park, E; Gottlieb, JJ; Cheung, B; Shek, PN; Baker, AJ				Park, Eugene; Gottlieb, James J.; Cheung, Bob; Shek, Pang N.; Baker, Andrew J.			A Model of Low-Level Primary Blast Brain Trauma Results in Cytoskeletal Proteolysis and Chronic Functional Impairment in the Absence of Lung Barotrauma	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; mild traumatic brain injury; model; neurofilament protein 200; primary blast; spectrin; white matter injury	POSTTRAUMATIC-STRESS-DISORDER; FLUID PERCUSSION INJURY; NEUROFILAMENT SUBUNITS; SHOCK-WAVE; RAT; PHOSPHORYLATION; OVERPRESSURE; ACTIVATION; PATHOLOGY; PRESSURE	Shock-wave exposure from improvised explosive devices (IEDs) has been implicated as a possible contributing factor to neurological impairment reported in combat veterans. However, evidence-based substantiation of this implication, particularly for low-level exposure in the absence of external signs of trauma, remain elusive. Accordingly, we constructed an open-ended shock tube producing a short-duration, low-amplitude shockwave. Low-level (11.5 kPa static overpressure) complex shock-wave exposure in rats resulted in no histological evidence of lung injury. By contrast, delayed cytoskeletal proteolysis of alpha II-spectrin was detected in the cortex and hippocampus by 12 h post-injury. Cell death was minimal and localized predominantly in the corpus callosum and periventricular regions. These regions, with presumably different density interfaces, exhibit biological responses to shockwaves consistent with interface turbulence described by Richtmyer-Meshkov instability. Evoked compound action potential (CAP) recordings from the corpus callosum showed a significant increase in the duration of CAP responses at 14 and 30 days post-injury, and a gradual depression in the unmyelinated fiber amplitude. Shielding the head attenuated alpha II-spectrin cytoskeletal breakdown, thus directly implicating low-level shock-wave exposure as a cause of brain injury in the rat. Despite anatomical and scaling differences in rats compared to humans, the results suggest the potential for undiagnosed traumatic brain pathologies occurring in combat veterans following shock-wave exposure.	[Baker, Andrew J.] St Michaels Hosp, Inst Med Sci,Dept Anesthesia, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Gottlieb, James J.] Univ Toronto, Inst Aerosp Studies, Toronto, ON, Canada; [Cheung, Bob; Shek, Pang N.] Def Res & Dev Canada DRDC, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Inst Med Sci, Dept Anesthesia, Toronto, ON M5S 1A1, Canada; [Baker, Andrew J.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada	Baker, AJ (corresponding author), St Michaels Hosp, Inst Med Sci,Dept Anesthesia, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca			Public Works Government Services Contract, Department of Defense Research Canada, PWGSC [W7711-078105/A]	This work is funded through the Public Works Government Services Contract, Department of Defense Research Canada, PWGSC contract #W7711-078105/A.	Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Baker WE., 1973, EXPLOSIONS AIR; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Brouillette M, 2002, ANNU REV FLUID MECH, V34, P445, DOI 10.1146/annurev.fluid.34.090101.162238; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Currey JD, 1999, J EXP BIOL, V202, P2495; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Guy R J, 1998, J R Nav Med Serv, V84, P79; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jung CW, 2005, MOL BRAIN RES, V141, P151, DOI 10.1016/j.molbrainres.2005.08.009; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Meshkov E., 1969, FLUID DYNAM+, V4, P101, DOI [10.1007/BF01015969, DOI 10.1007/BF01015969]; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; NAMANI R, 2009, C P IEEE ENG MED BIO, V1, P1117; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rao MV, 2003, NEUROCHEM RES, V28, P1041, DOI 10.1023/A:1023259207015; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; RICHTMYER RD, 1960, COMMUN PUR APPL MATH, V13, P297, DOI 10.1002/cpa.3160130207; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Ruff RL, 2008, NEW ENGL J MED, V358, P2178; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Shea TB, 2008, EUR J NEUROSCI, V27, P1893, DOI 10.1111/j.1460-9568.2008.06165.x; Sihag RK, 2007, EXP CELL RES, V313, P2098, DOI 10.1016/j.yexcr.2007.04.010; SLOAN SA, 1975, J FLUID MECH, V71, P769, DOI 10.1017/S0022112075002844; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taniuchi N, 2009, INT J MED SCI, V6, P1; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yu Q, 1996, SHOCK WAVES, V6, P249	54	38	39	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					343	357		10.1089/neu.2009.1050			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600002	21142686				2021-06-18	
J	Todis, B; Glang, A; Bullis, M; Ettel, D; Hood, D				Todis, Bonnie; Glang, Ann; Bullis, Michael; Ettel, Deborah; Hood, Donald			Longitudinal Investigation of the Post-High School Transition Experiences of Adolescents With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community adjustment; employment; post-secondary education; transition outcomes; traumatic brain injury	TO-COMMUNITY TRANSITION; QUALITY-OF-LIFE; INCARCERATED YOUTH; BEHAVIOR PROBLEMS; HEAD-INJURY; CHILDREN; CHILDHOOD; TERM; OUTCOMES; PERFORMANCE	Objective: To describe outcomes for youth with traumatic brain injury (TBI) transitioning from high school to adulthood. Design: Longitudinal design using univariate and multivariate analyses, including survival analysis to predict time to outcomes of interest and longitudinal growth modeling to evaluate factors that predict rates and levels of outcomes over time. Main Outcome Measures: employment, post-secondary education, and independent living status. Participants: Eighty-nine youth and young adults (aged 19-25 years) with TBI (19 mild-moderate TBI and 70 severe TBI). Results: Individuals entering adulthood following childhood TBI experienced fluctuations in rates of employment, enrollment in post-secondary education, and independent living. A higher likelihood of being enrolled in post-secondary education following graduation from high school was associated with being female, later age at injury, and higher socioeconomic status. Overall greater likelihood of employment was associated with higher socioeconomic status, while employment upon high school graduation was associated with more severe injury and lack of rehabilitations services. Greater likelihood of independent living was associated with later age at injury and nonreceipt of rehabilitation services, while shorter time until independent living was associated with less severe injury. Conclusion: Knowledge of how specific factors affect transition outcomes can be used to tailor transition interventions and resources to the needs of students with TBI. Findings related to special education and medical rehabilitation services should be interpreted with caution as the criteria for receipt of both types of services and the links between such services and functional outcomes are unclear.	[Todis, Bonnie; Glang, Ann; Ettel, Deborah; Hood, Donald] Teaching Res Inst, Eugene, OR 97401 USA; [Bullis, Michael] Univ Oregon, Coll Educ, Eugene, OR 97403 USA	Todis, B (corresponding author), Teaching Res Inst, 99 W 10th Ave,Ste 370, Eugene, OR 97401 USA.	todisb@wou.edu			US Department of Education, Office of Special Education and Rehabilitation ServicesUS Department of Education [H324C980115]	This study was funded by the US Department of Education, Office of Special Education and Rehabilitation Services Grant H324C980115 Resilience in Students with Traumatic Brain Injury: A Longitudinal Investigation.	Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Blackorby J, 1996, EXCEPT CHILDREN, V62, P399; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Bullis M, 2004, J SPEC EDUC, V38, P80, DOI 10.1177/00224669040380020201; Bullis M, 2002, EXCEPT CHILDREN, V69, P7; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; *CDCP, 2004, TRAUM BRAIN INJ TBI; Centers for Disease Control and Prevention, 2005, INT DAT TABL; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; *Eisenman L.T., 2003, EXCEPTIONALITY, V11, P89, DOI [10.1207/S15327035EX1102_04, DOI 10.1207/S15327035EX1102_]; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Garmezy N, 1988, STUDIES PSYCHOSOCIAL, P29; Gioia G.A., 2000, BEHAV RATING INVENTO; GLANG A, 2003, RESILIENCE STUDENTS; Halpern A.S., 1994, CAREER DEV EXCEPTION, V17, P115, DOI DOI 10.1177/088572889401700201; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Heinrich CJ, 2001, J PUBL ADM RES THEOR, V11, P109, DOI 10.1093/oxfordjournals.jpart.a003490; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Keogh B. K., 1993, LEARNING DISABILITIE, V8, P3; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1988, PEDIATR NEUROL, V4, P337, DOI 10.1016/0887-8994(88)90079-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Nybo T, 2005, ACTA NEUROL SCAND, V112, P338, DOI 10.1111/j.1600-0404.2005.00489.x; Nybo T, 1999, BRAIN INJURY, V13, P759; Oregon Department of Human Services Health Services, 1999, HOSP DISCH IND; Pew Research Center for the People and the Press, 2007, PORT GEN NEXT YOUNG; Raudenbus S, 2004, HLM6 HIERARCHICAL LI; Rivara Frederick P, 2004, Arch Pediatr Adolesc Med, V158, P513, DOI 10.1001/archpedi.158.6.513; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rusch FR, 1998, HIGH SCH TRANSITIONS; Rutter M. E., 1988, STUDIES PSYCHOSOCIAL; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Shandra CL, 2008, J VOCAT REHABIL, V29, P117; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; The American Academy of Physical Medicine and Rehabilitation, 2004, HOT STOR TOP BRAIN I; TODIS B, 1998, RESILIENCE STUDENTS; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; U. S. Census Bureau, STAT COUNT QUICKFACT; Van Heugten CM, 2006, BRAIN INJURY, V20, P895, DOI 10.1080/02699050600832015; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wagner M., 2005, HIGH SCH 1 LOOK POST; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; NATL LONGITUDINAL ST	59	38	39	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2011	26	2					138	149		10.1097/HTR.0b013e3181e5a87a			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	732OR	WOS:000288197200004	20631630				2021-06-18	
J	Zurek, J; Bartlova, L; Fedora, M				Zurek, Jiri; Bartlova, Ludmila; Fedora, Michal			Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children	BRAIN INJURY			English	Article						Children; brain injury; biomarkers; outcome; hyperphosphorylated neurofilament	MILD HEAD-INJURY; PROTEIN BIOMARKERS; PRACTICAL SCALE; SERUM; DAMAGE; BLOOD	Objective: The aim of the study was to determine whether serum levels of hyperphosphorylated neurofilament NF-H correlate with severity of brain injury in children. Methods: Forty-nine patients with traumatic brain injury (TBI) were enrolled into the prospective study. Venous blood samples were taken after admission and every 24 h for a maximum of 6 consecutive days. Serum NF-H concentrations were quantified by enzyme-linked immunosorbent assay. The outcome was evaluated 6 months after TBI using Glasgow Outcome Scale (GOS) in all patients. Results: The quantitative level of pNF-H remained significantly higher in patients with poor outcome (GOS = 1) in comparison with the other patients for the 2nd-4th day (p = 0.027; p = 0.019; p = 0.01). Levels of pNF-H were significantly higher in patients with diffuse axonal injury on initial CT scan (p = 0.004). Normal levels pNF-H in the paediatric population are unknown. Objective ROC analysis was identification of optimal cut-offs of proteins for prediction of GOS = 1. Conclusions: Although further, prospective study is warranted, these findings suggest that levels of hyperphosphorylated neurofilament NF-H correlate with mortality and may be useful as predictors of outcome in children with TBI.	[Zurek, Jiri; Fedora, Michal] Univ Childrens Hosp, Dept Anesthesia & Intens Care, Brno 62500, Czech Republic; [Bartlova, Ludmila] Univ Childrens Hosp, Dept Pediat Neurol, Brno 62500, Czech Republic	Zurek, J (corresponding author), Univ Childrens Hosp, Dept Anesthesia & Intens Care, Cernopolni 9, Brno 62500, Czech Republic.	jzurek@fnbrno.cz		Zurek, Jiri/0000-0002-6409-2560			Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JENNETT B, 1975, LANCET, V1, P480; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Schwartz SM, 2001, CRIT CARE MED, V29, pS214, DOI 10.1097/00003246-200110001-00003; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; TEASDALE G, 1974, LANCET, V2, P81; ZUREK J, 2010, CESKA SLOVENSKA NEUR, V1, P37	16	38	40	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2011	25	2					221	226		10.3109/02699052.2010.541895			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800008	21219092				2021-06-18	
J	Mukherjee, S; Katki, K; Arisi, GM; Foresti, ML; Shapiro, LA				Mukherjee, Sanjib; Katki, Khurshed; Arisi, Gabriel M.; Foresti, Maira L.; Shapiro, Lee A.			Early TBI-induced cytokine alterations are similarly detected by two distinct methods of multiplex assay	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						cytokine; TBI; fluid percussion injury; multiplex assay		Annually, more than a million persons experience traumatic brain injury (TBI) in the US and a substantial proportion of this population develop debilitating neurological disorders, such as, paralysis, cognitive deficits, and epilepsy. Despite the long-standing knowledge of the risks associated with TBI, no effective biomarkers or interventions exist. Recent evidence suggests a role for inflammatory modulators in TBI-induced neurological impairments. Current technological advances allow for the simultaneous analysis of the precise spatial and temporal expression patterns of numerous proteins in single samples which ultimately can lead to the development of novel treatments. Thus, the present study examined 23 different cytokines, including chemokines, in the ipsi and contralateral cerebral cortex of rats at 24 h after a fluid percussion injury (FPI). Furthermore, the estimation of cytokines were performed in a newly developed multiplex assay instrument, MAGPIX (Luminex Corp), and compared with an established instrument, Bio-Plex (Bio-Rad), in order to validate the newly developed instrument. The results show numerous inflammatory changes in the ipsi and contralateral side after FPI that were consistently reported by both technologies.	[Mukherjee, Sanjib; Katki, Khurshed; Arisi, Gabriel M.; Foresti, Maira L.; Shapiro, Lee A.] Scott & White Hosp, Neurosci Res Inst, Temple, TX USA; [Mukherjee, Sanjib; Katki, Khurshed; Arisi, Gabriel M.; Foresti, Maira L.; Shapiro, Lee A.] Cent Texas Vet Hlth Syst, Temple, TX USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX 76504 USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosurg, Temple, TX 76504 USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Temple, TX 76504 USA	Shapiro, LA (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Bldg 205,1901 South 1st St, Temple, TX 76504 USA.	lshapiro@medicine.tamhsc.edu	Foresti, Maira Licia/D-8292-2015; Arisi, Gabriel/J-8714-2012	Arisi, Gabriel/0000-0002-6832-3389	Foundation CIEN-Reina Sofia; FISInstituto de Salud Carlos III [PS09/00684]; CIBERNED, ISC-III from Spain	We would especially like to thank Dr. M.-X. Silveyra for her contribution, and M.-T. Garcia-Hedo and C. Serra-Basante for technical assistance. This work was supported by grants from Foundation CIEN-Reina Sofia, FIS (Grant PS09/00684), and CIBERNED, ISC-III from Spain to Javier Saez-Valero.	ARENDT T, 1992, NEUROCHEM INT, V21, P381, DOI 10.1016/0197-0186(92)90189-X; ATACK JR, 1986, J NEUROCHEM, V47, P263; ATACK JR, 1987, J NEUROCHEM, V48, P1687, DOI 10.1111/j.1471-4159.1987.tb05724.x; ATACK JR, 1983, NEUROSCI LETT, V40, P199, DOI 10.1016/0304-3940(83)90302-6; Ballard Clive G., 2005, Current Alzheimer Research, V2, P307; Basun H, 2002, DEMENT GERIATR COGN, V14, P156, DOI 10.1159/000063605; Berson A, 2008, BRAIN, V131, P109, DOI 10.1093/brain/awm276; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Brimijoin S, 1999, ENVIRON HEALTH PERSP, V107, P59, DOI 10.2307/3434472; BROCKMAN SK, 1986, J BIOL CHEM, V261, P1201; CHATEL JM, 1993, P NATL ACAD SCI USA, V90, P2476, DOI 10.1073/pnas.90.6.2476; CHIAPPA S, 1995, BIOCHEM PHARMACOL, V49, P955, DOI 10.1016/0006-2952(95)00004-J; Clarke NA, 2001, INT J GERIATR PSYCH, V16, P1104, DOI 10.1002/gps.472; Cribbs D. H., 1995, ALZHEIMERS RES, V1, P197; Darreh-Shori T, 2006, J NEURAL TRANSM, V113, P1791, DOI 10.1007/s00702-006-0526-2; Davidsson P, 2001, NEUROSCI LETT, V300, P157, DOI 10.1016/S0304-3940(01)01586-5; DAVIES P, 1976, LANCET, V2, P1403; Davis AA, 2010, J NEUROSCI, V30, P4190, DOI 10.1523/JNEUROSCI.6393-09.2010; Dong HX, 2009, BRAIN RES, V1303, P169, DOI 10.1016/j.brainres.2009.09.097; Dori A, 2005, CEREB CORTEX, V15, P419, DOI 10.1093/cercor/bhh145; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FISHMAN EB, 1986, ANN NEUROL, V19, P246, DOI 10.1002/ana.410190305; Fodero LR, 2002, J NEUROCHEM, V81, P441, DOI 10.1046/j.1471-4159.2002.00902.x; Fodero LR, 2001, J NEUROCHEM, V79, P1022, DOI 10.1046/j.1471-4159.2001.00640.x; Fu HJ, 2008, BIOCHEM BIOPH RES CO, V366, P631, DOI 10.1016/j.bbrc.2007.11.068; Garcia-Ayllon MS, 2007, J NEUROCHEM, V101, P1701, DOI 10.1111/j.1471-4159.2007.04461.x; Garcia-Ayllon MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008701; Garcia-Ayllon MS, 2006, HEPATOLOGY, V43, P444, DOI 10.1002/hep.21071; GEULA C, 1989, BRAIN RES, V498, P185, DOI 10.1016/0006-8993(89)90419-8; Giacobini E, 2002, J NEURAL TRANSM-SUPP, P181; Greenberg DS, 2010, NEURODEGENER DIS, V7, P60, DOI 10.1159/000285507; Greenfield SA, 2008, FEBS J, V275, P604, DOI 10.1111/j.1742-4658.2007.06235.x; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guevara J, 1998, J NEUROPATH EXP NEUR, V57, P905, DOI 10.1097/00005072-199810000-00003; HAMMOND P, 1988, J NEUROCHEM, V50, P1111, DOI 10.1111/j.1471-4159.1988.tb10580.x; HECKERS S, 1992, NEUROBIOL AGING, V13, P455, DOI 10.1016/0197-4580(92)90072-6; Hu W, 2003, J NEUROCHEM, V86, P470, DOI 10.1046/j.1471-4159.2003.01855.x; INESTROSA NC, 1981, J NEUROSCI, V1, P1260; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Inestrosa NC, 2008, FEBS J, V275, P625, DOI 10.1111/j.1742-4658.2007.06238.x; Kaduszkiewicz H, 2005, BMJ-BRIT MED J, V331, P321, DOI 10.1136/bmj.331.7512.321; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kang J., 1987, NATURE, P19; Kanninen K, 2004, NEUROSCI LETT, V367, P235, DOI 10.1016/j.neulet.2004.06.013; Kasa P, 1997, PROG NEUROBIOL, V52, P511, DOI 10.1016/S0301-0082(97)00028-2; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Lahiri D K, 1997, Ann N Y Acad Sci, V826, P416, DOI 10.1111/j.1749-6632.1997.tb48495.x; Lahiri DK, 2007, J PHARMACOL EXP THER, V320, P386, DOI 10.1124/jpet.106.112102; LAHIRI DK, 1994, J NEUROSCI RES, V37, P777, DOI 10.1002/jnr.490370612; LAYER PG, 1995, ALZ DIS ASSOC DIS, V9, P29, DOI 10.1097/00002093-199501002-00006; Li QQ, 2010, EXP GERONTOL, V45, P842, DOI 10.1016/j.exger.2010.06.008; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matrone C, 2008, P NATL ACAD SCI USA, V105, P13139, DOI 10.1073/pnas.0806133105; Melo JB, 2003, NEUROSCI RES, V45, P117, DOI 10.1016/S0168-0102(02)00201-8; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Mesulam M M, 1990, Adv Neurol, V51, P235; Mesulam MM, 2004, PROG BRAIN RES, V145, P67, DOI 10.1016/S0079-6123(03)45004-8; MESULAM MM, 1987, ANN NEUROL, V22, P223, DOI 10.1002/ana.410220206; Moreno RD, 1998, INT J DEV NEUROSCI, V16, P123, DOI 10.1016/S0736-5748(98)00008-2; MORI F, 1995, NEUROREPORT, V6, P633, DOI 10.1097/00001756-199503000-00012; MULLER F, 1985, BRAIN RES, V331, P295, DOI 10.1016/0006-8993(85)91555-0; Munoz-Torrero D, 2008, CURR MED CHEM, V15, P2433, DOI 10.2174/092986708785909067; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OGANE N, 1992, NEUROCHEM RES, V17, P489, DOI 10.1007/BF00969897; Pakaski M., 2001, Neurobiology (Budapest), V9, P55; Paraoanu LE, 2006, J MOL NEUROSCI, V30, P201, DOI 10.1385/JMN:30:1:201; Parnetti L, 2011, ACTA NEUROL SCAND, V124, P122, DOI 10.1111/j.1600-0404.2010.01435.x; Peng Y, 2006, J NEUROSCI RES, V84, P903, DOI 10.1002/jnr.20987; Pepeu G, 2009, CURR ALZHEIMER RES, V6, P86, DOI 10.2174/156720509787602861; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2005, J NEUROCHEM, V94, P629, DOI 10.1111/j.1471-4159.2005.03140.x; PERRY EK, 1977, LANCET, V1, P189; PERRY EK, 1986, J NEUROCHEM, V47, P1262; PERRY RH, 1980, AGE AGEING, V9, P9, DOI 10.1093/ageing/9.1.9; Rakonczay Z, 2003, ACTA BIOL HUNG, V54, P183, DOI 10.1556/ABiol.54.2003.2.7; Rees T, 2003, NEUROBIOL AGING, V24, P777, DOI 10.1016/S0197-4580(02)00230-0; Rees TM, 2003, DRUG TODAY, V39, P75, DOI 10.1358/dot.2003.39.1.740206; RIEGER F, 1976, J NEUROCHEM, V27, P121, DOI 10.1111/j.1471-4159.1976.tb01553.x; Rossner S, 1998, PROG NEUROBIOL, V56, P541, DOI 10.1016/S0301-0082(98)00044-6; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Saez-Valero J, 2000, J NEUROL NEUROSUR PS, V69, P664, DOI 10.1136/jnnp.69.5.664; Saez-Valero J, 1999, J NEUROCHEM, V72, P1600, DOI 10.1046/j.1471-4159.1999.721600.x; Saez-Valero J, 2002, NEUROSCI LETT, V325, P199, DOI 10.1016/S0304-3940(02)00282-3; Saez-Valero J, 2000, ACTA NEUROL SCAND, V102, P49, DOI 10.1034/j.1600-0404.2000.00307.x; SaezValero J, 1997, LANCET, V350, P929, DOI 10.1016/S0140-6736(97)24039-0; Sberna G, 1998, J NEUROCHEM, V71, P723; Sberna G, 1997, J NEUROCHEM, V69, P1177; Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122; Sihlbom C, 2008, NEUROCHEM RES, V33, P1332, DOI 10.1007/s11064-008-9588-x; Silman I, 2005, CURR OPIN PHARMACOL, V5, P293, DOI 10.1016/j.coph.2005.01.014; Silveyra M. X., 2011, NEUROBIOL AGING, DOI [10.1016/j.neurobiolaging.2011.04.006, DOI 10.1016/J.NEUROBIOLAGING.2011.04.006.[]; Silveyra M. X., 2011, NEUROBIOL AGING, DOI [10.1016/j.neurobiolaging.2011.03.006, DOI 10.1016/J.NEUROBIOLAGING.2011.03.006.[]; Silveyra MX, 2008, MOL CELL BIOL, V28, P2908, DOI 10.1128/MCB.02065-07; Silveyra MX, 2006, J NEUROCHEM, V96, P97, DOI 10.1111/j.1471-4159.2005.03514.x; Small DH, 1996, NEUROCHEM INT, V28, P453, DOI 10.1016/0197-0186(95)00099-2; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; STIEGER S, 1987, J NEUROCHEM, V49, P460, DOI 10.1111/j.1471-4159.1987.tb02887.x; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; SUNG SC, 1983, NEUROCHEM RES, V8, P303, DOI 10.1007/BF00965720; Talesa VN, 2001, MECH AGEING DEV, V122, P1961, DOI 10.1016/S0047-6374(01)00309-8; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Toiber D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003108; ULRICH J, 1990, ACTA NEUROPATHOL, V80, P624, DOI 10.1007/BF00307630; White AR, 2003, BRAIN RES, V966, P231, DOI 10.1016/S0006-8993(02)04173-2; WRIGHT CI, 1993, ANN NEUROL, V34, P373, DOI 10.1002/ana.410340312; Xie HDQ, 2010, J BIOL CHEM, V285, P11537, DOI 10.1074/jbc.M109.038711; YOUNKIN SG, 1986, FASEB J, V45, P2982; ZAKUT H, 1985, J NEUROCHEM, V45, P382, DOI 10.1111/j.1471-4159.1985.tb03999.x; Zhang Y, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-4; Zimmermann M, 2004, J NEUROCHEM, V90, P1489, DOI 10.1111/j.1471-4159.2004.02680.x; Zimmermann M, 2005, NEUROBIOL DIS, V19, P237, DOI 10.1016/j.nbd.2005.01.002	117	38	38	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.		2011	4								21	10.3389/fnmol.2011.00021			16	Neurosciences	Neurosciences & Neurology	V38VE	WOS:000209370100019	21954376	DOAJ Gold, Green Published			2021-06-18	
J	Bansal, V; Ryu, SY; Blow, C; Costantini, T; Loomis, W; Eliceiri, B; Baird, A; Wolf, P; Coimbra, R				Bansal, Vishal; Ryu, Seok Yong; Blow, Chelsea; Costantini, Todd; Loomis, William; Eliceiri, Brian; Baird, Andrew; Wolf, Paul; Coimbra, Raul			The Hormone Ghrelin Prevents Traumatic Brain Injury Induced Intestinal Dysfunction	JOURNAL OF NEUROTRAUMA			English	Article						ghrelin; intestinal permeability; tight junctions; traumatic brain injury	DELAYED GASTROINTESTINAL TRANSIT; DORSAL MOTOR NUCLEUS; KAPPA-B; BARRIER DYSFUNCTION; TIGHT JUNCTION; PERMEABILITY; INFLAMMATION; CYTOKINES; PIPELINE; PEPTIDE	Intestinal barrier breakdown following traumatic brain injury (TBI) is characterized by increased intestinal permeability, leading to bacterial translocation, and inflammation. The hormone ghrelin may prevent intestinal injury and have anti-inflammatory properties. We hypothesized that exogenous ghrelin prevents intestinal injury following TBI. A weight-drop model created severe TBI in three groups of anesthetized Balb/c mice. Group TBI: animals underwent TBI only; Group TBI/ghrelin: animals were given 10 mu g of ghrelin intraperitoneally prior and 1 h following TBI; Group sham: no TBI or ghrelin injection. Intestinal permeability was measured 6 h following TBI by detecting serum levels of FITC-Dextran after injection into the intact ileum. The terminal ileum was harvested for histology, expression of the tight junction protein MLCK and inflammatory cytokine TNF-alpha. Permeability increased in the TBI group compared to the sham group (109.7 +/- 21.8 mu g/mL vs. 32.2 +/- 10.1 mu g/mL; p<0.002). Ghrelin prevented TBI-induced permeability (28.3 +/- 4.2 mu g/mL vs. 109.7 +/- 21.8 mu g/mL; p<0.001). The intestines of the TBI group showed blunting and necrosis of villi compared to the sham group, while ghrelin injection preserved intestinal architecture. Intestinal MLCK increased 73% compared to the sham group (p<0.03). Ghrelin prevented TBI-induced MLCK expression to sham levels. Intestinal TNF-alpha increased following TBI compared to the sham group (46.2 +/- 7.1 pg/mL vs. 24.4 +/- 2.2 pg/mL p<0.001). Ghrelin reduced TNF-a to sham levels (29.2 +/- 5.0 pg/mL; p = NS). We therefore conclude that ghrelin prevents TBI-induced injury, as determined by intestinal permeability, histology, and intestinal levels of TNF-alpha. The mechanism for ghrelin mediating intestinal protection is likely multifactorial, and further studies are needed to delineate these possibilities.	[Bansal, Vishal; Ryu, Seok Yong; Blow, Chelsea; Costantini, Todd; Loomis, William; Eliceiri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Ryu, Seok Yong] Inje Univ, Sanggye Paik Hosp, Dept Emergency Med, Gimhae, South Korea; [Wolf, Paul] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Baird, Andrew/0000-0003-0027-9905; Eliceiri, Brian/0000-0003-1811-1916	Inje Research and Scholarship Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER	This research was supported in part by the 2009 Inje Research and Scholarship Foundation.	Ammori JB, 2008, SURGERY, V144, P159, DOI 10.1016/j.surg.2008.03.008; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Camilleri M, 2008, GASTROENTEROLOGY, V135, P1877, DOI 10.1053/j.gastro.2008.09.005; Chen G, 2008, INFLAMM RES, V57, P57, DOI 10.1007/s00011-007-7101-7; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; Costantini TW, 2009, J TRAUMA, V67, P1162, DOI 10.1097/TA.0b013e3181ba3577; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Costantini TW, 2009, J TRAUMA, V66, P17, DOI 10.1097/TA.0b013e318191bb1f; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Gonzalez-Rey E, 2006, GASTROENTEROLOGY, V130, P1707, DOI 10.1053/j.gastro.2006.01.041; Graham WV, 2006, J BIOL CHEM, V281, P26205, DOI 10.1074/jbc.M602164200; Grimal R., 2010, PRESENTATION ENQUETE, P1; Gura T, 2003, SCIENCE, V299, P849, DOI 10.1126/science.299.5608.849; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kemp CD, 2008, AM SURGEON, V74, P866; KOCH A, 2010, CRIT CARE, V14; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Miao YY, 2007, BIOCHEM BIOPH RES CO, V359, P795, DOI 10.1016/j.bbrc.2007.05.192; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; Sallam HS, 2007, AM J PHYSIOL-REG I, V292, pR253, DOI 10.1152/ajpregu.00100.2006; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; van der Lely AJ, 2009, HORM RES, V71, P129, DOI 10.1159/000178055; Waseern T, 2008, SURGERY, V143, P334, DOI 10.1016/j.surg.2007.09.039; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2009, CRIT CARE MED, V37, P2421, DOI 10.1097/CCM.0b013e3181a557a2; Zhang WZ, 2004, J PHYSIOL-LONDON, V559, P729, DOI 10.1113/jphysiol.2004.064121	39	38	41	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2255	2260		10.1089/neu.2010.1372			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400014	20858122	Green Published			2021-06-18	
J	Cantu, RC; Guskiewicz, K; Register-Mihalik, JK				Cantu, Robert C.; Guskiewicz, Kevin; Register-Mihalik, Johna K.			A Retrospective Clinical Analysis of Moderate to Severe Athletic Concussions	PM&R			English	Article							COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; RECURRENT CONCUSSION; NEUROPSYCHOLOGICAL FUNCTION; COGNITIVE IMPAIRMENT; POSTURAL CONTROL; SEX-DIFFERENCES; SYMPTOMS; DEFICITS; MILD	Objective: To investigate differences in clinical outcomes on the basis of gender and age after a moderate or severe concussion in a cohort of physically active subjects examined by a single clinician. Design: A descriptive, cross-sectional, retrospective chart review of consecutive patients. Setting: Outpatient assessments by a single clinician with expertise in sports concussion. Patients: Physically active subjects seen for evaluation after a concussion experienced while participating in sports (N = 194; 215 concussions; age mean standard deviation = 19.19 +/- 8.53 years) were included. Interventions (Independent Variables): Intergroup differences and associations were examined by gender, age group (<18 years and 18+ years), and concussion grade for all outcome measures. Main Outcome Measurements: Separate chi(2) tests were used to assess associations between gender, age group, and symptom duration group (<= 7 days, 8-90 days, >90 days), the presence of depression, the presence of loss of consciousness, altered school or work, and concussion grade. Separate independent samples I-tests was used to examine differences in symptom reporting and time to recovery. Results: No association was observed between gender and any measured characteristics (P > .05). Subjects 18 years or older took longer to recover (315.77 days), compared with younger subjects (91.31 days) (t(213) = 2.01, P = .049). Older subjects also reported more concussions than did younger ones, 4.33 and 2.37, respectively (t(213) = -3.77, P < .001). Conclusions: All concussions included in this study were moderate to severe in nature as defined by the Revised Cantu Grading Scale. Contrary to existing literature regarding gender differences in concussion of a lesser severity, no gender differences were observed in this sample. Age differences were observed, with the population of subjects who were 18 years and older experiencing a greater number and duration of concussion symptoms than the younger group. Developing evidence-based return-to-play progressions and rehabilitation strategies in this population is the next frontier for concussion researchers. PM R 2010;2:1088-1093	[Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA 01742 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Cantu, Robert C.; Guskiewicz, Kevin; Register-Mihalik, Johna K.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Cantu, RC (corresponding author), Emerson Hosp, Dept Surg, 131 ORNAC,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org		Register-Mihalik, Johna/0000-0002-4229-4743; Guskiewicz, Kevin/0000-0002-8682-2130			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	32	38	38	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12					1088	1093		10.1016/j.pmrj.2010.07.483			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V23SF	WOS:000208361800003	21145520				2021-06-18	
J	Kuo, JR; Lo, CJ; Chang, CP; Lin, HJ; Lin, MT; Chio, CC				Kuo, Jinn-Rung; Lo, Chong-Jeh; Chang, Ching-Ping; Lin, Hung-Jung; Lin, Mao-Tsun; Chio, Chung-Ching			Brain Cooling-Stimulated Angiogenesis and Neurogenesis Attenuated Traumatic Brain Injury in Rats	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Brain cooling; Angiogenesis; Neurogenesis; Gliosis	NEURAL STEM-CELLS; HUMAN HEAD-INJURY; FLUID PERCUSSION; HIPPOCAMPAL PATHOLOGY; IN-VIVO; ISCHEMIA; HYPOTHERMIA; SUPEROXIDE; MICE; PROLIFERATION	Background: Although brain cooling has been reported to be effective in improving the outcome after traumatic brain injury (TBI) in rats, the mechanisms of brain cooling-induced neuroprotective actions remain unclear. This study was to test whether angiogenesis and neurogenesis attenuating TBI could be brain cooling stimulated. Methods: Anesthetized rats, immediately after the onset of TBI, were divided into two groups and given the brain cooling (infusing 5 mL of 4 degrees C saline via the external jugular vein) or no brain cooling (infusing 5 mL of 37 degrees C saline via the external jugular vein). Results: Brain cooling without interference with the core temperature in rats significantly attenuated TBI-induced cerebral infarction (90 mm(3) vs. 250 mm(3)) and motor (61 degrees vs. 57 degrees maximal angle) and proprioceptive (14% vs. 42% maximal possible effect) function deficits, significantly reduced TBI-induced neuronal (24 vs. 62 neuronal-specific nuclear [NeuN]-TUNEL double-positive cells) and glial (5 vs. 35 GFAP-TUNEL double-positive cells) apoptosis (increased TUNEL-positive and caspase-3-positive cells), neuronal loss (102 vs. 66 NeuN-positive cells), and gliosis (40 vs. 66 GFAP-positive cells; 66 vs. 89 Iba1-positive cells), and significantly promoted angiogenesis (5-bromodeoxyuridine [BrdU]/endothelial cells vs. 1-BrdU/ endothelial cell; 58 vs. 31 vascular endothelial growth factor-positive cells), and neurogenesis (33 vs. 14 BrdU/NeuN positive cells). Conclusions: Brain cooling-stimulated angiogenesis and neurogenesis attenuated a fluid percussion TBI in rats.	[Kuo, Jinn-Rung; Lin, Hung-Jung; Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan; [Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Kuo, Jinn-Rung; Lo, Chong-Jeh] Natl Cheng Kung Univ, Sch Med, Inst Clin Med, Tainan 70101, Taiwan; [Kuo, Jinn-Rung; Chang, Ching-Ping; Lin, Hung-Jung] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Lo, Chong-Jeh] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Div Trauma & Emergency Surg, Kaohsiung, Taiwan; [Lin, Mao-Tsun] Taipei Med Univ, Inst Dis Prevent & Control, Taipei, Taiwan	Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan.	891201@mail.chi.mei.org.tw			Center of Excellence for Clinical Trial and Research in Neuroscience [NSC96-2314-B-384-006-MY3, NSC96-2314-B384-003-MY3, DOH99-TD-B-111-003]	Supported by grants NSC96-2314-B-384-006-MY3, NSC96-2314-B384-003-MY3, and DOH99-TD-B-111-003 Center of Excellence for Clinical Trial and Research in Neuroscience.	Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; DeKosky ST, 2004, J NEUROCHEM, V90, P998, DOI 10.1111/j.1471-4159.2004.02575.x; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gerner P, 2003, ANESTHESIOLOGY, V98, P1484, DOI 10.1097/00000542-200306000-00028; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1993, STROKE, V24, P427, DOI 10.1161/01.STR.24.3.427; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Magavi SS, 2000, NATURE, V405, P951; Marshall L F, 2000, Clin Neurosurg, V46, P105; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sudoh Y, 2003, PAIN, V103, P49, DOI 10.1016/S0304-3959(02)00375-5; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; THALHAMMER JG, 1995, ANESTHESIOLOGY, V82, P1013, DOI 10.1097/00000542-199504000-00026; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; van Zanten ARH, 2005, CRIT CARE MED, V33, P1449, DOI 10.1097/01.CCM.0000166710.64724.34; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wang Y, 1997, J NEUROSCI, V17, P4341; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262	37	38	41	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2010	69	6					1467	1472		10.1097/TA.0b013e3181f31b06			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	695RT	WOS:000285391000040	21150525				2021-06-18	
J	Reddy, DS; Gangisetty, O; Briyal, S				Reddy, Doodipala Samba; Gangisetty, Omkaram; Briyal, Seema			Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis	NEUROPHARMACOLOGY			English	Article						Progesterone; Epileptogenesis; Kindling; Disease-modifying; Neurosteroid; Progesterone receptor; Seizure	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; RECEPTOR KNOCKOUT MICE; GABA(A) RECEPTORS; MALE-RATS; ANTICONVULSANT ACTIVITY; ELECTRICAL-STIMULATION; CATAMENIAL EPILEPSY; STATUS EPILEPTICUS; GENDER-DIFFERENCES	Progesterone (P) is an endogenous anticonvulsant hormone. P is being evaluated as a treatment for epilepsy, traumatic brain injury, and other complex neurological conditions. Preclinical and clinical studies suggest that P appears to interrupt epileptogenic events. However, the potential disease-modifying effect of P in epileptogenic models is not widely investigated. In this study, we examined the effects of P on the development of hippocampus kindling in female mice. In addition, we determined the role of progesterone receptors (PR) in the P's effect on the kindling epileptogenesis utilizing PR knockout (PRKO) mice. P, at 25 mg/kg, did not affect seizures and did not exert sedative/motor effects in fully-kindled mice. P treatment (25 mg/kg, twice daily for 2 weeks) significantly suppressed the rate of development of behavioral kindled seizure activity evoked by daily hippocampus stimulation in wild-type (WT) mice, indicating a disease-modifying effect of P on limbic epileptogenesis. There was a significant increase in the rate of 'rebound or withdrawal' kindling during drug-free stimulation sessions following abrupt discontinuation of P treatment. A washout period after termination of P treatment prevented such acceleration in kindling. PRKO mice were kindled significantly slower than WT mice, indicating a modulatory role of PRs in seizure susceptibility. P's effects on early kindling progression was partially decreased in PRKO mice, but the overall (2-fold) delay in the rate of kindling for the induction of stage 5 seizures was unchanged in PRKO mice. Moreover, the acute anticonvulsant effect of P was undiminished in fully-kindled PRKO mice. These studies suggest that P exerts disease-modifying effects in the hippocampus kindling model at doses that do not significantly affect seizure expression and motor performance, and the kindling-retarding effects of P may occur partly through a complex PR-dependent and PR-independent mechanism. (C) 2010 Elsevier Ltd. All rights reserved.	[Reddy, Doodipala Samba; Gangisetty, Omkaram; Briyal, Seema] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, College Stn, TX 77843 USA	Reddy, DS (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, 228 Reynolds Med Bldg, College Stn, TX 77843 USA.	reddy@medicine.tamhsc.edu		Reddy, Samba/0000-0003-2735-9550	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS051398]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051398] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant NS051398 (to D.S.R.).	ALBERTSON TE, 1984, NEUROPHARMACOLOGY, V23, P1117, DOI 10.1016/0028-3908(84)90227-2; BACKSTROM T, 1984, ACTA NEUROL SCAND, V69, P240; BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; Biagini G, 2006, EXP NEUROL, V201, P519, DOI 10.1016/j.expneurol.2006.04.029; Biagini G, 2009, EPILEPSIA, V50, P53, DOI 10.1111/j.1528-1167.2008.01971.x; Brandt C, 2007, NEUROPHARMACOLOGY, V53, P207, DOI 10.1016/j.neuropharm.2007.05.001; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Christensen J, 2005, EPILEPSIA, V46, P956, DOI 10.1111/j.1528-1167.2005.51204.x; COUGHENOUR LL, 1977, PHARMACOL BIOCHEM BE, V6, P351, DOI 10.1016/0091-3057(77)90036-3; CRAIG CR, 1966, J PHARMACOL EXP THER, V153, P337; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; DeCoster MA, 2002, J NEUROSCI RES, V67, P634, DOI 10.1002/jnr.10131; DURMULLER N, 1994, EPILEPSY RES, V17, P167, DOI 10.1016/0920-1211(94)90016-7; Edwards HE, 2000, NEUROSCIENCE, V101, P895, DOI 10.1016/S0306-4522(00)00439-5; Edwards HE, 2001, BRAIN RES, V889, P260, DOI 10.1016/S0006-8993(00)03147-4; Edwards HE, 1999, BRAIN RES, V838, P136, DOI 10.1016/S0006-8993(99)01619-4; Engel J., 2007, EPILEPSY COMPREHENSI; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 2002, EPILEPSIA, V43, P14, DOI 10.1046/j.1528-1157.43.s.5.19.x; GEE KW, 1995, CRIT REV NEUROBIOL, V9, P207; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Herd MB, 2007, PHARMACOL THERAPEUT, V116, P20, DOI 10.1016/j.pharmthera.2007.03.007; HERZOG AG, 1995, NEUROLOGY, V45, P1660, DOI 10.1212/WNL.45.9.1660; Herzog AG, 1997, EPILEPSIA, V38, P1082, DOI 10.1111/j.1528-1157.1997.tb01197.x; Herzog AG, 1999, NEUROLOGY, V52, P1917, DOI 10.1212/WNL.52.9.1917-a; Herzog AG, 2008, NEUROLOGY, V70, P486, DOI 10.1212/01.wnl.0000278102.55701.d0; HOLMES GL, 1984, DEV BRAIN RES, V16, P45, DOI 10.1016/0165-3806(84)90061-0; HOLMES GL, 1984, DEV BRAIN RES, V16, P55, DOI 10.1016/0165-3806(84)90062-2; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kaminski RM, 2004, EPILEPSIA, V45, P864, DOI 10.1111/j.0013-9580.2004.04504.x; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Lonsdale D, 2003, EPILEPSIA, V44, P1494, DOI 10.1111/j.0013-9580.2003.59402.x; Lonsdale D, 2006, BRAIN RES, V1101, P110, DOI 10.1016/j.brainres.2006.05.005; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McHugh JC, 2008, INT REV NEUROBIOL, V83, P11, DOI 10.1016/S0074-7742(08)00002-0; McNamara J O, 1992, Adv Neurol, V57, P555; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Mohammad S, 1998, EPILEPSY RES, V30, P195, DOI 10.1016/S0920-1211(98)00004-7; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Nissinen J, 2004, EPILEPSY RES, V58, P119, DOI 10.1016/j.eplepsyres.2004.01.001; Patel M, 2004, FREE RADICAL BIO MED, V37, P1951, DOI 10.1016/j.freeradbiomed.2004.08.021; Pitkanen A, 2002, NEUROLOGY, V59, pS27, DOI 10.1212/WNL.59.9_suppl_5.S27; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reddy DS, 2009, EPILEPSY RES, V85, P1, DOI 10.1016/j.eplepsyres.2009.02.017; Reddy DS, 2001, EPILEPSIA, V42, P328, DOI 10.1046/j.1528-1157.2001.10100.x; Reddy DS, 2005, NEUROPHARMACOLOGY, V48, P14, DOI 10.1016/j.neuropharm.2004.09.002; Reddy DS, 2004, J PHARMACOL EXP THER, V310, P230, DOI 10.1124/jpet.104.065268; REDDY DS, 2010, SOC NEUROSCI; Rogawski MA, 2001, NEUROPHARMACOLOGY, V40, P28, DOI 10.1016/S0028-3908(00)00112-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Selye H, 1942, J LAB CLIN MED, V27, P1051; Shen H, 2010, SCIENCE, V327, P1515, DOI 10.1126/science.1184245; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Vezzani Annamaria, 2005, Epilepsy Curr, V5, P1, DOI 10.1111/j.1535-7597.2005.05101.x; WADA JA, 1978, NEUROLOGY, V28, P1026, DOI 10.1212/WNL.28.10.1026; WAHNSCHAFFE U, 1992, EPILEPSY RES, V13, P199, DOI 10.1016/0920-1211(92)90053-V; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yagami T, 2002, J NEUROCHEM, V81, P449, DOI 10.1046/j.1471-4159.2002.00800.x	74	38	38	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2010	59	7-8					573	581		10.1016/j.neuropharm.2010.08.017			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	682XN	WOS:000284436400002	20804775	Green Accepted			2021-06-18	
J	Harris, NG; Mironova, YA; Hovda, DA; Sutton, RL				Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.			Chondroitinase ABC Enhances Pericontusion Axonal Sprouting But Does Not Confer Robust Improvements in Behavioral Recovery	JOURNAL OF NEUROTRAUMA			English	Article						chondroitin sulfate proteoglycans; cortex; growth-associated protein 43; immunohistochemistry; plasticity; recovery of function; sprouting; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SULFATE PROTEOGLYCANS; FUNCTIONAL RECOVERY; CORPUS-CALLOSUM; RAT-BRAIN; REGENERATION; EXPRESSION; SCAR; DEGRADATION; PLASTICITY	Traumatic brain injury (TBI) results in enduring functional deficits. Strategies aimed at promoting plasticity within the injured brain may aid in enhancing functional outcome. We have previously shown that spontaneous pericontusional axon sprouting occurs within 7-14 days after controlled cortical impact injury in the adult rat, but ultimately fails due to an increasingly growth-inhibitory environment. We therefore sought to determine whether acute infusion of chondroitinase ABC into the site of the cortical contusion, to further reduce pericontusional growth-inhibitory chondroitin sulfate proteoglycans (CSPGs), would enhance and prolong the sprouting response. We also wanted to determine if chondroitinase-enhanced sprouting would ameliorate the behavioral deficits in forelimb function that occur in this model. Acute chondroitinase infusion decreased intact CSPGs and significantly increased pericontusional cortical grey and white matter growth-associated protein 43 (GAP43)-positive axon sprouting at 7 days post-injury. A return of intact CSPGs at later time points likely contributed to the absence of persistently increased levels of axon sprouting by 14-21 days post-injury. There was no overall benefit on forelimb function during the time of maximal sprouting or at any subsequent times in three of four behavioral outcome measures. However, there was a chondroitinase-induced improvement in recovery from unskilled limb use deficits on the staircase forelimb reaching test toward sham-injured values at 28 days, which was not achieved by the vehicle-treated rats, indicating that there is some minor functional benefit of the increased sprouting induced by chondroitinase treatment. The current results, together with data from spinal cord injury models after chondroitinase intervention, suggest that a combinatorial approach with the addition of neurotrophins and rehabilitation would result in more robust axon sprouting and consequently improve behavioral outcome.	[Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu		Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055910]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	We wish to thank Ms. Jessica Harnisch and Mr. Shant Damian for technical assistance, and Dr. David McArthur for help with statistics. This work was supported by the UCLA Brain Injury Research Center, and Award Number R01 NS055910 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not represent the official views of the NINDS or the National Institutes of Health.	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Carulli D, 2010, BRAIN, V133, P2331, DOI 10.1093/brain/awq145; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Corvetti L, 2005, J NEUROSCI, V25, P7150, DOI 10.1523/JNEUROSCI.0683-05.2005; Emery DL, 2000, J COMP NEUROL, V424, P521; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris N.G., 2003, J CEREB METAB BLOOD, V21, P1318; Harris N, 2009, J NEUROTRAUM, V26, pA37; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; HORNIK K, 2008, R PROJECT STAT COMPU; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Ikegami T, 2005, EUR J NEUROSCI, V22, P3036, DOI 10.1111/j.1460-9568.2005.04492.x; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; Matsui F, 2005, J NEUROSCI RES, V81, P837, DOI 10.1002/jnr.20603; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Rasband W.S., 2008, IMAGEJ; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tom VJ, 2009, J NEUROTRAUM, V26, P2323, DOI 10.1089/neu.2009.1047; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3	38	38	40	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1971	1982		10.1089/neu.2010.1470			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500005	20809786	Green Published			2021-06-18	
J	King, C; Robinson, T; Dixon, CE; Rao, GR; Larnard, D; Nemoto, CEM				King, Christopher; Robinson, Timothy; Dixon, C. Edward; Rao, Gutti R.; Larnard, Donald; Nemoto, C. Edwin M.			Brain Temperature Profiles during Epidural Cooling with the ChillerPad in a Monkey Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; non-human primate; selective brain cooling; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; TERM MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; SELECTIVE HYPOTHERMIA; MARKED PROTECTION; CORTICAL IMPACT; SAFETY; HEAD; NEUROPROTECTION; 15-DEGREES-C	Therapeutic hypothermia remains a promising treatment for patients with severe traumatic brain injury (TBI). Multiple animal studies have suggested that hypothermia is neuroprotective after TBI, but clinical trials have been inconclusive. Systemic hypothermia, the method used in almost all major clinical trials, is limited by the time to target temperature, the depth of hypothermia, and complications, problems that may be solved by selective brain cooling. We evaluated the effects on brain temperature of a cooling device called the ChillerPad,(TM) which is applied to the dura in a non-human primate TBI model using controlled cortical impact (CCI). The cortical surface was rapidly cooled to approximately 15 degrees C and maintained at that level for 24 h, followed by rewarming over about 10 h. Brain temperatures fell to 34-35 degrees C at a depth of 15 mm at the cortical gray/white matter interface, and to 28-32 degrees C at 10 mm deep. Intracranial pressure was mildly elevated (8-12 mm Hg) after cooling and rewarming, likely due to TBI. Other physiological variables were unchanged. Cooling was rapidly diminished at points distant from the cooling pad. The ChillerPad may be useful for highly localized cooling of the brain in circumstances in which a craniotomy is clinically indicated. However, because of the delay required by the craniotomy, other methods that are more readily available for inducing hypothermia may be used as a bridge between the time of injury to placement of the ChillerPad.	[King, Christopher] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA; [Rao, Gutti R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; [Robinson, Timothy] Tiroconsulting, Sandown, NH USA; [Larnard, Donald] Mantis Enterprises LLC, N Hampton, NH USA; [Nemoto, C. Edwin M.] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA	King, C (corresponding author), Univ Pittsburgh, Dept Emergency Med, Forbes Tower,Suite 10028, Pittsburgh, PA 15260 USA.	kingcc@upmc.edu			Seacoast Technologies, Portsmouth, New Hampshire	The authors wish to thank Dr. Geoffrey Manley (Department of Neurosurgery, University of California-San Francisco) for his helpful advice on the setting and timing for the use of the controlled cortical impact device in the monkey. This study was funded by a grant from Seacoast Technologies, Portsmouth, New Hampshire.	Cheng H, 2006, ACTA NEUROCHIR, V148, P559, DOI 10.1007/s00701-006-0735-3; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Clark DL, 2009, EXP NEUROL, V220, P391, DOI 10.1016/j.expneurol.2009.10.002; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; Covaciu L, 2008, RESUSCITATION, V76, P83, DOI 10.1016/j.resuscitation.2007.07.002; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Finkelstein EA., 2006, INCIDENCE EC BURDEN; HOFMAN MA, 1988, BRAIN BEHAV EVOLUT, V32, P17, DOI 10.1159/000116529; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lenhardt R, 2009, ANESTHESIOLOGY, V111, P110, DOI 10.1097/ALN.0b013e3181a979a3; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mascio CE, 2009, ASAIO J, V55, P287, DOI 10.1097/MAT.0b013e3181964861; Nemoto EM, 2006, ADV EXP MED BIOL, V578, P317; Nemoto EM, 2006, ADV EXP MED BIOL, V578, P311; OHTA T, 1992, NEUROSURGERY, V31, P1049, DOI 10.1227/00006123-199212000-00010; PARKINS WM, 1954, ANN SURG, V140, P284, DOI 10.1097/00000658-195409000-00004; Percy A, 2009, ANN THORAC SURG, V87, P117, DOI 10.1016/j.athoracsur.2008.10.025; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2001, J NEUROSURG, V94, P853; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu Wu-si, 2006, Chin J Traumatol, V9, P238; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SCHRECKINGER M, 2009, NEUROCRIT CARE; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Schwartz AE, 1996, NEUROSURGERY, V39, P577; Schwartz ID, 1996, PEDIATR RES, V39, P577; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d; SYDENHAM E, 2009, COCHRANE DATABASE SY; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Wagner KR, 2005, NEUROL RES, V27, P238, DOI 10.1179/016164105X25261; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wei G, 2008, J NEUROTRAUM, V25, P549, DOI 10.1089/neu.2007.0498; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Wolfson MR, 2008, NEUROCRIT CARE, V8, P437, DOI 10.1007/s12028-008-9064-0; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zhang LH, 2007, SURG NEUROL, V67, P117, DOI 10.1016/j.surneu.2006.05.064; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	52	38	41	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1895	1903		10.1089/neu.2009.1178			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600013	20684677				2021-06-18	
J	Broglio, SP; Vagnozzi, R; Sabin, M; Signoretti, S; Tavazzi, B; Lazzarino, G				Broglio, Steven P.; Vagnozzi, Roberto; Sabin, Matthew; Signoretti, Stefano; Tavazzi, Barbara; Lazzarino, Giuseppe			Concussion occurrence and knowledge in Italian football (soccer)	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						Mild traumatic brain injury; symptoms	HIGH-SCHOOL FOOTBALL; METABOLIC BRAIN VULNERABILITY; FOR-DISEASE-CONTROL; RECURRENT CONCUSSION; INTERNATIONAL-CONFERENCE; NEUROCOGNITIVE FUNCTION; TEMPORAL WINDOW; SPORT; PLAYERS; EPIDEMIOLOGY	The purpose of the study was to investigate concussion history, knowledge, injury identification, and management strategies among athletes, coaches, and medical staff in Italian club level football (soccer) clubs. Surveys (N= 727) were distributed among Italian football clubs. Athletes' surveys were designed to evaluate athlete knowledge of concussive signs and symptoms and injury reporting. Coaches' surveys explored the understanding of concussive signs and symptoms and management practices. Medical staff surveys explored the standard of care regarding concussions. A total of 342 surveys were returned, for a 47% response rate. Descriptive analyses indicated 10% of athletes sustaining a concussion in the past year and 62% of these injuries were not reported, primarily due to the athletes not thinking the injury was serious enough. Coaches consistently identified non-concussion related symptoms (98.7%), but were unable to identify symptoms associated with concussion (38.9%). Most understood that loss of consciousness is not the sole indicator of injury (82.6%). Medical staff reported a heavy reliance on the clinical exam (92%) and athlete symptom reports (92%) to make the concussion diagnosis and return to play decision, with little use of neurocognitive (16.7%) or balance (0.0%) testing. Italian football athletes appear to report concussions at a rate similar to American football players, with a slightly higher rate of unreported injuries. Most of these athletes were aware they were concussed, but did not feel the injury was serious enough to report. Although coaches served as the primary person to whom concussions were reported, the majority of coaches were unable to accurately identify concussion related symptoms. With little use for neurocognitive and postural control assessments, the medical personnel may be missing injuries or returning athletes to play too soon. Collectively, these findings suggest that athletes, coaches, and medical personnel would benefit from concussion based educational materials on the signs, symptoms, and evaluative techniques of concussion.	[Broglio, Steven P.; Sabin, Matthew] Univ Illinois, Neurotrauma Res Lab, Urbana, IL USA; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Rome, Italy; [Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy	Broglio, SP (corresponding author), Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61820 USA.	broglio@illinois.edu	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279	William and Flora Hewlett Foundation; Italian Ministry of University and Research (MIUR)Ministry of Education, Universities and Research (MIUR) [2007JBHZ5F]	The authors would like to thank the William and Flora Hewlett Foundation for supporting Dr. Broglio and the Italian Ministry of University and Research [(MIUR) PRIN 2007JBHZ5F] for their support of Dr. Vagnozzi and Dr. Tavazzi. In addition, we would like to thank Eren Havrilak for her assistance.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P934; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; *FIFA, 2008, BIG COUNT; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; O'Donoghue EM., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	34	38	38	0	19	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	SEP	2010	9	3					418	430					13	Sport Sciences	Sport Sciences	748AF	WOS:000289361700010	24149636	DOAJ Gold			2021-06-18	
J	Fedor, M; Berman, RF; Muizelaar, JP; Lyeth, BG				Fedor, Mark; Berman, Robert F.; Muizelaar, J. Paul; Lyeth, Bruce G.			Hippocampal Theta Dysfunction after Lateral Fluid Percussion Injury	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram; fluid percussion injury; memory; rat; theta rhythm; traumatic brain injury	LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; OSCILLATIONS; MEMORY; RHYTHM; STIMULATION; WORKING; RATS; FREQUENCY; DEFICITS	Chronic memory deficits are a major cause of morbidity following traumatic brain injury (TBI). In the rat, the hippocampal theta rhythm is a well-studied correlate of memory function. This study sought to investigate disturbances in hippocampal theta rhythm following lateral fluid percussion injury in the rat. A total of 13 control rats and 12 TBI rats were used. Electrodes were implanted in bilateral hippocampi and an electroencephalogram (EEG) was recorded while the rats explored a new environment, and also while navigating a modified version of the Barnes maze. Theta power and peak theta frequency were significantly attenuated in the injured animals. Further, injured rats were less likely to develop a spatial strategy for Barnes maze navigation compared to control rats. In conclusion, rats sustaining lateral fluid percussion injury demonstrated deficits in hippocampal theta activity. These deficits may contribute to the underlying memory problems seen in chronic TBI.	[Fedor, Mark; Berman, Robert F.; Muizelaar, J. Paul; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95618 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95618 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS29995]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER	Expert technical assistance was provided by Christina Kopriva, Maria Dynin, Damoon Rejaei, and Ken Van. This research was supported in part by National Institutes of Health grant NS29995.	BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Basar-Eroglu C, 2001, INT J PSYCHOPHYSIOL, V39, P167, DOI 10.1016/S0167-8760(00)00140-9; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Brazhnik ES, 1999, EXP BRAIN RES, V127, P244, DOI 10.1007/s002210050794; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GIVENS B, 1994, J NEUROSCI, V14, P3578; Goutagny R, 2009, NAT NEUROSCI, V12, P1491, DOI 10.1038/nn.2440; GREEN KF, 1979, ELECTROEN CLIN NEURO, V47, P420, DOI 10.1016/0013-4694(79)90158-5; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hyman JM, 2003, J NEUROSCI, V23, P11725; Jiang F, 1997, PHYSIOL BEHAV, V62, P1279, DOI 10.1016/S0031-9384(97)00306-5; Kahana MJ, 1999, NATURE, V399, P781, DOI 10.1038/21645; KRAUS JF, 2005, NEUROPSYCHIATRY TRAU, P3; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Li CY, 2005, J NEUROPHYSIOL, V93, P3001, DOI 10.1152/jn.00546.2004; Luber B, 2007, BRAIN RES, V1128, P120, DOI 10.1016/j.brainres.2006.10.011; Lyeth BG, 2001, HEAD TRAUMA, P115; Manns JR, 2007, NEUROBIOL LEARN MEM, V87, P9, DOI 10.1016/j.nlm.2006.05.007; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Oddie SD, 1998, NEUROSCI BIOBEHAV R, V22, P221, DOI 10.1016/S0149-7634(97)00003-1; OLTON DS, 1994, NEUROTOXICOLOGY, V15, P439; Olvera-Cortes E, 2004, BRAIN RES BULL, V62, P379, DOI 10.1016/j.brainresbull.2003.10.003; Olvera-Cortes E, 2002, BRAIN RES BULL, V58, P261, DOI 10.1016/S0361-9230(02)00769-4; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; Pan WX, 1997, BRAIN RES, V764, P101, DOI 10.1016/S0006-8993(97)00431-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pike FG, 2000, J PHYSIOL-LONDON, V529, P205, DOI 10.1111/j.1469-7793.2000.00205.x; Rizzuto DS, 2003, P NATL ACAD SCI USA, V100, P7931, DOI 10.1073/pnas.0732061100; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shirvalkar P, 2006, P NATL ACAD SCI USA, V103, P17007, DOI 10.1073/pnas.0604811103; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; VERTES RP, 1982, PROG NEUROBIOL, V19, P159, DOI 10.1016/0301-0082(82)90005-3; Villarreal DM, 2007, J NEUROSCI, V27, P13457, DOI 10.1523/JNEUROSCI.3702-07.2007; Vinogradova OS, 2001, HIPPOCAMPUS, V11, P578, DOI 10.1002/hipo.1073.abs; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; WIENER SI, 1989, J NEUROSCI, V9, P2737; WINSON J, 1974, ELECTROEN CLIN NEURO, V36, P291, DOI 10.1016/0013-4694(74)90171-0; Woldeit ML, 2010, NEUROSCIENCE, V165, P642, DOI 10.1016/j.neuroscience.2009.11.002; Wu M, 2000, J NEUROSCI, V20, P3900	57	38	38	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1605	1615		10.1089/neu.2010.1370			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500007	20597686	Green Published			2021-06-18	
J	Mihalik, JP; Greenwald, RM; Blackburn, JT; Cantu, RC; Marshall, SW; Guskiewicz, KM				Mihalik, Jason P.; Greenwald, Richard M.; Blackburn, J. Troy; Cantu, Robert C.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Effect of Infraction Type on Head Impact Severity in Youth Ice Hockey	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						ADOLESCENT ATHLETE; BIOMECHANICS; CONCUSSION; HELMETS; TRAUMATIC BRAIN INJURY	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SPINAL-INJURIES; CONCUSSION; ACCELERATION; SPORTS; BIOMECHANICS; MAGNITUDE	MIHALIK, J. P., R. M. GREENWALD, J. T. BLACKBURN, R. C. CANTU, S. W. MARSHALL, and K. M. GUSKIEWICZ. Effect of Infraction Type on Head Impact Severity in Youth Ice Hockey. Med. Sci. Sports Exerc., Vol. 42, No. 8, pp. 1431-1438, 2010. Purpose: To identify the effects of infractions sustained during participation in youth ice hockey on biomechanical measures of head impact severity. Methods: Sixteen adolescent Bantam-aged male ice hockey players (age = 14.0 +/- 0.5 yr, height = 171.3 +/- 4.5 cm, mass = 63.7 +/- 6.6 kg) were equipped with accelerometer-instrumented helmets to collect biomechanical measures relating to head impacts (linear acceleration, rotational acceleration, and Head Impact Technology severity profile (HITsp)) sustained while participating in ice hockey. Single-camera video footage from 54 games was synchronized with the head impact data, and all viewable collisions (n = 665) were evaluated as resulting from a legal collision or an infraction. Infractions were further categorized into boarding or charging, checking from behind, and elbowing or intentional head contact. Statistical analyses included random-intercepts general linear mixed models. Results: Infractions were observed in 17.3% (115/665) of all body collisions. Overall, collisions involving infractions had higher linear accelerations (P = 0.012) and HITsp (P = 0.021) than collisions with no infraction. Specifically, elbowing, head contact, and high sticking infractions resulted in greater linear acceleration (P = 0.005) and HITsp (P = 0.010) than collisions with no infraction. A strong trend for higher rotational accelerations in this infraction type compared with legal collisions was also present (P = 0.059). Conclusions: Infractions result in higher measures of head impact severity than noninfraction collisions. Athletes and coaches should conform to playing rules, and officials should enforce more stringently existing rules and assess more severe penalties to participants who purposefully attempt to foul an opponent at the youth ice hockey level.	[Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC USA; [Mihalik, Jason P.; Blackburn, J. Troy; Guskiewicz, Kevin M.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Curriculum Human Movement Sci, Chapel Hill, NC USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Blackburn, J. Troy] Univ N Carolina, Dept Exercise & Sport Sci, Neuromuscular Res Lab, Chapel Hill, NC USA; [Cantu, Robert C.] Emerson Hosp, Dept Sport Med, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA	Mihalik, JP (corresponding author), 209 Fetzer Gymnasium,South Rd,Campus Box 8700, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu	Mihalik, Jason P/E-7059-2010	Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233; Mihalik, Jason/0000-0001-6085-8322	Ontario Neurotrauma Foundation (Toronto, Ontario, Canada) [2005-PREV-BANT-387]; USA Hockey Foundation (Colorado Springs, CO); National Operating Committee on Standards for Athletic Equipment (Overland Park, KS); engineering team at Simbex (Lebanon, NH); HIT System technology	This study was supported in part by a grant from the Ontario Neurotrauma Foundation (Toronto, Ontario, Canada) to the University of North Carolina at Chapel Hill Injury Prevention Research Center (grant No. 2005-PREV-BANT-387). The USA Hockey Foundation (Colorado Springs, CO) and the National Operating Committee on Standards for Athletic Equipment (Overland Park, KS) also provided financial support.; The authors also thank the engineering team at Simbex (Lebanon, NH) for their continued support of this project.; Dr. Greenwald has a financial interest in the HIT System technology used to collect data for this study.	ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gwin J. T., 2009, J ASTM INT, V6, P1; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P70; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARCOTTE G, 1993, ASTM STP, V1212, P103, DOI DOI 10.1520/STP13128S; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARAYRE R, 1989, ASTM STP, V1050, P37; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; Tator CH, 2009, CLIN J SPORT MED, V19, P451, DOI 10.1097/JSM.0b013e3181bd0db6; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	31	38	38	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2010	42	8					1431	1438		10.1249/MSS.0b013e3181d2521a			8	Sport Sciences	Sport Sciences	626PH	WOS:000279977500001	20139779				2021-06-18	
J	Pan, HC; Yang, DY; Ou, YC; Ho, SP; Cheng, FC; Chen, CJ				Pan, Hung-Chuan; Yang, Dar-Yu; Ou, Yen-Chuan; Ho, Shu-Peng; Cheng, Fu-Chou; Chen, Chun-Jung			Neuroprotective Effect of Atorvastatin in an Experimental Model of Nerve Crush Injury	NEUROSURGERY			English	Article						Degeneration; Neuroprotection; Regeneration; Sciatic nerve; Statin	ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL DIABETIC-NEUROPATHY; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; PERIPHERAL-NERVE; SCIATIC-NERVE; AXONAL REGENERATION; ADULT RATS; MATRIX METALLOPROTEINASES	BACKGROUND: Statins have therapeutic benefits for the management of several disorders. A short-term course of a high-dose statin pretreatment has demonstrated neuroprotective effects against neurological diseases. However, the molecular basis underlying the neuroprotective action of statins remains unclear. OBJECTIVE: We investigated whether a short-term course of high-dose atorvastatin pretreatment has beneficial effects in protecting sciatic nerve from crush injury. METHODS: Atorvastatin (5 mg/kg) or saline was given orally to Sprague-Dawley rats for 7 days before injury. The rats were subjected to crush injury in the left sciatic nerve with a vessel clamp. Biochemical, functional, electrophysiological, and morphological alterations occurring during injury-induced degeneration/regeneration were examined. RESULTS: Atorvastatin improved injury-induced neurobehavioral/electrophysiological changes and axonal loss. Damage-associated alterations, including structural disruption, oxidative stress, inflammation, and apoptosis, were attenuated by atorvastatin. After injury, regeneration-associated genes, including growth-associated protein-43, myelin basic protein, ciliary neurotrophic factor, and collagen, were upregulated by atorvastatin. The suppression of extracellular signal-regulated kinase, AKT, signal transducer and activators of transcription-1, and necrosis factor-kappa B and the elevated activation of c-Jun N-terminal kinase, Smad2/3, and activating protein-1 were associated with the neuroprotective action of atorvastatin. CONCLUSION: These findings suggest that a short-term course of high-dose atorvastatin pretreatment can protect against sciatic nerve crush injury through modifying intracellular or extracellular environments, making it favorable for regeneration.	[Cheng, Fu-Chou; Chen, Chun-Jung] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung 407, Taiwan; [Pan, Hung-Chuan] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung 407, Taiwan; [Pan, Hung-Chuan] Chung Hwa Univ Med Technol, Tainan, Taiwan; [Pan, Hung-Chuan; Cheng, Fu-Chou; Chen, Chun-Jung] Natl Chung Hsing Univ, Inst Med Technol, Taichung 40227, Taiwan; [Pan, Hung-Chuan; Ho, Shu-Peng] Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan; [Yang, Dar-Yu] Chang Bing Chwan Mem Hosp, Dept Neurosurg, Changhua, Taiwan; [Ou, Yen-Chuan] Taichung Vet Gen Hosp, Div Urol, Taichung 407, Taiwan	Chen, CJ (corresponding author), Taichung Vet Gen Hosp, Dept Educ & Res, 160 Sect 3,Taichung Kang Rd, Taichung 407, Taiwan.	cjchen@vghtc.gov.tw		Ho, Shu-Peng/0000-0003-4607-3216	Taichung Veterans General Hospital [TCVGH-HK96800]; Hungkuang University, Taichung, Taiwan	This study was supported by grant (TCVGH-HK96800) from Taichung Veterans General Hospital and Hungkuang University, Taichung, Taiwan. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Al-Majed AA, 2000, J NEUROSCI, V20, P2602; AMINOFF MJ, 1999, ELECTRODIAGNOSIS CLI, P257; ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Boyd JG, 2003, MOL NEUROBIOL, V27, P277, DOI 10.1385/MN:27:3:277; Casals-Diaz L, 2009, EXP NEUROL, V217, P84, DOI 10.1016/j.expneurol.2009.01.014; Chen CJ, 2007, EXP NEUROL, V204, P443, DOI 10.1016/j.expneurol.2006.12.004; Chen CJ, 2006, NEUROCHEM INT, V49, P62, DOI 10.1016/j.neuint.2005.12.020; Chen CJ, 2004, J VIROL, V78, P12107, DOI 10.1128/JVI.78.22.12107-12119.2004; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen YS, 2000, BIOMATERIALS, V21, P1541, DOI 10.1016/S0142-9612(00)00028-4; Chen ZY, 2001, BRAIN RES, V902, P272, DOI 10.1016/S0006-8993(01)02395-2; Cohen-Boulakia FE, 2007, DIABETES METAB, V33, P189, DOI 10.1016/j.diabet.2006.11.012; Dinh P, 2009, MICROSURG, V29, P644, DOI 10.1002/micr.20685; Dold S, 2009, BRIT J PHARMACOL, V156, P466, DOI 10.1111/j.1476-5381.2008.00043.x; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Eto M, 2008, J PERIPHER NERV SYST, V13, P242, DOI 10.1111/j.1529-8027.2008.00183.x; Gegg ME, 2005, J IMMUNOL, V174, P2327, DOI 10.4049/jimmunol.174.4.2327; Gholami MR, 2008, EUR J PHARMACOL, V590, P111, DOI 10.1016/j.ejphar.2008.05.050; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hemandez-Romero MD, 2008, J NEUROCHEM, V105, P445, DOI 10.1111/j.1471-4159.2007.05148.x; Hwang SY, 2004, BIOCHEM BIOPH RES CO, V318, P691, DOI 10.1016/j.bbrc.2004.04.082; Ii M, 2005, CIRCULATION, V112, P93, DOI 10.1161/CIRCULATIONAHA.104.511964; Kieseier BC, 1999, NEUROLOGY, V53, P20, DOI 10.1212/WNL.53.1.20; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Kirsch C, 2003, PHARMACOPSYCHIATRY, V36, pS113; Labrador RO, 1998, EXP NEUROL, V149, P243, DOI 10.1006/exnr.1997.6650; LaFleur M, 1996, J EXP MED, V184, P2311; Lee AC, 2003, EXP NEUROL, V184, P295, DOI 10.1016/S0014-4886(03)00258-9; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; Liu QH, 2008, PERITON DIALYSIS INT, V28, pS88; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Marcol W, 2003, J NEUROSCI RES, V72, P417, DOI 10.1002/jnr.10560; Moro T, 2008, LIFE SCI, V83, P531, DOI 10.1016/j.lfs.2008.07.023; Nagao H, 1996, BRAIN RES, V719, P23, DOI 10.1016/0006-8993(96)00055-8; Omura K, 2004, BRAIN RES, V1001, P13, DOI 10.1016/j.brainres.2003.10.067; Pan HC, 2007, J CLIN NEUROSCI, V14, P1089, DOI 10.1016/j.jocn.2006.08.008; Pan HC, 2006, J CLIN NEUROSCI, V13, P570, DOI 10.1016/j.jocn.2005.06.007; Pan HC, 2009, NEUROCHEM RES, V34, P518, DOI 10.1007/s11064-008-9815-5; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pedraza L, 1997, NEURON, V18, P579, DOI 10.1016/S0896-6273(00)80299-8; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Rader DJ, 2003, CLIN CARDIOL, V26, P2, DOI 10.1002/clc.4960260103; Rezaie-Majd A, 2002, ARTERIOSCL THROM VAS, V22, P1194, DOI 10.1161/01.ATV.0000022694.16328.CC; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; ROSEN JM, 1989, ANN PLAS SURG, V22, P467, DOI 10.1097/00000637-198906000-00002; Sarkey JP, 2007, J NEUROCHEM, V100, P1265, DOI 10.1111/j.1471-4159.2006.04309.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shubayev VI, 2006, MOL CELL NEUROSCI, V31, P407, DOI 10.1016/j.mcn.2005.10.011; Shubayev VI, 2002, J PERIPHER NERV SYST, V7, P28, DOI 10.1046/j.1529-8027.2002.02003.x; Siebert H, 2001, J NEUROPATH EXP NEUR, V60, P85, DOI 10.1093/jnen/60.1.85; Stein EA, 2002, AM HEART J, V144, pS43, DOI 10.1067/mhj.2002.130302; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; Valsecchi AE, 2008, J NEUROCHEM, V107, P230, DOI 10.1111/j.1471-4159.2008.05614.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang JP, 1997, BRIT J PHARMACOL, V121, P409, DOI 10.1038/sj.bjp.0701147; Wang YP, 2006, J NEUROL SCI, V247, P47, DOI 10.1016/j.jns.2006.03.011; Wang YP, 2005, ANTIOXID REDOX SIGN, V7, P1513, DOI 10.1089/ars.2005.7.1513; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; Xu QG, 2008, NEUROSCIENCE, V152, P877, DOI 10.1016/j.neuroscience.2008.01.060; Yang DY, 2007, NEUROTOXICOLOGY, V28, P1220, DOI 10.1016/j.neuro.2007.08.003; Zou T, 2006, J NEUROPATH EXP NEUR, V65, P78, DOI 10.1097/01.jnen.0000195942.25163.f5	66	38	38	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2010	67	2					376	388		10.1227/01.NEU.0000371729.47895.A0			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	628HI	WOS:000280105800034	20539249	Bronze			2021-06-18	
J	Harris, T; Ellis, DY; Foster, L; Lockey, D				Harris, Tim; Ellis, Daniel Y.; Foster, Liz; Lockey, David			Cricoid pressure and laryngeal manipulation in 402 pre-hospital emergency anaesthetics: Essential safety measure or a hindrance to rapid safe intubation?	RESUSCITATION			English	Article						Airway; Intubation; Pre-hospital care; Cricoid pressure; Laryngeal manipulation	TRAUMATIC BRAIN-INJURY; IN-LINE STABILIZATION; TRACHEAL INTUBATION; SEQUENCE INTUBATION; ENDOTRACHEAL INTUBATION; DIFFICULT LARYNGOSCOPY; RANDOMIZED-TRIAL; INDUCTION; SPINE; MOVEMENT	Objectives: This is the first study to look at the effects of cricoid pressure/laryngeal manipulation on the laryngeal view and intubation success in the emergency or pre-hospital environment. Cricoid pressure is applied in the hope of reducing the incidence of aspiration. However the technique has never been evaluated in a randomized trial and may adversely affect laryngeal view. In order to improve intubating conditions cricoid pressure may be released and the larynx manipulated into a more favourable position. Methods: We carried out a prospective observational study to evaluate the effects of cricoid pressure and laryngeal manipulation on laryngeal view in our physician led pre-hospital trauma service. Results: 402 patients were included over a 16-month period. We intubated 98.8% patients on the first or second attempt. In 61 intubations (in 55 patients, 13.6%) the larynx required manipulation to facilitate intubation. In 22 intubations cricoid pressure was removed with the laryngeal view improving in 50%. Bimanual laryngeal manipulation was used in 25 intubations and the larynx better visualised in 60% of these. Backwards upwards rightwards pressure was applied to the larynx in 14 intubations and the laryngeal view improved in 64%. Two patients regurgitated when cricoid pressure was released. Both had prolonged periods of bag valve mask ventilation and difficult intubations. Discussion: The results suggest that cricoid pressure should be removed if the laryngeal view obtained is not sufficient to allow immediate intubation. Further manipulation of the larynx is likely to improve the chances of successful tracheal tube placement. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Harris, Tim] Royal London Hosp, Dept Emergency Med & Prehosp Care, London E11 BB, England; [Harris, Tim; Foster, Liz; Lockey, David] Londons Air Ambulance, London, England; [Ellis, Daniel Y.] Univ Coll Hosp, London, England; [Lockey, David] Frenchay Hosp, Bristol BS16 1LE, Avon, England	Harris, T (corresponding author), Royal London Hosp, Dept Emergency Med & Prehosp Care, London E11 BB, England.	tim.harris@bartsandthelondon.nhs.uk					Bernard Stephen, 2002, Emerg Med (Fremantle), V14, P406, DOI 10.1046/j.1442-2026.2002.00382.x; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; CRISWELL JC, 1994, ANAESTHESIA, V49, P900, DOI 10.1111/j.1365-2044.1994.tb04271.x; DAVIES HML, 2001, ORG REACT NY, V57, P8; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DONALDSON WF, 1993, SPINE, V18, P2020, DOI 10.1097/00007632-199310001-00015; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Ellis DY, 2007, ANN EMERG MED, V50, P653, DOI 10.1016/j.annemergmed.2007.05.006; Fairweather NL, 2003, ANAESTH INTENS CARE, V31, P451, DOI 10.1177/0310057X0303100415; Gabbott DA, 1997, ANAESTHESIA, V52, P586, DOI 10.1111/j.1365-2044.1997.138-az0131.x; Haslam N, 2005, ANAESTHESIA, V60, P41, DOI 10.1111/j.1365-2044.2004.04010.x; Helliwell V, 2001, RESUSCITATION, V49, P53, DOI 10.1016/S0300-9572(00)00307-5; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; Jacoby J, 2006, ANN EMERG MED, V47, P525, DOI 10.1016/j.annemergmed.2005.12.009; KNILL RL, 1993, CAN J ANAESTH, V40, P279, DOI 10.1007/BF03037041; Levitan RM, 2006, ANN EMERG MED, V47, P548, DOI 10.1016/j.annemergmed.2006.01.013; Mackay CA, 2001, EMERG MED J, V18, P20, DOI 10.1136/emj.18.1.20; MILLS P, 1988, ANAESTHESIA, V43, P788, DOI 10.1111/j.1365-2044.1988.tb05760.x; Putland J, 1998, ANAESTHESIA, V53, P313; Reid C, 2004, EMERG MED J, V21, P296, DOI 10.1136/emj.2003.007344; SAMS J, 1999, EMERGEN MED, V11, P84; SELLICK BA, 1961, LANCET, V2, P404; Stevenson AGM, 2007, EMERG MED J, V24, P394, DOI 10.1136/emj.2006.041988; Takahata O, 1997, ANESTH ANALG, V84, P419, DOI 10.1097/00000539-199702000-00033; Vanner R G, 1992, Int J Obstet Anesth, V1, P195, DOI 10.1016/0959-289X(92)80005-D; Vanner RG, 1999, ANAESTHESIA, V54, P1, DOI 10.1046/j.1365-2044.1999.00756.x; WALLS RM, 2000, EMERGENCY AIRWAY MAN	30	38	39	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUL	2010	81	7					810	816		10.1016/j.resuscitation.2010.02.023			7	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	623RC	WOS:000279758500009	20398995				2021-06-18	
J	Tanriverdi, F; Unluhizarci, K; Karaca, Z; Casanueva, FF; Kelestimur, F				Tanriverdi, F.; Unluhizarci, K.; Karaca, Z.; Casanueva, F. F.; Kelestimur, F.			Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers	PITUITARY			English	Article						Boxing; Traumatic brain injury; Growth hormone; Head trauma; Hypopituitarism	GH DEFICIENCY; BRAIN-INJURY; ADULTS	Traumatic brain injury (TBI) has been recently recognized as a leading cause of pituitary dysfunction. Current data clearly demonstrated that sports related head trauma due to boxing, kickboxing, and soccer might results in pituitary hormone deficiencies, isolated growth hormone (GH) deficiency in particular. In the present report physiologic dose GH replacement therapy (GHRT) was performed in two GH deficient retired amateur boxers for the first time. The boxers received recombinant GH for 6 months. After 6 months of GHRT there were substantial improvements, but not complete normalization, in the body composition parameters, lipid profiles and quality of life scores in both boxers. These preliminary results suggest that GHRT may have beneficial effects in retired boxers with severe isolated GH deficiency due to sports related head trauma. But more data with higher number of boxers and longer GHRT duration are warranted.	[Tanriverdi, F.; Unluhizarci, K.; Karaca, Z.; Kelestimur, F.] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Casanueva, F. F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr					[Anonymous], 1998, J CLIN ENDOCRINOL ME, V83, P379; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; Ives JC, 2007, J ATHL TRAINING, V42, P431; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi Fatih, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P131, DOI 10.1586/14737167.6.2.131; Tanriverdi F, 2008, OBES METAB-MILAN, V4, P118; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x	10	38	39	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	JUN	2010	13	2					111	114		10.1007/s11102-009-0204-0			4	Endocrinology & Metabolism	Endocrinology & Metabolism	584RS	WOS:000276770900003	19847653				2021-06-18	
J	Ferrier-Auerbach, AG; Erbes, CR; Polusny, MA; Rath, CM; Sponheim, SR				Ferrier-Auerbach, Amanda G.; Erbes, Christopher R.; Polusny, Melissa A.; Rath, Col Michael; Sponheim, Scott R.			Predictors of emotional distress reported by soldiers in the combat zone	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						PTSD; Trauma; Brain injury; Depression; Military; Stress	MENTAL-HEALTH PROBLEMS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; IRAQ; AFGHANISTAN; DEPLOYMENT	Objective: Few studies have examined rates of distress of military personnel during deployment to a war zone. Our study sought to (a) identify rates of self-reported posttraumatic stress disorder (PTSD) and depression symptoms during combat deployment, (b) characterize higher order dimensions of emotional distress experienced by soldiers during deployment, and (c) identify predictors of these dimensions of emotional distress. Method: Participants were 2677 National Guard soldiers deployed as part of Operation Iraqi Freedom in 2006-07. We performed a principal components factor analysis on items of the PTSD Checklist - Military Version and the Beck Depression Inventory to identify dimensions of emotional distress, followed by multiple regression analyses to identify factors that predicted these dimensions of distress. Results: Rates of PTSD and depression in our sample were 7% and 9%, respectively. Five dimensions of emotional distress emerged: negative affect/cognitions, trauma-specific re-experiencing and avoidance, vegetative symptoms, loss of interest/numbing symptoms, and arousal/irritability. Two dimensions, trauma-specific symptoms and arousal/irritability, appeared to be more indicative of trauma sequelae, while the other three dimensions were more indicative of depressive symptoms. Demographic factors, combat exposure (including injury and exposure to explosive blast), and attitudinal variables predicted trauma-specific aspects of distress. Symptoms characteristic of depression or generalized distress were predicted by female gender, recent prior deployment, and attitudinal factors but were not predicted by blast exposure or injury. Conclusions: These findings suggest specific targets for contextual and individual interventions to reduce deployment-related distress and point out the need for longitudinal follow-up to determine long-term implications for post-deployment functioning. Published by Elsevier Ltd.	[Ferrier-Auerbach, Amanda G.; Erbes, Christopher R.; Polusny, Melissa A.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN USA; [Erbes, Christopher R.; Polusny, Melissa A.; Sponheim, Scott R.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA; [Polusny, Melissa A.] Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Rath, Col Michael] Adjutant Gen Off, Minnesota Army Natl Guard, St Paul, MN USA; [Sponheim, Scott R.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA	Polusny, MA (corresponding author), VA Med Ctr 116A6,1 Vet Dr, Minneapolis, MN 55417 USA.	melissa.polusny@va.gov	Sponheim, Scott/J-3857-2017; Polusny, Melissa Anderson/N-8112-2014; Polusny, Melissa/X-8158-2019	Sponheim, Scott/0000-0002-2782-0856; Polusny, Melissa Anderson/0000-0002-4932-305X; Polusny, Melissa/0000-0002-4932-305X	VA HSR&D Rapid Response [08-252]	The authors would like to acknowledge MAJOR Cora Courage, PsyD, Minnesota Army National Guard for her consultation on troops' in-theater attitudes and for her assistance in data collection; James Hoelzle, PhD, for his statistical consultation; and Courtney Duffy, BA and Robyn Campbell, BA for their assistance in survey processing and data management. Ms. Campbell was employed as a research assistant funded by VA HSR&D Rapid Response Project #08-252; none of the other individuals acknowledged above were compensated for their assistance. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Army or the Department of Defense.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Byrne BM, 2005, J PERS ASSESS, V85, P17, DOI 10.1207/s15327752jpa8501_02; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; Cigrang J.A., 2005, PRAGMATIC CASE STUDI, V1, P1, DOI [10.14713/pcsp.v1i2.857, DOI 10.14713/PCSP.V1I2.857]; Gray MJ, 2004, J CONSULT CLIN PSYCH, V72, P909, DOI 10.1037/0022-006X.72.5.909; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; KENNEDY H, 2009, US SOLDIER ATTACKS F; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; KOENEN KC, 2009, J TRAUMA STRESS, P1; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Ramchand R., 2008, INVISIBLE WOUNDS WAR, P35; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Tanielian T, 2008, INVISIBLE WOUNDS WAR; *USA SURG GEN, 2006, OP IR FREED MENT HLT; *USA SURG GEN, 2008, OP IR FREED MENT HLT; *USA SURG GEN, 2005, OP IR FREED OIF 2 ME; *USA SURG GEN, 2003, OP IR FREED OIF MENT; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; WEATHERS FW, 1993, P ANN M INT SOC TRUM	25	38	44	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	MAY	2010	44	7					470	476		10.1016/j.jpsychires.2009.10.010			7	Psychiatry	Psychiatry	603XA	WOS:000278240200009	19939409				2021-06-18	
J	Smith, JS; Anderson, R; Pham, T; Bhatia, N; Steward, O; Gupta, R				Smith, Jeremy S.; Anderson, Ryan; Pham, Thu; Bhatia, Nitin; Steward, Oswald; Gupta, Ranjan			Role of Early Surgical Decompression of the Intradural Space After Cervical Spinal Cord Injury in an Animal Model	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							FORELIMB MOTOR FUNCTION; QUANTITATIVE ASSESSMENT; RATS; RECOVERY; PATHOPHYSIOLOGY; COMPRESSION; SURGERY; TRAUMA; BRAIN; MICE	Background: The role of decompressing the intradural space through a durotomy as a treatment option for acute traumatic cervical spinal cord injury has not been explored in an animal model, to our knowledge. We sought to determine the role of durotomy and duraplasty in the treatment of acute cervical spinal cord injury and its effects on inflammation, scar formation, and functional recovery. Methods: Seventy-two adult female Sprague-Dawley rats were assigned to three groups: contusion injury alone, contusion injury with a decompressive durotomy, and contusion injury with a decompressive durotomy followed by placement of a dural allograft. A mild (200-kdyn [2-N]) contusive injury was delivered to the exposed spinal cord at C5. The injured segment was reexposed four hours after injury, and a durotomy with decompression was performed. When a dural allograft was used it was affixed to the surrounding intact dura with use of a fibrin sealant. The Grip Strength Meter was used to assess forelimb function. Animals were killed at two and four weeks, and immunohistochemical analysis was performed to assess scar formation, inflammatory cell infiltration, and lesional volume. Results: Immunohistochemical analysis revealed increased scar formation, cavitation, and inflammatory response in the animals treated only with a decompressive durotomy. Relative to the group with a contusion injury alone, the animals treated with a durotomy followed by a dural allograft had decreased cavitation and scar formation. Lesional volume measurements showed a significantly increased cavitation size at four weeks in both the contusion-only (mean and standard deviation, 12.6 +/- 0.5 mm(3)) and durotomy-only (15.1 +/- 1 mm(3)) groups relative to the animals that had received a dural allograft following durotomy (6.8 +/- 1.4 mm(3)). Conclusions: Functional recovery after acute cervical spinal cord injury was better in animals treated with decompression of the intradural space and placement of a dural allograft than it was in animals treated with decompression alone. These functional data correlated directly with histological evidence of a decrease in spinal cord cavitation, inflammation, and scar formation.	[Smith, Jeremy S.; Anderson, Ryan; Pham, Thu; Bhatia, Nitin; Steward, Oswald; Gupta, Ranjan] Univ Calif Irvine, Irvine, CA USA	Smith, JS (corresponding author), Univ Calif, Dept Orthopaed Surg, Irvine Med Ctr, 101 City Dr S, Orange, CA 92868 USA.	jssmith@uci.edu		Steward, Oswald/0000-0001-7069-8756	NIH/NINDS (National Institutes of Health/National Institute of Neurological Disorders and Stroke)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Roman Reed Foundation	In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants in excess of $10,000 from the NIH/NINDS (National Institutes of Health/National Institute of Neurological Disorders and Stroke) and the Roman Reed Foundation. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity.	Anderson KD, 2005, EXP NEUROL, V194, P161, DOI 10.1016/j.expneurol.2005.02.006; Anderson KD, 2004, EXP NEUROL, V190, P184, DOI 10.1016/j.expneurol.2004.06.029; Anderson KD, 2007, EXP NEUROL, V206, P318, DOI 10.1016/j.expneurol.2007.05.024; Anderson KD, 2009, EXP NEUROL, V220, P23, DOI 10.1016/j.expneurol.2009.08.020; Anderson KD, 2009, EXP NEUROL, V220, P9, DOI 10.1016/j.expneurol.2009.06.012; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; Carlson GD, 2003, J BONE JOINT SURG AM, V85A, P86, DOI 10.2106/00004623-200301000-00014; DELAMARTER RB, 1995, J BONE JOINT SURG AM, V77A, P1042, DOI 10.2106/00004623-199507000-00010; Fehlings MG, 2006, SPINE, V31, pS28, DOI 10.1097/01.brs.0000217973.11402.7f; FERNANDEZ E, 1985, ACTA NEUROCHIR, V76, P145, DOI 10.1007/BF01418478; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; FUJII H, 1993, SPINE, V18, P2030, DOI 10.1097/00007632-199310001-00017; Horn TS, 2005, ARCH PHYS MED REHAB, V86, P1127, DOI 10.1016/j.apmr.2004.11.013; Iannotti C, 2006, J NEUROTRAUM, V23, P853, DOI 10.1089/neu.2006.23.853; Klekamp J, 2001, NEUROSURGERY, V48, P174, DOI 10.1097/00006123-200101000-00031; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; PERKINS PG, 1988, INJURY, V19, P397, DOI 10.1016/0020-1383(88)90132-5; Rasband, IMAGEJ IMAGE PROCESS; Rosenfeld RA, 1998, SOC SCI RES, V27, P23, DOI 10.1006/ssre.1997.0609; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Vaccaro AR, 1997, SPINE, V22, P2609, DOI 10.1097/00007632-199711150-00006	28	38	44	1	5	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	MAY	2010	92A	5					1206	1214		10.2106/JBJS.I.00740			9	Orthopedics; Surgery	Orthopedics; Surgery	591WH	WOS:000277335400018	20439667	Green Published			2021-06-18	
J	Thapa, A; Chandra, SP; Sinha, S; Sreenivas, V; Sharma, BS; Tripathi, M				Thapa, Amit; Chandra, Sarat P.; Sinha, Sumit; Sreenivas, V.; Sharma, Bhawani S.; Tripathi, Manjari			Post-traumatic seizures-A prospective study from a tertiary level trauma center in a developing country	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Post-traumatic seizure; Traumatic brain injury; Glasgow coma scale	PENETRATING HEAD-INJURY; BRAIN-INJURY; RISK-FACTORS; EPILEPSY; EPIDEMIOLOGY; PROPHYLAXIS; POPULATION; PREVENTION; CHILDREN; ADULTS	Rationale: No large studies till date are available from India on post-traumatic seizures (PTS). Methods: This is a prospective observational study of 520 patients with traumatic brain injury (TBI) (July 2007-2008). Patients admitted after 24 h of injury, with Glasgow coma scale (GCS) <= 4 were excluded. Results: At a median follow-up of 386 days, 59(11.4%) patients developed PTS. Incidence of immediate, early and late onset seizure were 6.5%, 2.1% and 2.7% respectively. In children, incidence of PTS was 18.3%. On univariate analysis, females, of age <10 years, with associated medical problems and with delayed loss of consciousness and poor GCS (<9), following fall from height, had significantly higher odds of PTS. On multivariate analysis, the risk of PTS was 3.7 times higher in patients who had fallen from height, 4.4 times higher in associated medical problems, and 3.7 times higher in severe head injury (GCS < 9) at presentation. PTS was associated with poor Glasgow outcome score and higher incidence of behavioral abnormality on follow up. 32% patient with PTS developed recurrent delayed seizures. Seizure recurrence was significantly higher in late onset PTS. PTS affected overall outcome of the patients in severe head injury. Conclusion: The risk of PTS was higher in patients who sustained fall from height, in GCS <9, and associated medical problems. About 1/3rd of the patients with early PTS developed recurrent delayed seizures. (C) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Chandra, Sarat P.] All India Inst Med Sci, Dept Neurosurg, CN Ctr, New Delhi 110029, India; [Tripathi, Manjari] All India Inst Med Sci, Dept Neurol, New Delhi 110029, India; [Sreenivas, V.] All India Inst Med Sci, Dept Biostat, New Delhi 110029, India; [Thapa, Amit; Chandra, Sarat P.; Sinha, Sumit; Sreenivas, V.; Sharma, Bhawani S.; Tripathi, Manjari] All India Inst Med Sci, Dept Trauma Ctr, New Delhi 110029, India	Chandra, SP (corresponding author), All India Inst Med Sci, Dept Neurosurg, CN Ctr, Room 607,6th Floor, New Delhi 110029, India.	saratpchandra@gmail.com	Thapa, Amit/L-3769-2013	Thapa, Amit/0000-0003-1896-3115			AARABI B, 2000, NEUROSURG FOCUS, V15, P8; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bushnik T, 2004, J HEAD TRAUMA REHAB, V19, P296, DOI 10.1097/00001199-200407000-00004; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; Marchal C, 1999, Rev Prat, V49, P383; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Pagni CA, 2005, ACT NEUR S, V93, P27; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NRHM, 1996, NEUROLOGICAL SURG, P1834; TREIMAN DM, 1993, EPILEPSIA, V34, pS17, DOI 10.1111/j.1528-1157.1993.tb05919.x; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Wang HC, 2008, J TRAUMA, V64, P883, DOI 10.1097/TA.0b013e31804a7fa4; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wiedemayer H, 2002, BRAIN INJURY, V16, P323, DOI 10.1080/02699050110102077; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YABLON SA, 2003, PHYS MED REHAB STATE, V15, P301	35	38	38	0	2	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	MAY	2010	19	4					211	216		10.1016/j.seizure.2010.02.004			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	598ZG	WOS:000277878700002	20202866				2021-06-18	
J	Mo, LH; Yang, ZY; Zhang, AF; Li, XG				Mo, Linhong; Yang, Zhaoyang; Zhang, Aifeng; Li, Xiaoguang			The repair of the injured adult rat hippocampus with NT-3-chitosan carriers	BIOMATERIALS			English	Article						Traumatic brain injury; Chitosan scaffold; Transplantation; Neurotrophin-3; Hippocampus; Cognitive function	NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; EXPERIMENTAL BRAIN-INJURY; NEURAL STEM-CELLS; NEUROTROPHIC FACTOR; SYNAPTIC-TRANSMISSION; FUNCTIONAL RECOVERY; REGENERATION; HYDROGEL; NEURONS	The injury of the CA1 region of the adult rat hippocampus causes cognitive impairment. In this study, animal models were established by mechanically injuring the CA1 region of the adult rat hippocampus, and into the injured area were implanted chitosan carriers loaded either with or without NT-3. Immunohistochemical and nerve tracer methods were adopted to observe the role of the above-mentioned carriers in repairing the injured brain and to observe the scar formation after the injury, and Morris water maze (MWM) tests were performed to evaluate the recovery degree of the cognitive function. The results showed that NT-3-chitosan carriers stimulated regeneration of a large amount of NF-positive nerve fiber and neuron-like cells into the injured area. The newly regenerated NF-positive nerve fibers in the injured area rebuilt a neural circuit with the contralateral CA1 region via corpus callosum. Comparison of the lesion control rats and the treated rats indicates that the chitosan carriers loaded either with or without NT-3 may significantly improve the cognitive function after the hippocampus injury. (C) 2009 Elsevier Ltd. All rights reserved.	[Mo, Linhong; Yang, Zhaoyang; Li, Xiaoguang] Capital Med Univ, Beijing Inst Neurosci, Beijing 100069, Peoples R China; [Yang, Zhaoyang; Li, Xiaoguang] Beihang Univ, Sch Biol Sci & Med Engn, Beijing 100191, Peoples R China; [Zhang, Aifeng] Capital Med Univ, Beijing Friendship Hosp, Beijing 100068, Peoples R China	Yang, ZY (corresponding author), Capital Med Univ, Beijing Inst Neurosci, 10 Youanmen Wai, Beijing 100069, Peoples R China.	yangzhaoyang@vip.sina.com; lxgchina@sina.com			National 863 Project [2006AA02A129]; Department of Science and Technology, Beijing, ChinaDepartment of Science & Technology (India) [D09080703660902]	This work was supported by the National 863 Project (Grant No.2006AA02A129), and Key Project of Department of Science and Technology (Grant No.D09080703660902), Beijing, China. The authors would like to express heartfelt thanks to Liwei Zhang, Tailing Wang, Weichang Chen, Hui Qiao, Xichao Ou, Yuewei Su and Suyu Zhong for their kind help and constructive comments.	Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; Blesch A, 1999, J NEUROSCI, V19, P3556; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huang WC, 2006, BIOCHEM BIOPH RES CO, V349, P963, DOI 10.1016/j.bbrc.2006.08.136; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; Li XG, 2009, BIOMATERIALS, V30, P4978, DOI 10.1016/j.biomaterials.2009.05.047; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; Liu Y, 1999, J NEUROSCI, V19, P4370; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Perez-Navarro E, 1999, NEUROSCIENCE, V91, P1257, DOI 10.1016/S0306-4522(98)00723-4; Piantino J, 2006, EXP NEUROL, V201, P359, DOI 10.1016/j.expneurol.2006.04.020; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Riedel G, 1999, NAT NEUROSCI, V2, P898; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tian WM, 2005, J CONTROL RELEASE, V102, P13, DOI 10.1016/j.jconrel.2004.09.025; Tokura S, 1996, MACROMOL SYMP, V101, P389, DOI 10.1002/masy.19961010144; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Woerly S, 1999, TISSUE ENG, V5, P467, DOI 10.1089/ten.1999.5.467; Woerly S, 2001, J NEUROSCI RES, V66, P1187; Zhang HZ, 2007, BRAIN RES, V1132, P29, DOI 10.1016/j.brainres.2006.09.117; ZHOU XF, 1994, BRAIN RES, V643, P162, DOI 10.1016/0006-8993(94)90022-1	32	38	45	2	25	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	MAR	2010	31	8					2184	2192		10.1016/j.biomaterials.2009.11.078			9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	563WR	WOS:000275167300023	20022104				2021-06-18	
J	Luh, C; Kuhlmann, CR; Ackermann, B; Timaru-Kast, R; Luhmann, HJ; Behl, C; Werner, C; Engelhard, K; Thal, SC				Luh, Clara; Kuhlmann, Christoph R.; Ackermann, Bianca; Timaru-Kast, Ralph; Luhmann, Heiko J.; Behl, Christian; Werner, Christian; Engelhard, Kristin; Thal, Serge C.			Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain edema; MLCK; myosin light chain; phosphorylation; pMLC; traumatic brain injury	CONTROLLED CORTICAL IMPACT; B-2 RECEPTOR ANTAGONIST; BARRIER DISRUPTION; GENE-EXPRESSION; CEREBRAL EDEMA; MICE; PERMEABILITY; DYSFUNCTION; MODULATION; REDUCTION	The role of the endothelial contractile apparatus in the process of brain edema formation after brain trauma is not characterized. Phosphorylation of myosin light chains by myosin light chain kinases (MLCK) activates endothelial contractile elements and results in a rearrangement of the cytoskeleton. This may enhance post-traumatic blood-brain barrier dysfunction. In order to investigate the role of the MLCK on brain edema formation and blood-brain barrier permeability after brain injury, mice were anesthetized and subjected to a controlled cortical impact (CCI). MLCK expression is significantly up-regulated after CCI with a maximum 12 h post-injury. Specific inhibition of MLCK by ML-7 resulted in a reduction of phosphorylation of myosin light chains and improved blood-brain-barrier integrity. Accordingly, ML-7 attenuated posttraumatic brain edema formation and intracranial hypertension 24 h after CCI. Prevention of brain edema formation did not translate into improved neurological outcome or reduced brain lesion. In conclusion, the results confirm that the endothelial contractile apparatus is activated by CCI and opens the endothelial barrier leading to vasogenic brain edema formation. Lack of neurological and histological improvement suggests that specific targeting of vasogenic brain edema at the endothelial level is not sufficient to limit secondary brain damage and has, therefore, to be combined with other potential neuroprotective strategies.	[Luh, Clara; Timaru-Kast, Ralph; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55131 Mainz, Germany; [Luh, Clara; Kuhlmann, Christoph R.; Luhmann, Heiko J.] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Med Ctr, D-55131 Mainz, Germany; [Ackermann, Bianca; Behl, Christian] Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Med Ctr, D-55131 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011; Luhmann, Heiko J./N-8797-2019	Thal, Serge/0000-0002-1222-8729; Luhmann, Heiko J./0000-0002-7934-8661; Behl, Christian/0000-0001-8453-2378			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Eutamene H, 2005, EUR RESPIR J, V25, P789, DOI 10.1183/09031936.05.00064704; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Ferrier L, 2003, GASTROENTEROLOGY, V125, P795, DOI 10.1016/S0016-5085(03)01057-6; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Haorah J, 2007, J NEUROCHEM, V100, P324, DOI 10.1111/j.1471-4159.2006.04245.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Ishmael JE, 2008, ACTA HISTOCHEM, V110, P172, DOI 10.1016/j.acthis.2007.08.005; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Ma TY, 1999, AM J PHYSIOL-GASTR L, V276, pG965; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	31	38	39	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2010	112	4					1015	1025		10.1111/j.1471-4159.2009.06514.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	546PH	WOS:000273822200015	19943851	Bronze			2021-06-18	
J	Claus, CP; Tsuru-Aoyagi, K; Adwanikar, H; Walker, B; Whetstone, W; Noble-Haeusslein, LJ				Claus, Catherine P.; Tsuru-Aoyagi, Kyoko; Adwanikar, Hita; Walker, Breset; Whetstone, William; Noble-Haeusslein, Linda J.			Age Is a Determinant of Leukocyte Infiltration and Loss of Cortical Volume after Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Inflammation; Traumatic brain injury; Developing brain; Cell death	NITRIC-OXIDE SYNTHASE; GLUTATHIONE-PEROXIDASE ACTIVITY; HEME OXYGENASE-2 PROTEIN; IMMATURE BRAIN; RAT-BRAIN; REGIONAL VULNERABILITY; SUPEROXIDE-DISMUTASE; BARRIER PERMEABILITY; MOUSE-BRAIN; HEAD-INJURY	There is increasing evidence that the inflammatory response differs in the injured developing brain as compared to the adult brain. Here we compared cerebral blood flow and profiled the inflammatory response in mice that had been subjected to traumatic brain injury (TBI) at postnatal day (P)21 or at adulthood. Relative blood flow, determined by laser Doppler, revealed a 30% decrease in flow immediately after injury followed by prominent hyperemia between 7 and 35 days after injury in both age groups. The animals were euthanized at 1-35 days after injury and the brains prepared for the immunolocalization and quantification of CD45-, GR-1-, CD4- and CD8-positive (+) cells. On average, the number of CD45+ leukocytes in the cortex was significantly higher in the P21 as compared to the adult group. A similar trend was seen for GR-1+ granulocytes, whereas no age-related differences were noted for CD4+ and CD8+ cells. While CD45+ and GR-1+ cells in the P21 group remained elevated, relative to shams, over the first 2 weeks after injury, the adult group showed a time course limited to the first 3 days after injury. The loss of ipsilateral cortical volumes at 2 weeks after injury was significantly greater in the adult relative to the P21 group. While the adult group showed no further change in cortical volumes, there was a significant loss of cortical volumes between 2 and 5 weeks after injury in the P21 group, reaching values similar to that of the adult group by 5 weeks after injury. Together, these findings demonstrate age-dependent temporal patterns of leukocyte infiltration and loss of cortical volume after TBI. Copyright (C) 2010 S. Karger AG, Basel	[Claus, Catherine P.; Tsuru-Aoyagi, Kyoko; Adwanikar, Hita; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Walker, Breset; Whetstone, William] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabilitat Sci, San Francisco, CA 94143 USA	Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.	Linda.Noble@ucsf.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R21NS065937]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R21NS065937] Funding Source: NIH RePORTER	The authors thank Seong E. Koh (MD) and Hovhannes Manvelyan (MD) for their contributions to this project. The study was supported by NIH/NINDS grants No. R01NS050159 and R21NS065937.	Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing JF, 1997, BRAIN RES PROTOC, V1, P165, DOI 10.1016/S1385-299X(96)00027-X; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LAWSON LJ, 1995, EUR J NEUROSCI, V7, P1584, DOI 10.1111/j.1460-9568.1995.tb01154.x; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maines MD, 1996, BRAIN RES, V722, P83, DOI 10.1016/0006-8993(96)00184-9; Mischel RE, 1997, NEUROSCI LETT, V231, P17, DOI 10.1016/S0304-3940(97)00531-4; Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137; PAXINOS G, 1986, RAT BRAIN STEREOTAXI, pR8; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Reed MG, 1998, J MICROSC-OXFORD, V190, P350; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Yoneyama-Sarnecky T, 2010, DEV NEUROSCI-BASEL, V32, P81, DOI 10.1159/000258700	45	38	38	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					454	465		10.1159/000316805			12	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900013	20847543	Green Published, Bronze			2021-06-18	
J	Han, SJ; Guo, Y; Granger-Donetti, B; Vicci, VR; Alvarez, TL				Han, Sang J.; Guo, Yi; Granger-Donetti, Berangere; Vicci, Vincent R.; Alvarez, Tara L.			Quantification of heterophoria and phoria adaptation using an automated objective system compared to clinical methods	OPHTHALMIC AND PHYSIOLOGICAL OPTICS			English	Article						dissociated phoria; eye-movements; heterophoria measurement; phoria adaptation; sustained convergence	TRAUMATIC BRAIN-INJURY; COVER TEST; VERGENCE ADAPTATION; PRISM ADAPTATION; INTEREXAMINER REPEATABILITY; EYE-MOVEMENTS; ACCOMMODATION; CONVERGENCE; DISTANCE; STIMULI	Purpose: To develop a system with which to quantify objectively the heterophoria to be measured throughout eye movement experiments. This study compared precision, resolution and accuracy characteristics of a limbus eye movement tracking system to the alternate cover test and the Maddox rod. Methods: Precision testing was performed using each technique with binocularly-normal subjects at different test sessions. Resolution was measured and compared between the three systems. The heterophoria or phoria was measured from 40 cm/16 inches objectively with the limbus eye movement system and the Maddox rod during a sustained convergence-induced phoria adaptation experiment using physical and haploscope visual targets to compare accuracy. Results: Precision testing quantified that the responses objectively recorded using the limbus tracking system exhibited similar standard deviations to the Maddox rod and the alternate cover test techniques. The limbus tracking method has the ability to quantify the response decay to phoria and has better resolution when compared to the clinical methods. When physical targets were used to induce phoria adaptation, the correlation was significant between the limbus eye movement tracking system and the Maddox rod after near and far adaptation, where the Maddox rod measurements were slightly more esophoric compared to those measured with the limbus tracking system. Conclusion: This objective limbus tracking system offers a better means by which to study the phoria and its adaptation throughout an eye movement experiment. The broader aim of this research is to establish a tool that will further the basic science of oculomotor control and binocular dysfunctions.	[Han, Sang J.; Guo, Yi; Alvarez, Tara L.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Granger-Donetti, Berangere] Essilor Inc Corp, St Maur, France; [Vicci, Vincent R.] Westfield & Kessler Rehabil, W Orange, NJ USA; [Vicci, Vincent R.] Westfield & Kessler Rehabil, Chester, NJ USA; [Vicci, Vincent R.] Westfield & Kessler Rehabil, Saddle Brook, NJ USA	Alvarez, TL (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	tara.l.alvarez@njit.edu		Guo, Yi/0000-0003-3103-6447; Alvarez, Tara/0000-0002-8797-1613	Essilor International; National Science Foundation CAREERNational Science Foundation (NSF) [BES-0447713]	This study was funded by Essilor International and the National Science Foundation CAREER BES-0447713 to TLA.	Baker FJ, 2003, OPHTHAL PHYSL OPT, V23, P507, DOI 10.1046/j.1475-1313.2003.00145.x; BARNARD NAS, 1995, OPHTHAL PHYSL OPT, V15, P413, DOI 10.1046/j.1475-1313.1995.9500053g.x; BIRNBAUM MH, 1985, AM J OPTOM PHYS OPT, V62, P732; BIRNBAUM MH, 1998, MYOPIA NEARWORK, P162; Brautaset RL, 2005, OPHTHAL PHYSL OPT, V25, P215, DOI 10.1111/j.1475-1313.2005.00276.x; Casillas EC, 2006, OPTOMETRY VISION SCI, V83, P237, DOI 10.1097/01.opx.0000214316.50270.24; Cheng D, 2008, OPHTHAL PHYSL OPT, V28, P225, DOI 10.1111/j.1475-1313.2008.00560.x; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; COOPER J, 1992, OPTOMETRY VISION SCI, V69, P300, DOI 10.1097/00006324-199204000-00008; EHRLICH DL, 1987, OPHTHAL PHYSL OPT, V7, P353, DOI 10.1111/j.1475-1313.1987.tb00760.x; Fogt N, 2001, OPTOMETRY VISION SCI, V78, P815, DOI 10.1097/00006324-200111000-00011; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Goss D A, 1999, J Am Optom Assoc, V70, P764; GOSS DA, 1990, OPTOMETRY VISION SCI, V67, P637, DOI 10.1097/00006324-199008000-00015; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HIRSCH M J, 1948, Am J Optom Arch Am Acad Optom, V25, P492; Howarth PA, 2000, OPTOMETRY VISION SCI, V77, P616, DOI 10.1097/00006324-200011000-00013; Jaschinski W, 2007, OPHTHAL PHYSL OPT, V27, P85, DOI 10.1111/j.1475-1313.2006.00448.x; Jiang Bai-Chuan, 2007, Optometry, V78, P129, DOI 10.1016/j.optm.2006.08.017; Johns HA, 2004, OPTOMETRY VISION SCI, V81, P939; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KRAN BS, 1988, AM J OPTOM PHYS OPT, V65, P703; Lam AKC, 2005, OPHTHAL PHYSL OPT, V25, P162, DOI 10.1111/j.1475-1313.2005.00270.x; MORLEY JW, 1992, J NEUROPHYSIOL, V67, P1475; MORRIS F M, 1960, Am J Optom Arch Am Acad Optom, V37, P327; NORTH RV, 1993, OPHTHAL PHYSL OPT, V13, P239, DOI 10.1111/j.1475-1313.1993.tb00465.x; OSHEA WF, 1988, AM J OPTOM PHYS OPT, V65, P787; OWENS DA, 1992, INVEST OPHTH VIS SCI, V33, P2733; PELI E, 1983, AM J OPTOM PHYS OPT, V60, P712; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Rainey BB, 1998, OPTOMETRY VISION SCI, V75, P719, DOI 10.1097/00006324-199810000-00016; ROMANO PE, 1971, AM J OPHTHALMOL, V72, P10, DOI 10.1016/0002-9394(71)91585-6; Scheiman M, 2001, VISUAL VESTIBULAR CO, P89; SCHOR CM, 1979, VISION RES, V19, P757, DOI 10.1016/0042-6989(79)90151-2; SCHOR CM, 1982, AM J OPTOM PHYS OPT, V59, P774; Schroeder TL, 1996, OPTOMETRY VISION SCI, V73, P389, DOI 10.1097/00006324-199606000-00006; SCOBEE RG, 1947, T AM ACAD OPHTHALMOL, V40, P179; SETHI B, 1986, OPHTHAL PHYSL OPT, V6, P151, DOI 10.1016/0275-5408(86)90006-2; SHEBILSKE WL, 1983, J EXP PSYCHOL HUMAN, V9, P270, DOI 10.1037/0096-1523.9.2.270; Spierer A, 1997, GRAEF ARCH CLIN EXP, V235, P345, DOI 10.1007/BF00937281; Wong EPF, 2002, OPTOMETRY VISION SCI, V79, P370, DOI 10.1097/00006324-200206000-00010; Ying SH, 2006, EXP BRAIN RES, V171, P297, DOI 10.1007/s00221-005-0267-8	43	38	38	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-5408	1475-1313		OPHTHAL PHYSL OPT	Ophthalmic Physiol. Opt.	JAN	2010	30	1					95	107		10.1111/j.1475-1313.2009.00681.x			13	Ophthalmology	Ophthalmology	531JE	WOS:000272660500010	19682268				2021-06-18	
J	Berlot, G; La Fata, C; Bacer, B; Biancardi, B; Viviani, M; Lucangelo, U; Gobbato, P; Torelli, L; Carchietti, E; Trillo, G; Daniele, M; Rinaldi, A				Berlot, Giorgio; La Fata, Cristina; Bacer, Barbara; Biancardi, Bruno; Viviani, Marino; Lucangelo, Umberto; Gobbato, Piero; Torelli, Lucio; Carchietti, Elio; Trillo, Giulio; Daniele, Massarutti; Rinaldi, Adriano			Influence of prehospital treatment on the outcome of patients with severe blunt traumatic brain injury: a single-centre study	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						ambulance; coma; helicopter; secondary brain injury; trauma	CARE	Aim, patients, and methods To compare retrospectively the outcomes of patients with severe traumatic brain injury (injury Severity Score, ISS total >= 15; the Abbreviated ISS-head, aISS(head) >= 9) admitted to our Intensive Care Unit by helicopter (helicopter emergency medical service, HEMS group=89) with those transported by ambulance (GROUND group=105) from January 2002 to December 2007. Results The groups were comparable for age, Glasgow Coma Scale, ISS total, and aISS(head). The preadmission time of the HEMS group was significantly longer as compared with the GROUND group, but the interval from admission to definitive care was significantly shorter. In the prehospital phase, HEMS patients were more aggressively treated, as indicated by a significantly greater number of procedures performed (i.e. tracheal intubation and positioning of intravenous lines) and larger volumes of fluids infused. The overall mortality was lower in the HEMS than in the GROUND patients (21 vs. 25% respectively, P<0.05). The survival with or without only minor neurological disabilities was higher in the HEMS than in the GROUND group (54 vs. 44% respectively, P<0.05); among the survivors, the rate of severe neurological disabilities was lower in the HEMS than in the GROUND group (25 vs. 31%, P<0.05). Conclusion In our experience, aggressive early treatment of patients with severe traumatic brain injury was associated with a better outcome likely because of the prevention of secondary brain injury and a shorter interval elapsing from the trauma to definitive care despite more time spent on the scene by the intervening team. European Journal of Emergency Medicine 16:312-317 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.	[Berlot, Giorgio; La Fata, Cristina; Bacer, Barbara; Biancardi, Bruno; Viviani, Marino; Lucangelo, Umberto; Gobbato, Piero; Rinaldi, Adriano] Univ Trieste, Dept Anaesthesia & Intens Care, Trieste, Italy; [Torelli, Lucio] Univ Trieste, Dept Biostat, Trieste, Italy; [Carchietti, Elio; Trillo, Giulio; Daniele, Massarutti] Friuli Venezia Giulia Helicopter Emergency Med Sy, Rome, Italy	Berlot, G (corresponding author), Cattinara Hosp, Dept Anaesthesia & Intens Care, Str Fiume 447, I-34149 Trieste, Italy.	berlot@inwind.it	Trillo, Giulio/AAC-1574-2020	BERLOT, GIORGIO/0000-0002-9231-8555			Berlot G, 2006, CRIT CARE CLIN, V22, P457, DOI 10.1016/j.ccc.2006.03.009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Frink M, 2007, UNFALLCHIRURG, V110, P334, DOI 10.1007/s00113-006-1222-2; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; Kerr W A, 1999, Prehosp Disaster Med, V14, P159; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; NARDI G, 1994, EUR J EMERG MED, V2, P69; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Sharma BR, 2005, INJURY, V36, P579, DOI 10.1016/j.injury.2004.09.009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014	18	38	41	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0969-9546	1473-5695		EUR J EMERG MED	Eur. J. Emerg. Med.	DEC	2009	16	6					312	317		10.1097/MEJ.0b013e32832d3aa1			6	Emergency Medicine	Emergency Medicine	528VE	WOS:000272474300005	19491690				2021-06-18	
J	Daboussi, A; Minville, V; Leclerc-Foucras, S; Geeraerts, T; Esquerre, JP; Payoux, P; Fourcade, O				Daboussi, Amel; Minville, Vincent; Leclerc-Foucras, Sophie; Geeraerts, Thomas; Esquerre, Jean Paul; Payoux, Pierre; Fourcade, Olivier			Cerebral Hemodynamic Changes in Severe Head Injury Patients Undergoing Decompressive Craniectomy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						intracranial pressure; decompressive craniectomy; transcranial Doppler; outcome	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; SURGICAL DECOMPRESSION; TISSUE OXYGEN; MANAGEMENT; PRESSURE; EDEMA; ICP; HEMICRANIECTOMY; PERFUSION	Objective: To assess the intracranial hemodynamic modifications induced by a decompressive craniectomy (DC) after severe traumatic brain injury (TBI), using transcranial Doppler (TCD) ultrasonography and intracranial pressure (ICP) sensor. Mortality rate and neurological outcomes were also evaluated after this procedure. Design: A prospective study was carried out on 26 TBI patients, measuring transcranial Doppler and ICP before, immediately after, and 48 hours after the DC, allowing for statistical analysis of hemodynamic changes. The mortality rate and the neurological Outcomes were assessed. Measurements and Results: After DC, ICP decreased from 37 +/- 17 to 20 +/- 13 mm Hg (P = 0.0003). The global cerebral blood flow was modified with diastolic velocities rising from 23 +/- 15 to 31 +/- 13 cm/s (P = 0.0038) and a pulsatility index decreasing from 1.70 +/- 0.66 to 1.18 +/- 0.37 (P = 0.0012). This normalization of the global cerebral hemodynamics after the DC was immediate, symmetric, and constant during the first 48 hours. Outcome was evaluated at 6 months: good recovery or moderate disability was observed in 11 patients (42%), persistent vegetative state in 7 patients (27%), and 8 patients died (31%). Conclusions: The DC results in a significant, immediate, and durable improvement of ICP associated with a normalization of cerebral blood flow velocities in most TBI patients with refractory intracranial hypertension.	[Daboussi, Amel; Esquerre, Jean Paul; Payoux, Pierre] CHU Purpan, Nucl Med Serv, F-31059 Toulouse 9, France; [Geeraerts, Thomas] Hop Bicetre, Dept Anesthesie Reanimat, Le Kremlin Bicetre, France; [Daboussi, Amel; Minville, Vincent; Leclerc-Foucras, Sophie; Fourcade, Olivier] Univ Toulouse 3, CHU Toulouse, F-31062 Toulouse, France	Fourcade, O (corresponding author), CHU Purpan, Nucl Med Serv, Pl Docteur Baylac, F-31059 Toulouse 9, France.	fourcade.o@chu-toulouse.fr	Minville, Vincent/ABE-4286-2020	Minville, Vincent/0000-0003-0516-4939; Payoux, Pierre/0000-0002-1374-1620			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; *AG NAT ACCR EV SA, 1999, ANN FR ANESTH, V18, P11; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; Heppner P, 2006, J NEUROSURG, V104, P738, DOI 10.3171/jns.2006.104.5.738; Jaeger M, 2005, ACT NEUR S, V95, P117; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; LINDEGAARD KF, 1992, TRANSCRANIAL DOPPLER, P67; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Munch E, 2000, NEUROSURGERY, V47, P315; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	41	38	44	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2009	21	4					339	345		10.1097/ANA.0b013e3181b1dbba			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	503RQ	WOS:000270557400010	19955897				2021-06-18	
J	Skoglund, K; Enblad, P; Marklund, N				Skoglund, Karin; Enblad, Per; Marklund, Niklas			Effects of the Neurological Wake-Up Test on Intracranial Pressure and Cerebral Perfusion Pressure in Brain-Injured Patients	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Cerebral perfusion pressure; Sedation; Propofol; Wake-up test; Neurological examination; Reaction Level Scale; Glasgow Coma Scale	INTENSIVE-CARE-UNIT; SUBARACHNOID HEMORRHAGE; VENTILATOR BUNDLE; SEDATION; EFFICACY; IMPACT; DETERIORATION; NEUROTRAUMA; MANAGEMENT; RECOVERY	To evaluate the effects of the neurological "wake-up test" (NWT), defined as interruption of continuous propofol sedation and evaluation of the patient's level of consciousness, on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in patients with severe subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI). A total of 127 NWT procedures in 21 severely brain-injured adult patients with either TBI (n = 12) or SAH (n = 9) were evaluated. ICP and CPP levels prior to, during and after the NWT procedure were recorded. During the NWT, ICP increased from 13.4 +/- A 6 mmHg at baseline to 22.7 +/- A 12 (P < 0.05) and the CPP increased from 75.6 +/- A 11 to 79.1 +/- A 21 mmHg (P < 0.05) in TBI patients. Eight patients showed a reduced CPP during the NWT due to increased ICP. In SAH patients, ICP increased from 10.6 +/- A 5 to 16.8 +/- A 8 mmHg (P < 0.05) and the CPP increased from 76.9 +/- A 13 to 84.6 +/- A 15 mmHg (P < 0.05). When continuous propofol sedation was interrupted and NWT was performed in severely brain-injured patients, the mean ICP and CPP levels were modestly increased. A subset of patients showed more pronounced changes. To date, the role of the NWT in the neurointensive care of TBI and SAH patients is unclear. Although the NWT is safe in the majority of patients and may provide useful clinical information about the patient's level of consciousness, alternate monitoring methods are suggested in patients showing marked ICP and/or CPP changes during NWT.	[Skoglund, Karin; Enblad, Per; Marklund, Niklas] Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden.	Niklas.Marklund@neurokir.uu.se		Marklund, Niklas/0000-0002-9797-5626	Laerdal Foundation for Acute Medicine; Swedish Research CouncilSwedish Research CouncilEuropean Commission	The authors are grateful to Monica Edberg, the NICU nurse staff, Dr. Tim Howells, and Dr. Camilla Frojd for excellent support during the study. This study was supported by the Laerdal Foundation for Acute Medicine and the Swedish Research Council.	Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; Anglen JO, 2003, J TRAUMA, V54, P1166, DOI 10.1097/01.TA.0000057232.66613.AC; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Blamoun J, 2009, AM J INFECT CONTROL, V37, P172, DOI 10.1016/j.ajic.2008.05.010; Bruder N, 2002, ANESTH ANALG, V94, P650, DOI 10.1097/00000539-200203000-00031; Bruder N, 1999, ANESTH ANALG, V89, P674, DOI 10.1097/00000539-199909000-00027; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carrasco G, 2000, CRIT CARE, V4, P217, DOI 10.1186/cc697; Cesarini KG, 1999, J NEUROSURG, V90, P664, DOI 10.3171/jns.1999.90.4.0664; Citerio Giuseppe, 2003, Curr Opin Crit Care, V9, P120, DOI 10.1097/00075198-200304000-00007; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Deogaonkar A, 2004, CRIT CARE MED, V32, P2403, DOI 10.1097/01.CCM.0000147442.14921.A5; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Gemma M, 2002, J NEUROSURG ANESTH, V14, P50, DOI 10.1097/00008506-200201000-00010; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Grande PO, 2002, INTENS CARE MED, V28, P529, DOI 10.1007/s00134-002-1236-3; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kerr ME, 1999, CRIT CARE MED, V27, P2776, DOI 10.1097/00003246-199912000-00028; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Nordstrom Carl-Henrik, 2003, Neurosurg Focus, V15, pE5; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; REILLY P, 1997, HEAD INJURY, P385; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; Ryttlefors M, 2007, NEUROSURGERY, V61, P704, DOI 10.1227/01.NEU.0000298898.38979.E3; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148; SKOGLUND K, 2009, 10 QUADR C WORLD FED; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; STROMGREN M, 2003, 7 QUADR C EUR ASS NE; TEASDALE G, 1974, LANCET, V2, P81; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Valadka AB, 2007, NEUROSURGERY, V61, P203, DOI 10.1227/01.NEU.0000255497.26440.01; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Wittbrodt ET, 2005, PHARMACOTHERAPY, V25, p3S, DOI 10.1592/phco.2005.25.5_Part_2.3S; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Youngquist P, 2007, JT COMM J QUAL PATIE, V33, P219, DOI 10.1016/S1553-7250(07)33026-2	50	38	40	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					135	142		10.1007/s12028-009-9255-3			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300002	19644774				2021-06-18	
J	Nechifor, M				Nechifor, Mihai			Magnesium in major depression	MAGNESIUM RESEARCH			English	Article	12th International Magnesium Symposium 2009	SEP 22-25, 2009	Iasi, ROMANIA			magnesium; major depression; reward system; amitriptyline; sertraline	ANXIETY-RELATED BEHAVIOR; TRAUMATIC BRAIN-INJURY; NMDA/GLUTAMATE MECHANISM; ERYTHROCYTE MAGNESIUM; DEFICIENT DIET; MICE; RATS; SUPPLEMENTATION; INVOLVEMENT; SYMPTOMS	There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs 59.1 +/- 3.2 mg/L in control group, p < 0.05) and only in patients with severe MD (Hamilton score > 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p < 0.05 vs before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl(2) 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.	Gr T Popa Univ Med & Pharmacol, Dept Pharmacol, Iasi 700115, Romania	Nechifor, M (corresponding author), Gr T Popa Univ Med & Pharmacol, Dept Pharmacol, Univ 16, Iasi 700115, Romania.	nechifor@umfiasi.ro					BANKI CM, 1985, BIOL PSYCHIAT, V20, P163, DOI 10.1016/0006-3223(85)90076-9; Barra A, 2007, MAGNESIUM RES, V20, P245; Barragan-Rodriguez L, 2008, MAGNESIUM RES, V21, P218; Chollet D, 2001, BEHAV GENET, V31, P413, DOI 10.1023/A:1012790321071; Eby GA, 2006, MED HYPOTHESES, V67, P362, DOI 10.1016/j.mehy.2006.01.047; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Hantouche EG, 1998, ENCEPHALE, V24, P469; HASEY GM, 1993, BIOL PSYCHIAT, V33, P133, DOI 10.1016/0006-3223(93)90314-4; Iezhitsa IN, 2002, MAGNESIUM RES, V15, P179; Jacka FN, 2009, AUST NZ J PSYCHIAT, V43, P45, DOI 10.1080/00048670802534408; Joffe RT, 1996, BIOL PSYCHIAT, V40, P428, DOI 10.1016/0006-3223(96)00063-7; LAWLEY SI, 1990, PHARMACOL BIOCHEM BE, V36, P539, DOI 10.1016/0091-3057(90)90253-E; Levine J, 1999, NEUROPSYCHOBIOLOGY, V39, P63, DOI 10.1159/000026562; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NAKAMURA MM, 1983, ALCOHOL CLIN EXP RES, V7, P188, DOI 10.1111/j.1530-0277.1983.tb05437.x; Nechifor M, 2004, METAL IONS BIOL MED, V8, P518; NECHIFOR M, 2002, MAGNESIUM RES PHYSL, P177; Nechifor M, 2008, MAGNESIUM RES, V21, P97; Nechifor M, 2007, NEW PERSPECTIVES IN MAGNESIUM RESEARCH: NUTRITION AND HEALTH, P369, DOI 10.1007/978-1-84628-483-0_30; Pizzagalli DA, 2008, J PSYCHIATR RES, V43, P76, DOI 10.1016/j.jpsychires.2008.03.001; Poleszak E, 2007, PHARMACOL BIOCHEM BE, V88, P158, DOI 10.1016/j.pbb.2007.07.018; Poleszak E, 2008, PHARMACOL REP, V60, P655; Singewald N, 2004, NEUROPHARMACOLOGY, V47, P1189, DOI 10.1016/j.neuropharm.2004.08.010; Spasov AA, 2008, ZH VYSSH NERV DEYAT+, V58, P476; Szewczyk B, 2008, PHARMACOL REP, V60, P588; WIDMER J, 1995, J AFFECT DISORDERS, V34, P201, DOI 10.1016/0165-0327(95)00018-I; Zieba A, 2000, HUM PSYCHOPHARM CLIN, V15, P631, DOI 10.1002/hup.231	27	38	38	0	10	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0953-1424			MAGNESIUM RES	Magnes. Res.	SEP	2009	22	3					163S	166S					4	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	491CZ	WOS:000269556100006	19780403				2021-06-18	
J	Garon, BR; Sierzant, T; Ormiston, C				Garon, Bernard R.; Sierzant, Tess; Ormiston, Charles			Silent Aspiration: Results of 2,000 Video Fluoroscopic Evaluations	JOURNAL OF NEUROSCIENCE NURSING			English	Article							FIBEROPTIC ENDOSCOPIC EVALUATION; ACUTE-STROKE; DETECTING ASPIRATION; SWALLOWING DISORDERS; CLINICAL EXAMINATION; ELDERLY-PATIENTS; PULSE OXIMETRY; DYSPHAGIA; RISK; HEAD	The purpose of this retrospective study of aspiration and the lack of a protective cough reflex at the vocal folds (silent aspiration) was to increase the awareness of nursing staffs of the diagnostic pathology groups associated with silent aspiration. Of the 2,000 patients evaluated in this study, 51% aspirated on the video fluoroscopic evaluation. Of the patients who aspirated, 55% had no protective cough reflex (silent aspiration). The diagnostic pathology groups with the highest rates of silent aspiration were brain cancer, brainstem stroke, head-neck cancer, pneumonia, dementia/Alzheimer, chronic obstructive lung disease, seizures, myocardial infarcts, neurodegenerative pathologies, right hemisphere stroke, closed head injury, and left hemisphere stroke. It is of high concern that the diagnostic groups identified in this research as having the highest risk of silent aspiration be viewed as "red-flag" patients by the nursing staff caring for them. Early nursing dysphagia screens, with close attention to the clinical symptoms associated with silent aspiration, and early referral for formal dysphagia evaluation are stressed.	[Garon, Bernard R.] HealthE St Josephs Hosp, Dept Phys Med, St Paul, MN USA; [Sierzant, Tess; Ormiston, Charles] HealthE St Josephs Hosp, Natl Brain Aneurysm Ctr, St Paul, MN USA	Garon, BR (corresponding author), HealthE St Josephs Hosp, Dept Phys Med, St Paul, MN USA.	brgaron@healtheast.org					Argon M, 2004, EUR J NUCL MED MOL I, V31, P94, DOI 10.1007/s00259-003-1276-0; ARVEDSON J, 1994, INT J PEDIATR OTORHI, V28, P173, DOI 10.1016/0165-5876(94)90009-4; Aviv JE, 2002, DYSPHAGIA, V17, P219, DOI 10.1007/s00455-002-0055-6; Belafsky PC, 2003, LARYNGOSCOPE, V113, P1969, DOI 10.1097/00005537-200311000-00021; BLITZER A, 1990, Dysphagia, V5, P129, DOI 10.1007/BF02412635; Borr C, 2007, DYSPHAGIA, V22, P225, DOI 10.1007/s00455-007-9078-3; Chan ED, 1998, CHEST, V114, P1704, DOI 10.1378/chest.114.6.1704; Cook I J, 1989, Dysphagia, V4, P8, DOI 10.1007/BF02407397; Daniels SK, 2000, ARCH PHYS MED REHAB, V81, P1030, DOI 10.1053/apmr.2000.6301; DeMatteo C, 2005, DEV MED CHILD NEUROL, V47, P149, DOI 10.1017/S0012162205000289; DEPIPPO KL, 1994, NEUROLOGY, V44, P1655, DOI 10.1212/WNL.44.9.1655; Doggett David L, 2002, Curr Atheroscler Rep, V4, P311; Donzelli J, 2005, DYSPHAGIA, V20, P283, DOI 10.1007/s00455-005-0027-8; Dusick Anna, 2003, Semin Pediatr Neurol, V10, P255, DOI 10.1016/S1071-9091(03)00071-8; Eibling DE, 2001, J OTOLARYNGOL, V30, P235, DOI 10.2310/7070.2001.20174; FEINBERG MJ, 1992, RADIOLOGY, V183, P811, DOI 10.1148/radiology.183.3.1584939; Goeleven A, 2006, AMYOTROPH LATERAL SC, V7, P235, DOI 10.1080/17482960600664870; Groher ME, 1986, DYSPHAGIA, V1, P3, DOI DOI 10.1007/BF02408233; Halvorsen RA, 2002, ABDOM IMAGING, V28, P244, DOI 10.1007/s00261-002-0034-2; Higo R, 2003, ANN OTO RHINOL LARYN, V112, P630, DOI 10.1177/000348940311200710; Higo R, 2003, EUR ARCH OTO-RHINO-L, V260, P124, DOI 10.1007/s00405-002-0527-1; Hiss SG, 2003, LARYNGOSCOPE, V113, P1386, DOI 10.1097/00005537-200308000-00023; HORNER J, 1991, ARCH NEUROL-CHICAGO, V48, P1170, DOI 10.1001/archneur.1991.00530230078026; HORNER J, 1988, NEUROLOGY, V38, P317, DOI 10.1212/WNL.38.2.317; Hudspeth MP, 2006, PEDIATRICS, V118, pE530, DOI 10.1542/peds.2006-0043; HUMPHREYS B, 1987, LARYNGOSCOPE, V97, P25; Keeling WB, 2007, ANN THORAC SURG, V83, P193, DOI 10.1016/j.athoracsur.2006.08.008; Kelly AM, 2006, CLIN OTOLARYNGOL, V31, P425, DOI 10.1111/j.1749-4486.2006.01292.x; Kelly AM, 2007, LARYNGOSCOPE, V117, P1723, DOI 10.1097/MLG.0b013e318123ee6a; Kendall KA, 2004, DYSPHAGIA, V19, P65, DOI 10.1007/s00455-003-0500-1; KIKUCHI R, 1994, AM J RESP CRIT CARE, V150, P251, DOI 10.1164/ajrccm.150.1.8025758; LANGMORE SE, 1991, ANN OTO RHINOL LARYN, V100, P678; Leder SB, 2000, DYSPHAGIA, V15, P201, DOI 10.1007/s004550000028; Leder SB, 2004, DYSPHAGIA, V19, P177, DOI 10.1007/s00455-004-0009-2; Leder SB, 2005, DYSPHAGIA, V20, P157, DOI 10.1007/s00455-005-0009-x; Leder SB, 2002, DYSPHAGIA, V17, P214, DOI 10.1007/s00455-002-0054-7; Leslie P, 2004, DYSPHAGIA, V19, P231, DOI 10.1007/s00455-004-0007-4; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; LOGEMANN JA, 1985, ANN OTO RHINOL LARYN, V94, P373; Mann G, 2000, CEREBROVASC DIS, V10, P380, DOI 10.1159/000016094; Marik PE, 2003, CHEST, V124, P328, DOI 10.1378/chest.124.1.328; MCCONNEL FMS, 1988, LARYNGOSCOPE, V98, P705; McCullough GH, 2005, J SPEECH LANG HEAR R, V48, P1280, DOI 10.1044/1092-4388(2005/089); McCullough GH, 2001, J COMMUN DISORD, V34, P55, DOI 10.1016/S0021-9924(00)00041-1; McGowan SL, 2007, NEUROCRIT CARE, V6, P90, DOI 10.1007/s12028-007-0024-x; Meyer KC, 2001, RESP PHYSIOL, V128, P23, DOI 10.1016/S0034-5687(01)00261-4; Miyazaki Y, 2002, YAKUGAKU ZASSHI, V122, P97, DOI 10.1248/yakushi.122.97; MUZ J, 1987, LARYNGOSCOPE, V97, P1180; Perlman PW, 2004, OTOLARYNG HEAD NECK, V130, P80, DOI 10.1016/j.otohns.2003.09.026; Perry L, 2001, DYSPHAGIA, V16, P7, DOI 10.1007/PL00021290; Ramsey D, 2005, DYSPHAGIA, V20, P218, DOI 10.1007/s00455-005-0018-9; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; Ravelli AM, 2006, CHEST, V130, P1520, DOI 10.1378/chest.130.5.1520; Rosenbek JC, 2004, J COMMUN DISORD, V37, P437, DOI 10.1016/j.jcomdis.2004.04.007; Rosenthal DI, 2006, J CLIN ONCOL, V24, P2636, DOI 10.1200/JCO.2006.06.0079; Schindler JS, 2002, LARYNGOSCOPE, V112, P589, DOI 10.1097/00005537-200204000-00001; SHAWKER TH, 1984, INVEST RADIOL, V19, P82, DOI 10.1097/00004424-198403000-00003; Simental Alfred A, 2004, Curr Oncol Rep, V6, P162, DOI 10.1007/s11912-004-0028-z; Siraj Q H, 2004, J Pak Med Assoc, V54, P219; Smith CH, 1999, DYSPHAGIA, V14, P1, DOI 10.1007/PL00009579; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; Svartengren M, 2005, EUR RESPIR J, V26, P609, DOI 10.1183/09031936.05.00002105; Tohara H, 2003, DYSPHAGIA, V18, P126, DOI 10.1007/s00455-002-0095-y; Trapl M, 2007, STROKE, V38, P2948, DOI 10.1161/STROKEAHA.107.483933; Wang TG, 2005, ARCH PHYS MED REHAB, V86, P730, DOI 10.1016/j.apmr.2004.10.021; Westergren A, 2006, INT NURS REV, V53, P143, DOI 10.1111/j.1466-7657.2006.00460.x; Yoshikawa M, 2005, J GERONTOL A-BIOL, V60, P506, DOI 10.1093/gerona/60.4.506; Zaugg M, 2000, Anesthesiol Clin North Am, V18, P47, DOI 10.1016/S0889-8537(05)70148-6	68	38	39	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	AUG	2009	41	4					178	185		10.1097/JNN.0b013e3181aaaade			8	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	516XM	WOS:000271576700002	19678503				2021-06-18	
J	Baki, SGA; Kao, HY; Kelemen, E; Fenton, AA; Bergold, PJ				Baki, Samah G. Abdel; Kao, Hsin-Yi; Kelemen, Eduard; Fenton, Andre A.; Bergold, Peter J.			A hierarchy of neurobehavioral tasks discriminates between mild and moderate brain injury in rats	BRAIN RESEARCH			English	Article						Controlled cortical impact; Injury severity; Active place avoidance; Perceptual segregation; Mnemonic segregation; Reversal learning	CONTROLLED CORTICAL IMPACT; BEHAVIORAL EVIDENCE; COGNITIVE DEFICITS; MICE; MEMORY; PLACE; NEURODEGENERATION; DISSOCIATION; NAVIGATION; AVOIDANCE	Behavioral analysis commonly assesses cognitive deficits in rodents following traumatic brain injury (TBI). We examined rats that received sham, mild or moderate injury in the controlled cortical impact model of TBI. The rats were tested in a novel hierarchy of four behavioral tasks with increasing cognitive demand. All three groups had similar performance on the first two phases of training: open field exploration and passive place avoidance using a stationary shock zone on a non-rotating arena. The similar performance on the first two tasks suggested comparable sensory, motor skills and contextual memory in all three groups. In phase three, rats were tested on active place avoidance, their ability to avoid a stationary shock zone on the rotating arena. Control and mildly-injured rats learned this task within four ten-minute trials while moderately-injured animals were impaired. Moderately-injured animals were also impaired if tested 3 weeks after injury. One day after phase three, sham- and mildly-injured animals were tested on a phase four conflict active avoidance task with the shock zone shifted 180 degrees from its phase three location and mildly-injured animals were impaired. The speed in which the animals complete the four phases of testing as well as the ability to discriminate between differing injury severity suggests that this set of neurobehavioral tasks will be useful to understand cognitive deficits underlying TBI as well as a useful screening method for therapeutic drugs. (C) 2009 Elsevier B.V. All rights reserved.	[Baki, Samah G. Abdel; Kao, Hsin-Yi; Kelemen, Eduard; Fenton, Andre A.; Bergold, Peter J.] Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA	Bergold, PJ (corresponding author), Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Box 29,450 Clarkson Ave, Brooklyn, NY 11203 USA.	pbergold@downstate.edu	Kelemen, Eduard/K-3649-2017	Fenton, Andre/0000-0002-5063-1156; Bergold, Peter/0000-0002-6335-1380	Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs	We thank Dr. Susanna Popp and Mr. Dino Dvorak for assistance in setting up the place avoidance apparatus. We thank Dr. Jennifer Libien and Ms. Lorraine Braithwaite-Harte for assistance with the histological analysis. This work was supported by Concept Award PT073028 to P.J.B. from the Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs.	Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bures J, 1997, PHILOS T ROY SOC B, V352, P1515, DOI 10.1098/rstb.1997.0138; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Cimadevilla JM, 2001, BRAIN RES BULL, V54, P559, DOI 10.1016/S0361-9230(01)00448-8; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fenton AA, 1998, P NATL ACAD SCI USA, V95, P11493, DOI 10.1073/pnas.95.19.11493; Fenton AA, 2003, NEUROBIOLOGY SPATIAL; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kubik S, 2005, J NEUROSCI, V25, P9205, DOI 10.1523/JNEUROSCI.1707-05.2005; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Mizumori SJ, 2008, HIPPOCAMPAL PLACE FI, P127; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serrano P, 2008, PLOS BIOL, V6, P2698, DOI 10.1371/journal.pbio.0060318; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wallace DG, 2002, BEHAV BRAIN RES, V131, P185, DOI 10.1016/S0166-4328(01)00384-9; Wesierska M, 2005, J NEUROSCI, V25, P2413, DOI 10.1523/JNEUROSCI.3962-04.2005	29	38	38	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 14	2009	1280						98	106		10.1016/j.brainres.2009.05.034			9	Neurosciences	Neurosciences & Neurology	469OS	WOS:000267909800012	19464271				2021-06-18	
J	Bernabeu, M; Laxe, S; Lopez, R; Stucki, G; Ward, A; Barnes, M; Kostanjsek, N; Reed, G; Tate, R; Whyte, J; Zasler, N; Cieza, A				Bernabeu, Montserrat; Laxe, Sara; Lopez, Raquel; Stucki, Gerold; Ward, Anthony; Barnes, Michael; Kostanjsek, Nenad; Reed, Geoffrey; Tate, Robyn; Whyte, John; Zasler, Nathan; Cieza, Alarcos			Developing Core Sets for Persons With Traumatic Brain Injury Based on the International Classification of Functioning, Disability, and Health	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						ICF Core Set; TBI, Neurorehabilitation; Head trauma	PATIENT-REPORTED OUTCOMES; QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; ICF; REHABILITATION; PROMIS	The authors outline the process for developing the International Classification of Functioning, Disability, and Health (ICF) Core Sets for traumatic brain injury (TBI). ICF Core Sets are selections of categories of the ICF that identify relevant categories of patients affected by specific diseases. Comprehensive and brief ICF Core Sets for TBI should become useful for clinical practice and for research. The final definition of the ICF Core Sets for TBI will be determined at an ICF Core Sets Consensus Conference, which will integrate evidence from preliminary studies. The development of ICF Core Sets is an inclusive and open process and rehabilitation professionals are invited to participate.	[Bernabeu, Montserrat; Laxe, Sara] Neurorehabil Hosp, Inst Guttmann, Brain Injury Unit, Barcelona 08196, Spain; [Lopez, Raquel] Neurorehabil Hosp, Inst Guttmann, Res Dept, Barcelona 08196, Spain; [Stucki, Gerold; Cieza, Alarcos] Univ Munich, Inst Hlth & Rehabil Sci, Munich, Germany; [Ward, Anthony] N Staffordshire Rehabil Ctr, Stoke On Trent, Staffs, England; [Barnes, Michael] Newcastle Univ, Hunters Moor Hosp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Kostanjsek, Nenad] WHO, CAS Classificat Assessment & Terminol Team, CH-1211 Geneva, Switzerland; [Reed, Geoffrey] WHO Projects & Int Union Psychol Sci, Madrid, Spain; [Tate, Robyn] Univ Sydney, No Clin Sch, Rehabil Studies Unit, Royal Rehabil Ctr Sydney, Ryde, NSW, Australia; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Zasler, Nathan] Int Brain Injury Assoc, Richmond, VA USA; [Zasler, Nathan] Concuss Care Ctr Virginia Ltd, Richmond, VA USA	Laxe, S (corresponding author), Neurorehabil Hosp, Inst Guttmann, Brain Injury Unit, Cami de Can Ruti S-N, Barcelona 08196, Spain.	slaxe@guttmann.com		Whyte, John/0000-0002-4381-1474			Aringer M, 2006, LUPUS, V15, P248, DOI 10.1191/0961203306lu2298xx; Biering-Sorensen F, 2006, SPINAL CORD, V44, P541, DOI 10.1038/sj.sc.3101918; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Brach M, 2004, J REHABIL MED, V36, P121, DOI 10.1080/16501960410016811; Brockow T, 2004, J REHABIL MED, V36, P30, DOI 10.1080/16501960410015371; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cieza A, 2004, J REHABIL MED, V36, P128, DOI 10.1080/16501960410016055; Cieza A, 2004, J REHABIL MED, V36, P69, DOI 10.1080/16501960410016037; Cieza A, 2004, J REHABIL MED, V36, P94, DOI 10.1080/16501960410016785; Cieza A, 2004, J REHABIL MED, V36, P81, DOI 10.1080/16501960410016028; Cieza A, 2004, J REHABIL MED, V36, P63, DOI 10.1080/16501960410016046; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; CIEZA AHR, CLIN J EPID IN PRESS; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Dreinhofer K, 2004, J REHABIL MED, V36, P75, DOI 10.1080/16501960410015498; Ewert T, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410015362; Fries JF, 2005, CLIN EXP RHEUMATOL, V23, pS53; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Geyh S, 2004, J REHABIL MED, V36, P56, DOI 10.1080/16501960410015399; Grill E, 2006, AM J PHYS MED REHAB, V85, P640, DOI 10.1097/01.phm.0000228537.17239.7f; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; IOM (Institute of Medicine), 2007, FUT DIS AM; Kesselring J, 2008, MULT SCLER J, V14, P252, DOI 10.1177/1352458507082615; Khan F, 2007, DISABIL REHABIL, V29, P205, DOI 10.1080/09638280600756141; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Ruof J, 2004, J REHABIL MED, V36, P100, DOI 10.1080/16501960410016802; Stucki A, 2004, J REHABIL MED, V36, P107, DOI 10.1080/16501960410016064; Stucki A, 2004, J REHABIL MED, V36, P114, DOI 10.1080/16501960410016794; Stucki G, 2004, J REHABIL MED, V36, P87, DOI 10.1080/16501960410015470; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; Stucki G, 2002, DISABIL REHABIL, V24, P281, DOI 10.1080/09638280110105222; Tschiesner U, 2007, EUR ARCH OTO-RHINO-L, V264, P1215, DOI 10.1007/s00405-007-0335-8; Ustun B, 2004, J REHABIL MED, V36, P7, DOI 10.1080/16501960410015344; van Echteld I, 2006, J RHEUMATOL, V33, P2475; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weigl M, 2004, J REHABIL MED, V36, P12, DOI 10.1080/16501960410015443; World Health Organization, INT CLASS FUNCT DIS	40	38	38	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2009	23	5					464	467		10.1177/1545968308328725			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	450JP	WOS:000266397100007	19221004	Green Accepted			2021-06-18	
J	Ponnuswamy, P; Ostermeier, E; Schrottle, A; Chen, J; Huang, PL; Ertl, G; Nieswandt, B; Kuhlencordt, PJ				Ponnuswamy, Padmapriya; Ostermeier, Eva; Schroettle, Angell; Chen, Jiqiu; Huang, Paul L.; Ertl, Georg; Nieswandt, Bernhard; Kuhlencordt, Peter J.			Oxidative Stress and Compartment of Gene Expression Determine Proatherosclerotic Effects of Inducible Nitric Oxide Synthase	AMERICAN JOURNAL OF PATHOLOGY			English	Article							VASCULAR SMOOTH-MUSCLE; E-DEFICIENT MICE; DIET-INDUCED ATHEROSCLEROSIS; TRAUMATIC BRAIN-INJURY; E-KNOCKOUT MICE; IN-VIVO; SUPEROXIDE GENERATION; NO-SYNTHASE; TETRAHYDROBIOPTERIN; 17-BETA-ESTRADIOL	Genetic and pharmacological inhibition of inducible nitric oxide synthase (iNOS) decreases atherosclerosis development. Potential proatherogenic effects of iNOS include iNOS mediated oxidative stress and iNOS expression in different cellular compartments. Lesional iNOS can potentially produce nitric oxide radicals (NO), superoxide radicals (O-2(-)), or both; these radicals may then react to form peroxynitrite. Alternatively, O-2(-) radicals from oxidases co-expressed with iNOS could react with NO to produce peroxynitrite. Therefore, the expression profiles of the genes that modulate the redox system in different iNOS-expressing cell compartments may determine the role of iNOS in atherosclerosis. We used apoE (apoE(-/-)) and apoE/iNOS double knockout (apoE(-/-)/iNOS(-/-)) mice to assess vascular NO, O-2(-), and peroxynitrite formation by electron spin resonance spectroscopy, high performance liquid chromatography, and 3-nitrotyrosine staining. The relevance of the iNOS expressing cell compartment was tested by bone marrow transplantation. We show that iNOS significantly contributes to vascular NO production and itself produces O-2(-), leading to peroxynitrite formation in atherosclerotic lesions. Our bone marrow transplantation experiments show that bone marrow derived cells exclusively mediate the proatherosclerotic effects of iNOS in mates, while both parenchymal and bone marrow derived iNOS equally contribute to atherosclerosis in females. Moreover, iNOS expression affects vascular remodeling. These findings establish for the first time that the proatherosclerotic effects of iNOS vary with sex in addition to the compartment of its expression. (Am J Pathol 2009, 174;2400-2410; DOI: 10.2353/ajpath.2009.080730)	[Kuhlencordt, Peter J.] Univ Munich, Med Poliklin, D-80336 Munich, Germany; [Chen, Jiqiu; Huang, Paul L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; [Nieswandt, Bernhard] Univ Wurzburg, Inst Clin Biochem & Pathobiochem, Wurzburg, Germany; [Ponnuswamy, Padmapriya; Ostermeier, Eva; Schroettle, Angell; Ertl, Georg] Univ Wurzburg, DFG Res Ctr Expt Biomed, Rudolf Virchow Ctr, Herz Kreislaufzentrum,Med Klin 1, Wurzburg, Germany	Kuhlencordt, PJ (corresponding author), Univ Munich, Med Poliklin, Pettenkoferstr 8A, D-80336 Munich, Germany.	peter.kuhlencordt@med.uni-muenchen.de		Huang, Paul/0000-0002-5436-8658	Deutsche-ForschungsgemeinschaftGerman Research Foundation (DFG) [KU-1206, 1206]; IZKF-Wurzburg; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033335] Funding Source: NIH RePORTER	Supported by grants from the Deutsche-Forschungsgemeinschaft (KU-1206(1) and 1206(2) and the IZKF-Wurzburg to P.K.	Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Behr-Roussel D, 2000, CIRCULATION, V102, P1033, DOI 10.1161/01.CIR.102.9.1033; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Binko J, 1998, AM J PHYSIOL-HEART C, V274, pH853; Bultinck J, 2006, FASEB J, V20, P2363, DOI 10.1096/fj.06-5798fje; Carr AC, 2000, ARTERIOSCL THROM VAS, V20, P1716, DOI 10.1161/01.ATV.20.7.1716; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; d'Uscio LV, 2001, ARTERIOSCL THROM VAS, V21, P1017, DOI 10.1161/01.ATV.21.6.1017; DARLEYUSMAR V, 1995, FEBS LETT, V369, P13; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Dikalova A, 2005, CIRCULATION, V112, P2668, DOI 10.1161/CIRCULATIONAHA.105.538934; Fink B, 2004, AM J PHYSIOL-CELL PH, V287, pC895, DOI 10.1152/ajpcell.00028.2004; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Giordano A, 2002, FEBS LETT, V514, P135, DOI 10.1016/S0014-5793(02)02245-7; Gunnett CA, 2001, ARTERIOSCL THROM VAS, V21, P1281, DOI 10.1161/hq0801.093509; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hattori Y, 2007, ARTERIOSCL THROM VAS, V27, P865, DOI 10.1161/01.ATV.0000258946.55438.0e; Hayashi T, 2006, ATHEROSCLEROSIS, V187, P316, DOI 10.1016/j.atherosclerosis.2005.10.023; Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje; Hickey MJ, 1997, FASEB J, V11, P955; HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014-5793(95)00124-R; Jones RJ, 2007, AM J PHYSIOL-HEART C, V292, pH2634, DOI 10.1152/ajpheart.01247.2006; Kauser K, 1998, BRIT J PHARMACOL, V123, P1089, DOI 10.1038/sj.bjp.0701715; Kleschyov AL, 2002, METHOD ENZYMOL, V359, P42; Koglin J, 1998, CIRCULATION, V97, P2059, DOI 10.1161/01.CIR.97.20.2059; Kolodziejska KE, 2005, P NATL ACAD SCI USA, V102, P4854, DOI 10.1073/pnas.0500485102; Koyuncu FM, 2006, HISTOL HISTOPATHOL, V21, P367, DOI 10.14670/HH-21.367; Kubes P, 2000, GUT, V47, P6, DOI 10.1136/gut.47.1.6; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Laursen JB, 2001, CIRCULATION, V103, P1282; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Mershon JL, 2002, AM J PHYSIOL-HEART C, V283, pH1169, DOI 10.1152/ajpheart.00397.2000; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; Navarro-Lerida I, 2004, J BIOL CHEM, V279, P55682, DOI 10.1074/jbc.M406621200; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215; Pan JM, 1996, BIOCHEM J, V314, P889, DOI 10.1042/bj3140889; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saini R, 2006, J LEUKOCYTE BIOL, V79, P519, DOI 10.1189/jlb.0605320; Shears LL, 1998, J AM COLL SURGEONS, V187, P295, DOI 10.1016/S1072-7515(98)00163-X; Stefano GB, 2000, CIRCULATION, V101, P1594, DOI 10.1161/01.CIR.101.13.1594; Upmacis RK, 2007, AM J PHYSIOL-HEART C, V293, pH2878, DOI 10.1152/ajpheart.01144.2006; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; XIA Y, 1997, P NATL ACAD SCI USA, V94, P6964; Zehntner SP, 2004, J NEUROIMMUNOL, V150, P70, DOI 10.1016/j.jneuroim.2004.01.020; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	55	38	40	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2009	174	6					2400	2410		10.2353/ajpath.2009.080730			11	Pathology	Pathology	449ZT	WOS:000266370600042	19465644	Green Published			2021-06-18	
J	Willemse-Van Son, AHP; Ribbers, GM; Hop, WCJ; Stam, HJ				Willemse-van Son, Agnes H. P.; Ribbers, Gerard M.; Hop, Wim C. J.; Stam, Henk J.			COMMUNITY INTEGRATION FOLLOWING MODERATE TO SEVERE TRAUMATIC BRAIN INJURY: A LONGITUDINAL INVESTIGATION	JOURNAL OF REHABILITATION MEDICINE			English	Article						prognosis; craniocerebral trauma; traumatic brain injury; community integration; participation	FUNCTIONAL ASSESSMENT MEASURE; ASSESSMENT MEASURE FIM+FAM; HEAD-INJURY; INTERRATER RELIABILITY; OUTCOMES; REHABILITATION; QUESTIONNAIRE; DISABILITY; PREDICTION; VARIABLES	Objective: To evaluate the course and identify determinants of community integration for up to 3 years following moderate to severe traumatic brain injury. Design: Prospective cohort study. Patients: A total of 119 patients with moderate to severe traumatic brain injury aged 16-67 years. Methods: The Community Integration Questionnaire was completed at 3, 6, 12, 18, 24 and 36 months post-injury. Repeated measures analysis of variance was performed to determine changes over time in the Community Integration Questionnaire and its subscales. Bivariate and multivariate regression analyses were used to identify determinants of community integration 36 months post-injury. Results: Compared with pre-injury, mean home integration, social integration, productivity, and total questionnaire scores decreased 3 months post-injury. Patient scores showed maximal improvement during the first year post-injury. Mean home integration, productivity, and total scores increased to a lesser extent during years 1-3 post-injury. Age, Barthel Index scores, hospital discharge destination, and pre-injury community integration scores were the major determinants of community integration 36 months post-injury (R-2 = 60%). Conclusion: After an initial decline, mean community integration scores gradually improve following moderate to severe traumatic brain injury. Understanding the course and determinants of community integration is necessary in order to determine functional prognosis following traumatic brain injury.	[Willemse-van Son, Agnes H. P.; Ribbers, Gerard M.; Stam, Henk J.] Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; [Willemse-van Son, Agnes H. P.; Ribbers, Gerard M.] Erasmus MC, Rijndam Rehabil Ctr, NL-3000 CA Rotterdam, Netherlands; [Hop, Wim C. J.] Erasmus MC, Dept Biostat, NL-3000 CA Rotterdam, Netherlands	Willemse-Van Son, AHP (corresponding author), Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanson-willemse@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; 	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	This study was performed as part of the "Long-term prognosis of functional outcome in neurological disorders", the Department of Rehabilitation Medicine, VU Medical Centre, Amsterdam, and supported by the Netherlands Organisation for Health Research and Development (project: 1435.0020).	Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Collin C, 1988, Int Disabil Stud, V10, P61; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Fleming J, 1999, BRAIN INJURY, V13, P417; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; World Health Organization, 2001, INT CLASS FUNCT DIS	41	38	38	0	12	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUN	2009	41	7					521	527		10.2340/16501977-0377			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	463HD	WOS:000267421100004	19543662	DOAJ Gold			2021-06-18	
J	Bruns, JJ; Jagoda, AS				Bruns, John J., Jr.; Jagoda, Andy S.			Mild Traumatic Brain Injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						brain-specific biomakers; computed tomography; mild brain injury; postconcussive symptoms; traumatic brain injury	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; S-100B; RELIABILITY; RULE; GUIDELINES; IMPACT	Mild traumatic brain injury accounts for 1% to 2% of emergency department visits in the United States. Up to 15% of these patients will have an acute intracranial lession identified on head compute d tomography lessthan 1% of mild traumatic brain will require neurosurgical intervention. Clinical research over the past decade has focussed on identifying the subgroup of patients with mild traumatic brain injury with acute traumatic lesions of computed tomography and specifically those at risk for harboring a potentially castrophic lesion. This research has been used to generate evidence-based guidelines to assit in clinical decision making. There is no evidence to support the use of plain film radiographs in the evaluation of patients with mild traumatic brain injury. The utility of brain-specific biomakers is rapidly evolving, and a growing body of evidence supports their potential role in determining the need for neuroimaging. Clinical predictors for identifying patients with abnormal computed tomography have been established and, if used, may have a significant positive impact on traumatic brain injury-related morbidity and with negative computed tomography are at almost counseled regarding postconcussive symptoms and should and referrals at discharge. Mt. Sinai J Med 76:129-137, 2009 (C) 2009 Mount Sinai School of Medicine	[Bruns, John J., Jr.; Jagoda, Andy S.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA	Bruns, JJ (corresponding author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.	john.bruns@mssm.edu					af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; AFGEIJERSTAM JL, 2006, BMJ-BRIT MED J, V333; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Bergman DA, 1999, PEDIATRICS, V104, P1407; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDCP, 2004, TRAUM BRAIN INJ US E; *CDCP, 2003, TBI REP C MILD TRAUM; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JAGODA A, 2008, ANN EMERG MED; JAGODA A, 2000, EMERGENCY MED CLIN N, P355; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; LEVITT MA, 1995, ACAD EMERG MED, V2, P675, DOI 10.1111/j.1553-2712.1995.tb03617.x; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIZOLI SB, 1994, ACCIDENT ANAL PREV, V26, P681, DOI 10.1016/0001-4575(94)90030-2; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	51	38	38	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					129	137		10.1002/msj.20101			9	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800006	19306376				2021-06-18	
J	Sena, MJ; Rivers, RM; Muizelaar, JP; Battistella, FD; Utter, GH				Sena, Matthew J.; Rivers, Ryan M.; Muizelaar, J. Paul; Battistella, Felix D.; Utter, Garth H.			Transfusion practices for acute traumatic brain injury: a survey of physicians at US trauma centers	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	36th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 18-21, 2007	Orlando, FL	Soc Critical Care Med		Anemia; Transfusion; Traumatic brain injury; Survey	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; CRITICALLY-ILL; OXYGENATION; ANEMIA; IMPACT; AGE; VASORESPONSIVITY; HEMODILUTION; MORTALITY	To determine whether physician specialty influences transfusion threshold in patients with acute severe traumatic brain injury (TBI). We surveyed transfusion preferences of chiefs of trauma surgery, chairs of neurosurgery, and surgical and neurosurgical ICU directors at all 187 US Level I trauma centers using a scenario-based, multiple-choice instrument administered by mail. We evaluated the hemoglobin value used as a transfusion threshold for patients with severe acute TBI in several scenarios as well as opinions regarding the rationale for transfusion. The response rate was 58% (312/534). Mean time in practice was 17 +/- A 8 years and 65% were board certified in critical care. Neurosurgeons (NS) used a greater mean hemoglobin threshold for transfusion of TBI patients than trauma surgeons (TS) and non-surgeon intensivists (CC) whether the intracranial pressure was normal (8.3 +/- A 1.2, 7.5 +/- A 1.0, and 7.5 +/- A 0.8 g/dL; NS, TS, and CC, respectively, P < 0.001) or elevated (8.9 +/- A 1.1, 8.0 +/- A 1.1, and 8.4 +/- A 1.1 g/dL; NS, TS, and CC, respectively, P < 0.001). All three groups commonly believed that secondary ischemic injury is an important problem following TBI (74, 66, and 63%, P = 0.32), but fewer NS believed that transfusions have important immunodulatory effects (25, 91, and 83%, P < 0.001). Neurosurgeons prefer more liberal transfusion of TBI patients than TS and CC, suggesting that actual practice may depend largely on which specialist is primarily managing care. The observed clinical equipoise would justify a randomized trial of liberal versus restrictive transfusion strategies in patients with TBI.	[Sena, Matthew J.; Rivers, Ryan M.; Battistella, Felix D.; Utter, Garth H.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA; [Muizelaar, J. Paul] Univ Calif Davis, Med Ctr, Dept Neurol Surg, Sacramento, CA 95817 USA	Sena, MJ (corresponding author), Univ Calif Davis, Med Ctr, Dept Surg, 2315 Stockton Blvd,Room 4206, Sacramento, CA 95817 USA.	matthew.sena@ucdmc.ucdavis.edu		Utter, Garth/0000-0001-7747-3429			*ACS, 2006, ACS SURG PRINC PRACT; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Claridge JA, 2002, AM SURGEON, V68, P566; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 2005, CRIT CARE MED, V33, P7, DOI 10.1097/01.CCM.0000151047.33912.A3; KRAUS J, 2005, EPIDEMIOLOGY TXB TRA, P3; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; LEE SH, 1994, J NEUROSURG, V80, P469, DOI 10.3171/jns.1994.80.3.0469; Longhi L, 2002, ACT NEUR S, V81, P315; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Peabody JW, 2004, ANN INTERN MED, V141, P771, DOI 10.7326/0003-4819-141-10-200411160-00008; Purdy FR, 1997, CAN J ANAESTH, V44, P1256, DOI 10.1007/BF03012772; Raghavan M, 2005, CHEST, V127, P295, DOI 10.1378/chest.127.1.295; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Reasoner DK, 1996, ANESTH ANALG, V82, P61, DOI 10.1097/00000539-199601000-00011; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Taylor RW, 2002, CRIT CARE MED, V30, P2249, DOI 10.1097/00003246-200210000-00012; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Weiskopf RB, 2000, ANESTHESIOLOGY, V92, P1646, DOI 10.1097/00000542-200006000-00023; Winn HR, 2004, YOUMANS NEUROLOGICAL; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	35	38	40	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2009	35	3					480	488		10.1007/s00134-008-1289-z			9	Critical Care Medicine	General & Internal Medicine	408FR	WOS:000263421400012	18854976				2021-06-18	
J	Kofler, M; Quirbach, E; Schauer, R; Singer, M; Saltuari, L				Kofler, Markus; Quirbach, Ellen; Schauer, Robert; Singer, Markus; Saltuari, Leopold			Limitations of Intrathecal Baclofen for Spastic Hemiparesis Following Stroke	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Intrathecal baclofen; Stroke; Gait; Spasticity	QUALITY-OF-LIFE; SPINAL ORIGIN; BRAIN INJURY; THERAPY; HEMIPLEGIA; HYPERTONIA; INFUSION; MANAGEMENT; OVERDOSE; BOLUS	Objective. Intrathecal baclofen (ITB) has become the first choice in the management of deleterious spasticity that does not respond to oral and intramuscular medications following spinal cord injury, traumatic brain injury, and cerebral palsy. The usefulness of ITB in severe spastic hemiparesis following stroke is studied. Methods. A total of 8 patients underwent clinical and video assessment following ITB bolus application (n = 5) and during continuous infusion via a temporary catheter system (n = 3). Results. The mean daily dosage alleviating spasticity on the hemiparetic side - without affecting the nonparetic side - was 119 mu g/day (range 50 to 360 mu g/day). However, 6 patients experienced functional deterioration as ITB weakened their paretic side such that the antigravity pattern they used for ambulation was suppressed. In 2 patients, spasticity-associated pain and spasms subsided and they underwent implantation of a long-term drug delivery system. Conclusions. ITB may reduce spasticity in a dose-dependent manner irrespective of its origin. Although not primarily antinociceptive in humans, ITB may alleviate pain if arising from increased muscle tone. A functional benefit may result if ITB can uncover "subclinical" motor control that had been suppressed by spasticity. However, when a patient uses antigravity patterns for ambulation in the absence of more complex motor control, ITB may cause the loss of residual walking ability, which becomes a major limitation for patients with hemiplegic stroke.	[Kofler, Markus; Quirbach, Ellen; Schauer, Robert; Singer, Markus; Saltuari, Leopold] Hosp Hochzirl, Dept Neurol, A-6170 Zirl, Austria	Kofler, M (corresponding author), Hosp Hochzirl, Dept Neurol, A-6170 Zirl, Austria.	markus.kofler@i-med.ac.at	Kofler, Markus/P-5585-2019	Kofler, Markus/0000-0002-2962-0903			Albright AL, 2007, DEV MED CHILD NEUROL, V49, P423, DOI 10.1111/j.1469-8749.2007.00423.x; Albright AL, 1996, J CHILD NEUROL, V11, P77, DOI 10.1177/088307389601100202; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DELHAAS EM, 1991, INT J CLIN PHARM TH, V29, P274; Dones I, 2006, NEUROMODULATION, V9, P87, DOI 10.1111/j.1525-1403.2006.00052.x; FAIGLE JW, 1972, POSTGRAD MED J, V48, P9; Francisco GE, 2003, ARCH PHYS MED REHAB, V84, P1194, DOI 10.1016/S0003-9993(03)00134-5; Francisco GE, 2001, STROKE, V32, P2108; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; *GUAR BRAIN, 1986, AIDS EX PER NERV SYS, P1; HERMAN RM, 1992, CLIN J PAIN, V8, P338, DOI 10.1097/00002508-199212000-00008; Hosny Amr, 2004, Pain Physician, V7, P345; Ivanhoe CB, 2006, ARCH PHYS MED REHAB, V87, P1509, DOI 10.1016/j.apmr.2006.08.323; Kofler M, 2002, BRAIN INJURY, V16, P825, DOI 10.1080/02699050210128898; KOFLER M, 1994, NEUROLOGY, V44, P25, DOI 10.1212/WNL.44.1.25; Lord SE, 1998, CLIN REHABIL, V12, P107, DOI 10.1191/026921598666182531; MATZAK H, 2002, NEUROREHAB NEURAL RE, P16; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; McCall TD, 2006, NEUROSURGERY, V59, P634, DOI 10.1227/01.NEU.0000227570.40402.77; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; OBrien CF, 1996, DRUG AGING, V9, P332, DOI 10.2165/00002512-199609050-00004; PENN RD, 1985, LANCET, V2, P125; Remy-Neris O, 2003, ARCH PHYS MED REHAB, V84, P643, DOI 10.1016/S0003-9993(02)04906-7; Sadiq SA, 2006, J NEUROL, V253, P563, DOI 10.1007/s00415-005-0060-4; SALTUARI L, 1990, NEW ENGL J MED, V322, P1533; Saltuari L, 1992, Acta Neurol (Napoli), V14, P195; SALTUARI L, 1992, LANCET, V339, P373, DOI 10.1016/0140-6736(92)91697-7; Sampson FC, 2002, J NEUROSURG, V96, P1052, DOI 10.3171/jns.2002.96.6.1052; STEERS WD, 1992, J UROLOGY, V148, P1849, DOI 10.1016/S0022-5347(17)37048-9; Taira T, 1995, STEREOT FUNCT NEUROS, V65, P101, DOI 10.1159/000098905; YOUNG RR, 1981, NEW ENGL J MED, V304, P96; Zahavi A, 2004, J NEUROL NEUROSUR PS, V75, P1553, DOI 10.1136/jnnp.2003.014282	36	38	38	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN	2009	23	1					26	31		10.1177/1545968308317700			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	388BU	WOS:000261996100004	18796543	Green Published			2021-06-18	
J	Silverberg, ND; Millis, SR				Silverberg, Noah D.; Millis, Scott R.			Impairment versus deficiency in neuropsychological assessment: Implications for ecological validity	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychological tests; Psychometrics; Activities of daily living; Work; Brain injury; Chronic; Cognition disorders	TRAUMATIC BRAIN-INJURY; GLASGOW OUTCOME SCALE; CLINICAL-NEUROPSYCHOLOGY; RATING-SCALE; TEST-SCORES; ABILITY; SENSITIVITY; POPULATION; INSTRUMENTS; DISABILITY	Neuropsychological test interpretation has relied on pre- and postmorbid comparisons, as exemplified by the use of demographically adjusted normative data. We argue that, when the assessment goal is to predict real-world functioning, this interpretive method Should be Supplemented by "absolute" scores. Such scores are derived from comparisons with the general healthy adult population (i.e., demographically unadjusted normative data) and reflect examinees' current ability, that is, the interaction between premorbid and injury/disease-related factors. In support of this view, we found that Substantial discrepancies between demographically adjusted and absolute scores were common in a traumatic brain injury sample, especially in participants with certain demographic profiles. Absolute scores predicted selected measures of functional Outcome better than demographically adjusted scores and also classified participants' functional status more accurately, to the extent that these scores diverged. In conclusion, the ecological validity of neuropsychological tests may be improved by the consideration of absolute scores. (JINS, 2009, 15, 94-102.)	[Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA	Silverberg, ND (corresponding author), GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca			US Department of Education-National Institute of Disability Research and RehabilitationUS Department of Education; Traumatic Brain Injury Model Systems Project [H133A020515-04]	The authors thank Robert Kotasek and Dr. Robin Hanks for their assistance in preparing the dataset. This Study was supported by a grant from the US Department of Education-National Institute of Disability Research and Rehabilitation - The Traumatic Brain Injury Model Systems Project (H133A020515-04). There were no other funding sources and no perceived conflicts of interest.	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Crowe SF, 2004, ARCH CLIN NEUROPSYCH, V19, P673, DOI 10.1016/j.acn.2003.09.002; DELIS DC, 2000, CALIFORNIA VERBAL LE; DIJKERS M, 2007, BRAIN INJURY MED PRI; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Guilmette TJ, 2008, CLIN NEUROPSYCHOL, V22, P122, DOI 10.1080/13854040601064559; Hallam B. J., 2007, AM J ALZHEIMERS DIS, V22, P456; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hammersley M, 2004, STUD EDUC ETHNOG, V9, P25; Hardin JW, 2007, GEN LINEAR MODEL EXT; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R K., 2004, COMPREHENSIVE NORMS; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Ivnik RJ, 2005, CLIN NEUROPSYCHOL, V19, P159, DOI 10.1080/13854040590945247; Lange RT, 2006, CLIN NEUROPSYCHOL, V20, P382, DOI 10.1080/13854040590967586; Lange RT, 2005, CLIN NEUROPSYCHOL, V19, P73, DOI 10.1080/13854040490888549; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEWIS R, 1979, MANNAL REPEATABLE CO; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Manly JJ, 2007, ARCH CLIN NEUROPSYCH, V22, P319, DOI 10.1016/j.acn.2007.01.006; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Mitrushina M., 2005, HDB NORMATIVE DATA N; Peterson DB, 2005, REHABIL PSYCHOL, V50, P105, DOI 10.1037/0090-5550.50.2.105; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; Reitan RM, 2005, APPL NEUROPSYCHOL, V12, P181, DOI 10.1207/s15324826an1204_1; SBORDONE RJ, 1999, FORENSIC NEUROPSYCHO; Schretlen DJ, 2005, J INT NEUROPSYCH SOC, V11, P784, DOI 10.1017/S1355617705050939; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Steinberg B, 2005, CLIN NEUROPSYCHOL, V19, P277, DOI 10.1080/13854040590948992; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; TESTA A, 2007, 35 ANN M INT NEUR SO; Tuokko H, 2003, AGING MENT HEALTH, V7, P259, DOI 10.1080/1360786031000120750; Tuokko H, 1996, J CLIN EXP NEUROPSYC, V18, P479, DOI 10.1080/01688639608405871; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WHITENECK G, 1997, ASSESSING MED REHABI; Williams JM, 1997, ARCH CLIN NEUROPSYCH, V12, P745, DOI 10.1016/S0887-6177(97)00048-6; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yantz CL, 2006, ARCH CLIN NEUROPSYCH, V21, P809, DOI 10.1016/j.acn.2006.09.001	47	38	38	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					94	102		10.1017/S1355617708090139			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300010	19128532				2021-06-18	
J	Zetterberg, H; Tanriverdi, F; Unluhizarci, K; Selcuklu, A; Kelestimur, F; Blennow, K				Zetterberg, Henrik; Tanriverdi, Fatih; Unluhizarci, Kursad; Selcuklu, Ahmet; Kelestimur, Fahrettin; Blennow, Kaj			Sustained release of neuron-specific enolase to serum in amateur boxers	BRAIN INJURY			English	Article						Boxing; biomarkers; neuron-specific enolase; brain injury	TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; ACID-BINDING PROTEINS; NEUROBIOCHEMICAL MARKERS; BIOCHEMICAL MARKERS; CEREBROSPINAL-FLUID; DAMAGE; CHILDREN; BIOMARKERS; MANAGEMENT	Primary objective: We assess the potential of a panel of serum biomarkers to identify chronic neuronal injury in amateur boxers as compared to healthy controls without any history of head trauma. Research design: Observational case-control study. Methods and procedures: A panel of serum biomarkers was measured by a novel biochip array technique on the Evidence Investigator. Serum samples were taken after a 2-month period of nonparticipation in boxing. Main outcomes and results: Boxers had higher serum levels of neuron-specific enolase (NSE, median [range] 11 [2.3-41] ng/mL) than controls (4.8 [0.78-27] ng/mL, p = 0.014) but unchanged levels of the other brain damage biomarker candidates, S-100B, brain-derived neurotrophic factor and heart-type fatty acid binding protein. Conclusions: The more than doubled median serum level of NSE in boxers after an extended resting period suggests that repetitive head trauma results in sustained release of this brain-specific protein to the peripheral circulation.	[Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden; [Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, Kayseri, Turkey; [Selcuklu, Ahmet] Erciyes Univ, Sch Med, Dept Neurosurg, Kayseri, Turkey	Zetterberg, H (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden.	henrik.zetterberg@gu.se			Scientific and Technical Research Council of TurkeyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Swedish Research CouncilSwedish Research CouncilEuropean Commission; Sahlgrenska University Hospital	We thank all study participants and Rita Persson for technical assistance. This study was funded by the Scientific and Technical Research Council of Turkey, the Swedish Research Council and the Sahlgrenska University Hospital.	Auer Johann, 2006, CJEM, V8, P13; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Canadas A., 2006, Journal of Cetacean Research and Management, V8, P13; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; FitzGerald SP, 2005, CLIN CHEM, V51, P1165, DOI 10.1373/clinchem.2005.049429; Grubb NR, 2007, HEART, V93, P1268, DOI 10.1136/hrt.2006.091314; Guleria S, 2008, J NEUROSCI RES, V86, P2271, DOI 10.1002/jnr.21664; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kemp P L, 1995, J R Nav Med Serv, V81, P182; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; McKeating EG, 1998, ACT NEUR S, V71, P117; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Selakovic V, 2005, J CLIN NEUROSCI, V12, P542, DOI 10.1016/j.jocn.2004.07.019; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Wunderlich MT, 2005, J NEUROL, V252, P718, DOI 10.1007/s00415-005-0725-z; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	30	38	38	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	9					723	726	PII 913450247	10.1080/02699050903120399			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	475UR	WOS:000268387600003	19636997				2021-06-18	
J	Cartagena, CM; Ahmed, F; Burns, MP; Pajoohesh-Ganji, A; Pak, DT; Faden, AI; Rebeck, GW				Cartagena, Casandra M.; Ahmed, Farid; Burns, Mark P.; Pajoohesh-Ganji, Ahdeah; Pak, Daniel T.; Faden, Alan I.; Rebeck, G. William			Cortical Injury Increases Cholesterol 24S Hydroxylase (Cyp46) Levels in the Rat Brain	JOURNAL OF NEUROTRAUMA			English	Article						glia cell response to injury; neurodegenerative disorders; traumatic brain injury	LIVER-X-RECEPTOR; DENSITY-LIPOPROTEIN-CHOLESTEROL; E-BASED PEPTIDE; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; IN-VITRO; CEREBROSPINAL-FLUID; GENE-EXPRESSION; NERVOUS-SYSTEM; HEAD-INJURY	In traumatic brain injury (TBI), cellular loss from initial impact as well as secondary neurodegeneration leads to increased cholesterol and lipid debris at the site of injury. Cholesterol accumulation in the periphery can trigger inflammatory mechanisms while cholesterol clearance may be anti-inflammatory. Here we investigated whether TBI altered the regulation of cholesterol 24S-hydroxylase (Cyp46), an enzyme that converts cholesterol to the more hydrophilic 24S-hydroxycholesterol. We examined by Western blot and immunohistochemistry changes in Cyp46 expression following fluid percussion injury. Under normal conditions, most Cyp46 was present in neurons, with very little measurable in glia. Cyp46 levels were significantly increased at 7 days post-injury, and cell type specific analysis at 3 days post-injury showed a significant increase in levels of Cyp46 (84%) in microglia. Since 24-hydroxycholesterol induces activation of genes through the liver X receptor (LXR), we examined protein levels of ATP-binding cassette transporter A1 and apolipoprotein E, two LXR regulated cholesterol homeostasis proteins. Apolipoprotein E and ATP-binding cassette transporter A1 were increased at 7 days post-injury, indicating that increased LXR activity coincided with increased Cyp46 levels. We found that activation of primary rat microglia by LPS in vitro caused increased Cyp46 levels. These data suggest that increased microglial Cyp46 activity is part of a system for removal of damaged cell membranes post-injury, by conversion of cholesterol to 24-hydroxycholesterol and by activation of LXR-regulated gene transcription.	[Cartagena, Casandra M.; Ahmed, Farid; Burns, Mark P.; Pajoohesh-Ganji, Ahdeah; Faden, Alan I.; Rebeck, G. William] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; [Pak, Daniel T.] Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA	Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	gwr2@georgetown.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Pajoohesh-Ganji, Ahdeah/0000-0002-1542-029X; Burns, Mark P/0000-0003-4750-2000	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AG14473, F31-AG025676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F31AG025676, R01AG014473] Funding Source: NIH RePORTER	We thank Dr. Suzana Petanceska for providing the anti-Cyp46 antibody and Dr. David Russell for providing the Cyp46 cDNA and CYP46 knock-out brain tissue. This research was supported by the National Institutes of Health (R01-AG14473, F31-AG025676).	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alexandrov P, 2005, NEUROREPORT, V16, P909, DOI 10.1097/00001756-200506210-00007; Ansell Benjamin J, 2007, Curr Atheroscler Rep, V9, P57, DOI 10.1007/BF02693941; Bar-On P, 2008, J NEUROCHEM, V105, P1656, DOI 10.1111/j.1471-4159.2008.05254.x; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Bonotis K, 2008, J NEUROIMMUNOL, V193, P183, DOI 10.1016/j.jneuroim.2007.10.020; Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Gasparovic C, 2001, NEUROSCI LETT, V301, P87, DOI 10.1016/S0304-3940(01)01616-0; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; Hansson GK, 2006, ANNU REV PATHOL-MECH, V1, P297, DOI 10.1146/annurev.pathol.1.110304.100100; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Kamada H, 2003, NEUROSCI RES, V45, P91, DOI 10.1016/S0168-0102(02)00203-1; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kim HJ, 2008, P NATL ACAD SCI USA, V105, P2094, DOI 10.1073/pnas.0711599105; Langley B, 2004, J NEUROSCI RES, V77, P621, DOI 10.1002/jnr.20210; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; McGeer PL, 2008, MOVEMENT DISORD, V23, P474, DOI 10.1002/mds.21751; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Navab Mohamad, 2007, Curr Atheroscler Rep, V9, P244, DOI 10.1007/s11883-007-0026-3; *NINDS, 2002, NIH PUBL; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605; Rebeck GW, 2004, NEUROBIOL LIPIDS, V3, P1; Reynolds AD, 2008, J NEUROCHEM, V104, P1504, DOI 10.1111/j.1471-4159.2007.05087.x; Rojo LE, 2008, ARCH MED RES, V39, P1, DOI 10.1016/j.arcmed.2007.10.001; Sanossian N, 2007, STROKE, V38, P1104, DOI 10.1161/01.STR.0000258347.19449.0F; Stannard AK, 2001, J BIOL CHEM, V276, P46011, DOI 10.1074/jbc.M104812200; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Teunissen CE, 2007, J NEUROSCI RES, V85, P1499, DOI 10.1002/jnr.21266; Turley SD, 1996, J LIPID RES, V37, P1953; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099; Walcher D, 2006, ARTERIOSCL THROM VAS, V26, P1022, DOI 10.1161/01.ATV.0000210278.67076.8f; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Z, 2008, NEUROPATH APPL NEURO, V34, P330, DOI 10.1111/j.1365-2990.2007.00893.x	63	38	38	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1087	1098		10.1089/neu.2007.0444			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900005	18729719	Green Published, Green Accepted			2021-06-18	
J	Neumann, JO; Chambers, IR; Citerio, G; Enblad, P; Gregson, BA; Howells, T; Mattern, J; Nilsson, P; Piper, I; Ragauskas, A; Sahuquillo, J; Yau, YH; Kiening, K				Neumann, J. -O.; Chambers, I. R.; Citerio, G.; Enblad, P.; Gregson, B. A.; Howells, T.; Mattern, J.; Nilsson, P.; Piper, I.; Ragauskas, A.; Sahuquillo, J.; Yau, Y. H.; Kiening, K.		BrainIT Grp	The use of hyperventilation therapy after traumatic brain injury in Europe: an analysis of the BrainIT database	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; hyperventilation	CEREBRAL-BLOOD-FLOW; HEAD-INJURY; MANAGEMENT; METABOLISM; OXYGENATION; ISCHEMIA	Objective: To assess the use of hyperventilation and the adherence to Brain Trauma Foundation-Guidelines (BTF-G) after traumatic brain injury (TBI). Setting: Twenty-two European centers are participating in the BrainIT initiative. Design: Retrospective analysis of monitoring data. Patients and participants: One hundred and fifty-one patients with a known time of trauma and at least one recorded arterial blood-gas (ABG) analysis. Measurements and results: A total number of 7,703 ABGs, representing 2,269 ventilation episodes (VE) were included in the analysis. Related minute-by-minute ICP data were taken from a 30 min time window around each ABG collection. Data are given as mean with standard deviation. (1) Patients without elevated intracranial pressure (ICP) (< 20 mmHg) manifested a statistically significant higher PaCO2 (36 +/- 5.7 mmHg) in comparison to patients with elevated ICP (< 20 mmHg; PaCO2: 34 +/- 5.4 mmHg, P < 0.001). (2) Intensified forced hyperventilation (PaCO2 <= 25 mmHg) in the absence of elevated ICP was found in only 49 VE (2%). (3) Early prophylactic hyperventilation (< 24 h after TBI; PaCO2 <= 35 mmHg, ICP < 20 mmHg) was used in 1,224 VE (54%). (4) During forced hyperventilation (PaCO2 <= 30 mmHg), simultaneous monitoring of brain tissue pO(2) or SjvO2 was used in only 204 VE (9%). Conclusion: While overall adherence to current BTF-G seems to be the rule, its recommendations on early prophylactic hyperventilation as well as the use of additional cerebral oxygenation monitoring during forced hyperventilation are not followed in this sample of European TBI centers. Descriptor: Neurotrauma.	[Neumann, J. -O.; Mattern, J.; Kiening, K.] Univ Klinikum Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany; [Chambers, I. R.] James Cook Univ Hosp, Dept Reg Med Phys, Middlesbrough, Cleveland, England; [Citerio, G.] Hosp San Gerardo, NeuroICU, Dept Perioperat Med & Intens Care, Monza, Italy; [Enblad, P.; Howells, T.; Nilsson, P.] Univ Uppsala Hosp, Dept Clin Neurosci, Neurosurg Sect, Uppsala, Sweden; [Gregson, B. A.] Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Piper, I.] So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; [Ragauskas, A.] Kaunas Univ Technol, Telemat Sci Lab, Kaunas, Lithuania; [Sahuquillo, J.] Vall Hebron Univ Hosp, Neurotraumatol Res Unit, Dept Neurosurg, Barcelona, Spain; [Yau, Y. H.] Western Gen Hosp, Dept Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland	Neumann, JO (corresponding author), Univ Klinikum Heidelberg, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Jan-Oliver.Neumann@med.uni-heidelberg.de	Ragauskas, Art/J-7486-2016; Citerio, Giuseppe/B-1839-2015; Sahuquillo, Juan/B-3577-2008	Ragauskas, Art/0000-0002-3536-554X; Citerio, Giuseppe/0000-0002-5374-3161; Sahuquillo, Juan/0000-0003-0713-5875; Gregson, Barbara/0000-0003-4868-9137			Barnes J, 2005, ACT NEUR S, V95, P39; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK MR, 2007, J NEUROTRAUMA S1, V24, pS87; BULLOCK MR, 2000, J NEUROTRAUM, V17, P513; Chambers IR, 2006, ACTA NEUROCHIR SUPPL, V96, P7; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; Kerr ME, 1996, CRIT CARE MED, V24, P785, DOI 10.1097/00003246-199605000-00010; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Oertel M, 2002, ACT NEUR S, V81, P71; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x	22	38	42	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	SEP	2008	34	9					1676	1682		10.1007/s00134-008-1123-7			7	Critical Care Medicine	General & Internal Medicine	339FF	WOS:000258562800019	18449528				2021-06-18	
J	Glang, A; Ylvisaker, M; Stein, M; Ehlhardt, L; Todis, B; Tyler, J				Glang, Ann; Ylvisaker, Mark; Stein, Marcy; Ehlhardt, Laurie; Todis, Bonnie; Tyler, Janet			Validated instructional practices: Application to students with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognitive strategy intervention; Direct Instruction; education; instructional methodologies; interventions	COGNITIVE REHABILITATION; YOUNG-CHILDREN; SHORT-TERM; LEARNING-DISABILITIES; BEHAVIORAL SUPPORTS; EXECUTIVE FUNCTIONS; HEAD-INJURY; MEMORY; METAANALYSIS; TBI	Objective: There is a lack of empirical evidence of effectiveness for instructional interventions for children with traumatic brain injury (TBI). This article addresses this issue by providing an in-depth examination of instructional methodologies validated with other populations of students (with and without disability) and their potential for teaching children with TBI. Design: Literature review. Conclusions: Two instructional approaches-Direct Instruction and cognitive strategy intervention-have significant evidence supporting their use with many populations of children, with and without disabilities, and address many of the common needs and learning characteristics of students with TBI, thus showing particular promise for these students. Given the efficacy of these 2 approaches with students with similar learning and behavioral characteristics, the authors recommend establishing and funding a systematic research agenda to test their effectiveness with students with TBI.	[Glang, Ann; Ehlhardt, Laurie; Todis, Bonnie] Western Oregon Univ, Teaching Res Inst, Eugene, OR 97401 USA; [Glang, Ann] Oregon Ctr Appl Sci, Eugene, OR USA; [Ylvisaker, Mark] Coll St Rose, Albany, NY USA; [Stein, Marcy] Univ Washington, Tacoma, WA USA; [Tyler, Janet] Univ Kansas, Med Ctr, Kansas Instruct Support Network, Kansas City, KS 66103 USA	Glang, A (corresponding author), Western Oregon Univ, Teaching Res Inst, 99 W 10th Ave,Suite370, Eugene, OR 97401 USA.	glanga@wou.edu					Adams G. L., 1996, RES DIRECT INSTRUCTI; Albin RW, 1988, GENERALIZATION MAINT, P99; Arroyos-Jurado E., 2006, EXCEPTIONALITY, V14, P125; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Baker S., 2002, LEARNING DISABILITIE, V17, P65, DOI DOI 10.1111/1540-5826.00032; BECKER WC, 1982, AM EDUC RES J, V19, P75; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; BULGREN C, 2006, TEACHING ADOLESCENTS, P79; Burgess PW, 1996, MEMORY, V4, P359, DOI 10.1080/096582196388906; Camine D., 1990, DIRECT INSTRUCTION R; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CARNINE D, 1980, J EDUC RES, V74, P106, DOI 10.1080/00220671.1980.10885292; CARNINE D, 1990, DIRECT INSTRUCTION R; CARNINE DW, 1982, J READING BEHAV, V14, P335, DOI 10.1080/10862968209547459; CARNINE DW, 1976, J APPL BEHAV ANAL, V9, P199, DOI 10.1901/jaba.1976.9-199; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COLVIN G, 1988, EDUC TREAT CHILD, V11, P341; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; ENGELMANN S, 1981, CORRECTIVE MATH; ENGLERT CS, 1984, REM SPEC EDUC, V5, P38, DOI DOI 10.1177/074193258400500208; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Feeney T, 2006, BRAIN INJURY, V20, P629, DOI 10.1080/02699050600744194; Feeney TJ, 2008, J POSIT BEHAV INTERV, V10, P115, DOI 10.1177/1098300707312540; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; GERSTEN R, 1982, EDUC EVAL POLICY AN, V4, P67; GERSTEN RM, 1982, ANAL INTERVEN DEVEL, V2, P305, DOI 10.1016/0270-4684(82)90026-X; GERSTEN RM, 1984, EDUC EVAL POLICY AN, V6, P109, DOI DOI 10.3102/01623737006002109; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GRAFMAN J, 2000, PRINCIPLES FRONTAL L, P292; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Graham S., 1996, MAKING WRITING PROCE; Graham S., 2003, HDB LEARNING DISABIL, P323; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; HORNER RH, 1987, RES DEV DISABIL, V8, P229, DOI 10.1016/0891-4222(87)90006-0; Horner RH., 1986, ED LEARNERS SEVERE H, P289; HORNER RH, 1986, J ASSOC PERS SEVERE, V4, P300; Kameenui E. J., 1990, DESIGNING INSTRUCTIO; Kennedy M., 1978, ED RES, V7, P3; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; KRYZANOWSKI J, 1980, J READING BEHAV, V12, P225, DOI 10.1080/10862968009547373; KULIK CLC, 1990, REV EDUC RES, V60, P265, DOI 10.2307/1170612; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; MADIGAN KA, 1997, EFFECTIVE ASSESSMENT; MARCHANDMARTELL.NE, 2006, J DIRECT INSTRUCTION, V6, P49; Mozzoni MP, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199602000-00003; National Reading Panel, 2000, TEACH CHILDR READ EV; Nesbit JC, 2006, REV EDUC RES, V76, P413, DOI 10.3102/00346543076003413; Paine SC, 1982, EDUC TREAT CHILD, V5, P93; Parsons J. L., 2004, J DIRECT INSTRUCTION, V4, P95; Perkins DN, 1997, AM PSYCHOL, V52, P1125; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; SCHWARTZ MF, 1993, J HEAD TRAUMA REHAB, V8, P59, DOI DOI 10.1097/00001199-199303000-00007; Shippen ME, 2005, REM SPEC EDUC, V26, P175, DOI 10.1177/07419325050260030501; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; STEBBINS LB, 1977, ED EXPT PLANNED VA A, V4; Stein M., 2006, DESIGNING EFFECTIVE; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Swanson HL, 2001, FOCUS EXCEPT CHILD, V34, P1; Swanson HL, 1998, REV EDUC RES, V68, P277, DOI 10.2307/1170599; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Thiemann KS, 2004, J SPEECH LANG HEAR R, V47, P126, DOI 10.1044/1092-4388(2004/012); Todis B., 1997, STUDENTS ACQUIRED BR, P33; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; Walker B., 2006, J DIRECT INSTRUCTION, V6, P35; WALKER HM, 1983, ANAL INTERVEN DEVEL, V3, P105, DOI 10.1016/0270-4684(83)90029-0; Watkins C. L., 2004, INTRO DIRECT INSTRUC, P28, DOI DOI 10.1080/10573560490264125; Watkins C. L, 1997, PROJECT FOLLOW CASE; WEEKS M, 1981, J APPL BEHAV ANAL, V14, P449, DOI 10.1901/jaba.1981.14-449; White W. A. T., 1988, EDUC TREAT CHILD, V11, P364, DOI [10.1177/105345129803300401, DOI 10.1177/1053451298033004O1]; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wittrock, 1986, HDB RES TEACHING, P376; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181	90	38	38	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					243	251		10.1097/01.HTR.0000327256.46504.9f			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900006	18650768				2021-06-18	
J	Nguyen, HX; Galvan, MD; Anderson, AJ				Nguyen, Hal X.; Galvan, Manuel D.; Anderson, Aileen J.			Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CENTRAL-NERVOUS-SYSTEM; C5A RECEPTOR; REGULATORY PROTEINS; ALZHEIMERS-DISEASE; ANAPHYLATOXIN C3A; MEMBRANE ATTACK; SLICE CULTURES; CELL-DEATH; EXPRESSION; COMPONENT	Background: The complement system has been suggested to affect injury or disease of the central nervous system (CNS) by regulating numerous physiological events and pathways. The activation of complement following traumatic CNS injury can also result in the formation and deposition of C5b-9 membrane attack complex (C5b-9/MAC), causing cell lysis or sublytic effects on vital CNS cells. Although complement proteins derived from serum/blood-brain barrier breakdown can contribute to injury or disease, infiltrating immune cells may represent an important local source of complement after injury. As the first immune cells to infiltrate the CNS within hours post-injury, polymorphonuclear leukocytes (PMNs) may affect injury through mechanisms associated with complement-mediated events. However, the expression/association of both early and terminal complement proteins by PMNs has not been fully characterized in vitro, and has not observed previously in vivo after traumatic spinal cord injury (SCI). Method: We investigated the expression of complement mRNAs using rt-PCR and the presence of complement proteins associated with PMNs using immunofluroescence and quantitative flow cytometry. Results: Stimulated or unstimulated PMNs expressed mRNAs encoding for C1q, C3, and C4, but not C5, C6, C7 or C9 in culture. Complement protein C1q or C3 was also detected in less than 30% of cultured PMNs. In contrast, over 70% of PMNs that infiltrated the injured spinal cord were associated with C1q, C3, C7 and C5b-9/MAC 3 days post-SCI. The localization/association of C7 or C5b-9/MAC with infiltrating PMNs in the injured spinal cord suggests the incorporation or internalization of C7 or C5b-9/MAC bound cellular debris by infiltrating PMNs because C7 and C5b-9/MAC were mostly localized to granular vesicles within PMNs at the spinal cord epicenter region. Furthermore, PMN presence in the injured spinal cord was observed for many weeks post-SCI, suggesting that this infiltrating cell population could chronically affect complement-mediated events and SCI pathogenesis after trauma. Conclusion: Data presented here provide the first characterization of early and terminal complement proteins associated with PMNs in vitro and in vivo after SCI. Data also suggest a role for PMNs in the local internalization or deliverance of complement and complement activation in the post-SCI environment.	[Nguyen, Hal X.; Anderson, Aileen J.] Univ Calif Irvine, Irvine, CA 92697 USA; [Nguyen, Hal X.] Univ Calif Irvine, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA 92697 USA; [Anderson, Aileen J.] Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA	Anderson, AJ (corresponding author), Univ Calif Irvine, 1105 Gillespie Neurosci Res Facil, Irvine, CA 92697 USA.	hnguyen@uci.edu; mgalvan@uci.edu; aja@uci.edu	Anderson, Aileen J/H-5926-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043428] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS043428, R01 NS43428-01] Funding Source: Medline		Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; Anderson AJ, 2004, J NEUROTRAUM, V21, P1831, DOI 10.1089/0897715042664894; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Bagamery K, 2005, CYTOM PART A, V65A, P84, DOI 10.1002/cyto.a.20133; BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200; Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; BOTTO M, 1992, J IMMUNOL, V149, P1348; Danet GH, 2002, P NATL ACAD SCI USA, V99, P10441, DOI 10.1073/pnas.162104799; Duce JA, 2006, NEUROBIOL AGING, V27, P633, DOI 10.1016/j.neurobiolaging.2005.03.027; Fan R, 2004, EXP NEUROL, V185, P241, DOI 10.1016/j.expneurol.2003.09.023; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1997, AM J PATHOL, V150, P31; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; HAYS AP, 1988, J NEUROIMMUNOL, V18, P231, DOI 10.1016/0165-5728(88)90101-4; HOGASEN AKM, 1995, J IMMUNOL, V154, P4734; JACK RM, 1988, J IMMUNOL, V140, P4286; Johns TG, 1997, MOL IMMUNOL, V34, P33, DOI 10.1016/S0161-5890(97)00005-9; JOHNSON E, 1988, SCAND J IMMUNOL, V27, P489, DOI 10.1111/j.1365-3083.1988.tb02375.x; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Jurianz K, 2001, INT J CANCER, V93, P848, DOI 10.1002/ijc.1406; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Krickhahn M, 2001, Ann Transplant, V6, P48; Lukasser-Vogl E, 2000, FEMS IMMUNOL MED MIC, V28, P15, DOI 10.1111/j.1574-695X.2000.tb01452.x; MARCHBANK KJ, 1995, IMMUNOLOGY, V85, P146; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Nataf S, 2001, BRAIN RES, V894, P321, DOI 10.1016/S0006-8993(01)02003-0; Nguyen HX, 2003, J PHYSIOL-LONDON, V547, P125, DOI 10.1113/jphysiol.2002.031450; NGUYEN HX, J NEUROCHEM IN PRESS, P7; Oka R, 2001, EUR J CANCER, V37, P1158, DOI 10.1016/S0959-8049(01)00089-2; OKUDA T, 1991, INT IMMUNOL, V3, P293, DOI 10.1093/intimm/3.4.293; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; PETTERSEN HB, 1990, SCAND J IMMUNOL, V31, P15, DOI 10.1111/j.1365-3083.1990.tb02738.x; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qian ZP, 1999, AM J PATHOL, V155, P1293, DOI 10.1016/S0002-9440(10)65231-5; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; QUIGG RJ, 1995, J IMMUNOL, V155, P1481; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011; Reynolds DN, 2004, ANN NY ACAD SCI, V1035, P165, DOI 10.1196/annals.1332.011; Rus H, 2005, IMMUNOL RES, V33, P103, DOI 10.1385/IR:33:2:103; Rus H, 2001, IMMUNOL RES, V24, P79, DOI 10.1385/IR:24:1:79; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3; van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Walker DG, 1998, BRAIN RES, V809, P31, DOI 10.1016/S0006-8993(98)00811-7; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; WOOD A, 1993, J NEUROSCI, V13, P3319; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; WURZNER R, 1994, J IMMUNOL, V152, P4624; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yu Chia-Lu, 1995, Proceedings of the National Science Council Republic of China Part B Life Sciences, V19, P225	60	38	39	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 25	2008	5								26	10.1186/1742-2094-5-26			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	325SD	WOS:000257607700001	18578885	DOAJ Gold, Green Published			2021-06-18	
J	Dhar, R; Diringer, MN				Dhar, Rajat; Diringer, Michael N.			The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage	NEUROCRITICAL CARE			English	Article						subarachnoid hemorrhage; inflammation; vasospasm; sepsis syndrome	DELAYED ISCHEMIC DEFICITS; C-REACTIVE PROTEIN; ACUTE BRAIN-INJURY; BLOOD-CELL COUNT; CEREBRAL VASOSPASM; CEREBROSPINAL-FLUID; ORGAN DYSFUNCTION; INTENSIVE-CARE; SEPSIS; SIMVASTATIN	Introduction Subarachnoid hemorrhage (SAH) can trigger immune activation sufficient to induce the systemic inflammatory response syndrome (SIRS). This may promote both extra-cerebral organ dysfunction and delayed cerebral ischemia, contributing to worse outcome. We ascertained the frequency and predictors of SIRS after spontaneous SAH, and determined whether degree of early systemic inflammation predicted the occurrence of vasospasm and clinical outcome. Methods Retrospective analysis of prospectively collected data on 276 consecutive patients admitted to a neurosciences intensive care unit with acute, non-traumatic SAH between 2002 and 2005. A daily SIRS score was derived by summing the number of variables meeting standard criteria (HR > 90, RR > 20, Temperature > 38 degrees C, or < 36 degrees C, WBC count < 4,000 or > 12,000). SIRS was considered present if two or more criteria were met, while SIRS burden over the first four days was calculated by averaging daily scores. Regression modeling was used to determine the relationship among SIRS burden (after controlling for confounders including infection, surgery, and corticosteroid use), symptomatic vasospasm, and outcome, determined by hospital disposition. Results SIRS was present in over half the patients on admission and developed in 85% within the first four days. Factors associated with SIRS included poor clinical grade, thick cisternal blood, larger aneurysm size, higher admission blood pressure, and surgery for aneurysm clipping. Higher SIRS burden was independently associated with death or discharge to nursing home (OR 2.20/point, 95% CI 1.27-3.81). All of those developing clinical vasospasm had evidence of SIRS, with greater SIRS burden predicting increased risk for delayed ischemic neurological deficits (OR 1.77/point, 95% CI 1.12-2.80). Conclusions Systemic inflammatory activation is common after SAH even in the absence of infection; it is more frequent in those with more severe hemorrhage and in those who undergo surgical clipping. Higher burden of SIRS in the initial four days independently predicts symptomatic vasospasm and is associated with worse outcome.	[Dhar, Rajat; Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA	Dhar, R (corresponding author), Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Neurol Neurosurg Intens Care Unit, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	dharr@neuro.wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Dhar, Rajat/0000-0002-5167-5097	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS035966-09, P01 NS035966] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [N535906] Funding Source: Medline		Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Bavbek M, 1998, STROKE, V29, P1930, DOI 10.1161/01.STR.29.9.1930; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BOWTON DL, 1989, CRIT CARE MED, V17, P399, DOI 10.1097/00003246-198905000-00004; Chello M, 2006, CRIT CARE MED, V34, P660, DOI 10.1097/01.CCM.0000201407.89977.EA; Choileain NN, 2006, ARCH SURG-CHICAGO, V141, P1132; CHYATTE D, 1989, STROKE, V20, P1021, DOI 10.1161/01.STR.20.8.1021; Clatterbuck RE, 2003, J NEUROSURG, V99, P376, DOI 10.3171/jns.2003.99.2.0376; de Oliveira JG, 2007, NEUROSURG REV, V30, P22, DOI 10.1007/s10143-006-0045-5; DILRAJ A, 1992, NEUROSURGERY, V31, P42, DOI 10.1227/00006123-199207000-00007; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Fassbender K, 2000, STROKE, V31, P2971, DOI 10.1161/01.STR.31.12.2971; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; German JW, 1996, NEUROSURGERY, V39, P141, DOI 10.1097/00006123-199607000-00028; Gosling P, 2006, CRIT CARE MED, V34, P2158, DOI 10.1097/01.CCM.0000228914.73550.BD; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; HUGHES JT, 1978, J NEUROSURG, V48, P515, DOI 10.3171/jns.1978.48.4.0515; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Malham GM, 2001, BRIT J NEUROSURG, V15, P381, DOI 10.1080/02688690120082378; McGirt MJ, 2006, NEUROSURGERY, V58, P945, DOI 10.1227/01.NEU.0000210262.67628.7E; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; MILLER JA, 1995, STROKE, V26, P2260, DOI 10.1161/01.STR.26.12.2260; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Moynihan J, 2004, J NEUROIMMUNOL, V147, P87, DOI 10.1016/j.jneuroim.2003.10.018; Napolitano LM, 2000, J TRAUMA, V49, P647, DOI 10.1097/00005373-200010000-00011; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Naredi S, 2006, INTENS CARE MED, V32, P1955, DOI 10.1007/s00134-006-0408-y; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; PETERSON JW, 1989, J NEUROSURG, V71, P718, DOI 10.3171/jns.1989.71.5.0718; Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Vincent JL, 2003, INTENS CARE MED, V29, pS74; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646	46	38	40	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2008	8	3					404	412		10.1007/s12028-008-9054-2			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	301DT	WOS:000255877300014	18196475	Green Accepted			2021-06-18	
J	Taussky, P; Widmer, HR; Takala, J; Fandino, J				Taussky, Philipp; Widmer, Hqns Rudolf; Takala, Jukka; Fandino, Javier			Outcome after acute traumatic subdural and epidural haematoma in Switzerland: a single-centre experience	SWISS MEDICAL WEEKLY			English	Article						traumatic brain injury; epidural haematoma; subdural haematoma	HEAD-INJURY; COMATOSE PATIENTS; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; EXTRADURAL HEMATOMA; BRAIN-INJURY; MORTALITY; REHABILITATION; CRANIOTOMY; PROGNOSIS	Background: Acute epidural and subdural haematomas remain among the most common causes of mortality and disability resulting from traumatic brain injury. In the last three decades improvements in rescue, neuromonitoring and intensive care have led to better outcomes. The purpose of this study was to evaluate the impact of these strategies on outcome in patients treated in a single institution in Switzerland. Methods: A total of 76 consecutive patients who underwent emergency craniotomy for acute traumatic epidural and subdural haematoma at University Hospital Bern between January 2000 and December 2003 were included in this study Results: Thirty-seven patients presented with an epidural haematoma and 46 with a subdural haematoma. In seven patients both haematomas could be documented. The median age was 54 years (IQR 28). The median initial GCS score was 7 (IQR 6). The median time from primary injury to surgery was 3 hours (IQR 2.5 hours). The median stay in the ICU was 3 days (IQR: 3 days). The outcome was favourable (GOS 4 and 5) in 43 patients (57%). Thirteen patients (17%) remained severely or moderately disabled (GOS 3). Finally, a total of 21 patients (28%) died or remained in a persistent vegetative state (GOS 1 and 2). Mortality was 41% for acute subdural haematoma (19/46) and 3% (1/37) for patients with epidural haematoma. Only age, GCS at admission and pupil abnormalities seemed to be associated with outcome. Time to surgery was not. Conclusion: In patients admitted with acute traumatic epidural and subdural haematomas that are treated within a median of 3 hours after primary injury, factors such as age, initial GCS and pupil abnormalities still appear to be the most important factors correlating with outcome.	[Taussky, Philipp; Widmer, Hqns Rudolf; Fandino, Javier] Univ Hosp Bern, Dept Neurosurg, CH-3010 Bern, Switzerland; [Takala, Jukka; Fandino, Javier] Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland	Fandino, J (corresponding author), Kantonsspital Aarau, Dept Neurosurg, Tellstr, CH-5001 Aarau, Switzerland.	javier.fandino@ksa.ch	Widmer, Hans Rudolf/O-5172-2017	Widmer, Hans Rudolf/0000-0003-3378-8765			Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; EDDY VA, 1995, AM SURGEON, V61, P24; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; MARSHALL LF, 2004, YOUMANS NEUROLOGICAL, P5019; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Prabhu SS, 2004, YOUMANS NEUROLOGICAL, P5145; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uzan M, 1998, J Neurosurg Sci, V42, P89; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	31	38	39	0	2	E M H SWISS MEDICAL PUBLISHERS LTD	MUTTENZ	FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	MAY 3	2008	138	19-20					281	285					5	Medicine, General & Internal	General & Internal Medicine	305TO	WOS:000256200900002	18491241	DOAJ Gold			2021-06-18	
J	Kalmar, K; Novack, TA; Nakase-Richardson, R; Sherer, M; Frol, AB; Gordon, WA; Hanks, RA; Giacino, JT; Ricker, JH				Kalmar, Kathleen; Novack, Thomas A.; Nakase-Richardson, Risa; Sherer, Mark; Frol, Alan B.; Gordon, Wayne A.; Hanks, Robin A.; Giacino, Joseph T.; Ricker, Joseph H.			Feasibility of a brief neuropsychologic test battery during acute inpatient rehabilitation after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation	GALVESTON ORIENTATION; AMNESIA TEST; HEAD-INJURY; RECOVERY; LOG	Objectives: To determine (1) if more than 50% of patients with moderate to severe traumatic brain injury (TBI) who met study criteria can complete a battery of neuropsychologic tests in less than 75 minutes 2 to 6 weeks after injury regardless of posttraumatic amnesia (PTA) status; (2) which tests are most likely to be completed; and (3) range of scores obtained. Design: Prospective multicenter observational study. Setting: Acute inpatient neurorehabilitation hospitals. Participants: Screened 543 Traumatic Brain Injury Model System patients with moderate to severe TBI: 354 were tested at 2 to 6 weeks postinjury. Interventions: Not applicable. Main Outcome Measure: Percentage of patients able to complete the neuropsychologic tests in less than 75 minutes. Results: Two hundred eighteen (62%) patients completed the battery in 66 minutes on average. Mean interval from injury to testing was 28.3+/-7.1 days. Tests completed with the highest frequency were California Verbal Learning Test-II, FAS, and animal naming. Performance was less impaired (P<.001) on all measures for patients who had emerged from PTA. Conclusions: Approximately two thirds of screened patients were able to complete a brief neuropsychologic test battery at 2 to 6 weeks postinjury, reggardless of PTA status. Although patients out of PTA were less impaired on all test measures, confusion did not preclude participation in the test batter), or prohibit assignment of test scores. Early neuropsychologic assessment after TBI is feasible even for many patients who are still in PTA.	[Kalmar, Kathleen] JFK Med Ctr, JFK Johnson Rehabil Inst, Brain Trauma Unit, 3EA, Edison, NJ 08818 USA; [Novack, Thomas A.] Spain Rehabil Ctr, Birmingham, AL USA; [Nakase-Richardson, Risa] James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; [Sherer, Mark] Mem Hermann TIRR, Houston, TX USA; [Frol, Alan B.] Baylor Inst Rehabil, Dept Phys Med & Rehabil, Dallas, TX USA; [Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Hanks, Robin A.] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA; [Giacino, Joseph T.] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ 08818 USA; [Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Kalmar, K (corresponding author), JFK Med Ctr, JFK Johnson Rehabil Inst, Brain Trauma Unit, 3EA, 65 James St, Edison, NJ 08818 USA.	kkalmar@solarishs.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Ricker, Joseph/0000-0003-3415-991X	National Institute on Disability and Rehabilitation Research [H133A020501, H133A020502, H133A020509, H133A020514, H133A020515, H133A020518, H133A020526]	Supported by the National Institute on Disability and Rehabilitation Research (grant nos. H133A020501, H133A020502, H133A020509, H133A020514, H133A020515, H133A020518, H133A020526).	Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELIS DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Heaton RK, 2004, REVISED COMPREHENSIV; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kongs SK, 2000, WISCONSIN CARD SORTI; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; Psychological Corporation, 2001, WECHSL TEST AD READ; Reitan R.M., 1993, HALSTEADREITAN NEURO; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2003, DEMONSTRATING UTILIT, P39; Smith A., 1973, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412	22	38	38	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					942	949		10.1016/j.apmr.2008.01.008			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900021	18452744				2021-06-18	
J	Fournier, NM; Calverley, KL; Wagner, JP; Poock, JL; Crossley, M				Fournier, N. M.; Calverley, K. L.; Wagner, J. P.; Poock, J. L.; Crossley, M.			Impaired social cognition 30 years after hemispherectomy for intractable epilepsy: The importance of the right hemisphere in complex social functioning	EPILEPSY & BEHAVIOR			English	Article						social cognition; hemispherectomy; the Awareness of Social Inferences Test; theory of mind; sarcasm; emotional expressions	TEMPORAL-LOBE EPILEPSY; INTERICTAL GLUCOSE HYPOMETABOLISM; TRAUMATIC BRAIN-INJURY; FACIAL EXPRESSIONS; EMOTION RECOGNITION; ECOLOGICAL VALIDITY; NEGATIVE EMOTIONS; ASPERGER-SYNDROME; PERCEPTION; MIND	Clinical research with individuals following hemispherectomy typically quantifies the success of surgical outcomes by focusing primarily on the achievement of seizure control and the preservation of general brain functions, such as movement, sensation, language, and memory. In addition to these outcomes, careful study of individuals following hemispherectomy also has the potential to contribute to our understanding of functional brain asymmetries involving other complex cognitive behaviors. In this study, we report preliminary evidence for the lateralization of social perception. We administered a series of neuropsychological tests that were developed to assess emotional recognition and the formation of social inferences and advanced social cognitive judgments, as they occur in everyday situations, to two adult participants who underwent complete anatomic left- or right-sided hemispherectomy. Our results show that despite a 30-year postsurgical period of recovery and consistent and high levels of family support and social engagement, distinct cognitive profiles are still evident between our right- and left-sided participants. In particular, participant S.M., who underwent an anatomic right hemispherectomy, showed the most severe impairments in identifying negative emotional expressions and conversational exchanges involving lies and sarcasm and in "mentalizing" the intent of others. In contrast, participant J.H., who underwent an anatomic left hemispherectomy was highly skilled interpersonally, despite evident language-related limitations, and showed only mild difficulties when asked to identify emotional expressions involving disgust and anger. These results suggest that the right hemisphere plays a particularly important role in social cognitive functioning and reasoning. Further examination of the extent of social perceptual difficulties prior to and following surgical intervention for epilepsy may guide the development of effective social skills training programs that can improve quality of life beyond seizure control. (C) 2007 Elsevier Inc. All rights reserved.	[Fournier, N. M.; Calverley, K. L.; Wagner, J. P.; Poock, J. L.; Crossley, M.] Univ Saskatchewan, Dept Psychol, Saskatoon, SK S7N 5A5, Canada	Fournier, NM (corresponding author), Univ Saskatchewan, Dept Psychol, Saskatoon, SK S7N 5A5, Canada.	nm.fournier@usask.ca	Fournier, Neil/AAI-8928-2020				Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; Arnold S, 1996, NEUROLOGY, V46, P1422, DOI 10.1212/WNL.46.5.1422; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Barr DJ, 2003, PSYCHON B REV, V10, P462, DOI 10.3758/BF03196507; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; BOROD JC, 1988, NEUROPSYCHOLOGIA, V26, P759, DOI 10.1016/0028-3932(88)90013-9; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Burneo JG, 2005, CAN MED ASSOC J, V172, P1175, DOI 10.1503/cmaj.045118; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Devinsky O, 2004, EPILEPSIA, V45, P34, DOI 10.1111/j.0013-9580.2004.452003.x; Devlin AM, 2003, BRAIN, V126, P556, DOI 10.1093/brain/awg052; DODRILL CB, 1984, EPILEPSIA, V25, P168, DOI 10.1111/j.1528-1157.1984.tb04173.x; EKMAN P, 1993, AM PSYCHOL, V48, P384, DOI 10.1037/0003-066X.48.4.384; EKMAN P, 2007, DARWIN FACIAL EXPRES, P169; ENGLE J, 1993, SURG TREATMENT EPILE, P609; Farrant A, 2005, EPILEPSY BEHAV, V7, P506, DOI 10.1016/j.yebeh.2005.07.018; FISKE ST, 1993, ANNU REV PSYCHOL, V44, P155, DOI 10.1146/annurev.psych.44.1.155; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frith CD, 2006, BRAIN RES, V1079, P36, DOI 10.1016/j.brainres.2005.12.126; Ganis G, 2003, CEREB CORTEX, V13, P830, DOI 10.1093/cercor/13.8.830; GOODGLASS H, 1983, ASSESSMENT APHASIAS; GOTT P S, 1973, Cortex, V9, P266; Heaton R. K, 1981, WISCONSIN CARD SORTI; JENSEN I, 1976, ACTA NEUROL SCAND, V54, P22, DOI 10.1111/j.1600-0404.1976.tb07618.x; Jokeit H, 1997, BRAIN, V120, P2283, DOI 10.1093/brain/120.12.2283; Keenan JP, 2005, CORTEX, V41, P695, DOI 10.1016/S0010-9452(08)70286-7; KELLY FD, 1973, PSYCHOL REP, V32, P1223, DOI 10.2466/pr0.1973.32.3c.1223; Killgore WDS, 2001, NEUROREPORT, V12, P2543, DOI 10.1097/00001756-200108080-00050; Kirsch HE, 2006, EPILEPSY BEHAV, V8, P71, DOI 10.1016/j.yebeh.2005.09.002; Kolb B., 2003, FUNDAMENTALS HUMAN N; LANTING S, 2006, P 7 NAT C CAN RUR HL; Lassonde M, 2006, EPILEPSIA, V47, P9, DOI 10.1111/j.1528-1167.2006.00680.x; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; Liegeois F, 2004, BRAIN, V127, P1229, DOI 10.1093/brain/awh159; Malcolm SR, 2005, LATERALITY, V10, P103, DOI 10.1080/13576500442000274; Mandal MK, 2004, BEHAV NEUROL, V15, P23, DOI 10.1155/2004/786529; MANDAL MK, 1991, CORTEX, V27, P247, DOI 10.1016/S0010-9452(13)80129-3; Mariotti P, 1998, NEUROPSYCHOLOGIA, V36, P1303, DOI 10.1016/S0028-3932(98)00031-1; McClelland S, 2006, EPILEPSIA, V47, P1337, DOI 10.1111/j.1528-1167.2006.00557.x; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Mitchell JP, 2005, J COGNITIVE NEUROSCI, V17, P1306, DOI 10.1162/0898929055002418; Mitchell RLC, 2005, BRAIN, V128, P963, DOI 10.1093/brain/awh466; Mohamed FB, 2006, RADIOLOGY, V238, P679, DOI 10.1148/radiol.2382050237; Noesselt T, 2005, CURR BIOL, V15, P424, DOI 10.1016/j.cub.2004.12.075; Pell MD, 2006, PROG BRAIN RES, V156, P303, DOI 10.1016/S0079-6123(06)56017-0; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Pourtois G, 2005, CORTEX, V41, P49, DOI 10.1016/S0010-9452(08)70177-1; Pulsifer MB, 2004, EPILEPSIA, V45, P243, DOI 10.1111/j.0013-9580.2004.15303.x; Rasmussen T, 1977, Ann N Y Acad Sci, V299, P355, DOI 10.1111/j.1749-6632.1977.tb41921.x; Reitan R. M., 1992, TRAIL MAKING TEST MA; Ross ED, 2007, PERCEPT MOTOR SKILL, V104, P155, DOI 10.2466/PMS-104.1.155-165; Schacher M, 2006, EPILEPSIA, V47, P2141, DOI 10.1111/j.1528-1167.2006.00857.x; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shaw P, 2007, NEUROPSYCHOLOGIA, V45, P2783, DOI 10.1016/j.neuropsychologia.2007.04.020; Spence SA, 2001, NEUROREPORT, V12, P2849, DOI 10.1097/00001756-200109170-00019; Stein MB, 2007, AM J PSYCHIAT, V164, P318, DOI 10.1176/appi.ajp.164.2.318; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; STONE VE, 2005, SOCIAL NEUROSCIENCE, P103; STRAUSS E, 1990, NEUROPSYCHOLOGIA, V28, P1221, DOI 10.1016/0028-3932(90)90057-U; Teuber H., 1974, NEUROSCIENCES 3 STUD, P71; Tharin S, 2007, NEUROSURGERY, V60, P185, DOI 10.1227/01.0000255386.95464.52; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Trevathan E, 2003, NEUROLOGY, V61, P432, DOI 10.1212/WNL.61.4.432; Trimble MR., 1991, PSYCHOSES EPILEPSY; Uddin LQ, 2005, NEUROIMAGE, V25, P926, DOI 10.1016/j.neuroimage.2004.12.018; Vargha-Khadem F, 1994, J Child Neurol, V9 Suppl 2, P67; VARGHAKHADEM F, 1992, ADV EXP MED BIOL, V325, P137; VERITY CM, 1982, NEUROLOGY, V32, P629, DOI 10.1212/WNL.32.6.629; Vining EPG, 1997, PEDIATRICS, V100, P163, DOI 10.1542/peds.100.2.163; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Warrington E., 1991, VISUAL OBJECT SPACE; WECHSLER D, 2007, WECHSLER ADULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wicker B, 2003, BRAIN RES REV, V43, P224, DOI 10.1016/j.brainresrev.2003.08.003	80	38	38	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	APR	2008	12	3					460	471		10.1016/j.yebeh.2007.12.009			12	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	282FU	WOS:000254553900015	18222112				2021-06-18	
J	Gueorguieva, I; Clark, SR; McMahon, CJ; Scarth, S; Rothwell, NJ; Tyrell, PJ; Hopkins, SJ; Rowland, M				Gueorguieva, Ivelina; Clark, Simon R.; McMahon, Catherine J.; Scarth, Sylvia; Rothwell, Nancy J.; Tyrell, Pippa J.; Hopkins, Stephen J.; Rowland, Malcolm			Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						interleukin-1 receptor antagonist; pharmacokinetics; CSF; patients; modelling; subarachnoid haemmorage; ischemia	BLOOD-BRAIN-BARRIER; CEREBRAL-ISCHEMIA; STROKE PATIENTS; RAT; INFARCTION; ANAKINRA; SYSTEM; INJURY; SAFETY; DAMAGE	AIM The naturally occurring interlukin-1 receptor antagonist (IL-1RA) markedly protects rodents against ischaemic, excitotoxic and traumatic brain injury, suggesting it may be of therapeutic value. The aim was to determine the pharmacokinetics of IL-1RA in cerebrospinal fluid (CSF) of patients, to allow modelling that would aid development of therapeutic regimens. METHODS When administered intravenously to patients soon after stroke, IL-1RA is safe and reduces the peripheral inflammatory response. However, IL-1RA is a large protein (17 kDa), which may limit brain penetration, thereby limiting its potential utility in brain injury. In seven patients with subarchnoid haemorrhage (SAH), IL-1RA was administered by intravenous bolus, then infusion for 24 h, and both blood and CSF, via external ventricular drains, were sampled during and after stopping the infusion. RESULTS Plasma steady-state concentrations were rapidly attained and maintained throughout the infusion, whereas CSF concentrations rose slowly towards a plateau during the 24-h infusion, reaching at best only 4% of that in plasma. Plasma kinetic parameters were within the literature range. Modelling of the combined data yielded rate constants entering and leaving the CSF of 0.0019 h(-1) [relative standard error (RSE) = 19%] and 0.1 h(-1) (RSE = 19%), respectively. CONCLUSIONS Peripherally administered IL-1RA crosses slowly into and out of the CSF of patients with SAH. However, there is a large concentration gradient of IL-1RA between plasma and CSF. These CSF:plasma data are consistent with very low permeation of IL-1RA into the CSF and elimination kinetics from it controlled by the volumetric turnover of CSF.	[Gueorguieva, Ivelina] Eli Lilly & Co, Global PK PD, Windlesham GU20 6PH, Surrey, England; [Gueorguieva, Ivelina; Rowland, Malcolm] Univ Manchester, Ctr Appl Pharmacokinet Res, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England; [Clark, Simon R.; McMahon, Catherine J.; Scarth, Sylvia; Tyrell, Pippa J.; Hopkins, Stephen J.] Hope Hosp, Stroke Serv, Salford M6 8HD, Lancs, England; [Clark, Simon R.; Rothwell, Nancy J.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Clark, Simon R.] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool, Merseyside, England	Gueorguieva, I (corresponding author), Eli Lilly & Co, Global PK PD, Sunninghill Rd,EMC Bldg, Windlesham GU20 6PH, Surrey, England.	gueorguieva_ivelina@lilly.com	Hopkins, Stephen/I-7363-2015; Clark, Simon/AAT-5610-2020	Hopkins, Stephen/0000-0001-7644-2823; Tyrrell, Pippa/0000-0001-9609-1231	The Sir Jules Thorn Charitable Trust [02JTA] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G19/24] Funding Source: Medline		ALKASSAB S, 1981, ACTA NEUROL SCAND, V64, P438; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; BEAL S, 1980, AM STAT, V34, P118, DOI 10.2307/2684123; Beal S, 1998, NONMEM USERS GUIDES; BERNE RM, 1990, PRINCIPLES PHYSL, P66; Clark SR, 2008, J CEREBR BLOOD F MET, V28, P387, DOI 10.1038/sj.jcbfm.9600537; CLARK SR, 2005, J CEREBRAL FLOW META, V25, pS45; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; Hammarlund-Udenaes M, 2000, ADV DRUG DELIVER REV, V45, P283, DOI 10.1016/S0169-409X(00)00109-5; KANDEL ER, 2000, PRINCIPLES NEURAL SC, P1296; Kosteljanetz M, 1988, Br J Neurosurg, V2, P161, DOI 10.3109/02688698808992665; Lipton P, 1999, PHYSIOL REV, V79, P1431; Luetmer PH, 2002, NEUROSURGERY, V50, P534, DOI 10.1097/00006123-200203000-00020; MAHONEY F I, 1965, Md State Med J, V14, P61; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Rothwell NJ, 1997, INT REV NEUROBIOL, V40, P281; TEASDALE G, 1974, LANCET, V2, P81; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VEROTTA D, 1995, J PHARMACOKINET BIOP, V23, P1, DOI 10.1007/BF02353780; Yang BB, 2003, CLIN PHARMACOL THER, V74, P85, DOI 10.1016/S0009-9236(03)00094-8	32	38	40	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	MAR	2008	65	3					317	325		10.1111/j.1365-2125.2007.03026.x			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	268VD	WOS:000253607000004	17875190	Bronze, Green Published			2021-06-18	
J	Sheth, RN; Manzano, G; Li, XM; Levi, AD				Sheth, Rishi N.; Manzano, Glen; Li, Xiuming; Levi, Allan D.			Transplantation of human bone marrow-derived stromal cells into the contused spinal cord of nude rats - Laboratory investigation	JOURNAL OF NEUROSURGERY-SPINE			English	Article						bone marrow stromal cells; differentiation; neuroprotection; rat; spinal cord injury; transplantation	MESENCHYMAL STEM-CELLS; COLONY-STIMULATING FACTOR; PROMOTE FUNCTIONAL RECOVERY; TRAUMATIC BRAIN-INJURY; IN-VITRO; SCHWANN-CELL; ADULT-RAT; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTORS; CEREBROSPINAL-FLUID	Object. Human bone marrow stromal cells (hMSCs) constitute a potential source of pluripotent stem cells. In the present study, hMSCs were transplanted into an area of spinal cord contusion in nude rats to determine their survival, differentiation, potential for neuroprotection, and influence on axonal growth and functional recovery. Methods. Twenty-nine animals received 6 x 10(5) hMSCs in 6 mu l medium 1 week after a contusion, while 14 control animals received an injection of 6 RI medium alone. Basso-Beattie-Bresnahan (BBB) tests were performed weekly. The spinal cords were collected at 6 weeks posttransplantation for histological analysis and assessment of tissue injury. Results. Immunostaining with anti-human mitochondria antibody and pretransplantation labeling with green fluorescent protein demonstrated that the grafted hMSCs survived and were capable of achieving a flattened appearance in the grafted area; however, none of the transplanted cells stained positively for human-specific neuronal, anti-neurofilament H or glial fibrillary acidic protein within the sites of engraftment. While neuronal or astrocytic differentiation was not seen, cells lining blood vessels in the vicinity of the transplant stained positively for antihuman endothelium CD 105 antibody. Staining for anti-neurofilament H antibody demonstrated abundant axonlike structures around the transplanted area in the hMSC group. Tissue sparing analysis showed that animals with grafted hMSCs had a smaller area of contusion cyst compared with controls, but there was no significant difference between the two groups in BBB scores. Conclusions. The grafted hMSCs survived for >= 6 weeks posttransplantation, although they did not differentiate into neural or glial cells. Cells with human endothelial characteristics were observed. Spinal cord-injured rats grafted with hMSCs had smaller contusion cavities, which did not have a significant influence on functional recovery.	[Sheth, Rishi N.; Manzano, Glen; Levi, Allan D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope LIFE Ctr, Miami, FL 33136 USA; [Li, Xiuming; Levi, Allan D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Levi, AD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope LIFE Ctr, 1095 NW 14th Terrace,D4-6, Miami, FL 33136 USA.	alevi@med.miami.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P40RR017447] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P40RR017447] Funding Source: Medline		Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059; Abouelfetouh A, 2004, BRAIN RES, V1029, P114, DOI 10.1016/j.brainres.2004.07.092; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSO DM, 1996, NEUROTRAUMA, V13, P343; BERESFORD JN, 1992, J CELL SCI, V102, P341; Blits B, 2005, RESTOR NEUROL NEUROS, V23, P313; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Corti S, 2002, J NEUROSCI RES, V70, P721, DOI 10.1002/jnr.10455; Deng YB, 2006, CYTOTHERAPY, V8, P210, DOI 10.1080/14653240600760808; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Grove JE, 2004, STEM CELLS, V22, P487, DOI 10.1634/stemcells.22-4-487; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Hamano K, 2000, CELL TRANSPLANT, V9, P439, DOI 10.1177/096368970000900315; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Hill CE, 2006, GLIA, V53, P338, DOI 10.1002/glia.20287; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Inoue M, 2003, GLIA, V44, P111, DOI 10.1002/glia.10285; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kitchel SH, 2005, NEUROSURGERY, V57, P286, DOI 10.1227/01.NEU.0000176412.17360.95; Koda M, 2007, BRAIN RES, V1149, P223, DOI 10.1016/j.brainres.2007.02.058; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221; LEVI ADO, 1994, EXP NEUROL, V130, P41, DOI 10.1006/exnr.1994.1183; LEVI ADO, 1994, J NEUROSCI, V14, P1309; Lou SJ, 2003, BRAIN RES, V968, P114, DOI 10.1016/S0006-8993(03)02224-8; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu P, 2005, EXP NEUROL, V193, P273, DOI 10.1016/j.expneurol.2005.01.031; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Ono K, 2003, J NEUROSCI RES, V72, P503, DOI 10.1002/jnr.10588; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Padovan CS, 2003, CELL TRANSPLANT, V12, P839, DOI 10.3727/000000003771000183; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Prockop DJ, 2001, CYTOTHERAPY, V3, P393, DOI 10.1080/146532401753277229; Rismanchi N, 2003, BRAIN RES, V991, P46, DOI 10.1016/j.brainres.2003.07.004; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Takami T, 2002, J NEUROSCI, V22, P6670; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TEWARIE RDN, 2006, CELL TRANSPLANT, V15, P563, DOI DOI 10.3727/000000006783981602; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Wakitani S, 2004, CELL TRANSPLANT, V13, P595, DOI 10.3727/000000004783983747; Walczak P, 2004, J NEUROSCI RES, V76, P244, DOI 10.1002/jnr.20042; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Ye M, 2005, NEUROREPORT, V16, P581, DOI 10.1097/00001756-200504250-00013; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004	86	38	50	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654			J NEUROSURG-SPINE	J. Neurosurg.-Spine	FEB	2008	8	2					153	162		10.3171/SPI/2008/8/2/153			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	259JD	WOS:000252934700008	18248287				2021-06-18	
J	Corrigan, JD; Deutschle, JJ				Corrigan, John D.; Deutschle, James J., Jr.			The presence and impact of traumatic brain injury among clients in treatment for co-occurring mental illness and substance abuse	BRAIN INJURY			English	Article						traumatic brain injury; substance abuse; mental illness	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; PSYCHIATRIC-DISORDERS; ASSOCIATION; DEPRESSION; MANIA; PSYCHOPATHOLOGY; INDIVIDUALS; RELIABILITY; PREVALENCE	Objectives: To compare diagnostic and treatment-related differences between persons participating in treatment for dually diagnosed substance use disorders and severe mental illness who have or do not have a history of traumatic brain injury (TBI). Design: Prospective cohort. Interventions: Not applicable. Primary measures: Demographic information, diagnostic data, pre-treatment status, treatment participation and staff assessment of functioning. Results: Seventy-two percent of participants in treatment for dually diagnosed substance use disorders and severe mental illness reported a history of at least one TBI. Participants with TBI had greater morbidity as reflected in more complex psychiatric diagnoses and greater likelihood of being diagnosed with an Axis II personality disorder. Participants with a TBI showed tendencies toward earlier onset of substance use and worse current functioning. Both a greater number of injuries and earlier age at first TBI showed some indications of being associated with worse morbidity. Conclusions: Individuals dually diagnosed with substance use disorders and severe mental illness may have a high rate of TBI, which in turn could contribute to important clinical and treatment differences. Results also suggested the need for validated methods of identifying aspects of a prior history of TBI that provide more information than presence/absence.	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Deutschle, James J., Jr.] Hopewell Counseling & Consultat, Newark, OH USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011		CSAT SAMHSA HHS [H79TI12708] Funding Source: Medline		ALTERMAN AI, 1985, J STUD ALCOHOL, V46, P256, DOI 10.15288/jsa.1985.46.256; BAMRAH JS, 1991, BRIT J PSYCHIAT, V158, P117, DOI 10.1192/bjp.158.1.117; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 2005, REHABILITATION TRAUM, P133; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Deb S, 1999, AM J PSYCHIAT, V156, P374; *DEP HLTH HUM SERV, 2005, RES 2005 NAT SURV DR; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Drake RE, 2001, PSYCHIAT SERV, V52, P469, DOI 10.1176/appi.ps.52.4.469; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; GORDON W, 2002, AM C REH MED PHIL PA; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Holtzer R, 2000, BRAIN INJURY, V14, P959, DOI 10.1080/02699050050191904; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LYONS J, 1998, GEN HOSP PSYCHIAT, V10, P292; MALLOY P, 1990, ADDICT BEHAV, V15, P431, DOI 10.1016/0306-4603(90)90029-W; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Mueser K. T., 2003, INTEGRATED TREATMENT; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RIESS H, 1987, J CLIN PSYCHIAT, V48, P29; Robinson RG, 2002, ARCH GEN PSYCHIAT, V59, P23, DOI 10.1001/archpsyc.59.1.23; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sacks S., 2005, SUBSTANCE ABUSE TREA; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; STEWART JT, 1988, J CLIN PSYCHIAT, V49, P74; STREETER CC, 1995, J NERV MENT DIS, V183, P577, DOI 10.1097/00005053-199509000-00003; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; TOWNSEND W, 1999, EMERGING BEST PRACTI; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANREEKUM R, 1993, J PSYCHIATR NEUROSCI, V18, P121; WALKER R, 2001, FUNCTIONALITY SCALE; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	49	38	38	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					223	231		10.1080/02699050801938967			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500003	18297594				2021-06-18	
J	Dolce, G; Quintieri, M; Serra, S; Lagani, V; Pignolo, L				Dolce, G.; Quintieri, M.; Serra, S.; Lagani, V.; Pignolo, L.			Clinical signs and early prognosis in vegetative state: A decisional tree, data-mining study	BRAIN INJURY			English	Article						vegetative state; early prognosis; data mining; classification and regression tree	TRAUMATIC BRAIN-INJURY; INTRATHECAL BACLOFEN; OWN NAME; CONSCIOUSNESS; STIMULATION; UNAWARENESS; PREDICTION; DYSTONIA; RECOVERY	Background and purpose: Residual brain function has been documented in vegetative state patients, yet early prognosis remains difficult. The purpose of this study was to identify by artificial intelligence procedures (classification and regression trees, data-mining) the significant neurological signs correlated to and predictive of outcome. Methods: Three hundred and thirty-three patients in vegetative state of traumatic or non-traumatic aetiology referred to the S.Anna Institute were retrospectively studied. Twenty-two neurological signs were assessed according to criteria included in the UNI ENI ISO 9001 : 2000 quality standards at admission (Time(0)) and after 50, 100 or 180 days and entered into a CART (classification and regression tree) data-mining procedure with a decisional tree j48 (Weka software and 10-fold cross-validation). Outcome was conventionally rated by the Glasgow outcome scale. Results and conclusions: Re-appearance with proper timing of spontaneous motility, eye tracking and oculo-cephalic reflex and disappearance of oral automatisms proved highly correlated to outcome and allowed early and reliable prognosis. These findings are consistent with the brain functional organization thought to sustain consciousness and warrant systematic investigation. Classification and regression trees and data-mining procedures proved applicable in neurology to sort out significant clinical signs also in clinical conditions characterized by paucity of signs such as the vegetative state. Extended application in clinical medicine is conceivable based on the approach peculiarities.	[Dolce, G.; Quintieri, M.; Serra, S.] S Anna Inst, Intens Care Unit Vegetat State, I-88900 Crotone, Italy; [Lagani, V.; Pignolo, L.] Univ Calabria, Dept Elect Informat & Syst, I-87036 Cosenza, Italy	Dolce, G (corresponding author), S Anna Inst, Intens Care Unit Vegetat State, Via Siris 11, I-88900 Crotone, Italy.	giulianodolce@libero.it	Serra, Sebastiano/AAP-8391-2021				ANDREWS K, 1996, INT WORKING PARTY RE; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Barton John, 2005, Stud Health Technol Inform, V117, P89; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1976, HDB CLIN NEUROLOGY, P699; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; DOLCE G, 1973, ELECTROEN CLIN NEURO, V34, P647, DOI 10.1016/0013-4694(73)90010-2; Dolce G., 2002; ERMES M, 2007, C P IEEE ENG MED BIO, V1, P3056; Fins JJ, 2007, CURR OPIN NEUROL, V20, P650, DOI 10.1097/WCO.0b013e3282f11f6d; FRANK E, 2004, MACHINE LEARNING WEK; Frank E, 1999, DATA MINING PRACTICA; Han J, 2001, DATA MINING CONCEPTS; HASSLER R, 1969, ELECTROEN CLIN NEURO, V27, P306, DOI 10.1016/0013-4694(69)90060-1; Hassler R., 1972, PATHOPHISIOLOGIE BEW, P1; Hildebrandt H, 2007, J NEUROL SCI, V260, P150, DOI 10.1016/j.jns.2007.04.035; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 2002, VEGETATIVE STATE; Jimenez-Fernandez Silvia, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2064; JOHN ER, 2008, LANCET IN PRESS; JUNG R, 1967, PSYCHIAT GEGENWART, V1, P612; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Machado C, 2007, CLIN EEG NEUROSCI, V38, P124, DOI 10.1177/155005940703800306; Morita I, 2007, ACTA NEUROCHIR SUPPL, V97, P455; Olshen RA, 1984, CLASSIFICATION REGRE; Owen AM, 2007, ARCH NEUROL-CHICAGO, V64, P1098, DOI 10.1001/archneur.64.8.1098; Owen AM, 2007, CURR OPIN NEUROL, V20, P632, DOI 10.1097/WCO.0b013e3282f15669; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Qiu J, 2007, LANCET NEUROL, V6, P946, DOI 10.1016/S1474-4422(07)70255-7; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Richard I, 2007, ACTA NEUROCHIR SUPPL, V97, P213; Riva G, 2003, CYBERPSYCHOL BEHAV, V6, P295, DOI 10.1089/109493103322011597; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Rubel Paul, 2004, Stud Health Technol Inform, V108, P123; SAMSON WT, 2004, KNOWLEDGE BASED DECI; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, ACTA NEUROCHIR, V112, P110, DOI 10.1007/BF01405137; SAZBON L, 1993, J NEUROL NEUROSUR PS, V56, P407, DOI 10.1136/jnnp.56.4.407; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166; Steinberg D., 1997, CART CLASSIFICATION; STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; TEASDALE G, 1974, LANCET, V2, P81; van Bemmel J.H., 1997, HDB MED INFORM; XIAO YXA, 2007, BRAIN INJURY, V21, P575; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	55	38	39	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					617	623		10.1080/02699050802132503			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300014	18568716				2021-06-18	
J	Osiurak, F; Aubin, G; Allain, P; Jarry, C; Richard, I; Le Gall, D				Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Richard, Isabelle; Le Gall, Didier			Object utilization and object usage: A single-case study	NEUROCASE			English	Article						tool use; apraxia; action; conceptual knowledge; object misuse	IDEOMOTOR APRAXIA; TOOL-USE; IDEATIONAL APRAXIA; SEMANTIC DEMENTIA; CORTICOBASAL DEGENERATION; SELECTIVE IMPAIRMENT; KNOWLEDGE; MEMORY; MANIPULATION; RECOGNITION	It has been suggested that both conceptual knowledge and the ability to infer function from structure can support object use. By contrast, we propose that object use requires solely the ability to reason about technical ends. Technical ends (e.g., cutting) are not purposes (e.g., eating), but the technical way to achieve them. This perspective suggests that there is no mutual relationship between technical ends and purposes since the same purpose (e.g., writing) can be achieved thanks to distinct technical ends (graving, tracing), and, inversely, the same technical end (e.g., tracing) can achieve different purposes (making up, writing). Thus, conceptual knowledge might determine which technical end is usually associated with a given purpose. To contribute to the discussion, we described the behaviour of a female patient with left temporal lobe lesions and bilateral frontal lobe lesions following a closed-head injury. Conceptual knowledge was impaired. She encountered difficulties in demonstrating the use of objects in isolation (e.g., using a screwdriver without the screw). The presence of a recipient (e.g., using a screwdriver with the screw) improved her performance. The performance was also normal when asked to perform unusual applications of objects to achieve a goal for which the usually applied object was not provided (e.g., screwing a screw with a knife). Consistent with the theoretical framework supported here, her performance profile suggests an intact ability to reason about technical ends (i.e., utilization), in the presence of a defective ability to determine the usual relationship between technical ends and purposes (i.e., usage).	[Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Le Gall, Didier] Univ Hosp Angers, Dept Neurol, Neuropsychol Unit, Angers, France; [Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Le Gall, Didier] Univ Angers, UPRES EA 2646, Psychol Lab, Angers, France; [Aubin, Ghislaine; Richard, Isabelle] Reg Ctr Rehabil Angers, Angers, France	Le Gall, D (corresponding author), Ctr Hosp Univ, Dept Neurol, Unite Neuropsychol, 4 Rue Larrey, F-49033 Angers 01, France.	DiLeGall@chu-angers.fr	Osiurak, Francois/F-1400-2011	Osiurak, Francois/0000-0003-3449-6377; ALLAIN, Philiooe/0000-0003-0668-0986			Agniel A., 1992, PROTOCOLE MONTREAL T; BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; Bartolo A, 2007, BEHAV NEUROL, V18, P143, DOI 10.1155/2007/241670; BERGEGO C, 1992, REV NEUROPSYCHOL, V2, P193; Bozeat S, 2002, COGN AFFECT BEHAV NE, V2, P236, DOI 10.3758/CABN.2.3.236; BREEDIN SD, 1994, COGNITIVE NEUROPSYCH, V11, P617, DOI 10.1080/02643299408251987; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 2001, NEUROCASE, V7, P445, DOI 10.1076/neur.7.6.445.16223; Buxbaum LJ, 2002, BRAIN LANG, V82, P179, DOI 10.1016/S0093-934X(02)00014-7; Buxbaum LJ, 2000, NEUROCASE, V6, P83, DOI 10.1093/neucas/6.2.83; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; Cubelli R, 2000, BRAIN COGNITION, V44, P144, DOI 10.1006/brcg.2000.1226; De Renzi E., 1989, HDB NEUROPSYCHOLOGY, P245; Deloche G, 1997, TEST DENOMINATION OR; DERENZI E, 1994, CORTEX, V30, P3, DOI 10.1016/S0010-9452(13)80322-X; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; DESGRANGES B, 1994, ANN PSYCHOL, V94, P345; DIXON R, 1995, COMPENSATING PSYCHOL; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Dumont C, 1999, NEUROCASE, V5, P447, DOI 10.1093/neucas/5.5.447; Fukutake T, 2003, EUR NEUROL, V49, P45, DOI 10.1159/000067027; Gagnepain J., 1994, LECONS INTRO THEORIE; Gagnepain J, 1990, VOULOIR DIRE SIGNE O; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GIBB WRG, 1989, BRAIN, V112, P1171, DOI 10.1093/brain/112.5.1171; Gibson JJ, 1986, ECOLOGICAL APPROACH; Goldenberg G, 1998, NEUROPSYCHOLOGIA, V36, P581, DOI 10.1016/S0028-3932(97)00165-6; Goldenberg G, 1999, NEUROPSYCHOLOGIA, V37, P559, DOI 10.1016/S0028-3932(98)00111-0; Goldenberg G, 1997, NEUROPSYCHOLOGIA, V35, P333, DOI 10.1016/S0028-3932(96)00085-1; Hayakawa Y, 2000, EUR NEUROL, V43, P76, DOI 10.1159/000008139; Heath M, 2003, NEUROCASE, V9, P156, DOI 10.1076/neur.9.2.156.15072; HEILMAN KM, 1982, NEUROLOGY, V32, P342, DOI 10.1212/WNL.32.4.342; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; Hodges JR, 1999, P NATL ACAD SCI USA, V96, P9444, DOI 10.1073/pnas.96.16.9444; Hodges JR, 2000, BRAIN, V123, P1913, DOI 10.1093/brain/123.9.1913; Humphreys GW, 2001, BEHAV BRAIN SCI, V24, P453, DOI 10.1017/S0140525X01004150; JEANNEROD M, 1997, COGNITIVE NEUROSCIEN; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; Lauro-Grotto R, 1997, CORTEX, V33, P593, DOI 10.1016/S0010-9452(08)70720-2; Le Gall D., 2000, TRAITE NEUROPSYCHOLO, P225; Le Gall D., 1998, APRAXIES ATECHNIES P; LEGALL D, 1995, REV INT PSYCHOPATHOL, V18, P229; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liepmann H., 1920, ERGEBNISSE GESELLSCH, V1, P516; Moreaud O, 1998, NEUROPSYCHOLOGIA, V36, P1295, DOI 10.1016/S0028-3932(98)00034-7; Moss HE, 1997, COGNITIVE NEUROPSYCH, V14, P901, DOI 10.1080/026432997381394; MOTOMURA N, 1994, CORTEX, V30, P167, DOI 10.1016/S0010-9452(13)80332-2; Negri GA, 2007, CORTEX, V43, P376, DOI 10.1016/S0010-9452(08)70463-5; Nespoulous J.-L., 1992, PROTOCOLE MONTREAL T; OCHIPA C, 1992, BRAIN, V115, P1061, DOI 10.1093/brain/115.4.1061; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PILGRIM E, 1991, COGNITIVE NEUROPSYCH, V8, P459, DOI 10.1080/02643299108253383; Raven JC, 1947, COLORED PROGR MATRIC; Rey A., 1959, TEST COPIE FIGURE CO; RIDDOCH MJ, 1988, COGNITIVE NEUROPSYCH, V5, P3, DOI 10.1080/02643298808252925; Rothi LJ, 1997, APRAXIA NEUROPSYCHOL, P29; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; Roy E. A., 1985, NEUROPSYCHOLOGICAL S, DOI DOI 10.1016/S0166-4115(08)61139-5; Rumiati RI, 1998, J EXP PSYCHOL HUMAN, V24, P631, DOI 10.1037/0096-1523.24.2.631; SABOURAUD O, 2006, DEBAT, V140, P68; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; Signoret J.L., 1989, BATTERIE EVALUATION; SIRIGU A, 1991, BRAIN, V114, P2555, DOI 10.1093/brain/114.6.2555; SNOWDEN JS, 1996, FRONTO TEMPORAL LOBA; Spatt J, 2002, J NEUROL, V249, P601, DOI 10.1007/s004150200070; Sunderland A, 2000, NEUROPSYCHOLOGIA, V38, P923, DOI 10.1016/S0028-3932(00)00021-X; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1975, Q J EXP PSYCHOL, V27, P635, DOI 10.1080/14640747508400525; Wilson BA, 2003, NEUROPSYCHOLOG REHAB, P1; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; ZANGWILL O L, 1960, Rev Neurol (Paris), V102, P595	74	38	38	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase		2008	14	2					169	183		10.1080/13554790802108372			15	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	317QX	WOS:000257035800007	18569742				2021-06-18	
J	Tamplin, J				Tamplin, Jeanette			A pilot study into the effect of vocal exercises and singing on dysarthric speech	NEUROREHABILITATION			English	Article						music therapy; singing; dysarthria; rehabilitation; TBI; stroke	INTELLIGIBILITY; INSTRUCTION; NATURALNESS; THERAPY	This pilot study aimed to investigate the effects of vocal exercises and singing on intelligibility and speech naturalness for subjects with acquired dysarthria following traumatic brain injury or stroke. A multiple case study design was used, involving pre, mid, and post-treatment assessments of intelligibility, rate, naturalness, and pause time for four subjects with dysarthria. Each subject participated in 24 individual music therapy sessions over eight weeks involving oral motor respiratory exercises, rhythmic and melodic articulation exercises, rhythmic speech cuing, vocal intonation therapy, and therapeutic singing using familiar songs. Results were measured using a standardized dysarthric speech assessment - the Sentence Intelligibility Test, waveform analysis, and ratings of speech naturalness. Statistically significant improvements in functional speech intelligibility were achieved but improvements in rate of speech were not significant. Speech naturalness improved post-treatment and a reduction in the number and length of pauses was verified via waveform analysis. Preliminary findings suggest that a program of vocal exercises and singing may facilitate more normative speech production for people with acquired dysarthria and support the need for further research in this area.	[Tamplin, Jeanette] Austin Hlth, Mus Therapy Serv, Melbourne, Vic, Australia	Tamplin, J (corresponding author), Royal Talbot Rehabil Ctr, 1 Yarra Blvd, Kew, Vic 3101, Australia.	jeanette.tamplin@austin.org.au	Tamplin, Jeanette/AAR-2855-2021	Tamplin, Jeanette/0000-0002-3623-033X			ABBS JH, 1989, DISORDERS COMMUNICAT; Baker F, 2005, BRAIN INJURY, V19, P519, DOI 10.1080/02699050400005150; BAKER F, 2004, EFFECTS SONG SINGING, P374; Baker J, 2000, J Sci Med Sport, V3, P110, DOI 10.1016/S1440-2440(00)80073-0; BANG C, 1986, MUSIC HLTH; BELLAIRE K, 1986, J COMMUN DISORD, V19, P271, DOI 10.1016/0021-9924(86)90033-X; Claeys M. S., 1989, MUSIC THERAPY PERSPE, V6, P71; COHEN J, 1994, BIO-TECHNOL, V12, P8, DOI 10.1038/nbt0194-8b; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen N., 1995, MUSIC THERAPY PERSPE, V13, P69; COHEN NS, 1995, J MUSIC THER, V32, P46, DOI 10.1093/jmt/32.1.46; COHEN NS, 1988, J MUSIC THER, V25, P85, DOI 10.1093/jmt/25.2.85; COHEN NS, 1992, J MUSIC THER, V29, P87, DOI 10.1093/jmt/29.2.102; COHEN NS, 1993, J MUSIC THER, V30, P81, DOI 10.1093/jmt/30.2.81; Darley F., 1975, MOTOR SPEECH DISORDE; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Duffy JR, 2019, MOTOR SPEECH DISORDE; HAMMEN VL, 1994, J SPEECH HEAR RES, V37, P244, DOI 10.1044/jshr.3702.244; Haneishi E, 2001, J MUSIC THER, V38, P273, DOI 10.1093/jmt/38.4.273; KENT RD, 1994, ADV ASSESSMENT TREAT; Lucia C. M., 1987, MUSIC THERAPY PERSPE, V4, P34; MACINTOSH GC, 1996, MUSICMEDICINE; METZ DE, 1980, SPEECH ASSESSMENT SP; Pilon MA, 1998, BRAIN INJURY, V12, P793, DOI 10.1080/026990598122188; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Sellars C, 2002, CLIN REHABIL, V16, P61, DOI 10.1191/0269215502cr468oa; STANDLEY JM, 1994, RES MUSIC THERAPY TR; TAYLOR D, 1997, BIOMEDICAL FDN MUSIC; THAUT M, 1991, J MUSIC THER, V28, P64, DOI 10.1093/jmt/28.2.64; Thaut M., 2005, RHYTHM MUSIC BRAIN S; Thaut M. H., 2000, SCI MODEL MUSIC THER; Thaut MH, 2001, FUNCT NEUROL, V16, P163; Thaut MH, 1996, MOVEMENT DISORD, V11, P193, DOI 10.1002/mds.870110213; Thaut MH, 1993, NEUROREHABIL NEURAL, V7, P9, DOI DOI 10.1177/136140969300700103; THAUT MH, 1995, INT J ARTS MED, V5, P4; THAUT MH, 1994, MUSICMEDICINE; THOMPSON B, 1995, WILDLIFE SOC B, V23, P1; Thompson EC, 1997, EUR J DISORDER COMM, V32, P397; Van der Merwe A., 1997, CLIN MANAGEMENT SENS; YORKSTON KM, 1981, J SPEECH HEAR DISORD, V46, P398, DOI 10.1044/jshd.4604.398; YORKSTON KM, 1990, J SPEECH HEAR DISORD, V55, P550, DOI 10.1044/jshd.5503.550; YORKSTON KM, 1996, SENTENCE INTELLIGIBL	43	38	40	0	25	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	3					207	216					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	311IK	WOS:000256593700002	18560137				2021-06-18	
J	Vaccari, JCDR; Corriveau, RA; Belousov, AB				Vaccari, Juan Carlos de Rivero; Corriveau, Roderick A.; Belousov, Andrei B.			Gap junctions are required for NMDA receptor-dependent cell death in developing neurons	JOURNAL OF NEUROPHYSIOLOGY			English	Article							DEVELOPING RAT-BRAIN; GLOBAL-ISCHEMIA; INTERCELLULAR COMMUNICATION; ELECTRICAL SYNAPSES; EFFECTIVE REDUCTION; CEREBRAL-ISCHEMIA; TRAUMATIC INJURY; OXIDATIVE STRESS; NERVOUS-SYSTEM; RODENT MODEL	A number of studies have indicated an important role for N-methyl-D-aspartate (NMDA) receptors in cell survival versus cell death decisions during neuronal development, trauma, and ischemia. Coupling of neurons by electrical synapses (gap junctions) is high or increases in neuronal networks during all three of these conditions. However, whether neuronal gap junctions contribute to NMDA receptor-regulated cell death is not known. Here we address the role of neuronal gap junction coupling in NMDA receptor-regulated cell death in developing neurons. We report that inactivation or hyperactivation of NMDA receptors induces neuronal cell death in primary hypothalamic cultures, specifically during the peak of developmental gap junction coupling. In contrast, increasing or decreasing NMDA receptor function when gap junction coupling is low has no or greatly reduced impact on cell survival. Pharmacological inactivation of gap junctions or knockout of neuronal connexin 36 prevents the cell death caused by NMDA receptor hypofunction or hyperfunction. The results indicate the critical role of neuronal gap junctions in cell death caused by increased or decreased NMDA receptor function in developing neurons. Based on these data, we propose the novel hypothesis that NMDA receptors and gap junctions work in concert to regulate neuronal survival.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, Baton Rouge, LA 70803 USA; Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; Coriell Inst Med Res, Camden, NJ USA	Belousov, AB (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 2146 W 39th Ave,MS 3051, Kansas City, KS 66160 USA.	abelousov@kumc.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA015088] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR-16816] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA-015088] Funding Source: Medline		Adams SM, 2004, J NEUROSCI, V24, P9441, DOI 10.1523/JNEUROSCI.3290-04.2004; Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.0.CO;2-#; Arumugam H, 2005, NAT NEUROSCI, V8, P1720, DOI 10.1038/nn1588; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Becker DL, 1999, EXP NEUROL, V156, P326, DOI 10.1006/exnr.1999.7027; Belluardo N, 2000, BRAIN RES, V865, P121, DOI 10.1016/S0006-8993(00)02300-3; Belousov AB, 2001, J NEUROSCI, V21, P2015, DOI 10.1523/JNEUROSCI.21-06-02015.2001; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Blanc EM, 1998, J NEUROCHEM, V70, P958; Buss Robert R., 2004, Anatomical Science International, V79, P191, DOI 10.1111/j.1447-073x.2004.00088.x; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOI DW, 1987, J NEUROSCI, V7, P357; Cole K, 2004, INT J DEV NEUROSCI, V22, P485, DOI 10.1016/j.ijdevneu.2004.07.015; CONNORS BW, 1983, J NEUROSCI, V3, P773; Contestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7; Cusato K, 2006, CELL DEATH DIFFER, V13, P1707, DOI 10.1038/sj.cdd.4401876; Cusato K, 2003, J NEUROSCI, V23, P6413; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/S0006-8993(96)00298-3; de Pina-Benabou MH, 2005, STROKE, V36, P2232, DOI 10.1161/01.STR.0000182239.75969.d8; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Farahani R, 2005, GLIA, V50, P351, DOI 10.1002/glia.20213; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gulisano M, 2000, NEUROREPORT, V11, P3823, DOI 10.1097/00001756-200011270-00045; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; Long MA, 2005, NAT NEUROSCI, V8, P61, DOI 10.1038/nn1361; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; Nakazawa K, 2004, NAT REV NEUROSCI, V5, P361, DOI 10.1038/nrn1385; Nodin C, 2005, J NEUROCHEM, V94, P1111, DOI 10.1111/j.1471-4159.2005.03241.x; OBRIETAN K, 1995, J NEUROPHYSIOL, V73, P1524; Oguro K, 2001, J NEUROSCI, V21, P7534; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; PARSON SH, 1995, NEURODEGENERATION, V4, P99, DOI 10.1006/neur.1995.0012; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rash JE, 2000, P NATL ACAD SCI USA, V97, P7573, DOI 10.1073/pnas.97.13.7573; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Scemes E, 1998, GLIA, V24, P74, DOI 10.1002/(SICI)1098-1136(199809)24:1<74::AID-GLIA8>3.0.CO;2-0; SCHEETZ AJ, 1994, FASEB J, V8, P745; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Striedinger K, 2005, EUR J NEUROSCI, V22, P605, DOI 10.1111/j.1460-9568.2005.04228.x; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; Udawatte C, 2005, APOPTOSIS, V10, P1019, DOI 10.1007/s10495-005-0776-8; Vaccari JCD, 2006, P NATL ACAD SCI USA, V103, P16971, DOI 10.1073/pnas.0608068103; Valiunas V, 2004, AM J PHYSIOL-CELL PH, V287, pC1596, DOI 10.1152/ajpcell.00225.2004; Velazquez JLP, 2006, EUR J NEUROSCI, V23, P1, DOI 10.1111/j.1460-9568.2005.04523.x; Velazquez JLP, 2003, NEUROSCIENTIST, V9, P5, DOI 10.1177/1073858402239586; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Yoon WJ, 2003, J NEUROCHEM, V85, P525, DOI 10.1046/j.1471-4159.2003.01724.x; Yoshida M, 2000, NEUROSCI RES, V36, P1, DOI 10.1016/S0168-0102(99)00100-5; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	64	38	39	1	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	NOV	2007	98	5					2878	2886		10.1152/jn.00362.2007			9	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	230UB	WOS:000250900300035	17855590				2021-06-18	
J	Tolonen, A; Turkka, J; Salonen, O; Ahoniemi, E; Alaranta, H				Tolonen, Anu; Turkka, Jukka; Salonen, Oili; Ahoniemi, Eija; Alaranta, Hannu			Traumatic brain injury is under-diagnosed in patients with spinal cord injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; spinal cord injury; co-occurrence; rehabilitation	CLOSED-HEAD-INJURY; FUNCTIONAL CLASSIFICATION; INTERNATIONAL STANDARDS; CONSCIOUSNESS; DEFICITS; AMNESIA; SCALE	Objective: To investigate the occurrence and severity of traumatic brain injury in patients with traumatic spinal cord injury. Design: Cross-sectional study with prospective neurological, neuropsychological and neuroradiological examinations and retrospective medical record review. Patients: Thirty-one consecutive, traumatic spinal cord injury patients on their first post-acute rehabilitation period in a national rehabilitation centre. Methods: The American Congress of Rehabilitation Medicine diagnostic criteria for mild traumatic brain injury were applied. Assessments were performed with neurological and neuropsychological examinations and magnetic resonance imaging 1.5T. Results: Twenty-three of the 31 patients with spinal cord injury (74%) met the diagnostic criteria for traumatic brain injury. Nineteen patients had sustained a loss of consciousness or post-traumatic amnesia. Four patients had a focal neurological finding and 21 had neuropsychological findings apparently due to traumatic brain injury. Trauma-related magnetic resonance imaging abnormalities were detected in 10 patients. Traumatic brain injury was classified as moderate or severe in 17 patients and mild in 6 patients. Conclusion: The results suggest a high frequency of traumatic brain injury in patients with traumatic spinal cord injury, and stress a special diagnostic issue to be considered in this patient group.	Finnish Associat People Mobil Disabilit, Kapyla Rehabil Ctr, FI-00251 Helsinki, Finland; Univ Helsinki, Dept Radiol, Helsinki, Finland	Tolonen, A (corresponding author), Finnish Associat People Mobil Disabilit, Kapyla Rehabil Ctr, POB 103, FI-00251 Helsinki, Finland.	anu.tolonen@invalidiliitto.fi					Ahmed S, 2000, BRAIN INJURY, V14, P765; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; AYYOUB Z, 2002, SPINAL CORD MED PRIN; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MAHMOUD A, 1999, INJURY REHABIL, V5, P42; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; OJANEN M, 1993, RESPIRATION, V60, P96; OJANEN M, 1997, EVALUATION, V3, P135; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	25	38	43	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2007	39	8					622	626		10.2340/16501977-0101			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	225UK	WOS:000250543400006	17896053	DOAJ Gold			2021-06-18	
J	Riordan, WP; Cotton, BA; Norris, PR; Waitman, LR; Jenkins, JM; Morris, JA				Riordan, William P.; Cotton, Bryan A.; Norris, Patrick R.; Waitman, Lemuel R.; Jenkins, Judith M.; Morris, John A.			beta-blocker exposure in patients with severe traumatic brain injury (TBI) and cardiac uncoupling	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		heart rate variability; cardiac uncoupling; beta-blocker; trauma; brain injury	HEART-RATE-VARIABILITY; SUBARACHNOID HEMORRHAGE; ORGAN DYSFUNCTION; SPECTRAL-ANALYSIS; DEATH; CATECHOLAMINES; COMPLICATIONS; PROPRANOLOL; PREDICTOR; PRESSURE	Background: Cardiac uncoupling and reduced heart rate (HR) variability are associated with increased mortality after severe traumatic brain injury (TBI). Recent data has shown beta-blocker (beta B) exposure is associated with improved survival in this patient population. The purpose of the present study was to evaluate the effect of beta B exposure on the mortality risk of patients with severe TBI and early cardiac uncoupling. Methods: From December 2000 to October 2005, 4,116 patients were admitted to the trauma intensive care unit. Four hundred forty-six patients (12%) had head Abbreviated Injury Scale score : 5 without neck injury and had continuous HR data for the first 24 hours. One hundred forty-one patients (29%) received beta B. Cardiac uncoupling was calculated as the percent of time that 5-minute HR standard deviation was between 0.3 bpm and 0.6 bpm on postinjury day 1. Results: A relationship between beta B and survival was observed when the population was considered irrespective of length of stay or beta B start time (p < 0.001). Cardiac uncoupling appears to stratify patients into groups who might receive additional benefit from beta B, and identifies patients with increasing mortality. However, the association of beta B with survival was attenuated when analyses accounted for selection bias in beta B administration. Conclusions: beta B exposure was associated with reduced mortality among patients with severe TBI. Though loss of HR variability has previously been associated with an increase in mortality, beta B exposure appears to be associated with increased survival across all stratifications of cardiac uncoupling. Key Words. Heart rate variability, Cardiac uncoupling, beta-Blocker, Trauma, Brain injury.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37212 USA	Riordan, WP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	william.riordan@vanderbilt.edu	Cotton, Bryan/A-7107-2009				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ARBABI S, 2006, 65 ANN M AAST SEP 28; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; COTTON BA, 2007, J TRAUMA, V62, P1; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; Fathizadeh P, 2004, CRIT CARE MED, V32, P1300, DOI 10.1097/01.CCM.0000127776.78490.E4; FEIBEL JH, 1981, ANN NEUROL, V9, P340, DOI 10.1002/ana.410090405; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P228, DOI 10.1097/00003246-199302000-00014; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Grogan EL, 2004, ANN SURG, V240, P547, DOI 10.1097/01.sla.0000137143.65540.9c; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Kemp CD, 2006, J AM COLL SURGEONS, V203, pS36, DOI 10.1016/j.jamcollsurg.2006.05.090; King ML, 1997, BRAIN INJURY, V11, P445; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Korpelainen JT, 1996, STROKE, V27, P2059, DOI 10.1161/01.STR.27.11.2059; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; Lampert R, 2003, AM J CARDIOL, V91, P137, DOI 10.1016/S0002-9149(02)03098-9; LOWENSOHN RI, 1977, LANCET, V1, P626; MALING HM, 1958, AM J PHYSIOL, V194, P590; MCLEOD AA, 1982, BRIT HEART J, V47, P221; MOREL DR, 1984, INTENS CARE MED, V10, P133, DOI 10.1007/BF00265802; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; MOWERY NT, 2006, AM ASS SURG TRAUM 65; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Neil-Dwyer G, 1990, Acta Neurochir Suppl (Wien), V47, P102; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Poulat P, 1998, EUR J PHARMACOL, V344, P251, DOI 10.1016/S0014-2999(97)01569-0; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; RIORDAN WP, 2007, SOC CRIT CAR MED 36; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SPARKS HV, 1970, CARDIOVASC RES, V4, P363, DOI 10.1093/cvr/4.3.363; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	63	38	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					503	510		10.1097/TA.0b013e3181271c34			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	211DA	WOS:000249503300004	18073593				2021-06-18	
J	Ubiali, F; Nava, S; Nessi, V; Frigerio, S; Parati, E; Bernasconi, P; Mantegazza, R; Baggi, F				Ubiali, Federica; Nava, Sara; Nessi, Valeria; Frigerio, Simona; Parati, Eugenio; Bernasconi, Pia; Mantegazza, Renato; Baggi, Fulvio			Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation	INTERNATIONAL IMMUNOLOGY			English	Article						NSC; one-way MLR; transplantation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CLASS-I; STEM/PROGENITOR CELLS; HUMAN MYOBLASTS; MUSCLE-CELLS; TRANSPLANTATION; DIFFERENTIATION; VITRO; STIMULATION	Neural stem cells (NSCs) transplantation has been proposed as a means of restoring damaged brain tissue, a possibility rendered more likely by reports of low NSCs immunogenicity in various experimental models because of low expression of MHC class I and II as well as co- stimulatory molecules. We investigated the immunogenicity of a human NSC line grown in normal culture conditions and in the presence of pro- inflammatory cytokines IFN-gamma and tumor necrosis factor alpha by one-way mixed lymphocyte reaction (MLR) experiments with peripheral blood lymphocytes from eight HLA-incompatible donors. NSCs stimulated lymphocyte proliferation in almost all donors tested, with stimulation indices in the range of the low-end distribution curve of MLR between donors. The healthy subject that gave negative MLR results was the best compatible donor with respect to NSC haplotype. Since we observed low MLR responses overall, we studied if NSCs might exert any immunomodulatory activity. We detected transcription and release of the immunomodulatory molecule transforming growth factor beta (TGF-beta)-1; moreover, the addition of TGF-beta 1 in MLR experiments down-regulated proliferative responses. To further confirm the immunological potential of human NSCs, we studied xenogeneic recognition of NSCs by immunocompetent cells derived from C57BL/6 mice, showing that NSCs can elicit an allo(xeno) response ex vivo. Our data indicate that NSCs have low but not negligible immunogenic potential that is sufficient to activate peripheral lymphocytes. Secretion of TGF-b1 might balance the immunogenicity of NSCs. Nevertheless, the possibility that allo-NSCs grafting might induce in the long term an immune activation, thus vanishing their therapeutical effect, should not be overlooked and deserves further investigation.	Neurol Inst Fdn Carlo Besta, I-20133 Milan, Italy	Baggi, F (corresponding author), Neurol Inst Fdn Carlo Besta, Via Celoria 11, I-20133 Milan, Italy.	baggi@istituto-besta.it	Frigerio, Simona/AAI-3264-2021; Bernasconi, Pia/AAB-7590-2019; Parati, Eugenio A/G-8765-2011; Mantegazza, Renato/AAB-7569-2019; Nava, Sara/J-8740-2016; Parati, Eugenio Agostino/AAN-5893-2021; Baggi, Fulvio/AAX-4132-2020	Frigerio, Simona/0000-0001-7078-075X; Mantegazza, Renato/0000-0002-9810-5737; Nava, Sara/0000-0001-9912-8255; Parati, Eugenio Agostino/0000-0001-5020-6523; Baggi, Fulvio/0000-0002-4618-0102; Bernasconi, Pia/0000-0003-0869-2104			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; BAGGI F, 1993, J NEUROIMMUNOL, V46, P57, DOI 10.1016/0165-5728(93)90233-O; BARKER CF, 1977, ADV IMMUNOL, V25, P1; Bernasconi P, 1998, J NEUROIMMUNOL, V85, P52, DOI 10.1016/S0165-5728(97)00254-3; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Curnow SJ, 1998, J NEUROIMMUNOL, V86, P53, DOI 10.1016/S0165-5728(98)00013-7; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Duan WM, 2002, NEUROSCIENCE, V115, P495, DOI 10.1016/S0306-4522(02)00382-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; GOEBELS N, 1992, J IMMUNOL, V149, P661; Grinnemo KH, 2004, J THORAC CARDIOV SUR, V127, P1293, DOI 10.1016/j.jtcvs.2003.07.037; Holzer U, 2006, J AUTOIMMUN, V26, P241, DOI 10.1016/j.jaut.2006.03.006; Imitola J, 2004, AM J PATHOL, V164, P1615, DOI 10.1016/S0002-9440(10)63720-0; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Isacson O, 2003, LANCET NEUROL, V2, P417, DOI 10.1016/S1474-4422(03)00437-X; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Mammolenti M, 2004, STEM CELLS, V22, P1101, DOI 10.1634/stemcells.22-6-1101; Mantegazza R, 1996, J NEUROIMMUNOL, V68, P53, DOI 10.1016/0165-5728(96)00068-9; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; McLaren FH, 2001, J NEUROIMMUNOL, V112, P35, DOI 10.1016/S0165-5728(00)00410-0; Mickelson EM, 1996, TISSUE ANTIGENS, V47, P27, DOI 10.1111/j.1399-0039.1996.tb02511.x; Modo M, 2003, NEUROSCI LETT, V337, P85, DOI 10.1016/S0304-3940(02)01301-0; Muraoka K, 2006, EXP NEUROL, V199, P311, DOI 10.1016/j.expneurol.2005.12.004; Odeberg J, 2005, J NEUROIMMUNOL, V161, P1, DOI 10.1016/j.jneuroim.2004.11.016; Pachter JS, 2003, J NEUROPATH EXP NEUR, V62, P593, DOI 10.1093/jnen/62.6.593; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Parati E A, 2004, J Endocrinol Invest, V27, P64; Parati EA, 2002, BRAIN RES, V925, P213, DOI 10.1016/S0006-8993(01)03291-7; Petersdorf EW, 2003, TISSUE ANTIGENS, V61, P1, DOI 10.1034/j.1399-0039.2003.610101.x; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Poltavtseva RA, 2002, DEV BRAIN RES, V134, P149, DOI 10.1016/S0165-3806(02)00274-2; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sung JL, 2003, INT IMMUNOPHARMACOL, V3, P233, DOI 10.1016/S1567-5769(02)00276-X; Tambur AR, 2004, NEUROL RES, V26, P243, DOI 10.1179/016164104225013932; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088	37	38	40	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0953-8178			INT IMMUNOL	Int. Immunol.	SEP	2007	19	9					1063	1074		10.1093/intimm/dxm079			12	Immunology	Immunology	227TV	WOS:000250681600004	17660500	Bronze			2021-06-18	
J	Clark, RSB; Vagni, VA; Nathaniel, PD; Jenkins, LW; Dixon, CE; Szabo, C				Clark, Robert S. B.; Vagni, Vincent A.; Nathaniel, Paula D.; Jenkins, Larry W.; Dixon, C. Edward; Szabo, Csaba			Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD(+) depletion and improves water maze performance after traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; head injury; ideno-isoquinolone; nicotinamide adenine dinucleotide; poly(ADP-ribose) synthetase	NF-KAPPA-B; CELL-DEATH; PEROXYNITRITE; TRANSCRIPTION; RIBOSYLATION; ACTIVATION; STRESS; P53	Poly( ADP-ribose) polymerase-1 (PARP-1) is an enzyme best known for its role in DNA repair and as a mediator of NAD(+) depletion and energy failure- induced cell death. We tested the effect of the potent and selective ideno-isoquinolone PARP-1 inhibitor INO-1001 after controlled cortical impact (CCI) in mice. Anesthetized adult male mice were subjected to moderate CCI ( velocity 6 m/sec, depth 1.2 mm) or sham-injury. Immediately after CCI or sham-injury mice received either INO1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 mu l over 5 min) in a randomized fashion. At 2 h, contused brain tissue was dissected and NAD(+) levels were measured. Separate mice underwent neuropathological outcome tests that included spatial memory acquisition ( Morris water maze days 14 - 20), and assessment of contusion volume and hippocampal cell death at day 21. Local treatment with INO-1001 preserved brain NAD(+) levels 2 h after CCI (vehicle = 67 +/- 7.6, INO-1001 = 95.8 +/- 4.4% uninjured hemisphere; n = 6/group, p = 0.03). In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI (n = 11/group, p <= 0.05). Histological damage did not differ between vehicle and INO-1001-treated mice after CCI. Treatment with INO-1001 prevented NAD(+) depletion and improved outcome, although modestly, identifying PARP-mediated energy failure as a contributor to the pathological sequelae of TBI. Further study testing the effects of PARP inhibitors is warranted, specifically in models of brain injury where energy failure is seen.	Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Szabo, Csaba/D-1882-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, R44 NS37985, P50 NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R44NS037985, R01NS038620] Funding Source: NIH RePORTER		Abusaad I, 1999, J COMP NEUROL, V408, P560, DOI 10.1002/(SICI)1096-9861(19990614)408:4<560::AID-CNE9>3.0.CO;2-P; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; DAWSON TM, 1995, NEW HORIZONS, V3, P86; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Jagtap PG, 2005, J MED CHEM, V48, P5100, DOI 10.1021/jm0502891; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Pacher P, 2004, J PHARMACOL EXP THER, V311, P485, DOI 10.1124/jpet.104.069658; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	22	38	38	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1399	1405		10.1089/neu.2007.0305			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500011	17711401				2021-06-18	
J	Myhre, MC; Grogaard, JB; Dyb, GA; Sandvik, L; Nordhov, M				Myhre, M. C.; Grogaard, J. B.; Dyb, G. A.; Sandvik, L.; Nordhov, M.			Traumatic head injury in infants and toddlers	ACTA PAEDIATRICA			English	Article						child abuse; head injury; infants and children; neglect; risk factors	YOUNG-CHILDREN; BRAIN-INJURY; HEMORRHAGE	Aim: To describe the presenting characteristics, type of injury and hospital course in young children with traumatic head injury, and to identify characteristics indicating that the trauma was inflicted. Methods: A retrospective medical record review of 91children less than 3 years of age who were admitted to a tertiary teaching hospital in Norway from 1995 through 2005 with a traumatic head injury. Patients were identified by diagnostic codes, and categorized by type of injury as skull fractures (n = 39), epidural haemorrhage (EDH) (n = 12), subdural haemorrhage (n = 27) and parenchymal brain injury (n = 13). Further the cases were classified as inflicted injury (n = 17), accident (n = 35) or indeterminate (n = 39). Results: The mechanism of injury was similar for EDHs and isolated skull fractures, and none were classified as inflicted. Sixty-three percent of the cases with subdural haematoma were classified as inflicted. When compared to the accident group, children in the inflicted group more frequently had subdural haemorrhage without a skull fracture (OR = 6.9, CI = 1.7-28.2), and seizures (OR = 9.5, CI = 2.1-43.3). Conclusions: Inflicted and accidental head injuries differed in presenting characteristics and injury type. Nearly two-third of the subdural haemorrhages were classified as inflicted, but none of the epidural EDHs or skull fractures. Inflicted injuries tended to present with seizures.	Ullevaal Univ Hosp, Dept Paediat Intens Care, N-0407 Oslo, Norway; Norwegian Ctr Violence & Traumat Strees Studies, Oslo, Norway; Ullevaal Univ Hosp, Clin Res Ctr, Oslo, Norway; Univ Hosp, Dept Paediat, Tromso, Norway	Myhre, MC (corresponding author), Ullevaal Univ Hosp, Dept Paediat Intens Care, N-0407 Oslo, Norway.	mimy@uus.no					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GRAHREMAN A, 2005, J NEUROSURG, V103, P213; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; King WJ, 2003, CAN MED ASSOC J, V168, P155; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Shugerman RP, 1996, PEDIATRICS, V97, P664; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380	22	38	39	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	AUG	2007	96	8					1159	1163		10.1111/j.1651-2227.2007.00356.x			5	Pediatrics	Pediatrics	193OD	WOS:000248282500013	17578493	Green Published			2021-06-18	
J	Giovannetti, T; Bettcher, BM; Libon, DJ				Giovannetti, Tania; Bettcher, Brianne Magouirk; Libon, David J.			Environmental adaptations improve everyday action performance in Alzheimer's disease: Empirical support from performance-based assessment	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		naturalistic action; activities of daily living; instrumental activities of daily living; rehabilitation; remediation	PROCEDURAL MEMORY STIMULATION; SUBCORTICAL VASCULAR DEMENTIA; CLOSED-HEAD-INJURY; NATURALISTIC ACTION; ACTION IMPAIRMENT; INTERVENTION; DEFICITS; NEUROPSYCHOLOGY; REHABILITATION; CAREGIVERS	Neuropsychologists often recommend that patients with dementia and their caregivers use environmental adaptations to improve everyday functioning. Although these recommendations are intuitive (e.g., reduce clutter), most have never been experimentally tested. This study examined whether and how environmental adaptations improved everyday action in Alzheimer's disease (AD). Forty-six outpatients completed the Naturalistic Action Test (NAT; M. F. Schwartz, L. J. Buxbaum, M. Ferraro, T. Veramonti, & M. Segal, 2003), which requires completion of 3 everyday tasks. The NAT was administered under 2 conditions: standard and user centered. The standard NAT followed the procedures of the manual; object placement was standardized, but objects were not meaningfully arranged on the tabletop. In the user-centered NAT, objects were arranged in the order needed in the task, and a visual cue to monitor performance was placed on the table. These conditions were counterbalanced across participants. The user-centered condition improved performance on all NAT items and reduced commission and omission error rates. However, post hoc examination of commission error types showed improvement of substitution and off-task errors but no difference in anticipation and perseveration errors. Thus, environmental adaptations improved everyday performance in AD by facilitating task accomplishment, object selection, and task-congruent actions.	Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA; Univ Med & Dent New Jersey, Sch Osteopath Med, New Jersey Inst Successful Aging, Newark, NJ 07103 USA	Giovannetti, T (corresponding author), Temple Univ, Dept Psychol, Weiss Hall,1701 N 13th St, Philadelphia, PA 19122 USA.	tgio@temple.edu	Giovannetti, Tania/H-3491-2019	Giovannetti, Tania/0000-0001-5661-152X			Adam S, 2000, NEUROPSYCHOL REHABIL, V10, P485, DOI 10.1080/09602010050143568; AKRITAS MG, 1994, J AM STAT ASSOC, V89, P336, DOI 10.2307/2291230; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Avila R, 2004, BRAZ J MED BIOL RES, V37, P1721, DOI 10.1590/S0100-879X2004001100018; Brawley EC, 2001, AGING MENT HEALTH, V5, pS79; Buxbaum LJ, 1998, COGNITIVE NEUROPSYCH, V15, P617, DOI 10.1080/026432998381032; Charness N, 2001, Aging Ment Health, V5, P65; CICERONE K, 1991, NEUROPSYCHOLOGY EVER; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; CLOUD BS, 1994, J INT NEUROPSYCH SOC, V1, P354; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CORCORAN MA, 1992, AM J OCCUP THER, V46, P801, DOI 10.5014/ajot.46.9.801; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Farina E, 2002, ACTA NEUROL SCAND, V105, P365, DOI 10.1034/j.1600-0404.2002.01086.x; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; FITTS PM, 1953, J EXP PSYCHOL, V46, P199, DOI 10.1037/h0062827; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forde EME, 2002, NEUROCASE, V8, P151, DOI 10.1093/neucas/8.1.151; Giovannetti T, 2006, J INT NEUROPSYCH SOC, V12, P45, DOI 10.1017/S1355617706060012; Giovannetti T, 2002, J INT NEUROPSYCH SOC, V8, P633, DOI 10.1017/S135561770280131X; Giovannetti T, 2002, NEUROPSYCHOLOGIA, V40, P1220, DOI 10.1016/S0028-3932(01)00229-9; Giovannetti T, 2006, ARCH CLIN NEUROPSYCH, V21, P607, DOI 10.1016/j.acn.2006.05.005; GIOVANNETTICARE.T, 1997, NEUROPSYCHOLOGY, V11, P400; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Guilarte TR, 2003, ANN NEUROL, V53, P50, DOI 10.1002/ana.10399; Hartmann K, 2005, NEUROPSYCHOLOGIA, V43, P625, DOI 10.1016/j.neuropsychologia.2004.07.015; Humphreys GW, 1998, COGN NEUROPSYCHOL, V15, P771; Irvine GI, 2006, HIPPOCAMPUS, V16, P149, DOI 10.1002/hipo.20142; JOSEPHSSON S, 1993, INT J GERIATR PSYCH, V8, P395, DOI 10.1002/gps.930080505; JOSEPHSSON S, 1995, OCCUP THER J RES, V15, P36, DOI 10.1177/153944929501500103; Kaplan E., 1983, BOSTON NAMING TEST; Kempermann G, 1999, HIPPOCAMPUS, V9, P321, DOI 10.1002/(SICI)1098-1063(1999)9:3<321::AID-HIPO11>3.0.CO;2-C; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; Lamar M, 2002, NEUROPSYCHOLOGIA, V40, P435, DOI 10.1016/S0028-3932(01)00125-7; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEVINE B, 2000, J CLIN EXPT NEUROPSY, V20, P30; Libon DJ, 2004, CLIN NEUROPSYCHOL, V18, P83, DOI 10.1080/13854040490507181; Libon DJ, 1996, ARCH CLIN NEUROPSYCH, V11, P193; LIBON DJ, 2005, J INT NEUROPSYCHO S1, V11, P92; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Noale M, 2003, DEMENT GERIATR COGN, V16, P7, DOI 10.1159/000069987; NORMAN D, 1990, NEUROLOGY, V65, P376; REASON J, 1990, HUAMN ERROR; Rusted J, 2002, NEUROCASE, V8, P111, DOI 10.1076/neur.8.1.111.16240; Schwartz M. F., 2003, NATURALISTIC ACTION; Schwartz MF, 1999, NEUROPSYCHOLOGIA, V37, P51; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; Seigal S, 1988, NONPARAMETRIC STAT B; SELNICK L, 2000, BEHAV INTERVENT, V15, P243; Sestito N., 2005, J INT NEUROPSYCHO S1, V11, P90; Spreen O., 1991, COMPENDIUM NEUROPSYC; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Winocur G, 2000, BRAIN COGNITION, V42, P120, DOI 10.1006/brcg.1999.1179; Yesavage J., 1986, HDB CLIN MEMORY ASSE, P213; Zanetti O, 1997, ACTA NEUROL SCAND, V95, P152, DOI 10.1111/j.1600-0404.1997.tb00087.x; Zanetti O, 2001, NEUROPSYCHOL REHABIL, V11, P263, DOI 10.1080/09602010042000088	60	38	38	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2007	21	4					448	457		10.1037/0894-4105.21.4.448			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	184GJ	WOS:000247628800006	17605578				2021-06-18	
J	Haukoos, JS; Gill, MR; Rabon, RE; Gravitz, CS; Green, SM				Haukoos, Jason S.; Gill, Michelle R.; Rabon, Rick E.; Gravitz, Craig S.; Green, Steven M.			Validation of the simplified motor score for the prediction of brain injury outcomes after trauma	ANNALS OF EMERGENCY MEDICINE			English	Article							GLASGOW COMA SCALE; HEAD-INJURIES; FIELD TRIAGE; RELIABILITY	Study objective: The Glasgow Coma Scale (GCS) score is widely used in the initial evaluation of patients with traumatic brain injury. This 15-point score, however, has been criticized as unnecessarily complex. Recently, a 3-point Simplified Motor Score (defined as obeys commands=2; localizes pain=1; withdrawals to pain or worse=0) was developed from the motor component of the GCS and was found to have a similar test performance for predicting outcomes after traumatic brain injury when compared with the GCS score as the criterion standard. The purpose of this study was to validate the Simplified Motor Score in a large heterogeneous trauma population. Methods: This was a secondary analysis of a prospectively maintained trauma registry with consecutive trauma patients who presented to a Level I trauma center from 1995 through 2004. Test performance of the GCS and the Simplified Motor Score relative to 4 clinically relevant traumatic brain injury outcomes (emergency intubation, clinically significant brain injury, neurosurgical intervention, and mortality) was evaluated with areas under the receiver operating characteristic curves (AUCs). Results: Of 21,170 patients included in the analysis, 18% underwent emergency intubation, 14% had clinically significant brain injuries, 7% underwent neurosurgical intervention, and 5% died. The AUCs for the GCS and its components ranged from 0.76 to 0.92 across the 4 outcome measures. The AUCs for the Simplified Motor Score ranged from 0.71 to 0.89, and the relative differences from the GCS AUCs ranged from 3% to 7%, with a median difference of 5%. Conclusion: In this external validation study, the 3-point Simplified Motor Score demonstrated similar test performance when compared with the 15-point GCS score and its components for the prediction of 4 clinically important traumatic brain injury outcomes.	Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO 80204 USA; Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Loma Linda Univ, Sch Med, Dept Emergency Med, Loma Linda, CA USA	Haukoos, JS (corresponding author), Denver Hlth Med Ctr, Dept Emergency Med, 777 Bannock St,Mail Code 0108, Denver, CO 80204 USA.	jason.haukoos@dhha.org					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; *AM COLL SURG COMM, 1998, MAN HEAD INJ; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; GORMICAN SP, 1982, ANN EMERG MED, V11, P132, DOI 10.1016/S0196-0644(82)80237-0; Grzybowski M, 1997, ACAD EMERG MED, V4, P818, DOI 10.1111/j.1553-2712.1997.tb03793.x; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; SEGATORE M, 1992, HEART LUNG, V21, P548; STARMARK JE, 1991, LANCET, V337, P1042, DOI 10.1016/0140-6736(91)92705-7; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Stevens RD, 2006, CRIT CARE MED, V34, P31, DOI 10.1097/01.CCM.0000194534.42661.9F; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tinkoff GH, 2002, J TRAUMA, V52, P1153, DOI 10.1097/00005373-200206000-00022; Tsao JW, 2005, ARCH NEUROL-CHICAGO, V62, P1126, DOI 10.1001/archneur.62.7.1126; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011	33	38	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUL	2007	50	1					18	24		10.1016/j.annemergmed.2006.10.004			7	Emergency Medicine	Emergency Medicine	186IX	WOS:000247773500006	17113193				2021-06-18	
J	Ramos-Mandujano, G; Vazquez-Juarez, E; Hernandez-Benitez, R; Pasantes-Morales, H				Ramos-Mandujano, Gerardo; Vazquez-Juarez, Erika; Hernandez-Benitez, Reyna; Pasantes-Morales, Herminia			Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes	GLIA			English	Article						intracerebral hemorrhage; PAR-1; volume-sensitive anion channel; DCPIB; tamoxifen; astrocyte swelling	PROTEASE-ACTIVATED RECEPTORS; SH-SY5Y NEUROBLASTOMA-CELLS; MUSCARINIC CHOLINERGIC-RECEPTORS; ISCHEMIC NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; G-BETA-GAMMA; CEREBRAL-ISCHEMIA; RAT ASTROCYTES; TAURINE RELEASE; POTENTIATION	High concentrations of thrombin (Thr) have been linked to neuronal damage in cerebral ischemia and traumatic brain injury. In the present study we found that Thr markedly enhanced swelling-activated efflux of H-3-glutamate from cultured astrocytes exposed to hyposmotic medium. Thr (0.5-5 U/mL) elicited small H-3-glutamate efflux under isosmotic conditions and increased the hyposmotic glutamate efflux by 5- to 10-fold, the maximum effect being observed at 15% osmolarity reduction. These Thr effects involve its protease activity and are fully mimicked by SFFLRN, the synthetic peptide activating protease-activated receptor-1. Thr potentiation of 3H-glutamate efflux was largely dependent on a Thr-elicited increases in cytosolic Ca 21 (Ca(2+)i) concentration ([Ca 21],). Preventing Ca(t+)i rise by treatment with EGTA-AM or with the phospholipase C blocker U73122 reduced the Thr-increased glutamate efflux by 68%. The protein kinase C blockers Go6976 or chelerythrine reduced the Thr effect by 19%-22%, while Ca/calmodulin blocker W7 caused a 63% inhibition. In addition to this Ca2+-sensitive pathway, Thr effect on glutamate efflux also involved activation of phosphoinositide-3 kinase (PI3K), since it was reduced by the PI3K inhibitor wortmannin (51% inhibition). Treating cells with EGTA-AM plus wortmannin essentially abolished Thr-dependent glutamate efflux. Thr-activated glutamate release was potently inhibited by the blockers of the volume-sensitive anion permeability pathway, NPPB (IC50 15.8 mu M), DCPIB (IC50 4.2 mu M), and tamoxifen (IC50 6.6 mu M). These results suggest that Thr may contribute to the excitotoxic neuronal injury by elevating extracellular glutamate release from glial cells. Therefore, this work may aid in search of neuroprotective strategies for treating cerebral ischemia and brain trauma. (C) 2007 Wiley-Liss, Inc.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biofis, Mexico City 04510, DF, Mexico	Pasantes-Morales, H (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biofis, Ciudad Univ, Mexico City 04510, DF, Mexico.	hpasante@ifc.unam.mx	Vazquez-Juarez, Erika/D-8183-2017	Vazquez-Juarez, Erika/0000-0003-1810-9621; Hernandez-Benitez, Reyna/0000-0003-2546-8956			Abdullaev IF, 2006, J PHYSIOL-LONDON, V572, P677, DOI 10.1113/jphysiol.2005.103820; AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cardin V, 2003, GLIA, V44, P119, DOI 10.1002/glia.10271; Cheema TA, 2005, J PHARMACOL EXP THER, V315, P755, DOI 10.1124/jpet.105.090787; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Decher T, 2001, BRIT J PHARMACOL, V134, P1467; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; Franco R, 2004, PFLUG ARCH EUR J PHY, V449, P159, DOI 10.1007/s00424-004-1322-1; Fujimoto S, 2007, NEUROSCIENCE, V144, P694, DOI 10.1016/j.neuroscience.2006.09.049; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Heacock AM, 2004, J PHARMACOL EXP THER, V311, P1097, DOI 10.1124/jpet.104.072553; Heacock AM, 2006, J PHARMACOL EXP THER, V317, P685, DOI 10.1124/jpet.105.098467; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Karabiyikoglu M, 2004, J CEREBR BLOOD F MET, V24, P159, DOI 10.1097/01.WCB.0000100062.36077.84; Kawai H, 1996, J PHARMACOL EXP THER, V278, P780; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; Loveday D, 2003, J NEUROCHEM, V87, P476, DOI 10.1046/j.1471-4159.2003.02021.x; Manolopoulos VG, 1997, BIOCHEM BIOPH RES CO, V232, P74, DOI 10.1006/bbrc.1997.6222; Mongin AA, 2005, AM J PHYSIOL-CELL PH, V288, pC204, DOI 10.1152/ajpcell.00330.2004; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Pike CJ, 1996, J NEUROCHEM, V66, P1374; Ribeiro MD, 2006, EXP NEUROL, V198, P199, DOI 10.1016/j.expneurol.2005.11.017; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; THOROED SM, 1995, J EXP BIOL, V198, P311; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Weinstein JR, 2005, J NEUROCHEM, V95, P1177, DOI 10.1111/j.1471-4159.2005.03499.x; Won SJ, 2002, J BIOCHEM MOL BIOL, V35, P67, DOI 10.5483/BMBRep.2002.35.1.067; Xi GH, 2002, STROKE, V33, P399; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	35	38	41	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2007	55	9					917	925		10.1002/glia.20513			9	Neurosciences	Neurosciences & Neurology	173EM	WOS:000246856300003	17437307				2021-06-18	
J	Ai, JL; Liu, E; Wang, JL; Chen, YH; Yu, J; Baker, AJ				Ai, Jinglu; Liu, Elaine; Wang, Jianli; Chen, Yonghong; Yu, Julie; Baker, Andrew J.			Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid-precursor protein (beta APP) accumulation; calpain inhibitor; compound action potential; corpus callosum; fluid percussion injury; MDL-28170; rat; therapeutic time window	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; SPINAL-CORD; MODEL; PATHOPHYSIOLOGY; ANTIBODIES; BREAKDOWN; RECOVERY; THERAPY	It is known that calpain activation is involved in human traumatic brain injury (TBI) and that calpain inhibition can have neuroprotective effects on both gray matter and white matter injury of TBI models. However, the role of calpain activation in the corpus callosum remains unclear and requires elucidation given its potential clinical relevance. We evaluated the neuroprotective effects of calpain inhibitor MDL-281-70 on corpus callosum function and structural destruction using a fluid percussion injury (FPI) model. The therapeutic time window for a single administration of MDL-28170 was up to 4 h post injury in protecting the corpus callosum structural integrity, and up to 30 min in protecting the axonal function evaluated 1 day following injury. When given 30 min prior injury, MDL-28170 showed neuroprotective effects that lasted up to 7 days. However, 30 min post injury administration of the drug afforded neuroprotection only up to 3 days. In contrast, two additional reinforcement injections at 24 and 48 h in addition to 30 min post FPI significantly protected both axonal function and structural integrity that lasted 14 days following FPI. Our data indicated that calpain inhibitor MDL-28170 is an effective neuroprotectant for axonal injury in corpus callosum following FPI with a therapeutic time window tip to 4 hours. Although delayed treatment (2 or 4 h post FPI) was effective in protecting the axonal structure, the axons saved may not be as functional as normal fibers. Multiple drug administrations may be necessary for achieving a persisting effectiveness of this compound.	Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, Toronto, ON M5B 1W8, Canada	Baker, AJ (corresponding author), Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; ARLINGHAUS L, 1991, EUR J PHARMACOL, V209, P123, DOI 10.1016/0014-2999(91)90022-I; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRORSON JR, 1995, J NEUROSCI, V15, P4515; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Chen ZF, 1997, BRAIN RES, V769, P188, DOI 10.1016/S0006-8993(97)00848-2; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hirokawa N, 1994, Prog Clin Biol Res, V390, P117; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; Jiang QB, 2000, J NEUROCHEM, V74, P2101, DOI 10.1046/j.1471-4159.2000.0742101.x; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Li PA, 1998, NEUROSCI LETT, V247, P17, DOI 10.1016/S0304-3940(98)00266-3; Lipton P, 1999, PHYSIOL REV, V79, P1431; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Machado SS, 1999, BIOCATAL BIOTRANSFOR, V17, P179, DOI 10.3109/10242429909040114; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORLEY P, 1994, BRAIN PATHOL, V4, P37; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang K K, 1997, Adv Pharmacol, V37, P117; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	57	38	40	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					960	978		10.1089/neu.2006.0224			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700005	17600513				2021-06-18	
J	Sgubin, D; Aztiria, E; Perin, A; Longatti, P; Leanza, G				Sgubin, D.; Aztiria, E.; Perin, A.; Longatti, P.; Leanza, G.			Activation of endogenous neural stem cells in the adult human brain following subarachnoid hemorrhage	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain insult; cell proliferation; neural progenitor; human	RNA-BINDING PROTEIN; DELAYED CEREBRAL-ISCHEMIA; DENTATE GYRUS; PROGENITOR CELLS; SUBVENTRICULAR ZONE; ENHANCED NEUROGENESIS; PRECURSOR CELLS; PROLIFERATION; HIPPOCAMPUS; NEURONS	In the adult human brain, the presence of neural stem cells has been documented in the subgranular layer of the dentate gyrus of the hippocampus and in the sub-ventricular zone of the lateral ventricles. Neurogenesis has also been reported in rodent models of ischemic stroke, traumatic brain injury, epileptic seizures, and intracerebral or subarachnoid hemorrhage. However, only sparse information is available about the occurrence of neurogenesis in the human brain under similar pathological conditions. In the present report, we describe neural progenitor cell proliferation in the brain of patients suffering from subarachnoid hemorrhage (SAH) resulting from ruptured aneurysm. Ten cerebral samples from both SAH and control patients obtained, respectively, during aneurysm clipping and deep brain tumor removal were analyzed by reverse transcription followed by polymerase chain reaction (RT-PCR) and/or immunohistochernistry (IHC). In tissue specimens from SAH patients, RT-PCR and IHC revealed the expression of a variety of markers consistent with CNS progenitor cells, including nestin, vimentin, SOX-2, and Musashil and -2. In the same specimens, double immunohistochemistry followed by confocal analysis revealed that Musashi2 consistently colocalized with the proliferation marker Ki67. By contrast, no such gene or protein expression profiles were detected in any of the control specimens. Thus, activation of neural progenitor cell proliferation may occur in adult human brain following subarachnoid hemorrhage, possibly contributing to the promotion of spontaneous recovery, in this pathological condition. (c) 2007 Wiley-Liss, Inc.	Univ Trieste, BRAIN Ctr Neurosci, Dept Physiol & Pathol, Trieste, Italy; Treviso Hosp, Neurosurg Unit, Treviso, Italy	Leanza, G (corresponding author), Univ Trieste, BRAIN Ctr Neurosci, Dept Physiol & Pathol, Trieste, Italy.	gileanza@dfp.units.it	Perin, Alessandro/AAM-6299-2021	Perin, Alessandro/0000-0002-6697-9835			Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Calza L, 1998, P NATL ACAD SCI USA, V95, P3209, DOI 10.1073/pnas.95.6.3209; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; HIJDRA A, 1986, NEUROLOGY, V36, P329, DOI 10.1212/WNL.36.3.329; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; Hop JW, 1998, STROKE, V29, P798, DOI 10.1161/01.STR.29.4.798; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Klassen H, 2004, J NEUROSCI RES, V77, P334, DOI 10.1002/jnr.20183; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Komitova M, 2002, J CEREBR BLOOD F MET, V22, P852, DOI 10.1097/00004647-200207000-00010; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Liu JL, 1998, J NEUROSCI, V18, P7768; Magavi SS, 2000, NATURE, V405, P951; Mino M, 2003, NEUROL RES, V25, P839, DOI 10.1179/016164103771953934; Nakagawa E, 2000, EPILEPSIA, V41, P10, DOI 10.1111/j.1528-1157.2000.tb01498.x; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Prunell GF, 2002, NEUROREPORT, V13, P2553, DOI 10.1097/00001756-200212200-00034; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499; Sakakibara S, 2001, J NEUROSCI, V21, P8091; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; SHINGO T, 2001, EXP NEUROL, V177, P1; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Shu HJ, 2002, BIOCHEM BIOPH RES CO, V293, P150, DOI 10.1016/S0006-291X(02)00175-4; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Takizawa T, 2001, NEUROL RES, V23, P724, DOI 10.1179/016164101101199243; Tang T, 2004, CHINESE MED J-PEKING, V117, P1342; Tzeng SF, 1999, NEUROREPORT, V10, P2287, DOI 10.1097/00001756-199908020-00012; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yoshimi K, 2005, ANN NEUROL, V58, P31, DOI 10.1002/ana.20506; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	68	38	47	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2007	85	8					1647	1655		10.1002/jnr.21303			9	Neurosciences	Neurosciences & Neurology	177UG	WOS:000247177400006	17455304				2021-06-18	
J	Taylor, CM; Aird, VH; Tate, RL; Lanumi, MH				Taylor, Christine M.; Aird, Vanessa H.; Tate, Robyn L.; Lanumi, Michele H.			Sequence of recovery during the course of emergence from the minimally conscious state	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; minimally conscious state; rehabilitation	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC AMNESIA	Objective: To document and examine recovery profiles of persons during the course of emergence from a minimally conscious state (MCS) after traumatic brain injury (TBI). Design: Case series. Setting: Participants in an inpatient brain injury rehabilitation program. Participants: Nine people with TBI who emerged from MCS. Interventions: Not applicable. Main Outcome Measure: The Western Neuro Sensory Stimulation Profile. Results: In all cases, stereotyped (nonreflexive) movement was the first behavior to resolve, yet by itself it was never sufficient to indicate emergence from the MCS. Two of the 9 patients showed consistent object manipulation before all 3 elements of functional communication. Conversely, in 2 patients, all 3 components of functional communication emerged before object manipulation. In the remaining 5 patients, object manipulation occurred along with components of functional communication. Conclusions: During the course of data collection, issues were raised about differentiation between the MCS and posttraumatic amnesia. The data are also discussed within the context of the work of Giacino et al and the development of their scale to measure duration of the MCS. These data support the theory that functional communication and object manipulation are the 2 key indicators of emergence from MCS.	Royal Rehabil Ctr Sydney, Brain Injury Rehabil Serv, Ryde, NSW 1680, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Taylor, CM (corresponding author), Royal Rehabil Ctr Sydney, Brain Injury Rehabil Serv, POB 6, Ryde, NSW 1680, Australia.	christine.taylor@royalrehab.com.au					ANSELL BJ, 1989, W NEURO SENSORY STIM; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALKMUS D, 1980, REHABILITATION HEAD; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Smith VH, 2001, BRAIN IMPAIR, V2, P29, DOI DOI 10.1375/BRIM.2.1.29; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Tate RL., 2000, BRAIN IMPAIR, V1, P116	13	38	38	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2007	88	4					521	525		10.1016/j.apmr.2007.01.013			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	160CC	WOS:000245913400019	17398255				2021-06-18	
J	Han, BS; Kim, SH; Kim, OL; Cho, SH; Kim, YH; Jang, SH				Han, Bong Soo; Kim, Seong Ho; Kim, Oh Lyong; Cho, Soo Ho; Kim, Yun-Hee; Jang, Sung Ho			Recovery of corticospinal tract with diffuse axonal injury: A diffusion tensor image study	NEUROREHABILITATION			English	Article						motor recovery; diffusion tensor image; corticospinal tract; diffuse axonal injury	TRAUMATIC BRAIN-INJURY; STROKE; DEGENERATION; MRI	Objectives: The purpose of this study is to identity the recovery process of the corticospinal tract with diffuse axonal injury (DAI) using diffusion tensor imaging (DTI). Design: A 47-year-old female patient and six age-matched control subjects were evaluated. The patient presented with quadriparesis (more severe in the right extremities than the left ones) due to DAI at the onset of traumatic brain injury. Over the 24-month period following the onset of the injury, motor function of the four extremities slowly recovered to range which was close to normal. Two longitudinal DTIs were acquired from the patient (at 10 weeks and 24 months from onset) and from the control subjects. Fractional anisotropy (FA) and an apparent diffusion coefficient were measured using the region of interest (ROI) method. Results: On the 10-week DTL FAs of ROIs of the brainstem in both hemispheres of the patient were significantly lower than those of the control subjects. Compared to normal controls, the patient showed significantly increased FA in both sides of the brainstem at 24 months after the onset, which occurred in parallel with the improvement in motor function. Conclusions: Recovery in this patient could be attributed to the recovery of the corticospinal tract with diffuse axonal injury.	Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea; Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Kangwon, South Korea; Yeungnam Univ, Sch Med, Dept Neurosurg, Taegu, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Phys Med & Rehabil, Sch Med, Seoul, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, 317-1,Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net	Han, Bong Soo/AAL-6704-2020				Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P11; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2004, ARCH PHYS MED REHAB, V85, P506, DOI 10.1016/S0003-9993(03)00468-4; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maeda Takahiro, 2005, Brain and Nerve (Tokyo), V57, P27; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; Yamada K, 2003, STROKE, V34, DOI 10.1161/01.STR.0000085827.54986.89; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	17	38	40	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	2					151	155					5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	195LB	WOS:000248412600012	17656842				2021-06-18	
J	Sorani, MD; Hempbill, JC; Morabito, D; Rosenthal, G; Manley, GT				Sorani, Marco D.; Hempbill, J. Claude, III; Morabito, Diane; Rosenthal, Guy; Manley, Geoffrey T.			New approaches to physiological informatics in neurocritical care	NEUROCRITICAL CARE			English	Article						traumatic brain injury; intensive care; physiological monitoring; intracranial pressure; hierarchical clustering.	TRAUMATIC BRAIN-INJURY; MULTICENTER ANALYSIS; INTENSIVE-CARE; BIOINFORMATICS; PREDICTION; REGRESSION; VARIABLES; RECOVERY; PRESSURE; DATABASE	Introduction: A fundamental purpose of neurocritical care is the management of secondary brain injury. This is often accomplished by monitoring and managing individual patient parameters including physiological vital signs. Yet, the ability to record physiological data exceeds our ability to fully integrate it into patient care. We propose that advances in monitoring must be accompanied by advances in methods of high-frequency, multivariate data analysis that integrate the multiple processes occurring in critically ill patients. Methods: We describe initial work in the emerging field of physiological informatics in critical care medicine. We analyzed data on 23 patients with brain injury from our Neurotrauma and Critical Care Database, which contains more than 20 physiological parameters recorded automatically at one-minute intervals via bedside monitors connected to standard personal computers. We performed exploratory data analysis, studied two patient cases in detail, and implemented a data-driven classification approach using hierarchical clustering. Results: In this study, we present challenges and opportunities for high-frequency multimodal monitoring to quantitatively detect secondary brain insults, and develop clustering methodology to construct multivariate physiological data "profiles" to classify patients for diagnosis and treatment. Conclusions: Recording of many physiological variables across multiple patients is feasible and can lead to new clinical insights. Computational and analytical methods previously used primarily for basic science may have clinical relevance and can potentially be adapted to provide physicians with improved ability to integrate complex information for decision making in neurocritical care.	Univ Calif San Francisco, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; San Francisco Injury Ctr, San Francisco, CA USA	Manley, GT (corresponding author), Univ Calif San Francisco, 1001 Potrero Ave Rm 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5F31NS049691, NS050173] Funding Source: Medline		Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Burnett DM, 2000, BRAIN INJURY, V14, P713; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Goldstein B, 2003, CRIT CARE MED, V31, P433, DOI 10.1097/01.CCM.0000050285.93097.52; Herskovits EH, 2003, NEUROIMAGE, V19, P1664, DOI 10.1016/S1053-8119(03)00231-3; Jones PA, 2003, PHYSIOL MEAS, V24, P201, DOI 10.1088/0967-3334/24/1/315; Kapetanovic IM, 2004, ANN NY ACAD SCI, V1020, P10, DOI 10.1196/annals.1310.003; Kentala E, 2000, ANN OTO RHINOL LARYN, V109, P170, DOI 10.1177/000348940010900211; Kett-White R, 2002, ADV TECH STAND NEUR, V27, P87; Kim JH, 2002, GENET MED, V4, p62S, DOI 10.1097/00125817-200211001-00013; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764	20	38	38	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2007	7	1					45	52		10.1007/s12028-007-0043-7			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	200EN	WOS:000248746800009	17565451				2021-06-18	
J	Sadowski-Cron, C; Schneider, J; Senn, P; Radanov, BP; Ballinari, P; Zimmermann, H				Sadowski-Cron, Charlotte; Schneider, Joerg; Senn, Pascal; Radanov, Bogdan P.; Ballinari, Pietro; Zimmermann, Heinz			Patients with mild traumatic brain injury: Immediate and long-term outcome compared to intra-cranial injuries on CT scan	BRAIN INJURY			English	Article						mild traumatic brain injury; intra-cranial injury; neurocognitive tests at admission; subjective complaints after 1 year; costs	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; ADULTS; MANAGEMENT; DIAGNOSIS; SEQUELAE; CLASSIFICATION; METAANALYSIS; DISABILITY; UTILITY	Background: Mild traumatic brain injury ( MTBI) defined as Glasgow Coma Scale ( GCS) 14 or 15 has shown contradictory short- and long- term outcomes. The objective of this study was to correlate intra- cranial injuries ( ICI) on CT scan to neurocognitive tests at admission and to complaints after 1 year. Methods: Two hundred and five patients with MTBI underwent a CT scan and were examined with neurocognitive tests. After 1 year complaints were assessed by phone interviews. Results: The neurocognitive tests in 51% of the patients showed significant deficits; there was no difference for patients with GCS 14 - 15, nor was there a difference between patients with ICI to patients without. After 1 year patients with ICI had significantly more complaints than patients without ICI, the most frequent complaint was headache and memory deficits. Conclusions: No correlation was found between GCS or ICI and the neurocognitive tests upon admission. After 1 year, patients with ICI have significantly more complaints than patients without ICI. No cost savings resulted by doing immediate CT scan on all.	Univ Bern, Inselspital, Dept Accid & Emergency Med, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland	Zimmermann, H (corresponding author), Inselspital Bern, Dept Emergency Med, CH-3010 Bern, Switzerland.	heinz.zimmermann@insel.ch		Senn, Pascal/0000-0002-4619-3341			af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; AFGEIJERSTAM JL, 2003, ACTA NEUROCHIR WIEN, V145, P850; American College of Surgeons, 2004, ATLS ADV TRAUM LIF S; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; *C NEUR SURG INC, 1966, CLIN NEUROSURG, V14, P424; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; Eng J, 2003, NEUROIMAG CLIN N AM, V13, P273, DOI 10.1016/S1052-5149(03)00015-7; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; IMHOF HG, 1992, HELV CHIR ACTA, V58, P667; Jacobs A, 1996, J NUCL MED, V37, P1605; JERET JS, 1993, J TRAUMA, V35, P490, DOI 10.1097/00005373-199309000-00030; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK M, 1995, NEUROSYCHOLOGICAL AS; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV B, 1986, FORTSCHR NEUROL PSYC, V54, P375, DOI 10.1055/s-2007-1001942; RADANOV BP, 1992, LANCET, V339, P749, DOI 10.1016/0140-6736(92)90654-L; Regard M., 1981, COGNITIVE RIGIDITY F; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	43	38	38	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1131	1137		10.1080/02699050600832569			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600003	17123929				2021-06-18	
J	Woertgen, C; Rothoerl, RD; Schebesch, KM; Albert, R				Woertgen, Chris; Rothoerl, Ralf Dirk; Schebesch, Karl Michael; Albert, Ruth			Comparison of craniotomy and craniectomy in patients with acute subdural haematoma	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						acute subdural haematoma; craniotomy; decompressive craniectomy; outcome	DECOMPRESSIVE CRANIECTOMY; PRACTICAL SCALE; HEMICRANIECTOMY	Despite the increasing acceptance of craniectomy in patients with traumatic brain injury, the value of early decompressive craniectomy in patients with acute subdural haematoma is still under debate. In this retrospective study, we reviewed 180 patients with traumatic acute subdural haematoma, 111 of whom were treated with haematoma evacuation via craniotomy and 69 of whom were treated with early decompressive craniectomy. Due to the higher incidence of signs of herniation for patients in the craniectomy group, the mortality rate in this group was higher than that in the craniotomy group (53% vs. 32.3%). However, overall there was no significant difference in outcome between the two groups. Age and clinical signs of herniation were significantly associated with an unfavourable outcome, regardless of the type of surgery. Decompressive craniectomy did not seem to have a therapeutic advantage over craniotomy in traumatic acute subdural haernatoma. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Regensburg, Dept Neurosurg, D-93042 Regensburg, Germany	Woertgen, C (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	chris.woertgen@klinik.uni-regensburg.de					Cooper P R, 1976, Surg Neurol, V5, P25; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; JENNETT B, 1975, LANCET, V1, P480; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; TEASDALE G, 1974, LANCET, V2, P81; TOKUTOMI T, 1992, RECENT ADV NEUROTRAU, P367; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	12	38	39	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	AUG	2006	13	7					718	721		10.1016/j.jocn.2005.08.019			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	099KD	WOS:000241592300002	16904897				2021-06-18	
J	Sang, Q; Kim, MH; Kumar, S; Bye, N; Morganti-Kossman, MC; Gunnersen, J; Fuller, S; Howitt, J; Hyde, L; Beissbarth, T; Scott, HS; Silke, J; Tan, SS				Sang, Qian; Kim, Mary H.; Kumar, Sharad; Bye, Nicole; Morganti-Kossman, Maria C.; Gunnersen, Jenny; Fuller, Stephanie; Howitt, Jason; Hyde, Lavinia; Beissbarth, Tim; Scott, Hamish S.; Silke, John; Tan, Seong-Seng			Nedd4-WW domain-binding protein 5 (Ndfip1) is associated with neuronal survival after acute cortical brain injury	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; cerebral cortex; SAGE; ubiquitination; differential gene expression; apoptosis	GENE-EXPRESSION; IDENTIFICATION; APOPTOSIS; PROFILE; CORTEX; NEUROPROTECTION; UBIQUITINATION; PROTOONCOGENE; PREVENTION; FAMILY	Understanding the transcriptional response to neuronal injury after trauma is a necessary prelude to formulation of therapeutic strategies. We used Serial Analysis of Gene Expression (SAGE) to identify 50,000 sequence tags representing 18,000 expressed genes in the cortex 2 h after traumatic brain injury (TBI). Asimilar tag library was obtained from sham-operated cortex. The SAGE data were validated on biological replicates using quantitative real-time-PCR on multiple samples at 2, 6, 12, and 24 h after TBI. This analysis revealed that the vast majority of genes showed a downward trend in their pattern of expression over 24 h. This was confirmed for a subset of genes using in situ hybridization and immunocytochemistry on brain sections. Of the overexpressed genes in the trauma library, Nedd4-WW (neural precursor cell expressed, developmentally downregulated) domain-binding protein 5 (N4WBP5) (also known as Ndfip1) is strongly expressed in surviving neurons around the site of injury. Overexpression of N4WBP5 in cultured cortical neurons increased the number of surviving neurons after gene transfection and growth factor starvation compared with control transfections. These results identify N4WBP5 as a neuroprotective protein and, based on its known interaction with the ubiquitin ligase Nedd4, would suggest protein ubiquitination as a possible survival strategy in neuronal injury.	Univ Melbourne, Howard Florey Inst, Brain Dev Lab, Parkville, Vic 3010, Australia; Monash Univ, Alfred Hosp, Trauma Res Inst, Melbourne, Vic 3004, Australia; Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA 5000, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Tan, SS (corresponding author), Univ Melbourne, Howard Florey Inst, Brain Dev Lab, Parkville, Vic 3010, Australia.	stan@hfi.unimelb.edu.au	Scott, Hamish/B-2122-2009; Kumar, Sharad/AAX-7787-2020; Beissbarth, Tim/B-3129-2013; Silke, John/B-7622-2008	Scott, Hamish/0000-0002-5813-631X; Kumar, Sharad/0000-0001-7126-9814; Beissbarth, Tim/0000-0001-6509-2143; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Silke, John/0000-0002-7611-5774; Gunnersen, Jenny/0000-0002-6310-7724; Howitt, Jason/0000-0001-9922-7931			ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beissbarth T, 2004, BIOINFORMATICS, V20, P31, DOI 10.1093/bioinformatics/bth924; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Boon WM, 2004, P NATL ACAD SCI USA, V101, P14972, DOI 10.1073/pnas.0406296101; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conti AC, 1998, J NEUROSCI, V18, P5663; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; Evans SJ, 2002, EUR J NEUROSCI, V16, P409, DOI 10.1046/j.1460-9568.2002.02097.x; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Heng JIT, 2003, BIOESSAYS, V25, P709, DOI 10.1002/bies.10299; Herbert C, 1997, EUR J CANCER PREV, V6, P44, DOI 10.1097/00008469-199702000-00008; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844	37	38	42	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 5	2006	26	27					7234	7244		10.1523/JNEUROSCI.1398-06.2006			11	Neurosciences	Neurosciences & Neurology	060LW	WOS:000238804700018	16822981	Bronze, Green Published			2021-06-18	
J	Cioni, M; Esquenazi, A; Hirai, B				Cioni, Matteo; Esquenazi, Alberto; Hirai, Barbara			Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						botulinum toxin; temporospatial parameters; gait; equinovarus foot	TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; HEMIPARETIC PATIENTS; HEMIPLEGIC GAIT; WALKING SPEED; SPASTIC FOOT; STROKE; PARAMETERS; INJECTION; EFFICACY	Objective: The aim of this study was to identify if botulinum toxin type A is a drug able to modify walking velocity, step length, and width of the base of support of adult patients with dynamic equinovarus foot deformity resulting from upper motor neuron syndrome. Design: This retrospective study analyzed data from 20 patients' files selected from 448 consecutive charts. The main Inclusion criteria were the presence of dynamic equinovarus foot deformity due to upper motor neuron syndrome, age between 20 and 80 yrs, evaluation of temporo-spatial parameters of gait by the Gait Mat 11 before and 4 wks after botulinum toxin type A injection to the calf muscles, and the ability to walk barefoot, unassisted, and without braces. For data analysis, based on walking velocity, we divided the patients into two groups, slow walking velocity (0.18-0.49 m/sec) and medium walking velocity (0.50-0.99 m/sec). Results: Width of the base of support was significantly reduced after botulinum toxin type A treatment, both for the affected (P < 0.005) and the unaffected limbs (P < 0.002), in the group of subjects walking at medium velocity. Walking velocity or step length of either group of patients was not significantly modified by botulinum toxin type A treatment. Conclusions: Based on this study, a significant effect of botulinum toxin type A on width of the base of support is evident and seems to be the result of a better position of the affected foot during the stance phase of locomotion leading to increased body stability and consequent reduction of width of the base of support of the unaffected limb. No change was evident in step length or walking velocity for this patient population.	Univ Catania, Dept Expt & Clin Pharmacol, Sch Med, I-95125 Catania, Italy; IRCCS, Oasi Inst Res Mental Retardat & Brain Aging, Troina, Italy; Moss Rehabil Hosp, Gait & Mot Anal Lab, Philadelphia, PA USA	Cioni, M (corresponding author), Univ Catania, Dept Expt & Clin Pharmacol, Sch Med, V A Doria 6, I-95125 Catania, Italy.			CIONI, Matteo/0000-0002-7594-6939			Barker S, 2006, MED ENG PHYS, V28, P460, DOI 10.1016/j.medengphy.2005.07.017; Bird AR, 1999, J AM PODIAT MED ASSN, V89, P405, DOI 10.7547/87507315-89-8-405; BOHANNON RW, 1987, ARCH PHYS MED REHAB, V68, P777; BRIN MF, 1997, MUSCLE NERVE       S, V6, P208; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; Esquenazi A., 2001, PHYS MED REHABILITAT, P93; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Gooch JL, 2004, ARCH PHYS MED REHAB, V85, P1121, DOI 10.1016/j.apmr.2003.09.032; Hesse S, 2001, DRUG AGING, V18, P255, DOI 10.2165/00002512-200118040-00003; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; Johnson CA, 2004, ARCH PHYS MED REHAB, V85, P902, DOI 10.1016/j.apmr.2003.08.081; Mancini F, 2005, NEUROL SCI, V26, P26, DOI 10.1007/s10072-005-0378-9; Mayer NH, 1997, MUSCLE NERVE, pS21; MOLTENI F, 2000, GAIT ANAL STATE ART, P263; MURRAY MP, 1978, AM J PHYS MED REHAB, V57, P278; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Ofluoglu D, 2003, AM J PHYS MED REHAB, V82, P832, DOI 10.1097/01.PHM.0000091986.32078.CD; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Pomeroy VM, 2004, CLIN REHABIL, V18, P222, DOI 10.1191/0269215504cr725oa; Richards C, 1996, GAIT POSTURE, V4, P12, DOI 10.1016/0966-6362(96)01063-6; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Roth EJ, 1997, AM J PHYS MED REHAB, V76, P128, DOI 10.1097/00002060-199703000-00008; Rousseaux M, 2005, J NEUROL SCI, V232, P51, DOI 10.1016/j.jns.2005.01.009; Stolze H, 2002, J NEUROL NEUROSUR PS, V73, P310, DOI 10.1136/jnnp.73.3.310; WAAGFJORD J, 1990, PHYS THER, V70, P549, DOI 10.1093/ptj/70.9.549; WAGENAAR RC, 1992, J BIOMECH, V25, P1007, DOI 10.1016/0021-9290(92)90036-Z; Whittle M, 1991, GAIT ANAL INTRO, P91; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45	30	38	43	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2006	85	7					600	606		10.1097/01.phm.0000223216.50068.bc			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	059IC	WOS:000238725500007	16788391				2021-06-18	
J	Johnston, MV; Sherer, M; Whyte, J				Johnston, MV; Sherer, M; Whyte, J			Applying evidence standards to rehabilitation research	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; ASSISTIVE TECHNOLOGY; CRITICAL-APPRAISAL; PUBLICATION BIAS; READERS GUIDE; INTERVENTIONS; CHALLENGE; OUTCOMES; COHORT	Objective: To describe evidence grading methods employed in the systematic reviews in this special series of articles. To provide an overview of results of these reviews to critique the quality of rehabilitation research. To identify issues in the application of evidence grading methods to rehabilitation. Design: Conceptual review of evidence-based practice and evidence grading methods. English-language research studies on rehabilitation of persons with spinal cord injury, traumatic brain injury, and burn for the 5-yr period of 1999-2004 were reviewed using methods of the American Academy of Neurology supplemented by Cochrane criteria and summarized. Results: Rehabilitation has a shortage of high-level studies. The number of level I treatment studies was quite limited (five in spinal cord injury, 15 in traumatic brain injury, 12 in burn rehabilitation), as was the number of level 2 studies (26, 4, and 2, respectively). Despite the large number of correlational studies published, the number of high-level (1 or 2) diagnostic and prognostic studies was surprisingly limited (34, 11, and 5, respectively). The rate of production of high-level studies is rapidly increasing. Problems were encountered in applying standard evidence criteria to complex issues encountered in some studies, suggesting limitations and issues in evidence grading methodology. Conclusions: Rehabilitation needs more high-level studies. Some improvements; in research methodology are relatively affordable (e.g., improved blinding), whereas others are expensive (e.g., large randomized controlled trials). Lower-level investigations reporting promising results need to be followed by more definitive, higher-level trials.	KMRREC, Res E, S Orange, NJ 07079 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA	Johnston, MV (corresponding author), KMRREC, Res E, 1199 Pleasant Valley Way, S Orange, NJ 07079 USA.			Whyte, John/0000-0002-4381-1474			Alderson P, 2004, COCHRANE REV HDB 4 2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; CAMPBELL DT, 1963, EXPT QUASI EXPERIENC; Chatfield C, 2004, ANAL TIME SERIES INT; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cook T.D., 1979, QUASI EXPT DESIGN AN; Edlund W, 2004, AM ACAD NEUROLOGY CL; Finkel S, 1995, CAUSAL ANAL PANEL DA; Fuhrer MJ, 2003, DISABIL REHABIL, V25, P1243, DOI 10.1080/09638280310001596207; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Gray JAM, 2001, EVIDENCE BASED HEALT; HALEY SM, 1994, PHYS THER, V74, P443, DOI 10.1093/ptj/74.5.443; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Jenicek M., 2003, FDN EVIDENCE BASED M; Jenicek Milos, 2001, CLIN CASE REPORTING; Jensen Peter S, 2005, Ment Health Serv Res, V7, P53, DOI 10.1007/s11020-005-1965-3; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; JOHNSTON MV, 1997, ASSESSING MED REHABI, V4, P1; KEITH R, 2005, IMPROVING ASSESSMETN, P33; Kline R.B, 2004, PRINCIPLES PRACTICE; Kravitz RL, 2004, MILBANK Q, V82, P661, DOI 10.1111/j.0887-378X.2004.00327.x; Law M., 2002, EVIDENCE BASED REHAB; Little RJ, 2000, ANNU REV PUBL HEALTH, V21, P121, DOI 10.1146/annurev.publhealth.21.1.121; Luther Stephen L, 2004, SCI Nurs, V21, P206; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Mann WC, 1999, ARCH FAM MED, V8, P210, DOI 10.1001/archfami.8.3.210; Montori VM, 2000, MAYO CLIN PROC, V75, P1284, DOI 10.4065/75.12.1284; Muche R, 2002, Rehabilitation (Stuttg), V41, P311; Norcross J.C., 2006, EVIDENCE BASED PRACT; Normand SLT, 2005, BMJ-BRIT MED J, V330, P1021, DOI 10.1136/bmj.330.7498.1021; Norris SL, 2005, ANN INTERN MED, V142, P1112, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00011; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Ottenbacher KJ, 1999, AM J OCCUP THER, V53, P181, DOI 10.5014/ajot.53.2.181; Ottenbacher KJ, 2001, AM J PHYS MED REHAB, V80, P786, DOI 10.1097/00002060-200110000-00014; *OXF CTR EV BAS ME, LEV EV GRAD REC; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; PAGLIARULO MA, 2001, INTR PHYS THERAPY; Philips Z, 2004, HEALTH TECHNOL ASSES, V8, P1; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rosner B., 2005, FUNDAMENTALS BIOSTAT; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; SACIKETT DL, 2000, EVIDENCE BASED MED P; Salmon W., 1997, CAUSALITY EXPLANATIO; Scherer M., 2001, ASSISTIVE TECHNOLOGY; Shadish W.R., 2002, EXPT QUASI EXPT DESI; Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; *US DEP ED WWC, 2005, WWC STUD REV STAND; Vray Muriel, 2004, Therapie, V59, P273, DOI 10.2515/therapie:2004054; West S, 2002, AHRQ PUBLICATION, V02-E016; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; World Health Organization, 2001, INT CLASS FUNCT DIS; ZOLA IK, 1989, MILBANK Q, V67, P401, DOI 10.2307/3350151; 2002, COCHRANE DATABASE SY, V1; 2001, SAMPLE POWER 2 0 COM	57	38	38	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2006	85	4					292	309		10.1097/01.phm.0000202079.58567.3b			18	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	026XI	WOS:000236376200002	16554683				2021-06-18	
J	Fager, S; Hux, K; Beukelman, DR; Karantounis, R				Fager, S; Hux, K; Beukelman, DR; Karantounis, R			Augmentative and alternative communication use and acceptance by adults with traumatic brain injury	AUGMENTATIVE AND ALTERNATIVE COMMUNICATION			English	Article						traumatic brain injury; augmentative and alternative communication		The purpose of this study was to document augmentative and alternative communication (AAC) acceptance and use patterns of 25 adults with traumatic brain injuries (TBI) who used either high- or low-tech AAC devices or strategies at some point during their recovery. Specifically, the purposes were to (a) document acceptance of AAC system recommendations, (b) identify AAC use patterns by persons who accepted the recommendation and for whom AAC intervention was implemented, (c) identify AAC access patterns for message formulation and encoding, and (d) document the kind of communicative functions that different AAC strategies supported. Information was gathered via a questionnaire from speech-language pathologists who provided AAC assessments and interventions at six different sites. The speech-language pathologists provided information about individuals with TBI from their clinics for whom they had recommended AAC. Results revealed that these adults generally accepted both high- and low-tech AAC recommendations and used their AAC systems for extended periods of time. Most utilized letter-by-letter message formulation strategies. When AAC technology was abandoned, it was usually a reflection of a loss of facilitator support rather than a rejection of the technology.	Univ Nebraska, Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, Lincoln, NE 68506 USA; Rose Med Ctr, Denver, CO USA	Fager, S (corresponding author), Univ Nebraska, Madonna Rehabil Hosp, Inst Rehabil Sci & Engn, 5401 S St, Lincoln, NE 68506 USA.	sfager@madonna.org	Hux, Karen/AAQ-2078-2020	Fager, Susan/0000-0001-8125-5977			Ball L.J., 2004, AAC AUGMENT ALTERN C, V20, P113, DOI DOI 10.1080/0743461042000216596; Beukelman D.R., 1998, AUGMENTATIVE ALTERNA; Beukelman DR, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P135; Beukelman DR, 2002, J MED SPEECH-LANG PA, V10, P237; Bruno J, 1989, AUGMENTATIVE ALTERNA, V5, P89; DeRuyter F., 1987, AUGMENTATIVE ALTERNA, V3, P18, DOI DOI 10.1080/07434618712331274209; Deruyter F, 1988, J HEAD TRAUMA REHAB, V3, P35; DERUYTER F, 1989, AUGMENTATIVE ALTERNA, V5, P49, DOI DOI 10.1080/07434618912331274966; DeRuyter F, 1991, COMMUNICATION DISORD, P317; Dongilli P, 1992, J HEAD TRAUMA REHAB, V7, P91; Doyle M, 2000, AUG ALTER COMMUN SER, P271; ENDERBY P, 1990, J DISORDERED COMMUNI, V23, P341; Fager S., 2003, AM SPEECH LANG HEAR; Fried-Oken M, 1992, J HEAD TRAUMA REHAB, V7, P59, DOI DOI 10.1097/00001199-199209000-00008; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hsieh MC, 1999, AUGMENTATIVE ALTERNA, V15, P216; Hux K, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P169; Hux K, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P93; Hux K, 2001, J MED SPEECH-LANG PA, V9, P71; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1990, Brain Injury, V4, P101, DOI 10.3109/02699059009026154; Keenan J, 1993, AUGMENTATIVE ALTERNA, V9, P184, DOI DOI 10.1080/07434619312331276591; KEETLEY A, 1994, EUROPEAN J DISORDERE, V29, P183; Ladtkow M, 1992, AUGMENTATIVE COMMUNI, P139; LAFONTAINE LM, 1987, AUGMENTATIVE ALTERNA, V3, P153; LASKER J, 1997, THEIS U NEBRASKALINC; LEVINE SP, 1992, J HEAD TRAUMA REHAB, V7, P46, DOI DOI 10.1097/00001199-199209000-00007; LIGHT J, 1990, AAC (Augmentative and Alternative Communication), V6, P184, DOI 10.1080/07434619012331275454; Light J., 1988, AUGMENTATIVE ALTERNA, V4, P2, DOI DOI 10.1080/07434618812331274557; Mathy P, 2000, AUG ALTER COMMUN SER, P183; Murphy J., 1995, AUGMENTATIVE ALTERNA, V11, P26, DOI 10.1080/07434619512331277119; SBORDONE RJ, 1988, J HEAD TRAUMA REHAB, V3, P55; Smith-Lewis M., 1987, AUGMENTATIVE ALTERNA, V3, P12; Trefler E., 1985, AUGMENTATIVE ALTERNA, V1, P151, DOI DOI 10.1080/07434618512331273651; WORKINGER M S, 1992, Brain Injury, V6, P183, DOI 10.3109/02699059209029657; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48	36	38	38	0	26	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0743-4618			AUGMENT ALTERN COMM	Augment. Altern. Commun.	MAR	2006	22	1					37	47		10.1080/07434610500243990			11	Audiology & Speech-Language Pathology; Rehabilitation	Audiology & Speech-Language Pathology; Rehabilitation	028FC	WOS:000236471300004	17114157				2021-06-18	
J	Knight, RG; Titov, N; Crawford, M				Knight, RG; Titov, N; Crawford, M			The effects of distraction on prospective remembering following traumatic brain injury assessed in a simulated naturalistic environment	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						prospective memory; virtual reality; neuropsychological assessment; logical memory; Ruff Selective Attention Test; executive functions	PROSPECTIVE MEMORY; EVENT	The aim of this investigation was to assess deficits in prospective remembering following chronic traumatic brain injuries (TBI), under conditions of high and low distraction. We constructed a virtual shopping precinct from photographs, sounds, and video Segments linked together. The street was divided into halves, a low distraction zone and a high distraction zone (with increased visual and auditory noise). Twenty persons with TBI (7 severe, 7 very severe, 6 extremely severe) and 20 matched controls completed ongoing and prospective memory tasks while "walking" along the street. In the ongoing task, participants were given ten errands to complete with a checklist accessible at any time. The prospective component required responding to three targets that appeared repeatedly. As predicted, the TBI group performed both the ongoing and the prospective components of the street task poorly compared with the controls and was more affected by distractions. The results suggest that the real-life deficits in memory skills reported by persons with TBI may become more apparent when remembering engages executive processes and that computer simulations can be used to construct sensitive measures of practical memory abilities.	Univ Otago, Dept Psychol, Dunedin, New Zealand	Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz		Titov, Nickolai/0000-0002-7268-729X			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; FARRIMOND SJ, 2006, IN PRESS APPL COGNIT, V20; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Jennett B, 1981, MANAGEMENT HEAD INJU; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDermott K, 2004, APPL COGNITIVE PSYCH, V18, P349, DOI 10.1002/acp.977; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Roediger H. L., 1996, PROSPECTIVE MEMORY T, P149; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Titov N, 2000, BRAIN INJURY, V14, P877; Titov N, 2005, BRAIN INJURY, V19, P315, DOI 10.1080/02699050400013725; Titov N, 2001, APPL COGNITIVE PSYCH, V15, P61, DOI 10.1002/1099-0720(200101/02)15:1<61::AID-ACP689>3.0.CO;2-Y; Wilson B. A, 1999, CASE STUDIES NEUROPS; Wilson BA, 1996, BEHAV ASSESSMENT DYS	25	38	40	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					8	16		10.1017/S1355617706060048			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800002	16433939				2021-06-18	
J	Tamietto, M; Torrini, G; Adenzato, M; Pietrapiana, P; Rago, R; Perino, C				Tamietto, M; Torrini, G; Adenzato, M; Pietrapiana, P; Rago, R; Perino, C			To drive or not to drive (after TBI)? A review of the literature and its implications for rehabilitation and future research	NEUROREHABILITATION			English	Article						TBI; brain injury; driving safety; rehabilitation	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INDIVIDUAL-DIFFERENCES; CEREBRAL-DAMAGE; RELATIVES VIEW; SELF-AWARENESS; PERFORMANCE; PERSONALITY; PREDICTORS; FITNESS	Development of reliable procedures to assess fitness to safe driving after traumatic brain injury ( TBI) is a crucial step in rehabilitation. However, prior studies are highly inconsistent in the choice of measures recommended for predicting driving fitness from different pre-driving measures. In the present paper the relevant literature is reviewed with the aim of shedding light on the reasons for these inconsistencies. The discrepant results reflect investigative choices which differ in five aspects: ( 1) the type of predictors used as pre-driving screening; ( 2) the type of measures considered as the criterion for the determination of fitness to drive after TBI; ( 3) the severity of the TBI in the sample of patients studied; ( 4) the extent of the neural structures damaged by TBI and the overlap of these areas with those involved in driving tasks; ( 5) the length of the follow-up considered. The strengths and weaknesses of the different methods and measures are discussed with their implications for future research and clinical rehabilitation. Encouraging findings come from recent studies that combined together medical, psychosocial, and personality measures, thereby improving the explanatory power of the predictors used. The use of post-injury driving fitness measures with great ecological and external validity seems equally promising in assessing actual driving in the real world.	Univ Turin, Dept Psychol, Turin, Italy; Univ Turin, Ctr Cognit Sci, Turin, Italy; Ausiliatrice Hosp, Fdn Carlo Gnocchi, ONLUS, Turin, Italy	Tamietto, M (corresponding author), Univ Turin, Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	tamietto@psych.unito.it	Adenzato, Mauro/I-5127-2012	Adenzato, Mauro/0000-0002-6997-9283; Tamietto, Marco/0000-0002-8815-8499			Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; Bogg T, 2004, PSYCHOL BULL, V130, P887, DOI 10.1037/0033-2909.130.6.887; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROWER W, 1992, 2 INT C OBJ EV ERH M; Calhoun VD, 2002, HUM BRAIN MAPP, V16, P158, DOI 10.1002/hbm.10032; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; DEBELLEIX X, 2001, EUROPA MEDICOPHYSICA, V37, P201; Dimarco F, 2001, EURA MEDICOPHYS, V37, P215; ELANDER J, 1993, PSYCHOL BULL, V113, P279, DOI 10.1037/0033-2909.113.2.279; ENGUM ES, 1989, COGNITIVE REHABILITA, V7, P22; Evans, 1991, TRAFFIC SAFETY DRIVE; Farmer J, 2000, BRAIN INJURY, V14, P109, DOI 10.1080/026990500120772; Finset A, 2000, BRAIN INJURY, V14, P887; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FORMISANO R, 2001, EUROPA MEDICOPHYSICA, V37, P257; FOX G, 1993, ASTB C TOK SEPT 1 11; Fox G K, 1992, Disabil Rehabil, V14, P140; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOLDBERG LR, 1993, AM PSYCHOL, V48, P26, DOI 10.1037/0003-066X.48.1.26; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Hartje W, 1991, NEUROPSYCHOL REHABIL, V3, P161; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P661; HOFMEIJER AMJ, 2002, EUROPA MEDICOPHYSICA, V38, P29; HUNT L, 1993, J AM GERIATR SOC, V71, P177; John O.P., 1999, HDB PERSONALITY THEO, V2nd ed., P102; JONES MH, 1978, 783 U SO CAL; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; Kapust L R, 1992, J Geriatr Psychiatry Neurol, V5, P210; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KORTELING JE, 1990, HUM FACTORS, V32, P95, DOI 10.1177/001872089003200107; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kosslyn SM, 1999, PHILOS T ROY SOC B, V354, P1283, DOI 10.1098/rstb.1999.0479; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; MICHON JA, 1989, ACCIDENT ANAL PREV, V21, P341, DOI 10.1016/0001-4575(89)90025-0; Michon John A., 1979, 7901 VK U GRON TRAFF; MIHAL WL, 1976, J APPL PSYCHOL, V61, P229, DOI 10.1037/0021-9010.61.2.229; Nouri F M, 1987, Int Disabil Stud, V9, P110; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; Novack TA, 2000, BRAIN INJURY, V14, P987; O'Shanick G J, 1989, Psychiatr Med, V7, P1; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; PERINO, 1997, GIORNALE ITALIANO RI, V1, P53; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; RAPPORT LJ, 1998, M AM PSYCH ASS SAN F; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; SCHWEITZER JR, 1994, ERGONOMICS REHABILIT, P85; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Uchiyama Y, 2003, NEUROSCI LETT, V352, P199, DOI 10.1016/j.neulet.2003.08.072; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANZOMEREN A, 1987, ARCH PHYS MED REHAB, V68, P607; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; WALLER PF, 1988, TRANSPORTATION AGING, V2, P72; Walter H, 2001, NEUROREPORT, V12, P1763, DOI 10.1097/00001756-200106130-00049; Wilson T, 1983, Int Rehabil Med, V5, P170	83	38	40	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2006	21	1					81	92					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045KY	WOS:000237742200011	16720941				2021-06-18	
J	Zygun, D; Berthiaume, L; Laupland, K; Kortbeek, J; Doig, C				Zygun, David; Berthiaume, Luc; Laupland, Kevin; Kortbeek, John; Doig, Christopher			SOFA is superior to MOD score for the determination of non-neurologic organ dysfunction in patients with severe traumatic brain injury: a cohort study	CRITICAL CARE			English	Article							SEVERE HEAD-INJURY; ACUTE LUNG INJURY; SUBARACHNOID HEMORRHAGE; INTENSIVE-CARE; CEREBROSPINAL-FLUID; FAILURE; MULTICENTER	Introduction The objective of the present study was to compare the discriminative ability of the Sequential Organ Failure Assessment ( SOFA) and Multiple Organ Dysfunction ( MOD) scoring systems with respect to hospital mortality and unfavorable neurologic outcome in patients with severe traumatic brain injury admitted to the intensive care unit. Method We performed a prospective cohort study at Foothills Medical Centre, the sole adult tertiary care trauma center servicing southern Alberta ( population about 1.3 million). All patients aged 16 years or older with severe traumatic brain injury and intensive care unit length of stay greater than 48 hours between 1 May 2000 and 31 April 2003 were included. Non-neurologic organ dysfunction was measured using the SOFA and MODS scoring systems. Determination of organ dysfunction for each non-neurologic organ system was compared between the two systems by calculating the proportion of patients with SOFA and MOD component score defined organ failure. Consistent with previous literature, organ system failure was defined as a component score of three or greater. Results The odds of death and unfavorable neurologic outcome in patients with SOFA defined cardiovascular failure were 14.7 times (95% confidence interval [CI] 5.9 - 36.3) and 7.6 times ( 95% CI 3.5 - 16.3) that of those without cardiovascular failure, respectively. The development of SOFA-defined cardiovascular failure was a reasonable discriminator of hospital mortality and unfavorable neurologic outcome ( area under the receiver operating characteristic [ROC] curve 0.75 and 0.73, respectively). The odds of death and unfavorable neurologic outcome in patients with MOD-defined cardiovascular failure were 2.6 times ( 95% CI 1.24 - 5.26) and 4.1 times ( 95% CI 1.3 - 12.4) that of those without cardiovascular failure, respectively. The development of MOD-defined cardiovascular failure was a poor discriminator of hospital mortality and unfavorable neurologic outcome ( area under the ROC curve 0.57 and 0.59, respectively). Neither SOFA-defined nor MOD-defined respiratory failure was significantly associated with hospital mortality. Conclusion In patients with brain injury, the SOFA scoring system has superior discriminative ability and stronger association with outcome compared with the MOD scoring system with respect to hospital mortality and unfavorable neurologic outcome.	Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Dept Surg, Calgary, AB, Canada	Zygun, D (corresponding author), Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada.	david.zygun@calgaryhealthregion.ca	Kortbeek, John B/AAO-5298-2020; Doig, Christopher/AAC-7949-2020; Laupland, kevin/AAJ-6339-2020; Laupland, Kevin/AAG-3656-2020	Doig, Christopher/0000-0002-8576-9139; Laupland, kevin/0000-0002-1205-5354; 			Bota DP, 2002, INTENS CARE MED, V28, P1619, DOI 10.1007/s00134-002-1491-3; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cook R, 2001, CRIT CARE MED, V29, P2046, DOI 10.1097/00003246-200111000-00002; Doig CJ, 2004, CRIT CARE MED, V32, P384, DOI 10.1097/01.CCM.0000108881.14082.10; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Hirashima Y, 1997, NEUROCHEM RES, V22, P1249, DOI 10.1023/A:1021985030331; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; Kossmann T, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P263; Marshall J., 1995, CLIN TRIALS TREATMEN; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Zimmerman JE, 1996, CRIT CARE MED, V24, P1633, DOI 10.1097/00003246-199610000-00006; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2002, YB INTENSIVE CARE EM, P899	22	38	38	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2006	10	4							R115	10.1186/cc5007			10	Critical Care Medicine	General & Internal Medicine	185LK	WOS:000247712300018	16882348	DOAJ Gold, Green Published			2021-06-18	
J	Bilgen, M				Bilgen, M			A new device for experimental modeling of central nervous system injuries	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; spinal cord injury; animal model; injury device	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; RAT; IMMATURE	This article introduces a new device for inducing central nerve system injuries in experimental studies with animal models. The construction of the device is based on a commercially available servo-drive system incorporating the latest instrumentation technology and software developed in house to control the motion profile of the injury bit. The software, which is available upon request from the author, was designed such that the user can set the mechanical properties of the motion. For the purpose of quality control, tests were described and performed to assess the ability of the device to reproduce the prescribed motion when operated repetitively under the same set of parameters. Experiments were then conducted on animals to injure mouse brain and rat spinal cord. Following the injuries, in vivo magnetic resonance imaging was performed on the animals to depict the pathologies of the resulting injuries in the corresponding neuronal tissues. Rat spinal cords injured mildly and severely were followed longitudinally for up to 28 days postinjury. The neurobehaviors of the animals evaluated using locomotor rating scores indicated the ability of the device to produce repeatable graded injuries.	Univ Kansas, Sch Med, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA	Bilgen, M (corresponding author), Univ Kansas, Sch Med, Hoglund Brain Imaging Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	mbilgen@kumc.edu					Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bassols GB., 1996, DOMINGUEZIA, V13, P7; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bilgen M, 2004, MAGN RESON MED, V52, P937, DOI 10.1002/mrm.20228; Bilgen M, 2005, MAGN RESON IMAGING, V23, P601, DOI 10.1016/j.mri.2005.02.003; Bilgen M, 2000, MAGN RESON MED, V43, P594; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Falconer JC, 1996, SPINE, V21, P104, DOI 10.1097/00007632-199601010-00025; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; NARAYANA PA, 2000, HDB CNS TRAUMA; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481	20	38	42	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2005	19	3					219	226		10.1177/1545968305278635			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	959LF	WOS:000231518500005	16093412				2021-06-18	
J	Othman, M; Lu, C; Klueber, K; Winstead, W; Roisen, FJ				Othman, M; Lu, C; Klueber, K; Winstead, W; Roisen, FJ			Clonal analysis of adult human olfactory neurosphere forming cells	BIOTECHNIC & HISTOCHEMISTRY			English	Article						clonal analysis; olfactory; progenitors; stem cells	EPIDERMAL-GROWTH-FACTOR; EMBRYONIC STEM-CELLS; NEURAL PROGENITORS; PRECURSOR CELLS; MOUSE BRAIN; NEURONS; IDENTIFICATION; EPITHELIUM; DIFFERENTIATION; MULTIPOTENT	Olfactory neuroepithelium (ONe) is unique because it contains progenitor cells capable of mitotic division that replace damaged or lost neurons throughout life. We isolated populations of ONe progenitors from adult cadavers and patients undergoing nasal sinus surgery that were heterogeneous and consisted of neuronal and glial progenitors. Progenitor lines have been obtained from these cultures that continue to divide and form nestin positive neurospheres. In the present study, we used clonal and population analyses to probe the self-renewal and multipotency of the neurosphere forming cells (NSFCs). NSFCs plated at the single cell level produced additional neurospheres; dissociation of these spheres resulted in mitotically active cells that continued to divide and produce spheres as long as they were subcultured. The mitotic activity of clonal NSFCs was assessed using bromodeoxyuridine (BrdU) incorporation. Lineage restriction of the clonal cultures was determined using a variety of antibodies that were characteristic of different levels of neuronal commitment: beta-tubulin isotype III, neural cell adhesion molecule (NCAM) and microtubule associated protein (MAP2), or glial restriction: astrocytes, glial fibrillary acidic protein (GFAP); and oligodendrocytes, galactocerebroside (GaIC). Furthermore, nestin expression, a marker indicative of progenitor nature, decreased in defined medium compared to serum-containing medium. Therefore, adult human ONe-derived neural progenitors retain their capacity for self-renewal, can be clonally expanded, and offer multipotent lineage restriction. Therefore, they are a unique source of progenitors for future cell replacement strategies in the treatment of neurotrauma and neurodegenerative diseases.	Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA	Roisen, FJ (corresponding author), Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.	fjrois01@louisville.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR15576] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER		Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Chang MY, 2004, DEV BRAIN RES, V153, P89, DOI 10.1016/j.devbrainres.2004.08.003; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; Engstrom CM, 2002, J NEUROSCI METH, V117, P111, DOI 10.1016/S0165-0270(02)00074-2; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; Gritti A, 1996, J NEUROSCI, V16, P1091; Huard JMT, 1998, J COMP NEUROL, V400, P469; Hulspas R, 1997, EXP NEUROL, V148, P147, DOI 10.1006/exnr.1997.6672; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Kramer PR, 2000, DEV BIOL, V227, P343, DOI 10.1006/dbio.2000.9896; Kukekov VG, 1997, GLIA, V21, P399, DOI 10.1002/(SICI)1098-1136(199712)21:4<399::AID-GLIA7>3.0.CO;2-Z; Leopold DA, 2000, LARYNGOSCOPE, V110, P417, DOI 10.1097/00005537-200003000-00016; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; Liu N, 1998, EXP NEUROL, V151, P173, DOI 10.1006/exnr.1998.6810; Liu ZP, 2003, J COMP NEUROL, V459, P368, DOI 10.1002/cne.10664; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Marshall CT, 2005, BRAIN RES, V1045, P45, DOI 10.1016/j.brainres.2005.03.041; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Meyer JR, 2000, J MED ETHICS, V26, P166, DOI 10.1136/jme.26.3.166; MORAN DT, 1982, BRAIN RES, V253, P39, DOI 10.1016/0006-8993(82)90671-0; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Mumm JS, 1996, P NATL ACAD SCI USA, V93, P11167, DOI 10.1073/pnas.93.20.11167; Murrell W, 1996, NEUROREPORT, V7, P1189, DOI 10.1097/00001756-199604260-00019; Ostenfeld T, 2004, STEM CELLS, V22, P798, DOI 10.1634/stemcells.22-5-798; Othman MM, 2003, BIOTECH HISTOCHEM, V78, P57, DOI 10.1080/10520290310001593801; Rao MS, 1999, ANAT RECORD, V257, P137; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; SATOH M, 1995, DEV BRAIN RES, V87, P111, DOI 10.1016/0165-3806(95)00057-K; Seaberg RM, 2005, DEV BIOL, V278, P71, DOI 10.1016/j.ydbio.2004.10.017; SHATOS MA, 2001, J REG MED, V2, P213; Shetty AK, 2004, HIPPOCAMPUS, V14, P595, DOI 10.1002/hipo.10206; Silani V, 1998, NEUROREPORT, V9, P1143, DOI 10.1097/00001756-199804200-00034; SOSNOWSKI JS, 1995, BRAIN RES, V702, P37, DOI 10.1016/0006-8993(95)00960-7; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Winstead W, 2005, AM J RHINOL, V19, P83, DOI 10.1177/194589240501900115; Xiao M, 2005, EXP NEUROL, V194, P12, DOI 10.1016/j.expneurol.2005.01.021; Zahir T, 2005, STEM CELLS, V23, P424, DOI 10.1634/stemcells.2004-0199; Zhang XD, 2004, EXP NEUROL, V186, P112, DOI 10.1016/j.expneurol.2003.10.022	52	38	45	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1052-0295	1473-7760		BIOTECH HISTOCHEM	Biotech. Histochem.	SEP-DEC	2005	80	5-6					189	200		10.1080/10520290500469777			12	Biotechnology & Applied Microbiology; Cell Biology	Biotechnology & Applied Microbiology; Cell Biology	038ZS	WOS:000237269200002	16720519				2021-06-18	
J	Delaney, JS; Abuzeyad, F; Correa, JA; Foxford, R				Delaney, JS; Abuzeyad, F; Correa, JA; Foxford, R			Recognition and characteristics of concussions in the emergency department population	JOURNAL OF EMERGENCY MEDICINE			English	Article						concussion; Emergency Department; head injury; risk factors; sports	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; ICE-HOCKEY INJURIES; SOCCER PLAYERS; FOOTBALL PLAYERS; HEAD-INJURY; CEREBRAL CONCUSSION; MULTIVARIATE-ANALYSIS; COMPUTED-TOMOGRAPHY; MANAGEMENT	An anonymous survey was conducted over a 6-month period of time using consenting Emergency Department (ED) patients in an attempt to better understand concussions occurring in the ED population. Calculations were made using the respondents' history and self-reported symptoms during the previous 12 months. Five hundred twenty-two of 700 approached patients responded to the anonymous questionnaire. Of respondents, 20.1% (105/522) answered that they had experienced symptoms of a concussion after being hit in the head during the previous 12 months. Of the 105 respondents who experienced a concussion, 88.6% (93/105) did not recognize that they had suffered a concussion. There were 28.2% (147/522) of all respondents who were actively engaging in at least one activity that was considered to be at high risk for concussions. Headache was the most common symptom for both recognized and unrecognized concussions. Respondents who experienced nausea after being hit in the head were the most likely to seek some form of medical attention, followed by people who suffered a loss of consciousness. Those patients who suffered a loss of consciousness were the most likely to visit an ED. Many patients have a poor understanding of concussions and these patients may be actively participating in high-risk activities while still suffering symptoms from a concussion. Therefore, these patients may be at risk for further concussions and Second Impact Syndrome. (c) 2005 Elsevier Inc.	McGill Univ, Dept Emergency Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, McGill Sport Med Clin, Montreal, PQ, Canada; Bahrain Def Force Hosp, Accident & Emergency Dept, Manama, Bahrain; McGill Univ, Dept Math & Stat, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Univ, Dept Emergency Med, Ctr Hlth, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.						Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian J, 2000, BRAIN INJURY, V14, P285; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CLINE DM, 1988, ANN EMERG MED, V17, P127, DOI 10.1016/S0196-0644(88)80297-X; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; DELANEY JS, 2001, INT S CONC SPORT; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gillogly S D, 2000, J Med Assoc Ga, V89, P39; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Schneider R., 1973, HEAD NECK INJURIES F; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Walshaw L K, 2000, Accid Emerg Nurs, V8, P210, DOI 10.1054/aaen.2000.0172; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	59	38	38	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	AUG	2005	29	2					189	197		10.1016/j.jemermed.2005.01.020			9	Emergency Medicine	Emergency Medicine	949FT	WOS:000230771200013	16029831				2021-06-18	
J	Ehlhardt, LA; Sohlberg, MM; Glang, A; Albin, R				Ehlhardt, LA; Sohlberg, MM; Glang, A; Albin, R			TEACH-M: A pilot study evaluating an instructional sequence for persons with impaired memory and executive functions	BRAIN INJURY			English	Article						cognitive rehabilitation; direct instruction; errorless learning; spaced retrieval; memory impairment; executive function impairment	FACE-NAME ASSOCIATIONS; ERRORLESS; ACQUISITION; REHABILITATION; WORK	Primary objective: The purpose of this pilot study was to evaluate an instructional package that facilitates learning and retention of multi-step procedures for persons with severe memory and executive function impairments resulting from traumatic brain injury. Research design: The study used a multiple baseline across participants design. Methods and procedures: Four participants, two males and two females, ranging in age from 36-58 years, were taught a 7-step e-mail task. The instructional package (TEACH-M) was the experimental intervention and the number of correct e-mail steps learned was the dependent variable. Main outcomes and results: Treatment effects were replicated across the four participants and maintained at 30 days post-treatment. Generalization and social validity data further supported the treatment programme. Conclusions: The results suggest that individuals with severe cognitive impairments are capable of learning new skills. Directions for future research include application of the instructional package to other multi-step procedures.	Western Oregon Univ, Teaching Res Inst Eugene, Eugene, OR 97401 USA; Univ Oregon, Eugene, OR 97403 USA	Ehlhardt, LA (corresponding author), Western Oregon Univ, Teaching Res Inst Eugene, 99 W 10th Ave,Suite 370, Eugene, OR 97401 USA.	lehlhart@oregon.uoregon.edu					Baker S., 2002, LEARNING DISABILITIE, V17, P65, DOI DOI 10.1111/1540-5826.00032; Camp C. J., 1998, CLIN GERONTOLOGIST, V19, P51, DOI DOI 10.1300/J018V19N01_; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Clare L, 2002, NEUROPSYCHOLOGY, V16, P538, DOI 10.1037//0894-4105.16.4.538; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Delis DC, 1987, CALIFORNIA VERBAL LE; Engelmann S., 1991, THEORY INSTRUCTION; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Frattali CM., 1998, MEASURING OUTCOMES S; FRY E, 1968, J READING        APR, P512; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; HORNER RD, 1978, J APPL BEHAV ANAL, V11, P189, DOI 10.1901/jaba.1978.11-189; Horner RH., 1986, ED LEARNERS SEVERE H, P289; Hunkin NM, 1998, NEUROPSYCHOL REHABIL, V8, P433, DOI 10.1080/713755581; Kalla T, 2001, NEUROPSYCHOL REHABIL, V11, P1; Kazdin A. E., 1982, SINGLE CASE RES DESI; Kern RS, 2002, AM J PSYCHIAT, V159, P1921, DOI 10.1176/appi.ajp.159.11.1921; Komatsu S, 2000, NEUROPSYCHOL REHABIL, V10, P113, DOI 10.1080/096020100389200; Landauer T. K., 1978, OPTIMUM REHEARSAL PA; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MADIGAN KA, 1997, STUDENTS ACQUIRED BR, P123; Mozzoni MP, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199602000-00003; Parsonson B. S., 1986, RES METHODS APPL BEH, P157, DOI DOI 10.1007/978-1-4684-8786-2_8; Richards S. B., 1999, SINGLE SUBJECT RES A; Smith GJ, 1999, PERCEPT MOTOR SKILL, V89, P951, DOI 10.2466/PMS.89.7.951-965; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 2002, PERSPECTIVES NEUROPH, V12, P4; SPOONER F, 1984, EDUC TRAIN MENT RET, V19, P114; Stein M, 1998, INTERV SCH CLIN, V33, P227, DOI 10.1177/105345129803300405; Swanson H. L., 1999, LEARNING DISABILITIE, V14, P129, DOI [DOI 10.1207/SLDRP1403_1, DOI 10.1207/SLDRP1403_]; Swanson HL, 1998, REV EDUC RES, V68, P277, DOI 10.2307/1170599; TRANEL D, 1995, HDB MEMORY DISORDERS, P27; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; WILSON B, 1985, RIVERMEAND BEHAV MEM; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Young DA, 2002, NEUROPSYCHOL REHABIL, V12, P257, DOI 10.1080/0960201044000066	42	38	38	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	8					569	583		10.1080/002699050400013550			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700002	16175811				2021-06-18	
J	Tasker, RC; Salmond, CH; Westland, AG; Pena, A; Gillard, JH; Sahakian, BJ; Pickard, JD				Tasker, RC; Salmond, CH; Westland, AG; Pena, A; Gillard, JH; Sahakian, BJ; Pickard, JD			Head circumference and brain and hippocampal volume after severe traumatic brain injury in childhood	PEDIATRIC RESEARCH			English	Article							VOXEL-BASED MORPHOMETRY; VENTRICULAR ENLARGEMENT; DIFFUSION TENSOR; CHILDREN; MRI; ATROPHY; GROWTH; ECHO; ADOLESCENTS; DEFICIENCY	Vulnerability of the hippocampus to traumatic brain injury (TBI) in adults is related to severity of injury and white matter atrophy. The objectives of this study were to determine features of anthropometry and cerebral morphometry late after TBI in childhood and to assess whether hippocampal volume is related to severity of initial ictus and changes in white matter at follow-up. Thirty-three patients underwent magnetic resonance imaging 4.9 y after severe TBI that necessitated intensive care; 23 had mechanical ventilation and intracranial pressure monitoring longer than 3 d. Magnetic resonance imaging analyses included volume of brain, hemisphere, ventricles, and hippocampal and perihippocampal regions; spatial distribution of voxel-based morphometry differences in white matter; and eigenvalues of diffusion tensor imaging diffusivity. Patients with longer intensive care ictus had smaller-than-expected occipitofrontal head circumference. Eight of these, identified by voxel-based morphometry, had periventricular white matter loss and smaller-than-expected brain volume for OFC, suggesting "atrophy"; the remainder had expected volume for a smaller OFC, suggesting "growth disturbance." Ninety-three percent of the variation in right hippocampal volume was accounted for by factors related to severity of injury and white matter atrophy. It is concluded that anthropometry and cerebral morphometric measurements late after severe TBI in childhood provides useful outcome data and indicate that, despite adequate growth in stature, effects of TBI on brain growth and hippocampal volume may extend into adulthood.	Univ Cambridge, Addenbrookes Hosp, Sch Clin, Dept Paediat, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Tasker, RC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin, Dept Paediat, Box 116,Hills Rd, Cambridge CB2 2QQ, England.	rct31@hermes.cam.ac.uk	Sahakian, Barbara/AAW-1198-2020; Tasker, Robert C/R-5837-2019	Sahakian, Barbara/0000-0001-7352-1745; Tasker, Robert/0000-0003-3647-8113	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline		ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; *CHILD GROWTH FDN, 1996, GROWTH CHARTS; COULTHARD MG, 1994, ARCH DIS CHILD, V71, P281, DOI 10.1136/adc.71.3.281-a; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; DEREUCK J, 1971, EUR NEUROL, V5, P321; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Gale CR, 2004, BRAIN, V127, P321, DOI 10.1093/brain/awh034; Gale CR, 2003, BRAIN, V126, P2273, DOI 10.1093/brain/awg225; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1996, DEV BRAIN RES, V91, P274; GUZMAN AL, 1992, ACTA PAEDIATR, V81, P698, DOI 10.1111/j.1651-2227.1992.tb12337.x; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Jezzard P, 1998, MAGNET RESON MED, V39, P801, DOI 10.1002/mrm.1910390518; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; ONUMA T, 1995, J NEUROSURG, V82, P995, DOI 10.3171/jns.1995.82.6.0995; Papadakis NG, 1999, J MAGN RESON, V137, P67, DOI 10.1006/jmre.1998.1673; Papadakis NG, 2000, MAGNET RESON MED, V44, P616, DOI 10.1002/1522-2594(200010)44:4<616::AID-MRM16>3.0.CO;2-T; Salmond CH, 2002, NEUROIMAGE, V17, P1027, DOI 10.1006/nimg.2002.1153; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Tasker Robert C., 2001, Indian Journal of Pediatrics, V68, P257, DOI 10.1007/BF02723203; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Tomita H, 1990, Adv Neurol, V52, P553; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; VanPaesschen W, 1997, ANN NEUROL, V41, P41, DOI 10.1002/ana.410410109; Verger K, 2001, BRAIN INJURY, V15, P211; Xing D, 1997, MAGN RESON IMAGING, V15, P771, DOI 10.1016/S0730-725X(97)00037-4	44	38	38	0	3	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	AUG	2005	58	2					302	308		10.1203/01.PDR.0000169965.08854.25			7	Pediatrics	Pediatrics	952HV	WOS:000230995500022	16006434	Bronze			2021-06-18	
J	Du, R; Meeker, M; Bacchetti, P; Larson, MD; Holland, MC; Manley, GT				Du, R; Meeker, M; Bacchetti, P; Larson, MD; Holland, MC; Manley, GT			Evaluation of the portable infrared pupillometer	NEUROSURGERY			English	Article						pupillometer; pupillary examination; traumatic brain injury	SEVERE HEAD-INJURY; PROGNOSIS		Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave 4M39, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Du, Rose/AAJ-2873-2020; Du, Rose/I-5402-2012	Du, Rose/0000-0003-2641-6496	ODCDC CDC HHS [R49/CCR903697] Funding Source: Medline		CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; LARSON MD, 1995, ARCH NEUROL-CHICAGO, V52, P369, DOI 10.1001/archneur.1995.00540280051018; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; MARSHALL LF, 1983, J NEUROSURG, V58, P566, DOI 10.3171/jns.1983.58.4.0566; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; VANDENBERGE JH, 1979, J NEUROL NEUROSUR PS, V42, P1163, DOI 10.1136/jnnp.42.12.1163	9	38	39	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2005	57	1					198	202		10.1227/01.NEU.0000163425.79170.CB			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	942ZQ	WOS:000230321800051	15987563				2021-06-18	
J	Matsuda, W; Komatsu, Y; Yanaka, K; Matsumura, A				Matsuda, W; Komatsu, Y; Yanaka, K; Matsumura, A			Levodopa treatment for patients in persistent vegetative or minimally conscious states	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			CLOSED-HEAD INJURY; BRAIN-STEM LESIONS; REMARKABLE IMPROVEMENT; L-DOPA; PARKINSONISM; AMANTADINE; NEUROTRANSMITTERS; RECOVERY; SYMPTOMS; DAMAGE	The persistent vegetative state (PVS) and the minimally conscious state (MCS) are conditions of altered consciousness after severe brain damage due to a variety of pathologies. However, the specific pathophysiological mechanisms and a therapeutic strategy for intervention have not as yet been established. We review previous reports of levodopa treatment for patients in PVS, MCS, or other mental disorders, and have focused on five representative cases: four of PVS and one of MCS after severe brain injury. In summary, our review suggests the effectiveness of levodopa treatment is probably dependent upon the following criteria: (1) Diagnosis of PVS or MCS as distinct from other related conditions, (2) Concomitant symptoms of parkinsonism, and (3) Concomitant neuroradiological findings of high intensity lesions in the dopaminergic pathway on T2 weighted MRI. The apparent success of levodopa in the five cases described may reflect a specific subgroup of PVS and MCS patients, where the administration of levodopa is effective. However, we should not regard PVS or MCS as a single entity, since levodopa is unlikely to be effective in all cases. Therapeutic strategies should aim to identify the key pathophysiological mechanism for each patient and target interventions accordingly.	Kyoto Univ, Dept Morphol Brain Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; Tsukuba Med Ctr Hosp, Tsukuba, Ibaraki, Japan; Inst Clin Med, Ibaraki, Japan	Matsuda, W (corresponding author), Kyoto Univ, Dept Morphol Brain Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan.	wako@mua.biglobe.ne.jp	Matsuda, Wakoto/D-2143-2018	Matsuda, Wakoto/0000-0001-8313-6103			ABRAMSKY O, 1974, SURGERY, V75, P188; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; [Anonymous], 2003, Clin Med (Lond), V3, P249; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bhatt M, 2000, MOVEMENT DISORD, V15, P313, DOI 10.1002/1531-8257(200003)15:2<313::AID-MDS1017>3.0.CO;2-P; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; DALY DD, 1958, NEUROLOGY, V8, P238, DOI 10.1212/WNL.8.3.238; Doder M, 1999, J NEUROL NEUROSUR PS, V66, P380, DOI 10.1136/jnnp.66.3.380; Evans AH, 2004, NEUROLOGY, V62, P2333, DOI 10.1212/01.WNL.0000130350.54120.09; FISCHER JE, 1971, LANCET, V2, P75, DOI 10.1016/s0140-6736(71)92048-4; FUKUSHIMA T, 1972, BRAIN NERVE, V24, P1673; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; JANKOVIC J, 1994, NEUROLOGY, V44, P2006, DOI 10.1212/WNL.44.11.2006; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P1082; JENNETT B, 1972, LANCET, V1, P734; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Koeda T, 1998, BRAIN DEV-JPN, V20, P124, DOI 10.1016/S0387-7604(98)00004-7; KOTCHOUBEY B, 2004, J NEUROLOGY NEUROSUR; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MATSUDA W, 2004, J NEUROLOGY NEUROSUR; MATSUDA W, 1999, BRAIN NERVE, V51, P1071; MATSUMURA A, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P192; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Nestler EJ, 2001, MOL NEUROPHARMACOLOG; PARKES JD, 1970, LANCET, V2, P1341; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; SACKS OW, 1972, NEUROLOGY, V22, P516, DOI 10.1212/WNL.22.5.516; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; Yoshikawa H, 1999, BRAIN DEV-JPN, V21, P140; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7; Zijlmans J, 2002, MOVEMENT DISORD, V17, P1086, DOI 10.1002/mds.10203	44	38	41	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					414	427		10.1080/09602010443000588			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900026	16350982				2021-06-18	
J	Sills, MR; Libby, AM; Orton, HD				Sills, MR; Libby, AM; Orton, HD			Prehospital and in-hospital mortality - A comparison of intentional and unintentional traumatic brain injuries in Colorado children	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							NURSE HOME VISITATION; SEVERITY SCORE ICISS; LENGTH-OF-STAY; INTERNATIONAL CLASSIFICATION; RANDOMIZED TRIAL; HEAD-INJURY; ABUSE; PREDICTORS; SURVIVAL; DISEASES	Objectives: To describe the incidence and case-fatality rates of traumatic brain injury (TBI) in young children in Colorado, to compare these injuries based on intentionality and outcome (prehospital death, in-hospital death, or survival), and to model the association of intentionality with TBI-related mortality. Methods: Cases were drawn from the 1994-2002 Colorado Traumatic Brain Injury Surveillance System. Incidence and case-fatality rates for intentional and unintentional TBI were calculated. We performed univariate comparisons based on the intentionality and outcome of the TBI. Multivariate logistic regression was used to estimate the association of intentionality and mortality, controlling for injury severity. Results: Of the 1333 children aged 0 to 36 months with TBI, 340 had intentional and 993 had unintentional TBI. Incidence for intentional and unintentional TBI was 16.1 and 47.0 per 100 000, respectively. Children with intentional TBI had a higher case-fatality rate, in-hospital death rate, and injury severity. Intentional TBI deaths were twice as likely to occur in hospital than prehospital, whereas unintentional TBI deaths were twice as likely to occur prehospital. Intentionality was significantly associated with mortality, with the effect increasing with increasing age. Conclusion: Intentionality-independent of severity-raises the mortality of TBI in young children.	Univ Colorado, Dept Pediat, Denver, CO 80218 USA; Univ Colorado, Dept Psychiat, Denver, CO 80218 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Sills, MR (corresponding author), Univ Colorado, Dept Pediat, 1056 E 19th Ave,B-251, Denver, CO 80218 USA.	sills.marion@tchden.org	Libby, Anne M/B-6984-2013; Libby, Anne M./K-3476-2015	Libby, Anne M/0000-0002-4564-9407; Sills, Marion/0000-0003-1322-0822	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [D14HP00153] Funding Source: Medline		Berkowitz Carol D., 1995, Emergency Medicine Clinics of North America, V13, P321; *COL DEP PUBL HLTH, COL HLTH INF DAT DEA; *COL DEP PUBL HLTH, COL HLTH INF DAT POP; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Fluke JD, 1999, CHILD ABUSE NEGLECT, V23, P633, DOI 10.1016/S0145-2134(99)00039-3; Hannan EL, 1999, J TRAUMA, V47, P8, DOI 10.1097/00005373-199907000-00003; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON CF, 2000, NELSONS TXB PEDIAT, P113; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kim Y, 2003, J TRAUMA, V54, P775, DOI 10.1097/01.TA.0000028251.15629.1D; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; OLDS D, 1995, PEDIATRICS, V95, P365; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Olsen SJ, 1996, EPIDEMIOLOGY, V7, P644, DOI 10.1097/00001648-199611000-00015; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler TM, 1998, J TRAUMA, V45, P234, DOI 10.1097/00005373-199808000-00006; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rubin D, 2001, CURR OPIN PEDIATR, V13, P388, DOI 10.1097/00008480-200110000-00002; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Rutledge R, 1998, J TRAUMA, V45, P791, DOI 10.1097/00005373-199810000-00032; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003; Southall DP, 1997, PEDIATRICS, V100, P735, DOI 10.1542/peds.100.5.735; Thurman DJ., 1995, GUIDELINES SURVEILLA; US Department of Health and Human Services, 2001, ADM CHILDR YOUTH FAM; World Health Organization, 1977, INT CLASS DIS 9 REV	31	38	40	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2005	159	7					665	670		10.1001/archpedi.159.7.665			6	Pediatrics	Pediatrics	941QP	WOS:000230229600012	15997001	Bronze			2021-06-18	
J	Turkstra, L; Ylvisaker, M; Coelho, C; Kennedy, M; Sohlberg, MM; Avery, J; Yorkston, K				Turkstra, L; Ylvisaker, M; Coelho, C; Kennedy, M; Sohlberg, MM; Avery, J; Yorkston, K			Practice guidelines for standardized assessment for persons with traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							AMNESIA TEST; ADOLESCENTS; ORIENTATION; DEFICITS; DAMAGE; TESTS	This article is one of a series of publications by the Academy of Neurologic Communication Disorders and Sciences (ANCDS) working groups on evidence-based clinical practice (EBP) in neurologic communication disorders. The EPB project was initiated in 1997, when ANCDS established committees of experts to develop EBP guidelines for the following areas: dysarthria, aphasia, dementia, apraxia, and cognitive-communication disorders associated with traumatic brain injury (TBI). The scope and mission of the EBP project are described in detail in previous publications (Golper et al., 2001; Kennedy et al., 2002; Sohlberg et al., 2003). This article was generated by the subcommittee on cognitive-communication disorders associated with TBI, and its purpose is to examine the evidence for the use of standardized, norm-referenced tests. Evaluation and assessment using nonstandardized tests and other approaches will be addressed in a separate publication. The full Technical Report is available at www.ancds.org.	Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA; Coll St Rose, Albany, NY USA; Univ Connecticut, New Haven, CT USA; Univ Minnesota, Minneapolis, MN USA; Univ Oregon, Eugene, OR 97403 USA; Univ Washington, Seattle, WA 98195 USA	Turkstra, L (corresponding author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu					Adamovich B. B., 1992, SCALES COGNITIVE ABI; *AM PSYCH ASS, 2002, AM PSYCHOL, V57, P1060, DOI DOI 10.1037/0003-066X.57.12.1060; *AM SPEECH LANG HE, 2004, ASHA S, V24; Anastasi A, 1997, PSYCHOL TESTING, V7th; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; BIDDLE AK, 2002, AC NEUR COMM DIS SCI; Blosser J, 2003, PEDIAT TRAUMATIC BRA; Carrow-Woolfolk E., 1999, COMPREHENSIVE ASSESS; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Delis D, 1994, CALIFORNIA VERBAL LE; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; Dunn L., 1981, PEABODY PICTURE VOCA; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Ellmo W, 1997, J NEW JERSEY SPEECH, V6, P17; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Frank EM, 1996, J MED SPEECH-LANG PA, V4, P81; Frank EM, 1997, J MED SPEECH-LANG PA, V5, P97; Frattali CM, 1995, AM SPEECH LANGUAGE H; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GARDNER MF, 1990, EXPRESSIVE 1 WORD PI; German D. J, 1990, TEST ADOLESCENT ADUL; German D.J., 1991, TEST WORD FINDING DI; GERMAN DJ, 1989, TEST WORD FINDING; GILLIS R, 1996, TRAUMATIC BRAIN INJU; Gioia G.A., 2000, BEHAV RATING INVENTO; GOLPER LC, 2001, EVIDENCE BASED PRACT; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; Holland A, 1999, COMMUNICATION ACTIVI; HOTZ G, UNPUB PEDIAT TEST BR; Kaplan E., 1988, CLIN NEUROPSYCHOLOGY, P125; Kaplan E., 2000, BOSTON NAMING TEST; Kennedy MRT, 2002, J MED SPEECH-LANG PA, V10, pIX; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; Kertesz A., 1982, W APHASIA BATTERY; LAPOINTE R, 1998, READING COMPREHENSIO; Larkins BM, 2004, BRAIN INJURY, V18, P691, DOI 10.1080/02699050310001617389; LARKINS BM, 2003, THESIS U QUEENSLAND; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; NELSON NW, 1991, COMMUNICATION DISORD, P191; Paul D R, 2005, QUALITY COMMUNICATIO; PAULBROWN D, 2003, ASHA S, V23, P47; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Randolph C., 2001, REPEATABLE BATTERY A; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; REYNOLDS C, 1993, TEST MEMORY LEARNING; ROSSSWAIN D, 1996, ROSS INFORMATION PRO; Schuell H., 1972, MINNESOTA TEST DIFFE; Schwartz R, 1989, ASHA, V31, P91; Secord, 1989, TEST LANGUAGE COMPET; Semel E., 1987, CLIN EVALUATION LANG; SEMEL W, 1995, CLIN EVALUATION LANG; SMITH K, IN PRESS CLIN PERFOR; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; SOHLBERG MM, 2001, COGNITIVE REHAVILITA; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; Stuss D.T., 1986, FRONTAL LOBES; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 1999, LANG SPEECH HEAR SER, V30, P132, DOI 10.1044/0161-1461.3002.132; *U BUFF, 1996, FUNCT IND MEAS; WEBSTER JS, 1996, WEBSTERS COLL DICT; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Woodcock R. W., 1989, WOODCOCK JOHNSON PSY; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159; ZACHMAN L, 1989, WORD TEST ADOLESCENT; ZIMMERMAN IL, 1991, PRESCHOOL LANGUAGE S	81	38	38	0	15	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	JUN	2005	13	2					IX	XXXVIII					30	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	934LC	WOS:000229709300002					2021-06-18	
J	Wright, DW; Ritchie, JC; Mullins, RE; Kellermann, AL; Denson, DD				Wright, DW; Ritchie, JC; Mullins, RE; Kellermann, AL; Denson, DD			Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						traumatic brain injury; pharmacokinetics; continuous infusion; progesterone	SEVERE HEAD-INJURY; HIGH-DOSE PROGESTERONE; CONTUSION INJURY; RATS; MANAGEMENT; EDEMA; GUIDELINES; PROTECTS	Progesterone ( PG) has been shown to provide substantial neuroprotection after traumatic brain injury ( TBI) in multiple animal models. As a first step in assessing applicability to humans, the authors examined the effects of acute TBI and extracranial trauma on the pharmacokinetics of PG given by intravenous infusion. Multiple blood samples were obtained from 11 female and 21 male trauma patients receiving PG and 1 female and 3 male patients receiving placebo infusions for 72 hours. Values for C-SS, CL, t(1/ 2), and V-d were obtained using AUC((0-72)) and postinfusion blood samples. C-SS values were 337 +/- 135 ng/ mL, which were significantly lower than the target concentration of 450 +/- 100 ng/ mL. The lower C-SS is attributed to the CL, which was higher than anticipated. In addition, t(1/2) was longer and V-d was higher than anticipated. These results demonstrate that stable PG concentrations can be rapidly achieved following TBI.	Emory Univ, Sch Med, Dept Emergency Med, Emergency Med Res Ctr, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30303 USA	Wright, DW (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Emergency Med Res Ctr, 49 Jessie Hill Jr Dr, Atlanta, GA 30303 USA.		Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS-39097-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039097] Funding Source: NIH RePORTER		Aebi S, 1999, CANCER CHEMOTH PHARM, V44, P259, DOI 10.1007/s002800050976; Allolio B, 1995, EUR J ENDOCRINOL, V133, P696, DOI 10.1530/eje.0.1330696; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boucher BA, 1998, CLIN PHARMACOKINET, V35, P209, DOI 10.2165/00003088-199835030-00004; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carlin CB, 1999, DIGEST SURG, V16, P192, DOI 10.1159/000018726; *CDCP NAT CTR INJ, 2003, TRAUM BRAIN INJ; CHAKMAKJIAN ZH, 1987, J REPROD MED, V32, P443; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHRISTEN RD, 1993, J CLIN ONCOL, V11, P2417, DOI 10.1200/JCO.1993.11.12.2417; Goldfien A, 1989, BASIC CLIN PHARM, P493; HARGROVE JT, 1989, AM J OBSTET GYNECOL, V161, P948, DOI 10.1016/0002-9378(89)90759-X; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/BF01709548; KRAUS J, 1997, HEAD INJURY, P1; Lancel M, 1996, AM J PHYSIOL-ENDOC M, V271, pE763; McIntosh TK, 1996, LAB INVEST, V74, P315; McKindley DS, 1998, PHARMACOTHERAPY, V18, P759; MONTVALE NJ, 1998, PHYS DESK REFERENCE; MURAD F, 1990, P1384; NILLIUS SJ, 1971, AM J OBSTET GYNECOL, V110, P470, DOI 10.1016/0002-9378(71)90686-7; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; PETTUS E, 2002, J NEUROTRAUM, V19, P1286; POISINDEX, 1997, DRUG EVALUATIONS TOX; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Segall A, 1999, J PHARMACEUT BIOMED, V19, P803, DOI 10.1016/S0731-7085(98)00120-4; SELECKI BR, 1982, AUST NZ J SURG, V52, P93, DOI 10.1111/j.1445-2197.1982.tb05297.x; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; STAMBROOK M, 1990, CAN J SURG, V33, P115; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; VENGPEDERSEN P, 1989, CLIN PHARMACOKINET, V17, P424, DOI 10.2165/00003088-198917060-00005; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	39	38	39	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2005	45	6					640	648		10.1177/0091270005276201			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	928VZ	WOS:000229301100004	15901745				2021-06-18	
J	Godbout, L; Grenier, MC; Braun, CMJ; Gagnon, S				Godbout, L; Grenier, MC; Braun, CMJ; Gagnon, S			Cognitive structure of executive deficits in patients with frontal lesions performing activities of daily living	BRAIN INJURY			English	Article						ageing; scripts; executive functions; activities of daily living	CLOSED-HEAD INJURY; TRAUMATIC BRAIN-INJURY; DUAL-TASK PERFORMANCE; PROSPECTIVE MEMORY; WORKING-MEMORY; EVERYDAY MEMORY; DAMAGE; IMPAIRMENTS; LOBE; ATTENTION	Objective. Executive function in activities of daily living (ADL) were investigated in 10 patients with excised frontal lobe tumours. Method. The patients with frontal lesions were compared to 10 normal controls with a neuropsychological test battery, a script generation task and a realistic implementation of complex multi-task ADL (planning and preparing a meal). Results. The patients manifested numerous basic executive deficits on the paper-pencil tests, were unimpaired on the script generation task despite an aberrant semantic structure and manifested marked anomalies in the meal preparation task. Conclusion. Frontal lobe deficits in lengthy complex multi-task ADL can be explained by impairment of several executive functions, generalized slowness of performance and paucity of behaviour.	Univ Quebec, Dept Psychol, Ctr Neurosci Cognit, Montreal, PQ H3C 3P8, Canada; Univ Quebec, Dept Psychol, Lab Neuropsychol Expt & Comparee, Quebec City, PQ, Canada; Univ Ottawa, Ecole Psychol, Ottawa, ON, Canada	Braun, CMJ (corresponding author), Univ Quebec, Dept Psychol, Ctr Neurosci Cognit, CP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.	braun.claude@uqam.ca					Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; ARTHUR G, 1947, POINT SCALE PERFORMA, V2; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Baddeley A. D., 1986, WORKING MEMORY; BAILLARGEON J, 1994, UNPUB ADAPTATION FRA; BASSETT SS, 1991, PSYCHOL MED, V21, P77, DOI 10.1017/S0033291700014677; BISSIACHI PS, 1996, PROSPECTIVE MEMORY T, P297; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Cahn-Weiner DA, 2000, CLIN NEUROPSYCHOL, V14, P187, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT187; Carlson MC, 1999, J GERONTOL B-PSYCHOL, V54, pS262, DOI 10.1093/geronb/54B.5.S262; CHATELOIS J, 1993, UNPUB TEST STROOP RE; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cooper R, 1997, PROCEEDINGS OF THE NINETEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P131; COOPER R, 1995, FR ART INT, V27, P27; CROVITZ HF, 1984, B PSYCHONOMIC SOC, V22, P413; Crozier S, 1999, NEUROPSYCHOLOGIA, V37, P1469, DOI 10.1016/S0028-3932(99)00054-8; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duyckaerts C, 1998, REV NEUROL-FRANCE, V154, pS8; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EUSTACHE F, 1996, MANUEL NEUROPSYCHOLO; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Fuster J, 1989, PREFRONTAL CORTEX; GABRIELI JDE, 1993, BEHAV NEUROSCI, V107, P899, DOI 10.1037/0735-7044.107.6.899; Gil R., 1996, NEUROPSYCHOLOGIE; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Godbout L, 2000, BRAIN COGNITION, V44, P490, DOI 10.1006/brcg.2000.1213; GODBOUT L, 2004, IN PRESS J CLIN EXPT; GODBOUT L, 2004, IN PRESS PHYS OCCUPA; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Grafman J., 1989, INTEGRATING THEORY P, P93; Halstead WC, 1985, HALSTEAD REITAN NEUR; Handler J., 1994, HANDB NEUR, P125; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Katai S, 1999, Rinsho Shinkeigaku, V39, P913; KEITH V, 1973, NONPARAMETRIC DESIGN; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KOLB B, 1981, NEUROPSYCHOLOGIA, V19, P491, DOI 10.1016/0028-3932(81)90016-6; KOLB B, 1989, FONDAMENTALS HUMAN N; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; McDaniel M. A., 1992, ADV LEARNING BEHAV D, V1, P23; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Meacham J. A., 1982, MEMORY OBSERVED REME, P327; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Partiot A, 1996, NEUROREPORT, V7, P761, DOI 10.1097/00001756-199602290-00020; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Ruff R.M., 1996, RUFF 2 7 SELECTIVE A; Sala SD, 1995, ANN NY ACAD SCI, V769, P161, DOI 10.1111/j.1749-6632.1995.tb38137.x; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Shapiro JK, 1998, BRAIN COGNITION, V37, P175; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Stuss D.T., 1986, FRONTAL LOBES; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; Thurstone L.L., 1962, PRIMARY MENTAL ABILI; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILKINS AJ, 1978, PRACTICAL ASPECTS ME, P27; WINOGRAD E, 1978, PRACTICAL ASPECTS ME, P348; WISE SP, 1996, NEUROSCIENCE, V8, P39	78	38	40	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2005	19	5					337	348		10.1080/02699050400005093			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	932JH	WOS:000229549500004	16094781				2021-06-18	
J	de Haro, J; Zurita, M; Ayllon, L; Vaquero, J				de Haro, J; Zurita, M; Ayllon, L; Vaquero, J			Detection of In-111-oxine-labeled bone marrow stromal cells after intravenous or intralesional administration in chronic paraplegic rats	NEUROSCIENCE LETTERS			English	Article						bone marrow stromal cells; stem cells; spinal cord injury; paraplegia; In-111-labeled cells	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; INTRACEREBRAL TRANSPLANTATION; FUNCTIONAL RECOVERY; ADULT RATS; STEM-CELLS; IN-111	Recent studies suggested that bone marrow stromal cells (BMSC) may have a therapeutic role in the treatment of paraplegia secondary to severe spinal cord injury (SCI). For this reason, we have studied the possibility of using nuclear medicine imaging techniques to evaluate the permanency and migration of BNISC after transplantation procedures in chronic paraplegic Wistar rats. After intravenous administration of (111) In-oxine- labeled BMSC, gammagraphic images showed that the activity distributed all over the organism, but in the spinal cord only scarce activity was identified. When (111) In-oxine-labeled BMSC were injected within the traumatic centromedullary cavity of paraplegic animals, the gammagraphic images showed persistent activity in the lesion zone, without any activity migrating to the rest of the organism, at least during the whole time of the study (10 days after transplantation procedures). Our results show the utility of (111) In labeling for to know the permanency and distribution of BMSC after grafting procedures, and suggest the convenience of the intralesional administration of BMSC, instead of the intravenous administration, in the treatment of chronic traumatic paraplegia. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, Neurosurg Serv,Puerta de Hierro Hosp, Madrid 28035, Spain; Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, Nucl Med Serv,Puerta de Hierro Hosp, Madrid 28035, Spain	Vaquero, J (corresponding author), Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, Neurosurg Serv,Puerta de Hierro Hosp, San Martin de Porres 4, Madrid 28035, Spain.	jvaqueroc@telefonica.net					Bai JZ, 2004, NEUROREPORT, V15, P1117, DOI 10.1097/00001756-200405190-00007; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Faraggi M, 1998, EUR J NUCL MED, V25, P205, DOI 10.1007/s002590050218; FROST P, 1978, P SOC EXP BIOL MED, V157, P61; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; ISSEKUTZ T, 1980, CLIN EXP IMMUNOL, V39, P215; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; THIERENS HMA, 1992, J NUCL MED, V33, P1167; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004	14	38	38	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 22	2005	377	1					7	11		10.1016/j.neulet.2004.11.060			5	Neurosciences	Neurosciences & Neurology	903FD	WOS:000227410100002	15722177				2021-06-18	
J	Tennant, A				Tennant, A			Admission to hospital following head injury in England: Incidence and socio-economic associations	BMC PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; SOCIAL DEPRIVATION; COMMUNITY	Background: Head injury in England is common. Evidence suggests that socio- economic factors may cause variation in incidence, and this variation may affect planning for services to meet the needs of those who have sustained a head injury. Methods: Socio- economic data were obtained from the UK Office for National Statistics and merged with Hospital Episodes Statistics obtained from the Department of Health. All patients admitted for head injury with ICD- 10 codes S00.0 - S09.9 during 2001 - 2 and 2002 - 3 were included and collated at the level of the extant Health Authorities ( HA) for 2002, and Primary Care Trust ( PCT) for 2003. Incidence was determined, and cluster analysis and multiple regression analysis were used to look at patterns and associations. Results: 112,718 patients were admitted during 2001 - 2 giving a hospitalised incidence rate for England of 229 per 100,000. This rate varied across the English HA's ranging from 91 - 419 per 100,000. The rate remained unchanged for 2002 - 3 with a similar magnitude of variation across PCT's. Three clusters of HA's were identified from the 2001 - 2 data; those typical of London, those of the Shire counties, and those of Other Urban authorities. Socio- economic factors were found to account for a high proportion of the variance in incidence for 2001 - 2. The same pattern emerged for 2002 - 3 at the PCT level. The use of public transport for travel to work is associated with a decreased incidence and lifestyle indicators, such as the numbers of young unemployed, increase the incidence. Conclusion: Head injury incidence in England varies by a factor of 4.6 across HA's and PCT's. Planning head injury related services at the local level thus needs to be based on local incidence figures rather than regional or national estimates. Socio- economic factors are shown to be associated with admission, including travel to work patterns and lifestyle indicators, which suggests that incidence is amenable to policy initiatives at the macro level as well as preventive programmes targeted at key groups.	Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9JT, W Yorkshire, England	Tennant, A (corresponding author), Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9JT, W Yorkshire, England.	alantennant@compuserve.com					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; Carolei A, 1997, STROKE, V28, P2500, DOI 10.1161/01.STR.28.12.2500; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; *HC, 2001, HEAD INJ REH HLTH CO; Horowitz I, 1983, Int Rehabil Med, V5, P32; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; Martin RCG, 2002, AM SURGEON, V68, P477; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; *NAT I CLIN EXC, 2003, TRIAG ASS INV EARL M, V4; Sosin DM, 1996, BRAIN INJURY, V10, P47; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; TENNANT A, 1995, TRAUMATIC BRAIN INJU, P12; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Townsend P., 1988, HLTH DEPRIVATION INE; VIAZQUEZBARQUER.A, 1990, NEUROLOGIA, V5, P155; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	29	38	39	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	MAR 4	2005	5								21	10.1186/1471-2458-5-21			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	908NG	WOS:000227793100001	15748288	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Kiraly, MA; Kiraly, SJ				Kiraly, MA; Kiraly, SJ			The effect of exercise on hippocampal integrity: Review of recent research	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						aging; Alzheimer's disease; antioxidant; cortisol; dementia; depression; exercise; hippocampus; ischemia; neuroprotection; stress; stroke; traumatic brain injury	MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-I; PHYSICAL-ACTIVITY; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; CELL-PROLIFERATION; DENTATE GYRUS; ANTIDEPRESSANT TREATMENT; ANTIOXIDANT SYSTEM; TREADMILL EXERCISE	Objectives: To review salient basic research regarding physical exercise as a major protective factor against hippocampal degradation and to emphasize its relevance to humans. Method: Recent mammalian and human research literature search and theoretical discussion. Results: The cascade of cellular damages from oxidative stress, nitrosative stress and gluco-corticoid effects are cumulative and age related. Exercise training reduces oxidative stress, nitro-sative stress and improves neuroendocrine autoregulation which counteracts damages from stress- and age-related neuronal degeneration, brain ischemia and traumatic brain injury. Conversely, lack of exercise and motility restrictions are associated with increased vulnerability from oxidative stress, nitrosative stress and glucocorticoid excesses, all of which precede amyloid deposition and are fundamental in the cascade of events resulting in neuronal degradation, especially in the hippocampi. Conclusions: Despite the paucity of human research, basic animal models and clinical data overwhelmingly support the notion that exercise treatment is a major protective factor against neurodegeneration of varied etiologies. The final common pathway of degradation is clearly related to oxidative stress, nitrosative stress, glucocorticoid dysregulation, inflammation and amyloid deposition. We conclude that people prone to chronic distress, brain ischemia, brain trauma, and the aged are at increased risk for neurodegenerative diseases such as Alzheimer's. Exercise training may be a major protective factor but without clinical guidelines, its prescription and success with treatment adherence remain elusive.	York Univ, N York, ON M3J 1P3, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Kiraly, SJ (corresponding author), B-51 Hummingbird Lane, Bowen Isl, BC V0N 1G0, Canada.	kiraly@shaw.ca					Albert MS, 1995, PSYCHOL AGING, V10, P578, DOI 10.1037/0882-7974.10.4.578; Anderson MF, 2002, DEV BRAIN RES, V134, P115; Ang ET, 2003, NEUROSCIENCE, V118, P335, DOI 10.1016/S0306-4522(02)00989-2; Asanuma M, 2004, CURR PHARM DESIGN, V10, P695, DOI 10.2174/1381612043453072; Behl C, 1998, EXP GERONTOL, V33, P689, DOI 10.1016/S0531-5565(98)00019-9; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Blair SN, 2001, MED SCI SPORT EXER, V33, pS379, DOI 10.1097/00005768-200106001-00007; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Bunce DJ, 1996, PSYCHOL AGING, V11, P671, DOI 10.1037/0882-7974.11.4.671; Cadet P, 2003, INT J MOL MED, V12, P485; CALABRESE V, 1989, Bollettino Societa Italiana Biologia Sperimentale, V65, P917; CAMERON HA, 1995, J NEUROSCI, V15, P4687; COHEN G, 1998, OXYGEN RADICAL TISSU, P130; Devi SA, 2004, NEUROBIOL AGING, V25, P501, DOI 10.1016/S0197-4580(03)00112-X; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Ellekjaer H, 2000, STROKE, V31, P14, DOI 10.1161/01.STR.31.1.14; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Evenson KR, 1999, STROKE, V30, P1333, DOI 10.1161/01.STR.30.7.1333; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V246, P359; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Fillit HM, 2002, MAYO CLIN PROC, V77, P681, DOI 10.4065/77.7.681; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Garza AA, 2004, PHARMACOL BIOCHEM BE, V77, P209, DOI 10.1016/j.pbb.2003.10.020; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Greenlund KJ, 2002, STROKE, V33, P565, DOI 10.1161/hs0202.102882; Grundman M, 2000, AM J CLIN NUTR, V71, p630S; Gutteridge JMC., 1985, FREE RADICALS BIOL M; HENSLEY K, 1995, P W PHARMACOL SOC, V38, P113; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961; JENKINS RR, 1984, INT J SPORTS MED, V5, P11, DOI 10.1055/s-2008-1025872; Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Khatri P, 2001, J AGING PHYS ACTIV, V9, P43, DOI 10.1123/japa.9.1.43; Kim YP, 2003, INT J SPORTS MED, V24, P114, DOI 10.1055/s-2003-38202; Kiraly SJ, 1997, CAN J PSYCHIAT, V42, P415, DOI 10.1177/070674379704200409; Kitamura T, 2003, NEUROSCI RES, V47, P55, DOI 10.1016/S0168-0102(03)00171-8; KOCHANEK KD, 2002, NATL VITAL STAT REPO, V52; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Koppal T, 1999, J NEUROCHEM, V72, P310, DOI 10.1046/j.1471-4159.1999.0720310.x; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; KURODA K, 1992, ACTA NEUROL SCAND, V86, P55, DOI 10.1111/j.1600-0404.1992.tb08054.x; LAMANNA JC, 1992, J APPL PHYSIOL, V72, P2238; Lanska DJ, 1998, NEUROLOGY, V50, P362, DOI 10.1212/WNL.50.2.362; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lee CD, 2003, STROKE, V34, P2475, DOI 10.1161/01.STR.0000091843.02517.9D; Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1; Lee MH, 2003, LIFE SCI, V73, P2455, DOI 10.1016/S0024-3205(03)00655-6; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; McIntosh LJ, 1998, BRAIN RES, V791, P209, DOI 10.1016/S0006-8993(98)00115-2; MURRAY KD, 1994, NEUROSCIENCE, V60, P37, DOI 10.1016/0306-4522(94)90202-X; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; NOVELLI GP, 1999, FREE RADICAL BIO MED, V9, P9; Ra SM, 2002, NEUROSCI LETT, V333, P123, DOI 10.1016/S0304-3940(02)01031-5; Radak Z, 2001, NEUROCHEM INT, V39, P33, DOI 10.1016/S0197-0186(01)00003-1; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Sapolsky R., 1992, STRESS AGING BRAIN M; SASCO AJ, 1992, ARCH NEUROL-CHICAGO, V49, P360, DOI 10.1001/archneur.1992.00530280040020; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; SOMANI SM, 1995, PHARMACOL BIOCHEM BE, V50, P635, DOI 10.1016/0091-3057(94)00357-2; Sumitani Kazunori, 2002, Nihon Seirigaku Zasshi, V64, P152; Trejo JL, 2002, REV NEUROSCIENCE, V13, P365; Trejo JL, 2001, J NEUROSCI, V21, P1628; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; *US DEP HHS, 1990, DHHS PUBL; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; Wannamethee SG, 2001, SPORTS MED, V31, P101, DOI 10.2165/00007256-200131020-00003; Widenfalk J, 1999, NEUROSCI RES, V34, P125, DOI 10.1016/S0168-0102(99)00051-6; Wilkins K, 1999, Chronic Dis Can, V20, P26; Williams P, 1997, AUST NZ J PUBL HEAL, V21, P45, DOI 10.1111/j.1467-842X.1997.tb01653.x; Wilson RS, 2003, NEUROLOGY, V61, P1479, DOI 10.1212/01.WNL.0000096167.56734.59; Yaffe K, 2001, ARCH INTERN MED, V161, P1703, DOI 10.1001/archinte.161.14.1703; Yanamoto H, 1998, BRAIN RES, V784, P239, DOI 10.1016/S0006-8993(97)01344-9; Young R J, 1979, Br J Sports Med, V13, P110; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	83	38	39	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2174	1541-3527		INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		2005	35	1					75	89		10.2190/HX7L-4B40-PQNY-2A4P			15	Psychiatry	Psychiatry	936PL	WOS:000229867800006	15977946				2021-06-18	
J	Pape, TLB; Heinemann, AW; Kelly, JP; Hurder, AG; Lundgren, S				Pape, TLB; Heinemann, AW; Kelly, JP; Hurder, AG; Lundgren, S			A measure of neurobehavioral functioning after coma. Part I: Theory, reliability, and validity of the Disorders of Consciousness Scale	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; coma; consciousness; measure; outcome; psychometrics; recovery	TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; REHABILITATION; MANAGEMENT; TOOL	This longitudinal validation study describes the psychometric properties of the Disorders of Consciousness Scale (DOCS). This is Part I of a two-part series. Part II illustrates and describes the clinical and scientific implementation of the DOCS measure. The study was conducted at one intensive care unit, two acute rehabilitation hospitals, and one long-term acute cl-ironic care hospital. Participants were unconscious after severe brain in injury (BI). We conducted interrater reliability using ratings, from interdisciplinary pairs. Results indicated a higher-than-expected level of agreement and no significant difference between any pairs (chi-square 8(5df) P = 0.15) (df = degrees of freedom). Examinations of ratings by discipline groups indicated that the DOCS is' impacted minimally by discipline. Validity analyses demonstrate that 23 of 34 test stimuli remain stable over time with no floor or ceiling effect. DOCS measures obtained within 94 days of injury predicted recovery of consciousness up to 1 year after injury (c-indices of 0.70 and 0.86). Positive (0.71) and negative (0.68) predictive values indicate that the DOCS predicts recovery and lack of recovery. Twenty-three of the DOCS test stimuli produce a reliable, valid, and stable measure of neurobehavioral recovery after severe BI that predicts recovery and lack of recovery of consciousness 1 year after injury.	Edward Hines Jr VA Hosp, Vet Hlth Adm, Res Serv, Dept Vet Affairs, Hines, IL 60141 USA; Marianjoy Rehab Hosp, Wheaton, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA; Rehabil Inst Chicago, Ctr Rehab Outcomes Res, Chicago, IL 60611 USA; Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; Edward Hines Jr Vet Adm Hosp, Cooperat Studies Program, Coordinating Ctr, Hines, IL 60141 USA; Minneapolis VA Med Ctr, Mental Behav Hlth Patient Serv Line, Minneapolis, MN USA	Pape, TLB (corresponding author), Edward Hines Jr VA Hosp, Vet Hlth Adm, Res Serv, Dept Vet Affairs, POB 5000,MC 151H, Hines, IL 60141 USA.	Theresa.Pape@med.va.gov	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Bender Pape, Theresa/0000-0001-7738-5963			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Fisher RA, 1925, P CAMB PHILOS SOC, V22, P700, DOI 10.1017/S0305004100009580; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Halper AS, 1991, CLIN MANAGEMENT COMM; Hedeker D, 2000, STAT METHODS MED RES, V9, P161, DOI 10.1191/096228000667253473; Heinemann AW, 2000, J HEAD TRAUMA REHAB, V15, pVI, DOI 10.1097/00001199-200002000-00001; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, LANCET, V1, P1031; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; Linacre J.M., 1994, RASCH MEASUREMENT T, V8, P350; Linacre JM, 1999, RASCH MEASUREMENT T, V13, P675; Linacre M., 1994, MANY FACET RASCH MEA; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; PAPE T, 2001, 84133F CFDA US DEP E; PAPE T, 1999, THESSI U ILLINOIS CH; Pape TLB, 2004, J REHABIL RES DEV, V41, P155, DOI 10.1682/JRRD.2004.02.0155; PAPE TLB, 1999, AM J PUBLIC HEALTH, V89, P1281; Wilson SL, 2000, BRAIN INJURY, V14, P319; WRIGHT B, 1998, RASCH MEAS T, V11, P602; Wright B.D., 1982, RATING SCALE ANAL; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; Wright BD., 1996, RASCH MEAS T, V8, P472; Wright BD., 1994, RASCH MEASUREMENT T, V8, P370, DOI DOI 10.1177/01461672012710004; Zasler ND, 1996, NEUROREHABILITATION, V6, P3, DOI 10.3233/NRE-1996-6102	32	38	39	1	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	JAN-FEB	2005	42	1					1	17		10.1682/JRRD.2004.03.0032			17	Rehabilitation	Rehabilitation	914DL	WOS:000228205100004	15742245				2021-06-18	
J	McCrory, P				McCrory, P			Preparticipation assessment for head injury	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury; concussion; athletic injuries; injury prevention	SPORT-RELATED CONCUSSION; APOLIPOPROTEIN; FOOTBALL	Objective: To determine the evidence base for recommendations regarding the pre-participation screening for head injury. Data Sources: The relevant literature was searched through the use of Medline (1966 to 2004), Google and Sport Discus (1975 to 2004) searches, hand searches of journals and reference lists and discussions with experts and sporting organisations worldwide. Data Synthesis/Methods: Consensus recommendations are summarized. No formal statistical analysis is presented Results: Although pre-participation examinations are widely performed, there are no evidence-based guidelines to direct physicians as to the minimum requirements for the baseline assessment of head injury. Conclusions: Expert consensus would suggest that a baseline neuropsychological examination, preferably using a computerised test battery, should be performed in order to guide return to play following subsequent concussive injuries. In addition, there are important medicolegal considerations in regard to the value of a documented assessment both at the start and end of an athlete's career with any team.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; Univ Melbourne, Brain Res Inst, Parkville, Vic 3052, Australia	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia.		McCrory, Paul/Q-8688-2019				ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; COLLIE A, 2004, IN PRESS BR J SPORTS; COLLIE A, 2004, IN PRESS J INT NEURO; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; McCrory P, 2000, SPORTS MED, V30, P221, DOI 10.2165/00007256-200030030-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; MCCRORY P, 2001, EVIDENCE BASED SPORT; McCrory Paul, 2002, Curr Sports Med Rep, V1, P28; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	19	38	38	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2004	14	3					139	144		10.1097/00042752-200405000-00006			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943BQ	WOS:000230327200006	15166902				2021-06-18	
J	Tam, SF; Man, WK				Tam, SF; Man, WK			Evaluating computer-assisted memory retraining programmes for people with post-head injury amnesia	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; SELF-EFFICACY; COGNITIVE REHABILITATION; FEEDBACK; INDIVIDUALS; OUTCOMES	Objective : The present study was designed to perform theory-driven empirical work that might contribute to a better understanding of computer-assisted training effects adopting theoretically different memory retraining strategies for people who had amnesia as a result of a brain injury. Research design : A pre-test and post-test control group quasi-experimental design was adopted to test the differences in effectiveness of four different computer-assisted memory training strategies, which were hypothesized to improve different memory skills of persons with brain injury. Method and procedures : Twenty-six persons with brain injury were randomly assigned to four age- and gender-matched memory training groups (self-paced, feedback, personalized, visual presentation) and they were trained using the related computer software, evaluated by the Rivermead Behavioural Memory Test (RBMT), self-efficacy scale and built-up computer performance records. Main outcomes and results : All the four memory training methods showed positive among the persons with brain injury as compared with a control group, although there was no statistically significant difference among the four training methods. However, clinical improvement was found in all four methods and the Feedback group showed significant improvement in self efficacy, in comparison with the other groups. Conclusion : This attempt to develop and evaluate different computer applications for memory retraining was made and the effectiveness of applying customized computer technology in memory rehabilitation was critically evaluated. Results of the present study showed that the unique customized therapeutic characteristics of computer-assisted memory retraining (e.g. self-paced practice, performance feedback, salient visual presentation and personalized training contents) are positive attributes of memory skill retraining outcomes.	Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China	Tam, SF (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.	rsalan@polyu.edu.hk					ARMSTRONG C, 1989, COGNITIVE REHABILITA, V1, P10; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BANDURA A, 1982, J PERS SOC PSYCHOL, V43, P5, DOI 10.1037/0022-3514.43.1.5; Bandura A., 1992, 6 THEORIES CHILD DEV, P1; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bellus SB, 1998, BRAIN INJURY, V12, P139, DOI 10.1080/026990598122764; Bracy O.D., 1999, COGN TECHNOL, V4, P19; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; BURDA PC, 1994, COMPUT HUM BEHAV, V10, P359, DOI 10.1016/0747-5632(94)90061-2; CERVONE D, 1986, J PERS SOC PSYCHOL, V50, P492, DOI 10.1037/0022-3514.50.3.492; Chen SHA, 1997, BRAIN INJURY, V11, P197; CLARK SC, 1997, DISS ABSTR INT, V58, P2177; Collins J. L., 1982, ANN M AM ED RES ASS; Daniels J. A., 2001, COUNS EDUC SUPERV, V41, P120, DOI [DOI 10.1002/J.1556-6978.2001.TB01276.X, 10.1002/j.1556-6978.2001.tb01276.x]; Escarti A, 1999, J APPL SPORT PSYCHOL, V11, P83, DOI 10.1080/10413209908402952; GILES GM, 1989, ARCH PHYS MED REHAB, V70, P156; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GREEN RC, 1994, ARCH NEUROL-CHICAGO, V51, P779, DOI 10.1001/archneur.1994.00540200055017; Johnson P, 1994, J COGNITIVE REHABILI, V12, P10; JOHNSON R, 1985, OCCUPATIONAL THERAPY, V48, P46; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P36; Man D.W.K., 2001, CLIN GERONTOLOGIST, V24, P27; MCGUIRE BE, 1990, IRISH J PSYCHOL, V11, P299, DOI 10.1080/03033910.1990.10557810; Miyake M, 2002, PSYCHOL REP, V90, P301, DOI 10.2466/pr0.2002.90.1.301; *NEUR WORK GROUP, 1998, HONG KONG J OCCUPATI, V9, P18; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SCHUNK DH, 1985, J EARLY ADOLESC, V5, P247, DOI DOI 10.1177/0272431685052008; SMART S, 1998, CLIN REHABIL, V2, P61; Tam SF, 1996, J PSYCHOL, V130, P51, DOI 10.1080/00223980.1996.9914987; TAM SF, 1982, P BME 92 BIOM ENG S, P53; Wilson B., 1992, CLIN MANAGEMENT MEMO, P120; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; YLVISAKER M, 1998, REHABILITATION TRAUM, P303; Zhang AQ, 2002, SOC BEHAV PERSONAL, V30, P281, DOI 10.2224/sbp.2002.30.3.281	37	38	40	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					461	470		10.1080/02699050310001646099			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600005	15195794				2021-06-18	
J	Schmitter-Edgecombe, M; Wright, MJ				Schmitter-Edgecombe, M; Wright, MJ			Event-based prospective memory following severe closed-head injury	NEUROPSYCHOLOGY			English	Article							PERFORMANCE; AGE; RETRIEVAL; TIME	Twenty-four severe closed-head injury (CHI) participants and 24 controls completed event-based prospective memory tasks concurrently with an ongoing working memory task. The event cue was either integrated with the ongoing working memory task (focal cue) or peripheral to it. Prospective remembering was poorer for the CHI group in both the focal- and peripheral-cue conditions. The groups did not differ on the ongoing task. The peripheral cue and the integrated focal cue also did not differ in ability to trigger prospective remembering. The results suggest that, even with highly salient event cues, severe CHI participants (> 1 year postinjury) are more likely than controls to exhibit prospective memory failures. The data revealed a link between CHI participants' prospective memory failures and momentary lapses of intention.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03 HD35838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD035838] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Benton A., 1976, MULTILINGUAL APHASIA; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NEUROL NEUROSUR PS, V39, P593; Brunfaut E, 2000, NEUROPSYCHOLOGIA, V38, P975, DOI 10.1016/S0028-3932(00)00016-6; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cohen J.D., 1996, PROSPECTIVE MEMORY T, P267; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; CRAIK FIM, 1996, PROSPECTIVE MEMORY T, P227; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Delis DC, 1987, CALIFORNIA VERBAL LE; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; FAHY JF, 1990, 10 ANN M NAT AC NEUR; Golden J. C., 1978, STROOP COLOR WORD TE; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Heaton R., 1981, MANUAL WISCONSIN CAR; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kucera H, 1967, COMPUTATIONAL ANAL P; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Marsh RL, 2000, APPL COGNITIVE PSYCH, V14, pS29, DOI 10.1002/acp.769; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mattis S, 1988, DEMENTIA RATING SCAL; Maylor EA, 1996, PSYCHOL AGING, V11, P74, DOI 10.1037/0882-7974.11.1.74; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; Meier B, 2000, APPL COGNITIVE PSYCH, V14, pS11, DOI 10.1002/acp.768; Nissley HM, 2002, NEUROPSYCHOLOGY, V16, P111, DOI 10.1037//0894-4105.16.1.111; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Park DC, 1997, PSYCHOL AGING, V12, P314, DOI 10.1037/0882-7974.12.2.314; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sattler JM, 1988, ASSESSMENT CHILDREN; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith A., 1991, SYMBOL DIGIT MODALIT; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Sohlberg M. M., 2001, COGNITIVE REHABILITA; TEASDALE G, 1974, LANCET, V2, P81; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1981, WAIS R MANUAL WECHSL; West R, 1999, PSYCHOL AGING, V14, P264, DOI 10.1037/0882-7974.14.2.264; West R, 2000, APPL COGNITIVE PSYCH, V14, pS115, DOI 10.1002/acp.774; West R, 2000, CEREB CORTEX, V10, P748, DOI 10.1093/cercor/10.8.748	51	38	39	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	2004	18	2					353	361		10.1037/0894-4105.18.2.353			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	810SX	WOS:000220725100016	15099157				2021-06-18	
J	Shimamura, M; Garcia, JM; Prough, DS; Hellmich, HL				Shimamura, M; Garcia, JM; Prough, DS; Hellmich, HL			Laser capture microdissection and analysis of amplified antisense RNA from distinct cell populations of the young and aged rat brain: effect of traumatic brain injury on hippocampal gene expression	MOLECULAR BRAIN RESEARCH			English	Article						traumatic brain injury; laser capture microdissection; hippocampal gene expression; RNA amplification; aging	MEMORY DYSFUNCTION; CEREBRAL-ISCHEMIA; CDNA SYNTHESIS; IN-SITU; RT-PCR; QUANTIFICATION; TRANSCRIPTION; SENESCENCE; DEFICITS; CYCLE	To explore the molecular mechanisms underlying the increased vulnerability of the aged brain to traumatic brain injury (TBI), we compared the expression of several age-related genes in the CA1, CA3 and dentate gyrus subfields of the young and aged rat hippocampus before and after lateral fluid percussion TBI. Using laser capture microdissection (LCM), we obtained hippocampal neurons and glia from the neuropil adjacent to the pyramidal and granule cell layers. Subsequently, we linearly amplified and analyzed the antisense mRNA using Northern blot and ribonuclease protection assays (RPA). Our procedures, which have not been previously applied to quantitative analysis of LCM mRNA from neural tissue, included a modified reverse transcription step to enhance full-length cDNA synthesis, thus enhancing the yield of larger components of in vitro-transcribed mRNA for downstream analysis. Northern analysis showed greater expression of two aging-associated genes, p21 and brain-derived neurotrophic factor (BDNF) in the aged hippocampus. The age-related differences in p21 and BDNF expression were particularly prominent after TBI. By quantitative RPA analysis, we found that the expression of p21, known to be induced in senescent cells, was significantly greater in the CA3 region of aged rats, an area that is selectively vulnerable to TBI. However, expression of genes associated with regenerative and repair functions was significantly decreased in aged hippocampus. Our RPA results indicate that substantial age-dependent differences in the transcriptional profile of distinct regions of the hippocampal formation may account, in part, for their differential susceptibility to brain injury. (C) 2003 Elsevier B.V All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Yokohama City Univ, Sch Med, Dept Neurol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; AMARAL DG, 1990, PROG BRAIN RES, V83, P1; Ambesi-Impiombato A, 2003, BRAIN RES PROTOC, V11, P189, DOI 10.1016/S1385-299X(03)00056-4; Antropova YG, 2002, B EXP BIOL MED+, V134, P81, DOI 10.1023/A:1020677209755; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bimonte HA, 2003, NEUROBIOL AGING, V24, P37, DOI 10.1016/S0197-4580(02)00015-5; Bonaventure P, 2002, BRAIN RES, V943, P38, DOI 10.1016/S0006-8993(02)02504-0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Busser J, 1998, J NEUROSCI, V18, P2801; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Donehower LA, 2002, J CELL PHYSIOL, V192, P23, DOI 10.1002/jcp.10104; Drosopoulos WC, 1998, J MOL MED-JMM, V76, P604, DOI 10.1007/s001090050257; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Feldman AL, 2002, BIOTECHNIQUES, V33, P906, DOI 10.2144/02334mt04; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hawkins PR, 2003, BIOTECHNIQUES, V34, P768, DOI 10.2144/03344st06; Hayashi M, 2001, BRAIN RES, V918, P191, DOI 10.1016/S0006-8993(01)03002-5; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoyer S, 2002, J NEURAL TRANSM, V109, P991, DOI 10.1007/s007020200082; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Kamme F, 2003, J NEUROSCI, V23, P3607; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Kramer DL, 2001, CANCER RES, V61, P7754; Luzzi V, 2001, AM J PATHOL, V158, P2005, DOI 10.1016/S0002-9440(10)64672-X; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McShea A, 1999, MED HYPOTHESES, V52, P525, DOI 10.1054/mehy.1997.0680; Meiners S, 2003, MOL NEUROBIOL, V27, P177, DOI 10.1385/MN:27:2:177; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Paccaud F, 2002, AGING CLIN EXP RES, V14, P314; Parlato R, 2002, ANAL BIOCHEM, V300, P139, DOI 10.1006/abio.2001.5463; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; Poldrack RA, 2003, NEUROPSYCHOLOGIA, V41, P245, DOI 10.1016/S0028-3932(02)00157-4; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Santos-Eggimann B, 2002, AGING CLIN EXP RES, V14, P287; Smith MA, 1996, BEHAV BRAIN RES, V78, P25, DOI 10.1016/0166-4328(95)00220-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Sykova E, 2002, HIPPOCAMPUS, V12, P269, DOI 10.1002/hipo.1101; Sykova E, 2001, Prog Brain Res, V132, P339; Tomasevic G, 1999, MOL BRAIN RES, V70, P304, DOI 10.1016/S0169-328X(99)00146-1; Tomasevic G, 1999, NEUROSCIENCE, V90, P781, DOI 10.1016/S0306-4522(98)00484-9; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wehrle-Haller B, 2003, J PATHOL, V200, P481, DOI 10.1002/path.1399; Wilkinson D. C., 1999, IN SITU HYBRIDIZATIO; Wittenberg GM, 2002, TRENDS NEUROSCI, V25, P501, DOI 10.1016/S0166-2236(02)02231-2; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5; Zhang JL, 1999, BIOCHEM J, V337, P231, DOI 10.1042/0264-6021:3370231; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406	63	38	40	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAR 17	2004	122	1					47	61		10.1016/j.molbrainres.2003.11.015			15	Neurosciences	Neurosciences & Neurology	804BD	WOS:000220273300006	14992815				2021-06-18	
J	Esquenazi, A				Esquenazi, A			Evaluation and management of spastic gait in patients with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						gait; spasticity; traumatic brain injury; upper motoneuron syndrome		Damage to the corticospinal system after brain injury interferes with activities of daily living, mobility, and communication. The chief cause of this interference has to do with impairment to produce and regulate voluntary movement accompanied by the presence of spasticity. This review advocates that the evaluation of "spasticity" should focus on 3 issues: (1) identifying the clinical pattern Of motor dysfunction and its source; (2) identifying the patient's ability to control muscles involved in the clinical pattern; and (3) the differential role of muscle stiffness and contracture as it relates to the functional problem. We have identified and described 6 clinical patterns of motor dysfunction affecting the lower limbs during gait, found in patients with traumatic brain injury and residual from upper motor neuron lesions. We have presented the use of dynamic electromyography to identify the voluntary and spastic characteristics of individual muscles in gait and the use of anesthetic nerve blocks to identify properties of stiffness and contracture in particular muscle groups. Treatment algorithms for these problems include identification of the muscles that contribute to the deformity across a joint; the stage of patient recovery; and most important, the clinical goals applicable to the patient. The treatment strategies based on the algorithm included in this article were focused on the use of chemodenervation of targeted muscles, neuro-orthopedic surgery, and other therapeutic strategies.	Albert Einstein Med Ctr, Dept Phys Med & Rehabil, Philadelphia, PA 19141 USA	Esquenazi, A (corresponding author), Albert Einstein Med Ctr, Dept Phys Med & Rehabil, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	aesquena@einstein.edu					ASHWORTH B, 1964, PRACTITIONER, V192, P540; Brin M F, 1997, Muscle Nerve Suppl, V6, pS208; CAMPBELL SK, 1991, CONT MANAGEMENT MOTO, P146; ESQUENAZI A, 1993, DELISAS REHABILITATI; Esquenazi A, 1995, GAIT ANAL THEORY APP, P412; FARMER SF, 1993, J PHYSIOL-LONDON, V463, P83, DOI 10.1113/jphysiol.1993.sp019585; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; JANKOVIC J, 1991, ARCH NEUROL-CHICAGO, V48, P1253, DOI 10.1001/archneur.1991.00530240057020; KOMAN LA, 1990, NIH CONSENSUS DEV C; Lance J., 1980, SPASTICITY DISORDERE; Mayer N, 1996, MED REHABILITATION T, P411; Mayer NH, 2004, J HEAD TRAUMA REHAB, V19, P119, DOI 10.1097/00001199-200403000-00005; Mayer NH, 2001, ADV NEUROL, V87, P311; Mayer NH, 1997, MUSCLE NERVE, pS21	14	38	39	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2004	19	2					109	118		10.1097/00001199-200403000-00004			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	809NR	WOS:000220643900004	15247822				2021-06-18	
J	Gracias, VH; Guillamondegui, OD; Stiefel, MF; Wilensky, EM; Bloom, S; Gupta, R; Pryor, JP; Reilly, PM; Leroux, PD; Schwab, CW				Gracias, VH; Guillamondegui, OD; Stiefel, MF; Wilensky, EM; Bloom, S; Gupta, R; Pryor, JP; Reilly, PM; Leroux, PD; Schwab, CW			Cerebral cortical oxygenation: A pilot study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		traumatic brain injury; intracranial pressure; cerebral perfusion pressure; cerebral hypoxia; brain tissue oxygenation	BRAIN-TISSUE OXYGEN; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; ANEURYSM SURGERY; PRESSURE; AUTOREGULATION; EXPERIENCE; REACTIVITY; TENSION	Background. Cerebral hypoxia (cerebral cortical oxygenation [PbrO(2)] < 20 mm Hg) monitored by direct measurement has been shown in animal and small clinical studies to be associated with poor outcome. We present our preliminary results observing PbrO(2) in patients with traumatic brain injury (TBI). Methods. A prospective observational cohort study was performed. Institutional review board approval was obtained. All patients with TBI who required measurement of intracranial pressure (ICP), cerebral perfusion pressure (CPP), and PbrO(2) because of a Glasgow Coma Scale score < 8 were enrolled. Data sets (ICP, CPP, PbrO(2), positive end-expiratory pressure (PEEP), PaO2, and PaCO2) were recorded during routine manipulation. Episodes of cerebral hypoxia were compared with episodes without. Results are displayed as mean SEM; t test, chi(2), and Fisher's exact test were used to answer questions of interest. Results: One hundred eighty-one data sets were abstracted from 20 patients. Thirty-five episodes of regional cerebral hypoxia were identified in 14 patients. Compared with episodes of acceptable cerebral oxygenation, episodes of cerebral hypoxia were noted to be associated with a significantly lower mean PaO2 (144 +/- 14 vs. 165 +/- 8; p < 0.01) and higher mean PEEP (8.8 +/- 0.7 vs. 7.1 +/- 0.3; p < 0.01). Mean ICP and CPP measurements were similar between groups. In a univariate analysis, cerebral hypoxic episodes were associated with PaO2 :5 100 mm Hg (p < 0.01) and PEEP > 5 cm H2O (p < 0.01), but not ICP > 20 mm Hg, CPP less than or equal to 65 mm Hg, or PaCO2 less than or equal to 35 mm Hg. Conclusion: Cerebral oxymetry is confirmed safe in the patient with multiple injuries with TBI. Occult cerebral hypoxia is present in the traumatic brain injured patient despite normal traditional measurements of cerebral perfusion. Further research is necessary to determine whether management protocols aimed at the prevention of cerebral cortical hypoxia will affect outcome.	Univ Penn, Sch Med, Dept Surg, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Gracias, VH (corresponding author), Univ Penn, Sch Med, Dept Surg, Div Traumatol & Surg Crit Care, 3440 Mkt St,1st Floor, Philadelphia, PA 19104 USA.	graciasv@uphs.upenn.edu					CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Gelabert-Gonzalez M, 2002, ACTA NEUROCHIR, V144, P863, DOI 10.1007/s00701-002-0975-9; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoffman WE, 2000, ANESTHESIOLOGY, V92, P442, DOI 10.1097/00000542-200002000-00026; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hutchinson PJ, 2000, NEUROSURGERY, V46, P201; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; Khaldi A, 2001, NEUROSURGERY, V49, P33; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	18	38	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					469	472		10.1097/01.TA.0000114274.95423.C0			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	808CM	WOS:000220547200001	15128115				2021-06-18	
J	Koh, JO; Cassidy, JD				Koh, JO; Cassidy, JD			Incidence study of head blows and concussions in competition taekwondo	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head blow; concussion; incidence; competition taekwondo	FOOTBALL PLAYERS; WORLD; CHAMPIONSHIPS; MANAGEMENT; INJURIES; SPORTS	Objective: To examine the incidence of head blows and concussions in competition taekwondo. Design: Incidence cohort design. Setting: Tackwondo tournament in 2001, in South Korea. Participants: A total of 2328 competitors (female, 676; male, 1652; age, 11-19 years) from 424 schools participated in the tournament. All recipients of head blows were interviewed immediately after the match. All matches were recorded on videotape. Main Outcome Measures: Head blow and concussion rates were calculated. Also, factors associated with head blows and concussions were analyzed. Results: The incidence of head blows and concussions was 226 and 50 per 1000 athlete exposures, respectively. Only 17% of competitors reported that they had had a concussion in the last 12 months. A multinomial logistic model showed that head blows and concussions were associated with young age and a lack of blocking skills. Conclusions: The incidence of head blows and concussions is high in competition taekwondo. Promoting blocking skills to prevent head blows could decrease concussions in taekwondo,	Yonsei Univ, Dept Sport & Leisure Studies, Seoul 120749, South Korea; Univ Toronto, Toronto Western Res Inst, Hlth Network, Div Outcomes & Populat Hlth, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON, Canada	Koh, JO (corresponding author), Yonsei Univ, Dept Sport & Leisure Studies, 134 Shinchon Dong, Seoul 120749, South Korea.	sunshinejkoh@hanmail.net		Koh, Jae Ok/0000-0002-3639-0739			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gordis L., 2000, EPIDEMIOLOGY; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MASTER EJ, 1999, JAMA-J AM MED ASSOC, V282, P971; MASTER EJT, 2000, PHYSICIAN SPORTSMED, V28, P87; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; *SPSS, 2002, SPSS COMP PROGR VERS; *STAT CORP, 2002, STAT COMP PROGR VERS; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; ZEMPER ED, 1994, AM SOC TEST MATER, V1229, P116, DOI 10.1520/STP12808S	24	38	40	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2004	14	2					72	79		10.1097/00042752-200403000-00004			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943BO	WOS:000230327000004	15014340				2021-06-18	
J	Krotz, M; Linsenmaier, U; Kanz, KG; Pfeifer, KJ; Mutschler, W; Reiser, M				Krotz, M; Linsenmaier, U; Kanz, KG; Pfeifer, KJ; Mutschler, W; Reiser, M			Evaluation of minimally invasive percutaneous CT-controlled ventriculostomy in patients with severe head trauma	EUROPEAN RADIOLOGY			English	Article						intracranial pressure; computed tomography; CT-controlled ventriculostomy; ventricular catheters; traumatic brain injury; craniocerebral trauma; multiple trauma	INTRA-CRANICAL PRESSURE; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; FIBEROPTIC DEVICE; INJURED PATIENTS; TISSUE PRESSURE; MANAGEMENT; INFECTIONS; DURATION	Evaluation of percutaneous CT-controlled ventriculostomy (PCV) in patients with severe traumatic brain injury to measure intracranial pressure as a component of early clinical care. A consecutive series of 52 interventions with PCV was prospectively analyzed with regard to technical success, procedural time, time from the initial cranial computed tomography (CCT) until procedure and transfer to the intensive care unit (ICU). Additionally, the data was compared with a retrospective control group of 12 patients with 13 procedures of conventional burr-hole ventriculostomy (OP-ICP). The PCV was successful in all cases (52 of 52; 95% CI 94-100%). In 1 case a minor hemorrhage into the ipsilateral lateral ventricle was observed on CT scans due to an initially unsuccessful puncture (95% CI 0-6%). No infections occurred (95% CI 0-6%). In the control group with OP-ICP one catheter infection and one unsuccessful catheter placement occurred (each 8%, 95% CI 0-20%). The PCV led to a significant decrease of procedure time from 45+/-11 min (OP-ICP) to 20+/-12 min (PCV). The interval from the initial CCT until procedure (PCV 28+/-11 min, OP-ICP 78+/-33 min) and transfer to the ICU (PCV 69+/-34 min, OP-ICP 138+/-34 min) could also be significantly reduced (each with p<0.05, Mann-Whitney U-test). Percutaneous CT-controlled ventriculostomy is a safe and efficient method for ICP catheter placement during initial trauma room management. It significantly reduces the time of initial trauma room treatment.	Univ Munich, Klinikum Innenstadt, Dept Clin Radiol, D-80336 Munich, Germany; Univ Munich, Klinikum Innenstadt, Dept Surg, D-80336 Munich, Germany	Krotz, M (corresponding author), Univ Munich, Klinikum Innenstadt, Dept Clin Radiol, Nussbaumstr 20, D-80336 Munich, Germany.	mkroetz@gmx.net					BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012; Kroetz MM, 2000, RADIOLOGY, V217, P184; Linsenmaier U, 2002, EUR RADIOL, V12, P1728, DOI 10.1007/s00330-001-1225-x; LINSENMAIER U, 2001, ROFO FORTSCHR RONTG, V173, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nast-Kolb D, 1999, UNFALLCHIRURG, V102, P338, DOI 10.1007/s001130050415; NASTKOLB D, 1997, ARCH CHIR S, V114, P330; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; PIEK J, 1990, INTENS CARE MED, V16, P184, DOI 10.1007/BF01724800; Prabhu VC, 1999, SURG NEUROL, V52, P226, DOI 10.1016/S0090-3019(99)00084-1; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Ruchholtz S, 1998, J TRAUMA, V45, P505, DOI 10.1097/00005373-199809000-00013; Ruchholtz S, 2000, UNFALLCHIRURG, V103, P30, DOI 10.1007/s001130050005; SAUL TG, 1982, AM SURGEON, V48, P477; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603	31	38	40	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	FEB	2004	14	2					227	233		10.1007/s00330-003-2134-y			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	767VD	WOS:000188493800008	14605843				2021-06-18	
J	Lambert, JC; Coyle, N; Lendon, C				Lambert, JC; Coyle, N; Lendon, C			The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease	JOURNAL OF MEDICAL GENETICS			English	Article							APOE PROMOTER POLYMORPHISMS; ALPHA GENE POLYMORPHISMS; TRAUMATIC BRAIN INJURY; REPLACEMENT THERAPY; TRANSGENIC MICE; RECEPTOR-ALPHA; HEAD-INJURY; POSTMENOPAUSAL WOMEN; MESSENGER-RNA; OLDER WOMEN	Background: The epsilon4 allele of the apolipoprotein E ( APOE) gene is a major genetic risk factor for Alzheimer's disease but appears to be associated with greater risk in women than in men. Some studies suggest that the level of APOE may of its own modulate the risk for Alzheimer's disease. Sex differences and an apparent benefit of oestrogen therapy suggest a role for oestrogen. APOE expression is influenced by oestrogen and oestrogen therapy may not benefit women bearing an APOE epsilon4 allele. These findings suggest an interaction between oestrogen and APOE in the Alzheimer's disease process. Aim: To explore the hypothesis that APOE expression is regulated by a genomic mechanism and is modified by the polymorphisms in APOE associated with risk for Alzheimer's disease. Methods: In vitro binding studies were undertaken between oestrogen receptors and fragments of the human APOE gene. APOE gene expression was studied to investigate a possible functional interaction. Results: APOE epsilon2/epsilon3/epsilon4 coding and - 219 G/T promoter polymorphisms influenced binding to the oestrogen receptor and altered transcriptional activity in response to oestrogen. Conclusions: An allele dependent modulation of oestrogen induced regulation of APOE might be involved in the increased risk for Alzheimer's disease in women bearing an epsilon4 allele.	Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England	Lendon, C (corresponding author), Univ Birmingham, Queen Elizabeth Psychiat Hosp, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England.	c.l.lendon@bham.ac.uk	Lambert, jean-charles/A-9553-2014; lambert, jean-charles/F-8787-2013	Lambert, jean-charles/0000-0003-0829-7817; lambert, jean-charles/0000-0003-0829-7817			Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Baum L, 2000, MICROSC RES TECHNIQ, V50, P278, DOI 10.1002/1097-0029(20000815)50:4<278::AID-JEMT5>3.0.CO;2-T; Behl C, 2002, PROG BRAIN RES, V138, P135, DOI 10.1016/S0079-6123(02)38075-0; Berr C, 2001, NEUROBIOL AGING, V22, P227, DOI 10.1016/S0197-4580(00)00227-X; Brandi ML, 1999, BIOCHEM BIOPH RES CO, V265, P335, DOI 10.1006/bbrc.1999.1665; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; Bretsky PM, 1999, ALZ DIS ASSOC DIS, V13, P216, DOI 10.1097/00002093-199910000-00007; Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; COEZY E, 1982, CANCER RES, V42, P317; Costa MM, 1999, BIOL PSYCHIAT, V46, P182, DOI 10.1016/S0006-3223(98)00355-2; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Geerlings MI, 2001, JAMA-J AM MED ASSOC, V285, P1475, DOI 10.1001/jama.285.11.1475; Growdon WB, 1999, NEUROSCI LETT, V272, P83, DOI 10.1016/S0304-3940(99)00557-1; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harwood DG, 1999, NEUROLOGY, V52, P551, DOI 10.1212/WNL.52.3.551; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Houlden H, 1998, AM J MED GENET, V81, P117, DOI 10.1002/(SICI)1096-8628(19980207)81:1<117::AID-AJMG19>3.0.CO;2-M; Inestrosa NC, 1998, MOL NEUROBIOL, V17, P73, DOI 10.1007/BF02802025; Isoe K, 1997, ALZHEIMERS RES, V3, P195; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Lambert JC, 1997, HUM MOL GENET, V6, P2151, DOI 10.1093/hmg/6.12.2151; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lambert JC, 2001, NEUROSCI LETT, V306, P193, DOI 10.1016/S0304-3940(01)01806-7; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x; Laws SM, 2002, MOL PSYCHIATR, V7, P886, DOI 10.1038/sj.mp.4001097; Lendon CL, 1997, HUM MUTAT, V10, P186; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; LESLIE KK, 1994, J SOC GYNECOL INVEST, V1, P238, DOI 10.1177/107155769400100311; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Maruyama H, 2000, ARCH NEUROL-CHICAGO, V57, P236, DOI 10.1001/archneur.57.2.236; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Payami H, 1996, AM J HUM GENET, V58, P803; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Seshadri S, 2001, ARCH NEUROL-CHICAGO, V58, P435, DOI 10.1001/archneur.58.3.435; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Srivastava RAK, 1997, J BIOL CHEM, V272, P33360, DOI 10.1074/jbc.272.52.33360; Steffens DC, 1999, J AM GERIATR SOC, V47, P1171, DOI 10.1111/j.1532-5415.1999.tb05195.x; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Stone DJ, 1998, J NEUROSCI, V18, P3180; Sun YL, 1998, J NEUROSCI, V18, P3261; Szklo M, 1996, AM J EPIDEMIOL, V144, P1048; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1997, J NEUROSCI, V17, P5678; Town T, 1998, NEUROSCI LETT, V252, P95, DOI 10.1016/S0304-3940(98)00567-9; WAKELING AE, 1991, CANCER RES, V51, P3867; Wang JC, 2000, NEUROLOGY, V55, P1644, DOI 10.1212/WNL.55.11.1644; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2	82	38	40	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-2593	1468-6244		J MED GENET	J. Med. Genet.	FEB 1	2004	41	2					104	112		10.1136/jmg.2003.005033			9	Genetics & Heredity	Genetics & Heredity	769VE	WOS:000188669800005	14757857	Bronze, Green Published			2021-06-18	
J	Cho, IH; Im, JY; Kim, D; Kim, KS; Lee, JK; Han, PL				Cho, IH; Im, JY; Kim, D; Kim, KS; Lee, JK; Han, PL			Protective effects of extracellular glutathione against Zn2+-induced cell death in vitro and in vivo	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Zn2+ toxicity; glutathione; kainic acid; astrocytes; neurons	CULTURED CORTICAL-NEURONS; OXIDATIVE STRESS; ZINC TOXICITY; BRAIN-INJURY; ASTROCYTES; CADMIUM; NEUROTOXICITY; EXPRESSION; INDUCTION; ACID	The central nervous system reserves high concentrations of free Zn2+ in certain excitatory synaptic vesicles. In pathological conditions such as transient cerebral ischemia, traumatic brain injury, and kainic acid (KA)-induced seizure, free Zn2+ is released in excess at synapses, which causes neuronal and glial death. We report here that glutathione (GSH) can be used as an effective means for protection of neural cells from Zn2+-induced cell death in vitro and in vivo. Chronic treatment with 35 muM Zn2+ led to death of primary cortical neurons and primary astrocytes. The Zn2+ toxicity of cortical neurons was partially protected by 1 mM of GSH, whereas the Zn2+ toxicity of primary astrocyte cultures was blocked completely by 100 pM of GSH. To evaluate the beneficial effects of GSH in vivo, an excitotoxin-induced neural cell death model was established by intracerebroventricular (i.c.v.) injection of 0.94 nmol (0.2 mug) KA, which produced selective neuronal death, especially in CA1 and CA3 hippocampal regions. The i.c.v. co-injection of 200 pmol of GSH significantly attenuated KA-induced neuronal cell death and reactive gliosis in hippocampus. The results of this study suggest the contribution of Zn2+ in the excitotoxin-induced neural cell death model and a potential value of GSH as a therapeutic means against Zn2+-induced pathogenesis in brain. (C) 2003 Wiley-Liss, Inc.	Ewha Womans Univ, Sch Med, Ewha Inst Neurosci, Dept Neurosci, Seoul 11783, South Korea; Ewha Womans Univ, Sch Med, Med Res Ctr, Seoul 11783, South Korea; Inha Univ, Sch Med, Dept Anat, Inchon, South Korea	Han, PL (corresponding author), Ewha Womans Univ, Sch Med, Ewha Inst Neurosci, Dept Neurosci, 70 Jongno 6 Ga, Seoul 11783, South Korea.	plhan@ewha.ac.kr					Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Burgalassi S, 2001, TOXICOL LETT, V122, P1, DOI 10.1016/S0378-4274(01)00261-2; Che YZ, 2001, MOL BRAIN RES, V94, P157, DOI 10.1016/S0169-328X(01)00233-9; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHOI DW, 1987, J NEUROSCI, V7, P357; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Dineley KE, 2000, NEUROBIOL DIS, V7, P310, DOI 10.1006/nbdi.2000.0303; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; DRINGEN R, 2000, PROG NEUROBIOL, V618, P181; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Fitch MT, 1999, J NEUROSCI, V19, P8182; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FUHR BJ, 1973, J AM CHEM SOC, V95, P6944, DOI 10.1021/ja00802a013; GRILL E, 1991, METHOD ENZYMOL, V205, P333; HAYASHI Y, 1991, METHOD ENZYMOL, V205, P348; Janssens N, 2001, J NEUROCHEM, V77, P1457, DOI 10.1046/j.1471-4159.2001.00369.x; Kim JM, 2002, INT PSYCHOGERIATR, V14, P187, DOI 10.1017/S1041610202008384; KIM U, 1999, ASIAN J SOC PSYCHOL, V2, P1; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Marotti T, 2000, NEUROPEPTIDES, V34, P121, DOI 10.1054/npep.2000.0801; McNaught KSP, 1999, J NEUROCHEM, V73, P2469, DOI 10.1046/j.1471-4159.1999.0732469.x; Noh KM, 1999, J NEUROCHEM, V72, P1609, DOI 10.1046/j.1471-4159.1999.721609.x; Noh KM, 2000, J NEUROSCI, V20; Piao CS, 2002, MOL BRAIN RES, V107, P137, DOI 10.1016/S0169-328X(02)00456-4; Rizzardini M, 2003, J NEUROL SCI, V207, P51, DOI 10.1016/S0022-510X(02)00357-X; Ryu JR, 2002, EXP BRAIN RES, V143, P257, DOI 10.1007/s00221-001-0991-7; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; Son MH, 2001, BIOCHEM PHARMACOL, V62, P1379, DOI 10.1016/S0006-2952(01)00780-8; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; White AR, 2003, J NEUROSCI RES, V71, P889, DOI 10.1002/jnr.10537	43	38	40	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 1	2003	74	5					736	743		10.1002/jnr.10794			8	Neurosciences	Neurosciences & Neurology	748EN	WOS:000186849700010	14635224				2021-06-18	
J	Lotocki, G; Alonso, OF; Frydel, T; Dietrich, WD; Keane, RW				Lotocki, G; Alonso, OF; Frydel, T; Dietrich, WD; Keane, RW			Monoubiquitination and cellular distribution of XIAP in neurons after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						inhibitors of apoptosis; XIAP; ubiquitin; traumatic brain injury	UBIQUITIN-PROTEIN LIGASE; APOPTOSIS PROTEIN; LINKED INHIBITOR; IN-VITRO; DEGRADATION; ACTIVATION; CASPASE-3; CLEAVAGE; DEATH; RATS	XIAP is a member of the inhibitor of apoptosis (IAP) gene family that, in addition to suppressing cell death by inhibition and polyubiquitination of caspases, is involved in an increasing number of signaling cascades. Moreover, the function and regulation of XIAP in the central nervous system (CNS) is poorly understood. In this study, the authors investigated the cell-type expression, the subcellular distribution, ubiquitination of XIAP, and levels of Smac/DIABLO in the normal adult rat brain and in brains subjected to moderate traumatic brain injury (TBI). In the normal brain, XIAP was predominantly expressed in the perinuclear region of neurons. Traumatized brains showed dramatic alterations in cellular and regional expression of XIAP early after injury. Stereologic analyses of the number of XIAP-positive cells within the hippocampus of both hemispheres showed a biphasic response. Immunoprecipitation and immunoblots of extracts derived from different brain regions demonstrated that a single ubiquitin modifies XIAP. Normal cortex contained significantly higher levels of monoubiquitinated XIAP than hippocampus. TBI induced alterations in levels of monoubiquitinated XIAP that correlated with changes in XIAP distribution and immunoreactivity, suggesting that monoubiquitination of XIAP may be a regulator of XIAP location or activity. Similar levels of Smac/DIABLO were present in lysates of normal and traumatized brains. These data demonstrate for the first time a region-specific regulation of XIAP monoubiquitination in the normal adult rat brain, and after TBI, that may be a key event in the regulation of XIAP function contributing to the pathogenesis following injury.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Miami Project Cure Paralysis, Miami, FL USA	Keane, RW (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30921-10] Funding Source: Medline		BIRKEYREFFEY A, 2001, J BIOL CHEM, V276, P26542; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Conti AC, 1998, J NEUROSCI, V18, P5663; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang HK, 2000, J BIOL CHEM, V275, P26661; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Korhonen L, 2001, MOL CELL NEUROSCI, V17, P364, DOI 10.1006/mcne.2000.0935; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Lotocki G, 2002, IUBMB LIFE, V54, P231, DOI 10.1080/15216540215675; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4845; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shibata M, 2002, NEUROREPORT, V13, P1985, DOI 10.1097/00001756-200210280-00031; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	28	38	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2003	23	10					1129	1136		10.1097/01.WCB.0000086938.68719.E0			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	729DD	WOS:000185755500003	14526223	Bronze			2021-06-18	
J	Poggi, G; Liscio, M; Adduci, A; Galbiati, S; Sommovigo, M; Degrate, A; Strazzer, S; Castelli, E				Poggi, G; Liscio, M; Adduci, A; Galbiati, S; Sommovigo, M; Degrate, A; Strazzer, S; Castelli, E			Neuropsychiatric sequelae in TBI: a comparison across different age groups	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; CHILDREN; CONSEQUENCES; INDIVIDUALS; ADJUSTMENT; DEPRESSION; DISORDERS; ISSUES; DAMAGE	Objective: Traumatic brain injury (TBI) is the leading cause of death and permanent disability in developmental age. Neurobehavioural symptoms are not uncommon in these patients. The aim of this study was to identify the main neuropsychiatric sequelae of TBI at different ages and study the possible correlations with clinical features in the acute phase and outcome in order to better plan rehabilitative treatment and re-entry into society. Method: Ninety-six post-traumatic patients, ranging from 0 - 18 years, underwent a complete psychological evaluation protocol at 1 year from trauma. Patients were divided into three different age groups ( 0 - 6 years; 7 - 13 years; 14 - 18 years) and received a protocol made up of age-appropriate scales. Results: Different psychological problems were found across the three groups; more frequently younger patients show internalizing problems such as withdrawal and closure, while, with age, behaviour problems become more frequent, characterized by hyperactivity and aggressiveness. Factors that were most predictive of psychological, behaviour and adjustment problems include GOS scores, the degree of impairment on the neurological examination and male gender. Conclusions: Psychological and behavioural problems differ across the three age groups and determine a different outcome, rehabilitation plan and re-entry into society. These problems should, thus, be investigated and treated specifically according to age.	IRCCS Eugenio Medea, I-23842 Bosisio Parini, LC, Italy	Poggi, G (corresponding author), IRCCS Eugenio Medea, Via Don Luigi Monza 20, I-23842 Bosisio Parini, LC, Italy.	gpoggi@bp.lnf.it	Poggi, Geraldina/K-4490-2016; Strazzer, Sandra/AAH-5712-2019; Castelli, Enrico/J-1887-2012; Galbiati, Susanna/AAH-6883-2019	Poggi, Geraldina/0000-0003-0589-6347; Strazzer, Sandra/0000-0001-8414-6565; Galbiati, Susanna/0000-0001-7209-4251			Achenbach T.M., 1983, CHILD BEHAV CHECKLIS; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Bowen A, 1999, BRAIN INJURY, V13, P547; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Deb S, 1999, AM J PSYCHIAT, V156, P374; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Franulic A, 2000, BRAIN INJURY, V14, P431; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Gualtieri CT, 1999, NEUROREHABILITATION, V13, P103; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; JENNETT B, 1975, LANCET, V1, P480; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NEWCOMER P, 1997, TEST ANSIA DEPRESSIO; Nybo T, 1999, BRAIN INJURY, V13, P759; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; ROBIN AH, 1999, ARCH PHYS MED REHAB, V80, P991; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SANAVIO E, 1996, CBA 2 0 COGNITIVE BE; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sherwin ED, 2000, BRAIN INJURY, V14, P267; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Thurber C A, 1998, Pediatr Rehabil, V2, P149; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	42	38	38	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2003	17	10					835	846		10.1080/0269905031000088612			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	719CR	WOS:000185186500002	12963550				2021-06-18	
J	Whyte, J				Whyte, J			Clinical trials in rehabilitation - What are the obstacles?	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Clinical Trials in Medical Rehabilitation Conference	NOV 01-02, 2002	PARSIPPANY, NEW JERSEY			rehabilitation; randomized clinical trials; rehabilitation research	TRAUMATIC BRAIN INJURY; OUTCOMES	Across rehabilitation, there is a shortage of treatments that have demonstrated efficacy and effectiveness through rigorously controlled clinical trials. Although rehabilitation efficacy and effectiveness research present many of the obstacles that are found in research on other biomedical domains, they also present a number of obstacles that are specific to the conceptual framework underlying rehabilitation practice. In this article, I review the specific challenges presented by the need to rigorously define the research participants, the treatment under investigation, and the outcomes by which treatment response will be measured. I also suggest research that will be necessary to surmount some of these obstacles.	Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		BORKOVEC TD, 1996, NIMH PSYCHOTHERAPY R, V5, P14; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Clifton GL, 2001, J NEUROSURG, V95, P733; Ebenbichler GR, 1998, BRIT MED J, V316, P731, DOI 10.1136/bmj.316.7133.731; Jull G, 2002, SPINE, V27, P1835, DOI 10.1097/00007632-200209010-00004; Robinson K. M., 1990, PRACTICAL MANAGEMENT, P201; Saunders, 1995, CLIN REHABIL, V9, P126, DOI DOI 10.1177/026921559500900207; SEGAL ME, 1997, PHYSICAL MED REHABIL, V11, P385; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Whyte J, 2001, AM J PHYS MED REHAB, V80, P865, DOI 10.1097/00002060-200111000-00012; Whyte J, 1997, ASSESSING MED REHABI, P43	12	38	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2003	82	10		S			S16	S21		10.1097/01.PHM.0000086992.95121.C2			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	724YP	WOS:000185516100004	14502034				2021-06-18	
J	Gaur, A; Sinclair, M; Caruso, E; Peretti, G; Zaleske, D				Gaur, A; Sinclair, M; Caruso, E; Peretti, G; Zaleske, D			Heterotopic ossification around the elbow following burns in children: Results after excision	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							BONE-FORMATION; INJURY	Background: Major burn injuries close to joints alter the function of the musculoskeletal system through tissue loss and limitation of joint motion. In children with involvement of the hand, wrist, and forearm, restriction of elbow motion secondary to heterotopic ossification following a burn injury severely limits the function of the upper extremity. The purpose of this study was to review elbow function following excision of heterotopic ossification around the elbow in children. Methods: Eight children (ten elbows) from a population of 3245 consecutive patients who were admitted to our pediatric burn center were found to have severe heterotopic ossification of the elbow, leading to an inability to reach the mouth for feeding and the head and the perineum for self-care. Excision of the heterotopic ossification was undertaken if the patient had this limitation of function and if movement was restricted to a total arc of motion of <50degrees. Pain was not an indication for the operation. The procedure was performed at an average of 17.3 months following the injury. Results: Seven children (nine elbows) were available for follow-up at an average of fifty-six months after surgery. All nine elbows had an improved arc of motion (an average increase of 57degrees). Following excision, heterotopic ossification did not recur. All children were able to reach the face and the perineum following the operation. Conclusions: Excision of heterotopic ossification around the elbow following a burn injury in children can improve the arc of motion and improve the function of the extremity. A relatively simple operative and postoperative regimen can achieve satisfactory results. Level of Evidence: Therapeutic study, Level IV (case series [no, or historical, control group]). See Instructions to Authors for a complete description of levels of evidence.	Med Coll Penn & Hahnemann Univ, Dept Orthoped Surg, Philadelphia, PA 19102 USA; Altona Childrens Hosp, D-22763 Hamburg, Germany; Luigi Sacco Univ Hosp, Dept Orthopaed, Milan, Italy; Hosp San Raffaele, Dept Orthopaed, I-20132 Milan, Italy; Childrens Natl Med Ctr, Pediat Orthopaed Dept, Washington, DC 20010 USA; Massachusetts Gen Hosp, Boston, MA USA; Boston Shriners Hosp, Boston, MA USA	Gaur, A (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Orthoped Surg, Philadelphia, PA 19102 USA.		Peretti, Giuseppe/K-6358-2016	Peretti, Giuseppe/0000-0001-9341-7187; caruso, enzo massimo/0000-0002-3118-2412			Beingessner DM, 2000, J HAND SURG-AM, V25A, P483, DOI 10.1053/jhsu.2000.6922; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Crawford C M, 1986, J Burn Care Rehabil, V7, P323, DOI 10.1097/00004630-198607000-00005; ELLEDGE ES, 1988, J TRAUMA, V28, P684, DOI 10.1097/00005373-198805000-00023; EVANS BE, 1959, J BONE JOINT SURG AM, V41, P785; EVANS EB, 1966, J BONE JOINT SURG AM, VA 48, P643, DOI 10.2106/00004623-196648040-00002; EVANS EB, 1991, CLIN ORTHOP RELAT R, P94; HOFFER MM, 1978, J TRAUMA, V18, P667, DOI 10.1097/00005373-197809000-00009; JAY MS, 1981, CLIN PEDIATR, V20, P734, DOI 10.1177/000992288102001108; Kluger G, 2000, J CHILD NEUROL, V15, P406, DOI 10.1177/088307380001500610; KOCH BM, 1992, ARCH PHYS MED REHAB, V73, P1104; Kolar J, 1971, Acta Chir Plast, V13, P133; KOLAR J, 1959, J BONE JOINT SURG AM, V41, P103, DOI 10.2106/00004623-195941010-00011; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; MUNSTER AM, 1972, J TRAUMA, V12, P1071, DOI 10.1097/00005373-197212000-00008; Pape HC, 2001, J ORTHOP TRAUMA, V15, P229, DOI 10.1097/00005131-200105000-00001; PETERSON SL, 1989, J TRAUMA, V29, P365, DOI 10.1097/00005373-198903000-00015; Pruitt B A Jr, 1974, Clin Plast Surg, V1, P667; PUZAS JE, 1989, CLIN ORTHOP RELAT R, P269; SCHIELE JP, 1972, RADIOLOGY, V104, P13; Shafritz AB, 1998, CLIN ORTHOP RELAT R, P46; Viola RW, 1999, J HAND SURG-AM, V24A, P370; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7	24	38	39	0	0	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG	2003	85A	8					1538	1543		10.2106/00004623-200308000-00016			6	Orthopedics; Surgery	Orthopedics; Surgery	708DP	WOS:000184552100016	12925635				2021-06-18	
J	Kroppenstedt, SN; Thomale, UW; Griebenow, M; Sakowitz, OW; Schaser, KD; Mayr, PS; Unterberg, AW; Stover, JF				Kroppenstedt, SN; Thomale, UW; Griebenow, M; Sakowitz, OW; Schaser, KD; Mayr, PS; Unterberg, AW; Stover, JF			Effects of early and late intravenous norepinephrine infusion on cerebral perfusion, microcirculation, brain-tissue oxygenation, and edema formation in brain-injured rats	CRITICAL CARE MEDICINE			English	Article						blood pressure elevation; brain edema; catecholamines; cerebral perfusion; intravital microscopy; laser Doppler flowmetry; orthogonal spectral polarization imaging; traumatic brain injury	CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID GLUTAMATE; BLOOD-FLOW; DOWN-REGULATION; BARRIER; NORADRENALINE; HYPOXANTHINE; METABOLISM; HYPEREMIA; DOPAMINE	Objectives: Reduction of cerebral perfusion during the early phase after traumatic brain injury is followed by a later phase of normal to increased perfusion. Thus, pharmacologically elevating mean arterial blood pressure with the aim of improving cerebral perfusion may exert different time-dependent effects on cortical perfusion, microcirculation, tissue oxygenation and brain edema formation after traumatic brain injury. Design: Randomized, placebo-controlled trial. Setting: Experimental laboratory at a university hospital. Subjects: A total of 37 male Sprague-Dawley rats subjected to a focal cortical contusion. Interventions: At 4 or 24 hrs after focal traumatic brain injury, mean arterial blood pressure was increased to 120 mm Hg for 90 mins by infusing norepinephrine. In rats receiving physiologic saline, mean arterial blood pressure remained unchanged. In the first series, pericontusional cortical perfusion was measured using the laser Doppler flowmetry scanning technique before injury and before, during, and after the infusion period. In a second series, intracranial and cerebral perfusion pressure and intraparenchymal perfusion and tissue oxygen measured within the contused and pericontusional cortex were recorded continuously before, during, and after norepinephrine infusion. Changes in cortical microcirculation were investigated by orthogonal polarization spectral imaging. At the end of each experiment, hemispheric swelling and water content were determined gravimetrically. Measurements and Main Results., At 4 and 24 hrs after traumatic brain injury, intravenous norepinephrine significantly increased pericontusional cortical perfusion, which was also reflected by an increase in diameters and flow velocities of pericontusional arterioles and venules. Cerebral perfusion pressure and intraparenchymal perfusion and tissue oxygen were significantly increased during norepinephrine infusion at 4 and 24 hrs. Hemispheric swelling and water content showed no difference between the groups. Conclusions: After cortical impact injury, early and late intravenous norepinephrine infusion pressure-dependently increased cerebral perfusion and tissue oxygenation without aggravating or reducing brain edema formation. Future studies are warranted to determine long-term changes of short and prolonged norepinephrine-induced increases in mean arterial blood pressure and cerebral perfusion pressure.	Humboldt Univ, Dept Neurosurg, Berlin, Germany; Humboldt Univ, Virchow Med Ctr, Charite, Dept Traumatol & Reconstruct Surg, Berlin, Germany; Oxford Optron, Oxford, England	Stover, JF (corresponding author), Humboldt Univ, Dept Neurosurg, Berlin, Germany.			Misch, Martin/0000-0001-5283-5753			ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Burger R, 1999, J NEUROTRAUM, V16, P1149, DOI 10.1089/neu.1999.16.1149; BUSIJA DW, 1987, J CEREBR BLOOD F MET, V7, P184, DOI 10.1038/jcbfm.1987.42; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; CHIUEH CC, 1978, BRAIN RES, V145, P291, DOI 10.1016/0006-8993(78)90863-6; Dings J, 1998, NEUROL RES, V20, pS71; Dong E, 1999, EUR J PHARMACOL, V384, P17, DOI 10.1016/S0014-2999(99)00652-4; EDVINSSON L, 1978, J PHYSIOL-LONDON, V274, P149, DOI 10.1113/jphysiol.1978.sp012140; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Groner W, 1999, NAT MED, V5, P1209; HARDEBO JE, 1977, ACTA PHYSIOL SCAND, V101, P342, DOI 10.1111/j.1748-1716.1977.tb06016.x; Heck DA, 1997, J PHARMACOL EXP THER, V282, P1219; HEMPELMANN RG, 1993, BRIT J PHARMACOL, V110, P1321, DOI 10.1111/j.1476-5381.1993.tb13963.x; HU ZW, 1992, J CARDIOVASC PHARM, V20, P982, DOI 10.1097/00005344-199212000-00020; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIRKEBY OJ, 1995, J APPL PHYSIOL, V79, P1479; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU J, 1993, ARCH BIOCHEM BIOPHYS, V302, P118, DOI 10.1006/abbi.1993.1189; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MCCALDEN TA, 1977, AM J PHYSIOL, V233, pH458; Noh JS, 1999, EXP NEUROL, V159, P217, DOI 10.1006/exnr.1999.7144; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; SAVAKI HE, 1982, BRAIN RES, V234, P65, DOI 10.1016/0006-8993(82)90473-5; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Thomale UW, 2001, J NEUROSCI METH, V108, P85, DOI 10.1016/S0165-0270(01)00375-2; Tirone TA, 2001, WORLD J SURG, V25, P461, DOI 10.1007/s002680020338; Unterberg AW, 1997, ACT NEUR S, V70, P106; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287	48	38	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2003	31	8					2211	2221		10.1097/01.CCM.0000080482.06856.62			11	Critical Care Medicine	General & Internal Medicine	712KV	WOS:000184797600020	12973182				2021-06-18	
J	Kipnis, J; Nevo, U; Panikashvili, D; Alexandrovich, A; Yoles, E; Akselrod, S; Shohami, E; Schwartz, M				Kipnis, J; Nevo, U; Panikashvili, D; Alexandrovich, A; Yoles, E; Akselrod, S; Shohami, E; Schwartz, M			Therapeutic vaccination for closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; autoimmune neuroprotection; strain differences; CNS inflammation; EAE-susceptibility; Cop-1 (Glatiramer acetate)	SPINAL-CORD INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; T-CELL LINES; RETINAL GANGLION-CELLS; MULTIPLE-SCLEROSIS; COPOLYMER 1; OPTIC-NERVE; PROTECTIVE AUTOIMMUNITY	Closed head injury often has a devastating outcome, partly because the insult, like other injuries to the central nervous system (CNS), triggers self-destructive processes. During studies of the response to other CNS insults, it was unexpectedly discovered that the immune system, if well controlled, provides protection against self-destructive activities. Here we show that in mice with closed head injury, the immune system plays a key role in the spontaneous recovery. Strain-related differences were observed in the ability to harness a T cell-dependent protective mechanism against the effects of the injury. We further show that the trauma-induced deficit could be reduced, both functionally and anatomically, by post-traumatic vaccination with Cop-1, a synthetic copolymer used to treat patients with multiple sclerosis and found (using a different treatment protocol) to effectively counteract the loss of neurons caused by axonal injury or glutamate-induced toxicity. We suggest that a compound such as Cop-1 can be safely developed as a therapeutic vaccine to boost the body's immune repair mechanisms, thereby providing multifactorial protection against the consequences of brain trauma.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sch Phys & Astron, Dept Med Phys, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.						Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; Aharoni R, 2002, J NEUROIMMUNOL, V126, P58, DOI 10.1016/S0165-5728(02)00053-X; Antel JP, 1999, J NEUROIMMUNOL, V100, P181, DOI 10.1016/S0165-5728(99)00186-1; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bar-Or A, 1999, J NEUROIMMUNOL, V100, P252, DOI 10.1016/S0165-5728(99)00193-9; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BENNUN A, 1982, J IMMUNOL, V129, P303; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; Benton RL, 2001, BRAIN RES, V893, P292, DOI 10.1016/S0006-8993(00)02995-4; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dal Canto MC, 2000, J NEUROIMMUNOL, V104, P79, DOI 10.1016/S0165-5728(99)00230-1; Farina C, 2001, BRAIN, V124, P705, DOI 10.1093/brain/124.4.705; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Kipnis J, 2002, TRENDS MOL MED, V8, P319, DOI 10.1016/S1471-4914(02)02373-0; Kipnis J, 2002, J NEUROIMMUNOL, V130, P78, DOI 10.1016/S0165-5728(02)00219-9; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KIPNIS J, 2002, P NATL ACAD SCI USA, V12, P12; Lundberg C, 2001, J COMP NEUROL, V431, P75; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; Mizrahi T, 2002, J IMMUNOL, V169, P5971, DOI 10.4049/jimmunol.169.10.5971; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Neumann H, 2000, J NEURAL TRANSM-SUPP, P59; Nevo U, 2003, TRENDS MOL MED, V9, P88, DOI 10.1016/S1471-4914(03)00024-8; O'Connor KC, 2001, J CLIN IMMUNOL, V21, P81, DOI 10.1023/A:1011064007686; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Schori H, 2001, J NEUROIMMUNOL, V119, P199, DOI 10.1016/S0165-5728(01)00358-7; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schwartz M, 2000, INVEST OPHTH VIS SCI, V41, P349; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Schwartz M, 2001, SURV OPHTHALMOL, V45, pS256, DOI 10.1016/S0039-6257(01)00208-9; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; Schwartz M, 2001, J MOL MED-JMM, V78, P594, DOI 10.1007/s001090000172; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Schwartz M, 1999, MOL MED TODAY, V5, P470, DOI 10.1016/S1357-4310(99)01592-0; Sela M, 1999, Int Rev Immunol, V18, P201, DOI 10.3109/08830189909043025; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Solberg Y, 1999, SURV OPHTHALMOL, V44, pS85, DOI 10.1016/S0039-6257(99)00093-4; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Streilein JW, 2000, ANN NY ACAD SCI, V917, P297; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Teitelbaum D, 1999, P NATL ACAD SCI USA, V96, P3842, DOI 10.1073/pnas.96.7.3842; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Weiner HL, 1999, P NATL ACAD SCI USA, V96, P3333, DOI 10.1073/pnas.96.7.3333; Wekerle H, 1996, IMMUNOL REV, V149, P231, DOI 10.1111/j.1600-065X.1996.tb00907.x; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROTRAUM, V18, P339, DOI 10.1089/08977150151071017; Yoon DH, 1999, YONSEI MED J, V40, P313, DOI 10.3349/ymj.1999.40.4.313	67	38	42	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					559	569		10.1089/089771503767168483			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900004	12906740				2021-06-18	
J	Rapoport, MJ; McCullagh, S; Streiner, D; Feinstein, A				Rapoport, MJ; McCullagh, S; Streiner, D; Feinstein, A			Age and major depression after mild traumatic brain injury	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article; Proceedings Paper	15th Annual Meeting of the American-Association-for-Geriatric-Psychiatry	FEB 24-27, 2002	ORLANDO, FLORIDA	Amer Assoc Geriatr Psychiat			HEAD-INJURY; SEQUELAE	The authors investigated the relationship between age and major depression in the acute period following mild traumatic brain injury (TBI). Methods: Patients with mild TBI (N=210) were assessed for the presence of major depression with the Structured Clinical Interview for DSM-IV. Results: Older patients (age 60 plus) had lower rates of major depression than younger patients. Conclusion: Older patients seem to be relatively resilient to major depression shortly after mild TBI.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Traumat Brain Injury Clin, Toronto, ON M4N 3M5, Canada	Rapoport, MJ (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave,FG37, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020; Streiner, David/E-6563-2011	Streiner, David/0000-0003-0610-6271			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Beekman ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P196; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; REIGER DA, 1988, ARCH GEN PSYCHIAT, V45, P977	11	38	38	0	6	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	1064-7481			AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	MAY-JUN	2003	11	3					365	369		10.1176/appi.ajgp.11.3.365			5	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	673DQ	WOS:000182565300015	12724117				2021-06-18	
J	Bounds, TA; Schopp, L; Johnstone, B; Unger, C; Goldman, H				Bounds, TA; Schopp, L; Johnstone, B; Unger, C; Goldman, H			Gender differences in a sample of vocational rehabilitation clients with TBI	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; INDIVIDUALS; WOMEN	Because traumatic brain injury affects between 1.5 and 2 mil lion individuals per year and results in long term vocational and financial difficulties, there is growing interest in determining those factors that predict successful outcomes for specific groups of individuals with TBI. An NIH consensus panel on TBI has suggested that women are one group that needs more attention, particularly given the studies indicating that men and women experience different cognitive [ 141, emotional [ 19], and vocational outcomes following TBI [5]. The current study evaluated differences in injury severity, demographics, neuropsychological abilities, and vocational and financial outcomes for 78 persons with TBI (55 male, 23 female) who received services from a state Vocational Rehabilitation Division (DVR). Despite similar injury severity, neuropsychological and demographic characteristics, more men (43.6%) received Maintenance services from MO-DVR than women (21.7%). Of note, only 4.4% of the women were successfully employed through DVR, compared to 23.6% of the men. In addition, 73.9% of the women had services terminated after being accepted by DVR but before services were initiated, compared to 56.4% of the men. The significance of these results is discussed, as are the limitations of the current project.	Univ Missouri, Sch Med, Dept Hlth Psychol, Columbia, MO 65212 USA; Missouri Dept Elementary & Secondary Educ, Div Vocat Rehabil, Jefferson City, MO 65102 USA	Bounds, TA (corresponding author), Univ Missouri, Sch Med, Dept Hlth Psychol, DC046-46,1 Hosp Dr, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			BROOKS N, 1987, BRAIN INJURY, V10, P5; CHANSKY NM, 1966, VOCAT GUID QUART, V15, P71, DOI 10.1002/j.2164-585X.1966.tb01162.x; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FINE M, 1988, WOMEN DISABILITIES; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Halstead WC, 1985, HALSTEAD REITAN NEUR; HARRISON DK, 1985, J APPL REHABILITATIO, V17, P14; HOLVEY JM, 1986, J APPL REHABILITATIO, V17, P51; HURT GD, 2000, NEUROPSYCHOLOGICAL M; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; KIMURA D, 1992, SCI AM, V267, P119; KLVE H, 1963, MED CLIN N AM; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; *NIH, 1999, REH PERS TRAUM BRAIN; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Reitan R. M., 1992, TRAIL MAKING TEST MA; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *TRAUM BRAIN INJ M, 2000, TBI FACTS FIGURES, V6; TREIMAN DJ, 1975, AM SOCIOL REV, V40, P174, DOI 10.2307/2094344; TURKHEIMER E, 1992, PSYCHOLOGICAL ASSESS, V4, P8; WECHSLER D, 1997, WMS, V3; Wechsler D, 1997, WAIS, VIII; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST	27	38	38	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2003	18	3					189	196					8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	733ZZ	WOS:000186031900002	14530583				2021-06-18	
J	Lew, HL; Lee, E; Date, ES; Zeiner, H				Lew, HL; Lee, E; Date, ES; Zeiner, H			Influence of medical comorbidities and complications on FIM (TM) change and length of stay during inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						medical comorbidities; medical complications; length of stay; FIM efficiency; inpatient rehabilitation; physician; physiatrist	STROKE REHABILITATION	Objective: This study was performed to evaluate the influence of medical problems on functional outcome measures of patients admitted for comprehensive inpatient rehabilitation. Design: In this retrospective database review of patients, demographic information, length of stay, FIM scores at admission and discharge, and FIM efficiency were collected and analyzed. Preexisting comorbidities and acute medical complications of all patients were identified, tabulated, and analyzed. Results: A total of 175 patients were categorized into three major groups. In the postorthopedic surgery group, the presence of preexisting medical comorbidities did not significantly affect admission or discharge FIM scores. In contrast, traumatic brain injury patients with preexisting medical comorbidities had a tendency to be admitted and discharged with lower FIM scores. However, traumatic brain injury patients with acute medical complications still made reasonable functional improvement during their extended stay, so that their FIM efficiency was adequately maintained. In the cerebrovascular accident group, almost all patients had preexisting medical issues. Conclusions: The rehabilitation population is diverse, and functional outcome measures for distinct disease entities may be differentially affected by factors such as preexisting medical comorbidities and acute medical complications. Except for life-threatening medical emergencies, rehabilitation patients may benefit by staying on the acute rehabilitation unit, where both medical management and a comprehensive rehabilitation program are provided with continuity.	VA Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA USA; Stanford Univ, Sch Med, Stanford, CA USA	Lew, HL (corresponding author), PM&R Serv, Comprehens Rehabil Ctr, VAPAHCS, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.						[Anonymous], 1993, GUIDE UNIFORM DATA S; CHAMIE M, 1995, DISABIL REHABIL, V17, P323, DOI 10.3109/09638289509166718; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; DROMERICK A, 1994, STROKE, V25, P358, DOI 10.1161/01.STR.25.2.358; GRANGER CV, 1996, PHYSICAL MED REHABIL, P247; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; JEFFERY DR, 1995, CURR OPIN NEUROL, V8, P62, DOI 10.1097/00019052-199502000-00010; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Paolucci S, 2000, ARCH PHYS MED REHAB, V81, P695, DOI 10.1053/apmr.2000.5583; Pinto AN, 1998, CEREBROVASC DIS, V8, P204, DOI 10.1159/000015852; ROTH EJ, 1988, STROKE, V19, P42, DOI 10.1161/01.STR.19.1.42; SIEGLER EL, 1994, ARCH INTERN MED, V154, P2185, DOI 10.1001/archinte.154.19.2185; Wright RE, 1996, ARCH PHYS MED REHAB, V77, P1049, DOI 10.1016/S0003-9993(96)90067-2	14	38	38	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2002	81	11					830	837		10.1097/00002060-200211000-00005			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	607FP	WOS:000178781700005	12394994				2021-06-18	
J	Seibert, PS; Reedy, DP; Hash, J; Webb, A; Stridh-Igo, P; Basom, J; Zimmerman, CG				Seibert, PS; Reedy, DP; Hash, J; Webb, A; Stridh-Igo, P; Basom, J; Zimmerman, CG			Brain injury: quality of life's greatest challenge	BRAIN INJURY			English	Article							PREFERENCE-BASED MEASURES; SEVERE HEAD-INJURY; OF-LIFE; COMMUNITY INTEGRATION; VALIDATION; VALIDITY; SCALE; COMA	The objectives of this investigation were to (1) identify elements that comprise an acceptable quality of life (Q-L) post-traumatic brain injury (TBI) from the perspectives of patients and families, and (2) explore patient and family satisfaction with treatment decisions relevant to QoL. The authors created, tested, and administered two forms (patient; family) of a 35-question interview to 33 participants in a longitudinal TBI study (14 women, 19 men) and 33 associated family members. Men associated ratings of QoL with numerous variables, while women's responses revealed no significant relationships shared by QoL and other variables. Women reported a poorer QoL than did men. Older patients reported a better QoL than did younger patients. Families emphasized the family relationship, emotional control, and ability to concentrate when considering overall QoL. Patients did not. The majority of patients and families expressed satisfaction with decisions made about acute treatment. QoL research is essential to illuminate best practice models.	St Alphonsus Reg Med Ctr, Idaho Neurol Inst, Boise, ID 83706 USA; Boise State Univ, Boise, ID 83725 USA	Seibert, PS (corresponding author), St Alphonsus Reg Med Ctr, Idaho Neurol Inst, 1055 N Curtis Rd, Boise, ID 83706 USA.		Stridh, Pernilla/J-2918-2012	Stridh, Pernilla/0000-0003-4855-0039			Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; *BRAIN INJ ASS, 2000, COSTS CAUS TRAUM BRA; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Carr AJ, 2001, BMJ-BRIT MED J, V322, P1240, DOI 10.1136/bmj.322.7296.1240; Collins R, 2000, J HEAD TRAUMA REHAB, V15, P1139, DOI 10.1097/00001199-200010000-00007; *CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Dempster M, 2000, SOC WORK HEALTH CARE, V32, P45; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lenert L, 2000, MED CARE, V38, P138; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maslow A., 1954, MOTIVATION PERSONALI; Mezzich JE, 2000, J NERV MENT DIS, V188, P301, DOI 10.1097/00005053-200005000-00008; MIRR MP, 1991, HEART LUNG, V20, P228; Murrell R, 1999, NEUROPSYCHOL REV, V9, P209, DOI 10.1023/A:1021686606648; Nease RF, 2000, MED CARE, V38, P155; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pearlman R A, 1992, J Clin Ethics, V3, P114; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stewart AL, 2000, MED CARE, V38, P102; Swenson JR, 2000, J PSYCHOSOM RES, V48, P405, DOI 10.1016/S0022-3999(99)00092-6; Testa MA, 2000, MED CARE, V38, P166; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Weitzner MA, 1996, J NEUROSURG, V84, P29, DOI 10.3171/jns.1996.84.1.0029; WHITENECK GG, 1992, ARCH PHYSICAL MED RE, V73, P1186; Withrow SJ, 1998, CLIN TECH SMALL AN P, V13, P1	40	38	39	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2002	16	10					837	848		10.1080/02699050210131939			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	599VG	WOS:000178355400001	12418997				2021-06-18	
J	Yokota, H; Naoe, Y; Nakabayashi, M; Unemoto, K; Kushimoto, S; Kurokawa, A; Node, Y; Yamamo, Y				Yokota, H; Naoe, Y; Nakabayashi, M; Unemoto, K; Kushimoto, S; Kurokawa, A; Node, Y; Yamamo, Y			Cerebral endothelial injury in severe head injury: The significance of measurements of serum thrombomodulin and the von Willebrand factor	JOURNAL OF NEUROTRAUMA			English	Article						cerebral endothelial injury; severe head injury; thrombomodulin; von Willebrand factor	VONWILLEBRAND-FACTOR; TRAUMA; COAGULOPATHY	Thrombomodulin (TM), which is located in the surface of the endothelium in the arteries, veins, and capillaries of major organs such as the brain, lungs, liver, kidneys, skeletal muscles, and gastrointestinal tract, is one of several indicators of endothelial injury. Von Willebrand factor (vWf), which is synthesized by endothelial cells, is also an endothelial specific glycoprotein. The serum level of vWf increases in response to various stimuli without endothelial injury. An elevated serum level of vWf may suggest endothelial activation in severe head injury. We hypothesize that the degree of cerebral endothelial activation or injury depends on the type of head injury and that measuring the TM and vWf is useful for predicting delayed traumatic intracerebral. hematoma (DTICH), produced by weakness of the vessel wall, occuring either as a direct or indirect effect of head injury. The values of vWf in focal brain injury (ranging from 332.5 +/- 52.8% to 361.7 +/- 86.2%) were significantly higher than those in diffuse axonal injury from 2 h to 7 days after the injury occurred (ranging from 201.6 +/- 59.5% to 242.5 +/- 51.7%). The serum level of TM in focal brain injury (ranging from 3.84 +/- 1.54 to 4.12 +/- 1.46 U/mL) was higher than that in diffuse axonal injury (ranging from 2.96 +/- 0.63 to 3.67 +/- 1.70 U/mL), but these differences were not statistically significant. In patients with DTICH, TM was significantly higher than in patients without DTICH (p < 0.01). The results of our study demonstrate that the degree of endothelial activation in focal brain injury was significantly higher than in diffuse brain injury. In addition, the serum level of TM in patients with DTICH was significantly higher than in patients without DTICH. These findings suggest that cerebral tissue injury is often accompanied by cerebral endothelial activation, and that these two phenomena should be distinguished from each other. The levels of serum TM and vWf appear to be good indicators of the cerebral endothelial injury and of endothelial activation in severe head injury.	Tama Nagayama Hosp, Nippon Med Sch, Dept Emergency & Crit Care, Tokyo 2068512, Japan; Main Hosp, Nippon Med Sch, Dept Crit Care Med, Tokyo, Japan	Yokota, H (corresponding author), Tama Nagayama Hosp, Nippon Med Sch, Dept Emergency & Crit Care, 1-7-1 Nagayama Tama City, Tokyo 2068512, Japan.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; ATRAS S, 1969, J TRAUMA, V9, P522; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BOLLINGER O, 1891, VIRCHOW, V2, P457; BOROWIECKI B, 1969, J TRAUM, V9, P522; COOPER PR, 1985, COMMENT NEUROSURGERY, V19, P531; FAN L, 1993, SOC NEUR ABSTR, V76, P9; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HANDIN IR, 2000, HARRISONS, P745; Ikegami K, 1998, J TRAUMA, V44, P789, DOI 10.1097/00005373-199805000-00008; INNEE D, 1964, J CLIN PATHOL, V17, P113; ISHII H, 1994, THROMBIN THROMBOMODU, P121; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; MELLION BT, 1992, COMPLICATIONS SEQUEL, P51; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; RUGGERI ZM, 1993, FASEB J, V7, P308; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SIMMONS RL, 1969, ANN SURG, V169, P455, DOI 10.1097/00000658-196904000-00001; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TAKANO S, 1990, BLOOD, V76, P2024; TAKASHIMA S, 1969, BRIT J EXP PATHOL, V50, P533; TOVI D, 1973, ACTA NEUROL SCAND, V49, P152; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; VERWEIJ CL, 1988, HAEMOSTASIS, V18, P224; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; YOKOTA H, 1995, NEUROCHEMICAL MONITO, P98	32	38	43	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1007	1015		10.1089/089771502760341929			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900002	12482114				2021-06-18	
J	Kumar, A; Cook, IA				Kumar, A; Cook, IA			White matter injury, neural connectivity and the pathophysiology of psychiatric disorders	DEVELOPMENTAL NEUROSCIENCE			English	Article						white matter; connectivity; myelin; axons; mood disorder; psychiatric disorders	MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; PREFRONTAL CORTEX; BASAL GANGLIA; HEAD-INJURY; MRI; LESIONS	Psychiatric disorders are characterized by diverse clinical manifestations that include deficits in cognition, perception, mood and arousal. These complex processes are not mediated by any specific brain region but require the coordinated activity of several areas that are anatomically connected. Impairments in these neural circuits may therefore be expected to result in an attenuation of the functions regulated by them. The white matter provides the structural and physiological substrate of neural circuits in the central nervous system. We propose that injury to the white matter, from diverse biological sources, may compromise neural connectivity by associated axonal injury or impaired conductivity. Either mechanism could result in clusters of signs and symptoms that are currently recognized as psychiatric disorders. The role of white matter impairment in the pathophysiology of psychiatric illness is under-appreciated in the neurosciences. Focused translational research aimed at identifying the links between white matter compromise and specific behaviors are necessary for a more thorough understanding of the etiology of mental illness to emerge. Copyright (C) 2002 S. Karger AG, Basel.	Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA	Kumar, A (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, 37-384B,760 Westwood Plaza, Los Angeles, CA 90024 USA.	akumar@mednet.ucla.edu					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Akbarian S, 1996, ARCH GEN PSYCHIAT, V53, P425; ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO, P191; Alexopoulos GS, 1997, ARCH GEN PSYCHIAT, V54, P915; BENNETT DA, 1994, DEMENTIA, V5, P148, DOI 10.1159/000106713; Bjartmar C, 1999, J NEUROCYTOL, V28, P383, DOI 10.1023/A:1007010205037; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Buchsbaum MS, 1998, NEUROREPORT, V9, P425, DOI 10.1097/00001756-199802160-00013; Callicott JH, 2000, CEREB CORTEX, V10, P1078, DOI 10.1093/cercor/10.11.1078; Campagnoni A, 2001, BRAIN PATHOL, V11, P74; Catalaa I, 1999, AM J NEURORADIOL, V20, P1613; COOK IA, IN PRESS ARCH NEUROL; de Groot JC, 2000, ANN NEUROL, V47, P145; Dichgans M, 1999, NEUROLOGY, V52, P1361, DOI 10.1212/WNL.52.7.1361; Duman RS, 2002, NEUROPSYCHOPHARMACOL, V26, P141, DOI 10.1016/S0893-133X(01)00415-8; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.3.CO;2-A; FEINSTEIN A, 1992, J NEUROL NEUROSUR PS, V55, P869, DOI 10.1136/jnnp.55.10.869; Filley CM, 1998, NEUROLOGY, V50, P1535, DOI 10.1212/WNL.50.6.1535; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FILLEY CM, 2001, BEHAV NEUROLOGY WHIT; Foong J, 2001, BRAIN, V124, P882, DOI 10.1093/brain/124.5.882; Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9; GALASKO D, 1988, PSYCHIAT CLIN N AM, V11, P151; GESCHWIN.N, 1965, BRAIN, V88, P585, DOI 10.1093/brain/88.3.585; Geula C, 1998, NEUROLOGY, V51, pS18, DOI 10.1212/WNL.51.1_Suppl_1.S18; Gitelman DR, 1999, BRAIN, V122, P1093, DOI 10.1093/brain/122.6.1093; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Hamakawa H, 1998, EUR ARCH PSY CLIN N, V248, P53, DOI 10.1007/s004060050017; Harrison JE, 1999, AM J MED GENET, V88, P642, DOI 10.1002/(SICI)1096-8628(19991215)88:6<642::AID-AJMG12>3.0.CO;2-O; HONER WG, 1987, ARCH NEUROL-CHICAGO, V44, P187, DOI 10.1001/archneur.1987.00520140053017; HYDE TM, 1992, ARCH NEUROL-CHICAGO, V49, P401, DOI 10.1001/archneur.1992.00530280095028; Kato T, 1996, J PSYCHIATR NEUROSCI, V21, P248; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Krishnan KRR, 1997, AM J PSYCHIAT, V154, P497; Kumar A, 2002, NEUROPSYCHOPHARMACOL, V26, P229, DOI 10.1016/S0893-133X(01)00331-1; KUMAR A, IN PRESS FRONTAL WHI; Lewis DA, 2002, NEUROPSYCHOPHARMACOL, V26, P143, DOI 10.1016/S0893-133X(01)00393-1; Lim KO, 1998, ARCH GEN PSYCHIAT, V55, P346, DOI 10.1001/archpsyc.55.4.346; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Morris JS, 1999, NEUROIMAGE, V10, P163, DOI 10.1006/nimg.1999.0455; Murata T, 2001, INT J GERIATR PSYCH, V16, P1129, DOI 10.1002/gps.501; Nicholl CR, 2001, CLIN REHABIL, V15, P657, DOI 10.1191/0269215501cr427oa; O'Sullivan M, 2001, NEUROLOGY, V57, P632, DOI 10.1212/WNL.57.4.632; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rajkowska G, 2000, BIOL PSYCHIAT, V48, P766, DOI 10.1016/S0006-3223(00)00950-1; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Rosebush PI, 1999, J NEUROPSYCH CLIN N, V11, P315, DOI 10.1176/jnp.11.3.315; SADOVNICK AD, 1991, NEUROLOGY, V41, P1193, DOI 10.1212/WNL.41.8.1193; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; Steffens DC, 2002, DEPRESS ANXIETY, V15, P23, DOI 10.1002/da.1081; STUSS DT, 1990, SUBCORTICAL DEMENTIA, P145; Taylor WD, 2001, BIOL PSYCHIAT, V50, P179, DOI 10.1016/S0006-3223(01)01160-X; Thomas AJ, 2001, J NEUROL NEUROSUR PS, V70, P83, DOI 10.1136/jnnp.70.1.83; Thomas MA, 2001, MAGNET RESON MED, V46, P58, DOI 10.1002/mrm.1160; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WALLIN A, 1989, ACTA NEUROL SCAND, V80, P518, DOI 10.1111/j.1600-0404.1989.tb03920.x	60	38	39	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.	JUL-AUG	2002	24	4					255	261		10.1159/000066746			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	629BV	WOS:000180031300001	12457063				2021-06-18	
J	Wedekind, C; Hesselmann, V; Lippert-Gruner, M; Ebel, M				Wedekind, C; Hesselmann, V; Lippert-Gruner, M; Ebel, M			Trauma to the pontomesencephalic brainstem - a major clue to the prognosis of severe traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brainstem reflexes; evoked potentials; magnetic resonance imaging; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; EVOKED-POTENTIALS; STEM LESIONS	The objective of this study was to assess the significance of an injury to the pontomesencephalic brainstem in severe traumatic brain injury [Glasgow coma score (GCS) below 8]. Forty victims of severe traumatic brain injury with and with out compounding pathologies almost equally distributed among both groups were studied. The outcome (mean follow-up, 11.3 months) was assessed by means of the Glasgow outcome score (GOS) and of the Disability rating scale (DRS). Injury of the brainstem was detected by electrophysiological investigation (evoked potentials, brainstem reflexes) and magnetic resonance imaging (MRI) carried out early after trauma. Statistical analysis (Wilcoxon signed rank test for matched pairs) revealed a significantly worse initial GCS (median 5 versus 6), GOS (median 3 versus 4), and DRS score (median 6 versus 2) for the group with brainstem lesions than for the group without such lesions. Moreover, there was a significant accumulation of lesions of the corpus callosum, the basal ganglia, and the (para-)hippocampal area detected by MRI in the brainstem lesion group. In addition, the finding of an abnormal cortical component of the median nerve evoked somatosensory potential was significantly more frequent in the patients with brainstem injury. Traumatic brainstem lesions diagnosed by MRI and/or electrophysiological investigation are associated with injury to other 'deeply' situated parts of the brain. The finding of a brainstem lesion influences to the outcome of patients after severe traumatic brain injury.	Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany; Univ Cologne, Dept Radiol, D-50924 Cologne, Germany	Wedekind, C (corresponding author), Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany.						CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; HOPF HC, 1994, MUSCLE NERVE, V17, P475, DOI 10.1002/mus.880170502; JENNETT B, 1975, LANCET, V1, P480; JORG J, 1998, EVOZIERTE POTENTIALE; Klug N, 1987, Acta Neurochir Suppl (Wien), V40, P57; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sachs L., 1997, ANGEW STAT; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010	16	38	40	0	2	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2002	16	3					256	260		10.1080/02688690220148842			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	585MU	WOS:000177529200008	12201395				2021-06-18	
J	Ding, YC; Zhou, YD; Lai, Q; Li, J; Park, H; Diaz, FG				Ding, YC; Zhou, YD; Lai, Q; Li, J; Park, H; Diaz, FG			Impaired motor activity and motor learning function in rat with middle cerebral artery occlusion	BEHAVIOURAL BRAIN RESEARCH			English	Article						motor activity; motor learning; motor behavior tasks; ischemic stroke; neurological deficits; infarct	TRAUMATIC BRAIN INJURY; COGNITIVE IMPAIRMENT; ALCOHOL EXPOSURE; ISCHEMIC STROKE; INFARCT VOLUME; ADULT-RATS; RECOVERY; CORTEX; DEFICITS; SENSORIMOTOR	The poor quality of life after a stroke is largely attributed to deficits in cognitive-motor functioning. The goals of this study were to detect if damaged motor learning function were attributed to motor deficits in rats following a transient middle cerebral artery (MCA) occlusion. Stroke was induced by a 2-h occlusion of the MCA using an intraluminal filament. Motor functions were evaluated from 5 up to 28 days after reperfusion in ischemic and control rats. Motor function was detected by a series of motor tests (runway traversing and beam balancing, as well Lis foot fault placing, parallel bar crossing, rope and ladder climbing), and motor learning behavior was determined by analyzing the rate of improvement of impaired function during performance of the motor tasks. Significant (P < 0.001) motor deficits were detected in the stroke group (n = 10) while performing motor tasks that involve extensive coordination, in comparison to the controls (n = 12). Although motor behavior was improved with repeated behavior testing, unparalleled rate of improvement of motor performance on rope and ladder climbing tests was found between the two groups. suggesting an impaired motor learning function. Brain tissue damage was detected in the ischemic animals 28 days after surgery, demonstrated by 40% infaret volume of contralateral hemisphere. Both motor learning and motor function were impaired in ischemic rats. The motor tests used in this study are sensitive, semi-quantitative, and reproducible measurements of functional impairment in rats following an ischemic stroke. (C) 2002 Elsevier Science B.V. All rights reserved.	Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Educ, Div Hlth Phys Educ & Recreat, Detroit, MI 48201 USA	Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Lande Med Res Bldg,Room 48,550 E Canfield, Detroit, MI 48201 USA.	yding@neurosurgery.wayne.edu					Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BORLONGAN CV, 1995, PHARMACOL BIOCHEM BE, V52, P225, DOI 10.1016/0091-3057(95)00108-9; BORLONGAN CV, 1995, PHYSIOL BEHAV, V58, P909, DOI 10.1016/0031-9384(95)00103-P; Borlongan CV, 2000, NEUROREPORT, V11, P4063, DOI 10.1097/00001756-200012180-00031; CARR JH, 1989, PHYSIOTHERAPY, V75, P372; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eccles J C, 1978, Exp Brain Res, V31, P153; Friel KM, 1998, SOMATOSENS MOT RES, V15, P173, DOI 10.1080/08990229870745; Goodlett CR, 1996, PHARMACOL BIOCHEM BE, V55, P531, DOI 10.1016/S0091-3057(96)00248-1; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanlon RE, 1996, ARCH PHYS MED REHAB, V77, P811, DOI 10.1016/S0003-9993(96)90262-2; HIRAKAWA M, 1994, STROKE, V25, P2471, DOI 10.1161/01.STR.25.12.2471; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; Jones TA, 1999, J NEUROSCI, V19, P10153; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Kleim JA, 1996, J NEUROSCI, V16, P4529; Klintsova AY, 1998, BRAIN RES, V800, P48, DOI 10.1016/S0006-8993(98)00495-8; KOIZUMI J, 1985, P 10 M JAP STOK SOC; Kwa VIH, 1996, J NEUROL, V243, P599, DOI 10.1007/BF00900948; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MARSTON HM, 1995, NEUROREPORT, V6, P1067, DOI 10.1097/00001756-199505090-00029; MELCER T, 1995, NEUROTOXICOL TERATOL, V17, P103, DOI 10.1016/0892-0362(94)00058-L; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; Mohr J.P., 1986, STROKE PATHOPHYSIOLO, P377; MORI S, 1995, STROKE, V26, P620, DOI 10.1161/01.STR.26.4.620; Nudo RJ, 2000, NEUROPHARMACOLOGY, V39, P733, DOI 10.1016/S0028-3908(99)00254-3; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P505, DOI 10.1038/jcbfm.1995.62; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; SAITO I, 1987, STROKE, V18, P863, DOI 10.1161/01.STR.18.5.863; Sakai N, 1996, BEHAV BRAIN RES, V77, P181, DOI 10.1016/0166-4328(95)00232-4; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TOMINAGA T, 1989, STROKE, V20, P513, DOI 10.1161/01.STR.20.4.513; vanderStaay FJ, 1996, BRAIN RES, V715, P180, DOI 10.1016/0006-8993(95)01581-7; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; Yonemori F, 1998, J CEREBR BLOOD F MET, V18, P1099, DOI 10.1097/00004647-199810000-00006; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	50	38	43	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	APR 15	2002	132	1					29	36	PII S0166-4328(01)00405-3	10.1016/S0166-4328(01)00405-3			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	539PR	WOS:000174880100004	11853855				2021-06-18	
J	Fortin, S; Godbout, L; Braun, CMJ				Fortin, S; Godbout, L; Braun, CMJ			Strategic sequence planning and prospective memory impairments in frontally lesioned head trauma patients performing activities of daily living	BRAIN AND COGNITION			English	Article; Proceedings Paper	12th Annual Meeting on Tennet - Theoretical and Experimental Neuropsychology	JUN 21-23, 2001	UNIV QUEBEC, MONTREAL, CANADA		UNIV QUEBEC		BRAIN-DAMAGE; DEFICITS; INJURY	The aim of this research was to study strategic sequence planning and prospective memory in activities of daily living (ADL) in 10 patients with frontal lobe lesions after a mild to moderate closed head injury (CHI). The lesions were documented radiologically. The CHI patients were compared to 12 normal controls with a neuropsychological test battery and a realistic simulation of complex multitask ADL (planning and preparing a meal). Though the CHI patients were significantly slow on one test and subject to interference on an attention test. they manifested no basic executive or memory deficit on the paper-pencil tests. However, the CHI patients manifested marked anomalies in the organization of behavior in the meal preparation task. While small sequences of actions were easily produced, large action sets could not be correctly executed. An outstanding difficulty in strategic planning and prospective memory, particularly time-based more than event-based, appears to be an important underpinning of the impairment of ADL observed in the CHI patients with frontal lobe lesions. (C) 2002 Elsevier Science (USA).	Univ Quebec, Ctr Neurosci Cognit, Dept Psychol, Montreal, PQ H3C 3P8, Canada; Univ Quebec, Dept Psychol, Lab Neuropsychol Expt & Comparee, Trois Rivieres, PQ GA9 5H7, Canada	Braun, CMJ (corresponding author), Univ Quebec, Ctr Neurosci Cognit, Dept Psychol, BP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.						Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Godbout L, 2000, BRAIN COGNITION, V43, P220; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; van den Broek MD, 2000, BRAIN INJURY, V14, P455	13	38	38	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	MAR-APR	2002	48	2-3					361	365		10.1006/brcg.2001.1378			5	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	536ED	WOS:000174687000075	12030468				2021-06-18	
J	Dillman, RO; Beutel, LD; Barth, NM; de Leon, C; O'Connor, AA; DePriest, C; Nayak, SK				Dillman, RO; Beutel, LD; Barth, NM; de Leon, C; O'Connor, AA; DePriest, C; Nayak, SK			Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival	CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS			English	Article						cancer; vaccines; tumor cell lines; delayed type tumor hypersensitivity	ACTIVE-SPECIFIC IMMUNOTHERAPY; COLORECTAL-CANCER; GENE-THERAPY; MELANOMA; IMMUNIZATION; CARCINOMA; CULTURES	Objective: We established short-term cultures of pure tumor cells for use as autologous tumor cell vaccines in an effort to study the effects of patient-specific immunotherapy. Patients and Methods: Surgically, resected fresh tumor was obtained from patients with metastatic cancer. Successful tumor cell lines (5 X 10(7)) were expanded to 10(8) cells, irradiated, and cryopreserved for clinical use. Following a baseline test of delayed-type hypersensitivity (DTH) to an i.d. injection of 106 irradiated autologous tumor cells, patients received 3 weekly s.c. injections of 10(7) cells, had a repeat DTH test at week-4, then received monthly vaccinations for 5 months. A positive DTH test was defined as greater than or equal to 10 mm induration; survival was determined from the first DTH test. Results: Short-term cell lines were successfully established for 299/695 patients (43%). Vaccines were prepared for 231 patients, 142 of whom were treated, and 125 had a baseline DTH test recorded. Median follow Lip at the time of analysis was greater than 5 years. There was no difference in survival for any of the following: gender, age > 50 years, melanoma histology, anergy to common recall antigens or baseline DTH test result. Only 17 patients had a positive DTH at baseline (14%), but DTH converted from negative to positive in 31/80 (39%) of those mho were tested, and in 31/108 (29%) of all patients (intent-to-convert analysis). For the 48 patients who were DTH-positive at entry, or converted to DTH-positive, the median survival was 30.5 months and 5-year survival 41% compared to 11.4 months and 9% 5-year survival for 77 patients whose DTH was never positive (P-2=0.003). However, survival was even better for patients whose DTH test converted to positive compared to patients who were DTH-positive at baseline (median 37.5 vs 11.9 mos, P-2=0.066). Concussion: This patient-specific, cell culture-derived, autologous tumor cell vaccine induced anti-tumor immune reactivity that was associated with improved survival in patients with advanced cancer.	Hoag Canc Ctr, Newport Beach, CA 92658 USA	Dillman, RO (corresponding author), Hoag Canc Ctr, 1 Hoag Dr,Bldg 41, Newport Beach, CA 92658 USA.	rdillman@hoaghospital.org					BAILAR JC, 1992, MED USES STAT; BARTH A, 1994, CANCER RES, V54, P3342; Berd D, 1998, SEMIN ONCOL, V25, P646; Berd D, 1998, SEMIN ONCOL, V25, P605; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BYSTRYN JC, 1992, CANCER, V69, P157; Chan AD, 1998, SEMIN ONCOL, V25, P611; DILLMAN RO, 1993, J IMMUNOTHER, V14, P65, DOI 10.1097/00002371-199307000-00009; Dillman RO, 2001, CRIT REV ONCOL HEMAT, V39, P115, DOI 10.1016/S1040-8428(01)00110-X; Dillman RO, 1997, CANCER BIOTHER RADIO, V12, P229, DOI 10.1089/cbr.1997.12.229; Dillman RO, 1999, CANCER BIOTHER RADIO, V14, P443, DOI 10.1089/cbr.1999.14.443; Dillman RO, 2001, CANCER BIOTHER RADIO, V16, P205, DOI 10.1089/10849780152389393; Dillman RO, 2000, CANCER BIOTHER RADIO, V15, P161, DOI 10.1089/cbr.2000.15.161; Dillman RO, 1998, CANCER BIOTHER RADIO, V13, P165, DOI 10.1089/cbr.1998.13.165; HASPEL MV, 1985, CANCER RES, V45, P3951; HOOVER HC, 1984, CANCER RES, V44, P1671; HOOVER HC, 1993, J CLIN ONCOL, V11, P390, DOI 10.1200/JCO.1993.11.3.390; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESSLER DA, 1993, NEW ENGL J MED, V329, P1169, DOI 10.1056/NEJM199310143291607; Livingston P, 1998, SEMIN ONCOL, V25, P636; MILLER K, 1995, CANCER, V75, P495, DOI 10.1002/1097-0142(19950115)75:2<495::AID-CNCR2820750212>3.0.CO;2-S; Mitchell MS, 1998, SEMIN ONCOL, V25, P623; MITCHELL MS, 1990, J CLIN ONCOL, V8, P856, DOI 10.1200/JCO.1990.8.5.856; Nayak SK, 2000, IN VITRO CELL DEV-AN, V36, P188; NAYAK SK, 1991, CLIN BIOTECHNOL, V3, P237; Salgaller ML, 1997, J IMMUNOTHER, V20, P1, DOI 10.1097/00002371-199701000-00001; Schirrmacher V, 1998, SEMIN ONCOL, V25, P677; Simons JW, 1998, SEMIN ONCOL, V25, P661; SZNOL M, 1999, PPO UPDATES, V13, P1	29	38	38	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1084-9785	1557-8852		CANCER BIOTHER RADIO	Cancer Biother. Radiopharm.	FEB	2002	17	1					51	66		10.1089/10849780252824073			16	Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging	Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging	528FG	WOS:000174233300007	11915174				2021-06-18	
J	Prabhu, VC; Bailes, JE				Prabhu, VC; Bailes, JE			Chronic subdural hematoma complicating arachnoid cyst secondary to soccer-related head injury: Case report	NEUROSURGERY			English	Article						arachnoid cyst; head injury; "heading," soccer; subdural hematoma	INTRACYSTIC HEMORRHAGE; BRAIN INJURY; PLAYERS; FOOTBALL; RUPTURE	OBJECTIVE AND IMPORTANCE: Soccer has become a popular sport, with more than 200 million Federation International Football Association-registered soccer players worldwide and 16 million participants in the United States. The risk of sustaining a significant head injury from a strike to a soccer ball with the head is unknown, but it may be increased with the presence of an underlying congenital arachnoid cyst. CLINICAL PRESENTATION: We describe the case of a 16-year-old female patient who sustained a large chronic and subacute subdural hematoma without a loss of consciousness from being struck on the head by a soccer ball. Because of the large size of the hematoma and her contralateral symptoms, surgery was performed. INTERVENTION: A temporal craniotomy for evacuation of a large chronic and subacute subdural hematoma with removal and fenestration of the arachnoid cyst resulted in resolution of her symptoms. Rigid craniotomy fixation of this small operative flap should allow the patient to return to soccer participation in the future. CONCLUSION: Although many may not consider soccer a contact sport, recent epidemiological data suggest that it is a common cause of sports-related concussion. In addition, as our case report demonstrates, there is a risk of significant intracranial injury and hematoma formation subsequent to a strike on the head by a soccer ball, and arachnoid cysts may contribute an additional risk of head injury.	W Virginia Univ, Sch Med, Hlth Sci Ctr 3610, Dept Neurosurg, Morgantown, WV 26506 USA	Bailes, JE (corresponding author), W Virginia Univ, Sch Med, Hlth Sci Ctr 3610, Dept Neurosurg, POB 9183, Morgantown, WV 26506 USA.						Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Choi JU, 1998, PEDIATR NEUROSURG, V29, P260, DOI 10.1159/000028733; Huang D, 1999, AM J NEURORADIOL, V20, P1284; ILDAN F, 1994, NEUROSURG REV, V17, P229, DOI 10.1007/BF00418441; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kadiogly H H, 1994, Zentralbl Neurochir, V55, P172; Kawanishi A, 1999, NEUROL MED-CHIR, V39, P231, DOI 10.2176/nmc.39.231; Lipinski CA, 1997, PEDIATR EMERG CARE, V13, P27, DOI 10.1097/00006565-199702000-00009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Ochi M, 1996, EUR RADIOL, V6, P640; Oka Yoshihisa, 1994, Neurologia Medico-Chirurgica, V34, P95, DOI 10.2176/nmc.34.95; Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P341; Tucker AM, 1997, SPORTS MED, V23, P21, DOI 10.2165/00007256-199723010-00003; Vigil DV, 1998, CLIN J SPORT MED, V8, P234, DOI 10.1097/00042752-199807000-00013; Youmans IR, 1996, NEUROLOGICAL SURG, P967	21	38	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2002	50	1					195	197					3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	506AC	WOS:000172946900046	11844251				2021-06-18	
J	Turnbull, SJ; Campbell, EA; Swann, IJ				Turnbull, SJ; Campbell, EA; Swann, IJ			Post-traumatic stress disorder symptoms following a head injury: does amnesia for the event influence the development of symptoms?	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; BRAIN INJURY; VICTIMS; SCALE; POPULATION; COMMUNITY; PTSD	Background: There is controversy as to whether PTSD can develop following a brain injury with a loss of consciousness. However, no studies have specifically examined the influence of the memories that the individuals may or may not have on the development of symptoms. Aims: To consider how amnesia for the traumatic event effects the development and profile of traumatic stress symptoms. Method: Fifteen hundred case records from an Accident and Emergency Unit were screened to identify 371 individuals with traumatic brain injury who were sent questionnaires by post. The 53 subsequent valid responses yielded three groups: those with no memory (n = 14), untraumatic memories (n = 14), and traumatic memories (n = 26) of the index event. The IES-R was used as a screening measure followed by a structured interview (CAPS-DX) to determine caseness and provide details of symptom profile. Results: Groups with no memories or traumatic memories of the index event reported higher levels of psychological distress than the group with untraumatic memories. Ratings of PTSD symptoms were less severe in the no memory groups compared to those with traumatic memories. Conclusions: Psychological distress was associated with having traumatic or no memories of an index event. Amnesia for the event did not protect against PTSD; however, it does appear to protect against the severity and presence of specific intrusive symptoms.	Astley Ainslie Hosp, Lothian Primary Care NHS Trust, Dept Psychol, Edinburgh EH9 2HL, Midlothian, Scotland; Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland; Glasgow Royal Infirm, Accid & Emergency Unit, Glasgow G4 0SF, Lanark, Scotland	Turnbull, SJ (corresponding author), Astley Ainslie Hosp, Lothian Primary Care NHS Trust, Dept Psychol, 133 Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.						American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Blake D.D., 1996, CLIN ADM PTSD SCALE; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Koren D, 1999, AM J PSYCHIAT, V156, P367; KOSS MP, 1989, PSYCHOL WOMEN QUART, V13, P27, DOI 10.1111/j.1471-6402.1989.tb00983.x; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Middelboe T., 1992, European Psychiatry, V7, P183; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	38	39	0	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					775	785		10.1080/02699050110034334			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400003	11516346				2021-06-18	
J	Powell, JM; Machamer, JE; Temkin, NR; Dikmen, SS				Powell, JM; Machamer, JE; Temkin, NR; Dikmen, SS			Self-report of extent of recovery and barriers to recovery after traumatic brain injury: A longitudinal study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						awareness; brain injuries; cognition; recovery of function; rehabilitation	IMPAIRED AWARENESS; HEAD-INJURY; REHABILITATION; QUALITY; ADULTS	Objective: To examine the perspective of survivors of traumatic brain injury (TBI) regarding the extent and nature of their recovery over time. Design: Inception cohort, longitudinal study. Setting: Level I trauma center. Participants: One hundred fifty-seven consecutively hospitalized individuals with TBI (mean age, 36.1 yr; 80% men) with a broad range of injury severity. Interventions: Not applicable. Main Outcome Measures: Participants reported the extent of their recovery and barriers to full recovery at 1, 6, and 12 months. Results: Participants reported a median return to normal at the 3 follow-up times of 65%, 80%, and 85%. After I month, self-reported extent of recovery correlated well with performance on the Glasgow Outcome Scale (p <.001 at 6 and 12mo) and Wechsler Adult Intelligence Scale Performance IQ (p =.001 at 12mo). The major reported barrier to recovery was physical difficulties, which constituted over half of the concerns at all time periods. Report of physic al-related concerns decreased significantly (p =.002) over time whereas cognition-related concerns increased significantly (p =.02). Conclusion: Brain injury survivors consider themselves to have greater recovery than previously reported by clinicians or family members, consider physical problems a significant factor in their recovery, and appear to become more aware of cognitive impairments over time.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Powell, JM (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline		BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; CORBET B, 1995, SPINAL CORD INJURY C, P212; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Miles M.B., 1994, QUALITATIVE DATA ANA; Peters DE, 1996, AM J PHYS MED REHAB, V75, P144, DOI 10.1097/00002060-199603000-00016; Peters DJ, 1996, DISABIL REHABIL, V18, P593, DOI 10.3109/09638289609166320; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zar J. H., 1984, BIOSTATISTICAL ANAL, V3; 1999, FED REG, V64, P45744	24	38	38	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2001	82	8					1025	1030		10.1053/apmr.2001.25082			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	459WT	WOS:000170275000003	11494180				2021-06-18	
J	Schultheis, MT; Mourant, RR				Schultheis, MT; Mourant, RR			Virtual reality and driving: Tthe road to better assessment for cognitively impaired populations	PRESENCE-TELEOPERATORS AND VIRTUAL ENVIRONMENTS			English	Article							TRAUMATIC BRAIN INJURY; CEREBRAL-DAMAGE; PERFORMANCE; ENVIRONMENTS; PREDICTION	Individuals with cognitive impairments can be faced with difficulties that may challenge their ability to drive an automobile, and this impairment is often very disruptive to vocational, social, and domestic activities. Rehabilitation specialists are often given the task of determining capacity to drive. However, traditional assessment methods are fraught with various limitations, including dependence on subjective interpretation of behaviors, nonstandardized procedures, and few ecologically valid measures. A virtual reality-based driving-assessment system (VR-DAS) offers the opportunity to overcome many of the limitations of current methodologies. Specifically, a VR-DAS permits the development of relevant driving scenarios that can provide objective and quantifiable measures of driving behaviors, allowing for increasing standardization and consistency of protocols. VR-DAS also allows for the creation of realistic and interactive driving scenarios at varying levels of challenge and complexity. When coupled with the immersive features offered through a head-mounted display (HMD), the VR-DAS may allow drivers to experience the sense of real-life driving, resulting in behavior and responsiveness that may be more predictive of actual driving ability. To examine these potential benefits and the validity of a VR-DAS, a collaborative study is presently being conducted, comparing VR-DAS performance and actual behind-the-wheel performance in adults with acquired brain injury (such as traumatic brain injury and stroke).	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosic Lab, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Northeastern Univ, Dept Mech Ind & Mfg Engn, Boston, MA 02115 USA	Schultheis, MT (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosic Lab, W Orange, NJ USA.	mschultheis@kmrrec.org		Schultheis, Maria/0000-0002-6558-548X			BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROWN DJ, 1998, P 2 EUR C DIS VIRT R, P11; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GIANUTSOS R, 1994, BEHAV RES METH INSTR, V26, P183, DOI 10.3758/BF03204615; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Haikonen S, 1998, Appl Neuropsychol, V5, P24, DOI 10.1207/s15324826an0501_3; HIRSEKORN L, 1998, CYBERPSYCHOLOGY BEHA, V1, P385; Hoffman HG, 2000, PAIN, V85, P305, DOI 10.1016/S0304-3959(99)00275-4; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER; KEWMAN DG, 1985, REHABIL PSYCHOL, V30, P11; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; LEVINE O, 1998, P HUM FACT ERG SOC 4, P1136; LINGS S, 1991, APPL ERGON, V22, P75, DOI 10.1016/0003-6870(91)90305-2; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Michon J.A., 1985, HUMAN BEHAV TRAFFIC; Mourant R. R., 1999, P 41 ANN M HUM FACT, P1268; Nash EB, 2000, INT J HUM-COMPUT INT, V12, P1, DOI 10.1207/S15327590IJHC1201_1; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; Rizzo A., 1994, P 2 INT C VIRT REAL, P135; RIZZO AA, 1997, PSYCHONEUROPHYSIOLOG, P123; Rosenthal M., 1999, REHABILITATION ADULT; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1996, P MED MEETS VIRT REA, P100; SCHIFF W, 1994, BEHAV RES METH INSTR, V26, P192, DOI 10.3758/BF03204617; Schultheis MT, 1999, ARCH CLIN NEUROPSYCH, V14, P794; WACHTEL J, 2000, P 8 ANN MED MEETS VI, P100; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; WESTWOOD JD, 2000, MED MEETS VIRTUAL RE, P207; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]	37	38	38	0	13	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	1054-7460	1531-3263		PRESENCE-TELEOP VIRT	Presence-Teleoper. Virtual Env.	AUG	2001	10	4					431	439		10.1162/1054746011470271			9	Computer Science, Cybernetics; Computer Science, Software Engineering	Computer Science	492AT	WOS:000172143800008					2021-06-18	
J	Jury, MA; Flynn, MC				Jury, MA; Flynn, MC			Auditory and vestibular sequelae to traumatic brain injury: a pilot study	NEW ZEALAND MEDICAL JOURNAL			English	Article							HEAD-INJURY; HEARING-LOSS	Aim. To investigate the incidence of persisting auditory and vestibular sequelae in a group of 30 young adults recovering from Traumatic Brain Injury (TBI). Methods. 30 participants, aged 21-45 years, with TBI suffered 19 months to 27 years previously, underwent a semi-structured interview and pure-tone hearing test in their home. Participants who failed the hearing screen then undertook a more comprehensive audiological evaluation. Results. A variety of sequelae to TBI were reported. These were interpreted as tinnitus (53%), vestibular dysfunction (83%), abnormal facial sensory symptoms (27%) and intolerance to loud/sudden noises (87%). Ten (33%) participants demonstrated significant sensorineural hearing impairment in addition to speech recognition performance significantly worse than would have been predicted from their hearing impairment. Conclusions. Findings from this study will be of benefit to health professionals working in this area of rehabilitation as they seek to provide functional assessments and devise programmes to treat the often devastating auditory processing problems of people recovering from TBI.	Univ Canterbury, Dept Speech & Language Therapy, Christchurch 1, New Zealand	Flynn, MC (corresponding author), Univ Canterbury, Dept Speech & Language Therapy, Private Bag 4800, Christchurch 1, New Zealand.			Flynn, Mark/0000-0002-6162-9510			AGUILAR EA, 1986, ARCH OTOLARYNGOL, V94, P211; ASHA (American Speech-Language-Hearing Association), 1990, ASHA S2, V32, P17; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Beukelman D., 1991, COMMUNICATION DISORD, P1; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; COCKRELL J L, 1992, Brain Injury, V6, P261, DOI 10.3109/02699059209029667; LARKINS B, 1998, TRAUMATIC BRAIN INJU; Lubinski R, 1997, BRAIN INJURY, V11, P103, DOI 10.1080/026990597123692; LYOS AT, 1995, ARCH OTOLARYNGOL, V121, P795; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; PODOSHIN L, 1975, ARCH OTOLARYNGOL, V101, P15; VARTIAINEN E, 1985, ACTA OTO-LARYNGOL, V99, P529, DOI 10.3109/00016488509182257; WILSON D, 1998, HEARING IMPAIRMENT A	13	38	40	0	4	SOUTHERN COLOUR PRINT	DUNEDIN	PO BOX 920, DUNEDIN, NEW ZEALAND	0028-8446			NEW ZEAL MED J	N. Z. Med. J.	JUN 22	2001	114	1134					286	288					3	Medicine, General & Internal	General & Internal Medicine	447BC	WOS:000169547800004	11480511				2021-06-18	
J	Pillai, S; Praharaj, SS; Mohanty, A; Kolluri, VRS				Pillai, S; Praharaj, SS; Mohanty, A; Kolluri, VRS			Prognostic factors in children with severe diffuse brain injuries: A study of 74 patients	PEDIATRIC NEUROSURGERY			English	Article						head trauma; prognostic factors; diffuse brain injury	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; GLASGOW COMA SCALE; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; OUTCOME PREDICTION; DATA-BANK; AGE; ADOLESCENTS; MANAGEMENT	Severe diffuse brain injury in children has a devastating influence on their physical and psychological development. This retrospective study was undertaken to analyse the factors that influence outcome in children with such injuries. The short-term outcomes (Glasgow outcome score) of 74 children (age less than or equal to 15 years) with severe diffuse brain injury and no focal operable mass lesions on CT scan, admitted between 1992 and 1998 at the National Institute of Mental Health and Neurosciences were analysed. The prognostic factors analysed were age, gender, time after injury to admission, nature of injury, highest post-resuscitation Glasgow coma score (GCS), pupillary reaction, horizontal oculocephalic reflex and CT scan findings. The following factors were found to be independent predictors of poor outcome: GCS 3-5 (p < 0.003), absent verbal response (p < 0.001), motor response score of 1-3 (p < 0.001), absent pupillary reaction (p < 0.001), absent oculocephalic reflex (p < 0.001) and presence of traumatic subarachnoid haemorrhage on CT scan (p < 0.002). These independent variables were then subjected to a stepwise logistic regression analysis, and the most important variables for predicting outcome were oculocephalic reflex and GCS, which together correctly predicted unfavourable outcome with a sensitivity of 79% and a specificity of 65%, An early CT scan or a single CT scan did not have any prognostic significance. Copyright (C) 2001 S. Karger AG,Basel.	Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India	Praharaj, SS (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Hosur Rd, Bangalore 560029, Karnataka, India.	sspraharaj@hotmail.com					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CARDIA E, 1990, CHILD NERV SYST, V6, P23, DOI 10.1007/BF00262261; COURVILLE CB, 1965, ARCH SURG-CHICAGO, V90, P157; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FACCO E, 1986, CHILD NERV SYST, V2, P67; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Fleischer A S, 1976, Surg Neurol, V6, P31; FRANCEL PC, 1996, NEUROL SURG, V4, P1730; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUMPHREYS RP, 1983, CONCEPTS PEDIAT NEUR, P230; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Paret Gideon, 1999, Harefuah, V136, P677; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; Prpic I, 1993, Lijec Vjesn, V115, P224; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Sganzerla E P, 1989, Minerva Anestesiol, V55, P177; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 1996, ACTA NEUROCHIR, V138, P543, DOI 10.1007/BF01411174; VAPALAHTI M, 1986, ANN CLIN RES, V18, P37; Woischneck D, 1998, ACT NEUR S, V71, P138; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P405; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	43	38	39	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	FEB	2001	34	2					98	103		10.1159/000056002			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	420EH	WOS:000167991100007	11287810				2021-06-18	
J	Davey, NJ; Nowicky, AV; Zaman, R				Davey, NJ; Nowicky, AV; Zaman, R			Somatotopy of perceptual threshold to cutaneous electrical stimulation in man	EXPERIMENTAL PHYSIOLOGY			English	Article							2-POINT DISCRIMINATION; NEUROPATHY	Neurological testing tools for measuring and monitoring somatosensory function lack resolution and are often dependent on the clinician testing. In this study we have measured perceptual threshold (PT) to electrical stimulation of the skin and compared it with two-point discriminative ability (TPDA) in 12 control subjects. Tests were made on both sides of the body at American Spinal Injury Association (ASIA) key points on seven spinal dermatomes (C3 (neck), C4 (shoulder), C5 (upper arm), C6 (thumb), T8 (abdomen), L3 (knee), L5 (foot)) and in the mandibular (chin) and maxillary (cheek) fields of the trigeminal (V) nerve. Electrical stimulation (0.5 ms pulse width; 3 Hz) was applied via a self-adhesive cathode and an anode strapped to the wrist or ankle. The stimulus intensity was adjusted and PT was recorded as the lowest current at which the subject reported sensation. Sites were tested in random order. Indices for both TPDA and PT differed according to the dermatome tested but there was no correlation between TPDA and PT for any dermatome. There was good correlation between results from equivalent dermatomes on left and right sides for both PT and TPDA. Women frequently had lower mean (+/- S.E.) PTs and better TPDA than men; differences were significant (P < 0.05) for PT on the knee (women, 1.31 +/- 0.15 mA; men, 2.05 +/- 0.26 mA) and the foot (women, 2.90 +/- 0.19 mA; men, 4.13 +/- 0.28 mA) and for TPDA on the thumb (women, 3.8 +/- 0.2 mm; men, 7.8 +/- 1.3 mm) and the knee (women, 17.8 +/- 1.6 mm; men, 27.1 +/- 4.0 mm). Four subjects repeated the experiment on another day and the results correlated well with the first test for PT (r(2), 0.62) and TPDA (r(2), 0.48). PT differs between dermatomes in a predictable way but does not relate to TPDA. PT is easy to measure and may be a useful assessment tool with which to monitor recovery or deterioration in neuropathies, neurotrauma or after surgery.	Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England; Brunel Univ, Dept Sport Sci, London TW7 5DU, England	Davey, NJ (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England.		Nowicky, Alexander/AAI-7299-2020	Nowicky, Alexander/0000-0001-8955-4349			Aszmann OC, 1998, J RECONSTR MICROSURG, V14, P417, DOI 10.1055/s-2007-1000202; Chu NS, 1996, MUSCLE NERVE, V19, P183, DOI 10.1002/(SICI)1097-4598(199602)19:2<183::AID-MUS9>3.0.CO;2-A; DELLON AL, 1987, J HAND SURG-AM, V12A, P693, DOI 10.1016/S0363-5023(87)80049-7; DONAGHUE VM, 1995, DIABETES RES CLIN PR, V29, P37, DOI 10.1016/0168-8227(95)01107-O; IRNICH W, 1989, BIOMED TECH, V34, P207, DOI 10.1515/bmte.1989.34.9.207; Kozarski J, 1999, Vojnosanit Pregl, V56, P599; Lincoln N. B., 1991, CLIN REHABIL, V5, P273, DOI DOI 10.1177/026921559100500403; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MERCHUT M P, 1990, Electromyography and Clinical Neurophysiology, V30, P293; PITEI DL, 1994, DIABETIC MED, V11, P872, DOI 10.1111/j.1464-5491.1994.tb00371.x; RENDELL MS, 1989, DIABETES CARE, V12, P636, DOI 10.2337/diacare.12.9.636; SHIMOKATA H, 1995, GERONTOLOGY, V41, P267; Takekuma K, 2000, J Epidemiol, V10, pS33; Zamyslowska-Szmytke Ewa, 1995, Medycyna Pracy, V46, P47	14	38	39	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0958-0670			EXP PHYSIOL	Exp. Physiol.	JAN	2001	86	1					127	130		10.1113/eph8602086			4	Physiology	Physiology	401EJ	WOS:000166914100016	11434326	Bronze			2021-06-18	
J	Green, P; Iverson, GL				Green, P; Iverson, GL			Effects of injury severity and cognitive exaggeration on olfactory deficits in head injury compensation claims	NEUROREHABILITATION			English	Article						olfaction; neuropsychological assessment; brain injury; anosmia	IMPAIRMENT	The purpose of this study was to examine the relationship between exaggeration and scores on a test of olfactory discrimination in patients being assessed in connection with a claim for financial benefits. Participants were 448 patients referred to a private practice in Edmonton, Alberta, Canada for psychological or neuropsychological assessment, related to evaluation of impairment and disability resulting from a work-related or non-work related accident. All patients were involved in some form of compensation claim at the time of their evaluation. All patients completed two tests designed to detect exaggerated cognitive deficits, the Computerized Assessment of Response Bias (CARB) and the Word Memory Test (WMT) as part of their evaluation, The diagnostic groups included 322 head injury cases, varying from very minor to very severe. Normative data for the smell test were derived from 126 patients with orthopedic injuries who passed both the CARB and the WMT Patients with more severe traumatic brain injuries were 10-12 times more likely to have olfactory deficits than persons with trivial to mild head injuries, In a subgroup of patients who failed either the CARB or the WMT, there was no relationship between injury severity and total scores on the smell test. Therefore, the dose-response relationship between brain injury severity and olfactory deficits is severely attenuated when patients who are probably exaggerating their cognitive deficits are included in the analyses, Those patients with trivial to mild head injuries who demonstrated adequate effort on both the CARB and the WMT were no more likely to show olfactory deficits than the non-head-injured orthopedic control subjects. Therefore, anosmia following mild traumatic brain injury should not be concluded from self-reports or from tests of smell unless tests of effort have been passed. Effort should also be controlled in group studies of olfaction.	Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Green, P (corresponding author), Neurobiohav Associates, Suite 201,17107-107 Ave, Edmonton, AB T5S 1G3, Canada.			Iverson, Grant/0000-0001-7348-9570			ALLEN LM, 1999, S CARB WMT MANUALS; CONDOR R, 1992, COMPUTERIZED ASSESSM; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; Cox, 1997, MANUAL COMPUTERIZED; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P55; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Green P, 1998, ARCH CLIN NEUROPSYCH, V13, P138; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 1999, S CARB WMT MANUALS; GREEN P, 1997, NATL ACAD NEUROPSYCH; GREEN P, IN PRESS CLIN NEUROP; Green P., 1996, WORD MEMORY TEST USE; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; POURMAND R, 1999, PRACTICING NEUROLOGY; Reynolds CR, 1998, CRIT ISS NE, P261; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P839; ROHLING ML, IN PRESS ARCH CLIN N; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; van der Werf SP, 2000, NEUROPSY NEUROPSY BE, V13, P199; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745	25	38	40	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2001	16	4					237	243					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	521VC	WOS:000173861200008	11790910				2021-06-18	
J	Jurado, MA; Mataro, M; Verger, K; Bartumeus, F; Junque, C				Jurado, MA; Mataro, M; Verger, K; Bartumeus, F; Junque, C			Phonemic and semantic fluencies in traumatic brain injury patients with focal frontal lesions	BRAIN INJURY			English	Article							DAMAGED RIGHT-HANDERS; VERBAL-FLUENCY; WORD FLUENCY; LOBE; DEMENTIA; CORTEX; FMRI; PET	The purpose of this study was to investigate the effect of focal frontal lesions, identified by magnetic resonance imaging (MRI), in a group of traumatic brain injured (TBI) patients, in order to clarify the sensitivity of phonemic and semantic fluency tasks as tests of frontal lobe functioning. Thirteen TBI patients were included and matched with a normal control group of 26 subjects. Frontal lobe patients produced significantly fewer words than the control group in the phonemic fluency condition. Semantic performance correlated with lesion size, but phonemic performance did not, corroborating the idea that the two have different brain-based substrates. Although, as a group effect, frontal lesions impaired fluency, not all patients were impaired, even in the presence of large bilateral frontal lesions.	Univ Barcelona, Fac Psicol, Dept Psiquiatria & Psicobiol Clin, Barcelona 08035, Spain; St Pau Hosp, Barcelona, Spain	Jurado, MA (corresponding author), Univ Barcelona, Fac Psicol, Dept Psiquiatria & Psicobiol Clin, Passeig Vall Dhebron 171, Barcelona 08035, Spain.		Junque, Carme/B-4400-2011; JURADO, MARIA ANGELES/E-1745-2011; Mataro, Maria/B-4524-2011	Junque, Carme/0000-0002-6381-3063; JURADO, MARIA ANGELES/0000-0002-9403-1670; Mataro, Maria/0000-0002-9946-2656			Barr A, 1996, J CLIN EXP NEUROPSYC, V18, P810, DOI 10.1080/01688639608408304; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BOIVIN MJ, 1992, CORTEX, V28, P231, DOI 10.1016/S0010-9452(13)80051-2; Crossley M, 1997, J CLIN EXP NEUROPSYC, V19, P52, DOI 10.1080/01688639708403836; Damasio H., 1989, LESION ANAL NEUROPSY; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; Goulet P, 1997, NEUROPSYCHOLOGIA, V35, P1565, DOI 10.1016/S0028-3932(97)00081-X; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; JOANETTE Y, 1988, BRAIN LANG, V34, P54, DOI 10.1016/0093-934X(88)90124-1; JOANETTE Y, 1986, NEUROPSYCHOLOGIA, V24, P875, DOI 10.1016/0028-3932(86)90087-4; Jurado MA, 1997, NEUROPSYCHOLOGIA, V35, P635, DOI 10.1016/S0028-3932(96)00112-1; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MARTIN A, 1994, NEUROPSYCHOLOGIA, V32, P1487, DOI 10.1016/0028-3932(94)90120-1; MARTIN RC, 1990, NEUROPSYCHOLOGIA, V28, P823, DOI 10.1016/0028-3932(90)90006-A; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; Milner B, 1964, FRONTAL GRANULAR COR, P313; Newcombe F., 1969, MISSILE WOUNDS BRAIN; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; PENDLETON MG, 1982, J CLIN NEUROPSYCHOL, V4, P307, DOI 10.1080/01688638208401139; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phelps EA, 1997, NEUROREPORT, V8, P561, DOI 10.1097/00001756-199701200-00036; Pujol J, 1996, ACTA NEUROL SCAND, V93, P403; RAMIER AM, 1970, REV NEUROL, V123, P17; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; WECHSLER D, 1976, ESCALA INTELIGENCIA	27	38	41	0	2	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2000	14	9					789	795					7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357YT	WOS:000089530300003	11030453				2021-06-18	
J	Stover, JF; Unterberg, AW				Stover, JF; Unterberg, AW			Increased cerebrospinal fluid glutamate and taurine concentrations are associated with traumatic brain edema formation in rats	BRAIN RESEARCH			English	Article						amino acid; cell swelling; controlled cortical impact injury; excitotoxicity; high-performance liquid chromatography; volume-regulation	EXCITATORY AMINO-ACIDS; CORTICAL EXTRACELLULAR LEVELS; HIPPOCAMPAL SLICES; CONTUSION TRAUMA; CEREBRAL-CORTEX; IMPACT INJURY; RELEASE; BARRIER; ASTROCYTES; DISRUPTION	Glutamate-mediated excitotoxicity results in cell swelling and contributes to brain edema formation. Since increased extracellular taurine reflects glutamate-induced cell swelling in vitro, elevated CSF taurine could therefore unmask glutamate-mediated cytotoxic edema formation under in vivo conditions. For this, the temporal profile of brain edema and changes in cisternal CSF glutamate and taurine levels were determined in 28 rats following focal traumatic brain injury. Compared to six non-traumatized rats, CSF glutamate (4.8+/-0.3 vs. 10+/-0.9 mu M) and taurine levels (12+/-1.3 vs. 41+/-3 mu M) were significantly increased at 8 h after trauma (P<0.001). Over time, CSF glutamate and taurine were significantly increased by 24 (glutamate: 38+/-4.4 mu M) and 48 h (taurine: 51+/-4 mu M), respectively. While CSF glutamate closely reflected changes in hemispheric water content, alterations in CSF taurine occurred diametrically to those seen for glutamate. Under the present study design, increased CSF taurine could reflect glutamate-induced cell swelling. In addition, neuronal release of taurine with its inhibitory and antiexcitotoxic functions could explain the observed diametric changes in CSF glutamate, CSF taurine, and hemispheric water content. Therefore, increasing taurine could be a therapeutic approach in attenuating post-traumatic glutamate-mediated cell damage. (C) 2000 Elsevier Science B,V. All rights reserved.	Charite Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany	Stover, JF (corresponding author), Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 01, D-13353 Berlin, Germany.	john.stover@charite.de					Baskaya MK, 1997, NEUROSCI LETT, V226, P33; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; French E D, 1986, Adv Exp Med Biol, V203, P349; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HOLOPAINEN I, 1989, NEUROSCIENCE, V29, P425, DOI 10.1016/0306-4522(89)90069-9; KAMISAKI Y, 1993, BRAIN RES, V627, P181; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1992, BRAIN RES, V577, P121, DOI 10.1016/0006-8993(92)90544-J; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; KURIYAMA K, 1980, FED PROC, V39, P2680; MADL JE, 1993, J NEUROSCI, V13, P4429; MAGNUSSON KR, 1991, BRAIN RES, V549, P1, DOI 10.1016/0006-8993(91)90592-J; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; MENENDEZ N, 1989, NEUROSCI LETT, V102, P64, DOI 10.1016/0304-3940(89)90308-X; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OJA SS, 1983, ACTA NEUROL SCAND, V67, P5; OKAMOTO K, 1983, BRAIN RES, V265, P163, DOI 10.1016/0006-8993(83)91350-1; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PASANTESMORALES H, 1990, GLIA, V3, P427, DOI 10.1002/glia.440030514; Saransaari P, 1999, NEUROSCIENCE, V94, P949, DOI 10.1016/S0306-4522(99)00384-X; SARANSAARI P, 1991, NEUROSCIENCE, V45, P451, DOI 10.1016/0306-4522(91)90240-O; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SCHURR A, 1987, LIFE SCI, V40, P2059, DOI 10.1016/0024-3205(87)90098-1; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Stroop R, 1998, ACT NEUR S, V71, P303; TABER KH, 1986, BRAIN RES, V386, P113, DOI 10.1016/0006-8993(86)90147-2; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; ZUCCARELLO M, 1993, J NEUROTRAUM, V10, P397, DOI 10.1089/neu.1993.10.397	38	38	38	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2000	875	1-2					51	55		10.1016/S0006-8993(00)02597-X			5	Neurosciences	Neurosciences & Neurology	352DM	WOS:000089199300006	10967298				2021-06-18	
J	Lang, EW; Chesnut, RM				Lang, EW; Chesnut, RM			A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic brain injury patients	BRITISH JOURNAL OF NEUROSURGERY			English	Article						autoregulation; blood pressure; cerebral perfusion pressure; cerebrovascular circulation; data acquisition; individual therapy; intracranial pressure; monitoring; traumatic brain injury	SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; AUTO-REGULATION; PLATEAU WAVES; VOLUME; HYPERTENSION; METABOLISM; MANAGEMENT	To avoid ischaemic secondary insults after severe head injury (SHI) it would be helpful to know the relationship between cerebral perfusion pressure (CPP) and intracranial pressure (ICP). Static cerebrovascular autoregulation (AR) was tested in 14 patients after SHI. Mean arterial pressure (MAP) was varied to detect changes in intracranial pressure (ICP) indicative of intact AR. Three types of responses were observed: (1) MAP elevation causes an increase in ICP; (2) MAP elevation has no or very little effect on ICP; (3) MAP elevation lowers ICP; Changes between types 1/2 and type 3 suggests AR breakpoints. Varying response types and breakpoints were observed between and within patients. Lower AR breakpoints were seen from 60 to 80 mmHg CPP, upper breakpoints were as high as 112. CPP monitoring achieves a twofold utility in targeted therapy: (1) defining the range of intact AR; and (2) lower AR breakpoint assessment to avoid secondary insults. Although the precise relationship between pAR breakpoints and the adequacy of cerebral perfusion to meet metabolic needs remains unclear, a technique such as described here is simple and has much to offer in targeting therapy toward specific pathophysiological processes in traumatic brain injury.	Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA; San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94110 USA	Lang, EW (corresponding author), Dept Neurosurg, Weimarer Str 8, D-24106 Kiel, Germany.	lange@nch.uni-kiel.de		Chesnut, Randall/0000-0001-6377-3666			BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1996, GUIDELINES MANAGEMEN; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; CZOSNYKA M, 1994, ACTA NEUROCHIR, V126, P113, DOI 10.1007/BF01476419; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; DeWitt D S, 1995, New Horiz, V3, P376; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; Halliday A, 1996, CRIT CARE MED, V24, P1273, DOI 10.1097/00003246-199607000-00039; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; JONES KC, 1994, J HOME HLTH CARE PRA, V6, P1; KONTOS HA, 1985, ANN BIOMED ENG, V13, P329, DOI 10.1007/BF02584251; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Magi E, 1996, CRIT CARE MED, V24, P1275, DOI 10.1097/00003246-199607000-00041; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NAU R, 1992, CLIN NEUROL NEUROSUR, V94, P143, DOI 10.1016/0303-8467(92)90071-A; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROSNER MJ, 1994, INTRACRANIAL PRESSUR, V9, P222; ROSNER MJ, 1993, NEUROSURGICAL INTENS, V30, P57; Schneck MJ, 1998, CRIT CARE MED, V26, P1787, DOI 10.1097/00003246-199811000-00012; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; TEASDALE G, 1974, LANCET, V2, P81; TSUTSUME H, 1986, INTRACRANIAL PRESSUR, V5, P661; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459	48	38	40	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	APR	2000	14	2					117	126					10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	316NC	WOS:000087172700006	10889883				2021-06-18	
J	Homayoun, P; Parkins, NE; Soblosky, J; Carey, ME; de Turco, EBR; Bazan, NG				Homayoun, P; Parkins, NE; Soblosky, J; Carey, ME; de Turco, EBR; Bazan, NG			Cortical impact injury in rats promotes a rapid and sustained increase in polyunsaturated free fatty acids and diacylglycerols	NEUROCHEMICAL RESEARCH			English	Article						arachidonic acid; diacylglycerols; docosahexaenoic acid; free fatty acids; phospholipase A(2); phospholipase C; traumatic brain injury	EXPERIMENTAL BRAIN INJURY; CYTOSOLIC PHOSPHOLIPASE A(2); INDUCED STATUS EPILEPTICUS; NERVOUS-SYSTEM; ARACHIDONIC-ACID; BOVINE BRAIN; ELECTROCONVULSIVE SHOCK; SUBCELLULAR-FRACTIONS; DOCOSAHEXAENOIC ACID; FOREBRAIN ISCHEMIA	Neurotrauma activates the release of membrane phospholipid-derived second messengers, such as free arachidonic acid (20:4n-6, AA) and diacylglycerols (DAGs). In the present study, we analyze the effect of cortical impact injury of low-grade severity applied to the rat frontal right sensory motor cortex (FRC) on the accumulation of free fatty acids (FFAs) and DAGs in eight brain areas 30 min and 24 hours after the insult. At these times, accumulation of FFAs and DAGs occurred mainly in the damaged FRC. The cerebellum was the only other brain area that displayed a significant accumulation of DAGs by day one post-injury. By 30 min, accumulation of free AA in the FRC displayed the greatest relative increase (300% over sham value), followed by foe docosahexaenoic acid (22:6n-3, DHA, 150%), while both 20:4-DAGs and 22:6-DAGs were increased 100% over sham values. At day one, free 22:6 and 22:6-DAGs showed the greatest increase (590% and 230%, respectively). These results suggest that TBI elicits the hydrolysis of phospholipids enriched in excitable membranes, targeting early on 20:4-phospholipids (by 30 min post- trauma) and followed 24 hours later by preferential hydrolysis of DHA-phospholipids. These lipid metabolic changes may contribute to the initiation and maturation of neuronal and fiber track degeneration observed following cortical impact injury.	Louisiana State Univ, Neurosci Ctr Execellence, Hlth Sci Ctr, New Orleans, LA 70112 USA; Dept Neurosurg, New Orleans, LA USA	Bazan, NG (corresponding author), Louisiana State Univ, Neurosci Ctr Execellence, Hlth Sci Ctr, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444			AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; Bazan N G, 1980, Adv Neurol, V28, P197; BAZAN NG, 1993, PROG BRAIN RES, V96, P247; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1971, ACTA PHYSIOL LAT AM, V21, P101; BAZAN NG, 1995, J NEUROTRAUM, V12, P789; BAZAN NG, 1990, LIPID MEDIATORS ISCH, P277; BENISTANT C, 1995, J LIPID RES, V36, P2311; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; Bonventre JV, 1996, J LIPID MEDIAT CELL, V14, P15, DOI 10.1016/0929-7855(96)00503-2; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COTMAN C, 1969, BIOCHEMISTRY-US, V8, P4606, DOI 10.1021/bi00839a056; DETURCO EBR, 1983, J NEUROCHEM, V40, P252, DOI 10.1111/j.1471-4159.1983.tb12679.x; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; FAROOQUI AA, 1992, ADV EXP MED BIOL, V318, P11; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; GOTO Y, 1988, STROKE, V19, P728, DOI 10.1161/01.STR.19.6.728; HAYES RL, 1991, CENTRAL NERVOUS SYST, P9; Homayoun P, 1997, J NEUROCHEM, V69, P199; HOMAYOUN P, 1988, J NEUROCHEM, V51, P45, DOI 10.1111/j.1471-4159.1988.tb04833.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Lecomte M, 1996, J NEUROCHEM, V66, P2160; MARCHESELLI VL, 1990, J NUTR BIOCHEM, V1, P382, DOI 10.1016/0955-2863(90)90009-A; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OWADA Y, 1994, MOL BRAIN RES, V25, P364, DOI 10.1016/0169-328X(94)90174-0; PETE MJ, 1994, J BIOL CHEM, V269, P19494; Pete MJ, 1996, J BIOL CHEM, V271, P18114, DOI 10.1074/jbc.271.30.18114; Pete MJ, 1996, BBA-LIPID LIPID MET, V1299, P325, DOI 10.1016/0005-2760(95)00225-1; POLITI LE, 1985, NEUROCHEM PATHOL, V3, P249; Rabin O, 1997, J NEUROCHEM, V68, P2111; Rabin O, 1998, J NEUROCHEM, V70, P325; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; REDDY TS, 1984, EUR J BIOCHEM, V145, P21, DOI 10.1111/j.1432-1033.1984.tb08517.x; REDDY TS, 1985, J NEUROSCI RES, V13, P381, DOI 10.1002/jnr.490130305; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SUN GY, 1972, BIOCHIM BIOPHYS ACTA, V280, P306, DOI 10.1016/0005-2760(72)90098-7; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VISIOLI F, 1993, J NEUROCHEM, V61, P1835, DOI 10.1111/j.1471-4159.1993.tb09824.x; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOELK H, 1973, H-S Z PHYSIOL CHEM, V354, P90, DOI 10.1515/bchm2.1973.354.1.90	59	38	40	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	FEB	2000	25	2					269	276		10.1023/A:1007583806138			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	305PW	WOS:000086550300013	10786712				2021-06-18	
J	Whyte, J; Schuster, K; Polansky, M; Adams, J; Coslett, HB				Whyte, J; Schuster, K; Polansky, M; Adams, J; Coslett, HB			Frequency and duration of inattentive behavior after traumatic brain injury: Effects of distraction, task, and practice	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain injuries; attention; distraction	CLOSED-HEAD-INJURY; ATTENTION; AROUSAL; SCALE; COMA	Traumatic brain injury (TBI) is associated with impairments of attention, most typically measured through tests of information processing, or by subjective symptom endorsement by patients, families, and clinicians. We have previously shown increased rates of off-task behavior among patients with TBI versus controls as defined by videotaped records of independent work in distracting environments. In this research, we report on a more detailed method of coding such videotaped records which allows measurement of the precise number of off-task behaviors, their durations, and their relationship to distracting events. Using this method, we studied 20 patients with recent moderate-to-severe TBI and 20 demographically comparable controls as they performed independent work tasks while being subjected to controlled distracting events. This research confirms that patients are markedly less attentive than controls both in the presence of distractions and in their absence, that distractions have an influence on off-task behavior in both groups, and that the disruptive impact of distracters wanes relatively quickly for controls but not for patients. The duration of distraction produced by various classes of distracting events appeared similar for patients and controls, although the power to detect differences in behavioral duration between groups was limited. The pattern of inattentiveness among patients showed minimal relationship to measures of injury severity within this sample.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA; Allegheny Univ Hlth Sci, Sch Publ Hlth, Philadelphia, PA 19102 USA; Drexel Univ, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Neurol, Philadelphia, PA 19122 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27715] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027715] Funding Source: NIH RePORTER		AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; LEVIN HS, 1989, COMPREHENSIVE NEUROL, V2, P53; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt H. L., 1992, SENSORS COMPREHENSIV, V3, P717; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; TEASDALE G, 1974, LANCET, V2, P81; *TRIANGL RES COLL, 1995, OBS COD SYST TOOLS V; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WHYTE J, 1994, AM J PHYS MED REHAB, V73, P2; Whyte J, 1998, REHABILITATION MED P, P1191	20	38	38	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2000	6	1					1	11		10.1017/S1355617700611013			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	276KD	WOS:000084876200001	10761362				2021-06-18	
J	Schootman, M; Fuortes, L				Schootman, M; Fuortes, L			Functional status following traumatic brain injuries: population-based rural-urban differences	BRAIN INJURY			English	Article							HEAD-INJURY; OUTCOMES; REHABILITATION; DISABILITY	Many studies have described functional outcomes following traumatic brain injury (TBI), but few have attempted to contrast differences in functional status and receipt of services of persons residing in rural and urban counties. Persons hospitalized with TBI completed a self-administered survey 1-1.5 years after their injury. Survivors of TBI in rural areas were more likely to be functionally dependent and reported a lower health status than their urban counterparts. Additionally, those who did not receive any TBI-related services but perceived an additional service need were more likely to be functionally dependent than those who received services and did not perceive any additional need. Perceived service needs of those functionally dependent are described. Further investigations into this rural-urban difference are warranted to maximize functional status following TBI for all individuals.	Bur Injury & Disabil Prevent, Des Moines, IA USA; Univ Iowa, Iowa City, IA USA	Schootman, M (corresponding author), Washington Univ, Div Hlth Behav Res, Campus Box 8504,4444 Forest Pk Ave,Suite 6700, St Louis, MO 63108 USA.	mschootm@im.wustl.edu	Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824	FDA HHS [CFDA 93.234A] Funding Source: Medline		DIRMEN S, 1993, BRAIN INJURY, V7, P113; GOLDSTEIN MS, 1984, AM J PUBLIC HEALTH, V74, P611, DOI 10.2105/AJPH.74.6.611; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; IDLER EL, 1991, J GERONTOL, V46, pS55, DOI 10.1093/geronj/46.2.S55; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; KILGORE KM, 1995, ARCH PHYS MED REHAB, V76, pSC21; LOLLAR DJ, 1994, P REC S 17 19 FEBR C; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schootman M, 1998, BIOM HLTH R, V21, P73; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Torner James C., 1996, P19; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	16	38	38	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1999	13	12					995	1004					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600005	10628504				2021-06-18	
J	Faden, AI; Fox, GB; Fan, L; Araldi, GL; Qiao, LX; Wang, SM; Kozikowski, AP				Faden, AI; Fox, GB; Fan, L; Araldi, GL; Qiao, LX; Wang, SM; Kozikowski, AP			Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						brain trauma cell culture; neuroprotection rodent brain injury models; thyrotropin-releasing hormone analogs	THYROTROPIN-RELEASING-HORMONE; SPINAL-CORD INJURY; DOSE-RESPONSE; RAT; YM-14673; NALOXONE; DEXAMETHASONE; HYPOTENSION; CATS	Thyrotropin-releasing hormone (TRH) and certain TRH analogs show substantial neuroprotective effects in experimental brain or spinal cord trauma but also have other physiological actions (autonomic, analeptic, and endocrine) that may be undesirable for the treatment of neurotrauma in humans. We developed a novel TRH analog (2-ARA-53a), with substitutions at the NH2-terminus and imidazole ring, that preserves the neuroprotective action of TRH-like compounds while decreasing or eliminating their autonomic, analeptic, and endocrine effects. Rats administered 2-ARA-53a (1.0 mg/kg, n = 17) intravenously 30 min after lateral fluid percussion brain injury showed marked improvement in motor recovery compared with vehicle-treated controls (n = 14). Treatment of mice subjected to moderate controlled cortical impact brain injury, at the same dose and time after trauma (n = 8), improved both motor recovery and cognitive performance in a water maze place learning task compared with vehicle-treated controls (n = 8). In injured rats, no autonomic or analeptic effects were observed with this compound, and endocrine effects were significantly reduced with 2-ARA-53a, in contrast to those found with a typical NH2-terminal-substituted TRH analog (YM-14673). These findings demonstrate that the neuroprotective effects of TRH-related compounds can be dissociated from their other major physiological actions and suggest a potential role for dual-substituted TRH analogs in the treatment of clinical neurotrauma.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu					AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; BASSIRI RM, 1981, J CLIN INVEST, V52, P16316; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; CEYLAN S, 1992, RES EXP MED, V192, P23, DOI 10.1007/BF02576254; CEYLAN S, 1990, RES EXP MED, V190, P111, DOI 10.1007/PL00020013; DeWitt DS, 1997, J NEUROTRAUM, V14, P931, DOI 10.1089/neu.1997.14.931; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KIEFFER JD, 1974, ACTA ENDOCRINOL-COP, V76, P495; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; OLSON GL, 1995, J MED CHEM, V38, P2866, DOI 10.1021/jm00015a009; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Povlishock JT., 1996, NEUROTRAUMA, P1325; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; RENAUD LP, 1979, SCIENCE, V205, P1275, DOI 10.1126/science.224461; TAKAMI K, 1991, JPN J PHARMACOL, V57, P405, DOI 10.1254/jjp.57.405; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; WANG GL, 1991, CHINESE MED J-PEKING, V104, P939	38	38	38	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	OCT	1999	277	4					R1196	R1204					9	Physiology	Physiology	259XR	WOS:000083919700034					2021-06-18	
J	Morgan, AS; Mackay, LE				Morgan, AS; Mackay, LE			Causes and complications associated with swallowing disorders in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aspiration; dysphagia; pneumonia; severe brain injury; swallowing impairment	PROLONGED INTUBATION; ASPIRATION PNEUMONIA; EARLY TRACHEOSTOMY; AIRWAY MANAGEMENT; HEAD-INJURY; DYSFUNCTION; VENTILATION; SAFE	A major complication commonly seen in persons with severe brain injury is swallowing dysfunction. The neuropathology leading to impaired swallowing is discussed. In addition, Other risk factors associated with dysfunctional swallowing, such as tracheostomy and the need for prolonged ventilatory support, are discussed. Within the intensive care environment, the consequences of impaired swallowing leading to aspiration-a major cause of pneumonia-are discussed.	St Francis Hosp & Med Ctr, Dept Surg, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Trauma Serv, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Otolaryngol Sect, Farmington, CT USA	Morgan, AS (corresponding author), St Francis Hosp & Med Ctr, Dept Surg, 114 Woodland St, Hartford, CT 06105 USA.						AASS AS, 1975, ACTA ANAESTH SCAND, V19, P127, DOI 10.1111/j.1399-6576.1975.tb05232.x; BARBA CA, 1995, SURGERY, V118, P879, DOI 10.1016/S0039-6060(05)80279-X; BLOOMFIELD EL, 1989, CRIT CARE CLIN, V5, P881; BONANNO PC, 1971, ANN SURG, V174, P29, DOI 10.1097/00000658-197107010-00005; BOYD SW, 1992, LARYNGOSCOPE, V102, P559, DOI 10.1288/00005537-199205000-00015; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; CRAVEN DE, 1982, NEW ENGL J MED, V306, P1505, DOI 10.1056/NEJM198206243062501; CRAVEN DE, 1984, AM REV RESPIR DIS, V129, P625; CUNNINGHAM ET, 1991, NORMAL ABNORMAL SWAL; DANE TEB, 1975, CHEST, V67, P398, DOI 10.1378/chest.67.4.398; DEPASO WJ, 1991, CLIN CHEST MED, V12, P269; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; FRIMAN L, 1976, ANAESTHESIA, V31, P479, DOI 10.1111/j.1365-2044.1976.tb12353.x; GARDNER AMN, 1958, Q J MED, V27, P227; Groher ME, 1992, DYSPHAGIA DIAGNOSIS; Hagen C, 1981, TOP LANG DIS, V1, P73; HOCKMAN CH, 1979, PROG NEUROBIOL, V12, P15, DOI 10.1016/0301-0082(79)90009-1; HSIEH AH, 1992, AM REV RESP, V146, P20; KHAWAJA IT, 1992, POSTGRAD MED, V92, P165; KLINGBEIL GEG, 1988, ARCH PHYS MED REHAB, V69, P493; LANZA DC, 1990, LARYNGOSCOPE, V100, P958; LAW JH, 1993, CHEST, V104, P136, DOI 10.1378/chest.104.1.136; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; LESNIK I, 1992, AM SURGEON, V58, P346; MACKAY L, 1993, DYSPHAGIA, V8, P161; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; MACKAY LE, 1997, MAXIMIZING BRAIN INJ; Martner J, 1975, Acta Physiol Scand Suppl, V425, P1; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MILLER JD, 1984, SURG NEUROL, V22, P186, DOI 10.1016/0090-3019(84)90050-8; NOWAK P, 1987, AM J OTOLARYNG, V8, P91, DOI 10.1016/S0196-0709(87)80030-3; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; REIS DJ, 1973, SCIENCE, V182, P845, DOI 10.1126/science.182.4114.845; RODRIGUEZ JL, 1990, SURGERY, V108, P655; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; STAUFFER J, 1981, AM J MED, V70, P70; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; vanHeurn LWE, 1996, CHEST, V109, P1466, DOI 10.1378/chest.109.6.1466; VEIS SL, 1985, ARCH PHYS MED REHAB, V66, P372; WHILED RE, 1984, LARYNGOSCOPE, V94, P367; WHITED RE, 1979, ANN OTO RHINOL LARYN, V88, P474, DOI 10.1177/000348947908800405; Woratyla S P, 1995, Conn Med, V59, P643	43	38	38	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					454	461		10.1097/00001199-199910000-00006			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600006	10653941				2021-06-18	
J	Zahn, TP; Mirsky, AF				Zahn, TP; Mirsky, AF			Reaction time indicators of attention deficits in closed head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; VISUAL DOMINANCE; SCHIZOPHRENIA; DYSFUNCTION	The nature of deficits in attention in closed head injury (CHI) was studied by three reaction time RT) paradigms given to 20 patients who had a CHI 2 or more years previously and to 25 controls. We studied the effects of temporal uncertainty by varying the length and regularity of the preparatory interval, the effects of stimulus modality uncertainty on simple RT to tones and lights, and the effects of response selection in choice RT. The CHI group showed slower and more variable RT than controls under all conditions. In addition, a long preparatory interval on the preceding trial retarded RT more in the CHI group, and they showed greater effects of stimulus modality uncertainty. Both of these findings suggest a difficulty in shifting attention to unexpected stimuli. These greater effects on RT of variations of attention or preparation in CHI may account for their greater within-subject variability possibly due to frontal lobe damage.	NIMH, Lab Brain & Cognit, Sect Clin & Expt Neuropsychol, Bethesda, MD 20892 USA	Zahn, TP (corresponding author), NIMH, Lab Brain & Cognit, Sect Clin & Expt Neuropsychol, Bldg 10,Room 4C104,10 Ctr Dr,MSC 1366, Bethesda, MD 20892 USA.						BENTON AL, 1962, J NERV MENT DIS, V136, P413; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; COLAVITA FB, 1974, PERCEPT PSYCHOPHYS, V16, P409, DOI 10.3758/BF03203962; COSTA LD, 1962, PERCEPT MOTOR SKILL, V14, P391; Dixon W. J., 1992, BMDP STAT SOFTWARE M; EGETH HE, 1977, PERCEPT PSYCHOPHYS, V22, P77, DOI 10.3758/BF03206083; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; KRISTOFFERSON MW, 1967, J ABNORM PSYCHOL, V72, P388, DOI 10.1037/h0020107; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; NIEMI P, 1981, PSYCHOL BULL, V89, P133, DOI 10.1037/0033-2909.89.1.133; NUECHTERLEIN KH, 1977, SCHIZOPHRENIA BULL, V3, P373, DOI 10.1093/schbul/3.3.373; OLBRICH R, 1972, J NERV MENT DIS, V155, P356; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1976, PSYCHOL REV, V83, P157, DOI 10.1037/0033-295X.83.2.157; RIST F, 1991, HDB SCHIZOPHRENIA, V5, P241; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; SUTTON S, 1961, AM J PSYCHOL, V74, P224, DOI 10.2307/1419407; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VONZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; ZAHN TP, 1991, J ABNORM CHILD PSYCH, V19, P233, DOI 10.1007/BF00909980; Zahn TP, 1998, J ABNORM PSYCHOL, V107, P97, DOI 10.1037/0021-843X.107.1.97; ZAHN TP, 1999, IN PRESS INT J PSYCH	28	38	41	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1999	21	3					352	367		10.1076/jcen.21.3.352.924			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	234FW	WOS:000082474700007	10474174				2021-06-18	
J	Karli, DC; Burke, DT; Kim, HJ; Calvanio, R; Fitzpatrick, M; Temple, D; MacNeil, M; Pesez, K; Lepak, P				Karli, DC; Burke, DT; Kim, HJ; Calvanio, R; Fitzpatrick, M; Temple, D; MacNeil, M; Pesez, K; Lepak, P			Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation	BRAIN INJURY			English	Article							AMANTADINE TREATMENT; SYMPTOMS; PATIENT	Traumatic brain injury poses significant and diverse challenges to rehabilitation efforts. Neurobehavioural deficits represent a particularly difficult barrier to rehabilitative progress and societal reintegration. Early studies have identified dopaminergic drugs such as amantadine, bromocriptine and sinemet as potentially assistive in countering these deficits. To date, side effect profiles have been relatively benign, noted most frequently in small-scale case trials. The case of a 40-year-old patient with bilateral frontal traumatic brain injuries, and previous arteriovenous malformation (AVM) bleed with significant ataxia, dysarthria and neurobehavioural deficits is presented. This ions range study demonstrates, through multiple varied dosing schedules, a trade off between the benefits and side effects of dopaminergic therapy, with implications for a larger brain injury population.	Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; Spaulding Rehabil Hosp, Dept Neuropsychol, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Nursing, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Phys Therapy, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Occupat Therapy, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Dept Speech Therapy, Boston, MA 02114 USA	Burke, DT (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.						Chandler M C, 1988, Brain Inj, V2, P309; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; HORVATH TB, 1974, J NEUROL NEUROSUR PS, V37, P416, DOI 10.1136/jnnp.37.4.416; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WOLF AP, 1995, BRAIN INJURY, V9, P487, DOI 10.3109/02699059509008208	14	38	39	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1999	13	1					63	68		10.1080/026990599121908			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	158TA	WOS:000078131200009	9972445				2021-06-18	
J	Pearce, S; McDonald, S; Coltheart, M				Pearce, S; McDonald, S; Coltheart, M			Interpreting ambiguous advertisements: The effect of frontal lobe damage	BRAIN AND COGNITION			English	Article							CLOSED-HEAD-INJURY; LANGUAGE; DEFICITS; ABILITY; REQUESTS	Despite intact primary language processes patients with frontal lobe deficits often have impaired communication skills including impaired capacity to understand conversational inference. This study examined the ability of three patients with demonstrated frontal lobe pathology to interpret lexically ambiguous advertisements, When compared to a nonbrain-damaged control group it was found that the frontal lobe patients were poorer at comprehending the abstract or inferred meanings inherent in the advertisements. The pattern of performance across the patients did, nevertheless, differ despite a similar end result. These findings are discussed in relation to theories concerning the contribution of the frontal Lobes to language function. (C) 1998 Academic Press.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Royal Brisbane Hosp, Brisbane, Qld 4029, Australia; Macquarie Univ, Dept Psychol, N Ryde, NSW, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Coltheart, Max/0000-0002-6580-0047			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Baddeley A. D., 1990, WORKING MEMORY; Bowden S., 1992, CLIN NEUROPSYCHOL, V6, P43; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Damasio A., 1983, NEUROPSYCHOLOGY HUMA; Heaton R., 1981, MANUAL WISCONSIN CAR; HOLLAND A, 1984, LANGUAGE DISORDERS A; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R, 1973, WORKING BRAIN; Luria A. R., 1976, BASIC PROBLEMS NEURO; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Milner B., 1964, FRONTAL GRANULAR COR; NIPPOLD MA, 1988, J SPEECH HEAR RES, V31, P466, DOI 10.1044/jshr.3103.466; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; RUBENS AB, 1976, STUDIES NEUROLINGUIS; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; Walsh K., 1987, NEUROPSYCHOLOGY CLIN; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; WIIG EH, 1988, NEUROPSYCHOLOGICAL S	34	38	39	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	NOV	1998	38	2					150	164		10.1006/brcg.1998.1018			15	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	137LV	WOS:000076917000003	9853094				2021-06-18	
J	Yablon, SA; Jackson, MS; Meythaler, JM; Birmingham, JD; Englander, JSG				Yablon, SA; Jackson, MS; Meythaler, JM; Birmingham, JD; Englander, JSG		Brain Injury Special Interest Grp Amer Acad Ph	Practice parameter: Antiepileptic drug treatment of posttraumatic seizures	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							POST-TRAUMATIC EPILEPSY; SEVERE BRAIN INJURIES; FOLLOW-UP; PHENYTOIN; CARBAMAZEPINE; PROPHYLAXIS; ANTICONVULSANT; HEAD; PREVENTION; RECURRENCE	The practice of antiepileptic drug (AED) prophylaxis for posttraumatic seizures (PTS) is common, although results of clinical trials raise questions regarding the benefits of such treatment. A subcommittee of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation was impaneled to review published literature regarding AED prophylaxis of PTS and formulate recommendations in the form of a practice parameter. The subcommittee presents the following recommendations: (1) Treatment standard: Prophylactic use of phenytoin (PHT), carbamazepine (CBZ), sodium valproate (VPA), or phenobarbital (PB) is not recommended for preventing late PTS, defined as seizures that occur after 1 week of injury, in the patient in whom there has been no history of seizures following a nonpenetrating traumatic brain injury (TBI). (2) It is recommended as a treatment option that PHT, PB, and CBZ may be used to prevent early PTS in patients at high risk for seizures following TBI. (3) Prophylactic use of PHT, CBZ, VPA, or PB is not recommended for preventing late PTS following penetrating TBI. (C) 1998 by the American Academy of Physical Medicine and Rehabilitation.	Amer Acad Phys Med & Rehabil, Brain Injury Special Interest Grp, Chicago, IL 60611 USA	Yablon, SA (corresponding author), Amer Acad Phys Med & Rehabil, Brain Injury Special Interest Grp, Chicago, IL 60611 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BIRKMAYER W, 1951, Wien Klin Wochenschr, V63, P606; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; BRODIE MJ, 1990, LANCET, V336, P350, DOI 10.1016/0140-6736(90)91886-F; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; DEUTSCHMAN CS, 1985, NEUROSURGERY, V17, P510, DOI 10.1227/00006123-198509000-00021; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; ENGEL J, 1990, SEIZURES EPILEPSY; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GOOCH LAW, 1995, ARCH PHYS MED REHAB, V76, P1041; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; Hoff H, 1947, MON PSYCHIATR NEUROL, V114, P105; JENNETT B, 1990, REHABILITATION ADULT, P89; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kollevold T, 1978, J OSLO CITY HOSP, V28, P78; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MCCARTHY A D, 1991, Archives of Physical Medicine and Rehabilitation, V72, P818; MCNAMARA JO, 1989, ANN NEUROL, V26, P675, DOI 10.1002/ana.410260514; MEADOR KJ, 1993, EPILEPSIA, V34, P153, DOI 10.1111/j.1528-1157.1993.tb02389.x; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P628, DOI 10.1016/S0003-9993(96)90308-1; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; PECHADRE JC, 1991, PRESSE MED, V20, P841; PENRY JK, 1979, NEUROLOGY, V29, P600; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SCHMUTZ M, 1988, J NEURAL TRANSM, V72, P245, DOI 10.1007/BF01243423; SHEUER ML, 1990, NEW ENGL J MED, V323, P1468; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TEMPKIN NR, 1997, EPILEPSIA S8, V38, P102; TURNER IM, 1977, ANN NEUROL, V2, P221, DOI 10.1002/ana.410020307; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; 1986, INT DICT MED BIOL	41	38	40	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					594	597					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500023	9596407				2021-06-18	
J	Wildburger, R; Zarkovic, N; Tonkovic, G; Skoric, T; Frech, S; Hartleb, M; Loncaric, I; Zarkovic, K				Wildburger, R; Zarkovic, N; Tonkovic, G; Skoric, T; Frech, S; Hartleb, M; Loncaric, I; Zarkovic, K			Post-traumatic hormonal disturbances: Prolactin as a link between head injury and enhanced osteogenesis	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						severe head injury; bone fracture healing; growth regulation; hypertrophic callus formation; heterotopic ossifications; PRL; GH; PTH; ACTH; cortisol	FIBROBLAST GROWTH-FACTOR; METABOLIC RESPONSE; SPINAL-CORD; HYPERPROLACTINEMIC AMENORRHEA; MESSENGER-RNA; BRAIN INJURY; IN-VITRO; PITUITARY; TISSUE; STRESS	Traumatic brain injury (TBI) combined with fractures of long bones or large joints is often associated with enhanced osteogenesis (early fracture healing accompanied by hypertrophic callus formation and/or heterotopic ossifications). Humoral factors that cause enhanced osteogenesis in patients with TBI are not yet identified. The aim of this study was to reveal if post-traumatic change(s) of hormone levels in patients with TBI and bone fractures could be associated with the phenomenon of enhanced osteogenesis. The blood values of adrenocorticotropic hormone (ACTH), cortisol, growth hormone (GH), parathyroid hormone (PTH) and prolactin (PRL) were studied weekly over a period of three months after injury in patients with bone fractures only, those with TBI only or combined bone fractures and TBI (patients exerting enhanced osteogenesis). Stress-hormones, ACTH and cortisol, or the hormones related to the bone growth (GH and PTH) did not show any particular post-traumatic changes in the blood of patients with combined injury that could be associated with the enhanced osteogenesis. On the other hand, patients with combined bone fractures and TBI accompanied by enhanced osteogenesis had significantly elevated PRL levels in blood during the 5th week of the pest-traumatic period. Thus, the maximal PRL values were measured at the time when in this group of patients fractures were in consolidation and hypertrophic callus or heterotopic ossifications were developing (as verified by x-ray imaging). Hence, PRL does not only influence physiology of the bone metabolism but also seems to be one of the humoral factors involved in the phenomenon of enhanced osteogenesis in patients with TBI. (C) 1998, Editrice Kurtis.	Graz Univ, Clin Tramatol, A-8036 Graz, Austria; Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia; Horfervit Pharma Gmbh, Oldenburg, Germany; KBC, Fac Med, Dept Neuropathol, Zagreb, Croatia	Wildburger, R (corresponding author), Graz Univ, Clin Tramatol, Auenbruggerpl 7A, A-8036 Graz, Austria.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			ALEXANDER JW, 1993, HOST DEFENSE DYSFUNC, P995; ARNOLD J, 1993, PATHOPHYSIOLOGY SHOC, P145; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cellbio.4.1.551; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; Canalis Ernesto, 1996, P29; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; DEJERINE MME, 1918, ANN MED, V5, P497; DICARLO R, 1992, BRAIN RES, V570, P341, DOI 10.1016/0006-8993(92)90599-5; DIDUCH DR, 1993, J BONE JOINT SURG AM, V75A, P92, DOI 10.2106/00004623-199301000-00012; EMANUELE NV, 1992, MOL ENDOCRINOL, V6, P35, DOI 10.1210/me.6.1.35; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; FIORE CE, 1988, HORM METAB RES, V20, P40, DOI 10.1055/s-2007-1010744; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GREENSPAN SL, 1986, ANN INTERN MED, V104, P777, DOI 10.7326/0003-4819-104-6-777; Hermanussen M, 1995, Arctic Med Res, V54, P45; HUME DM, 1959, ANN SURG, V150, P697, DOI 10.1097/00000658-195910000-00013; JOERRING S, 1992, ARCH ORTHOP TRAUM SU, V111, P265, DOI 10.1007/BF00571521; KJAER A, 1994, EUR J ENDOCRINOL, V131, P391, DOI 10.1530/eje.0.1310391; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; KOH CY, 1993, MOL CELLUALER ENDOCR, V92, P21; KRISHNAMRA N, 1993, BONE MINER, V23, P253, DOI 10.1016/S0169-6009(08)80102-X; LARSEN PJ, 1994, PEPTIDES, V15, P783, DOI 10.1016/0196-9781(94)90030-2; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; MURAYEV OB, 1994, ANESTEZIOL REANIMAT, V5, P14; NAGY E, 1991, ENDOCRINOLOGY, V128, P2776, DOI 10.1210/endo-128-6-2776; PARROTT RF, 1994, RES VET SCI, V56, P234, DOI 10.1016/0034-5288(94)90109-0; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Renner U, 1996, EUR J ENDOCRINOL, V135, P515, DOI 10.1530/eje.0.1350515; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; SCHLECHTE J, 1992, J CLIN ENDOCR METAB, V75, P698, DOI 10.1210/jc.75.3.698; SCHLECHTE J, 1987, J CLIN ENDOCR METAB, V64, P1021, DOI 10.1210/jcem-64-5-1021; SIEGEL JH, 1991, SHOCK SEPSIS ORGAN F, P149; SOBUS KML, 1993, ARCH PHYS MED REHAB, V74, P902; THIEDE MA, 1989, MOL ENDOCRINOL, V3, P1443, DOI 10.1210/mend-3-9-1443; TORRING O, 1993, ACTA ENDOCRINOL-COP, V128, P423; TRABER DL, 1991, SHOCK SEPSIS ORGAN F, P145; WANG YH, 1992, AM J PHYS MED REHAB, V71, P328, DOI 10.1097/00002060-199212000-00004; WEISSMAN C, 1990, ANESTHESIOLOGY, V73, P308, DOI 10.1097/00000542-199008000-00020; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; WILDBURGER R, 1995, MED SCI RES, V223, P219; WILSON DM, 1992, ENDOCRINOLOGY, V131, P2488, DOI 10.1210/en.131.5.2488; WOLFE RR, 1989, DIABETES METAB REV, V5, P149, DOI 10.1002/dmr.5610050205; Zarkovic N, 1996, EUR J CLIN CHEM CLIN, V34, P23; Zellweger R, 1996, J IMMUNOL, V157, P5748	48	38	46	0	1	EDITRICE KURTIS S R L	MILAN	VIA LUIGI ZOJA 30, 20153 MILAN, ITALY	0391-4097			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	FEB	1998	21	2					78	86		10.1007/BF03350319			9	Endocrinology & Metabolism	Endocrinology & Metabolism	ZH579	WOS:000073125600002	9585380				2021-06-18	
J	Scott, JG; Krull, KR; Williamson, DJG; Adams, RL; Iverson, GL				Scott, JG; Krull, KR; Williamson, DJG; Adams, RL; Iverson, GL			Oklahoma Premorbid Intelligence Estimation (OPIE): Utilization in clinical samples	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	22nd Annual Meeting of the International-Neuropsychological-Society	FEB 02-06, 1994	CINCINNATI, OH	Int Neuropsychol Soc			ADULT READING TEST; WAIS-R; DEMOGRAPHIC-VARIABLES; CROSS-VALIDATION; INDEX; PERFORMANCE; UTILITY	The present research is an effort to evaluate a new method of estimating premorbid IQ in which both demographic and current performance methods are utilized in a regression algorithm. Two hundred and twenty-seven patient files from the archives of the University of Oklahoma Health Sciences Center were used to evaluate the Oklahoma Premorbid Intelligence Estimation (OPIE) procedure. This procedure combines both premorbid demographic variables of age, education, occupation, and race with current performance on the WAIS-R Vocabulary and Picture Completion subtests in estimating premorbid IQ. The results are presented for clinical populations including those with dementia, traumatic brain injury, cerebral vascular accident, neoplasm, epilepsy, and a medical control chronic pain group. Results indicate that the OPIE produces a less restricted range of scores than other currently available methods of estimating premorbid IQ without systematic under- or over-estimation of IQ. Considerations for the use of this method with diffuse and cerebrally lateralized populations are discussed.	UNIV HOUSTON,HOUSTON,TX 77004; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA	Scott, JG (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT PSYCHIAT & BEHAV SCI,POB 26901,OKLAHOMA CITY,OK 73190, USA.		Krull, Kevin R/N-3882-2018	Krull, Kevin R/0000-0002-0476-7001; Iverson, Grant/0000-0001-7348-9570			ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BRYAN J, 1992, J CLIN EXPT NEUROPSY, V14, P64; CORRIGAN S, 1991, ARCH CLIN NEUROPSYCH, V17, P323; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EPPINGER MG, 1987, J CONSULT CLIN PSYCH, V55, P86, DOI 10.1037/0022-006X.55.1.86; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; Heaton R.K., 1991, COMPREHENSIVE NORMS; Ivnik R. J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Kareken DA, 1994, PSYCHOL ASSESSMENT, V6, P83, DOI [10.1037/1040-3590.6.2.83, DOI 10.1037/1040-3590.6.2.83]; KLESGES R E C, 1981, Clinical Neuropsychology, V3, P32; KLESGES RC, 1987, INT J CLIN NEUROPSYC, V9, P1; Krull K R, 1995, Appl Neuropsychol, V2, P35, DOI 10.1207/s15324826an0201_6; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Mitchell AJ, 2008, CLIN NEUROPSYCHOL, V79, P1386, DOI DOI 10.1080/13854049208401878; MORTENSEN EL, 1991, J CLIN EXP NEUROPSYC, V13, P361, DOI 10.1080/01688639108401050; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; SHERER M, 1994, ARCH CLIN NEUROPSYCH, V9, P427, DOI 10.1016/0887-6177(94)90005-1; SILVERSTEIN AB, 1987, J CLIN PSYCHOL, V43, P493, DOI 10.1002/1097-4679(198709)43:5<493::AID-JCLP2270430511>3.0.CO;2-V; SWEET JJ, 1990, PSYCHOL ASSESSMENT J, V2, P41; Wechsler D., 1958, MEASUREMENT APPRAISA; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINS AN, 1993, CLIN NEUROPSYCHOL, V7, P70; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	28	38	38	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1997	11	2					146	154		10.1080/13854049708407043			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	XE119	WOS:A1997XE11900005					2021-06-18	
J	Betz, P; Puschel, K; Miltner, E; Lignitz, E; Eisenmenger, W				Betz, P; Puschel, K; Miltner, E; Lignitz, E; Eisenmenger, W			Morphometrical analysis of retinal hemorrhages in the shaken baby syndrome	FORENSIC SCIENCE INTERNATIONAL			English	Article						shaken baby syndrome; child abuse; retinal hemorrhage; morphometry	CARDIOPULMONARY-RESUSCITATION; CHILD-ABUSE; AUTOPSY FINDINGS; INFANT SYNDROME; HEAD-INJURY; EYES	A morphometrical analysis of retinal hemorrhages was performed in cases of physical child abuse including the shaken baby syndrome and in controls (severe head injury, intravital brain death, non-traumatic intracranial hemorrhage, SIDS including cardiopulmonary resuscitation). The extent of the retinal hemorrhages was significantly different between both groups. In all cases of physical child abuse, massive retinal hemorrhages in at least one eye could be found ranging between a maximum value of 19.2 and 73.2% of the entire retinal area. In contrast, only two cases of the control group (severe head injury with skull fractures and intracranial bleeding following traffic accident or fall) showed slight hemorrhages of 3.33 or 1.18% of the retinal area but only in one eye. Therefore, the results provide evidence that massive intraretinal hemorrhages indicate violent shaking - in particular in association with other signs of physical child abuse.	UNIV HAMBURG,DEPT LEGAL MED,D-20246 HAMBURG,GERMANY; UNIV GREIFSWALD,DEPT LEGAL MED,O-2200 GREIFSWALD,GERMANY	Betz, P (corresponding author), UNIV MUNICH,DEPT LEGAL MED,FRAUENLOBSTR 7A,D-80337 MUNICH,GERMANY.						BACON CJ, 1978, BRIT MED J, V1, P281, DOI 10.1136/bmj.1.6108.281; BENNETT HS, 1980, CLIN PEDIATR, V19, P633, DOI 10.1177/000992288001900912; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; CAFFEY J, 1974, PEDIATRICS, V54, P396; COLLAN Y, 1983, ACTA STEREOL, V2, P214; DAVID DB, 1994, BRIT J OPHTHALMOL, V78, P234, DOI 10.1136/bjo.78.3.234; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EGGE K, 1980, ACTA OPHTHALMOL, V58, P231; EGGE K, 1981, ACTA OBSTET GYN SCAN, V60, P153; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; GILKES MJ, 1967, LANCET, V2, P468; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; GOETTING MG, 1990, PEDIATRICS, V85, P585; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HERTLE RW, 1990, PEDIATRICS, V86, P649; JAIN BK, 1994, BRIT J OPHTHALMOL, V78, P236, DOI 10.1136/bjo.78.3.236; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; KELLEY JS, 1972, AM J OPHTHALMOL, V74, P278, DOI 10.1016/0002-9394(72)90545-4; KIRSCHNER RH, 1985, AM J DIS CHILD, V139, P873, DOI 10.1001/archpedi.1985.02140110027022; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; MCLELLAN NJ, 1986, ARCH DIS CHILD, V61, P1130, DOI 10.1136/adc.61.11.1130; MORGAN OG, 1945, T OPHTHAL SOC UK, V65, P366; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; MUSHIN A, 1971, BRIT J OPHTHALMOL, V55, P343, DOI 10.1136/bjo.55.5.343; NASHELSKY MB, 1995, AM J FOREN MED PATH, V16, P154, DOI 10.1097/00000433-199506000-00016; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; Sethi S K, 1990, N C Med J, V51, P246; SEZEN F, 1971, BRIT J OPHTHALMOL, V55, P248, DOI 10.1136/bjo.55.4.248; SPAIDE RF, 1987, J CLIN NEURO-OPHTHAL, V7, P108; Terson A, 1926, ANN OCUL, V163, P666; TOMASI LG, 1975, AM J DIS CHILD, P1335; UNTERHARNSCHEID.F, 1993, SPEZIELLE PATHOLOGIS; WEEDN VW, 1990, AM J FOREN MED PATH, V11, P79, DOI 10.1097/00000433-199003000-00012; Weibel E.R., 1979, STEREOLOGICAL METHOD, V1	42	38	39	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAR 5	1996	78	1					71	80		10.1016/0379-0738(95)01866-2			10	Medicine, Legal	Legal Medicine	UC269	WOS:A1996UC26900009	8855047				2021-06-18	
J	Urculo, E; Arrazola, M; Arrazola, M; Riu, I; Moyua, A				Urculo, E; Arrazola, M; Arrazola, M; Riu, I; Moyua, A			Delayed glossopharyngeal and vagus nerve paralysis following occipital condyle fracture - Case report	JOURNAL OF NEUROSURGERY			English	Article						glossopharyngeal nerve; vagus nerve; head injury; occipital condyle fracture	ANATOMY	This report describes a case of delayed glossopharyngeal and vagus nerve paralysis following a closed head injury. A depressed fracture of the occipital condyle was diagnosed using high-resolution computerized tomography (CT) scanning and three-dimensional CT images. Magnetic resonance imaging complemented the study. The anatomical features, mechanisms, diagnosis, and treatment of this unusual lesion are discussed.	POLICLIN GUIPUZCOA, SERV RADIOL NEURORADIOL, E-20011 SAN SEBASTIAN, SPAIN	Urculo, E (corresponding author), POLICLIN GUIPUZCOA, NEUROSURG SERV, PARQUE MIRAMON S-N, E-20011 SAN SEBASTIAN, SPAIN.						ALKER GJ, 1975, RADIOLOGY, V114, P611; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; DEOLIVEIRA E, 1985, SURG NEUROL, V24, P293, DOI 10.1016/0090-3019(85)90042-4; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; DICHIRO GD, 1964, J NEUROSURG, V21, P447, DOI 10.3171/jns.1964.21.6.0447; DICKMAN CA, 1991, J NEUROSURG, V75, P221, DOI 10.3171/jns.1991.75.2.0221; DIETERMANN JL, 1983, TRAUMATOLOGY SKULL B; DOLAN KD, 1979, CRC CR REV DIAGN IM, V12, P101; ELGAMMAL T, 1990, RADIOLOGY DIAGNOSIS, V3; GOLDSTEIN SJ, 1982, SURG NEUROL, V17, P350, DOI 10.1016/0090-3019(82)90308-1; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; Hollerhage H G, 1986, Zentralbl Neurochir, V47, P250; Kretschmann H., 1992, CRANIAL NEUROIMAGING; LANG J, 1991, CLIN ANATOMY POSTERI; MARIANI PJ, 1990, ANN EMERG MED, V19, P1447, DOI 10.1016/S0196-0644(05)82618-6; MENZEL J, 1981, CRANIAL NERVES ANATO; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; RHOTON AL, 1975, J NEUROSURG, V42, P541, DOI 10.3171/jns.1975.42.5.0541; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008	24	38	38	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1996	84	3					522	525		10.3171/jns.1996.84.3.0522			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TW713	WOS:A1996TW71300024	8609569				2021-06-18	
J	BIASCA, N; SIMMEN, HP; BARTOLOZZI, AR; TRENTZ, O				BIASCA, N; SIMMEN, HP; BARTOLOZZI, AR; TRENTZ, O			REVIEW OF TYPICAL ICE-HOCKEY INJURIES - SURVEY OF THE NORTH-AMERICAN NHL AND HOCKEY-CANADA VERSUS EUROPEAN LEAGUES	UNFALLCHIRURG			English	Article								Ice hockey is considerd to be one of the fastest and roughest of all sports. Prospective injury reports of the North American National Hockey League, the Canadian Amateur Hockey Association and of several European teams (UdSSR, CSSR, Sweden and Switzerland) are reviewed to evaluate the patterns, anatomic locations, circumstances and sequelae of ice hockey-related injuries. Although different injury reporting systems are used in North America and Europe, knee injuries (sprains of the collateral ligaments) accounted for the majority of games missed (40%), followed by injuries to the shoulder (dislocation, acromio-clavicular joint separation, rotator cuff strain and tears, 20%), the groin (15%), and the back (10%). Mandatory helmets and face masks reduced the number of facial and eye injuries to a quarter from 1972 to 1983. The frequency of only concussion but also cervical spine lesions is increasing. The prevention of head, face, eye and neck injuries should mainly be accomplished by enforcement of current rules (mandatory helmets with face masks) and institution of new rules. Improvement in protective equipment would also have the effect of decreasing the frequency of injuries.		BIASCA, N (corresponding author), UNIV ZURICH HOSP,DEPT SURG,CH-8091 ZURICH,SWITZERLAND.							0	38	38	1	18	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0177-5537			UNFALLCHIRURG	Unfallchirurg	MAY	1995	98	5					283	288					6	Emergency Medicine; Surgery	Emergency Medicine; Surgery	RB436	WOS:A1995RB43600006	7610390				2021-06-18	
J	DUSART, I; MOREL, MP; SOTELO, C				DUSART, I; MOREL, MP; SOTELO, C			PARASAGITTAL COMPARTMENTATION OF ADULT-RAT PURKINJE-CELLS EXPRESSING THE LOW-AFFINITY NERVE GROWTH-FACTOR RECEPTOR - CHANGES OF PATTERN EXPRESSION AFTER A TRAUMATIC LESION	NEUROSCIENCE			English	Article							SPINAL-CORD; CEREBELLUM; IMMUNOREACTIVITY; BANDS; BRAIN	The pattern of expression of p75, the low affinity nerve growth factor receptor, in the adult rat cerebellum and its fate after a traumatic lesion were analysed using immunohistochemical localization of this receptor. A subset of Purkinje cells was immunoreactive for low affinity nerve growth factor receptor in the intact adult cerebellum. These cells were arranged in alternating positive and negative parasagittal compartments along the cerebellar cortex. This pattern of expression had 90% homology with zebrin I. After a traumatic lesion, the specific pattern of expression of zebrin I remained unchanged, whereas the low affinity nerve growth factor receptor pattern changed as early as one day: Purkinje cells near the lesion site, independent of zebrin I staining, became immunoreactive. During the first week, the increase in immunoreactivity remained high. Thereafter, there was a short, fast decrease followed by a long period in which a faint immunostaining on lesioned Purkinje cells is maintained for up to one year. The increase in the expression of the low affinity nerve growth factor receptor by all traumatically affected Purkinje cells suggests a correlation between this specific up-regulation and the high resistance of these neurons to axotomy or other traumatic injuries.		DUSART, I (corresponding author), HOP LA PITIE SALPETRIERE,INSERM,U106,47 BLVD HOP,F-75651 PARIS 13,FRANCE.			Dusart, Isabelle/0000-0002-3211-4323; Sotelo, Constantino/0000-0001-8051-2492			ARMSTRONG DM, 1987, J COMP NEUROL, V264, P421, DOI 10.1002/cne.902640309; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COHENCORY S, 1989, EXP NEUROL, V105, P104, DOI 10.1016/0014-4886(89)90177-5; DAVIES AM, 1994, NATURE, V368, P193, DOI 10.1038/368193a0; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; GAGE FH, 1989, NEURON, V2, P1177, DOI 10.1016/0896-6273(89)90184-0; GORENSTEIN C, 1987, BRAIN RES, V418, P68, DOI 10.1016/0006-8993(87)90963-2; GOULD E, 1987, DEV BRAIN RES, V34, P303, DOI 10.1016/0165-3806(87)90218-5; HAWKES R, 1987, J COMP NEUROL, V256, P29, DOI 10.1002/cne.902560104; KOH S, 1991, J COMP NEUROL, V313, P494, DOI 10.1002/cne.903130310; MARTINEZMURILLO R, 1993, NEUROSCIENCE, V52, P587, DOI 10.1016/0306-4522(93)90408-8; PIORO EP, 1990, NEUROSCIENCE, V34, P89, DOI 10.1016/0306-4522(90)90305-N; PIORO EP, 1988, BRAIN RES, V455, P182, DOI 10.1016/0006-8993(88)90131-X; RENDE M, 1993, J COMP NEUROL, V338, P560, DOI 10.1002/cne.903380406; SOTELO C, 1991, PHILOS T R SOC B, V331, P307, DOI 10.1098/rstb.1991.0022; YAN Q, 1988, J NEUROSCI, V8, P3481	16	38	38	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	NOV	1994	63	2					351	356		10.1016/0306-4522(94)90534-7			6	Neurosciences	Neurosciences & Neurology	PV683	WOS:A1994PV68300001	7891850				2021-06-18	
J	MILLIS, SR; PUTNAM, SH				MILLIS, SR; PUTNAM, SH			THE RECOGNITION MEMORY TEST IN THE ASSESSMENT OF MEMORY IMPAIRMENT AFTER FINANCIALLY COMPENSABLE MILD HEAD-INJURY - A REPLICATION	PERCEPTUAL AND MOTOR SKILLS			English	Article								The current investigation replicated the findings from a 1992 study by Millis. 20 subjects with claimed mild head injury who were seeking financial compensation obtained significantly lower scores on both subtests of the Recognition Memory Test than did 66 rehabilitation inpatients with documented moderate and severe traumatic brain injuries. The direct discriminant function derived by Millis was cross-validated on the current sample and yielded an improved over-all correct classification rate of 83%, with 85% and 82% of the mild and severe traumatic brain-injured subjects classified correctly, respectively. Over-all correct classification rate in the original study was 76%.		MILLIS, SR (corresponding author), WAYNE STATE UNIV,SCH MED,REHABIL INST MICHIGAN,261 MACK BLVD,DETROIT,MI 48201, USA.						LEVIN H, 1975, J NERV MENT DIS, V167, P675; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Warrington EK., 1984, RECOGNITION MEMORY T; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	4	38	38	0	1	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	AUG	1994	79	1	2				384	386		10.2466/pms.1994.79.1.384			3	Psychology, Experimental	Psychology	PJ038	WOS:A1994PJ03800004	7808871				2021-06-18	
J	PAPERO, PH; PRIGATANO, GP; SNYDER, HM; JOHNSON, DL				PAPERO, PH; PRIGATANO, GP; SNYDER, HM; JOHNSON, DL			CHILDRENS ADAPTIVE BEHAVIORAL COMPETENCE AFTER HEAD-INJURY	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							BRAIN-DAMAGE; SEQUELAE; TRAUMA	Eighty-six children were evaluated in a cross-sectional study 1 to 3 years after hospitalization for closed head injury in order to ascertain the effects of head injury severity, age, and chronicity of injury on the development of adaptive behavioural competence as measured by the Vineland Adaptive Behavior Scales. Twenty-three subjects had sustained moderate to severe injuries and 63 had sustained mild injuries, based on neurosurgical criteria including the Glasgow Coma Score, CT scans, and other medical variables. It was hypothesised that severity of head injury would adversely affect overall adaptive competence. It was also predicted that social competence would be less well developed in children with moderate to severe injury than in those with mild injury. Study findings provided partial support for these hypotheses. An unavoidable confounding of age and gender resulted in the decision to examine the data by gender to determine whether the data could be analysed without regard for this factor. An unexpected gender effect was observed. Severity of injury did adversely influence the adaptive competence of boys, especially in the area of social competency, but hypotheses were not upheld for girls. Discussion focuses on issues related to gender and adaptive outcome, parent report of adaptive functioning in light of gender and cultural factors, the relationship of neuropsychological functioning and adaptive competence, and the nature of social deficits following pediatric traumatic brain injury.	GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,WASHINGTON,DC 20010; BARROW NEUROL INST,PHOENIX,AZ							Beery K, 1989, VMI DEV TEST VISUAL; Brooks N., 1984, CLOSED HEAD INJURY P; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; DODRILL CB, 1984, J CONSULT CLIN PSYCH, V54, P520; EIBAN CF, 1984, ARCH PHYSICAL MED RE, V65, P168; EICHELBERGER MR, 1991, EMSC FOCUS TRAUMATIC; EWINGCOBBS L, 1987, J CLIN EXPT NEUROPSY, V2, P575; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Fuld P. A., 1977, FULD OBJECT MEMORY E; GAGNON J, 1989, SUPERANOVA ACCESSIBL; Gleason Jean B., 1987, LANGUAGE GENDER SEX, P189, DOI DOI 10.1017/CBO9780511621918.010; Jennett B, 1981, MANAGEMENT HEAD INJU; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MACCOBY EE, 1990, AM PSYCHOL, V45, P513, DOI 10.1037/0003-066X.45.4.513; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; ODDY M, 1978, BRIT J PSYCHIAT, V122, P567; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1991, J CLIN EXP NEUROPSYC, V13, P437; Reitan RM., 1985, HALSTEAD REITAN NEUR; RICHARDSON SA, 1986, AM J MENT RETARD, V91, P250; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sparrow S., 1984, VINELAND ADAPTIVE BE; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wechsler D., 1974, MANUAL WECHSLER INTE; 1987, LEARNING DISABILITIE	30	38	38	0	1	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		1993	3	4					321	340		10.1080/09602019308401445			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	MR361	WOS:A1993MR36100003					2021-06-18	
J	MAZZUCCHI, A; CATTELANI, R; MISSALE, G; GUGLIOTTA, M; BRIANTI, R; PARMA, M				MAZZUCCHI, A; CATTELANI, R; MISSALE, G; GUGLIOTTA, M; BRIANTI, R; PARMA, M			HEAD-INJURED SUBJECTS AGED OVER 50 YEARS - CORRELATIONS BETWEEN VARIABLES OF TRAUMA AND NEUROPSYCHOLOGICAL FOLLOW-UP	JOURNAL OF NEUROLOGY			English	Article						AGING; HEAD INJURY; MENTAL DETERIORATION; DEMENTIA	COGNITIVE SEQUELAE; CONSECUTIVE SERIES; BRAIN INJURY; MEMORY; PROGNOSIS; RECOVERY; MODERATE; SCALE	Neuropsychological follow-up was studied in 70 consecutive head-injured subjects aged over 50 years. Diffuse deterioration (28%), moderate deterioration (25%) and dementia (21%) were the most frequent sequelae. Analysis of correlations between neuropsychological sequelae and trauma variables showed that: (1) mild trauma did not necessarily imply good prognosis and could be followed by very severe consequences; (2) duration of post-traumatic amnesia was correlated with coma duration but not with neuropsychological outcome; (3) on the whole, no prognostic predictor of the outcome was found.		MAZZUCCHI, A (corresponding author), UNIV PARMA,DEPT NEUROL,NEUROPSYCHOL UNIT,STR QUARTIERE 4,I-43100 PARMA,ITALY.		Missale, Gabriele/J-6083-2016; Brianti, Rodolfo/H-2152-2013	Missale, Gabriele/0000-0001-6691-8701; Brianti, Rodolfo/0000-0001-8069-3502			AGRESTI A, 1984, ANAL ORDINAL CATEGOR; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROOKS D N, 1974, Cortex, V10, P224; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DERENZI E, 1975, CORTEX, V11, P33; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Everitt B, 1977, ANAL CONTINGENCY TAB; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1981, MANAGEMENT HEAD INJU, P317; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Mazzucchi A, 1984, Riv Neurol, V54, P1; MEIER MJ, 1983, MAY ANN M MIDW PSYCH; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Raven J. C., 1938, STANDARD PROGR MATRI; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Spinnler H., 1987, ITAL J NEUROL SCI S, V8, pS1; STREET RF, 1931, CONTRIBUTIONS ED, V481; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VILKKI J, 1988, J NEUROL NEUROSUR PS, V51, P1452, DOI 10.1136/jnnp.51.11.1452; Wechsler D., 1958, MEASUREMENT APPRAISA; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; WILSON R S, 1979, Journal of Clinical Neuropsychology, V1, P49, DOI 10.1080/01688637908401097; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	43	38	38	0	4	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-5354			J NEUROL	J. Neurol.	MAY	1992	239	5					256	260					5	Clinical Neurology	Neurosciences & Neurology	HT306	WOS:A1992HT30600005	1607886				2021-06-18	
J	SZYMANSKI, HV; LINN, R				SZYMANSKI, HV; LINN, R			A REVIEW OF THE POSTCONCUSSION SYNDROME	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						BRAIN INJURY; BRAIN CONCUSSION; PSYCHOPHARMACOLOGY; TOMOGRAPHY; EMISSION-COMPUTED; DEPRESSION; TOMOGRAPHY; X-RAY COMPUTED; ATTENTION; MEMORY; MAGNETIC RESONANCE IMAGING	MINOR HEAD-INJURY; BRAIN INJURY; COMPUTERIZED-TOMOGRAPHY; REACTION-TIME; POPULATION; TRAUMA; ATTENTION; SEQUELAE; SCANS; DRUGS	Objective: This review will focus on aspects of the postconcussion syndrome (PCS), including accompanying symptomatology, neuropsychological changes, brain imaging studies and treatment. Method: In each topic area, those research studies resulting in the most interpretable data are reported. Since there is little research in some aspects of the PCS, some studies of limited merit are described, with their limitations outlined, in lieu of not reporting any study. The section on psychopharmacology largely consists of opinions of recognized clinicians, since there is almost no research on the psychopharmacology of PCS. Results: Mild traumatic brain injury is a relatively frequent occurrence which often results in the postconcussion syndrome (PCS), consisting of complaints of irritability, fatigue, headache, difficulty concentrating, dizziness, and memory problems. Anxiety and depression are also frequently present, especially later in its course. Although the PCS has often been thought to reflect a psychological response to injury, there is considerable recent evidence to suggest that it is primarily a physiologic disturbance. For most individuals, treatment consists primarily of education of the patient and his/her family, along with supportive counseling regarding emerging problems at work or at home. A subgroup of patients, however, may require psychopharmacologic intervention. Conclusion: More research is needed in all aspects of PCS, especially its neurophysiology and pharmacologic treatment. Relationships between neurophysiological changes and behavioral and neuropsychological changes are unknown. New imaging techniques, such as single-photon emission tomography, and positron emission tomography will likely play an important role in understanding the physiology of this disorder.	SUNY BUFFALO,BUFFALO,NY 14260							ALAVI A, 1989, J NEUROPSYCHIAT, V1, pS45; ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAILEY BN, 1989, MINOR HEAD INJURY; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BLACK P, 1969, LATE EFFECTS HEAD IN, pCH14; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CARTLIDGE NEF, 1982, HEAD INJURY; CASSIDY JW, 1989, NEUROBEHAVIOURAL SEQ; COPE DN, 1989, NEUROBEHAVIORAL SEQU; COURVILLE CB, 1987, PATHOLOGY CENTRAL NE; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1989, MILD HEAD INJURY; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1988, PHARM APPROACHES TRE; GRAVES EJ, 1989, VITAL HLTH STATIS 13, V100; GRAY BG, 1992, J NUCL MED, V33, P52; GREBER R, 1985, ATTENTION SHORT TERM; GRONWALL D, 1974, LANCET, V2, P605; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; GUTTMANN E, 1946, J MENT SCI, V92, P1; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; Holbourn AHS, 1943, LANCET, V2, P438; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1983, INTRO NEUROSURGERY; JONES RR, 1974, SURGICAL NEUROLOGY, V22, P101; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KILLIAN GA, 1984, J ABNORM PSYCHOL, V93, P58, DOI 10.1037/0021-843X.93.1.58; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1987, MILD MODERATE HEAD I; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANGFITT TW, 1982, CLIN NEUROSURG, V29, P3523; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewis A. J., 1942, P ROY SOC MED, V35, P607; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LINN RT, 1992, J CLIN EXPT NEUROPSY, V14, P78; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISTER RG, 1985, NEUROSCI BIOBEHAV R, V9, P87, DOI 10.1016/0149-7634(85)90034-X; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MCLEAN A, 1986, NOV ANN M NAT HEAD I; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; MILLER JD, 1989, MILD MODERATE HEAD I; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MYSIW WJ, 1986, ARCH PHYS MED REHAB, V67, P677; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1989, MILD HEAD INJURY; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1987, MILD HEAD INJURY; RUTHERFORD WH, 1977, LANCET, V2, P1021; RUTHERFORD WH, 1989, MILD HEAD INJURY; SEKINO H, 1981, Neurologia Medico-Chirurgica, V21, P677; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Symonds C P, 1937, Proc R Soc Med, V30, P1081; TARSH MJ, 1985, BRIT J PSYCHIAT, V146, P18, DOI 10.1192/bjp.146.1.18; TEASDALE G, 1974, LANCET, V2, P81; TUNE LE, 1982, AM J PSYCHIAT, V139, P1460; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1989, TRAUMATIC BRAIN INJU; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WISE RA, 1982, BEHAV BRAIN SCI, V5, P39, DOI 10.1017/S0140525X00010372; Wood R. L. L., 1989, PHYS MED REHABIL, V3, P123; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; WRIGHTSON P, 1989, MILD HEAD INJURY; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	82	38	38	0	6	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1992	22	4					357	375		10.2190/XARA-B1EF-J2HC-VAE0			19	Psychiatry	Psychiatry	KN858	WOS:A1992KN85800005	1293065				2021-06-18	
J	SCHENCK, CH; MAHOWALD, MW				SCHENCK, CH; MAHOWALD, MW			INJURIOUS SLEEP BEHAVIOR DISORDERS (PARASOMNIAS) AFFECTING PATIENTS ON INTENSIVE-CARE UNITS	INTENSIVE CARE MEDICINE			English	Article						SLEEP INJURY; PARASOMNIAS; INTENSIVE CARE UNIT; NIGHT TERRORS; SLEEPWALKING; REM SLEEP BEHAVIOR DISORDER; POLYSOMNOGRAPHY	OPEN-HEART SURGERY	There are no previous reports on parasomnias (sleep behavior disorders) affecting patients on intensive care units (ICUs). During 8 years of clinical practice, we evaluated over 200 adults with complaints of injurious, sleep-related behaviors, 20 of whom had ICU admissions while their parasomnias had been active and generally undiagnosed/untreated. Mean age during ICU confinement was 62.8 (+/- SD 13.1) years; 85.0% (17/20) were males. Patients underwent comprehensive clinical examinations along with extensive polysomnographic and audiovisual monitoring (electrooculogram, 9 channel EEG with paper speeds of 15 and 30 mm/sec, electromyogram [submental and 4 limbs], EKG, airflow). The polysomnographic studies were diagnostic for the REM sleep behavior disorder (vigorous dream-enactment during rapid eye movement [REM] sleep) in 85.0% (17/20) of patients, and for night terrors/sleepwalking in 15.0% (3/20). Three groups of parasomnia-ICU relationships were identified: i) Parasomnias originating in ICUs, stroke-induced (n = 3); ii) Admission to ICUs resulting from parasomnia-induced injuries: C2 odontoid process fracture and C3 spinous process fracture with severe concussion (n = 2); iii) Parasomnias in patients admitted to ICUs for various other medical problems (n = 15). Physicians should be thus alerted about the possibility of injurious, but usually treatable, parasomnias in ICU patients.	HENNEPIN CTY MED CTR,DEPT PSYCHIAT,MINNEAPOLIS,MN 55415; HENNEPIN CTY MED CTR,DEPT NEUROL,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455	SCHENCK, CH (corresponding author), HENNEPIN CTY MED CTR,MINNESOTA REG SLEEP DISORDERS CTR,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.						AURELL J, 1985, BRIT MED J, V290, P1029, DOI 10.1136/bmj.290.6474.1029; BOYSEN PG, 1989, TXB CRITICAL CARE, P572; BROUGHTON R, 1978, ELECTROEN CLIN NEURO, V45, P348, DOI 10.1016/0013-4694(78)90187-6; CARSKADON MA, 1990, PRINCIPLES PRACTICE, P3; DOHNO S, 1979, PERCEPT MOTOR SKILL, V48, P199, DOI 10.2466/pms.1979.48.1.199; JOHNS MW, 1974, BRIT J SURG, V61, P377, DOI 10.1002/bjs.1800610513; JOUVET M, 1965, CR SOC BIOL, V159, P895; KARACAN I, 1974, STRESS HEART, P163; KAVEY NB, 1990, NEUROLOGY, V49, P749; MAHOWALD M W, 1990, Pediatrician, V17, P21; MAHOWALD MW, 1990, J CLIN NEUROPHYSIOL, V7, P119, DOI 10.1097/00004691-199001000-00009; MAHOWALD MW, 1990, J FORENSIC SCI, V35, P413; MAHOWALD MW, 1989, PRINCIPLES PRACTICE, P389; MAHOWALD MW, 1990, HDB SLEEP DISORDERS, P567; ORR WC, 1977, AM J CARDIOL, V39, P196, DOI 10.1016/S0002-9149(77)80191-4; Rechtschaffen A, 1968, MANUAL STANDARDIZED; RICHARDSON GS, 1978, ELECTROEN CLIN NEURO, V45, P621, DOI 10.1016/0013-4694(78)90162-1; SCHENCK CH, 1989, AM J PSYCHIAT, V146, P1166; SCHENCK CH, 1987, JAMA-J AM MED ASSOC, V257, P1786, DOI 10.1001/jama.257.13.1786; SCHENCK CH, 1986, SLEEP, V9, P293, DOI 10.1093/sleep/9.2.293; SCHENCK CH, 1990, CLEVE CLIN J MED S, V57, pS9; SCHENCK CH, 1989, DISSOCIATION, V2, P194; SIEGEL JM, 1990, J CLIN NEUROPHYSIOL, V7, P49, DOI 10.1097/00004691-199001000-00005; 1987, DIAGNOSTIC STATISTIC; 1990, INT CLASSIFICATION S	25	38	38	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.		1991	17	4					219	224		10.1007/BF01709881			6	Critical Care Medicine	General & Internal Medicine	GC112	WOS:A1991GC11200008	1744307				2021-06-18	
J	TORG, JS; SENNETT, B; VEGSO, JJ; PAVLOV, H				TORG, JS; SENNETT, B; VEGSO, JJ; PAVLOV, H			AXIAL LOADING INJURIES TO THE MIDDLE CERVICAL-SPINE SEGMENT - AN ANALYSIS AND CLASSIFICATION OF 25 CASES	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								Injuries to the cervical spine at the C3-C4 level involving the bony elements, intervertebral disks, and ligamentous structures are rare. We present 25 cases of traumatic C3-C4 injuries sustained by young athletes and documented by the National Football Head and Neck Injury Registry. Review of the cases reveals that the response of energy inputs at the C3-C4 level differ from those involving the upper (C1-C2) and lower (C4-C5-C6-C7) cervical segments. Specifically, the C3-C4 lesions appear to be unique with regard to the infrequency of bony fracture, difficulty in effecting and maintaining reduction, and a more favorable recovery following early, aggressive treatment. In the majority of instances, injury at this level results from axial loading of the cervical spine. Lesions were distributed into specific categories: 1) acute intervertebral disc herniation (N = 4), 2) anterior subluxation of C3 on C4 (N = 4), 3) unilateral facet dislocation (N = 6), 4) bilateral facet dislocation (N = 7), and 5) fracture of vertebral body C4 (N = 4). Analysis of these 25 cases suggests that traumatic lesions of the cervical spine in general can be classified as involving the upper (C1-C2), middle (C3-C4), or lower (C4-C7) segments. This is based on our observations from this series that C3-C4 lesions 1) generally do not involve fracture of the bony elements; 2) acute intervertebral disc herniations are frequenty associated with transient quadriplegia; 3) reduction of anterior subluxation of C3 on C4 is difficult to maintain; 4) reduction of unilateral facet dislocation is difficult to obtain by skeletal traction and is best managed by closed manipulation and reduction under general anesthesia; and 5) reduction of bilateral facet dislocation is difficult to obtain by skeletal traction and is best managed by open methods. The more favorable results observed in this series of immediate reduction of both unilateral and bilateral facet dislocations deserves emphasis. In two cases of unilateral facet dislocation reduced within 3 hours of injury and subsequently fused anteriorly, significant neurologic recovery occurred. The other four patients, two who underwent an open reduction and laminectomy and two treated closed with skeletal traction, remained quadriplegic. In the four instances of bilateral facet dislocation where reduction was achieved by either closed or open methods, although there was no neurologic recovery, all four patients survived their injuries. However, the three patients who were not successfully reduced died.		TORG, JS (corresponding author), UNIV PENN,CTR SPORTS MED,WEIGHTMAN HALL,235 S 33RD ST,PHILADELPHIA,PA 19104, USA.							0	38	39	0	3	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1991	19	1					6	20		10.1177/036354659101900103			15	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EV643	WOS:A1991EV64300003	2008932				2021-06-18	
J	RICHARDS, JS; BROWN, L; HAGGLUND, K; BUA, G; REEDER, K				RICHARDS, JS; BROWN, L; HAGGLUND, K; BUA, G; REEDER, K			SPINAL-CORD INJURY AND CONCOMITANT TRAUMATIC BRAIN INJURY - RESULTS OF A LONGITUDINAL INVESTIGATION	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article									UNIV ALABAMA,DEPT REHABIL MED,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35233				Hagglund, Kristofer/0000-0001-7748-7492			BENTON A L, 1978, Archives of Neurology, V35, P364; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BOLL TJ, 1981, HDB CLIN NEUROPSYCHO; BUSCHKE J, 1974, NEUROLOGY, V11, P1019; COLOHAN RT, 1986, J HEAD TRAUMA REHABI, V1, P13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DEWOLFE AS, 1971, J CONSULT CLIN PSYCH, V36, P197, DOI 10.1037/h0030731; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; DRICKER J, 1978, NEUROPSYCHOLOGIA, V16, P683, DOI 10.1016/0028-3932(78)90003-9; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; HAMSHER KD, 1979, ARCH NEUROL-CHICAGO, V36, P837, DOI 10.1001/archneur.1979.00500490051008; HARRIS P, 1986, PARAPLEGIA, V5, P215; KEREKJARTO M, 1962, 23 K DTSCH GES PSYCH; LABATE L, 1963, J CLIN PSYCHOL, V19, P87, DOI 10.1002/1097-4679(196301)19:1<87::AID-JCLP2270190113>3.0.CO;2-N; LABATE L, 1962, J CONSULT PSYCHOL, V26, P479; LANDSDELL H, 1977, J CONSULT CLIN PSYCH, V45, P412; LARRABEE GJ, 1983, J CLIN NEUROPSYCHOL, V5, P159, DOI 10.1080/01688638308401162; LEZAK MD, 1982, 5TH EUR C INT NEUR S; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; PENDLETON MG, 1982, J CLIN PSYCHOL, V38, P392, DOI 10.1002/1097-4679(198204)38:2<392::AID-JCLP2270380232>3.0.CO;2-W; PORTER RW, 1977, 19TH P VET ADM SPIN, P188; REY A, 1964, EXAMEN CLIN PSYCHIOL; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SCHUENEMAN A, 1982, SCI DIG, V4, P35; SHAW DJ, 1966, J CLIN PSYCHOL, V22, P176, DOI 10.1002/1097-4679(196604)22:2<176::AID-JCLP2270220215>3.0.CO;2-O; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; STOVER SL, 1986, SPINAL CORD INJURY F; Talland G.A., 1965, DERANGED MEMORY; WAGNER KA, 1984, P AM SPINAL INJURY A, P96; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; Young J.S., 1982, SPINAL CORD INJURY S; ZUBRICK S, 1978, 6TH INT NEUR SOC M M	33	38	39	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	1988	67	5					211	216		10.1097/00002060-198810000-00005			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	Q9739	WOS:A1988Q973900005	3179011				2021-06-18	
J	Barthelemy, NR; Horie, K; Sato, C; Bateman, RJ				Barthelemy, Nicolas R.; Horie, Kanta; Sato, Chihiro; Bateman, Randall J.			Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; CEREBROSPINAL-FLUID; COGNITIVE DECLINE; PROTEIN; PATHOLOGY; KINETICS; MARKER; RATIO	Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of beta-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms' profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).	[Barthelemy, Nicolas R.; Horie, Kanta; Sato, Chihiro; Bateman, Randall J.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Bateman, Randall J.] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA; [Bateman, Randall J.] Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimers Dis Res Ctr, St Louis, MO 63130 USA	Barthelemy, NR; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA.; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimers Dis Res Ctr, St Louis, MO 63130 USA.	barthelemy.nicolas@wustl.edu; batemanr@wustl.edu		Bateman, Randall/0000-0002-7729-1702	Alzheimer's Association Research Fellowship [AARF-16-443265]; Rainwater Charitable Foundation; National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095773]; Tau SILK Consortium (AbbVie)AbbVie; Tau SILK Consortium (Biogen)Biogen; Tau SILK Consortium (Eli Lilly and Company); Coins for Alzheimer's Research Trust grant	Funding for this work includes the Alzheimer's Association Research Fellowship AARF-16-443265 (to N.R. Barth ' elemy), the Rainwater Charitable Foundation (to R.J. Bateman and N.R. Barth ' elemy), the National Institutes of Health, National Institute of Neurological Disorders and Stroke grant R01NS095773 (R.J. Bateman), the Tau SILK Consortium (AbbVie, Biogen, and Eli Lilly and Company; principal investigator, R.J. Bateman), and the Coins for Alzheimer's Research Trust grant (to C. Sato).	Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Barthelemy N., 2015, ALZHEIMERS DEMENT 19, V11, P870, DOI [10.1016/j.jalz.2015.08.063, DOI 10.1016/J.JALZ.2015.08.063]; Barthelemy N.R., 2018, ALZHEIMERS DEMENT 4, V14, P273, DOI [10.1016/j.jalz.2018.06.024, DOI 10.1016/J.JALZ.2018.06.024]; Barthelemy NR, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00596-4; Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Barthelemy NR, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00121; Barthelemy NR, 2016, J PROTEOME RES, V15, P667, DOI 10.1021/acs.jproteome.5b01001; Barthelemy NR., 2017, TAU HYPERPHOSPHORYLA, DOI [10.1101/226977, DOI 10.1101/226977]; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Cicognola C, 2019, ACTA NEUROPATHOL, V137, P279, DOI 10.1007/s00401-018-1948-2; Darlix A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5287-z; Fagan AM, 2007, ARCH NEUROL-CHICAGO, V64, P343, DOI 10.1001/archneur.64.3.noc60123; Fagan AM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007901; Geyer PE, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20156297; Janelidze S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15436-0; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Kasai T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188802; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P989, DOI 10.1016/j.jalz.2018.02.013; Mielke MM, 2017, JAMA NEUROL, V74, P1073, DOI 10.1001/jamaneurol.2017.1359; Nakamura A, 2018, NATURE, V554, P249, DOI 10.1038/nature25456; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Ovod V, 2017, ALZHEIMERS DEMENT, V13, P841, DOI 10.1016/j.jalz.2017.06.2266; Patterson BW, 2015, ANN NEUROL, V78, P439, DOI 10.1002/ana.24454; Potter R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005615; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Roberts KF, 2014, ANN NEUROL, V76, P837, DOI 10.1002/ana.24270; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Schindler SE, 2019, NEUROLOGY, V93, pE1647, DOI 10.1212/WNL.0000000000008081; Tatebe H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0206-8; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; Zetterberg H, 2017, NEUROPATH APPL NEURO, V43, P194, DOI 10.1111/nan.12378; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163	36	37	37	11	16	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0022-1007	1540-9538		J EXP MED	J. Exp. Med.	NOV	2020	217	11							e20200861	10.1084/jem.20200861			12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	OO5MI	WOS:000587422000017	32725127	Green Published, Other Gold			2021-06-18	
J	Ho, KM; Rao, S; Honeybul, S; Zellweger, R; Wibrow, B; Lipman, J; Holley, A; Kop, A; Geelhoed, E; Corcoran, T; Misur, P; Edibam, C; Baker, RI; Chamberlain, J; Forsdyke, C; Rogers, FB				Ho, Kwok M.; Rao, Sudhakar; Honeybul, Stephen; Zellweger, Rene; Wibrow, Bradley; Lipman, Jeffrey; Holley, Anthony; Kop, Alan; Geelhoed, Elizabeth; Corcoran, Tomas; Misur, Philip; Edibam, Cyrus; Baker, Ross I.; Chamberlain, Jenny; Forsdyke, Claire; Rogers, Frederick B.			A Multicenter Trial of Vena Cava Filters in Severely Injured Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; AMERICAN-COLLEGE; MAJOR TRAUMA; RISK; THROMBOPROPHYLAXIS; PREVENTION; PROGRESSION; HEMORRHAGE	BackgroundWhether early placement of an inferior vena cava filter reduces the risk of pulmonary embolism or death in severely injured patients who have a contraindication to prophylactic anticoagulation is not known. MethodsIn this multicenter, randomized, controlled trial, we assigned 240 severely injured patients (Injury Severity Score >15 [scores range from 0 to 75, with higher scores indicating more severe injury]) who had a contraindication to anticoagulant agents to have a vena cava filter placed within the first 72 hours after admission for the injury or to have no filter placed. The primary end point was a composite of symptomatic pulmonary embolism or death from any cause at 90 days after enrollment; a secondary end point was symptomatic pulmonary embolism between day 8 and day 90 in the subgroup of patients who survived at least 7 days and did not receive prophylactic anticoagulation within 7 days after injury. All patients underwent ultrasonography of the legs at 2 weeks; patients also underwent mandatory computed tomographic pulmonary angiography when prespecified criteria were met. ResultsThe median age of the patients was 39 years, and the median Injury Severity Score was 27. Early placement of a vena cava filter did not result in a significantly lower incidence of symptomatic pulmonary embolism or death than no placement of a filter (13.9% in the vena cava filter group and 14.4% in the control group; hazard ratio, 0.99; 95% confidence interval [CI], 0.51 to 1.94; P=0.98). Among the 46 patients in the vena cava filter group and the 34 patients in the control group who did not receive prophylactic anticoagulation within 7 days after injury, pulmonary embolism developed in none of those in the vena cava filter group and in 5 (14.7%) in the control group, including 1 patient who died (relative risk of pulmonary embolism, 0; 95% CI, 0.00 to 0.55). An entrapped thrombus was found in the filter in 6 patients. ConclusionsEarly prophylactic placement of a vena cava filter after major trauma did not result in a lower incidence of symptomatic pulmonary embolism or death at 90 days than no placement of a filter.	[Ho, Kwok M.; Chamberlain, Jenny] Univ Western Australia, Dept Intens Care Med, Perth, WA, Australia; [Honeybul, Stephen] Univ Western Australia, Dept Neurosurg, Perth, WA, Australia; [Misur, Philip] Univ Western Australia, Dept Radiol, Perth, WA, Australia; [Rao, Sudhakar; Zellweger, Rene; Forsdyke, Claire] Univ Western Australia, State Trauma Unit, Perth, WA, Australia; [Kop, Alan] Univ Western Australia, Ctr Implant Technol & Retrieval Anal, Dept Med Engn & Phys, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Royal Perth Hosp, Sch Populat & Global Hlth, Perth, WA, Australia; [Geelhoed, Elizabeth] Univ Western Australia, Allied Hlth, Perth, WA, Australia; [Wibrow, Bradley; Corcoran, Tomas] Univ Western Australia, Med & Pharmacol, Perth, WA, Australia; [Ho, Kwok M.] Murdoch Univ, Sch Vet & Life Sci, Perth, WA, Australia; [Baker, Ross I.] Murdoch Univ, Western Australian Ctr Thrombosis & Haemostasis, Perth, WA, Australia; [Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Nedlands, WA, Australia; [Wibrow, Bradley] Sir Charles Gairdner Hosp, Dept Intens Care Med, Nedlands, WA, Australia; Sir Charles Gairdner Hosp, Nedlands, WA, Australia; [Lipman, Jeffrey; Holley, Anthony] Royal Brisbane & Womens Hosp, Crit Care Serv, Brisbane, Qld, Australia; [Lipman, Jeffrey; Holley, Anthony] Univ Queensland, Brisbane, Qld, Australia; [Edibam, Cyrus] Fiona Stanley Hosp, Dept Intens Care Med, Murdoch, WA, Australia; [Rogers, Frederick B.] Univ Penn, Lancaster Gen Hosp, Trauma Serv, Lancaster, PA USA	Ho, KM (corresponding author), Royal Perth Hosp, Dept Intens Care Med, 197 Wellington St, Perth, WA 6000, Australia.	kwok.ho@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Baker, Ross/AAG-5798-2021	Ho, Kwok M./0000-0002-6705-6004; Baker, Ross/0000-0002-2728-6788; Geelhoed, Elizabeth/0000-0001-6718-9264; Holley, Anthony/0000-0001-8042-6084	Medical Research Foundation of Royal Perth Hospital	Funded by the Medical Research Foundation of Royal Perth Hospital and others	Allen CJ, 2016, J AM COLL SURGEONS, V222, P65, DOI 10.1016/j.jamcollsurg.2015.10.014; Axis Research Mind, 2018, INF VEN CAV IVC FILT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bandle J, 2014, J TRAUMA ACUTE CARE, V76, P213, DOI 10.1097/TA.0b013e3182aa2fa9; Bikdeli B, 2017, J AM COLL CARDIOL, V70, P1587, DOI 10.1016/j.jacc.2017.07.775; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chiasson TC, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000098; Cook AD, 2017, JAMA SURG, V152, P724, DOI 10.1001/jamasurg.2017.1018; Duszak R, 2011, J AM COLL RADIOL, V8, P483, DOI 10.1016/j.jacr.2010.12.021; Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Haut ER, 2014, JAMA SURG, V149, P194, DOI 10.1001/jamasurg.2013.3970; Ho KM, 2015, BRIT J ANAESTH, V114, P63, DOI 10.1093/bja/aeu195; Ho KM, 2014, ANAESTH INTENS CARE, V42, P709, DOI 10.1177/0310057X1404200605; Ho KM, 2010, BRIT J ANAESTH, V105, P596, DOI 10.1093/bja/aeq254; Ho KM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016747; Ho KM, 2013, CIRCULATION, V128, P1003, DOI 10.1161/CIRCULATIONAHA.113.002690; Ho KM, 2011, CHEST, V140, P1436, DOI 10.1378/chest.11-1444; Kaufman JA, 2006, J VASC INTERV RADIOL, V17, P449, DOI 10.1097/01.RVI.0000203418-39769.0D; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; Knudson MM, 2011, ANN SURG, V254, P625, DOI 10.1097/SLA.0b013e3182300209; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Pastorek RA, 2014, J NEUROTRAUM, V31, P1737, DOI 10.1089/neu.2014.3366; Rao A, 2017, NEUROSURGERY, V64, P182, DOI 10.1093/neuros/nyx210; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Rogers FB, 2012, J TRAUMA ACUTE CARE, V73, P511, DOI 10.1097/TA.0b013e3182588b54; Rosenthal D, 1994, Cardiovasc Surg, V2, P52; Shackford SR, 2007, J TRAUMA, V63, P764, DOI 10.1097/01.ta.0000240444.14664.5f; Shah M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006449; Sing RF, 2006, J TRAUMA, V60, P732, DOI 10.1097/01.ta.0000210285.22571.66; Skrifvars MB, 2017, INTENS CARE MED, V43, P419, DOI 10.1007/s00134-016-4655-2; Steele N, 2005, J BONE JOINT SURG BR, V87B, P209, DOI 10.1302/0301-620X.87B2.14447; Stefanidis D, 2006, AM J SURG, V192, P789, DOI 10.1016/j.amjsurg.2006.08.046; Weinberg I., 2016, APPROPRIATE USE INFE	40	37	38	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2019	381	4					328	337		10.1056/NEJMoa1806515			10	Medicine, General & Internal	General & Internal Medicine	IM4VO	WOS:000477993600008	31259488	Bronze			2021-06-18	
J	Mu, XY; He, H; Wang, JY; Long, W; Li, QF; Liu, HL; Gao, YL; Ouyang, LF; Ren, QJ; Sun, S; Wang, JY; Yang, J; Liu, Q; Sun, YM; Liu, CL; Zhang, XD; Hu, WP				Mu, Xiaoyu; He, Hua; Wang, Junying; Long, Wei; Li, Qifeng; Liu, Haile; Gao, Yalong; Ouyang, Lufei; Ren, Qinjuan; Sun, Si; Wang, Jingya; Yang, Jiang; Liu, Qiang; Sun, Yuanming; Liu, Changlong; Zhang, Xiao-Dong; Hu, Wenping			Carbogenic Nanozyme with Ultrahigh Reactive Nitrogen Species Selectivity for Traumatic Brain Injury	NANO LETTERS			English	Article						Traumatic brain injury; reactive oxygen and nitrogen species; nanozyme; catalytic selectivity	SIRNA DELIVERY; RENAL CLEARANCE; NANOPARTICLES; NEUROINFLAMMATION; NEUROPROTECTION; SUPEROXIDE; GENERATION; EFFICIENT	Reactive oxygen and nitrogen species (RONS), especially reactive nitrogen species (RNS) are intermediate products during incidence of nervous system diseases, showing continuous damage for traumatic brain injury (TBI). Here, we developed a carbogenic nanozyme, which shows an antioxidant activity 12 times higher than ascorbic acid (AA) and behaves as multienzyme mimetics. Importantly, the nanozyme exhibits an ultrahigh scavenging efficiency (similar to 16 times higher than AA) toward highly active RNS, such as (NO)-N-center dot and ONOO- as well as traditional reactive oxygen species (ROS) including O-2(center dot-), H2O2, and (OH)-O-center dot. In vitro experiments show that neuron cells injured by H2O2 or lipopolysaccharide can be significantly recovered after carbogenic nanozyme treatment via scavenging all kinds of RONS. Moreover, the carbogenic nanozyme can serve as various enzyme mimetics and eliminate the harmful peroxide and glutathione disulfide from injured mice, demonstrating its potential as a therapeutic for acute TBI.	[Mu, Xiaoyu; Wang, Junying; Liu, Haile; Ouyang, Lufei; Ren, Qinjuan; Sun, Si; Liu, Changlong; Zhang, Xiao-Dong; Hu, Wenping] Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China; [He, Hua] China Univ Petr East China, State Key Lab Heavy Oil Proc, Qingdao 266580, Shandong, Peoples R China; [He, Hua] China Univ Petr East China, Ctr Bioengn & Biotechnol, Qingdao 266580, Shandong, Peoples R China; [Long, Wei; Wang, Jingya; Liu, Qiang; Sun, Yuanming] Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Mol Nucl Med, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Long, Wei; Wang, Jingya; Liu, Qiang; Sun, Yuanming] Peking Union Med Coll, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Yang, Jiang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, Xiao-Dong; Hu, Wenping] Tianjin Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China	Zhang, XD (corresponding author), Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China.; Zhang, XD (corresponding author), Tianjin Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.	xiaodongzhang@tju.edu.cn	Nanozymes, Nanozymes/D-8197-2019; Zhang, Xiaodong/F-4665-2015	Zhang, Xiaodong/0000-0002-7212-0138; He, Hua/0000-0002-6084-1034	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21874154, 81471786, 91859101]; Independent Innovation Foundation of Tianjin University	We gratefully acknowledge the financial support from the National Natural Science Foundation of China (No. 21874154, No. 81471786 and No. 91859101), and the Independent Innovation Foundation of Tianjin University.	Bao QQ, 2018, ACS NANO, V12, P6794, DOI 10.1021/acsnano.8b01994; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340; Choi YK, 2016, NAT MED, V22, P1335, DOI 10.1038/nm.4188; Fan KL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03903-8; Fan KL, 2017, CHEM COMMUN, V53, P424, DOI 10.1039/c6cc08542c; Gao L, 2015, ACS NANO, V9, P10979, DOI 10.1021/acsnano.5b04261; Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/nnano.2014.274, 10.1038/NNANO.2014.274]; Heckman KL, 2013, ACS NANO, V7, P10582, DOI 10.1021/nn403743b; Holthoff JH, 2010, BIOCHEM PHARMACOL, V80, P1260, DOI 10.1016/j.bcp.2010.06.027; Hou CX, 2012, ACS NANO, V6, P8692, DOI 10.1021/nn302270b; Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672; Huang YY, 2016, ANGEW CHEM INT EDIT, V55, P6646, DOI 10.1002/anie.201600868; Jalilov AS, 2017, ACS NANO, V11, P2024, DOI 10.1021/acsnano.6b08211; Kang JY, 2016, ADV MATER, V28, P7962, DOI 10.1002/adma.201600634; Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780; Kozielski KL, 2014, ACS NANO, V8, P3232, DOI 10.1021/nn500704t; Kwon EJ, 2016, ACS NANO, V10, P7926, DOI 10.1021/acsnano.6b03858; Kwon HJ, 2018, ANGEW CHEM INT EDIT, V57, P9408, DOI 10.1002/anie.201805052; Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045; Li F, 2017, ANGEW CHEM INT EDIT, V56, P9910, DOI 10.1002/anie.201705989; Li JC, 2018, ANGEW CHEM INT EDIT, V57, P3995, DOI 10.1002/anie.201800511; Liu Y., 2017, J AM CHEM SOC, V139, P856; Liu Y, 2018, ACS NANO, V12, P4886, DOI 10.1021/acsnano.8b01893; Lv W, 2018, ACS NANO, V12, P5417, DOI 10.1021/acsnano.8b00477; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Samuel ELG, 2015, P NATL ACAD SCI USA, V112, P2343, DOI 10.1073/pnas.1417047112; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Soh M, 2017, ANGEW CHEM INT EDIT, V56, P11399, DOI 10.1002/anie.201704904; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Turjanski AG, 2000, J AM CHEM SOC, V122, P10468, DOI 10.1021/ja002006u; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vernekar AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6301; Wei H, 2013, CHEM SOC REV, V42, P6060, DOI 10.1039/c3cs35486e; Wu JJX, 2019, CHEM SOC REV, V48, P1004, DOI 10.1039/c8cs00457a; Xu BL, 2019, ANGEW CHEM INT EDIT, V58, P4911, DOI 10.1002/anie.201813994; Xu JL, 2016, ADV FUNCT MATER, V26, P4124, DOI 10.1002/adfm.201504416; Xu ZB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06164-7; Yao J, 2018, CHEM SCI, V9, P2927, DOI 10.1039/c7sc05476a; Yin WY, 2016, ACS NANO, V10, P11000, DOI 10.1021/acsnano.6b05810; Yoo D, 2017, ACS NANO, V11, P8600, DOI 10.1021/acsnano.7b03426; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang H, 2018, NANO LETT, V18, P4985, DOI 10.1021/acs.nanolett.8b01818; Zhang P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08731-y; Zhang W, 2016, J AM CHEM SOC, V138, P5860, DOI 10.1021/jacs.5b12070; Zhang XD, 2016, ADV MATER, V28, P6872, DOI 10.1002/adma.201600706; Zhang XD, 2016, ACS NANO, V10, P4511, DOI 10.1021/acsnano.6b00321; Zhang XD, 2014, ADV MATER, V26, P4565, DOI 10.1002/adma.201400866; Zhu P, 2018, ACS NANO, V12, P3780, DOI 10.1021/acsnano.8b00999	49	37	38	27	134	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1530-6984	1530-6992		NANO LETT	Nano Lett.	JUL	2019	19	7					4527	4534		10.1021/acs.nanolett.9b01333			8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	II9QA	WOS:000475533900040	31244237				2021-06-18	
J	Kheiri, G; Dolatshahi, M; Rahmani, F; Rezaei, N				Kheiri, Ghazaleh; Dolatshahi, Mahsa; Rahmani, Farzaneh; Rezaei, Nima			Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy	REVIEWS IN THE NEUROSCIENCES			English	Article						autophagy; mitogen-activated protein kinase (MAPK); neuroinflammation; oxidative stress; receptor for advanced glycation end products	ACTIVATED PROTEIN-KINASE; GLYCATION END-PRODUCTS; P38 MAP KINASE; (+)-2-(1-HYDROXYL-4-OXOCYCLOHEXYL) ETHYL CAFFEATE; IMPROVES COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; A-BETA; TAU PHOSPHORYLATION; N-BENZYLCINNAMIDE; OXIDATIVE STRESS	A myriad of environmental and genetic factors, as well as the physiologic process of aging, contribute to Alzheimer's disease (AD) pathology. Neuroinflammation is and has been a focus of interest, as a common gateway for initiation of many of the underlying pathologies of AD. Amyloid beta (A beta) toxicity, increasing RAGE expression, tau hyperphosphorylation, induction of apoptosis, and deregulated autophagy are among other mechanisms, partly entangled and being explained by activation of mitogen-activated protein kinase (MAPK) and MAPK signaling. p38 MAPK is the most essential regulator of A beta induced toxicity from this family. p38 induces NF-kappa B activation, glutamate excitotoxicity, and disruption of synaptic plasticity, which are other implications of all justifying the p38 MAPK as a potential target to break the vicious AP toxicity cycle. Until recently, many in vivo and in vitro studies have investigated the effects of p38 MAPK inhibitors in AD. The pyridinyl imidazole compounds SB202190 and SB203580 have shown promising anti-apoptotic results in vivo. MW108 inhibits activation of p38 and is able to postpone cognitive decline in animal models. The PD169316, with anti-inflammatory, anti-oxidative, and anti-apoptotic features, has improved spatial memory in vivo. Natural compounds from Camellia sinensis (green tea), polyphenols from olive oil, pinocembrin from propolis, and the puerarine extract isoflavones, have shown strong antiapoptotic features, mediated by p38 MAPK inhibition. Use of these drug targets is limited due to central nervous system side effects or cross-reactivity with other kinases, predicting the low efficacy of these drugs in clinical trials.	[Kheiri, Ghazaleh; Dolatshahi, Mahsa; Rahmani, Farzaneh; Rezaei, Nima] USERN, NeuroImaging Network NIN, Tehran 19166, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Dr Qarib St,Keshavarz Blvd, Tehran 14194, Iran; [Kheiri, Ghazaleh; Dolatshahi, Mahsa; Rahmani, Farzaneh] Univ Tehran Med Sci, SSRC, Tehran 1416753955, Iran	Rezaei, N (corresponding author), USERN, NeuroImaging Network NIN, Tehran 19166, Iran.; Rezaei, N (corresponding author), Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Dr Qarib St,Keshavarz Blvd, Tehran 14194, Iran.	rezaei_nima@tums.ac.ir	Dolatshahi, Mahsa/AAL-5273-2021; Rezaei, Nima/B-4245-2008	Rezaei, Nima/0000-0002-3836-1827	Tehran University of Medical SciencesTehran University of Medical Sciences	Tehran University of Medical Sciences supported this study.	Abdoulaye IA, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5012341; Alam J, 2016, AUTOPHAGY, V12, P2516, DOI 10.1080/15548627.2016.1238555; Arunsundar M, 2015, NEUROTOX RES, V27, P143, DOI 10.1007/s12640-014-9492-x; Ashabi G, 2013, BASIC CLIN PHARMACOL, V112, P145, DOI 10.1111/bcpt.12000; Ashabi G, 2012, BEHAV BRAIN RES, V232, P165, DOI 10.1016/j.bbr.2012.04.006; Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Bachstetter AD, 2014, J NEUROIMMUNE PHARM, V9, P454, DOI 10.1007/s11481-014-9543-3; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Bartus RT, 2009, PSYCHOPHARMACOLOGY, V202, P15, DOI 10.1007/s00213-008-1365-7; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blum S, 1999, J NEUROSCI, V19, P3535; Bodles AM, 2005, NEUROBIOL AGING, V26, P9, DOI 10.1016/j.neurobiolaging.2004.02.022; Bramham CR, 2010, EXP BRAIN RES, V200, P125, DOI 10.1007/s00221-009-1959-2; Bullido MJ, 2008, NEUROBIOL AGING, V29, P1160, DOI 10.1016/j.neurobiolaging.2007.02.023; BURNS A, 2009, BMJ-BRIT MED J, V338, DOI DOI 10.1136/BMJ.B158; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; Cai YF, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00027; Cao GY, 2015, J ETHNOPHARMACOL, V168, P31, DOI 10.1016/j.jep.2015.03.041; Cardaci S, 2010, BIOCHEM J, V430, P439, DOI 10.1042/BJ20100503; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chan SHH, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-17; Chang CH, 2010, J MED FOOD, V13, P548, DOI 10.1089/jmf.2009.1291; Chang KH, 2010, J NEUROCHEM, V113, P1221, DOI 10.1111/j.1471-4159.2010.06687.x; Chen LL, 2017, AUTOPHAGY, V13, P1969, DOI 10.1080/15548627.2017.1371393; Chicca A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0307-7; Choi IS, 2011, J ALZHEIMERS DIS, V27, P127, DOI 10.3233/JAD-2011-110545; Chowdhury S, 2006, NEURON, V52, P445, DOI 10.1016/j.neuron.2006.08.033; Chueh FS, 2004, J PHARMACOL SCI, V96, P420, DOI 10.1254/jphs.FP0040424; Colie S, 2017, SCI REP-UK, V7, DOI 10.1038/srep45306; Correa SAL, 2012, J NEUROSCI, V32, P13039, DOI 10.1523/JNEUROSCI.0930-12.2012; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CZQP Technology, 2016, PHAS 2 STUD PIN INJ; Daniels WMU, 2001, METAB BRAIN DIS, V16, P175, DOI 10.1023/A:1012541011123; Dehghani R, 2018, REV NEUROSCIENCE, V29, P161, DOI 10.1515/revneuro-2017-0042; Delgado M, 2008, GLIA, V56, P1091, DOI 10.1002/glia.20681; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Desideri E, 2014, AUTOPHAGY, V10, P1652, DOI 10.4161/auto.29456; Devi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032792; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; Dong WG, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0646-z; Dorostkar MM, 2015, ACTA NEUROPATHOL, V130, P1, DOI 10.1007/s00401-015-1449-5; Emamian ES, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00033; Endersby R, 2008, ONCOGENE, V27, P5416, DOI 10.1038/onc.2008.239; Fang F, 2018, HUM MOL GENET, V27, P1002, DOI 10.1093/hmg/ddy017; Fernandez F, 2012, CELL ADHES MIGR, V6, P333, DOI 10.4161/cam.20892; Ferrer I, 1990, Arch Neurobiol (Madr), V53, P222; Fulga TA, 2007, NAT CELL BIOL, V9, P139, DOI 10.1038/ncb1528; Gabr AA, 2017, BBA-MOL BASIS DIS, V1863, P2942, DOI 10.1016/j.bbadis.2017.06.020; Genheden M, 2015, J NEUROSCI, V35, P972, DOI 10.1523/JNEUROSCI.2641-14.2015; Ghasemi R, 2014, NEUROPHARMACOLOGY, V85, P113, DOI 10.1016/j.neuropharm.2014.01.036; Ghidoni R, 2008, J NEURAL TRANSM, V115, P1047, DOI 10.1007/s00702-008-0069-9; Giraldo E, 2014, REDOX BIOL, V2, P873, DOI 10.1016/j.redox.2014.03.002; Haghshomar M., 2017, NEUROSCIENCE; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Ho DT, 1997, J NEUROCHEM, V68, P106; Hotulainen P, 2010, J CELL BIOL, V189, P619, DOI 10.1083/jcb.201003008; Hu WC, 2014, CHEM-BIOL INTERACT, V224, P108, DOI 10.1016/j.cbi.2014.10.011; Huai YP, 2013, NEURAL REGEN RES, V8, P1733, DOI 10.3969/j.issn.1673-5374.2013.19.001; Hyun S, 2015, J MICROBIOL BIOTECHN, V25, P334, DOI 10.4014/jmb.1411.11073; Imbimbo BP, 2005, NEUROIMAG CLIN N AM, V15, P727, DOI 10.1016/j.nic.2005.09.009; Jeong K, 2014, APOPTOSIS, V19, P1399, DOI 10.1007/s10495-014-1013-0; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jung YY, 2014, BIOMOL THER, V22, P232, DOI 10.4062/biomolther.2014.030; Kano Y, 2007, BRAIN RES, V1154, P1, DOI 10.1016/j.brainres.2007.03.087; Kanungo Jyotshna, 2017, Brain Disord Ther, V6, DOI 10.4172/2168-975X.1000232; Karelina K, 2012, LEARN MEMORY, V19, P550, DOI 10.1101/lm.025775.112; Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129; Kennedy DO, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121332; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kim EJ, 2013, J ETHNOPHARMACOL, V146, P294, DOI 10.1016/j.jep.2012.12.047; Kim HS, 2015, ARCH PHARM RES, V38, P813, DOI 10.1007/s12272-014-0456-8; Kim TI, 2009, FREE RADICAL BIO MED, V47, P1601, DOI 10.1016/j.freeradbiomed.2009.09.008; Kim YH, 2010, INT IMMUNOPHARMACOL, V10, P1560, DOI 10.1016/j.intimp.2010.09.007; Knight ZA, 2011, CURR TOP MICROBIOL, V347, P263, DOI 10.1007/82_2010_44; Knobloch M, 2008, MOL NEUROBIOL, V37, P73, DOI 10.1007/s12035-008-8018-z; Kuang X, 2008, PHARMACOL BIOCHEM BE, V88, P213, DOI 10.1016/j.pbb.2007.08.006; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kurz A, 2011, PROG NEURO-PSYCHOPH, V35, P373, DOI 10.1016/j.pnpbp.2010.07.018; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Lan X, 2016, MOL NEUROBIOL, V53, P1794, DOI 10.1007/s12035-015-9125-2; Lauretti E, 2015, AGING CELL, V14, P1067, DOI 10.1111/acel.12381; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee YK, 2011, J NUTR BIOCHEM, V22, P476, DOI 10.1016/j.jnutbio.2010.04.002; Lee YJ, 2011, FREE RADICAL BIO MED, V50, P66, DOI 10.1016/j.freeradbiomed.2010.10.698; Lee YJ, 2012, J ALZHEIMERS DIS, V29, P677, DOI 10.3233/JAD-2012-111835; Lei H, 2014, J ASIAN NAT PROD RES, V16, P854, DOI 10.1080/10286020.2014.939586; Leung K., 2010, CHINESE MED, V5, P20, DOI DOI 10.1186/1749-8546-5-20; Li W, 2012, LIFE SCI, V91, P809, DOI 10.1016/j.lfs.2012.08.028; Li X, 2004, NEUROREPORT, V15, P2237, DOI 10.1097/00001756-200410050-00019; Li XH, 2015, CLIN INTERV AGING, V10, P549, DOI 10.2147/CIA.S74042; Li YK, 2003, J NEUROSCI, V23, P1605; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Lim DY, 2014, CANCER PREV RES, V7, P856, DOI 10.1158/1940-6207.CAPR-13-0286; Liu R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-105; Liu RX, 2016, AM J TRANSL RES, V8, P4082; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Ma L, 2003, BRAIN RES, V966, P167, DOI 10.1016/S0006-8993(02)04149-5; Macauley SL, 2014, J NEUROSCI, V34, P13077, DOI 10.1523/JNEUROSCI.2518-14.2014; Maphis N, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0221-y; Sabogal-Guaqueta AM, 2016, NEUROPHARMACOLOGY, V102, P111, DOI 10.1016/j.neuropharm.2015.11.002; Matos M, 2008, NEUROSCIENCE, V156, P898, DOI 10.1016/j.neuroscience.2008.08.022; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Moghaddam HS, 2017, REV NEUROSCIENCE, V28, P509, DOI 10.1515/revneuro-2016-0068; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Mufson EJ, 2012, ACTA NEUROPATHOL, V123, P13, DOI 10.1007/s00401-011-0884-1; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Munoz L, 2010, NEUROPHARMACOLOGY, V58, P561, DOI 10.1016/j.neuropharm.2009.11.010; Nai Y, 2018, HUM EXP TOXICOL, V37, P929, DOI 10.1177/0960327117745693; Nakamura Y, 2011, EMBO J, V30, P719, DOI 10.1038/emboj.2010.357; Ning B, 2013, J MOL NEUROSCI, V49, P380, DOI 10.1007/s12031-012-9893-3; Nobre AC, 2008, ASIA PAC J CLIN NUTR, V17, P167; Ojala JO, 2017, J CLIN MED, V6, DOI 10.3390/jcm6050055; Ojala JO, 2008, J NEUROIMMUNOL, V205, P86, DOI 10.1016/j.jneuroim.2008.09.012; Omata Yasuhiro, 2014, Am J Neurodegener Dis, V3, P134; Onyango IG, 2005, MOL CELL NEUROSCI, V29, P333, DOI 10.1016/j.mcn.2005.02.012; Ossoukhova A, 2015, HUM PSYCHOPHARM CLIN, V30, P108, DOI 10.1002/hup.2463; Pan YX, 2013, J CLIN NEUROSCI, V20, P726, DOI 10.1016/j.jocn.2012.09.012; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peebles CL, 2010, P NATL ACAD SCI USA, V107, P18173, DOI 10.1073/pnas.1006546107; Pei JJ, 2001, J ALZHEIMERS DIS, V3, P41, DOI 10.3233/JAD-2001-3107; Peng Y, 2012, J ALZHEIMERS DIS, V29, P379, DOI 10.3233/JAD-2011-111577; Peng Y, 2010, J NEUROSCI, V30, P8180, DOI 10.1523/JNEUROSCI.0340-10.2010; Penzes P, 2011, BRAIN RES REV, V67, P184, DOI 10.1016/j.brainresrev.2011.01.003; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Polotow TG, 2015, MAR DRUGS, V13, P6117, DOI 10.3390/md13106117; Puangmalai N, 2017, NEURAL REGEN RES, V12, P1492, DOI 10.4103/1673-5374.215262; Qi QQ, 2018, NEUROSCI LETT, V672, P59, DOI 10.1016/j.neulet.2017.11.051; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rehman SU, 2018, CEREB CORTEX, V28, P2854, DOI 10.1093/cercor/bhx164; REINIKAINEN KJ, 1990, J NEUROSCI RES, V27, P576, DOI 10.1002/jnr.490270419; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Rivera-Cervantes MC, 2015, J MOL NEUROSCI, V55, P596, DOI 10.1007/s12031-014-0398-0; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.0.CO;2-9; Rocca DL, 2008, NAT CELL BIOL, V10, P259, DOI 10.1038/ncb1688; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Sasaki N, 2002, NEUROSCI LETT, V326, P117, DOI 10.1016/S0304-3940(02)00310-5; Scheff SW, 1996, DEMENTIA, V7, P226, DOI 10.1159/000106884; Schnoder L, 2016, J BIOL CHEM, V291, P2067, DOI 10.1074/jbc.M115.695916; Scholey A, 2010, PSYCHOPHARMACOLOGY, V212, P345, DOI 10.1007/s00213-010-1964-y; Schuehly W, 2011, CHEM BIOL, V18, P1053, DOI 10.1016/j.chembiol.2011.05.012; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shen JN, 2015, CURR ALZHEIMER RES, V12, P892, DOI 10.2174/156720501209151019111244; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; Soane L, 2007, J NEUROSCI RES, V85, P3407, DOI 10.1002/jnr.21498; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Spires-Jones TL, 2008, J NEUROSCI, V28, P862, DOI 10.1523/JNEUROSCI.3072-08.2008; Stein IS, 2015, J NEUROSCI, V35, P12303, DOI 10.1523/JNEUROSCI.4289-14.2015; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Sun AY, 2003, EXP NEUROL, V183, P394, DOI 10.1016/S0014-4886(03)00180-8; Sutinen EM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-199; Tan MS, 2012, NEUROSCI LETT, V516, P226, DOI 10.1016/j.neulet.2012.03.093; Tang SC, 2017, NEUROMOL MED, V19, P579, DOI 10.1007/s12017-017-8471-9; Thangnipon W, 2016, NEUROSCI LETT, V610, P6, DOI 10.1016/j.neulet.2015.10.050; Thangnipon W, 2015, ARCH PHARM RES, V38, P1380, DOI 10.1007/s12272-015-0593-8; Thangnipona W, 2013, NEUROSCI LETT, V556, P20, DOI 10.1016/j.neulet.2013.09.071; Torres M, 2015, APOPTOSIS, V20, P712, DOI 10.1007/s10495-015-1099-z; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; de la Torre AV, 2013, PHARMACOL RES, V70, P116, DOI 10.1016/j.phrs.2013.01.007; Vignini A, 2013, CURR DIABETES REV, V9, P218, DOI 10.2174/1573399811309030003; Wang G, 2012, PROG NEUROBIOL, V98, P207, DOI 10.1016/j.pneurobio.2012.06.003; Wang HM, 2010, THIRTEENTH NATIONAL CONFERENCE ON PACKAGING ENGINEERING, TNCPE 13, P1; Wang S, 2014, J CLIN NEUROSCI, V21, P810, DOI 10.1016/j.jocn.2013.08.017; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Watterson DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066226; Wei W, 2010, NAT NEUROSCI, V13, P190, DOI 10.1038/nn.2476; Wenk GL, 2003, J CLIN PSYCHIAT, V64, P7; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213; Wu J, 2011, CELL, V147, P615, DOI 10.1016/j.cell.2011.09.036; Wu ZF, 2014, MOL NEUROBIOL, V50, P986, DOI 10.1007/s12035-014-8675-z; Xiang J, 2014, INT J CLIN EXP MED, V7, P1706; Xiong ZL, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00238; Xu J, 2012, NEUROPHARMACOLOGY, V62, P2424, DOI 10.1016/j.neuropharm.2012.02.014; Xu W, 2016, NEUROCHEM INT, V100, P44, DOI 10.1016/j.neuint.2016.08.012; Yamagishi S, 2003, J BIOCHEM, V133, P719, DOI 10.1093/jb/mvg092; Yan HQ, 2017, NEUROL RES, V39, P337, DOI 10.1080/01616412.2016.1268775; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan Shirley ShiDu, 2012, Front Biosci (Schol Ed), V4, P240; Yang S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/215798; Yang ZH, 2012, J ASIAN NAT PROD RES, V14, P14, DOI 10.1080/10286020.2011.620393; Yasuda S., 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P45; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu Y, 2008, EXP BRAIN RES, V184, P307, DOI 10.1007/s00221-007-1100-3; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang CH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007257; Zhang HY, 2011, EXP GERONTOL, V46, P30, DOI 10.1016/j.exger.2010.09.013; Zhang L, 2010, NEUROCHEM INT, V57, P547, DOI 10.1016/j.neuint.2010.06.021; Zheng L, 2011, AUTOPHAGY, V7, P1528, DOI 10.4161/auto.7.12.18051; Zheng QH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005803; Zhou W, 2013, FUTURE MED CHEM, V5, P1559, DOI 10.4155/fmc.13.125; Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880	202	37	39	4	26	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	JAN	2019	30	1					9	30		10.1515/revneuro-2018-0008			22	Neurosciences	Neurosciences & Neurology	HF3HI	WOS:000454125700002	29804103				2021-06-18	
J	Witcher, KG; Bray, CE; Dziabis, JE; McKim, DB; Benner, BN; Rowe, RK; Kokiko-Cochran, ON; Popovich, PG; Lifshitz, J; Eiferman, DS; Godbout, JP				Witcher, Kristina G.; Bray, Chelsea E.; Dziabis, Julia E.; McKim, Daniel B.; Benner, Brooke N.; Rowe, Rachel K.; Kokiko-Cochran, Olga N.; Popovich, Phillip G.; Lifshitz, Jonathan; Eiferman, Daniel S.; Godbout, Jonathan P.			Traumatic brain injury-induced neuronal damage in the somatosensory cortex causes formation of rod-shaped microglia that promote astrogliosis and persistent neuroinflammation	GLIA			English	Article						astrocytes; CSF1R antagonist; fluid percussion injury; microglia; neuroinflammation; traumatic brain injury	PSYCHIATRIC-DISORDERS; AXONAL INJURY; CELL; ACTIVATION; AXOTOMY; PROLIFERATION; INFLAMMATION; REACTIVITY; DEFICITS; ATROPHY	Microglia undergo dynamic structural and transcriptional changes during the immune response to traumatic brain injury (TBI). For example, TBI causes microglia to form rod-shaped trains in the cerebral cortex, but their contribution to inflammation and pathophysiology is unclear. The purpose of this study was to determine the origin and alignment of rod microglia and to determine the role of microglia in propagating persistent cortical inflammation. Here, diffuse TBI in mice was modeled by midline fluid percussion injury (FPI). Bone marrow chimerism and BrdU pulse-chase experiments revealed that rod microglia derived from resident microglia with limited proliferation. Novel data also show that TBI-induced rod microglia were proximal to axotomized neurons, spatially overlapped with dense astrogliosis, and aligned with apical pyramidal dendrites. Furthermore, rod microglia formed adjacent to hypertrophied microglia, which clustered among layer V pyramidal neurons. To better understand the contribution of microglia to cortical inflammation and injury, microglia were eliminated prior to TBI by CSF1R antagonism (PLX5622). Microglial elimination did not affect cortical neuron axotomy induced by TBI, but attenuated rod microglial formation and astrogliosis. Analysis of 262 immune genes revealed that TBI caused profound cortical inflammation acutely (8 hr) that progressed in nature and complexity by 7 dpi. For instance, gene expression related to complement, phagocytosis, toll-like receptor signaling, and interferon response were increased 7 dpi. Critically, these acute and chronic inflammatory responses were prevented by microglial elimination. Taken together, TBI-induced neuronal injury causes microglia to structurally associate with neurons, augment astrogliosis, and propagate diverse and persistent inflammatory/immune signaling pathways.	[Witcher, Kristina G.; Bray, Chelsea E.; Dziabis, Julia E.; McKim, Daniel B.; Benner, Brooke N.; Kokiko-Cochran, Olga N.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, 231 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Kokiko-Cochran, Olga N.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA; [Eiferman, Daniel S.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA	Godbout, JP (corresponding author), Ohio State Univ, Dept Neurosci, 231 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu		Rowe, Rachel/0000-0002-9034-3159	Ray W. Poppleton Endowment; National Institute of Dental and Craniofacial Research TrainingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32-DE-01-4320]; National Institute of Neurological Disease and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30-NS-04758]; American Surgical Society Fellowship; OSU Center for Brain and Spinal Cord Repair; College of Medicine Dean's Discovery; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56-NS-090311]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE014320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758] Funding Source: NIH RePORTER	Ray W. Poppleton Endowment; National Institute of Dental and Craniofacial Research Training, Grant/Award Number: T32-DE-01-4320; National Institute of Neurological Disease and Stroke, Grant/Award Number: P30-NS-04758; American Surgical Society Fellowship; OSU Center for Brain and Spinal Cord Repair; College of Medicine Dean's Discovery; NINDS, Grant/Award Number: R56-NS-090311	Alway Y, 2016, PSYCHOL MED, V46, P1331, DOI 10.1017/S0033291715002986; Bachstetter AD, 2017, NEUROBIOL AGING, V52, P98, DOI 10.1016/j.neurobiolaging.2016.12.028; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Cronk JC, 2018, J EXP MED, V215, P1627, DOI 10.1084/jem.20180247; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Ji P, 2016, BRAIN BEHAV IMMUN, V54, P243, DOI 10.1016/j.bbi.2016.02.010; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Lifshitz J, 2016, BRAIN INJURY, V30, P1293, DOI 10.1080/02699052.2016.1193628; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mandyam CD, 2007, NEUROSCIENCE, V146, P108, DOI 10.1016/j.neuroscience.2006.12.064; Mattugini N, 2018, GLIA, V66, P1644, DOI 10.1002/glia.23329; McKim DB, 2018, MOL PSYCHIATR, V23, P1421, DOI 10.1038/mp.2017.64; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Morrison H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13581-z; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rice RA, 2017, GLIA, V65, P931, DOI 10.1002/glia.23135; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Rowe RK, 2016, METHODS MOL BIOL, V1462, P211, DOI 10.1007/978-1-4939-3816-2_13; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sierra A, 2016, GLIA, V64, P1801, DOI 10.1002/glia.23046; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Villacampa N, 2015, GLIA, V63, P1166, DOI 10.1002/glia.22807; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Wofford KL, 2017, EXP NEUROL, V290, P85, DOI 10.1016/j.expneurol.2017.01.004; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Yuan TF, 2015, SCI REP-UK, V5, DOI 10.1038/srep10788; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	54	37	37	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	DEC	2018	66	12					2719	2736		10.1002/glia.23523			18	Neurosciences	Neurosciences & Neurology	HF2MH	WOS:000454070100014	30378170	Green Accepted			2021-06-18	
J	Doran, SJ; Ritzel, RM; Glaser, EP; Henry, RJ; Faden, AI; Loane, DJ				Doran, Sarah J.; Ritzel, Rodney M.; Glaser, Ethan P.; Henry, Rebecca J.; Faden, Alan I.; Loane, David J.			Sex Differences in Acute Neuroinflammation after Experimental Traumatic Brain Injury Are Mediated by Infiltrating Myeloid Cells	JOURNAL OF NEUROTRAUMA			English	Article						macrophage; microglia; neuroinflammation; sex differences; traumatic brain injury	GENDER-DIFFERENCE; INFARCT VOLUME; HEAD-INJURY; RAT MODEL; MILD; NEURODEGENERATION; PREDICTORS; MICROGLIA; RECOVERY; MODERATE	The inflammatory response to moderate-severe controlled cortical impact (CCI) in adult male mice has been shown to exhibit greater glial activation compared with age-matched female mice. However, the relative contributions of resident microglia and infiltrating peripheral myeloid cells to this sexually dimorphic neuroinflammatory responses remains unclear. Here, 12-week-old male and female C57Bl/6 mice were subjected to sham or CCI, and brain samples were collected at 1, 3, or 7 days post-injury for flow cytometry analysis of cytokines, reactive oxygen species (ROS), and phagocytosis in resident microglia (CD45(int)CD11b+) versus infiltrating myeloid cells (CD45(hi)CD11b+). Motor (rotarod, cylinder test), affect (open field), and cognitive (Y-maze) function tests also were performed. We demonstrate that male microglia had increased phagocytic activity and higher ROS levels in the non-injured brain, whereas female microglia had increased production of tumor necrosis factor (TNF) alpha and interleukin (IL)-1 beta. Following CCI, males showed a significant influx of peripheral myeloid cells by 1 day post-injury followed by proliferation of resident microglia at 3 days. In contrast, myeloid infiltration and microglial activation responses in female CCI mice were significantly reduced. No sex differences were observed for TNF alpha, IL-1 beta, transforming growth factor beta, NOX2, ROS production, or phagocytic activity in resident microglia or infiltrating cells at any time. However, across these functions, infiltrating myeloid cells were significantly more reactive than resident microglia. Female CCI mice also had improved motor function at 1 day post-injury compared with male mice. Thus, we conclude that sexually dimorphic responses to moderate-severe CCI result from the rapid activation and infiltration of pro-inflammatory myeloid cells to brain in male, but not female, mice.	[Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA	Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@som.umaryland.edu		Faden, Alan I./0000-0003-0128-2348; Ritzel, Rodney/0000-0002-0160-2930; Henry, Rebecca/0000-0001-8548-1170; Loane, David/0000-0003-0393-3503	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, F32NS105355, T32AI095190]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS082308, F32NS105355] Funding Source: NIH RePORTER	We would like to acknowledge Victoria Meadows, B.Sc., Nivedita Hegdekar, B.Sc., Nicholas Braganca, B.Sc., and Wesley Shoap, B.Sc., for their technical assistance. We thank Xiaoxuan Fan, Ph.D., and Karen Underwood, B.Sc., of the University of Maryland Greenebaum Comprehensive Cancer Center Flow Cytometry Facility for support with flow cytometry studies. This work was supported by National Institutes of Health grants R01NS082308 (D.J. Loane), R01NS037313 (A.I. Faden), F32NS105355 (R.M. Ritzel), and T32AI095190 (S.J. Doran).	Acaz-Fonseca E, 2015, GLIA, V63, P1966, DOI 10.1002/glia.22867; Albrecht JS, 2016, J TRAUMA ACUTE CARE, V81, P486, DOI 10.1097/TA.0000000000001118; Armstead WM, 2017, J NEUROTRAUM, V34, P1666, DOI 10.1089/neu.2016.4770; Bai RJ, 2017, NEUROCHEM RES, V42, P2892, DOI 10.1007/s11064-017-2310-0; Bai RJ, 2017, MED SCI MONITOR, V23, P1707, DOI 10.12659/MSM.901124; Banerjee A, 2013, TRANSL STROKE RES, V4, P554, DOI 10.1007/s12975-013-0268-z; Baum J, 2016, WORLD NEUROSURG, V90, P525, DOI 10.1016/j.wneu.2015.12.012; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Caplan HW, 2017, J NEUROSCI RES, V95, P509, DOI 10.1002/jnr.23854; Clevenger AC, 2018, J MOL NEUROSCI, V64, P410, DOI 10.1007/s12031-018-1038-x; Dale DC, 2008, BLOOD, V112, P935, DOI 10.1182/blood-2007-12-077917; Dotson AL, 2017, J NEUROSCI RES, V95, P437, DOI 10.1002/jnr.23784; Dotson AL, 2015, J NEUROIMMUNOL, V278, P289, DOI 10.1016/j.jneuroim.2014.11.020; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; Khaksari M, 2018, TRANSL STROKE RES, V9, P393, DOI 10.1007/s12975-017-0588-5; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441-017-2753-2; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P1; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; McFadyen MP, 2003, GENES BRAIN BEHAV, V2, P214, DOI 10.1034/j.1601-183X.2003.00028.x; Meyer MR, 2011, ACTA PHYSIOL, V203, P259, DOI 10.1111/j.1748-1716.2010.02237.x; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Russell KL, 2011, J NEUROSCI METH, V199, P214, DOI 10.1016/j.jneumeth.2011.05.008; Schellinck HM, 2010, ADV STUD BEHAV, V41, P255, DOI 10.1016/S0065-3454(10)41007-4; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Spychala MS, 2017, J NEUROSCI RES, V95, P462, DOI 10.1002/jnr.23962; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Taylor AN, 2018, J NEUROTRAUM, V35, P630, DOI 10.1089/neu.2017.5238; Tosun C, 2013, BRAIN SCI, V3, P215, DOI 10.3390/brainsci3010215; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Wright DK, 2017, ANN CLIN TRANSL NEUR, V4, P640, DOI 10.1002/acn3.441; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052	61	37	38	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					1040	1053		10.1089/neu.2018.6019		NOV 2018	14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR6CG	WOS:000450730100001	30259790	Green Published, Bronze			2021-06-18	
J	Obusez, EC; Lowe, M; Oh, SH; Wang, I; Bullen, J; Ruggieri, P; Hill, V; Lockwood, D; Emch, T; Moon, D; Loy, G; Lee, J; Kiczek, M; Massand, M; Statsevych, V; Stultz, T; Jones, SE				Obusez, Emmanuel C.; Lowe, Mark; Oh, Se-Hong; Wang, Irene; Bullen, Jennifer; Ruggieri, Paul; Hill, Virginia; Lockwood, Daniel; Emch, Todd; Moon, Doksu; Loy, Gareth; Lee, Jonathan; Kiczek, Matthew; Massand, Manoj; Statsevych, Volodymyr; Stultz, Todd; Jones, Stephen E.			7T MR of intracranial pathology: Preliminary observations and comparisons to 3T and 1.5T	NEUROIMAGE			English	Article						7T; Amyotrophic Lateral Sclerosis; Cavernous malformation; Cerebral Amyloid Angiopathy; Cortical infarcts; Epilepsy; Ultra-high-field MRI; Intracranial neuropathology; Intracranial pathology; Intracranial tumor; Multiple sclerosis; Mild traumatic brain injury; Orbital melanoma	AMYOTROPHIC-LATERAL-SCLEROSIS; PROSPECTIVE MOTION CORRECTION; CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; CORTICOSPINAL TRACT; IN-VIVO; CORTICAL MICROINFARCTS; SUPERFICIAL SIDEROSIS	Purpose: There have been an increasing number of studies involving ultra-high-field 7T of intracranial pathology, however, comprehensive clinical studies of neuropathology at 7T still remain limited. 7T has the advantage of a higher signal-to-noise ratio and a higher contrast-to-noise ratio, compared to current low field clinical MR scanners. We hypothesized 7T applied clinically, may improve detection and characterization of intracranial pathology. Materials and methods: We performed an IRB-approved 7T prospective study of patients with neurological disease who previously had lower field 3T and 1.5T. All patients underwent 7T scans, using comparable clinical imaging protocols, with the aim of qualitatively comparing neurological lesions at 7T with 3T or 1.5T. To qualitatively assess lesion conspicuity at 7T compared with low field, 80-paired images were viewed by 10 experienced neuroradiologists and scored on a 5-point scale. Inter-rater agreement was characterized using a raw percent agreement and mean weighted kappa. Results: One-hundred and four patients with known neurological disease have been scanned to date. Fifty-five patients with epilepsy, 18 patients with mild traumatic brain injury, 11 patients with known or suspected multiple sclerosis, 9 patients with amyotrophic lateral sclerosis, 4 patients with intracranial neoplasm, 2 patients with orbital melanoma, 2 patients with cortical infarcts, 2 patients with cavernous malformations, and 1 patient with cerebral amyloid angiopathy. From qualitative observations, we found better resolution and improved detection of lesions at 7T compared to 3T. There was a 55% raw inter-rater agreement that lesions were more conspicuous on 7T than 3T/1.5T, compared with a 6% agreement that lesions were more conspicuous on 3T/1.5T than 7T. Conclusion: Our findings show that the primary clinical advantages of 7T magnets, which include higher signal-to-noise ratio, higher contrast-to-noise ratio, smaller voxels and stronger susceptibility contrast, may increase lesion conspicuity, detection and characterization compared to low field 1.5T and 3T. However, low field which detects a plethora of intracranial pathology remains the mainstay for diagnostic imaging until limitations at 7T are addressed and further evidence of utility provided.	[Obusez, Emmanuel C.; Bullen, Jennifer; Ruggieri, Paul; Hill, Virginia; Lockwood, Daniel; Emch, Todd; Moon, Doksu; Loy, Gareth; Lee, Jonathan; Kiczek, Matthew; Massand, Manoj; Statsevych, Volodymyr; Stultz, Todd; Jones, Stephen E.] Cleveland Clin, Imaging Inst, Dept Neuroradiol, Cleveland, OH 44195 USA; [Lowe, Mark; Oh, Se-Hong; Jones, Stephen E.] Cleveland Clin, Mellen Ctr, Cleveland, OH 44195 USA; [Wang, Irene] Cleveland Clin, Epilepsy Ctr, Cleveland, OH 44195 USA	Jones, SE (corresponding author), Cleveland Clin, Imaging Inst, Dept Diagnost Radiol, Mail Code U15,9500 Euclid Ave, Cleveland, OH 44195 USA.	joness19@ccf.org					Abdel-Fahim R, 2014, MULT SCLER RELAT DIS, V3, P258, DOI 10.1016/j.msard.2013.10.004; Balchandani P, 2015, AM J NEURORADIOL, V36, P1204, DOI 10.3174/ajnr.A4180; Biller A., 2015, AM J NEURORADIOL; Breyer T, 2010, ACAD RADIOL, V17, P421, DOI 10.1016/j.acra.2009.10.013; Charidimou A, 2015, BRAIN, V138, P2126, DOI 10.1093/brain/awv162; da Rocha AJ, 2004, AM J NEURORADIOL, V25, P1509; De Ciantis A, 2016, EPILEPSIA, V57, P445, DOI 10.1111/epi.13313; de Graaf WL, 2013, EUR RADIOL, V23, P528, DOI 10.1007/s00330-012-2619-7; de Moortele P.- F., 2009, NEUROIMAGE, V46, P432; De Reuck J, 2013, CEREBROVASC DIS, V36, P412, DOI 10.1159/000355042; Dula AN, 2015, MULT SCLER; Duyn JH, 2012, NEUROIMAGE, V62, P1241, DOI 10.1016/j.neuroimage.2011.10.065; Edelvik A, 2013, NEUROLOGY, V81, P1244, DOI 10.1212/WNL.0b013e3182a6ca7b; Eichner C, 2014, MAGN RESON MED, V72, P949, DOI 10.1002/mrm.25389; Garbelli R, 2012, BRAIN, V135, P2337, DOI 10.1093/brain/aws149; Ge Y, 2008, ARCH NEUROL-CHICAGO, V65, P812, DOI 10.1001/archneur.65.6.812; Gizewski ER, 2014, NEURORADIOLOGY, V56, P177, DOI 10.1007/s00234-013-1312-0; Grams AE, 2013, CLIN NEURORADIOL, V23, P17, DOI 10.1007/s00062-012-0144-3; Haines K, 2010, J MAGN RESON, V203, P323, DOI 10.1016/j.jmr.2010.01.003; Hargreaves BA, 2004, MAGN RESON MED, V52, P590, DOI 10.1002/mrm.20168; Harteveld A. A., 2016, EUR RADIOL; Hecht MJ, 2005, NEURORADIOLOGY, V47, P805, DOI 10.1007/s00234-005-1421-5; Hecht MJ, 2002, J NEUROL SCI, V199, P59, DOI 10.1016/S0022-510X(02)00104-1; Hecht MJ, 2001, J NEUROL SCI, V186, P37, DOI 10.1016/S0022-510X(01)00503-2; Kerchner GA, 2011, J ALZHEIMERS DIS, V26, P91, DOI 10.3233/JAD-2011-0023; Kollia K, 2009, AM J NEURORADIOL, V30, P699, DOI 10.3174/ajnr.A1434; Kraff O, 2009, INVEST RADIOL, V44, P518, DOI 10.1097/RLI.0b013e3181b4c0cf; Kwan JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035241; Liu GB, 2015, ACTA RADIOL, V56, P1256, DOI 10.1177/0284185114552883; Lusebrink F, 2013, NEUROIMAGE, V70, P122, DOI 10.1016/j.neuroimage.2012.12.016; Madai VI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037631; Madan N, 2009, EPILEPSIA, V50, P9, DOI 10.1111/j.1528-1167.2009.02292.x; Marques JP, 2010, NEUROIMAGE, V49, P1271, DOI 10.1016/j.neuroimage.2009.10.002; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Monninghoff C, 2010, ROFO-FORTSCHR RONTG, V182, P764, DOI 10.1055/s-0029-1245440; Moenninghoff C, 2010, KOREAN J RADIOL, V11, P244, DOI 10.3348/kjr.2010.11.2.244; Moenninghoff C, 2010, EUR RADIOL, V20, P704, DOI 10.1007/s00330-009-1592-2; Ngai S, 2007, AM J NEURORADIOL, V28, P250; Ni J, 2015, J ALZHEIMERS DIS, V43, P1325, DOI 10.3233/JAD-140864; Noebauer-Huhmann IM, 2015, EUR RADIOL, V25, P106, DOI 10.1007/s00330-014-3351-2; Novak V, 2005, MAGN RESON IMAGING, V23, P539, DOI 10.1016/j.mri.2005.02.010; Phal PM, 2008, AM J ROENTGENOL, V191, P890, DOI 10.2214/AJR.07.3933; Sakai N, 2013, AM J NEURORADIOL, V34, P2139, DOI 10.3174/ajnr.A3564; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Singh AD, 2016, OCUL ONCOL PATHOL, V2, P178, DOI 10.1159/000443650; Springer E, 2016, INVEST RADIOL, V51, P469, DOI 10.1097/RLI.0000000000000256; Tallantyre EC, 2010, J MAGN RESON IMAGING, V32, P971, DOI 10.1002/jmri.22115; Teeuwisse WM, 2012, MAGN RESON MED, V67, P912, DOI 10.1002/mrm.24176; Tellez-Zenteno JF, 2010, EPILEPSY RES, V89, P310, DOI 10.1016/j.eplepsyres.2010.02.007; Thomas BP, 2008, J MAGN RESON IMAGING, V28, P1266, DOI 10.1002/jmri.21576; U. S. Food and Drug Administration, 2014, CRIT SIGN RISK INV M; Van de Moortele PF, 2009, NEUROIMAGE, V46, P432, DOI 10.1016/j.neuroimage.2009.02.009; van der Kolk AG, 2015, AM J NEURORADIOL, V36, P694, DOI 10.3174/ajnr.A4178; van der Kolk AG, 2013, EUR J RADIOL, V82, P708, DOI 10.1016/j.ejrad.2011.07.007; van Veluw SJ, 2015, J CEREBR BLOOD F MET, V35, P676, DOI 10.1038/jcbfm.2014.258; van Veluw SJ, 2013, J CEREBR BLOOD F MET, V33, P322, DOI 10.1038/jcbfm.2012.196; Wuerfel J, 2012, MULT SCLER J, V18, P1592, DOI 10.1177/1352458512441270; Yang QX, 2006, J MAGN RESON IMAGING, V24, P197, DOI 10.1002/jmri.20603; Yarach U, 2016, MAGN RESON MATER PHY, V29, P319, DOI 10.1007/s10334-015-0515-2; Yarach U, 2015, MAGN RESON MED, V73, P1562, DOI 10.1002/mrm.25283; Yu JX, 2014, AMYOTROPH LAT SCL FR, V15, P357, DOI 10.3109/21678421.2014.906618; Zucca I, 2016, ANN NEUROL, V79, P42, DOI 10.1002/ana.24541	62	37	38	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR	2018	168				SI		459	476		10.1016/j.neuroimage.2016.11.030			18	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FZ5LQ	WOS:000427634500034	27915116				2021-06-18	
J	Li, WT; Chen, RH; Lv, J; Wang, HK; Liu, Y; Peng, Y; Qian, ZY; Fu, G; Nie, LM				Li, Weitao; Chen, Ronghe; Lv, Jing; Wang, Hongke; Liu, Yu; Peng, Ya; Qian, Zhiyu; Fu, Guo; Nie, Liming			In Vivo Photoacoustic Imaging of Brain Injury and Rehabilitation by High-Efficient Near-Infrared Dye Labeled Mesen-chymal Stem Cells with Enhanced Brain Barrier Permeability	ADVANCED SCIENCE			English	Article						blood-brain barrier; bone mesenchymal stem cells; photoacoustic tomography; Prussian blue; traumatic brain injury	MESENCHYMAL STROMAL CELLS; LIVING SUBJECTS; NANOPARTICLES; TRACKING; DESIGN; GROWTH	Stem cell migration and interaction with pathology are critical to understand the complexity and status of disease recovery progress. However, the dynamic visualization still remains a great challenge due to imaging technical limitation, cell labeling difficulty, or blood-brain barrier (BBB). Herein, fast photoacoustic tomography (PAT) with optical molecular probes is applied to noninvasively monitor traumatic brain injury (TBI) and its rehabilitation. The vascular distribution and TBI hemorrhage are clearly imaged, longitudinally monitored, and quantified. Bone mesenchymal stem cells (BMSCs) labeled with modified Prussian blue particles (PBPs), excellent near-infrared dyes and photoacoustic contrasts, are intravenously injected to the mice for improved observation and efficient therapy. BMSCs are demonstrated to be capable of overcoming BBB with enhanced delivery of PBPs to the brain parenchyma. Notably, the versatile BMSCs are observed by PAT to home to the damage region and repair the ruptured vasculature. Moreover, the wound treated by BMSCs exhibits much faster recovery speed than that without treatment. These findings can potentially provide a new noninvasive and high-resolution approach to image TBI, monitor recovery process, and especially trace BMSCs. This study will stimulate extensive researches on brain diseases and provide promising strategies of dye labeled BMSCs in regenerative medicine.	[Li, Weitao; Wang, Hongke; Qian, Zhiyu] Nanjing Univ Aeronaut & Astronaut, Coll Automat Engn, Dept Biomed Engn, Nanjing 210016, Jiangsu, Peoples R China; [Chen, Ronghe; Lv, Jing; Wang, Hongke; Liu, Yu; Peng, Ya; Nie, Liming] Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China; [Chen, Ronghe; Lv, Jing; Wang, Hongke; Liu, Yu; Peng, Ya; Nie, Liming] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361102, Peoples R China; [Fu, Guo] Xiamen Univ, Sch Life Sci, Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol & Innovat, Xiamen 361102, Peoples R China	Nie, LM (corresponding author), Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.; Nie, LM (corresponding author), Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361102, Peoples R China.	nielm@xmu.edu.cn	Nie, Liming/AAI-4354-2020	Nie, Liming/0000-0002-1781-4612	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571744, 81601489, 61378092]; National Basic Research Program of China (863 Program)National Basic Research Program of ChinaNational High Technology Research and Development Program of China [2015AA020502]; Science Foundation of Fujian ProvinceNatural Science Foundation of Fujian Province [2014Y2004]; Jiangsu Science and Technology Support Plan (Social Development) [BE2016759]; Fundamental Research Funds for the central UniversitiesFundamental Research Funds for the Central Universities [20720170065 21, 20720170036]	W.L., R.C., and J.L. contributed equally to this work. This work was supported by National Natural Science Foundation of China (Grant Nos. 81571744, 81601489 and 61378092), National Basic Research Program of China (863 Program 2015AA020502), Science Foundation of Fujian Province (Grant No. 2014Y2004), Jiangsu Science and Technology Support Plan (Social Development) (Grant No. BE2016759), and the Fundamental Research Funds for the central Universities (Grant Nos. 20720170065 21 and 20720170036).	Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Chen WQ, 2014, NANO TODAY, V9, P759, DOI 10.1016/j.nantod.2014.12.002; Gao JH, 2009, NANO TODAY, V4, P37, DOI 10.1016/j.nantod.2008.10.009; Gloviczki ML, 2011, HYPERTENSION, V58, P1066, DOI 10.1161/HYPERTENSIONAHA.111.171405; Hu ZH, 2014, MOL PHARMACEUT, V11, P3798, DOI 10.1021/mp500321h; Huang P, 2014, J AM CHEM SOC, V136, P8307, DOI 10.1021/ja503115n; Huang XL, 2014, ACS NANO, V8, P4403, DOI 10.1021/nn4062726; Kim J, 2016, NANOSCALE, V8, P8512, DOI 10.1039/c6nr02143c; Koliatsos VE, 2015, REGEN MED, V10, P917, DOI 10.2217/rme.15.62; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Liang XL, 2013, CHEM COMMUN, V49, P11029, DOI 10.1039/c3cc42510j; Liu SY, 2016, ACS APPL MATER INTER, V8, P11925, DOI 10.1021/acsami.5b12371; Liu Y, 2016, ADV MATER, V28, P6411, DOI 10.1002/adma.201506460; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d; Mayer AR, 2015, HUM BRAIN MAPP, V36, P4394, DOI 10.1002/hbm.22930; Mohtasebi MS, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/457614; Muroski ME, 2014, J AM CHEM SOC, V136, P14763, DOI 10.1021/ja505190q; Nie LM, 2014, ACS NANO, V8, P12141, DOI 10.1021/nn505989e; Nie LM, 2014, SMALL, V10, P1585, DOI 10.1002/smll.201302924; Nie LM, 2014, NANOSCALE, V6, P1271, DOI 10.1039/c3nr05468c; Nie LM, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.110506; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Picinich SC, 2007, EXPERT OPIN BIOL TH, V7, P965, DOI 10.1517/14712598.7.7.965; Ratto F, 2016, ADV FUNCT MATER, V26, P7178, DOI 10.1002/adfm.201600836; Reitz M, 2012, STEM CELL TRANSL MED, V1, P866, DOI 10.5966/sctm.2012-0045; Rich LJ, 2015, RADIOLOGY, V275, P110, DOI 10.1148/radiol.14140654; Rosa M, 2016, J NEUROTRAUM, V33, P1015, DOI 10.1089/neu.2015.4062; Schulze F, 2014, SMALL, V10, P4340, DOI 10.1002/smll.201400707; Shokouhimehr M, 2010, J MATER CHEM, V20, P5251, DOI 10.1039/b923184f; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Tang YH, 2015, ADV FUNCT MATER, V25, P1024, DOI 10.1002/adfm.201402930; Treble-Barna A, 2017, J NEUROTRAUM, V34, P353, DOI 10.1089/neu.2016.4476; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Xu CT, 2012, ACS NANO, V6, P4788, DOI 10.1021/nn3015807; Yao JJ, 2016, NAT METHODS, V13, P67, DOI [10.1038/NMETH.3656, 10.1038/nmeth.3656]; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310; Zhu XH, 2013, NEUROIMAGE, V64, P437, DOI 10.1016/j.neuroimage.2012.09.028	39	37	41	4	48	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2198-3844			ADV SCI	Adv. Sci.	FEB	2018	5	2							1700277	10.1002/advs.201700277			11	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	FX6MR	WOS:000426200000004	29619293	DOAJ Gold, Green Published			2021-06-18	
J	Grima, NA; Rajaratnam, SMW; Mansfield, D; Sletten, TL; Spitz, G; Ponsford, JL				Grima, Natalie A.; Rajaratnam, Shantha M. W.; Mansfield, Darren; Sletten, Tracey L.; Spitz, Gershon; Ponsford, Jennie L.			Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial	BMC MEDICINE			English	Article						Sleep; Insomnia; Traumatic brain injury; Acquired brain injury	PROLONGED-RELEASE MELATONIN; RUNNING CIRCADIAN-RHYTHMS; BLIND SUBJECTS; INSOMNIA; DISORDERS; ASSOCIATION; TETRAPLEGIA; PREVALENCE; ALERTNESS; THERAPY	Background: The study aimed to determine the efficacy of melatonin supplementation for sleep disturbances in patients with traumatic brain injury (TBI). Methods: This is a randomised double-blind placebo-controlled two-period two-treatment (melatonin and placebo) crossover study. Outpatients were recruited from Epworth and Austin Hospitals Melbourne, Australia. They had mild to severe TBI (n = 33) reporting sleep disturbances post-injury (mean age 37 years, standard deviation 11 years; 67% men). They were given prolonged-release melatonin formulation (2 mg; Circadin (R)) and placebo capsules for 4 weeks each in a counterbalanced fashion separated by a 48-hour washout period. Treatment was taken nightly 2 hours before bedtime. Serious adverse events and side-effects were monitored. Results: Melatonin supplementation significantly reduced global Pittsburgh Sleep Quality Index scores relative to placebo, indicating improved sleep quality [melatonin 7.68 vs. placebo 9.47, original score units; difference -1.79; 95% confidence interval (CI), -2.70 to -0.88; p <= 0.0001]. Melatonin had no effect on sleep onset latency (melatonin 1.37 vs. placebo 1.42, log units; difference -0.05; 95% CI, -0.14 to 0.03; p = 0.23). With respect to the secondary outcomes, melatonin supplementation increased sleep efficiency on actigraphy, and vitality and mental health on the SF-36 v1 questionnaire (p <= 0.05 for each). Melatonin decreased anxiety on the Hospital Anxiety Depression Scale and fatigue on the Fatigue Severity Scale (p <= 0.05 for both), but had no significant effect on daytime sleepiness on the Epworth Sleepiness Scale (p = 0.15). No serious adverse events were reported. Conclusions: Melatonin supplementation over a 4-week period is effective and safe in improving subjective sleep quality as well as some aspects of objective sleep quality in patients with TBI.	[Grima, Natalie A.] Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA; [Rajaratnam, Shantha M. W.; Sletten, Tracey L.; Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol Sci, 18 Innovat Walk,Clayton Campus,Wellington Rd, Melbourne, Vic 3800, Australia; [Mansfield, Darren] Monash Hlth, Monash Lung & Sleep, 246 Clayton Rd, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, 18 Innovat Walk,Clayton Campus,Wellington Rd, Melbourne, Vic 3800, Australia.; Ponsford, JL (corresponding author), Epworth Healthcare, Monash Epworth Rehabil Res Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@monash.edu		Sletten, Tracey/0000-0002-0005-7838; Rajaratnam, Shantha/0000-0001-7527-8558	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1028733]	Funding of the study was supported by an Australian National Health and Medical Research Council project grant (1028733). The funder provided input into study design, but it was not involved in the collection, analysis or interpretation of the data. The funder played no role in the preparation, review, writing or approval of the manuscript.	American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S, Vthird; American Academy of Sleep Medicine, 2001, INT CLASS SLEEP DIS, P208; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Bruni O, 2017, EUR J PAEDIATR NEURO, V21, P420, DOI 10.1016/j.ejpn.2017.01.009; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V75, P447, DOI 10.1210/jc.75.2.447; Cunnington D, 2013, MED J AUSTRALIA, V199, pS36, DOI 10.5694/mja13.10718; Department of Health and Ageing, 2009, ANN REP, P42; Department of Health and Ageing Therapeutic Goods Administration, 2011, AUSTR PUBL ASS REP M; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; GOLOMBEK DA, 1993, EUR J PHARMACOL, V237, P231, DOI 10.1016/0014-2999(93)90273-K; Grima NA, 2016, NEUROREHAB NEURAL RE, V30, P972, DOI 10.1177/1545968316650279; Hack LM, 2003, J BIOL RHYTHM, V18, P420, DOI 10.1177/0748730403256796; HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598; Imbach LL, 2016, NEUROLOGY, V86, P1945, DOI 10.1212/WNL.0000000000002697; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lavie P, 1997, J BIOL RHYTHM, V12, P657, DOI 10.1177/074873049701200622; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lemoine P, 2007, J SLEEP RES, V16, P372, DOI 10.1111/j.1365-2869.2007.00613.x; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Lockley SW, 2000, J ENDOCRINOL, V164, pR1, DOI 10.1677/joe.0.164R001; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Marseglia L, 2015, INT J MOL SCI, V16, P1209, DOI 10.3390/ijms16011209; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nguyen S, 2017, ARCH PHYS MED REHAB, V98, P1508, DOI 10.1016/j.apmr.2017.02.031; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V82, P131; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Rajaratnam SMW, 2004, J PHYSIOL-LONDON, V561, P339, DOI 10.1113/jphysiol.2004.073742; Rogers NL, 2003, SLEEP, V26, P1058; Sack RL, 2000, NEW ENGL J MED, V343, P1070, DOI 10.1056/NEJM200010123431503; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shochat T, 1997, AM J PHYSIOL-REG I, V273, pR364; Sinclair KL, 2012, BEHAV SLEEP MED; Spong J, 2014, SPINAL CORD, V52, P629, DOI 10.1038/sc.2014.84; Spong J, 2013, SLEEP DISORD, V2013, P1; Valko PO, 2016, SLEEP, V39, P1249, DOI 10.5665/sleep.5844; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; Wade AG, 2010, BIOMED CENTRAL MED, V8; Wade AG, 2007, CURR MED RES OPIN, V23, P2597, DOI 10.1185/030079907X233098; Wade AG, 2011, CURR MED RES OPIN, V27, P87, DOI 10.1185/03007995.2010.537317; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189	51	37	38	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7015			BMC MED	BMC Med.	JAN 19	2018	16								8	10.1186/s12916-017-0995-1			10	Medicine, General & Internal	General & Internal Medicine	FT4JN	WOS:000423121400001	29347988	DOAJ Gold, Green Published			2021-06-18	
J	Zhou, J; Wang, HD; Shen, RM; Fang, J; Yang, YQ; Dai, W; Zhu, YH; Zhou, ML				Zhou, Jian; Wang, Handong; Shen, Ruiming; Fang, Jiang; Yang, Youqin; Dai, Wei; Zhu, Yihao; Zhou, Mengliang			Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Mitoquinone (MitoQ); traumatic brain injury; nuclear factor erythroid 2-related factor 2; oxidative stress; apoptosis; neuroprotection	INDUCED OXIDATIVE STRESS; ISCHEMIA-REPERFUSION INJURY; CLOSED-HEAD INJURY; CELL-DEATH; RAT-BRAIN; DISEASE; DAMAGE; MODEL; TOXICITY; MITOQUINONE	Mitoquinone (MitoQ) is a powerful mitochondrial-targeted antioxidant whose neuroprotective effects have been shown in a variety of animal models of neurological diseases. However, its roles in traumatic brain injury (TBI) remain unexplored. The primary objective of this study was to investigate the neuroprotection afforded by MitoQ in a mouse model of TBI, and the involvement of the Nrf2-ARE signaling pathway in the putative neuroprotective mechanism. Mice were randomly divided into four groups: sham group, TBI group, TBI + vehicle group, and TBI + MitoQ group. MitoQ (4 mg/kg, administered intraperitoneally) or an equal volume of vehicle was given at 30 min after TBI. After 24 h, brain samples were harvested for analysis. The results demonstrated that treatment with MitoQ significantly improved neurological deficits, alleviated brain edema and inhibited cortical neuronal apoptosis. Furthermore, MitoQ administration increased the activity of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPx), whereas it decreased the malondialdehyde (MDA) content. In addition, MitoQ treatment reduced Bax protein translocation to mitochondria and cytochrome c release into the cytosol. Moreover, MitoQ greatly accelerated the Nrf2 nuclear translocation and subsequently upregulated the expression of Nrf2 downstream proteins, including heme oxygenase-1 (HO-1) and quinone oxidoreductase 1 (Nqo1). In conclusion, the results in the study demonstrate that MitoQ exerts neuroprotective effects in the mouse model of TBI, possibly by activating the Nrf2-ARE pathway.	[Zhou, Jian; Wang, Handong; Dai, Wei] Nanjing Med Univ, Jinling Hosp, Jinling Clin Med Coll, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Zhou, Jian] Hainan Med Coll, Affiliated Hosp 1, Dept Neurosurg, Haikou 570102, Hainan, Peoples R China; [Shen, Ruiming] Hainan Med Coll, Affiliated Hosp 1, Dept Rheumatol, Haikou 570102, Hainan, Peoples R China; [Fang, Jiang] Southeast Univ, Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Yang, Youqin] Xinxiang Med Univ, Affiliated Hosp 1, Dept Neurosurg, Xinxiang 453100, Henan, Peoples R China; [Zhu, Yihao; Zhou, Mengliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Med Univ, Jinling Hosp, Jinling Clin Med Coll, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Fundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81571162, 81401026]	This study was grant-supported by the National Natural Science Fundation of China (No. 81371357, No. 81571162 and No. 81401026).	Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Ahmed E, 2015, J NEUROL NEUROSCI, V6; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Escribano-Lopez I, 2016, REDOX BIOL, V10, P200, DOI 10.1016/j.redox.2016.10.017; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gonzalez Y, 2014, ONCOTARGET, V5, P1526, DOI 10.18632/oncotarget.1715; Graham D, 2009, HYPERTENSION, V54, P322, DOI 10.1161/HYPERTENSIONAHA.109.130351; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Ma T, 2011, J NEUROSCI, V31, P5589, DOI 10.1523/JNEUROSCI.6566-10.2011; Manczak M, 2010, J ALZHEIMERS DIS, V20, pS609, DOI 10.3233/JAD-2010-100564; Neuzil J, 2007, REDOX REP, V12, P148, DOI 10.1179/135100007X200227; Oyewole AO, 2015, FASEB J, V29, P4766, DOI 10.1096/fj.15-275404; Paradies G, 2014, WORLD J GASTROENTERO, V20, P14205, DOI 10.3748/wjg.v20.i39.14205; Rao VA, 2010, J BIOL CHEM, V285, P34447, DOI 10.1074/jbc.M110.133579; Rehman Hasibur, 2016, Int J Physiol Pathophysiol Pharmacol, V8, P14; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Ross MF, 2008, BIOCHEM J, V411, P633, DOI 10.1042/BJ20080063; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003; Solesio ME, 2013, BBA-MOL BASIS DIS, V1832, P174, DOI 10.1016/j.bbadis.2012.07.009; Szeto HH, 2006, AAPS J, V8, pE521, DOI 10.1208/aapsj080362; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Wani WY, 2011, NEUROPHARMACOLOGY, V61, P1193, DOI 10.1016/j.neuropharm.2011.07.008; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiao L, 2017, REDOX BIOL, V11, P297, DOI 10.1016/j.redox.2016.12.022; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yin XL, 2016, HUM MOL GENET, V25, P1739, DOI 10.1093/hmg/ddw045	43	37	38	1	6	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2018	10	6					1887	1899					13	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	GL8HJ	WOS:000437458800028	30018728				2021-06-18	
J	Truettner, JS; Bramlett, HM; Dietrich, WD				Truettner, Jessie S.; Bramlett, Helen M.; Dietrich, W. Dalton			Posttraumatic therapeutic hypothermia alters microglial and macrophage polarization toward a beneficial phenotype	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Cytokines; inflammation; macrophages; microglial; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; BARRIER PERMEABILITY; MODERATE HYPOTHERMIA; WHITE-MATTER; RAT; NEUROINFLAMMATION; ACTIVATION; NEURODEGENERATION; NEUROPROTECTION	Posttraumatic inflammatory processes contribute to pathological and reparative processes observed after traumatic brain injury (TBI). Recent findings have emphasized that these divergent effects result from subsets of proinflammatory (M1) or anti-inflammatory (M2) microglia and macrophages. Therapeutic hypothermia has been tested in preclinical and clinical models of TBI to limit secondary injury mechanisms including proinflammatory processes. This study evaluated the effects of posttraumatic hypothermia (PTH) on phenotype patterns of microglia/ macrophages. Sprague-Dawley rats underwent moderate fluid percussion brain injury with normothermia (37 degrees C) or hypothermia (33 degrees C). Cortical and hippocampal regions were analyzed using flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR) at several periods after injury. Compared to normothermia, PTH attenuated infiltrating cortical macrophages positive for CD11b(+) and CD45 high. At 24 h, the ratio of iNOS(+) (M1) to arginase(+) (M2) cells after hypothermia showed a decrease compared to normothermia. RT-PCR of M1-associated genes including iNOS and IL-1 beta was significantly reduced with hypothermia while M2-associated genes including arginase and CD163 were significantly increased compared to normothermic conditions. The injury-induced increased expression of the chemokine Ccl2 was also reduced with PTH. These studies provide a link between temperature-sensitive alterations in macrophage/microglia activation and polarization toward a M2 phenotype that could be permissive for cell survival and repair.	[Truettner, Jessie S.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,Suite 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS089443, R01 NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS089443] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by R01 NS089443 and R01 NS042133 from NIH/NINDS.	Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dietrich WD, 2016, BRAIN RES, V1640, P94, DOI 10.1016/j.brainres.2015.12.034; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gruenbaum SE, 2016, CNS DRUGS, V30, P791, DOI 10.1007/s40263-016-0355-2; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Horst K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154788; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Saigal S, 2015, INDIAN J CRIT CARE M, V19, P537, DOI 10.4103/0972-5229.164806; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stocchetti N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0887-8; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yenari MA, 2013, FRONT NEUROL NEUROSC, V32, P122, DOI 10.1159/000346428; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	40	37	38	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2017	37	8					2952	2962		10.1177/0271678X16680003			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	FC0FO	WOS:000406514300025	27864465	Green Published, Bronze			2021-06-18	
J	Neukomm, LJ; Burdett, TC; Seeds, AM; Hampel, S; Coutinho-Budd, JC; Farley, JE; Wong, J; Karadeniz, YB; Osterloh, JM; Sheehan, AE; Freeman, MR				Neukomm, Lukas J.; Burdett, Thomas C.; Seeds, Andrew M.; Hampel, Stefanie; Coutinho-Budd, Jaeda C.; Farley, Jonathan E.; Wong, Jack; Karadeniz, Yonca B.; Osterloh, Jeannette M.; Sheehan, Amy E.; Freeman, Marc R.			Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly	NEURON			English	Article							TRAUMATIC BRAIN-INJURY; UBIQUITIN-LIGASE; WALLERIAN DEGENERATION; NEUROPROTECTIVE EFFICACY; DROSOPHILA-MELANOGASTER; SELF-DESTRUCTION; MOSAIC ANALYSIS; CELL-DEATH; SARM1; RECEPTOR	Axon degeneration is a hallmark of neurodegenerative disease and neural injury. Axotomy activates an intrinsic pro-degenerative axon death signaling cascade involving loss of the NAD(+) biosynthetic enzyme Nmnat/Nmnat2 in axons, activation of dSarm/Sarm1, and subsequent Sarm-dependent depletion of NAD(+). Here we identify Axundead (Axed) as a mediator of axon death. axed mutants suppress axon death in several types of axons for the lifespan of the fly and block the pro-degenerative effects of activated dSarm in vivo. Neurodegeneration induced by loss of the sole fly Nmnat ortholog is also fully blocked by axed, but not dsarm, mutants. Thus, pro-degenerative pathwaysactivatedby dSarm signaling or Nmnat elimination ultimately converge on Axed. Remarkably, severed axons morphologically preserved by axon death pathway mutations remain integrated in circuits and able to elicit complex behaviors after stimulation, indicating that blockade of axon death signaling results in long-term functional preservation of axons.	[Neukomm, Lukas J.; Burdett, Thomas C.; Coutinho-Budd, Jaeda C.; Farley, Jonathan E.; Wong, Jack; Karadeniz, Yonca B.; Osterloh, Jeannette M.; Sheehan, Amy E.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA; [Seeds, Andrew M.; Hampel, Stefanie] Howard Hughes Med Inst, Janelia Res Campus, Ashburn, VA USA; [Burdett, Thomas C.; Freeman, Marc R.] Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA; [Seeds, Andrew M.; Hampel, Stefanie] Univ Puerto Rico, Inst Neurobiol, Med Sci Campus, San Juan, PR 00936 USA; [Osterloh, Jeannette M.] Gladstone Inst, San Francisco, CA USA	Neukomm, LJ; Freeman, MR (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA.; Freeman, MR (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	lukas.neukomm@gmail.com; freemmar@ohsu.edu	Neukomm, Lukas/I-8636-2019	Neukomm, Lukas/0000-0002-5007-3959; Hampel, Stefanie/0000-0001-8287-549X; Freeman, Marc/0000-0003-3481-3715; Seeds, Andrew/0000-0002-4932-6496	Charles A. King Trust Postdoctoral Fellowship by Harold Whitworth Pierce Charitable Trust; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS053538]	The authors wish to thank Freeman laboratory members and colleagues in the field for feedback, comments, and suggestions. This work was supported by the Charles A. King Trust Postdoctoral Fellowship supported by the Harold Whitworth Pierce Charitable Trust (to L.J.N.) and by NINDS grant R01 NS053538 (to M.R.F.). During the period of this study, M.R.F. was an Investigator with the Howard Hughes Medical Institute.	Babetto E, 2013, CELL REP, V3, P1422, DOI 10.1016/j.celrep.2013.04.013; Backhaus B, 1984, DROSOPH INF SERV, V60, P210; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Cambronne XA, 2016, SCIENCE, V352, P1474, DOI 10.1126/science.aad5168; Chuang CF, 2005, GENE DEV, V19, P270, DOI 10.1101/gad.1276505; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Coutinho-Budd J, 2013, CURR OPIN NEUROBIOL, V23, P1073, DOI 10.1016/j.conb.2013.07.002; De Jesus-Cortes H., 2015, NPJ PARKINSONS DIS, V1, P889; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Fang YS, 2012, CURR BIOL, V22, P590, DOI 10.1016/j.cub.2012.01.065; Geisler S, 2016, BRAIN, V139, P3092, DOI 10.1093/brain/aww251; Gerdts J, 2016, NEURON, V89, P449, DOI 10.1016/j.neuron.2015.12.023; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2015, CELL REP, V10, P1974, DOI 10.1016/j.celrep.2015.02.060; Gilley J, 2013, J NEUROSCI, V33, P13410, DOI 10.1523/JNEUROSCI.1534-13.2013; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Hampel S, 2015, ELIFE, V4, DOI 10.7554/eLife.08758; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hoopfer ED, 2006, NEURON, V50, P883, DOI 10.1016/j.neuron.2006.05.013; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee T, 2000, NEURON, V28, P807, DOI 10.1016/S0896-6273(00)00155-0; Li N, 2015, GENE DEV, V29, P157, DOI 10.1101/gad.251785.114; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Metaxakis A, 2005, GENETICS, V171, P571, DOI 10.1534/genetics.105.041848; Milde S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001539; Muthukumar AK, 2014, NAT NEUROSCI, V17, P1340, DOI 10.1038/nn.3791; Neukomm LJ, 2014, P NATL ACAD SCI USA, V111, P9965, DOI 10.1073/pnas.1406230111; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Potter CJ, 2010, CELL, V141, P536, DOI 10.1016/j.cell.2010.02.025; Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297; Sasaki Y, 2016, ELIFE, V5, DOI 10.7554/eLife.19749; Sebo ZL, 2014, FLY, V8, P52, DOI 10.4161/fly.26828; Seeds AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02951; Simonin Y, 2007, EUR J NEUROSCI, V25, P2269, DOI 10.1111/j.1460-9568.2007.05501.x; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Stork T, 2014, NEURON, V83, P388, DOI 10.1016/j.neuron.2014.06.026; Summers DW, 2014, J NEUROSCI, V34, P9338, DOI 10.1523/JNEUROSCI.0877-14.2014; Tasdemir-Yilmaz OE, 2014, GENE DEV, V28, P20, DOI 10.1101/gad.229518.113; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Venken KJT, 2011, NAT METHODS, V8, P737, DOI 10.1038/nmeth.1662; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Wang AL, 2006, J NEUROSCI RES, V84, P1799, DOI 10.1002/jnr.21075; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Xiong X, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001440; Xu DB, 2005, DEVELOPMENT, V132, P2125, DOI 10.1242/dev.01790; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Zhai RG, 2006, PLOS BIOL, V4, P2336, DOI 10.1371/journal.pbio.0040416	59	37	39	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	JUL 5	2017	95	1					78	+		10.1016/j.neuron.2017.06.031			19	Neurosciences	Neurosciences & Neurology	EZ7CB	WOS:000404876500012	28683272	Bronze			2021-06-18	
J	Treleaven, J				Treleaven, Julia			Dizziness, Unsteadiness, Visual Disturbances, and Sensorimotor Control in Traumatic Neck Pain	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						cervical spine; proprioception; WAD; whiplash	WHIPLASH-ASSOCIATED DISORDERS; CERVICOCEPHALIC KINESTHETIC SENSIBILITY; CERVICAL ARTERIAL DISSECTION; EYE-MOVEMENT DISTURBANCES; SPORT-RELATED CONCUSSION; JOINT POSITION ERROR; SOFT-TISSUE INJURY; PERSISTENT WHIPLASH; POSTURAL STABILITY; VESTIBULAR REHABILITATION	There is considerable evidence to support the importance of cervical afferent dysfunction in the development of dizziness, unsteadiness, visual disturbances, altered balance, and altered eye and head movement control following neck trauma, especially in those with persistent symptoms. However, there are other possible causes for these symptoms, and secondary adaptive changes should also be considered in differential diagnosis. Understanding the nature of these symptoms and differential diagnosis of their potential origin is important for rehabilitation. In addition to symptoms, the evaluation of potential impairments (altered cervical joint position and movement sense, static and dynamic balance, and ocular mobility and coordination) should become an essential part of the routine assessment of those with traumatic neck pain, including those with concomitant injuries such as concussion and vestibular or visual pathology or deficits. Once adequately assessed, appropriate tailored management should be implemented. Research to further assist differential diagnosis and to understand the most important contributing factors associated with abnormal cervical afferent input and subsequent disturbances to the sensorimotor control system, as well as the most efficacious management of such symptoms and impairments, is important for the future.	[Treleaven, Julia] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Neck Pain & Whiplash Res Grp, St Lucia, Qld, Australia	Treleaven, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, St Lucia, Qld 4072, Australia.	j.treleaven@uq.edu.au	Treleaven, Julia/N-1379-2019	Treleaven, Julia/0000-0002-6258-3972			Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Asama Y, 2012, ACTA OTO-LARYNGOL, V132, P1168, DOI 10.3109/00016489.2012.699197; Bagust J, 2005, ARCH PHYS MED REHAB, V86, P1062, DOI 10.1016/j.apmr.2004.05.022; Bahat HS, 2015, MANUAL THER, V20, P295, DOI 10.1016/j.math.2014.10.002; Baloh R. W., 1996, DISORDERS VESTIBULAR; Barnett BP, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-014-0329-y; Bexander CSM, 2012, EXP BRAIN RES, V217, P67, DOI 10.1007/s00221-011-2973-8; Bianco A, 2014, ACTA OTO-LARYNGOL, V134, P947, DOI 10.3109/00016489.2014.906749; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Brown S, 2003, CLIN EXP OPHTHALMOL, V31, P424, DOI 10.1046/j.1442-9071.2003.00690.x; Chen XQ, 2013, MANUAL THER, V18, P562, DOI 10.1016/j.math.2013.05.015; Ciavarro GL, 2006, J BIOMECH, V39, pS149; Cohen JM, 2009, CEPHALALGIA, V29, P162; Cohen JM, 2011, HEADACHE, V51, P1393, DOI 10.1111/j.1526-4610.2011.01934.x; Corneil BD, 2002, J NEUROPHYSIOL, V88, P1980, DOI 10.1152/jn.2002.88.4.1980; Cote JN, 2009, GAIT POSTURE, V29, P603, DOI 10.1016/j.gaitpost.2008.12.014; Daenen L, 2012, PAIN PHYSICIAN, V15, P405; Daenen L, 2012, RHEUMATOLOGY, V51, P1492, DOI 10.1093/rheumatology/kes050; de Vries J, 2015, MANUAL THER, V20, P736, DOI 10.1016/j.math.2015.04.015; de Vries J, 2016, PHYS THER, V96, P1190, DOI 10.2522/ptj.20150211; Della Casa E, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-16; Dispenza F, 2011, AM J OTOLARYNG, V32, P376, DOI 10.1016/j.amjoto.2010.07.009; Dispenza F, 2011, AURIS NASUS LARYNX, V38, P185, DOI 10.1016/j.anl.2010.08.007; Elliott J, 2006, SPINE, V31, pE847, DOI 10.1097/01.brs.0000240841.07050.34; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Falla D, 2004, MANUAL THER, V9, P125, DOI 10.1016/j.math.2004.05.003; Fattori B, 1996, ACUPUNCTURE ELECTRO, V21, P207, DOI 10.3727/036012996816356861; Ferrari R, 1999, ARTHRIT CARE RES, V12, P70, DOI 10.1002/1529-0131(199902)12:1<70::AID-ART11>3.0.CO;2-B; Field S, 2008, MANUAL THER, V13, P183, DOI 10.1016/j.math.2006.12.005; Findling O, 2011, GAIT POSTURE, V34, P473, DOI 10.1016/j.gaitpost.2011.06.021; FISCHER AJEM, 1995, J NEUROL SCI, V132, P35, DOI 10.1016/0022-510X(95)00118-L; Freitag P, 2001, NEUROREHAB NEURAL RE, V15, P31, DOI 10.1177/154596830101500105; Furman JM, 2001, J ANXIETY DISORD, V15, P9, DOI 10.1016/S0887-6185(00)00040-2; Geiger G, 2012, UNFALLCHIRURG, V115, P629, DOI 10.1007/s00113-011-2151-2; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Morganti LOG, 2016, BRAZ J OTORHINOLAR, V82, P397, DOI 10.1016/j.bjorl.2015.06.003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Grimm RJ, 2002, J WHIPLASH REL DISOR, V1, P65, DOI DOI 10.3109/J180V0LN01_06; Grip H, 2009, J CLIN MONIT COMPUT, V23, P31, DOI 10.1007/s10877-009-9160-5; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Hansson EE, 2006, J REHABIL MED, V38, P387, DOI 10.1080/16501970600768992; Hansson EE, 2013, J REHABIL MED, V45, P906, DOI 10.2340/16501977-1197; Heikkila H, 2000, MANUAL THER, V5, P151, DOI 10.1054/math.2000.0357; Heikkila HV, 1998, ARCH PHYS MED REHAB, V79, P1089, DOI 10.1016/S0003-9993(98)90176-9; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Herdman S, 2000, VESTIBULAR REHABILIT; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; HILDINGSSON C, 1993, ACTA ORTHOP SCAND, V64, P129, DOI 10.3109/17453679308994552; Humphreys BK, 2002, J WHIPLASH RELATED D, V1, P99, DOI DOI 10.3109/J180V0LN01_09; Imai T, 2016, ACTA OTO-LARYNGOL, V136, P283, DOI 10.3109/00016489.2015.1121547; Janssen M, 2015, SPINE, V40, pE1052, DOI 10.1097/BRS.0000000000001016; Jull G., 2008, WHIPLASH HEADACHE NE; Kloen P, 1999, ARCH ORTHOP TRAUM SU, V119, P478, DOI 10.1007/s004020050027; Knox JJ, 2006, CLIN J PAIN, V22, P512, DOI 10.1097/01.ajp.0000210997.53082.c9; Kongsted A, 2007, CLIN REHABIL, V21, P1038, DOI 10.1177/0269215507075519; Kristjansson E, 2004, ARCH PHYS MED REHAB, V85, P490, DOI 10.1016/S0003-9993(03)00619-1; Kristjansson E, 2010, SPINE, V35, pE1298, DOI 10.1097/BRS.0b013e3181e7fc0a; L'Heureux-Lebeau B, 2014, OTOL NEUROTOL, V35, P1858, DOI 10.1097/MAO.0000000000000506; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Lee Jae-Wook, 2013, Korean J Audiol, V17, P18, DOI 10.7874/kja.2013.17.1.18; Lempert T, 2014, REV NEUROL-FRANCE, V170, P401, DOI 10.1016/j.neurol.2013.05.010; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Madeleine P, 2004, ARCH PHYS MED REHAB, V85, P432, DOI 10.1016/j.apmr.2003.03.003; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; Montfoort I, 2008, J NEUROTRAUM, V25, P687, DOI 10.1089/neu.2007.0314; Montfoort I, 2006, INVEST OPHTH VIS SCI, V47, P2881, DOI 10.1167/iovs.05-1561; Mosimann UP, 2000, BRAIN, V123, P828, DOI 10.1093/brain/123.4.828; Nacci A, 2011, ACTA OTORHINOLARYNGO, V31, P378; Oddsdottir G., 2006, THESIS; Oddsdottir GL, 2012, MANUAL THER, V17, P60, DOI 10.1016/j.math.2011.08.009; Oka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132191; Padula WV, 1996, NEUROREHABILITATION, V6, P165, DOI 10.3233/NRE-1996-6302; Passatore M, 2006, EUR J APPL PHYSIOL, V98, P423, DOI 10.1007/s00421-006-0312-8; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Pedler A, 2013, MANUAL THER, V18, P72, DOI 10.1016/j.math.2012.07.006; Peterson BW, 2004, PROG BRAIN RES, V143, P369, DOI 10.1016/S0079-6123(03)43035-5; Phillips LA, 2010, EUR SPINE J, V19, P945, DOI 10.1007/s00586-010-1276-2; Cobo EP, 2010, SPINE, V35, pE338, DOI 10.1097/BRS.0b013e3181c9b075; Cobo EP, 2009, MED CLIN-BARCELONA, V132, P616, DOI 10.1016/j.medcli.2008.11.039; Provinciali L, 1996, SCAND J REHABIL MED, V28, P105; Reid SA, 2015, MANUAL THER, V20, P148, DOI 10.1016/j.math.2014.08.003; Reid SA, 2014, ARCH PHYS MED REHAB, V95, P1603, DOI 10.1016/j.apmr.2014.04.009; Reneker JC, 2015, J SCI MED SPORT, V18, P366, DOI 10.1016/j.jsams.2014.05.002; REVEL M, 1991, ARCH PHYS MED REHAB, V72, P288; Richter HO, 2014, WORK, V47, P413, DOI 10.3233/WOR-131776; Richter HO, 2010, PERCEPTION, V39, P119, DOI 10.1068/p6418; Sandlund J, 2006, J REHABIL MED, V38, P44, DOI 10.1080/16501970510042847; Sandlund J, 2008, J REHABIL MED, V40, P366, DOI 10.2340/16501977-0175; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Silva AG, 2013, PHYSIOTHER THEOR PR, V29, P1, DOI 10.3109/09593985.2012.677111; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; Solarino B, 2009, ACTA OTO-LARYNGOL, V129, P976, DOI 10.1080/00016480802527552; Stalnacke BM, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/528265; Stapley PJ, 2006, CLIN NEUROPHYSIOL, V117, P610, DOI 10.1016/j.clinph.2005.11.007; Sterling M, 2003, PAIN, V103, P65, DOI 10.1016/S0304-3959(02)00420-7; Stokell R, 2011, MANUAL THER, V16, P394, DOI 10.1016/j.math.2011.01.012; Storaci R, 2006, EUR SPINE J, V15, P1811, DOI 10.1007/s00586-006-0085-0; Swait G, 2007, SPINE, V32, pE692, DOI 10.1097/BRS.0b013e31815a5a1b; Szabo T.J., 1996, HUMAN SUBJECT KINEMA; Takasaki H, 2013, ARCH PHYS MED REHAB, V94, P1328, DOI 10.1016/j.apmr.2012.12.013; Takasaki H, 2012, ARCH PHYS MED REHAB, V93, P1774, DOI 10.1016/j.apmr.2012.05.013; Taylor J, 1996, J MUSCULOSKELET PAIN, V4, P61, DOI DOI 10.1300/J094V04N04_07; Thomas LC, 2016, MANUAL THER, V21, P2, DOI 10.1016/j.math.2015.07.008; Thomas LC, 2015, J ORTHOP SPORT PHYS, V45, P503, DOI 10.2519/jospt.2015.5877; Thunberg J, 2001, PAIN, V91, P15, DOI 10.1016/S0304-3959(00)00415-2; Tjell C, 1998, AM J OTOL, V19, P76; Tranter RMD, 2009, J FORENSIC LEG MED, V16, P53, DOI 10.1016/j.jflm.2008.09.001; Treleaven J, 2006, MANUAL THER, V11, P99, DOI 10.1016/j.math.2005.04.003; Treleaven J, 2005, J REHABIL MED, V37, P219, DOI 10.1080/16501970410024299; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2012, J ORTHOP SPORT PHYS, V42, pA65; Treleaven J, 2008, ARCH PHYS MED REHAB, V89, P522, DOI 10.1016/j.apmr.2007.11.002; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; Treleaven J, 2016, MANUAL THER, V22, P122, DOI 10.1016/j.math.2015.10.017; Treleaven J, 2015, MANUAL THER, V20, P183, DOI 10.1016/j.math.2014.08.005; Treleaven J, 2014, MANUAL THER, V19, P203, DOI 10.1016/j.math.2014.01.005; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Treleaven J, 2011, MANUAL THER, V16, P252, DOI 10.1016/j.math.2010.11.002; Treleaven J, 2010, MANUAL THER, V15, P206, DOI 10.1016/j.math.2009.05.001; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Wenngren BI, 2002, ACTA OTO-LARYNGOL, V122, P276, DOI 10.1080/000164802753648150; Wieser T, 2004, NEUROL SCI, V25, P8, DOI 10.1007/s10072-004-0218-6; Wilhelmsen K, 2014, PHYS THER, V94, P1024, DOI 10.2522/ptj.20130070; Williams K, 2017, MUSCULOSKEL SCI PRAC, V29, P115, DOI 10.1016/j.msksp.2017.03.012; Woodhouse A, 2010, EXP BRAIN RES, V201, P261, DOI 10.1007/s00221-009-2033-9; Yu LJ, 2011, MANUAL THER, V16, P339, DOI 10.1016/j.math.2010.12.006	132	37	37	0	17	J O S P T	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011	1938-1344		J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	JUL	2017	47	7					492	502		10.2519/jospt.2017.7052			11	Orthopedics; Rehabilitation; Sport Sciences	Orthopedics; Rehabilitation; Sport Sciences	EZ4HG	WOS:000404673600007	28622488				2021-06-18	
J	Cummiskey, B; Schiffmiller, D; Talavage, TM; Leverenz, L; Meyer, JJ; Adams, D; Nauman, EA				Cummiskey, Brian; Schiffmiller, David; Talavage, Thomas M.; Leverenz, Larry; Meyer, Janette J.; Adams, Douglas; Nauman, Eric A.			Reliability and accuracy of helmet-mounted and head-mounted devices used to measure head accelerations	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART P-JOURNAL OF SPORTS ENGINEERING AND TECHNOLOGY			English	Article						Traumatic brain injury; head accelerations; telemetry; football; impulse hammer	HIGH-SCHOOL FOOTBALL; TRAUMATIC BRAIN-INJURY; AMERICAN FOOTBALL; IMPACT; PLAYERS; CONCUSSION; IMPAIRMENT; SYSTEM	The attention given to brain injury has grown in recent years as its effects have become better understood. A desire to investigate the causal agents of head trauma in athletes has led to the development and use of several devices that track head impacts. In order to determine which devices best measure these impacts, a Hybrid III headform was used to quantify the accuracy for translational and angular accelerations. Testing was performed by mounting each device into the helmet as instructed by its manufacturer, fitting the helmet on the headform, and impacting the helmet using an impulse hammer. The root mean square error for the peak translational acceleration varied with location. The worst root mean square error for a head-mounted device was 74.7% while the worst for a helmet-mounted device was 298%. Head-mounted devices consistently outperformed those mounted in helmets, suggesting that future sensor designs should avoid attachment to the helmet. Deployment to a high school football team affirmed differences between two of the device models, but strongly indicated that head-mounted systems require further development to account for variation between individuals, the relative motion of the skin, and helmet-sensor interactions. Future work needs to account for these issues, refine the algorithms used to estimate the translational and angular accelerations, and examine technologies that better locate the source of the impact.	[Cummiskey, Brian; Schiffmiller, David; Talavage, Thomas M.; Leverenz, Larry; Nauman, Eric A.] Purdue Univ, 585 Purdue Mall, W Lafayette, IN 47906 USA; [Meyer, Janette J.; Adams, Douglas] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA	Nauman, EA (corresponding author), Purdue Univ, 585 Purdue Mall, W Lafayette, IN 47906 USA.	enauman@purdue.edu			BrainScope	The authors would like to thank X2 Biosystems Inc. for donating several of their xPatch devices for our use, Triax for loaning us a pair of units of the SIM-G, and BrainScope for providing partial support for this study.	Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Adams DE, 2012, TOPICS MODAL ANAL 1, V5, P277; [Anonymous], 2001, RATES TBI RELATED EM; Bartsch A, 2012, J NEUROSURG, V116, P222, DOI 10.3171/2011.9.JNS111059; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM, 2014, ATHL TRAIN SPORTS HL, V5, P119; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Goldsmith Werner, 2005, Critical Reviews in Biomedical Engineering, V33, P105, DOI 10.1615/CritRevBiomedEng.v33.i2.20; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; NUSHOLTZ GS, 1984, P 28 STAPP CAR CRASH, P41; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	29	37	37	0	17	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1754-3371	1754-338X		P I MECH ENG P-J SPO	Proc. Inst. Mech. Eng. Part P-J. Sport. Eng. Technol.	JUN	2017	231	2					144	153		10.1177/1754337116658395			10	Engineering, Mechanical; Sport Sciences	Engineering; Sport Sciences	EX5JE	WOS:000403276400008					2021-06-18	
J	Wammes, JD; Good, TJ; Fernandes, MA				Wammes, Jeffrey D.; Good, Tyler J.; Fernandes, Myra A.			Autobiographical and episodic memory deficits in mild traumatic brain injury	BRAIN AND COGNITION			English	Article						Mild traumatic brain injury; Concussion; Aging; Episodic memory; Semantic memory; Autobiographical memory	DIFFUSE AXONAL INJURY; NEUROPSYCHOLOGICAL OUTCOMES; HEAD-INJURY; COGNITIVE SEQUELAE; CONCUSSION; SPORTS; LONG; ABNORMALITIES; RECOLLECTION; METAANALYSIS	Those who have suffered a concussion, otherwise known as a mild traumatic brain injury (mTBI), often complain of lingering memory problems. However, there is little evidence in the behavioral literature reliably demonstrating memory deficits. Thus, in the present study, cognitive profiles including measures of general executive functioning and processing speed, as well as episodic and semantic memory were collected in younger and older adult participants with or without a remote (>1 year prior to testing) mTBI. We first investigated whether there were observable episodic and autobiographical memory impairments associated with mTBI within an otherwise healthy' young group. Next, because previous work had demonstrated some overlap in patterns of behavioral impairment in normally aging adults and younger adults with a history of mTBI (e.g. Ozen, Fernandes, Clark, & Roy, 2015), we sought to determine whether these groups displayed similar cognitive profiles. Lastly, we conducted an exploratory analysis to test whether having suffered an mTBI might exacerbate age-related cognitive decline. Results showed the expected age-related decline in episodic memory performance, coupled with a relative preservation of semantic memory in older adults. Importantly, this pattern was also present in younger adults with a history of remote mTBI. No differences were observed across older adult groups based on mTBI status. Logistic regression analyses, using each measure in our battery as a predictor, successfully classified mTBI status in younger participants with a high degree of specificity (79.5%). These results indicate that those who have had an mTBI demonstrate a distinct cognitive signature, characterized by impairment in episodic and autobiographical memory, coupled with a relative preservation of semantic memory. (C) 2016 Elsevier Inc. All rights reserved.	[Wammes, Jeffrey D.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada; [Good, Tyler J.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Good, Tyler J.] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada	Wammes, JD (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	jwammes@uwaterloo.ca		Wammes, Jeffrey/0000-0002-8923-5441	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was funded by a scholarship from the Natural Science and Engineering Research Council (NSERC) awarded to author J.W.; and an NSERC Discovery grant awarded to author M.F. The authors would like to thank Jingwen Cao for her dedication to helping us complete this project.	ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; Alves W., 1992, PHYS MED REHABILITAT, V6, P21; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Army Individual Test Battery, 1944, MAN DIR SCOR; Baayen R. H., 1995, The CELEX lexical database. Linguistic data consortium; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bornstein R. A., 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Bradley M. M., 1999, PSYCHOLOGY C, VC-1, P1; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Bucur B, 2008, NEUROBIOL AGING, V29, P1070, DOI 10.1016/j.neurobiolaging.2007.02.008; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeza R, 1997, NEUROREPORT, V8, P3479, DOI 10.1097/00001756-199711100-00013; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Christiansen K., 2016, NEUROIMAGE; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Douet V, 2015, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00343; Dritschel BH, 1998, BRAIN INJURY, V12, P875; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Farber M., 1994, SPORTS ILLUSTRATED; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Karr JE, 2014, NEUROPSYCHOL REV, V24, P428, DOI 10.1007/s11065-014-9271-8; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kausler D. H., 1994, LEARNING MEMORY NORM, P276; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kinnunen K. M., 2010, BRAIN, V347; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LIGHT LL, 1991, ANNU REV PSYCHOL, V42, P333, DOI 10.1146/annurev.ps.42.020191.002001; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McRae K, 2005, BEHAV RES METHODS, V37, P547, DOI 10.3758/BF03192726; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITCHELL DB, 1989, J EXP PSYCHOL LEARN, V15, P31, DOI 10.1037/0278-7393.15.1.31; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nyberg L, 1996, J GERONTOL B-PSYCHOL, V51, pP234, DOI 10.1093/geronb/51B.4.P234; Ozen LJ, 2015, AGING NEUROPSYCHOL C, V22, P517, DOI 10.1080/13825585.2014.993584; Ozen LJ, 2013, BRAIN INJURY, V27, P1244, DOI 10.3109/02699052.2013.804207; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; Ozen LJ, 2010, J INT NEUROPSYCH SOC, V16, P556, DOI 10.1017/S1355617710000202; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Piolino P, 2006, PSYCHOL AGING, V21, P510, DOI 10.1037/0882-7974.21.3.510; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rasmussen KW, 2014, J NEUROPSYCHOL, V8, P34, DOI 10.1111/jnp.12003; Raven J. C., 1958, USING MILL HILL VOCA; Raven J. C., 1989, MILL HILL VOCABULARY; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reuter-Lorenz PA, 2008, CURR DIR PSYCHOL SCI, V17, P177, DOI 10.1111/j.1467-8721.2008.00570.x; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rudebeck SR, 2009, J NEUROSCI, V29, P14987, DOI 10.1523/JNEUROSCI.4707-09.2009; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Steffener J, 2009, BRAIN IMAGING BEHAV, V3, P142, DOI 10.1007/s11682-008-9056-x; Stirling DP, 2010, TRENDS MOL MED, V16, P160, DOI 10.1016/j.molmed.2010.02.002; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Verhaeghen P, 2003, PSYCHOL AGING, V18, P332, DOI 10.1037/0882-7974.18.2.332; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wittenbrook JM, 1941, J NERV MENT DIS, V94, P170, DOI 10.1097/00005053-194194020-00004; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yonelinas AP, 2002, J MEM LANG, V46, P441, DOI 10.1006/jmla.2002.2864; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhuang L, 2012, J ALZHEIMERS DIS, V29, P629, DOI 10.3233/JAD-2012-111766	107	37	37	0	40	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	FEB	2017	111						112	126		10.1016/j.bandc.2016.11.004			15	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	EI3CC	WOS:000392366300013	27886529				2021-06-18	
J	Yang, H; Gu, ZT; Li, L; Maegele, M; Zhou, BY; Li, F; Zhao, M; Zhao, KS				Yang, Hong; Gu, Zheng-tao; Li, Li; Maegele, Mac; Zhou, Bi-ying; Li, Feng; Zhao, Ming; Zhao, Ke-sen			SIRT1 plays a neuroprotective role in traumatic brain injury in rats via inhibiting the p38 MAPK pathway	ACTA PHARMACOLOGICA SINICA			English	Article						traumatic brain injury; lateral fluid-percussion; SIRT1; p38; mitochondria; sirtinol; SB203580; neuroprotection	ACTIVATED PROTEIN-KINASES; REDUCE OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; HEMORRHAGIC-SHOCK; CEREBRAL ISCHEMIA/REPERFUSION; GLUCOSE DEPRIVATION; ALZHEIMERS-DISEASE; FOREBRAIN ISCHEMIA; SLICE CULTURES; CELL-DEATH	Traumatic brain injury (TBI) is a major cause of disability and death in patients who experience a traumatic injury. Mitochondrial dysfunction is one of the main factors contributing to secondary injury in TBI-associated brain damage. Evidence of compromised mitochondrial function after TBI has been, but the molecular mechanisms underlying the pathogenesis of TBI are not well understood. Silent information regulator family protein 1 (SIRT1), a member of the NAD(+)-dependent protein deacetylases, has been shown to exhibit neuroprotective activities in animal models of various pathologies, including ischemic brain injury, subarachnoid hemorrhage and several neurodegenerative diseases. In this study, we investigated whether SIRT1 also exert neuroprotective effect post-TBI, and further explored the possible regulatory mechanisms involved in TBI pathogenesis. A lateral fluid-percussion (LFP) brain injury model was established in rats to mimic the insults of TBI. The expression levels of SIRT1, p-p38, cleaved caspase-9 and cleaved caspase-3 were all markedly increased and reached a maximum at 12 h post-TBI. In addition, mitochondrial function was impaired, evidenced by the presence of swollen and irregularly shaped mitochondria with disrupted and poorly defined cristae, a relative increase of the percentage of neurons with low Delta psi m, the opening of mPTP, and a decrease in neuronal ATP content, especially at 12 h post-TBI. Pretreatment with the SIRT1 inhibitor sirtinol (10 mg/kg, ip) induced p-p38 activation, exacerbated mitochondrial damage, and promoted the activation of the mitochondrial apoptosis pathway. In contrast, pretreatment with the p38 inhibitor SB203580 (200 mu g/kg, ip) significantly attenuated post-TBI-induced expression of both cleaved caspase-9 and cleaved caspase-3 and mitochondrial damage, whereas it had no effects on SIRT1 expression. Together, these results reveal that the 12 h after TBI may be a crucial time at which secondary damage occurs; the activation of SIRT1 expression and inhibition of the p38 MAPK pathway may play a neuroprotective role in preventing secondary damage post-TBI. For this reason, both SIRT1 and p38 are likely to be important targets to prevent secondary damage post-TBI.	[Yang, Hong; Gu, Zheng-tao; Li, Li; Li, Feng] Southern Med Univ, Affiliated Hosp 3, Dept Intens Care Unit, Guangzhou 510630, Guangdong, Peoples R China; [Maegele, Mac] Private Univ Witten Herdecke, CMMC, Inst Res Operat Med IFOM, Ostmerheimerstr 200, D-51109 Cologne, Germany; [Yang, Hong; Gu, Zheng-tao; Li, Li; Zhou, Bi-ying; Zhao, Ming; Zhao, Ke-sen] Southern Med Univ, Dept Pathophysiol, Guangdong Prov Key Lab Shock & Microcirculat Res, Guangzhou 510515, Guangdong, Peoples R China	Zhao, M; Zhao, KS (corresponding author), Southern Med Univ, Dept Pathophysiol, Guangdong Prov Key Lab Shock & Microcirculat Res, Guangzhou 510515, Guangdong, Peoples R China.	15602239057@163.com; zhaoks@fimmu.com					Bai XZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10277; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Baur JA, 2012, NAT REV DRUG DISCOV, V11, P443, DOI 10.1038/nrd3738; Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5; Boeck CR, 2013, MOL CELL BIOCHEM, V384, P129, DOI 10.1007/s11010-013-1790-8; Brewer GJ, 2007, NAT PROTOC, V2, P1490, DOI 10.1038/nprot.2007.207; Calvanese V, 2010, P NATL ACAD SCI USA, V107, P13736, DOI 10.1073/pnas.1001399107; Chen B, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-77; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crouser ED, 2002, CRIT CARE MED, V30, P2722, DOI 10.1097/00003246-200212000-00017; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fu B, 2014, NEUROSCIENCE, V281, P251, DOI 10.1016/j.neuroscience.2014.09.058; Fujimoto S, 2004, NEUROSCI RES, V50, P179, DOI 10.1016/j.neures.2004.06.013; Gajavelli S, 2015, J BIOENERG BIOMEMBR, V47, P133, DOI 10.1007/s10863-014-9589-1; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Hernandez-Jimenez M, 2013, STROKE, V44, P2333, DOI 10.1161/STROKEAHA.113.001715; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hurtado O, 2013, J NEUROCHEM, V126, P819, DOI 10.1111/jnc.12269; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jayasena T, 2013, AGEING RES REV, V12, P867, DOI 10.1016/j.arr.2013.06.003; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Khan RS, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-3; Khan RS, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00063; Kobeissy F, 2015, BRAIN NEUROTRAUMA MO; Lalla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00016; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee SI, 2011, J ENDODONT, V37, P1525, DOI 10.1016/j.joen.2011.07.006; Li H, 2015, J NEUROL SCI, V357, P270, DOI 10.1016/j.jns.2015.08.004; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu XW, 2014, MOL MED REP, V10, P1942, DOI 10.3892/mmr.2014.2402; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; Park GJ, 2013, J PERIODONTAL RES, V48, P483, DOI 10.1111/jre.12030; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; Ray B, 2009, J NEUROSCI METH, V184, P294, DOI 10.1016/j.jneumeth.2009.08.018; RINK A, 1995, AM J PATHOL, V147, P1575; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630; Strassburger M, 2008, EUR J PHARMACOL, V592, P55, DOI 10.1016/j.ejphar.2008.06.099; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun QR, 2014, BIOCHEM BIOPH RES CO, V447, P485, DOI 10.1016/j.bbrc.2014.04.019; Takeda K, 2002, GENES CELLS, V7, P1099, DOI 10.1046/j.1365-2443.2002.00591.x; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Wang L, 2009, EUR J PHARMACOL, V609, P40, DOI 10.1016/j.ejphar.2009.03.033; Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018; Wang WB, 2015, J NEUROL SCI, V348, P121, DOI 10.1016/j.jns.2014.11.018; Wang XM, 2013, EXPERT OPIN INV DRUG, V22, P169, DOI 10.1517/13543784.2013.748033; Wang XM, 2012, AM J PHYSIOL-REG I, V302, pR805, DOI 10.1152/ajpregu.00350.2011; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamashita S, 2009, BRAIN RES, V1301, P171, DOI 10.1016/j.brainres.2009.08.096; Yang Y, 2015, J PINEAL RES, V58, P61, DOI 10.1111/jpi.12193; Zhang XF, 2015, J INEQUAL APPL, DOI 10.1186/1029-242X-2015-1; Zhao Y., 2012, J NANOTECHNOL, V2012, P1, DOI DOI 10.1186/1741-7015-10-3]; Zhou X., 2014, J COMPUTER SYSTEM SC, V1, P1; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	60	37	39	0	14	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	FEB	2017	38	2					168	181		10.1038/aps.2016.130			14	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	EJ2AY	WOS:000393013400002	28017962	Green Published, Bronze			2021-06-18	
J	Barnard, E; Yates, D; Edwards, A; Fragoso-Iniguez, M; Jenks, T; Smith, JE				Barnard, Ed; Yates, David; Edwards, Antoinette; Fragoso-Iniguez, Marisol; Jenks, Tom; Smith, Jason E.			Epidemiology and aetiology of traumatic cardiac arrest in England and Wales - A retrospective database analysis	RESUSCITATION			English	Article						Trauma; Cardiac arrest; Traumatic cardiac arrest; Epidemiology	RESUSCITATION COUNCIL GUIDELINES; SPECIAL CIRCUMSTANCES; INJURY; ALGORITHM; OUTCOMES	Background: Historically, reported survival from traumatic cardiac arrest (TCA) was extremely low. More recent publications have recorded survival to discharge of up to 8%. This improvement is likely to be multi-factorial; however, there are currently no published data describing the epidemiology or aetiology of TCA in England and Wales to guide future practice improvement. Methods: Population-based analysis of 2009-2015 Trauma Audit and Research Network (TARN) data. The primary aim was to describe the 30-day survival following TCA. Patients of all ages with traumatic cardiac arrest pre-hospital or in the emergency department (ED) were included. Data are described as number (%), and median [interquartile range]. Two-group analysis with Chi-squared test was performed. Results: During the study period 227,944 patients were included in the TARN database. Seven hundred and five (0.3%) suffered TCA: 74.3% were male, aged 44.3 [25.2-83.2] years, ISS 29 [21-75], and 601 (85.2%) had blunt injuries. 612 (86.8%) had a severe traumatic brain injury and or severe haemorrhage. Overall 30-day survival was 7.5% (95%CI 5.6-9.5) 'pre-hospital only' TCA 11.5%, 'ED only' TCA 3.9%, p < 0.02. No patients who were in TCA both pre-hospital and in the ED survived. Conclusion: This study has shown that short-term survival from TCA in this large civilian registry is 7.5%. Early and aggressive management of patients with TCA, using protocols that target the reversible causes of TCA, should be initiated. Further work to establish novel ways to manage patients with reversible causes of TCA is indicated. Resuscitation in this patient group is not futile. Crown Copyright (C) 2016 Published by Elsevier Ireland Ltd. All rights reserved.	[Barnard, Ed] Inst Naval Med, Crescent Rd, Gosport PO12 2DL, Hants, England; [Barnard, Ed; Smith, Jason E.] Royal Ctr Def Med Res & Acad, Acad Dept Mil Emergency Med, Birmingham, W Midlands, England; [Yates, David; Edwards, Antoinette; Fragoso-Iniguez, Marisol; Jenks, Tom] Univ Manchester, Salford Royal NHS Fdn Trust, Trauma Audit & Res Network, Manchester, Lancs, England; [Smith, Jason E.] Derriford Hosp, Emergency Dept, Plymouth, Devon, England	Barnard, E (corresponding author), Inst Naval Med, Crescent Rd, Gosport PO12 2DL, Hants, England.	ukbarnard@gmail.com	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421; Edwards, Antoinette/0000-0003-1427-0725			Barnard EBG, 2015, EMERG MED J, V32, P926, DOI 10.1136/emermed-2015-205217; Battistella FD, 1999, ARCH SURG-CHICAGO, V134, P742, DOI 10.1001/archsurg.134.7.742; Bodnar D, 2014, EMERG MED J, V31, P93, DOI 10.1136/emermed-2012-201969; Leis CC, 2013, J TRAUMA ACUTE CARE, V74, P634, DOI 10.1097/TA.0b013e31827d5d3c; Cureton EL, 2012, J TRAUMA ACUTE CARE, V73, P102, DOI 10.1097/TA.0b013e3182569ebc; Hayashi M, 2015, CIRC RES, V116, P1887, DOI 10.1161/CIRCRESAHA.116.304521; Huber-Wagner S, 2007, RESUSCITATION; HUSSAIN LM, 1994, BRIT MED J, V308, P1077, DOI 10.1136/bmj.308.6936.1077; Intercollegiate Board for Training in Pre-hospital Emergency Medicine, 2015, GUID SUBSP TRAIN; JENNETT B, 1975, LANCET, V1, P480; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Lockey D, 2006, ANN EMERG MED, V48, P240, DOI 10.1016/j.annemergmed.2006.03.015; Lockey DJ, 2013, RESUSCITATION, V84, P738, DOI 10.1016/j.resuscitation.2012.12.003; Morrison JJ, 2013, J TRAUMA ACUTE CARE, V74, P825, DOI 10.1097/TA.0b013e31827e1d26; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; Russell RJ, 2011, PHILOS T R SOC B, V366, P171, DOI 10.1098/rstb.2010.0232; Sherren PB, 2013, CRIT CARE, V17, DOI 10.1186/cc12504; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; Smith JE, 2015, J ROY SOC MED, V108, P11, DOI 10.1177/0141076814560837; Soar J, 2010, RESUSCITATION, V81, P1400, DOI 10.1016/j.resuscitation.2010.08.015; Tarmey NT, 2011, RESUSCITATION, V82, P1194, DOI 10.1016/j.resuscitation.2011.04.018; Truhlar A, 2015, RESUSCITATION, V95, P148, DOI 10.1016/j.resuscitation.2015.07.017; Wang HC, 2014, BRAIN INJURY, V28, P1491, DOI 10.3109/02699052.2014.943288	23	37	37	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JAN	2017	110						90	94		10.1016/j.resuscitation.2016.11.001			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	EO0HX	WOS:000396380000021	27855275				2021-06-18	
J	Griffin, JM; Lee, MK; Bangerter, LR; Van Houtven, CH; Friedemann-Sanchez, G; Phelan, SM; Carlson, KF; Meis, LA				Griffin, Joan M.; Lee, Minji K.; Bangerter, Lauren R.; Van Houtven, Courtney Harold; Friedemann-Sanchez, Greta; Phelan, Sean M.; Carlson, Kathleen F.; Meis, Laura A.			Burden and Mental Health Among Caregivers of Veterans With Traumatic Brain Injury/Polytrauma	AMERICAN JOURNAL OF ORTHOPSYCHIATRY			English	Article						caregiving; traumatic brain injury; veterans; mental health; social support	SOCIAL SUPPORT; INJURY TBI; STRESS; REHABILITATION; DEPRESSION; INTERVIEW; FAMILIES; VERSION; SYSTEM; INDEX	Veterans who survive multiple traumatic injuries, including traumatic brain injuries (TBI), must often rely on family caregivers for ongoing care and support with reintegration. Understanding factors associated with caregiving that help or harm caregivers' health is critical for identifying appropriate and effective interventions that support caregiver health and promote the provision of quality care to veterans. This study utilized cross-sectional data from the Family and Caregiver Experiences Study, a survey of 564 caregivers caring for veterans who served after September 11, 2001, survived TBI/polytrauma during service, and received inpatient rehabilitation care in a Veterans Affairs Polytrauma Rehabilitation Center. Structural equation modeling was used to examine the relationship between caregiver stress (i.e., veterans' neurobehavioral problems and intensity of care required), and caregiver well-being (i.e., caregiver burden and mental health). Analyses also examined how intrapersonal, family or social, and financial resources mediate and moderate the relationship between caregiver stress and well-being. Results indicate that veterans' neurobehavioral problems and intensity of required care were associated with more caregiver burden, and more burden was associated with poor mental health. Intrapersonal and family or social resources mediated the relationship between veteran functioning and mental health. Family or social resources also moderated the relationship between care intensity and burden. The model explained a moderate amount of variability in burden (59%) and a substantial amount in mental health (75%). We conclude that caregivers of veterans with neurobehavioral problems who require intense care are at risk for burden and poor mental health. Increasing resources to bolster family or social resources may reduce risks.	[Griffin, Joan M.] Mayo Clin, Div Hlth Care Policy & Res HCPR, 200 First St Southwest, Rochester, MN 55905 USA; [Griffin, Joan M.] Minneapolis VA Healthcare Syst, Minneapolis, MN USA; [Lee, Minji K.; Phelan, Sean M.] Mayo Clin, Rochester, MN USA; [Bangerter, Lauren R.] Penn State Univ, Dept Human Dev & Family Studies, University Pk, PA 16802 USA; [Van Houtven, Courtney Harold] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA; [Van Houtven, Courtney Harold] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27706 USA; [Friedemann-Sanchez, Greta] Univ Minnesota, Humphrey Sch Publ Affairs, Minneapolis, MN 55455 USA; [Carlson, Kathleen F.] VA Portland Hlth Care Syst, Ctr Improve Veteran Involvement Care, Portland, OR USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97201 USA; [Meis, Laura A.] Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Meis, Laura A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	Griffin, JM (corresponding author), Mayo Clin, Div Hlth Care Policy & Res HCPR, 200 First St Southwest, Rochester, MN 55905 USA.	griffin.joan@mayo.edu		Friedemann-Sanchez, Greta/0000-0002-0493-7218; Van Houtven, Courtney/0000-0002-0783-1611; Griffin, Joan/0000-0001-8120-3229	Department of Veterans AffairsUS Department of Veterans Affairs; VA Health Services Research and Development (HSRD) serviceUS Department of Veterans Affairs [SDR-07-044]	This research was supported by the Department of Veterans Affairs and a grant from VA Health Services Research and Development (HSR&D) service (SDR-07-044). The findings and conclusions are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or HSR&D.	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; [Anonymous], 2010, S C; Balducci C, 2008, GERONTOLOGIST, V48, P276, DOI 10.1093/geront/48.3.276; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Carlson KF, 2012, J HEAD TRAUMA REHAB, V27, P14, DOI 10.1097/HTR.0b013e318236bd86; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Chalmers RP, 2012, J STAT SOFTW, V48, P1; Chin WW, 1998, QUANT METH SER, P295; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; Cribbie RA, 2007, STRUCT EQU MODELING, V14, P98, DOI 10.1207/s15328007sem1401_5; Crowley SL, 1997, J PERS ASSESS, V68, P508, DOI 10.1207/s15327752jpa6803_4; Degeneffe C. E., 2015, FAMILIES REHABILITAT, P213; Dillman DA, 2014, INTERNET PHONE MAIL, P4; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Finney SJ, 2006, QUANT METH EDUC BEHA, P269; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Griffin J. M., 2014, MILITARY DEPLOYMENT, P259, DOI [10.1007/978-1-4614-8712-8_14, DOI 10.1007/978-1-4614-8712-8_14]; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Hancock G. R., 2001, STRUCTURAL EQUATION, P195; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HOLM S, 1979, SCAND J STAT, V6, P65; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53; Jamshidian M, 2010, PSYCHOMETRIKA, V75, P649, DOI 10.1007/s11336-010-9175-3; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KESSLER RC, 1988, J SOC ISSUES, V44, P69, DOI 10.1111/j.1540-4560.1988.tb02092.x; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lazarus R.S., 1984, STRESS APPRAISAL COP; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mueller RO., 2008, BEST PRACTICES STRUC, P488, DOI [10.4135/9781412995627.d38, DOI 10.4135/9781412995627.D38]; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pearlin LI, 2005, J HEALTH SOC BEHAV, V46, P205, DOI 10.1177/002214650504600206; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Pilkonis PA, 2011, ASSESSMENT, V18, P263, DOI 10.1177/1073191111411667; Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112; Pornprasertmanit S., 2015, USEFUL TOOLS FOR STR; Ramchand R., 2014, HIDDEN HEROES AMERIC; Rosenberg M., 1979, BASIC BOOKS; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Siegert RJ, 2010, J REHABIL MED, V42, P302, DOI 10.2340/16501977-0511; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Urbach N., 2010, J INFORM TECHNOLOGY, V11, P5, DOI DOI 10.1037/0021-9010.90.4.710; Vaglio Joseph Jr, 2004, Health Qual Life Outcomes, V2, P24, DOI 10.1186/1477-7525-2-24; Van Houtven CH, 2012, INQUIRY-J HEALTH CAR, V49, P339, DOI 10.5034/inquiryjrnl_49.04.01; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; VINOKUR A, 1987, J APPL SOC PSYCHOL, V17, P1007, DOI 10.1111/j.1559-1816.1987.tb02345.x; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	52	37	37	0	5	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0002-9432	1939-0025		AM J ORTHOPSYCHIAT	Am. J. Orthopsychiatr.		2017	87	2			SI		139	148		10.1037/ort0000207			10	Psychiatry; Social Work	Psychiatry; Social Work	EN2SD	WOS:000395859400004	28206801	Bronze			2021-06-18	
J	Kim, HC; Kim, E; Bae, JI; Lee, KH; Jeon, YT; Hwang, JW; Lim, YJ; Min, SW; Park, HP				Kim, Hyun-Chang; Kim, Eugene; Bae, Jung Il; Lee, Kook Hyun; Jeon, Young-Tae; Hwang, Jung-Won; Lim, Young-Jin; Min, Seong-Won; Park, Hee-Pyoung			Sevoflurane Postconditioning Reduces Apoptosis by Activating the JAK-STAT Pathway After Transient Global Cerebral Ischemia in Rats	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						apoptosis; brain; ischemia; JAK/STAT signaling pathway; sevoflurane	COLONY-STIMULATING FACTOR; TRAUMATIC BRAIN-INJURY; REPERFUSION INJURY; JAK2/STAT3 PATHWAY; SIGNAL TRANSDUCER; NEURONAL APOPTOSIS; JAK/STAT PATHWAY; EXPRESSION; BCL-2; NEUROPROTECTION	Background: The antiapoptotic effects of sevoflurane post-conditioning are responsible for neuroprotection against cerebral ischemia-reperfusion injury. Phosphorylation of the Janus family tyrosine kinases (JAK) 2-signal transducers and activators of transcription (STAT) 3 pathway is linked to antiapoptosis. Here, we determined whether the antiapoptotic effects of sevoflurane postconditioning are associated with activation of the JAK2-STAT3 pathway after global transient cerebral ischemia in rats. Materials and Methods: Forty-five rats were randomly assigned to 5 groups: sham (n=5), control (10 min of ischemia, n=10), sevoflurane postconditioning (2 periods of sevoflurane inhalation after ischemia for 10 min, n=10), AG490 (a JAK2 selective inhibitor, intraperitoneal administration of 40 mg/kg before ischemia, n=10), and sevoflurane postconditioning plus AG490 group (n=10). The number of apoptotic cells as well as the expression of JAK2, phosphorylated JAK2 (P-JAK2), STAT3, phosphorylated STAT3 (P-STAT3), Bcl-2 (antiapoptotic protein), and Bax (proapoptotic protein) were evaluated 3 days after ischemia. Results: The apoptotic cell count was significantly lower in the sevoflurane postconditioning group than in the control, AG490, and sevoflurane postconditioning plus AG490 groups. JAK2 and STAT3 levels were comparable among all 5 groups. P-JAK2, P-STAT3, and Bcl-2 levels were higher and Bax levels were lower in the sevoflurane postconditioning group relative to the control, AG490, and sevoflurane postconditioning plus AG490 groups. Conclusions: Sevoflurane postconditioning reduced apoptosis by increasing P-JAK and P-STAT expression after transient global ischemia in rats, and AG490 reversed the beneficial antiapoptotic effects of sevoflurane postconditioning, suggesting that the JAK-STAT pathway may be involved in the antiapoptotic mechanism of sevoflurane postconditioning.	[Kim, Hyun-Chang] Keimyung Univ, Dongsan Hosp, Coll Med, Dept Anesthesiol & Pain Med, Daegu, South Korea; [Kim, Eugene] Hosp Catholic Univ Daegu, Dept Anesthesiol & Pain Med, Daegu, South Korea; [Bae, Jung Il; Lee, Kook Hyun; Lim, Young-Jin; Park, Hee-Pyoung] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Min, Seong-Won] Seoul Natl Univ, Coll Med, SMG SNU Boramae Med Ctr, Dept Anesthesiol & Pain Med, 5-20 Boramae Ro, Seoul 07061, South Korea; [Jeon, Young-Tae; Hwang, Jung-Won] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam, South Korea	Min, SW (corresponding author), Seoul Natl Univ, Coll Med, SMG SNU Boramae Med Ctr, Dept Anesthesiol & Pain Med, 5-20 Boramae Ro, Seoul 07061, South Korea.; Park, HP (corresponding author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, 101 Daehakro, Seoul 03080, South Korea.	swmin@snu.ac.kr; hppark@snu.ac.kr	Kim, Eugene/E-2446-2019	Kim, Eugene/0000-0002-1926-4191; Park, Hee-Pyoung/0000-0002-4772-0780	Seoul National University Hospital [0420130360]; Keimyung University [2015-0170]	Supported by research grants funded by Seoul National University Hospital (number: 0420130360) and Keimyung University (number: 2015-0170).	Adamczyk S, 2010, BRIT J ANAESTH, V104, P191, DOI 10.1093/bja/aep365; Barry SP, 2007, TRENDS MOL MED, V13, P82, DOI 10.1016/j.molmed.2006.12.002; Boengler K, 2010, BASIC RES CARDIOL, V105, P771, DOI 10.1007/s00395-010-0124-1; Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Cheppudira BP, 2015, BIOMED REP, V3, P703, DOI 10.3892/br.2015.497; Constantin G, 1998, EUR J IMMUNOL, V28, P3523, DOI 10.1002/(SICI)1521-4141(199811)28:11<3523::AID-IMMU3523>3.0.CO;2-X; Damm J, 2013, NEUROPHARMACOLOGY, V71, P98, DOI 10.1016/j.neuropharm.2013.03.014; Drenger B, 2011, ANESTHESIOLOGY, V114, P1364, DOI 10.1097/ALN.0b013e31820efafd; Feng DY, 2015, EUR NEUROPSYCHOPHARM, V25, P1287, DOI 10.1016/j.euroneuro.2015.04.020; Freitas MCS, 2010, LIVER TRANSPLANT, V16, P600, DOI 10.1002/lt.22036; Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709; Gross ER, 2006, AM J PHYSIOL-HEART C, V291, pH827, DOI 10.1152/ajpheart.00003.2006; Gustafsson LL, 1996, ANESTHESIOLOGY, V84, P415, DOI 10.1097/00000542-199602000-00021; Hausenloy DJ, 2007, HEART FAIL REV, V12, P217, DOI 10.1007/s10741-007-9026-1; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jeon YT, 2013, J NEUROSURG ANESTH, V25, P43, DOI 10.1097/ANA.0b013e31826ca3bc; Jung JE, 2011, STROKE, V42, P3574, DOI 10.1161/STROKEAHA.111.626648; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Komine-Kobayashi M, 2006, J CEREBR BLOOD F MET, V26, P402, DOI 10.1038/sj.jcbfm.9600195; Lecour S, 2009, J MOL CELL CARDIOL, V46, P607, DOI 10.1016/j.yjmcc.2009.01.003; Lee H, 2015, BRIT J ANAESTH, V114, P307, DOI 10.1093/bja/aeu268; Lei C, 2011, ANESTH ANALG, V113, P153, DOI 10.1213/ANE.0b013e31821a9fbe; Li LX, 2011, BRAIN RES BULL, V86, P390, DOI 10.1016/j.brainresbull.2011.09.005; Liu L, 2015, CELL PHYSIOL BIOCHEM, V35, P126, DOI 10.1159/000369681; Luo Y, 2008, ANESTHESIOLOGY, V109, P782, DOI 10.1097/ALN.0b013e3181895f88; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niture SK, 2013, FREE RADICAL BIO MED, V57, P119, DOI 10.1016/j.freeradbiomed.2012.12.014; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Sehara Y, 2013, J NEUROSCI, V33, P12364, DOI 10.1523/JNEUROSCI.1852-13.2013; Seo JH, 2013, BRIT J ANAESTH, V110, P988, DOI 10.1093/bja/aet009; Shyu WC, 2008, J CLIN INVEST, V118, P133, DOI 10.1172/JCI32723; Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204-014-1448-7; Song YX, 2013, NEUROCHEM RES, V38, P610, DOI 10.1007/s11064-012-0959-y; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Tian YK, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-53; Wang JK, 2010, BRAIN RES, V1357, P142, DOI 10.1016/j.brainres.2010.08.009; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yan LH, 2012, J SURG RES, V178, P578, DOI 10.1016/j.jss.2012.06.007; Yang NS, 2008, NEPHROL DIAL TRANSPL, V23, P91, DOI 10.1093/ndt/gfm509; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; Zhou TF, 2013, J SURG RES, V183, P304, DOI 10.1016/j.jss.2012.11.035; Zhu HB, 2013, EUR J PHARMACOL, V714, P23, DOI 10.1016/j.ejphar.2013.05.043	50	37	44	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2017	29	1					37	45		10.1097/ANA.0000000000000331			9	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	EG6AY	WOS:000391127400006	27337676				2021-06-18	
J	LoBue, C; Wadsworth, H; Wilmoth, K; Clem, M; Hart, J; Womack, KB; Didehbani, N; Lacritz, LH; Rossetti, HC; Cullum, CM				LoBue, Christian; Wadsworth, Hannah; Wilmoth, Kristin; Clem, Matthew; Hart, John, Jr.; Womack, Kyle B.; Didehbani, Nyaz; Lacritz, Laura H.; Rossetti, Heidi C.; Cullum, C. Munro			Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease	CLINICAL NEUROPSYCHOLOGIST			English	Article						National Alzheimer's Coordinating Center (NACC); traumatic brain injury (TBI); dementia; Alzheimer's disease (AD); age of onset	APOLIPOPROTEIN-E; HEAD-INJURY; RISK-FACTORS; COGNITIVE IMPAIRMENT; DEMENTIA; ALLELE; DIAGNOSIS; PATHOLOGY; THERAPY; HEALTH	Objective: This study examined whether a history of traumatic brain injury (TBI) is associated with earlier onset of Alzheimer disease (AD), independent of apolipoprotein epsilon 4 status (Apoe4) and gender. Method: Participants with a clinical diagnosis of AD (n=7625) were obtained from the National Alzheimer's Coordinating Center Uniform Data Set, and categorized based on self-reported lifetime TBI with loss of consciousness (LOC) (TBI+ vs. TBI-) and presence of Apoe4. ANCOVAs, controlling for gender, race, and education were used to examine the association between history of TBI, presence of Apoe4, and an interaction of both risk factors on estimated age of AD onset. Results: Estimated AD onset differed by TBI history and Apoe4 independently (p's<.001). The TBI+ group had a mean age of onset 2.5years earlier than the TBI- group. Likewise, Apoe4 carriers had a mean age of onset 2.3years earlier than non-carriers. While the interaction was non-significant (p=.34), participants having both a history of TBI and Apoe4 had the earliest mean age of onset compared to those with a TBI history or Apoe4 alone (M-Difference=2.8 and 2.7years, respectively). These results remained unchanged when stratified by gender. Conclusions: History of self-reported TBI can be associated with an earlier onset of AD-related cognitive decline, regardless of Apoe4 status and gender. TBI may be related to an underlying neurodegenerative process in AD, but the implications of age at time of injury, severity, and repetitive injuries remain unclear.	[LoBue, Christian; Wadsworth, Hannah; Wilmoth, Kristin; Clem, Matthew; Hart, John, Jr.; Womack, Kyle B.; Didehbani, Nyaz; Lacritz, Laura H.; Rossetti, Heidi C.; Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.; Lacritz, Laura H.; Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.; Didehbani, Nyaz] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX USA	LoBue, C (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.	Christian.lobue@utsouthwestern.edu	Cullum, C. Munro/AAC-2496-2019; Wilmoth, Kristin/ABB-4014-2020; Womack, Kyle/O-5422-2018	Cullum, C. Munro/0000-0001-9706-5465; Wilmoth, Kristin/0000-0003-4192-8756; Womack, Kyle/0000-0002-6060-9075; Didehbani, Nyaz/0000-0001-6121-5759	University of Texas Southwestern Alzheimer's Disease Center [NIH/NIA] [P3012300-19]; Texas Alzheimer's Research and Care Consortium (TARCC); NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124]; The NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681, U01 AG032984]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010133, P50AG005138, P50AG033514, P30AG012300, P30AG010161, P50AG005131, P50AG005146, U01AG016976, P50AG005142, P30AG008017, P50AG016574, P30AG008051, P30AG010129, P50AG016573, P30AG035982, P50AG005133, P50AG023501, P50AG008702, P30AG010124, P50AG025688, P50AG016570, P30AG019610, P50AG005134, P30AG013846, P30AG028383, P50AG005681, P50AG005136, P30AG013854, U01AG032984] Funding Source: NIH RePORTER	This work was supported by the University of Texas Southwestern Alzheimer's Disease Center [NIH/NIA grant number P3012300-19] and the Texas Alzheimer's Research and Care Consortium (TARCC). NACC data are funded by NIA [grant number P30 AG019610] (PI Eric Reiman, MD), [grant number P30 AG013846] (PI Neil Kowall, MD), [grant number P50 AG008702] (PI Scott Small, MD), [grant number P50 AG025688] (PI Allan Levey, MD, PhD), [grant number P30 AG010133] (PI Andrew Saykin, PsyD), [grant number P50 AG005146] (PI Marilyn Albert, PhD), [grant number P50 AG005134] (PI Bradley Hyman, MD, PhD), [grant number P50 AG016574] (PI Ronald Petersen, MD, PhD), [grant number P50 AG005138] (PI Mary Sano, PhD), [grant number P30 AG008051] (PI Steven Ferris, PhD), [grant number P30 AG013854] (PI M. Marsel Mesulam, MD), [grant number P30 AG008017] (PI Jeffrey Kaye, MD), [grant number P30 AG010161] (PI David Bennett, MD), [grant number P30 AG010129] (PI Charles DeCarli, MD), [grant number P50 AG016573] (PI Frank LaFerla, PhD), [grant number P50 AG016570] (PI David Teplow, PhD), [grant number P50 AG005131] (PI Douglas Galasko, MD), [grant number P50 AG023501] (PI Bruce Miller, MD), [grant number P30 AG035982] (PI Russell Swerdlow, MD), [grant number P30 AG028383] (PI Linda Van Eldik, PhD), [grant number P30 AG010124] (PI John Trojanowski, MD, PhD), [grant number P50 AG005133] (PI Oscar Lopez, MD), [grant number P50 AG005142] (PI Helena Chui, MD), [grant number P30 AG012300] (PI Roger Rosenberg, MD), [grant number P50 AG005136] (PI Thomas Montine, MD, PhD), [grant number P50 AG033514] (PI Sanjay Asthana, MD, FRCP), [grant number P50 AG005681] (PI John Morris, MD); Alzheimer's Disease Genetic Consortium (ADGC) is funded by NIA [grant number U01 AG032984].	Altmann A, 2014, ANN NEUROL, V75, P563, DOI 10.1002/ana.24135; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Corder EH, 2004, ANN NY ACAD SCI, V1019, P24, DOI 10.1196/annals.1297.005; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Faul M, 2010, TRAUMATIC BRAIN INJU, V2, P1; Fleisher AS, 2013, NEUROBIOL AGING, V34, P1, DOI 10.1016/j.neurobiolaging.2012.04.017; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kok E, 2009, ANN NEUROL, V65, P650, DOI 10.1002/ana.21696; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; Luchsinger JA, 2005, NEUROLOGY, V65, P545, DOI 10.1212/01.wnl.0000172914.08967.dc; Maiti TK, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.8.FOCUS15329; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Miller MA, 2010, BRAIN INJURY, V24, P1468, DOI 10.3109/02699052.2010.520299; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Naj AC, 2014, JAMA NEUROL, V71, P1394, DOI 10.1001/jamaneurol.2014.1491; Nelson PT, 2009, J NEUROPATH EXP NEUR, V68, P1, DOI 10.1097/NEN.0b013e3181919a48; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Thal DR, 2014, J ALZHEIMERS DIS, V42, pS421, DOI 10.3233/JAD-141461; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Ungar L, 2014, BRAIN IMAGING BEHAV, V8, P262, DOI 10.1007/s11682-013-9272-x; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Xu W, 2015, J NEUROL NEUROSUR PS, V86, P1299, DOI 10.1136/jnnp-2015-310548	49	37	37	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					85	98		10.1080/13854046.2016.1257069			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300005	27855547	Green Accepted			2021-06-18	
J	McQuistion, K; Zens, T; Jung, HS; Beems, M; Leverson, G; Liepert, A; Scarborough, J; Agarwal, S				McQuistion, Kaitlyn; Zens, Tiffany; Jung, Hee Soo; Beems, Megan; Leverson, Glen; Liepert, Amy; Scarborough, John; Agarwal, Suresh			Insurance status and race affect treatment and outcome of traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Insurance status; Race; Ethnicity; Outcomes; Rehabilitation	END-OF-LIFE; RACIAL DISPARITIES; ETHNIC DISPARITIES; REHABILITATION PLACEMENT; MECHANICAL VENTILATION; DISCHARGE DISPOSITION; SOCIOECONOMIC-STATUS; FUNCTIONAL OUTCOMES; CARE; MORTALITY	Background: There is increasing evidence that race and socioeconomic factors affect patient outcomes after traumatic brain injury (TBI). Our goal was to assess the effect of race, ethnicity and insurance status on hospital length of stay, procedures performed, mortality, and discharge disposition after TBI. Methods: This was a retrospective cohort study using the National Trauma Data Bank (2002-2012) to analyze patients aged 14-89 y with one of five closed head injuries. Univariate regressions identified demographic and injury characteristics that were significant predictors of outcomes. These variables were then included in multivariate regression models. Results: We analyzed 187,354 TBI patients. The sample was 78% white, 9% black, 9% Hispanic, 3% Asian, and 1% native American, and included 42% Medicare, 30% private insurance, 12% uninsured, 8% other insurance, and 8% Medicaid. Compared with white patients, black and Hispanic patients were more likely to have a TBI procedure (blacks odds ratio [OR] = 1.19, P < 0.001; Hispanics OR = 1.33, P < 0.001), had longer hospital stays (blacks coeff = 1.02, P < 0.001; Hispanics coeff = 0.61, P < 0.001), were less likely to die in the hospital (blacks OR = 0.90, P = 0.006; Hispanics OR = 0.90, P = 0.007), and more (black OR = 1.09, P = 0.001) or less likely (Hispanic OR = 0.76, P < 0.001) to be discharged to rehabilitation. Compared with the privately insured, the uninsured were less likely to have a TBI procedure (OR = 0.90, P = 0.001), had longer hospital stays (coeff = 0.24, P < 0.001), were more likely to die in the hospital (OR = 1.37, P < 0.001), and less likely to be discharged to rehabilitation (OR = 0.53, P < 0.001). Conclusions: Race/ethnicity and insurance status significantly affect TBI patient outcomes, even after controlling for demographic and injury characteristics. (C) 2016 Elsevier Inc. All rights reserved.	[McQuistion, Kaitlyn; Zens, Tiffany; Jung, Hee Soo; Beems, Megan; Leverson, Glen; Liepert, Amy; Scarborough, John; Agarwal, Suresh] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Trauma & Acute Care Surg, Madison, WI USA	Agarwal, S (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Sect Trauma Acute Care Surg Burn & Surg Crit Care, 600 Highland Ave G5-335, Madison, WI 53792 USA.; Agarwal, S (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Trauma, 600 Highland Ave G5-335, Madison, WI 53792 USA.	agarwal@surgery.wisc.edu		Beems, Megan/0000-0002-2767-5994	University of Wisconsin Shapiro Summer Research Program; University of Wisconsin School of Medicine and Public Health Department of Surgery	The authors thank the University of Wisconsin Shapiro Summer Research Program and the University of Wisconsin School of Medicine and Public Health Department of Surgery for supporting this research.	Alban RF, 2010, AM SURGEON, V76, P1108; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Asemota AO, 2013, J NEUROTRAUM, V30, P2057, DOI 10.1089/neu.2013.3091; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Bradbury R C, 2001, Health Serv Manage Res, V14, P203, DOI 10.1258/0951484011912708; Brasel KJ, 2002, J SURG RES, V107, P223, DOI 10.1006/jsre.2002.6512; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohen R. A., 2015, HLTH INSURANCE COVER; Cooper Z, 2012, J HEALTH CARE POOR U, V23, P857, DOI 10.1353/hpu.2012.0064; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Dunlay SM, 1995, ARCH INTERN MED, V155, P2056; Egede LE, 2012, AM J PUBLIC HEALTH, V102, pS266, DOI 10.2105/AJPH.2011.300176; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Faul M, 2010, TRAUMATIC BRAIN INJU, P13, DOI DOI 10.3171/2009.10.JNS091500; Gerszten PC, 2001, AM J MED QUAL, V16, P212, DOI 10.1177/106286060101600605; Grace Sherry L, 2005, J Cardiopulm Rehabil, V25, P24, DOI 10.1097/00008483-200501000-00006; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Hwabejire JO, 2013, JAMA SURG, V148, P956, DOI 10.1001/jamasurg.2013.2148; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kane WG, 2014, J HEAD TRAUMA REHAB, V29, pE10, DOI 10.1097/HTR.0000000000000028; Khaliq Amir A, 2003, J Health Hum Serv Adm, V25, P471; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Kwak J, 2005, GERONTOLOGIST, V45, P634, DOI 10.1093/geront/45.5.634; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, P1986, DOI 10.2105/AJPH.2014.302087; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCutcheon BA, 2015, J NEUROSURG, V123, P406, DOI 10.3171/2015.3.JNS131356; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Missios S, 2016, INJURY, V47, P154, DOI 10.1016/j.injury.2015.06.037; Muni S, 2011, CHEST, V139, P1025, DOI 10.1378/chest.10-3011; MURPHY L D, 1990, Brain Injury, V4, P95, DOI 10.3109/02699059009026153; Nandi A, 2014, EPIDEMIOLOGY, V25, P170, DOI 10.1097/EDE.0000000000000038; Nirula R, 2009, J TRAUMA, V66, P255, DOI 10.1097/TA.0b013e31815ede46; Pentland B, 1988, Br J Neurosurg, V2, P61, DOI 10.3109/02688698808999660; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rubin MA, 2014, J CRIT CARE, V29, P49, DOI 10.1016/j.jcrc.2013.08.023; Sacks GD, 2011, J TRAUMA, V71, P1011, DOI 10.1097/TA.0b013e3182092c27; Selassie AW, 2014, J HEAD TRAUMA REHAB, V29, pE8, DOI 10.1097/HTR.0b013e3182976ad3; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83; 1998, NIH CONSENS STATEMEN, V16, P1	53	37	37	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2016	205	2					261	271		10.1016/j.jss.2016.06.087			11	Surgery	Surgery	EC2VG	WOS:000387981700001	27664871				2021-06-18	
J	Kerr, ZY; Simon, JE; Grooms, DR; Roos, KG; Cohen, RP; Dompier, TP				Kerr, Zachary Y.; Simon, Janet E.; Grooms, Dustin R.; Roos, Karen G.; Cohen, Randy P.; Dompier, Thomas P.			Epidemiology of Football Injuries in the National Collegiate Athletic Association, 2004-2005 to 2008-2009	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						college football; injury rates; practice seasons; scrimmages	SURVEILLANCE SYSTEM; UNITED-STATES; HIGH-SCHOOL; SPORTS; YOUTH; CONCUSSION; PLAYERS; PROGRAM	Background: Research has found that injury rates in football are higher in competition than during practice. However, there is little research on the association between injury rates and type of football practices and how these specific rates compare with those in competitions. Purpose: This study utilized data from the National Collegiate Athletic Association Injury Surveillance System (NCAA ISS) to describe men's collegiate football practice injuries (academic years 2004-2005 to 2008-2009) in 4 event types: competitions, scrimmages, regular practices, and walkthroughs. Study Design: Descriptive epidemiological study. Methods: Football data during the 2004-2005 to 2008-2009 academic years were analyzed. Annually, an average of 60 men's football programs provided data (9.7% of all universities sponsoring football). Injury rates per 1000 athlete-exposures (AEs), injury rate ratios (RRs), 95% CIs, and injury proportions were reported. Results: The NCAA ISS captured 18,075 football injuries. Most injuries were reported in regular practices (55.9%), followed by competitions (38.8%), scrimmages (4.4%), and walkthroughs (0.8%). Most AEs were reported in regular practices (77.6%), followed by walkthroughs (11.5%), competitions (8.6%), and scrimmages (2.3%). The highest injury rate was found in competitions (36.94/1000 AEs), followed by scrimmages (15.7/1000 AEs), regular practices (5.9/1000 AEs), and walkthroughs (0.6/1000 AEs). These rates were all significantly different from one another. Distributions of injury location and diagnoses were similar across all 4 event types, with most injuries occurring at the lower extremity (56.0%) and consisting of sprains and strains (50.6%). However, injury mechanisms varied. The proportion of injuries due to player contact was greatest in scrimmages (66.8%), followed by regular practices (48.5%) and walkthroughs (34.9%); in contrast, the proportion of injuries due to noncontact/overuse was greatest in walkthroughs (41.7%), followed by regular practices (35.6%) and scrimmages (21.9%). Conclusion: Injury rates were the highest in competitions but then varied by the type of practice event, with higher practice injury rates reported in scrimmage. In addition, greater proportions of injuries were reported in regular practices, and greater proportions of exposures were reported in regular practices and walkthroughs. Efforts to minimize injury in all types of practice events are essential to mitigating injury incidence related to both contact and noncontact.	[Roos, Karen G.; Dompier, Thomas P.] Sports Injury Res & Prevent Inc, Datalys Ctr, Indianapolis, IN USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA; [Simon, Janet E.; Grooms, Dustin R.] Ohio Univ, Sch Appl Hlth Sci & Wellness, Div Athlet Training, Athens, OH 45701 USA; [Grooms, Dustin R.] Ohio Univ, Ohio Musculoskeletal & Neurol Inst, Athens, OH 45701 USA; [Dompier, Thomas P.] Univ Arizona, Athlet Training, Tucson, AZ USA	Kerr, ZY (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu	Grooms, Dustin/AAO-8917-2021	Grooms, Dustin/0000-0001-6102-8224			Albright JP, 2004, AM J SPORT MED, V32, P1394, DOI 10.1177/0363546504264159; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bizzini M, 2015, BRIT J SPORT MED, V49, P577, DOI 10.1136/bjsports-2015-094765; Dick R, 2007, J ATHL TRAINING, V42, P221; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; DURANT RH, 1991, AM J DIS CHILD, V145, P1119, DOI 10.1001/archpedi.1991.02160100051022; ESPN, IV LEAG LIM FULL CON; ESPN, PAC 12 LIM CONT PRAC; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; Martens R, 1974, Exerc Sport Sci Rev, V2, P155; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; National Collegiate Athletic Association, FOOTB PRACT GUID; National Collegiate Athletic Association, STUD ATHL PART 1981; Oxendine J. B., 1970, QUEST, V13, P23, DOI [10.1080/00336297.1970.10519673, DOI 10.1080/00336297.1970.10519673]; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Silvers-Granelli H, 2015, AM J SPORT MED, V43, P2628, DOI 10.1177/0363546515602009; Steiner ME, 2016, SPORTS HEALTH, V8, P217, DOI 10.1177/1941738115626689; Swanik C, 2015, J ATHL TRAINING, V50, P1100, DOI 10.4085/1062-6050-50.10.08	25	37	37	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	SEP	2016	4	9							2325967116664500	10.1177/2325967116664500			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DZ0RL	WOS:000385547300001	27635412	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Zhong, JJ; Jiang, L; Cheng, CJ; Huang, ZJ; Zhang, HR; Liu, H; He, JC; Cao, F; Peng, JH; Jiang, Y; Sun, XC				Zhong, Jianjun; Jiang, Li; Cheng, Chongjie; Huang, Zhijian; Zhang, Hongrong; Liu, Han; He, Junchi; Cao, Fang; Peng, Jianhua; Jiang, Yong; Sun, Xiaochuan			Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Long noncoding RNA	PROMOTES CELL-PROLIFERATION; RAT CEREBRAL-CORTEX; GENE-EXPRESSION; POOR-PROGNOSIS; GASTRIC-CANCER; DISEASE; PROFILE; IDENTIFICATION; ACTIVATION; MALAT1	Background and objective: The present study aims to detect the altered lncRNA expression in the mouse cortex after traumatic brain injury (TBI). We also simultaneously detected the altered mRNA profile to further analyze the possible function of lncRNA. Method: C57BL/6 mice (n=18) were used to construct a controlled cortical impact model. At 24 h post-TBI, the cortex around injury site was collected and the total RNA was extracted to construct the cDNA library. RNA sequencing (RNA-seq) was carried out followed by RT-PCR for confirmation. Bioinformatic analysis (including GO analysis, KEGG pathway and co-expression analysis) also were performed. Results: A total of 64,530 transcripts were detected in the current sequencing study, in which 27,457 transcripts were identified as mRNA and 37,073 transcripts as lncRNA. A total of 1580 mRNAs (1430 up regulated and 150 down-regulated) and 823 lncRNAs (667 up-regulated and 156 down-regulated) were significantly changed according to the criteria ((l)log(2)((fold change))vertical bar > 1 and P < 0.05). These altered mRNAs were mainly related to inflammatory and immunological activity, metabolism, neuronal and vascular network. The expression of single lncRNA may be related with several mRNAs, and so was the mRNA. Also, a total of 360 new mRNAs and 8041 new lncRNAs were identified. The good reproducibility and reliability of RNA-seq were confirmed by RT-PCR. Conclusion: Numerous lncRNAs and mRNAs were significantly altered in mouse cortex around the injury site 24 h after TBI. Our present data may provide a promising approach for further study about TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Zhong, Jianjun; Jiang, Li; Cheng, Chongjie; Huang, Zhijian; Zhang, Hongrong; Liu, Han; He, Junchi; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Cao, Fang] Zunyi Med Coll, Affiliated Hosp 1, Dept Cerebrovasc, Zunyi 653000, Guizhou, Peoples R China; [Peng, Jianhua; Jiang, Yong] Southwest Med Univ, Affiliated Hosp, Dept Neurosurg, Luzhou 646000, Sichaun, Peoples R China	Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.		He, Junchi/AAD-8482-2019	Huang, Zhijian/0000-0002-8241-0761; sun, xiao chuan/0000-0001-6992-332X; Peng, Jianhua/0000-0003-3348-9538	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159, 81371319]; Chongqing Graduate Innovation Project [40010200100417]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K15385] Funding Source: KAKEN	This work was supported by grants from the National Natural Science Foundation of China (Grant No.: 81571159, 81371319) and the Chongqing Graduate Innovation Project (grant No.: 40010200100417). We express special acknowledgement to "Chongqing Key Labrotory of Biochemistry and Molecular Pharmacology" for providing experimental platform.	Bali KK, 2014, TRENDS MOL MED, V20, P437, DOI 10.1016/j.molmed.2014.05.006; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Francelle L, 2015, NEUROBIOL AGING, V36, DOI 10.1016/j.neurobiolaging.2014.11.014; Goh CS, 2000, J MOL BIOL, V299, P283, DOI 10.1006/jmbi.2000.3732; Gomez JA, 2013, CELL, V152, P743, DOI 10.1016/j.cell.2013.01.015; Hannon MJ, 2013, J CLIN ENDOCR METAB, V98, P3229, DOI 10.1210/jc.2013-1555; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jiang BC, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0047-9; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson R, 2012, NEUROBIOL DIS, V46, P245, DOI 10.1016/j.nbd.2011.12.006; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Li ZH, 2014, P NATL ACAD SCI USA, V111, P1002, DOI 10.1073/pnas.1313768111; Liu JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.466; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lucafo M, 2015, CURR MOL MED, V15, P94, DOI 10.2174/1566524015666150114122354; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265; Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017; Ng SY, 2012, EMBO J, V31, P522, DOI 10.1038/emboj.2011.459; Puthanveetil P, 2015, J CELL MOL MED, V19, P1418, DOI 10.1111/jcmm.12576; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Ramos AD, 2013, CELL STEM CELL, V12, P616, DOI 10.1016/j.stem.2013.03.003; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Ruan YL, 1997, J NEUROSCI RES, V50, P383, DOI 10.1002/(SICI)1097-4547(19971101)50:3<383::AID-JNR4>3.0.CO;2-E; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Shi ZH, 2015, CELL PHYSIOL BIOCHEM, V36, P542, DOI 10.1159/000430119; Sun M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-319; Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z; Thum T, 2014, CIRC RES, V114, P1366, DOI 10.1161/CIRCRESAHA.114.303896; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilhelm BT, 2008, NATURE, V453, P1239, DOI 10.1038/nature07002; Yan K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010132; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431; Yu B, 2013, NEUROSCI LETT, V534, P117, DOI 10.1016/j.neulet.2012.12.014; Zangrando J, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-460; Zhong J., 2016, NEUROSCIENCE; Zhu JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101707; Zhu L, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0157-3	55	37	43	2	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2016	1646						589	600		10.1016/j.brainres.2016.07.002			12	Neurosciences	Neurosciences & Neurology	DT9TH	WOS:000381844700066	27380725				2021-06-18	
J	Baker, R; Esquenazi, A; Benedetti, MG; Desloovere, K				Baker, Richard; Esquenazi, Alberto; Benedetti, Maria Grazia; Desloovere, Kaat			Gait analysis: clinical facts	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Gait; Cerebral palsy; Amputees; Hemiparesis	MUSCLE-TENDON LENGTHS; ANKLE-FOOT ORTHOSIS; LOW-BACK-PAIN; TOXIN TYPE-A; CEREBRAL-PALSY; DECISION-MAKING; INTEROBSERVER VARIABILITY; HEMIPARETIC GAIT; PROSTHETIC GAIT; MOTOR FUNCTION	Gait analysis is a well-established tool for the quantitative assessment of gait disturbances providing functional diagnosis, assessment for treatment planning, and monitoring of disease progress. There is a large volume of literature on the research use of gait analysis, but evidence on its clinical routine use supports a favorable cost-benefit ratio in a limited number of conditions. Initially gait analysis was introduced to clinical practice to improve the management of children with cerebral palsy. However, there is good evidence to extend its use to patients with various upper motor neuron diseases, and to lower limb amputation. Thereby, the methodology for properly conducting and interpreting the exam is of paramount relevance. Appropriateness of gait analysis prescription and reliability of data obtained are required in the clinical environment. This paper provides an overview on guidelines for managing a clinical gait analysis service and on the principal clinical domains of its application: cerebral palsy, stroke, traumatic brain injury and lower limb amputation.	[Baker, Richard] Univ Salford, Hlth Sci Res Ctr, Salford, Lancs, England; [Esquenazi, Alberto] MossRehab Gait & Mot Anal Lab, 60 Township Line Road, Elkins Pk, PA 19027 USA; [Benedetti, Maria Grazia] Rizzoli Orthoped Inst, Phys Med & Rehabil Unit, Bologna, Italy; [Desloovere, Kaat] Leuven Catholic Univ, Dept Rehabil Sci, Leuven, Belgium	Esquenazi, A (corresponding author), MossRehab Gait & Mot Anal Lab, 60 Township Line Road, Elkins Pk, PA 19027 USA.	aesquena@einstein.edu	Desloovere, Kaat/F-3240-2014; Leardini, Alberto/C-8189-2019	Desloovere, Kaat/0000-0002-8507-5276; Leardini, Alberto/0000-0003-3547-7370			Ackermann M, 2010, J BIOMECH, V43, P1055, DOI 10.1016/j.jbiomech.2009.12.012; ARMSTRONG DM, 1986, PROG NEUROBIOL, V26, P273, DOI 10.1016/0301-0082(86)90021-3; Arnold AS, 2006, J BIOMECH, V39, P1498, DOI 10.1016/j.jbiomech.2005.03.026; Arnold AS, 2006, GAIT POSTURE, V23, P273, DOI 10.1016/j.gaitpost.2005.03.003; Baker R., 2013, HDB CLIN GAIT ANAL; Baker R, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-4; Beckung E, 2007, DEV MED CHILD NEUROL, V49, P751, DOI 10.1111/j.1469-8749.2007.00751.x; Brand R. A., 1987, IOWA ORTHOPAEDIC J, V9, P61; BRAND RA, 1981, J BIOMECH, V14, P655, DOI 10.1016/0021-9290(81)90093-2; BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; Cook RE, 2003, J PEDIATR ORTHOPED, V23, P292, DOI 10.1097/00004694-200305000-00004; Dallmeijer AJ, 2011, GAIT POSTURE, V33, P326, DOI 10.1016/j.gaitpost.2010.10.092; Damiano DL, 1998, ARCH PHYS MED REHAB, V79, P119, DOI 10.1016/S0003-9993(98)90287-8; De Groote F, 2013, P 14 INT S COMP SIM; DELP SL, 1990, IEEE T BIO-MED ENG, V37, P757, DOI 10.1109/10.102791; Den Otter AR, 2007, GAIT POSTURE, V25, P342, DOI 10.1016/j.gaitpost.2006.04.007; Desloovere K, 2012, EUR J PAEDIATR NEURO, V16, P20, DOI 10.1016/j.ejpn.2011.08.009; Desloovere K, 2007, DEV MED CHILD NEUROL, V49, P56, DOI 10.1017/S001216220700014X; Desloovere K, 2006, GAIT POSTURE, V24, P142, DOI 10.1016/j.gaitpost.2006.08.003; Dietz V, 1997, ELECTROEN CLIN NEURO, V103, P333, DOI 10.1016/S0013-4694(97)00047-7; Dobson F, 2006, DEV MED CHILD NEUROL, V48, P429, DOI 10.1017/S0012162206000946; Dodd KJ, 2002, ARCH PHYS MED REHAB, V83, P1157, DOI 10.1053/apmr.2002.34286; Duysens J, 1998, GAIT POSTURE, V7, P131, DOI 10.1016/S0966-6362(97)00042-8; Eek MN, 2008, GAIT POSTURE, V28, P366, DOI 10.1016/j.gaitpost.2008.05.004; Eek MN, 2011, GAIT POSTURE, V33, P333, DOI 10.1016/j.gaitpost.2010.10.093; Esqucnazi A, 2013, J PROSTH ORTH, V25, P15; Esquenazi A, 2004, Eura Medicophys, V40, P111; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Esquenazi A, 2011, PHYS MED REHABILITAT, P99; Esquenazi A, 1994, STATE ART REV, V8, P201; Esquenazi A, 2015, TOXICON, V107, P109, DOI 10.1016/j.toxicon.2015.08.004; Fosang A, 2006, GAIT POSTURE, V24, P406, DOI 10.1016/j.gaitpost.2005.09.015; Fosang AL, 2003, DEV MED CHILD NEUROL, V45, P664, DOI 10.1017/S0012162203001245; Franki I, 2014, CLIN REHABIL, V28, P1039, DOI 10.1177/0269215514544984; Franki I, 2014, RES DEV DISABIL, V35, P1160, DOI 10.1016/j.ridd.2014.01.025; FRIBERG O, 1984, PROSTHET ORTHOT INT, V8, P124; Frontera WR, 1997, MUSCLE NERVE, V20, P938, DOI 10.1002/(SICI)1097-4598(199708)20:8<938::AID-MUS2>3.0.CO;2-7; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; Gage JR, 2003, J PEDIATR ORTHOPED, V23, P290, DOI 10.1097/00004694-200305000-00003; Gage JR, 2009, IDENTIFICATION TREAT, P107; GITTER A, 1991, AM J PHYS MED REHAB, V70, P142, DOI 10.1097/00002060-199106000-00006; Goldberg SR, 2003, J BIOMECH, V36, P1111, DOI 10.1016/S0021-9290(03)00106-4; Gorton GE, 2009, GAIT POSTURE, V29, P398, DOI 10.1016/j.gaitpost.2008.10.060; Graham HK, 2000, GAIT POSTURE, V11, P67, DOI 10.1016/S0966-6362(99)00054-5; Gurney B, 2001, J BONE JOINT SURG AM, V83A, P907, DOI 10.2106/00004623-200106000-00013; Heinen F, 2010, EUR J PAEDIATR NEURO, V14, P45, DOI 10.1016/j.ejpn.2009.09.005; Hicks J, 2007, GAIT POSTURE, V26, P546, DOI 10.1016/j.gaitpost.2006.12.003; Hicks JL, 2008, J BIOMECH, V41, P960, DOI 10.1016/j.jbiomech.2008.01.002; Hicks JI, 2009, IDENTIFICATION TREAT, P285; Himmelmann K, 2010, ACTA PAEDIATR, V99, P1337, DOI 10.1111/j.1651-2227.2010.01819.x; Himmelmann K, 2011, DEV MED CHILD NEUROL, V53, P516, DOI 10.1111/j.1469-8749.2011.03932.x; Hsu AL, 2003, ARCH PHYS MED REHAB, V84, P1185, DOI 10.1016/S0003-9993(03)00030-3; JAEGERS SMHJ, 1995, ARCH PHYS MED REHAB, V76, P736, DOI 10.1016/S0003-9993(95)80528-1; Jagadamma KC, 2010, PROSTHET ORTHOT INT, V34, P270, DOI 10.3109/03093646.2010.503225; Jonkers I, 2006, GAIT POSTURE, V23, P222, DOI 10.1016/j.gaitpost.2005.02.005; Jonkers I, 2003, GAIT POSTURE, V17, P264, DOI 10.1016/S0966-6362(02)00102-9; Jonkers I, 2009, GAIT POSTURE, V29, P129, DOI 10.1016/j.gaitpost.2008.07.010; Kulkarni J, 2005, CLIN REHABIL, V19, P81, DOI 10.1191/0269215505cr819oa; Lamontagne A, 2002, GAIT POSTURE, V15, P244, DOI 10.1016/S0966-6362(01)00190-4; Landau W, 2011, DEV MED CHILD NEUROL, V53, P768, DOI [10.1111/j.1469-8749.2010.03777.x, 10.1111/j.1469-8749.2011.04006.x]; Lee JD, 2011, BRAIN, V134, P1199, DOI 10.1093/brain/awr021; Lofterod B, 2007, ACTA ORTHOP, V78, P74, DOI 10.1080/17453670610013448; McDowell BC, 2000, GAIT POSTURE, V12, P114, DOI 10.1016/S0966-6362(00)00068-0; McGinley JL, 2009, GAIT POSTURE, V29, P360, DOI 10.1016/j.gaitpost.2008.09.003; Molenaers G, 2013, J CHILD ORTHOP, V7, P383, DOI 10.1007/s11832-013-0511-x; Morgenroth DC, 2010, AM J PHYS MED REHAB, V89, P635, DOI 10.1097/PHM.0b013e3181e71d90; MUTCH L, 1992, DEV MED CHILD NEUROL, V34, P547; Nieuwenhuys A, 2016, DEV MED CHILD NEUROL, V58, P306, DOI 10.1111/dmcn.12892; Nolan L, 2003, GAIT POSTURE, V17, P142, DOI 10.1016/S0966-6362(02)00066-8; Owen E, 2010, PROSTHET ORTHOT INT, V34, P254, DOI 10.3109/03093646.2010.485597; Pinzone O, 2014, GAIT POSTURE, V40, P286, DOI 10.1016/j.gaitpost.2014.03.185; Rademaker KJ, 2004, SEMIN PERINATOL, V28, P279, DOI 10.1053/j.semperi.2004.08.005; Riad J, 2007, J PEDIATR ORTHOPED, V27, P758, DOI 10.1097/BPO.0b013e3181558a15; Richards C, 1996, GAIT POSTURE, V4, P12, DOI 10.1016/0966-6362(96)01063-6; Ries AJ, 2014, GAIT POSTURE, V40, P539, DOI 10.1016/j.gaitpost.2014.06.011; Rodda JM, 2004, J BONE JOINT SURG BR, V86B, P251, DOI 10.1302/0301-620X.86B2.13878; Ross SA, 2007, ARCH PHYS MED REHAB, V88, P1114, DOI 10.1016/j.apmr.2007.06.011; Schwartz MH, 2014, GAIT POSTURE, V39, P778, DOI 10.1016/j.gaitpost.2013.10.016; Schwartz MH, 2013, GAIT POSTURE, V37, P473, DOI 10.1016/j.gaitpost.2012.08.016; Scianni A, 2009, AUST J PHYSIOTHER, V55, P81, DOI 10.1016/S0004-9514(09)70037-6; Selles RW, 1999, ARCH PHYS MED REHAB, V80, P1593, DOI 10.1016/S0003-9993(99)90336-2; Skranes J, 2010, DEV MED CHILD NEUROL, V52, P279; TORBURN L, 1995, J REHABIL RES DEV, V32, P111; Toro B, 2007, GAIT POSTURE, V25, P157, DOI 10.1016/j.gaitpost.2006.02.004; Treweek SP, 1998, PROSTHET ORTHOT INT, V22, P178; Trost JP, 2008, DEV MED CHILD NEUROL, V50, P765, DOI 10.1111/j.1469-8749.2008.03031.x; van der Krogt MM, 2010, J REHABIL MED, V42, P656, DOI 10.2340/16501977-0579; van der Krogt MM, 2010, ANN BIOMED ENG, V38, P1593, DOI 10.1007/s10439-010-9952-2; WALL JC, 1986, ARCH PHYS MED REHAB, V67, P550; Wolf S, 2006, GAIT POSTURE, V23, P331, DOI 10.1016/j.gaitpost.2005.04.004; World Health Organization, 2001, INT CLASS FUNCT DIS; Wren TAL, 2005, J PEDIATR ORTHOPED, V25, P79, DOI 10.1097/00004694-200501000-00018; Wren TAL, 2011, GAIT POSTURE, V34, P364, DOI 10.1016/j.gaitpost.2011.06.002; Wren TAL, 2011, GAIT POSTURE, V34, P149, DOI 10.1016/j.gaitpost.2011.03.027; Wright JG, 2003, J PEDIATR ORTHOPED, V23, P288, DOI 10.1097/00004694-200305000-00002	95	37	43	3	28	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	AUG	2016	52	4					560	574					15	Rehabilitation	Rehabilitation	DZ6TL	WOS:000385994700016	27618499				2021-06-18	
J	Sariaslan, A; Lichtenstein, P; Larsson, H; Fazel, S				Sariaslan, Amir; Lichtenstein, Paul; Larsson, Henrik; Fazel, Seena			Triggers for Violent Criminality in Patients With Psychotic Disorders	JAMA PSYCHIATRY			English	Article							OF-THE-LITERATURE; CASE-CROSSOVER; BIPOLAR DISORDER; RISK-ASSESSMENT; SELF-HARM; POPULATION; SUICIDE; SCHIZOPHRENIA; CRIME; AGGRESSION	IMPORTANCE Absolute and relative risks of violence are increased in patients with psychotic disorders, but the contribution of triggers for violent acts to these risks is uncertain. OBJECTIVE To examine whether a range of triggers for violent acts are associated with risks of violence in patients diagnosed with psychotic disorders and in individuals without a psychiatric diagnosis. DESIGN, SETTING, AND PARTICIPANTS Using a sample of all individuals born in Sweden between 1958 and 1988 (N = 3 123 724), we identified patients in the National Patient Register who were diagnosed with schizophrenia spectrum disorders (n = 34 903) and bipolar disorder (n = 29 692), as well as unaffected controls (n = 2 763 012). We then identified, within each subsample, persons who had experienced any of the following triggers for violent acts between January 1, 2001, and December 15, 2013: exposure to violence, parental bereavement, self-harm, traumatic brain injury, unintentional injuries, and substance intoxication. By using within-individual models, we conducted conditional logistic regression to compare the risk of the individual engaging in violent acts in the week following the exposure to a trigger with the risk during earlier periods of equivalent length. All time-invariant confounders (eg, genetic and early environmental influences) were controlled for by this research design and we further adjusted for time-varying sociodemographic factors. MAIN OUTCOMES AND MEASURES Adjusted odds ratios (aORs) of violent crime occurring in the week following the exposure to a trigger event compared with earlier periods. RESULTS Among the sample of 2 827 607 individuals (1 492 186 male and 1 335 421 female), all of the examined trigger events were associated with increased risk of violent crime in the week following exposure. The largest 1-week absolute risk of violent crime was observed following exposure to violence (70-177 violent crimes per 10 000 persons). For most triggers, the relative risks did not vary significantly by diagnosis, including unintentional injuries (aOR range, 3.5-4.8), self-harm (aOR range, 3.9-4.2), and substance intoxication (aOR range, 3.0-4.0). Differences by diagnosis included parental bereavement, which was significantly higher in patients with schizophrenia spectrum disorders (aOR, 5.0; 95% CI, 3.0-8.1) compared with controls (aOR, 1.7; 95% CI, 1.3-2.2). CONCLUSIONS AND RELEVANCE In addition to identifying risk factors for violence, clarifying the timing of the triggers may provide opportunities to improve risk assessment and management in individuals with psychotic disorders.	[Sariaslan, Amir; Fazel, Seena] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Lichtenstein, Paul; Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Larsson, Henrik] Univ Orebro, Dept Med Sci, Orebro, Sweden	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365; Sariaslan, Amir/0000-0002-6151-3278	Wellcome TrustWellcome TrustEuropean Commission [095806]; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); Swedish Research CouncilSwedish Research CouncilEuropean Commission [2010-3184, 2011-2492, 2013-5867]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD061817]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061817] Funding Source: NIH RePORTER	This study was supported by grant 095806 from the Wellcome Trust; the Swedish Council for Working Life and Social Research; grants 2010-3184, 2011-2492, and 2013-5867 from the Swedish Research Council; and grant HD061817 from the National Institute of Child Health and Human Development.	Caine ED, 2011, PUBLIC HLTH POPULATI; Caine ED, 2013, AM J PUBLIC HEALTH, V103, P822, DOI 10.2105/AJPH.2012.301078; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Douglas KS, 2005, PSYCHOL PUBLIC POL L, V11, P347, DOI 10.1037/1076-8971.11.3.347; Edmondson D, 2013, EUR HEART J, V34, P300, DOI 10.1093/eurheartj/ehs398; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; Elzerbi C, 2015, ADDICTION, V110, P1082, DOI 10.1111/add.12960; Fazel S, 2006, AM J PSYCHIAT, V163, P1397, DOI 10.1176/appi.ajp.163.8.1397; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Fazel S, 2010, ARCH GEN PSYCHIAT, V67, P931, DOI 10.1001/archgenpsychiatry.2010.97; Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Frisell T, 2012, EPIDEMIOLOGY, V23, P713, DOI 10.1097/EDE.0b013e31825fa230; Gayer-Anderson C, 2013, EPIDEMIOL PSYCH SCI, V22, P131, DOI 10.1017/S2045796012000406; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Haggard-Grann U, 2006, ADDICTION, V101, P100, DOI 10.1111/j.1360-0443.2005.01293.x; Haggard-Grann U, 2006, SOC PSYCH PSYCH EPID, V41, P532, DOI 10.1007/s00127-006-0056-0; Hallden K., 2008, INT STANDARD CLASSIF; Hawton K, 2014, LANCET, V383, P1147, DOI 10.1016/S0140-6736(13)62118-2; Heiskanen M, 2010, INT STAT CRIME JUSTI, P21; Jennings WG, 2012, AGGRESS VIOLENT BEH, V17, P16, DOI 10.1016/j.avb.2011.09.003; Kuhlhorn E, 2007, SERIOUS VIOLENCE HOS; Large MM, 2011, SCHIZOPHR RES, V125, P209, DOI 10.1016/j.schres.2010.11.026; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Lundholm L, 2013, DRUG ALCOHOL DEPEN, V129, P110, DOI 10.1016/j.drugalcdep.2012.09.019; McGuire J, 2008, PHILOS T R SOC B, V363, P2577, DOI 10.1098/rstb.2008.0035; Merikangas KR, 2011, ARCH GEN PSYCHIAT, V68, P241, DOI 10.1001/archgenpsychiatry.2011.12; Mittleman MA, 2014, INT J EPIDEMIOL, V43, P1645, DOI 10.1093/ije/dyu081; Mittleman MA, 2011, CIRCULATION, V124, P346, DOI 10.1161/CIRCULATIONAHA.110.968776; National Institute of Public Health, 2007, ALC STAT 2007; NICE, 2011, ALC US DIS DIAGN ASS; Nilsson A C, 1994, Lakartidningen, V91, P603; Nilsson AC., 1994, LAKARTIDNINGEN, V91, P603; O'Donnell O, 2015, J AFFECT DISORDERS, V175, P325, DOI 10.1016/j.jad.2014.12.051; Office for National Statistics, 2015, CRIM ENGL WAL YEAR E; Penn JV, 2003, J AM ACAD CHILD PSY, V42, P762, DOI 10.1097/01.CHI.0000046869.56865.46; Purtle J, 2015, ANN INTERN MED, V163, P715, DOI 10.7326/M15-0586; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Sariaslan A, MOL PSYCHIAT; Sariaslan A, 2015, SCHIZOPHRENIA BULL, V41, P494, DOI 10.1093/schbul/sbu105; Sariaslan A, 2014, BRIT J PSYCHIAT, V205, P286, DOI 10.1192/bjp.bp.113.136200; Sellgren C, 2011, ACTA PSYCHIAT SCAND, V124, P447, DOI 10.1111/j.1600-0447.2011.01747.x; Singh JP, 2011, SCHIZOPHRENIA BULL, V37, P899, DOI 10.1093/schbul/sbr093; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; The Swedish National Council for Crime Prevention, 2015, EXP CRIM 2014 RES NA; Troquete NAC, 2013, BRIT J PSYCHIAT, V202, P365, DOI 10.1192/bjp.bp.112.113043; Wikstrom POH, 2006, PATHWAY CRIME, P61, DOI 10.1017/CBO9780511489341.004; Wilcox HC, 2010, J AM ACAD CHILD PSY, V49, P514, DOI 10.1016/j.jaac.2010.01.020; Witt K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055942; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018; World Health Organization, GLOB HLTH OBS DAT RE	51	37	37	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	AUG	2016	73	8					796	803		10.1001/jamapsychiatry.2016.1349			8	Psychiatry	Psychiatry	DW9OX	WOS:000383991700009	27410165	Bronze, Green Accepted			2021-06-18	
J	Logsdon, AE; Lucke-Wold, BP; Nguyen, L; Matsumoto, RR; Turner, RC; Rosen, CL; Huber, JD				Logsdon, Aric E.; Lucke-Wold, Brandon P.; Nguyen, Linda; Matsumoto, Rae R.; Turner, Ryan C.; Rosen, Charles L.; Huber, Jason D.			Salubrinal reduces oxidative stress, neuroinflammation and impulsive-like behavior in a rodent model of traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Oxidative stress; Endoplasmic reticulum stress; Neuroinflammation; Impulsive-like behavior	ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; IMPROVES FUNCTIONAL RECOVERY; NADPH-OXIDASE; MOUSE MODEL; ER STRESS; SIGNALING PATHWAYS; ACTIVATION; INHIBITION; JNK	Traumatic brain injury (TBI) is the leading cause of trauma related morbidity in the developed world. TBI has been shown to trigger secondary injury cascades including endoplasmic reticulum (ER) stress, oxidative stress, and neuroinflammation. The link between secondary injury cascades and behavioral outcome following TBI is poorly understood warranting further investigation. Using our validated rodent blast TBI model, we examined the interaction of secondary injury cascades following single injury and how these interactions may contribute to impulsive-like behavior after a clinically relevant repetitive TBI paradigm. We targeted these secondary pathways acutely following single injury with the cellular stress modulator, salubrinal (SAL). We examined the neuroprotective effects of SAL administration on significantly reducing ER stress: janus-N-terminal kinase (JNK) phosphorylation and C/EBP homology protein (CHOP), oxidative stress: superoxide and carbonyls, and neuroinflammation: nuclear factor kappa beta (NF kappa B) activity, inducible nitric oxide synthase (iNOS) protein expression, and pro-inflammatory cytokines at 24 h post-TBI. We then used the more clinically relevant repeat injury paradigm and observed elevated NF kappa B and iNOS activity. These injury cascades were associated with impulsive-like behavior measured on the elevated plus maze. SAL administration attenuated secondary iNOS activity at 72 h following repetitive TBI, and most importantly prevented impulsive-like behavior. Overall, these results suggest a link between secondary injury cascades and impulsive-like behavior that can be modulated by SAL administration. (c) 2016 Elsevier B.V. All rights reserved.	[Logsdon, Aric E.; Nguyen, Linda; Huber, Jason D.] W Virginia Univ, Dept Pharmaceut Sci, Sch Pharm, Hlth Sci Ctr, One Med Ctr Dr, Morgantown, WV 26506 USA; [Logsdon, Aric E.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Rosen, Charles L.; Huber, Jason D.] W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Matsumoto, Rae R.] Touro Univ Calif, Deans Off, Coll Pharm, Vallejo, CA USA; [Logsdon, Aric E.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Rosen, Charles L.; Huber, Jason D.] W Virginia Univ, Centers Neurosci, Sch Med, Morgantown, WV 26506 USA	Huber, JD (corresponding author), W Virginia Univ, Dept Pharmaceut Sci, Sch Pharm, Hlth Sci Ctr, One Med Ctr Dr, Morgantown, WV 26506 USA.	alogsdol@mix.wvu.edu; bwold@mix.wvu.edu; Inguyenl@mix.wvu.edu; rae.matsumoto@tu.edu; rcturner@hsc.wvu.edu; crosen@hsc.wvu.edu; jdhuber@hsc.wvu.edu	Nguyen, Linda/AAQ-1755-2021	Turner, Ryan/0000-0001-5523-0645	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR016550, P30 RR032138/GM103488, P20 RR016477]; West Virginia University Health Sciences Center Office of Research and Graduate Education; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM08174]; American Foundation of Pharmaceutical Education; American Medical Association Foundation Seed Grant; Neurosurgery Research AMP; Education Foundation Medical Student Summer Research Fellowship; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P30RR032138, P20RR016477, P20RR016455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081740, P30GM103488, U54GM104942] Funding Source: NIH RePORTER	We thank Dr. James P. O'Callaghan and Dr. Diane B. Miller of the Center for Disease Control (CDC) and the National Institute for Occupational Safety and Health (NIOSH). We appreciate guidance of Dr. James W. Simpkins during manuscript preparation (Director of Stroke Center). The authors acknowledge the assistance with animal work done by Xinlan Li (Dept. of Neurosurgery). The authors acknowledge the technical assistance performed by Kelly E. Smith. The authors are grateful for the assistance of Dr. Robert T.T. Gettens and Nicholas St. John of Western New England University for their help with design of the blast model and Mr. Peter Bennett and Mr. James Edward Robson for model construction. Imaging experiments and image analysis were performed in the West Virginia University Microscope Imaging Facility, which has been supported by the National Institutes of Health (NIH) Grants P20 RR016550, P30 RR032138/GM103488 and P20 RR016477. This work was supported by a Research Funding and Development (RFDG) grant from the West Virginia University Health Sciences Center Office of Research and Graduate Education (to JDH and CLR), a training grant from the NIH (to RCT) (5T32GM08174), and an American Foundation of Pharmaceutical Education pre-doctoral fellowship (to AFL and BPL). An American Medical Association Foundation Seed Grant and Neurosurgery Research & Education Foundation Medical Student Summer Research Fellowship was awarded (to BPL).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abdul-Muneer PM, 2014, MOL NEUROBIOL; Abdullah Z, 2014, MOL CELL NEUROSCI, V61, P72, DOI 10.1016/j.mcn.2014.06.002; Adhikari A, 2011, NEURON, V71, P898, DOI 10.1016/j.neuron.2011.07.027; Ansari MA, 2014, FREE RADICAL BIO MED, V77, P21, DOI 10.1016/j.freeradbiomed.2014.08.025; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Banks SJ, 2014, J NEUROPSYCH CLIN N, V26, P44, DOI 10.1176/appi.neuropsych.12070185; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bellezza I, 2014, INT J BIOCHEM CELL B, V51, P159, DOI 10.1016/j.biocel.2014.03.023; Bidzan L, 2012, MED SCI MONITOR, V18, pCR182, DOI 10.12659/MSM.882523; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Bracchi-Ricard V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-92; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Colla E, 2012, J NEUROSCI, V32, P3306, DOI 10.1523/JNEUROSCI.5367-11.2012; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Damjanac M, 2007, BRAIN RES, V1128, P40, DOI 10.1016/j.brainres.2006.05.050; Dash P. K., 2015, J NEUROTRAUMA; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deslauriers AM, 2011, J IMMUNOL, V187, P4788, DOI 10.4049/jimmunol.1004111; Faden A. I., 2015, BR J PHARM; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hayashi T, 2015, PSYCHIAT CLIN NEUROS, V69, P179, DOI 10.1111/pcn.12262; Hong Y, 2016, INT IMMUNOPHARMACOL, V33, P83, DOI 10.1016/j.intimp.2016.02.002; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hsieh YH, 2007, BIOCHEM BIOPH RES CO, V359, P643, DOI 10.1016/j.bbrc.2007.05.154; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Huang X., 2012, NEUROBIOL AGING, V33, pe1009; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Kumar R. G., 2014, BRAIN BEHAV IMMUN; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liu Y, 2014, CAN J CARDIOL, V30, P368, DOI 10.1016/j.cjca.2013.11.001; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Lucke-Wold B. P., 2014, J NEUROTRAUMA; Lucke-Wold B. P., 2014, MOL NEUROBIOL; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Lucke-Wold BP, 2016, J NEUROSURG, V124, P687, DOI 10.3171/2015.3.JNS141802; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Mar AC, 2011, J NEUROSCI, V31, P6398, DOI 10.1523/JNEUROSCI.6620-10.2011; Uranga RM, 2009, TOXICOL SCI, V111, P331, DOI 10.1093/toxsci/kfp152; Michael A. P., 2015, J NEUROTRAUMA; Mosienko V, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.44; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; Ohri SS, 2013, NEUROBIOL DIS, V58, P29, DOI 10.1016/j.nbd.2013.04.021; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Prell T, 2014, J NEUROIMMUNOL, V270, P29, DOI 10.1016/j.jneuroim.2014.03.005; Quan X., 2015, BIOCH BIOPHYS RES CO; Rebetez MML, 2015, BRAIN INJURY, V29, P1175, DOI 10.3109/02699052.2015.1035326; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Ruan J, 2015, BIOCHEM BIOPH RES CO, V456, P122, DOI 10.1016/j.bbrc.2014.11.045; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Sominsky L, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00201; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Toklu H.Z., 2015, BRAIN NEUROTRAUMA MO; Tsai KH, 2012, J CELL PHYSIOL, V227, P1347, DOI 10.1002/jcp.22847; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Wu LL, 2014, LIFE SCI, V110, P44, DOI 10.1016/j.lfs.2014.06.020; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	84	37	38	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 15	2016	1643						140	151		10.1016/j.brainres.2016.04.063			12	Neurosciences	Neurosciences & Neurology	DP4EE	WOS:000378448200015	27131989	Green Accepted			2021-06-18	
J	Chamard, E; Lefebvre, G; Lassonde, M; Theoret, H				Chamard, Emilie; Lefebvre, Genevieve; Lassonde, Maryse; Theoret, Hugo			Long-Term Abnormalities in the Corpus Callosum of Female Concussed Athletes	JOURNAL OF NEUROTRAUMA			English	Article						athletes; corpus callosum; diffusion tensor imaging; female; sports concussion	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; DIFFUSIVITY MEASURES; AXONAL INJURY; MILD; MOTOR; TRACTOGRAPHY; GENDER	Concussion is an injury affecting millions of individuals annually that can be associated with long-term sequelae. Recent studies have reported long-term abnormalities in the white matter (WM) tracts of male athletes. The corpus callosum (CC) and corticospinal tract (CST) have been shown to be particularly vulnerable to concussion, which may be related to abnormal interhemispheric functional connectivity and motor impairments. These anatomical pathways, however, have not been investigated in female athletes despite the functional significance of the CC and CST to adequate sports performance. In the present study, 8 healthy, unconcussed female athletes (soccer, hockey) were compared with 10 female athletes (soccer, hockey, water polo) 6 months post-concussion. Diffusion tensor imaging (DTI) of the CC and CST was conducted in a 3T magnetic resonance imaging (MRI) scanner. DTI analysis showed no significant differences between groups within the CST but revealed differences between groups in the CC. The concussed group had lower mean diffusivity (t = 2.14; p = 0.048) and lower radial diffusivity (t = 2.91; p = 0.010) in the region of the CC projecting to the prefrontal cortex. A lower volume of WM fibers was found in the region projecting to the premotor and supplementary motor areas (t = 2.14; p = 0.048). Finally, lower axial diffusivity (AD) was observed in the CC area projecting mainly to the parietal and temporal area (t = 2.23; p = 0.041). Long-term alterations in the CC of female athletes appear to affect mostly the anterior part of the CC projecting to the prefrontal and premotor areas. Further studies are needed to determine whether these alterations are associated with a higher risk of sustaining a subsequent concussive injury.	[Chamard, Emilie; Lefebvre, Genevieve; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Lassonde, Maryse; Theoret, Hugo] CHU St Justine, Ctr Rech, Montreal, PQ, Canada	Theoret, H (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit CERNEC, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797	CIHRCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Avants B., 2009, ADV NORMALIZATION TO; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr M., 2005, HUMAN NERVOUS SYSTEM; Bear MF., 2007, NEUROSCIENCE EXPLORI, V3; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chamberland M, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00059; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Descoteaux M, 2008, LECT NOTES COMPUT SC, V5242, P122, DOI 10.1007/978-3-540-85990-1_15; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Garyfallidis E, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00008; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gooijers J, 2014, NEUROSCI BIOBEHAV R, V43, P1, DOI 10.1016/j.neubiorev.2014.03.008; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Henry LC, 2014, PROG NEUROL SURG, V28, P63, DOI 10.1159/000358763; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Herweh Christian, 2016, NEURORADIOLOGY; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pinel J., 2013, BIOPSYCHOLOGY; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sponheim S. R., 2011, NEUROIMAGE, P1; Toga A.W., 2002, BRAIN MAPPING METHOD; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Wassermann D, 2013, LECT NOTES COMPUT SC, V8149, P647, DOI 10.1007/978-3-642-40811-3_81; Whittingstall K, 2014, CORTEX, V56, P85, DOI 10.1016/j.cortex.2013.02.004; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	61	37	38	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1220	+		10.1089/neu.2015.3948			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200388	26414496				2021-06-18	
J	Ercole, A; Thelin, EP; Holst, A; Bellander, BM; Nelson, DW				Ercole, A.; Thelin, E. P.; Holst, A.; Bellander, B. M.; Nelson, D. W.			Kinetic modelling of serum S100b after traumatic brain injury	BMC NEUROLOGY			English	Article						S100b protein; Human; Traumatic brain injury; Biomarkers; Kinetics	PROGNOSTIC BIOMARKER; CEREBROSPINAL-FLUID; PROTEIN; BLOOD; MARKER; S-100B; RELEASE; DAMAGE; HEAD; IMMUNOASSAY	Background: An understanding of the kinetics of a biomarker is essential to its interpretation. Despite this, little kinetic modelling of blood biomarkers can be found in the literature. S100b is an astrocyte related marker of brain injury used primarily in traumatic brain injury (TBI). Serum levels are expected to be the net result of a multi-compartmental process. The optimal sample times for TBI prognostication, and to follow injury development, are unclear. The purpose of this study was to develop a kinetic model to characterise the temporal course of serum S100b concentration after primary traumatic brain injury. Methods: Data of serial serum S100b samples from 154 traumatic brain injury patients in a neurointensive care unit were retrospectively analysed, including only patients without secondary peaks of this biomarker. Additionally, extra-cranial S100b can confound samples earlier than 12 h after trauma and were therefore excluded. A hierarchical, Bayesian gamma variate kinetic model was constructed and the parameters estimated by Markov chain Monte Carlo sampling. Results: We demonstrated that S100b concentration changes dramatically over timescales that are clinically important for early prognostication with a peak at 27.2 h (95 % credible interval [25.6, 28.8]). Baseline S100b levels was found to be 0.11 mu g/L (95 % credible interval [0.10, 0.12]). Conclusions: Even small differences in injury to sample time may lead to marked changes in S100b during the first days after injury. This must be taken into account in interpretation. The model offers a way to predict the peak and trajectory of S100b from 12 h post trauma in TBI patients, and to identify deviations from this, possibly indicating a secondary event. Kinetic modelling, providing an equation for the peak and projection, may offer a way to reduce the ambiguity in interpretation of, in time, randomly sampled acute biomarkers and may be generally applicable to biomarkers with, in time, well defined hits.	[Ercole, A.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Thelin, E. P.; Bellander, B. M.] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden; [Holst, A.] KTH Royal Inst Technol, Sch Comp Sci & Commun, Stockholm, Sweden; [Nelson, D. W.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden	Nelson, DW (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden.	david.nelson@karolinska.se	Thelin, Eric Peter/K-2144-2012; Ercole, Ari/B-6288-2009	Thelin, Eric Peter/0000-0002-2338-4364; Ercole, Ari/0000-0001-8350-8093	Stockholm City Council; Swedish Institute of Computer Science; SICS; Karolinska InstituteKarolinska Institutet	AE would like to acknowledge the assistance of Carmen Lopez-Soto in preparing the data for initial evaluation. DN would like to acknowledge the assistance of Gunilla Malmborg-Bornhall for maintenance of the Karolinska traumatic injury database. The study was financed in part the Stockholm City Council (ET, BMB), Swedish Institute of Computer Science, SICS (AH) and the Karolinska Institute (DN).	Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Carpenter KLH, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00026; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; DAVENPORT R, 1983, J NUCL MED, V24, P945; Development Core Team, 2008, R LANG ENV STAT COMP; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Martenson ED, 2001, J CLIN ONCOL, V19, P824, DOI 10.1200/JCO.2001.19.3.824; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Plummer M., 2003, P 3 INT WORKSHOP DIS, P20; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SHANNON CE, 1949, P IRE, V37, P10, DOI 10.1109/JRPROC.1949.232969; SHEPPARD C W, 1954, Minn Med, V37, P93; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; USUI A, 1989, CLIN CHEM, V35, P1942; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127	36	37	38	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	JUN 17	2016	16								93	10.1186/s12883-016-0614-3			8	Clinical Neurology	Neurosciences & Neurology	DO8PN	WOS:000378045700001	27315805	DOAJ Gold, Green Published			2021-06-18	
J	Myer, GD; Yuan, WH; Foss, KDB; Smith, D; Altaye, M; Reches, A; Leach, J; Kiefer, AW; Khoury, JC; Weiss, M; Thomas, S; Dicesare, C; Adams, J; Gubanich, PJ; Geva, A; Clark, JF; Meehan, WP; Mihalik, JP; Krueger, D				Myer, Gregory D.; Yuan, Weihong; Foss, Kim D. Barber; Smith, David; Altaye, Mekibib; Reches, Amit; Leach, James; Kiefer, Adam W.; Khoury, Jane C.; Weiss, Michal; Thomas, Staci; Dicesare, Chris; Adams, Janet; Gubanich, Paul J.; Geva, Amir; Clark, Joseph F.; Meehan, William P., III; Mihalik, Jason P.; Krueger, Darcy			The Effects of External Jugular Compression Applied during Head Impact Exposure on Longitudinal Changes in Brain Neuroanatomical and Neurophysiological Biomarkers: a Preliminary Investigation	FRONTIERS IN NEUROLOGY			English	Article						head injury; pediatric traumatic brain injury; traumatic brain injury; EEG	WHITE-MATTER INTEGRITY; COLLEGIATE FOOTBALL PLAYERS; DIFFUSION TENSOR; CORPUS-CALLOSUM; WORKING-MEMORY; AXONAL INJURY; UNITED-STATES; MILD; CONNECTIVITY; MODERATE	Objectives: Utilize a prospective in vivo clinical trial to evaluate the potential for mild neck compression applied during head impact exposure to reduce anatomical and physiological biomarkers of brain injury. Methods: This project utilized a prospective randomized controlled trial to evaluate effects of mild jugular vein (neck) compression (collar) relative to controls (no collar) during a competitive hockey season (males; 16.3 +/- 1.2 years). The collar was designed to mildly compress the jugular vein bilaterally with the goal to increase intracranial blood volume to reduce risk of brain slosh injury during head impact exposure. Helmet sensors were used to collect daily impact data in excess of 20 g (games and practices) and the primary outcome measures, which included changes in white matter (WM) microstructure, were assessed by diffusion tensor imaging (DTI). Specifically, four DTI measures: fractional anisotropy, mean diffusivity (MD), axial diffusivity, and radial diffusivity (RD) were used in the study. These metrics were analyzed using the tract-based Spatial Statistics (TBSS) approach - a voxel-based analysis. In addition, electroencephalography-derived event-related potentials were used to assess changes in brain network activation (BNA) between study groups. Results: For athletes not wearing the collar, DTI measures corresponding to a disruption of WM microstructure, including MD and RD, increased significantly from pre-season to mid-season (p < 0.05). Athletes wearing the collar did not show a significant change in either MD or RD despite similar accumulated linear accelerations from head impacts (p > 0.05). In addition to these anatomical findings, electrophysiological network analysis of the degree of congruence in the network electrophysiological activation pattern demonstrated concomitant changes in brain network dynamics in the non-collar group only (p < 0.05). Similar to the DTI findings, the increased change in BNA score in the non-collar relative to the collar group was statistically significant (p < 0.01). Changes in DTI outcomes were also directly correlated with altered brain network dynamics (r = 0.76; p < 0.05) as measured by BNA. Conclusion: Group differences in the longitudinal changes in both neuroanatomical and electrophysiological measures, as well as the correlation between the measures, provide initial evidence indicating that mild jugular vein compression may have reduced alterations in the WM response to head impacts during a competitive hockey season. The data indicate sport-related alterations in WM microstructure were ameliorated by application of jugular compression during head impact exposure. These results may lead to a novel line of research inquiry to evaluate the effects of protecting the brain from sports-related head impacts via optimized intracranial fluid dynamics.	[Myer, Gregory D.; Foss, Kim D. Barber; Smith, David; Kiefer, Adam W.; Thomas, Staci; Dicesare, Chris; Gubanich, Paul J.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Foss, Kim D. Barber; Kiefer, Adam W.; Thomas, Staci; Dicesare, Chris] Cincinnati Childrens Hosp Med Ctr, Human Performance Lab, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Kiefer, Adam W.; Gubanich, Paul J.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Penn, Dept Orthopaed, Philadelphia, PA 19104 USA; [Myer, Gregory D.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Myer, Gregory D.] Univ Cincinnati, Dept Orthopaed Surg, Cincinnati, OH USA; [Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Foss, Kim D. Barber] Mt St Joseph Univ, Div Hlth Sci, Dept Athlet Training, Cincinnati, OH USA; [Smith, David] NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL USA; [Altaye, Mekibib; Khoury, Jane C.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Reches, Amit; Weiss, Michal; Geva, Amir] ElMindA Ltd, Herzliyya, Israel; [Leach, James; Adams, Janet] Cincinnati Childrens Hosp Med Ctr, Div Radiol, Cincinnati, OH 45229 USA; [Kiefer, Adam W.] Univ Cincinnati, Dept Psychol, Ctr Cognit Act & Percept, Cincinnati, OH 45221 USA; [Geva, Amir] Ben Gurion Univ Negev, Dept Elect & Comp Engn, POB 653, IL-84105 Beer Sheva, Israel; [Clark, Joseph F.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Dept Pediat & Orthoped, Boston, MA USA; [Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Krueger, Darcy] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA	Myer, GD (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA.; Myer, GD (corresponding author), Cincinnati Childrens Hosp Med Ctr, Human Performance Lab, Cincinnati, OH 45229 USA.; Myer, GD (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.; Myer, GD (corresponding author), Univ Penn, Dept Orthopaed, Philadelphia, PA 19104 USA.; Myer, GD (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA USA.; Myer, GD (corresponding author), Univ Cincinnati, Dept Orthopaed Surg, Cincinnati, OH USA.	greg.myer@cchmc.org	Meijer, Anna/K-5118-2016; Kiefer, Adam/F-1756-2018; DiCesare, Christopher/ABH-9573-2020; DiCesare, Christopher/AAA-3327-2021; Myer, Gregory/H-6572-2016	DiCesare, Christopher/0000-0002-6576-4904; Geva, Amir/0000-0003-3159-3673; Myer, Gregory/0000-0002-9983-8422	Heidt Family Foundation; Q30 Innovations, LLC; Q30 Sports Innovations	The authors would like to thank Adam Tramonte and Jason Kamp, John Sullivan, Michael Gordon, and Ken Rushford for their support and assistance to conduct this study. Thanks to the hockey parents and players. We appreciate their patience with the testing scheduling, follow-ups, and equipment additions. The authors would like to thank Lacey Haas, Brynne Williams, and Matt Lanier in the Imaging Research Center. Their support made this study possible. The authors would like to acknowledge the support of ElMindA for providing the EEG equipment and supportive analyses. Funding for this study was provided by The Heidt Family Foundation and Q30 Innovations, LLC. Q30 Sports Innovations has financial interests in the development of the Q-Collar.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barth JT, 2001, J ATHL TRAINING, V36, P253; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOUYSSOU M, 1985, J DENT RES, V64, P721; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Brooks MA, 2013, AM AC PED ANN C SESS; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Courtney M., 2007, ARXIV07113804; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fisher JA, 2013, EFFECT JUGULAR VEIN; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; GILLAND O, 1969, AMER J ROENTGENOL RA, V106, P369, DOI 10.2214/ajr.106.2.369; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hatt A, 2015, AM J NEURORADIOL, V36, P1971, DOI 10.3174/ajnr.A4361; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Kontos AP, 2016, BRAIN IMAGING BEHAV, V10, P594, DOI 10.1007/s11682-015-9412-6; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Leach JL, 2013, AM SOC NEUR ANN M SA; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Mongan P, 2013, PRACTICAL APPROACH N; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; Newcombe VFJ, 2016, NEUROREHAB NEURAL RE, V30, P49, DOI 10.1177/1545968315584004; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Reches A, 2016, EUR J PAIN, V20, P250, DOI 10.1002/ejp.716; Reches A, 2014, NEUROIMAGE, V88, P228, DOI 10.1016/j.neuroimage.2013.11.020; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shahaf G, 2012, CLIN NEUROPHYSIOL, V123, P1568, DOI 10.1016/j.clinph.2011.12.010; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith DW, 2013, ORTHOP J SPORTS MED, V1, DOI 10.1177/2325967113511588; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Sui J, 2014, NEUROIMAGE, V102, P11, DOI 10.1016/j.neuroimage.2013.09.044; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Treble A, 2013, J NEUROTRAUM, V30, P1609, DOI 10.1089/neu.2013.2934; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Wallerson R, 2014, WALL ST J ONLINE; Wilcox BJ, 2014, J ATHL TRAINING, V49, P514, DOI 10.4085/1062-6050-49.3.19; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	64	37	38	1	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 6	2016	7								74	10.3389/fneur.2016.00074			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DN5BG	WOS:000377080400001	27375546	DOAJ Gold, Green Published			2021-06-18	
J	Estraneo, A; Loreto, V; Guarino, I; Boemia, V; Paone, G; Moretta, P; Trojano, L				Estraneo, Anna; Loreto, Vincenzo; Guarino, Ivan; Boemia, Virginia; Paone, Giuseppe; Moretta, Pasquale; Trojano, Luigi			Standard EEG in diagnostic process of prolonged disorders of consciousness	CLINICAL NEUROPHYSIOLOGY			English	Article						Disorders of consciousness; Vegetative state; Minimally conscious state; EEG background activity; EEG reactivity; Rehabilitation	COMA RECOVERY SCALE; ANOXIC VEGETATIVE STATE; BRAIN-INJURY; UNRESPONSIVE WAKEFULNESS; PREDICTORS; BEHAVIOR; RESPONSIVENESS; REACTIVITY; ALPHA; PAIN	Objective: This cross-sectional study assessed the ability of standard EEG in distinguishing vegetative state (VS) from minimally conscious state plus (MCS+) or MCS minus (MCS-), and to correlate EEG features with aetiology and level of responsiveness assessed by Coma Recovery Scale-Revised (CRS-R). Methods: We analyzed background EEG activity and EEG reactivity to eye opening and closing and to tactile, acoustic, nociceptive stimuli and Intermittent Photic Stimulation (IPS) in 73 inpatients (VS = 37, MC- = 11, MCS+ = 25), with traumatic (n = 21), vascular (n = 25) or anoxic (n = 27) aetiology. Results: All patients, but one, showed abnormal background activity. EEG abnormalities were more severe in VS than in MCS+ or MCS-, and in anoxic than other aetiologies. MCS+ patients with normal or Mildly Abnormal background activity showed higher scores on CRS-R than patients with moderate to severe EEG abnormalities. Reactivity to IPS, and acoustic stimuli was significantly more frequent in MCS+ and MCS- than in VS patients. Conclusions: EEG features differ between VS and MCS- or MCS+ patients and can provide evidence of relative sparing of thalamocortical connections in MCS+ patients. In anoxic patients EEG organization is more severely impaired and provides less discriminative diagnostic information. Significance: Conventional EEG can help clinicians to disentangle VS from MCS patients. (C) 2016 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Estraneo, Anna; Loreto, Vincenzo; Guarino, Ivan; Boemia, Virginia; Paone, Giuseppe; Moretta, Pasquale] Salvatore Maugeri Fdn, Sci Inst Telese Terme BN, IRCCS, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy; [Trojano, Luigi] Univ Naples 2, Dept Psychol, Neuropsychol Lab, Viale Ellittico 31, I-81100 Caserta, Italy	Estraneo, A (corresponding author), Salvatore Maugeri Fdn, IRCCS, Res Lab, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.; Estraneo, A (corresponding author), Salvatore Maugeri Fdn, IRCCS, Neurehabil Unit Disorder Consciousness, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.	anna.estraneo@fsm.it	Moretta, Pasquale/AAE-5162-2021; Trojano, Luigi/F-2396-2016	Moretta, Pasquale/0000-0003-2244-254X; Trojano, Luigi/0000-0002-0328-9642			Bekinschtein TA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00005; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2010, CLIN NEUROPHYSIOL, V121, P274, DOI 10.1016/j.clinph.2009.11.008; Bagnato S, 2015, CLIN NEUROPHYSIOL, V126, P959, DOI 10.1016/j.clinph.2014.08.005; Bagnato S, 2011, J PERIPHER NERV SYST, V16, P315, DOI 10.1111/j.1529-8027.2011.00363.x; Boccagni C, 2011, J CLIN NEUROPHYSIOL, V28, P489, DOI 10.1097/WNP.0b013e318231c8c8; Bodien YG, 2016, ARCH PHYS MED REHAB, V97, P490, DOI 10.1016/j.apmr.2015.08.422; Bruno M.-A., 2012, COMA DISORD CONSCIOU, P11, DOI [10.1007/978-1-4471-2440-5_2, DOI 10.1007/978-1-4471-2440-5_2]; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Estraneo A, 2015, EUR J PHYS REHAB MED, V51, P627; Estraneo A, 2013, NEUROLOGY, V81, P1274; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Fernandez-Espejo D, 2015, JAMA NEUROL, V72, P1442, DOI 10.1001/jamaneurol.2015.2614; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirschberg R, 2011, NEUROL CLIN, V29, P773, DOI 10.1016/j.ncl.2011.07.009; Hofmeijer J, 2015, NEUROLOGY, V85, P137, DOI 10.1212/WNL.0000000000001742; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Klimesch W, 1998, NEUROSCI LETT, V244, P73, DOI 10.1016/S0304-3940(98)00122-0; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kulkarni VP, 2007, J CLIN NEUROPHYSIOL, V24, P433, DOI 10.1097/WNP.0b013e31815c2810; Latronico N, 2005, CURR OPIN CRIT CARE, V11, P126, DOI 10.1097/01.ccx.0000155357.24360.89; Logi F, 2011, BRAIN INJURY, V25, P972, DOI 10.3109/02699052.2011.589795; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Striano S, 1992, Acta Neurol (Napoli), V14, P275; Takahashi T, 2011, NIEDERMEYERS ELECTRO, P215; Trojano L, 2013, J NEUROL, V260, P306, DOI 10.1007/s00415-012-6717-x; Trojano L, 2012, J NEUROL, V259, P1888, DOI 10.1007/s00415-012-6435-4; Tsetsou S, 2015, RESUSCITATION, V97, P34, DOI 10.1016/j.resuscitation.2015.09.380; Yu T, 2013, NEUROLOGY, V80, P345, DOI 10.1212/WNL.0b013e31827f0846	41	37	40	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUN	2016	127	6					2379	2385		10.1016/j.clinph.2016.03.021			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DL3YH	WOS:000375569100012	27178856				2021-06-18	
J	Meissner, L; Gallozzi, M; Balbi, M; Schwarzmaier, S; Tiedt, S; Terpolilli, NA; Plesnila, N				Meissner, Lilja; Gallozzi, Micaela; Balbi, Matilde; Schwarzmaier, Susanne; Tiedt, Steffen; Terpolilli, Nicole A.; Plesnila, Nikolaus			Temporal Profile of MicroRNA Expression in Contused Cortex after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						mouse; traumatic brain injury; microarray; penumbra; miRNA; controlled cortical impact	DOWN-REGULATION; PROTECTS; DEATH; RNA; PATHOPHYSIOLOGY; EFFICACY; NEURONS; IMPACT; EFA6A; ARF6	MicroRNAs (miRNAs) were recently identified as important regulators of gene expression under a wide range of physiological and pathophysiological conditions. Thus, they may represent a novel class of molecular targets for the management of traumatic brain injury (TBI). In this study, we investigated the temporal profile of miRNA expression during the development of secondary brain damage after experimental TBI. For this purpose, we used a controlled cortical impact model in C57Bl/6 mice (n = 6) to induce a cortical contusion and analyzed miRNA expression in the traumatized cortex by microarray analysis during the development of secondary contusion expansion-i.e., at 1, 6, and 12 h after TBI. Of a total 780 mature miRNA sequences analyzed, 410 were detected in all experimental groups. Of these, 158 miRNAs were significantly upregulated or downregulated in TBI compared with sham-operated animals, and 52 miRNAs increased more than twofold. We validated the upregulation of five of the most differentially expressed miRNAs (miR-21*, miR-144, miR-184, miR-451, miR-2137) and the downregulation of four of the most differentially expressed miRNAs (miR-107, miR-137, miR-190, miR-541) by quantitative polymerase chain reaction (qPCR). miR-2137, the most differentially expressed miRNA after TBI, was further investigated by in situ hybridization and was found to be upregulated in neurons within the traumatic penumbra. This study gives a comprehensive picture of miRNA expression levels during secondary contusion expansion after TBI and may pave the way for the identification of novel targets for the management of brain trauma.	[Meissner, Lilja; Gallozzi, Micaela; Balbi, Matilde; Schwarzmaier, Susanne; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland; [Meissner, Lilja; Balbi, Matilde; Tiedt, Steffen; Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany; [Terpolilli, Nicole A.] Univ Munich, Inst Surg Res, Med Ctr, D-81377 Munich, Germany; [Plesnila, Nikolaus] Munich Cluster Syst Neurol SyNergy, Munich, Germany	Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; Terpolilli, Nicole/AAG-3598-2021	Tiedt, Steffen/0000-0002-8817-8457			Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Behrman S, 2011, J CELL BIOL, V192, P919, DOI 10.1083/jcb.201010055; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Choi S, 2006, J NEUROSCI, V26, P4811, DOI 10.1523/JNEUROSCI.4182-05.2006; Coolen M, 2009, CURR OPIN NEUROBIOL, V19, P461, DOI 10.1016/j.conb.2009.09.006; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Funk K, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-32; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lv GW, 2014, J CELL BIOCHEM, V115, P93, DOI 10.1002/jcb.24636; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McKiernan RC, 2012, EXP NEUROL, V237, P346, DOI 10.1016/j.expneurol.2012.06.029; McKiernan RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035921; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ribaudo R, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1011s04; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Roshan R, 2009, DRUG DISCOV TODAY, V14, P1123, DOI 10.1016/j.drudis.2009.09.009; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakagami H, 2004, EUR J NEUROSCI, V19, P863, DOI 10.1111/j.0953-816X.2004.03195.x; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Tang XQ, 2007, RNA, V13, P1803, DOI 10.1261/rna.498607; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang WX, 2008, BBA-GENE REGUL MECH, V1779, P749, DOI 10.1016/j.bbagrm.2008.01.005; Wang XH, 2012, CARDIOVASC RES, V94, P379, DOI 10.1093/cvr/cvs096; Yu DN, 2010, GENE DEV, V24, P1620, DOI 10.1101/gad.1942110; Zhang K, 2014, ONCOTARGET, V5, P12916, DOI 10.18632/oncotarget.2682; Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	45	37	38	0	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					713	720		10.1089/neu.2015.4077			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900001	26426744				2021-06-18	
J	Quintard, H; Patet, C; Zerlauth, JB; Suys, T; Bouzat, P; Pellerin, L; Meuli, R; Magistretti, PJ; Oddo, M				Quintard, Herve; Patet, Camille; Zerlauth, Jean-Baptiste; Suys, Tamarah; Bouzat, Pierre; Pellerin, Luc; Meuli, Reto; Magistretti, Pierre J.; Oddo, Mauro			Improvement of Neuroenergetics by Hypertonic Lactate Therapy in Patients with Traumatic Brain Injury Is Dependent on Baseline Cerebral Lactate/Pyruvate Ratio	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; cerebral microdialysis; hypertonic; lactate; traumatic brain injury	INTRACRANIAL HYPERTENSIVE EPISODES; POSITRON-EMISSION-TOMOGRAPHY; NUCLEAR-MAGNETIC-RESONANCE; NEUROPROTECTIVE ROLE; ENERGY-METABOLISM; SODIUM LACTATE; BLOOD LACTATE; PERFUSION CT; GLUCOSE; MICRODIALYSIS	Energy dysfunction is associated with worse prognosis after traumatic brain injury (TBI). Recent data suggest that hypertonic sodium lactate infusion (HL) improves energy metabolism after TBI. Here, we specifically examined whether the efficacy of HL (3h infusion, 30-40 mu mol/kg/min) in improving brain energetics (using cerebral microdialysis [CMD] glucose as a main therapeutic end-point) was dependent on baseline cerebral metabolic state (assessed by CMD lactate/pyruvate ratio [LPR]) and cerebral blood flow (CBF, measured with perfusion computed tomography [PCT]). Using a prospective cohort of 24 severe TBI patients, we found CMD glucose increase during HL was significant only in the subgroup of patients with elevated CMD LPR >25 (n = 13; +0.13 [95% confidence interval (CI) 0.08-0.19] mmol/L, p < 0.001; vs. +0.04 [-0.05-0.13] in those with normal LPR, p = 0.33, mixed-effects model). In contrast, CMD glucose increase was independent from baseline CBF (coefficient +0.13 [0.04-0.21] mmol/L when global CBF was <32.5 mL/100 g/min vs. +0.09 [0.04-0.14] mmol/L at normal CBF, both p < 0.005) and systemic glucose. Our data suggest that improvement of brain energetics upon HL seems predominantly dependent on baseline cerebral metabolic state and support the concept that CMD LPR - rather than CBF - could be used as a diagnostic indication for systemic lactate supplementation following TBI.	[Quintard, Herve; Patet, Camille; Suys, Tamarah; Bouzat, Pierre; Oddo, Mauro] Univ Lausanne Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, CHU Vaudois, Lausanne, Switzerland; [Zerlauth, Jean-Baptiste; Meuli, Reto] Univ Lausanne Hosp, CHU Vaudois, Dept Med Radiol, Lausanne, Switzerland; [Magistretti, Pierre J.] Univ Lausanne Hosp, CHU Vaudois, Dept Psychiat, Ctr Neurosci Psychiat, Lausanne, Switzerland; [Quintard, Herve] Nice Univ Hosp, Dept Anesthesia & Intens Care, Nice, France; [Bouzat, Pierre] Grenoble Univ Hosp, Dept Anesthesia & Intens Care, Grenoble, France; [Pellerin, Luc] Univ Lausanne, Inst Physiol, Lausanne, Switzerland; [Magistretti, Pierre J.] KAUST, Div Biol & Environm Sci & Engn, Thuwal, Saudi Arabia; [Magistretti, Pierre J.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Neuroenerget & Cellular Dynam, Lausanne, Switzerland	Oddo, M (corresponding author), CHUV Univ Hosp, Dept Intens Care Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Oddo, Mauro/R-3370-2016; Bouzat, Pierre/AAC-4105-2019; Pellerin, Luc/A-8912-2017; Bouzat, Pierre/L-6881-2014	Oddo, Mauro/0000-0002-6155-2525; Bouzat, Pierre/0000-0003-4667-6738; Pellerin, Luc/0000-0002-1016-1970; Magistretti, Pierre Julius/0000-0002-6678-320X			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzat P, 2015, CRIT CARE MED, V43, P445, DOI 10.1097/CCM.0000000000000720; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P133, DOI 10.1097/MCC.0000000000000072; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Dalsgaard MK, 2004, J PHYSIOL-LONDON, V554, P571, DOI 10.1113/jphysiol.2003.055053; Barros LF, 2013, TRENDS NEUROSCI, V36, P396, DOI 10.1016/j.tins.2013.04.002; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Herzog RI, 2013, J CLIN INVEST, V123, P1988, DOI 10.1172/JCI65105; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Levy B, 2005, LANCET, V365, P871, DOI 10.1016/S0140-6736(05)71045-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maran A, 2000, DIABETOLOGIA, V43, P733, DOI 10.1007/s001250051371; Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001; Patet C, 2015, J NEUROTRAUM, V32, P1560, DOI 10.1089/neu.2014.3781; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Rosafio K, 2014, GLIA, V62, P477, DOI 10.1002/glia.22618; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schurr A, 1997, J NEUROCHEM, V69, P423; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Sotelo-Hitschfeld T, 2012, GLIA, V60, P674, DOI 10.1002/glia.22304; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2001, AM J NEURORADIOL, V22, P905; Yang JY, 2014, P NATL ACAD SCI USA, V111, P12228, DOI 10.1073/pnas.1322912111	43	37	39	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					681	687		10.1089/neu.2015.4057			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700007	26421521	Green Published, Other Gold			2021-06-18	
J	Meulenbroek, P; Turkstra, LS				Meulenbroek, Peter; Turkstra, Lyn S.			Job stability in skilled work and communication ability after moderate-severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article							LONG-TERM OUTCOMES; HEAD-INJURY; ACUTE PREDICTORS; NEUROPSYCHOLOGICAL STATUS; PROGNOSTIC-FACTORS; FOLLOW-UP; RETURN; EMPLOYMENT; REHABILITATION; RECOVERY		[Meulenbroek, Peter] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Meulenbroek, Peter] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Turkstra, Lyn S.] Univ Wisconsin, Dept Commun Sci & Disorders, Madison, WI USA	Meulenbroek, P (corresponding author), Northwestern Univ, Rehabil Inst Chicago, Dept Phys Med & Rehabil, 345 E Super St,Rm 1328, Chicago, IL 60611 USA.	peter.meulenbroek@northwestern.edu		Meulenbroek, Peter/0000-0003-4233-9910	National Institutes of Health (NIH): National Institute for Deafness and other Communication Disorders (NIDCD) [1F31DC011462-01A1]; Walker Foundation Grant; Mary E. Switzer Merit Research Fellowship [H133F140026]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services; Advanced Rehabilitation Research Training Award: Interventions for Neurologic Communication Disorders [H133P120013]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31DC011462] Funding Source: NIH RePORTER	Research for this study was supported by a pre-doctoral fellowship award granted by the National Institutes of Health (NIH): National Institute for Deafness and other Communication Disorders (NIDCD) #1F31DC011462-01A1 (to Dr. Peter Meulenbroek) and funding from The Walker Foundation Grant (to Dr. Lyn S. Turkstra). Preparation of this manuscript was supported by an Advanced Rehabilitation Research Training Award: Interventions for Neurologic Communication Disorders #H133P120013 (to Dr. Leora R. Cherney), and from a Mary E. Switzer Merit Research Fellowship #H133F140026 (to Dr. Peter Meulenbroek) from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). The authors have no conflicts of interest to report.	BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bjorkdahl A, 2010, BRAIN INJURY, V24, P1061, DOI 10.3109/02699052.2010.494588; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown J., 1993, NELSON DENNY READING; Bureau of Labor Statistics, 2013, EMPL MAJ IND SECT; BURTON LF, 1987, J REHABIL, V53, P71; BUTLER RW, 1989, CLIN NEUROPSYCHOL, V3, P235; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Conrad C., 1998, STRATEGIC ORG COMMUN; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Crosling G, 2002, ENGL SPECIF PURP, V21, P41, DOI 10.1016/S0889-4906(00)00031-4; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Gale HF, 2002, IND RELAT, V41, P48; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Gunnarsson B.-L., 2009, CONTINUUM DISCOURSE; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Holmes J., 2003, POWER POLITENESS WOR; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Isaki E, 2000, BRAIN INJURY, V14, P441; Johnson R, 1987, Int Disabil Stud, V9, P49; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; MacDonald S., 2005, FAVRES FUNCTIONAL AS; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mayo NE, 2009, J REHABIL MED, V41, P209, DOI 10.2340/16501977-0343; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Meulenbroek P, 2013, CLIN APH C; Meulenbroek P, 2015, J VOCAT REH IN PRESS, V43; National Center for O* NET Development, 2010, O NET DESCR JOB ZON; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Penn C, 2000, NEUROGENIC COMMUNICA, P103; Possl O, 2001, BRAIN INJURY, V15, P15; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Rietdijk R, 2013, BRAIN INJURY, V27, P812, DOI 10.3109/02699052.2013.775491; Roberts CB, 2004, INT J REHABIL RES, V27, P145, DOI 10.1097/01.mrr.0000127142.43208.3b; Robles MM, 2012, BUS PROF COMMUN Q, V75, P453, DOI 10.1177/1080569912460400; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; SALZBERG CL, 1986, APPL RES MENT RETARD, V7, P299, DOI 10.1016/S0270-3092(86)80003-0; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schnurr S., 2013, EXPLORING PROFESSION; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Soeker MS, 2012, WORK, V42, P589, DOI 10.3233/WOR-2012-1414; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Stubbs M., 1983, DISCOURSE ANAL SOCIO; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; Thornborrow J., 2002, POWER TALK LANGUAGE; Thurman D. J, 2007, BRAIN INJURY MED PRI, P44; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 2011, HANDBOOK OF PSYCHOLINGUISTIC AND COGNITIVE PROCESSES: PERSPECTIVES IN COMMUNICATION DISORDERS, P603; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Tyerman A., 2008, PSYCHOL APPROACHES R, P376; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Watanabe S, 2013, WORK, V45, P273, DOI 10.3233/WOR-131594; Wechsler D., 2013, WAIS 4; Wechsler D, 1997, WMS 3 WECHSLER MEMOR; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Williams MW, 2013, CLIN NEUROPSYCHOL, V27, P356, DOI 10.1080/13854046.2013.765507; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Woodcock R.W., 2001, WOODCOCK JOHNSON 3 T; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	90	37	37	1	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	FEB 27	2016	38	5					452	461		10.3109/09638288.2015.1044621			10	Rehabilitation	Rehabilitation	DA5HS	WOS:000367834600006	25958999	Green Accepted			2021-06-18	
J	Lettieri, CJ; Williams, SG; Collen, JF				Lettieri, Christopher J.; Williams, Scott G.; Collen, Jacob F.			OSA Syndrome and Posttraumatic Stress Disorder Clinical Outcomes and Impact of Positive Airway Pressure Therapy	CHEST			English	Article						continuous positive airway pressure; CPAP adherence; obstructive sleep apnea; posttraumatic stress disorder; quality of life	OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; CPAP USE; DAYTIME SLEEPINESS; MILITARY PERSONNEL; FUNCTIONAL STATUS; ADHERENCE; INSOMNIA; NIGHTMARES	BACKGROUND: We sought to determine the impact of OSA syndrome (OSAS) on symptoms and quality of life (QoL) among patients with posttraumatic stress disorder (PTSD). In addition, we assessed adherence and response to positive airway pressure (PAP) therapy in this population. METHODS: This was a case-controlled observational cohort study at the Sleep Disorders Center of an academic military medical center. Two hundred consecutive patients with PTSD underwent sleep evaluations. Patients with PTSD with and without OSAS were compared with 50 consecutive age-matched patients with OSAS without PTSD and 50 age-matched normal control subjects. Polysomnographic data, sleep-related symptoms and QoL measures, and objective PAP usage were obtained. RESULTS: Among patients with PTSD, more than one-half (56.6%) received a diagnosis of OSAS. Patients with PTSD and OSAS had lower QoL and more somnolence compared with the other groups. Patients with PTSD demonstrated significantly lower adherence and response to PAP therapy. Resolution of sleepiness occurred in 82% of patients with OSAS alone, compared with 62.5% of PAP-adherent and 21.4% of nonadherent patients with PTSD and OSAS (P < .001). Similarly, posttreatment Functional Outcomes of Sleep Questionnaire >= 17.9 was achieved in 72% of patients with OSAS, compared with only 56.3% of patients with PTSD and OSA who were PAP adherent and 26.2% who were nonadherent (P < .03). CONCLUSIONS: In patients with PTSD, comorbid OSAS is associated with worsened symptoms, QoL, and adherence and response to PAP. Given the negative impact on outcomes, the possibility of OSAS should be considered carefully in patients with PTSD. Close follow-up is needed to optimize PAP adherence and efficacy in this at-risk population.	[Lettieri, Christopher J.; Williams, Scott G.; Collen, Jacob F.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD USA; [Lettieri, Christopher J.] Walter Reed Natl Mil Med Ctr, Dept Pulm Crit Care & Sleep Med, Bethesda, MD USA; [Williams, Scott G.] Womack Army Med Ctr, Dept Pulm Crit Care & Sleep Med, Ft Bragg, NC USA; [Collen, Jacob F.] Brooke Army Med Ctr, Dept Pulm Crit Care & Sleep Med, Ft Sam Houston, TX 78234 USA	Collen, JF (corresponding author), Brooke Army Med Ctr, Pulm Crit Care & Sleep Med, San Antonio Mil Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	jacob.f.collen.mil@mail.mil		Lettieri, Christopher/0000-0001-7950-2908			Aloia Mark S, 2007, Behav Sleep Med, V5, P229; Aloia MS, 2013, SLEEP, V36, P1655; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Nguyen ATD, 2006, J CLIN SLEEP MED, V2, P170; [Anonymous], 2012, RAND CROSS TRIAL 2 T; [Anonymous], STANF FAT VIS NUM SC; [Anonymous], 2013, EFF CPAP THER PTSD S; Antic NA, 2011, SLEEP, V34, P111, DOI 10.1093/sleep/34.1.111; Arnetz BB, 2012, PSYCHOSOM MED, V74, P824, DOI 10.1097/PSY.0b013e31826bf1ec; Bartlett D, 2013, SLEEP, V36, P1647, DOI 10.5665/sleep.3118; Budhiraja R, 2007, SLEEP, V30, P320; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Collen JF, 2012, J CLIN SLEEP MED, V8, P667, DOI 10.5664/jcsm.2260; Crawford MR, 2014, SLEEP MED REV, V18, P123, DOI 10.1016/j.smrv.2013.03.002; Damiani MF, 2013, CHEST, V143, P1569, DOI 10.1378/chest.12-2174; Dickerson SS, 2013, HEART LUNG, V42, P346, DOI 10.1016/j.hrtlng.2013.07.011; El-Solh AA, 2010, SLEEP, V33, P1495, DOI 10.1093/sleep/33.11.1495; Iber C, 2007, AASM MANUAL SCORING; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kinoshita LM, 2012, SLEEP BREATH, V16, P1201, DOI 10.1007/s11325-011-0632-8; Kline CE, 2012, J CLIN SLEEP MED, V8, P357, DOI 10.5664/jcsm.2022; Kline CE, 2011, SLEEP, V34, P1631, DOI 10.5665/sleep.1422; Krakow B, 2004, J TRAUMA STRESS, V17, P257, DOI 10.1023/B:JOTS.0000029269.29098.67; Krakow B, 2002, J NERV MENT DIS, V190, P442, DOI 10.1097/00005053-200207000-00004; Krakow B, 2000, J PSYCHOSOM RES, V49, P291, DOI 10.1016/S0022-3999(00)00147-1; Krakow B, 2001, BIOL PSYCHIAT, V49, P948, DOI 10.1016/S0006-3223(00)01087-8; Krakow B, 2006, J NERV MENT DIS, V194, P433, DOI 10.1097/01.nmd.0000221286.65021.e0; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Lamarche LJ, 2007, J CLIN PSYCHIAT, V68, P1257, DOI 10.4088/JCP.v68n0813; Lewis KE, 2004, SLEEP, V27, P134, DOI 10.1093/sleep/27.1.134; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; Moyer CA, 2001, SLEEP MED, V2, P477, DOI 10.1016/S1389-9457(01)00072-7; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Mysliwiec V, 2013, CHEST, V143, P582, DOI 10.1378/chest.12-2269; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; Reimer MA, 2003, SLEEP MED REV, V7, P335, DOI 10.1053/smrv.2001.0220; Sharafkhaneh A, 2005, SLEEP, V28, P1405, DOI 10.1093/sleep/28.11.1405; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Stepnowsky Carl J Jr, 2002, Sleep Med, V3, P239, DOI 10.1016/S1389-9457(01)00162-9; Tamanna S, 2014, J CLIN SLEEP MED, V10, P631, DOI 10.5664/jcsm.3786; Weathers F. W., 1993, ANN M INT SOC TRAUM; Weaver TE, 2001, SLEEP MED REV, V5, P103, DOI 10.1053/smrv.2001.0152; Weaver TE, 1997, SLEEP, V20, P835; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Weaver TE, 2007, SLEEP, V30, P711, DOI 10.1093/sleep/30.6.711; Weaver TE, 2012, AM J RESP CRIT CARE, V186, P677, DOI 10.1164/rccm.201202-0200OC; Wickwire EM, 2010, SLEEP MED, V11, P772, DOI 10.1016/j.sleep.2010.03.012; Wickwire EM, 2010, CHEST, V137, P1449, DOI 10.1378/chest.09-1485; Williams SG, 2015, SLEEP BREATH, V19, P175, DOI 10.1007/s11325-014-0984-y; Youakim JM, 1998, PSYCHOSOMATICS, V39, P168, DOI 10.1016/S0033-3182(98)71365-9; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080	57	37	39	0	6	AMER COLL CHEST PHYSICIANS	GLENVIEW	2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA	0012-3692			CHEST	Chest	FEB	2016	149	2					483	490		10.1378/chest.15-0693			8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	DD1DC	WOS:000369660400031	26291560	Bronze			2021-06-18	
J	Liu, W; Soderlund, K; Senseney, JS; Joy, D; Yeh, PH; Ollinger, J; Sham, EB; Liu, T; Wang, Y; Oakes, TR; Riedy, G				Liu, Wei; Soderlund, Karl; Senseney, Justin S.; Joy, David; Yeh, Ping-Hong; Ollinger, John; Sham, Elyssa B.; Liu, Tian; Wang, Yi; Oakes, Terrence R.; Riedy, Gerard			Imaging Cerebral Microhemorrhages in Military Service Members with Chronic Traumatic Brain Injury	RADIOLOGY			English	Article							SUSCEPTIBILITY; MICROBLEEDS; LESIONS	Purpose: To detect cerebral microhemorrhages in military service members with chronic traumatic brain injury by using susceptibility-weighted magnetic resonance (MR) imaging. The longitudinal evolution of microhemorrhages was monitored in a subset of patients by using quantitative susceptibility mapping. Materials and Methods: The study was approved by the Walter Reed National Military Medical Center institutional review board and is compliant with HIPAA guidelines. All participants underwent two-dimensional conventional gradient-recalled-echo MR imaging and three-dimensional flow-compensated multiecho gradient-recalled-echo MR imaging (processed to generate susceptibility-weighted images and quantitative susceptibility maps), and a subset of patients underwent follow-up imaging. Microhemorrhages were identified by two radiologists independently. Comparisons of microhemorrhage number, size, and magnetic susceptibility derived from quantitative susceptibility maps between baseline and follow-up imaging examinations were performed by using the paired t test. Results: Among the 603 patients, cerebral microhemorrhages were identified in 43 patients, with six excluded for further analysis owing to artifacts. Seventy-seven percent (451 of 585) of the microhemorrhages on susceptibility-weighted images had a more conspicuous appearance than on gradient-recalled-echo images. Thirteen of the 37 patients underwent follow-up imaging examinations. In these patients, a smaller number of microhemorrhages were identified at follow-up imaging compared with baseline on quantitative susceptibility maps (mean +/- standard deviation, 9.8 microhemorrhages +/- 12.8 vs 13.7 microhemorrhages +/- 16.6; P = .019). Quantitative susceptibility mapping-derived quantitative measures of microhemorrhages also decreased over time: -0.85 mm(3) per day +/- 1.59 for total volume (P = .039) and -0.10 parts per billion per day +/- 0.14 for mean magnetic susceptibility (P = .016). Conclusion: The number of microhemorrhages and quantitative susceptibility mapping-derived quantitative measures of microhemorrhages all decreased over time, suggesting that hemosiderin products undergo continued, subtle evolution in the chronic stage. (C) RSNA, 2015	[Liu, Wei; Soderlund, Karl; Senseney, Justin S.; Joy, David; Yeh, Ping-Hong; Ollinger, John; Sham, Elyssa B.; Oakes, Terrence R.; Riedy, Gerard] Walter Reed Natl Mil Med Ctr, NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA; [Joy, David; Oakes, Terrence R.; Riedy, Gerard] Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Joy, David] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Liu, Tian; Wang, Yi] Cornell Univ, Dept Biomed Engn, New York, NY 10021 USA; [Liu, Wei; Sham, Elyssa B.] NorthTide Grp, Sterling, VA USA	Riedy, G (corresponding author), Walter Reed Natl Mil Med Ctr, NICoE, 4860 S Palmer Rd, Bethesda, MD 20889 USA.; Riedy, G (corresponding author), Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.	gerard.p.riedy.civ@mail.mil		Joy, David/0000-0001-9941-9538	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300606]; Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074437]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB013443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072370] Funding Source: NIH RePORTER	Supported by Center for Neuroscience and Regenerative Medicine grant no. 300606 and Congressionally Directed Medical Research Programs grant no. PT074437.	Chen WW, 2014, RADIOLOGY, V271, P183, DOI 10.1148/radiol.13130353; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Liu T, 2011, MAGN RESON MED, V66, P777, DOI 10.1002/mrm.22816; Mori N, 2008, INVEST RADIOL, V43, P574, DOI 10.1097/RLI.0b013e31817fb432; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; National Center for Injury Prevention and Control, REP C MILD TRAUM BRA; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zhang J., 2014, P 22 M INT SOC MAGN, P112; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022	22	37	37	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	FEB	2016	278	2					536	545		10.1148/radiol.2015150160			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	DO3SQ	WOS:000377702200028	26371749	Green Accepted, Bronze			2021-06-18	
J	Oldenburg, C; Lundin, A; Edman, G; Nygren-de Boussard, C; Bartfai, A				Oldenburg, Christian; Lundin, Anders; Edman, Gunnar; Nygren-de Boussard, Catharina; Bartfai, Aniko			Cognitive reserve and persistent post-concussion symptoms-A prospective mild traumatic brain injury (mTBI) cohort study	BRAIN INJURY			English	Article						mild head injury; cognitive impairment; post-concussion syndrome; post-concussion symptoms; Brain concussion	GOOD-OLD-DAYS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; DAYS BIAS; MEMORY; METAANALYSES; DISABILITY; PREDICTION; RECOVERY; INDIVIDUALS	Primary objective: Having three or more persisting (i.e. > 3 months) post-concussion symptoms (PCS) affects a significant number of patients after a mild traumatic brain injury (mTBI). A common complaint is cognitive deficits. However, several meta-analyses have found no evidence of long-term cognitive impairment in mTBI patients. The study sought to answer two questions: first, is there a difference in cognitive performance between PCS and recovered mTBI patients? Second, is lower cognitive reserve a risk factor for developing PCS? Research design: Prospective inception cohort study. Methods and procedure: One hundred and twenty-two adult patients were recruited from emergency departments within 24 hours of an mTBI. Three months post-injury, participants completed the Rivermead Post Concussion Symptoms Questionnaire and a neuropsychological assessment. A healthy control group (n = 35) were recruited. The estimate of cognitive reserve was based upon sub-test Information from Wechsler Adult Intelligence Scale and international classifications of educational level and occupational skill level. Main outcome and results: mTBI patients showed reduced memory performance. Patients with lower cognitive reserve were 4.14-times more likely to suffer from PCS. Conclusions: mTBI may be linked to subtle executive memory deficits. Lower cognitive reserve appears to be a risk factor for PCS and indicates individual vulnerabilities.	[Oldenburg, Christian; Nygren-de Boussard, Catharina; Bartfai, Aniko] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden; [Oldenburg, Christian; Nygren-de Boussard, Catharina; Bartfai, Aniko] Danderyd Hosp, Dept Rehabil Med Stockholm, S-18288 Stockholm, Sweden; [Lundin, Anders] Dizziness Ctr, Neuropsychiat Sect, Stockholm, Sweden; [Edman, Gunnar] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Ctr Family Med CeFAM, Stockholm, Sweden; [Edman, Gunnar] Tiohundra AB, Dept Psychiat, Norrtalje, Sweden	Oldenburg, C (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.; Oldenburg, C (corresponding author), Danderyd Hosp, Dept Rehabil Med Stockholm, S-18288 Stockholm, Sweden.	christian.oldenburg@ki.se		Oldenburg, Christian/0000-0003-4647-9136			Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bergman H, 1983, PSYKOLOGHANDBOKEN; Bigler E. D., 2007, COGNITIVE RESERVE TH, P85; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, P567, DOI [10.1234/12345678, DOI 10.1234/12345678]; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Dunkley BT, 2015, NEUROIMAGE-CLIN, V7, P611, DOI 10.1016/j.nicl.2015.02.020; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Golden C., 1978, STROOP COLOR WORD TE; GOLDEN CJ, 1976, J CLIN PSYCHOL, V32, P654, DOI 10.1002/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2010, CLIN NEUROPSYCHOL, V24, P137, DOI 10.1080/13854040902927546; GRONWALL D, 1974, LANCET, V2, P605; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; International Labour Office, 2012, INT STAND CLASS OCC; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kaplan E, 1991, DELIS WAIS R NEUROPS; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannsjo M, 2012, EUROPEAN J NEUROLOGY, V20, P124; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; Levi Y., 2013, J INT NEUROPSYCH SOC, V19, P1; Lezak MD, 2012, NEUROPSYCHOLOGICAL A, P1161; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Matsui M, 2008, PROG NEURO-PSYCHOPH, V32, P1854, DOI 10.1016/j.pnpbp.2008.08.018; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; National Center for Injury Prevention and Control Report to Congress on Mild Traumatic Brain Injury in the United States, 2003, REP C MILD TRAUM BRA; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Strauss E, 2006, COMPENDIUM NEUROPSYC, P1216; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Sullivan KA, 2012, BRAIN INJURY, V26, P1098, DOI 10.3109/02699052.2012.666367; TEASDALE G, 1974, LANCET, V2, P81; UNESCO, 2011, INT STANDARD CLASSIF; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Wechlser D., 1992, WAIS R MANUAL; Wechsler, 1981, WAIS R MANUAL; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105	80	37	37	0	34	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN 28	2016	30	2					146	155		10.3109/02699052.2015.1089598			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DF3MM	WOS:000371248400003	26618716				2021-06-18	
J	Shan, RZ; Szmydynger-Chodobska, J; Warren, OU; Mohammad, F; Zink, BJ; Chodobski, A				Shan, Rongzi; Szmydynger-Chodobska, Joanna; Warren, Otis U.; Mohammad, Farah; Zink, Brian J.; Chodobski, Adam			A New Panel of Blood Biomarkers for the Diagnosis of Mild Traumatic Brain Injury/Concussion in Adults	JOURNAL OF NEUROTRAUMA			English	Article						blood biomarkers; concussion; diagnosis; mild traumatic brain injury	ICE HOCKEY PLAYERS; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; INJURY; SERUM; CONCUSSIONS; SEVERITY; COPEPTIN	No routine tests currently exist to objectively diagnose mild traumatic brain injury (mTBI)/concussion. Previously reported biomarkers for mTBI represented proteins released from damaged neurons or glia. However, low levels of these proteins, and/or the complexity of assays used for their detection, limits implementation of these biomarkers in routine practice. Here, we sought to identify proteins whose synthesis is altered post-mTBI and whose blood levels could be measured using standard immunoassays. Adult patients sustaining a concussion within the past 24h were enrolled. Controls were uninjured subjects and patients with orthopedic injury (OI). Four candidate biomarkers were identified: copeptin; galectin 3 (LGALS3); matrix metalloproteinase 9 (MMP9); and occludin (OCLN). A 3.4-fold decrease (p<0.0001) in plasma concentration of copeptin was found in mTBI patients within 8h after accident, compared to uninjured controls. Plasma levels of LGALS3, MMP9, and OCLN increased 3.6- to 4.5-fold (p<0.0001) within the same time frame postinjury. Levels of at least two biomarkers were altered beyond their respective cut-off values in 90% of mTBI patients, whereas in none of uninjured controls were levels of two biomarkers simultaneously changed. A positive correlation (r=0.681; p<0.001) between plasma levels of LGALS3 and OCLN was also found in mTBI patients, whereas in OI patients or uninjured subjects, these variables did not correlate. This panel of biomarkers discerns, with high accuracy, patients with isolated concussion from uninjured individuals within the first 8h after accident. These biomarkers can also aid in diagnosing concussion in the presence of OI.	[Shan, Rongzi; Szmydynger-Chodobska, Joanna; Chodobski, Adam] Brown Univ, Alpert Med Sch, Dept Emergency Med, Neurotrauma & Brain Barriers Res Lab, Providence, RI 02903 USA; [Warren, Otis U.; Zink, Brian J.] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA; [Mohammad, Farah] Henry Ford Hosp, Dept Surg, Detroit, MI 48202 USA	Chodobski, A (corresponding author), Brown Univ, Alpert Med Sch, Dept Emergency Med, Coro Ctr West, Room 112,1 Hoppin St, Providence, RI 02903 USA.	adam_chodobski@brown.edu			Department of Emergency Medicine at the Alpert Medical School of Brown University	The authors thank Branden Stearns, Darin Chheng, and Sarah Smith for their help in the recruitment of research subjects. The authors also thank Julie Sarri for her secretarial assistance. This study was supported by funds from the Department of Emergency Medicine at the Alpert Medical School of Brown University and by a fund from Diane N. Weiss.	Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chodobski A., 2014, VASCULAR MECH CNS TR, P3; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Lin CC, 2010, JALA-J LAB AUTOM, V15, P253, DOI 10.1016/j.jala.2010.01.013; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Terrando N, 2011, ANN NEUROL, V70, P986, DOI 10.1002/ana.22664; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	32	37	37	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					49	57		10.1089/neu.2014.3811			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200006	25794137				2021-06-18	
J	van den Heuvel, TLA; van der Eerden, AW; Manniesing, R; Ghafoorian, M; Tan, T; Andriessen, TMJC; Vyvere, TV; van den Hauwe, L; Romeny, BMT; Goraj, BM; Platel, B				van den Heuvel, T. L. A.; van der Eerden, A. W.; Manniesing, R.; Ghafoorian, M.; Tan, T.; Andriessen, T. M. J. C.; Vyvere, T. Vande; van den Hauwe, L.; Romeny, B. M. ter Haar; Goraj, B. M.; Platel, B.			Automated detection of cerebral microbleeds in patients with traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Computer Aided Detection; Cerebral Microbleeds; Traumatic Brain Injury; Susceptibility Weighted Imaging	DIFFUSE AXONAL INJURY; MR-IMAGES; OPTIMIZATION; REGISTRATION; RELIABILITY; ROBUST	In this paper a Computer Aided Detection (CAD) system is presented to automatically detect Cerebral Microbleeds (CMBs) in patients with Traumatic Brain Injury (TBI). It is believed that the presence of CMBs has clinical prognostic value in TBI patients. To study the contribution of CMBs in patient outcome, accurate detection of CMBs is required. Manual detection of CMBs in TBI patients is a time consuming task that is prone to errors, because CMBs are easily overlooked and are difficult to distinguish from blood vessels. This study included 33 TBI patients. Because of the laborious nature of manually annotating CMBs, only one trained expert manually annotated the CMBs in all 33 patients. A subset of ten TBI patients was annotated by six experts. Our CAD systemmakes use of both Susceptibility Weighted Imaging (SWI) and T1 weighted magnetic resonance images to detect CMBs. After pre-processing these images, a two-step approach was used for automated detection of CMBs. In the first step, each voxel was characterized by twelve features based on the dark and spherical nature of CMBs and a random forest classifier was used to identify CMB candidate locations. In the second step, segmentations were made from each identified candidate location. Subsequently an object-based classifier was used to remove false positive detections of the voxel classifier, by considering seven object-based features that discriminate between spherical objects (CMBs) and elongated objects (blood vessels). A guided user interface was designed for fast evaluation of the CAD system result. During this process, an expert checked each CMB detected by the CAD system. A Fleiss' kappa value of only 0.24 showed that the inter-observer variability for the TBI patients in this study was very large. An expert using the guided user interface reached an average sensitivity of 93%, which was significantly higher (p=0.03) than the average sensitivity of 77% (sd 12.4%) that the six experts manually detected. Furthermore, with the use of this CAD system the reading time was substantially reduced from one hour to 13 minutes per patient, because the CAD system only detects on average 25.9 false positives per TBI patient, resulting in 0.29 false positives per definite CMB finding. (C) 2016 The Authors. Published by Elsevier Inc.	[van den Heuvel, T. L. A.; van der Eerden, A. W.; Manniesing, R.; Tan, T.; Goraj, B. M.; Platel, B.] Radboudumc, Dept Radiol & Nucl Med, Nijmegen, Netherlands; [van den Heuvel, T. L. A.; Romeny, B. M. ter Haar] Eindhoven Univ Technol, Dept Biomed Image Anal, Eindhoven, Netherlands; [Ghafoorian, M.] Radboud Univ Nijmegen, Inst Comp & Informat Sci, Nijmegen, Netherlands; [Andriessen, T. M. J. C.] Rivas Healthcare Grp, Dept Psychol, Gorinchem, Netherlands; [Vyvere, T. Vande; van den Hauwe, L.] Univ Antwerp, Univ Antwerp Hosp, Dept Radiol, Antwerp, Belgium; [Vyvere, T. Vande; van den Hauwe, L.] Icometrix, Leuven, Belgium; [Romeny, B. M. ter Haar] Northeastern Univ, Shenyang, Peoples R China; [Goraj, B. M.] Med Ctr Postgrad Educ Warsaw, Dept Diagnost Imaging, Warsaw, Poland	van den Heuvel, TLA (corresponding author), Geert Grootepl 10, NL-6500 HB Nijmegen, Netherlands.	Thomas.vandenHeuvel@radboudumc.nl	Berendschot, Tos TJM/M-8509-2016; van den Heuvel, Thomas/N-7185-2015; Manniesing, Rashindra/G-9728-2015; Romenij, Bart M. ter Haar/A-5323-2013; Platel, Bram/D-2132-2009; Ghafoorian, Mohsen/AAH-7397-2019; van der Eerden, Anke/H-9413-2017	Berendschot, Tos TJM/0000-0002-8101-939X; van den Heuvel, Thomas/0000-0003-3736-7693; Manniesing, Rashindra/0000-0002-4616-6298; Platel, Bram/0000-0002-1936-6825; van der Eerden, Anke/0000-0002-9182-9089			Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Barnes SRS, 2011, MAGN RESON IMAGING, V29, P844, DOI 10.1016/j.mri.2011.02.028; Bian W, 2013, NEUROIMAGE-CLIN, V2, P282, DOI 10.1016/j.nicl.2013.01.012; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Dou Q, 2016, IEEE T MED IMAGING, V35, P1182, DOI 10.1109/TMI.2016.2528129; Faziollahi A, 2014, I S BIOMED IMAGING, P113, DOI 10.1109/ISBI.2014.6867822; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Ghafaryasl B, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P138, DOI 10.1109/ISBI.2012.6235503; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kuijf HJ, 2012, NEUROIMAGE, V59, P2266, DOI 10.1016/j.neuroimage.2011.09.061; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Romeny BMT, 2011, BIOL MED PHYS BIOMED, P177, DOI 10.1007/978-3-642-15816-2_7; Sato Y, 1998, Med Image Anal, V2, P143, DOI 10.1016/S1361-8415(98)80009-1; Sato Y., 1997, CVRMED MRCAS; Seghier ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017547; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Werring DJ, 2011, CEREBRAL MICROBLEEDS; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	25	37	37	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2016	12						241	251		10.1016/j.nicl.2016.07.002			11	Neuroimaging	Neurosciences & Neurology	EF3AI	WOS:000390196400028	27489772	DOAJ Gold, Green Published			2021-06-18	
J	Kober, SE; Schweiger, D; Witte, M; Reichert, JL; Grieshofer, P; Neuper, C; Wood, G				Kober, Silvia Erika; Schweiger, Daniela; Witte, Matthias; Reichert, Johanna Louise; Grieshofer, Peter; Neuper, Christa; Wood, Guilherme			Specific effects of EEG based neurofeedback training on memory functions in post-stroke victims	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Cognitive rehabilitation; EEG; Neurofeedback; Memory; Stroke recovery	TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; COGNITIVE IMPAIRMENT; ALPHA; PERFORMANCE; RHYTHM; SLEEP; HYPERACTIVITY; OSCILLATIONS; BIOFEEDBACK	Background: Using EEG based neurofeedback (NF), the activity of the brain is modulated directly and, therefore, the cortical substrates of cognitive functions themselves. In the present study, we investigated the ability of stroke patients to control their own brain activity via NF and evaluated specific effects of different NF protocols on cognition, in particular recovery of memory. Methods: N = 17 stroke patients received up to ten sessions of either SMR (N = 11, 12-15 Hz) or Upper Alpha (N = 6, e.g. 10-12 Hz) NF training. N = 7 stroke patients received treatment as usual as control condition. Furthermore, N = 40 healthy controls performed NF training as well. To evaluate the NF training outcome, a test battery assessing different cognitive functions was performed before and after NF training. Results: About 70 % of both patients and controls achieved distinct gains in NF performance leading to improvements in verbal short- and long-term memory, independent of the used NF protocol. The SMR patient group showed specific improvements in visuo-spatial short-term memory performance, whereas the Upper Alpha patient group specifically improved their working memory performance. NF training effects were even stronger than effects of traditional cognitive training methods in stroke patients. NF training showed no effects on other cognitive functions than memory. Conclusions: Post-stroke victims with memory deficits could benefit from NF training as much as healthy controls. The used NF training protocols (SMR, Upper Alpha) had specific as well as unspecific effects on memory. Hence, NF might offer an effective cognitive rehabilitation tool improving memory deficits of stroke survivors.	[Kober, Silvia Erika; Schweiger, Daniela; Witte, Matthias; Reichert, Johanna Louise; Neuper, Christa; Wood, Guilherme] Graz Univ, Dept Psychol, A-8010 Graz, Austria; [Kober, Silvia Erika; Neuper, Christa; Wood, Guilherme] BioTechMed Graz, Graz, Austria; [Grieshofer, Peter] Klin Judendorf Strassengel, Gratwein Strassengel, Austria; [Neuper, Christa] Graz Univ Technol, Inst Knowledge Discovery, Lab Brain Comp Interfaces, A-8010 Graz, Austria	Kober, SE (corresponding author), Graz Univ, Dept Psychol, Univ Pl 2-3, A-8010 Graz, Austria.	silvia.kober@uni-graz.at		Wood, Guilherme/0000-0001-5055-5336	European Community's Seventh-Framework-Programme FP7, CONTRAST project [287320]	This work was partially supported by the European Community's Seventh-Framework-Programme FP7/2007-2013, CONTRAST project, under grant agreement nr. 287320. Possible inaccuracies of information are under the responsibility of the project team. The text reflects solely the views of its authors. The European Commission is not liable for any use that may be made of the information contained therein. The authors are grateful to Alexandra Pongratz, Aida Mujkanovic, Margit Krenn, Katharina Farveleder, Julia Schobel and Jasmin Wiesler for data acquisition.	Allison BZ, 2010, HUM-COMPUT INT-SPRIN, P35, DOI 10.1007/978-1-84996-272-8_3; Angelakis E, 2007, CLIN NEUROPSYCHOL, V21, P110, DOI 10.1080/13854040600744839; Arns M, 2009, CLIN EEG NEUROSCI, V40, P180, DOI 10.1177/155005940904000311; Bearden TS, 2003, APPL PSYCHOPHYS BIOF, V28, P241, DOI 10.1023/A:1024689315563; Benjamini Y, 2001, ANN STAT, V29, P1165; Birbaumer N, 2013, TRENDS COGN SCI, V17, P295, DOI 10.1016/j.tics.2013.04.009; Bortz J., 2005, STAT HUMAN SOZIALWIS, V6th; Bounias M., 2001, Journal of Neurotherapy, V5, P23, DOI 10.1300/J184v05n04_03; Brain Products GmbH, 2009, BRAINVISION AN 2 0 1; Cannon K. B., 2010, J NEUROTHERAPY, V14, P107, DOI [10.1080/10874201003772155, DOI 10.1080/10874201003772155]; Dempster T, 2009, APPL PSYCHOPHYS BIOF, V34, P309, DOI 10.1007/s10484-009-9112-3; Doppelmayr M., 2011, THE J, V15, P115, DOI [10.1080/10874208.2011.570689, DOI 10.1080/10874208.2011.570689]; Doppelmayr M, 2007, BIOFEEDBACK, V3, P126; Draganova R, 1999, PHYSIOL RES, V48, P157; Elliott M, 2014, BRAIN INJURY, V28, P1610, DOI 10.3109/02699052.2014.934921; Escolano C, 2013, IEEE ENG MED BIO, P6293, DOI 10.1109/EMBC.2013.6610992; Escolano C, 2012, IEEE ENG MED BIO, P4643, DOI 10.1109/EMBC.2012.6347002; Escolano C, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00296; Escolano C, 2011, IEEE ENG MED BIO, P2327, DOI 10.1109/IEMBS.2011.6090651; Fox DJ, 2005, APPL PSYCHOPHYS BIOF, V30, P365, DOI 10.1007/s10484-005-8422-3; Gruzelier JH, 2014, NEUROSCI BIOBEHAV R, V44, P124, DOI 10.1016/j.neubiorev.2013.09.015; Hanslmayr S, 2005, APPL PSYCHOPHYS BIOF, V30, P1, DOI 10.1007/s10484-005-2169-8; Harting C., 2000, WECHSLER GEDACHTNIST; Hoedlmoser K, 2008, SLEEP, V31, P1401; Hofer D, 2014, LERNEN LERNSTORUNGEN, V3, P1; Hoffmann T, 2010, TOP STROKE REHABIL, V17, P99, DOI 10.1310/tsr1702-99; HOLM S, 1979, SCAND J STAT, V6, P65; Huber H. P., 1973, PSYCHOMETRISCHE EINZ; Huber H. P., 1977, BEHAV ANAL MODIFICAT, V2, P1; Kessler J, 1990, MINI MENTAL STATUS E; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Kober SE, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00695; Kober SE, 2015, CLIN NEUROPHYSIOL, V126, P82, DOI 10.1016/j.clinph.2014.03.031; Kropotov JD, 2009, QUANTITATIVE EEG, EVENT-RELATED POTENTIALS AND NEUROTHERAPY, P1; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; May G, 2013, ANN CLIN PSYCHIATRY, V25, P289; Melkas S, 2014, DEGENER NEUROL NEURO, V4, P21, DOI 10.2147/DNND.S37353; Michels L, 2008, NEUROIMAGE, V40, P1296, DOI 10.1016/j.neuroimage.2007.12.048; Nan WY, 2012, INT J PSYCHOPHYSIOL, V86, P83, DOI 10.1016/j.ijpsycho.2012.07.182; Nelson LA, 2007, TOP STROKE REHABIL, V14, P59, DOI 10.1310/tsr1404-59; Niemann H., 2008, CALIFORNIA VERBAL LE; Ninaus M, 2015, BIOL PSYCHOL, V110, P126, DOI 10.1016/j.biopsycho.2015.07.009; Ninaus M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00914; PFURTSCHELLER G, 1992, ELECTROEN CLIN NEURO, V83, P62, DOI 10.1016/0013-4694(92)90133-3; PFURTSCHELLER G, 1981, ELECTROEN CLIN NEURO, V51, P253, DOI 10.1016/0013-4694(81)90139-5; Putman J.A., 2002, J NEUROTHER, V5, P27, DOI DOI 10.1300/J184V05N03_; ROZELLE GR, 1995, BIOFEEDBACK SELF-REG, V20, P211, DOI 10.1007/BF01474514; Schabus M, 2014, BIOL PSYCHOL, V95, P126, DOI 10.1016/j.biopsycho.2013.02.020; Schelling D., 2001, VVM VISUELLER VERBAL; STERMAN MB, 1970, SCIENCE, V167, P1146, DOI 10.1126/science.167.3921.1146; Sterman MB, 1996, BIOFEEDBACK SELF-REG, V21, P3, DOI 10.1007/BF02214147; Sterman MB, 2000, CLIN ELECTROENCEPHAL, V31, P45, DOI 10.1177/155005940003100111; Thornton KE, 2009, APPL PSYCHOPHYS BIOF, V34, P59, DOI 10.1007/s10484-009-9075-4; Ullman MT, 2004, COGNITION, V92, P231, DOI 10.1016/j.cognition.2003.10.008; Vernon D, 2003, INT J PSYCHOPHYSIOL, V47, P75, DOI 10.1016/S0167-8760(02)00091-0; Vernon DJ, 2005, APPL PSYCHOPHYS BIOF, V30, P347, DOI 10.1007/s10484-005-8421-4; Weber E, 2011, APPL PSYCHOPHYS BIOF, V36, P37, DOI 10.1007/s10484-010-9142-x; Witte M, 2013, FRONT HUM NEUROSCI, V7, P1; Wood G, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00171; Zimmermann P, 2007, **DROPPED REF**	61	37	39	0	28	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	DEC 1	2015	12								107	10.1186/s12984-015-0105-6			13	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	CX6EI	WOS:000365793600001	26625906	DOAJ Gold, Green Published			2021-06-18	
J	Rao, W; Zhang, L; Peng, C; Hui, H; Wang, K; Su, N; Wang, L; Dai, SH; Yang, YF; Chen, T; Luo, P; Fei, Z				Rao, Wei; Zhang, Lei; Peng, Cheng; Hui, Hao; Wang, Kai; Su, Ning; Wang, Li; Dai, Shu-hui; Yang, Yue-fan; Chen, Tao; Luo, Peng; Fei, Zhou			Downregulation of STIM2 improves neuronal survival after traumatic brain injury by alleviating calcium overload and mitochondrial dysfunction	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Traumatic brain injury; Neurons; SOCE; Mitochondria dysfunction; Calcium homeostasis	CA2+ ENTRY; INDUCED APOPTOSIS; GENE-EXPRESSION; ER STRESS; HOMER 1A; IN-VITRO; PROTEINS; CHANNELS; DISEASE; NEUROPROTECTION	Although store-operated calcium entry (SOCE) has been implicated in several neurological disorders, the exact mechanism for its role in traumatic brain injury (TBI) has not been elucidated. In this study, we found that TBI upregulated the expression of a calcium sensor protein called stromal interactive molecule 2 (STIM2); however, the levels of its homologue, STIM1, were unaffected. Both STIM1 and STIM2 are crucial components of SOCE, both in vivo and in vitro. Using shRNA, we discovered that downregulation of STIM2, but not STIM1, significantly improved neuronal survival in both an in vitro and in vivo model of TBI, decreasing neuronal apoptosis, and preserving neurological function. This neuroprotection was associated with alleviating TBI-induced calcium overload and preserving mitochondrial function. Additionally, downregulation of STIM2 not only inhibited Ca2+ release from the endoplasmic reticulum (ER), but also reduced SOCE-mediated Ca2+ influx, decreased mitochondrial Ca2+, restored mitochondrial morphology and improved mitochondrial function, including MMP maintenance, ROS production and ATP synthesis. These results indicate that inhibition of STIM2 can protect neurons from TEI by inhibiting calcium overload and preserving mitochondrial function. This suggests that STIM2 might be an effective interventional target for TBI. (C) 2015 Elsevier B.V. All rights reserved.	[Rao, Wei; Zhang, Lei; Peng, Cheng; Hui, Hao; Wang, Kai; Su, Ning; Wang, Li; Dai, Shu-hui; Yang, Yue-fan; Chen, Tao; Luo, Peng; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China.	feizhou@fmmu.edu.cn	Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81430043]; National Science and Technology Major Project of China [2013ZX 09113109-02C]; National Science and Technology Pillar Program of China [2012BAI11B02]; Program for Changjiang Scholars and Innovative Research Team in UniversityProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT-14208]; Key Project of the Twelfth Five-year Plan of Scientific Research of China [AWS11J008]; Science and Technology Project of Shaanxi [2013KTCQ03-01]	We are indebted to the members of our laboratories at the Department of Neurosurgery, Xijing Hospital of the Fourth Military Medical University. The work was funded by the National Natural Science Foundation of China (No. 81430043), the National Science and Technology Major Project of China (2013ZX 09J13109-02C), the National Science and Technology Pillar Program of China (No. 2012BAI11B02), the Program for Changjiang Scholars and Innovative Research Team in University (No. IRT-14208), the Key Project of the Twelfth Five-year Plan of Scientific Research of China (AWS11J008) and the Science and Technology Project of Shaanxi (No. 2013KTCQ03-01).	Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Baba A, 2003, J NEUROSCI, V23, P7737; Bakowski D, 2012, PFLUG ARCH EUR J PHY, V464, P27, DOI 10.1007/s00424-012-1095-x; Berna-Erro A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000522; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Bojarski L, 2009, BBA-MOL CELL RES, V1793, P1050, DOI 10.1016/j.bbamcr.2008.11.008; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Cetin A, 2006, NAT PROTOC, V1, P3166, DOI 10.1038/nprot.2006.450; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Fei F, 2014, NEUROSCIENCE, V267, P187, DOI 10.1016/j.neuroscience.2014.02.037; Gemes G, 2011, J NEUROSCI, V31, P3536, DOI 10.1523/JNEUROSCI.5053-10.2011; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gruszczynska-Biegala J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019285; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hartmann J, 2014, NEURON, V82, P635, DOI 10.1016/j.neuron.2014.03.027; Johnstone LS, 2010, J CELL MOL MED, V14, P1890, DOI 10.1111/j.1582-4934.2010.01097.x; Kawamata H, 2014, J NEUROSCI, V34, P2331, DOI 10.1523/JNEUROSCI.2689-13.2014; Korkotian E, 2014, J NEUROSCI, V34, P11641, DOI 10.1523/JNEUROSCI.0381-14.2014; Laker RC, 2014, J BIOL CHEM, V289, P12005, DOI 10.1074/jbc.M113.530527; Lalonde J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005242; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Li B, 2014, FREE RADICAL RES, V48, P758, DOI 10.3109/10715762.2014.905687; Li Y, 2013, BRAIN RES, V1495, P95, DOI 10.1016/j.brainres.2012.12.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4; Lowery R.L., 2014, JOVE-J VIS EXP, V17, P1; Luo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.116; Luo P, 2012, APOPTOSIS, V17, P975, DOI 10.1007/s10495-012-0736-z; Majewski L, 2015, BBA-MOL CELL RES, V1853, P1940, DOI 10.1016/j.bbamcr.2015.01.019; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mitchell CB, 2012, J NEUROCHEM, V122, P1155, DOI 10.1111/j.1471-4159.2012.07840.x; Moccia F, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00153; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Muller MS, 2014, GLIA, V62, P526, DOI 10.1002/glia.22623; Novgorodov SA, 2014, J BIOL CHEM, V289, P13142, DOI 10.1074/jbc.M113.530311; Quintana A, 2012, CELL CALCIUM, V52, P57, DOI 10.1016/j.ceca.2012.02.005; Rao W, 2013, BIOCHEM BIOPH RES CO, V441, P351, DOI 10.1016/j.bbrc.2013.10.054; Selvaraj S, 2012, J CLIN INVEST, V122, P1354, DOI 10.1172/JCI61332; Singaravelu K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174029; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Skibinska-Kijek A, 2009, ACTA NEUROBIOL EXP, V69, P413; Soboloff J, 2012, NAT REV MOL CELL BIO, V13, P549, DOI 10.1038/nrm3414; Somasundaram A, 2014, J NEUROSCI, V34, P9107, DOI 10.1523/JNEUROSCI.0263-14.2014; Spaethling J, 2012, NEUROBIOL DIS, V46, P646, DOI 10.1016/j.nbd.2012.03.003; Stathopulos PB, 2009, J BIOL CHEM, V284, P728, DOI 10.1074/jbc.C800178200; Steinbeck JA, 2011, EXP NEUROL, V232, P185, DOI 10.1016/j.expneurol.2011.08.022; Sun SY, 2014, NEURON, V82, P79, DOI 10.1016/j.neuron.2014.02.019; Suzuki J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5153; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wang WZ, 2015, J BIOL CHEM, V290, P168, DOI 10.1074/jbc.M114.617167; Wu J, 2011, CHEM BIOL, V18, P777, DOI 10.1016/j.chembiol.2011.04.012; Xia JS, 2014, J PHYSIOL-LONDON, V592, P3443, DOI 10.1113/jphysiol.2014.275065; Zeiger W, 2013, J BIOL CHEM, V288, P26955, DOI 10.1074/jbc.M113.473355; Zhang M, 2014, NEUROREPORT, V25, P507, DOI 10.1097/WNR.0000000000000127; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	59	37	38	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0925-4439	1879-260X		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	NOV	2015	1852	11					2402	2413		10.1016/j.bbadis.2015.08.014			12	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CS5QJ	WOS:000362132700007	26300487	Bronze			2021-06-18	
J	Yao, XM; Uchida, K; Papadopoulos, MC; Zador, Z; Manley, GT; Verkman, AS				Yao, Xiaoming; Uchida, Kazuyoshi; Papadopoulos, Marios C.; Zador, Zsolt; Manley, Geoffrey T.; Verkman, Alan S.			Mildly Reduced Brain Swelling and Improved Neurological Outcome in Aquaporin-4 Knockout Mice following Controlled Cortical Impact Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						AQP4; brain edema; brain trauma; controlled cortical impact injury; cytotoxic edema	GLOBAL CEREBRAL-ISCHEMIA; AQP4 EXPRESSION; WATER CHANNELS; RECEPTOR ANTAGONIST; EDEMA; RATS; CONTUSION; BLOOD; BARRIER; ASTROCYTES	Brain edema following traumatic brain injury (TBI) is associated with considerable morbidity and mortality. Prior indirect evidence has suggested the involvement of astrocyte water channel aquaporin-4 (AQP4) in the pathogenesis of TBI. Here, focal TBI was produced in wild type (AQP4(+/+)) and knockout (AQP4(-/-)) mice by controlled cortical impact injury (CCI) following craniotomy with dura intact (parameters: velocity 4.5m/sec, depth 1.7mm, dwell time 150 msec). AQP4-deficient mice showed a small but significant reduction in injury volume in the first week after CCI, with a small improvement in neurological outcome. Mechanistic studies showed reduced intracranial pressure at 6h after CCI in AQP4(-/-) mice, compared with AQP4(+/+) control mice (11 vs. 19mm Hg), with reduced local brain water accumulation as assessed gravimetrically. Transmission electron microscopy showed reduced astrocyte foot-process area in AQP4(-/-) mice at 24h after CCI, with greater capillary lumen area. Blood-brain barrier disruption assessed by Evans blue dye extravasation was similar in AQP4(+/+) and AQP4(-/-) mice. We conclude that the mildly improved outcome in AQP4(-/-) mice following CCI results from reduced cytotoxic brain water accumulation, though concurrent cytotoxic and vasogenic mechanisms in TBI make the differences small compared to those seen in disorders where cytotoxic edema predominates.	[Yao, Xiaoming; Uchida, Kazuyoshi; Zador, Zsolt; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Yao, Xiaoming; Verkman, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Yao, Xiaoming; Verkman, Alan S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Papadopoulos, Marios C.] Univ London, Acad Neurosurg Unit, London, England	Yao, XM (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci East Tower,513 Parnassus Ave, San Francisco, CA 94143 USA.	xiaoming.yao@ucsf.edu		Zador, Zsolt/0000-0001-9767-3372; Papadopoulos, Marios/0000-0001-9174-4176; zador, zsolt/0000-0003-4297-616X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK35124, EY13574, EB00415, DK72517, NS050173]; Guthy-Jackson Charitable Foundation; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2014-06-004] Funding Source: researchfish; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK035124, P30DK072517, R37DK035124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050173] Funding Source: NIH RePORTER	This work was supported by grants DK35124, EY13574, EB00415, DK72517 and NS050173 from the National Institutes of Health and a grant from the Guthy-Jackson Charitable Foundation.	Akdemir G, 2014, NEUROSCI LETT, V574, P70, DOI 10.1016/j.neulet.2014.03.073; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Belayev L, 2003, STROKE, V34, P758, DOI 10.1161/01.STR.0000056169.45365.15; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Katada R, 2014, FASEB J, V28, P705, DOI 10.1096/fj.13-231274; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu H, 2013, CHINESE MED J-PEKING, V126, P4316, DOI 10.3760/cma.j.issn.0366-6999.20131139; Lv QS, 2013, BRAIN RES, V1493, P80, DOI 10.1016/j.brainres.2012.11.028; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; Marmarou A, 2000, ACT NEUR S, V76, P349; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nielsen S, 1997, J NEUROSCI, V17, P171; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Portella G, 2000, ACT NEUR S, V76, P273; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Weed LH, 1919, AM J PHYSIOL, V48, P531; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	44	37	37	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1458	1464		10.1089/neu.2014.3675			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500004	25790314	Green Published			2021-06-18	
J	Patton, DA; McIntosh, AS; Kleiven, S				Patton, Declan A.; McIntosh, Andrew S.; Kleiven, Svein			The Biomechanical Determinants of Concussion: Finite Element Simulations to Investigate Tissue-Level Predictors of Injury During Sporting Impacts to the Unprotected Head	JOURNAL OF APPLIED BIOMECHANICS			English	Article						biomechanics; head injury; modeling; sport		Biomechanical studies of concussions have progressed from qualitative observations of head impacts to physical and numerical reconstructions, direct impact measurements, and finite element analyses. Supplementary to a previous study, which investigated maximum principal strain, the current study used a detailed finite element head model to simulate unhelmeted concussion and no-injury head impacts and evaluate the effectiveness of various tissue-level brain injury predictors: strain rate, product of strain and strain rate, cumulative strain damage measure, von Mises stress, and intracranial pressure. Von Mises stress was found to be the most effective predictor of concussion. It was also found that the thalamus and corpus callosum were brain regions with strong associations with concussion. Tentative tolerance limits for tissue-level predictors were proposed in an attempt to broaden the understanding of unhelmeted concussions. For the thalamus, tolerance limits were proposed for a 50% likelihood of concussion: 2.24 kPa, 24.0 s(-1), and 2.49 s(-1) for von Mises stress, strain rate, and the product of strain and strain rate, respectively. For the corpus callosum, tolerance limits were proposed for a 50% likelihood of concussion: 3.51 kPa, 25.1 s(-1), and 2.76 s(-1) for von Mises stress, strain rate, and the product of strain and strain rate, respectively.	[Patton, Declan A.] Univ New S Wales, Fac Sci, Kensington, NSW 2033, Australia; [Patton, Declan A.; McIntosh, Andrew S.] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia; [Kleiven, Svein] Royal Inst Technol, Sch Technol & Hlth, Stockholm, Sweden	Patton, DA (corresponding author), Univ New S Wales, Fac Sci, POB 1, Kensington, NSW 2033, Australia.	declan@unswalumni.com					Anderson RWG, 1999, IRCOBI C SITG SPAIN; [Anonymous], 2009, PASW STAT; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Liying Zhang K.H.Y., 2003, P 2003 SUMM BIOENG C, P0137; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; MILLER RT, 1998, 42 STAPP CAR CRASH C; Newman JA, 1999, IRCOBI C SITG SPAIN; Newman JA, 2000, IRCOBI C MONTP FRANC; Patton DA, 2013, J APPL BIOMECH, V29, P721, DOI 10.1123/jab.29.6.721; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; SHREIBER DI, 1997, 41 STAPP CAR CRASH C; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Zhang L, 2008, IRCOBI C BERN SWITZ; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310	30	37	37	0	19	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	AUG	2015	31	4					264	268		10.1123/jab.2014-0223			5	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	CO3YI	WOS:000359096800009	25781376				2021-06-18	
J	Hue, CD; Cho, FS; Cao, SQ; Bass, CR; Meaney, DF; Morrison, B				Hue, Christopher D.; Cho, Frances S.; Cao, Siqi; Bass, Cameron R.Dale; Meaney, David F.; Morrison, Barclay, III			Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						bEnd.3; blood-brain barrier; dexamethasone; primary blast injury; recovery	TRABECULAR MESHWORK; MODEL; PERMEABILITY; DISRUPTION; MECHANISMS; RESISTANCE; STEROIDS; TARGET	Owing to the frequent incidence of blast-induced traumatic brain injury (bTBI) in recent military conflicts, there is an urgent need to develop effective therapies for bTBI-related pathologies. Blood-brain barrier (BBB) breakdown has been reported to occur after primary blast exposure, making restoration of BBB function and integrity a promising therapeutic target. We tested the hypothesis that treatment with dexamethasone (DEX) after primary blast injury potentiates recovery of an in vitro BBB model consisting of mouse brain endothelial cells (bEnd.3). DEX treatment resulted in complete recovery of transendothelial electrical resistance and hydraulic conductivity 1 day after injury, compared with 3 days for vehicle-treated injured cultures. Administration of RU486 (mifepristone) inhibited effects of DEX, confirming that barrier restoration was mediated by glucocorticoid receptor signaling. Potentiated recovery with DEX treatment was accompanied by stronger zonula occludens (ZO)-1 tight junction immunostaining and expression, suggesting that increased ZO-1 expression was a structural correlate to BBB recovery after blast. Interestingly, augmented ZO-1 protein expression was associated with specific upregulation of the alpha(+) isoform but not the alpha(-) isoform. This is the first study to provide a mechanistic basis for potentiated functional recovery of an in vitro BBB model because of glucocorticoid treatment after primary blast injury.	[Hue, Christopher D.; Cho, Frances S.; Cao, Siqi; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Bass, Cameron R.Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC8904,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; , Siqi/0000-0001-9779-4174; Meaney, David/0000-0002-0954-4122	Multidisciplinary University Research Initiative from the Army Research Office [W911MF-10-1-0526]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE-07-07425]	This work was supported by a Multidisciplinary University Research Initiative from the Army Research Office (W911MF-10-1-0526), and a National Science Foundation Graduate Research Fellowship (CDH; DGE-07-07425).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alvarado JA, 2004, AM J PHYSIOL-CELL PH, V286, pC621, DOI 10.1152/ajpcell.00108.2003; BALDA MS, 1993, AM J PHYSIOL, V264, pC918; Blecharz KG, 2010, MULT SCLER J, V16, P293, DOI 10.1177/1352458509358189; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Cucullo L, 2004, BRAIN RES, V997, P147, DOI 10.1016/j.brainres.2003.09.079; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Eigenmann DE, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-33; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Forster C, 2006, J PHYSIOL-LONDON, V573, P413, DOI 10.1113/jphysiol.2006.106385; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3; KIMBERLY R P, 1991, Current Opinion in Rheumatology, V3, P373, DOI 10.1097/00002281-199106000-00008; Lamprecht MR, 2014, BRAIN RES, V1563, P131, DOI 10.1016/j.brainres.2014.03.037; Li GL, 2010, ANN BIOMED ENG, V38, P2499, DOI 10.1007/s10439-010-0023-5; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; MILLER DH, 1992, J NEUROL NEUROSUR PS, V55, P450, DOI 10.1136/jnnp.55.6.450; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Poungvarin N, 2004, STROKE, V35, P229, DOI 10.1161/01.STR.0000105931.81723.26; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Romero IA, 2003, NEUROSCI LETT, V344, P112, DOI 10.1016/S0304-3940(03)00348-3; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Sheth B, 1997, DEVELOPMENT, V124, P2027; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SINGER KL, 1994, J BIOL CHEM, V269, P16108; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330; WALSH D, 1992, CLEV CLIN J MED, V59, P505, DOI 10.3949/ccjm.59.5.505; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zhuo YH, 2010, MOL VIS, V16, P61	40	37	37	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2015	35	7					1191	1198		10.1038/jcbfm.2015.38			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CL7FI	WOS:000357137500018	25757751	Green Published, Bronze			2021-06-18	
J	Tham, SW; Fales, J; Palermo, TM				Tham, See Wan; Fales, Jessica; Palermo, Tonya M.			Subjective and Objective Assessment of Sleep in Adolescents with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						actigraphy; adolescents; pain; sleep; traumatic brain injury	SCHOOL-AGE-CHILDREN; MINOR HEAD-INJURY; CHRONIC PAIN; LONGITUDINAL COURSE; WAKE DISTURBANCES; RISK-FACTORS; CES-D; INSOMNIA; IMPACT; DEPRESSION	There is increased recognition that sleep problems may develop in children and adolescents after mild traumatic brain injury (mTBI). However, few studies have utilized both subjective and objective measures to comprehensively assess sleep problems in the pediatric population following the acute post-TBI period. The aims of this study were to compare sleep in adolescents with mTBI to healthy adolescents using subjective and objective measures, and to identify the clinical correlates associated with sleep problems. One hundred adolescents (50 adolescents with mTBI recruited from three to twelve months post-injury and 50 healthy adolescents) completed questionnaires assessing sleep quality, depression, and pain symptoms, and underwent 10 day actigraphic assessment of sleep patterns. Adolescents with mTBI reported poorer sleep quality and demonstrated significantly shorter actigraphic-measured sleep duration, poorer sleep efficiency, and more wake time after onset of sleep, compared with healthy adolescents (all, p<0.05). For both groups of adolescents, poorer self-reported sleep quality was predicted by greater depressive symptoms. Poorer actigraphic sleep efficiency was predicted by membership in the mTBI group after controlling for age, sex, depressive symptoms, and presence of pain. Our findings suggest that adolescents may experience subjective and objective sleep disturbances up to one year following mTBI. These findings require further replication in larger samples. Additionally, research is needed to identify possible mechanisms for poor sleep in youth with mTBI.	[Tham, See Wan; Palermo, Tonya M.] Univ Washington, Sch Med, Seattle, WA USA; [Tham, See Wan; Fales, Jessica; Palermo, Tonya M.] Seattle Childrens Res Inst, Seattle, WA USA; [Fales, Jessica] Washington State Univ Vancouver, Vancouver, WA USA	Tham, SW (corresponding author), M-S CW8-6,POB 5371, Seattle, WA 98145 USA.	see.tham@seattlechildrens.org			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24 HD060068] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32GM086270-03] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30 NR 011400] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD060068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30NR011400] Funding Source: NIH RePORTER		Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carskadon MA, 1998, SLEEP, V21, P871, DOI 10.1093/sleep/21.8.871; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; Dierker LC, 2001, J AM ACAD CHILD PSY, V40, P929, DOI 10.1097/00004583-200108000-00015; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fallone G, 2002, SLEEP MED REV, V6, P287, DOI 10.1053/smrv.2001.0192; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GARRISON CZ, 1991, J AM ACAD CHILD PSY, V30, P636, DOI 10.1097/00004583-199107000-00017; Gregory AM, 2008, SLEEP, V31, P1745, DOI 10.1093/sleep/31.12.1745; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Iglowstein I, 2003, PEDIATRICS, V111, P302, DOI 10.1542/peds.111.2.302; Johnson NL, 2007, SLEEP, V30, P899, DOI 10.1093/sleep/30.7.899; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LeBourgeois MK, 2005, PEDIATRICS, V115, P257, DOI 10.1542/peds.2004-0815H; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; MORRISON DN, 1992, J AM ACAD CHILD PSY, V31, P94, DOI 10.1097/00004583-199201000-00014; Murray CB, 2012, J CLIN CHILD ADOLESC, V41, P482, DOI 10.1080/15374416.2012.658613; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Owens JA, 2005, SLEEP MED, V6, P63, DOI 10.1016/j.sleep.2004.07.015; Palermo TM, 2005, J PAIN, V6, P201, DOI 10.1016/j.jpain.2004.12.005; Palermo TM, 2004, PAIN, V109, P461, DOI 10.1016/j.pain.2004.02.023; Palermo TM, 2012, J PAIN, V13, P1099, DOI 10.1016/j.jpain.2012.08.003; Palermo TM, 2011, PAIN, V152, P89, DOI 10.1016/j.pain.2010.09.035; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Roberts RE, 2002, J PSYCHOSOM RES, V53, P561, DOI 10.1016/S0022-3999(02)00446-4; ROBERTS RE, 1990, PSYCHIAT RES, V31, P69, DOI 10.1016/0165-1781(90)90110-Q; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Sadeh A, 2000, DEV PSYCHOL, V36, P291, DOI 10.1037/0012-1649.36.3.291; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; von Baeyer CL, 2009, EUR J PAIN, V13, P1005, DOI 10.1016/j.ejpain.2009.08.006; WEBSTER JB, 1982, SLEEP, V5, P389, DOI 10.1093/sleep/5.4.389; Wiggins KL, 2009, J THROMB HAEMOST, V7, P263, DOI 10.1111/j.1538-7836.2008.03243.x; Wolfson AR, 1998, CHILD DEV, V69, P875, DOI 10.1111/j.1467-8624.1998.tb06149.x	40	37	37	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					847	852		10.1089/neu.2014.3559			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700010	25707446	Green Published			2021-06-18	
J	Jacotte-Simancas, A; Costa-Miserachs, D; Coll-Andreu, M; Torras-Garcia, M; Borlongan, CV; Portell-Cortes, I				Jacotte-Simancas, Alejandra; Costa-Miserachs, David; Coll-Andreu, Margalida; Torras-Garcia, Meritxell; Borlongan, Cesar V.; Portell-Cortes, Isabel			Effects of Voluntary Physical Exercise, Citicoline, and Combined Treatment on Object Recognition Memory, Neurogenesis, and Neuroprotection after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						neurogenesis and neuroprotection; voluntary physical exercise; traumatic brain injury; object recognition memory; citicoline	CLOSED-HEAD INJURY; GROWTH-FACTOR; NEUROTROPHIC FACTOR; CDP-CHOLINE; HIPPOCAMPAL; TERM; COMBINATION; DYSFUNCTION; MECHANISMS; COGNITION	The biochemical and cellular events that lead to secondary neural damage after traumatic brain injury (TBI) contribute to long-term disabilities, including memory deficits. There is a need to search for single and/or combined treatments aimed at reducing these TBI-related disfunctions. The effects of citicoline and of voluntary physical exercise in a running wheel (3 weeks), alone or in combination, on TBI-related short-term (3 h) and long-term (24 h) object recognition memory (ORM) deficits and on neurogenesis and neuroprotection were examined using a rodent model of TBI (controlled cortical impact injury). Citicoline improved memory deficits at the two times tested, while physical exercise only in the long-term test. Physical exercise had a clear neuroprotective effect as indicated by reduced interhemispheric differences in hippocampal formation and lateral ventricle volumes and in density of mature neurons in the hilus of the dentate gyrus and the perirhinal cortex. Physical exercise also increased cell proliferation and neurogenesis in the granular cell layer of the dentate gyrus. Some degree of neuroprotection of citicoline was suggested by reduced interhemispheric differences in the volume of the hippocampal formation. Contrary to what was expected, the effects of citicoline and physical exercise did not sum up. Further, a negative interference between both treatments was found in several behavioral and histological variables. The promising profiles of both treatments as therapeutic tools in TBI when applied singly underscore the need to perform further works looking for other combined treatment regimens that increase the benefit of each treatment alone.	[Jacotte-Simancas, Alejandra; Costa-Miserachs, David; Coll-Andreu, Margalida; Torras-Garcia, Meritxell; Portell-Cortes, Isabel] Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, E-08193 Barcelona, Spain; [Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL USA	Costa-Miserachs, D (corresponding author), Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, E-08193 Barcelona, Spain.	David.Costa@uab.cat	Costa-Miserachs, David/N-2794-2019; Torras-Garcia, Meritxell/K-9068-2014; Costa-Miserachs, David/E-1318-2011; Coll-Andreu, Margalida/C-9119-2011; Portell-Cortes, Isabel/C-5991-2011	Costa-Miserachs, David/0000-0001-5781-0774; Torras-Garcia, Meritxell/0000-0003-2511-8788; Costa-Miserachs, David/0000-0001-5781-0774; Coll-Andreu, Margalida/0000-0003-4106-2606; Portell-Cortes, Isabel/0000-0002-7710-0101	Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission [BES 2008_007827, SEJ2006-14226-PSIC]; Ministerio de Ciencia y TecnologiaSpanish GovernmentEuropean Commission [PSI 2009-08034]	A.J.S. was a recipient of a pre-doctoral fellowship from the Ministerio de Educacion y Ciencia (BES 2008_007827).; This work was supported by the Ministerio de Educacion y Ciencia (SEJ2006-14226-PSIC) and by the Ministerio de Ciencia y Tecnologia (PSI 2009-08034).	Aasebo IEJ, 2011, EUR J NEUROSCI, V33, P1094, DOI 10.1111/j.1460-9568.2011.07608.x; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Arenth PM, 2011, PM&R, V3, pS123, DOI 10.1016/j.pmrj.2011.03.012; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Brown MW, 2012, NEUROPSYCHOLOGIA, V50, P3122, DOI 10.1016/j.neuropsychologia.2012.07.034; Bustamante A, 2012, J NEUROCHEM, V123, P217, DOI 10.1111/j.1471-4159.2012.07891.x; Carro E, 2001, J NEUROSCI, V21, P5678; Chen MF, 2013, J PHYSIOL-LONDON, V591, P985, DOI 10.1113/jphysiol.2012.241125; Christie BR, 2006, HIPPOCAMPUS, V16, P199, DOI 10.1002/hipo.20151; Clarke JR, 2010, P NATL ACAD SCI USA, V107, P2652, DOI 10.1073/pnas.0915059107; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Fehrenbach E, 2006, SPORTS MED, V36, P373, DOI 10.2165/00007256-200636050-00001; Ferreira AFB, 2011, BRAIN RES, V1425, P111, DOI 10.1016/j.brainres.2011.10.004; Fioravanti M, 2006, CLIN INTERV AGING, V1, P247, DOI 10.2147/ciia.2006.1.3.247; Fogelman D, 2012, PM&R, V4, P908, DOI 10.1016/j.pmrj.2012.09.028; Garcia-Capdevila S, 2009, BEHAV BRAIN RES, V202, P162, DOI 10.1016/j.bbr.2009.03.020; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Halldorsson JG, 2012, BRAIN INJURY, V26, P1, DOI 10.3109/02699052.2011.635359; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Kim JS, 2008, J RADIAT RES, V49, P517, DOI 10.1269/jrr.08020; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marques-Aleixo I, 2012, PROG NEUROBIOL, V99, P149, DOI 10.1016/j.pneurobio.2012.08.002; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Qian K, 2014, NEUROCHEM RES, V39, P1206, DOI 10.1007/s11064-014-1299-x; Ratey JJ, 2011, REV NEUROSCIENCE, V22, P171, DOI 10.1515/RNS.2011.017; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Secades JJ, 2011, REV NEUROLOGIA, V52, pS1, DOI 10.33588/rn.52S02.2010787; Seo HS, 2010, PHARMACOL BIOCHEM BE, V94, P588, DOI 10.1016/j.pbb.2009.11.015; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Snyder JS, 2009, HIPPOCAMPUS, V19, P898, DOI 10.1002/hipo.20552; Takasaki K, 2011, J PHARMACOL SCI, V116, P232, DOI 10.1254/jphs.11013FP; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041; Yang M, 2010, NEUROBIOL LEARN MEM, V93, P487, DOI 10.1016/j.nlm.2010.01.006; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	58	37	38	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2015	32	10					739	751		10.1089/neu.2014.3502			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CH3ZP	WOS:000353970200009	25144903				2021-06-18	
J	Kirkwood, G; Parekh, N; Ofori-Asenso, R; Pollock, AM				Kirkwood, Graham; Parekh, Nikesh; Ofori-Asenso, Richard; Pollock, Allyson M.			Concussion in youth rugby union and rugby league: a systematic review	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Rugby; Children; Adolescent; Sporting injuries	CHRONIC TRAUMATIC ENCEPHALOPATHY; EMERGENCY-DEPARTMENTS; RECURRENT CONCUSSION; CONSENSUS STATEMENT; DATA-COLLECTION; UNITED-STATES; INJURIES; PLAYERS; SPORT; EPIDEMIOLOGY	Background Children and adolescents who play rugby are at increased risk of concussion and its effects. Competitive rugby union and rugby league feature as major sports in the school sport curriculum in the UK. There is a need for a thorough understanding of the epidemiology of concussion in youth rugby, the mechanisms involved in injuries and predisposing risk factors. Data Sources The publication databases Pubmed, Embase and SportDISCUS were searched in April 2014 for primary research studies of child and adolescent rugby union and rugby league (under 20years) in English language with data on concussion injuries. The review was conducted within a larger all injury systematic review on rugby union and rugby league where key words used in the search included rugby, injury and concussion with child, adolescent, paediatric and youth. Results There were 25 studies retrieved with data on child or adolescent rugby and concussion, 20 were on rugby union, three on rugby league and in two the code of rugby was unspecified. There was significant heterogeneity in the definitions of injuries and of concussion. The incidence of child and adolescent match concussion ranged from 0.2 to 6.9 concussions per 1000 player-hours for rugby union and was 4.6 and 14.7 concussions per 1000 player-hours for rugby league, equivalent to a probability of between 0.3% and 11.4% for rugby union and of 7.7% and 22.7% for rugby league. Conclusions There is a significant risk of concussion in children and adolescents playing rugby union and rugby league evident from the studies included in this systematic review. There is a need for reliable data through routine monitoring and reporting in schools and clubs and in hospital emergency departments in order to inform prevention. Concussion protocols should be implemented and tested.	[Kirkwood, Graham; Ofori-Asenso, Richard; Pollock, Allyson M.] Queen Mary Univ London, Ctr Primary Care & Publ Hlth, London E1 2AB, England; [Parekh, Nikesh] Lewisham & Greenwich NHS Trust, London, England	Pollock, AM (corresponding author), Queen Mary Univ London, Ctr Primary Care & Publ Hlth, Yvonne Carter Bldg,58 Turner St, London E1 2AB, England.	a.pollock@qmul.ac.uk		pollock, allyson/0000-0002-7388-3110	Barts Charity through the Centre for Trauma Sciences project	The authors thank Dr Andreas Freitag (AF) and Dr Sebastian Scharer (SS) for literature searching as part of a larger rugby injury study. The authors thank also the Barts Charity for funding for staff through the Centre for Trauma Sciences project.	American Academy of Neurology, POS POL DOC; [Anonymous], 2013, BBC NEWS; Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Boufous S, 2004, AUST NZ J PUBL HEAL, V28, P482, DOI 10.1111/j.1467-842X.2004.tb00032.x; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; England Professional Rugby Injury Surveillance Project Steering Group, ENGL PROF RUGB INJ S; Fridman L, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-30; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2011, CLIN J SPORT MED, V21, P356, DOI 10.1097/JSM.0b013e31821f5085; Gabbett TJ, 2008, J SCI MED SPORT, V11, P323, DOI 10.1016/j.jsams.2007.06.003; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Kaplan KM, 2008, BULL HOSP JT DIS, V66, P86; King D, 2013, NZ J SPORTS MED, V40, P64; King D, 2006, NZ J SPORTS MED, V34, P21; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; Lawton G, NEW SCI; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LEWIS ER, 1996, SPORTS EXERC INJURY, V2, P186; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; NATHAN M, 1983, S AFR MED J, V64, P132; Nicol A, 2011, J PUBLIC HEALTH-UK, V33, P256, DOI 10.1093/pubmed/fdq047; Parekh N, 2012, BRIT J SPORT MED, V46, P611, DOI 10.1136/bjsports-2011-090431; Raftery M, 2014, BRIT J SPORT MED, V48, P79, DOI 10.1136/bjsports-2013-093051; ROUX CE, 1987, S AFR MED J, V71, P307; Rugby Football Union (RFU), RET PLAY CONC; Rugby League International Federation, RANK; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Sparks J P, 1985, Br J Sports Med, V19, P71; Sparks J P, 1981, Br J Sports Med, V15, P30; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sugerman S, 1983, AUST J SPORTS MED EX, V15, P5; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Upton PAH, 1996, S AFR MED J, V86, P531; Watson AWS, 1997, NZ J SPORTS MED, V25, P22; Yard EE, 2006, J ATHL TRAINING, V41, P325; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	56	37	37	1	46	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					506	510		10.1136/bjsports-2014-093774			5	Sport Sciences	Sport Sciences	CF4OI	WOS:000352529000006	25586912	Bronze			2021-06-18	
J	Davenport, ND; Lim, KO; Sponheim, SR				Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.			White Matter Abnormalities Associated With Military PTSD in the Context of Blast TBI	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; diffusion magnetic resonance imaging; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSION-TENSOR; TRACT INTEGRITY; INDIVIDUAL-DIFFERENCES; TRAIT ANXIETY; AFGHANISTAN; CINGULUM; IRAQ; CONNECTIVITY	Mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) are common among recent military veterans and involve substantial symptom overlap, making clinical distinction and effective intervention difficult. Emerging evidence of cerebral white matter abnormalities associated with mTBI may provide a biological measure to inform diagnosis and treatment, but the potentially confounding effects between PTSD and mTBI have largely gone unexamined. We collected diffusion imaging data from 133 recently-deployed American service members who developed PTSD and/or sustained mTBI, or had neither condition. Effects of PTSD and mTBI on traditional tensor-based measures of cerebral white matter integrity (fractional anisotropy [FA] and mean diffusivity [MD]) were compared in anatomical regions of interest and individual voxels throughout the brain. Generalized FA (GFA), which allows for multiple fiber orientations per voxel, was also included to improve sensitivity in white matter areas containing crossing or diverging axon bundles. PTSD was consistently associated with high GFA in select brain regions, greater likelihood of regions and voxels with abnormally low MD, and a greater number of voxels with abnormally high FA, while mTBI was associated with fewer high MD regions. Overall, PTSD was associated with more restricted diffusion (low MD) and greater anisotropy (high GFA) in regions of crossing/diverging fibers poorly characterized by a single tensor (FA), suggesting that interstitial fibers may be involved. Contrary to earlier results in a sample without PTSD, mTBI was not associated with anisotropy abnormalities, perhaps indicating the cooccurrence of PTSD and mTBI requires special consideration with regard to structural brain connectivity. Hum Brain Mapp 36:1053-1064, 2015.(c) 2014 Wiley Periodicals, Inc.	[Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN USA; [Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Sponheim, Scott R.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA	Davenport, ND (corresponding author), VA Med Ctr B68 2, 1 Vet Dr, Minneapolis, MN 55417 USA.	nicholas.davenport@va.gov	Sponheim, Scott/J-3857-2017; Lim, Kelvin/AAF-6833-2020; Davenport, Nicholas/AAY-8057-2020	Sponheim, Scott/0000-0002-2782-0856; Davenport, Nicholas/0000-0002-3441-7256; Lim, Kelvin/0000-0002-2390-7268	Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000622-01A1, 1IK2RX000709-01A3]; Veterans AffairsUS Department of Veterans Affairs [I01RX000622] Funding Source: NIH RePORTER	Contract grant sponsor: Congressionally Directed Medical Research Program; Contract grant number: PT074550 and W81XWH-08-2-0038; Contract grant sponsor: Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service; Contract grant number: 1I01RX000622-01A1 (S.R.S.) and 1IK2RX000709-01A3 (N.D.D.)	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson MJ, 2001, AUST NZ J STAT, V43, P75, DOI 10.1111/1467-842X.00156; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Assemlal H-E, 2007, Proceedings 2007 IEEE International Conference on Image Processing, ICIP 2007, P133; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Christensen J, 2004, PSYCHIAT RES-NEUROIM, V130, P71, DOI 10.1016/j.pscychresns.2003.08.002; Clewett D, 2014, NEUROPSYCHOLOGY, V28, P631, DOI 10.1037/neu0000060; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; First MB., 2002, STRUCTURED CLIN INTE; Fried I, 1997, J NEUROPSYCH CLIN N, V9, P420; Fritzsche KH, 2010, NEUROIMAGE, V51, P242, DOI 10.1016/j.neuroimage.2010.02.007; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lochner C, 2012, J PSYCHIATR NEUROSCI, V37, P193, DOI 10.1503/jpn.110059; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Modi S, 2013, BEHAV BRAIN RES, V238, P188, DOI 10.1016/j.bbr.2012.10.007; Montag C, 2012, NEUROSCIENCE, V217, P77, DOI 10.1016/j.neuroscience.2012.05.017; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Sekiguchi A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/180468; Sekiguchi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083967; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sullivan EV, 2006, NEUROSCI BIOBEHAV R, V30, P749, DOI 10.1016/j.neubiorev.2006.06.002; Sullivan EV, 2003, EUR J RADIOL, V45, P244, DOI 10.1016/S0720-048X(02)00313-3; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358	57	37	37	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2015	36	3					1053	1064		10.1002/hbm.22685			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CB4QI	WOS:000349612500018	25387950	Green Published			2021-06-18	
J	Liao, GP; Harting, MT; Hetz, RA; Walker, PA; Shah, SK; Corkins, CJ; Hughes, TG; Jimenez, F; Kosmach, SC; Day, MC; Tsao, K; Lee, DA; Worth, LL; Baumgartner, JE; Cox, CS				Liao, George P.; Harting, Matthew T.; Hetz, Robert A.; Walker, Peter A.; Shah, Shinil K.; Corkins, Christopher J.; Hughes, Travis G.; Jimenez, Fernando; Kosmach, Steven C.; Day, Mary-Clare; Tsao, KuoJen; Lee, Dean A.; Worth, Laura L.; Baumgartner, James E.; Cox, Charles S., Jr.			Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cell therapy; clinical trial; intracranial pressure; pediatrics; stem cell; traumatic brain injury	MULTIPLE ORGAN DYSFUNCTION; INTRACRANIAL HYPERTENSION; PROGENITOR CELLS; PELOD SCORE; TIME-COURSE; EDEMA; TRANSPLANTATION; VALIDATION; THERAPIES; MANNITOL	Objectives: The devastating effect of traumatic brain injury is exacerbated by an acute secondary neuroinflammatory response, clinically manifest as elevated intracranial pressure due to cerebral edema. The treatment effect of cell-based therapies in the acute post-traumatic brain injury period has not been clinically studied although preclinical data demonstrate that bone marrow-derived mononuclear cell infusion down-regulates the inflammatory response. Our study evaluates whether pediatric traumatic brain injury patients receiving IV autologous bone marrow-derived mononuclear cells within 48 hours of injury experienced a reduction in therapeutic intensity directed toward managing elevated intracranial pressure relative to matched controls. Design: The study was a retrospective cohort design comparing pediatric patients in a phase I clinical trial treated with IV autologous bone marrow-derived mononuclear cells (n = 10) to a control group of age-and severity-matched children (n = 19). Setting: The study setting was at Children's Memorial Hermann Hospital, an American College of Surgeons Level 1 Pediatric Trauma Center and teaching hospital for the University of Texas Health Science Center at Houston from 2000 to 2008. Patients: Study patients were 5-14 years with postresuscitation Glasgow Coma Scale scores of 5-8. Interventions: The treatment group received 6 million autologous bone marrow-derived mononuclear cells/kg body weight IV within 48 hours of injury. The control group was treated in an identical fashion, per standard of care, guided by our traumatic brain injury management protocol, derived from American Association of Neurological Surgeons guidelines. Measurements and Main Results: The primary measure was the Pediatric Intensity Level of Therapy scale used to quantify treatment of elevated intracranial pressure. Secondary measures included the Pediatric Logistic Organ Dysfunction score and days of intracranial pressure monitoring as a surrogate for length of neurointensive care. A repeated-measure mixed model with marginal linear predictions identified a significant reduction in the Pediatric Intensity Level of Therapy score beginning at 24 hours posttreatment through week 1 (p < 0.05). This divergence was also reflected in the Pediatric Logistic Organ Dysfunction score following the first week. The duration of intracranial pressure monitoring was 8.2 +/- 1.3 days in the treated group and 15.6 +/- 3.5 days (p = 0.03) in the time-matched control group. Conclusions: IV autologous bone marrow-derived mononuclear cell therapy is associated with lower treatment intensity required to manage intracranial pressure, associated severity of organ injury, and duration of neurointensive care following severe traumatic brain injury. This may corroborate preclinical data that autologous bone marrow-derived mononuclear cell therapy attenuates the effects of inflammation in the early post-traumatic brain injury period.	[Liao, George P.; Harting, Matthew T.; Hetz, Robert A.; Walker, Peter A.; Shah, Shinil K.; Corkins, Christopher J.; Hughes, Travis G.; Jimenez, Fernando; Kosmach, Steven C.; Day, Mary-Clare; Tsao, KuoJen; Baumgartner, James E.; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Lee, Dean A.; Worth, Laura L.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Therapy, Div Pediat, Houston, TX 77030 USA	Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu	Lee, Dean Anthony/AAK-8443-2021	Lee, Dean Anthony/0000-0001-6693-5392; Harting, Matthew/0000-0002-8929-8311	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01 RR 02558, UL1 RR024148, T32 GM 0879201]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Athersys; CBR; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558, UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	Supported, in part, by grants M01 RR 02558, UL1 RR024148, and T32 GM 0879201 from the National Institutes of Health. Dr. Liao and Ms.; Day received support for article research from the National Institutes of Health (NIH). Their institutions received grant support from the NIH. Drs. Harting, Hetz, Shah, Jimenez, Tsao, Lee, and Worth received support for article research from the NIH. Dr. Kosmach received support for article research from the NIH. His institution received grant support from the NIH/National Institute of Neurological Disorders and Stroke. Dr. Cox consulted for CBR, lectured for CBR, has patents with Athersys and EMIT, and received support for article research from the NIH. Dr. Cox and his institution received grant support from the NIH, Athersys, and CBR; received royalties from EMIT; and has stock with EMIT. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS5; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS49; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS56; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS38; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cuende N, 2012, STEM CELL TRANSL MED, V1, P403, DOI 10.5966/sctm.2011-0064; Garcia PCR, 2010, INTENS CARE MED, V36, P116, DOI 10.1007/s00134-009-1489-1; Hetz RA, 2012, TRANSL STROKE RES, V3, P318, DOI 10.1007/s12975-012-0192-7; Huh Jimmy W, 2009, Anesthesiol Clin, V27, P213, DOI 10.1016/j.anclin.2009.05.006; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kamat P, 2012, PEDIATR CRIT CARE ME, V13, pE33, DOI 10.1097/PCC.0b013e31820ac08f; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Leteurtre S, 2006, LANCET, V367, P897, DOI 10.1016/S0140-6736(06)68371-2; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maltais S, 2011, EUR J CARDIO-THORAC, V39, P368, DOI 10.1016/j.ejcts.2010.04.022; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Poulsom R, 2001, J PATHOL, V195, P229, DOI 10.1002/path.976; Robertson Brian D, 2013, J Inj Violence Res, V5, P51, DOI 10.5249/jivr.v5i1.205; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Thukral A, 2007, INDIAN PEDIATR, V44, P683; Walker PA, 2010, MINERVA PEDIATR, V62, P91; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2010, REGEN MED, V5, P65, DOI 10.2217/RME.09.73; Walker PA, 2009, J TRAUMA, V67, pS120, DOI 10.1097/TA.0b013e3181ad323a; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108; Zygun DA, 2009, CRIT CARE, V13, DOI 10.1186/cc8014	53	37	37	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2015	16	3					245	255		10.1097/PCC.0000000000000324			11	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	CD1AZ	WOS:000350807300009	25581630	Green Accepted			2021-06-18	
J	Mychasiuk, R; Hehar, H; Ma, I; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene; Esser, Michael J.			Dietary intake alters behavioral recovery and gene expression profiles in the brain of juvenile rats that have experienced a concussion	Frontiers in Behavioral Neuroscience			English	Article						caloric restriction; high fat diet; mild traumatic brain injury; gRT-PCR; telomere; sex-differences	SATURATED-FAT DIET; CALORIC RESTRICTION; NEUROTROPHIC FACTOR; SEX-DIFFERENCES; ALZHEIMERS-DISEASE; TELOMERE LENGTH; SYNAPTIC PLASTICITY; NEURONAL PLASTICITY; INJURY; OBESITY	Concussion and mild traumatic brain injury (mTBI) research has made minimal progress diagnosing who will suffer from lingering symptomology or generating effective treatment strategies. Research demonstrates that dietary intake affects many biological systems including brain and neurological health. This study determined if exposure to a high fat diet (H ED) or caloric restriction (CR) altered post-concussion susceptibility or resiliency using a rodent model of pediatric concussion. Rats were maintained on HFD, CR, or standard diet (STD) throughout life (including the prenatal period and weaning). At postnatal day 30, male and female rats experienced a concussion or a sham injury which was followed by 17 days of testing. Prefrontal cortex and hippocampus tissue was collected for molecular profiling. Gene expression changes in BDNF, CREB, DNMT1, FGF-2, IGF1, LEP, PGC-1c I, SIRT1, Tau, and TERT were analyzed with respect to injury and diet. Analysis of telomere length (TL) using peripheral skin cells and brain tissue found that TL in skin significantly correlated with TL in brain tissue and TL was affected by dietary intake and injury status. With respect to mTBI outcomes, diet was correlated with recovery as animals on the HFD often displayed poorer performance than animals on the CR diet. Molecular analysis demonstrated that diet induced epigenetic changes that can be associated with differences in individual predisposition and resiliency to post-concussion syndrome.	[Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute (ACHRI); Alberta Children's Hospital Foundation; ARCHI; Markin USRP for Health and Wellness	Dr. Michael Esser reports funding from Alberta Children's Hospital Research Institute (ACHRI) and the Alberta Children's Hospital Foundation. Dr. Richelle Mychasiuk reports funding from ARCHI. Irene Ma has no financial interests to disclose. Harleeen Hehar reports funding from the Markin USRP for Health and Wellness.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barzilai N, 1999, J GERONTOL A-BIOL, V54, pB89, DOI 10.1093/gerona/54.3.B89; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Butt AM, 2005, NEUROSCI LETT, V375, P28, DOI 10.1016/j.neulet.2004.10.060; Cassidy A, 2010, AM J CLIN NUTR, V91, P1273, DOI 10.3945/ajcn.2009.28947; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dunn GA, 2011, HORM BEHAV, V59, P290, DOI 10.1016/j.yhbeh.2010.05.004; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Eisenberg DTA, 2011, AM J HUM BIOL, V23, P149, DOI 10.1002/ajhb.21127; Entringer S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003580; Ferezou-Viala J, 2007, AM J PHYSIOL-REG I, V293, pR1056, DOI 10.1152/ajpregu.00117.2007; Fusco S, 2012, P NATL ACAD SCI USA, V109, P621, DOI 10.1073/pnas.1109237109; Garrido P, 2011, AGING DIS, V2, P80; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Harris RBS, 2000, ANNU REV NUTR, V20, P45, DOI 10.1146/annurev.nutr.20.1.45; Hood MY, 2000, INT J OBESITY, V24, P1319, DOI 10.1038/sj.ijo.0801396; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kalichman L, 2007, AM J PHYS MED REHAB, V86, P650, DOI 10.1097/PHM.0b013e318115f41b; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kolb B., 2008, FUNDAMENTALS HUMAN N; Langdon KD, 2011, NEUROSCIENCE, V182, P82, DOI 10.1016/j.neuroscience.2011.03.028; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Li YY, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-98; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Mattson MP, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/neuro.24.005.2010; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; Max JE, 1998, BRAIN INJURY, V12, P41; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Molteni R, 2001, BRAIN RES REV, V37, P249, DOI 10.1016/S0165-0173(01)00128-X; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Paul L, 2011, J NUTR BIOCHEM, V22, P895, DOI 10.1016/j.jnutbio.2010.12.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Rabinovsky ED, 2004, NEUROL RES, V26, P204, DOI 10.1179/016164104225013851; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Savage JS, 2007, J LAW MED ETHICS, V35, P22, DOI 10.1111/j.1748-720X.2007.00111.x; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Vera E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053760; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Witte AV, 2009, P NATL ACAD SCI USA, V106, P1255, DOI 10.1073/pnas.0808587106; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu MV, 2009, CELL, V139, P61, DOI 10.1016/j.cell.2009.07.036; Zilles K., 1985, CORTEX RAT STEREOTAX	68	37	37	0	16	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	FEB 5	2015	9								17	10.3389/fnbeh.2015.00017			17	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	CA4CH	WOS:000348851400001	25698949	DOAJ Gold, Green Published			2021-06-18	
J	Badaut, J; Ajao, DO; Sorensen, DW; Fukuda, AM; Pellerin, L				Badaut, J.; Ajao, D. O.; Sorensen, D. W.; Fukuda, A. M.; Pellerin, L.			CAVEOLIN EXPRESSION CHANGES IN THE NEUROVASCULAR UNIT AFTER JUVENILE TRAUMATIC BRAIN INJURY: SIGNS OF BLOOD-BRAIN BARRIER HEALING?	NEUROSCIENCE			English	Article						blood-brain barrier; endothelium; astrocyte; juvenile traumatic brain injury; caveolin	ENDOTHELIAL PERMEABILITY; NITRIC-OXIDE; TIGHT JUNCTIONS; P-GLYCOPROTEIN; NULL MICE; IN-VIVO; RATS; ASTROCYTES; OCCLUDIN; BREAKDOWN	Traumatic brain injury (TBI) is one of the major causes of death and disability in pediatrics, and results in a complex cascade of events including the disruption of the blood-brain barrier (BBB). A controlled-cortical impact on post-natal 17-day-old rats induced BBB disruption by IgG extravasation from 1 to 3 days after injury and returned to normal at day 7. In parallel, we characterized the expression of three caveolin isoforms, caveolin 1 (cav-1), caveolin 2 (cav-2) and caveolin 3 (cav-3). While cav-1 and cav-2 are expressed on endothelial cells, both cav-1 and cav-3 were found to be present on reactive astrocytes, in vivo and in vitro. Following TBI, cav-1 expression was increased in blood vessels at 1 and 7 days in the perilesional cortex. An increase of vascular cav-2 expression was observed 7 days after TBI. In contrast, astrocytic cav-3 expression decreased 3 and 7 days after TBI. Activation of endothelial nitric oxide synthase (eNOS) (via its phosphorylation) was detected 1 day after TBI and phospho-eNOS was detected both in association with blood vessels and with astrocytes. The molecular changes involving caveolins occurring in endothelial cells following juvenile-TBI might participate, independently of eNOS activation, to a mechanism of BBB repair while, they might subserve other undefined roles in astrocytes. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Badaut, J.] Univ Bordeaux, CNRS UMR5287, F-33076 Bordeaux, France; [Badaut, J.; Ajao, D. O.; Sorensen, D. W.; Fukuda, A. M.] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA; [Badaut, J.; Sorensen, D. W.] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA; [Pellerin, L.] Univ Lausanne, Dept Physiol, Lausanne, Switzerland	Badaut, J (corresponding author), Univ Bordeaux, CNRS UMR 5287, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Jerome.badaut@u-bordeaux.fr	Pellerin, Luc/A-8912-2017	Pellerin, Luc/0000-0002-1016-1970; Fukuda, Andrew/0000-0002-7927-6602	National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure [0923559]; Loma Linda University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	A portion of this material was performed in the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core that is supported by the National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure Grant No. 0923559 (Dr Sean M. Wilson) and the Loma Linda University School of Medicine.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bernatchez PN, 2005, P NATL ACAD SCI USA, V102, P761, DOI 10.1073/pnas.0407224102; Bucci M, 2000, NAT MED, V6, P1362; Cameron PL, 1997, J NEUROSCI, V17, P9520; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V252, P552, DOI 10.1006/bbrc.1998.9691; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Gonzalez MI, 2007, J BIOL CHEM, V282, P29855, DOI 10.1074/jbc.M704738200; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Jasmin JF, 2007, CIRC RES, V100, P721, DOI 10.1161/01.RES.0000260180.42709.29; Jodoin J, 2003, J NEUROCHEM, V87, P1010, DOI 10.1046/j.1471-4159.2003.02081.x; Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833; Lajoie P, 2009, J CELL BIOL, V185, P381, DOI 10.1083/jcb.200811059; McCaffrey G, 2007, J NEUROCHEM, V103, P2540, DOI 10.1111/j.1471-4159.2007.04943.x; McCaffrey G, 2012, J NEUROCHEM, V122, P962, DOI 10.1111/j.1471-4159.2012.07831.x; McCaffrey G, 2009, J NEUROCHEM, V110, P58, DOI 10.1111/j.1471-4159.2009.06113.x; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006; Razani B, 2001, J BIOL CHEM, V276, P38121; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Regina A, 2004, J NEUROSCI RES, V75, P291, DOI 10.1002/jnr.10865; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Shin T, 2005, J NEUROIMMUNOL, V165, P11, DOI 10.1016/j.jneuroim.2005.03.019; Shin T, 2007, BRAIN RES, V1141, P228, DOI 10.1016/j.brainres.2007.01.009; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siddiqui MR, 2011, J CELL BIOL, V193, P841, DOI 10.1083/jcb.201012129; Stamatovic SM, 2009, J BIOL CHEM, V284, P19053, DOI 10.1074/jbc.M109.000521; Virgintino D, 2002, NEUROSCIENCE, V115, P145, DOI 10.1016/S0306-4522(02)00374-3; Wiencken AE, 1999, GLIA, V26, P280; Zschocke J, 2005, GLIA, V49, P275, DOI 10.1002/glia.20116	41	37	39	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 29	2015	285						215	226		10.1016/j.neuroscience.2014.10.035			12	Neurosciences	Neurosciences & Neurology	AX7PE	WOS:000347106700018	25450954	Green Published, Green Accepted			2021-06-18	
J	Campos-Pires, R; Armstrong, SP; Sebastiani, A; Luh, C; Gruss, M; Radyushkin, K; Hirnet, T; Werner, C; Engelhard, K; Franks, NP; Thal, SC; Dickinson, R				Campos-Pires, Rita; Armstrong, Scott P.; Sebastiani, Anne; Luh, Clara; Gruss, Marco; Radyushkin, Konstantin; Hirnet, Tobias; Werner, Christian; Engelhard, Kristin; Franks, Nicholas P.; Thal, Serge C.; Dickinson, Robert			Xenon Improves Neurologic Outcome and Reduces Secondary Injury Following Trauma in an In Vivo Model of Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						brain injury; head trauma; inert gases; neuroprotection; xenon	D-ASPARTATE RECEPTOR; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; COMPETITIVE-INHIBITION; GLYCINE SITE; INTRACEREBRAL-HEMORRHAGE; INTRACRANIAL-PRESSURE; COGNITIVE DEFICITS; GAIT ABNORMALITIES; POTASSIUM CHANNELS	Objectives: To determine the neuroprotective efficacy of the inert gas xenon following traumatic brain injury and to determine whether application of xenon has a clinically relevant therapeutic time window. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57BL/6N mice (n = 196). Interventions: Seventy-five percent xenon, 50% xenon, or 30% xenon, with 25% oxygen (balance nitrogen) treatment following mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Outcome following trauma was measured using 1) functional neurologic outcome score, 2) histological measurement of contusion volume, and 3) analysis of locomotor function and gait. Our study shows that xenon treatment improves outcome following traumatic brain injury. Neurologic outcome scores were significantly (p < 0.05) better in xenon-treated groups in the early phase (24 hr) and up to 4 days after injury. Contusion volume was significantly (p < 0.05) reduced in the xenon-treated groups. Xenon treatment significantly (p < 0.05) reduced contusion volume when xenon was given 15 minutes after injury or when treatment was delayed 1 or 3 hours after injury. Neurologic outcome was significantly (p < 0.05) improved when xenon treatment was given 15 minutes or 1 hour after injury. Improvements in locomotor function (p < 0.05) were observed in the xenon-treated group, 1 month after trauma. Conclusions: These results show for the first time that xenon improves neurologic outcome and reduces contusion volume following traumatic brain injury in mice. In this model, xenon application has a therapeutic time window of up to at least 3 hours. These findings support the idea that xenon may be of benefit as a neuroprotective treatment in patients with brain trauma.	[Campos-Pires, Rita; Armstrong, Scott P.; Dickinson, Robert] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England; [Sebastiani, Anne; Luh, Clara; Hirnet, Tobias; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Med Ctr, D-55122 Mainz, Germany; [Gruss, Marco] Klinikum Hanau, Dept Anaesthesiol, Hanau, Germany; [Radyushkin, Konstantin] Johannes Gutenberg Univ Mainz, Mouse Behav Outcome Unit, Focus Program Translat Neurosci, D-55122 Mainz, Germany; [Franks, Nicholas P.] Univ London Imperial Coll Sci Technol & Med, Dept Life Sci, London, England	Dickinson, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England.	r.dickinson@imperial.ac.uk	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Franks, Nicholas/0000-0003-4874-4212	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1247958] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_12015, MC_PC_13064] Funding Source: Medline		Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; Arola OJ, 2013, CRIT CARE MED, V41, P2116, DOI 10.1097/CCM.0b013e31828a4337; Azzopardi D, 2013, ARCH DIS CHILD-FETAL, V98, pF437, DOI 10.1136/archdischild-2013-303786; Banks P, 2010, ANESTHESIOLOGY, V112, P614, DOI 10.1097/ALN.0b013e3181cea398; Bantel C, 2009, ANESTHESIOLOGY, V110, P986, DOI 10.1097/ALN.0b013e31819dadc7; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Baumert JH, 2009, J CARDIOTHOR VASC AN, V23, P614, DOI 10.1053/j.jvca.2009.01.028; Baumert JH, 2007, ANESTH ANALG, V105, P1200, DOI 10.1213/01.ane.0000284697.73471.9c; Bickler PE, 2012, ANESTHESIOLOGY, V117, P280, DOI 10.1097/ALN.0b013e318260a7b9; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Coburn M, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-180; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Harris K, 2013, ANESTHESIOLOGY, V119, P1137, DOI 10.1097/ALN.0b013e3182a2a265; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kawamata T, 1997, ACT NEUR S, V70, P191; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Limatola V, 2010, NEUROSCIENCE, V165, P874, DOI 10.1016/j.neuroscience.2009.10.063; Liu Y, 2013, BEHAV BRAIN RES, V257, P166, DOI 10.1016/j.bbr.2013.10.007; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Martin D, 2004, HOSP MED, V65, P674, DOI 10.12968/hosp.2004.65.11.17047; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mio Y, 2009, ANESTH ANALG, V108, P858, DOI 10.1213/ane.0b013e318192a520; Mountney A, 2013, J NEUROSCI METH, V212, P1, DOI 10.1016/j.jneumeth.2012.08.025; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PITTINGER CB, 1953, ANESTHESIOLOGY, V14, P10, DOI 10.1097/00000542-195301000-00002; Preckel B, 2006, ANESTHESIOLOGY, V105, P187, DOI 10.1097/00000542-200607000-00029; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Shu Y, 2010, ANESTHESIOLOGY, V113, P360, DOI 10.1097/ALN.0b013e3181d960d7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teig M, 2010, J NEUROSURG ANESTH, V22, P357, DOI 10.1097/ANA.0b013e3181f0dada; Thal SC, 2014, CRIT CARE MED, V42, P129, DOI 10.1097/CCM.0b013e3182a639fd; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang XH, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-142; Warner DS, 2004, ANESTH ANALG, V99, P1208, DOI 10.1213/01.ANE.0000139930.04010.0D; Weber NC, 2006, EUR J PHARMACOL, V539, P1, DOI 10.1016/j.ejphar.2006.03.054; Weber NC, 2008, ANESTH ANALG, V107, P1807, DOI 10.1213/ane.Ob013e31818874bf; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Yang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037020	72	37	39	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2015	43	1					149	158		10.1097/CCM.0000000000000624			10	Critical Care Medicine	General & Internal Medicine	AW6XN	WOS:000346409100039	25188549	Green Accepted			2021-06-18	
J	Post, A; Kendall, M; Koncan, D; Cournoyer, J; Hoshizaki, TB; Gilchrist, MD; Brien, S; Cusimano, MD; Marshall, S				Post, Andrew; Kendall, Marshall; Koncan, David; Cournoyer, Janie; Hoshizaki, T. Blaine; Gilchrist, Michael D.; Brien, Susan; Cusimano, Michael D.; Marshall, Shawn			Characterization of persistent concussive syndrome using injury reconstruction and finite element modelling	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Persistent concussive syndrome; Brain injury; Biomechanics; Concussion	TRAUMATIC BRAIN-INJURY; IMPACT; TISSUE; FALLS	Concussions occur 1.7 million times a year in North America, and account for approximately 75% of all traumatic brain injuries (TBI). Concussions usually cause transient symptoms but 10 to 20% of patients can have symptoms that persist longer than a month. The purpose of this research was to use reconstructions and finite element modeling to determine the brain tissue stresses and strains that occur in impacts that led to persistent post concussive symptoms (PCS) in hospitalized patients. A total of 21 PCS patients had their head impacts reconstructed using computational, physical and finite element methods. The dependent variables measured were maximum principal strain, von Mises stress (VMS), strain rate, and product of strain and strain rate. For maximum principal strain alone there were large regions of brain tissue incurring 30 to 40% strain. This large field of strain was also evident when using strain rate, product of strain and strain rate. In addition, VMS also showed large magnitudes of stress throughout the cerebrum tissues. The distribution of strains throughout the brain tissues indicated peak responses were always present in the grey matter (0.481), with the white matter showing significantly lower strains (0.380) (p <0.05). The impact conditions of the PCS cases were severe in nature, with impacts against non-compliant surfaces (concrete, steel, ice) resulting in higher brain deformation. PCS biomechanical parameters were shown to fit between those that have been shown to cause transient post concussive symptoms and those that lead to actual pathologic damage like contusion, however, values of all metrics were characterized by large variance and high average responses. This data supports the theory that there exists a progressive continuum of impacts that lead to a progressive continuum of related severity of injury from transient symptoms to pathological damage. (C) 2014 Elsevier Ltd. All rights reserved.	[Post, Andrew; Kendall, Marshall; Koncan, David; Cournoyer, Janie; Hoshizaki, T. Blaine; Gilchrist, Michael D.; Brien, Susan] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland; [Brien, Susan] Hull Hosp, Gatineau, PQ, Canada; [Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada; [Marshall, Shawn] Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada	Post, A (corresponding author), 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650; Cournoyer, Janie/0000-0001-9043-7756; Post, Andrew/0000-0002-5960-5552			Adamec J, 2010, J FORENSIC SCI, V55, P1615, DOI 10.1111/j.1556-4029.2010.01445.x; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Di Mascio M, 2013, J STRENGTH COND RES, V27, P909, DOI 10.1519/JSC.0b013e31825ff099; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly M.C., 2007, THESIS U COLL DUBLIN; GENNARELLI TA, 1971, 15TH P STAPP CAR CRA, P797; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Ho J., 2008, THESIS ROYAL I TECHN; Holbourn A.H.S., 1943, MECH HEAD INJURIES; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki T.B., 2013, J NEUROL NEUROPHYSIO, V5, P181; Karton C, 2013, J ASTM INT, DOI [10.1520/STP155220120175, DOI 10.1520/STP155220120175]; Kendall M., 2012, P IRCOBI C DUBL IR; King AI, 2003, IRCOBI C LISB PORT; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Margaret K.Y., 2005, CLIN NEUROPSYCHOL, V116, P780; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; MILLER RT, 1998, 42 STAPP CAR CRASH C, P155; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Nahum A, 1977, 21 STAPP CAR CRASH C; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Post A, 2013, THESIS U OTTAWA; Post A, 2014, J NEUROSURG, V120, P453, DOI 10.3171/2013.10.JNS131101; Post A, 2012, TRAUMA, V14, P327, DOI 10.1177/1460408612446573; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rojas IL, 2009, AM J SPORT MED, V37, P558, DOI 10.1177/0363546508328105; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Yang JK, 2011, COMPUTATIONAL BIOMECHANICS FOR MEDICINE: SOFT TISSUES AND THE MUSCULOSKELETAL SYSTEM, P5, DOI 10.1007/978-1-4419-9619-0_2; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	36	37	39	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	JAN	2015	41						325	335		10.1016/j.jmbbm.2014.07.034			11	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	AW3XW	WOS:000346217400031	25154550				2021-06-18	
J	Valko, PO; Gavrilov, YV; Yamamoto, M; Finn, K; Reddy, H; Haybaeck, J; Weis, S; Scammell, TE; Baumann, CR				Valko, Philipp O.; Gavrilov, Yury V.; Yamamoto, Mihoko; Finn, Kristen; Reddy, Hasini; Haybaeck, Johannes; Weis, Serge; Scammell, Thomas E.; Baumann, Christian R.			Damage to Histaminergic Tuberomammillary Neurons and Other Hypothalamic Neurons with Traumatic Brain Injury	ANNALS OF NEUROLOGY			English	Article							DAYTIME SLEEPINESS; NARCOLEPSY; MODAFINIL	The need for increased sleep after traumatic brain injury is a common and disabling complaint, yet its etiology is unknown. Previous studies have demonstrated diffuse damage to various hypothalamic systems, but the integrity of the histaminergic tuberomammillary nucleus, a major arousal-promoting system located in the posterior hypothalamus, has never been examined in head trauma patients. Here, we demonstrate that severe head trauma is associated with a marked loss (41%) of histaminergic neurons. Reduced histamine signaling may contribute to increased sleep need, and therapies that enhance histaminergic tone may improve arousal after head trauma or other conditions. ANN NEUROL 2015;77:177-182	[Valko, Philipp O.; Gavrilov, Yury V.; Yamamoto, Mihoko; Finn, Kristen; Scammell, Thomas E.; Baumann, Christian R.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Valko, Philipp O.; Gavrilov, Yury V.; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Gavrilov, Yury V.] Russian Acad Med Sci, Inst Expt Med, Dept Gen Pathol & Pathol Physiol, St Petersburg, Russia; [Reddy, Hasini] Beth Israel Deaconess Med Ctr, Dept Neuropathol, Boston, MA 02215 USA; [Haybaeck, Johannes] Med Univ Graz, Inst Pathol, Dept Neuropathol, Graz, Austria; [Weis, Serge] Johannes Kepler Univ Linz, Dept Neuropathol, State Neuropsychiat Hosp Wagner Jauregg, A-4040 Linz, Austria	Valko, PO (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	philipp.valko@usz.ch	Gavrilov, Yury/AAA-2915-2019; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Baumann, Christian/0000-0003-3417-1978; Gavrilov, Yury/0000-0003-1409-7686	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32003B-125504]; Clinical Research Priority Program "Sleep and Health" of the University of Zurich	This study was supported by the Swiss National Science Foundation (grant No. 32003B-125504) and the Clinical Research Priority Program "Sleep and Health" of the University of Zurich.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Dauvilliers Y, 2013, LANCET NEUROL, V12, P1068, DOI 10.1016/S1474-4422(13)70225-4; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Jego S, 2013, NAT NEUROSCI, V16, P1637, DOI 10.1038/nn.3522; John J, 2013, ANN NEUROL, V74, P786, DOI 10.1002/ana.23968; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Ko EM, 2003, BRAIN RES, V992, P220, DOI 10.1016/j.brainres.2003.08.044; Konadhode RR, 2013, J NEUROSCI, V33, P10257, DOI 10.1523/JNEUROSCI.1225-13.2013; Luppi PH, 2013, SLEEP MED, V14, P714, DOI 10.1016/j.sleep.2013.02.004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Monti JM, 2013, SLEEP MED REV, V17, P293, DOI 10.1016/j.smrv.2012.10.002; Parmentier R, 2002, J NEUROSCI, V22, P7695; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Steininger TL, 1999, BRAIN RES, V840, P138, DOI 10.1016/S0006-8993(99)01648-0; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tabbal SD, 2012, EXP NEUROL, V237, P355, DOI 10.1016/j.expneurol.2012.07.008; Takahashi K, 2006, J NEUROSCI, V26, P10292, DOI 10.1523/JNEUROSCI.2341-06.2006; Valko PO, 2013, ANN NEUROL, V74, P794, DOI 10.1002/ana.24019	20	37	42	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2015	77	1					177	182		10.1002/ana.24298			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AZ7UN	WOS:000348423200017	25363332	Green Accepted			2021-06-18	
J	Schatz, P; Robertshaw, S				Schatz, Philip; Robertshaw, Stacey			Comparing Post-Concussive Neurocognitive Test Data to Normative Data Presents Risks for Under-Classifying "Above Average" Athletes	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; mTBI; Neuropsychological assessment; Baseline assessment	TEST-RETEST RELIABILITY; SPORT-RELATED CONCUSSION; COUNSELING PSYCHOMETRIC ISSUES; IMPACT TEST BATTERY; CONSTRUCT-VALIDITY; CLINICAL UTILITY; RELIABLE CHANGE; RECOVERY; PSYCHOTHERAPY; PERFORMANCE	We compared classification accuracy of post-concussion test data against baseline and normative data, accounting for baseline level of performance. Athletes (N = 250) completed baseline and post-concussion ImPACT assessments, within 7 days of concussion (verified by sports medicine professionals and self-reported symptoms). Athletes were classified as "below average," " average," or "above average" at baseline. Change from baseline was calculated using reliable change indices (RCIs) and regression-based measures (RBz), and comparison to normative data was achieved using z-scores. Normative comparisons identified fewer symptomatic, concussed athletes than RCIs and RBz. Both RCIs and RBz consistently identified "impairment" at 1 and 1.5 SD, regardless of baseline level, whereas normative comparisons identified 46-48% fewer athletes performing "above average" at baseline using a cut-off of 1 SD and 36-38% fewer using a cut-off of 1.5 SD. The use of normative comparisons may differentially classify concussed, symptomatic athletes who are outside the "average" range at baseline.	[Schatz, Philip; Robertshaw, Stacey] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	Dr P.S. has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation and the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications, Inc. However, these entities had no role in the conceptualization of the study, the collection or analysis of data, the writing of the article, or the decision to submit it for publication. Ms S.R. has no Conflict of Interest to declare.	Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Barth JT., 1989, MILD HEAD INJURY, P257; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Collins M. W., 1998, JOURNAL OF HEAD TRAU, V13, P9; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HSU LM, 1995, J CONSULT CLIN PSYCH, V63, P141, DOI 10.1037/0022-006X.63.1.141; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kvalseth TO, 2003, PSYCHOL REP, V93, P1283, DOI 10.2466/PR0.93.7.1283-1290; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2011, IMPACT TECHNICAL MAN, V2013; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Rabinowitz AR, 2012, J INT NEUROPSYCH SOC, V18, P139, DOI 10.1017/S1355617711001275; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P., 2009, THE AMERICAN JOURNAL, V38, P47; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	43	37	37	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2014	29	7					625	632		10.1093/arclin/acu041			8	Psychology, Clinical; Psychology	Psychology	AU9DA	WOS:000345890600003	25178629	Bronze, Green Published			2021-06-18	
J	Sekhon, MS; McBeth, P; Zou, J; Qiao, L; Kolmodin, L; Henderson, WR; Reynolds, S; Griesdale, DEG				Sekhon, Mypinder S.; McBeth, Paul; Zou, Jie; Qiao, Lu; Kolmodin, Leif; Henderson, William R.; Reynolds, Steve; Griesdale, Donald E. G.			Association Between Optic Nerve Sheath Diameter and Mortality in Patients with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Optic nerve sheath diameter; Computed tomography; Traumatic brain injury; Intracranial pressure; Cerebral spinal fluid	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; HYPERTENSION; IMPACT; ULTRASONOGRAPHY; EPIDEMIOLOGY; VALIDATION; DISABILITY; ULTRASOUND; SONOGRAPHY	Increased intracranial pressure (ICP) is associated with worse outcomes following traumatic brain injury (TBI). Studies have confirmed that ICP is correlated with optic nerve sheath diameter (ONSD) on ultrasound. The aim of our study was to assess the independent relationship between ONSD measured using CT and mortality in a population of patients admitted with severe TBI. We conducted a retrospective cohort study of patients with a TBI requiring ICP monitoring admitted to the ICU between April 2006 and May 2012 to two neurotrauma centers. ONSD was independently measured by two physicians blinded to patient outcomes. Multivariable logistic regression modeling was used to assess an association between ONSD and hospital mortality. A total of 220 patients were included in the analysis. Overall, the cohort had a mean age of 35 (SD 17) years and 171 of 220 (79 %) were male. The median admission GCS was 6 (IQR 3-8). Intra-class correlation coefficient between raters for ONSD measurements was 0.92 (95 % CI 0.90-0.94, P < 0.0001). On multivariable analysis, each 1 mm increase in ONSD was associated with a twofold increase in hospital mortality (OR 2.0, 95 % CI 1.2-3.2, P = 0.007). Using linear regression, ONSD was independently associated with increased ICP in the first 48 h after admission (beta = 4.4, 95 % CI 2.5-6.3, P < 0.0001). In patients with TBI, ONSD measured on CT scanning was independently associated with ICP and mortality.	[Sekhon, Mypinder S.; McBeth, Paul; Zou, Jie; Qiao, Lu; Kolmodin, Leif; Henderson, William R.; Griesdale, Donald E. G.] Univ British Columbia, Div Crit Care Med, Dept Med, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada; [Reynolds, Steve] Univ British Columbia, Dept Crit Care Med, Royal Columbian Hosp, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.] Univ British Columbia, Ctr Clin Epidemiol & Evaluat, Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada	Sekhon, MS (corresponding author), Univ British Columbia, Div Crit Care Med, Dept Med, Vancouver Gen Hosp, Room 2438,Jim Pattison Pavil,2nd Floor, Vancouver, BC V5Z 1M9, Canada.	mypindersekhon@gmail.com		Griesdale, Donald/0000-0001-5985-8624	VGH & UBC Hospital Foundation Best of Health Fund	We would like to acknowledge the staff of the Vancouver General and Royal Columbian Hospitals for their support in the completion of this study. Dr. Griesdale is funded by the VGH & UBC Hospital Foundation Best of Health Fund.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Launey Y, 2014, J NEUROTRAUM, V31, P984, DOI 10.1089/neu.2012.2829; Legrand A, 2013, CRIT CARE, V17, DOI 10.1186/cc12589; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Moretti R, 2011, ACTA ANAESTH SCAND, V55, P644, DOI 10.1111/j.1399-6576.2011.02432.x; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Potgieter DW, 2011, ANAESTH INTENS CARE, V39, P95, DOI 10.1177/0310057X1103900116; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	33	37	40	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2014	21	2					245	252		10.1007/s12028-014-0003-y			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AQ9AR	WOS:000343132900011	24969027				2021-06-18	
J	Weber, DJ; Gracon, ASA; Ripsch, MS; Fisher, AJ; Cheon, BM; Pandya, PH; Vittal, R; Capitano, ML; Kim, Y; Allette, YM; Riley, AA; McCarthy, BP; Territo, PR; Hutchins, GD; Broxmeyer, HE; Sandusky, GE; White, FA; Wilkes, DS				Weber, Daniel J.; Gracon, Adam S. A.; Ripsch, Matthew S.; Fisher, Amanda J.; Cheon, Bo M.; Pandya, Pankita H.; Vittal, Ragini; Capitano, Maegan L.; Kim, Youngsong; Allette, Yohance M.; Riley, Amanda A.; McCarthy, Brian P.; Territo, Paul R.; Hutchins, Gary D.; Broxmeyer, Hal E.; Sandusky, George E.; White, Fletcher A.; Wilkes, David S.			The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation	SCIENCE TRANSLATIONAL MEDICINE			English	Article							GLYCATION END-PRODUCTS; MOBILITY GROUP BOX-1; THERAPEUTIC TARGET; RECEPTOR DOMAIN; RAGE; INFLAMMATION; ACTIVATION; MIGRATION; CONTRIBUTES; APOPTOSIS	Traumatic brain injury (TBI) results in systemic inflammatory responses that affect the lung. This is especially critical in the setting of lung transplantation, where more than half of donor allografts are obtained postmortem from individuals with TBI. The mechanism by which TBI causes pulmonary dysfunction remains unclear but may involve the interaction of high-mobility group box-1 (HMGB1) protein with the receptor for advanced glycation end products (RAGE). To investigate the role of HMGB1 and RAGE in TBI-induced lung dysfunction, RAGE-sufficient (wild-type) or RAGE-deficient (RAGE(-/-)) C57BL/6 mice were subjected to TBI through controlled cortical impact and studied for cardiopulmonary injury. Compared to control animals, TBI induced systemic hypoxia, acute lung injury, pulmonary neutrophilia, and decreased compliance (a measure of the lungs' ability to expand), all of which were attenuated in RAGE(-/-) mice. Neutralizing systemic HMGB1 induced by TBI reversed hypoxia and improved lung compliance. Compared to wild-type donors, lungs from RAGE(-/-) TBI donors did not develop acute lung injury after transplantation. In a study of clinical transplantation, elevated systemic HMGB1 in donors correlated with impaired systemic oxygenation of the donor lung before transplantation and predicted impaired oxygenation after transplantation. These data suggest that the HMGB1-RAGE axis plays a role in the mechanism by which TBI induces lung dysfunction and that targeting this pathway before transplant may improve recipient outcomes after lung transplantation.	[Weber, Daniel J.; Gracon, Adam S. A.; Fisher, Amanda J.; Pandya, Pankita H.; Vittal, Ragini; White, Fletcher A.; Wilkes, David S.] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA; [Weber, Daniel J.; Gracon, Adam S. A.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Ripsch, Matthew S.; Fisher, Amanda J.; Cheon, Bo M.; Kim, Youngsong; Allette, Yohance M.; White, Fletcher A.] Indiana Univ Sch Med, Dept Anesthesia, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Pandya, Pankita H.; Vittal, Ragini; Capitano, Maegan L.; Broxmeyer, Hal E.; Wilkes, David S.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Riley, Amanda A.; McCarthy, Brian P.; Territo, Paul R.; Hutchins, Gary D.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Sandusky, George E.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA	Wilkes, DS (corresponding author), Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA.	dwilkes@iupui.edu	VITTAL, RAGINI/AAE-9052-2020; White, Fletcher/F-3203-2015	White, Fletcher/0000-0002-8408-9262	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL096845]; National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P01AI084853, R01 DK100905]; Indiana Spinal Cord and Brain Injury Research Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL109288, R01HL096845, R01HL112669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P01AI084853, P01AI056097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK100905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM077229] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002209] Funding Source: NIH RePORTER	Funding: This work was supported by NIH grants R01 HL096845 and National Institute of Allergy and Infectious Diseases P01AI084853 to D. S. W., and R01 DK100905 and Indiana Spinal Cord and Brain Injury Research Fund to F.A.W.	Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bhangoo S, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-38; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bierhaus A, 2004, J CLIN INVEST, V114, P1741, DOI 10.1172/JCI200418058; Bittle GJ, 2013, J HEART LUNG TRANSPL, V32, P760, DOI 10.1016/j.healun.2013.04.012; Bopp C, 2008, CRIT CARE, V12, DOI 10.1186/cc6164; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Buckley ST, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/917108; Christie JD, 2009, AM J RESP CRIT CARE, V180, P1010, DOI 10.1164/rccm.200901-0118OC; Cypel M, 2013, CURR OPIN ORGAN TRAN, V18, P513, DOI 10.1097/MOT.0b013e328365191b; Cypel M, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000266; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Fan L, 2011, AM J TRANSPLANT, V11, P911, DOI 10.1111/j.1600-6143.2011.03482.x; Feldman P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-180; Fitzgerald KA, 2006, CELL, V125, P834, DOI 10.1016/j.cell.2006.05.014; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hreggvidsdottir HS, 2012, MOL MED, V18, P224, DOI 10.2119/molmed.2011.00327; Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Iori V, 2013, NEUROBIOL DIS, V58, P102, DOI 10.1016/j.nbd.2013.03.006; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kreissl MC, 2006, J NUCL MED, V47, P974; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; PROFANT M, 1978, SIAM J APPL MATH, V34, P666, DOI 10.1137/0134053; Putranto EW, 2013, INT J MOL MED, V32, P938, DOI 10.3892/ijmm.2013.1467; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Qin YH, 2009, J IMMUNOL, V183, P6244, DOI 10.4049/jimmunol.0900390; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Raman KG, 2006, AM J PHYSIOL-GASTR L, V291, pG556, DOI 10.1152/ajpgi.00055.2006; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Rouhiainen A, 2004, BLOOD, V104, P1174, DOI 10.1182/blood-2003-10-3536; Rouhiainen Ari, 2013, Methods Mol Biol, V963, P239, DOI 10.1007/978-1-62703-230-8_15; Rouze NC, 2004, IEEE T NUCL SCI, V51, P757, DOI 10.1109/TNS.2004.829738; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Sharma AK, 2013, AM J TRANSPLANT, V13, P2255, DOI 10.1111/ajt.12368; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sirois CM, 2013, J EXP MED, V210, P2447, DOI 10.1084/jem.20120201; Soon VC, 2007, IEEE NUCL SCI CONF R, P3468, DOI 10.1109/NSSMIC.2007.4436877; Studholme C, 1998, P SOC PHOTO-OPT INS, V3338, P132, DOI 10.1117/12.310835; Toshchakov VY, 2011, J IMMUNOL, V186, P4819, DOI 10.4049/jimmunol.1002424; Toshchakov VU, 2005, J IMMUNOL, V175, P494, DOI 10.4049/jimmunol.175.1.494; Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Zoelen MAD, 2009, SHOCK, V31, P280, DOI 10.1097/SHK.0b013e318186262d; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wolfson RK, 2011, MICROVASC RES, V81, P189, DOI 10.1016/j.mvr.2010.11.010; Wu XJ, 2013, MOL CELL BIOCHEM, V380, P249, DOI 10.1007/s11010-013-1680-0; Yang D, 2007, J LEUKOCYTE BIOL, V81, P59, DOI 10.1189/jlb.0306180; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Zampell JC, 2011, AM J PHYSIOL-CELL PH, V300, pC1107, DOI 10.1152/ajpcell.00378.2010; Zandarashvili L, 2013, J BIOL CHEM, V288, P11621, DOI 10.1074/jbc.M113.449942	63	37	38	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	SEP 3	2014	6	252							252ra124	10.1126/scitranslmed.3009443			12	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	AO4KD	WOS:000341305400008	25186179	Green Accepted			2021-06-18	
J	Baral, A; Ye, HX; Jiang, PC; Yao, Y; Mao, Y				Baral, Aparajita; Ye, Hong Xing; Jiang, Pu Cha; Yao, Yu; Mao, Ying			B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients	ONCOLOGY LETTERS			English	Article						glioma; B7 family; B7-H3; B7-H1; cerebral spinal fluid; blood serum	COSTIMULATORY MOLECULE B7-H3; HUMAN PANCREATIC-CANCER; T-CELL ACTIVATION; CARCINOMA; MELANOMA; SURVIVAL; PROGNOSIS; RESPONSES; THERAPY; ANTIGEN	The B7 family consists of activating and inhibitory molecules that regulate immune responses. Recent research demonstrated the roles of soluble B7-H3 (sB7-H3) and soluble B7-H1 (sB7-H1) in the blood serum of various tumors; however, none of these studies investigated the expression of these proteins in the cerebral spinal fluid (CSF) and blood serum of patients with glioma. The aim of the present study was to investigate the expression of B7-H3 and B7-H1 in the CSF, blood serum and tissues of patients with glioma and their correlation with clinicopathological data. Between January 2012 and November 2012, samples were obtained from 78 patients with glioma, four CSF samples were obtained from patients with a moderate traumatic brain injury, four brain tissue samples were obtained from patients with a traumatic brain injury and 40 blood serum samples were obtained from healthy individuals. The expression of B7-H3 and B7-H1 in the CSF, blood serum and tumor samples of the patients with high-grade glioma was found to be higher than that in the patients with low-grade glioma. However, no significant differences in sB7-H3 and sB7-H1 expression were observed in the blood serum of the patients with glioma compared with the healthy control subjects. In addition, the expression of sB7-H3 and sB7-H1 in the CSF of the patients with glioma was higher than that in the CSF of the patients with a moderate traumatic brain injury. Furthermore, in the patients with glioma, B7-H3 and B7-H1 expression in the CSF and tumor tissue, although not in the blood serum, correlated with the glioma grade.	[Baral, Aparajita; Jiang, Pu Cha] Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan 430071, Hubei, Peoples R China; [Baral, Aparajita; Ye, Hong Xing; Yao, Yu; Mao, Ying] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China; [Mao, Ying] Fudan Univ, State Key Lab Med Neurobiol, Inst Biomed Sci, Shanghai 200032, Peoples R China	Yao, Y (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurosurg, 12 Wulumuqi Rd, Shanghai 200040, Peoples R China.	yu_yao03@126.com; yingmao168@hotmail.com			National Science Foundation for Distinguished Young Scholars of ChinaNational Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars [81272797]; Innovation Program of Shanghai Municipal Education CommissionInnovation Program of Shanghai Municipal Education Commission [13ZZ010]	The present study was supported by a grant from the National Science Foundation for Distinguished Young Scholars of China (grant no. 81272797) that was awarded to Professor Ying Mao and a grant from the Innovation Program of Shanghai Municipal Education Commission (grant no. 13ZZ010), which was awarded to Professor Yu Yao.	Boorjian SA, 2008, CLIN CANCER RES, V14, P4800, DOI 10.1158/1078-0432.CCR-08-0731; Chapoval AI, 2001, NAT IMMUNOL, V2, P269, DOI 10.1038/85339; Chen XQ, 2009, J MOL NEUROSCI, V37, P86, DOI 10.1007/s12031-008-9133-z; Chen YW, 2008, CURR CANCER DRUG TAR, V8, P404, DOI 10.2174/156800908785133141; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Frigola X, 2011, CLIN CANCER RES, V17, P1915, DOI 10.1158/1078-0432.CCR-10-0250; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Hashiguchi M, 2008, P NATL ACAD SCI USA, V105, P10495, DOI 10.1073/pnas.0802423105; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lemke D, 2012, CLIN CANCER RES, V18, P105, DOI 10.1158/1078-0432.CCR-11-0880; Loos M, 2008, CANCER LETT, V268, P98, DOI 10.1016/j.canlet.2008.03.056; Loos M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-463; Luo LQ, 2004, J IMMUNOL, V173, P5445, DOI 10.4049/jimmunol.173.9.5445; Ma LX, 2007, J HEPATOL, V46, P98, DOI 10.1016/j.jhep.2006.07.031; MERIMSKY O, 1994, TUMOR BIOL, V15, P188, DOI 10.1159/000217892; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Streit M, 2003, ONCOGENE, V22, P3172, DOI 10.1038/sj.onc.1206457; Suh WK, 2003, NAT IMMUNOL, V4, P899, DOI 10.1038/ni967; Sun J, 2010, CANCER IMMUNOL IMMUN, V59, P1163, DOI 10.1007/s00262-010-0841-1; Sun YP, 2006, LUNG CANCER-J IASLC, V53, P143, DOI 10.1016/j.lungcan.2006.05.012; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Wu CP, 2006, WORLD J GASTROENTERO, V12, P457, DOI 10.3748/wjg.v12.i3.457; Yamato I, 2009, BRIT J CANCER, V101, P1709, DOI 10.1038/sj.bjc.6605375; Yao Y, 2009, NEURO-ONCOLOGY, V11, P757, DOI 10.1215/15228517-2009-014; Zang XX, 2010, MODERN PATHOL, V23, P1104, DOI 10.1038/modpathol.2010.95; Zhang GB, 2008, IMMUNOLOGY, V123, P538, DOI 10.1111/j.1365-2567.2007.02723.x	28	37	39	0	12	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	SEP	2014	8	3					1195	1201		10.3892/ol.2014.2268			7	Oncology	Oncology	AN8LB	WOS:000340854600046	25120686	Green Published, Bronze			2021-06-18	
J	Longhi, L; Orsini, F; De Blasio, D; Fumagalli, S; Ortolano, F; Locatelli, M; Stocchetti, N; De Simoni, MG				Longhi, Luca; Orsini, Franca; De Blasio, Daiana; Fumagalli, Stefano; Ortolano, Fabrizio; Locatelli, Marco; Stocchetti, Nino; De Simoni, Maria-Grazia			Mannose-Binding Lectin Is Expressed After Clinical and Experimental Traumatic Brain Injury and Its Deletion Is Protective	CRITICAL CARE MEDICINE			English	Article						complement system; inflammation; mannose-binding lectin; pathophysiology; traumatic brain injury	CONTROLLED CORTICAL IMPACT; LONG-LASTING PROTECTION; COMPLEMENT ACTIVATION; CONTUSION VOLUME; DEFICIENCY; SYSTEM; INHIBITION; PATHWAY; MICE	Objective: Mannose-binding lectin protein is the activator of the lectin complement pathway. Goals were 1) to investigate mannose-binding lectin expression after human and experimental traumatic brain injury induced by controlled cortical impact and 2) to evaluate whether mannose-binding lectin deletion is associated with reduced sequelae after controlled cortical impact. Design: Translational research, combining a human/experimental observational study and a prospective experimental study. Setting: University hospital/research laboratory. Patients and Subjects: Brain-injured patients, C57Bl/6 mice, and mannose-binding lectin-A and mannose-binding lectin-C double-knockout (-/-) mice. Interventions: Using anti-human mannose-binding lectin antibody, we evaluated mannose-binding lectin expression in tissue samples from six patients who underwent surgery for a cerebral contusion. Immunohistochemistry was also performed on tissues obtained from mice at 30 minutes; 6, 12, 24, 48, and 96 hours; and 1 week after controlled cortical impact using anti-mouse mannose-binding lectin-A and mannose-binding lectin-C antibodies. We evaluated the effects of mannose-binding lectin deletion in wild-type and mannose-binding lectin-A and mannose-binding lectin-C double-knockout mice. Functional outcome was evaluated using the neuroscore and beam walk tests for 4 weeks postinjury (n = 11). Histological injury was evaluated by comparing neuronal cell counts in the cortex adjacent to the contusion (n = 11). Measurements and Main Results: Following human traumatic brain injury, we observed mannose-binding lectin-positive immunostaining in the injured cortex as early as few hours and up to 5 days postinjury. Similarly in mice, we observed mannose-binding lectin-C-positive immunoreactivity in the injured cortex beginning 30 minutes and persisting up to 1 week postinjury. The extent of mannose-binding lectin-A expression was lower when compared with that of mannose-binding lectin-C. We observed attenuated sensorimotor deficits in mannose-binding lectin (-/-) mice compared with wild-type mice at 2-4 weeks postinjury. Furthermore, we observed reduced cortical cell loss at 5 weeks postinjury in mannose-binding lectin (-/-) mice compared with wild-type mice. Conclusions: Mannose-binding lectin expression was documented after traumatic brain injury. The reduced sequelae associated with mannose-binding lectin absence suggest that mannose-binding lectin modulation might be a potential target after traumatic brain injury.	[Longhi, Luca; Fumagalli, Stefano; Ortolano, Fabrizio; Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplantat, Neurosurg Intens Care Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Orsini, Franca; De Blasio, Daiana; Fumagalli, Stefano; De Simoni, Maria-Grazia] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [De Blasio, Daiana] Univ G dAnnunzio, Dept Biomed Sci, Pescara, Italy; [Locatelli, Marco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosurg, Milan, Italy; Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; Mario Negri Inst Pharmacol Res, Milan, Italy	De Simoni, MG (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy.	desimoni@marionegri.it	Fumagalli, Stefano/I-3097-2019; Longhi, Luca/AAF-9903-2021; De Simoni, Maria Grazia/I-6021-2012; Stocchetti, Nino/O-7444-2017	Longhi, Luca/0000-0001-9894-8788; De Simoni, Maria Grazia/0000-0001-6695-5297; Stocchetti, Nino/0000-0003-3250-6834; Ortolano, Fabrizio/0000-0003-1996-948X; Orsini, Franca/0000-0001-7415-9936; locatelli, marco/0000-0003-0778-3653; Fumagalli, Stefano/0000-0003-3598-6263	Fondazione CariploFondazione Cariplo [2012-0590]	Dr. Longhi received grant support from Fondazione Cariplo (grant number 2012-0590). His institution received grant support from Fondazione Cariplo (the study was done as part of a funded research project on brain trauma). Dr. Orsini was funded by fellowship in memory of Mrs. Amalia Ghezzi. Dr. Fumagalli's institution received grant support from - Fondazione Cariplo. Dr. De Simoni received support for article research from - Fondazione Cariplo (grant number 2012-0590). Her institution received grant support (the study was done as part of a funded research project on brain trauma). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433; Endo Y, 2011, INT J BIOCHEM CELL B, V43, P705, DOI 10.1016/j.biocel.2011.02.003; Farber K, 2009, J NEUROSCI RES, V87, P644, DOI 10.1002/jnr.21875; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Hansen S, 2000, J IMMUNOL, V164, P2610, DOI 10.4049/jimmunol.164.5.2610; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Orsini F, 2012, CIRCULATION, V126, P1484, DOI 10.1161/CIRCULATIONAHA.112.103051; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Osthoff M, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-99; Osthoff M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021338; Pedersen ED, 2009, SCAND J IMMUNOL, V69, P555, DOI 10.1111/j.1365-3083.2009.02253.x; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Trendelenburg M, 2010, EUR HEART J, V31, P1181, DOI 10.1093/eurheartj/ehp597; van der Pol P, 2012, AM J TRANSPLANT, V12, P877, DOI 10.1111/j.1600-6143.2011.03887.x; Wagner S, 2003, J IMMUNOL, V170, P1462, DOI 10.4049/jimmunol.170.3.1462; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	32	37	37	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2014	42	8					1910	1918		10.1097/CCM.0000000000000399			9	Critical Care Medicine	General & Internal Medicine	AL7QV	WOS:000339330700041	24810526				2021-06-18	
J	Oliveira, MD; Kairalla, AC; Fonoff, ET; Martinez, RCR; Teixeira, MJ; Bor-Seng-Shu, E				Oliveira, Marcelo de Lima; Kairalla, Ana Carolina; Fonoff, Erich Talamoni; Ruiz Martinez, Raquel Chacon; Teixeira, Manoel Jacobsen; Bor-Seng-Shu, Edson			Cerebral Microdialysis in Traumatic Brain Injury and Subarachnoid Hemorrhage: State of the Art	NEUROCRITICAL CARE			English	Article						Microdialysis; Metabolism; Brain injury; Monitoring; Subarachnoid hemorrhage; Critical care	PENTOSE-PHOSPHATE PATHWAY; PERFUSION-PRESSURE; METABOLIC CRISIS; INTRACRANIAL HYPERTENSION; GLUCOSE-METABOLISM; BLOOD-FLOW; LACTATE; RATIO; AUTOREGULATION; ASSOCIATION	Cerebral microdialysis (CMD) is a laboratory tool that provides on-line analysis of brain biochemistry via a thin, fenestrated, double-lumen dialysis catheter that is inserted into the interstitium of the brain. A solute is slowly infused into the catheter at a constant velocity. The fenestrated membranes at the tip of the catheter permit free diffusion of molecules between the brain interstitium and the perfusate, which is subsequently collected for laboratory analysis. The major molecules studied using this method are glucose, lactate, pyruvate, glutamate, and glycerol. The collected substances provide insight into the neurochemical features of secondary injury following traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) and valuable information about changes in brain metabolism within a short time frame. In this review, the authors detail the CMD technique and its associated markers and then describe pertinent findings from the literature about the clinical application of CMD in TBI and SAH.	[Oliveira, Marcelo de Lima; Kairalla, Ana Carolina; Fonoff, Erich Talamoni; Teixeira, Manoel Jacobsen; Bor-Seng-Shu, Edson] Univ Sao Paulo, Sch Med, Div Neurol Surg, Hosp Clin, BR-04040001 Sao Paulo, Brazil; [Ruiz Martinez, Raquel Chacon] Univ Sao Paulo, Dept Surg, Sch Med, Discipline Surg Tech, BR-04040001 Sao Paulo, Brazil	Bor-Seng-Shu, E (corresponding author), Univ Sao Paulo, Sch Med, Div Neurol Surg, Hosp Clin, Rua Loefgreen,1-272 Vila Clementino, BR-04040001 Sao Paulo, Brazil.	edsonshu@hotmail.com	BOR-SENG-SHU, EDSON/AAC-9762-2019; Fonoff, Erich Talamoni/E-4327-2012	BOR-SENG-SHU, EDSON/0000-0002-6713-8974; Fonoff, Erich Talamoni/0000-0001-7831-9941; de-Lima-Oliveira, Marcelo/0000-0002-7418-1516			Asgari S, 2013, NEUROCRIT CARE, V19, P56, DOI 10.1007/s12028-013-9821-6; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Bor-Seng-Shu E, 2013, NEUROSURG REV, V36, P361, DOI 10.1007/s10143-013-0453-2; Bor-Seng-Shu E, 2010, J NEUROSURG, V112, P1351, DOI 10.3171/2009.10.JNS091426; Bouras T, 2021, J NEUROTRAUM, V38, P1137, DOI 10.1089/neu.2011.1790; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; De Andrade AF, 2012, ARQ NEURO-PSIQUIAT, V70, P640, DOI 10.1590/S0004-282X2012000800017; De Fazio M, 2011, NEUROCRIT CARE, V14, P91, DOI 10.1007/s12028-010-9494-3; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Guiza F, 2013, NEUROL CRIT CARE, DOI [10.1097/CCM.0b013e3182742d0a, DOI 10.1097/CCM.0B013E3182]; Hanggi D, 2011, NEUROCRIT CARE, V15, P318, DOI 10.1007/s12028-011-9583-y; Helbok R, 2011, STROKE, V42, P1534, DOI 10.1161/STROKEAHA.110.604488; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2008, CRIT CARE MED, V36, P2952, DOI 10.1097/CCM.0b013e3181872178; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Klaus S, 2004, CRIT CARE, V8, P363, DOI 10.1186/cc2882; Kristal BS, 1997, J NEUROCHEM, V69, P524; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mendelowitsch A, 2001, METHODS, V23, P73, DOI 10.1006/meth.2000.1107; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Nordstrom CH, 2010, CHILD NERV SYST, V26, P465, DOI 10.1007/s00381-009-1035-z; Nordstron CH, 2010, CHILD NERV SYST, V26, P456; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; RONQUIST G, 1992, ACTA NEUROCHIR, V114, P8, DOI 10.1007/BF01401106; Rooyackers O, 2004, CURR OPIN CLIN NUTR, V7, P515, DOI 10.1097/00075197-200409000-00003; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Schlenk F, 2008, CRIT CARE, V12, P1; Schlenk F, 2009, CRIT CARE, V13, DOI 10.1186/cc7689; Soehle M, 2007, ACTA NEUROCHIR, V149, P575, DOI 10.1007/s00701-007-1149-6; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stahl N, 2013, ACTA ANAESTHSIOL SCA, V45, P977; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wartenberg KE, 2011, CURR OPIN CRIT CARE, V17, P85, DOI 10.1097/MCC.0b013e328342f83d; Westermaier T, 2011, NEUROSURGERY, V68, P223, DOI 10.1227/NEU.0b013e3181fe23c1; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725; Zetterling M, 2011, J NEUROSURG, V115, P66, DOI 10.3171/2011.3.JNS10899	68	37	37	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2014	21	1					152	162		10.1007/s12028-013-9884-4			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AL7XP	WOS:000339350500023	24072457				2021-06-18	
J	Liu, J; Kou, ZF; Tian, YQ				Liu, Jun; Kou, Zhifeng; Tian, Yongquan			Diffuse axonal injury after traumatic cerebral microbleeds: an evaluation of imaging techniques	NEURAL REGENERATION RESEARCH			English	Article						nerve regeneration; neuroimaging; traumatic brain injury; cerebral microbleeds; diffuse axonal injury; gradient-recalled-echo; susceptibility weighted imaging; review; neural regeneration	BRAIN-INJURY; OUTCOMES; CELLS; IDENTIFICATION; HYPERTENSION; MODULATION; ACTIVATION; CHILDREN; EFFICACY; FIELD	Previous neuropathological studies regarding traumatic brain injury have primarily focused on changes in large structures, for example, the clinical prognosis after cerebral contusion, intracerebral hematoma, and epidural and subdural hematoma. In fact, many smaller injuries can also lead to severe neurological disorders. For example, cerebral microbleeds result in the dysfunction of adjacent neurons and the disassociation between cortex and subcortical structures. These tiny changes cannot be adequately visualized on CT or conventional MRI. In contrast, gradient echo sequence-based susceptibility-weighted imaging is very sensitive to blood metabolites and microbleeds, and can be used to evaluate traumatic cerebral microbleeds with high sensitivity and accuracy. Cerebral microbleed can be considered as an important imaging marker for diffuse axonal injury with potential relevance for prognosis. For this reason, based on experimental and clinical studies, this study reviews the role of imaging data showing traumatic cerebral microbleeds in the evaluation of cerebral neuronal injury and neurofunctional loss.	[Liu, Jun] Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha 410083, Hunan, Peoples R China; [Liu, Jun; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Biomed Engn & Radiol, Detroit, MI USA; [Liu, Jun; Tian, Yongquan] Cent South Univ, Sch Publ Adm, Changsha 410083, Hunan, Peoples R China	Tian, YQ (corresponding author), Cent South Univ, Sch Publ Adm, Changsha 410083, Hunan, Peoples R China.	tianyq@csu.edu.cn	liu, jun/AAW-9645-2020	liu, jun/0000-0002-0344-4745	Hunan Provincial Science and Technology Department [2009FJ3092]	Funding: This study was supported by grants from the State-Funded Construction Projects Key Clinical Specialist (2013-2015) and the Hunan Provincial Science and Technology Department, No. 2009FJ3092.	Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Cai J, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-306; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chen CT, 2014, HYPERTENSION, V63, P61, DOI 10.1161/HYPERTENSIONAHA.113.01838; Chen CH, 2013, OPT LETT, V38, P3137, DOI 10.1364/OL.38.003137; Chen JJ, 2013, PSYCHIAT RES, V210, P1260, DOI 10.1016/j.psychres.2013.09.007; Costello MG, 2013, J NEUROSCI, V33, P16394, DOI 10.1523/JNEUROSCI.1899-13.2013; Ding YM, 2013, BIOMED OPT EXPRESS, V4, P2518, DOI 10.1364/BOE.4.002518; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fu YY, 2013, CHEM COMMUN, V49, P11266, DOI 10.1039/c3cc46571c; Gao JZ, 2013, INT J MED SCI, V10, P1560, DOI 10.7150/ijms.6611; Gao XH, 2014, MOL BIOL REP, V41, P467, DOI 10.1007/s11033-013-2881-z; GLENSKI JA, 1984, MAYO CLIN PROC, V59, P530, DOI 10.1016/S0025-6196(12)61490-6; Guo Q, 2014, EUR J CLIN MICROBIOL, V33, P465, DOI 10.1007/s10096-013-1979-5; Guo Z, 2013, THER HYPOTHERMIA TEM, V3, P126, DOI 10.1089/ther.2013.0006; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; HOSKING MP, 1989, JAMA-J AM MED ASSOC, V261, P1909; Hou W, 2013, DALTON T, V43, P865; Jiang X, 2013, LECT NOTES COMPUT SC, V8150, P674, DOI 10.1007/978-3-642-40763-5_83; Ju MJ, 2013, CRIT CARE, V17, DOI 10.1186/cc13053; Kang FX, 2013, J ENVIRON QUAL, V42, P1441, DOI 10.2134/jeq2012.0499; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krishna Ranga, 2012, J Med Case Rep, V6, P66, DOI 10.1186/1752-1947-6-66; Labaceno Gainza D, 1989, Rev Cubana Enferm, V5, P51; Li P, 2013, DIABETES RES CLIN PR, V102, P35, DOI 10.1016/j.diabres.2013.08.009; Li QH, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-415; Lin Sheyu, 2013, Tsitol Genet, V47, P22; Liu Dan, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P584, DOI 10.3760/cma.j.issn.2095-4352.2013.10.003; Liu Q, 2013, ARCH VIROL; Lu QS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-651; Metting Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064461; Mori Y, 2014, INT IMMUNOL, V26, P93, DOI 10.1093/intimm/dxt044; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Seghier ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017547; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi L, 2013, CHEM COMMUN, V50, P872; Shi R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071242; Shimizu A, 2013, SCI REP-UK, V3, DOI 10.1038/srep03097; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Song B, 2013, CIRC J, V77, P2997, DOI 10.1253/circj.CJ-13-0805; Sun CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3717; Sun MY, 2013, ACS APPL MATER INTER, V5, P12681, DOI 10.1021/am4040224; Tao RR, 2014, ANTIOXID REDOX SIGN, V21, P1, DOI 10.1089/ars.2013.5381; Tchekmedyian A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079639; Tie GP, 2013, APPL OPTICS, V52, P6645, DOI 10.1364/AO.52.006645; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wang HY, 2014, CYTOTHERAPY, V16, P309, DOI 10.1016/j.jcyt.2013.07.011; Wang L, 2013, ISRN NEUROL, V2013; Wang XY, 2014, FOOD CHEM, V145, P984, DOI 10.1016/j.foodchem.2013.09.021; Wang Y, 2014, J AFFECT DISORDERS, V152, P131, DOI 10.1016/j.jad.2013.08.010; Wang Yu-peng, 2013, Zhonghua Xin Xue Guan Bing Za Zhi, V41, P587; WARNER DO, 1988, AM REV RESPIR DIS, V137, P90, DOI 10.1164/ajrccm/137.1.90; WARNER MA, 1988, ANN SURG, V207, P380, DOI 10.1097/00000658-198804000-00003; WARNER MA, 1988, J UROLOGY, V139, P486, DOI 10.1016/S0022-5347(17)42499-2; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wei LJ, 2014, MICROBIOL RES, V169, P469, DOI 10.1016/j.micres.2013.08.002; Wu X, 2013, ACS APPL MATER INTER, V5, P10895, DOI 10.1021/am403092m; Xiao JZ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003325; Xiao ZH, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-200; Xu XG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078106; Yang D, 2014, CELL MOL IMMUNOL, V11, P71, DOI 10.1038/cmi.2013.43; Yin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080851; Zen K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3436; Zeng YB, 2013, REV SCI INSTRUM, V84, DOI 10.1063/1.4822113; Zhang DM, 2014, ENVIRON POLLUT, V184, P123, DOI 10.1016/j.envpol.2013.08.022; Zhang J, 2014, HUM BRAIN MAPP, V35, P3314, DOI 10.1002/hbm.22404; Zhang S, 2014, AM J EMERG MED, V32, P92, DOI 10.1016/j.ajem.2013.10.009; Zhang ZZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-229; Zhao Chen, 2013, Zhonghua Yi Xue Za Zhi, V93, P2309; Zhong Xiao-Fei, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P646; Zhou WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072102; Zhu BB, 2013, OPT LETT, V38, P3496, DOI 10.1364/OL.38.003496; Zhu D, 2013, REP PROG PHYS, V76, DOI 10.1088/0034-4885/76/10/106501; Zhu D, 2013, NEUROIMAGE; Zhu D, 2013, BIOCH PHARM; Zhu DQ, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-131; Zhu DJ, 2014, HUM BRAIN MAPP, V35, P2911, DOI 10.1002/hbm.22373; Zhu DM, 2013, IEEE ACM T COMPUT BI, V10, P1469, DOI 10.1109/TCBB.2013.127; Zhu DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078501; Zhu DY, 2014, BIO-MED MATER ENG, V24, P741, DOI 10.3233/BME-130862; Zhu D, 2013, BIOORG MED CHEM LETT, V23, P6274, DOI 10.1016/j.bmcl.2013.09.083; Zhu DL, 2013, CHINESE MED J-PEKING, V126, P4072, DOI 10.3760/cma.j.issn.0366-6999.20123345; Zhu X, 2013, EUR ARCH OTORHINOLAR	84	37	39	0	29	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	JUN	2014	9	12					1222	1230		10.4103/1673-5374.135330			9	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	AL0FY	WOS:000338804000010	25206786	DOAJ Gold, Green Published			2021-06-18	
J	Weiner, MW; Veitch, DP; Hayes, J; Neylan, T; Grafman, J; Aisen, PS; Petersen, RC; Jack, C; Jagust, W; Trojanowski, JQ; Shaw, LM; Saykin, AJ; Green, RC; Harvey, D; Toga, AW; Friedl, KE; Pacifico, A; Sheline, Y; Yaffe, K; Mohlenoff, B				Weiner, Michael W.; Veitch, Dallas P.; Hayes, Jacqueline; Neylan, Thomas; Grafman, Jordan; Aisen, Paul S.; Petersen, Ronald C.; Jack, Clifford; Jagust, William; Trojanowski, John Q.; Shaw, Leslie M.; Saykin, Andrew J.; Green, Robert C.; Harvey, Danielle; Toga, Arthur W.; Friedl, Karl E.; Pacifico, Anthony; Sheline, Yvette; Yaffe, Kristine; Mohlenoff, Brian		Dept Def Alzheimer's Dis	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative	ALZHEIMERS & DEMENTIA			English	Article						Traumatic brain injury; Posttraumatic stress disorder; Alzheimer's disease; Veterans; Neuroimaging	AMYLOID PROTEIN DEPOSITION; MILD COGNITIVE IMPAIRMENT; ADDICTION SEVERITY INDEX; HEAD-INJURY; APOLIPOPROTEIN-E; CEREBROSPINAL-FLUID; BIOMARKER SIGNATURE; N-ACETYLASPARTATE; FLORBETAPIR F-18; TERM SURVIVORS	Both traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are common problems resulting from military service, and both have been associated with increased risk of cognitive decline and dementia resulting from Alzheimer's disease (AD) or other causes. This study aims to use imaging techniques and biomarker analysis to determine whether traumatic brain injury (TBI) and/or PTSD resulting from combat or other traumas increase the risk for AD and decrease cognitive reserve in Veteran subjects, after accounting for age. Using military and Department of Veterans Affairs records, 65 Vietnam War veterans with a history of moderate or severe TBI with or without PTSD, 65 with ongoing PTSD without TBI, and 65 control subjects are being enrolled in this study at 19 sites. The study aims to select subject groups that are comparable in age, gender, ethnicity, and education. Subjects with mild cognitive impairment (MCI) or dementia are being excluded. However, a new study just beginning, and similar in size, will study subjects with TBI, subjects with PTSD, and control subjects with MCI. Baseline measurements of cognition, function, blood, and cerebrospinal fluid biomarkers; magnetic resonance images (structural, diffusion tensor, and resting state blood-level oxygen dependent (BOLD) functional magnetic resonance imaging); and amyloid positron emission tomographic (PET) images with florbetapir are being obtained. One-year follow-up measurements will be collected for most of the baseline procedures, with the exception of the lumbar puncture, the PET imaging, and apolipoprotein E genotyping. To date, 19 subjects with TBI only, 46 with PTSD only, and 15 with TBI and PTSD have been recruited and referred to 13 clinics to undergo the study protocol. It is expected that cohorts will be fully recruited by October 2014. This study is a first step toward the design and statistical powering of an AD prevention trial using at-risk veterans as subjects, and provides the basis for a larger, more comprehensive study of dementia risk factors in veterans. (C) 2014 Published by Elsevier Inc. on behalf of The Alzheimer's Association.	[Weiner, Michael W.; Veitch, Dallas P.; Hayes, Jacqueline] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Weiner, Michael W.; Neylan, Thomas; Yaffe, Kristine; Mohlenoff, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Weiner, Michael W.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Psychiat, Chicago, IL 60611 USA; [Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Jack, Clifford] Mayo Clin, Dept Radiol, Rochester, MN USA; [Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Inst Aging, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Udall Parkinsons Res Ctr, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Shaw, Leslie M.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Saykin, Andrew J.] Indiana Univ, Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN USA; [Saykin, Andrew J.] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Green, Robert C.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Green, Robert C.] Harvard Univ, Sch Med, Boston, MA USA; [Harvey, Danielle] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA; [Toga, Arthur W.] Univ So Calif, Inst Neuroimaging & Informat, Lab Neuroimaging, Los Angeles, CA USA; [Pacifico, Anthony] US Army Med Res & Mat Command, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Sheline, Yvette] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Weiner, MW (corresponding author), Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94143 USA.	michael.weiner@ucsf.edu	Friedl, Karl/M-1803-2019; Harvey, Danielle/A-5496-2017; Jagust, William/ABE-6426-2020; Jack, Clifford R/F-2508-2010; Saykin, Andrew/A-1318-2007	Friedl, Karl/0000-0002-3134-8427; Jack, Clifford R/0000-0001-7916-622X; Veitch, Dallas/0000-0002-9918-0640; Saykin, Andrew/0000-0002-1376-8532	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); DODUnited States Department of Defense [W81XWH-12-2-0012]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH060482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, U24AG021886, U19AG010483] Funding Source: NIH RePORTER	ADNI is funded by the National Institute on Aging and National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Avid Radiopharmaceuticals, Inc; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization for ADNI is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI DOD data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. We thank all the veterans for their generous participation in this ADNI DOD study. This research was also supported by DOD award number W81XWH-12-2-0012.	Ahmadi N, 2011, AM J CARDIOL, V108, P29, DOI 10.1016/j.amjcard.2011.02.340; Aisen PS, 2010, ALZHEIMERS DEMENT, V6, P239, DOI 10.1016/j.jalz.2010.03.006; Apfel BA, 2011, BIOL PSYCHIAT, V69, P541, DOI 10.1016/j.biopsych.2010.09.044; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Bilbul M, 2011, CAN J NEUROL SCI, V38, P580, DOI 10.1017/S0317167100012129; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Elashoff J. D., 2000, NQUERY ADVISOR VERSI; Farias ST, 2008, NEUROPSYCHOLOGY, V22, P531, DOI 10.1037/0894-4105.22.4.531; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Forsberg A, 2008, NEUROBIOL AGING, V29, P1456, DOI 10.1016/j.neurobiolaging.2007.03.029; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Furst AJ, 2012, NEUROBIOL AGING, V33, P215, DOI 10.1016/j.neurobiolaging.2010.03.011; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Institute NC, 2011, DICT CANC TERMS PACK; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jagust WJ, 2009, NEUROLOGY, V73, P1193, DOI 10.1212/WNL.0b013e3181bc010c; Jagust WJ, 2010, ALZHEIMERS DEMENT, V6, P221, DOI 10.1016/j.jalz.2010.03.003; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kaplan E., 1983, BOSTON NAMING TEST; Katzman R, 1996, NEUROLOGY, V46, P889; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/jnp.12.2.233; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kessler R. B., 1995, ARCH GEN PSYCHIAT, V5, P1048, DOI DOI 10.1001/ARCHPSYC.1995.03950240066012; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lister-James J, 2011, SEMIN NUCL MED, V41, P300, DOI 10.1053/j.semnuclmed.2011.03.001; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maruish M.E., 1994, USE PSYCHOL TESTING, P217; Mattsson N, 2011, ALZHEIMERS DEMENT, V7, P386, DOI 10.1016/j.jalz.2011.05.2243; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCFALL ME, 1991, J NERV MENT DIS, V179, P33, DOI 10.1097/00005053-199101000-00007; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Nasreddine ZS, 2003, CAN J NEUROL SCI, V30, P30; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Okamura N, 2010, IDRUGS, V13, P890; Olsson A, 2005, CLIN CHEM, V51, P336, DOI 10.1373/clinchem.2004.039347; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Pfeffer RI, 1982, GERONTOLOGY, V37, P323, DOI DOI 10.1093/GER0NJ/37.3.323; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rowe CC, 2010, NEUROBIOL AGING, V31, P1275, DOI 10.1016/j.neurobiolaging.2010.04.007; Salloway S, 2011, ARCH NEUROL-CHICAGO, V68, P19, DOI 10.1001/archneurol.2010.344; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Samuelson KW, 2009, J INT NEUROPSYCH SOC, V15, P853, DOI 10.1017/S1355617709990282; Saykin AJ, 2010, ALZHEIMERS DEMENT, V6, P265, DOI 10.1016/j.jalz.2010.03.013; Schoenborn CA, 2003, SERIES 10 DATA NATL, V214, P1; Schuff N, 2001, BIOL PSYCHIAT, V50, P952, DOI 10.1016/S0006-3223(01)01245-8; Schuff N, 1997, ANN NY ACAD SCI, V821, P516, DOI 10.1111/j.1749-6632.1997.tb48319.x; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shaw LM, 2008, NEUROSIGNALS, V16, P19, DOI 10.1159/000109755; Shaw LM, 2011, ACTA NEUROPATHOL, V121, P597, DOI 10.1007/s00401-011-0808-0; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Shen L, 2010, NEUROIMAGE, V53, P1051, DOI 10.1016/j.neuroimage.2010.01.042; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith TC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-69; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Subramanian SV, 2006, AM J EPIDEMIOL, V164, P823, DOI 10.1093/aje/kwj313; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Toledo JB, 2013, BRAIN, V136, P2697, DOI 10.1093/brain/awt188; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wechsler D., 1987, WECHSLER MEMORY SCAL; Weiner Michael W, 2012, Alzheimers Dement, V8, pS1, DOI 10.1016/j.jalz.2011.09.172; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007; Williams John W, 2010, Evid Rep Technol Assess (Full Rep), P1; Wolk DA, 2009, ANN NEUROL, V65, P557, DOI 10.1002/ana.21598; Wong DF, 2010, J NUCL MED, V51, P913, DOI 10.2967/jnumed.109.069088; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yehuda R, 2007, NEURON, V56, P19, DOI 10.1016/j.neuron.2007.09.006	114	37	39	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S226	S235		10.1016/j.jalz.2014.04.005			10	Clinical Neurology	Neurosciences & Neurology	CP8GM	WOS:000360130700016	24924673	Green Published, Green Accepted, Other Gold			2021-06-18	
J	Ganesh, T; Jiang, JX; Yang, MS; Dingledine, R				Ganesh, Thota; Jiang, Jianxiong; Yang, Myung-Soon; Dingledine, Ray			Lead Optimization Studies of Cinnamic Amide EP2 Antagonists	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							PROSTAGLANDIN RECEPTOR EP2; AMYOTROPHIC-LATERAL-SCLEROSIS; COLLAGEN-INDUCED ARTHRITIS; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PROSTANOID RECEPTORS; INFLAMMATORY PROCESSES; MICROGLIAL ACTIVATION; STATUS EPILEPTICUS; OXIDATIVE DAMAGE	Prostanoid receptor EP2 can play a proinflammatory role, exacerbating disease pathology in a variety of central nervous system and peripheral diseases. A highly selective EP2 antagonist could be useful as a drug to mitigate the inflammatory consequences of EP2 activation. We recently identified a cinnamic amide class of EP2 antagonists. The lead compound in this class (5d) displays anti-inflammatory and neuroprotective actions. However, this compound exhibited moderate selectivity to EP2 over the DP1 prostanoid receptor (similar to 10-fold) and low aqueous solubility. We now report compounds that display up to 180-fold selectivity against DP1 and up to 9-fold higher aqueous solubility than our previous lead. The newly developed compounds also display higher selectivity against EP4 and IP receptors and a comparable plasma pharmacokinetics. Thus, these compounds are useful for proof of concept studies in a variety of models where EP2 activation is playing a deleterious role.	[Ganesh, Thota; Jiang, Jianxiong; Yang, Myung-Soon; Dingledine, Ray] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Ganesh, T (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	tganesh@emory.edu	Jiang, Jianxiong/A-1987-2010	Jiang, Jianxiong/0000-0003-3955-8928; Dingledine, Ray/0000-0001-7128-4520	Alzheimer's Drug Discovery Foundation; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99/R00NS082379, U01NS058158]; NARSADNARSAD; Epilepsy Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99NS082379, U01NS058158] Funding Source: NIH RePORTER	This work was supported by Alzheimer's Drug Discovery Foundation (T.G.), NIH/NINDS Grants K99/R00NS082379 (to J.J.) and U01NS058158 (to R.D.), NARSAD Young Investigator Grant (to J.J.), and the Epilepsy Foundation (to J.J.).	Abraham NS, 2007, ALIMENT PHARM THER, V25, P913, DOI 10.1111/j.1365-2036.2007.03292.x; af Forselles KJ, 2011, BRIT J PHARMACOL, V164, P1847, DOI 10.1111/j.1476-5381.2011.01495.x; Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Akula KK, 2008, EPILEPSY RES, V78, P60, DOI 10.1016/j.eplepsyres.2007.10.008; Alavijeh Mohammad S, 2005, NeuroRx, V2, P554, DOI 10.1602/neurorx.2.4.554; Banu SK, 2009, MOL ENDOCRINOL, V23, P1291, DOI 10.1210/me.2009-0017; Baxter E.W., 2002, ORG REACT, V59, P1, DOI DOI 10.1002/0471264180.0R059.01; Bevan CD, 2000, ANAL CHEM, V72, P1781, DOI 10.1021/ac9912247; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Breitner JC, 2011, ALZHEIMERS DEMENT, V7, P402, DOI 10.1016/j.jalz.2010.12.014; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495-200059040-00017; de Rooij J, 1998, NATURE, V396, P474; Dhir A, 2005, CLIN EXP PHARMACOL P, V32, P579, DOI 10.1111/j.1440-1681.2005.04233.x; Donnini S, 2007, FASEB J, V21, P2418, DOI 10.1096/fj.06-7581com; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028; Ganesh T, 2014, J MED CHEM, V57, P4454, DOI 10.1021/jm401431x; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Grosser T, 2010, ANNU REV MED, V61, P17, DOI 10.1146/annurev-med-011209-153129; Hagmann WK, 2008, J MED CHEM, V51, P4359, DOI 10.1021/jm800219f; Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017; Hirata T, 2011, CHEM REV, V111, P6209, DOI 10.1021/cr200010h; Ho L, 1999, J NEUROSCI RES, V57, P295; Holtman L, 2009, EPILEPSY RES, V84, P56, DOI 10.1016/j.eplepsyres.2008.12.006; Holtman L, 2010, EPILEPSY RES, V91, P49, DOI 10.1016/j.eplepsyres.2010.06.011; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Jiang JX, 2013, TRENDS PHARMACOL SCI, V34, P413, DOI 10.1016/j.tips.2013.05.003; Jiang JX, 2013, P NATL ACAD SCI USA, V110, P3591, DOI 10.1073/pnas.1218498110; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jiang JX, 2012, P NATL ACAD SCI USA, V109, P3149, DOI 10.1073/pnas.1120195109; Jiang JX, 2010, P NATL ACAD SCI USA, V107, P2307, DOI 10.1073/pnas.0909310107; Jin JJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-2; Jung KH, 2006, NEUROBIOL DIS, V23, P237, DOI 10.1016/j.nbd.2006.02.016; Liang XB, 2005, J NEUROSCI, V25, P10180, DOI 10.1523/JNEUROSCI.3591-05.2005; Liang XB, 2008, ANN NEUROL, V64, P304, DOI 10.1002/ana.21437; Loscher Wolfgang, 2005, NeuroRx, V2, P86, DOI 10.1602/neurorx.2.1.86; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Narumiya S, 1999, PHYSIOL REV, V79, P1193; Pardridge William M, 2005, NeuroRx, V2, P3; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Polascheck N, 2010, EXP NEUROL, V224, P219, DOI 10.1016/j.expneurol.2010.03.014; Przedborski S, 2010, MOVEMENT DISORD, V25, pS55, DOI 10.1002/mds.22638; Quan Y, 2013, J BIOL CHEM, V288, P9293, DOI 10.1074/jbc.M113.455816; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Roy S, 2006, TETRAHEDRON, V62, P7838, DOI 10.1016/j.tet.2006.05.049; Sheibanie AF, 2007, ARTHRITIS RHEUM-US, V56, P2608, DOI 10.1002/art.22794; Shie FS, 2005, AM J PATHOL, V166, P1163, DOI 10.1016/S0002-9440(10)62336-X; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sung YM, 2006, ONCOGENE, V25, P5507, DOI 10.1038/sj.onc.1209538; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178	61	37	37	1	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	MAY 22	2014	57	10					4173	4184		10.1021/jm5000672			12	Chemistry, Medicinal	Pharmacology & Pharmacy	AI0BB	WOS:000336510100019	24773616	Bronze, Green Published			2021-06-18	
J	Bondi, CO; Cheng, JP; Tennant, HM; Monaco, CM; Kline, AE				Bondi, Corina O.; Cheng, Jeffrey P.; Tennant, Heather M.; Monaco, Christina M.; Kline, Anthony E.			Old Dog, New Tricks: The Attentional Set-Shifting Test as a Novel Cognitive Behavioral Task after Controlled Cortical Impact Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; attentional set-shifting; executive function; traumatic brain injury; behavior	TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; MEDIAL PREFRONTAL CORTEX; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ENVIRONMENTAL ENRICHMENT; TEST-PERFORMANCE; EXECUTIVE FUNCTION; NEUROBEHAVIORAL BENEFIT; CHOLINERGIC MARKERS; FLUID PERCUSSION	Cognitive impairment associated with prefrontal cortical dysfunction is a major component of disability in traumatic brain injury (TBI) survivors. Specifically, deficits of cognitive flexibility and attentional set-shifting are present across all levels of injury severity. Though alterations in spatial learning have been extensively described in experimental models of TBI, studies investigating more complex cognitive deficits are relatively scarce. Hence, the aim of this preclinical study was to expand on this important issue by evaluating the effect of three injury levels on executive function and behavioral flexibility performance as assessed using an attentional set-shifting test (AST). Isoflurane-anesthetized male rats received a controlled cortical impact (CCI) injury (2.6, 2.8, and 3.0 mm cortical depth at 4 m/sec) or sham injury, whereas an additional group had no surgical manipulation (naive). Four weeks postsurgery, rats were tested on the AST, which involved a series of discriminative tasks of increasing difficulty, such as simple and compound discriminations, stimulus reversals, and intra- and extradimensional (ED) shifts. TBI produced accompanying impact depth-dependent increases in cortical lesion volumes, with the 3.0-mm cortical depth group displaying significantly larger injury volumes than the 2.6-mm group (p=0.05). Further, injury severity-induced deficits in ED set-shifting and stimulus reversals, as well as increases in total response error rates and total set loss errors, were observed. These novel findings demonstrate executive function and behavioral flexibility deficits in our animal model of CCI injury and provide the impetus to integrate the AST in the standard neurotrauma behavioral battery to further evaluate cognitive dysfunction after TBI. Ongoing experiments in our laboratory are assessing AST performance after pharmacological and rehabilitative therapies post-TBI, as well as elucidating possible mechanisms underlying the observed neuropsychological deficits.	[Bondi, Corina O.; Cheng, Jeffrey P.; Tennant, Heather M.; Monaco, Christina M.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Cheng, Jeffrey P.; Tennant, Heather M.; Monaco, Christina M.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, 3471 Fifth Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207; Bondi, Corina/0000-0002-5733-4912	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD069620, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grants HD069620 and NS060005 (to A.E.K.).	Andreollo NA, 2012, ABCD-ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102-67202012000100011; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Bakker K, 2014, J NEUROTRAUM, V31, P308, DOI 10.1089/neu.2013.3045; Benge JF, 2007, BRAIN INJURY, V21, P395, DOI 10.1080/02699050701311091; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Birrell JM, 2000, J NEUROSCI, V20, P4320; Bondi CO, 2008, NEUROPSYCHOPHARMACOL, V33, P320, DOI 10.1038/sj.npp.1301410; Bondi CO, 2010, PROG NEURO-PSYCHOPH, V34, P913, DOI 10.1016/j.pnpbp.2010.04.016; Broberg BV, 2009, PSYCHOPHARMACOLOGY, V206, P631, DOI 10.1007/s00213-009-1540-5; Brooks JM, 2012, NEUROPSYCHOPHARMACOL, V37, P2476, DOI 10.1038/npp.2012.106; CABEZA R, 2004, COGNITIVE NEUROSCIEN; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Cao AH, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-10; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Chiarello C, 1996, BRAIN COGNITION, V30, P81, DOI 10.1006/brcg.1996.0006; Chudasama Y, 2006, BIOL PSYCHOL, V73, P19, DOI 10.1016/j.biopsycho.2006.01.005; Clarke HF, 2007, CEREB CORTEX, V17, P18, DOI 10.1093/cercor/bhj120; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crofts HS, 2001, CEREB CORTEX, V11, P1015, DOI 10.1093/cercor/11.11.1015; Dias R, 1996, BEHAV NEUROSCI, V110, P872, DOI 10.1037/0735-7044.110.5.872; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Godsil BP, 2013, EUR NEUROPSYCHOPHARM, V23, P1165, DOI 10.1016/j.euroneuro.2012.10.018; Goetghebeur PJD, 2010, PSYCHOPHARMACOLOGY, V212, P635, DOI 10.1007/s00213-010-1990-9; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hang Rong-Hua, 2011, Fa Yi Xue Za Zhi, V27, P346; Hashimoto K, 2008, EUR NEUROL, V59, P24, DOI 10.1159/000109257; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Ikeda K, 1995, TOHOKU J EXP MED, V177, P343, DOI 10.1620/tjem.177.343; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kobayashi M, 2009, CHEM SENSES, V34, P573, DOI 10.1093/chemse/bjp038; Kos T, 2011, PSYCHOPHARMACOLOGY, V214, P911, DOI 10.1007/s00213-010-2102-6; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Lapiz MDS, 2006, NEUROSCIENCE, V137, P1039, DOI 10.1016/j.neuroscience.2005.09.031; Li HB, 1999, BRAIN RES BULL, V48, P113, DOI 10.1016/S0361-9230(98)00157-9; Liston C, 2006, J NEUROSCI, V26, P7870, DOI 10.1523/JNEUROSCI.1184-06.2006; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Lopez-Mascaraque L, 2002, CELL DEATH DIFFER, V9, P1279, DOI 10.1038/sj.cdd.4401076; Lu XCM, 1998, NEUROSCIENCE, V84, P849, DOI 10.1016/S0306-4522(97)00520-4; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Marek GJ, 1999, EUR J PHARMACOL, V367, P197, DOI 10.1016/S0014-2999(98)00945-5; Martens KM, 2012, J NEUROTRAUM, V29, P2505, DOI 10.1089/neu.2012.2388; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McAlonan K, 2003, BEHAV BRAIN RES, V146, P97, DOI 10.1016/j.bbr.2003.09.019; McGaughy J, 2008, NEUROSCIENCE, V153, P63, DOI 10.1016/j.neuroscience.2008.01.064; Merriam EP, 1999, AM J PSYCHIAT, V156, P780; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Rajan R, 2006, SCIENCE, V311, P666, DOI 10.1126/science.1122096; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Sebastian V, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00038; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Tait DS, 2007, EUR J NEUROSCI, V25, P3719, DOI 10.1111/j.1460-9568.2007.05612.x; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tollefson GD, 1996, J CLIN PSYCHIAT, V57, P31; Tong J, 2013, J NEUROTRAUM, V30, P247, DOI 10.1089/neu.2012.2493; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Tunbridge EM, 2004, J NEUROSCI, V24, P5331, DOI 10.1523/JNEUROSCI.1124-04.2004; Vertes RP, 2004, SYNAPSE, V51, P32, DOI 10.1002/syn.10279; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033; Young JW, 2010, COGN AFFECT BEHAV NE, V10, P243, DOI 10.3758/CABN.10.2.243; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	93	37	37	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					926	937		10.1089/neu.2013.3295			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200005	24397572	Green Published			2021-06-18	
J	Knight, SJ; Anderson, VA; Spencer-Smith, MM; Da Costa, AC				Knight, Sarah J.; Anderson, Vicki A.; Spencer-Smith, Megan M.; Da Costa, Annette C.			Neurodevelopmental Outcomes in Infants and Children With Single-Suture Craniosynostosis: A Systematic Review	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							POSTOPERATIVE DEVELOPMENTAL ATTAINMENT; TRAUMATIC BRAIN INJURY; SAGITTAL SYNOSTOSIS; LONG-TERM; NONSYNDROMIC CRANIOSYNOSTOSIS; COGNITIVE-DEVELOPMENT; METOPIC SYNOSTOSIS; MENTAL-DEVELOPMENT; YOUNG-CHILDREN; SPINA-BIFIDA	Children with single-suture craniosynostosis (SSC) are increasingly considered to be at high risk of adverse neurodevelopmental outcomes. This systematic review aimed to synthesise and critically appraise the existing literature on the neurodevelopmental features of SSC, with particular attention to methodological quality. A total of 33 articles based on 27 cohorts met inclusion criteria. In the context of variable methodological design and quality, most neurodevelopmental studies indicated that children with SSC are at increased risk for difficulties in cognitive, language, and motor domains during infancy (both pre- and post-surgery) and childhood. Limited information exists on factors influencing outcome.	[Knight, Sarah J.; Anderson, Vicki A.; Spencer-Smith, Megan M.; Da Costa, Annette C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Knight, Sarah J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Knight, Sarah J.; Anderson, Vicki A.; Da Costa, Annette C.] Univ Melbourne, Melbourne, Vic, Australia; [Knight, Sarah J.; Anderson, Vicki A.] Monash Childrens, Victorian Paediat Rehabil Serv, Melbourne, Vic, Australia; [Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Spencer-Smith, Megan M.] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Da Costa, Annette C.] Royal Childrens Hosp, Dept Plast & Maxillofacial Surg, Melbourne, Vic, Australia	Knight, SJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	sarah.knight@mcri.edu.au	Knight, Sarah/AAZ-8515-2020	Knight, Sarah/0000-0002-9908-2231; Spencer-Smith, Megan/0000-0002-1047-0829			Aldridge K, 2005, ANAT REC PART A, V285A, P690, DOI 10.1002/ar.a.20201; Aldridge K, 2002, J ANAT, V201, P31, DOI 10.1046/j.1469-7580.2002.00074.x; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Arnaud E, 2002, PLAST RECONSTR SURG, V110, P6, DOI 10.1097/00006534-200207000-00002; Ballantyne AO, 2007, CHILD NEUROPSYCHOL, V13, P494, DOI 10.1080/09297040601114878; Becker DB, 2005, PLAST RECONSTR SURG, V116, P400, DOI 10.1097/01.prs.0000172763.71043.b8; Bellew M, 2005, ARCH DIS CHILD, V90, P346, DOI 10.1136/adc.2003.035824; Bellew M, 2011, J NEUROSURG-PEDIATR, V7, P121, DOI 10.3171/2010.11.PEDS10216; Boltshauser E, 2003, NEUROPEDIATRICS, V34, P293; Bottero L, 1998, PLAST RECONSTR SURG, V102, P952, DOI 10.1097/00006534-199809040-00002; Chieffo D, 2010, J NEUROS-PEDIATR, V5, P232, DOI 10.3171/2009.10.PEDS09231; Cohen M., 2000, CRANIOSYNOSTOSIS DIA, V2; Cohen SR, 2004, PLAST RECONSTR SURG, V114, P841, DOI 10.1097/01.PRS.0000132854.14237.A8; Da Costa AC, 2006, PLAST RECONSTR SURG, V118, P175, DOI 10.1097/01.prs.0000221009.93022.50; Da Costa AC, 2012, CHILD NERV SYST, V28, P869, DOI 10.1007/s00381-011-1660-1; Dennis M, 1996, J NEURO-ONCOL, V29, P91, DOI 10.1007/BF00165522; Dennis M., 2007, COGNITIVE RESERVE TH, P53; Fletcher JM, 2005, J NEUROSURG, V102, P268, DOI 10.3171/ped.2005.102.3.0268; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; Gewalli F, 2001, ANN PLAS SURG, V46, P415, DOI 10.1097/00000637-200104000-00011; Kapp-Simon KA, 2005, CLEFT PALATE-CRAN J, V42, P377, DOI 10.1597/04-044.1; Kapp-Simon KA, 1998, CLEFT PALATE-CRAN J, V35, P197, DOI 10.1597/1545-1569(1998)035<0197:MDALDI>2.3.CO;2; Kapp-Simon KA, 2007, CHILD NERV SYST, V23, P269, DOI 10.1007/s00381-006-0251-z; KAPPSIMON KA, 1993, PLAST RECONSTR SURG, V92, P831, DOI 10.1097/00006534-199392050-00008; Kelleher MO, 2006, J NEUROSURG, V105, P382, DOI 10.3171/ped.2006.105.5.382; Korpilahti P, 2012, CHILD NERV SYST, V28, P419, DOI 10.1007/s00381-011-1623-6; Lajeunie E, 1998, AM J MED GENET, V75, P211, DOI 10.1002/(SICI)1096-8628(19980113)75:2<211::AID-AJMG19>3.0.CO;2-S; Lattanzi W, 2012, CHILD NERV SYST, V28, P1301, DOI 10.1007/s00381-012-1781-1; Limperopoulos C, 2002, J PEDIATR-US, V141, P51, DOI 10.1067/mpd.2002.125227; Loddenkemper T, 2007, PEDIATRICS, V119, P930, DOI 10.1542/peds.2006-2530; Lomax-Bream LE, 2007, DEV NEUROPSYCHOL, V31, P1, DOI 10.1207/s15326942dn3101_1; Magge SN, 2002, J CRANIOFAC SURG, V13, P99, DOI 10.1097/00001665-200201000-00023; Mathijssen I, 2006, J NEUROSURG, V105, P16, DOI 10.3171/ped.2006.105.1.16; Mendonca DA, 2009, J CRANIOFAC SURG, V20, P85, DOI 10.1097/SCS.0b013e3181955244; Nejad E. A., 2010, Iranian Journal of Child Neurology, V3, P45; Panchal J, 2001, PLAST RECONSTR SURG, V108, P1492, DOI 10.1097/00006534-200111000-00007; Richtsmeier JT, 2006, J EXP ZOOL PART B, V306B, P360, DOI 10.1002/jez.b.21092; Ruiz-Correa S, 2007, CLEFT PALATE-CRAN J, V44, P548, DOI 10.1597/06-190.1; Shipster C, 2003, DEV MED CHILD NEUROL, V45, P34, DOI 10.1017/S0012162203000070; Sidoti EJ, 1996, PLAST RECONSTR SURG, V97, P276, DOI 10.1097/00006534-199602000-00002; Singer S, 1999, AM J MED GENET, V83, P382, DOI 10.1002/(SICI)1096-8628(19990423)83:5<382::AID-AJMG8>3.0.CO;2-A; Speltz ML, 2007, PLAST RECONSTR SURG, V119, P1874, DOI 10.1097/01.prs.0000259184.88265.3f; Speltz ML, 2004, J PEDIATR PSYCHOL, V29, P651, DOI 10.1093/jpepsy/jsh068; Speltz ML, 1997, CLEFT PALATE-CRAN J, V34, P374, DOI 10.1597/1545-1569(1997)034<0374:PAPMAP>2.3.CO;2; Starr JR, 2007, J NEUROSURG, V107, P103, DOI 10.3171/PED-07/08/103; Starr JR, 2010, NEUROSURGERY, V67, P408, DOI 10.1227/01.NEU.0000371992.72539.8B; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P149, DOI 10.1017/S1355617704102038; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Toth K, 2008, CHILD NEUROPSYCHOL, V14, P339, DOI 10.1080/09297040701594888; Treyvaud K, 2009, PEDIATRICS, V123, P555, DOI 10.1542/peds.2008-0477; Virtanen R, 1999, PEDIATRICS, V103, P791, DOI 10.1542/peds.103.4.791; Warschausky S, 2005, PLAST RECONSTR SURG, V115, P1518, DOI 10.1097/01.PRS.0000160270.27558.64; Westmacott R, 2009, STROKE, V40, P2012, DOI 10.1161/STROKEAHA.108.533976; ZEITSER I, 2008, J THORACIC CARDIOVAS, V135, P91, DOI DOI 10.1016/J.JTCVS.2007.04.074	56	37	37	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	APR 3	2014	39	3					159	186		10.1080/87565641.2014.886690			28	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	AF1PX	WOS:000334486900001	24742309				2021-06-18	
J	Kirkwood, MW; Peterson, RL; Connery, AK; Baker, DA; Grubenhoff, JA				Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.; Grubenhoff, Joseph A.			Postconcussive Symptom Exaggeration After Pediatric Mild Traumatic Brain Injury	PEDIATRICS			English	Article						mild TBI; concussion; postconcussive symptoms; postconcussion syndrome; symptom exaggeration; feigning; neuropsychological; validity testing; pediatrics	POST-CONCUSSIVE SYMPTOMS; VALIDITY TEST FAILURE; HEAD-INJURY; TEST-PERFORMANCE; NEUROPSYCHOLOGICAL TESTS; NEUROCOGNITIVE OUTCOMES; MILITARY SAMPLE; CASE SERIES; CHILDREN; METAANALYSIS	BACKGROUND: A minority of pediatric patients who have mild traumatic brain injury (mTBI) report persistent postconcussive symptoms. In adults, failure on validity tests, which help to detect exaggerated or feigned problems, is associated with symptom complaints. No pediatric studies have examined the relationship between validity test performance and symptom report. We hypothesized that children failing a validity test would report significantly more postconcussive symptoms than those passing. METHODS: Using a consecutive clinical case series design, we examined 191 patients aged 8 to 17 years seen for neuropsychological evaluation after mTBI. Participants were administered a validity test (Medical Symptom Validity Test; MSVT) and completed a graded symptom scale as part of a neuropsychological battery. RESULTS: A total of 23 participants (12%) failed the MSVT. The Fail group endorsed significantly more postconcussive symptoms than the Pass group, with a large effect size (P < .001; d = 1.1). MSVT performance remained a robust unique predictor of symptom report even after controlling for other influential factors (eg, female gender, premorbid psychiatric problems). CONCLUSIONS: A subset of children who had persistent complaints after mTBI may be exaggerating or feigning symptoms. If such negative response bias remains undetected, errors in etiologic statements and less than optimal treatment may occur. Because the detection of invalid responding is well established in neuropsychology, clinical neuropsychologists should be incorporated routinely into clinical care for patients who have persistent complaints. To better control for noninjury effects in future pediatric mTBI studies, researchers should add validity tests to neurobehavioral outcome batteries.	[Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Grubenhoff, Joseph A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Grubenhoff, Joseph A.] Childrens Hosp Colorado, Aurora, CO 80045 USA	Kirkwood, MW (corresponding author), Childrens Hosp Colorado, Concuss Program, B285,13123 East 16th Ave, Aurora, CO 80045 USA.	michael.kirkwood@childrenscolorado.org		Grubenhoff, Joseph/0000-0001-5072-4064			Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BIJUR PE, 1990, PEDIATRICS, V86, P337; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chafetz M, 2011, APPL NEUROPSYCHOL, V18, P143, DOI 10.1080/09084282.2011.570619; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Conti RP, 2004, PSYCHOL REP, V94, P987; DeRight J, 2015, CHILD NEUROPSYCHOL, V21, P1, DOI 10.1080/09297049.2013.864383; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Flaro L, 2007, PEDIAT FORENSIC NEUR, P139; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2011, J PERS ASSESS, V93, P508, DOI 10.1080/00223891.2011.594132; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P, 2001, NEUROREHABILITATION, V16, P231; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2004, MANUAL MED SYMPTOM V; Green P, 2012, DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION, P201, DOI 10.1007/978-1-4614-0442-2_6; GREENFELD D, 1987, HOSP COMMUNITY PSYCH, V38, P73; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jones A, 2012, CLIN NEUROPSYCHOL, V26, P790, DOI 10.1080/13854046.2012.693202; Kirkwood M. W, 2012, PEDIAT FORENSIC NEUR, P136; Kirkwood MW, 2014, CHILD NEUROPSYCHOL, V20, P245, DOI 10.1080/09297049.2012.759553; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Libow JA, 2000, PEDIATRICS, V105, P336, DOI 10.1542/peds.105.2.336; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stutts JT, 2003, J DEV BEHAV PEDIATR, V24, P276, DOI 10.1097/00004703-200308000-00009; Sweet JJ, 2013, J EXP PSYCHOPATHOL, V4, P6, DOI 10.5127/jep.022311; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vu JA, 2011, EXCEPT CHILDREN, V77, P263, DOI 10.1177/001440291107700301; Wechsler D., 2011, WECHLSER ABBREVIATED; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates K. O., 2012, MILD TRAUMATIC BRAIN, P124; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	75	37	37	0	21	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2014	133	4					643	650		10.1542/peds.2013-3195			8	Pediatrics	Pediatrics	AG3TU	WOS:000335343500011	24616360				2021-06-18	
J	Lu, XY; Wang, HD; Xu, JG; Ding, K; Li, T				Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao			NADPH oxidase inhibition improves neurological outcome in experimental traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; NADPH oxidase; NOX2; Apocynin	OXYGEN SPECIES PRODUCTION; APOCYNIN; DAMAGE; NOX2; BARRIER	Purpose: Traumatic brain injury (TB!) is a worldwide health problem with oxidative stress recognized as a major pathogenetic factor. The present experimental study was designed to explore the neuroprotective effect of NADPH oxidase (NOX) inhibitor, apocynin, on mouse TBI. Methods: Moderately severe weight-drop impact head injury was induced in adult male mice, randomly divided into four groups: sham, TBI, TBI + vehicle and TBI + apocynin treatment. Apocynin (50 mg/kg) was injected intraperitoneally 30 min before TBI. The expression of NOX2 protein was investigated using immunoblotting techniques 1 and 24 h after TBI. Neurological score was evaluated 24 h after TBI. Blood-brain barrier disruption was detected by Evans blue extravasation and cortical apoptosis was analyzed by TUNEL assay. Additionally, we assessed tissue levels of malondialdehyde (MDA). Results: NOX2 expression increased rapidly following TBI in male mice, with an early peak at 1 h, followed by a second peak at 24 h. Pre-treatment with the NOX inhibitor, apocynin markedly inhibited NOX2 expression. Apocynin also attenuated MDA levels and TBI-induced blood-brain barrier dysfunction. In addition apocynin significantly attenuated TBI-induced neurological deficits and cortical apoptosis. Conclusion: Pre-treatment with apocynin effectively attenuates markers of cerebral oxidative stress after TBI, thus supporting the hypothesis that apocynin is a potential neuroprotectant and adjunct therapy for TBI patients. (C) 2014 Elsevier Ltd. All rights reserved.	[Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Lu, Xin-Yu] Jiangsu Univ, Dept Neurosurg, Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Science and Technology Development Fund of Zhenjiang [SH20130037]	This study was supported by the Science and Technology Development Fund of Zhenjiang (No. SH20130037).	Altintas R, 2013, J ENDOUROL, V27, P617, DOI 10.1089/end.2012.0556; Ano Y, 2010, NEUROSCI LETT, V469, P39, DOI 10.1016/j.neulet.2009.11.040; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; De Silva TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028393; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kandasamy R, 2013, INT J NEUROSCI, V123, P385, DOI 10.3109/00207454.2012.761983; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Ling HP, 2013, J SURG RES, V179, pE227, DOI 10.1016/j.jss.2012.03.030; Liu WL, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-22; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016; Pepping JK, 2013, AM J PHYSIOL-ENDOC M, V304, pE392, DOI 10.1152/ajpendo.00398.2012; Peters EA, 2001, FREE RADICAL BIO MED, V31, P1442, DOI 10.1016/S0891-5849(01)00725-0; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sahna E, 2003, UROL RES, V31, P188, DOI 10.1007/s00240-003-0314-5; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; Weston RM, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/648061; Ximenes VF, 2007, ARCH BIOCHEM BIOPHYS, V457, P134, DOI 10.1016/j.abb.2006.11.010; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	29	37	38	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	APR	2014	69						14	19		10.1016/j.neuint.2014.02.006			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AF8SG	WOS:000334985300003	24589771				2021-06-18	
J	Bivona, U; Riccio, A; Ciurli, P; Carlesimo, GA; Delle Donne, V; Pizzonia, E; Caltagirone, C; Formisano, R; Costa, A				Bivona, Umberto; Riccio, Angela; Ciurli, Paola; Carlesimo, Giovanni Augusto; Delle Donne, Valentina; Pizzonia, Elisa; Caltagirone, Carlo; Formisano, Rita; Costa, Alberto			Low Self-Awareness of Individuals With Severe Traumatic Brain Injury Can Lead to Reduced Ability to Take Another Person's Perspective	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						empathy; self-awareness; Theory of Mind; traumatic brain injury	COMPETENCE RATING-SCALE; FRONTOTEMPORAL DEMENTIA; NEURAL BASIS; EXECUTIVE FUNCTION; LOBE CONTRIBUTIONS; ASPERGER-SYNDROME; PEOPLE THINKING; MIND; EMPATHY; DEFICITS	Aims of this study were (i) to verify whether a deficit or a lack of self-awareness can lead to difficulties in assuming another person's perspective after a severe traumatic brain injury (TBI); (ii) to verify whether perspective-taking deficits emerge more from performance-based tasks than self-reports; and (iii) to evaluate the possible relationships between perspective-taking difficulties and some clinical, neuropsychological, neuropsychiatric, and neuroimaging variables. The Interpersonal Reactivity Index, Empathy Quotient, first-order false-belief, and faux pas written stories were administered to 28 patients with severe TBI and 28 healthy controls. The Awareness Questionnaire was also administered to TBI patients and their caregivers. Patients were split into 2 groups (impaired self-awareness vs adequate self-awareness) on the basis of the discrepancy Awareness Questionnaire score. Both TBI groups obtained lower scores than healthy controls on the Fantasy subscale of the Interpersonal Reactivity Index, the reality question of the false-belief stories, and the memory questions of the faux pas test. Only impaired self-awareness patients tended to obtain lower scores in first-order false-belief detection. Impaired self-awareness patients also performed significantly worse than both healthy controls and adequate self-awareness patients on the faux pas tasks. The analysis suggests a causal relationship between low self-awareness and perspective-taking difficulties in this population of patients.	[Bivona, Umberto; Riccio, Angela; Ciurli, Paola; Carlesimo, Giovanni Augusto; Delle Donne, Valentina; Pizzonia, Elisa; Caltagirone, Carlo; Formisano, Rita; Costa, Alberto] Santa Lucia Fdn, Rome, Italy; [Carlesimo, Giovanni Augusto; Caltagirone, Carlo] Univ Roma Tor Vergata, Rome, Italy	Bivona, U (corresponding author), IRCCS Fdn Santa Lucia, Via Ardeatina 306, I-00179 Rome, Italy.	u.bivona@hsantalucia.it	Costa, Alberto/AAA-7038-2019; Riccio, Angela/K-2745-2016	Riccio, Angela/0000-0002-4098-9461; COSTA, Alberto/0000-0002-4784-5524			Aboulafia-Brakha T, 2011, J NEUROPSYCHOL, V5, P39, DOI 10.1348/174866410X533660; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; Baron-Cohen S., 2000, UNDERSTANDING OTHER; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Bonino S., 1998, EMPATIA PROCESSI CON; BROTHERS L, 1992, J COGNITIVE NEUROSCI, V4, P107, DOI 10.1162/jocn.1992.4.2.107; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Carruthers P., 1996, THEORIES THEORIES MI; Churchland PM, 1991, FUTURE FOLK PSYCHOL, P51; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Ciurli P, 2010, J INT NEUROPSYCH SOC, V16, P360, DOI 10.1017/S135561770999141X; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Costa A, 2008, BEHAV NEUROL, V19, P71, DOI 10.1155/2008/694632; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DAVIES M, 1995, MENTAL SIMULATION; DAVIES M, 1995, FOLK PSYCHOL; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; DENNETT DC, 1978, BEHAV BRAIN SCI, V1, P568, DOI 10.1017/S0140525X00076664; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Eslinger PJ, 2012, BEHAV NEUROL, V25, P127, DOI [10.3233/BEN-2011-0351, 10.1155/2012/286427]; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Frith U, 2001, CURR DIR PSYCHOL SCI, V10, P151, DOI 10.1111/1467-8721.00137; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gallese V, 2003, PSYCHOPATHOLOGY, V36, P171, DOI 10.1159/000072786; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GALLUP GG, 1982, AM J PRIMATOL, V2, P237, DOI 10.1002/ajp.1350020302; Glodzik-Sobanska L, 2005, J NEUROL SCI, V238, P19, DOI 10.1016/j.jns.2005.06.004; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldman A.I., 1989, MIND LANG, V4, P161, DOI DOI 10.1111/J.1468-0017.1989.TB00249.X; Gordon R.M., 1996, THEORIES THEORIES MI, P11, DOI DOI 10.1017/CB09780511597985.003; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Gunning Dixon FM, 2003, NEUROPSYCHOLOGIA, V41, P1929; Hagen C., 1972, LEVELS COGNITIVE FUN; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton RK, 2000, FORMA COMPLETA REVIS, P1; HOGAN R, 1969, J CONSULT CLIN PSYCH, V33, P307, DOI 10.1037/h0027580; JENNETT B, 1975, LANCET, V1, P480; Keenan J.P., 2003, FACE MIRROR SEARCH O; Keysers C, 2004, NEURON, V42, P335, DOI 10.1016/S0896-6273(04)00156-4; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levkovitz Y, 2011, BRAIN STIMUL, V4, P266, DOI 10.1016/j.brs.2010.12.004; Long C. J., 1992, HDB HEAD TRAUMA ACUT; McDonald S., 1999, J HEAD TRAUMA REHAB, V16, P612; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MILLER PH, 1970, CHILD DEV, V41, P613, DOI 10.1111/j.1467-8624.1970.tb01018.x; Morin A, 2006, CONSCIOUS COGN, V15, P358, DOI 10.1016/j.concog.2005.09.006; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Newsome MR, 2010, NEUROPSYCHOLOGY, V24, P139, DOI 10.1037/a0017432; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Orsini A., 2003, B PSICOL APPL, V239, P73; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; SELMAN RL, 1971, CHILD DEV, V42, P1721, DOI 10.2307/1127580; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2002, PRINCIPLES FRONTAL L; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Zamboni G, 2008, NEUROLOGY, V71, P736, DOI 10.1212/01.wnl.0000324920.96835.95	102	37	38	1	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					157	171		10.1097/HTR.0b013e3182864f0b			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600010	23524876				2021-06-18	
J	Fuller, G; Hasler, RM; Mealing, N; Lawrence, T; Woodford, M; Juni, P; Lecky, F				Fuller, Gordon; Hasler, Rebecca M.; Mealing, Nicole; Lawrence, Thomas; Woodford, Maralyn; Juni, Peter; Lecky, Fiona			The association between admission systolic blood pressure and mortality in significant traumatic brain injury: A multi-centre cohort study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Craniocerebral trauma; Hypotension; Systolic blood pressure; Resuscitation	PROGNOSTIC VALUE; MULTIPLE IMPUTATION; SECONDARY INSULTS; HEAD-INJURY; HYPOTENSION; REGRESSION; PREDICTORS; ACCURATE	Introduction: Low systolic blood pressure (SBP) is an important secondary insult following traumatic brain injury (TBI), but its exact relationship with outcome is not well characterised. Although a SBP of <90 mmHg represents the threshold for hypotension in consensus TBI treatment guidelines, recent studies suggest redefining hypotension at higher levels. This study therefore aimed to fully characterise the association between admission SBP and mortality to further inform resuscitation endpoints. Methods: We conducted a multicentre cohort study using data from the largest European trauma registry. Consecutive adult patients with AIS head scores >2 admitted directly to specialist neuroscience centres between 2005 and July 2012 were studied. Multilevel logistic regression models were developed to examine the association between admission SBP and 30 day inpatient mortality. Models were adjusted for confounders including age, severity of injury, and to account for differential quality of hospital care. Results: 5057 patients were included in complete case analyses. Admission SBP demonstrated a smooth u-shaped association with outcome in a bivariate analysis, with increasing mortality at both lower and higher values, and no evidence of any threshold effect. Adjusting for confounding slightly attenuated the association between mortality and SBP at levels <120 mmHg, and abolished the relationship for higher SBP values. Case-mix adjusted odds of death were 1.5 times greater at <120 mmHg, doubled at <100 mmHg, tripled at <90 mmHg, and six times greater at SBP <70 mmHg, p <0.01. Conclusions: These findings indicate that TBI studies should model SBP as a continuous variable and may suggest that current TBI treatment guidelines, using a cut-off for hypotension at SBP <90 mmHg, should be reconsidered. (C) 2013 Elsevier Ltd. All rights reserved.	[Fuller, Gordon; Lawrence, Thomas; Woodford, Maralyn] Salford Royal Hosp, Trauma Audit & Res Network, Hlth Sci Res Grp, Manchester Acad Hlth Sci Ctr, Salford M6 8HD, Lancs, England; [Hasler, Rebecca M.] Univ Hosp Bern, Dept Emergency Med, CH-3010 Bern, Switzerland; [Mealing, Nicole; Juni, Peter] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Lecky, Fiona] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	Fuller, G (corresponding author), Salford Royal Hosp, Trauma Audit & Res Network, Hlth Sci Res Grp, Manchester Acad Hlth Sci Ctr, Mayo Bldg,Eccles Old Rd, Salford M6 8HD, Lancs, England.	gordonwfuller@doctors.net.uk		Fuller, Gordon Ward/0000-0001-8532-3500; Lawrence, Thomas/0000-0003-3648-7634	National Institute for Health ResearchNational Institute for Health Research (NIHR) [DRF-2011-04-050] Funding Source: researchfish; Department of HealthEuropean Commission [DRF-2011-04-050] Funding Source: Medline		Allison P.D., 2001, MISSING DATA; Bagley SC, 2001, J CLIN EPIDEMIOL, V54, P979, DOI 10.1016/S0895-4356(01)00372-9; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Bruns B, 2008, J TRAUMA, V65, P1217, DOI 10.1097/TA.0b013e318184ee63; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bur A, 2000, CRIT CARE MED, V28, P371, DOI 10.1097/00003246-200002000-00014; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Davis JW, 2003, J TRAUMA, V55, P860, DOI 10.1097/01.TA.0000092686.91877.DE; *DEP HLTH, HOSP EP STAT; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Edmonds ZV, 2002, ANN EMERG MED, V39, P233, DOI 10.1067/mem.2002.122017; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fuller G, 2011, J INTENSIVE CARE SOC, V12, P1; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; Hasler RM, 2011, RESUSCITATION, V82, P1202, DOI 10.1016/j.resuscitation.2011.04.021; Hosmer D, 1989, APPL LOGISTIC REGRES; Klein M, 1994, LOGISTIC REGRESSION; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lesko MM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-72; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McMahon CG, 2010, J TRAUMA, V69, P1169, DOI 10.1097/TA.0b013e3181cc8889; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Pater C, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-6; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; White IR, 2010, STAT MED, V29, P2920, DOI 10.1002/sim.3944; Zafar SN, 2011, J TRAUMA, V71, P1179, DOI 10.1097/TA.0b013e3182140d38	42	37	38	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2014	45	3					612	617		10.1016/j.injury.2013.09.008			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	302BH	WOS:000330575800027	24206920				2021-06-18	
J	Mychasiuk, R; Hehar, H; Farran, A; Esser, MJ				Mychasiuk, R.; Hehar, H.; Farran, A.; Esser, M. J.			Mean girls: Sex differences in the effects of mild traumatic brain injury on the social dynamics of juvenile rat play behaviour	BEHAVIOURAL BRAIN RESEARCH			English	Article						Sprague Dawley rat; Pediatric; Development; Play fighting behaviour; Concussion	CONCUSSION SYMPTOMS; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; CHILDREN; DEFENSE; NEUROSCIENCE; PLASTICITY; ATTENTION; OUTCOMES; ATTACK	Clinical studies indicate that children who experience a traumatic brain injury (TBI) are often the victim of peer rejection, have very few mutual friends, and are at risk for long-term behavioural and social impairments. Owing to the fact that peer play is critical for healthy development, it is possible that the long-term impairments are associated not only with the TBI, but also altered play during this critical period of brain development. This study was designed to determine if social dynamics and juvenile play are altered in rats that experience a mild TBI (mTBI) early in life. Play-fighting behaviours were recorded and analyzed for young male and female Sprague Dawley rats that were given either an mTBI or a sham injury. The study found that the presence of an mTBI altered the play fighting relationship, and the nature of the alterations were dependent upon the sex of the pairing and the injury status of their peers. Sham rats were significantly less likely to initiate play with an mTBI rat, and were more likely to respond to a play initiation from an mTBI rat with an avoidant strategy. This effect was significantly more pronounced in female rats, whereby it appeared that female rats with an mTBI were particularly rejected and most often excluded from play experiences. Male rats with an mTBI learned normal play strategies from their sham peers (when housed in mixed cages), whereas female rats with an mTBI show heightened impairment in these conditions. Play therapy may need to be incorporated into treatment strategies for children with TBI. (C) 2013 Elsevier B.V. All rights reserved.	[Mychasiuk, R.; Hehar, H.; Farran, A.; Esser, M. J.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg,Room 277,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Foundation; University of Calgary, Department of Paediatrics	The authors would like to thank Irene Ma for her technical assistance and the Alberta Children's Hospital Research Foundation & The University of Calgary, Department of Paediatrics for their assistance with funding.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell HC, 2010, BEHAV BRAIN RES, V207, P7, DOI 10.1016/j.bbr.2009.09.029; Bell HC, 2009, BEHAV NEUROSCI, V123, P1158, DOI 10.1037/a0017617; Biben M., 1998, ANIMAL PLAY EVOLUTIO; Bigler ED, 2013, NEUROREHABILITATION, V32, P707, DOI 10.3233/NRE-130896; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Burnett S, 2011, NEUROSCI BIOBEHAV R, V35, P1654, DOI 10.1016/j.neubiorev.2010.10.011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Darwish D, 2001, CHILD ABUSE NEGLECT, V25, P13, DOI 10.1016/S0145-2134(00)00228-3; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; GHEUSI G, 1994, BEHAV PROCESS, V33, P59, DOI 10.1016/0376-6357(94)90060-4; Himmler BT, 2013, JOVE-J VIS EXP, DOI 10.3791/4288; Hol T, 1999, BEHAV BRAIN RES, V100, P91, DOI 10.1016/S0166-4328(98)00116-8; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Joseph R, 1999, CHILD PSYCHIAT HUM D, V29, P189, DOI 10.1023/A:1022660923605; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KOLB B, 1974, J COMP PHYSIOL PSYCH, V87, P466, DOI 10.1037/h0036969; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kolb B, 2009, PAED CHILD HEALT-CAN, V14, P651, DOI 10.1093/pch/14.10.651; Kolb Teskey B, 2010, DEV PSYCHOBIOL, V54, P311; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; Mychasiuk R, 2013, J NEUROTRAUMA UNPUB; NONNEMAN AJ, 1974, BEHAV BIOL, V12, P41, DOI 10.1016/S0091-6773(74)91011-6; Pellis SM, 2007, CURR DIR PSYCHOL SCI, V16, P95, DOI 10.1111/j.1467-8721.2007.00483.x; Pellis SM, 2010, AM J PLAY, V2, P278; Pellis SM, 2006, BEHAV NEUROSCI, V120, P72, DOI 10.1037/0735-7044.120.1.72; PELLIS SM, 1990, DEV PSYCHOBIOL, V23, P215, DOI 10.1002/dev.420230303; PELLIS SM, 1991, PSYCHOL REC, V41, P175, DOI 10.1007/BF03395104; PELLIS SM, 1992, BRAIN BEHAV EVOLUT, V39, P270, DOI 10.1159/000114124; Pellis SM, 1998, ANIMAL PLAY EVOLUTIO, P115, DOI DOI 10.1017/CBO9780511608575.007; Schallert T, 2002, PHARM CEREBRAL ISCHE; Smith LK, 1998, DEV PSYCHOBIOL, V33, P147, DOI 10.1002/(SICI)1098-2302(199809)33:2<147::AID-DEV5>3.3.CO;2-H; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531	45	37	39	1	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2014	259						284	291		10.1016/j.bbr.2013.10.048			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AB3CA	WOS:000331667700034	24231261				2021-06-18	
J	Theparambil, SM; Ruminot, I; Schneider, HP; Shull, GE; Deitmer, JW				Theparambil, Shefeeq M.; Ruminot, Ivan; Schneider, Hans-Peter; Shull, Gary E.; Deitmer, Joachim W.			The Electrogenic Sodium Bicarbonate Cotransporter NBCe1 Is a High-Affinity Bicarbonate Carrier in Cortical Astrocytes	JOURNAL OF NEUROSCIENCE			English	Article						bicarbonate; glial cells; NBCe1-KO; pH; proton concentration; Xenopus oocytes	CENTRAL-NERVOUS-SYSTEM; SOLUBLE ADENYLYL-CYCLASE; DEPOLARIZATION-INDUCED ALKALINIZATION; TRAUMATIC BRAIN-INJURY; CARBONIC-ANHYDRASE-II; GLIAL-CELLS; NA+-HCO3-COTRANSPORTER; FLUORESCENT PROTEINS; INTRACELLULAR PH; EXTRACELLULAR PH	The electrogenic sodium bicarbonate cotransporter NBCe1 (SLC4A4) is a robust regulator of intracellular H+ and a significant base carrier in many cell types. Using wild-type (WT) and NBCe1-deficient (NBC-KO) mice, we have studied the role of NBCe1 in cortical astrocytes in culture and in situ by monitoring intracellular H+ using the H+-sensitive dye BCECF [2',7' -bis-(carboxyethyl)-5-(and-6)-carboxyfluorescein] in wide-field and confocal microscopy. Adding 0.1-3 mM HCO3- to an O-2-gassed, HEPES-buffered saline solution lowered the intracellular H+ concentration with a K-m of 0.65 mM HCO3- in WT astrocytes, but slowly raised [H+](1) in NBCe1-KO astrocytes. HumanNBCe1 heterologously expressed in Xenopus oocytes could be activated by adding 1-3mM HCO3-, and even by residual HCO3- in a nominally CO2/HCO3--free saline solution. Our results demonstrate a surprisingly high apparent bicarbonate sensitivity mediated by NBCe1 in cortical astrocytes, suggesting that NBCe1 may operate over a wide bicarbonate concentration in these cells.	[Theparambil, Shefeeq M.; Ruminot, Ivan; Schneider, Hans-Peter; Deitmer, Joachim W.] Univ Kaiserslautern, Abt Allgemeine Zool, FB Biol, D-67653 Kaiserslautern, Germany; [Shull, Gary E.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Deitmer, JW (corresponding author), Univ Kaiserslautern, Abt Allgemeine Zool, FB Biol, PB 3049, D-67653 Kaiserslautern, Germany.	deitmer@biologie.uni-kl.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DE 231/24-1]; Research Initiative of Membrane Proteins of the University of Kaiserslautern	This study was supported by grants from the Deutsche Forschungsgemeinschaft (DE 231/24-1), and the Research Initiative of Membrane Proteins of the University of Kaiserslautern (to J.W.D.). Weare grateful to Dr. Frank Kirchhoff, Hombur/Saar, Germany, for providing the GFRT transgenic mice; and to Dr. Ursula Seidler, Hannover, Germany, for helping with the breeding of NBCe1-KO mice. We thank Dr. Holger M. Becker, Kaiserslautern, for critically reading an early version of this manuscript.	Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Becker HM, 2007, J BIOL CHEM, V282, P13508, DOI 10.1074/jbc.M700066200; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BROOKES N, 1994, AM J PHYSIOL-CELL PH, V267, pC1633; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Choi HB, 2012, NEURON, V75, P1094, DOI 10.1016/j.neuron.2012.08.032; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DEITMER JW, 1990, J PHYSIOL-LONDON, V421, P617, DOI 10.1113/jphysiol.1990.sp017965; Deitmer JW, 1998, J PHYSIOL-LONDON, V512, P459, DOI 10.1111/j.1469-7793.1998.459be.x; DEITMER JW, 1989, J PHYSIOL-LONDON, V411, P179, DOI 10.1113/jphysiol.1989.sp017567; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; DEITMER JW, 2009, NEW ENCY NEUROSCIENC, V6, P739; DeVries SH, 2001, NEURON, V32, P1107, DOI 10.1016/S0896-6273(01)00535-9; Gawenis LR, 2007, J BIOL CHEM, V282, P9042, DOI 10.1074/jbc.M607041200; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hirrlinger PG, 2005, MOL CELL NEUROSCI, V30, P291, DOI 10.1016/j.mcn.2005.08.011; Igarashi T, 1999, NAT GENET, V23, P264, DOI 10.1038/15440; Majumdar D, 2010, NEUROSCIENCE, V171, P951, DOI 10.1016/j.neuroscience.2010.09.037; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; PAPPAS CA, 1994, J NEUROPHYSIOL, V72, P2816; Ransom BR, 2000, PROG BRAIN RES, V125, P217; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; ROSE CR, 1994, J PHYSIOL-LONDON, V481, P1, DOI 10.1113/jphysiol.1994.sp020413; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Ruminot I, 2011, J NEUROSCI, V31, P14264, DOI 10.1523/JNEUROSCI.2310-11.2011; Russell MB, 2011, LANCET NEUROL, V10, P457, DOI 10.1016/S1474-4422(11)70048-5; Stridh MH, 2012, J PHYSIOL-LONDON, V590, P2333, DOI 10.1113/jphysiol.2011.220152; Suzuki M, 2010, P NATL ACAD SCI USA, V107, P15963, DOI 10.1073/pnas.1008705107; Svichar N, 2011, J NEUROSCI, V31, P6997, DOI 10.1523/JNEUROSCI.6088-10.2011; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Yin T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072379; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	36	37	38	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 22	2014	34	4					1148	1157		10.1523/JNEUROSCI.2377-13.2014			10	Neurosciences	Neurosciences & Neurology	298YM	WOS:000330360700009	24453308	Green Published, Bronze			2021-06-18	
J	Robin, NC; Agoston, Z; Biechele, TL; James, RG; Berndt, JD; Moon, RT				Robin, Nicholas C.; Agoston, Zsuzsa; Biechele, Travis L.; James, Richard G.; Berndt, Jason D.; Moon, Randall T.			Simvastatin Promotes Adult Hippocampal Neurogenesis by Enhancing Wnt/beta-Catenin Signaling	STEM CELL REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; ISOPRENOIDS FARNESYL; PROTEIN PRENYLATION; ALZHEIMERS-DISEASE; STATINS; MICE; ACTIVATION; PATHWAY; MODULATION	Statins improve recovery from traumatic brain injury and show promise in preventing Alzheimer disease. However, the mechanisms by which statins may be therapeutic for neurological conditions are not fully understood. In this study, we present the initial evidence that oral administration of simvastatin in mice enhances Wnt signaling in vivo. Concomitantly, simvastatin enhances neurogenesis in cultured adult neural progenitor cells as well as in the dentate gyrus of adult mice. Finally, we find that statins enhance Wnt signaling through regulation of isoprenoid synthesis and not through cholesterol. These findings provide direct evidence that Wnt signaling is enhanced in vivo by simvastatin and that this elevation of Wnt signaling is required for the neurogenic effects of simvastatin. Collectively, these data add to the growing body of evidence that statins may have therapeutic value for treating certain neurological disorders.	[Robin, Nicholas C.; Biechele, Travis L.; Moon, Randall T.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; [Robin, Nicholas C.; Agoston, Zsuzsa; Biechele, Travis L.; James, Richard G.; Berndt, Jason D.; Moon, Randall T.] Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA; [Robin, Nicholas C.; Agoston, Zsuzsa; Biechele, Travis L.; James, Richard G.; Berndt, Jason D.; Moon, Randall T.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Robin, Nicholas C.; Agoston, Zsuzsa; Biechele, Travis L.; James, Richard G.; Berndt, Jason D.; Moon, Randall T.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [James, Richard G.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA 98101 USA	Moon, RT (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	rtmoon@uw.edu	Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; james, richard/0000-0002-2302-7367	Howard Hughes Medical InstituteHoward Hughes Medical Institute; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 GM01619, U01 HL100395]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL100395, R00HL103768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007507] Funding Source: NIH RePORTER	This work was supported by the Howard Hughes Medical Institute and National Institutes of Health grants P01 GM01619 and U01 HL100395.	Biechele TL, 2010, CHEM BIOL, V17, P1177, DOI 10.1016/j.chembiol.2010.08.012; Bonaguidi MA, 2011, CELL, V145, P1142, DOI 10.1016/j.cell.2011.05.024; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Eckert GP, 2009, NEUROBIOL DIS, V35, P251, DOI 10.1016/j.nbd.2009.05.005; ENDO A, 1992, J LIPID RES, V33, P1569; FEARS R, 1981, BIOCHEM J, V199, P1; Garbe DS, 2012, CELL MOL NEUROBIOL, V32, P1159, DOI 10.1007/s10571-012-9841-3; Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818; Hooff GP, 2012, MOL NEUROBIOL, V46, P179, DOI 10.1007/s12035-012-8285-6; Hughes AD, 1996, J HUM HYPERTENS, V10, P387; Jang MH, 2013, CELL STEM CELL, V12, P215, DOI 10.1016/j.stem.2012.11.021; Karki K, 2009, STROKE, V40, P3384, DOI 10.1161/STROKEAHA.108.544395; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lin CL, 2008, AM J NEPHROL, V28, P290, DOI 10.1159/000111142; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Luo YP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000898; Mahmood A., 2009, NEUROSURGERY, V65, P191, DOI DOI 10.1227/01.NEU.0000343540.24780.D6; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Palmer TD, 1999, J NEUROSCI, V19, P8487; Qiao LJ, 2011, MOL CELLS, V32, P437, DOI 10.1007/s10059-011-0107-6; Salins P, 2007, NEUROSCI LETT, V412, P211, DOI 10.1016/j.neulet.2006.07.045; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Seib DRM, 2013, CELL STEM CELL, V12, P204, DOI 10.1016/j.stem.2012.11.010; Smrt RD, 2007, NEUROBIOL DIS, V27, P77, DOI 10.1016/j.nbd.2007.04.005; Tamai I, 2000, J PHARM SCI-US, V89, P1371, DOI 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D; Tong XK, 2012, J NEUROSCI, V32, P4705, DOI 10.1523/JNEUROSCI.0169-12.2012; Tong XK, 2009, NEUROBIOL DIS, V35, P406, DOI 10.1016/j.nbd.2009.06.003; Wexler EM, 2009, STEM CELLS, V27, P1130, DOI 10.1002/stem.36; Wong WB, 2013, PHARMACOEPIDEM DR S, V22, P345, DOI 10.1002/pds.3381; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmerman Z.F., 2012, COLD SPRING HARB PER, V4, P4	37	37	39	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	2213-6711			STEM CELL REP	Stem Cell Rep.	JAN 14	2014	2	1					9	17		10.1016/j.stemcr.2013.11.002			9	Cell & Tissue Engineering; Cell Biology	Cell Biology	AI1XA	WOS:000336647300002	24511465	DOAJ Gold, Green Published			2021-06-18	
J	Andrewes, HE; Walker, V; O'Neill, B				Andrewes, H. E.; Walker, V.; O'Neill, B.			Exploring the use of positive psychology interventions in brain injury survivors with challenging behaviour	BRAIN INJURY			English	Article						Depression; positive psychology; traumatic brain injury; treatment	SELF-CONCEPT; NEUROPSYCHOLOGIC REHABILITATION; DEPRESSION; IDENTITY; THERAPY; ANXIETY	Objective: To investigate the feasibility and effectiveness of conducting two positive psychology interventions to improve mood and self-concept with survivors of traumatic brain injury (TBI), within a neuro-rehabilitation hospital. Method and procedures: Ten patients with brain injury were randomly allocated to an intervention and control group. The efficacy of the first intervention, `three positive things in life' was measured via Seligman's Authentic Happiness Index (AHI), at base-line, directly following the intervention and at the end of the 12-week group programme. The second intervention, the `Value in Action (VIA) signature strengths intervention' was measured by the Head Injury Semantic Differential Scale (HISDS) at baseline and at the end of the group. Results: Compared to baseline and control group scores, the AHI index showed an increase in the intervention group's happiness following the intervention and at the end of the 12-week programme, albeit the latter increase was non-significant. The HISDS showed non-significant improvement in self-concept and reduction in polarization of the self in the present, future and past in the second intervention. Anecdotal evidence revealed a clear improved mood following the interventions. Conclusion: This study shows promising results for the effectiveness of Positive Psychology interventions and methods to improve feasibility when applying this treatment within a hospital setting.	[Andrewes, H. E.; Walker, V.; O'Neill, B.] Brain Injury Rehabil Trust, Glasgow, Lanark, Scotland; [O'Neill, B.] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland	Andrewes, HE (corresponding author), Brain Injury Rehabil Trust, Graham Anderson House, Glasgow, Lanark, Scotland.	hollya@student.unimelb.edu.au					Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bateman A, 2013, NEUROPAGE INTRO; Ben-Yishay Y, 2008, NEUROPSYCHOL REHABIL, V18, P513, DOI 10.1080/09602010802141525; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Dewar BK, 2007, NEUROPSYCHOL REHABIL, V17, P602, DOI 10.1080/09602010601051610; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; Evans JJ, 2013, BRAIN IMPAIR, V12, P117; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; Myles SS, 2007, INT J PSYCHOL PSYCHO, V4, P487; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Osgood C, 1957, MEASUREMENT MEANING, P77; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Peterson C., 2004, CHARACTER STRENGTHS; ROBINSON RG, 1985, PSYCHOSOMATICS, V26, P769, DOI 10.1016/S0033-3182(85)72790-9; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Schueller SM, 2010, J POSIT PSYCHOL, V5, P253, DOI 10.1080/17439761003794130; Seligman M. E. P., 2006, AUTHENTIC HAPPINESS; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Snaith R.P., 1994, ACTA PSYCHIAT SCAND, V67, P361; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Tyerman A, 1987, THESIS U LONDON; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	37	39	1	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					965	971		10.3109/02699052.2014.888764			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600011	24826958				2021-06-18	
J	Taylor, PA; Ludwigsen, JS; Ford, CC				Taylor, Paul A.; Ludwigsen, John S.; Ford, Corey C.			Investigation of blast-induced traumatic brain injury	BRAIN INJURY			English	Article						Blast; mild traumatic brain injury; modelling; simulation	WHITE-MATTER	Objective: Many troops deployed in Iraq and Afghanistan have sustained blast-related, closed-head injuries from being within non-lethal distance of detonated explosive devices. Little is known, however, about the mechanisms associated with blast exposure that give rise to traumatic brain injury (TBI). This study attempts to identify the precise conditions of focused stress wave energy within the brain, resulting from blast exposure, which will correlate with a threshold for persistent brain injury. Methods: This study developed and validated a set of modelling tools to simulate blast loading to the human head. Using these tools, the blast-induced, early-time intracranial wave motions that lead to focal brain damage were simulated. Results: The simulations predict the deposition of three distinct wave energy components, two of which can be related to injury-inducing mechanisms, namely cavitation and shear. Furthermore, the results suggest that the spatial distributions of these damaging energy components are independent of blast direction. Conclusions: The predictions reported herein will simplify efforts to correlate simulation predictions with clinical measures of TBI and aid in the development of protective headwear.	[Taylor, Paul A.; Ludwigsen, John S.] Sandia Natl Labs, Terminal Ballist Technol, Albuquerque, NM 87185 USA; [Ford, Corey C.] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA	Taylor, PA (corresponding author), Sandia Natl Labs, Terminal Ballist Technol, POB 5800, Albuquerque, NM 87185 USA.	pataylo@sandia.gov					Bayly PV, 2013, APPL IMAGING TECHNIQ, V4, P117; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Brennen CE, 2003, P 5 INT S CAV OS JAP; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Carter DR, 1984, APPLETON LANGE; Centers for Disease Control and Prevention, 2007, TRAUM BRAIN INJ US; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischer H., 1991, US MILITARY CASUALTY, P1; Grujicic M, 2010, MULTIDISCIP MODEL MA, V6, P335, DOI 10.1108/15736101011080097; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; Hertel ES, 1998, CTH REFERENCE MANUAL; Hertel ES., 1995, SHOCK WAVES MARSEILL, P377, DOI [DOI 10.1007/978-3-642-78829-1_61, 10.1007/978-3-642-78829-1_61]; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; SIERRA Solid Mechanics Team, 2011, SIERR SOLIDMECHANICS; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	31	37	38	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					879	895		10.3109/02699052.2014.888478			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600001	24766453	Green Published, Bronze			2021-06-18	
J	Li, Q; Tian, Y; Wang, ZF; Liu, SB; Mi, WL; Ma, HJ; Wu, GC; Wang, J; Yu, J; Wang, YQ				Li, Q.; Tian, Y.; Wang, Z. -F.; Liu, S. -B.; Mi, W. -L.; Ma, H-J; Wu, G. -C.; Wang, J.; Yu, J.; Wang, Y. -Q.			INVOLVEMENT OF THE SPINAL NALP1 INFLAMMASOME IN NEUROPATHIC PAIN AND ASPIRIN-TRIGGERED-15-EPI-LIPDXIN A4 INDUCED ANALGESIA	NEUROSCIENCE			English	Article						NALP1 inflammasome; interleukin; neuropathic pain; aspirin-triggered-15-epi-lipoxin A4; caspase	TRAUMATIC BRAIN-INJURY; MOLECULAR PLATFORM; LIPID MEDIATORS; NERVE INJURY; LIPOXIN; CYTOKINES; RATS; IL-1-BETA; MINOCYCLINE; ACTIVATION	Neuroinflammation plays an important role in nerve-injury-induced neuropathic pain, but the explicit molecular mechanisms of neuroinflammation in neuropathic pain remain unclear. As one of the most critical inflammatory cytokines, interleukin-113 (IL-ID) has been regarded as broadly involved in the pathology of neuropathic pain. The inflammasome caspase-1 platform is one primary mechanism responsible for the maturation of IL-ID. Lipoxins, a type of endogenous anti-inflammatory lipid, have proved to be effective in relieving neuropathic pain behaviors. The present study was designed to examine whether the inflammasome caspase-1 IL-ID platform is involved in chronic constriction injury (CCI)-induced neuropathic pain and in lipoxin-induced analgesia. After rats were subjected to the CCI surgery, mature IL-ID was significantly increased in the ipsilateral spinal cord, and the inflammasome platform consisting of NALP1 (NAcht leucine-rich-repeat protein 1), caspase-1 and ASC (apoptosis-associated speck-like protein containing a caspase-activating recruitment domain) was also activated in spinal astrocytes and neurons, especially at the superficial laminae of the spinal dorsal horn; The aspirin-triggered-15epi-lipoxin A4 (ATL), which shares the potent actions of the endogenous lipoxins, was administered to the CCI rats. Repeated intrathecal injection with ATL markedly attenuated the CCI-induced thermal hyperalgesia and significantly inhibited NALP1 inflammasome activation, caspase-1 cleavage, and IL-10 maturation. These results suggested that spinal NALP1 inflammasome was involved in the CCI-induced neuropathic pain and that the analgesic effect of ATL was associated with suppressing NALP1 inflammasome activation. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	Shanghai Med Coll, Sch Basic Med Sci, Dept Integrat Med & Neurobiol, Shanghai, Peoples R China; Inst Brain Sci, Inst Acupuncture Res, Shanghai, Peoples R China; Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China	Wang, YQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Integrat Med & Neurobiol, Mail Box 291,138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.	wangyanqing@shmu.edu.cn	Mi, Wenli/P-5541-2019		National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [2013CB531906]; Excellent Doctoral Graduate Research Program of Fudan University [30970975, 31000495, 81171045, 81072875, 81371247, 31121061]; Ministry of Education of ChinaMinistry of Education, China [20100071120046, 20100071120042]	This work was supported by the National Key Basic Research program of China (2013CB531906), the National Natural Science Fund of China (30970975, 31000495, 81171045, 81072875, 81371247 and 31121061), the Excellent Doctoral Graduate Research Program of Fudan University and the Doctoral Fund of the Ministry of Education of China (Nos. 20100071120046, 20100071120042).	Alexander GM, 2005, PAIN, V116, P213, DOI 10.1016/j.pain.2005.04.013; Amin B, 2012, NEUROSCIENCE, V224, P15, DOI 10.1016/j.neuroscience.2012.07.058; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cunha TM, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-63; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hu S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-278; Jha Mithilesh Kumar, 2012, Immune Netw, V12, P41, DOI 10.4110/in.2012.12.2.41; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kleibeuker W, 2008, BRAIN BEHAV IMMUN, V22, P200, DOI 10.1016/j.bbi.2007.07.009; Kohno T, 2003, J PHYSIOL-LONDON, V548, P131, DOI 10.1113/jphysiol.2002.036186; Liao KC, 2009, INFECT IMMUN, V77, P4455, DOI 10.1128/IAI.00276-09; Luo CL, 2013, BRAIN RES, V1502, P1, DOI 10.1016/j.brainres.2013.01.037; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mawhinney LJ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-123; McCarberg B, 2006, AM J MANAG CARE, V12, pS263; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Pedra JHF, 2009, CURR OPIN IMMUNOL, V21, P10, DOI 10.1016/j.coi.2009.01.006; Romano M, 2010, THESCIENTIFICWORLDJO, V10, P1048, DOI 10.1100/tsw.2010.113; Salminen A, 2008, J CELL MOL MED, V12, P2255, DOI 10.1111/j.1582-4934.2008.00496.x; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Shi XY, 2011, ANESTH ANALG, V113, P175, DOI 10.1213/ANE.0b013e31821a0258; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Sonetti D, 2004, ACTA BIOL HUNG, V55, P273, DOI 10.1556/ABiol.55.2004.1-4.33; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Sun T, 2012, EUR J PAIN, V16, P18, DOI 10.1016/j.ejpain.2011.05.005; Sung CS, 2012, GLIA, V60, P2004, DOI 10.1002/glia.22415; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Thacker MA, 2007, ANESTH ANALG, V105, P838, DOI 10.1213/01.ane.0000275190.42912.37; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xu JJ, 2006, ANESTH ANALG, V103, P714, DOI 10.1213/01.ane.0000226100.46866.ea; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zou J, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00077	42	37	44	0	36	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 19	2013	254						230	240		10.1016/j.neuroscience.2013.09.028			11	Neurosciences	Neurosciences & Neurology	255ZN	WOS:000327279400021	24076348				2021-06-18	
J	Chen, CC; Wei, ST; Tsaia, SC; Chen, XX; Cho, DY				Chen, Chun-Chung; Wei, Sung-Tai; Tsaia, Shiu-Chiu; Chen, Xian-Xiu; Cho, Der-Yang			Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brain contusion; cerebrolysin; cognitive abilities screening instrument score; head injury; traumatic brain injury	HEAD-INJURY	In adults, mild traumatic brain injury (MTBI) frequently results in impairments of cognitive functions which would lead to psychological consequences in the future. Cerebrolysin is a nootropic drug, and can significantly improve cognitive function in patients with Alzheimer's disease and stroke. The purpose of this study was to investigate how Cerebrolysin therapy enhances cognitive recovery for mild traumatic brain injury patients using a double-blinded, placebo-controlled, randomized phase II pilot study. Patients having head injury within 24 h sent to our hospital were screened and recruited if patients were alert and conscious, and had intracranial contusion haemorrhage. From July 2009 to June 2010, totally, thirty-two patients were recruited in the double-blinded, placebo-controlled, and randomized study. Patients were randomized to receive Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60-min period for 5 days) or placebo (Group B, same dosage and administration of normal saline as Group A). The primary outcome measures were differences of cognitive function including Mini-Mental Status Examination (MMSE), and Cognitive Abilities Screening Instrument (CASI) scores between baseline and week 1, between baseline and week 4, and between baseline and week 12. Thirty-two patients completed the trial. For Group A, the CASI score difference between baseline and week 12 was 21.0 +/- 20.4, a significantly greater change than that of Group B (7.6 +/- 12.1) (p = 0.0461). Besides, drawing function (one of the domains of CASI; p = 0.0066) on week 4 and both drawing function (p = 0.0472) and long-term memory (one of the domains of CASI; p = 0.0256) on week 12were also found to be significantly improved in the patients receiving Cerebrolysin treatment. Our results suggest that Cerebrolysin improves the cognitive function of the MTBI in patients at 3rd month after injury, especially for long-term memory and drawing function.	[Chen, Chun-Chung; Wei, Sung-Tai; Tsaia, Shiu-Chiu; Cho, Der-Yang] China Med Univ Hosp, Dept Neurosurg, Taichung 40402, Taiwan; [Chen, Chun-Chung; Cho, Der-Yang] China Med Univ, Coll Med, Taichung, Taiwan; [Chen, Xian-Xiu] China Med Univ, Inst Publ Hlth, Taichung, Taiwan	Chen, CC (corresponding author), China Med Univ Hosp, Dept Neurosurg, 2 Yu Der Rd, Taichung 40402, Taiwan.	cck36701@gmail.com		Chen, XianXiu/0000-0002-7955-9506			Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; [Anonymous], 2005, MED SCI, V26, P104; Bae CY, 2000, J AM GERIATR SOC, V48, P1566, DOI 10.1111/j.1532-5415.2000.tb03865.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Graves A. B., 1993, ALZHEIMERS DIS ADV C, P113; Gromova OA, 2003, ZH NEVROPATOL PSIKH, V103, P59; Gromova OA, 1998, ZH NEVROPATOL PSIKH, V98, P27; Heiss WD, 2012, STROKE, V43, P630, DOI 10.1161/STROKEAHA.111.628537; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kraus F, 2005, TXB TRAUMATIC BRAIN; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Prigatano GP, 1998, BNI Q, V4, P30; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; TEASDALE G, 1974, LANCET, V2, P81; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59	20	37	41	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	DEC	2013	27	6					803	807		10.3109/02688697.2013.793287			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	268KF	WOS:000328168100018	23656173				2021-06-18	
J	Farooqui, A; Hiser, B; Barnes, SL; Litofsky, NS				Farooqui, Ali; Hiser, Bradley; Barnes, Stephen L.; Litofsky, N. Scott			Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						deep venous thrombosis; traumatic brain injury; chemoprophylaxis; Lovenox; heparin	MOLECULAR-WEIGHT HEPARIN; DEEP VENOUS THROMBOSIS; ENOXAPARIN PROPHYLAXIS; HEAD; NEUROSURGERY; PREVENTION; EVENT	Object. Patients with traumatic brain injury (TBI) are at risk for development of thromboembolic disease. The use of chemoprophylaxis in this patient group has not fully been characterized. The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious. Methods. In May 2009, a protocol was instituted for patients with TBI where chemoprophylaxis for thromboembolic disease (either 30 mg of Lovenox twice daily or 5000 U of heparin 3 times a day) was initiated 24 hours after an intracranial hemorrhage (ICH) was demonstrated as stable on head CT image. Two cohorts were evaluated: Cohort A included patients from May 2008 through April 2009 who had no routine administration of chemoprophylaxis, and Cohort B included patients from May 2009 through May 2010 after the protocol was instituted. The groups were compared, with the major outcomes being deep venous thrombosis (DVT), pulmonary embolism, and increase in size of ICH. Results. Of the 312 patients with TBI who were seen during the study course, 236 patients met criteria for inclusion in the study: 107 patients in Cohort A and 129 patients in Cohort B. The DVT rate was 6 occurrences (5.61%) in Cohort A and 0 occurrences (0%) in Cohort B, which was a statistically significant difference (p = 0.0080). Pulmonary embolism was found in 4 patients (3.74%) in Cohort A and 1 patient (0.78%) in Cohort B, a difference that did not reach statistical significance (p = 0.18). Three instances (2.8%) in Cohort A and 1 instance (0.7%) in Cohort B of increased ICH occurred after starting anticoagulation for chemoprophylaxis; this was not statistically different (p = 0.33). Conclusions. Use of chemoprophylaxis in TBI 24 hours after stable head CT is safe and decreases the rate of DVT formation.	[Farooqui, Ali; Litofsky, N. Scott] Univ Missouri, Sch Med, Div Neurol Surg, Columbia, MO 65212 USA; [Barnes, Stephen L.] Univ Missouri, Sch Med, Div Acute Care Surg, Columbia, MO 65212 USA; [Hiser, Bradley] St Lukes Med Ctr, Kansas City, MO USA	Litofsky, NS (corresponding author), Univ Missouri, Sch Med, Div Neurol Surg, 1 Hosp Dr,MC 321, Columbia, MO 65212 USA.	litofskyn@health.missouri.edu		Barnes, Stephen/0000-0001-6186-1435	Division of Neurological Surgery, University of Missouri-Columbia School of Medicine	This work was supported by research funds from the Division of Neurological Surgery, University of Missouri-Columbia School of Medicine. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Barmparas G, 2012, AM SURGEON, V78, P1166; Cage TA, 2009, J NEURO-ONCOL, V93, P151, DOI 10.1007/s11060-009-9886-4; Chibbaro S, 2008, SURG NEUROL, V70, P117, DOI 10.1016/j.surneu.2007.06.081; Collen JF, 2008, CHEST, V134, P237, DOI 10.1378/chest.08-0023; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Khaldi A, 2011, J NEUROSURG, V114, P40, DOI 10.3171/2010.8.JNS10332; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Kwiatt ME, 2012, J TRAUMA ACUTE CARE, V73, P625, DOI 10.1097/TA.0b013e318265cab9; Minshall CT, 2011, J TRAUMA, V71, P396, DOI 10.1097/TA.0b013e31822734c9; Mohseni Shahin, 2012, J Emerg Trauma Shock, V5, P11, DOI 10.4103/0974-2700.93102; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; O'Carroll CB, 2011, NEUROLOGIST, V17, P232, DOI 10.1097/NRL.0b013e318222d6c0; Rayan N, 2012, J TRAUMA ACUTE CARE, V72, P585, DOI 10.1097/TA.0b013e318243da4d; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Saadeh Y, 2012, J TRAUMA ACUTE CARE, V73, P426, DOI 10.1097/TA.0b013e31825a758b; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Thorson CM, 2012, CRIT CARE MED, V40, P2967, DOI 10.1097/CCM.0b013e31825bcb60	23	37	38	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2013	119	6					1576	1582		10.3171/2013.8.JNS13424			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	257EU	WOS:000327367200031	24053504				2021-06-18	
J	Pascual, JL; Murcy, MA; Li, SH; Gong, WF; Eisenstadt, R; Kumasaka, K; Sims, C; Smith, DH; Browne, K; Allen, S; Baren, J				Pascual, Jose L.; Murcy, Mohammad A.; Li, Shenghui; Gong, Wanfeng; Eisenstadt, Rachel; Kumasaka, Kenichiro; Sims, Carrie; Smith, Douglas H.; Browne, Kevin; Allen, Steve; Baren, Jill			Neuroprotective effects of progesterone in traumatic brain injury: blunted in vivo neutrophil activation at the blood-brain barrier	AMERICAN JOURNAL OF SURGERY			English	Article						Intravital microscopy; Neutrophil; Endothelium; Blood-brain barrier; Traumatic brain injury; Progesterone	HYPERTONIC SALINE; INFLAMMATION; HORMONES; SODIUM; EDEMA	BACKGROUND: Progesterone (PRO) may confer a survival advantage in traumatic brain injury (TBI) by reducing cerebral edema. We hypothesized that PRO reduces edema by blocking polymorphonuclear (PMN) interactions with endothelium (EC) in the blood-brain barrier (BBB). METHODS: CD1 mice received repeated PRO (16 mg/kg intraperitoneally) or vehicle (cyclodextrin) for 36 hours after TBI. Sham animals underwent craniotomy without TBI. The modified Neurological Severity Score graded neurologic recovery. A second craniotomy allowed in vivo observation of pial EC/PMN interactions and vascular macromolecule leakage. Wet/dry ratios assessed cerebral edema. RESULTS: Compared with the vehicle, PRO reduced subjective cerebral swelling (2.9 +/- .1 vs 1.2 +/- .1, P < .001), PMN rolling (95 +/- 1.8 vs 57 +/- 2.0 cells/100 mu m/min P < .001), total EC/PMN adhesion (2.0 +/- .4 vs .8 +/- .1 PMN/100 mu m, P < .01), and vascular permeability (51.8% +/- 4.9% vs 27.1% +/- 4.6%, P < .01). TBI groups had similar a Neurological Severity Score and cerebral wet/dry ratios (P > .05). CONCLUSIONS: PRO reduces live pericontusional EC/PMN and BBB macromolecular leakage after TBI. Direct PRO effects on the microcirculation warrant further investigation. (C) 2013 Elsevier Inc. All rights reserved.	[Pascual, Jose L.; Murcy, Mohammad A.; Gong, Wanfeng; Eisenstadt, Rachel; Kumasaka, Kenichiro; Sims, Carrie; Allen, Steve] Univ Penn, Div Traumatol Surg Crit Care & Emergency Surg, Dept Surg, Perelman Sch Med,Trauma Ctr Penn, Philadelphia, PA 19104 USA; [Li, Shenghui] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Tianjin, Peoples R China; [Smith, Douglas H.; Browne, Kevin] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA; [Baren, Jill] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA	Pascual, JL (corresponding author), Univ Penn, Div Traumatol Surg Crit Care & Emergency Surg, Dept Surg, Perelman Sch Med,Trauma Ctr Penn, 3400 Spruce St,Maloney Bldg,5th Floor, Philadelphia, PA 19104 USA.	jose.pascual@uphs.upenn.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12 HL109009] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL109009] Funding Source: NIH RePORTER		BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Chaveiro A, 2010, REPROD DOMEST ANIM, V45, pE40, DOI 10.1111/j.1439-0531.2009.01519.x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hermenegildo C, 2005, J PHARMACOL EXP THER, V315, P722, DOI 10.1124/jpet.105.090456; Kim JV, 2006, J IMMUNOL, V177, P5269, DOI 10.4049/jimmunol.177.8.5269; Li S, 2011, CRIT CARE MED, V39, P1493, DOI 10.1097/CCM.0b013e31821201d3; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; MIYAGI M, 1992, J PERIODONTOL, V63, P28, DOI 10.1902/jop.1992.63.1.28; Orvieto R, 1999, AM J REPROD IMMUNOL, V42, P288; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Pascual JL, 2003, J TRAUMA, V54, pS133, DOI 10.1097/01.TA.0000064526.33647.63; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; ROTH JA, 1983, AM J VET RES, V44, P247; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	26	37	39	0	8	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2013	206	6					840	845		10.1016/j.amjsurg.2013.07.016			6	Surgery	Surgery	267CT	WOS:000328075000004	24112683	Green Accepted			2021-06-18	
J	Biderman, P; Einav, S; Fainblut, M; Stein, M; Singer, P; Medalion, B				Biderman, Philippe; Einav, Sharon; Fainblut, Michael; Stein, Michael; Singer, Pierre; Medalion, Benjamin			Extracorporeal life support in patients with multiple injuries and severe respiratory failure: A single-center experience?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Extracorporeal membrane oxygenation; adult respiratory distress syndrome; multiple trauma; traumatic brain injury	MEMBRANE-OXYGENATION; LUNG ASSIST; PROFOUND HYPOTHERMIA; SUSPENDED ANIMATION; SWINE MODEL; INDUCTION; REVERSAL; ARREST; BLOOD; TRIAL	BACKGROUND: The use of extracorporeal life support in trauma casualties is limited by concerns regarding hemorrhage, particularly in the presence of traumatic brain injury (TBI). We report the use of extracorporeal membrane oxygenation (ECMO)/interventional lung assist (iLA) as salvage therapy in trauma patients. High-flow technique without anticoagulation was used in patients with coagulopathy or TBI. METHODS: Data were collected from all adult trauma patients referred to one center for ECMO/iLA treatment owing to severe hypoxemic respiratory failure. RESULTS: Ten casualties had a mean (SD) Injury Severity Score (ISS) of 50.3 (10.5) (mean [SD] age, 29.8 [7.7] years; 60% male) and were supported 9.5 (4.5) days on ECMO (n = 5) and 7.6 (6.5) days on iLA (n = 5). All experienced blunt injury with severe chest injuries, including one cardiac perforation. Most were coagulopathic before initiation of ECMO/iLA support. Among the seven patients with TBI, four had active intracranial hemorrhage. Complications directly related to support therapy were not lethal; these included hemorrhage from a cannulation site (n = 1), accidental removal of a cannula (n = 1), and pressure sores (n = 3). Deaths occurred owing to septic (n = 2) and cardiogenic shock (n = 1). Survival rates were 60% and 80% on ECMO and iLA, respectively. Follow-up of survivors detected no neurologic deterioration. CONCLUSION: ECMO/iLA therapy can be used as a rescue therapy in adult trauma patients with severe hypoxemic respiratory failure, even in the presence of coagulopathy and/or brain injury. The benefits of rewarming, acid-base correction, oxygenation, and circulatory support must be weighed individually against the risk of hemorrhage. Further research should determine whether ECMO therapy also confers survival benefit. (J Trauma Acute Care Surg. 2013;75:907-912. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Biderman, Philippe; Fainblut, Michael; Medalion, Benjamin] Tel Aviv Univ, Rabin Med Ctr, Dept Cardiothorac Surg, IL-69978 Tel Aviv, Israel; [Stein, Michael] Tel Aviv Univ, Rabin Med Ctr, Trauma Unit, IL-69978 Tel Aviv, Israel; [Singer, Pierre] Tel Aviv Univ, Rabin Med Ctr, Dept Gen Intens Care, IL-69978 Tel Aviv, Israel; [Einav, Sharon] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Gen Intens Care Unit, Jerusalem, Israel	Biderman, P (corresponding author), Tel Aviv Univ, Rabin Med Ctr, Dept Cardiothorac Surg, 39 Jabotinsky St, IL-49100 Petah Tiqwa, Israel.	philipb2@clalit.org.il					Alam HB, 2006, J TRAUMA, V61, P1321, DOI 10.1097/01.ta.0000244414.76523.d8; Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Behringer W, 2003, CRIT CARE MED, V31, P1523, DOI 10.1097/01.CCM.0000063450.73967.40; Bein T, 2010, INT J EMERG MED, V3, P177, DOI 10.1007/s12245-010-0192-x; Bellamy R, 1996, CRIT CARE MED, V24, pS24; Brederlau J, 2004, J CARDIOTHOR VASC AN, V18, P777, DOI 10.1053/j.jvca.2004.08.022; Capone A, 1996, J TRAUMA, V40, P388, DOI 10.1097/00005373-199603000-00011; Casas F, 2005, ARTIF ORGANS, V29, P557, DOI 10.1111/j.1525-1594.2005.29092.x; Chaiwat O, 2009, ANESTHESIOLOGY, V110, P351, DOI 10.1097/ALN.0b013e3181948a97; GENTILELLO LM, 1992, J TRAUMA, V32, P316, DOI 10.1097/00005373-199203000-00009; Lambrechts DL, 2003, TEX HEART I J, V30, P65; Madershahian N, 2007, J CARDIAC SURG, V22, P180, DOI 10.1111/j.1540-8191.2007.00381.x; Masroor S, 2004, J TRAUMA, V57, P389, DOI 10.1097/01.TA.0000037285.52097.8C; Meduri GU, 2008, INTENS CARE MED, V34, P61, DOI 10.1007/s00134-007-0933-3; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; PERCHINSKY MJ, 1995, AM J SURG, V169, P488, DOI 10.1016/S0002-9610(99)80201-3; Petrucci N, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub3; Reng M, 2000, LANCET, V356, P219, DOI 10.1016/S0140-6736(00)02485-5; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Tagarakis Georgios I, 2009, Recent Pat Cardiovasc Drug Discov, V4, P177; TAYLOR MJ, 1995, CIRCULATION, V91, P431, DOI 10.1161/01.CIR.91.2.431; Wallace DJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8946; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; Zimmermann M, 2006, BRIT J ANAESTH, V96, P63, DOI 10.1093/bja/aei274	25	37	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2013	75	5					907	912		10.1097/TA.0b013e3182a8334f			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300IP	WOS:000330457900025	24158215				2021-06-18	
J	Shi, J; Longo, FM; Massa, SM				Shi, Jian; Longo, Frank M.; Massa, Stephen M.			A Small Molecule p75(NTR) Ligand Protects Neurogenesis After Traumatic Brain Injury	STEM CELLS			English	Article						Traumatic brain injury; Neurotrophin; Neurogenesis; Hippocampus	P75 NEUROTROPHIN RECEPTOR; CELL-ADHESION MOLECULE; REGULATES HIPPOCAMPAL NEUROGENESIS; NERVE GROWTH-FACTOR; DENTATE GYRUS; UP-REGULATION; EXPRESSION PATTERNS; FUNCTIONAL RECOVERY; PROGENITOR CELLS; NEWBORN NEURONS	The p75 neurotrophin receptor (p75(NTR)) influences the proliferation, survival, and differentiation of neuronal precursors and its expression is induced in injured brain, where it regulates cell survival. Here, we test the hypotheses that pharmacologic modulation of p75(NTR) signaling will promote neural progenitor survival and proliferation, and improve outcomes of traumatic brain injury (TBI). LM11A-31, an orally available, blood-brain barrier-permeant small-molecule p75(NTR) signaling modulator, significantly increased proliferation and survival, and decreased JNK phosphorylation, in hippocampal neural stem/progenitor cells in culture expressing wild-type p75(NTR), but had no effect on cells expressing a mutant neurotrophin-unresponsive form of the receptor. The compound also enhanced the production of mature neurons from adult hippocampal neural progenitors in vitro. In vivo, intranasal administration of LM11A-31 decreased postinjury hippocampal and cortical neuronal death, neural progenitor cell death, gliogenesis, and microglial activation, and enhanced long-term hippocampal neurogenesis and reversed spatial memory impairments. LM11A-31 diminished the postinjury increase of SOX2-expressing early progenitor cells, but protected and increased the proliferation of endogenous polysialylated-neural cell adhesion molecule positive intermediate progenitors, and restored the long-term production of mature granule neurons. These findings suggest that modulation of p75(NTR) actions using small molecules such as LM11A-31 may constitute a potent therapeutic strategy for TBI. Stem Cells2013;31:2561-2574	[Shi, Jian; Massa, Stephen M.] Dept Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA USA; [Shi, Jian; Massa, Stephen M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Massa, SM (corresponding author), San Francisco VA Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	Stephen.Mas-sa@ucsf.edu			Department of DefenseUnited States Department of Defense [DOD DAMD17-03-1-0532]; Veterans AdministrationUS Department of Veterans Affairs	These studies were supported by the Department of Defense (DOD DAMD17-03-1-0532 to SMM); and the Veterans Administration (SMM).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bernabeu RO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-136; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Catts VS, 2008, EUR J NEUROSCI, V28, P883, DOI 10.1111/j.1460-9568.2008.06390.x; Colditz MJ, 2010, EXP BRAIN RES, V200, P161, DOI 10.1007/s00221-009-1947-6; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Diarra Adama, 2009, Biochem Biophys Res Commun, V390, P352, DOI 10.1016/j.bbrc.2009.09.116; Dougherty KD, 1999, J COMP NEUROL, V407, P77, DOI 10.1002/(SICI)1096-9861(19990428)407:1<77::AID-CNE6>3.0.CO;2-S; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Galvao RP, 2008, J NEUROSCI, V28, P13368, DOI 10.1523/JNEUROSCI.2918-08.2008; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gascon E, 2005, EUR J NEUROSCI, V21, P69, DOI 10.1111/j.1460-9568.2004.03849.x; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gu Yan, 2013, Curr Top Behav Neurosci, V15, P31, DOI 10.1007/7854_2012_217; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Islam O, 2009, CURR NEUROVASC RES, V6, P42, DOI 10.2174/156720209787466028; James SE, 2008, NEUROTOXICOLOGY, V29, P605, DOI 10.1016/j.neuro.2008.04.008; Kaneko N, 2006, GENES CELLS, V11, P1145, DOI 10.1111/j.1365-2443.2006.01010.x; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Knowles JK, 2013, NEUROBIOL AGING, V34, P2052, DOI 10.1016/j.neurobiolaging.2013.02.015; Knowles JK, 2009, J NEUROSCI, V29, P10627, DOI 10.1523/JNEUROSCI.0620-09.2009; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Longo FM, 2008, CNS NEUROL DISORD-DR, V7, P63, DOI 10.2174/187152708783885093; Longo FM, 2013, NAT REV DRUG DISCOV, V12, P507, DOI 10.1038/nrd4024; Lopez-Fernandez MA, 2007, J NEUROSCI, V27, P4552, DOI 10.1523/JNEUROSCI.0396-07.2007; Luikart BW, 2012, BEHAV BRAIN RES, V227, P348, DOI 10.1016/j.bbr.2011.03.048; Maric D, 1998, METHODS, V16, P247, DOI 10.1006/meth.1998.0682; Markram K, 2007, NEUROSCIENCE, V144, P788, DOI 10.1016/j.neuroscience.2006.10.024; Massa SM, 2006, J NEUROSCI, V26, P5288, DOI 10.1523/JNEUROSCI.3547-05.2006; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Meeker RB, 2012, J NEUROIMMUNE PHARM, V7, P388, DOI 10.1007/s11481-011-9325-0; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MRZLJAK L, 1993, CEREB CORTEX, V3, P133, DOI 10.1093/cercor/3.2.133; Namba T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025303; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; NYAKAS C, 1987, BRAIN RES BULL, V18, P533, DOI 10.1016/0361-9230(87)90117-1; Pehar M, 2006, EUR J NEUROSCI, V24, P1575, DOI 10.1111/j.1460-9568.2006.05040.x; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Seki T, 2002, J NEUROSCI RES, V70, P327, DOI 10.1002/jnr.10387; Seki T, 1999, J COMP NEUROL, V410, P115, DOI 10.1002/(SICI)1096-9861(19990719)410:1<115::AID-CNE10>3.0.CO;2-C; Shi J, 2005, CELL DEATH DIFFER, V12, P1601, DOI 10.1038/sj.cdd.4401676; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Sotthibundhu A, 2009, NEUROBIOL AGING, V30, P1975, DOI 10.1016/j.neurobiolaging.2008.02.004; Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Van der Borght K, 2005, BEHAV NEUROSCI, V119, P926, DOI 10.1037/0735-7044.119.4.926; Van Hoesen GW, 1999, ANN NY ACAD SCI, V877, P575; Venero C, 2006, EUR J NEUROSCI, V23, P1585, DOI 10.1111/j.1460-9568.2006.04663.x; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Waterhouse EG, 2012, J NEUROSCI, V32, P14318, DOI 10.1523/JNEUROSCI.0709-12.2012; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Yang T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003604; Ying WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2728, DOI 10.2741/2267; Young KM, 2007, J NEUROSCI, V27, P5146, DOI 10.1523/JNEUROSCI.0654-07.2007; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang JS, 2007, NAT NEUROSCI, V10, P77, DOI 10.1038/nn1816; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	76	37	41	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	NOV	2013	31	11					2561	2574		10.1002/stem.1516			14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	252QY	WOS:000327025600025	23940017	Bronze			2021-06-18	
J	Zhang, YQ; Li, Y; Wang, SB; Han, ZY; Huang, XT; Li, SH; Chen, FL; Niu, RD; Dong, JF; Jiang, RC; Zhang, JN				Zhang, Yongqiang; Li, Ying; Wang, Shaobo; Han, Zhenying; Huang, Xintao; Li, Shenghui; Chen, Fanglian; Niu, Rongdong; Dong, Jing-fei; Jiang, Rongcai; Zhang, Jianning			Transplantation of expanded endothelial colony-forming cells improved outcomes of traumatic brain injury in a mouse model	JOURNAL OF SURGICAL RESEARCH			English	Article						Endothelial colony-forming cells; Traumatic brain injury; Cell transplantation; Angiogenesis; Functional recovery	NEURAL STEM-CELLS; CORD BLOOD-CELLS; PROGENITOR CELLS; GROWTH-FACTOR; AUTOLOGOUS TRANSPLANTATION; THERAPEUTIC ANGIOGENESIS; CROSS-TALK; IN-VITRO; NEOVASCULARIZATION; OUTGROWTH	Background: Endothelial progenitor cells (EPCs) are critical for repairing injured tissue. Endothelial colony-forming cells (ECFCs) are a homogeneous subtype of EPCs. We investigated whether intravenously infused human ECFCs homed to injured brain promoted angiogenesis and ameliorate neurologic disabilities in a mouse model of traumatic brain injury. Materials and methods: ECFCs were generated by in vitro propagation of EPCs from human umbilical cord blood. Young female nude mice received intravenously ECFCs from human newborns (1 x 10(6)) 1 h after they were exposed to lateral fluid percussion injury. Neurologic function was evaluated by a modified neurologic severity score and Morris water maze. ECFC homing and neovascularization at the site of injury were examined by fluorescence in situ hybridization and histochemistry on days 2 and 14 after injury, respectively. Results: Donor ECFCs were detected in injured brain 24 h after infusion. The modified neurologic severity score and Morris water maze tests were used to evaluate neurologic disability, and found the rate of neurologic disability was improved in mice that received ECFCs. Microvessel density and expression of the proangiogenic growth factors stromal cell -derived factor-1 and vascular endothelial growth factor were also increased in the region of injured brain from mice that received ECFCs compared with those received vehicle control. Conclusions: These data suggest that ECFCs are effective in promoting neovascularization and improving neurologic functions after traumatic brain injury. (C) 2013 Published by Elsevier Inc.	[Zhang, Yongqiang; Wang, Shaobo; Han, Zhenying; Huang, Xintao; Li, Shenghui; Chen, Fanglian; Niu, Rongdong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Li, Ying] Tianjin Med Univ, Gen Hosp, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin 300052, Peoples R China; [Dong, Jing-fei] Univ Washington, Sch Med, Puget Sound Blood Ctr Res Inst, Seattle, WA USA	Zhang, JN (corresponding author), Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com		Huang, Xintao/0000-0002-9683-9518	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81100920, 81200907]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCQNJC07200, 12JCQNJC6800]	We acknowledge Li Liu, Yanjun Zhang, Weiyun Cui, and Lei Zhou for their assistance with the technical aspects of experiments and data interpretation. This work is supported by the National Natural Science Foundation of China (grants 81271361; 81100920; 81200907) and Tianjin Research Program of Application Foundation and Advanced Technology (grants 12JCQNJC07200; 12JCQNJC6800).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Barresi V, 2007, ACTA NEUROPATHOL, V114, P147, DOI 10.1007/s00401-007-0251-4; Bogoslovsky T, 2010, NEUROLOGY, V75, P2059, DOI 10.1212/WNL.0b013e318200d741; Bompais H, 2004, BLOOD, V103, P2577, DOI 10.1182/blood-2003-08-2770; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chu K, 2008, STROKE, V39, P1441, DOI 10.1161/STROKEAHA.107.499236; Di Stefano R, 2009, THROMB RES, V123, P925, DOI 10.1016/j.thromres.2008.10.013; Erbs S, 2005, CIRC RES, V97, P756, DOI 10.1161/01.RES.0000185811.71306.8b; Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Huang PP, 2004, THROMB HAEMOSTASIS, V91, P606, DOI 10.1160/TH03-06-0343; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jujo K, 2008, J MOL CELL CARDIOL, V45, P530, DOI 10.1016/j.yjmcc.2008.08.003; Kogler G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Lavergne M, 2011, CELL PROLIFERAT, V44, P44, DOI 10.1111/j.1365-2184.2010.00722.x; Lee CW, 2011, HYPERTENS RES, V34, P999, DOI 10.1038/hr.2011.68; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Moise KJ, 2005, OBSTET GYNECOL, V106, P1393, DOI 10.1097/01.AOG.0000188388.84901.e4; Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Renault MA, 2007, MICROVASC RES, V74, P159, DOI 10.1016/j.mvr.2007.08.005; Rocha V, 2006, BIOL BLOOD MARROW TR, V12, P34, DOI 10.1016/j.bbmt.2005.09.006; Rosenkranz K, 2010, J NEUROSCI RES, V88, P1223, DOI 10.1002/jnr.22292; Senegaglia AC, 2008, REV BRAS CIR CARDIOV, V23, P467, DOI 10.1590/S0102-76382008000400003; Sharma M, 2011, STEM CELLS DEV, V20, P933, DOI 10.1089/scd.2010.0263; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Ward NL, 2004, NEUROL RES, V26, P870, DOI 10.1179/016164104X3798; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	42	37	40	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	NOV	2013	185	1					441	449		10.1016/j.jss.2013.05.073			9	Surgery	Surgery	238MP	WOS:000325951100084	23953790				2021-06-18	
J	Empey, PE; de Mendizabal, NV; Bell, MJ; Bies, RR; Anderson, KB; Kochanek, PM; Adelson, PD; Poloyac, SM				Empey, Philip E.; de Mendizabal, Nieves Velez; Bell, Michael J.; Bies, Robert R.; Anderson, Kacey B.; Kochanek, Patrick M.; Adelson, P. David; Poloyac, Samuel M.		Pediat TBI Consortium Hypothermia	Therapeutic Hypothermia Decreases Phenytoin Elimination in Children with Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						children; drug metabolism; hypothermia; phenytoin; pharmacokinetics; traumatic brain injury	MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CARDIAC-ARREST; PHARMACOKINETICS; METABOLISM; PHARMACODYNAMICS; FOSPHENYTOIN; NEUROTRAUMA	Objective: Preclinical and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic injury, may also lead to drug toxicity that may limit its benefit. Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that drug levels are elevated. Fosphenytoin is metabolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic medication. The objective of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmacokinetics in children with severe traumatic brain injury. Design: Pharmacokinetic analysis of subjects participating in a multicenter randomized phase III study of therapeutic hypothermia for severe traumatic brain injury. Setting: ICU at the Children's Hospital of Pittsburgh. Patients: Nineteen children with severe traumatic brain injury. Interventions: None. Measurements and Main Results: A sum of 121 total and 114 free phenytoin levels were evaluated retrospectively in 10 hypothermia-treated and nine normothermia-treated children who were randomized to 48 hours of cooling to 32-33 degrees C followed by slow rewarming or controlled normothermia. Drug dosing, body temperatures, and demographics were collected during cooling, rewarming, and posttreatment periods (8 d). A trend toward elevated free phenytoin levels in the hypothermia group (p = 0.051) to a median of 2.2 mg/L during rewarming was observed and was not explained by dosing differences. Nonlinear mixed-effects modeling incorporating both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-variant component of the maximum velocity of phenytoin metabolism (V-max) 4.6-fold (11.6-2.53 mg/hr) and reduced the overall V-max by similar to 50%. Simulations showed that the increased risk for drug toxicity extends many days beyond the end of the cooling period. Conclusions: Therapeutic hypothermia significantly reduces phenytoin elimination in children with severe traumatic brain injury leading to increased drug levels for an extended period of time after cooling. Pharmacokinetic interactions between hypothermia and medications should be considered when caring for children receiving this therapy.	[Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [de Mendizabal, Nieves Velez; Bies, Robert R.] Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA; [de Mendizabal, Nieves Velez; Bies, Robert R.] Indiana Univ, Indiana Clin & Translat Sci Inst, Indianapolis, IN 46204 USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Anderson, Kacey B.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Child Hlth, Div Neurosurg Childrens Neurosci, Phoenix, AZ USA	Poloyac, SM (corresponding author), 3501 Terrace St,807 Salk Hall, Pittsburgh, PA 15261 USA.	poloyac@pitt.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019; Empey, Philip/L-9604-2019	Kochanek, Patrick M/0000-0002-2627-913X; Empey, Philip/0000-0001-7474-2339	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Indiana CTSI; NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS); Laerdal Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Integra Life Sciences; Codman; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM073031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS052478, P01NS030318] Funding Source: NIH RePORTER	Dr. Empey received grant support from the National Institutes of Health (NIH). Dr. Bell received grant support from NIH. Dr. Bies has received grant support from Indiana CTSI through a gift of Eli Lilly and Company. He has received payment for lectures from NIGMS and has received travel reimbursements from Indiana CTSI, Uppsala University, and NIAID/NIDA. Dr. Poloyac received grant support from NIH and support for travel from the American College of Clinical Pharmacy. Dr. Kochanek received grant support from the Laerdal Foundation and National Institutes of Health and disclosed having United States provisional patents (Method of Inducing EPR Following Cardiopulmonary Arrest and Small Molecule Inhibitors of RNA Binding MOTIF (RBM) Proteins for the Treatment of Acute Cellular Injury) and a CMU Invention Disclosure (Validation of a Multiplex Biomarker Panel for Detection of Abusive Head Trauma in Well-Appearing Children Carnegie Mellon University, Center for Technology Transfer and Enterprise Creation). Dr. Adelson received grant support from NIH, Integra Life Sciences, and Codman and consulted for Tramatec.	Adams BD, 2006, J EMERG MED, V30, P75, DOI 10.1016/j.jemermed.2005.01.034; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson BJ, 2005, PAEDIAT PERINAT DRUG, V6, P133; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BAUER LA, 1983, CLIN PHARMACOKINET, V8, P545, DOI 10.2165/00003088-198308060-00006; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; Boucher BA, 1996, PHARMACOTHERAPY, V16, P777; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Davis Parke, 2012, ANDA 084349 DILANTIN; de Haan TR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-45; de Toledo JS, 2010, PEDIATR CRIT CARE ME, V11, P439, DOI 10.1097/PCC.0b013e3181c510e9; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Frend V, 2007, CLIN NEUROPHARMACOL, V30, P362, DOI 10.1097/WNF.0b013e318059ae1c; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McKindley DS, 1997, J CLIN PHARMACOL, V37, P129, DOI 10.1002/j.1552-4604.1997.tb04771.x; OMARA NB, 1995, CRIT CARE MED, V23, P1418, DOI 10.1097/00003246-199508000-00017; Pfizer Pharmaceuticals, 2011, DIL PHEN SOD; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Stowe CD, 2000, J CLIN PHARMACOL, V40, P1452; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; von Winckelmann SL, 2008, PHARMACOTHERAPY, V28, P1391, DOI 10.1592/phco.28.11.1391; VOZEH S, 1981, J PHARMACOKINET BIOP, V9, P131, DOI 10.1007/BF01068078; Zhou JQ, 2011, DRUG METAB DISPOS, V39, P2209, DOI 10.1124/dmd.111.040642; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127	40	37	38	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2013	41	10					2379	2387		10.1097/CCM.0b013e318292316c			9	Critical Care Medicine	General & Internal Medicine	225AP	WOS:000324935000034	23896831	Green Accepted			2021-06-18	
J	Lim, SW; Wang, CC; Wang, YH; Chio, CC; Niu, KC; Kuo, JR				Lim, Sher-Wei; Wang, Che-Chuan; Wang, Yun-Han; Chio, Chung-Ching; Niu, Ko-Chi; Kuo, Jinn-Rung			Microglial activation induced by traumatic brain injury is suppressed by postinjury treatment with hyperbaric oxygen therapy	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Hyperbaric oxygen therapy; Microglia; Tumor necrosis factor-alpha; Anti-inflammation	LATERAL FLUID-PERCUSSION; MITOCHONDRIAL-FUNCTION; CEREBRAL OXYGENATION; RAT MODEL; INFLAMMATION; MECHANISMS; PHYSIOLOGY; NEUROTRAUMA; EXPRESSION; CONTUSIONS	Background: The mechanisms underlying the protective effects of hyperbaric oxygen (HBO) therapy on traumatic brain injury (TBI) are unclear. TBI initiates a neuroinflammatory cascade characterized by activation of microglia and increased production of proinflammatory cytokines. In this study, we attempted to ascertain whether the occurrence of neuroinflammation exhibited during TBI can be reduced by HBO. Methods: TBI was produced by the fluid percussion technique in rats. HBO (100% O-2 at 2.0 absolute atmospheres) was then used at 1 h (HBO I) or 8 h (HBO II) after TBI. Neurobehavior was evaluated by the inclined plane test on the 72 h after TBI and then the rats were killed. The infarction area was evaluated by Triphenyltetrazolium chloride. Immunofluorescence staining was used to evaluate neuronal apoptosis (TUNEL + NeuN), microglial cell aggregation count (OX42 + DAPI), and tumor necrosis factor-alpha (TNF-alpha) expression in microglia cell (OX42 + TNF-alpha). Results: The maximum grasp angle in the inclined plane test and cerebral infarction of the rats after TBI were significantly attenuated by HBO therapy regardless of whether the rats were treated with HBO 1 or 8 h after TBI compared with the controls. TBI-induced microglial activation, TNF-alpha expression, and neuronal apoptosis were also significantly reduced by HBO therapy. Conclusions: Our results demonstrate that treatment of TBI during the acute phase of injury can attenuate microgliosis and proinflammatory cytokine TNF-alpha expression resulting in a neuroprotective effect. Even treating TBI with HBO after 8 h had a therapeutic effect. (C) 2013 Elsevier Inc. All rights reserved.	[Lim, Sher-Wei; Wang, Che-Chuan; Wang, Yun-Han; Chio, Chung-Ching; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan 710, Taiwan; [Niu, Ko-Chi] Chi Mei Med Ctr, Dept Hyperbar Oxygen, Tainan 710, Taiwan; [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan	Lim, SW (corresponding author), Chi Mei Med Ctr, Traumat Brain Ctr, Dept Neurosurg, 901 Jong Hwa Rd, Tainan 710, Taiwan.	kuojinnrung@gmail.com		Swanson, Raymond/0000-0002-3664-5359	 [NSC100-2314-B-384-005];  [CMNSC10010]	The project was supported by grants NSC100-2314-B-384-005 and CMNSC10010.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hanisch UK, 2004, GLIA, V14, P97; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Lin MT, 1997, AM J PHYSIOL-HEART C, V273, pH2072; LIN MT, 1994, NEUROSCI LETT, V174, P17, DOI 10.1016/0304-3940(94)90108-2; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Nemoto EM, 2007, NEUROL RES, V29, P116, DOI 10.1179/016164107X174138; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Niu KC, 2007, EUR J PHARMACOL, V570, P229, DOI 10.1016/j.ejphar.2007.05.056; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oppel L, 2003, BRAIN INJURY, V17, P225, DOI 10.1080/0269905021000030814; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Sahni T, 2012, BRIT J NEUROSURG, V26, P202, DOI 10.3109/02688697.2011.626879; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Sukoff MH, 2001, J NEUROSURG, V95, P544; Sukoff MH, 1984, HYPERB OXYGEN REV, V5, P35; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	43	37	46	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2013	184	2					1076	1084		10.1016/j.jss.2013.04.070			9	Surgery	Surgery	215XE	WOS:000324243500058	23726237				2021-06-18	
J	Chiu, SL; Osternig, L; Chou, LS				Chiu, Shiu-Ling; Osternig, Louis; Chou, Li-Shan			Concussion induces gait inter-joint coordination variability under conditions of divided attention and obstacle crossing	GAIT & POSTURE			English	Article						Concussion; Gait; Obstacle avoidance; Attention; Inter-joint coordination	TRAUMATIC BRAIN-INJURY; BIMANUAL COORDINATION; BALANCE; WALKING; TASK; PERFORMANCE; COLLEGIATE; LOCOMOTION; MOVEMENTS; CAPACITY	This study investigated the effect of concussion on the pattern and variability of inter-joint coordination during level walking (Level), obstacle crossing (OB), and walking with a concurrent cognitive test (ATT). Gait analyses of 23 concussed and 23 matched healthy adults were performed. Continuous relative phase (CRP), derived from phase angles of two adjacent joints, was used to assess inter-joint coordination. Cross-correlation measures and root-mean-square (RMS) differences were used to compare CRP patterns of the Level condition to those of OB and ATT conditions, respectively. Deviation phase (DP) was used to evaluate variability of inter-joint coordination for each task. For hip-knee and knee-ankle CRP patterns, RMS differences between OB and Level and between ATT and Level in concussed subjects were significantly greater than those of healthy adults. No significant group differences were detected for the cross-correlation measures of hip-knee and knee-ankle CRP patterns. In stance phase, a significant task effect on DP values was detected in hip-knee inter-joint coordination. For knee-ankle inter-joint coordination, concussed subjects showed significantly greater DP values than healthy controls during OB and ATT. In swing phase, concussed individuals showed greater DP values in hip-knee and knee-ankle inter-joint coordination compared to healthy controls. The findings suggest that the ability to modulate inter-joint coordination patterns when accommodating to gait perturbations is affected by concussion. (C) 2013 Elsevier B.V. All rights reserved.	[Chiu, Shiu-Ling; Osternig, Louis; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu					Barela JA, 2000, HUM MOVEMENT SCI, V19, P251, DOI 10.1016/S0167-9457(00)00014-2; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BURGESSLIMERICK R, 1993, J BIOMECH, V26, P91, DOI 10.1016/0021-9290(93)90617-N; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Chiu SL, 2012, J BIOMECH, V45, P275, DOI 10.1016/j.jbiomech.2011.10.028; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Cordo PJ, 2004, PROG BRAIN RES, V143, P29, DOI 10.1016/S0079-6123(03)43003-3; Drew T, 2008, BRAIN RES REV, V57, P199, DOI 10.1016/j.brainresrev.2007.07.017; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hamill J, 1999, CLIN BIOMECH, V14, P297, DOI 10.1016/S0268-0033(98)90092-4; Holtzer R, 2011, J GERONTOL A-BIOL, V66, P879, DOI 10.1093/gerona/glr068; HURMUZLU Y, 1994, J BIOMECH, V27, P1495, DOI 10.1016/0021-9290(94)90199-6; Kelly JP, 1997, NEUROLOGY, V48, P581; Lacquaniti F, 1997, ARCH ITAL BIOL, V135, P353; Lu TW, 2008, GAIT POSTURE, V27, P309, DOI 10.1016/j.gaitpost.2007.04.007; Matthews A, 2006, NEUROSCI LETT, V400, P172, DOI 10.1016/j.neulet.2006.02.043; McFadyen BJ, 1997, EXP BRAIN RES, V114, P500, DOI 10.1007/PL00005659; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Monno A, 2002, ACTA PSYCHOL, V110, P187, DOI 10.1016/S0001-6918(02)00033-1; PATLA AE, 1991, J EXP PSYCHOL HUMAN, V17, P603, DOI 10.1037/0096-1523.17.3.603; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Zackowski KM, 2002, EXP BRAIN RES, V146, P511, DOI 10.1007/s00221-002-1191-9	30	37	38	2	16	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2013	38	4					717	722		10.1016/j.gaitpost.2013.03.010			6	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	231MV	WOS:000325421900029	23578796				2021-06-18	
J	Franke, H; Parravicini, C; Lecca, D; Zanier, ER; Heine, C; Bremicker, K; Fumagalli, M; Rosa, P; Longhi, L; Stocchetti, N; De Simoni, MG; Weber, M; Abbracchio, MP				Franke, Heike; Parravicini, Chiara; Lecca, Davide; Zanier, Elisa R.; Heine, Claudia; Bremicker, Kristina; Fumagalli, Marta; Rosa, Patrizia; Longhi, Luca; Stocchetti, Nino; De Simoni, Maria-Grazia; Weber, Marco; Abbracchio, Maria P.			Changes of the GPR17 receptor, a new target for neurorepair, in neurons and glial cells in patients with traumatic brain injury	PURINERGIC SIGNALLING			English	Article						Activated microglia; Adult neural precursors; Human brain injury; Lesion repair; Reactive astrocytes	LEUKOTRIENE; ANTAGONIST; EXPRESSION; BINDING	Unveiling the mechanisms participating in the damage and repair of traumatic brain injury (TBI) is fundamental to develop new therapies. The P2Y-like GPR17 receptor has recently emerged as a sensor of damage and a key actor in lesion remodeling/repair in the rodent brain, but its role in humans is totally unknown. Here, we characterized GPR17 expression in brain specimens from seven intensive care unit TBI patients undergoing neurosurgery for contusion removal and from 28 autoptic TBI cases (and 10 control subjects of matched age and gender) of two university hospitals. In both neurosurgery and autoptic samples, GPR17 expression was strong inside the contused core and progressively declined distally according to a spatio-temporal gradient. Inside and around the core, GPR17 labeled dying neurons, reactive astrocytes, and activated microglia/macrophages. In peri-contused parenchyma, GPR17 decorated oligodendrocyte precursor cells (OPCs) some of which had proliferated, indicating re-myelination attempts. In autoptic cases, GPR17 expression positively correlated with death for intracranial complications and negatively correlated with patients' post-traumatic survival. Data indicate lesion-specific sequential involvement of GPR17 in the (a) death of irreversibly damaged neurons, (b) activation of microglia/macrophages remodeling the lesion, and (c) activation/proliferation of multipotent parenchymal progenitors (both reactive astrocytes and OPCs) starting repair processes. Data validate GPR17 as a target for neurorepair and are particularly relevant to setting up new therapies for TBI patients.	[Franke, Heike; Heine, Claudia; Bremicker, Kristina] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, D-04109 Leipzig, Germany; [Parravicini, Chiara; Lecca, Davide; Fumagalli, Marta; Abbracchio, Maria P.] Univ Milan, Dept Pharmacol & Biomol Sci, Lab Mol & Cellular Pharmacol Purinerg Transmiss, I-20133 Milan, Italy; [Zanier, Elisa R.; De Simoni, Maria-Grazia] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy; [Heine, Claudia] Univ Leipzig, Translat Ctr Regenerat Med TRM, D-04109 Leipzig, Germany; [Rosa, Patrizia] CNR, Dept Med Pharmacol, Inst Neurosci, Milan, Italy; [Longhi, Luca; Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy; [Longhi, Luca; Stocchetti, Nino] IRCCS Ca Granda Osped Maggiore Policlin, Neurosurg Care Unit, I-20122 Milan, Italy; [Weber, Marco] Univ Halle, Inst Legal Med, Halle, Saale, Germany	Abbracchio, MP (corresponding author), Univ Milan, Dept Pharmacol & Biomol Sci, Lab Mol & Cellular Pharmacol Purinerg Transmiss, Via Balzaretti 9, I-20133 Milan, Italy.	mariapia.abbracchio@unimi.it	Abbracchio, Maria Pia/B-9342-2014; Zanier, Elisa/AAA-8095-2020; Lecca, Davide/A-8850-2010; Weber, Marco/J-9620-2012; De Simoni, Maria Grazia/I-6021-2012; Longhi, Luca/AAF-9903-2021; Stocchetti, Nino/O-7444-2017; Weber, Marco/Z-4601-2019	Abbracchio, Maria Pia/0000-0002-7833-3388; Lecca, Davide/0000-0002-3258-363X; De Simoni, Maria Grazia/0000-0001-6695-5297; Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Weber, Marco/0000-0002-6666-0592; Zanier, Elisa/0000-0002-3011-8718; Fumagalli, Marta/0000-0002-0158-842X; Rosa, Patrizia/0000-0002-2590-6955	Italian PRIN-COFIN [2006059022, 2008XFMEA3]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [FR 1253/3-2]; Fondazione Cariplo fellowship [2008.2907]; Fondazione Italiana Sclerosi MultiplaFondazione Italiana Sclerosi Multipla (FISM) [2010/R/2]; German Federal Ministry of Education and Research (BMBF, PtJ-Bio)Federal Ministry of Education & Research (BMBF) [0313909]; European Fund for Regional Development (EFRE)European Commission; Free State of Saxony [SAB12525]	The authors thank Prof. Enzo Wanke, University of Bicocca-Milan and Dr. Annalisa Buffo, University of Turin for useful discussion. The authors are also grateful to Prof. J. Dressler and Benjamin Ondruschka (Institute for Legal Medicine, Medical Faculty University of Leipzig) for providing autoptic samples, to Dr. Mauro Pluderi, MD, and Dr. Marco Locatelli, MD, from the Department of Neurosurgery of the Ospedale Maggiore Policlinico di Milano for assistance in resection of contusions and collection of neurosurgical brain samples, and to Mrs. Katrin Becker (RBI of Pharmacology and Toxicology, Leipzig) for expert technical assistance. This work was partially supported by the Italian PRIN-COFIN (Project Prot. 2006059022 and 2008XFMEA3 to M.P.A) and by Deutsche Forschungsgemeinschaft (FR 1253/3-2); C.P. was supported by a Fondazione Cariplo fellowship (project number 2008.2907); M.F. is supported by a fellowship from Fondazione Italiana Sclerosi Multipla (grant N. 2010/R/2); C.H. was supported by a funding from the German Federal Ministry of Education and Research (BMBF, PtJ-Bio, 0313909), the European Fund for Regional Development (EFRE), and the Free State of Saxony (grant no. SAB12525).	Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184; Benned-Jensen T, 2010, BRIT J PHARMACOL, V159, P1092, DOI 10.1111/j.1476-5381.2009.00633.x; Berninger B, 2007, J NEUROSCI, V27, P8654, DOI 10.1523/JNEUROSCI.1615-07.2007; Boda E, 2010, ARCH ITAL BIOL, V148, P119; Boda E, 2011, GLIA, V59, P1958, DOI 10.1002/glia.21237; Buccioni M, 2011, PURINERG SIGNAL, V7, P463, DOI 10.1007/s11302-011-9245-8; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Ceruti S, 2009, BRAIN, V132, P2206, DOI 10.1093/brain/awp147; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Daniele S, 2011, J PHARMACOL EXP THER, V338, P559, DOI 10.1124/jpet.110.178715; Daniele S, 2010, CELL SIGNAL, V22, P697, DOI 10.1016/j.cellsig.2009.12.006; De Biase LM, 2010, J NEUROSCI, V30, P3600, DOI 10.1523/JNEUROSCI.6000-09.2010; Eberini I, 2011, J COMPUT AID MOL DES, V25, P743, DOI 10.1007/s10822-011-9455-8; Fumagalli M, 2011, FRONT BIOSCI-LANDMRK, V16, P2326, DOI 10.2741/3856; Fumagalli M, 2011, J BIOL CHEM, V286, P10593, DOI 10.1074/jbc.M110.162867; Heinrich C, 2011, NAT PROTOC, V6, P214, DOI 10.1038/nprot.2010.188; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Lecca D, 2008, BIOCHEM PHARMACOL, V75, P1869, DOI 10.1016/j.bcp.2007.12.009; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Maekawa A, 2009, P NATL ACAD SCI USA, V106, P11685, DOI 10.1073/pnas.0905364106; Marchetti B, 2005, TRENDS PHARMACOL SCI, V26, P517, DOI 10.1016/j.tips.2005.08.007; Pugliese AM, 2009, AM J PHYSIOL-CELL PH, V297, pC1028, DOI 10.1152/ajpcell.00658.2008; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; Richardson WD, 2011, NEURON, V70, P661, DOI 10.1016/j.neuron.2011.05.013; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Wunder F, 2010, BRIT J PHARMACOL, V160, P399, DOI 10.1111/j.1476-5381.2010.00730.x; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155	30	37	38	0	14	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1573-9538	1573-9546		PURINERG SIGNAL	Purinergic Signal.	SEP	2013	9	3					451	462		10.1007/s11302-013-9366-3			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	209HQ	WOS:000323746700013	23801362	Green Published			2021-06-18	
J	Styrke, J; Sojka, P; Bjornstig, U; Bylund, PO; Stalnacke, BM				Styrke, Johan; Sojka, Peter; Bjornstig, Ulf; Bylund, Per-Olof; Stalnacke, Britt-Marie			SEX DIFFERENCES IN SYMPTOMS, DISABILITY AND LIFE SATISFACTION THREE YEARS AFTER MILD TRAUMATIC BRAIN INJURY: A POPULATION-BASED COHORT STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; minor head injury; sex differences; post-concussion syndrome; follow-up studies; quality of life; principal component analysis; odds ratio	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; FOLLOW-UP; GENDER-DIFFERENCES; YOUNG-PEOPLE; QUESTIONNAIRE; EPIDEMIOLOGY; PREVALENCE; PREDICTORS; SEVERITY	Objective: To investigate sex differences in symptoms, structure of symptoms, disability and life satisfaction 3 years after mild traumatic brain injury. Secondary aims were to find risk factors for adverse outcome. Design: Population-based cohort study. Patients: The cohort comprised 137,000 inhabitants at risk in a defined population served by a single hospital in northern Sweden. Patients attending the emergency department following a mild traumatic brain injury in 2001 were included. Methods: Of 214 patients aged 18-64 years, 163 answered a questionnaire on symptoms, disability, and life-satisfaction 3 years post-injury. The instruments were analysed with descriptive statistics. A principal component analysis of the Rivermead Post-Concussion Symptoms Questionnaire was conducted. Risk factors were identified using logistic regression. Results: Post-concussion syndrome was found in 50% of the women and 30% of the men. Disability was found in 52% of the women and 37% of the men, and 57% of the women and 56% of the men were satisfied with their lives. For both genders, high frequency of symptoms was a risk factor for disability and low life satisfaction. Back pain was a risk factor for disability. Living alone was a risk factor for low levels of life satisfaction. The principal component analysis revealed differences between the sexes. Conclusion: There are sex differences in outcome 3 years after mild traumatic brain injury. Women and men should be analysed separately.	[Styrke, Johan; Bjornstig, Ulf] Umea Univ, Dept Surg & Perioperat Sci, Div Surg, SE-90185 Umea, Sweden; [Sojka, Peter] Mid Sweden Univ, Dept Hlth Sci, Ostersund, Sweden; [Bylund, Per-Olof] Umea Univ Hosp, Emergency & Disaster Med Ctr, S-90185 Umea, Sweden; [Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, SE-90185 Umea, Sweden	Styrke, J (corresponding author), Umea Univ, Dept Surg & Perioperat Sci, Div Surg, SE-90185 Umea, Sweden.	johan.styrke@surgery.umu.se	Styrke, Johan/AAE-1193-2021		Swedish Association of Brain Injured and Families; Department of Research and Development, Vasternorrland County Council	The authors would like to thank Gabriel Granasen for assisting in the statistical analysis and Asta Strandberg for helping us to administer the questionnaires. This work was supported by grants from the Swedish Association of Brain Injured and Families and the Department of Research and Development, Vasternorrland County Council.	Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Covassin T, 2012, J NEUROSCI NURS, V44, P124, DOI 10.1097/JNN.0b013e318252737d; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Demakis GJ, 2010, ARCH CLIN NEUROPSYCH, V25, P191, DOI 10.1093/arclin/acq004; Edna T H, 1987, J Oslo City Hosp, V37, P41; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fayol P., 2009, Annals of Physical and Rehabilitation Medicine, V52, P497, DOI 10.1016/j.annrmp.2008.06.003; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Walker BF, 2000, J SPINAL DISORD, V13, P205, DOI 10.1097/00002517-200006000-00003; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; World Health Organization, 2010, INT STAT CLASS DIS R; Zhang SR, 2009, J REHABIL MED, V41, P1062, DOI 10.2340/16501977-0462; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	40	37	38	0	19	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					749	757		10.2340/16501977-1215			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500009	24002310	DOAJ Gold, Green Published			2021-06-18	
J	Schaible, EV; Steinstrasser, A; Jahn-Eimermacher, A; Luh, C; Sebastiani, A; Kornes, F; Pieter, D; Schafer, MK; Engelhard, K; Thal, SC				Schaible, Eva-Verena; Steinstraesser, Arne; Jahn-Eimermacher, Antje; Luh, Clara; Sebastiani, Anne; Kornes, Frida; Pieter, Dana; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.			Single Administration of Tripeptide alpha-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice	PLOS ONE			English	Article							MELANOCYTE-STIMULATING HORMONE; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; MELANOCORTIN RECEPTORS; MICROGLIAL ACTIVATION; CEREBRAL-ISCHEMIA; TIME-COURSE; EXPRESSION; PEPTIDES; NEUROPROTECTION	Following traumatic brain injury (TBI) neuroinflammatory processes promote neuronal cell loss. Alpha-melanocyte-stimulating hormone (alpha-MSH) is a neuropeptide with immunomodulatory properties, which may offer neuroprotection. Due to short half-life and pigmentary side-effects of alpha-MSH, the C-terminal tripeptide alpha-MSH(11-13) may be an anti-inflammatory alternative. The present study investigated the mRNA concentrations of the precursor hormone proopiomelanocortin (POMC) and of melanocortin receptors 1 and 4 (MC1R/MC4R) in naive mice and 15 min, 6, 12, 24, and 48 h after controlled cortical impact (CCI). Regulation of POMC and MC4R expression did not change after trauma, while MC1R levels increased over time with a 3-fold maximum at 12 h compared to naive brain tissue. The effect of alpha-MSH(11-13) on secondary lesion volume determined in cresyl violet stained sections (intraperitoneal injection 30 min after insult of 1 mg/kg alpha-MSH(11-13) or 0.9% NaCl) showed a considerable smaller trauma in alpha-MSH(11-13) injected mice. The expression of the inflammatory markers TNF-alpha and IL-1 beta as well as the total amount of Iba-1 positive cells were not reduced. However, cell branch counting of Iba-1 positive cells revealed a reduced activation of microglia. Furthermore, tripeptide injection reduced neuronal apoptosis analyzed by cleaved caspase-3 and NeuN staining. Based on the results single alpha-MSH(11-13) administration offers a promising neuroprotective property by modulation of inflammation and prevention of apoptosis after traumatic brain injury.	[Schaible, Eva-Verena; Steinstraesser, Arne; Luh, Clara; Sebastiani, Anne; Kornes, Frida; Pieter, Dana; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany; [Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Focus Program Translat Neurosci, D-55122 Mainz, Germany; [Jahn-Eimermacher, Antje] Johannes Gutenberg Univ Mainz, Inst Med Biostat Epidemiol & Informat, D-55122 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Schafer, Michael K.E./0000-0001-6055-6244			Aronsson AF, 2006, NEUROPEPTIDES, V40, P65, DOI 10.1016/j.npep.2005.10.006; Bhardwaj RS, 1996, J IMMUNOL, V156, P2517; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Caruso C, 2004, NEUROENDOCRINOLOGY, V79, P278, DOI 10.1159/000079321; Caruso C, 2007, ENDOCRINOLOGY, V148, P4918, DOI 10.1210/en.2007-0366; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Catania A, 2010, THESCIENTIFICWORLDJO, V10, P1840, DOI 10.1100/tsw.2010.173; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chai BX, 2006, PEPTIDES, V27, P2846, DOI 10.1016/j.peptides.2006.05.005; Charnley M, 2008, PEPTIDES, V29, P1004, DOI 10.1016/j.peptides.2008.02.004; Chen G, 2008, NEUROPEPTIDES, V42, P331, DOI 10.1016/j.npep.2008.01.004; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Dalmasso G, 2008, GASTROENTEROLOGY, V134, P166, DOI 10.1053/j.gastro.2007.10.026; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; DEANGELIS E, 1995, MICROVASC RES, V50, P25, DOI 10.1006/mvre.1995.1035; Delgado R, 1998, J LEUKOCYTE BIOL, V63, P740; Dessinioti C, 2011, PHOTOCHEM PHOTOBIOL, V87, P978, DOI 10.1111/j.1751-1097.2011.00970.x; Elliott RJ, 2004, J INVEST DERMATOL, V122, P1010, DOI 10.1111/j.0022-202X.2004.22404.x; Faden AI, 2011, ANN NEUROL, V70, P345, DOI 10.1002/ana.22555; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Getting SJ, 2002, TRENDS PHARMACOL SCI, V23, P447, DOI 10.1016/S0165-6147(02)02103-X; Getting SJ, 2003, J PHARMACOL EXP THER, V306, P631, DOI 10.1124/jpet.103.051623; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Giuliani D, 2011, ACTA NEUROPATHOL, V122, P443, DOI 10.1007/s00401-011-0873-4; Haddad JJE, 2001, BIOCHEM J, V355, P29, DOI 10.1042/bj3550029; HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033; Huang QH, 1998, AM J PHYSIOL-REG I, V275, pR524; Ichiyama T, 1999, BRAIN RES, V836, P31, DOI 10.1016/S0006-8993(99)01584-X; Kishi T, 2003, J COMP NEUROL, V457, P213, DOI 10.1002/cne.10454; Land Stephen C, 2012, Int J Physiol Pathophysiol Pharmacol, V4, P59; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; Manna SX, 2006, EUR J IMMUNOL, V36, P754, DOI 10.1002/eji.200535209; Mountjoy KG, 2010, ADV EXP MED BIOL, V681, P29, DOI 10.1007/978-1-4419-6354-3_3; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nahon JL, 2006, CR BIOL, V329, P623, DOI 10.1016/j.crvi.2006.03.021; Rajora N, 1997, J NEUROSCI, V17, P2181; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Savos AV, 2011, J CEREBR BLOOD F MET, V31, P606, DOI 10.1038/jcbfm.2010.130; Spaccapelo L, 2011, EUR J PHARMACOL, V670, P479, DOI 10.1016/j.ejphar.2011.09.015; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tatro JB, 1996, NEUROIMMUNOMODULAT, V3, P259, DOI 10.1159/000097281; Taylor Andrew W., 1994, Neuroimmunomodulation, V1, P188, DOI 10.1159/000097167; TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Todd SR, 2009, J TRAUMA, V66, P465, DOI 10.1097/TA.0b013e31818b1e04; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; vandeMeent HV, 1997, NEUROSURGERY, V40, P122, DOI 10.1097/00006123-199701000-00028; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WILSON JF, 1980, J ENDOCRINOL, V86, P61, DOI 10.1677/joe.0.0860061; Wong KY, 1997, NEUROIMMUNOMODULAT, V4, P37; XIA Y, 1995, NEUROREPORT, V6, P2193, DOI 10.1097/00001756-199511000-00022; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zierath D, 2011, STROKE, V42, P3415, DOI 10.1161/STROKEAHA.111.627331	66	37	40	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e71056	10.1371/journal.pone.0071056			10	Multidisciplinary Sciences	Science & Technology - Other Topics	218XC	WOS:000324465000173	23940690	DOAJ Gold, Green Published			2021-06-18	
J	Asl, SZ; Khaksari, M; Khachki, AS; Shahrokhi, N; Nourizade, S				Asl, Saleh Zahedi; Khaksari, Mohammad; Khachki, Ali Siahposht; Shahrokhi, Nader; Nourizade, Shahla			Contribution of estrogen receptors alpha and beta in the brain response to traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; propyl pyrazole triol; diarylpropionitrile; estrogen receptor; neuroprotection	SEX STEROID-HORMONES; AGED FEMALE RATS; ER-ALPHA; INTRACRANIAL-PRESSURE; CEREBRAL-ISCHEMIA; INFLAMMATORY RESPONSE; OVARIECTOMIZED RATS; GLOBAL-ISCHEMIA; CELL-DEATH; IN-VIVO	Object. Although there is evidence that estradiol has neuroprotective effects after traumatic brain injury (TBI) in female rats, it is unclear which estrogen receptor (ER) subtype, ER alpha or ER beta, mediates this effect. The authors therefore examined the roles of the different ERs in this effect. Here the authors used the ER alpha selective agonist propyl pyrazole trio! (PPT) and the ER beta selective agonist diarylpropionitrile (DPN) alone and in combination in female rats to investigate this question. Methods. Before the ovariectomized animals were injured using the Marmarou TBI technique, they were randomly divided into the following 9 groups: control, sham, TBI, vehicle, El (physiological dose of 17-beta estradiol), E2 (pharmacological dose of 17-beta estradiol), PPT, DPN, and PPT+DPN. Levels of blood-brain barrier (BBB) disruption (5 hours) and water content (24 hours) were evaluated after TBI. In groups receiving drugs or vehicle, treatment was administered as a single dose intraperitoneally 30 minutes after induction of TBI. Results. Results showed that brain edema or brain water content after TBI was lower (p < 0.001) in the E2, PPT, DPN, and PPT+DPN groups than it was in the vehicle group. After trauma, the Evans blue dye content or BBB permeability was significantly higher in the TBI and vehicle groups (p < 0.001) than in the E2, PPT, DPN, and PPT+DPN groups. The inhibitory effects of PPT+DPN on brain water content, neurological scores, and Evans blue dye content were the highest for all groups. Although both PPT and DPN increased neurological scores after TBI, PPT appears to be more effective in increasing neurological scores. Conclusions. Neuroprotective effects of estradiol on brain edema, BBB permeability, and neurological scores are mediated through both ER alpha and ER beta. This may suggest a therapeutic potential in the brain trauma for ER-specific agonists.	[Asl, Saleh Zahedi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, Tehran, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Physiol Res Ctr, Kerman 7614715977, Iran; [Khachki, Ali Siahposht; Shahrokhi, Nader] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman 7614715977, Iran; [Nourizade, Shahla] Urmia Univ Med Sci, Orumiyeh, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Sch Med, 22 Bahman Blvd, Kerman 7614715977, Iran.	Khaksar38@yahoo.co.uk	Haddad, Mohammad Khaksari/AAB-9025-2019; Shahrokhi, Nader/AAV-3747-2020	Haddad, Mohammad Khaksari/0000-0003-0770-4281; Shahrokhi, Nader/0000-0002-0149-7819	Physiology Research Center of Kerman University of Medical Sciences; Endocrine Research Center of Shahid Beheshti University of Medical Sciences	The present study was financially supported by the Physiology Research Center of Kerman University of Medical Sciences and the Endocrine Research Center of Shahid Beheshti University of Medical Sciences.	Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; Bains M, 2007, EXP NEUROL, V204, P767, DOI 10.1016/j.expneurol.2007.01.020; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004; Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gonzales KL, 2008, ENDOCRINOLOGY, V149, P4615, DOI 10.1210/en.2008-0511; Gorres BK, 2011, J PHYSIOL-LONDON, V589, P2041, DOI 10.1113/jphysiol.2010.199018; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewis DK, 2008, J NEUROIMMUNOL, V195, P47, DOI 10.1016/j.jneuroim.2008.01.006; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Liu X, 2005, J NEUROSCI RES, V81, P653, DOI 10.1002/jnr.20583; Marik P, 1999, J EMERG MED, V17, P711, DOI 10.1016/S0736-4679(99)00055-4; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mazzucco CA, 2006, NEUROSCIENCE, V141, P1793, DOI 10.1016/j.neuroscience.2006.05.032; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Mitra SW, 2003, ENDOCRINOLOGY, V144, P2055, DOI 10.1210/en.2002-221069; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Ogura E, 2008, PEPTIDES, V29, P456, DOI 10.1016/j.peptides.2007.11.007; Patkar S, 2011, NEUROSCI RES, V71, P78, DOI 10.1016/j.neures.2011.05.006; Santollo J, 2009, PHYSIOL BEHAV, V97, P193, DOI 10.1016/j.physbeh.2009.02.021; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Sarvari M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-82; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sharma PK, 2006, NEUROBIOL AGING, V27, P880, DOI 10.1016/j.neurobiolaging.2005.04.003; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Smith JA, 2011, NEUROCHEM RES, V36, P1587, DOI 10.1007/s11064-010-0336-7; Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Szymczak S, 2006, HIPPOCAMPUS, V16, P453, DOI 10.1002/hipo.20172; Thammacharoen S, 2009, BRAIN RES, V1268, P88, DOI 10.1016/j.brainres.2009.02.067; Tiwari-Woodruff S, 2009, J NEUROL SCI, V286, P81, DOI 10.1016/j.jns.2009.04.023; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Walf AA, 2008, NEUROBIOL LEARN MEM, V89, P513, DOI 10.1016/j.nlm.2008.01.008; Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Xia Y, 2009, NEUROSCIENCE, V162, P292, DOI 10.1016/j.neuroscience.2009.04.068; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	59	37	37	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					353	361		10.3171/2013.4.JNS121636			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400015	23724987				2021-06-18	
J	Tang, HL; Hua, F; Wang, J; Sayeed, I; Wang, XJ; Chen, ZJ; Yousuf, S; Atif, F; Stein, DG				Tang, Huiling; Hua, Fang; Wang, Jun; Sayeed, Iqbal; Wang, Xiaojing; Chen, Zhengjia; Yousuf, Seema; Atif, Fahim; Stein, Donald G.			Progesterone and vitamin D: Improvement after traumatic brain injury in middle-aged rats	HORMONES AND BEHAVIOR			English	Article						Aging; Combination treatments; Functional repair; Progesterone; Traumatic brain injury; Vitamin D deficiency; Vitamin D3 hormone	D DEFICIENCY; D HORMONE; WORKING-MEMORY; NEUROPROTECTION; STROKE; SEX; PREVALENCE; EXPRESSION; CYTOKINES; RESPONSES	Progesterone (PROG) and vitamin D hormone (VDH) have both shown promise in treating traumatic brain injury (TBI). Both modulate apoptosis, inflammation, oxidative stress, and excitotoxicity. We investigated whether 21 days of VDH deficiency would alter cognitive behavior after TBI and whether combined PROG and VDH would improve behavioral and morphological outcomes more than either hormone alone in VDH-deficient middle-aged rats given bilateral contusions of the medial frontal cortex. PROG (16 mg/kg) and VDH (5 mu g/kg) were injected intraperitoneally 1 h post-injury. Eight additional doses of PROG were injected subcutaneously over 7 days post-injury. VDH deficiency itself did not significantly reduce baseline behavioral functions or aggravate impaired cognitive outcomes. Combination therapy showed moderate improvement in preserving spatial and reference memory but was not significantly better than PROG monotherapy. However, combination therapy significantly reduced neuronal loss and the proliferation of reactive astrocytes, and showed better efficacy compared to VDH or PROG alone in preventing MAP-2 degradation. VDH + PROG combination therapy may attenuate some of the potential long-term, subtle, pathophysiological consequences of brain injury in older subjects. (c) 2013 Elsevier Inc. All rights reserved.	[Tang, Huiling; Hua, Fang; Wang, Jun; Sayeed, Iqbal; Yousuf, Seema; Atif, Fahim; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Wang, Xiaojing; Chen, Zhengjia] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD061971]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER	This work was supported by NIH grant 1R01HD061971 to DGS. The authors would like to thank Leslie McCann for the invaluable editorial assistance and Jason S. Lee and Kristen Carroll for their contribution to the paper.	Annweiler C, 2010, NEUROLOGY, V74, P27, DOI 10.1212/WNL.0b013e3181beecd3; Atalay B, 2007, BRIT J NEUROSURG, V21, P281, DOI 10.1080/02688690701364781; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Balden R, 2012, ENDOCRINOLOGY, V153, P2420, DOI 10.1210/en.2011-1783; Baldi E, 2005, NEUROSCI LETT, V378, P176, DOI 10.1016/j.neulet.2004.12.029; Becker A, 2005, BEHAV BRAIN RES, V161, P306, DOI 10.1016/j.bbr.2005.02.015; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Briones TL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-244; Buell JS, 2008, MOL ASPECTS MED, V29, P415, DOI 10.1016/j.mam.2008.05.001; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carroll JC, 2010, ENDOCRINOLOGY, V151, P2713, DOI 10.1210/en.2009-1487; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Chatterjee M, 2001, MUTAT RES-FUND MOL M, V475, P69, DOI 10.1016/S0027-5107(01)00080-X; Chisholm NC, 2013, BRAIN RES, V1514, P40, DOI 10.1016/j.brainres.2013.02.020; Chisholm NC, 2012, ENDOCRINOLOGY, V153, P4874, DOI 10.1210/en.2012-1412; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; de Abreu DAF, 2010, BEHAV BRAIN RES, V208, P603, DOI 10.1016/j.bbr.2010.01.005; DeLuca GC, 2013, NEUROPATH APPL NEURO, V39, P458, DOI 10.1111/nan.12020; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Diamond TH, 2005, MED J AUSTRALIA, V183, P10, DOI 10.5694/j.1326-5377.2005.tb06879.x; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; Evatt ML, 2008, ARCH NEUROL-CHICAGO, V65, P1348, DOI 10.1001/archneur.65.10.1348; Evatt ML, 2011, ARCH NEUROL-CHICAGO, V68, P314, DOI 10.1001/archneurol.2011.30; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Felmingham KL, 2012, PSYCHONEUROENDOCRINO, V37, P1896, DOI 10.1016/j.psyneuen.2012.03.026; Frick KM, 2000, NEUROSCIENCE, V95, P293; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; GAGE FH, 1989, NEUROBIOL AGING, V10, P347, DOI 10.1016/0197-4580(89)90047-X; Galea LAM, 2000, HORM BEHAV, V37, P86, DOI 10.1006/hbeh.1999.1560; Gallagher M, 1997, ANNU REV PSYCHOL, V48, P339, DOI 10.1146/annurev.psych.48.1.339; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Heaney RP, 2004, AM J CLIN NUTR, V80, p1706S, DOI 10.1093/ajcn/80.6.1706S; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; Holick MF, 2005, AM J KIDNEY DIS, V45, P1119, DOI 10.1053/j.ajkd.2005.04.015; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Kojima G, 2012, STROKE, V43, P2163, DOI 10.1161/STROKEAHA.112.651752; Kuningas M, 2009, NEUROBIOL AGING, V30, P466, DOI 10.1016/j.neurobiolaging.2007.07.001; Lin AMY, 2005, ANN NY ACAD SCI, V1053, P319, DOI 10.1196/annals.1344.028; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Luckhaus C, 2009, J NEURAL TRANSM, V116, P905, DOI 10.1007/s00702-009-0241-x; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Markham JA, 2002, NEUROBIOL AGING, V23, P579, DOI 10.1016/S0197-4580(02)00004-0; MARKOWSKA AL, 1989, NEUROBIOL AGING, V10, P31, DOI 10.1016/S0197-4580(89)80008-9; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; Minasyan A, 2007, J STEROID BIOCHEM, V104, P274, DOI 10.1016/j.jsbmb.2007.03.032; Narayanan R, 2004, BONE, V35, P134, DOI 10.1016/j.bone.2004.02.014; Newmark HL, 2007, MOVEMENT DISORD, V22, P461, DOI 10.1002/mds.21317; Paris JJ, 2011, BRAIN RES, V1379, P149, DOI 10.1016/j.brainres.2010.10.099; PAULSON PE, 1994, BEHAV NEUROSCI, V108, P624, DOI 10.1037/0735-7044.108.3.624; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; SHARMA N, 1994, CELL MOTIL CYTOSKEL, V27, P234, DOI 10.1002/cm.970270305; Solomon JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029354; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; Stein DG, 2011, PM&R, V3, pS100, DOI 10.1016/j.pmrj.2011.03.010; Sun Q, 2012, STROKE, V43, P1470, DOI 10.1161/STROKEAHA.111.636910; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Valtuena J., 2013, CARDIORESPIRATORY FI, DOI DOI 10.1093/QJMED/HCT089; Veliskova J, 2013, HORM BEHAV, V63, P267, DOI 10.1016/j.yhbeh.2012.03.018; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579	69	37	42	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0018-506X	1095-6867		HORM BEHAV	Horm. Behav.	AUG	2013	64	3					527	538		10.1016/j.yhbeh.2013.06.009			12	Behavioral Sciences; Endocrinology & Metabolism	Behavioral Sciences; Endocrinology & Metabolism	235QM	WOS:000325735800014	23896206	Green Accepted			2021-06-18	
J	Cabral, KP; Fraser, GL; Duprey, J; Gibbons, BA; Hayes, T; Florman, JE; Seder, DB				Cabral, Katherine P.; Fraser, Gilles L.; Duprey, Jennifer; Gibbons, Beth A.; Hayes, Timothy; Florman, Jeffrey E.; Seder, David B.			Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Intracerebral hemorrhage; Traumatic brain injury; Coagulopathy; Subarachnoid hemorrhage; Subdural hematoma; Oral anticoagulation therapy; Hematoma expansion	FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; ORAL ANTICOAGULANT REVERSAL; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; RAPID REVERSAL; HEMATOMA GROWTH; TRAUMA PATIENTS; VITAMIN-K; MANAGEMENT	Prothrombin complex concentrates (PCCs) offer a means for the rapid reversal of warfarin, particularly in the setting of life-threatening bleeding. We evaluated the effectiveness and safety of a PCC-based protocol in patients with warfarin-associated intracerebral hemorrhage (ICH), subdural hematoma (SDH), or subarachnoid hemorrhage (SAH). This was a retrospective case-series review of patients treated with an institution-approved warfarin reversal protocol. Patients with intracranial hemorrhage and known warfarin use with an international normalized ratio (INR)>1.4 received fresh frozen plasma (FFP), vitamin K (phytonadione), and weight-based, 3-factor PCC (Profilnine (R) SD) dose based on the initial INR. Demographic and clinical information, the degree of and time to INR normalization, and adverse events were recorded. The thirty study patients included 19 with primary ICH, 7 with SDH, and 4 with SAH. The mean age was 72.8 (+/- 11) years, including 11 (37%) patients >= 80 years old. The median presenting INR was 2.3 (IQR 2-3.3) and post-treatment INR was 1.4 (IQR 1.3-1.5, Z score 6.4, p < 0.001). Median time from PCC administration to the first follow up INR was 95 (IQR 50-140) min. No patient's INR increased by more than 0.3 over 72 h. Nine patients (30%) underwent neurosurgical procedures after PCC administration and no procedure-related bleeding complication was noted. Adverse events included 3 instances of early hematoma expansion, one ischemic stroke in a patient with endocarditis on post-PCC day 1, one pulmonary embolism 5 weeks after PCC treatment, and one coronary in-stent thrombosis 60 days after PCC treatment. 6 patients died prior to hospital discharge of anticipated complications of their initial event, and none from identifiable thrombotic complications of PCC. A 3-factor PCC preparation (Profilnine (R) SD), administered with FFP and vitamin K to patients with acute warfarin-associated intracranial bleeding is a reasonable approach to urgent warfarin reversal. However, randomized, prospective trials are needed to verify the safety and clinical effectiveness of PCC administration in this population. (C) 2012 Elsevier B.V. All rights reserved:	[Cabral, Katherine P.] Albany Coll Pharm, Dept Pharm Practice, Albany, NY USA; [Fraser, Gilles L.] Maine Med Ctr, Dept Pharm, Portland, ME USA; [Fraser, Gilles L.; Duprey, Jennifer] Maine Med Ctr, Dept Crit Care Serv, Portland, ME USA; [Hayes, Timothy; Seder, David B.] Maine Med Ctr, Blood Bank, Portland, ME USA; [Florman, Jeffrey E.; Seder, David B.] Maine Med Ctr, Neurosci Inst, Portland, ME USA; [Gibbons, Beth A.; Florman, Jeffrey E.] Univ Vermont, Sch Med, Dept Surg, Burlington, VT 05405 USA	Seder, DB (corresponding author), Tufts Univ, Maine Med Ctr, Sch Med, 22 Bramhall St, Portland, ME 04102 USA.	dseder@cmamaine.com	Seder, David B./M-4829-2019	Seder, David/0000-0002-9717-1038; fraser, gilles/0000-0003-0841-7946			Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Baggs JH, 2012, ANN PHARMACOTHER, V46, P51, DOI 10.1345/aph.1Q588; Bershad EM, 2010, NEUROCRIT CARE, V12, P403, DOI 10.1007/s12028-009-9310-0; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Cartmill M, 2000, BRIT J NEUROSURG, V14, P458; Chapman SA, 2011, ANN PHARMACOTHER, V45, P869, DOI 10.1345/aph.1P605; Cucchiara B, 2008, STROKE, V39, P2993, DOI 10.1161/STROKEAHA.108.520668; Flaherty ML, 2008, NEUROLOGY, V71, P1084, DOI 10.1212/01.wnl.0000326895.58992.27; FREDRIKSSON K, 1992, STROKE, V23, P972, DOI 10.1161/01.STR.23.7.972; Goldstein JN, 2006, STROKE, V37, P151, DOI 10.1161/01.STR.0000195047.21562.23; Guest JF, 2010, CLIN THER, V32, P2478, DOI 10.1016/j.clinthera.2011.01.011; Holland L, 2009, TRANSFUSION, V49, P1171, DOI 10.1111/j.1537-2995.2008.02080.x; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Kalina M, 2008, AM SURGEON, V74, P858; Kohler M, 1999, THROMB RES, V95, pS13, DOI 10.1016/S0049-3848(99)00079-1; Lankiewicz MW, 2006, J THROMB HAEMOST, V4, P967, DOI 10.1111/j.1538-7836.2006.01815.x; Lee SB, 2006, NEUROLOGY, V67, P1272, DOI 10.1212/01.wnl.0000238104.75563.2f; Lubetsky A, 2004, THROMB RES, V113, P371, DOI 10.1016/j.thromres.2004.04.004; Majeed A, 2012, THROMB RES, V129, P146, DOI 10.1016/j.thromres.2011.07.024; Makris M, 1997, THROMB HAEMOSTASIS, V77, P477; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Preston FE, 2002, BRIT J HAEMATOL, V116, P619, DOI 10.1046/j.0007-1048.2001.03295.x; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Safaoui MN, 2009, AM J SURG, V197, P785, DOI 10.1016/j.amjsurg.2008.04.003; Schulman S, 2008, CHEST, V133, p257S, DOI 10.1378/chest.08-0674; Siddiq F, 2008, NEUROCRIT CARE, V8, P36, DOI 10.1007/s12028-007-9011-5; TABERNER DA, 1976, BRIT MED J, V2, P83, DOI 10.1136/bmj.2.6027.83; Vigue B, 2007, INTENS CARE MED, V33, P721, DOI 10.1007/s00134-007-0528-z	29	37	37	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2013	115	6					770	774		10.1016/j.clineuro.2012.07.006			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	158GG	WOS:000319956900027	22835715				2021-06-18	
J	Steinmetz, S; Tipold, A; Loscher, W				Steinmetz, Sonja; Tipold, Andrea; Loescher, Wolfgang			Epilepsy after head injury in dogs: A natural model of posttraumatic epilepsy	EPILEPSIA			English	Article						Traumatic brain injury; Seizures; Risk factors; Biomarkers; Antiepileptogenesis	TRAUMATIC BRAIN-INJURY; CANINE EPILEPSY; SEIZURE CLASSIFICATION; STATUS EPILEPTICUS; ANIMAL-MODELS; LEVETIRACETAM; EFFICACY; GENDER; EPILEPTOGENESIS; EPIDEMIOLOGY	Purpose In humans, traumatic brain injury (TBI) is one of the most common causes of acquired (symptomatic) epilepsy, but as yet there is no treatment to prevent the development of epilepsy after TBI. Animal models of posttraumatic epilepsy (PTE) are important to characterize epileptogenic mechanisms of TBI and to identify clinically effective antiepileptogenic treatments. The prevalence and phenomenology of naturally occurring canine epilepsy are similar to those in human epilepsy. However, the risk of epilepsy after TBI has not been systemically studied in dogs. We therefore performed a large retrospective study in 1,000 dogs referred to our clinical department over a period of 11.5years with the aim to determine the incidence of early and late seizures after head trauma in this species. Methods Two strategies were used: in group I (n=392), we evaluated whether dogs referred for the treatment of a head trauma (group Ia) or other trauma (group Ib) developed seizures after the trauma, whereas in group II (n=608) we evaluated whether dogs referred for the treatment of recurrent epileptic seizures had a history of head trauma. Data for this study were obtained from our clinical database, questionnaires sent to the dogs' owners, and owner interviews. Key Findings In group Ia, 6.6% of the dogs developed PTE, which was significantly different from group Ib (1.9%), indicating that head trauma increased the risk of developing epilepsy by a factor of 3.4. The risk of PTE increased with severity of TBI; 14.3% of the dogs with skull fracture developed PTE. In group II, 15.5% of the dogs with epilepsy had a history of head injury, which was significantly higher than the incidence of PTE determined for group Ia. Significance Our study indicates that head trauma in dogs is associated with a significant risk of developing epilepsy. Therefore, dogs with severe TBI are an interesting natural model of PTE that provides a novel translational platform for studies on human PTE.	[Steinmetz, Sonja; Tipold, Andrea] Univ Vet Med, Dept Small Anim Med & Surg, D-30559 Hannover, Germany; [Tipold, Andrea; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany; [Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany	Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973	Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany) within the DFG Research Unit (FOR) 1103German Research Foundation (DFG) [Lo 274/11-1, TI 309/4-1]	We thank Asla Pitkanen for constructive discussion during preparation of the manuscript and Christina Brauer and Karl Rohn for help during performing the study. The study was supported by grants (Lo 274/11-1; TI 309/4-1) from the Deutsche Forschungsgemeinschaft (DFG; Bonn, Germany) within the DFG Research Unit (FOR) 1103.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Berendt M, 1999, J VET INTERN MED, V13, P14, DOI 10.1892/0891-6640(1999)013&lt;0014:EASCID&gt;2.3.CO;2; Berendt M, 1999, ACTA NEUROL SCAND, V99, P276, DOI 10.1111/j.1600-0404.1999.tb00676.x; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Brauer C, 2011, VET J, V187, P272, DOI 10.1016/j.tvjl.2009.10.023; Chandler K, 2006, VET J, V172, P207, DOI 10.1016/j.tvjl.2005.07.001; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CROFT PG, 1965, VET REC, V77, P438; CUNNINGHAM JG, 1971, J AM VET MED ASSOC, V158, P589; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Davis KA, 2011, EPILEPSY RES, V96, P116, DOI 10.1016/j.eplepsyres.2011.05.011; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Ekenstedt KJ, 2012, MAMM GENOME, V23, P28, DOI 10.1007/s00335-011-9362-2; Engel Jerome Jr., 1994, Emergency Medicine Clinics of North America, V12, P895; Engel J, 2011, BIOMARK MED, V5, P537, DOI [10.2217/BMM.11.62, 10.2217/bmm.11.62]; Engel JJ, 2008, EPILEPSY COMPREHENSI, P767; FENNER WR, 1981, VET CLIN N AM-SMALL, V11, P31, DOI 10.1016/S0195-5616(81)50004-0; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Geary JG, 2008, J SMALL ANIM PRACT, V8, P577; Govendir M, 2005, AUST VET J, V83, P602, DOI 10.1111/j.1751-0813.2005.tb13269.x; Guha A, 2004, POSTGRAD MED J, V80, P650, DOI 10.1136/pgmj.2004.019570; Hardy BT, 2012, J VET INTERN MED, V26, P334, DOI 10.1111/j.1939-1676.2011.00868.x; Hawthorne JC, 1999, J AM ANIM HOSP ASSOC, V35, P135, DOI 10.5326/15473317-35-2-135; Hayes GM, 2009, J VET EMERG CRIT CAR, V19, P629, DOI 10.1111/j.1476-4431.2009.00478.x; HOLLIDAY TA, 1970, EPILEPSIA, V11, P281, DOI 10.1111/j.1528-1157.1970.tb03892.x; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Koestner A, 1989, Probl Vet Med, V1, P516; Leitgeb J, 2011, J TRAUMA, V71, P1620, DOI 10.1097/TA.0b013e318226ea0e; Leppik IE, 2011, EPILEPSIA, V52, P31, DOI 10.1111/j.1528-1167.2011.03231.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2004, EPILEPSIA, V45, P1228, DOI 10.1111/j.0013-9580.2004.21204.x; LOSCHER W, 1985, ARZNEIMITTEL-FORSCH, V35, P82; LOSCHER W, 1984, FED PROC, V43, P276; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Mani R, 2011, NEUROSCI LETT, V497, P251, DOI 10.1016/j.neulet.2011.03.010; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Munana KR, 2012, J VET INTERN MED, V26, P341, DOI 10.1111/j.1939-1676.2011.00866.x; Nowend KL, 2011, MAMM GENOME, V22, P476, DOI 10.1007/s00335-011-9348-0; Pakozdy A, 2008, ACTA VET HUNG, V56, P471, DOI 10.1556/AVet.56.2008.4.5; PALMER AC, 1972, VET REC, V90, P167, DOI 10.1136/vr.90.7.167; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Podell M, 1996, VET CLIN N AM-SMALL, V26, P779, DOI 10.1016/S0195-5616(96)50105-1; PODELL M, 1995, J AM VET MED ASSOC, V206, P1721; Scantlebury MH, 2010, EPILEPSY RES, V89, P27, DOI 10.1016/j.eplepsyres.2009.11.002; Schwartz-Porsche D., 1994, CLIN SYNDROMES VET N, P234; SCHWARTZPORSCHE D, 1982, J AM VET MED ASSOC, V181, P592; SCHWARTZPORSCHE D, 1985, J VET PHARMACOL THER, V8, P113, DOI 10.1111/j.1365-2885.1985.tb00934.x; Stein VM, 2012, VET IMMUNOL IMMUNOP, V146, P101, DOI 10.1016/j.vetimm.2012.02.003; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Volk HA, 2008, VET J, V176, P310, DOI 10.1016/j.tvjl.2007.03.002; von Klopmann T, 2007, J SMALL ANIM PRACT, V48, P134, DOI 10.1111/j.1748-5827.2006.00290.x; Wessmann A, 2009, VET J, V180, P290, DOI 10.1016/j.tvjl.2007.12.023; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7	61	37	37	1	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	APR	2013	54	4					580	588		10.1111/epi.12071			9	Clinical Neurology	Neurosciences & Neurology	117PL	WOS:000316965500006	23294259	Bronze			2021-06-18	
J	Dennis, M; Simic, N; Agostino, A; Taylor, HG; Bigler, ED; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Dennis, Maureen; Simic, Nevena; Agostino, Alba; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Irony and Empathy in Children with Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Sarcasm; Childhood head injury; Glasgow Coma Scale; Social cognition; Speech acts	HEAD-INJURY; PREDICTION; EXPERIENCE; ABILITY; MILD; MIND	Social communication involves influencing what other people think and feel about themselves. We use the term conative theory of mind (ToM) to refer to communicative interactions involving one person trying to influence the mental and emotional state of another, paradigmatic examples of which are irony and empathy. This study reports how children with traumatic brain injury (TBI) understand ironic criticism and empathic praise, on a task requiring them to identify speaker belief and intention for direct conative speech acts involving literal truth, and indirect speech acts involving either ironic criticism or empathic praise. Participants were 71 children in the chronic state of a single TBI and 57 age- and gender-matched children with orthopedic injuries (OI). Group differences emerged on indirect speech acts involving conation (i.e., irony and empathy), but not on structurally and linguistically identical direct speech acts, suggesting specific deficits in this aspect of social cognition in school-age children with TBI. Deficits in children with mild-moderate TBI were less widespread and more selective than those of children with more severe injuries. Deficits in understanding the social, conative function of indirect speech acts like irony and empathy have widespread and deep implications for social function in children with TBI. (JINS, 2013, 19, 338-348)	[Dennis, Maureen; Simic, Nevena] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Simic, Nevena] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Agostino, Alba] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Dept Pediat, Cleveland, OH 44106 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Rubin, Kenneth] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Psychiat, Cleveland, OH USA	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	maureen.dennis@sickkids.ca	Vannatta, Kathryn/E-4237-2011; Yeates, Keith/AAJ-4223-2020; Gerhardt, Cynthia/E-3109-2011; Rubin, Kenneth H/M-5276-2018; Stancin, Terry/L-7993-2019	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892; Agostino, Alexandra/0000-0001-8739-0061	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1 RO1 HD 04946]	Preparation of this study was supported by National Institute of Child Health and Human Development Grant 1 RO1 HD 04946, "Social Outcomes in Pediatric Traumatic Brain Injury,'' to Keith Yeates. No conflicts of interest exist.	ACKERMAN BP, 1981, DEV PSYCHOL, V17, P472; ACKERMAN BP, 1982, CHILD DEV, V53, P1075; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Crystal D., 1997, CAMBRIDGE ENCY LANGU, P121; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; DEGROOT A, 1995, METAPHOR SYMB ACT, V10, P255, DOI 10.1207/s15327868ms1004_2; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dews Shelly, 1995, AM PSYCH ASS NEW YOR; GIBBS RW, 1995, DISCOURSE PROCESS, V20, P187, DOI 10.1080/01638539509544937; GIBBS RW, 1984, COGNITIVE SCI, V8, P275, DOI 10.1016/S0364-0213(84)80004-X; Hancock JT, 2000, J COGN DEV, V1, P227, DOI 10.1207/S15327647JCD010204; Harris M, 2003, DISCOURSE PROCESS, V36, P147, DOI 10.1207/S15326950DP3603_1; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Hein G, 2010, NEURON, V68, P149, DOI 10.1016/j.neuron.2010.09.003; HILGARD ER, 1980, J HIST BEHAV SCI, V16, P107, DOI 10.1002/1520-6696(198004)16:2<107::AID-JHBS2300160202>3.0.CO;2-Y; Howard I, 2005, ETHNIC DIS, V15, pS51; Huang L, 2011, SOC PSYCHOL PERS SCI, V2, P351, DOI 10.1177/1948550610391677; HUTCHEON L, 1992, DIACRITICS, V22, P2, DOI 10.2307/465234; Krach S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018675; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leggitt JS, 2000, DISCOURSE PROCESS, V29, P1, DOI 10.1207/S15326950dp2901_1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Masten CL, 2011, NEUROIMAGE, V55, P381, DOI 10.1016/j.neuroimage.2010.11.060; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Mobbs D, 2009, SCIENCE, V324, P900, DOI 10.1126/science.1170539; Olsson A, 2007, SOC COGN AFFECT NEUR, V2, P3, DOI 10.1093/scan/nsm005; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Pexman PM, 2007, J NEUROLINGUIST, V20, P178, DOI 10.1016/j.jneuroling.2006.06.001; Rameson LT, 2012, J COGNITIVE NEUROSCI, V24, P235, DOI 10.1162/jocn_a_00130; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833; TEASDALE G, 1974, LANCET, V2, P81; Wilson D., 1995, RELEVANCE COMMUNICAT; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Winner E., 1997, PROBLEM MEANING BEHA; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008	48	37	37	0	29	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2013	19	3					338	348		10.1017/S1355617712001440			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	107DV	WOS:000316195900011	23331976				2021-06-18	
J	Lazaridis, C; Smielewski, P; Steiner, LA; Brady, KM; Hutchinson, P; Pickard, JD; Czosnyka, M				Lazaridis, Christos; Smielewski, Piotr; Steiner, Luzius A.; Brady, Ken M.; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek			Optimal cerebral perfusion pressure: are we ready for it?	NEUROLOGICAL RESEARCH			English	Article						Cerebral blood flow autoregulation; Pressure reactivity; Intracranial pressure; Cerebral perfusion pressure; Traumatic brain injury; Brain tissue oxygen tension	TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; BLOOD-FLOW; CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; CARDIAC-ARREST; CARDIOPULMONARY BYPASS; ENERGY-METABOLISM	Objectives: Cerebral perfusion pressure (CPP)-oriented therapy and the Lund concept lie on opposite ends of the CPP scale, in the management of head injury. Optimization of CPP by monitoring cerebral vascular pressure reactivity is an alternative approach that may reconcile these two divergent approaches, preventing both injurious hypotension and hypertension with an individualized CPP target. Methods: Indices describing cerebral vascular reactivity or cerebral blood flow autoregulation, derived from intracranial pressure, near-infrared spectroscopy, or transcranial Doppler are reviewed in this manuscript. Results: Indices of cerebrovascular reactivity and autoregulation typically converge to a U-shape curve when viewed as a function of CPP, with the best reactivity metrics indicating optimal CPP. In a retrospective study of prospectively collected data from head-injured patients, Steiner et al. demonstrated that a greater distance between averaged over total monitoring time-CPP and optimal CPP, correlated with unfavourable outcome. A recent study of 300 head-injured patients (2003-2009) showed that hypotension below optimal CPP was associated with greater mortality rate, while hypertension above optimal CPP was associated with an increase in severe disability. Discussion: Pilot studies indicating feasibility of autoregulation-oriented CPP optimization have been performed in adult and paediatric traumatic brain injury, aneurysmal subarachnoid haemorrhage, and in patients undergoing cardiothoracic surgery. It remains to be prospectively demonstrated whether optimal CPP management is able to improve outcome.	[Lazaridis, Christos; Smielewski, Piotr; Steiner, Luzius A.; Brady, Ken M.; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Lazaridis, Christos] Med Univ S Carolina, Neurosci Intens Care Unit, Charleston, SC 29425 USA; [Steiner, Luzius A.] Univ Lausanne Hosp, Dept Anesthesia, Lausanne, Switzerland; [Brady, Ken M.] Texas Childrens Hosp, Dept Anesthesiol & Pediat, Houston, TX 77030 USA	Lazaridis, C (corresponding author), Med Univ S Carolina, Dept Neurosci Neurosci Crit Care & Stroke, 96 Jonathan Lucas St,Ste 307 CSB, Charleston, SC 29425 USA.	lazaridi@musc.edu	Steiner, Luzius/J-1987-2019	Smielewski, Peter/0000-0001-5096-3938	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; Department of HealthEuropean Commission [NF-SI-0508-10327] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Andropoulos DB, 2010, J THORAC CARDIOV SUR, V139, P543, DOI 10.1016/j.jtcvs.2009.08.022; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Barber PA, 2008, STROKE, V39, P1427, DOI 10.1161/STROKEAHA.107.502989; BARZO P, 1993, NEUROSURGERY, V32, P611; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; Bijlenga P, 2010, NEUROCRIT CARE, V13, P17, DOI 10.1007/s12028-010-9362-1; Bisschops LLA, 2012, CRIT CARE MED, V40, P1136, DOI 10.1097/CCM.0b013e3182377050; Brady KM, 2010, STROKE, V41, P1957, DOI 10.1161/STROKEAHA.109.575167; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 1997, STROKE, V41, P17; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Eide PK, 2007, NEUROL RES, V29, P798, DOI 10.1179/016164107X224132; Eide PK, 2012, J NEUROSURG, V116, P961, DOI 10.3171/2012.1.JNS111313; Frumento RJ, 2003, ANN THORAC SURG, V75, P479, DOI 10.1016/S0003-4975(02)04475-2; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grande PO, 2011, J NEUROSURG ANESTH, V23, P358, DOI 10.1097/01.ana.0000405612.20356.84; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Lamy A, 2012, NEW ENGL J MED, V366, P1489, DOI 10.1056/NEJMoa1200388; LASSEN NA, 1984, HDB PHYSL CARDIOVASC, V3, P21; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Lazaridis C, 2010, NEUROSURG CLIN N AM, V21, P353, DOI 10.1016/j.nec.2009.10.006; Lee JK, 2012, ANESTH ANALG, V114, P825, DOI 10.1213/ANE.0b013e31824762d5; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McQuillen PS, 2007, STROKE, V38, P736, DOI 10.1161/01.STR.0000247941.41234.90; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Minhas PS, 2003, NEUROSURGERY, V52, P1017, DOI 10.1227/01.NEU.0000058231.08870.1F; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Piechnik S, 1998, ACT NEUR S, V71, P269; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Rasulo FA, 2012, J NEUROSURG ANESTH, V24, P3, DOI 10.1097/ANA.0b013e318224030a; Ratsep T, 2001, J NEUROSURG, V95, P393, DOI 10.3171/jns.2001.95.3.0393; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Smielewski P, 2005, ACT NEUR S, V95, P43; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; Takasu A, 2001, RESUSCITATION, V49, P273, DOI 10.1016/S0300-9572(00)00360-9; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320; 2000, J NEUROTRAUMA, V17, P457	71	37	37	0	20	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	MAR	2013	35	2					138	148		10.1179/1743132812Y.0000000150			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	101KL	WOS:000315773800009	23452576				2021-06-18	
J	Armstrong, CM; Reger, GM; Edwards, J; Rizzo, AA; Courtney, CG; Parsons, TD				Armstrong, Christina M.; Reger, Greg M.; Edwards, Joseph; Rizzo, Albert A.; Courtney, Christopher G.; Parsons, Thomas D.			Validity of the Virtual Reality Stroop Task (VRST) in active duty military	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Stroop test; Executive functioning; Virtual reality; Validity; Active duty military	TRAUMATIC BRAIN-INJURY; SERIAL-ADDITION TASK; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; PERFORMANCE ASSESSMENT TEST; OUTCOMES; PASAT; CONCUSSION; NORMS; IRAQ	Virtual environments provide the ability to systematically deliver test stimuli in simulated contexts relevant to real world behavior. The current study evaluated the validity of the Virtual Reality Stroop Task (VRST), which presents test stimuli during a virtual reality military convoy with simulated combat threats. Active duty Army personnel (N=49) took the VRST, a customized version of the Automated Neuropsychological Assessment Metrics (ANAM)Fourth Edition TBI Battery (2007) that included the addition of the ANAM Stroop and Tower tests, and traditional neuropsychological measures, including the Delis-Kaplan Executive Function System version of the ColorWord Interference Test. Preliminary convergent and discriminant validity was established, and performance on the VRST was significantly associated with computerized and traditional tests of attention and executive functioning. Valid virtual reality cognitive assessments open new lines of inquiry into the impact of environmental stimuli on performance and offer promise for the future of neuropsychological assessments used with military personnel.	[Armstrong, Christina M.; Reger, Greg M.; Edwards, Joseph] Def Ctr Excellence DCoE Psychol Hlth & Traumat Br, Natl Ctr Telehlth & Technol T2, Tacoma, WA 98431 USA; [Rizzo, Albert A.; Courtney, Christopher G.; Parsons, Thomas D.] Univ So Calif, Inst Creat Technol, Los Angeles, CA USA	Armstrong, CM (corresponding author), Def Ctr Excellence DCoE Psychol Hlth & Traumat Br, Natl Ctr Telehlth & Technol T2, Old Madigan Army Med Ctr Bldg 9933A, Tacoma, WA 98431 USA.	drchristinaarmstrong@gmail.com	Armstrong, Christina M./AAU-4242-2020	Armstrong, Christina M./0000-0002-2942-6553; Edwards, Joe/0000-0003-4451-8103; Parsons, Thomas/0000-0003-0331-5019	Telemedicine and Advanced Technology Research Center (TATRC)	We would like to thank Lisa Thomas and Emily Fantelli for their support in this project. We would also like to acknowledge Telemedicine and Advanced Technology Research Center (TATRC), which funded a portion of this research. Thomas D. Parsons changed positions and is now at Clinical Neuropsychology and Simulation Lab, University of North Texas, Denton, TX, USA. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 2007, AUT NEUR ASS METR VE; Armed Forces Health Surveillance Center, 2011, TBI NUMB SEV ALL ARM; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binet, 1904, ANN PSYCHOL, V11, P191, DOI [10.3406/psy.1904.3675, DOI 10.3406/PSY.1904.3675]; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Department of Defense, 2009, DEM 2009 PROF MIL CO; Diehr MC, 2003, J CLIN EXP NEUROPSYC, V25, P571, DOI 10.1076/jcen.25.4.571.13876; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kolasinski E. M., 1995, 1027 US ARM RES I SI; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; MACLEOD CM, 1992, J EXP PSYCHOL GEN, V121, P12, DOI 10.1037/0096-3445.121.1.12; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Parsons TD, 2004, J CLIN EXP NEUROPSYC, V26, P95, DOI 10.1076/jcen.26.1.95.23932; Parsons TD, 2007, ANN REV CYBERTHERAPY, V5, P164; Parsons Thomas D, 2012, Stud Health Technol Inform, V173, P331; Parsons TD, 2011, STUD COMPUT INTELL, V337, P271; Parsons TD, 2011, STUD HEALTH TECHNOL, V163, P433, DOI 10.3233/978-1-60750-706-2-433; Parsons TD, 2009, LECT NOTES ARTIF INT, V5639, P243, DOI 10.1007/978-3-642-02728-4_26; Parsons TD, 2008, STUD HEALTH TECHNOL, V132, P351; Parsons TD, 2008, ANN REV CYBERTHERAPY, V6, P23; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; SPIRDUSO WW, 1980, J GERONTOL, V35, P850, DOI 10.1093/geronj/35.6.850; Spreen O, 2006, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Weathers F., 1991, PTSD CHECKLIST MILIT; Wechsler D., 1939, MEASUREMENT ADULT IN	46	37	38	2	31	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB 1	2013	35	2					113	123		10.1080/13803395.2012.740002			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	092HM	WOS:000315111000001	23157431	Green Published			2021-06-18	
J	Larrabee, GJ; Binder, LM; Rohling, ML; Ploetz, DM				Larrabee, Glenn J.; Binder, Laurence M.; Rohling, Martin L.; Ploetz, Danielle M.			Meta-Analytic Methods and the Importance of Non-TBI Factors Related to Outcome in Mild Traumatic Brain Injury: Response to Bigler et al. (2013)	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Meta-analysis; Non brain injury factors	POST-CONCUSSIVE SYNDROME; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; COMPLICATED MILD; RISK; PREDICTORS; DISORDER; BLAST	Bigler et al. (2013, The Clinical Neuropsychologist) contend that weak methodology and poor quality of the studies comprising our recent meta-analysis led us to miss detecting a subgroup of mild traumatic brain injury (mTBI) characterized by persisting symptomatic complaint and positive biomarkers for neurological damage. Our computation of non-significant Q, tau(2) , and I-2 statistics contradicts the existence of a subgroup of mTBI with poor outcome, or variation in effect size as a function of quality of research design. Consistent with this conclusion, the largest single contributor to our meta-analysis, Dikmen, Machamer, Winn, and Temkin (1995, Neuropsychology, 9, 80) yielded an effect size, 0.02, that was smaller than our overall effect size of 0.07 despite using the most liberal definition of mTBI: loss of consciousness less than 1 hour, with no exclusion of subjects who had positive CT scans. The evidence is weak for biomarkers of mTBI, such as diffusion tensor imaging and for demonstrable neuropathology in uncomplicated mTBI. Postconcussive symptoms, and reduced neuropsychological test scores are not specific to mTBI but can result from pre-existing psychosocial and psychiatric problems, expectancy effects and diagnosis threat. Moreover, neuropsychological impairment is seen in a variety of primary psychiatric disorders, which themselves are predictive of persistent complaints following mTBI. We urge use of prospective studies with orthopedic trauma controls in future investigations of mTBI to control for these confounding factors.	[Rohling, Martin L.; Ploetz, Danielle M.] Univ S Alabama, Mobile, AL 36688 USA	Larrabee, GJ (corresponding author), 2650 Bahia Vista St Suite 308, Sarasota, FL 34239 USA.	glarrabee@aol.com					Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Batty GD, 2007, ANN EPIDEMIOL, V17, P278, DOI 10.1016/j.annepidem.2006.07.010; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler E. D., 2012, PTSD MILD TRAUMATIC, P15; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Camilli G, 2010, TEACH COLL REC, V112, P579; Cappa KA, 2011, HEALTH PSYCHOL, V30, P542, DOI 10.1037/a0025220; Cheng ASK, 2011, ACCIDENT ANAL PREV, V43, P1464, DOI 10.1016/j.aap.2011.02.024; Choi J, 2009, BIOL PSYCHIAT, V65, P227, DOI 10.1016/j.biopsych.2008.06.022; COHADON F, 1991, J NEUROL SCI, V103, pS27; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; DICKER BG, 1992, J HEAD TRAUMA REHAB, V7, P83; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Edlund W, 2004, CLIN PRACTICE GUIDEL; ELANDER J, 1993, PSYCHOL BULL, V113, P279, DOI 10.1037/0033-2909.113.2.279; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geary EK, 2011, J INT NEUROPSYCH SOC, V17, P709, DOI 10.1017/S1355617711000646; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 2004, REVISED COMPREHENSIV; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rohling Martin L, 2002, CNS Spectr, V7, P387; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; ROSENTHAL R, 1984, METAANALYTIC PROCEDU; Ruff R.M., 1989, MILD HEAD INJURY, P176; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Saito Y, 2008, RADIOLOGY, V246, P536, DOI 10.1148/radiol.2462061469; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Symonds CP, 1943, LANCET, V1, P7; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wechsler D., 2001, WECHSLER TEST ADULT; Weiser M, 2004, ACTA PSYCHIAT SCAND, V110, P471, DOI 10.1111/j.1600-0447.2004.00385.x; Weiss A, 2009, PSYCHOSOM MED, V71, P385, DOI 10.1097/PSY.0b013e318198de78; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	97	37	37	0	27	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB 1	2013	27	2					215	237		10.1080/13854046.2013.769634			23	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	146MH	WOS:000319094700003	23414416				2021-06-18	
J	Sheth, KN; Stein, DM; Aarabi, B; Hu, P; Kufera, JA; Scalea, TM; Hanley, DF				Sheth, Kevin N.; Stein, Deborah M.; Aarabi, Bizhan; Hu, Peter; Kufera, Joseph A.; Scalea, Thomas M.; Hanley, Daniel F.			Intracranial Pressure Dose and Outcome in Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Head trauma; Trauma; Intracranial pressure; Critical care	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; HYPERTENSION; INSULTS; IMPACT; CARE	Detecting and treating elevated intracranial pressure (ICP) is a cornerstone of management in patients with severe traumatic brain injury. The aim of this study was to determine the association between area under the curve measurement of elevated ICP and clinical outcome. Single center observational study using prospectively collected data at a University hospital, level one-trauma center. Sixty prospective patients with severe traumatic brain injury were prospectively enrolled over a 2-year period. Intracranial pressure measurements were captured using a real-time automated, high resolution vital signs data recording system. Mortality and functional outcome were assessed at 30 days, 3 and 6 months using Extended Glasgow Outcome Scale. Increasing elevated intracranial pressure time dose was associated with mortality (OR 1.08; 95 % confidence interval [CI], 1.01-1.15, p = 0.03) and poor functional outcome at 3 (OR 1.04; CI 1.00-1.07, p = 0.03) and 6 months (1.04; CI 1.01-1.08, p = 0.02). However, there was no association between episodic ICP data and outcome. These results suggest that pressure time dose measurement of intracranial pressure may be used to predict outcome in severe traumatic brain injury and may be a candidate biomarker in this disease.	[Sheth, Kevin N.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Aarabi, Bizhan] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Scalea, Thomas M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Aarabi, Bizhan; Hu, Peter; Kufera, Joseph A.; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Ctr, Baltimore, MD 21201 USA; [Hanley, Daniel F.] Johns Hopkins Med Inst, Brain Injury Outcomes Program, Baltimore, MD 21205 USA	Sheth, KN (corresponding author), Univ Maryland, Sch Med, Dept Neurol, 110 S Paca St,3rd Floor, Baltimore, MD 21201 USA.	ksheth@som.umaryland.edu		Stein, Deborah/0000-0003-3683-3963	American Academy of Neurology Clinical Research Award	Funding support was provided through American Academy of Neurology Clinical Research Award (KNS).	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2007, ACAD EMERG MED, V14, P695, DOI 10.1197/j.aem.2007.03.1358; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Ditillo M, 2011, J TRAUMA, V71, P373; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; O'Phelan KH, 2009, NEUROCRIT CARE, V10, P280, DOI 10.1007/s12028-008-9183-7; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; Wijman CAC, 2012, NEUROCRIT CARE, V16, P42, DOI 10.1007/s12028-011-9609-5; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	37	37	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2013	18	1					26	32		10.1007/s12028-012-9780-3			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	086SY	WOS:000314708500005	23055087				2021-06-18	
J	Brennan, GP; Jimenez-Mateos, EM; McKiernan, RC; Engel, T; Tzivion, G; Henshall, DC				Brennan, Gary P.; Jimenez-Mateos, Eva M.; McKiernan, Ross C.; Engel, Tobias; Tzivion, Guri; Henshall, David C.			Transgenic Overexpression of 14-3-3 Zeta Protects Hippocampus against Endoplasmic Reticulum Stress and Status Epilepticus In Vivo	PLOS ONE			English	Article							TEMPORAL-LOBE EPILEPSY; INDUCED NEURONAL DEATH; EXPERIMENTALLY EVOKED SEIZURES; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; ER STRESS; MISFOLDED PROTEINS; CELL-DEATH; APOPTOSIS; MICE	14-3-3 proteins are ubiquitous molecular chaperones that are abundantly expressed in the brain where they regulate cell functions including metabolism, the cell cycle and apoptosis. Brain levels of several 14-3-3 isoforms are altered in diseases of the nervous system, including epilepsy. The 14-3-3 zeta (zeta) isoform has been linked to endoplasmic reticulum (ER) function in neurons, with reduced levels provoking ER stress and increasing vulnerability to excitotoxic injury. Here we report that transgenic overexpression of 14-3-3 zeta in mice results in selective changes to the unfolded protein response pathway in the hippocampus, including down-regulation of glucose-regulated proteins 78 and 94, activating transcription factors 4 and 6, and Xbp1 splicing. No differences were found between wild-type mice and transgenic mice for levels of other 14-3-3 isoforms or various other 14-3-3 binding proteins. 14-3-3 zeta overexpressing mice were potently protected against cell death caused by intracerebroventricular injection of the ER stressor tunicamycin. 14-3-3 zeta overexpressing mice were also potently protected against neuronal death caused by prolonged seizures. These studies demonstrate that increased 14-3-3 zeta levels protect against ER stress and seizure-damage despite down-regulation of the unfolded protein response. Delivery of 14-3-3 zeta may protect against pathologic changes resulting from prolonged or repeated seizures or where injuries provoke ER stress.	[Brennan, Gary P.; Jimenez-Mateos, Eva M.; McKiernan, Ross C.; Engel, Tobias; Henshall, David C.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; [Tzivion, Guri] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland.	dhenshall@rcsi.ie	Jimenez-Mateos, Eva/AAG-8072-2019; Brennan, Gary/K-4009-2019	Brennan, Gary/0000-0002-4262-0481; Henshall, David/0000-0001-6237-9632; Engel, Tobias/0000-0001-9137-0637; Jimenez-Mateos, Eva/0000-0001-6417-6580	Science Foundation IrelandScience Foundation IrelandEuropean Commission [08/IN.1/B1875, 08/RFP/1745]; Health Research Board award [HRA-POR/2011/41]	This study was funded by Science Foundation Ireland awards 08/IN.1/B1875 and 08/RFP/1745 and by Health Research Board award HRA-POR/2011/41. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197; Bronisz A, 2006, MOL BIOL CELL, V17, P3897, DOI 10.1091/mbc.E06-05-0470; Cheah PS, 2012, MOL PSYCHIATR, V17, P451, DOI 10.1038/mp.2011.158; Concannon CG, 2008, J NEUROCHEM, V105, P891, DOI 10.1111/j.1471-4159.2007.05187.x; Dunleavy M, 2010, AM J PATHOL, V176, P330, DOI 10.2353/ajpath.2010.090119; Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Engel T, 2010, J NEUROCHEM, V115, P92, DOI 10.1111/j.1471-4159.2010.06909.x; Engel T, 2010, FASEB J, V24, P853, DOI 10.1096/fj.09-145870; Fujikawa DG, 2006, STATUS EPILEPTICUS M, V36, P463; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2012, JASPERS BASIC MECH E, P262; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; Kaneko K, 2006, MED HYPOTHESES, V67, P169, DOI 10.1016/j.mehy.2006.01.019; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI200112978; Lin JH, 2007, ANN REV PATHOL; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu GL, 2012, NEUROL SCI; Liu GL, 2011, BRAIN RES BULL, V84, P94, DOI 10.1016/j.brainresbull.2010.10.004; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; MARTIN H, 1994, J NEUROCHEM, V63, P2259; Maruo K, 2003, BRAIN RES, V977, P294, DOI 10.1016/S0006-8993(03)02838-5; Miller-Delaney SFC, 2012, J NEUROSCI, V32, P1577, DOI 10.1523/JNEUROSCI.5180-11.2012; Murphy BM, 2010, CELL DEATH DIFFER, V17, P459, DOI 10.1038/cdd.2009.134; Murphy N, 2008, BIOMARKERS, V13, P377, DOI [10.1080/13547500802027971, 10.1080/13547500802027971 ]; Murphy N, 2008, J NEUROCHEM, V106, P978, DOI 10.1111/j.1471-4159.2008.05447.x; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Noh HS, 2006, J NEUROSCI RES, V84, P1829, DOI 10.1002/jnr.21057; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Olney J W, 1986, Adv Neurol, V44, P857; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Ramser EM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013462; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Schindler CK, 2006, J NEUROCHEM, V99, P561, DOI 10.1111/j.1471-4159.2006.04153.x; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Steinacker P, 2005, MOL CELL BIOL, V25, P1339, DOI 10.1128/MCB.25.4.1339-1346.2005; Stetler RA, 2008, J NEUROSCI, V28, P13038, DOI 10.1523/JNEUROSCI.4407-08.2008; Tanaka K, 2010, EPILEPSY RES, V88, P151, DOI 10.1016/j.eplepsyres.2009.10.012; Toyo-oka K, 2003, NAT GENET, V34, P274, DOI 10.1038/ng1169; Umahara T, 2004, ACTA NEUROPATHOL, V108, P279, DOI 10.1007/s00401-004-0885-4; Umahara T, 2011, BRAIN RES, V1410, P1, DOI 10.1016/j.brainres.2011.06.036; van der Brug MP, 2002, BRAIN RES, V956, P110, DOI 10.1016/S0006-8993(02)03487-X; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010409; WANG S, 1993, NEUROCHEM INT, V23, P575, DOI 10.1016/0197-0186(93)90106-F; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yacoubian TA, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.4; Yamamoto A, 2006, J NEUROPATH EXP NEUR, V65, P217, DOI 10.1097/01.jnen.0000202886.22082.2a	55	37	37	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2013	8	1							e54491	10.1371/journal.pone.0054491			11	Multidisciplinary Sciences	Science & Technology - Other Topics	077JK	WOS:000314023600061	23359526	DOAJ Gold, Green Published			2021-06-18	
J	Al Nimer, F; Lindblom, R; Strom, M; Guerreiro-Cacais, AO; Parsa, R; Aeinehband, S; Mathiesen, T; Lidman, O; Piehl, F				Al Nimer, Faiez; Lindblom, Rickard; Strom, Mikael; Guerreiro-Cacais, Andre Ortlieb; Parsa, Roham; Aeinehband, Shahin; Mathiesen, Tiit; Lidman, Olle; Piehl, Fredrik			Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Inbred rat strains; Complement; Genetic; Neutrophils; Macrophages; Microglia; NK cells; CXCL1; Neurofilament light	MAJOR HISTOCOMPATIBILITY COMPLEX; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; NEUROFILAMENT LIGHT; EXPRESSION; BLOOD; SUSCEPTIBILITY; SUBSET; MHC	Increasing evidence suggests that genetic background affects outcome of traumatic brain injuries (TB!). Still, there is limited detailed knowledge on what pathways/processes are affected by genetic heterogeneity. The inbred rat strains DA and PVC differ in neuronal survival following TBI. We here carried out global expressional profiling to identify differentially regulated pathways governing the response to an experimental controlled brain contusion injury. One of the most differentially regulated molecular networks concerned immune cell trafficking. Subsequent characterization of the involved cells using flow cytometry demonstrated greater infiltration of neutrophils and monocytes, as well as a higher degree of microglia activation in DA compared to PVG rats. In addition, DA rats displayed a higher number of NK cells and a higher ratio of CD161bright compared to CD161dim NK cells. Local expression of complement pathway molecules such as Cl and C3 was higher in DA and both the key complement component C3 and membrane-attack complex (MAC) could be demonstrated on axons and nerve cells. A stronger activation of the complement system in DA was associated with higher cerebrospinal fluid levels of neurofilament-light, a biomarker for nerve/axonal injury. In summary, we demonstrate substantial differences between DA and PVC rats in activation of inflammatory pathways; in particular, immune cell influx and complement activation associated with neuronal/axonal injury after TBI. These findings suggest genetic influences acting on inflammatory activation to be of importance in TBI and motivate further efforts using experimental forward genetics to identify genes/pathways that affect outcome. (C) 2012 Elsevier Inc. All rights reserved.	[Al Nimer, Faiez] Karolinska Univ Hosp, CMM, Neuroimmunol Unit, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Mathiesen, Tiit] Karolinska Univ Hosp, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden	Al Nimer, F (corresponding author), Karolinska Univ Hosp, CMM, Neuroimmunol Unit, Dept Clin Neurosci, L8 04, S-17176 Stockholm, Sweden.	faiez.al.nimer@ki.se	Guerreiro-Cacais, Andre Ortlieb/AAE-8417-2019; Nimer, Faiez Al/ABB-9465-2020; Piehl, Fredrik/E-3451-2013	Parsa, Roham/0000-0002-0864-6098; Lindblom, Rickard/0000-0001-7913-4981; Mathiesen, Tiit/0000-0001-9463-1919; Al Nimer, Faiez/0000-0003-0937-5995; Guerreiro-Cacais, Andre Ortlieb/0000-0002-4561-2823	European UnionEuropean Commission [LSHM-CT-2005-018637, LSHG-CT-2005019015, HEALTH-F4-2010-241504]; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Swedish Association of Persons with Neurological Disabilities	This study was supported by the 6th Framework Program of the European Union, NeuroproMiSe, LSHM-CT-2005-018637, EURA-Tools, LSHG-CT-2005019015, and the 7th Framework Program of the European Union, EURATrans, HEALTH-F4-2010-241504, by the Swedish Research Council, the Swedish Brain Foundation and the Swedish Association of Persons with Neurological Disabilities.	Abrams MB, 2007, EUR J NEUROSCI, V26, P1118, DOI 10.1111/j.1460-9568.2007.05725.x; Al Nimer F., 2012, ANTIOXID REDOX SIGNA; Al Nimer F, 2011, BRAIN BEHAV IMMUN, V25, P981, DOI 10.1016/j.bbi.2010.10.017; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Dominguez C.A., 2012, EUR J PAIN; Dominguez CA, 2008, PAIN, V136, P313, DOI 10.1016/j.pain.2007.07.009; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Harnesk K, 2008, J IMMUNOL, V180, P3289, DOI 10.4049/jimmunol.180.5.3289; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Inngjerdingen M, 2012, J IMMUNOL, V188, P2499, DOI 10.4049/jimmunol.1003939; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Johnson TA, 2011, J IMMUNOL, V187, P570, DOI 10.4049/jimmunol.1003823; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kheradmand T, 2008, J LEUKOCYTE BIOL, V83, P1128, DOI 10.1189/jlb.0907626; Kim EY, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2755; KORNBLUM J, 1968, J IMMUNOL, V101, P702; Kumar A., 2012, BRAIN BEHAV IMMUN; Lidman O, 2003, J NEUROSCI, V23, P9817; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marta M, 2010, GENES IMMUN, V11, P21, DOI 10.1038/gene.2009.62; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McElroy JP, 2011, NEUROL CLIN, V29, P219, DOI 10.1016/j.ncl.2010.12.002; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Norgren N, 2005, BRAIN RES BULL, V67, P264, DOI 10.1016/j.brainresbull.2005.06.031; Norimatsu Y, 2012, AM J PATHOL, V180, P1625, DOI 10.1016/j.ajpath.2011.12.012; Piehl F, 2009, NEUROSCIENCE, V158, P1143, DOI 10.1016/j.neuroscience.2008.08.031; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Salzer J, 2010, MULT SCLER J, V16, P287, DOI 10.1177/1352458509359725; Sheridan JP, 2011, MULT SCLER J, V17, P1441, DOI 10.1177/1352458511414755; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Strom M, 2012, NEUROMOL MED, V14, P15, DOI 10.1007/s12017-011-8164-8; Sun XC, 2008, CHIN J TRAUMATOL, V11, P247, DOI 10.1016/S1008-1275(08)60051-6; Swanberg M, 2005, NAT GENET, V37, P486, DOI 10.1038/ng1544; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Teunissen CE, 2005, LANCET NEUROL, V4, P32, DOI 10.1016/S1474-4422(04)00964-0; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	49	37	37	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JAN	2013	27						109	122		10.1016/j.bbi.2012.10.002			14	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	058JE	WOS:000312629100015	23044177				2021-06-18	
J	Almenawer, SA; Bogza, I; Yarascavitch, B; Sne, N; Farrokhyar, F; Murty, N; Reddy, K				Almenawer, Saleh A.; Bogza, Iulia; Yarascavitch, Blake; Sne, Niv; Farrokhyar, Forough; Murty, Naresh; Reddy, Kesava			The Value of Scheduled Repeat Cranial Computed Tomography After Mild Head Injury: Single-Center Series and Meta-analysis	NEUROSURGERY			English	Article						Follow-up CT; Intracranial hemorrhage; Meta-analysis; Mild head injury; Repeat computed tomography	TRAUMATIC BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; CT-SCAN; RADIATION; UTILITY; PROGRESSION; RISK; MANAGEMENT; CANCER; RULE	BACKGROUND: After an initial computed tomography (CT) scan revealing intracranial hemorrhage resulting from traumatic brain injury, a standard of care in many trauma centers is to schedule a repeat CT scan to rule out possible progression of bleed. OBJECTIVE: To evaluate the utility of routine follow-up CT in changing the management of mild head injury patients despite clinical stability, although repeat imaging is indicated to assess a deteriorating patient. METHODS: The trauma database at our institution was retrospectively reviewed and the literature was searched to identify patients after mild head injury with positive initial CT finding and scheduled repeat scan. Patients were divided into 2 groups for comparison. Group A included patients who had intervention based on neurological examination changes. Group B comprised patients requiring a change in management according to CT results exclusively. The meta-analysis of the present cohort and included articles was performed with a random-effects model. RESULTS: Overall, 15 studies and 445 patients met our eligibility criteria, totaling 2693 patients. Intervention rates of groups A and B were 2.7% (95% confidence interval, 1.7-3.9; P = .003) and 0.6% (95% confidence interval, 0.3-1; P = .21), respectively. The statistical difference between both intervention rates was clinically significant with P < .001. CONCLUSION: The available evidence indicates that it is unnecessary to schedule a repeat CT scan after mild head injury when patients are unchanged or improving neurologically. In the absence of supporting data, we question the value of routine follow-up imaging given the associated accumulative increase in cost and risks.	[Almenawer, Saleh A.; Bogza, Iulia; Yarascavitch, Blake; Murty, Naresh; Reddy, Kesava] McMaster Univ, Div Neurosurg, Hamilton, ON, Canada; [Sne, Niv; Farrokhyar, Forough] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	Almenawer, SA (corresponding author), 100 Main St E,Ste 42B, Hamilton, ON L8N 3W4, Canada.	Dr_menawer@hotmail.com	Farrokhyar, Forough/AAQ-6005-2021	Farrokhyar, Forough/0000-0001-9928-9016; Yarascavitch, Blake/0000-0003-1810-1267			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Huynh T, 2006, AM SURGEON, V72, P1162; Kalender WA, 2006, PHYS MED BIOL, V51, pR29, DOI 10.1088/0031-9155/51/13/R03; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Khaldi A, 2010, J NEUROSURG, V113, P1021, DOI 10.3171/2009.11.JNS081048; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; LUND E, 1982, NEURORADIOLOGY, V22, P181, DOI 10.1007/BF00341246; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Pauwels EKJ, 2011, ACTA RADIOL, V52, P767, DOI 10.1258/ar.2011.100496; Peace K, 2010, J NEUROSCI NURS, V42, P109, DOI 10.1097/JNN.0b013e3181ce5c5b; Roka Y B, 2008, Nepal Med Coll J, V10, P225; Schuster R, 2005, AM SURGEON, V71, P701; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sifri ZC, 2011, J TRAUMA, V71, P1605, DOI 10.1097/TA.0b013e31822b3728; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; TEASDALE G, 1974, LANCET, V2, P81; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f	41	37	37	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2013	72	1					56	62		10.1227/NEU.0b013e318276f899			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	060II	WOS:000312769400027	23254767				2021-06-18	
J	Lewis, M; Ghassemi, P; Hibbeln, J				Lewis, Michael; Ghassemi, Parviz; Hibbeln, Joseph			Therapeutic use of omega-3 fatty acids in severe head trauma	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; BRAIN-INJURY; ENTERAL NUTRITION; TRANSIENT; APOPTOSIS	Traumatic brain injury (TBI) has long been recognized as the leading cause of traumatic death and disability. Tremendous advances in surgical and intensive care unit management of the primary injury, including maintaining adequate oxygenation, controlling intracranial pressure, and ensuring proper cerebral perfusion pressure, have resulted in reduced mortality. However, the secondary injury phase of TBI is a prolonged pathogenic process characterized by neuroinflammation, excitatory amino acids, free radicals, and ion imbalance. There are no approved therapies to directly address these underlying processes. Here, we present a case that was intentionally treated with substantial amounts of omega-3 fatty acids (n-3FA) to provide the nutritional foundation for the brain to begin the healing process following severe TBI. Recent animal research supports the use of n-3FA, and clinical experience suggests that benefits may be possible from substantially and aggressively adding n-3FA to optimize the nutritional foundation of severe TBI patients and must be in place if the brain is to be given the opportunity to repair itself to the best possible extent. Administration early in the course of treatment, in the emergency department or sooner, has the potential to improve outcomes from this potentially devastating public health problem.	[Lewis, Michael] Brain Hlth Educ & Res Fdn, Arlington, VA 22206 USA; [Hibbeln, Joseph] NIAAA, NIH, Rockville, MD 20852 USA	Lewis, M (corresponding author), Brain Hlth Educ & Res Fdn, Arlington, VA 22206 USA.	dr.michael.lewis@gmail.com; peter@arctelcom.com; Joseph.hibbeln@nih.gov			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000115] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA AA000115-12] Funding Source: Medline		Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Akbar M, 2002, J NEUROCHEM, V82, P655, DOI 10.1046/j.1471-4159.2002.01015.x; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; Bistrian BR, 2003, JPEN-PARENTER ENTER, V27, P168, DOI 10.1177/0148607103027003168; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; Michael-Titus AT, 2009, CLIN LIPIDOL, V4, P343, DOI 10.2217/CLP.09.19; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Okada M, 1996, NEUROSCIENCE, V71, P17, DOI 10.1016/0306-4522(95)00427-0; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Willatts P, 1998, LANCET, V352, P688, DOI 10.1016/S0140-6736(97)11374-5; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Yavin E, 2009, NEUROSCIENCE, V162, P1011, DOI 10.1016/j.neuroscience.2009.05.012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	29	37	39	0	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	2013	31	1							273.e5	10.1016/j.ajem.2012.05.014			4	Emergency Medicine	Emergency Medicine	062WM	WOS:000312954600077	22867826	Green Accepted			2021-06-18	
J	Thiagarajan, P; Ciuffreda, KJ				Thiagarajan, Preethi; Ciuffreda, Kenneth J.			Effect of oculomotor rehabilitation on vergence responsivity in mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						acquired brain injury; mild traumatic brain injury; nearwork symptoms; neuroplasticity; oculomotor dysfunction; oculomotor learning; oculomotor rehabilitation; traumatic brain injury; vergence; vergence dysfunction; visual attention	EYE-MOVEMENTS; CONVERGENCE INSUFFICIENCY; VISUAL DYSFUNCTION; NEURAL PLASTICITY; DISPARITY; AREA; MILITARY; NEURONS; ACCOMMODATION; ADAPTATION	A range of dynamic and static vergence responses were evaluated in 12 individuals with mild traumatic brain injury (age: 29 +/ 3 yr) having near vision symptoms. All measures were performed in a crossover design before and after oculomotor training (OMT) and placebo (P) training. Following OMT, peak velocity for both convergence and divergence increased significantly. Increased peak velocity was significantly correlated with increased clinically based vergence prism flipper rate. Steady-state response variability for convergence reduced significantly following OMT. The maximum amplitude of convergence, relative fusional amplitudes, and near stereoacuity improved significantly. In addition, symptoms reduced significantly, and visual attention improved markedly. None of the measures were found to change significantly following P training. The significant improvement in most aspects of vergence eye movements following OMT demonstrates considerable residual brain plasticity via oculomotor learning. The improved vergence affected positively on nearwork-related symptoms and visual attention.	[Thiagarajan, Preethi; Ciuffreda, Kenneth J.] SUNY Coll Optometry, Dept Biol & Vis Sci, New York, NY 10036 USA	Thiagarajan, P (corresponding author), SUNY Coll Optometry, Dept Biol & Vis Sci, 33 West 42nd St, New York, NY 10036 USA.	pthiagarajan@sunyopt.edu			U.S. Army; Department of Defense (Telemedicine and Advanced Technology Research Center)United States Department of Defense [W81XWH-10-1-1041, W81XWH-12-1-0240]; College of Optometrists in Vision Development; SUNY College of Optometry Graduate Program	This material was based on work supported by the U.S. Army, Department of Defense (Telemedicine and Advanced Technology Research Center awards W81XWH-10-1-1041 and W81XWH-12-1-0240), College of Optometrists in Vision Development, and SUNY College of Optometry Graduate Program.	Abernethy B, 2005, BIOPHYSICAL FDN HUMA, P51; ALQURAINY IA, 1995, BRIT J ORAL MAX SURG, V33, P71, DOI 10.1016/0266-4356(95)90203-1; Alvarez TL, 2010, OPTOMETRY VISION SCI, V87, P985, DOI 10.1097/OPX.0b013e3181fef1aa; Arlinghaus KA, 2011, TXB TRAUMATIC BRAIN, P55; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benjamin WJ, 2006, BORISHS CLIN REFRACT; BERNE SA, 1990, J OPTOM VIS DEV, V21, P13; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brautaset RL, 2006, INVEST OPHTH VIS SCI, V47, P2876, DOI 10.1167/iovs.04-1372; Bulson R, 2012, J REHABIL RES DEV, V49, P1075, DOI 10.1682/JRRD.2011.02.0017; Candler R., 1944, BR ORTHOPTIC J, V2, P56; Capo-Aponte JE, 2012, J REHABIL RES DEV, V49, P1377, DOI 10.1682/JRRD.2011.07.0128; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen HW, 2010, PM&R, V2, pS306, DOI 10.1016/j.pmrj.2010.10.006; Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda KJ, 2011, OPTOMETRY, V82, P61, DOI 10.1016/j.optm.2010.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda KJ, 1995, EYE MOVEMENT BASICS; Cohen A H, 1992, J Am Optom Assoc, V63, P569; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Coronado Victor G, 2010, TRAUMATIC BRAIN INJU; CROSS AG, 1948, ANN ROY COLL SURG, V2, P233; Cross AG, 1945, T OPHTHAL SOC UK, V65, P20; Cuiffreda K., 1992, J BEHAV OPTOM, V3, P3; DeAngelis GC, 1998, NATURE, V394, P677; FISHER SK, 1990, PERCEPTION, V19, P171, DOI 10.1068/p190171; Gamlin PD, 2000, NATURE, V407, P1003, DOI 10.1038/35039506; Gamlin PDR, 2002, ANN NY ACAD SCI, V956, P264, DOI 10.1111/j.1749-6632.2002.tb02825.x; Genovesio A, 2004, J NEUROPHYSIOL, V91, P2670, DOI 10.1152/jn.00712.2003; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HELLERSTEIN LF, 1994, J BEHAV OPTOMETRY, V5, P143; Helvie R, 2011, VISION REHABILITATION: MULTIDISCIPLINARY CARE OF THE PATIENT FOLLOWING BRAIN INJURY, P45, DOI 10.1201/b10524-4; Hung GK, 1997, VISION RES, V37, P1197, DOI 10.1016/S0042-6989(97)00271-X; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; KELLER EL, 1974, J NEUROPHYSIOL, V37, P316; KERKHOFF G, 1994, BRAIN INJURY, V8, P15, DOI 10.3109/02699059409150955; Khan AA, 2005, DIGITAL SIGNAL PROCE; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; Leigh J., 2006, NEUROLOGY EYE MOVEME; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Ludlam WM, 1996, NEUROREHABILITATION, V6, P183, DOI 10.3233/NRE-1996-6304; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; MANAS L, 1958, Am J Optom Arch Am Acad Optom, V35, P428; MAYS LE, 1984, J NEUROPHYSIOL, V51, P1091; MAYS LE, 1986, J NEUROPHYSIOL, V56, P1007; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; NORTH R, 1981, AM J OPTOM PHYS OPT, V58, P746; Prince SJD, 2000, J NEUROSCI, V20, P3387, DOI 10.1523/JNEUROSCI.20-09-03387.2000; Rambold H, 2005, ANN NY ACAD SCI, V1039, P567, DOI 10.1196/annals.1325.069; Rambold H, 2004, NEUROLOGY, V62, P1850, DOI 10.1212/01.WNL.0000125331.95849.62; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P339, DOI 10.1113/jphysiol.1961.sp006812; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; RON S, 1978, SCAND J REHABIL MED, V10, P39; Rosenfield M, 1997, OPTOMETRY VISION SCI, V74, P303, DOI 10.1097/00006324-199705000-00027; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Scheiman M., 2008, CLIN MANAGEMENT BINO, V3rd; Scheiman M, 2001, VISUAL VESTIBULAR CO; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Schor CM., 1983, VERGENCE EYE MOVEMEN, P484; Semmlow JL, 2002, IEEE T BIO-MED ENG, V49, P805, DOI 10.1109/TBME.2002.800758; SEMMLOW JL, 1993, OPHTHAL PHYSL OPT, V13, P48, DOI 10.1111/j.1475-1313.1993.tb00426.x; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suchoff IB, 2001, VISUAL VESTIBULAR CO; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Takemura A, 2001, J NEUROPHYSIOL, V85, P2245; Thiagarajan P., 2012, THESIS STATE U NEW Y; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Thiagarajan P, 2010, OPTOMETRY VISION SCI, V87, P487, DOI 10.1097/OPX.0b013e3181e19ec2; Trenerry MR., 1990, VISUAL SEARCH ATTENT; VAEGAN, 1979, AM J OPTOM PHYS OPT, V56, P23; Warraich Z, 2010, PM&R, V2, pS208, DOI 10.1016/j.pmrj.2010.10.016; WESTHEIMER G, 1973, INVEST OPHTH VISUAL, V12, P618; Yuan WH, 1999, IEEE T BIO-MED ENG, V46, P1191, DOI 10.1109/10.790495	87	37	37	0	10	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2013	50	9					1223	1239		10.1682/JRRD.2012.12.0235			17	Rehabilitation	Rehabilitation	287IE	WOS:000329534500009	24458963	Bronze			2021-06-18	
J	Zhang, LY; Makwana, R; Sharma, S				Zhang, Liying; Makwana, Rahul; Sharma, Sumit			Brain response to primary blast wave using validated finite element models of human head and advanced combat helmet	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; primary blast; finite element model; advanced combat helmet model; human head model; intracranial pressure; brain strain and strain rate; head protection		Blast-induced traumatic brain injury has emerged as a "signature injury" in combat casualty care. Present combat helmets are designed primarily to protect against ballistic and blunt impacts, but the current issue with helmets is protection concerning blasts. In order to delineate the blast wave attenuating capability of the Advanced Combat Helmet (ACH), a finite element (FE) study was undertaken to evaluate the head response against blast loadings with and without helmet using a partially validated FE model of the human head and ACH. Four levels of overpressures (0.27-0.66 MPa) from the Bowen's lung iso-damage threshold curves were used to simulate blast insults. Effectiveness of the helmet with respect to head orientation was also investigated. The resulting biomechanical responses of the brain to blast threats were compared for human head with and without the helmet. For all Bowen's cases, the peak intracranial pressures (ICP) in the head ranged from 0.68 to 1.8 MPa in the coup cortical region. ACH was found to mitigate ICP in the head by 10-35%. Helmeted head resulted in 30% lower average peak brain strains and product of strain and strain rate. Among three blast loading directions with ACH, highest reduction in peak ICP (44%) was due to backward blasts whereas the lowest reduction in peak ICP and brain strains was due to forward blast (27%). The biomechanical responses of a human head to primary blast insult exhibited directional sensitivity owing to the different geometry contours and coverage of the helmet construction and asymmetric anatomy of the head. Thus, direction-specific tolerances are needed in helmet design in order to offer omni-directional protection for the human head. The blasts of varying peak overpressures and durations that are believed to produce the same level of lung injury produce different levels of mechanical responses in the brain, and hence "iso-damage" curves for brain injury are likely different than the Bowen curves for lung injury.	[Zhang, Liying; Makwana, Rahul; Sharma, Sumit] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA	Zhang, LY (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI USA.; Zhang, LY (corresponding author), Wayne State Univ, Bioengn Ctr, 818 West Hancock St, Detroit, MI 48201 USA.	lzhang@wayne.edu	MAKWANA, RAHUL/H-9629-2019		Department of Defence [W81XWH-08-1-0678]	This work was partially supported by a Department of Defence award W81XWH-08-1-0678.	Aare M, 2007, INT J IMPACT ENG, V34, P596, DOI 10.1016/j.ijimpeng.2005.08.001; Allsop D, 1988, P 32 STAPP CAR CRASH; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bir C, 2011, TECHNICAL REPORT; Bowen IG, 1968, DASA2113 DEP DEF DEF; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; Crawford, 1985, LLNL EXPLOSIVES HDB; Defense Manpower Data Center, 2011, GLOB WAR TERR CAUS M; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of the Army, 2008, 10847020410 DEP ARM; Duetekom MJ, 1999, P 18 INT S BALL; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Galford JE, 1969, 69BHF6; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; King AI, 2003, P BIOM IMP, P1; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Li JZ, 2010, IFMBE PROC, V31, P1518, DOI 10.1007/978-3-642-14515-5_387; Liying Zhang K.H.Y., 2003, P 2003 SUMM BIOENG C, P0137; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; McEntire BJ, 2005, 200512 USAARL; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss W C, 2011, LLNLSR471496, DOI 10.2172/1021058; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Nyquist G. W., 1986, P 30 STAPP CAR CRASH; Sewell RGS, 1979, TP5920 NAV WEAP CTR; Sharma S, 2011, P INJ BIOM S; Stevenson C, 2009, J MIL VETERANS HEALT, V17, P17; Takhounts EG, 2004, STAPP CAR CRASH J, V47, P107; Trosseille X., 1992, P 36 STAPP CAR CRASH; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Ward C, 1980, P 24 STAPP CAR CRASH; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Xin X, 2009, INTERACTION BLAST HE; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang L, 2010, TECHNICAL REPORT; Zhang LH, 2008, 2008 PROCEEDINGS OF INFORMATION TECHNOLOGY AND ENVIRONMENTAL SYSTEM SCIENCES: ITESS 2008, VOL 1, P123; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	49	37	37	0	12	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								88	10.3389/fneur.2013.00088			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000087	23935591	DOAJ Gold, Green Published			2021-06-18	
J	Freund, P; Schneider, T; Nagy, Z; Hutton, C; Weiskopf, N; Friston, KJ; Wheeler-Kingshott, CA; Thompson, AJ				Freund, Patrick; Schneider, Torben; Nagy, Zoltan; Hutton, Chloe; Weiskopf, Nikolaus; Friston, Karl J.; Wheeler-Kingshott, Claudia A.; Thompson, Alan J.			Degeneration of the Injured Cervical Cord Is Associated with Remote Changes in Corticospinal Tract Integrity and Upper Limb Impairment	PLOS ONE			English	Article							VOXEL-BASED MORPHOMETRY; SPINAL-CORD; MULTIPLE-SCLEROSIS; WHITE-MATTER; WALLERIAN DEGENERATION; MRI; MOTOR; ATROPHY; PATHWAYS; RECOVERY	Background: Traumatic spinal cord injury (SCI) leads to disruption of axons and macroscopic tissue loss. Using diffusion tensor imaging (DTI), we assessed degeneration of the corticospinal tract (CST) in the cervical cord above a traumatic lesion and explored its relationship with cervical atrophy, remote axonal changes within the cranial CST and upper limb function. Methods: Nine cervical injured volunteers with bilateral motor and sensory impairment and ten controls were studied. DTI of the cervical cord and brain provided measurements of fractional anisotropy (FA), while anatomical MRI assessed cross-sectional spinal cord area (i.e. cord atrophy). Spinal and central regions of interest (ROI) included the bilateral CST in the cervical cord and brain. Regression analysis identified correlations between spinal FA and cranial FA in the CST and disability. Results: In individuals with SCI, FA was significantly lower in both CSTs throughout the cervical cord and brain when compared with controls (p <= 0.05). Reduced FA of the cervical cord in patients with SCI was associated with smaller cord area (p = 0.002) and a lower FA of the cranial CST at the internal capsule level (p = 0.001). Lower FA in the cervical CST also correlated with impaired upper limb function, independent of cord area (p = 0.03). Conclusion: Axonal degeneration of the CST in the atrophic cervical cord, proximal to the site of injury, parallels cranial CST degeneration and is associated with disability. This DTI protocol can be used in longitudinal assessment of microstructural changes immediately following injury and may be utilised to predict progression and monitor interventions aimed at promoting spinal cord repair.	[Freund, Patrick; Thompson, Alan J.] UCL, Inst Neurol, Dept Brain Repair & Rehabil, London, England; [Freund, Patrick; Nagy, Zoltan; Hutton, Chloe; Weiskopf, Nikolaus; Friston, Karl J.] UCL, Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Freund, Patrick] UCL, Royal Natl Orthopaed Hosp, Spinal Cord Injury Ctr, London, England; [Freund, Patrick] Swiss Parapleg Res, Nottwil, Switzerland; [Schneider, Torben; Wheeler-Kingshott, Claudia A.] UCL, Inst Neurol, Dept Neuroinflammat, NMR Res Unit, London, England	Freund, P (corresponding author), UCL, Inst Neurol, Dept Brain Repair & Rehabil, London, England.	p.freund@ucl.ac.uk	Nagy, Zoltan/AAI-2485-2019; Friston, Karl/D-9230-2011; Wheeler-Kingshott, Claudia A M Gandini/AAH-7480-2019; Weiskopf, Nikolaus/ABI-5713-2020; Freund, Patrick/D-4193-2013; Weiskopf, Nikolaus/B-9357-2008; Thompson, Alan J/C-2654-2008	Nagy, Zoltan/0000-0001-6611-6362; Friston, Karl/0000-0001-7984-8909; Wheeler-Kingshott, Claudia A M Gandini/0000-0002-4832-1300; Weiskopf, Nikolaus/0000-0001-5239-1881; Freund, Patrick/0000-0002-4851-2246; Weiskopf, Nikolaus/0000-0001-5239-1881; Thompson, Alan J/0000-0002-4333-8496	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische Stipendien [PASMP3-124194]; Swiss Paraplegic Research (Nottwil); Wellcome TrustWellcome TrustEuropean Commission; Department of Health's National Institute for Health Research Biomedical Research Centers funding scheme	This study was supported by the Swiss National Science Foundation (Grant No: PBFR33-120920), Schweizerische Stiftung fur medizinische und biologische Stipendien (Grant No: PASMP3-124194), the Swiss Paraplegic Research (Nottwil) and the Wellcome Trust. This work was undertaken at University College London Hospitals/University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centers funding scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS R, 1994, IEEE T PATTERN ANAL, V16, P641, DOI 10.1109/34.295913; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Buss A, 2005, BRAIN, V128, P356, DOI 10.1093/brain/awh355; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Cook PA, 2007, J MAGN RESON IMAGING, V25, P1051, DOI 10.1002/jmri.20905; Dietz V, 2006, LANCET NEUROL, V5, P688, DOI 10.1016/S1474-4422(06)70522-1; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Ellaway PH, 2011, BRAIN RES BULL, V84, P343, DOI 10.1016/j.brainresbull.2010.08.007; Ellingson BM, 2008, AM J NEURORADIOL, V29, P1976, DOI 10.3174/ajnr.A1272; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, EUR J NEUROSCI, V34, P1839, DOI 10.1111/j.1460-9568.2011.07895.x; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund P, 2010, MULT SCLER J, V16, P1193, DOI 10.1177/1352458510376180; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850; Gouw AA, 2008, BRAIN, V131, P3286, DOI 10.1093/brain/awn265; Granert O, 2011, NEUROIMAGE, V54, P32, DOI 10.1016/j.neuroimage.2010.08.013; Hoogervorst ELJ, 2002, ARCH NEUROL-CHICAGO, V59, P113, DOI 10.1001/archneur.59.1.113; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kakulas B A, 1984, Cent Nerv Syst Trauma, V1, P117; Lee JE, 2009, NEUROIMAGE, V44, P870, DOI 10.1016/j.neuroimage.2008.09.041; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Petersen JA, 2012, J NEUROTRAUM, V29, P1556, DOI 10.1089/neu.2011.2027; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Schneider T, 2011, 19 ANN SCI M EXH 201, P4556; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wheeler-Kingshott CAM, 2002, NEUROIMAGE, V16, P93, DOI 10.1006/nimg.2001.1022; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072	39	37	42	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e51729	10.1371/journal.pone.0051729			7	Multidisciplinary Sciences	Science & Technology - Other Topics	066QV	WOS:000313236200158	23251612	DOAJ Gold, Green Published			2021-06-18	
J	Turner, RC; Naser, ZJ; Bailes, JE; Smith, DW; Fisher, JA; Rosen, CL				Turner, Ryan C.; Naser, Zachary J.; Bailes, Julian E.; Smith, David W.; Fisher, Joseph A.; Rosen, Charles L.			Effect of slosh mitigation on histologic markers of traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; slosh; rat; jugular vein compression	AXONAL INJURY; HEAD-INJURY; DOCOSAHEXAENOIC ACID; DENTATE GYRUS; FLUORO-JADE; MODEL; PROGESTERONE; HIPPOCAMPUS; ASTROCYTES; SUPPLEMENTATION	Object. Helmets successfully prevent most cranial fractures and skull traumas, but traumatic brain injury (TBI) and concussions continue to occur with frightening frequency despite the widespread use of helmets on the athletic field and battlefield. Protection against such injury is needed. The object of this study was to determine if slosh mitigation reduces neural degeneration, gliosis, and neuroinflammation. Methods. Two groups of 10 adult male Sprague-Dawley rats were subjected to impact-acceleration TBI. One group of animals was fitted with a collar inducing internal jugular vein (IJV) compression prior to injury, whereas the second group received no such collar prior to injury. All rats were killed 7 days postinjury, and the brains were fixed and embedded in paraffin. Tissue sections were processed and stained for markers of neural degeneration (Fluoro-Jade B), gliosis (glial fibrillary acidic protein), and neuroinflammation (ionized calcium binding adapter molecule 1). Results. Compared with the controls, animals that had undergone IJV compression had a 48.7%-59.1% reduction in degenerative neurons, a 36.8%-45.7% decrease in reactive astrocytes, and a 44.1%-65.3% reduction in microglial activation. Conclusions. The authors concluded that IJV compression, a form of slosh mitigation, markedly reduces markers of neurological injury in a common model of TBI. Based on findings in this and other studies, slosh mitigation may have potential for preventing TBI in the clinical population. (http://thejns.org/doi/abs/10.3171/2012.8.JNS12358)	[Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Hlth Sci Ctr, Morgantown, WV 26506 USA; [Bailes, Julian E.] NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL USA; [Fisher, Joseph A.] Univ Toronto, Dept Anesthesiol, Univ Hlth Network, Toronto, ON, Canada	Rosen, CL (corresponding author), W Virginia Univ, Sch Med, Dept Neurosurg, Hlth Sci Ctr, 1 Med Ctr Dr,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu		Turner, Ryan/0000-0001-5523-0645	Mary Babb Randolph Cancer Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20RR016440]; West Virginia University; Department of Neurosurgery; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM81741]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081741] Funding Source: NIH RePORTER	The authors gratefully acknowledge the support of Ms. Penny Humberson as lab manager and Dr. James O'Callaghan and Dr. Diane Miller of the National Institute of Occupational Safety and Health (NIOSH) for providing reagents and supplies. The technical support of Ms. Diana Richardson of NIOSH was essential in preparing tissues for analysis. The authors also thank Dr. Karen Martin, for technical expertise, and the West Virginia University Imaging Facility, which is supported in part by the Mary Babb Randolph Cancer Center and NIH Grant No. P20RR016440.; This work was funded by West Virginia University and the Department of Neurosurgery. Additional financial support was provided by the National Institutes of Health Grant No. 5T32GM81741 (R.C.T.).	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Bignami A, 1991, GLIAL CELLS CENTRAL; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Fitch MT, 1999, J NEUROSCI, V19, P8182; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Ibrahim RA., 2001, APPL MECH REV, V54, P133, DOI [10.1115/1.3097293, DOI 10.1115/1.3097293]; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAY PRA, 1976, LANCET, V1, P454; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; PATRA P, 1988, SURG RADIOL ANAT, V10, P107, DOI 10.1007/BF02307818; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; Wang LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026490; Wygnanski-Jaffe T, 2007, EYE, V21, P83, DOI 10.1038/sj.eye.6702163; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	30	37	37	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2012	117	6					1110	1118		10.3171/2012.8.JNS12358			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	042IC	WOS:000311463900018	22998060				2021-06-18	
J	Hilario, A; Ramos, A; Millan, JM; Salvador, E; Gomez, PA; Cicuendez, M; Diez-Lobato, R; Lagares, A				Hilario, A.; Ramos, A.; Millan, J. M.; Salvador, E.; Gomez, P. A.; Cicuendez, M.; Diez-Lobato, R.; Lagares, A.			Severe Traumatic Head Injury: Prognostic Value of Brain Stem Injuries Detected at MRI	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							GLASGOW OUTCOME SCALE; DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE; VEGETATIVE STATE; LESIONS; CLASSIFICATION; MODERATE	BACKGROUND AND PURPOSE: Traumatic brain injuries represent an important cause of death for young people. The main objectives of this work are to correlate brain stem injuries detected at MR imaging with outcome at 6 months in patients with severe TBI, and to determine which MR imaging findings could be related to a worse prognosis. MATERIALS AND METHODS: One hundred and eight patients with severe TBI were studied by MR imaging in the first 30 days after trauma. Brain stem injury was categorized as anterior or posterior, hemorrhagic or nonhemorrhagic, and unilateral or bilateral. Outcome measures were GOSE and Barthel Index 6 months postinjury. The relationship between MR imaging findings of brain stem injuries, outcome, and disability was explored by univariate analysis. Prognostic capability of MR imaging findings was also explored by calculation of sensitivity, specificity, and area under the ROC curve for poor and good outcome. RESULTS: Brain stem lesions were detected in 51 patients, of whom 66% showed a poor outcome, as expressed by the GOSE scale. Bilateral involvement was strongly associated with poor outcome (P < .05). Posterior location showed the best discriminatory capability in terms of outcome (OR 6.8, P < .05) and disability (OR 4.8, P < .01). The addition of nonhemorrhagic and anterior lesions or unilateral injuries showed the highest odds and best discriminatory capacity for good outcome. CONCLUSIONS: The prognosis worsens in direct relationship to the extent of traumatic injury. Posterior and bilateral brain stem injuries detected at MR imaging are poor prognostic signs. Nonhemorrhagic injuries showed the highest positive predictive value for good outcome.	[Hilario, A.; Ramos, A.; Millan, J. M.; Salvador, E.] Hosp 12 Octubre, Dept Radiol, E-28041 Madrid, Spain; [Gomez, P. A.; Cicuendez, M.; Diez-Lobato, R.; Lagares, A.] Hosp 12 Octubre, Dept Neurosurg, E-28041 Madrid, Spain	Hilario, A (corresponding author), Hosp 12 Octubre, Dept Radiol, Ave Cordoba S-N, E-28041 Madrid, Spain.	amayahilario@yahoo.es	Gomez, Pedro/N-5051-2019; Lagares, Alfonso/B-2969-2011	Gomez, Pedro/0000-0002-4185-5238; Lagares, Alfonso/0000-0003-3996-0554; Salvador, Elena/0000-0002-8324-6502			Aguas J, 2005, NEUROCIRUGIA, V16, P14; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; JENKINS A, 1986, LANCET, V2, P445; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lagares A, 2006, NEUROCIRUGIA, V17, P105; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; MAHONEY F I, 1965, Md State Med J, V14, P61; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	30	37	40	0	6	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV	2012	33	10					1925	1931		10.3174/ajnr.A3092			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	045QH	WOS:000311711400016	22576887	Green Published, Other Gold			2021-06-18	
J	Whiteneck, G; Gassaway, J; Dijkers, MP; Heinemann, AW; Kreider, SED				Whiteneck, Gale; Gassaway, Julie; Dijkers, Marcel P.; Heinemann, Allen W.; Kreider, Scott E. D.			Relationship of patient characteristics and rehabilitation services to outcomes following spinal cord injury: The SCIRehab Project	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Tetraplegia; Paraplegia; Rehabilitation; Physical; Social participation; Quality of life; Activities of daily living; Spinal cord injury model system; Practice-based evidence	CLINICAL-PRACTICE IMPROVEMENT; THERAPY TREATMENT TIME; TRAUMATIC BRAIN; INPATIENT REHABILITATION; SEVERITY; STAY; CARE; COMPLICATIONS; RECOVERY; ILLNESS	Background/objective: To examine associations of patient characteristics along with treatment quantity delivered by seven clinical disciplines during inpatient spinal cord injury (SCI) rehabilitation with outcomes at rehabilitation discharge and 1-year post-injury. Methods: Six inpatient SCI rehabilitation centers enrolled 1376 patients during the 5-year SCIRehab study. Clinicians delivering standard care documented details of treatment. Outcome data were derived from SCI Model Systems Form I and II and a project-specific interview conducted at approximately 1-year post-injury. Regression modeling was used to predict outcomes; models were cross-validated by examining relative shrinkage of the original model R-2 using 75% of the dataset to the R-2 for the same outcome using a validation subsample. Results: Patient characteristics are strong predictors of outcome; treatment duration adds slightly more predictive power. More time in physical therapy was associated positively with motor Functional Independence Measure at discharge and the 1-year anniversary, CHART Physical Independence, Social Integration, and Mobility dimensions, and smaller likelihood of rehospitalization after discharge and reporting of pressure ulcer at the interview. More time in therapeutic recreation also had multiple similar positive associations. Time spent in other disciplines had fewer and mixed relationships. Seven models validated well, two validated moderately well, and four validated poorly. Conclusion: Patient characteristics explain a large proportion of variation in multiple outcomes after inpatient rehabilitation. The total amount of treatment received during rehabilitation from each of seven disciplines explains little additional variance. Reasons for this and the phenomenon that sometimes more hours of service predict poorer outcome, need additional study.	[Whiteneck, Gale; Kreider, Scott E. D.] Craig Hosp, Dept Res, Englewood, CO 80113 USA; [Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA	Whiteneck, G (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craig-hospital.org	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Rehabilitative Services, US Department of EducationUS Department of Education [H133A060103, H133N060005, H133N060027, H133N060014]	The contents of this paper were developed under grants from the National Institute on Disability and Rehabilitation Research, Office of Rehabilitative Services, US Department of Education, to Craig Hospital (grant numbers H133A060103 and H133N060005) and to The Mount Sinai School of Medicine (grant number H133N060027), and Rehabilitation Institute of Chicago (grant number H133N060014). The opinions contained in this publication are those of the grantees and do not necessarily reflect those of the US Department of Education.	Abeyta N, 2009, J SPINAL CORD MED, V32, P336, DOI 10.1080/10790268.2009.11760787; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Berns S, 1957, REHABILITATION MONOG; Brougham R, 2011, J SPINAL CORD MED, V34, P186, DOI 10.1179/107902611X12971826988174; Burnett DM, 2002, NEUROREHABILITATION, V17, P187; Cahow C, 2009, J SPINAL CORD MED, V32, P298, DOI 10.1080/10790268.2009.11760783; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P733, DOI 10.1016/S0003-9993(99)90219-8; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1284, DOI 10.1016/j.apmr.2009.02.009; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MPJM, 2002, SPINAL CORD, V40, P351, DOI 10.1038/sj.sc.3101310; Fiedler R.C., 1996, FUNCTIONAL EVALUATIO, P75; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Foy T, 2011, J SPINAL CORD MED, V34, P162, DOI 10.1179/107902611X12971826988093; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2011, J SPINAL CORD MED, V34, P176, DOI 10.1179/107902611X12971826988138; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; Gordan W, 2009, J SPINAL CORD MED, V32, P307, DOI 10.1080/10790268.2009.11760784; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Hammond FM, 2011, J SPINAL CORD MED, V34, P216, DOI 10.1179/107902611X12971826988291; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Horn S D, 1995, Med Interface, V8, P60; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 1996, NUTRITION, V12, P384; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; HORN SD, 1997, CLIN PRACTICE IMPROV; Horn SD., 1995, MED INTERFACE, V8, P70; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Horn SD, 2010, MED CARE, V48, pS17, DOI 10.1097/MLR.0b013e3181d57473; Huston T, 2011, J SPINAL CORD MED, V34, P196, DOI 10.1179/107902611X12971826988219; Jette AM, 2005, ARCH PHYS MED REHAB, V86, pS124, DOI 10.1016/j.apmr.2005.09.015; Johnson K, 2009, J SPINAL CORD MED, V32, P329, DOI 10.1080/10790268.2009.11760786; Kalpakjian CZ, 2011, ARCH PHYS MED REHAB, V92, P433, DOI 10.1016/j.apmr.2010.07.239; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Mallinson T, 2011, RASCH MEAS T, V251, P1317; Marino R, 2003, REFERENCE MANUAL INT; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Nair KPS, 2005, SPINAL CORD, V43, P558, DOI 10.1038/sj.sc.3101752; Natale A, 2009, J SPINAL CORD MED, V32, P270, DOI 10.1080/10790268.2009.11760781; National Spinal Cord Injury Statistical Center, 2011, DAT COLL SYLL NAT SP; Nizam A, 1998, APPL REGRESSION ANAL; Ottenbacher KJ, 2005, ARCH PHYS MED REHAB, V86, pS121; Ozelie R, 2009, J SPINAL CORD MED, V32, P283, DOI 10.1080/10790268.2009.11760782; Parent S, 2011, J NEUROTRAUM, V28, P1363, DOI 10.1089/neu.2009.1151; ROACH MJ, 2002, TOP SPINAL CORD INJ, V7, P101; Rundquist J, 2011, J SPINAL CORD MED, V34, P205, DOI 10.1179/107902611X12971826988255; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Seel R T, 2001, J Spinal Cord Med, V24, P241; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Taylor-Schroeder S, 2011, J SPINAL CORD MED, V34, P149, DOI 10.1179/107902611X12971826988057; Whiteneck G, 2011, J SPINAL CORD MED, V34, P133, DOI 10.1179/107902611X12971826988011; Whiteneck G, 2009, J SPINAL CORD MED, V32, P251, DOI 10.1080/10790268.2009.11760779; Whiteneck G, 2009, J SPINAL CORD MED, V32, P249; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P361, DOI 10.1016/j.apmr.2010.07.241; Whiteneck GG, 1992, GUIDE USE CHART CRAI; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007; Wilson C, 2009, J SPINAL CORD MED, V32, P319, DOI 10.1080/10790268.2009.11760785	63	37	37	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	NOV	2012	35	6					484	502		10.1179/2045772312Y.0000000057			19	Clinical Neurology	Neurosciences & Neurology	058YF	WOS:000312670400003	23318033	Green Published			2021-06-18	
J	Chiang, LC; Chen, WC; Dai, YT; Ho, YL				Chiang, Li-Chi; Chen, Wan-Chou; Dai, Yu-Tzu; Ho, Yi-Lwun			The effectiveness of telehealth care on caregiver burden, mastery of stress, and family function among family caregivers of heart failure patients: A quasi-experimental study	INTERNATIONAL JOURNAL OF NURSING STUDIES			English	Article						Telehealth; Telenursing; Discharge planning; Family caregiver; Heart failure	TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; CHINESE VERSION; HEALTH-CARE; INTERVENTION; MANAGEMENT; HOME; METAANALYSIS; INVENTORY; RELIABILITY	Background: Telehealth care was developed to provide home-based monitoring and support for patients with chronic disease. The positive effects on physical outcome have been reported; however, more evidence is required concerning the effects on family caregivers and family function for heart failure patients transitioning from the hospital to home. Objective: To evaluate the effectiveness of nursing-led transitional care combining discharge plans and telehealth care on family caregiver burden, stress mastery and family function in family caregivers of heart failure patients compared to those receiving traditional discharge planning only. Design: This is a quasi-experimental study design. Methods: Sixty-three patients with heart failure were assessed for eligibility and invited to participate in either telehealth care or standard care in a medical centre from May to October 2010. Three families refused to participate in data collection. Thirty families who chose telehealth care after discharge from the hospital to home comprised the experimental group: the others families receiving discharge planning only comprised the comparison group. Telenursing specialist provided the necessary family nursing interventions by 24-h remote monitoring of patients' health condition and counselling by telephone, helping the family caregivers successfully transition from hospital to home. Data on caregiver burden, stress mastery and family function were collected before discharge from the hospital and one month later at home. Effects of group, time, and group x time interaction were analysed using Mixed Model in SPSS (17.0). Results: Family caregivers in both groups had significantly lower burden, higher stress mastery, and better family function at one-month follow-up compared to before discharge. The total score of caregiver burden, stress mastery and family function was significantly improved for the family caregivers in the experimental group compared to the comparison group at posttest. Two subscales of family function-Relationships between family and subsystems and Relationships between family and society were improved in the experimental group compared to the comparison group, but Relationships between family and family members was not different. Conclusions: The results provide evidence that telehealth care combined with discharge planning could reduce family caregiver burden, improve stress mastery, and improve family function during the first 30 days at home after heart failure patients are discharged from the hospital. Telenursing specialists cared caregivers with the concepts of providing transitional care to help them successful cross the critical transition stage. (C) 2012 Elsevier Ltd. All rights reserved.	[Chiang, Li-Chi] Natl Def Med Ctr, Sch Nursing, Taipei, Taiwan; [Chiang, Li-Chi] China Med Univ, Taipei, Taiwan; [Chiang, Li-Chi] Natl Def Med Ctr, Sch Nursing, Taichung, Taiwan; [Chiang, Li-Chi] China Med Univ, Taichung, Taiwan; [Chen, Wan-Chou; Dai, Yu-Tzu] Natl Taiwan Univ Hosp, Dept Nursing, Taipei, Taiwan; [Dai, Yu-Tzu] Natl Taiwan Univ, Coll Med, Dept Nursing, Taipei 10764, Taiwan; [Ho, Yi-Lwun] Natl Taiwan Univ, Dept Internal Med, Natl Taiwan Univ Hosp, Div Cardiol, Taipei 10764, Taiwan	Ho, YL (corresponding author), NTU Telehlth Ctr, NTUH E Wing B Block,3rd Floor,7 Chung Shan S Rd, Taipei 100, Taiwan.	abundantia0909@gmail.com; yutzu@ntu.edu.tw; ylho@ntu.edu.tw	Chiang, Li-Chi/AAW-9661-2020	DAI, YU-TZU/0000-0002-3803-3516; Chiang, Li-Chi/0000-0002-6383-7495; HO, YI-LWUN/0000-0002-8936-9570	Tele-Health Center in National Taiwan University Hospital; National Science CouncilMinistry of Science and Technology, Taiwan [NSC97-2314-B-039-034-MY3]	This is supported the Tele-Health Center in National Taiwan University Hospital. This study has some supported by grants from the National Science Council (no. NSC97-2314-B-039-034-MY3).	[ACC AHA], 2005, J AM COLL CARDIOL, V46, pe1; American Heart Association, 2008, HEAT DIS STROK STAT; American Nurses Association, 1997, NURS TRENDS ISS ANA; Anker SD, 2011, LANCET, V378, P731, DOI 10.1016/S0140-6736(11)61229-4; Armola R R, 2001, Lippincotts Case Manag, V6, P246, DOI 10.1097/00129234-200111000-00005; Bakas T, 2006, NURS RES, V55, P180, DOI 10.1097/00006199-200605000-00004; Brislin R.W., 1973, CROSS CULTURAL RES M; Carelock J, 2001, AM J NURS, V101, P26, DOI 10.1097/00000446-200112000-00017; Caserta MS, 1996, INT J AGING HUM DEV, V43, P21, DOI 10.2190/2DKF-292P-A53W-W0A8; Chan Y H, 2004, Singapore Med J, V45, P354; Chaudhry SI, 2007, J CARD FAIL, V13, P56, DOI 10.1016/j.cardfail.2006.09.001; Chou KR, 2002, NURS RES, V51, P324, DOI 10.1097/00006199-200209000-00009; Clarke M, 2011, J TELEMED TELECARE, V17, P7, DOI 10.1258/jtt.2010.100113; Cleland John G F, 2002, Heart Fail Rev, V7, P229, DOI 10.1023/A:1020024122726; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collins LG, 2011, AM FAM PHYSICIAN, V83, P1309; Davidson PM, 2007, J CARDIOVASC NURS, V22, P58, DOI 10.1097/00005082-200701000-00009; Dias VP, 2009, ST HEAL T, V146, P202, DOI 10.3233/978-1-60750-024-7-202; Duvall EM, 1985, MARRIAGE FAMILY DEV; Finkel S, 2007, AM J GERIAT PSYCHIAT, V15, P443, DOI 10.1097/JGP.0b013e3180437d87; Hagan Natalie, 2007, Aust Crit Care, V20, P113, DOI 10.1016/j.aucc.2007.05.004; Harkness KI, 2007, J CARD FAIL, V13, P577, DOI 10.1016/j.cardfail.2007.03.013; Ho YL, 2007, J FORMOS MED ASSOC, V106, P313, DOI 10.1016/S0929-6646(09)60258-8; Hoglund AT, 2008, J CLIN NURS, V17, P2979, DOI 10.1111/j.1365-2702.2008.02345.x; Hohashi N, 2008, J FAM NURS, V14, P201, DOI 10.1177/1074840708315967; Hu G, 2010, CIRCULATION, V121, P237, DOI 10.1161/CIRCULATIONAHA.109.887893; Huang C.R., 2008, 6 C INT SOC GER ISG0, P1; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2; International Council of Nurses, 2001, NURS MATT TEL; Jerant Anthony F, 2003, Home Health Care Serv Q, V22, P1, DOI 10.1300/J027v22n01_01; Jonsson AM, 2008, TELEMED J E-HEALTH, V14, P1057, DOI 10.1089/tmj.2008.0022; Kang XF, 2011, J CARDIOVASC NURS, V26, P386, DOI 10.1097/JCN.0b013e3182076a69; Klersy C, 2009, J AM COLL CARDIOL, V54, P1683, DOI 10.1016/j.jacc.2009.08.017; Koehler F., 2011, J AM HEART ASS; Lorentz Madeline M, 2008, Home Healthc Nurse, V26, P237, DOI 10.1097/01.NHH.0000316702.22633.30; Luttik ML, 2007, J CARDIOVASC NURS, V22, P131, DOI 10.1097/00005082-200703000-00010; Manning S, 2011, J CARDIOVASC NURS, V26, P368, DOI 10.1097/JCN.0b013e318202b15c; Meleis A. I., 2010, TRANSITIONS THEORY M; Meleis A.I., 1986, NURSING RES METHODOL, P237; Meleis AI, 2000, ADV NURS SCI, V23, P12, DOI 10.1097/00012272-200009000-00006; Molloy GJ, 2006, EUR J CARDIOV PREV R, V13, P381, DOI 10.1097/00149831-200606000-00014; Naditz A, 2009, TELEMED J E-HEALTH, V15, P825, DOI 10.1089/tmj.2009.9938; Natanzon A, 2009, AM J MED SCI, V338, P211, DOI 10.1097/MAJ.0b013e3181a3936f; National Taiwan University Hospital-TeleCare, 2011, INTR FRAM TEL CAR; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pattenden J F, 2007, Eur J Cardiovasc Nurs, V6, P273, DOI 10.1016/j.ejcnurse.2007.01.097; Pressler SJ, 2009, AM J CRIT CARE, V18, P149, DOI 10.4037/ajcc2009300; Radhakrishnan K., 2011, J CARDIOVASCULAR NUR, P1; Riegel B., 2010, TRANSITIONS THEORY M; ROBERTS CS, 1982, NURS RES, V31, P231; Schumacher K L, 1994, Image J Nurs Sch, V26, P119; Schwartz Kim A, 2011, N C Med J, V72, P216; Snooks HA, 2008, J ADV NURS, V61, P631, DOI 10.1111/j.1365-2648.2007.04546.x; Stewart S, 2005, EUR J HEART FAIL, V7, P590, DOI 10.1016/j.ejheart.2004.07.021; Tung HH, 2012, J CARDIOVASC NURS, V27, P16, DOI 10.1097/JCN.0b013e318211284b; Vreeland DG, 2011, CRIT CARE NURS Q, V34, P235, DOI 10.1097/CNQ.0b013e31821ffe5d; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Winkler S, 2010, J AM COLL CARDIOL, V55, P1505, DOI 10.1016/j.jacc.2009.12.028; YOUNGER JB, 1993, NURS RES, V42, P68; YOUNGER JB, 1991, ADV NURS SCI, V14, P76, DOI 10.1097/00012272-199109000-00009	66	37	44	2	79	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0020-7489	1873-491X		INT J NURS STUD	Int. J. Nurs. Stud.	OCT	2012	49	10					1230	1242		10.1016/j.ijnurstu.2012.04.013			13	Nursing	Nursing	028HA	WOS:000310412200005	22633448				2021-06-18	
J	Hohl, A; Gullo, JD; Silva, CCP; Bertotti, MM; Felisberto, F; Nunes, JC; de Souza, B; Petronilho, F; Soares, FMS; Prediger, RDS; Dal-Pizzol, F; Linhares, MN; Walz, R				Hohl, Alexandre; Gullo, Jackson da Silva; Pestana Silva, Claudia Carvalho; Bertotti, Melina More; Felisberto, Francine; Nunes, Jean Costa; de Souza, Bruna; Petronilho, Fabricia; Schneider Soares, Flavia Mahatma; Schroder Prediger, Rui Daniel; Dal-Pizzol, Felipe; Linhares, Marcelo Neves; Walz, Roger			Plasma levels of oxidative stress biomarkers and hospital mortality in severe head injury: A multivariate analysis	JOURNAL OF CRITICAL CARE			English	Article						Traumatic brain injury; Prognosis; TBARS; Carbonyl; Oxidative stress; Hospital mortality	TRAUMATIC BRAIN-INJURY; COMA DATA-BANK; LIPID-PEROXIDATION; WISTAR RATS; KAINIC ACID; CNS INJURY; MECHANISMS; STROKE; IMPACT; CITY	Introduction: The association between biomarkers of oxidative stress and the prognosis of patients with traumatic brain injury (TBI) remains inconclusive. Objective: The objective was to investigate the association between plasma levels of lipid peroxidation (thiobarbituric acid reactive species [TBARS]) and protein oxidation (carbonyl) biomarkers and the hospital mortality of patients with severe TBI. Methods: Plasma levels of TBARS and carbonyl were determined in 79 consecutive patients with severe TBI (Glasgow Coma Scale [GCS] <= 8) at a median of 12 hours (interquartile range [IQ] 25-75, 6.5-19.0), 30 hours (IQ 25-75, 24.7-37.0), and 70 (IQ 25-75, 55.0-78.5) hours after TBI and were compared with age-and sex-matched controls. The association between the TBARS and carbonyl levels and the hospital mortality was analyzed by multiple logistic regression analysis. Results: The mean age of patients was 34.8 years. Eighty-six percent were male. The TBARS and carbonyl levels were significantly higher in patients than in controls. There was a trend (P = .09) for higher plasma levels of TBARS and carbonyl proteins at 12 hours, but not at 30 or 70 hours, after trauma in nonsurvivors than in survivors. These findings were not confirmed after the adjustments by multiple logistic regression analysis. The final model showed a higher adjusted odds ratio for death for patients with admission GCS lower than 5 (odds ratio [OR] = 4.04; 95% confidence interval [CI], 1.33-12.13; P = .01) than those with higher GCS scores. Abnormal pupils were also associated with higher mortality (OR = 3.97; 95% CI, 1.22-12.13; P = .02). There was a nonsignificant trend for association between glucose greater than or equal to 150 mm/dL in the first 12 hours and death than levels between 70 and 149 mg/dL (OR = 2.92; 95% CI, 0.96-9.02; P = .06). Conclusions: Plasma levels of TBARS and carbonyl increase significantly in the first 70 hours after severe TBI but are not independently associated with the hospital mortality. (C) 2012 Elsevier Inc. All rights reserved.	[Hohl, Alexandre; de Souza, Bruna; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, HU, Florianopolis, SC, Brazil; [Hohl, Alexandre; Gullo, Jackson da Silva; Pestana Silva, Claudia Carvalho; Bertotti, Melina More; Nunes, Jean Costa; Schneider Soares, Flavia Mahatma; Schroder Prediger, Rui Daniel; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas CeNAp, Univ Hosp, Florianopolis, SC, Brazil; [Felisberto, Francine; Petronilho, Fabricia; Dal-Pizzol, Felipe] Univ Extremo Sul Catarinense, Lab Fisiopatol Expt, Unidade Acad Ciencias Saude, Criciuma, SC, Brazil; [Schroder Prediger, Rui Daniel] Univ Fed Santa Catarina, Lab Expt Doencas Neurodegenerat, Dept Farmacol, Florianopolis, SC, Brazil; [Bertotti, Melina More; Linhares, Marcelo Neves] HGCR, Serv Neurocirurgia, Florianopolis, SC, Brazil; [Linhares, Marcelo Neves; Walz, Roger] HGCR, Ctr Epilepsia Estado Santa Catarina CEPESC, Florianopolis, SC, Brazil	Walz, R (corresponding author), UFSC, Dept Clin Med, Univ Hosp, 3 Andar,Campus Univ, Trindade Florianopolis, SC, Brazil.		Diaz, Alexandre Paim/AAD-8323-2019; Petronilho, Fabricia/D-8822-2013; Dal-Pizzol, Felipe/F-2756-2015; Hohl, Alexandre/R-9269-2019; Neurociencia, Inct/I-1011-2013; Prediger, Rui Daniel/AAV-3419-2020; Prediger, Rui D/C-4036-2013; Walz, Roger/K-9096-2013	Diaz, Alexandre Paim/0000-0002-6591-6648; Dal-Pizzol, Felipe/0000-0003-3003-8977; Hohl, Alexandre/0000-0002-8073-5837; Prediger, Rui Daniel/0000-0002-7547-6463; Prediger, Rui D/0000-0002-7547-6463; Walz, Roger/0000-0002-9875-6687; Mahatma Schneider Soares, Flavia/0000-0001-5968-1312	Brazilian Council for Scientific and Technologic Development, Brazil; Foundation for Scientific Research and Technology of the State of Santa Catarina	This work was supported by the Brazilian Council for Scientific and Technologic Development, Brazil and the Foundation for Scientific Research and Technology of the State of Santa Catarina. The technical support for biological sample collection came from Laboratorio Biomedico (Florianopolis) under the Pharm. Saulo Correia de Mello supervision.	Dal-Pizzol F, 2000, NEUROSCI LETT, V291, P179, DOI 10.1016/S0304-3940(00)01409-9; Dal-Pizzol F, 2007, METAB BRAIN DIS, V22, P25, DOI 10.1007/s11011-006-9033-2; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Grotto D, 2007, J PHARMACEUT BIOMED, V43, P619, DOI 10.1016/j.jpba.2006.07.030; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Klamt F, 2001, FREE RADICAL BIO MED, V30, P1137; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nayak CD, 2007, INDIAN J MED SCI, P381; Nayak C, 2007, CLIN CHEM LAB MED, V45, P629, DOI 10.1515/CCLM.2007.123; Nayak CD, 2008, NEUROL INDIA, V56, P31, DOI 10.4103/0028-3886.39309; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Perel P, 2006, BMC MED INFORM DECIS, P38; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Petronilho F., 2009, J SURG RES; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Scholpp J, 2004, J NEUROTRAUM, V21, P667, DOI 10.1089/0897715041269632; Schwarzbold M, 2008, NEUROPSYCH DIS TREAT, P1176; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0	29	37	39	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	OCT	2012	27	5							523.e11	10.1016/j.jcrc.2011.06.007			9	Critical Care Medicine	General & Internal Medicine	025PP	WOS:000310204300025	21803537				2021-06-18	
J	Cadotte, DW; Bosma, R; Mikulis, D; Nugaeva, N; Smith, K; Pokrupa, R; Islam, O; Stroman, PW; Fehlings, MG				Cadotte, David W.; Bosma, Rachael; Mikulis, David; Nugaeva, Natalia; Smith, Karen; Pokrupa, Ronald; Islam, Omar; Stroman, Patrick W.; Fehlings, Michael G.			Plasticity of the Injured Human Spinal Cord: Insights Revealed by Spinal Cord Functional MRI	PLOS ONE			English	Article							MONOCLONAL-ANTIBODY IN-1; VASCULAR MECHANISMS; NEURITE OUTGROWTH; FMRI	Introduction: While numerous studies have documented evidence for plasticity of the human brain there is little evidence that the human spinal cord can change after injury. Here, we employ a novel spinal fMRI design where we stimulate normal and abnormal sensory dermatomes in persons with traumatic spinal cord injury and perform a connectivity analysis to understand how spinal networks process information. Methods: Spinal fMRI data was collected at 3 Tesla at two institutions from 38 individuals using the standard SEEP functional MR imaging techniques. Thermal stimulation was applied to four dermatomes in an interleaved timing pattern during each fMRI acquisition. SCI patients were stimulated in dermatomes both above (normal sensation) and below the level of their injury. Sub-group analysis was performed on healthy controls (n = 20), complete SCI (n = 3), incomplete SCI (n = 9) and SCI patients who recovered full function (n = 6). Results: Patients with chronic incomplete SCI, when stimulated in a dermatome of normal sensation, showed an increased number of active voxels relative to controls (p = 0.025). There was an inverse relationship between the degree of sensory impairment and the number of active voxels in the region of the spinal cord corresponding to that dermatome of abnormal sensation (R-2 = 0.93, p<0.001). Lastly, a connectivity analysis demonstrated a significantly increased number of intraspinal connections in incomplete SCI patients relative to controls suggesting altered processing of afferent sensory signals. Conclusions: In this work we demonstrate the use of spinal fMRI to investigate changes in spinal processing of somatosensory information in the human spinal cord. We provide evidence for plasticity of the human spinal cord after traumatic injury based on an increase in the average number of active voxels in dermatomes of normal sensation in chronic SCI patients and an increased number of intraspinal connections in incomplete SCI patients relative to healthy controls.	[Cadotte, David W.; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Cadotte, David W.; Fehlings, Michael G.] Toronto Western Hosp, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Cadotte, David W.; Nugaeva, Natalia; Fehlings, Michael G.] Univ Hlth Network, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON, Canada; [Bosma, Rachael; Stroman, Patrick W.] Queens Univ, Ctr Neurosci Studies, Kingston, ON, Canada; [Mikulis, David] Univ Toronto, Toronto Western Hosp, Div Neuroradiol, Dept Radiol, Toronto, ON M5T 2S8, Canada; [Smith, Karen] Providence Hlth Care, Spinal Rehabil Unit, Kingston, ON, Canada; [Pokrupa, Ronald] Queens Univ, Kingston Gen Hosp, Div Neurosurg, Kingston, ON, Canada; [Islam, Omar] Queens Univ, Kingston Gen Hosp, Div Neuroradiol & Head & Neck Imaging, Dept Radiol, Kingston, ON, Canada; [Islam, Omar] Queens Univ, Hotel Dieu Hosp, Div Neuroradiol & Head & Neck Imaging, Dept Radiol, Kingston, ON, Canada; [Stroman, Patrick W.] Queens Univ, Dept Diagnost Radiol, Kingston, ON, Canada; [Stroman, Patrick W.] Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada; [Fehlings, Michael G.] Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Div Genet & Dev, Toronto, ON, Canada	Fehlings, MG (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada.	Michael.Fehlings@uhn.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892; Fehlings, Michael/0000-0002-5722-6364	Ontario Neurotrauma Foundation; Rick Hansen Institute; Congress of Neurological Surgeons; American Association of Neurological Surgeons (Codman Neurotrauma Award); Cervical Spine Research Society; Gerry and Tootsie Halbert Chair in Neural Repair and Regeneration at the University of Toronto	The authors are grateful to their funding sources that include the Ontario Neurotrauma Foundation, Rick Hansen Institute, Congress of Neurological Surgeons, American Association of Neurological Surgeons (Codman Neurotrauma Award), Cervical Spine Research Society and the Gerry and Tootsie Halbert Chair in Neural Repair and Regeneration at the University of Toronto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; DeVivo M, 2006, SPINAL CORD, V44, P535, DOI 10.1038/sj.sc.3101958; Endo T, 2008, EXP NEUROL, V209, P155, DOI 10.1016/j.expneurol.2007.09.017; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings MG, PLOS ONE, V7; Figley CR, 2011, EUR J NEUROSCI, V33, P577, DOI 10.1111/j.1460-9568.2010.07584.x; Figley CR, 2009, NEUROIMAGE, V44, P421, DOI 10.1016/j.neuroimage.2008.08.040; Figley CR, 2012, MAGN RESON IMAGING; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Furlan JC, J NEUROTRAUMA, V28, P1371; Gesierich B, CEREB CORTEX; HANDWERKER HO, 1975, PAIN, V1, P147, DOI 10.1016/0304-3959(75)90099-8; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kakulas BA, 2004, SPINAL CORD, V42, P549, DOI 10.1038/sj.sc.3101670; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kornelsen J, 2007, SPINAL CORD, V45, P485, DOI 10.1038/sj.sc.3102019; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lang J, 1982, Gegenbaurs Morphol Jahrb, V128, P417; Leitch JK, 2010, MAGN RESON IMAGING, V28, P1225, DOI 10.1016/j.mri.2010.03.032; Maieron M, 2007, J NEUROSCI, V27, P4182, DOI 10.1523/JNEUROSCI.3910-06.2007; Mikulis DJ, 2002, NEUROLOGY, V58, P794, DOI 10.1212/WNL.58.5.794; Murphy K, 2007, NEUROIMAGE, V34, P565, DOI 10.1016/j.neuroimage.2006.09.032; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Spillmann AA, 1997, EUR J NEUROSCI, V9, P549, DOI 10.1111/j.1460-9568.1997.tb01631.x; Stroman PW, 2008, MAGN RESON MED, V59, P700, DOI 10.1002/mrm.21534; Stroman PW, 2002, NEUROIMAGE, V17, P1854, DOI 10.1006/nimg.2002.1305; Stroman PW, 2002, MAGN RESON IMAGING, V20, P1, DOI 10.1016/S0730-725X(02)00468-X; Stroman PW, MAGN RESON MED; Stroman PW, 2011, MAGN RESON MED; Summers PE, 2010, NEUROIMAGE, V50, P1408, DOI 10.1016/j.neuroimage.2010.01.043; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023; Xuan Y, PLOS ONE, V7, pe30570	36	37	37	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2012	7	9							e45560	10.1371/journal.pone.0045560			11	Multidisciplinary Sciences	Science & Technology - Other Topics	014PP	WOS:000309388400105	23029097	DOAJ Gold, Green Published			2021-06-18	
J	Kwiatt, ME; Patel, MS; Ross, SE; Lachant, MT; MacNew, HG; Ochsner, MG; Norwood, SH; Speier, L; Kozar, R; Gerber, JA; Rowell, S; Krishnakumar, S; Livingston, DH; Manis, G; Haan, JM				Kwiatt, Michael E.; Patel, Mitul S.; Ross, Steven E.; Lachant, Mary T.; MacNew, Heather G.; Ochsner, M. Gage; Norwood, Scott H.; Speier, LaDonna; Kozar, Rosemary; Gerber, Jonathan A.; Rowell, Susan; Krishnakumar, Sheetal; Livingston, David H.; Manis, George; Haan, James M.			Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; venous thromboembolism prophylaxis; low-molecular weight heparin	INTERMITTENT PNEUMATIC COMPRESSION; INTRACRANIAL HEMORRHAGE; ENOXAPARIN; THROMHOEMBOLISM; MANAGEMENT	BACKGROUND: Venous thromboembolism (VTE) is a significant risk in trauma patients. Although low-molecular weight heparin (LMWH) is effective in VTE prophylaxis, its use for patients with traumatic intracranial hemorrhage remains controversial. The purpose of this study was to evaluate the safety of LMWH for VTE prophylaxis in blunt intracranial injury. METHODS: We conducted a retrospective multicenter study of LMWH chemoprophylaxis on patients with intracranial hemorrhage caused by blunt trauma. Patients with brain Abbreviated Injury Scale score of 3 or higher, age 18 years or older, and at least one repeated head computed tomographic scan were included. Patients with previous VTE; on preinjury anticoagulation; hospitalized for less than 48 hours; on heparin for VTE prophylaxis; or required emergent thoracic, abdominal, or vascular surgery at admission were excluded. Patients were divided into two groups: those who received LMWH and those who did not. The primary outcome was progression of intracranial hemorrhage on repeated head computed tomographic scan. RESULTS: The study included 1,215 patients, of which 220 patients (18.1%) received LMWH and 995 (81.9%) did not. Hemorrhage progression occurred in 239 of 995 control subjects and 93 of 220 LMWH patients (24% vs. 42%, p < 0.001). Hemorrhage progression occurred in 32 patients after initiating LMWH (14.5%). Nine of these patients (4.1%) required neurosurgical intervention for hemorrhage progression. CONCLUSION: Patients receiving LMWH were at higher risk for hemorrhage progression. We were unable to demonstrate safety of LMWH for VTE prophylaxis in patients with brain injury. The risk of using LMWH may exceed its benefit. (J Trauma Acute Care Surg. 2012; 73: 625-628. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Kwiatt, Michael E.; Patel, Mitul S.; Ross, Steven E.; Lachant, Mary T.] Cooper Univ Hosp, Off Surg Educ, Camden, NJ 08103 USA; [Livingston, David H.; Manis, George] Univ Med & Dent New Jersey, New Jersey Univ Hosp, Newark, NJ USA; [MacNew, Heather G.; Ochsner, M. Gage] Mem Univ Med Ctr, Savannah, GA USA; [Norwood, Scott H.; Speier, LaDonna] E Texas Med Ctr, Tyler, TX USA; [Kozar, Rosemary; Gerber, Jonathan A.] Univ Texas Hlth Sci Ctr, Houston, TX USA; [Rowell, Susan; Krishnakumar, Sheetal] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Haan, James M.] Via Christi Reg Med Ctr, Wichita, KS USA	Kwiatt, ME (corresponding author), Cooper Univ Hosp, Off Surg Educ, 3 Cooper Plaza,Suite 411, Camden, NJ 08103 USA.	kwiatt-michael@cooperhealth.edu	Rowell, Susan/S-7480-2019	MacNew, Heather/0000-0002-8417-837X			Adams RC, 2008, J TRAUMA, V65, P300, DOI 10.1097/TA.0b013e31817cf744; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 1994, NEW ENGL J MED, V42, P456; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Ginzburg E, 2003, BRIT J SURG, V90, P1338, DOI 10.1002/bjs.4309; Huseynova K, 2009, J AM COLL SURGEONS, V208, P547, DOI 10.1016/j.jamcollsurg.2009.01.002; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Patel NY, 2000, J TRAUMA, V49, P132; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87	19	37	41	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					625	628		10.1097/TA.0b013e318265cab9			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	009TK	WOS:000309047900014	22929493				2021-06-18	
J	Nelson, NW; Hoelzle, JB; Doane, BM; McGuire, KA; Ferrier-Auerbach, AG; Charlesworth, MJ; Lamberty, GJ; Polusny, MA; Arbisi, PA; Sponheim, SR				Nelson, Nathaniel W.; Hoelzle, James B.; Doane, Bridget M.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Lamberty, Gregory J.; Polusny, Melissa A.; Arbisi, Paul A.; Sponheim, Scott R.			Neuropsychological Outcomes of US Veterans with Report of Remote Blast-Related Concussion and Current Psychopathology	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Operation Iraqi Freedom; Mild Traumatic Brain Injury; Post-traumatic Stress Disorder; Cognition	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; ADMINISTERED PTSD SCALE; OPERATION-IRAQI-FREEDOM; OEF/OIF VETERANS; TEST-SCORES; PERFORMANCE; METAANALYSIS; AFGHANISTAN	This study explored whether remote blast-related MTBI and/or current Axis I psychopathology contribute to neuropsychological outcomes among OEF/OIF veterans with varied combat histories. OEF/OIF veterans underwent structured interviews to evaluate history of blast-related MTBI and psychopathology and were assigned to MTBI (n=18), Axis I (n=24), Co-morbid MTBI/Axis I (n=34), or post-deployment control (n=28) groups. A main effect for Axis I diagnosis on overall neuropsychological performance was identified (F(3,100) = 4.81; p=.004), with large effect sizes noted for the Axis I only (d=.98) and Co-morbid MTBI/Axis I (d=.95) groups relative to the control group. The latter groups demonstrated primary limitations on measures of learning/memory and processing speed. The MTBI only group demonstrated performances that were not significantly different from the remaining three groups. These findings suggest that a remote history of blast-related MTBI does not contribute to objective cognitive impairment in the late stage of injury. Impairments, when present, are subtle and most likely attributable to PTSD and other psychological conditions. Implications for clinical neuropsychologists and future research are discussed. (JINS, 2012, 18, 845-855)	[Nelson, Nathaniel W.] Univ St Thomas, Grad Sch Profess Psychol, Minneapolis, MN 55403 USA; [Nelson, Nathaniel W.; Doane, Bridget M.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Lamberty, Gregory J.; Polusny, Melissa A.; Arbisi, Paul A.; Sponheim, Scott R.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA; [Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Lamberty, Gregory J.; Polusny, Melissa A.; Arbisi, Paul A.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Polusny, Melissa A.] Ctr Chron Dis Outcomes Res, Minneapolis, MN USA	Nelson, NW (corresponding author), Univ St Thomas, Grad Sch Profess Psychol, MOH 217,1000 LaSalle Ave, Minneapolis, MN 55403 USA.	nels0600@stthomas.edu	Polusny, Melissa Anderson/N-8112-2014; Polusny, Melissa/X-8158-2019; Sponheim, Scott/J-3857-2017	Polusny, Melissa Anderson/0000-0002-4932-305X; Polusny, Melissa/0000-0002-4932-305X; Sponheim, Scott/0000-0002-2782-0856	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI)	This study was supported by Grants funded in part by the Congressionally Directed Medical Research Programs (number PT074550, contract W81XWH-08-2-0038) to Scott R. Sponheim, PhD, and the Minnesota Veterans Research Institute (MVRI) to Nathaniel W. Nelson, PhD. The authors have no other financial or other relationships that could be interpreted as a conflict of interests affecting this manuscript.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Calhoun PS, 2008, J CLIN PSYCHIAT, V69, P1686, DOI 10.4088/JCP.v69n1103; Delis DC, 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Erbes CR, 2009, PSYCHOL SERV, V6, P175, DOI 10.1037/a0016662; First M.B., 2007, STRUCTURED CLIN INTE; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Golden C., 1978, STROOP COLOR WORD TE; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meyers J., 1995, MEYERS SCORING SYSTE; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nelson N.W., NEUROPSYCHO IN PRESS; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Psychological Corporation, 2001, WECHSLER TEST ADULT; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	58	37	37	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2012	18	5					845	855		10.1017/S1355617712000616			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	999KB	WOS:000308309100007	22687547	Green Published			2021-06-18	
J	Wei, XE; Zhang, YZ; Li, YH; Li, MH; Li, WB				Wei, Xiao-Er; Zhang, Yu-Zhen; Li, Yue-Hua; Li, Ming-Hua; Li, Wen-Bin			Dynamics of Rabbit Brain Edema in Focal Lesion and Perilesion Area after Traumatic Brain Injury: A MRI Study	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; cytotoxic edema; diffusion-weighted imaging; dynamic contrast-enhanced MRI; rabbit; traumatic brain injury; vasogenic edema	BARRIER PERMEABILITY; CEREBRAL-ISCHEMIA; MODULATION; EXPRESSION; RECEPTORS; LEAKAGE; TARGET	To understand the dynamics of brain edema in different areas after traumatic brain injury (TBI) in rabbit, we used dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) to monitor blood-brain barrier (BBB) permeability and cytotoxic brain edema after weight drop-induced TBI in rabbit. The dynamics of BBB permeability and brain edema were quantified using K-trans and apparent diffusion coefficient (ADC) in the focal and perifocal lesion areas, as well as the area contralateral to the lesion. In the focal lesion area, K-trans began to increase at 3 h post-TBI, peaked at 3 days, and decreased gradually while remaining higher than sham injury animals at 7 and 30 days. ADC was more variable, increased slightly at 3 h, decreased to its lowest value at 7 days, then increased to a peak at 30 days. In the perifocal lesion area, K-trans began to increase at 1 day, peaked at 3-7 days, and returned to control level by 30 days. ADC showed a trend to increase at 1 day, followed by a continuous increase thereafter. In the contralateral area, no changes in K-trans and ADC were observed at any time-point. These data demonstrate that different types of brain edema predominate in the focal and perifocal lesion areas. Specifically cytotoxic edema was predominant in the focal lesion area while vasogenic edema predominated in the perifocal area in acute phase. Furthermore, secondary opening of the BBB after TBI may appear if secondary injury is not controlled. BBB damage may be a driving force for cytotoxic brain edema and could be a new target for TBI intervention.	[Wei, Xiao-Er; Zhang, Yu-Zhen; Li, Yue-Hua; Li, Ming-Hua; Li, Wen-Bin] Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 6, Dept Radiol, Shanghai 200233, Peoples R China	Li, WB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 6, Dept Radiol, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.	liwenbin@sh163.net			Science and Technology Commission of Shanghai Municipality, ShanghaiScience & Technology Commission of Shanghai Municipality (STCSM) [08411951200]	This study was supported in part by a grant from Science and Technology Commission of Shanghai Municipality, Shanghai (grant no. 08411951200).	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Abo-Ramadan U, 2009, EXP NEUROL, V219, P328, DOI 10.1016/j.expneurol.2009.06.002; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Cao Y, 2009, CLIN CANCER RES, V15, P1747, DOI 10.1158/1078-0432.CCR-08-1420; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Ferrier MC, 2007, NEOPLASIA, V9, P546, DOI 10.1593/neo.07289; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Haris M, 2008, J MAGN RESON IMAGING, V28, P588, DOI 10.1002/jmri.21491; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Infante-Duarte C, 2008, J MOL MED, V86, P975, DOI 10.1007/s00109-007-0292-0; Lahoud-Rahme MS, 2009, RESUSCITATION, V80, P484, DOI 10.1016/j.resuscitation.2009.01.007; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Marmarou A, 2000, ACT NEUR S, V76, P349; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Qu YZ, 2009, EUR J PHARMACOL, V606, P137, DOI 10.1016/j.ejphar.2009.01.022; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skaper SD, 2007, ANN NY ACAD SCI, V1122, P23, DOI 10.1196/annals.1403.002; Song S.K., 2010, NEUROBIOL AGING; Sourbron S, 2009, MAGN RESON MED, V62, P205, DOI 10.1002/mrm.22005; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; Turkbey B, 2010, DIAGN INTERV RADIOL, V16, P186, DOI 10.4261/1305-3825.DIR.2537-08.1; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	37	37	45	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	14					2413	2420		10.1089/neu.2010.1510			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	004SM	WOS:000308701400005	21675826	Green Published			2021-06-18	
J	Grujicic, A; LaBerge, M; Grujicic, M; Pandurangan, B; Runt, J; Tarter, J; Dillon, G				Grujicic, A.; LaBerge, M.; Grujicic, M.; Pandurangan, B.; Runt, J.; Tarter, J.; Dillon, G.			Potential Improvements in Shock-Mitigation Efficacy of a Polyurea-Augmented Advanced Combat Helmet	JOURNAL OF MATERIALS ENGINEERING AND PERFORMANCE			English	Article						Advanced Combat Helmet; internal lining/external coating; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BLAST; AFGHANISTAN; CAPABILITY; MODEL; TBI	The design of the currently used Advanced Combat Helmet (ACH) has been optimized to attain maximum protection against ballistic impacts (fragments, shrapnel, etc.) and hard-surface collisions. However, the ability of the ACH to protect soldiers against blast loading appears not to be as effective. Polyurea, a micro-segregated elastomeric copolymer has shown superior shock-mitigation capabilities. In the present work, a combined Eulerian/Lagrangian transient non-linear dynamics computational fluid/solid interaction analysis is used to investigate potential shock-mitigation benefits which may result from different polyurea-based design augmentations of the ACH. Specific augmentations include replacement of the currently used suspension-pad material with polyurea and the introduction of a thin polyurea internal lining/external coating to the ACH shell. Effectiveness of different ACH designs was quantified by: (a) establishing the main forms of mild traumatic brain injury (mTBI); (b) identifying the key mechanical causes for these injuries; and (c) quantifying the extents of reductions in the magnitude of these mechanical causes. The results obtained show that while the ACH with a 2-mm-thick polyurea internal lining displays the best blast mitigation performance, it does not provide sufficient protection against mTBI.	[Grujicic, A.; LaBerge, M.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA; [Grujicic, M.; Pandurangan, B.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA; [Runt, J.] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16082 USA; [Tarter, J.; Dillon, G.] Penn State Univ, Appl Res Labs, University Pk, PA 16082 USA	Grujicic, A (corresponding author), Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA.	gmica@clemson.edu			Office of Naval Research (ONR) through Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]	The material presented in this paper is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head'', Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University. The authors are indebted to Dr. Roshdy Barsoum of ONR for continuing support and interest in the present work and to Professors G. Settles and M. Hargather for stimulating discussions and friendship.	ABAQUS, 2010, ABAQUS VERS 6 10EF 1; Altair Engineering Inc, 2010, HYP HYPERWORKS 10 0; Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; *ANSYS INC, 2007, ANSYS AUT 2D 3D VERS; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Christou GA, 2010, THESIS MIT; Cooper P., 1996, EXPLOSIVES ENG; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI [10.1108/eb023876, DOI 10.1108/EB023876, DOI 10.1108/EB023876>]; Davison L, 2008, FUNDAMENTALS SHOCKWA; Goel R., 2011, THESIS MIT; Grujicic M, 2010, MULTIDISCIP MODEL MA, V6, P335, DOI 10.1108/15736101011080097; Grujicic M, 2011, P I MECH ENG L-J MAT, V225, P182, DOI 10.1177/0954420711401959; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Grujicic M, 2012, J MATER ENG PERFORM, V21, P2, DOI 10.1007/s11665-011-9875-6; Grujicic M, 2011, MAT SCI ENG A-STRUCT, V528, P3799, DOI 10.1016/j.msea.2011.01.081; Grujicic M, 2010, MAT SCI ENG A-STRUCT, V527, P7741, DOI 10.1016/j.msea.2010.08.042; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2009, MATER DESIGN, V30, P4273, DOI 10.1016/j.matdes.2009.04.028; Grujicic M, 2011, J MATER SCI, V46, P1767, DOI 10.1007/s10853-010-4998-y; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyde David W, 1988, USERS GUIDE MICROCOM; Moore DF, 2008, ANN NEUROL, V64, pS30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wallsten S. J., 2005, 0519 SOC SCI RES NET; Walsh SM, 2005, ARLTR3700; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	28	37	38	0	43	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1059-9495	1544-1024		J MATER ENG PERFORM	J. Mater. Eng. Perform.	AUG	2012	21	8					1562	1579		10.1007/s11665-011-0065-3			18	Materials Science, Multidisciplinary	Materials Science	975ZD	WOS:000306549400002					2021-06-18	
J	Kline, AE; Olsen, AS; Sozda, CN; Hoffman, AN; Cheng, JP				Kline, Anthony E.; Olsen, Adam S.; Sozda, Christopher N.; Hoffman, Ann N.; Cheng, Jeffrey P.			Evaluation of a Combined Treatment Paradigm Consisting of Environmental Enrichment and the 5-HT1A Receptor Agonist Buspirone after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral outcome; controlled cortical impact; functional recovery; hippocampus; learning and memory; Morris water maze; serotonin (5-HT1A)-receptor agonist; traumatic brain injury	MEDIATED FUNCTIONAL IMPROVEMENT; COGNITIVE DEFICITS; UNITED-STATES; NEUROBEHAVIORAL BENEFIT; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; TREATMENT REGIMEN; CLINICAL-TRIALS; GROWTH-FACTOR; 8-OH-DPAT	Environmental enrichment (EE) and serotonin(1A) (5-HT1A)-receptor agonists provide significant benefit after experimental traumatic brain injury (TBI). The aim of this study was to test the hypothesis that combining these therapies would produce an effect that is more robust than either therapy alone. Anesthetized adult male rats received a cortical impact or sham injury and then were randomly assigned to EE or standard (STD) housing where they received either buspirone (0.3 mg/kg) or vehicle (1.0 mL/kg) once daily for 3 weeks. Motor and cognitive assessments were conducted on post-injury days 1-5 and 14-19, respectively. CA1/3 neurons were quantified at 3 weeks. No differences were observed among buspirone and vehicle sham groups in any task regardless of housing condition and thus the data were pooled. CA3 cell loss was reduced in the TBI + EE + buspirone and TBI + EE + vehicle groups. Motor recovery, spatial learning, and memory retention were enhanced in the TBI + EE + buspirone, TBI + EE + vehicle, and TBI + STD + buspirone groups versus the TBI + STD + vehicle group (p <= 0.005). Moreover, spatial learning was significantly better in the TBI + EE + buspirone group versus the TBI + STD + buspirone group (p < 0.0001). No differences were revealed between the buspirone and vehicle EE groups. These data show that EE and buspirone benefit functional outcome after TBI, but their combination is not more robust than either alone, which does not support the hypothesis. The lack of an additive effect may be due to the early-and-continuous EE paradigm on its own producing marked benefits, resulting in a ceiling effect. The evaluation of buspirone in a delayed-and-abbreviated EE paradigm is ongoing in our laboratory.	[Kline, Anthony E.; Olsen, Adam S.; Sozda, Christopher N.; Hoffman, Ann N.; Cheng, Jeffrey P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.; Olsen, Adam S.; Sozda, Christopher N.; Hoffman, Ann N.; Cheng, Jeffrey P.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Olsen, Adam/0000-0003-0957-9867; Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700, NS060005]	This work was supported, in part, by National Institutes of Health grants HD043851, HD046700, and NS060005 (A.E.K.).	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Olsen A.S., 2012, J NEUROTRAUM, DOI [10.1089/neu.2012.2385, DOI 10.1089/NEU.2012.2385]; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	55	37	37	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1960	1969		10.1089/neu.2012.2385			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400398	22471653	Green Published			2021-06-18	
J	Lee, HF; Lee, TS; Kou, YR				Lee, Hung-Fu; Lee, Tzong-Shyuan; Kou, Yu Ru			Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Triptolide; Traumatic brain injury; Apoptosis; Cytokines; Inflammation	CLOSED-HEAD INJURY; NF-KAPPA-B; TNF-ALPHA; TIME-COURSE; CELL-DEATH; IN-VITRO; INFLAMMATION; INHIBITION; MICE; EXPRESSION	Traumatic brain injury (TBI) is characterized by neuroinflammation, brain edema, and cerebral damage leading to impairment of neurobehavioral function. Triptolide (PG-490), a diterpenoid component from Tripterygium wilfordii Hook F., has anti-inflammatory properties. Whether triptolide has neuroprotective functions when treating TBI is unclear. To investigate this possibility, Sprague-Dawley rats were treated with triptolide immediately after TBI had been induced by a controlled cortical impact procedure or after a sham procedure. TBI produced neuroinflammation when measured on day 1 after TBI, induced cerebral damage when measured on day 1 and day 3, and impaired neurobehavioral functioning over a 28-day observation period. Triptolide suppressed TBI-induced increases in contusion volume, cell apoptosis, edema and the levels of various pro-inflammatory mediators in the brain. Thriptolide reversed the TBI-induced decrease in brain levels of anti-inflammatory cytokine interleukin-10. Importantly, triptolide improved neurobehavioral outcomes regarding motor, sensory, reflex and balance function. We conclude that triptolide confers neuroprotection against TBI, at least in part, via its anti-inflammatory activity. (c) 2012 Elsevier B.V. All rights reserved.	[Lee, Hung-Fu; Lee, Tzong-Shyuan; Kou, Yu Ru] Natl Yang Ming Univ, Inst Physiol, Sch Med, Taipei 112, Taiwan; [Lee, Hung-Fu] Cheng Hsin Gen Hosp, Dept Neurosurg, Taipei, Taiwan; [Kou, Yu Ru] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Sch Med, Taipei 112, Taiwan	Lee, TS (corresponding author), Natl Yang Ming Univ, Inst Physiol, Sch Med, Taipei 112, Taiwan.	tslee@ym.edu.tw; yrkou@ym.edu.tw	Lee, Tzong-Shyuan/AAE-5803-2020	Lee, Tzong-Shyuan/0000-0002-9593-4062; Kou, Yu Ru/0000-0002-4681-9009	Cheng Hsin General Hospital [98-15]; Yang-Ming University/Cheng Hsin Hospital Joint Research Programs [98F-117-CY12, 100F-117-CY21]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC 98-2320-B-010-016-MY3, NSC-99-2320-B-010-017-MY3]; Ministry of Education, Aim for the Top University Plan, TaiwanMinistry of Education, Taiwan	This work was supported by a grant 98-15 from the Cheng Hsin General Hospital, grants 98F-117-CY12 and 100F-117-CY21 from the Yang-Ming University/Cheng Hsin Hospital Joint Research Programs, grants NSC 98-2320-B-010-016-MY3 and NSC-99-2320-B-010-017-MY3 from the National Science Council, and a grant from Ministry of Education, Aim for the Top University Plan, Taiwan. We thank Dr. Szu-Fu Chen, Dr. Che-Feng Chang, Miss Wei-Shan Chien, Miss Jhih-Syuan Lin for their technical support and Dr. Ralph Kirby, Department of Life Sciences, National Yang-Ming University, for his help in language editing.	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fahrig T, 2005, MOL PHARMACOL, V67, P1544, DOI 10.1124/mol.104.008177; Faul JL, 2000, AM J RESP CRIT CARE, V162, P2252, DOI 10.1164/ajrccm.162.6.2002018; Gong YT, 2008, J NEUROCHEM, V107, P779, DOI 10.1111/j.1471-4159.2008.05653.x; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hoyle GW, 2010, AM J PHYSIOL-LUNG C, V298, pL830, DOI 10.1152/ajplung.00014.2010; Ikeda-Matsuo Y, 2011, J NEUROIMMUNOL, V238, P34, DOI 10.1016/j.jneuroim.2011.06.014; Jiao J, 2008, J NEUROIMMUNOL, V205, P32, DOI 10.1016/j.jneuroim.2008.08.006; Kelso ML, 2011, PROG MOL BIOL TRANSL, V98, P85, DOI 10.1016/B978-0-12-385506-0.00003-X; Kim YH, 2004, EUR J PHARMACOL, V494, P1, DOI 10.1016/j.ejphar.2004.04.040; Krakauer T, 2005, IMMUNOPHARM IMMUNOT, V27, P53, DOI [10.1081/IPH-200051294, 10.1081/IPH-51294]; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li RZ, 2004, JPN HEART J, V45, P657, DOI 10.1536/jhj.45.657; Li W, 2008, XENOBIOTICA, V38, P1551, DOI 10.1080/00498250802503359; Lin N, 2007, BIOCHEM PHARMACOL, V73, P136, DOI 10.1016/j.bcp.2006.08.027; Liu L, 2010, TOXICOLOGY, V271, P57, DOI 10.1016/j.tox.2010.03.004; Liu QY, 2006, BIOCHEM BIOPH RES CO, V345, P1122, DOI 10.1016/j.bbrc.2006.05.024; Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu Y, 2006, INVEST OPHTH VIS SCI, V47, P3796, DOI 10.1167/iovs.06-0319; Matta R, 2009, AM J TRANSL RES, V1, P267; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Qiu Daoming, 2003, Drugs R D, V4, P1, DOI 10.2165/00126839-200304010-00001; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sharma HS, 1997, ACT NEUR S, V70, P269; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stanley JL, 2005, J PSYCHOPHARMACOL, V19, P221, DOI 10.1177/0269881105051524; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Su ZD, 2010, GLIA, V58, P901, DOI 10.1002/glia.20972; Tao XL, 1998, ARTHRITIS RHEUM-US, V41, P130, DOI 10.1002/1529-0131(199801)41:1<130::AID-ART16>3.3.CO;2-W; Wu Shao-xi, 2005, Chin J Integr Med, V11, P147; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao GH, 2000, AM J PHYSIOL-LUNG C, V279, pL958; Zhou HF, 2003, NEUROREPORT, V14, P1091, DOI 10.1097/01.wnr.0000073682.00308.47; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	37	40	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048			RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	JUN 15	2012	182	1					1	8		10.1016/j.resp.2012.01.016			8	Physiology; Respiratory System	Physiology; Respiratory System	964UR	WOS:000305722700001	22366865				2021-06-18	
J	Kasotakis, G; Michailidou, M; Bramos, A; Chang, YC; Velmahos, G; Alam, H; King, D; de Moya, MA				Kasotakis, George; Michailidou, Maria; Bramos, Athanosios; Chang, Yuchiao; Velmahos, George; Alam, Hasan; King, David; de Moya, Marc A.			Intraparenchymal vs Extracranial Ventricular Drain Intracranial Pressure Monitors in Traumatic Brain Injury: Less Is More?	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							SEVERE HEAD-INJURY; INTENSIVE-CARE; COMPLICATIONS; INTUBATION; MANAGEMENT; PROPHYLAXIS; EXPERIENCE; PLACEMENT; INFECTION; MANNITOL	BACKGROUND: Management of severe traumatic brain injury has centered on continuous intracranial pressure (ICP) monitoring with intraparenchymal ICP monitors (IPM) or extracranial ventricular drains (EVD). Our hypothesis was that neurologic outcomes are unaffected by the type of ICP monitoring device. STUDY DESIGN: We reviewed 377 adult patients with traumatic brain injury requiring ICP monitoring. Primary outcome was Glasgow Outcome Score (GOS) 1 month after injury. Secondary outcomes included mortality, monitoring-related complications, and length of ICU and hospital stay. RESULTS: There were 253 patients managed with an IPM and 124 with an EVD. There was no difference in GlasgowOutcome Score (2.7 +/- 1.3 vs 2.5 +/- 1.3, p = 0.45), mortality (30.9% vs 32.2%, p = 0.82), and hospital length of stay (LOS) (15.6 +/- 12.4 days vs 16.4 +/- 10.7 days, p = 0.57). Device-related complications (11.9% vs 31.1%, p < 0.001), duration of ICP monitoring (3.8 +/- 2.6 days vs 7.3 +/- 5.6 days, p < 0.001), and ICU LOS (7.6 +/- 5.6 days vs 9.5 +/- 6.2 days, p = 0.004) were longer in the EVD group. Age, opening ICP, and size of midline shift were independent predictors for neurologic outcomes and mortality, when type and severity of brain injury, as well as overall injury severity were controlled for. Duration of ICP monitoring and opening ICP were independent predictors for hospital LOS and the former predicted prolonged ICU stay. Device-related complications were affected by type of device. CONCLUSIONS: Use of EVDs in adult traumatic brain injury patients is associated with prolonged ICP monitoring, ICU LOS, and more frequent device-related complications. (J Am Coll Surg 2012;214:950-957. (C) 2012 by the American College of Surgeons)	[Kasotakis, George; Michailidou, Maria; Bramos, Athanosios; Chang, Yuchiao; Velmahos, George; Alam, Hasan; King, David; de Moya, Marc A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, Boston, MA 02114 USA	de Moya, MA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.			Kasotakis, George/0000-0002-7630-0742; King, David/0000-0003-1028-1478			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Brain Trauma Foundation, 2007, GUID MAN SEV TRAUM B; Centers for Disease Control and Prevention NCfIPaC, 2007, TRAUM BRAIN INJ US; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLARK WC, 1989, NEUROSURGERY, V25, P20; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Devlin JW, 2010, CRIT CARE MED, V38, pS231, DOI 10.1097/CCM.0b013e3181de125a; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flibotte JJ, 2004, NEUROCRIT CARE, V1, P61, DOI 10.1385/NCC:1:1:61; FRIEDMAN WA, 1980, J NEUROSURG, V53, P662, DOI 10.3171/jns.1980.53.5.0662; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GUILLAUME J, 1951, REV NEUROL, V84, P131; Guyot LL, 1998, ACT NEUR S, V71, P47; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; JENNETT B, 1975, LANCET, V1, P480; Khan SH, 1998, ACT NEUR S, V71, P50; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; Marshall LF, 2004, J NEUROSURG, V100, P367, DOI 10.3171/jns.2004.100.3.0367; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; May Addison K, 2006, Surg Infect (Larchmt), V7, P409, DOI 10.1089/sur.2006.7.409; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; PANG DL, 1994, J NEUROSURG, V80, P750, DOI 10.3171/jns.1994.80.4.0750; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Prabhu VC, 1999, SURG NEUROL, V52, P226, DOI 10.1016/S0090-3019(99)00084-1; Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z; Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Servadei F, 2002, ACT NEUR S, V81, P81; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHULTS WT, 1993, NEUROSURGERY, V33, P135; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stoikes NF, 2008, SURG INFECT, V9, P503, DOI 10.1089/sur.2007.032; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; Vasilevskis EE, 2010, CHEST, V138, P1224, DOI 10.1378/chest.10-0466	52	37	38	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	JUN	2012	214	6					950	957		10.1016/j.jamcollsurg.2012.03.004			8	Surgery	Surgery	958NM	WOS:000305245800012	22541986				2021-06-18	
J	Piao, CS; Loane, DJ; Stoica, BA; Li, SH; Hanscom, M; Cabatbat, R; Blomgren, K; Faden, AI				Piao, Chun-Shu; Loane, David J.; Stoica, Bogdan A.; Li, Shihong; Hanscom, Marie; Cabatbat, Rainier; Blomgren, Klas; Faden, Alan I.			Combined inhibition of cell death induced by apoptosis inducing factor and caspases provides additive neuroprotection in experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Apoptosis inducing factor; Caspase; Cyclophilin A	INDEPENDENT PROGRAMMED NECROSIS; OXYGEN-GLUCOSE DEPRIVATION; CYCLOPHILIN-A; CEREBRAL-ISCHEMIA; NEURONAL DEATH; HISTONE H2AX; POLY(ADP-RIBOSE) POLYMERASE; NEUROLOGICAL DYSFUNCTION; RHEUMATOID-ARTHRITIS; HYPOXIA-ISCHEMIA	Neuronal programmed cell death (PCD) contributes to delayed tissue damage after traumatic brain injury (TBI). Both caspase-dependent and caspase-independent mechanisms have been implicated, with the latter including apoptosis inducing factor (AIF). The peptidyl-proplyl isomerase Cyclophilin A (CypA) transports AIF from the cytosol to the nucleus, a key step for AIF-dependent cell death. We compared the effects of single versus combined inhibition of caspase and AIF pathways in a mouse controlled cortical impact (CCI) model, by examining the effects of CypA gene knockout (CypA(-/-)), caspase inhibition with a pan-caspase inhibitor (boc-aspartyl(oMe)-fluoromethylketone, BAF), or combined modulation. TBI caused caspase activation as well as translocation of AIF to the nucleus. Markers of caspase activation including caspase-specific fodrin cleavage fragments and number of FLIVO-positive cells were reduced in BAF-treated CypA(+/+) mice, whereas markers of AIF activation including AIF/H2AX interaction and AIF translocation to the nucleus were attenuated in CypA(-/-) mice. Each single intervention, (CypA(-/-) or BAF-treated CypA(+/+)) reduced the number of apoptotic cells (TUNEL-positive) in the cortex and improved long-term sensorimotor function; CypA(-/-) also attenuated microglial activation after injury. Importantly, BAF-treated CypA(-/-) mice, showed greater effects than either intervention alone on multiple outcomes including: reduction in TUNEL-positive cells, decrease in neuroinflammation, improved motor and cognitive recovery, and attenuation of lesion volume and neuronal loss in the hippocampus. Using two in vitro neuronal cell death models known to induce AIF-mediated PCD, we also showed that neurons from CypA(-/-) animals were protected and that effects were unrelated to caspase activation. These data indicate that AIF-mediated and caspase-dependent pathways contribute independently and in parallel to secondary injury after TBI, and suggest that combined therapeutic strategies directed at multiple PCD pathways may provide superior neuroprotection than those directed at single mechanisms. (C) 2012 Elsevier Inc. All rights reserved.	[Piao, Chun-Shu; Loane, David J.; Stoica, Bogdan A.; Li, Shihong; Hanscom, Marie; Cabatbat, Rainier; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Blomgren, Klas] Univ Gothenburg, Ctr Brain Repair & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden; [Faden, Alan I.] Karolinska Inst, Karolinska Univ Hosp Q2 07, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Organized Res, Dept Anesthesiol, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Organized Res, Dept Anesthesiol, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Blomgren, Klas/0000-0002-0476-7271; Loane, David/0000-0003-0393-3503; Hanscom, Marie/0000-0001-8308-135X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 RO1 NS0618839]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER	We thank Michael Murray II, Michael Dinizo, Stephanie Custer, Kelly Wilson, and Nicole Hockenbury for expert technical assistance. This work is supported by NIH grant 1 RO1 NS0618839.	Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Baritaud M, 2010, CELL CYCLE, V9, P3166, DOI 10.4161/cc.9.16.12552; Boulos S, 2007, NEUROBIOL DIS, V25, P54, DOI 10.1016/j.nbd.2006.08.012; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colgan J, 2005, J IMMUNOL, V174, P6030, DOI 10.4049/jimmunol.174.10.6030; Conti AC, 1998, J NEUROSCI, V18, P5663; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; El Ghouzzi V, 2007, J NEUROPATH EXP NEUR, V66, P838, DOI 10.1097/NEN.0b013e318148b822; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hilton G.D., 2008, J CEREB BLOOD FLOW M; Joza N, 2009, ANN NY ACAD SCI, V1171, P2, DOI 10.1111/j.1749-6632.2009.04681.x; Kabadi S.V., 2011, NEUROTHERAPEUTICS; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kim H, 2005, CLIN IMMUNOL, V116, P217, DOI 10.1016/j.clim.2005.05.004; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2005, J NEUROSCI RES, V80, P369, DOI 10.1002/jnr.20465; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Osato K, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.63; Piao CS, 2009, J CEREBR BLOOD F MET, V29, P759, DOI 10.1038/jcbfm.2008.168; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; RINK A, 1995, AM J PATHOL, V147, P1575; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Satoh K, 2008, CIRCULATION, V117, P3088, DOI 10.1161/CIRCULATIONAHA.107.756106; Satoh K, 2009, NAT MED, V15, P649, DOI 10.1038/nm.1958; Seizer P, 2011, ARTERIOSCL THROM VAS, V31, P1377, DOI 10.1161/ATVBAHA.111.225771; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki J, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/916514; Thal SE, 2011, NEUROSCI LETT, V499, P1, DOI 10.1016/j.neulet.2011.05.016; Tomita T, 2006, INT J MOL MED, V18, P257; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Wei YA, 2010, ATHEROSCLEROSIS, V213, P415, DOI 10.1016/j.atherosclerosis.2010.09.033; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	64	37	40	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2012	46	3					745	758		10.1016/j.nbd.2012.03.018			14	Neurosciences	Neurosciences & Neurology	950DK	WOS:000304629300024	22426396	Green Accepted			2021-06-18	
J	Kabadi, SV; Stoica, BA; Hanscom, M; Loane, DJ; Kharebava, G; Murray, MG; Cabatbat, RM; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Hanscom, Marie; Loane, David J.; Kharebava, Giorgi; Murray, Michael G., II; Cabatbat, Rainier M.; Faden, Alan I.			CR8, a Selective and Potent CDK Inhibitor, Provides Neuroprotection in Experimental Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						Cell cycle; Traumatic brain injury; Cyclindependent kinases; Neurodegeneration; Neuroprotection; CR8	CONTROLLED CORTICAL IMPACT; CYCLIN-DEPENDENT KINASES; SPINAL-CORD-INJURY; MORRIS WATER MAZE; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; DEGENERATING NEURONS; THERAPEUTIC TARGET; SPATIAL MEMORY; LEARNING-TASK	Traumatic brain injury (TBI) induces secondary injury mechanisms, including cell cycle activation (CCA), that leads to neuronal death and neurological dysfunction. We recently reported that delayed administration of roscovitine, a relatively selective cyclin-dependent kinase (CDK) inhibitor, inhibits CCA and attenuates neurodegeneration and functional deficits following controlled cortical impact (CCI) injury in mice. Here we evaluated the neuroprotective potential of CR8, a more potent second-generation roscovitine analog, using the mouse CCI model. Key CCA markers (cyclin A and B1) were significantly up-regulated in the injured cortex following TBI, and phosphorylation of CDK substrates was increased. Central administration of CR8 after TBI, at a dose 20 times less than previously required for roscovitine, attenuated CCA pathways and reduced post-traumatic apoptotic cell death at 24 h post-TBI. Central administration of CR8, at 3 h after TBI, significantly attenuated sensorimotor and cognitive deficits, decreased lesion volume, and improved neuronal survival in the cortex and dentate gyrus. Moreover, unlike roscovitine treatment in the same model, CR8 also attenuated post-traumatic neurodegeneration in the CA3 region of the hippocampus and thalamus at 21 days. Furthermore, delayed systemic administration of CR8, at a dose 10 times less than previously required for roscovitine, significantly improved cognitive performance after CCI. These findings further demonstrate the neuroprotective potential of cell cycle inhibitors following experimental TBI. Given the increased potency and efficacy of CR8 as compared to earlier purine analog types of CDK inhibitors, this drug should be considered as a candidate for future clinical trials of TBI.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Hanscom, Marie; Loane, David J.; Kharebava, Giorgi; Murray, Michael G., II; Cabatbat, Rainier M.; Faden, Alan I.] Univ Maryland, Dept Anesthesiol, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA	Stoica, BA (corresponding author), Univ Maryland, Dept Anesthesiol, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA.	bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Hanscom, Marie/0000-0001-8308-135X; Loane, David/0000-0003-0393-3503	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	We thank David Knipp, Stephanie Custer, and Titilola Akintola for expert technical assistance. This work was supported by a grant from the National Institutes of Health (grant No. R01 NS052568).	Arendt T, 2003, PROG NEUROBIOL, V71, P83, DOI 10.1016/j.pneurobio.2003.09.007; Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Copani A, 1999, FASEB J, V13, P2225; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gilbert PE, 2009, PROG NEURO-PSYCHOPH, V33, P774, DOI 10.1016/j.pnpbp.2009.03.037; Goldstein LB, 2003, ILAR J, V44, P125, DOI 10.1093/ilar.44.2.125; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Jerman T, 2006, LEARN MEMORY, V13, P458, DOI 10.1101/lm.246906; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2011, J NEUROTRAUMA   0906; Komina Oxane, 2011, J Exp Ther Oncol, V9, P27; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lee I, 2005, BEHAV NEUROSCI, V119, P145, DOI 10.1037/0735-7044.119.1.145; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LUNDBERG A, 1998, MOL CELL BIOL, V23, P1044; Maestre C, 2008, EMBO J, V27, P2736, DOI 10.1038/emboj.2008.195; MARTIN JM, 1996, NEUROANATOMY TEXT AT; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Mori T, 1998, ACT NEUR S, V71, P120; Mosch B, 2007, J NEUROSCI, V27, P6859, DOI 10.1523/JNEUROSCI.0379-07.2007; Nauta W. J. H., 1986, FUNDAMENTAL NEUROANA; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nutley BP, 2005, MOL CANCER THER, V4, P125; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Vincent I, 1997, J NEUROSCI, V17, P3588; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wesierska-Gadek J, 2011, J CELL BIOCHEM, V112, P761, DOI 10.1002/jcb.23004	57	37	37	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2012	9	2					405	421		10.1007/s13311-011-0095-4			17	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	926EX	WOS:000302815200015	22167461	Bronze, Green Accepted, Green Published			2021-06-18	
J	Rivara, FP; Ennis, SK; Mangione-Smith, R; MacKenzie, EJ; Jaffe, KM				Rivara, Frederick P.; Ennis, Stephanie K.; Mangione-Smith, Rita; MacKenzie, Ellen J.; Jaffe, Kenneth M.		Natl Expert Panel Dev Pediat Rehab	Quality of Care Indicators for the Rehabilitation of Children With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Quality of health care; Rehabilitation	COGNITIVE REHABILITATION; OUTCOMES; APPROPRIATENESS; MORTALITY; GUIDELINE	Rivara FP, Ennis SK, Mangione-Smith R, MacKenzie EJ, Jaffe KM, and the National Expert Panel for the Development of Pediatric Rehabilitation Quality Care Indicators. Quality of care indicators for the rehabilitation of children with traumatic brain injury. Arch Phys Med Rehabil 2012;93: 381-5. Objective: To develop measurement tools for assessing compliance with identifiable processes of inpatient care for children with traumatic brain injury (TBI) that are reliable, valid, and amenable to implementation. Design: Literature review and expert panel using the RAND/UCLA Appropriateness Method and a Delphi technique. Setting: Not applicable. Participants: Children with TBI. Interventions: Not applicable. Main Outcome Measure: Quality of care indicators. Results: A total of 119 indicators were developed across the domains of general management; family-centered care; cognitive-communication, speech, language, and swallowing impairments; gross and fine motor skill impairments; neuropsychologic, social, and behavioral impairments; school reentry; and community integration. There was a high degree of agreement on these indicators as valid and feasible quality measures for children with TBI. Conclusions: These indicators are an important step toward building a better base of evidence about the effectiveness and efficiency of the components of acute inpatient rehabilitation for pediatric patients with TBI.	[Rivara, Frederick P.; Ennis, Stephanie K.; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Rivara, Frederick P.; Mangione-Smith, Rita] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Ennis, Stephanie K.; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Rivara, Frederick P.; Mangione-Smith, Rita] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu		Gaebler-Spira, Deborah/0000-0001-6827-4241; Krach, Linda/0000-0002-0993-8199	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD059049-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD059049] Funding Source: NIH RePORTER	Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant no. R21 HD059049-01A1).	Brain Trauma Foundation, 1995, GUID MAN SEV TBI; Brain Trauma Foundation, 2003, GUID AC MED MAN SEV; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; BROOK RH, 1994, METHODOLOGICAL PERSP; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Duncan PW, 2007, ARCH PHYS MED REHAB, V88, P1482, DOI 10.1016/j.apmr.2007.08.118; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fitch K, 2006, RAND UCLA APPROPRIAT; GRADY ML, 1992, MED EFFECTIVENESS RE; Hoenig H, 2002, MED CARE, V40, P1036, DOI 10.1097/00005650-200211000-00005; Hoenig H, 2001, HEALTH SERV RES, V35, P1293; *I MED, 2001, CROSS QUAL CHASM NEW; KAHN KL, 1988, MED CARE, V26, P415, DOI 10.1097/00005650-198804000-00010; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; LaClair BJ, 2001, AM J PHYS MED REHAB, V80, P235, DOI 10.1097/00002060-200103000-00017; Mangione-Smith R, 2007, NEW ENGL J MED, V357, P1515, DOI 10.1056/NEJMsa064637; McGlynn EA, 1999, WOMEN HEALTH ISS, V9, P184, DOI 10.1016/S1049-3867(99)00009-2; McGory ML, 2009, ANN SURG, V250, P338, DOI 10.1097/SLA.0b013e3181ae575a; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Reker DM, 2002, ARCH PHYS MED REHAB, V83, P750, DOI 10.1053/apmr.2002.99736; Rubin HR, 2001, INT J QUAL HEALTH C, V13, P489, DOI 10.1093/intqhc/13.6.489; Schuster MA, 1997, ARCH PEDIAT ADOL MED, V151, P1085, DOI 10.1001/archpedi.1997.02170480015003; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wilkerson DL, 1997, ARCH PHYS MED REHAB, V78, pS31, DOI 10.1016/S0003-9993(97)90153-2; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Zumsteg JM, 2012, ARCH PHYS MED REHAB, V93, P386, DOI 10.1016/j.apmr.2011.08.018	38	37	37	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2012	93	3					381	385		10.1016/j.apmr.2011.08.015			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	902GW	WOS:000301027600001	22280892	Green Accepted			2021-06-18	
J	Zollman, FS; Larson, EB; Wasek-Throm, LK; Cyborski, CM; Bode, RK				Zollman, Felise S.; Larson, Eric B.; Wasek-Throm, Laura K.; Cyborski, Cherina M.; Bode, Rita K.			Acupuncture for Treatment of Insomnia in Patients With Traumatic Brain Injury: A Pilot Intervention Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						actigraphy; acupuncture; insomnia; sleep; TBI; traumatic brain injury	MELATONIN SECRETION; SLEEP; RECOVERY; ACTIGRAPHY; DEPRESSION; QUALITY	Objectives: To assess the efficacy of acupuncture in treating insomnia in traumatic brain injury (TBI) survivors as compared to medication, to determine whether acupuncture has fewer cognitive and affective adverse effects than does medication. Participants: Twenty-four adult TBI survivors, randomized to acupuncture or control arms. Setting: Outpatient rehabilitation clinic. Measures: Insomnia Severity Index (degree of insomnia); actigraphy (sleep time); Hamilton Depression Rating Scale (depression); Repeatable Battery for the Assessment of Neuropsychological Status and Paced Auditory Serial Addition Test (cognitive function) administered at baseline and postintervention. Results: Sleep time did not differ between the treatment and control groups after intervention, whereas cognition improved in the former but not the latter. Conclusion: Acupuncture has a beneficial effect on perception of sleep or sleep quality and on cognition in our small sample of patients with TBI. Further studies of this treatment modality are warranted to validate these findings and to explore factors that contribute to treatment efficacy.	[Zollman, Felise S.; Larson, Eric B.; Cyborski, Cherina M.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Wasek-Throm, Laura K.] Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA	Zollman, FS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA.	f-zollman@northwestern.edu	Larson, Eric/AAD-9567-2021		CDMRP (US Army Medical Research and Material Command) [W81XWH-08-1-0752]	This work was supported by CDMRP (US Army Medical Research and Material Command #W81XWH-08-1-0752).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 2004, NCCAM PUBL D; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; He Jing, 2005, J Tradit Chin Med, V25, P171; Helms J, 1995, ACUPUNCTURE ENERGETI; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kim YS, 2004, AM J CHINESE MED, V32, P771, DOI 10.1142/S0192415X04002399; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Li Y, 1993, J Tradit Chin Med, V13, P5; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCall WV, 2000, J SLEEP RES, V9, P43, DOI 10.1046/j.1365-2869.2000.00186.x; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Phillips K D, 2001, J Assoc Nurses AIDS Care, V12, P27, DOI 10.1016/S1055-3290(06)60168-4; Randolph C, 1998, REPEATABLE BATTERY A; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; SADEH A, 1995, SLEEP, V18, P288, DOI 10.1093/sleep/18.4.288; Sok SR, 2003, J ADV NURS, V44, P375, DOI 10.1046/j.0309-2402.2003.02816.x; Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19; Tang NKY, 2004, BEHAV RES THER, V42, P27, DOI 10.1016/S0005-7967(03)00068-8; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; THAXTON L, 2007, BRAIN INJURY MED PRI, P557; Tsay SL, 2004, AM J CHINESE MED, V32, P407, DOI 10.1142/S0192415X04002065; VANHILTEN JJ, 1993, SLEEP, V16, P146, DOI 10.1093/sleep/16.2.146; WANG X, 1988, Journal of Traditional Chinese Medicine, V8, P127; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zollman FS, 2010, BRAIN INJURY, V24, P748, DOI 10.3109/02699051003692167	39	37	37	2	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					135	142		10.1097/HTR.0b013e3182051397			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100006	21386714				2021-06-18	
J	Thomas, TC; Hinzman, JM; Gerhardt, GA; Lifshitz, J				Thomas, Theresa Currier; Hinzman, Jason M.; Gerhardt, Greg A.; Lifshitz, Jonathan			Hypersensitive Glutamate Signaling Correlates with the Development of Late-Onset Behavioral Morbidity in Diffuse Brain-Injured Circuitry	JOURNAL OF NEUROTRAUMA			English	Article						amperometry; brain trauma; fluid percussion glutamate; thalamocortical system	AGE-RELATED-CHANGES; FLUID-PERCUSSION; EXTRACELLULAR GLUTAMATE; MULTISITE MICROELECTRODES; NEURONAL INJURY; AXONAL INJURY; RAT-BRAIN; EXPRESSION; POTASSIUM; CORTEX	In diffuse brain-injured rats, robust sensory sensitivity to manual whisker stimulation develops over 1 month post-injury, comparable to agitation expressed by brain-injured individuals with overstimulation. In the rat, whisker somatosensation relies on thalamocortical glutamatergic relays between the ventral posterior medial (VPM) thalamus and barrel fields of somatosensory cortex (S1BF). Using novel glutamate-selective microelectrode arrays coupled to amperometry, we test the hypothesis that disrupted glutamatergic neurotransmission underlies the whisker sensory sensitivity associated with diffuse brain injury. We report hypersensitive glutamate neurotransmission that parallels and correlates with the development of post-traumatic sensory sensitivity. Hypersensitivity is demonstrated by significant 110% increases in VPM extracellular glutamate levels, and 100% increase in potassium-evoked glutamate release in the VPM and S1BF, with no change in glutamate clearance. Further, evoked glutamate release showed 50% greater sensitivity to a calcium channel antagonist in brain-injured over uninjured VPM. In conjunction with no changes in glutamate transporter gene expression and exogenous glutamate clearance efficiency, these data support a presynaptic origin for enduring post-traumatic circuit alterations. In the anatomically-distinct whisker circuit, the injury-induced functional alterations correlate with the development of late-onset behavioral morbidity. Effective therapies to modulate presynaptic glutamate function in diffuse-injured circuits may translate into improvements in essential brain function and behavioral performance in other brain-injured circuits in rodents and in humans.	[Thomas, Theresa Currier; Hinzman, Jason M.; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Coll Med, Lexington, KY 40536 USA; [Thomas, Theresa Currier; Hinzman, Jason M.; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Hinzman, Jason M.; Gerhardt, Greg A.] Univ Kentucky, Ctr Microelectrode Technol, Coll Med, Lexington, KY 40536 USA; [Hinzman, Jason M.; Gerhardt, Greg A.] Univ Kentucky, Morris K Udall Parkinsons Dis Res Ctr Excellence, Coll Med, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Dept Phys Med & Rehabil, Coll Med, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Coll Med, Biomed & Biol Sci Res Bldg,B463 741 S Limestone S, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666	Kentucky Spinal Cord and Head Injury Research Trust [7-11, R01 NS065052, T32 AG000242, P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS077098, R01NS065052, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242] Funding Source: NIH RePORTER	The authors would like to sincerely thank Francois Pomerleau and Peter Huettl for their help with installing and maintenance of the FAST system, Amanda Lisembee, Katelyn McNamara, Kelley Hall, Tuoxin Cao, and Shima Dowla for technical assistance with the experiments, Richard Rogers, Ph.D. and Gerlinda Hermann, Ph.D. for instruction on the fabrication of double-barrel micropipettes, and George M. Smith, Ph.D. and Pooja Talauliker, Ph.D. for critical feedback on the manuscript. This work was supported by the Kentucky Spinal Cord and Head Injury Research Trust grant #7-11 to Jonathan Lifshitz, R01 NS065052 to Jonathan Lifshitz, T32 AG000242 to Greg A. Gerhardt in support of Theresa C. Thomas, U.K. College of Medicine, and P30 NS051220 to Edward D. Hall, Ph.D.	Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Burmeister JJ, 2004, P ANN INT IEEE EMBS, V26, P5348; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Burmeister JJ, 2000, ANAL CHEM, V72, P187, DOI 10.1021/ac9907991; Cai X, 2007, J NEUROSCI, V27, P59, DOI 10.1523/JNEUROSCI.4502-06.2007; CASS WA, 1992, J NEUROCHEM, V59, P259, DOI 10.1111/j.1471-4159.1992.tb08899.x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Conti AC, 1998, J NEUROSCI, V18, P5663; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Day BK, 2006, J NEUROCHEM, V96, P1626, DOI 10.1111/j.1471-4159.2006.03673.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Emery DL, 2000, J COMP NEUROL, V424, P521; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; FRIEDEMANN MN, 1992, NEUROBIOL AGING, V13, P325, DOI 10.1016/0197-4580(92)90046-Z; GERHARDT G, 1985, J PHARMACOL EXP THER, V235, P259; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hascup ER, 2010, J NEUROCHEM, V115, P1608, DOI 10.1111/j.1471-4159.2010.07066.x; Hascup K. N., 2006, ELECTROCHEMICAL METH, P407; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Homola A, 2006, NEUROSCI LETT, V404, P137, DOI 10.1016/j.neulet.2006.05.028; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kidd FL, 1999, NATURE, V400, P569; LAND PW, 1995, J COMP NEUROL, V355, P573, DOI 10.1002/cne.903550407; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Latour I, 2003, GLIA, V41, P347, DOI 10.1002/glia.10162; Lifshitz J., 2011, BRAIN STRUCT FUNCT; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCCANN MJ, 1990, J PHYSIOL-LONDON, V428, P95, DOI 10.1113/jphysiol.1990.sp018202; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MOUSSY F, 1994, ANAL CHEM, V66, P674, DOI 10.1021/ac00077a015; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; Nickell J, 2005, J NEURAL TRANSM, V112, P87, DOI 10.1007/s00702-004-0151-x; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paxinos G., 2007, RAT BRAIN IN STEREOT; Pomerleau F, 2003, ANN NY ACAD SCI, V1003, P454, DOI 10.1196/annals.1300.051; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Quintero JE, 2007, EXP NEUROL, V208, P238, DOI 10.1016/j.expneurol.2007.08.002; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Schubert D, 2007, BRAIN STRUCT FUNCT, V212, P107, DOI 10.1007/s00429-007-0147-z; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Thomas TC, 2009, NEUROPSYCHOPHARMACOL, V34, P436, DOI 10.1038/npp.2008.74; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Waite P, 1995, RAT NERVOUS SYSTEM; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Yamaki T, 1998, BRAIN RES PROTOC, V3, P100, DOI 10.1016/S1385-299X(98)00030-0; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	72	37	37	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					187	200		10.1089/neu.2011.2091			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300001	21939393	Green Published			2021-06-18	
J	Bartsch, A; Benzel, E; Miele, V; Prakash, V				Bartsch, Adam; Benzel, Edward; Miele, Vincent; Prakash, Vikas			Impact test comparisons of 20th and 21st century American football helmets Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						concussion; American football; football helmet; high school football; youth football; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; UNITED-STATES; GAME IMPACTS; HEAD-INJURY; COLLEGIATE; RISK; EPIDEMIOLOGY	Object. Concussion is the signature American football injury of the 21st century. Modern varsity helmets, as compared with vintage leather helmets, or "leatherheads," are widely believed to universally improve protection by reducing head impact doses and head injury risk for the 3 million young football players in the US. The object of this study was to compare the head impact doses and injury risks with 11 widely used 21st century varsity helmets and 2 early 20th century leatherheads and to hypothesize what the results might mean for children wearing similar varsity helmets. Methods. In an injury biomechanics laboratory, the authors conducted front, oblique front, lateral, oblique rear, and rear head impact tests at 5.0 m/second using helmeted headforms, inducing near-and subconcussive head impact doses on par with approximately the 95th percentile of on-field collision severity. They also calculated impact dose injury risk parameters common to laboratory and on-field traumatic neuromechanics: linear acceleration, angular acceleration, angular velocity, Gadd Severity Index, diffuse axonal injury, acute subdural hematoma, and brain contusion. Results. In many instances the head impact doses and head injury risks while wearing vintage leatherheads were comparable to or better than those while wearing several widely used 21st century varsity helmets. Conclusions. The authors do not advocate reverting to leather headgear, but they do strongly recommend, especially for young players, instituting helmet safety designs and testing standards, which encourage the minimization of linear and angular impact doses and injury risks in near-and subconcussive head impacts. (DOI: 10.3171/2011.9.JNS111059)	[Bartsch, Adam; Benzel, Edward] Cleveland Clin, Spine Res Lab, Cleveland, OH 44113 USA; [Benzel, Edward; Miele, Vincent] Cleveland Clin, Neurol Inst, Dept Neurosurg, Cleveland, OH 44113 USA; [Bartsch, Adam; Benzel, Edward; Miele, Vincent; Prakash, Vikas] Case Western Reserve Univ, Cleveland Traumat Neuromech Consortium, Cleveland, OH 44106 USA; [Prakash, Vikas] Case Western Reserve Univ, Dept Mech Engn, Cleveland, OH 44106 USA; [Miele, Vincent] United Hosp Ctr, Neurospine Ctr, Bridgeport, WV USA	Bartsch, A (corresponding author), Cleveland Clin, Spine Res Lab, Luth2-C,1730 W 25th St, Cleveland, OH 44113 USA.	bartsca@ccf.org					Bandak FA, SIMON SIMULATED INJU; Bandak FA, 3 DIMENSIONAL FINITE; Battista J, 2011, NY TIMES        0323; Battista J, 2010, NY TIMES        1019; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Fenner Jr H, 2005, FIN REP WORKSH CRIT; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gadd CW, USE WEIGHTED IMPULSE; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Higgins M, 2007, J ATHL TRAINING, V42, P5; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR, EFFECT LONG DURATION; Hodgson VR, COMP HEAD ACCELERATI; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McElhaney James H, 2005, Stapp Car Crash J, V49, pv; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mertz H, INJURY RISK CURVES C; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; National Operating Committee on Standards for Athletic Equipment, 2009, ND00298M09 NOCSAE, P1; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2008, 00108M08B NOCSAE, P1; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prasad P, POSITION US DELEGATI; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schwartz A, 2009, NY TIMES        1202; Society of Automotive Engineers, INSTR IMP TEST PART; Society of Automotive Engineers, SIGN CONV VEH CRASH; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Versace J, REV SEVERITY INDEX; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2	52	37	37	0	33	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2012	116	1					222	233		10.3171/2011.9.JNS111059			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	869XJ	WOS:000298632500037	22054210	Bronze			2021-06-18	
J	Moreau, OK; Yollin, E; Merlen, E; Daveluy, W; Rousseaux, M				Moreau, Odile Kozlowski; Yollin, Edwige; Merlen, Emilie; Daveluy, Walter; Rousseaux, Marc			Lasting Pituitary Hormone Deficiency after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						activities of daily living; cognitive disorders; pituitary deficiency; sequelae; traumatic brain injury	POSTTRAUMATIC DIABETES-INSIPIDUS; GROWTH-FACTOR-I; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; GH DEFICIENCY; ANTERIOR LOBE; HEAD-INJURY; ACUTE-PHASE; LONG-TERM; HIGH-RISK	Pituitary deficiencies have been reported after traumatic brain injury (TBI) and may contribute to lasting cognitive disorders in this context. In a population of TBI patients with persistent cognitive and/or behavioral disorders, we sought to determine the prevalence of lasting pituitary deficiency and relationships with TBI severity, cognitive disorders, and impairments in activities of daily living (ADL). Fifty-five patients were included (mean age 36.1 years; 46 men) at least 1 year after TBI. They underwent a comprehensive evaluation of pituitary function (basic tests and stimulation), initial TBI severity, and long-term outcomes (cognitive performance, Glasgow Outcome Scale score, impact on ADL, and quality of life [QoL]). We used chi-squared and Mann-Whitney tests to probe for significant (p <= 0.05) relationships between pituitary disorders and other parameters. Thirty-eight (69%) patients had at least one pituitary hormone deficiency. Growth hormone deficiency was more prevalent (severe: 40.0%; partial: 23.6%) than corticotropin (27.3%) or thyrotropin (21.8%) deficiencies. Other deficiencies were rare. Growth hormone deficiency was associated with attention and verbal memory disorders and reduced involvement in ADL. We did not find any relationship between pituitary deficiency and the TBI's initial severity. In a multivariate analysis, the TBI severity was introduced as a first factor, and pituitary deficits as a secondary factor for explaining the late outcome (ADL and QoL). In conclusion, TBI patients with cognitive sequelae must undergo pituitary screening because growth hormone, corticotropin, and thyrotropin deficits are particularly common and can adversely affect ADL and reduce QoL.	[Yollin, Edwige; Merlen, Emilie] CHRU, Huriez Hosp, Endocrinol Unit, Lille, France	Moreau, OK (corresponding author), CHRU Univ Lille Nord de France, Swynghedauw Hosp, Neurol Rehabil Unit, Lille, France.	odile.moreau@chru-lille.fr					Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brooks N., 1994, EVALUATION TRAUMATIC, V1994, P1; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; DANIEL PM, 1959, LANCET, V2, P927; Ellison DH, 2007, NEW ENGL J MED, V356, P2064, DOI 10.1056/NEJMcp066837; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Ghigo E, 2008, GROWTH HORM IGF RES, V18, P1, DOI 10.1016/j.ghir.2007.07.004; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; HOECK HC, 1995, EUR J ENDOCRINOL, V133, P305, DOI 10.1530/eje.0.1330305; JENNETT B, 1975, LANCET, V1, P480; Jeong JH, 2010, J NEUROSURG, V113, P532, DOI 10.3171/2009.10.JNS091152; KAWAI K, 1995, J NEUROSURG, V83, P368, DOI 10.3171/jns.1995.83.2.0368; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MASSOL J, 1987, NEURORADIOLOGY, V29, P299, DOI 10.1007/BF00451773; Mathe JF, 2005, ANN FR ANESTH, V24, P688, DOI 10.1016/j.annfar.2005.03.029; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider HJ, 2003, EUR J ENDOCRINOL, V149, P377, DOI 10.1530/eje.0.1490377; SHEEHAN HL, 1961, ACTA ENDOCRINOL-COP, V37, P479, DOI 10.1530/acta.0.0370479; STABLER B, 1992, CLIN ENDOCRINOL, V36, P467, DOI 10.1111/j.1365-2265.1992.tb02247.x; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Truelle JL, 2008, ACTA NEUROCHIR SUPPL, V101, P125; van Dam PS, 2004, EUR J PHARMACOL, V490, P87, DOI 10.1016/j.ejphar.2004.02.047; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Van der Linden M., 2004, VALUATION TROUBLES M; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Wechsler R., 1989, ECHELLE INTELLIGENCE; ZIMMERMANN P, 1994, TEST ATTENTIONAL PER	56	37	37	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					81	89		10.1089/neu.2011.2048			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300009	21992034				2021-06-18	
J	Viano, DC; Halstead, D				Viano, David C.; Halstead, David			Change in Size and Impact Performance of Football Helmets from the 1970s to 2010	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Protective headgear; Recreation and sport; Concussion; Helmets; Sport equipment	PROFESSIONAL FOOTBALL; GAME IMPACTS; NECK INJURY; CONCUSSION; HEAD; PLAYER; BIOMECHANICS	Linear impactor tests were conducted on football helmets from the 1970s-1980s to complement recently reported tests on 1990s and 2010s helmets. Helmets were placed on the Hybrid III head with an array of accelerometers to determine translational and rotational acceleration. Impacts were at four sites on the helmet shell at 3.6-11.2 m/s. The four generations of helmets show a continuous improvement in response from bare head impacts in terms of Head Injury Criterion (HIC), peak head acceleration and peak rotational acceleration. Helmets of 2010s weigh 1.95 +/- 0.2 kg and are 2.7 times heavier than 1970s designs. They are also 4.3 cm longer, 7.6 cm higher, and 4.9 cm wider. The extra size and weight allow the use of energy absorbing padding that lowers forces in helmet impacts. For frontal impacts at 7.4 m/s, the four best performing 2010s helmets have HIC of 148 +/- 23 compared to 179 +/- 42 for the 1990s baseline, 231 +/- 27 for the 1980s, 253 +/- 22 for the 1970s helmets, and 354 +/- 3 for the bare head. The additional size and padding of the best 2010s helmets provide superior attenuation of impact forces in normal play and in conditions associated with concussion than helmets of the 1970s-1990s.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Halstead, David] Univ Tennessee, Coll Engn, Sports Biomech Impact Res Lab, Knoxville, TN 37996 USA; [Halstead, David] So Impact Res Ctr LLC, Rockford, TN 37853 USA	Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			National Football League	Funding for this research was provided by the National Football League. SIRC has previous and ongoing relationships with some of the helmet manufacturers, NOCSAE and others. These were acknowledged at the onset. The testing reported here was completed while the lead author was a member of the NFL's MTBI Committee and oversaw the evaluations. The views presented here are those of the authors and not necessarily those of the sponsor or any helmet manufacturer. The impact testing and data were collected by Ms. Elizabeth McCalley at SIRC; her assistance is greatly appreciated. The data was analyzed by ProBiomechanics LLC without the involvement of SIRC. Dr. Chantal Parenteau merged, tabulated and analyzed the data at ProBiomechanics LLC; her assistance is also greatly appreciated.	[Anonymous], 1998, 00298M03 NOCSAE; [Anonymous], 1998, 02198M05 NOCSAE; [Anonymous], 2004, 00104M05 NOCSAE; BACKAITIS SH, 1994, HYBRID, V3; BISHOP PJ, 1984, AM J SPORT MED, V12, P233, DOI 10.1177/036354658401200313; Casson IR, 2008, NEUROSURGERY, V62, P204, DOI 10.1227/01.NEU.0000311079.65895.3E; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Hodgson V. R., 1980, INTERSCHOL ATHLETIC, V7, P11; Hodgson V. R., 1970, 14 STAPP CAR CRASH C; Hodgson V. R., 1972, 16 STAPP CAR CRASH C, V45, P1; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; HODGSON VR, 1985, UTILITY HEAD INJURY; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; Mertz HJ, 1996, 960099 SAE; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Myers Thomas J., 1993, Bio-Medical Materials and Engineering, V3, P15; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S., 2009, J BIOMECH ENG, V131, P610; Torg J S, 1999, Am J Orthop (Belle Mead NJ), V28, P128; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	31	37	37	0	30	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		175	184		10.1007/s10439-011-0395-1			10	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700016	21994057				2021-06-18	
S	Xiong, Y; Mahmood, A; Meng, YL; Zhang, YL; Zhang, ZG; Morris, DC; Chopp, M		Goldstein, AL; Garaci, E		Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Zhang, Zheng Gang; Morris, Daniel C.; Chopp, Michael			Neuroprotective and neurorestorative effects of thymosin beta 4 treatment following experimental traumatic brain injury	THYMOSINS IN HEALTH AND DISEASE II	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	3rd International Symposium on Thymosins in Health and Disease	MAR 14-16, 2012	Washington, DC	George Washington Univ, Ist Superiore Sanita (ISS), Univ Rome Tor Vergata		thymosin beta 4; traumatic brain injury; rat; neuroprotection; neurorestoration	ERYTHROPOIETIN ENHANCES NEUROGENESIS; ADULT HIPPOCAMPAL NEUROGENESIS; STROMAL CELL TRANSPLANTATION; CORTICAL IMPACT INJURY; DENTATE GYRUS; CLINICAL-TRIALS; NEURONAL DEATH; SPATIAL MEMORY; NITRIC-OXIDE; CA3 REGION	Traumatic brain injury (TBI) remains a leading cause of mortality and morbidity worldwide. No effective pharmacological treatments are available for TBI because all phase II/III TBI clinical trials have failed. This highlights a compelling need to develop effective treatments for TBI. Endogenous neurorestoration occurs in the brain after TBI, including angiogenesis, neurogenesis, synaptogenesis, oligodendrogenesis, and axonal remodeling, which may be associated with spontaneous functional recovery after TBI. However, the endogenous neurorestoration following TBI is limited. Treatments amplifying these neurorestorative processes may promote functional recovery after TBI. Thymosin beta 4 (T beta 4) is the major G-actin-sequestering molecule in eukaryotic cells. In addition, T beta 4 has other properties including antiapoptosis and anti-inflammation, promotion of angiogenesis, wound healing, stem/progenitor cell differentiation, and cell migration and survival, which provide the scientific foundation for the corneal, dermal, and cardiac wound repair multicenter clinical trials. Here, we describe T beta 4 as a neuroprotective and neurorestorative candidate for treatment of TBI.	[Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Morris, Daniel C.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS62002, PO1 NS42345, PO1 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345, P01NS023393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG038648] Funding Source: NIH RePORTER	The authors would like to thank Susan MacPhee-Gray for editorial assistance. T beta 4 was provided by RegeneRx Biopharmaceuticals, Inc. under the Materials Transfer Agreement. This work was supported by NIH Grants RO1 NS62002 (Ye Xiong), PO1 NS42345 (Asim Mahmood, Michael Chopp), and PO1 NS023393 (Michael Chopp).	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Crockford D, 2010, ANN NY ACAD SCI, V1194, P179, DOI 10.1111/j.1749-6632.2010.05492.x; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Dettin M, 2011, CELL IMMUNOL, V271, P299, DOI 10.1016/j.cellimm.2011.07.008; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo SZ, 2009, STROKE, V40, pS4, DOI 10.1161/STROKEAHA.108.534388; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Han HS, 2005, CURR NEUROVASC RES, V2, P409, DOI 10.2174/156720205774962647; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hastings NB, 2002, J COMP NEUROL, V452, P324, DOI 10.1002/cne.10386; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; Kempermann G, 2002, DEV BRAIN RES, V134, P1, DOI 10.1016/S0165-3806(01)00224-3; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kuhn HG, 2007, CURR PHARM BIOTECHNO, V8, P127; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Markakis EA, 1999, J COMP NEUROL, V406, P449; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Paxinos G, 1997, RAT BRAIN STEREOTACT; Philp D, 2003, FASEB J, V17, P2103, DOI 10.1096/fj.03-0121fje; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Smart Nicola, 2007, Angiogenesis, V10, P229, DOI 10.1007/s10456-007-9077-x; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2006, EXP EYE RES, V83, P502, DOI 10.1016/j.exer.2006.02.001; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; Taupin P, 2007, REGEN MED, V2, P51, DOI 10.2217/17460751.2.1.51; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yamashima T, 2007, REV NEUROSCIENCE, V18, P67; Yang XT, 2011, BRAIN RES BULL, V84, P1, DOI 10.1016/j.brainresbull.2010.09.008; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao YB, 2011, J CELL PHYSIOL, V226, P2798, DOI 10.1002/jcp.22624	86	37	38	0	9	BLACKWELL SCIENCE PUBL	OXFORD	OSNEY MEAD, OXFORD OX2 0EL, ENGLAND	0077-8923		978-1-57331-910-2	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2012	1270						51	58		10.1111/j.1749-6632.2012.06683.x			8	Biochemistry & Molecular Biology; Medicine, Research & Experimental; Multidisciplinary Sciences	Biochemistry & Molecular Biology; Research & Experimental Medicine; Science & Technology - Other Topics	BDB63	WOS:000312489700009	23050817	Green Accepted			2021-06-18	
J	Hu, SK; Xi, GH; Jin, H; He, YD; Keep, RF; Hua, Y				Hu, Shukun; Xi, Guohua; Jin, Hang; He, Yangdong; Keep, Richard F.; Hua, Ya			Thrombin-induced autophagy: A potential role in intracerebral hemorrhage	BRAIN RESEARCH			English	Article						Autophagy; Cell death; Cerebral hemorrhage; Thrombin	TRAUMATIC BRAIN-INJURY; CELL-DEATH; CEREBRAL-ISCHEMIA; MICE; MECHANISM; PATHWAY	Autophagy occurs in the brain after intracerebral hemorrhage (ICH) and thrombin contributes to ICH-induced brain injury and cell death. In this study, we investigated whether thrombin may activate autophagy (in vivo and in cultured astrocytes) and its potential role in ICH. Autophagy was examined using electron microscopy, conversion of light chain 3(LC3) from the LC3-I form to LC3-II, cathepsin D Western blotting and monodansylcadaverine (MDC) staining to detect autophagic vacuoles. 3-Methyladenine (3-MA) was used as an autophagy inhibitor. In vivo, we found that intracaudate injection of thrombin increased conversion of LC3-I to LC3-II, cathepsin D levels, and formation of autophagic vacuoles in the ipsilateral basal ganglia. ICH-induced upregulation of LC3-I to LC3-II conversion and cathepsin D levels was reduced by a thrombin inhibitor, hirudin. In cultured astrocytes, thrombin enhanced the conversion of LC3-I to LC3-II and increased MDC-labeled autophagic vacuoles. 3-MA inhibited thrombin-induced autophagic vacuole formation and exacerbated thrombin-induced cell death. These results indicate that thrombin activates autophagy in the brain and that thrombin has a role in ICH-induced autophagy. (C) 2011 Elsevier B.V. All rights reserved.	[Hu, Shukun; Xi, Guohua; Jin, Hang; He, Yangdong; Keep, Richard F.; Hua, Ya] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA	Hua, Y (corresponding author), Univ Michigan, Dept Neurosurg, R5018 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	yahua@umich.edu		Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-017760, NS-039866, NS-057539]; American Heart Association (AHA)American Heart Association [0840016N]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039866, R01NS017760, R01NS057539] Funding Source: NIH RePORTER	This study was supported by grants NS-017760, NS-039866 and NS-057539 from the National Institutes of Health (NIH) and 0840016N from American Heart Association (AHA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and AHA.	Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Araki T, 2006, CELL BIOL INT, V30, P93, DOI 10.1016/j.cellbi.2005.10.020; Gong Y, 2011, ACTA NEUROCHIR SUPPL, V111, P113, DOI 10.1007/978-3-7091-0693-8_18; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Hu HT, 2010, BRAIN RES, V1361, P93, DOI 10.1016/j.brainres.2010.09.025; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee JY, 2009, BRAIN RES, V1287, P126, DOI 10.1016/j.brainres.2009.06.028; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NITATORI T, 1995, J NEUROSCI, V15, P1001; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yang SX, 2008, STROKE, V39, P2079, DOI 10.1161/STROKEAHA.107.508911	25	37	40	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 18	2011	1424						60	66		10.1016/j.brainres.2011.09.062			7	Neurosciences	Neurosciences & Neurology	854IG	WOS:000297487600007	22015349	Green Accepted, Green Published			2021-06-18	
J	Bell, KR; Brockway, JA; Hart, T; Whyte, J; Sherer, M; Fraser, RT; Temkin, NR; Dikmen, SS				Bell, Kathleen R.; Brockway, Jo Ann; Hart, Tessa; Whyte, John; Sherer, Mark; Fraser, Robert T.; Temkin, Nancy R.; Dikmen, Sureyya S.			Scheduled Telephone Intervention for Traumatic Brain Injury: A Multicenter Randomized Controlled Trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation; Telephone; Treatment outcome	ROUTINE FOLLOW-UP; PARTICIPATION ASSESSMENT; FAMILY CAREGIVERS; PRIMARY-CARE; REHABILITATION; DEPRESSION; PSYCHOTHERAPY; MANAGEMENT; MODERATE; SCALE	Bell KR, Brockway JA, Hart T, Whyte J, Sherer M, Fraser RT, Temkin NR, Dikmen SS. Scheduled telephone intervention for traumatic brain injury: a multicenter randomized controlled trial. Arch Phys Med Rehabil 2011;92: 1552-60. Objective: To evaluate the effect of a Scheduled Telephone Intervention (STI) compared with usual care (UC) on function, health/emotional status, community/work activities, and well-being at 1 and 2 years after traumatic brain injury (TBI). Design: Two group, randomized controlled trial. Setting: Telephone contacts with subjects recruited in inpatient rehabilitation. Participants: Eligible subjects (N=433) with TBI (age>16y) were randomly assigned to STI plus UC (n=210) or UC (n=223) at discharge. STI subjects (n=169) completed the outcome at year 1 (118 at year 2) and 174 UC subjects at year 1 (123 at year 2). Interventions: STI subjects received calls at 2 and 4 weeks and 2, 3, 5, 7, 9, 12, 15, 18, and 21 months consisting of brief training in problem solving, education, or referral. Main Outcome Measures: A composite outcome at 1 year was the primary endpoint. Analysis on intent-to-treat basis used linear regression adjusted for site, Glasgow Coma Scale, race/ethnicity, age, FIM, sex, and Disability Rating Scale (DRS). Secondary analyses were conducted on individual and composite measures (FIM, DRS, community participation indicators, Glasgow Outcome Scale [Extended], Short Form-12 Health Survey, Brief Symptom Inventory-18, EuroQOL, and modified Perceived Quality of Life). Results: No significant differences were noted between the groups at years 1 or 2 for primary (P=.987 regression for year 1, P=.983 for year 2) or secondary analyses. Conclusions: This study failed to replicate the findings of a previous single center study of telephone-based counseling. While telephone mediated treatment has shown promise in other studies, this model of flexible counseling in problem solving and education for varied problems was not effective over and above usual care.	[Bell, Kathleen R.; Brockway, Jo Ann; Fraser, Robert T.; Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Hart, Tessa; Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA	Bell, KR (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	krbell@uw.edu		Bell, Kathleen/0000-0002-0928-2046; Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research, Department of Education [H133A040004, H133A020508, H133A070040, H133A70033]	Supported by the National Institute on Disability and Rehabilitation Research, Department of Education (grant nos. H133A040004, H133A020508, H133A070040, H133A70033).	Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Campbell C H, 1988, Rehabil Nurs, V13, P320; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Engli M, 1993, J Neurosci Nurs, V25, P78; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feenstra TL, 2005, VALUE HEALTH, V8, P178, DOI 10.1111/j.1524-4733.2005.04008.x; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fortney JC, 2007, J GEN INTERN MED, V22, P1086, DOI 10.1007/s11606-007-0201-9; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Johnson K, 2000, Intensive Crit Care Nurs, V16, P144, DOI 10.1054/iccn.2000.1478; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Mittag O, 2006, INT J REHABIL RES, V29, P295, DOI 10.1097/MRR.0b013e328010ba9a; Mohr DC, 2005, ARCH GEN PSYCHIAT, V62, P1007, DOI 10.1001/archpsyc.62.9.1007; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paterson B, 2001, Rehabil Nurs, V26, P48; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PONSFORD J, 2003, BRAIN INJURY, P17453; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Smith J E, 2000, Care Manag J, V2, P27; Spearman RC, 2007, BRAIN INJURY, V21, P837, DOI 10.1080/02699050701426857; The EuroQol Group, 1990, HLTH POLICY, V16, P199; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	37	38	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2011	92	10					1552	1560		10.1016/j.apmr.2011.05.018			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	833DE	WOS:000295861200004	21963122				2021-06-18	
J	Gao, JH; Hu, J; Buckley, T; White, K; Hass, C				Gao, Jianbo; Hu, Jing; Buckley, Thomas; White, Keith; Hass, Chris			Shannon and Renyi Entropies to Classify Effects of Mild Traumatic Brain Injury on Postural Sway	PLOS ONE			English	Article							COLLEGIATE FOOTBALL PLAYERS; CONCUSSION ASSESSMENT; TIME-SERIES; HEAD-INJURY; STABILITY; ENCEPHALOPATHY; COMPLEXITY; DEFICITS; IMPACT	Background: Mild Traumatic Brain Injury (mTBI) has been identified as a major public and military health concern both in the United States and worldwide. Characterizing the effects of mTBI on postural sway could be an important tool for assessing recovery from the injury. Methodology/Principal Findings: We assess postural sway by motion of the center of pressure (COP). Methods for data reduction include calculation of area of COP and fractal analysis of COP motion time courses. We found that fractal scaling appears applicable to sway power above about 0.5 Hz, thus fractal characterization is only quantifying the secondary effects (a small fraction of total power) in the sway time series, and is not effective in quantifying long-term effects of mTBI on postural sway. We also found that the area of COP sensitively depends on the length of data series over which the COP is obtained. These weaknesses motivated us to use instead Shannon and Renyi entropies to assess postural instability following mTBI. These entropy measures have a number of appealing properties, including capacity for determination of the optimal length of the time series for analysis and a new interpretation of the area of COP. Conclusions: Entropy analysis can readily detect postural instability in athletes at least 10 days post-concussion so that it appears promising as a sensitive measure of effects of mTBI on postural sway. Availability: The programs for analyses may be obtained from the authors.	[Gao, Jianbo] PMB Intelligence LLC, W Lafayette, IN USA; [Hu, Jing] Affymetrix Inc, Santa Clara, CA USA; [Buckley, Thomas] Georgia So Univ, Grad Athlet Training Program, Statesboro, GA 30460 USA; [White, Keith] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA; [Hass, Chris] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA	Gao, JH (corresponding author), PMB Intelligence LLC, W Lafayette, IN USA.	jbgao@pmbintelligence.com	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; White, Keith/0000-0002-4442-5743	Army Research Office [56382LSJDO, W911NF-10-1-0425]; Div Of Civil, Mechanical, & Manufact InnNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1031958] Funding Source: National Science Foundation	This work was supported in part by Army Research Office grants #56382LSJDO and #W911NF-10-1-0425. The views expressed herein are those of the authors and do not reflect the views of the Army Research Office. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amoud H, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-12; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Duarte M, 2008, EXP BRAIN RES, V191, P265, DOI 10.1007/s00221-008-1521-7; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gao J.B., 2007, MULTISCALE ANAL COMP; Gao JB, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016117; Gao JB, 2011, PLOS ONE IN PRESS; Gao JB, 2010, IEEE SIGNAL PROC LET, V17, P237, DOI 10.1109/LSP.2009.2037773; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu J, 2009, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2009/02/P02066; Hunt T, 2010, CLIN SPORT MED, V29, P5, DOI 10.1016/j.csm.2009.09.002; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mandelbrot B.B, 1982, FRACTAL GEOMETRY NAT; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PENG CK, 1994, PHYS REV E, V49, P1685, DOI 10.1103/PhysRevE.49.1685; Riley MA, 2002, J MOTOR BEHAV, V34, P99, DOI 10.1080/00222890209601934; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Thurner S, 2002, AUDIOL NEURO-OTOL, V7, P240, DOI 10.1159/000063740; Tung WW, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.046210; Valovich TC, 2003, J ATHL TRAINING, V38, P51	37	37	37	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2011	6	9							e24446	10.1371/journal.pone.0024446			8	Multidisciplinary Sciences	Science & Technology - Other Topics	819CN	WOS:000294803100033	21931720	DOAJ Gold, Green Published			2021-06-18	
J	Bay, E; de-Leon, MB				Bay, Esther; de-Leon, Marita B.			Chronic Stress and Fatigue-Related Quality of Life After Mild to Moderate Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fatigue; psychological; quality of life; stress; traumatic brain injury	IMPACT SCALE; EVENT SCALE; HEAD-INJURY; SYMPTOMS; INDIVIDUALS; VALIDATION; COMPLAINTS; RECOVERY	Objective: To determine relationships among chronic stress, fatigue-related quality of life (QOL-F), and related covariates after mild to moderate traumatic brain injury (TBI). Design: Observational and cross-sectional. Participants: A total of 84 community-dwelling individuals with mild to moderate TBI recruited from multiple out patient rehabilitation clinics assessed on average 15 months after injury. Method: Self-report surveys and chart abstraction. Measures: Neurofunctional Behavioral Inventory, Perceived Stress Scale-14, Impact of Events Scale, McGill Pain Short-form Scale, and modified version of the Fatigue Impact Scale. Results: QOL-F was associated with somatic symptoms, perceived situational stress, but not with event-related stress (posttraumatic stress disorder symptoms) related to index TBI, preinjury demographic, or postinjury characteristics. Somatic symptoms and chronic situational stress accounted for 42% of the variance in QOL-F. Conclusions: QOL-F in community-dwelling individuals with mild to moderate TBI is associated with chronic situational stress and somatic symptoms. Symptom management strategies may need to include general stress management to reduce fatigue burden and improve quality of life.	[Bay, Esther; de-Leon, Marita B.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA	Bay, E (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 300, Ann Arbor, MI 48108 USA.	pdq@med.umich.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Medical Rehabilitation Research [5-T32-HD007422-17]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007422] Funding Source: NIH RePORTER	This study was funded by Office of Vice-President of Research to Dr. Bay at Michigan State University. Dr de-Leon was supported by the National Institutes of Health, the National Institute of Child Health and Human Development, the National Center for Medical Rehabilitation Research grant 5-T32-HD007422-17.	ARNDT M, 2009, P SPARR MED CTR MSU; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/088971804780957108; Bay E, 2009, WESTERN J NURS RES, V31, P731, DOI 10.1177/0193945909334856; Bay E, 2009, BIOL RES NURS, V10, P213, DOI 10.1177/1099800408326453; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1995, MEASURING STRESS AGU; COHEN SA, 1992, PSYCHOL BULL, P155; de Leon MB, 2009, ARCH PHYS MED REHAB, V90, P956, DOI 10.1016/j.apmr.2008.12.016; DELUCA J, 2005, FATIGUE ITS DEFINITI; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Ferrans CE, 2005, J NURS SCHOLARSHIP, V37, P336, DOI 10.1111/j.1547-5069.2005.00058.x; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Fisk JD, 2002, QUAL LIFE RES, V11, P263, DOI 10.1023/A:1015295106602; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; MCEWEN B, 2002, END STRESS WE KNOW I; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Tellez N, 2005, MULT SCLER J, V11, P198, DOI 10.1191/1352458505ms1148oa; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Whitehead L, 2009, J PAIN SYMPTOM MANAG, V37, P107, DOI 10.1016/j.jpainsymman.2007.08.019; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	37	37	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2011	26	5					355	363		10.1097/HTR.0b013e3181f20146			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	814VO	WOS:000294485500004	21169862	Green Accepted			2021-06-18	
J	Liu, W; Shen, Y; Plane, JM; Pleasure, DE; Deng, WB				Liu, Wei; Shen, Yan; Plane, Jennifer M.; Pleasure, David E.; Deng, Wenbin			Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia	EXPERIMENTAL NEUROLOGY			English	Article						Erythropoietin; Carbamylated erythropoietin; White matter injury; Oligodendrocyte; Microglia; PARP-1; Hypoxia-ischemia; Lipopolysaccharide; Periventricular leukomalacia	APOPTOSIS-INDUCING FACTOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; WHITE-MATTER INJURY; POLY(ADP-RIBOSE) POLYMERASE-1; CELL-DEATH; NEUROLOGICAL FUNCTION; NEONATAL STROKE	Periventricular leukomalacia (PVL) is the predominant pathology in premature infants, characterized by prominent cerebral white matter injury, and commonly caused by hypoxia-ischemia and inflammation. Activated microglia trigger white matter damage and play a major role in the development of PVL Erythropoietin (EPO) and its derivative carbamylated erythropoietin (CEPO) have been shown to be neuroprotective in several brain disease models. Here we investigated whether EPO and CEPO could provide protection in mouse models of PVL induced by hypoxia-ischemia or hypoxia-ischemia-inflammation. We administered EPO or CEPO to mice with PVL, and found that both EPO and CEPO treatments decreased microglia activation, oligodendrocyte damage and myelin depletion. We also noted improved performance in neurological function assays. Inhibited disease progression in PVL mice by EPO or CEPO treatment was associated with decreased poly-(ADP-ribose) polymerase-1 (PARP-1) activity. PARP-1 activity was increased dramatically in activated microglia in untreated mice with PVL Furthermore, we demonstrated that the neuroprotective properties of EPO and CEPO were diminished after PARP-1 gene depletion. The therapeutic doses of EPO and CEPO used in this study did not interfere with normal oligodendrocyte maturation and myelination. Together, our data demonstrate that EPO and CEPO are neuroprotective in cerebral white matter injury via a novel microglial PARP-1 dependent mechanism, and hold promise as a future treatment for PVL and other hypoxic-ischemic/inflammatory white matter diseases. (C) 2011 Elsevier Inc. All rights reserved.	[Liu, Wei; Shen, Yan; Plane, Jennifer M.; Deng, Wenbin] Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; [Pleasure, David E.] Univ Calif Davis, Sch Med, Dept Neurol, Sacramento, CA 95817 USA; [Pleasure, David E.; Deng, Wenbin] Shriners Hosp Calif, Inst Pediat Regenerat Med, Sacramento, CA 95817 USA	Deng, WB (corresponding author), UC Davis Sch Med, Dept Cell Biol & Human Anat, Inst Pediat Regenerat Med, Shriners Hosp Children, Room 653,2425 Stockton Blvd, Sacramento, CA 95817 USA.	wbdeng@ucdavis.edu	tao, li/G-7956-2011		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS059043, R01 ES015988]; Roche Foundation for Anemia Research (RoFAR); National Multiple Sclerosis SocietyNational Multiple Sclerosis Society; Feldstein Medical Foundation; Shriners Hospitals for Children; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD087566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES015988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059043] Funding Source: NIH RePORTER	We thank Warren Pharmaceuticals, Ossining, NY and H. Lundbeck A/S, Denmark for generously providing carbamylated erythropoietin. This study was supported by grants to W.D. from the NIH (R01 NS059043 and R01 ES015988), Roche Foundation for Anemia Research (RoFAR), National Multiple Sclerosis Society, Feldstein Medical Foundation, and Shriners Hospitals for Children. The authors declare no conflicts of interest.	Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; Billiards SS, 2006, J COMP NEUROL, V497, P199, DOI 10.1002/cne.20991; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Buntinx M, 2004, J NEUROSCI RES, V76, P834, DOI 10.1002/jnr.20118; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Csete M, 2004, NEUROSCI LETT, V359, P124, DOI 10.1016/j.neulet.2004.01.068; Dammann O, 2002, MENT RETARD DEV D R, V8, P46, DOI 10.1002/mrdd.10005; Deng WB, 2008, ARCH NEUROL-CHICAGO, V65, P1291, DOI 10.1001/archneur.65.10.1291; Deng WB, 2010, NAT REV NEUROL, V6, P328, DOI 10.1038/nrneurol.2010.53; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Follett PL, 2000, J NEUROSCI, V20, P9235; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Goncalves LF, 2002, MENT RETARD DEV D R, V8, P3, DOI 10.1002/mrdd.10008; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Gonzalez FF, 2009, DEV NEUROSCI-BASEL, V31, P403, DOI 10.1159/000232558; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Iwai M, 2010, STROKE, V41, P1032, DOI 10.1161/STROKEAHA.109.570325; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Li JR, 2005, P NATL ACAD SCI USA, V102, P9936, DOI 10.1073/pnas.0502552102; Li XL, 2010, J NEUROCHEM, V113, P1012, DOI 10.1111/j.1471-4159.2010.06667.x; Lykissas MG, 2007, CLIN NEUROL NEUROSUR, V109, P639, DOI 10.1016/j.clineuro.2007.05.013; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Martin JA, 2008, PEDIATRICS, V121, P788, DOI 10.1542/peds.2007-3753; McPherson RJ, 2010, CURR OPIN PEDIATR, V22, P139, DOI 10.1097/MOP.0b013e328336eb57; Milano M, 2005, J Oncol Pharm Pract, V11, P145, DOI 10.1191/1078155205jp162oa; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Nakajima H, 2004, J BIOL CHEM, V279, P42774, DOI 10.1074/jbc.M407923200; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Pang Y, 2005, J NEUROSCI RES, V80, P226, DOI 10.1002/jnr.20450; Platt MJ, 2007, LANCET, V369, P43, DOI 10.1016/S0140-6736(07)60030-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rees S, 2010, J NEUROPATH EXP NEUR, V69, P306, DOI 10.1097/NEN.0b013e3181d27138; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; Segovia KN, 2008, ANN NEUROL, V63, P520, DOI 10.1002/ana.21359; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tomimatsu T, 2002, BRAIN RES, V926, P108, DOI 10.1016/S0006-8993(01)03311-X; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; van der Kooij MA, 2008, BRAIN RES REV, V59, P22, DOI 10.1016/j.brainresrev.2008.04.007; Veto S, 2010, BRAIN, V133, P822, DOI 10.1093/brain/awp337; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Volpe JJ, 2005, PEDIATRICS, V116, P221, DOI 10.1542/peds.2005-0191; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wei L, 2006, J PHARMACOL EXP THER, V317, P109, DOI 10.1124/jpet.105.094391; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	67	37	46	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2011	230	2					227	239		10.1016/j.expneurol.2011.04.021			13	Neurosciences	Neurosciences & Neurology	783CF	WOS:000292058400009	21596035	Green Accepted			2021-06-18	
J	Melo, JRT; Di Rocco, F; Blanot, S; Cuttaree, H; Sainte-Rose, C; Oliveira, J; Zerah, M; Meyer, PG				Tude Melo, Jose Roberto; Di Rocco, Federico; Blanot, Stephane; Cuttaree, Harry; Sainte-Rose, Christian; Oliveira-Filho, Jamary; Zerah, Michel; Meyer, Philippe G.			Transcranial Doppler can predict intracranial hypertension in children with severe traumatic brain injuries	CHILDS NERVOUS SYSTEM			English	Article						Traumatic brain injury; Brain lesion; Intracranial pressure; Cerebral perfusion pressure; Children; Transcranial Doppler	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; SUBARACHNOID HEMORRHAGE; INITIAL MANAGEMENT; SALVADOR CITY; BLOOD-FLOW; EXPERIENCE; VASOSPASM; FRANCE	Purpose The purpose of this study is to evaluate the accuracy of emergency Transcranial Doppler (TCD) to predict intracranial hypertension and abnormal cerebral perfusion pressure in children with severe traumatic brain injury (TBI). Patients and methods A descriptive and retrospective cross-sectional study was designed through data collected from medical records of children with severe TBI (Glasgow coma scale a parts per thousand currency sign8), admitted to a level I pediatric trauma center, between January 2000 and December 2005. Early TCD examination was performed upon admission, and TCD profiles were considered as altered using previously validated threshold values for diastolic velocity (< 25 cm/s) and pulsatility index (> 1.31) or when no-flow/backflow was detected. Invasive intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring were considered as the gold standard to measure intracranial hypertension (ICH). Statistical analyses compared TCD profiles to increased ICP (a parts per thousand yen20 mmHg) and abnormal cerebral perfusion pressure (< 50 mmHg) at admission. Results Non-invasive TCD and ICP monitoring were performed in 117 severe head-injured children. Mean age was 7.6 +/- 4.4 years, with a male prevalence (71%). Median initial Glasgow coma scale was 6. TCD had 94% of sensitivity to identify ICH at admission and a negative predict value of 95% to identify normal ICP at admission. Its sensitivity to predict abnormal cerebral perfusion pressure was 80%. Conclusions The high sensitivity of admission TCD to predict ICH and abnormal CPP after trauma demonstrates that TCD is an excellent first-line examination to determine those children who need urgent aggressive treatment and continuous invasive ICP monitoring.	[Blanot, Stephane; Cuttaree, Harry; Meyer, Philippe G.] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Pediat Surg Crit Care Unit, Paris, France; [Tude Melo, Jose Roberto; Oliveira-Filho, Jamary] Univ Fed Bahia, Sch Med, BR-41170290 Salvador, BA, Brazil; [Tude Melo, Jose Roberto; Di Rocco, Federico; Sainte-Rose, Christian; Zerah, Michel] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Pediat Neurosurg, Paris, France	Melo, JRT (corresponding author), Alameda Jasmins 200,Apt 702B, BR-40296200 Salvador, BA, Brazil.	robertotude@gmail.com	Oliveira-Filho, Jamary/B-6441-2016; ZERAH, Michel/E-6473-2012; DI ROCCO, Federico/C-6343-2015; Meyer, Philippe/ABE-4242-2020	Oliveira-Filho, Jamary/0000-0003-1915-0423; Meyer, Philippe/0000-0002-3829-6631; Di Rocco, Federico/0000-0003-2145-5533	CAPES-Brazil (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	CAPES-Brazil (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) funded Jose Roberto Tude Melo's studies abroad.	Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Bardella IJ, 1999, AM FAM PHYSICIAN, V60, P1743; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Bekar A, 2008, NEUROL RES, V30, P465, DOI 10.1179/174313208X284269; Bellner Johan, 2005, Lakartidningen, V102, P840; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE2; De Riggo Julius, 2007, Biomedical Papers (Olomouc), V151, P285; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Hindy-Francois C, 2009, TRANSPLANTATION, V87, P616, DOI 10.1097/TP.0b013e3181963d91; Javouhey E, 2009, PEDIATR CRIT CARE ME, V10, P472, DOI 10.1097/PCC.0b013e318198b1cb; Jesus PAP, 2006, ARQ NEURO-PSIQUIAT, V64, P207, DOI 10.1590/S0004-282X2006000200007; Melo JRT, 2004, ARQ NEURO-PSIQUIAT, V62, P711, DOI 10.1590/S0004-282X2004000400027; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; Meyer P G, 2001, Curr Opin Crit Care, V7, P81, DOI 10.1097/00075198-200104000-00005; Meyer PG, 2005, CHILD NERV SYST, V21, P133, DOI 10.1007/s00381-004-1016-1; Murillo-Cabezas F, 2002, NEUROCIRUGIA, V13, P196; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; Ng SCP, 2006, ACTA NEUROCHIR SUPPL, V96, P21; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Ricard-Hibon A, 2000, ANN FR ANESTH, V19, P286; Melo JRT, 2006, ARQ NEURO-PSIQUIAT, V64, P994, DOI 10.1590/S0004-282X2006000600020; Rodriguez-Nunez A, 2008, J NEUROSURG SCI, V52, P17; SAFIN AM, 2007, ZH VOPR NEIROKHIR IM, V2, P16; Sviri GE, 2006, STROKE, V37, P2738, DOI 10.1161/01.STR.0000244765.29502.85; Takahashi K, 2008, NEUROL SURG TOKYO, V36, P901; TER MA, 2002, CRIT CARE MED, V30, P1616; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Trabold F, 2002, ANN FR ANESTH, V21, P141, DOI 10.1016/S0750-7658(01)00513-5; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Visocchi M, 2008, ACT NEUR S, V101, P137; Visocchi M, 2007, ACTA NEUROCHIR, V149, P347, DOI 10.1007/s00701-006-1102-0	41	37	39	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JUN	2011	27	6					979	984		10.1007/s00381-010-1367-8			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	762NU	WOS:000290487400019	21207041				2021-06-18	
J	Dagal, A; Lam, AM				Dagal, Armagan; Lam, Arthur M.			Cerebral blood flow and the injured brain: how should we monitor and manipulate it?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral blood flow; cerebral oximetry; laser Doppler flowmetry; neuromonitoring; transcranial Doppler ultrasonography	INTENSIVE-CARE-UNIT; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; TRANSCRANIAL DOPPLER; TISSUE OXYGEN; AUTOREGULATION; ISCHEMIA; REACTIVITY; MANAGEMENT; OXIMETRY	Purpose of review Cerebral ischemia plays a major role in the pathophysiology of the injured brain, including traumatic brain injury and subarachnoid hemorrhage, thus improvement in outcome may necessitate monitoring and optimization of cerebral blood flow (CBF). To interpret CBF results in a meaningful way, it may be necessary to quantify cerebral autoregulation as well as cerebral metabolism. This review addresses the recent evidence related to the changes in CBF and its monitoring/management in traumatic brain injury. Recent findings Recent evidence on the management of patients with traumatic brain injury have focused on the importance of cerebral autoregulation in maintaining perfusion, which necessitates the measurement of CBF. However, adequate CBF measurements alone would not indicate the amount of oxygen delivered to neuronal tissues. Technologic advancements in measurement devices have enabled the assessment of the metabolic state of the cerebral tissue for the purpose of guiding therapy, progress as well as prognostification. Summary Current neurocritical care management strategies are focused on the prevention and limitation of secondary brain injury where neuronal insult continues to evolve during the hours and days after the primary injury. Appropriately chosen multimodal monitoring including CBF and management measures can result in reduction in mortality and morbidity.	[Lam, Arthur M.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA 98104 USA; [Dagal, Armagan] Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA	Lam, AM (corresponding author), Swedish Med Ctr, Swedish Neurosci Inst, 500 17th St,226W, Seattle, WA 98104 USA.	Arthur.lam@swedish.org					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Artru F, 2004, J NEUROSURG ANESTH, V16, P226, DOI 10.1097/00008506-200407000-00007; Barazangi N, 2008, NEUROL INDIA, V56, P405; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Butcher K, 2010, CAN J NEUROL SCI, V37, P17, DOI 10.1017/S0317167100009604; Calderon-Arnulphi M, 2009, NEUROL RES, V31, P605, DOI 10.1179/174313209X383286; Chesnut RM, 2004, CRIT CARE CLIN, V20, P25, DOI 10.1016/S0749-0704(03)00090-3; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Daboussi A, 2009, J NEUROSURG ANESTH, V21, P339, DOI 10.1097/ANA.0b013e3181b1dbba; Dagal A, 2009, CURR OPIN ANESTHESIO, V22, P547, DOI 10.1097/ACO.0b013e32833020be; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Giustiniano E, 2010, J CARDIOVASC MED, V11, P522, DOI 10.2459/JCM.0b013e32833246e7; Highton D, 2010, CURR OPIN ANESTHESIO, V23, P576, DOI 10.1097/ACO.0b013e32833e1536; Hirsch Jennifer C, 2010, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V13, P51, DOI 10.1053/j.pcsu.2010.01.005; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hoeffner EG, 2005, J NEURO-OPHTHALMOL, V25, P313, DOI 10.1097/01.wno.0000189832.00129.2e; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kim DH, 2006, NEUROCRIT CARE, V4, P77, DOI 10.1385/NCC:4:1:077; Kincaid MS, 2008, CURR OPIN ANESTHESIO, V21, P552, DOI 10.1097/ACO.0b013e32830edc0b; Klaessens JHGM, 2003, PHYSIOL MEAS, V24, pN35, DOI 10.1088/0967-3334/24/4/N03; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lee SC, 2005, J CLIN NEUROSCI, V12, P520, DOI 10.1016/j.jocn.2004.07.016; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Littlejohns Linda R, 2003, Crit Care Nurse, V23, P17; Littlejohns LR, 2003, CRIT CARE NURSE, V23, P6; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Martin KK, 2009, AM J SURG, V197, P55, DOI 10.1016/j.amjsurg.2007.12.060; MATTA BF, 1994, ANESTH ANALG, V79, P745; Molina Carlos A, 2007, Cerebrovasc Dis, V24 Suppl 1, P1, DOI 10.1159/000107373; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Pennekamp CWA, 2009, EUR J VASC ENDOVASC, V38, P539, DOI 10.1016/j.ejvs.2009.07.008; Rigamonti A, 2008, CAN J ANAESTH, V55, P112, DOI 10.1007/BF03016323; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; SHARMA D, 2010, NEUROCRIT CARE; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Springborg JB, 2005, BRIT J ANAESTH, V94, P259, DOI 10.1093/bja/aei004; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vohra Hunaid A, 2009, Interact Cardiovasc Thorac Surg, V9, P318, DOI 10.1510/icvts.2009.206367; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; Wright WL, 2007, J NEUROL SCI, V261, P10, DOI 10.1016/j.jns.2007.04.027	52	37	42	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					131	137		10.1097/ACO.0b013e3283445898			7	Anesthesiology	Anesthesiology	732AS	WOS:000288154100003	21386665				2021-06-18	
J	Resch, JE; May, B; Tomporowski, PD; Ferrara, MS				Resch, Jacob E.; May, Bryson; Tomporowski, Phillip D.; Ferrara, Michael S.			Balance Performance With a Cognitive Task: A Continuation of the Dual-Task Testing Paradigm	JOURNAL OF ATHLETIC TRAINING			English	Article						posture; stability; executive function; response time; concussions; mild traumatic brain injuries	MILD HEAD-INJURY; POSTURAL CONTROL; STABILITY; CONCUSSION; LOAD; SWAY	Context: To ensure that concussed athletes return to play safely, we need better methods of measuring concussion severity and monitoring concussion resolution. Objective: To develop a dual-task model that assesses postural stability and cognitive processing in concussed athletes. Design: Repeated measures study. Setting: University laboratory. Patients or Other Participants: Twenty healthy, college-aged students (10 men, 10 women; age = 20 +/- 1.86 years, height = 173 +/- 4.10 cm, mass = 71.83 + 35.77 kg). Intervention(s): Participants were tested individually in 2 sessions separated by 2 days. In one session, a balance task and a cognitive task were performed separately. In the other session, the balance and cognitive tasks were performed concurrently. The balance task consisted of 6 conditions of the Sensory Organization Test performed on the NeuroCom Smart Balance Master. The cognitive task consisted of an auditory switch task (3 trials per condition, 60 seconds per trial). Main Outcome Measure(s): For the balance test, scores for each Sensory Organization Test condition; the visual, vestibular, somatosensory, and visual-conflict subscores; and the composite balance score were calculated. For the cognitive task, response time and accuracy were measured. Results: Balance improved during 2 dual-task conditions: fixed support and fixed visual reference (t(18) = -2.34, P < .05) and fixed support and sway visual reference (t(18) = -2.72, P = .014). Participants' response times were longer (F(1,18) = 67.77, P < .001, eta(2) = 0.79) and choice errors were more numerous under dual-task conditions than under single-task conditions (F(1,18) = 5.58, P = .03, eta(2) = 0.24). However, differences were observed only during category-switch trials. Conclusions: Balance was either maintained or improved under dual-task conditions. Thus, postural control took priority over cognitive processing when the tasks were performed concurrently. Furthermore, dual-task conditions can isolate specific mental processes that may be useful for evaluating concussed individuals.	[Resch, Jacob E.; Ferrara, Michael S.] St Marys Athlet Training Res & Educ Lab, Athens, GA USA; [May, Bryson; Tomporowski, Phillip D.] Univ Georgia, Cognit & Skill Acquisit Lab, Dept Kinesiol, Athens, GA 30602 USA	Resch, JE (corresponding author), Univ Texas Arlington, Dept Kinesiol, Maverick Act Ctr 113, Arlington, TX 76019 USA.	resch@uta.edu		Resch, Jacob/0000-0001-6031-3197			Andersson G, 2002, BRAIN RES BULL, V58, P135, DOI 10.1016/S0361-9230(02)00770-0; Barra J, 2006, EXP BRAIN RES, V174, P734, DOI 10.1007/s00221-006-0519-2; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; KERR B, 1985, J EXP PSYCHOL HUMAN, V11, P617, DOI 10.1037/0096-1523.11.5.617; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Martin JH, 1996, NEUROANATOMY TEXT AT, P323; MAXWELL SE, 2004, DESIGNING EXPT ANAL, P641; May B, 2009, MIL MED, V174, P1308, DOI 10.7205/MILMED-D-00-0809; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; *NEUROCOM INT INC, 2001, NEUROCOM SYST OP MAN, P1; PETERSON C, 2002, THESIS U GEORGIA ATH; Rankin JK, 2000, J GERONTOL A-BIOL, V55, pM112, DOI 10.1093/gerona/55.3.M112; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; Vuillerme N, 2004, BRAIN RES BULL, V63, P161, DOI 10.1016/j.brainresbull.2004.02.006; Vuillerme N, 2000, NEUROSCI LETT, V291, P77, DOI 10.1016/S0304-3940(00)01374-4; Vuillerme N, 2007, PSYCHOL RES-PSYCH FO, V71, P192, DOI 10.1007/s00426-005-0018-2	24	37	41	0	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2011	46	2					170	175		10.4085/1062-6050-46.2.170			6	Sport Sciences	Sport Sciences	737QY	WOS:000288584500009	21391802	Bronze, Green Published			2021-06-18	
J	Alley, MD; Schimizze, BR; Son, SF				Alley, Matthew D.; Schimizze, Benjamin R.; Son, Steven F.			Experimental modeling of explosive blast-related traumatic brain injuries	NEUROIMAGE			English	Article							HEAD IMPACT; BIOMECHANICS; MECHANISM; WAVES	This study aims to characterize the interaction of explosive blast waves through simulated anatomical systems. We have developed physical models and a systematic approach for testing traumatic brain injury (TBI) mechanisms and occurrences. A simplified series of models consisting of spherical poly(methyl methacrylate) (PMMA) shells housing synthetic gelatins as brain simulants have been utilized. A series of experiments was conducted to compare the sensitivity of the system response to mechanical properties of the simulants under high strain-rate explosive blasts. Small explosive charges were directed at the models to produce a realistic blast wave in a scaled laboratory setting. Blast profiles were measured and analyzed to compare system response severity. High-speed shadowgraph imaging captured blast wave interaction with the head model while particle tracking captured internal response for displacement and strain correlation. The results suggest amplification of shock waves inside the head near material interfaces due to impedance mismatches. In addition, significant relative displacement was observed between the interacting materials suggesting large strain values of nearly 5%. Further quantitative results were obtained through shadowgraph imaging of the blasts confirming a separation of time scales between blast interaction and bulk movement. These results lead to a conclusion that primary blast effects may potentially contribute significantly to the occurrence of military associated TBI. Published by Elsevier Inc.	[Alley, Matthew D.; Schimizze, Benjamin R.; Son, Steven F.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA	Alley, MD (corresponding author), 325 S Windstone CT, Bloomington, IN 47403 USA.	mdalley.purdue.me@gmail.com; bschimiz@purdue.edu; sson@purdue.edu		Son, Steven/0000-0001-7498-2922	JIEDDO/ARO [W911NF-07-1-0035]	The authors would also like to acknowledge and thank the collaborations of Professor Raul Radovitzky and supportive students of the Massachusetts Institute of Technology as well as the support from JIEDDO/ARO ("Mechanical Properties Measurements and Blast Loading Experiments on Brains for Model Calibration and Validation," Contract #: W911NF-07-1-0035) through research funding. Data collection and documentation was completed by the listed authors however, monetary and intellectual resources were provided through the referenced sponsorship.	ALLEN RM, 2003, EXPT NUMERICAL STUDY; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BOUAMOUL A, 2007, 23 INT S BALL TARR S; Bowen I., 1968, DASA2113; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cooper P., 1996, EXPLOSIVES ENG; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; FOURNIER E, 2007, BLAST HEADFORM DEV D, P56; Fox R.W., 2004, INTRO FLUID MECH, V6th; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Halabieh O, 2008, LECT NOTES COMPUT SC, V5104, P107, DOI 10.1007/978-3-540-70521-5_12; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Kinney G.F., 1985, EXPLOSIVE SHOCKS AIR; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; *MIT, 2008, MIT TBI SEL HEAD MAT; PRABHU R, 2008, LOW STRAIN RATE MECH; RADOVITZKY R, 2007, MECH PROPERTIES MEAS; Roberts JC, 2005, J HOPKINS APL TECH D, V26, P84; Settles G. S., 2006, SCHLIEREN SHADOWGRAP; Settles GS, 2006, AM SCI, V94, P22, DOI 10.1511/2006.1.22; Simmonds K., 2004, NRL REV, P156; SOCRATE S, 2008, LOW STRAIN RATE MECH; STEWART C, 2006, BLAST INJURIES, P88; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TAYLOR PA, 2007, BRAIN INJURY, P7; Wang ZL, 2003, MIL MED, V168, P330; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilson C., 2007, IMPROVISED EXPLOSIVE; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014; Ziejewski M., 2007, BRAIN INJ PROF, V4, P10	32	37	37	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JAN	2011	54			1			S45	S54		10.1016/j.neuroimage.2010.05.030			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600007	20580931				2021-06-18	
J	Tobinick, E				Tobinick, Edward			Rapid Improvement of Chronic Stroke Deficits after Perispinal Etanercept Three Consecutive Cases	CNS DRUGS			English	Article							TUMOR-NECROSIS-FACTOR; MONTREAL COGNITIVE ASSESSMENT; TRAUMATIC BRAIN-INJURY; FACTOR-ALPHA; ACTIVATED MICROGLIA; CEREBROSPINAL-FLUID; ISCHEMIC-STROKE; GAIT SPEED; TNF; MODEL	Background: Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive levels of tumour necrosis factor (TNF) and resultant neurotoxicity. Etanercept, a potent biologic TNF antagonist, reduces microglial activation in experimental models and has been therapeutically effective in models of brain and neuronal injury. Perispinal administration of etanercept, previously reported to be beneficial for the treatment of Alzheimer's disease, may facilitate delivery of etanercept into the brain. Objective: The objective of this report is to document the initial clinical response to perispinal etanercept in the first chronic stroke cohort so treated. Methods: Three consecutive patients with stable and persistent chronic neurological deficits due to strokes that had failed to resolve despite previous treatment and rehabilitation were evaluated at an outpatient clinic. They were treated off-label with perispinal etanercept as part of the clinic's practice of medicine. Results: All three patients had chronic hemiparesis, in addition to other stroke deficits. Their stroke distributions were right middle cerebral artery (MCA), brainstem (medulla) and left MCA. The two patients with MCA strokes had both received acute thrombolytic therapy. Each of the three patients was treated with an initial dose of perispinal etanercept 13, 35 and 36 months following their acute stroke, respectively. Significant clinical improvement following perispinal etanercept administration was observed in all patients. Onset of clinical response was evident within 10 minutes of perispinal injection in all patients. Improvements in hemiparesis, gait, hand function, hemi-sensory deficits, spatial perception, speech, cognition and behaviour were noted among the patients treated. Each patient received a second perispinal etanercept dose at 22-26 days after the first dose that was followed by additional clinical improvement. Conclusions: Open-label administration of perispinal etanercept resulted in rapid neurological improvement in three consecutive patients with chronic neurological dysfunction due to strokes occurring 13-36 months earlier. These results suggest that stroke may result in chronic TNF-mediated pathophysiology that may be amenable to therapeutic intervention long after the acute event. Randomized clinical trials of perispinal etanercept for selected patients with chronic neurological dysfunction following stroke are indicated.	[Tobinick, Edward] Neurol Res Inst, Los Angeles, CA USA	Tobinick, E (corresponding author), Univ Calif Los Angeles, Sch Med, 100 UCLA Med Plaza,Suite 205, Los Angeles, CA 90095 USA.	etmd@ucla.edu		Tobinick, Edward/0000-0001-7614-499X			Atkinson HH, 2007, J GERONTOL A-BIOL, V62, P844, DOI 10.1093/gerona/62.8.844; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Baron JC, 2005, CEREBROVASC DIS, V20, P154, DOI 10.1159/000087199; BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; Baron JC, 1999, STROKE, V30, P1150; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; Beattie MS, 2010, EUR J NEUROSCI, V32, P290, DOI 10.1111/j.1460-9568.2010.07343.x; Buchhave P, 2010, NEUROBIOL AGING, V31, P1877, DOI 10.1016/j.neurobiolaging.2008.10.012; Chen YM, 2010, JOINT BONE SPINE, V77, P366, DOI 10.1016/j.jbspin.2010.01.017; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Elfferich MD, 2010, RESPIRATION, V80, P212, DOI 10.1159/000314225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman P J, 1990, Int Disabil Stud, V12, P119; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Griffin WST, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-3; Hughes JL, 2010, NEUROIMAGE, V49, P19, DOI 10.1016/j.neuroimage.2009.08.047; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Kang YM, 2009, CARDIOVASC RES, V83, P737, DOI 10.1093/cvr/cvp160; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Lechan Ronald M, 2007, Acta Biomed, V78 Suppl 1, P84; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; Menza M, 2010, PSYCHOSOMATICS, V51, P474, DOI 10.1176/appi.psy.51.6.474; Nadeau S, 1999, NEUROSCIENCE, V93, P1449, DOI 10.1016/S0306-4522(99)00225-0; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Purser JL, 2003, J GERONTOL A-BIOL, V58, P1125; Sarajarvi T, 2010, J ALZHEIMERS DIS, V21, P763, DOI 10.3233/JAD-2010-100597; SHEN CH, ANESTH ANALG; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tobinick E, 2007, CURR ALZHEIMER RES, V4, P550, DOI 10.2174/156720507783018217; Tobinick Edward, 2006, MedGenMed, V8, P53; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick E, 2009, CNS DRUGS, V23, P713, DOI 10.2165/11310810-000000000-00000; Tobinick E, 2009, DRUG DISCOV TODAY, V14, P168, DOI 10.1016/j.drudis.2008.10.005; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tobinick Edward L, 2009, BMC Res Notes, V2, P28; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Walberer Maureen, 2010, Exp Transl Stroke Med, V2, P22, DOI 10.1186/2040-7378-2-22; Zaremba J, 2001, BIOMED PHARMACOTHER, V55, P258, DOI 10.1016/S0753-3322(01)00058-0; Zhang LC, 2003, BRAIN RES, V989, P1, DOI 10.1016/S0006-8993(03)03123-8	53	37	37	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs		2011	25	2					145	155		10.2165/11588400-000000000-00000			11	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	724DS	WOS:000287556900004	21254790				2021-06-18	
J	Maeda, H; Zhu, BL; Ishikawa, T; Michiue, T				Maeda, Hitoshi; Zhu, Bao-li; Ishikawa, Takaki; Michiue, Tomomi			Forensic molecular pathology of violent deaths	FORENSIC SCIENCE INTERNATIONAL			English	Article						Forensic pathology; Molecular biology; Pathophysiology of death; mRNA quantification; Violent death; Molecular autopsy	ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; INTRANUCLEAR UBIQUITIN IMMUNOREACTIVITY; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TRAUMATIC BRAIN-INJURY; WOUND AGE; PULMONARY SURFACTANT; GENE-EXPRESSION; SUDDEN-DEATH; TIME-COURSE	In forensic pathology, while classical morphology remains a core procedure to investigate deaths, a spectrum of ancillary procedures has been developed and incorporated to detail the pathology. Among them, postmortem biochemistry is important to investigate the systemic pathophysiological changes involved in the dying process that cannot be detected by morphology. In addition, recent advances in molecular biology have provided a procedure to investigate genetic bases of diseases that might present with sudden death, which is called 'molecular autopsy'. Meanwhile, the practical application of RNA analyses to postmortem investigation has not been accepted due to rapid decay after death; however, recent experimental and practical studies using real-time reverse transcription-PCR have suggested that the relative quantification of mRNA transcripts can be applied in molecular pathology for postmortem investigation of deaths, which may be called 'advanced molecular autopsy'. In a broad sense, forensic molecular pathology implies applied medical sciences to investigate the genetic basis of diseases, and the pathophysiology of diseases and traumas leading to death at a biological molecular level in the context of forensic pathology. The possible applications include analyses of local pathology, including tissue injury, ischemia/hypoxia and inflammation at the site of insult or specific tissue damage from intoxication, systemic responses to violence or environmental hazards, disorders due to intoxication, and systemic pathophysiology of fatal process involving major life-support organs. A review of previous studies suggests that systematic postmortem quantitative analysis of mRNA transcripts can be established from multi-faceted aspects of molecular biology and incorporated into death investigations in forensic pathology, to support and reinforce morphological evidence. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Maeda, Hitoshi; Zhu, Bao-li; Ishikawa, Takaki; Michiue, Tomomi] Osaka City Univ, Sch Med, Dept Legal Med, Abeno Ku, Osaka 5458585, Japan; [Zhu, Bao-li] China Med Univ, Dept Forens Pathol, Sch Forens Med, Shenyang 110001, Liaoning, Peoples R China	Maeda, H (corresponding author), Osaka City Univ, Sch Med, Dept Legal Med, Abeno Ku, Asahi Machi 1-4-3, Osaka 5458585, Japan.	legalmed@med.osaka-cu.ac.jp	Ishikawa, Takaki/AAP-7005-2020		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22590642] Funding Source: KAKEN		An JL, 2010, INT J LEGAL MED, V124, P99, DOI 10.1007/s00414-009-0375-2; Bacci S, 2006, INT J LEGAL MED, V120, P138, DOI 10.1007/s00414-005-0030-5; Bai RF, 2008, FORENSIC SCI INT, V175, P193, DOI 10.1016/j.forsciint.2007.07.006; Barrachina M, 2006, NEUROCHEM INT, V49, P276, DOI 10.1016/j.neuint.2006.01.018; BARTON AJL, 1993, J NEUROCHEM, V61, P1, DOI 10.1111/j.1471-4159.1993.tb03532.x; Basso C, 2008, VIRCHOWS ARCH, V452, P11, DOI 10.1007/s00428-007-0505-5; Bauer M, 2007, FORENSIC SCI INT-GEN, V1, P69, DOI 10.1016/j.fsigen.2006.11.002; Bauer Martin, 2003, Leg Med (Tokyo), V5, P220, DOI 10.1016/j.legalmed.2003.08.001; Becker J, 2004, FORENSIC SCI INT, V140, P13, DOI 10.1016/j.forsciint.2003.10.012; Chen XS, 2006, FORENSIC SCI INT, V162, P170, DOI 10.1016/j.forsciint.2006.06.044; Cina SJ, 2001, AM J FOREN MED PATH, V22, P173, DOI 10.1097/00000433-200106000-00012; COE JI, 1993, AM J FOREN MED PATH, V14, P91, DOI 10.1097/00000433-199306000-00001; Cohle SD, 2001, CARDIOVASC PATHOL, V10, P219, DOI 10.1016/S1054-8807(01)00093-X; de la Grandmaison GL, 2006, FORENSIC SCI INT, V156, P138, DOI 10.1016/j.forsciint.2004.12.024; De Paepe ME, 2002, DIAGN MOL PATHOL, V11, P170, DOI 10.1097/00019606-200209000-00008; Dettmeyer RB, 2006, FORENSIC SCI INT, V156, P51, DOI 10.1016/j.forsciint.2004.12.015; Dettmeyer R, 2008, FORENSIC SCI INT, V174, P229, DOI 10.1016/j.forsciint.2007.05.009; Dirnhofer R, 2006, RADIOGRAPHICS, V26, P1305, DOI 10.1148/rg.265065001; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Dressler J, 1998, LANCET, V352, P38, DOI 10.1016/S0140-6736(05)79520-9; Ellingsen CL, 2004, AM J FOREN MED PATH, V25, P213, DOI 10.1097/01.paf.0000127404.35694.94; Fernandez-Rodriguez A, 2006, FORENSIC SCI INT, V161, P8, DOI 10.1016/j.forsciint.2005.10.012; Ferrer-Dufol A, 2009, TOXICOL LETT, V186, P2, DOI 10.1016/j.toxlet.2008.10.025; Fineschi V, 2005, INT J LEGAL MED, V119, P94, DOI 10.1007/s00414-004-0498-4; FINGER JM, 1987, CLIN CHIM ACTA, V170, P209, DOI 10.1016/0009-8981(87)90130-6; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Grellner W, 2005, FORENSIC SCI INT, V153, P174, DOI 10.1016/j.forsciint.2004.08.021; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hausmann R, 2004, FOREN PATHOL REV, P53; HAWGOOD S, 1990, J CLIN INVEST, V86, P1, DOI 10.1172/JCI114670; Hayashi T, 2004, INT J LEGAL MED, V118, P320, DOI 10.1007/s00414-004-0468-x; Hayashi T, 2009, INT J LEGAL MED, V123, P7, DOI 10.1007/s00414-008-0235-5; He FG, 2008, FORENSIC SCI INT, V176, P152, DOI 10.1016/j.forsciint.2007.08.005; Heinrich M, 2007, INT J LEGAL MED, V121, P136, DOI 10.1007/s00414-006-0131-9; Huang WL, 2004, DRUG METAB DISPOS, V32, P1434, DOI 10.1124/dmd.104.001313; Iino M, 2003, INT J LEGAL MED, V117, P153, DOI 10.1007/s00414-003-0370-y; Ikematsu K, 2008, FORENSIC SCI INT, V179, P152, DOI 10.1016/j.forsciint.2008.05.007; Ikematsu Kazuya, 2004, Leg Med (Tokyo), V6, P97, DOI 10.1016/j.legalmed.2003.11.002; Ikematsu Kazuya, 2006, Legal Medicine, V8, P128, DOI 10.1016/j.legalmed.2005.08.012; Ikematsu Kazuya, 2003, Leg Med (Tokyo), V5, P15, DOI 10.1016/S1344-6223(02)00072-X; Ikernatsu Kazuya, 2007, Legal Medicine, V9, P265, DOI 10.1016/j.legalmed.2007.03.001; Inoue H, 2002, FORENSIC SCI INT, V130, P127, DOI 10.1016/S0379-0738(02)00352-3; Ishida K, 2000, FORENSIC SCI INT, V113, P127, DOI 10.1016/S0379-0738(00)00252-8; Ishida K, 2004, MOL TOXICOLOGY PROTO, V291, P415; Ishida Kaori, 2002, Leg Med (Tokyo), V4, P7, DOI 10.1016/S1344-6223(01)00056-6; Ishida Y, 2008, INT J LEGAL MED, V122, P409, DOI 10.1007/s00414-008-0255-1; Ishida Y, 2004, J LEUKOCYTE BIOL, V75, P59, DOI 10.1189/jlb.0403152; Ishida Yuko, 2006, Legal Medicine, V8, P102, DOI 10.1016/j.legalmed.2005.08.010; Ishikawa T, 2005, INT J LEGAL MED, V119, P231, DOI 10.1007/s00414-005-0540-1; Ishikawa T, 2008, FORENSIC SCI INT, V179, P147, DOI 10.1016/j.forsciint.2008.04.023; Ishikawa T, 2007, FORENSIC SCI INT, V171, P136, DOI 10.1016/j.forsciint.2006.10.016; Ishikawa T, 2007, INT J LEGAL MED, V121, P395, DOI 10.1007/s00414-006-0138-2; Ishikawa T, 2010, LEGAL MED-TOKYO, V12, P121, DOI 10.1016/j.legalmed.2010.01.004; JOHNSON SA, 1986, J NEUROSCI RES, V16, P267, DOI 10.1002/jnr.490160123; Kagawa Shinichiro, 2009, Legal Medicine, V11, P70, DOI 10.1016/j.legalmed.2008.09.004; Kakizaki E, 2008, FORENSIC SCI INT, V176, P236, DOI 10.1016/j.forsciint.2007.09.018; Karch Steven B, 2007, J Forensic Leg Med, V14, P389, DOI 10.1016/j.jflm.2007.04.008; Kernbach-Wighton Gerhard, 2009, Leg Med (Tokyo), V11 Suppl 1, pS31, DOI 10.1016/j.legalmed.2009.01.075; Kibayashi K, 2009, INT J LEGAL MED, V123, P371, DOI 10.1007/s00414-008-0278-7; Kitamura Osamu, 2005, Leg Med (Tokyo), V7, P340, DOI 10.1016/j.legalmed.2005.08.006; Kitamura O, 2007, INT J LEGAL MED, V121, P163, DOI 10.1007/s00414-006-0087-9; Kitamura O, 2010, LEGAL MED-TOKYO, V12, P57, DOI 10.1016/j.legalmed.2009.11.001; KONDO T, FORENSIC SC IN PRESS; Kondo Toshikazu, 2007, Legal Medicine, V9, P109, DOI 10.1016/j.legalmed.2006.11.009; Kuliwaba JS, 2005, BBA-MOL BASIS DIS, V1740, P1, DOI 10.1016/j.bbadis.2005.03.005; Landi KK, 2008, J FORENSIC SCI, V53, P213, DOI 10.1111/j.1556-4029.2007.00604.x; Li DR, 2009, HISTOL HISTOPATHOL, V24, P1113, DOI 10.14670/HH-24.1113; Li Dong-Ri, 2006, Legal Medicine, V8, P71, DOI 10.1016/j.legalmed.2005.07.004; Li Dong-Ri, 2006, Legal Medicine, V8, P78, DOI 10.1016/j.legalmed.2005.09.002; Li DR, 2010, LEGAL MED, V12, P63, DOI 10.1016/j.legalmed.2009.11.005; Liu NG, 2006, FORENSIC SCI INT, V162, P178, DOI 10.1016/j.forsciint.2006.06.040; Loddenkotter B, 2005, INT J LEGAL MED, V119, P202, DOI 10.1007/s00414-005-0531-2; Luna A, 2009, Leg Med (Tokyo), V11 Suppl 1, pS27, DOI 10.1016/j.legalmed.2009.02.040; Madea Burkhard, 2009, Leg Med (Tokyo), V11 Suppl 1, pS36, DOI 10.1016/j.legalmed.2009.01.111; Maeda Hitoshi, 2003, Leg Med (Tokyo), V5 Suppl 1, pS318, DOI 10.1016/S1344-6223(02)00160-8; Maeda Hitoshi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS46, DOI 10.1016/j.legalmed.2009.01.048; Maeda H, 2008, FORENSIC SCI MED PAT, V4, P175, DOI 10.1007/s12024-008-9029-9; Marschall S, 2006, INT J LEGAL MED, V120, P355, DOI 10.1007/s00414-006-0105-y; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Michiue T, 2008, FORENSIC SCI INT, V178, P185, DOI 10.1016/j.forsciint.2008.03.019; Michiue Tomomi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS168, DOI 10.1016/j.legalmed.2009.01.105; Michiue T, 2010, LEGAL MED, V12, P73, DOI 10.1016/j.legalmed.2009.11.007; Morling N, 2009, BIOCHEM SOC T, V37, P438, DOI 10.1042/BST0370438; Morris JA, 2006, J CLIN PATHOL, V59, P1, DOI 10.1136/jcp.2005.028183; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nakajima T, 2006, FORENSIC SCI INT, V158, P157, DOI 10.1016/j.forsciint.2005.05.028; Nogami Makoto, 2009, Legal Medicine, V11, P213, DOI 10.1016/j.legalmed.2009.05.001; Oehmichen M, 1997, EXP TOXICOL PATHOL, V49, P233, DOI 10.1016/S0940-2993(97)80017-6; Oehmichen M, 2004, FORENSIC SCI INT, V144, P221, DOI 10.1016/j.forsciint.2004.04.057; OEHMICHEN M, 1984, Z RECHTSMED, V91, P287, DOI 10.1007/BF02332322; Ohshima T, 1998, INT J LEGAL MED, V111, P251, DOI 10.1007/s004140050163; Ohshima T, 2000, FORENSIC SCI INT, V113, P153, DOI 10.1016/S0379-0738(00)00269-3; Osawa Motoki, 2008, Legal Medicine, V10, P143, DOI 10.1016/j.legalmed.2007.10.002; Pampin JB, 2006, J FORENSIC SCI, V51, P120, DOI 10.1111/j.1556-4029.2005.00014.x; PARDUE S, 1994, CELL MOL NEUROBIOL, V14, P341, DOI 10.1007/BF02088715; Paulding WR, 2000, ADV EXP MED BIOL, V475, P111; Perez-Carceles MD, 2004, FORENSIC SCI INT, V142, P1, DOI 10.1016/j.forsciint.2004.02.007; PHANG TW, 1994, J FORENSIC SCI, V39, P1275; Popivanova BK, 2003, BRAIN RES, V970, P195, DOI 10.1016/S0006-8993(03)02343-6; Preece P, 2003, MOL BRAIN RES, V118, P60, DOI 10.1016/S0169-328X(03)00337-1; Preuss J, 2008, FORENSIC SCI INT, V176, P248, DOI 10.1016/j.forsciint.2007.09.017; Quan L, 2008, INT J LEGAL MED, V122, P481, DOI 10.1007/s00414-008-0276-9; Quan L, 2001, INT J LEGAL MED, V115, P6, DOI 10.1007/s004140000200; Quan L, 2001, INT J LEGAL MED, V114, P310, DOI 10.1007/s004140000192; Quan Li, 2005, Legal Medicine, V7, P144, DOI 10.1016/j.legalmed.2004.11.002; Sato Y, 2000, INT J LEGAL MED, V113, P140, DOI 10.1007/s004140050285; Saukko P, 2004, KNIGHTS FORENSIC PAT, P1; Sawaguchi T, 2005, FORENSIC SCI INT, V149, P205, DOI 10.1016/j.forsciint.2004.10.015; Schneider PM, 2007, FORENSIC SCI INT, V165, P238, DOI 10.1016/j.forsciint.2006.06.067; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shimada I, 2008, INT J LEGAL MED, V122, P373, DOI 10.1007/s00414-008-0226-6; Shinone K, 2010, LEGAL MED-TOKYO, V12, P79, DOI 10.1016/j.legalmed.2010.01.001; Smolina IV, 2005, B EXP BIOL MED+, V140, P187, DOI 10.1007/s10517-005-0441-9; Sun JH, 2010, INT J LEGAL MED, V124, P27, DOI 10.1007/s00414-009-0323-1; Takahashi Hiroyuki, 2009, Legal Medicine, V11, P181, DOI 10.1016/j.legalmed.2009.03.008; Takamiya M, 2005, INT J LEGAL MED, V119, P16, DOI 10.1007/s00414-004-0453-4; Takamiya M, 2003, INT J LEGAL MED, V117, P46, DOI 10.1007/s00414-002-0354-3; Takamiya Masataka, 2006, Legal Medicine, V8, P214, DOI 10.1016/j.legalmed.2006.05.002; Takamiya M, 2008, INT J LEGAL MED, V122, P143, DOI 10.1007/s00414-007-0183-5; Takamiya Masataka, 2008, Legal Medicine, V10, P131, DOI 10.1016/j.legalmed.2007.11.003; Tanaka Jin, 2003, Leg Med (Tokyo), V5, P146, DOI 10.1016/S1344-6223(03)00076-2; Tanaka Toshiko, 2004, Leg Med (Tokyo), V6, P203, DOI 10.1016/j.legalmed.2004.05.002; Tao LY, 2006, FORENSIC SCI INT, V162, P174, DOI 10.1016/j.forsciint.2006.06.021; Tester DJ, 2006, CURR OPIN CARDIOL, V21, P166, DOI 10.1097/01.hco.0000221576.33501.83; Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013; Weis A, 2008, FORENSIC SCI INT, V175, P102, DOI 10.1016/j.forsciint.2007.05.015; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; Yasojima K, 2001, BRAIN RES PROTOC, V8, P212, DOI 10.1016/S1385-299X(01)00119-2; Yoshida C, 2011, INT J LEGAL MED, V125, P11, DOI 10.1007/s00414-009-0374-3; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1; Ishikawa Takaki, 2006, Legal Medicine, V8, P28, DOI 10.1016/j.legalmed.2006.05.004; Zhao D, 2008, FORENSIC SCI INT, V177, P176, DOI 10.1016/j.forsciint.2007.12.004; Zhao Dong, 2006, Legal Medicine, V8, P132, DOI 10.1016/j.legalmed.2005.09.001; Zhao Dong, 2009, Leg Med (Tokyo), V11 Suppl 1, pS286, DOI 10.1016/j.legalmed.2009.02.014; Zhao Dong, 2009, Leg Med (Tokyo), V11 Suppl 1, pS43, DOI 10.1016/j.legalmed.2009.01.066; Zhu B L, 2001, Leg Med (Tokyo), V3, P23, DOI 10.1016/S1344-6223(01)00006-2; Zhu B L, 2001, Leg Med (Tokyo), V3, P134, DOI 10.1016/S1344-6223(01)00020-7; Zhu Bao-Li, 2006, Legal Medicine, V8, P94, DOI 10.1016/j.legalmed.2005.10.003; Zhu Bao-Li, 2006, Legal Medicine, V8, P86, DOI 10.1016/j.legalmed.2005.10.004; Zhu BL, 2007, INT J LEGAL MED, V121, P28, DOI 10.1007/s00414-006-0102-1; Zhu Bao-Li, 2008, Legal Medicine, V10, P11, DOI 10.1016/j.legalmed.2007.06.002; Zhu Bao-Li, 2007, Legal Medicine, V9, P241, DOI 10.1016/j.legalmed.2007.01.010; Zhu Bao-Li, 2005, Legal Medicine, V7, P103, DOI 10.1016/j.legalmed.2004.08.004; Zhu BL, 2007, FORENSIC SCI INT, V173, P122, DOI 10.1016/j.forsciint.2007.02.013; Zhu Bao-Li, 2002, Leg Med (Tokyo), V4, P1, DOI 10.1016/S1344-6223(01)00051-7; Zhu Bao-Li, 2005, Legal Medicine, V7, P139, DOI 10.1016/j.legalmed.2004.10.007; Zhu BL, 2001, FORENSIC SCI INT, V117, P205, DOI 10.1016/S0379-0738(00)00410-2; Zhu BL, 2000, INT J LEGAL MED, V113, P268, DOI 10.1007/s004149900109	150	37	40	1	26	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC 15	2010	203	1-3					83	92		10.1016/j.forsciint.2010.07.024			10	Medicine, Legal	Legal Medicine	683HJ	WOS:000284464200011	20719442				2021-06-18	
J	Carlson, AP; Ramirez, P; Kennedy, G; McLean, AR; Murray-Krezan, C; Stippler, M				Carlson, Andrew P.; Ramirez, Pedro; Kennedy, George; McLean, A. Robb; Murray-Krezan, Cristina; Stippler, Martina			Low rate of delayed deterioration requiring surgical treatment in patients transferred to a tertiary care center for mild traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						mild traumatic brain injury; cortical contusion; skull fracture; traumatic subarachnoid hemorrhage; subdural hematoma; brain concussion	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; NEUROSURGERY; MANAGEMENT; RULE; CT; TELERADIOLOGY; CONSULTATION; TELEMEDICINE	Object. Patients with mild traumatic brain injury (mTBI) only rarely need neurosurgical intervention; however, there is a subset of patients whose condition will deteriorate. Given the high resource utilization required for interhospital transfer and the relative infrequency of the need for intervention, this study was undertaken to determine how often patients who were transferred required intervention and if there were factors that could predict that need. Methods. The authors performed a retrospective review of cases involving patients who were transferred to the University of New Mexico Level 1 trauma center for evaluation of mTBI between January 2005 and December 2009. Information including demographic data, lesion type, need for neurosurgical intervention, and short-term outcome was recorded. Results. During the 4-year study period, 292 patients (age range newborn to 92 years) were transferred for evaluation of mTBI. Of these 292 patients, 182 (62.3%) had an acute traumatic finding of some kind; 110 (60.4%) of these had a follow-up CT to evaluate progression, whereas 60 (33.0%) did not require a follow-up CT. In 15 cases (5.1% overall), the patients were taken immediately to the operating room (either before or after the first CT). Only 4 patients (1.5% overall) had either clinical or radiographic deterioration requiring delayed surgical intervention after the second CT scan. Epidural hematoma (EDH) and subdural hematoma (SDH) were both found to be significantly associated with the need for surgery (OR 29.5 for EDH, 95% CI 6.6-131.8; OR 9.7 for SDH, 95% CI 2.4-39.1). There were no in-hospital deaths in the series, and 97% of patients were discharged with a Glasgow Coma Scale score of 15. Conclusions. Most patients who are transferred with mTBI who need neurosurgical intervention have a surgical lesion initially. Only a very small percentage will have a delayed deterioration requiring surgery, with EDH and SDH being more concerning lesions. In most cases of mTBI, triage can be performed by a neurosurgeon and the patient can be observed without interhospital transfer. (DOI: 10.3171/2010.8.FOCUS10182)	[Carlson, Andrew P.; Ramirez, Pedro; Stippler, Martina] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Kennedy, George; McLean, A. Robb] Univ New Mexico, Dept Emergency Med, Albuquerque, NM 87131 USA; [Murray-Krezan, Cristina] Univ New Mexico, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA	Stippler, M (corresponding author), Univ New Mexico, Dept Neurosurg, MSC10-5615,1 Univ New Mexico, Albuquerque, NM 87131 USA.	mstippler@salud.unm.edu	Murray-Krezan, Cristina/O-3834-2016; Carlson, Andrew P/B-4369-2012	Murray-Krezan, Cristina/0000-0002-5488-1080; Carlson, Andrew P/0000-0003-2189-3699	Clinical Translational Science Center at UNM	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Statistical analysis was supported via a grant through the Clinical Translational Science Center at UNM.	Ashkenazi I, 2007, EMERG MED J, V24, P550, DOI 10.1136/emj.2006.044461; Clement CM, 2006, ANN EMERG MED, V48, P245, DOI 10.1016/j.annemergmed.2006.04.008; Edmonds Marcia, 2006, Evid Based Med, V11, P61, DOI 10.1136/ebm.11.2.61; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Gray WP, 1998, NEUROSURGERY, V42, P103, DOI 10.1097/00006123-199801000-00020; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hebb MO, 2007, CAN J SURG, V50, P187; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Houkin K, 1999, NEUROL MED-CHIR, V39, P773, DOI 10.2176/nmc.39.773; Huynh T, 2006, AM SURGEON, V72, P1162; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kreutzer J, 2008, J TELEMED TELECARE, V14, P67, DOI 10.1258/jtt.2007.060605; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Newgard CD, 2005, EMERG MED J, V22, P855, DOI 10.1136/emj.2004.020206; Ng WH, 2007, SURG NEUROL, V67, P338, DOI 10.1016/j.surneu.2006.10.056; Pirris SM, 2010, NEUROSURGERY, V66, P999, DOI 10.1227/01.NEU.0000368443.43565.2A; Qushmaq Ismael, 2006, ACP J Club, V144, P53; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Schulmeyer FJ, 1999, ST HEAL T, V64, P115; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Smith Eric E, 2008, Crit Pathw Cardiol, V7, P173, DOI 10.1097/HPC.0b013e318184e2bc; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Urban V, 1996, Eur J Emerg Med, V3, P5, DOI 10.1097/00063110-199603000-00001; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Waran V, 2008, J TRAUMA, V64, P362, DOI 10.1097/TA.0b013e318070cc88; Wong HT, 2006, NEUROSURGERY, V59, P607, DOI 10.1227/01.NEU.0000228926.13395.F9	33	37	38	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E3	10.3171/2010.8.FOCUS10182			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900004	21039137	Green Accepted			2021-06-18	
J	Moro, N; Sutton, RL				Moro, Nobuhiro; Sutton, Richard L.			Beneficial effects of sodium or ethyl pyruvate after traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Cell Death; Cytochrome oxidase; Ethyl pyruvate; Functional recovery; Inflammation; Microglia; Neuroprotection; Rats; Sodium pyruvate; Traumatic brain injury	CYTOCHROME-C-OXIDASE; CORTICAL CONTUSION INJURY; WIDE THERAPEUTIC WINDOW; FOCAL CEREBRAL-ISCHEMIA; HEMORRHAGIC-SHOCK; HUNTINGTONS-DISEASE; HEAD-INJURY; ANTIINFLAMMATORY MECHANISM; ENDOTHELIAL-CELLS; OXIDATIVE DAMAGE	Sodium pyruvate (SP) treatment initiated within 5 min post-injury is neuroprotective in a rat model of unilateral cortical contusion injury (CCI). The current studies examined: (1) effects of delayed SP treatments (1000 mg/kg, i.p., at 1, 12 and 24 h), (2) effects of single (1 h) or multiple (1, 12 and 24 h) ethyl pyruvate treatments (EP; at 20 or 40 mg/kg, i.p.), and (3) mechanisms of action for pyruvate effects after CCI. In Experiment 1, both SP and EP treatment(s) significantly reduced the number of dead/dying cells in the ipsilateral hippocampus (dentate hilus + CA3(c) and/or CA3(a-b) regions) at 72 h post-CCI. Pyruvate treatment (s) attenuated CCI-induced reductions of cerebral cytochrome oxidase activity at 72 h, significantly improving activity in peri-contusional cortex after multiple SP or EP treatments. Optical density measures of ipsilateral CD11b immuno-staining were significantly increased 72 h post-CCI, but these measures of microglia activation were not different from sham injury values in SP and EP groups with three post-CCI treatments. In Experiment 2, three treatments (1, 12 and 24 h) of SP (1000 mg/kg) or EP (40 mg/kg) significantly improved recovery of beam-walking and neurological scores in the first 3 weeks after CCI, and EP treatments significantly improved spatial working memory 1 week post-CCI. Ipsilateral CA3(b) neuronal loss, but not cortical tissue loss, was significantly reduced 1 month post-CCI with pyruvate treatments begun 1 h post-CCI. Thus, delayed pyruvate treatments after CCI are neuroprotective and improve neurobehavioral recovery; these effects may be mediated by improved metabolism and reduced inflammation. (C) 2010 Elsevier Inc. All rights reserved.	[Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Sutton, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	rsutton@mednet.ucla.edu			UCLA Brain Injury Research Center; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER	The authors thank Mr. Peter Nguyen for assistance with behavioral assessments and Ms. Sima Ghavim for her superb technical assistance in the histological analyses. This work was supported by the UCLA Brain Injury Research Center and Award Number P01NS058489 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not necessarily represent official views of the NINDS or the National Institutes of Health.	Alvarez G, 2003, J NEUROSCI RES, V73, P260, DOI 10.1002/jnr.10648; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen W, 2010, NEUROCHEM RES, V35, P336, DOI 10.1007/s11064-009-0059-9; Cho IH, 2006, J NEUROSCI RES, V84, P1505, DOI 10.1002/jnr.21052; Choi JS, 2010, BIOCHEM BIOPH RES CO, V394, P854, DOI 10.1016/j.bbrc.2010.03.105; Dai W, 2009, BRAIN RES, V1251, P287, DOI 10.1016/j.brainres.2008.11.034; Das UN, 2006, NUTRITION, V22, P965, DOI 10.1016/j.nut.2006.05.009; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fink MP, 2007, J INTERN MED, V261, P349, DOI 10.1111/j.1365-2796.2007.01789.x; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Gonzalez SV, 2005, J NEUROCHEM, V95, P284, DOI 10.1111/j.1471-4159.2005.03365.x; Gonzalez-Falcon A, 2003, BRAIN RES, V990, P1, DOI 10.1016/S0006-8993(03)03378-X; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hollander M., 1999, NONPARAMETRIC STAT M; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hurd RE, 2010, MAGN RESON MED, V63, P1137, DOI 10.1002/mrm.22364; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007; Kashiwagi A, 1997, DIABETES, V46, P2088, DOI 10.2337/diabetes.46.12.2088; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kim HS, 2008, FREE RADICAL BIO MED, V45, P950, DOI 10.1016/j.freeradbiomed.2008.06.009; Kim JB, 2005, BRAIN RES, V1060, P188, DOI 10.1016/j.brainres.2005.08.029; Kim SW, 2010, NEUROTOX RES, V17, P39, DOI 10.1007/s12640-009-9075-4; Kim TY, 2007, EXP NEUROL, V208, P159, DOI 10.1016/j.expneurol.2007.08.013; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lee JY, 2001, J NEUROSCI, V21; Lee YJ, 2004, J APPL PHYSIOL, V96, P793, DOI 10.1152/japplphysiol.00797.2003; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McNay EC, 2000, P NATL ACAD SCI USA, V97, P2881, DOI 10.1073/pnas.050583697; Mizutani A, 2010, PULM PHARMACOL THER, V23, P308, DOI 10.1016/j.pupt.2010.03.002; Mongan PD, 2003, J SURG RES, V112, P180, DOI 10.1016/S0022-4804(03)00148-3; Mongan PD, 2002, AM J PHYSIOL-HEART C, V283, pH1634, DOI 10.1152/ajpheart.01073.2001; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854; MONTGOMERY CM, 1956, J BIOL CHEM, V221, P359; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Park JH, 2007, NEUROSCI LETT, V413, P265, DOI 10.1016/j.neulet.2006.11.058; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Phelan H, 2002, J TRAUMA, V52, P675, DOI 10.1097/00005373-200204000-00010; Ryu JK, 2006, NEUROSCIENCE, V141, P1835, DOI 10.1016/j.neuroscience.2006.05.043; Ryu JK, 2003, EXP NEUROL, V183, P700, DOI 10.1016/S0014-4886(03)00214-0; Ryu JK, 2004, EXP NEUROL, V187, P150, DOI 10.1016/j.expneurol.2004.01.006; Sappington PL, 2003, SHOCK, V20, P521, DOI 10.1097/01.shk.0000092697.10326.8b; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHOLZ TD, 1995, AM J PHYSIOL-HEART C, V268, pH82; Sharma AB, 2008, RESUSCITATION, V76, P108, DOI 10.1016/j.resuscitation.2007.04.028; Sharma P, 2003, BRAIN RES, V992, P104, DOI 10.1016/j.brainres.2003.08.043; Sharma P, 2010, SHOCK, V33, P532, DOI 10.1097/SHK.0b013e3181cc02b3; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Shen HX, 2010, NEUROBIOL DIS, V37, P711, DOI 10.1016/j.nbd.2009.12.010; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; Suh SW, 2005, DIABETES, V54, P1452, DOI 10.2337/diabetes.54.5.1452; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tokumaru O, 2009, NEUROCHEM RES, V34, P775, DOI 10.1007/s11064-008-9871-x; Varma SD, 1998, FREE RADICAL RES, V28, P131, DOI 10.3109/10715769809065799; Verwer RWH, 2002, FASEB J, V16, P54, DOI 10.1096/fj.01-0504com; Wang Q, 2009, ANESTHESIOLOGY, V110, P1279, DOI 10.1097/ALN.0b013e3181a160d6; Wang Q, 2009, NEUROBIOL DIS, V36, P223, DOI 10.1016/j.nbd.2009.07.018; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315; Yu YM, 2005, STROKE, V36, P2238, DOI 10.1161/01.STR.0000181779.83472.35; Zeng JY, 2007, ANESTHESIOLOGY, V107, P630, DOI 10.1097/01.anes.0000281898.01966.1e; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x	68	37	39	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2010	225	2					391	401		10.1016/j.expneurol.2010.07.013			11	Neurosciences	Neurosciences & Neurology	654SV	WOS:000282191500019	20670624	Green Accepted			2021-06-18	
J	Schnuriger, B; Inaba, K; Branco, BC; Salim, A; Russell, K; Lam, L; Plurad, D; Demetriades, D				Schnuriger, Beat; Inaba, Kenji; Branco, Bernardino C.; Salim, Ali; Russell, Katie; Lam, Lydia; Plurad, David; Demetriades, Demetrios			Organ Donation: An Important Outcome after Resuscitative Thoracotomy	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							EMERGENCY-ROOM THORACOTOMY; CARDIAC-ARREST; TRAUMA; CHEST	BACKGROUND: The persistent shortage of transplantable organs remains a critical issue around the world. The purpose of this study was to investigate outcomes, including organ procurement, in trauma patients undergoing resuscitative emergency department thoracotomy (EDT). Our hypothesis was that potential organ donor rescue is one of the important outcomes after traumatic arrest and EDT. STUDY DESIGN: Retrospective study at Los Angeles County and University of Southern California Medical Center. Patients undergoing resuscitative EDT from January 1, 2006 through June 30, 2009 were analyzed. Primary outcomes measures included survival. Secondary outcomes included organ donation and the brain-dead potential organ donor. RESULTS: During the 42-month study period, a total of 263 patients underwent EDT. Return of a pulse was achieved in 85 patients (32.3%). Of those patients, 37 (43.5%) subsequently died in the operating room and 48 (56.5%) survived to the surgical intensive care unit. Overall, 5 patients (1.9%) survived to discharge and 11 patients (4.2%) became potential organ donors. Five of the 11 potential organ donors had sustained a blunt mechanism injury. Of the 11 potential organ donors, 8 did not donate: 4 families declined consent, 3 because of poor organ function, and 1 expired due to cardiopulmonary collapse. Eventually 11 organs (6 kidneys, 2 livers, 2 pancreases, and 1 small bowel) were harvested from 3 donors. Two of the 3 donors had sustained blunt injury and 1 penetrating mechanism of injury. CONCLUSIONS: Procurement of organs is one of the tangible outcomes after EDT. These organs have the potential to alter the survival and quality of life of more recipients than the number of survivors of the procedure itself. (J Am Coll Surg 2010;211:450-455. (C) 2010 by the American College of Surgeons)	[Schnuriger, Beat; Inaba, Kenji; Branco, Bernardino C.; Lam, Lydia; Plurad, David; Demetriades, Demetrios] Univ So Calif, LAC USC Med Ctr, Div Trauma Surg & Crit Care, Los Angeles, CA 90033 USA; [Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Russell, Katie] Univ Utah, Dept Surg, Salt Lake City, UT USA	Inaba, K (corresponding author), Univ So Calif, LAC USC Med Ctr, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St,Inpatient Tower C,5th Floor,Room, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu	INABA, KENJI/AAC-8532-2020				Asensio JA, 2001, J AM COLL SURGEONS, V193, P303; BRIGGS BD, 1956, JAMA-J AM MED ASSOC, V160, P1439, DOI 10.1001/jama.1956.02960520001001; DELGUERCIO LR, 1965, CIRCULATION, V31, P171; DEMETRIADES D, 1987, J TRAUMA, V27, P483, DOI 10.1097/00005373-198705000-00004; Fialka C, 2004, J TRAUMA, V57, P809, DOI 10.1097/01.TA.0000124266.39529.6E; IVATURY RR, 1991, J TRAUMA, V31, P1076, DOI 10.1097/00005373-199131080-00005; Martin SK, 2002, J TRAUMA, V53, P876, DOI 10.1097/00005373-200211000-00011; Powell DW, 2004, J AM COLL SURGEONS, V199, P211, DOI 10.1016/j.jamcollsurg.2004.04.004; Rhee PM, 2000, J AM COLL SURGEONS, V190, P288, DOI 10.1016/S1072-7515(99)00233-1; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; Sheppard FR, 2006, SURGERY, V139, P574, DOI 10.1016/j.surg.2005.12.005; TURK LN, 1954, NEW ENGL J MED, V251, P795, DOI 10.1056/NEJM195411112512001; Tuttle-Newhall JE, 2009, AM J TRANSPLANT, V9, P879, DOI 10.1111/j.1600-6143.2009.02565.x	13	37	37	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2010	211	4					450	455		10.1016/j.jamcollsurg.2010.06.012			6	Surgery	Surgery	663ZO	WOS:000282928900002	20729100				2021-06-18	
J	Eberle, BM; Schnuriger, B; Inaba, K; Gruen, JP; Demetriades, D; Belzberg, H				Eberle, Barbara M.; Schnueriger, Beat; Inaba, Kenji; Gruen, J. Peter; Demetriades, Demetrios; Belzberg, Howard			Decompressive craniectomy: Surgical control of traumatic intracranial hypertension may improve outcome	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Decompressive craniectomy; Severe traumatic brain injury; Intractable intracranial hypertension; Glasgow outcome score	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURIES; BRAIN-INJURY; MANAGEMENT; EXPERIENCE; IMPACT; EDEMA	Introduction: The purpose of this study was to assess the role of decompressive craniectomy (DC) in patients with post-traumatic intractable intracranial hypertension (ICH) in the absence of an evacuable intracerebral haemorrhage. Methods: Retrospective study at LAC+USC Medical Centre including patients who underwent DC for post-traumatic malignant brain swelling or ICH without space occupying haemorrhage, during the period 01/2004 to 12/2008. The analysis included the effect of DC on intracranial pressure (ICP) and timing of DC on functional outcomes and survival. Results: Of 106 patients who underwent DC, 43 patients met inclusion criteria. Of those, 34 were operated within the first 24 h from admission. DC decreased the ICP significantly from 37.8 +/- 12.1 mmHg to 12.7 +/- 8.2 mmHg in survivors and from 52.8 +/- 13.0 to 32.0 +/- 17.3 mmHg in non-survivors. Overall 25.6% died (11 of 43), and 32.5% (14 of 43) remained in vegetative state or were severely disabled. Favourable outcome (Glasgow Outcome Scale 4 and 5) was observed in 41.9% (18 of 43). No tendency towards either increased or decreased incidence in favourable outcome was found relative to the time from admission to DC. Six of the 18 patients (33.3%) with favourable outcome were operated on within the first 6 h. Conclusions: DC lowers ICP and raises CPP to high normal levels in survivors compared to non-survivors. The timing of DC showed no clear trend, for either good neurological outcome or death. Overall, the survival rate of 74.4% is promising and 41.9% had favourable neurological outcome. (C) 2010 Elsevier Ltd. All rights reserved.	[Eberle, Barbara M.; Schnueriger, Beat; Inaba, Kenji; Demetriades, Demetrios; Belzberg, Howard] LAC USC Med Ctr, Dept Surg, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA USA; [Gruen, J. Peter] LAC USC Med Ctr, Dept Neurosurg, Los Angeles, CA USA	Belzberg, H (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Gen Hosp, LAC USC Med Ctr,Crit Care Serv, 1200 N State St,C5L100, Los Angeles, CA 90033 USA.	belzberg@usc.edu	INABA, KENJI/AAC-8532-2020				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Davella D, 2000, J Neurosurg Sci, V44, P19; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Farin A, 2004, ACT NEUR S, V89, P101; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munch E, 2000, NEUROSURGERY, V47, P315; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	31	37	39	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2010	41	9					894	898		10.1016/j.injury.2010.02.023			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	634SL	WOS:000280605500003	21574279				2021-06-18	
J	Ferraris, VA; Ferraris, SP; Saha, SP				Ferraris, Victor A.; Ferraris, Suellen P.; Saha, Sibu P.			The Relationship Between Mortality and Preexisting Cardiac Disease in 5,971 Trauma Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	94th Annual Clinical Congress of the American-College-of-Surgeons (ACS) / 63rd Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical Problems	OCT 12-16, 2008	San Francisco, CA	Amer Coll Surg (ACS)		Trauma; Cardiac risk factors; Mortality; Logistic regression; Propensity score; Congestive heart failure; Adrenergic beta-antagonists; Warfarin; Clopidogrel	PREINJURY WARFARIN USE; BETA-BLOCKER EXPOSURE; ACTIVATED FACTOR-VII; INTENSIVE-CARE-UNIT; INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; BRAIN-INJURY; HEAD-INJURIES; ANTICOAGULATION; EFFICACY	Background: We observed significant morbidity and mortality in patients with preexisting cardiac disease who suffer severe traumatic injuries. We wondered about the types of injury seen and about the cardiac risks factors that predispose to worse outcomes in these patients. Our hypothesis is that significant cardiac comorbidity is associated with adverse trauma outcomes. Methods: We reviewed 10,144 trauma admissions to the University of Kentucky during a 5-year period (2002-2007) in patients 21 years or older. The types and extent of injuries were characterized, and risk factors for poor outcome were assessed. Propensity analysis assessed variable interaction and adjusted for important multivariate cardiovascular risk factors. Results: Of the 10,144 adult trauma patients, there was adequate cardiovascular history before emergency treatment in 5,971 patients (58.9%). Of the 700 trauma deaths, 236 (33.7%) had adequate medical history to allow accurate assessment of cardiovascular disease. Significant multivariate predictors of trauma-related death included older age (odds ratio [OR] = 0.938), injury severity score (OR = 0.893 per unit score), major burn (OR = 5.907), assault with a weapon (OR = 3.205), systolic blood pressure divided by Glasgow coma score (OR = 0.958 per score unit), and female (OR = 1.629). In the cohort of 236 deaths with adequate medical history, severe head and chest injuries caused death in 187 patients (79.2%). Significant propensity-adjusted cardiovascular risks of trauma death included preinjury warfarin use (OR = 2.309, p = 0.001), congestive heart failure (CHF) (OR = 2.060, p = 0.011), and preinjury beta-blocker use (OR = 2.62, p = 0.001). The highest mortality rates occurred in patients with combinations of these cardiovascular risk factors. For example, patients on warfarin with CHF had a 26.3% mortality rate, whereas patients on warfarin and beta-blocker had a 27.3% mortality rate. Conclusions: Preinjury cardiac risk factors, especially preinjury warfarin, beta-blocker use, and CHF, are independent multivariate predictors of mortality in patients suffering significant trauma. Although head and chest injuries are the most frequent causes of death, patients with more than one preinjury cardiac risk factor have 5 to 10 times the mortality risk compared with those without cardiac risks.	[Ferraris, Victor A.] Univ Kentucky, Div Cardiovasc & Thorac Surg, Kentucky Clin A301, Dept Surg, Lexington, KY 40536 USA; [Ferraris, Victor A.; Ferraris, Suellen P.] Lexington Vet Affairs Med Ctr, Dept Surg, Lexington, KY USA	Ferraris, VA (corresponding author), Univ Kentucky, Div Cardiovasc & Thorac Surg, Kentucky Clin A301, Dept Surg, 740 S Limestone, Lexington, KY 40536 USA.	ferraris@earthlink.net					Alexander JQ, 2000, AM SURGEON, V66, P855; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Asensio JA, 2001, AM J SURG, V182, P743, DOI 10.1016/S0002-9610(01)00809-1; Austin PC, 2007, J THORAC CARDIOV SUR, V134, P1128, DOI 10.1016/j.jtcvs.2007.07.021; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Blackstone EH, 2002, J THORAC CARDIOV SUR, V123, P8, DOI 10.1067/mtc.2002.120329; Blow O, 1999, J TRAUMA, V47, P964, DOI 10.1097/00005373-199911000-00028; Chang MC, 2000, J TRAUMA, V49, P26, DOI 10.1097/00005373-200007000-00004; Chiu W, 2007, J TRAUMA, V63, P510; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Enderson BL, 2007, J TRAUMA, V62, P33; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Friese RS, 2008, J TRAUMA, V64, P1061, DOI 10.1097/TA.0b013e3181684cf0; Gage BF, 2006, ARCH INTERN MED, V166, P241, DOI 10.1001/archinte.166.2.241; Grandhi R, 2008, AM SURGEON, V74, P802; Hardy JF, 2008, ANN THORAC SURG, V86, P1038, DOI 10.1016/j.athoracsur.2008.05.013; Hui T, 2002, AM SURGEON, V68, P1111; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ityas C, 2008, J CLIN ANESTH, V20, P276, DOI 10.1016/j.jclinane.2007.12.012; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Jafary FH, 2005, ACTA CARDIOL, V60, P557, DOI 10.2143/AC.60.5.2004980; Kalina M, 2008, AM SURGEON, V74, P858; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; London JA, 2006, SURG CLIN N AM, V86, P1503, DOI 10.1016/j.suc.2006.08.003; Macdonald DJM, 2006, POSTGRAD MED J, V82, DOI 10.1136/pgmj.2006.047381; Mallarkey G, 2008, DRUGS, V68, P1665, DOI 10.2165/00003495-200868120-00005; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Neideen T, 2008, J TRAUMA, V65, P1016, DOI 10.1097/TA.0b013e3181897eac; Paladino L, 2008, RESUSCITATION, V77, P363, DOI 10.1016/j.resuscitation.2008.01.022; Parmar K. A., 2006, SMJ Singapore Medical Journal, V47, P676; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pryor JP, 2007, J TRAUMA, V62, P61; Raff T, 1996, Acta Chir Plast, V38, P122; Ranucci M, 2008, ARCH SURG-CHICAGO, V143, P296, DOI 10.1001/archsurg.2007.66; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Stanworth SJ, 2007, COCHRANE DB SYST REV, V2; Tharmarajah P, 2007, J ORTHOP TRAUMA, V21, P26, DOI 10.1097/BOT.0b013e31802c4f3c; Weninger P, 2008, J TRAUMA, V65, P799, DOI 10.1097/TA.0b013e3181820dae; Williams TM, 2008, J TRAUMA, V65, P772, DOI 10.1097/TA.0b013e3181877ff7; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; You H, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005951.pub2	48	37	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					645	652		10.1097/TA.0b013e3181d8941d			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	649HX	WOS:000281760800040	20526211				2021-06-18	
J	Klein, Y; Donchik, V; Jaffe, D; Simon, D; Kessel, B; Levy, L; Kashtan, H; Peleg, K				Klein, Yoram; Donchik, Valery; Jaffe, Dena; Simon, Daniel; Kessel, Boris; Levy, Leon; Kashtan, Hanoch; Peleg, Kobi			Management of Patients With Traumatic Intracranial Injury in Hospitals Without Neurosurgical Service	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injuries; Closed neurosurgery; Trauma centers; Telemedicine; Patients transfer	PROSPECTIVE MULTICENTER TRIAL; GLASGOW COMA SCALE; BRAIN-INJURY; IMPLEMENTATION	Background: Many patients with intracranial bleeding (ICB) are being evaluated in hospitals with no neurosurgical service. Some of the patients may be safely managed in the primary hospital without transferring them to a designated neurosurgical center. In Israel, there are three approaches to alert patients with ICB: mandatory transfer, remote telemedicine neurosurgical consultation, and clinical-radiologic guidelines. We evaluated the outcome of alert patients with low-risk ICB who were managed in centers without neurosurgical service. Methods: A retrospective cohort comparative study. Patients with ICB and a Glasgow Coma Score >12 were included. Low-risk ICB was defined as solitary brain contusion of <1 cm in diameter, limited small subarachnoid hemorrhage, or subdural hematoma of <5 mm in maximal width and length. The decision to transfer the patients to a neurosurgical center was based on one of the three models. Hospital A: mandatory transfer. Hospital B: telemedicine-based consultation with a remote neurosurgeon. Hospital C: clinical-radiologic algorithm-based guidelines. Primary endpoint was the neurologic outcome of patients at discharge. Results: There were 152 patients in group A, 98 patients in group B, and 73 patients in group C. All patients of group A were transferred to a neurosurgical center. Fifty-eight percent of patients from hospital B and 26% of patients from hospital C were hospitalized in the primary center despite a proven ICB. These patients were discharged without any neurologic sequel of their injury. Two patients from group B and one patient from group C needed a delayed transfer to a neurosurgical center. None of the patient needed delayed neurosurgical intervention. Conclusions: Despite the small sample size of this study, the presented data suggest that some patients with ICB can be safely and definitively managed in centers with no on-site neurosurgical service. The need for transfer may be based on telemedicine consultation or clinical-radiologic guidelines. Further larger scale studies are warranted.	[Klein, Yoram] Kaplan Med Ctr, Div Trauma & Emergency Surg, Rehovot, Israel; [Donchik, Valery] Kaplan Med Ctr, Div Vasc Surg, Rehovot, Israel; [Kashtan, Hanoch] Kaplan Med Ctr, Dept Surg B, Rehovot, Israel; [Jaffe, Dena; Peleg, Kobi] Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, Tel Hashomer, Israel; [Simon, Daniel] Sheba Med Ctr, Div Trauma, Tel Hashomer, Israel; [Kessel, Boris] Hillel Yaffe Med Ctr, Div Trauma, Hadera, Israel; [Levy, Leon] Rambam Med Ctr, Haifa, Israel	Klein, Y (corresponding author), Kaplan Med Ctr, Div Trauma & Emergency Surg, Rehovot, Israel.	yoramkl@clalit.org.il					Ashkenazi I, 2007, EMERG MED J, V24, P550, DOI 10.1136/emj.2006.044461; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Hangiandreou NJ, 1997, J DIGIT IMAGING, V10, P36, DOI 10.1007/BF03168652; Junck KL, 1998, J DIGIT IMAGING, V11, P159, DOI 10.1007/BF03168291; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Onzuka J, 2008, CAN J EMERG MED, V10, P205; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	9	37	37	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					544	548		10.1097/TA.0b013e3181c99936			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	649HX	WOS:000281760800013	20234328				2021-06-18	
J	Liliang, PC; Liang, CL; Lu, K; Wang, KW; Weng, HC; Hsieh, CH; Tsai, YD; Chen, HJ				Liliang, Po-Chou; Liang, Cheng-Loong; Lu, Kang; Wang, Kuo-Wei; Weng, Hui-Ching; Hsieh, Ching-Hua; Tsai, Yu-Duan; Chen, Han-Jung			Relationship between injury severity and serum tau protein levels in traumatic brain injured rats	RESUSCITATION			English	Article						Tau protein; Biomarker; Traumatic brain injury; Immunoblotting; ELISA	CORTICAL IMPACT INJURY; CLEAVED-TAU; CEREBROSPINAL-FLUID; NEURONAL DAMAGE; S-100B PROTEIN; HEAD-INJURY; MARKER; BIOMARKER	Background: Although serum tau protein levels increase following TBI, the time course is unknown. The aim of the present study was to determine whether serum tau protein levels increased in both a severity-dependent and time-dependent manner in an experimental model of rat traumatic brain injury (TBI). Methods: A total of 24 Sprague-Dawley rats were subjected to varying grades of TBI using a contusion injury model on the right parietal cortex. Enzyme-linked Immunoabsorbent Assay (ELISA) analysis for serum was performed at 15 min pre-injury, 1, 6, 24, 48, and 168 h post-injury. Immunoblotting for serum tau protein, neurological evaluation and histological observation were also performed. Results: Tau protein levels rapidly increased after 1 h in both mild and severe TBI groups (p < 0.001), and declined after 6 h. In the sham-operated group, tau protein levels did not change significantly after TBI. Tau protein levels were severity-dependent at 1 and 6 h after TBI. The levels were higher in the severe TBI group than in the mild TBI group at 1 h (p < 0.001) and 6 h (p < 0.001). Conclusions: Serum tau protein levels were severity-dependent and time-dependent at 1 and 6 h after TBI. However, the serum tau protein may not be a useful marker 24 h after TBI. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Liliang, Po-Chou; Liang, Cheng-Loong; Lu, Kang; Wang, Kuo-Wei; Tsai, Yu-Duan; Chen, Han-Jung] I Shou Univ, Dept Neurosurg, E Da Hosp, Yan Chau Shiang 824, Kaohsiung Count, Taiwan; [Weng, Hui-Ching] I Shou Univ, Dept Hlth Management, Yan Chau Shiang 824, Kaohsiung Count, Taiwan; [Hsieh, Ching-Hua] Chang Gung Univ, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg,Coll Med, Kaohsiung, Taiwan	Chen, HJ (corresponding author), I Shou Univ, Dept Neurosurg, E Da Hosp, 1 Yi Da Rd, Yan Chau Shiang 824, Kaohsiung Count, Taiwan.	ed100172@edah.org.tw			Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC 95-2314-B-214-006]; E-Da Hospital [EDAHP97017]	This work was supported by research grants from Taiwan National Science Council Grant NSC 95-2314-B-214-006 and E-Da Hospital EDAHP97017 to P.C. Liliang.	ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lin JW, 2008, ACT NEUR S, V101, P113; Lin JW, 2006, SURG NEUROL, V66, pS20, DOI 10.1016/j.surneu.2006.04.005; MARION DW, 1996, NEUROTRAUMA, P767; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, ACT NEUR S, V81, P205; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	27	37	41	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	SEP	2010	81	9					1205	1208		10.1016/j.resuscitation.2010.05.016			4	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	653TU	WOS:000282120600028	20598429				2021-06-18	
